<!DOCTYPE html>

<html>

<head>

<meta charset="utf-8" />
<meta name="generator" content="pandoc" />
<meta http-equiv="X-UA-Compatible" content="IE=EDGE" />




<title>Pancreatobiliary Pathology Society Journal Watch</title>

<script>// Pandoc 2.9 adds attributes on both header and div. We remove the former (to
// be compatible with the behavior of Pandoc < 2.8).
document.addEventListener('DOMContentLoaded', function(e) {
  var hs = document.querySelectorAll("div.section[class*='level'] > :first-child");
  var i, h, a;
  for (i = 0; i < hs.length; i++) {
    h = hs[i];
    if (!/^h[1-6]$/i.test(h.tagName)) continue;  // it should be a header h1-h6
    a = h.attributes;
    while (a.length > 0) h.removeAttribute(a[0].name);
  }
});
</script>
<script>/*! jQuery v1.11.3 | (c) 2005, 2015 jQuery Foundation, Inc. | jquery.org/license */
!function(a,b){"object"==typeof module&&"object"==typeof module.exports?module.exports=a.document?b(a,!0):function(a){if(!a.document)throw new Error("jQuery requires a window with a document");return b(a)}:b(a)}("undefined"!=typeof window?window:this,function(a,b){var c=[],d=c.slice,e=c.concat,f=c.push,g=c.indexOf,h={},i=h.toString,j=h.hasOwnProperty,k={},l="1.11.3",m=function(a,b){return new m.fn.init(a,b)},n=/^[\s\uFEFF\xA0]+|[\s\uFEFF\xA0]+$/g,o=/^-ms-/,p=/-([\da-z])/gi,q=function(a,b){return b.toUpperCase()};m.fn=m.prototype={jquery:l,constructor:m,selector:"",length:0,toArray:function(){return d.call(this)},get:function(a){return null!=a?0>a?this[a+this.length]:this[a]:d.call(this)},pushStack:function(a){var b=m.merge(this.constructor(),a);return b.prevObject=this,b.context=this.context,b},each:function(a,b){return m.each(this,a,b)},map:function(a){return this.pushStack(m.map(this,function(b,c){return a.call(b,c,b)}))},slice:function(){return this.pushStack(d.apply(this,arguments))},first:function(){return this.eq(0)},last:function(){return this.eq(-1)},eq:function(a){var b=this.length,c=+a+(0>a?b:0);return this.pushStack(c>=0&&b>c?[this[c]]:[])},end:function(){return this.prevObject||this.constructor(null)},push:f,sort:c.sort,splice:c.splice},m.extend=m.fn.extend=function(){var a,b,c,d,e,f,g=arguments[0]||{},h=1,i=arguments.length,j=!1;for("boolean"==typeof g&&(j=g,g=arguments[h]||{},h++),"object"==typeof g||m.isFunction(g)||(g={}),h===i&&(g=this,h--);i>h;h++)if(null!=(e=arguments[h]))for(d in e)a=g[d],c=e[d],g!==c&&(j&&c&&(m.isPlainObject(c)||(b=m.isArray(c)))?(b?(b=!1,f=a&&m.isArray(a)?a:[]):f=a&&m.isPlainObject(a)?a:{},g[d]=m.extend(j,f,c)):void 0!==c&&(g[d]=c));return g},m.extend({expando:"jQuery"+(l+Math.random()).replace(/\D/g,""),isReady:!0,error:function(a){throw new Error(a)},noop:function(){},isFunction:function(a){return"function"===m.type(a)},isArray:Array.isArray||function(a){return"array"===m.type(a)},isWindow:function(a){return null!=a&&a==a.window},isNumeric:function(a){return!m.isArray(a)&&a-parseFloat(a)+1>=0},isEmptyObject:function(a){var b;for(b in a)return!1;return!0},isPlainObject:function(a){var b;if(!a||"object"!==m.type(a)||a.nodeType||m.isWindow(a))return!1;try{if(a.constructor&&!j.call(a,"constructor")&&!j.call(a.constructor.prototype,"isPrototypeOf"))return!1}catch(c){return!1}if(k.ownLast)for(b in a)return j.call(a,b);for(b in a);return void 0===b||j.call(a,b)},type:function(a){return null==a?a+"":"object"==typeof a||"function"==typeof a?h[i.call(a)]||"object":typeof a},globalEval:function(b){b&&m.trim(b)&&(a.execScript||function(b){a.eval.call(a,b)})(b)},camelCase:function(a){return a.replace(o,"ms-").replace(p,q)},nodeName:function(a,b){return a.nodeName&&a.nodeName.toLowerCase()===b.toLowerCase()},each:function(a,b,c){var d,e=0,f=a.length,g=r(a);if(c){if(g){for(;f>e;e++)if(d=b.apply(a[e],c),d===!1)break}else for(e in a)if(d=b.apply(a[e],c),d===!1)break}else if(g){for(;f>e;e++)if(d=b.call(a[e],e,a[e]),d===!1)break}else for(e in a)if(d=b.call(a[e],e,a[e]),d===!1)break;return a},trim:function(a){return null==a?"":(a+"").replace(n,"")},makeArray:function(a,b){var c=b||[];return null!=a&&(r(Object(a))?m.merge(c,"string"==typeof a?[a]:a):f.call(c,a)),c},inArray:function(a,b,c){var d;if(b){if(g)return g.call(b,a,c);for(d=b.length,c=c?0>c?Math.max(0,d+c):c:0;d>c;c++)if(c in b&&b[c]===a)return c}return-1},merge:function(a,b){var c=+b.length,d=0,e=a.length;while(c>d)a[e++]=b[d++];if(c!==c)while(void 0!==b[d])a[e++]=b[d++];return a.length=e,a},grep:function(a,b,c){for(var d,e=[],f=0,g=a.length,h=!c;g>f;f++)d=!b(a[f],f),d!==h&&e.push(a[f]);return e},map:function(a,b,c){var d,f=0,g=a.length,h=r(a),i=[];if(h)for(;g>f;f++)d=b(a[f],f,c),null!=d&&i.push(d);else for(f in a)d=b(a[f],f,c),null!=d&&i.push(d);return e.apply([],i)},guid:1,proxy:function(a,b){var c,e,f;return"string"==typeof b&&(f=a[b],b=a,a=f),m.isFunction(a)?(c=d.call(arguments,2),e=function(){return a.apply(b||this,c.concat(d.call(arguments)))},e.guid=a.guid=a.guid||m.guid++,e):void 0},now:function(){return+new Date},support:k}),m.each("Boolean Number String Function Array Date RegExp Object Error".split(" "),function(a,b){h["[object "+b+"]"]=b.toLowerCase()});function r(a){var b="length"in a&&a.length,c=m.type(a);return"function"===c||m.isWindow(a)?!1:1===a.nodeType&&b?!0:"array"===c||0===b||"number"==typeof b&&b>0&&b-1 in a}var s=function(a){var b,c,d,e,f,g,h,i,j,k,l,m,n,o,p,q,r,s,t,u="sizzle"+1*new Date,v=a.document,w=0,x=0,y=ha(),z=ha(),A=ha(),B=function(a,b){return a===b&&(l=!0),0},C=1<<31,D={}.hasOwnProperty,E=[],F=E.pop,G=E.push,H=E.push,I=E.slice,J=function(a,b){for(var c=0,d=a.length;d>c;c++)if(a[c]===b)return c;return-1},K="checked|selected|async|autofocus|autoplay|controls|defer|disabled|hidden|ismap|loop|multiple|open|readonly|required|scoped",L="[\\x20\\t\\r\\n\\f]",M="(?:\\\\.|[\\w-]|[^\\x00-\\xa0])+",N=M.replace("w","w#"),O="\\["+L+"*("+M+")(?:"+L+"*([*^$|!~]?=)"+L+"*(?:'((?:\\\\.|[^\\\\'])*)'|\"((?:\\\\.|[^\\\\\"])*)\"|("+N+"))|)"+L+"*\\]",P=":("+M+")(?:\\((('((?:\\\\.|[^\\\\'])*)'|\"((?:\\\\.|[^\\\\\"])*)\")|((?:\\\\.|[^\\\\()[\\]]|"+O+")*)|.*)\\)|)",Q=new RegExp(L+"+","g"),R=new RegExp("^"+L+"+|((?:^|[^\\\\])(?:\\\\.)*)"+L+"+$","g"),S=new RegExp("^"+L+"*,"+L+"*"),T=new RegExp("^"+L+"*([>+~]|"+L+")"+L+"*"),U=new RegExp("="+L+"*([^\\]'\"]*?)"+L+"*\\]","g"),V=new RegExp(P),W=new RegExp("^"+N+"$"),X={ID:new RegExp("^#("+M+")"),CLASS:new RegExp("^\\.("+M+")"),TAG:new RegExp("^("+M.replace("w","w*")+")"),ATTR:new RegExp("^"+O),PSEUDO:new RegExp("^"+P),CHILD:new RegExp("^:(only|first|last|nth|nth-last)-(child|of-type)(?:\\("+L+"*(even|odd|(([+-]|)(\\d*)n|)"+L+"*(?:([+-]|)"+L+"*(\\d+)|))"+L+"*\\)|)","i"),bool:new RegExp("^(?:"+K+")$","i"),needsContext:new RegExp("^"+L+"*[>+~]|:(even|odd|eq|gt|lt|nth|first|last)(?:\\("+L+"*((?:-\\d)?\\d*)"+L+"*\\)|)(?=[^-]|$)","i")},Y=/^(?:input|select|textarea|button)$/i,Z=/^h\d$/i,$=/^[^{]+\{\s*\[native \w/,_=/^(?:#([\w-]+)|(\w+)|\.([\w-]+))$/,aa=/[+~]/,ba=/'|\\/g,ca=new RegExp("\\\\([\\da-f]{1,6}"+L+"?|("+L+")|.)","ig"),da=function(a,b,c){var d="0x"+b-65536;return d!==d||c?b:0>d?String.fromCharCode(d+65536):String.fromCharCode(d>>10|55296,1023&d|56320)},ea=function(){m()};try{H.apply(E=I.call(v.childNodes),v.childNodes),E[v.childNodes.length].nodeType}catch(fa){H={apply:E.length?function(a,b){G.apply(a,I.call(b))}:function(a,b){var c=a.length,d=0;while(a[c++]=b[d++]);a.length=c-1}}}function ga(a,b,d,e){var f,h,j,k,l,o,r,s,w,x;if((b?b.ownerDocument||b:v)!==n&&m(b),b=b||n,d=d||[],k=b.nodeType,"string"!=typeof a||!a||1!==k&&9!==k&&11!==k)return d;if(!e&&p){if(11!==k&&(f=_.exec(a)))if(j=f[1]){if(9===k){if(h=b.getElementById(j),!h||!h.parentNode)return d;if(h.id===j)return d.push(h),d}else if(b.ownerDocument&&(h=b.ownerDocument.getElementById(j))&&t(b,h)&&h.id===j)return d.push(h),d}else{if(f[2])return H.apply(d,b.getElementsByTagName(a)),d;if((j=f[3])&&c.getElementsByClassName)return H.apply(d,b.getElementsByClassName(j)),d}if(c.qsa&&(!q||!q.test(a))){if(s=r=u,w=b,x=1!==k&&a,1===k&&"object"!==b.nodeName.toLowerCase()){o=g(a),(r=b.getAttribute("id"))?s=r.replace(ba,"\\$&"):b.setAttribute("id",s),s="[id='"+s+"'] ",l=o.length;while(l--)o[l]=s+ra(o[l]);w=aa.test(a)&&pa(b.parentNode)||b,x=o.join(",")}if(x)try{return H.apply(d,w.querySelectorAll(x)),d}catch(y){}finally{r||b.removeAttribute("id")}}}return i(a.replace(R,"$1"),b,d,e)}function ha(){var a=[];function b(c,e){return a.push(c+" ")>d.cacheLength&&delete b[a.shift()],b[c+" "]=e}return b}function ia(a){return a[u]=!0,a}function ja(a){var b=n.createElement("div");try{return!!a(b)}catch(c){return!1}finally{b.parentNode&&b.parentNode.removeChild(b),b=null}}function ka(a,b){var c=a.split("|"),e=a.length;while(e--)d.attrHandle[c[e]]=b}function la(a,b){var c=b&&a,d=c&&1===a.nodeType&&1===b.nodeType&&(~b.sourceIndex||C)-(~a.sourceIndex||C);if(d)return d;if(c)while(c=c.nextSibling)if(c===b)return-1;return a?1:-1}function ma(a){return function(b){var c=b.nodeName.toLowerCase();return"input"===c&&b.type===a}}function na(a){return function(b){var c=b.nodeName.toLowerCase();return("input"===c||"button"===c)&&b.type===a}}function oa(a){return ia(function(b){return b=+b,ia(function(c,d){var e,f=a([],c.length,b),g=f.length;while(g--)c[e=f[g]]&&(c[e]=!(d[e]=c[e]))})})}function pa(a){return a&&"undefined"!=typeof a.getElementsByTagName&&a}c=ga.support={},f=ga.isXML=function(a){var b=a&&(a.ownerDocument||a).documentElement;return b?"HTML"!==b.nodeName:!1},m=ga.setDocument=function(a){var b,e,g=a?a.ownerDocument||a:v;return g!==n&&9===g.nodeType&&g.documentElement?(n=g,o=g.documentElement,e=g.defaultView,e&&e!==e.top&&(e.addEventListener?e.addEventListener("unload",ea,!1):e.attachEvent&&e.attachEvent("onunload",ea)),p=!f(g),c.attributes=ja(function(a){return a.className="i",!a.getAttribute("className")}),c.getElementsByTagName=ja(function(a){return a.appendChild(g.createComment("")),!a.getElementsByTagName("*").length}),c.getElementsByClassName=$.test(g.getElementsByClassName),c.getById=ja(function(a){return o.appendChild(a).id=u,!g.getElementsByName||!g.getElementsByName(u).length}),c.getById?(d.find.ID=function(a,b){if("undefined"!=typeof b.getElementById&&p){var c=b.getElementById(a);return c&&c.parentNode?[c]:[]}},d.filter.ID=function(a){var b=a.replace(ca,da);return function(a){return a.getAttribute("id")===b}}):(delete d.find.ID,d.filter.ID=function(a){var b=a.replace(ca,da);return function(a){var c="undefined"!=typeof a.getAttributeNode&&a.getAttributeNode("id");return c&&c.value===b}}),d.find.TAG=c.getElementsByTagName?function(a,b){return"undefined"!=typeof b.getElementsByTagName?b.getElementsByTagName(a):c.qsa?b.querySelectorAll(a):void 0}:function(a,b){var c,d=[],e=0,f=b.getElementsByTagName(a);if("*"===a){while(c=f[e++])1===c.nodeType&&d.push(c);return d}return f},d.find.CLASS=c.getElementsByClassName&&function(a,b){return p?b.getElementsByClassName(a):void 0},r=[],q=[],(c.qsa=$.test(g.querySelectorAll))&&(ja(function(a){o.appendChild(a).innerHTML="<a id='"+u+"'></a><select id='"+u+"-\f]' msallowcapture=''><option selected=''></option></select>",a.querySelectorAll("[msallowcapture^='']").length&&q.push("[*^$]="+L+"*(?:''|\"\")"),a.querySelectorAll("[selected]").length||q.push("\\["+L+"*(?:value|"+K+")"),a.querySelectorAll("[id~="+u+"-]").length||q.push("~="),a.querySelectorAll(":checked").length||q.push(":checked"),a.querySelectorAll("a#"+u+"+*").length||q.push(".#.+[+~]")}),ja(function(a){var b=g.createElement("input");b.setAttribute("type","hidden"),a.appendChild(b).setAttribute("name","D"),a.querySelectorAll("[name=d]").length&&q.push("name"+L+"*[*^$|!~]?="),a.querySelectorAll(":enabled").length||q.push(":enabled",":disabled"),a.querySelectorAll("*,:x"),q.push(",.*:")})),(c.matchesSelector=$.test(s=o.matches||o.webkitMatchesSelector||o.mozMatchesSelector||o.oMatchesSelector||o.msMatchesSelector))&&ja(function(a){c.disconnectedMatch=s.call(a,"div"),s.call(a,"[s!='']:x"),r.push("!=",P)}),q=q.length&&new RegExp(q.join("|")),r=r.length&&new RegExp(r.join("|")),b=$.test(o.compareDocumentPosition),t=b||$.test(o.contains)?function(a,b){var c=9===a.nodeType?a.documentElement:a,d=b&&b.parentNode;return a===d||!(!d||1!==d.nodeType||!(c.contains?c.contains(d):a.compareDocumentPosition&&16&a.compareDocumentPosition(d)))}:function(a,b){if(b)while(b=b.parentNode)if(b===a)return!0;return!1},B=b?function(a,b){if(a===b)return l=!0,0;var d=!a.compareDocumentPosition-!b.compareDocumentPosition;return d?d:(d=(a.ownerDocument||a)===(b.ownerDocument||b)?a.compareDocumentPosition(b):1,1&d||!c.sortDetached&&b.compareDocumentPosition(a)===d?a===g||a.ownerDocument===v&&t(v,a)?-1:b===g||b.ownerDocument===v&&t(v,b)?1:k?J(k,a)-J(k,b):0:4&d?-1:1)}:function(a,b){if(a===b)return l=!0,0;var c,d=0,e=a.parentNode,f=b.parentNode,h=[a],i=[b];if(!e||!f)return a===g?-1:b===g?1:e?-1:f?1:k?J(k,a)-J(k,b):0;if(e===f)return la(a,b);c=a;while(c=c.parentNode)h.unshift(c);c=b;while(c=c.parentNode)i.unshift(c);while(h[d]===i[d])d++;return d?la(h[d],i[d]):h[d]===v?-1:i[d]===v?1:0},g):n},ga.matches=function(a,b){return ga(a,null,null,b)},ga.matchesSelector=function(a,b){if((a.ownerDocument||a)!==n&&m(a),b=b.replace(U,"='$1']"),!(!c.matchesSelector||!p||r&&r.test(b)||q&&q.test(b)))try{var d=s.call(a,b);if(d||c.disconnectedMatch||a.document&&11!==a.document.nodeType)return d}catch(e){}return ga(b,n,null,[a]).length>0},ga.contains=function(a,b){return(a.ownerDocument||a)!==n&&m(a),t(a,b)},ga.attr=function(a,b){(a.ownerDocument||a)!==n&&m(a);var e=d.attrHandle[b.toLowerCase()],f=e&&D.call(d.attrHandle,b.toLowerCase())?e(a,b,!p):void 0;return void 0!==f?f:c.attributes||!p?a.getAttribute(b):(f=a.getAttributeNode(b))&&f.specified?f.value:null},ga.error=function(a){throw new Error("Syntax error, unrecognized expression: "+a)},ga.uniqueSort=function(a){var b,d=[],e=0,f=0;if(l=!c.detectDuplicates,k=!c.sortStable&&a.slice(0),a.sort(B),l){while(b=a[f++])b===a[f]&&(e=d.push(f));while(e--)a.splice(d[e],1)}return k=null,a},e=ga.getText=function(a){var b,c="",d=0,f=a.nodeType;if(f){if(1===f||9===f||11===f){if("string"==typeof a.textContent)return a.textContent;for(a=a.firstChild;a;a=a.nextSibling)c+=e(a)}else if(3===f||4===f)return a.nodeValue}else while(b=a[d++])c+=e(b);return c},d=ga.selectors={cacheLength:50,createPseudo:ia,match:X,attrHandle:{},find:{},relative:{">":{dir:"parentNode",first:!0}," ":{dir:"parentNode"},"+":{dir:"previousSibling",first:!0},"~":{dir:"previousSibling"}},preFilter:{ATTR:function(a){return a[1]=a[1].replace(ca,da),a[3]=(a[3]||a[4]||a[5]||"").replace(ca,da),"~="===a[2]&&(a[3]=" "+a[3]+" "),a.slice(0,4)},CHILD:function(a){return a[1]=a[1].toLowerCase(),"nth"===a[1].slice(0,3)?(a[3]||ga.error(a[0]),a[4]=+(a[4]?a[5]+(a[6]||1):2*("even"===a[3]||"odd"===a[3])),a[5]=+(a[7]+a[8]||"odd"===a[3])):a[3]&&ga.error(a[0]),a},PSEUDO:function(a){var b,c=!a[6]&&a[2];return X.CHILD.test(a[0])?null:(a[3]?a[2]=a[4]||a[5]||"":c&&V.test(c)&&(b=g(c,!0))&&(b=c.indexOf(")",c.length-b)-c.length)&&(a[0]=a[0].slice(0,b),a[2]=c.slice(0,b)),a.slice(0,3))}},filter:{TAG:function(a){var b=a.replace(ca,da).toLowerCase();return"*"===a?function(){return!0}:function(a){return a.nodeName&&a.nodeName.toLowerCase()===b}},CLASS:function(a){var b=y[a+" "];return b||(b=new RegExp("(^|"+L+")"+a+"("+L+"|$)"))&&y(a,function(a){return b.test("string"==typeof a.className&&a.className||"undefined"!=typeof a.getAttribute&&a.getAttribute("class")||"")})},ATTR:function(a,b,c){return function(d){var e=ga.attr(d,a);return null==e?"!="===b:b?(e+="","="===b?e===c:"!="===b?e!==c:"^="===b?c&&0===e.indexOf(c):"*="===b?c&&e.indexOf(c)>-1:"$="===b?c&&e.slice(-c.length)===c:"~="===b?(" "+e.replace(Q," ")+" ").indexOf(c)>-1:"|="===b?e===c||e.slice(0,c.length+1)===c+"-":!1):!0}},CHILD:function(a,b,c,d,e){var f="nth"!==a.slice(0,3),g="last"!==a.slice(-4),h="of-type"===b;return 1===d&&0===e?function(a){return!!a.parentNode}:function(b,c,i){var j,k,l,m,n,o,p=f!==g?"nextSibling":"previousSibling",q=b.parentNode,r=h&&b.nodeName.toLowerCase(),s=!i&&!h;if(q){if(f){while(p){l=b;while(l=l[p])if(h?l.nodeName.toLowerCase()===r:1===l.nodeType)return!1;o=p="only"===a&&!o&&"nextSibling"}return!0}if(o=[g?q.firstChild:q.lastChild],g&&s){k=q[u]||(q[u]={}),j=k[a]||[],n=j[0]===w&&j[1],m=j[0]===w&&j[2],l=n&&q.childNodes[n];while(l=++n&&l&&l[p]||(m=n=0)||o.pop())if(1===l.nodeType&&++m&&l===b){k[a]=[w,n,m];break}}else if(s&&(j=(b[u]||(b[u]={}))[a])&&j[0]===w)m=j[1];else while(l=++n&&l&&l[p]||(m=n=0)||o.pop())if((h?l.nodeName.toLowerCase()===r:1===l.nodeType)&&++m&&(s&&((l[u]||(l[u]={}))[a]=[w,m]),l===b))break;return m-=e,m===d||m%d===0&&m/d>=0}}},PSEUDO:function(a,b){var c,e=d.pseudos[a]||d.setFilters[a.toLowerCase()]||ga.error("unsupported pseudo: "+a);return e[u]?e(b):e.length>1?(c=[a,a,"",b],d.setFilters.hasOwnProperty(a.toLowerCase())?ia(function(a,c){var d,f=e(a,b),g=f.length;while(g--)d=J(a,f[g]),a[d]=!(c[d]=f[g])}):function(a){return e(a,0,c)}):e}},pseudos:{not:ia(function(a){var b=[],c=[],d=h(a.replace(R,"$1"));return d[u]?ia(function(a,b,c,e){var f,g=d(a,null,e,[]),h=a.length;while(h--)(f=g[h])&&(a[h]=!(b[h]=f))}):function(a,e,f){return b[0]=a,d(b,null,f,c),b[0]=null,!c.pop()}}),has:ia(function(a){return function(b){return ga(a,b).length>0}}),contains:ia(function(a){return a=a.replace(ca,da),function(b){return(b.textContent||b.innerText||e(b)).indexOf(a)>-1}}),lang:ia(function(a){return W.test(a||"")||ga.error("unsupported lang: "+a),a=a.replace(ca,da).toLowerCase(),function(b){var c;do if(c=p?b.lang:b.getAttribute("xml:lang")||b.getAttribute("lang"))return c=c.toLowerCase(),c===a||0===c.indexOf(a+"-");while((b=b.parentNode)&&1===b.nodeType);return!1}}),target:function(b){var c=a.location&&a.location.hash;return c&&c.slice(1)===b.id},root:function(a){return a===o},focus:function(a){return a===n.activeElement&&(!n.hasFocus||n.hasFocus())&&!!(a.type||a.href||~a.tabIndex)},enabled:function(a){return a.disabled===!1},disabled:function(a){return a.disabled===!0},checked:function(a){var b=a.nodeName.toLowerCase();return"input"===b&&!!a.checked||"option"===b&&!!a.selected},selected:function(a){return a.parentNode&&a.parentNode.selectedIndex,a.selected===!0},empty:function(a){for(a=a.firstChild;a;a=a.nextSibling)if(a.nodeType<6)return!1;return!0},parent:function(a){return!d.pseudos.empty(a)},header:function(a){return Z.test(a.nodeName)},input:function(a){return Y.test(a.nodeName)},button:function(a){var b=a.nodeName.toLowerCase();return"input"===b&&"button"===a.type||"button"===b},text:function(a){var b;return"input"===a.nodeName.toLowerCase()&&"text"===a.type&&(null==(b=a.getAttribute("type"))||"text"===b.toLowerCase())},first:oa(function(){return[0]}),last:oa(function(a,b){return[b-1]}),eq:oa(function(a,b,c){return[0>c?c+b:c]}),even:oa(function(a,b){for(var c=0;b>c;c+=2)a.push(c);return a}),odd:oa(function(a,b){for(var c=1;b>c;c+=2)a.push(c);return a}),lt:oa(function(a,b,c){for(var d=0>c?c+b:c;--d>=0;)a.push(d);return a}),gt:oa(function(a,b,c){for(var d=0>c?c+b:c;++d<b;)a.push(d);return a})}},d.pseudos.nth=d.pseudos.eq;for(b in{radio:!0,checkbox:!0,file:!0,password:!0,image:!0})d.pseudos[b]=ma(b);for(b in{submit:!0,reset:!0})d.pseudos[b]=na(b);function qa(){}qa.prototype=d.filters=d.pseudos,d.setFilters=new qa,g=ga.tokenize=function(a,b){var c,e,f,g,h,i,j,k=z[a+" "];if(k)return b?0:k.slice(0);h=a,i=[],j=d.preFilter;while(h){(!c||(e=S.exec(h)))&&(e&&(h=h.slice(e[0].length)||h),i.push(f=[])),c=!1,(e=T.exec(h))&&(c=e.shift(),f.push({value:c,type:e[0].replace(R," ")}),h=h.slice(c.length));for(g in d.filter)!(e=X[g].exec(h))||j[g]&&!(e=j[g](e))||(c=e.shift(),f.push({value:c,type:g,matches:e}),h=h.slice(c.length));if(!c)break}return b?h.length:h?ga.error(a):z(a,i).slice(0)};function ra(a){for(var b=0,c=a.length,d="";c>b;b++)d+=a[b].value;return d}function sa(a,b,c){var d=b.dir,e=c&&"parentNode"===d,f=x++;return b.first?function(b,c,f){while(b=b[d])if(1===b.nodeType||e)return a(b,c,f)}:function(b,c,g){var h,i,j=[w,f];if(g){while(b=b[d])if((1===b.nodeType||e)&&a(b,c,g))return!0}else while(b=b[d])if(1===b.nodeType||e){if(i=b[u]||(b[u]={}),(h=i[d])&&h[0]===w&&h[1]===f)return j[2]=h[2];if(i[d]=j,j[2]=a(b,c,g))return!0}}}function ta(a){return a.length>1?function(b,c,d){var e=a.length;while(e--)if(!a[e](b,c,d))return!1;return!0}:a[0]}function ua(a,b,c){for(var d=0,e=b.length;e>d;d++)ga(a,b[d],c);return c}function va(a,b,c,d,e){for(var f,g=[],h=0,i=a.length,j=null!=b;i>h;h++)(f=a[h])&&(!c||c(f,d,e))&&(g.push(f),j&&b.push(h));return g}function wa(a,b,c,d,e,f){return d&&!d[u]&&(d=wa(d)),e&&!e[u]&&(e=wa(e,f)),ia(function(f,g,h,i){var j,k,l,m=[],n=[],o=g.length,p=f||ua(b||"*",h.nodeType?[h]:h,[]),q=!a||!f&&b?p:va(p,m,a,h,i),r=c?e||(f?a:o||d)?[]:g:q;if(c&&c(q,r,h,i),d){j=va(r,n),d(j,[],h,i),k=j.length;while(k--)(l=j[k])&&(r[n[k]]=!(q[n[k]]=l))}if(f){if(e||a){if(e){j=[],k=r.length;while(k--)(l=r[k])&&j.push(q[k]=l);e(null,r=[],j,i)}k=r.length;while(k--)(l=r[k])&&(j=e?J(f,l):m[k])>-1&&(f[j]=!(g[j]=l))}}else r=va(r===g?r.splice(o,r.length):r),e?e(null,g,r,i):H.apply(g,r)})}function xa(a){for(var b,c,e,f=a.length,g=d.relative[a[0].type],h=g||d.relative[" "],i=g?1:0,k=sa(function(a){return a===b},h,!0),l=sa(function(a){return J(b,a)>-1},h,!0),m=[function(a,c,d){var e=!g&&(d||c!==j)||((b=c).nodeType?k(a,c,d):l(a,c,d));return b=null,e}];f>i;i++)if(c=d.relative[a[i].type])m=[sa(ta(m),c)];else{if(c=d.filter[a[i].type].apply(null,a[i].matches),c[u]){for(e=++i;f>e;e++)if(d.relative[a[e].type])break;return wa(i>1&&ta(m),i>1&&ra(a.slice(0,i-1).concat({value:" "===a[i-2].type?"*":""})).replace(R,"$1"),c,e>i&&xa(a.slice(i,e)),f>e&&xa(a=a.slice(e)),f>e&&ra(a))}m.push(c)}return ta(m)}function ya(a,b){var c=b.length>0,e=a.length>0,f=function(f,g,h,i,k){var l,m,o,p=0,q="0",r=f&&[],s=[],t=j,u=f||e&&d.find.TAG("*",k),v=w+=null==t?1:Math.random()||.1,x=u.length;for(k&&(j=g!==n&&g);q!==x&&null!=(l=u[q]);q++){if(e&&l){m=0;while(o=a[m++])if(o(l,g,h)){i.push(l);break}k&&(w=v)}c&&((l=!o&&l)&&p--,f&&r.push(l))}if(p+=q,c&&q!==p){m=0;while(o=b[m++])o(r,s,g,h);if(f){if(p>0)while(q--)r[q]||s[q]||(s[q]=F.call(i));s=va(s)}H.apply(i,s),k&&!f&&s.length>0&&p+b.length>1&&ga.uniqueSort(i)}return k&&(w=v,j=t),r};return c?ia(f):f}return h=ga.compile=function(a,b){var c,d=[],e=[],f=A[a+" "];if(!f){b||(b=g(a)),c=b.length;while(c--)f=xa(b[c]),f[u]?d.push(f):e.push(f);f=A(a,ya(e,d)),f.selector=a}return f},i=ga.select=function(a,b,e,f){var i,j,k,l,m,n="function"==typeof a&&a,o=!f&&g(a=n.selector||a);if(e=e||[],1===o.length){if(j=o[0]=o[0].slice(0),j.length>2&&"ID"===(k=j[0]).type&&c.getById&&9===b.nodeType&&p&&d.relative[j[1].type]){if(b=(d.find.ID(k.matches[0].replace(ca,da),b)||[])[0],!b)return e;n&&(b=b.parentNode),a=a.slice(j.shift().value.length)}i=X.needsContext.test(a)?0:j.length;while(i--){if(k=j[i],d.relative[l=k.type])break;if((m=d.find[l])&&(f=m(k.matches[0].replace(ca,da),aa.test(j[0].type)&&pa(b.parentNode)||b))){if(j.splice(i,1),a=f.length&&ra(j),!a)return H.apply(e,f),e;break}}}return(n||h(a,o))(f,b,!p,e,aa.test(a)&&pa(b.parentNode)||b),e},c.sortStable=u.split("").sort(B).join("")===u,c.detectDuplicates=!!l,m(),c.sortDetached=ja(function(a){return 1&a.compareDocumentPosition(n.createElement("div"))}),ja(function(a){return a.innerHTML="<a href='#'></a>","#"===a.firstChild.getAttribute("href")})||ka("type|href|height|width",function(a,b,c){return c?void 0:a.getAttribute(b,"type"===b.toLowerCase()?1:2)}),c.attributes&&ja(function(a){return a.innerHTML="<input/>",a.firstChild.setAttribute("value",""),""===a.firstChild.getAttribute("value")})||ka("value",function(a,b,c){return c||"input"!==a.nodeName.toLowerCase()?void 0:a.defaultValue}),ja(function(a){return null==a.getAttribute("disabled")})||ka(K,function(a,b,c){var d;return c?void 0:a[b]===!0?b.toLowerCase():(d=a.getAttributeNode(b))&&d.specified?d.value:null}),ga}(a);m.find=s,m.expr=s.selectors,m.expr[":"]=m.expr.pseudos,m.unique=s.uniqueSort,m.text=s.getText,m.isXMLDoc=s.isXML,m.contains=s.contains;var t=m.expr.match.needsContext,u=/^<(\w+)\s*\/?>(?:<\/\1>|)$/,v=/^.[^:#\[\.,]*$/;function w(a,b,c){if(m.isFunction(b))return m.grep(a,function(a,d){return!!b.call(a,d,a)!==c});if(b.nodeType)return m.grep(a,function(a){return a===b!==c});if("string"==typeof b){if(v.test(b))return m.filter(b,a,c);b=m.filter(b,a)}return m.grep(a,function(a){return m.inArray(a,b)>=0!==c})}m.filter=function(a,b,c){var d=b[0];return c&&(a=":not("+a+")"),1===b.length&&1===d.nodeType?m.find.matchesSelector(d,a)?[d]:[]:m.find.matches(a,m.grep(b,function(a){return 1===a.nodeType}))},m.fn.extend({find:function(a){var b,c=[],d=this,e=d.length;if("string"!=typeof a)return this.pushStack(m(a).filter(function(){for(b=0;e>b;b++)if(m.contains(d[b],this))return!0}));for(b=0;e>b;b++)m.find(a,d[b],c);return c=this.pushStack(e>1?m.unique(c):c),c.selector=this.selector?this.selector+" "+a:a,c},filter:function(a){return this.pushStack(w(this,a||[],!1))},not:function(a){return this.pushStack(w(this,a||[],!0))},is:function(a){return!!w(this,"string"==typeof a&&t.test(a)?m(a):a||[],!1).length}});var x,y=a.document,z=/^(?:\s*(<[\w\W]+>)[^>]*|#([\w-]*))$/,A=m.fn.init=function(a,b){var c,d;if(!a)return this;if("string"==typeof a){if(c="<"===a.charAt(0)&&">"===a.charAt(a.length-1)&&a.length>=3?[null,a,null]:z.exec(a),!c||!c[1]&&b)return!b||b.jquery?(b||x).find(a):this.constructor(b).find(a);if(c[1]){if(b=b instanceof m?b[0]:b,m.merge(this,m.parseHTML(c[1],b&&b.nodeType?b.ownerDocument||b:y,!0)),u.test(c[1])&&m.isPlainObject(b))for(c in b)m.isFunction(this[c])?this[c](b[c]):this.attr(c,b[c]);return this}if(d=y.getElementById(c[2]),d&&d.parentNode){if(d.id!==c[2])return x.find(a);this.length=1,this[0]=d}return this.context=y,this.selector=a,this}return a.nodeType?(this.context=this[0]=a,this.length=1,this):m.isFunction(a)?"undefined"!=typeof x.ready?x.ready(a):a(m):(void 0!==a.selector&&(this.selector=a.selector,this.context=a.context),m.makeArray(a,this))};A.prototype=m.fn,x=m(y);var B=/^(?:parents|prev(?:Until|All))/,C={children:!0,contents:!0,next:!0,prev:!0};m.extend({dir:function(a,b,c){var d=[],e=a[b];while(e&&9!==e.nodeType&&(void 0===c||1!==e.nodeType||!m(e).is(c)))1===e.nodeType&&d.push(e),e=e[b];return d},sibling:function(a,b){for(var c=[];a;a=a.nextSibling)1===a.nodeType&&a!==b&&c.push(a);return c}}),m.fn.extend({has:function(a){var b,c=m(a,this),d=c.length;return this.filter(function(){for(b=0;d>b;b++)if(m.contains(this,c[b]))return!0})},closest:function(a,b){for(var c,d=0,e=this.length,f=[],g=t.test(a)||"string"!=typeof a?m(a,b||this.context):0;e>d;d++)for(c=this[d];c&&c!==b;c=c.parentNode)if(c.nodeType<11&&(g?g.index(c)>-1:1===c.nodeType&&m.find.matchesSelector(c,a))){f.push(c);break}return this.pushStack(f.length>1?m.unique(f):f)},index:function(a){return a?"string"==typeof a?m.inArray(this[0],m(a)):m.inArray(a.jquery?a[0]:a,this):this[0]&&this[0].parentNode?this.first().prevAll().length:-1},add:function(a,b){return this.pushStack(m.unique(m.merge(this.get(),m(a,b))))},addBack:function(a){return this.add(null==a?this.prevObject:this.prevObject.filter(a))}});function D(a,b){do a=a[b];while(a&&1!==a.nodeType);return a}m.each({parent:function(a){var b=a.parentNode;return b&&11!==b.nodeType?b:null},parents:function(a){return m.dir(a,"parentNode")},parentsUntil:function(a,b,c){return m.dir(a,"parentNode",c)},next:function(a){return D(a,"nextSibling")},prev:function(a){return D(a,"previousSibling")},nextAll:function(a){return m.dir(a,"nextSibling")},prevAll:function(a){return m.dir(a,"previousSibling")},nextUntil:function(a,b,c){return m.dir(a,"nextSibling",c)},prevUntil:function(a,b,c){return m.dir(a,"previousSibling",c)},siblings:function(a){return m.sibling((a.parentNode||{}).firstChild,a)},children:function(a){return m.sibling(a.firstChild)},contents:function(a){return m.nodeName(a,"iframe")?a.contentDocument||a.contentWindow.document:m.merge([],a.childNodes)}},function(a,b){m.fn[a]=function(c,d){var e=m.map(this,b,c);return"Until"!==a.slice(-5)&&(d=c),d&&"string"==typeof d&&(e=m.filter(d,e)),this.length>1&&(C[a]||(e=m.unique(e)),B.test(a)&&(e=e.reverse())),this.pushStack(e)}});var E=/\S+/g,F={};function G(a){var b=F[a]={};return m.each(a.match(E)||[],function(a,c){b[c]=!0}),b}m.Callbacks=function(a){a="string"==typeof a?F[a]||G(a):m.extend({},a);var b,c,d,e,f,g,h=[],i=!a.once&&[],j=function(l){for(c=a.memory&&l,d=!0,f=g||0,g=0,e=h.length,b=!0;h&&e>f;f++)if(h[f].apply(l[0],l[1])===!1&&a.stopOnFalse){c=!1;break}b=!1,h&&(i?i.length&&j(i.shift()):c?h=[]:k.disable())},k={add:function(){if(h){var d=h.length;!function f(b){m.each(b,function(b,c){var d=m.type(c);"function"===d?a.unique&&k.has(c)||h.push(c):c&&c.length&&"string"!==d&&f(c)})}(arguments),b?e=h.length:c&&(g=d,j(c))}return this},remove:function(){return h&&m.each(arguments,function(a,c){var d;while((d=m.inArray(c,h,d))>-1)h.splice(d,1),b&&(e>=d&&e--,f>=d&&f--)}),this},has:function(a){return a?m.inArray(a,h)>-1:!(!h||!h.length)},empty:function(){return h=[],e=0,this},disable:function(){return h=i=c=void 0,this},disabled:function(){return!h},lock:function(){return i=void 0,c||k.disable(),this},locked:function(){return!i},fireWith:function(a,c){return!h||d&&!i||(c=c||[],c=[a,c.slice?c.slice():c],b?i.push(c):j(c)),this},fire:function(){return k.fireWith(this,arguments),this},fired:function(){return!!d}};return k},m.extend({Deferred:function(a){var b=[["resolve","done",m.Callbacks("once memory"),"resolved"],["reject","fail",m.Callbacks("once memory"),"rejected"],["notify","progress",m.Callbacks("memory")]],c="pending",d={state:function(){return c},always:function(){return e.done(arguments).fail(arguments),this},then:function(){var a=arguments;return m.Deferred(function(c){m.each(b,function(b,f){var g=m.isFunction(a[b])&&a[b];e[f[1]](function(){var a=g&&g.apply(this,arguments);a&&m.isFunction(a.promise)?a.promise().done(c.resolve).fail(c.reject).progress(c.notify):c[f[0]+"With"](this===d?c.promise():this,g?[a]:arguments)})}),a=null}).promise()},promise:function(a){return null!=a?m.extend(a,d):d}},e={};return d.pipe=d.then,m.each(b,function(a,f){var g=f[2],h=f[3];d[f[1]]=g.add,h&&g.add(function(){c=h},b[1^a][2].disable,b[2][2].lock),e[f[0]]=function(){return e[f[0]+"With"](this===e?d:this,arguments),this},e[f[0]+"With"]=g.fireWith}),d.promise(e),a&&a.call(e,e),e},when:function(a){var b=0,c=d.call(arguments),e=c.length,f=1!==e||a&&m.isFunction(a.promise)?e:0,g=1===f?a:m.Deferred(),h=function(a,b,c){return function(e){b[a]=this,c[a]=arguments.length>1?d.call(arguments):e,c===i?g.notifyWith(b,c):--f||g.resolveWith(b,c)}},i,j,k;if(e>1)for(i=new Array(e),j=new Array(e),k=new Array(e);e>b;b++)c[b]&&m.isFunction(c[b].promise)?c[b].promise().done(h(b,k,c)).fail(g.reject).progress(h(b,j,i)):--f;return f||g.resolveWith(k,c),g.promise()}});var H;m.fn.ready=function(a){return m.ready.promise().done(a),this},m.extend({isReady:!1,readyWait:1,holdReady:function(a){a?m.readyWait++:m.ready(!0)},ready:function(a){if(a===!0?!--m.readyWait:!m.isReady){if(!y.body)return setTimeout(m.ready);m.isReady=!0,a!==!0&&--m.readyWait>0||(H.resolveWith(y,[m]),m.fn.triggerHandler&&(m(y).triggerHandler("ready"),m(y).off("ready")))}}});function I(){y.addEventListener?(y.removeEventListener("DOMContentLoaded",J,!1),a.removeEventListener("load",J,!1)):(y.detachEvent("onreadystatechange",J),a.detachEvent("onload",J))}function J(){(y.addEventListener||"load"===event.type||"complete"===y.readyState)&&(I(),m.ready())}m.ready.promise=function(b){if(!H)if(H=m.Deferred(),"complete"===y.readyState)setTimeout(m.ready);else if(y.addEventListener)y.addEventListener("DOMContentLoaded",J,!1),a.addEventListener("load",J,!1);else{y.attachEvent("onreadystatechange",J),a.attachEvent("onload",J);var c=!1;try{c=null==a.frameElement&&y.documentElement}catch(d){}c&&c.doScroll&&!function e(){if(!m.isReady){try{c.doScroll("left")}catch(a){return setTimeout(e,50)}I(),m.ready()}}()}return H.promise(b)};var K="undefined",L;for(L in m(k))break;k.ownLast="0"!==L,k.inlineBlockNeedsLayout=!1,m(function(){var a,b,c,d;c=y.getElementsByTagName("body")[0],c&&c.style&&(b=y.createElement("div"),d=y.createElement("div"),d.style.cssText="position:absolute;border:0;width:0;height:0;top:0;left:-9999px",c.appendChild(d).appendChild(b),typeof b.style.zoom!==K&&(b.style.cssText="display:inline;margin:0;border:0;padding:1px;width:1px;zoom:1",k.inlineBlockNeedsLayout=a=3===b.offsetWidth,a&&(c.style.zoom=1)),c.removeChild(d))}),function(){var a=y.createElement("div");if(null==k.deleteExpando){k.deleteExpando=!0;try{delete a.test}catch(b){k.deleteExpando=!1}}a=null}(),m.acceptData=function(a){var b=m.noData[(a.nodeName+" ").toLowerCase()],c=+a.nodeType||1;return 1!==c&&9!==c?!1:!b||b!==!0&&a.getAttribute("classid")===b};var M=/^(?:\{[\w\W]*\}|\[[\w\W]*\])$/,N=/([A-Z])/g;function O(a,b,c){if(void 0===c&&1===a.nodeType){var d="data-"+b.replace(N,"-$1").toLowerCase();if(c=a.getAttribute(d),"string"==typeof c){try{c="true"===c?!0:"false"===c?!1:"null"===c?null:+c+""===c?+c:M.test(c)?m.parseJSON(c):c}catch(e){}m.data(a,b,c)}else c=void 0}return c}function P(a){var b;for(b in a)if(("data"!==b||!m.isEmptyObject(a[b]))&&"toJSON"!==b)return!1;

return!0}function Q(a,b,d,e){if(m.acceptData(a)){var f,g,h=m.expando,i=a.nodeType,j=i?m.cache:a,k=i?a[h]:a[h]&&h;if(k&&j[k]&&(e||j[k].data)||void 0!==d||"string"!=typeof b)return k||(k=i?a[h]=c.pop()||m.guid++:h),j[k]||(j[k]=i?{}:{toJSON:m.noop}),("object"==typeof b||"function"==typeof b)&&(e?j[k]=m.extend(j[k],b):j[k].data=m.extend(j[k].data,b)),g=j[k],e||(g.data||(g.data={}),g=g.data),void 0!==d&&(g[m.camelCase(b)]=d),"string"==typeof b?(f=g[b],null==f&&(f=g[m.camelCase(b)])):f=g,f}}function R(a,b,c){if(m.acceptData(a)){var d,e,f=a.nodeType,g=f?m.cache:a,h=f?a[m.expando]:m.expando;if(g[h]){if(b&&(d=c?g[h]:g[h].data)){m.isArray(b)?b=b.concat(m.map(b,m.camelCase)):b in d?b=[b]:(b=m.camelCase(b),b=b in d?[b]:b.split(" ")),e=b.length;while(e--)delete d[b[e]];if(c?!P(d):!m.isEmptyObject(d))return}(c||(delete g[h].data,P(g[h])))&&(f?m.cleanData([a],!0):k.deleteExpando||g!=g.window?delete g[h]:g[h]=null)}}}m.extend({cache:{},noData:{"applet ":!0,"embed ":!0,"object ":"clsid:D27CDB6E-AE6D-11cf-96B8-444553540000"},hasData:function(a){return a=a.nodeType?m.cache[a[m.expando]]:a[m.expando],!!a&&!P(a)},data:function(a,b,c){return Q(a,b,c)},removeData:function(a,b){return R(a,b)},_data:function(a,b,c){return Q(a,b,c,!0)},_removeData:function(a,b){return R(a,b,!0)}}),m.fn.extend({data:function(a,b){var c,d,e,f=this[0],g=f&&f.attributes;if(void 0===a){if(this.length&&(e=m.data(f),1===f.nodeType&&!m._data(f,"parsedAttrs"))){c=g.length;while(c--)g[c]&&(d=g[c].name,0===d.indexOf("data-")&&(d=m.camelCase(d.slice(5)),O(f,d,e[d])));m._data(f,"parsedAttrs",!0)}return e}return"object"==typeof a?this.each(function(){m.data(this,a)}):arguments.length>1?this.each(function(){m.data(this,a,b)}):f?O(f,a,m.data(f,a)):void 0},removeData:function(a){return this.each(function(){m.removeData(this,a)})}}),m.extend({queue:function(a,b,c){var d;return a?(b=(b||"fx")+"queue",d=m._data(a,b),c&&(!d||m.isArray(c)?d=m._data(a,b,m.makeArray(c)):d.push(c)),d||[]):void 0},dequeue:function(a,b){b=b||"fx";var c=m.queue(a,b),d=c.length,e=c.shift(),f=m._queueHooks(a,b),g=function(){m.dequeue(a,b)};"inprogress"===e&&(e=c.shift(),d--),e&&("fx"===b&&c.unshift("inprogress"),delete f.stop,e.call(a,g,f)),!d&&f&&f.empty.fire()},_queueHooks:function(a,b){var c=b+"queueHooks";return m._data(a,c)||m._data(a,c,{empty:m.Callbacks("once memory").add(function(){m._removeData(a,b+"queue"),m._removeData(a,c)})})}}),m.fn.extend({queue:function(a,b){var c=2;return"string"!=typeof a&&(b=a,a="fx",c--),arguments.length<c?m.queue(this[0],a):void 0===b?this:this.each(function(){var c=m.queue(this,a,b);m._queueHooks(this,a),"fx"===a&&"inprogress"!==c[0]&&m.dequeue(this,a)})},dequeue:function(a){return this.each(function(){m.dequeue(this,a)})},clearQueue:function(a){return this.queue(a||"fx",[])},promise:function(a,b){var c,d=1,e=m.Deferred(),f=this,g=this.length,h=function(){--d||e.resolveWith(f,[f])};"string"!=typeof a&&(b=a,a=void 0),a=a||"fx";while(g--)c=m._data(f[g],a+"queueHooks"),c&&c.empty&&(d++,c.empty.add(h));return h(),e.promise(b)}});var S=/[+-]?(?:\d*\.|)\d+(?:[eE][+-]?\d+|)/.source,T=["Top","Right","Bottom","Left"],U=function(a,b){return a=b||a,"none"===m.css(a,"display")||!m.contains(a.ownerDocument,a)},V=m.access=function(a,b,c,d,e,f,g){var h=0,i=a.length,j=null==c;if("object"===m.type(c)){e=!0;for(h in c)m.access(a,b,h,c[h],!0,f,g)}else if(void 0!==d&&(e=!0,m.isFunction(d)||(g=!0),j&&(g?(b.call(a,d),b=null):(j=b,b=function(a,b,c){return j.call(m(a),c)})),b))for(;i>h;h++)b(a[h],c,g?d:d.call(a[h],h,b(a[h],c)));return e?a:j?b.call(a):i?b(a[0],c):f},W=/^(?:checkbox|radio)$/i;!function(){var a=y.createElement("input"),b=y.createElement("div"),c=y.createDocumentFragment();if(b.innerHTML="  <link/><table></table><a href='/a'>a</a><input type='checkbox'/>",k.leadingWhitespace=3===b.firstChild.nodeType,k.tbody=!b.getElementsByTagName("tbody").length,k.htmlSerialize=!!b.getElementsByTagName("link").length,k.html5Clone="<:nav></:nav>"!==y.createElement("nav").cloneNode(!0).outerHTML,a.type="checkbox",a.checked=!0,c.appendChild(a),k.appendChecked=a.checked,b.innerHTML="<textarea>x</textarea>",k.noCloneChecked=!!b.cloneNode(!0).lastChild.defaultValue,c.appendChild(b),b.innerHTML="<input type='radio' checked='checked' name='t'/>",k.checkClone=b.cloneNode(!0).cloneNode(!0).lastChild.checked,k.noCloneEvent=!0,b.attachEvent&&(b.attachEvent("onclick",function(){k.noCloneEvent=!1}),b.cloneNode(!0).click()),null==k.deleteExpando){k.deleteExpando=!0;try{delete b.test}catch(d){k.deleteExpando=!1}}}(),function(){var b,c,d=y.createElement("div");for(b in{submit:!0,change:!0,focusin:!0})c="on"+b,(k[b+"Bubbles"]=c in a)||(d.setAttribute(c,"t"),k[b+"Bubbles"]=d.attributes[c].expando===!1);d=null}();var X=/^(?:input|select|textarea)$/i,Y=/^key/,Z=/^(?:mouse|pointer|contextmenu)|click/,$=/^(?:focusinfocus|focusoutblur)$/,_=/^([^.]*)(?:\.(.+)|)$/;function aa(){return!0}function ba(){return!1}function ca(){try{return y.activeElement}catch(a){}}m.event={global:{},add:function(a,b,c,d,e){var f,g,h,i,j,k,l,n,o,p,q,r=m._data(a);if(r){c.handler&&(i=c,c=i.handler,e=i.selector),c.guid||(c.guid=m.guid++),(g=r.events)||(g=r.events={}),(k=r.handle)||(k=r.handle=function(a){return typeof m===K||a&&m.event.triggered===a.type?void 0:m.event.dispatch.apply(k.elem,arguments)},k.elem=a),b=(b||"").match(E)||[""],h=b.length;while(h--)f=_.exec(b[h])||[],o=q=f[1],p=(f[2]||"").split(".").sort(),o&&(j=m.event.special[o]||{},o=(e?j.delegateType:j.bindType)||o,j=m.event.special[o]||{},l=m.extend({type:o,origType:q,data:d,handler:c,guid:c.guid,selector:e,needsContext:e&&m.expr.match.needsContext.test(e),namespace:p.join(".")},i),(n=g[o])||(n=g[o]=[],n.delegateCount=0,j.setup&&j.setup.call(a,d,p,k)!==!1||(a.addEventListener?a.addEventListener(o,k,!1):a.attachEvent&&a.attachEvent("on"+o,k))),j.add&&(j.add.call(a,l),l.handler.guid||(l.handler.guid=c.guid)),e?n.splice(n.delegateCount++,0,l):n.push(l),m.event.global[o]=!0);a=null}},remove:function(a,b,c,d,e){var f,g,h,i,j,k,l,n,o,p,q,r=m.hasData(a)&&m._data(a);if(r&&(k=r.events)){b=(b||"").match(E)||[""],j=b.length;while(j--)if(h=_.exec(b[j])||[],o=q=h[1],p=(h[2]||"").split(".").sort(),o){l=m.event.special[o]||{},o=(d?l.delegateType:l.bindType)||o,n=k[o]||[],h=h[2]&&new RegExp("(^|\\.)"+p.join("\\.(?:.*\\.|)")+"(\\.|$)"),i=f=n.length;while(f--)g=n[f],!e&&q!==g.origType||c&&c.guid!==g.guid||h&&!h.test(g.namespace)||d&&d!==g.selector&&("**"!==d||!g.selector)||(n.splice(f,1),g.selector&&n.delegateCount--,l.remove&&l.remove.call(a,g));i&&!n.length&&(l.teardown&&l.teardown.call(a,p,r.handle)!==!1||m.removeEvent(a,o,r.handle),delete k[o])}else for(o in k)m.event.remove(a,o+b[j],c,d,!0);m.isEmptyObject(k)&&(delete r.handle,m._removeData(a,"events"))}},trigger:function(b,c,d,e){var f,g,h,i,k,l,n,o=[d||y],p=j.call(b,"type")?b.type:b,q=j.call(b,"namespace")?b.namespace.split("."):[];if(h=l=d=d||y,3!==d.nodeType&&8!==d.nodeType&&!$.test(p+m.event.triggered)&&(p.indexOf(".")>=0&&(q=p.split("."),p=q.shift(),q.sort()),g=p.indexOf(":")<0&&"on"+p,b=b[m.expando]?b:new m.Event(p,"object"==typeof b&&b),b.isTrigger=e?2:3,b.namespace=q.join("."),b.namespace_re=b.namespace?new RegExp("(^|\\.)"+q.join("\\.(?:.*\\.|)")+"(\\.|$)"):null,b.result=void 0,b.target||(b.target=d),c=null==c?[b]:m.makeArray(c,[b]),k=m.event.special[p]||{},e||!k.trigger||k.trigger.apply(d,c)!==!1)){if(!e&&!k.noBubble&&!m.isWindow(d)){for(i=k.delegateType||p,$.test(i+p)||(h=h.parentNode);h;h=h.parentNode)o.push(h),l=h;l===(d.ownerDocument||y)&&o.push(l.defaultView||l.parentWindow||a)}n=0;while((h=o[n++])&&!b.isPropagationStopped())b.type=n>1?i:k.bindType||p,f=(m._data(h,"events")||{})[b.type]&&m._data(h,"handle"),f&&f.apply(h,c),f=g&&h[g],f&&f.apply&&m.acceptData(h)&&(b.result=f.apply(h,c),b.result===!1&&b.preventDefault());if(b.type=p,!e&&!b.isDefaultPrevented()&&(!k._default||k._default.apply(o.pop(),c)===!1)&&m.acceptData(d)&&g&&d[p]&&!m.isWindow(d)){l=d[g],l&&(d[g]=null),m.event.triggered=p;try{d[p]()}catch(r){}m.event.triggered=void 0,l&&(d[g]=l)}return b.result}},dispatch:function(a){a=m.event.fix(a);var b,c,e,f,g,h=[],i=d.call(arguments),j=(m._data(this,"events")||{})[a.type]||[],k=m.event.special[a.type]||{};if(i[0]=a,a.delegateTarget=this,!k.preDispatch||k.preDispatch.call(this,a)!==!1){h=m.event.handlers.call(this,a,j),b=0;while((f=h[b++])&&!a.isPropagationStopped()){a.currentTarget=f.elem,g=0;while((e=f.handlers[g++])&&!a.isImmediatePropagationStopped())(!a.namespace_re||a.namespace_re.test(e.namespace))&&(a.handleObj=e,a.data=e.data,c=((m.event.special[e.origType]||{}).handle||e.handler).apply(f.elem,i),void 0!==c&&(a.result=c)===!1&&(a.preventDefault(),a.stopPropagation()))}return k.postDispatch&&k.postDispatch.call(this,a),a.result}},handlers:function(a,b){var c,d,e,f,g=[],h=b.delegateCount,i=a.target;if(h&&i.nodeType&&(!a.button||"click"!==a.type))for(;i!=this;i=i.parentNode||this)if(1===i.nodeType&&(i.disabled!==!0||"click"!==a.type)){for(e=[],f=0;h>f;f++)d=b[f],c=d.selector+" ",void 0===e[c]&&(e[c]=d.needsContext?m(c,this).index(i)>=0:m.find(c,this,null,[i]).length),e[c]&&e.push(d);e.length&&g.push({elem:i,handlers:e})}return h<b.length&&g.push({elem:this,handlers:b.slice(h)}),g},fix:function(a){if(a[m.expando])return a;var b,c,d,e=a.type,f=a,g=this.fixHooks[e];g||(this.fixHooks[e]=g=Z.test(e)?this.mouseHooks:Y.test(e)?this.keyHooks:{}),d=g.props?this.props.concat(g.props):this.props,a=new m.Event(f),b=d.length;while(b--)c=d[b],a[c]=f[c];return a.target||(a.target=f.srcElement||y),3===a.target.nodeType&&(a.target=a.target.parentNode),a.metaKey=!!a.metaKey,g.filter?g.filter(a,f):a},props:"altKey bubbles cancelable ctrlKey currentTarget eventPhase metaKey relatedTarget shiftKey target timeStamp view which".split(" "),fixHooks:{},keyHooks:{props:"char charCode key keyCode".split(" "),filter:function(a,b){return null==a.which&&(a.which=null!=b.charCode?b.charCode:b.keyCode),a}},mouseHooks:{props:"button buttons clientX clientY fromElement offsetX offsetY pageX pageY screenX screenY toElement".split(" "),filter:function(a,b){var c,d,e,f=b.button,g=b.fromElement;return null==a.pageX&&null!=b.clientX&&(d=a.target.ownerDocument||y,e=d.documentElement,c=d.body,a.pageX=b.clientX+(e&&e.scrollLeft||c&&c.scrollLeft||0)-(e&&e.clientLeft||c&&c.clientLeft||0),a.pageY=b.clientY+(e&&e.scrollTop||c&&c.scrollTop||0)-(e&&e.clientTop||c&&c.clientTop||0)),!a.relatedTarget&&g&&(a.relatedTarget=g===a.target?b.toElement:g),a.which||void 0===f||(a.which=1&f?1:2&f?3:4&f?2:0),a}},special:{load:{noBubble:!0},focus:{trigger:function(){if(this!==ca()&&this.focus)try{return this.focus(),!1}catch(a){}},delegateType:"focusin"},blur:{trigger:function(){return this===ca()&&this.blur?(this.blur(),!1):void 0},delegateType:"focusout"},click:{trigger:function(){return m.nodeName(this,"input")&&"checkbox"===this.type&&this.click?(this.click(),!1):void 0},_default:function(a){return m.nodeName(a.target,"a")}},beforeunload:{postDispatch:function(a){void 0!==a.result&&a.originalEvent&&(a.originalEvent.returnValue=a.result)}}},simulate:function(a,b,c,d){var e=m.extend(new m.Event,c,{type:a,isSimulated:!0,originalEvent:{}});d?m.event.trigger(e,null,b):m.event.dispatch.call(b,e),e.isDefaultPrevented()&&c.preventDefault()}},m.removeEvent=y.removeEventListener?function(a,b,c){a.removeEventListener&&a.removeEventListener(b,c,!1)}:function(a,b,c){var d="on"+b;a.detachEvent&&(typeof a[d]===K&&(a[d]=null),a.detachEvent(d,c))},m.Event=function(a,b){return this instanceof m.Event?(a&&a.type?(this.originalEvent=a,this.type=a.type,this.isDefaultPrevented=a.defaultPrevented||void 0===a.defaultPrevented&&a.returnValue===!1?aa:ba):this.type=a,b&&m.extend(this,b),this.timeStamp=a&&a.timeStamp||m.now(),void(this[m.expando]=!0)):new m.Event(a,b)},m.Event.prototype={isDefaultPrevented:ba,isPropagationStopped:ba,isImmediatePropagationStopped:ba,preventDefault:function(){var a=this.originalEvent;this.isDefaultPrevented=aa,a&&(a.preventDefault?a.preventDefault():a.returnValue=!1)},stopPropagation:function(){var a=this.originalEvent;this.isPropagationStopped=aa,a&&(a.stopPropagation&&a.stopPropagation(),a.cancelBubble=!0)},stopImmediatePropagation:function(){var a=this.originalEvent;this.isImmediatePropagationStopped=aa,a&&a.stopImmediatePropagation&&a.stopImmediatePropagation(),this.stopPropagation()}},m.each({mouseenter:"mouseover",mouseleave:"mouseout",pointerenter:"pointerover",pointerleave:"pointerout"},function(a,b){m.event.special[a]={delegateType:b,bindType:b,handle:function(a){var c,d=this,e=a.relatedTarget,f=a.handleObj;return(!e||e!==d&&!m.contains(d,e))&&(a.type=f.origType,c=f.handler.apply(this,arguments),a.type=b),c}}}),k.submitBubbles||(m.event.special.submit={setup:function(){return m.nodeName(this,"form")?!1:void m.event.add(this,"click._submit keypress._submit",function(a){var b=a.target,c=m.nodeName(b,"input")||m.nodeName(b,"button")?b.form:void 0;c&&!m._data(c,"submitBubbles")&&(m.event.add(c,"submit._submit",function(a){a._submit_bubble=!0}),m._data(c,"submitBubbles",!0))})},postDispatch:function(a){a._submit_bubble&&(delete a._submit_bubble,this.parentNode&&!a.isTrigger&&m.event.simulate("submit",this.parentNode,a,!0))},teardown:function(){return m.nodeName(this,"form")?!1:void m.event.remove(this,"._submit")}}),k.changeBubbles||(m.event.special.change={setup:function(){return X.test(this.nodeName)?(("checkbox"===this.type||"radio"===this.type)&&(m.event.add(this,"propertychange._change",function(a){"checked"===a.originalEvent.propertyName&&(this._just_changed=!0)}),m.event.add(this,"click._change",function(a){this._just_changed&&!a.isTrigger&&(this._just_changed=!1),m.event.simulate("change",this,a,!0)})),!1):void m.event.add(this,"beforeactivate._change",function(a){var b=a.target;X.test(b.nodeName)&&!m._data(b,"changeBubbles")&&(m.event.add(b,"change._change",function(a){!this.parentNode||a.isSimulated||a.isTrigger||m.event.simulate("change",this.parentNode,a,!0)}),m._data(b,"changeBubbles",!0))})},handle:function(a){var b=a.target;return this!==b||a.isSimulated||a.isTrigger||"radio"!==b.type&&"checkbox"!==b.type?a.handleObj.handler.apply(this,arguments):void 0},teardown:function(){return m.event.remove(this,"._change"),!X.test(this.nodeName)}}),k.focusinBubbles||m.each({focus:"focusin",blur:"focusout"},function(a,b){var c=function(a){m.event.simulate(b,a.target,m.event.fix(a),!0)};m.event.special[b]={setup:function(){var d=this.ownerDocument||this,e=m._data(d,b);e||d.addEventListener(a,c,!0),m._data(d,b,(e||0)+1)},teardown:function(){var d=this.ownerDocument||this,e=m._data(d,b)-1;e?m._data(d,b,e):(d.removeEventListener(a,c,!0),m._removeData(d,b))}}}),m.fn.extend({on:function(a,b,c,d,e){var f,g;if("object"==typeof a){"string"!=typeof b&&(c=c||b,b=void 0);for(f in a)this.on(f,b,c,a[f],e);return this}if(null==c&&null==d?(d=b,c=b=void 0):null==d&&("string"==typeof b?(d=c,c=void 0):(d=c,c=b,b=void 0)),d===!1)d=ba;else if(!d)return this;return 1===e&&(g=d,d=function(a){return m().off(a),g.apply(this,arguments)},d.guid=g.guid||(g.guid=m.guid++)),this.each(function(){m.event.add(this,a,d,c,b)})},one:function(a,b,c,d){return this.on(a,b,c,d,1)},off:function(a,b,c){var d,e;if(a&&a.preventDefault&&a.handleObj)return d=a.handleObj,m(a.delegateTarget).off(d.namespace?d.origType+"."+d.namespace:d.origType,d.selector,d.handler),this;if("object"==typeof a){for(e in a)this.off(e,b,a[e]);return this}return(b===!1||"function"==typeof b)&&(c=b,b=void 0),c===!1&&(c=ba),this.each(function(){m.event.remove(this,a,c,b)})},trigger:function(a,b){return this.each(function(){m.event.trigger(a,b,this)})},triggerHandler:function(a,b){var c=this[0];return c?m.event.trigger(a,b,c,!0):void 0}});function da(a){var b=ea.split("|"),c=a.createDocumentFragment();if(c.createElement)while(b.length)c.createElement(b.pop());return c}var ea="abbr|article|aside|audio|bdi|canvas|data|datalist|details|figcaption|figure|footer|header|hgroup|mark|meter|nav|output|progress|section|summary|time|video",fa=/ jQuery\d+="(?:null|\d+)"/g,ga=new RegExp("<(?:"+ea+")[\\s/>]","i"),ha=/^\s+/,ia=/<(?!area|br|col|embed|hr|img|input|link|meta|param)(([\w:]+)[^>]*)\/>/gi,ja=/<([\w:]+)/,ka=/<tbody/i,la=/<|&#?\w+;/,ma=/<(?:script|style|link)/i,na=/checked\s*(?:[^=]|=\s*.checked.)/i,oa=/^$|\/(?:java|ecma)script/i,pa=/^true\/(.*)/,qa=/^\s*<!(?:\[CDATA\[|--)|(?:\]\]|--)>\s*$/g,ra={option:[1,"<select multiple='multiple'>","</select>"],legend:[1,"<fieldset>","</fieldset>"],area:[1,"<map>","</map>"],param:[1,"<object>","</object>"],thead:[1,"<table>","</table>"],tr:[2,"<table><tbody>","</tbody></table>"],col:[2,"<table><tbody></tbody><colgroup>","</colgroup></table>"],td:[3,"<table><tbody><tr>","</tr></tbody></table>"],_default:k.htmlSerialize?[0,"",""]:[1,"X<div>","</div>"]},sa=da(y),ta=sa.appendChild(y.createElement("div"));ra.optgroup=ra.option,ra.tbody=ra.tfoot=ra.colgroup=ra.caption=ra.thead,ra.th=ra.td;function ua(a,b){var c,d,e=0,f=typeof a.getElementsByTagName!==K?a.getElementsByTagName(b||"*"):typeof a.querySelectorAll!==K?a.querySelectorAll(b||"*"):void 0;if(!f)for(f=[],c=a.childNodes||a;null!=(d=c[e]);e++)!b||m.nodeName(d,b)?f.push(d):m.merge(f,ua(d,b));return void 0===b||b&&m.nodeName(a,b)?m.merge([a],f):f}function va(a){W.test(a.type)&&(a.defaultChecked=a.checked)}function wa(a,b){return m.nodeName(a,"table")&&m.nodeName(11!==b.nodeType?b:b.firstChild,"tr")?a.getElementsByTagName("tbody")[0]||a.appendChild(a.ownerDocument.createElement("tbody")):a}function xa(a){return a.type=(null!==m.find.attr(a,"type"))+"/"+a.type,a}function ya(a){var b=pa.exec(a.type);return b?a.type=b[1]:a.removeAttribute("type"),a}function za(a,b){for(var c,d=0;null!=(c=a[d]);d++)m._data(c,"globalEval",!b||m._data(b[d],"globalEval"))}function Aa(a,b){if(1===b.nodeType&&m.hasData(a)){var c,d,e,f=m._data(a),g=m._data(b,f),h=f.events;if(h){delete g.handle,g.events={};for(c in h)for(d=0,e=h[c].length;e>d;d++)m.event.add(b,c,h[c][d])}g.data&&(g.data=m.extend({},g.data))}}function Ba(a,b){var c,d,e;if(1===b.nodeType){if(c=b.nodeName.toLowerCase(),!k.noCloneEvent&&b[m.expando]){e=m._data(b);for(d in e.events)m.removeEvent(b,d,e.handle);b.removeAttribute(m.expando)}"script"===c&&b.text!==a.text?(xa(b).text=a.text,ya(b)):"object"===c?(b.parentNode&&(b.outerHTML=a.outerHTML),k.html5Clone&&a.innerHTML&&!m.trim(b.innerHTML)&&(b.innerHTML=a.innerHTML)):"input"===c&&W.test(a.type)?(b.defaultChecked=b.checked=a.checked,b.value!==a.value&&(b.value=a.value)):"option"===c?b.defaultSelected=b.selected=a.defaultSelected:("input"===c||"textarea"===c)&&(b.defaultValue=a.defaultValue)}}m.extend({clone:function(a,b,c){var d,e,f,g,h,i=m.contains(a.ownerDocument,a);if(k.html5Clone||m.isXMLDoc(a)||!ga.test("<"+a.nodeName+">")?f=a.cloneNode(!0):(ta.innerHTML=a.outerHTML,ta.removeChild(f=ta.firstChild)),!(k.noCloneEvent&&k.noCloneChecked||1!==a.nodeType&&11!==a.nodeType||m.isXMLDoc(a)))for(d=ua(f),h=ua(a),g=0;null!=(e=h[g]);++g)d[g]&&Ba(e,d[g]);if(b)if(c)for(h=h||ua(a),d=d||ua(f),g=0;null!=(e=h[g]);g++)Aa(e,d[g]);else Aa(a,f);return d=ua(f,"script"),d.length>0&&za(d,!i&&ua(a,"script")),d=h=e=null,f},buildFragment:function(a,b,c,d){for(var e,f,g,h,i,j,l,n=a.length,o=da(b),p=[],q=0;n>q;q++)if(f=a[q],f||0===f)if("object"===m.type(f))m.merge(p,f.nodeType?[f]:f);else if(la.test(f)){h=h||o.appendChild(b.createElement("div")),i=(ja.exec(f)||["",""])[1].toLowerCase(),l=ra[i]||ra._default,h.innerHTML=l[1]+f.replace(ia,"<$1></$2>")+l[2],e=l[0];while(e--)h=h.lastChild;if(!k.leadingWhitespace&&ha.test(f)&&p.push(b.createTextNode(ha.exec(f)[0])),!k.tbody){f="table"!==i||ka.test(f)?"<table>"!==l[1]||ka.test(f)?0:h:h.firstChild,e=f&&f.childNodes.length;while(e--)m.nodeName(j=f.childNodes[e],"tbody")&&!j.childNodes.length&&f.removeChild(j)}m.merge(p,h.childNodes),h.textContent="";while(h.firstChild)h.removeChild(h.firstChild);h=o.lastChild}else p.push(b.createTextNode(f));h&&o.removeChild(h),k.appendChecked||m.grep(ua(p,"input"),va),q=0;while(f=p[q++])if((!d||-1===m.inArray(f,d))&&(g=m.contains(f.ownerDocument,f),h=ua(o.appendChild(f),"script"),g&&za(h),c)){e=0;while(f=h[e++])oa.test(f.type||"")&&c.push(f)}return h=null,o},cleanData:function(a,b){for(var d,e,f,g,h=0,i=m.expando,j=m.cache,l=k.deleteExpando,n=m.event.special;null!=(d=a[h]);h++)if((b||m.acceptData(d))&&(f=d[i],g=f&&j[f])){if(g.events)for(e in g.events)n[e]?m.event.remove(d,e):m.removeEvent(d,e,g.handle);j[f]&&(delete j[f],l?delete d[i]:typeof d.removeAttribute!==K?d.removeAttribute(i):d[i]=null,c.push(f))}}}),m.fn.extend({text:function(a){return V(this,function(a){return void 0===a?m.text(this):this.empty().append((this[0]&&this[0].ownerDocument||y).createTextNode(a))},null,a,arguments.length)},append:function(){return this.domManip(arguments,function(a){if(1===this.nodeType||11===this.nodeType||9===this.nodeType){var b=wa(this,a);b.appendChild(a)}})},prepend:function(){return this.domManip(arguments,function(a){if(1===this.nodeType||11===this.nodeType||9===this.nodeType){var b=wa(this,a);b.insertBefore(a,b.firstChild)}})},before:function(){return this.domManip(arguments,function(a){this.parentNode&&this.parentNode.insertBefore(a,this)})},after:function(){return this.domManip(arguments,function(a){this.parentNode&&this.parentNode.insertBefore(a,this.nextSibling)})},remove:function(a,b){for(var c,d=a?m.filter(a,this):this,e=0;null!=(c=d[e]);e++)b||1!==c.nodeType||m.cleanData(ua(c)),c.parentNode&&(b&&m.contains(c.ownerDocument,c)&&za(ua(c,"script")),c.parentNode.removeChild(c));return this},empty:function(){for(var a,b=0;null!=(a=this[b]);b++){1===a.nodeType&&m.cleanData(ua(a,!1));while(a.firstChild)a.removeChild(a.firstChild);a.options&&m.nodeName(a,"select")&&(a.options.length=0)}return this},clone:function(a,b){return a=null==a?!1:a,b=null==b?a:b,this.map(function(){return m.clone(this,a,b)})},html:function(a){return V(this,function(a){var b=this[0]||{},c=0,d=this.length;if(void 0===a)return 1===b.nodeType?b.innerHTML.replace(fa,""):void 0;if(!("string"!=typeof a||ma.test(a)||!k.htmlSerialize&&ga.test(a)||!k.leadingWhitespace&&ha.test(a)||ra[(ja.exec(a)||["",""])[1].toLowerCase()])){a=a.replace(ia,"<$1></$2>");try{for(;d>c;c++)b=this[c]||{},1===b.nodeType&&(m.cleanData(ua(b,!1)),b.innerHTML=a);b=0}catch(e){}}b&&this.empty().append(a)},null,a,arguments.length)},replaceWith:function(){var a=arguments[0];return this.domManip(arguments,function(b){a=this.parentNode,m.cleanData(ua(this)),a&&a.replaceChild(b,this)}),a&&(a.length||a.nodeType)?this:this.remove()},detach:function(a){return this.remove(a,!0)},domManip:function(a,b){a=e.apply([],a);var c,d,f,g,h,i,j=0,l=this.length,n=this,o=l-1,p=a[0],q=m.isFunction(p);if(q||l>1&&"string"==typeof p&&!k.checkClone&&na.test(p))return this.each(function(c){var d=n.eq(c);q&&(a[0]=p.call(this,c,d.html())),d.domManip(a,b)});if(l&&(i=m.buildFragment(a,this[0].ownerDocument,!1,this),c=i.firstChild,1===i.childNodes.length&&(i=c),c)){for(g=m.map(ua(i,"script"),xa),f=g.length;l>j;j++)d=i,j!==o&&(d=m.clone(d,!0,!0),f&&m.merge(g,ua(d,"script"))),b.call(this[j],d,j);if(f)for(h=g[g.length-1].ownerDocument,m.map(g,ya),j=0;f>j;j++)d=g[j],oa.test(d.type||"")&&!m._data(d,"globalEval")&&m.contains(h,d)&&(d.src?m._evalUrl&&m._evalUrl(d.src):m.globalEval((d.text||d.textContent||d.innerHTML||"").replace(qa,"")));i=c=null}return this}}),m.each({appendTo:"append",prependTo:"prepend",insertBefore:"before",insertAfter:"after",replaceAll:"replaceWith"},function(a,b){m.fn[a]=function(a){for(var c,d=0,e=[],g=m(a),h=g.length-1;h>=d;d++)c=d===h?this:this.clone(!0),m(g[d])[b](c),f.apply(e,c.get());return this.pushStack(e)}});var Ca,Da={};function Ea(b,c){var d,e=m(c.createElement(b)).appendTo(c.body),f=a.getDefaultComputedStyle&&(d=a.getDefaultComputedStyle(e[0]))?d.display:m.css(e[0],"display");return e.detach(),f}function Fa(a){var b=y,c=Da[a];return c||(c=Ea(a,b),"none"!==c&&c||(Ca=(Ca||m("<iframe frameborder='0' width='0' height='0'/>")).appendTo(b.documentElement),b=(Ca[0].contentWindow||Ca[0].contentDocument).document,b.write(),b.close(),c=Ea(a,b),Ca.detach()),Da[a]=c),c}!function(){var a;k.shrinkWrapBlocks=function(){if(null!=a)return a;a=!1;var b,c,d;return c=y.getElementsByTagName("body")[0],c&&c.style?(b=y.createElement("div"),d=y.createElement("div"),d.style.cssText="position:absolute;border:0;width:0;height:0;top:0;left:-9999px",c.appendChild(d).appendChild(b),typeof b.style.zoom!==K&&(b.style.cssText="-webkit-box-sizing:content-box;-moz-box-sizing:content-box;box-sizing:content-box;display:block;margin:0;border:0;padding:1px;width:1px;zoom:1",b.appendChild(y.createElement("div")).style.width="5px",a=3!==b.offsetWidth),c.removeChild(d),a):void 0}}();var Ga=/^margin/,Ha=new RegExp("^("+S+")(?!px)[a-z%]+$","i"),Ia,Ja,Ka=/^(top|right|bottom|left)$/;a.getComputedStyle?(Ia=function(b){return b.ownerDocument.defaultView.opener?b.ownerDocument.defaultView.getComputedStyle(b,null):a.getComputedStyle(b,null)},Ja=function(a,b,c){var d,e,f,g,h=a.style;return c=c||Ia(a),g=c?c.getPropertyValue(b)||c[b]:void 0,c&&(""!==g||m.contains(a.ownerDocument,a)||(g=m.style(a,b)),Ha.test(g)&&Ga.test(b)&&(d=h.width,e=h.minWidth,f=h.maxWidth,h.minWidth=h.maxWidth=h.width=g,g=c.width,h.width=d,h.minWidth=e,h.maxWidth=f)),void 0===g?g:g+""}):y.documentElement.currentStyle&&(Ia=function(a){return a.currentStyle},Ja=function(a,b,c){var d,e,f,g,h=a.style;return c=c||Ia(a),g=c?c[b]:void 0,null==g&&h&&h[b]&&(g=h[b]),Ha.test(g)&&!Ka.test(b)&&(d=h.left,e=a.runtimeStyle,f=e&&e.left,f&&(e.left=a.currentStyle.left),h.left="fontSize"===b?"1em":g,g=h.pixelLeft+"px",h.left=d,f&&(e.left=f)),void 0===g?g:g+""||"auto"});function La(a,b){return{get:function(){var c=a();if(null!=c)return c?void delete this.get:(this.get=b).apply(this,arguments)}}}!function(){var b,c,d,e,f,g,h;if(b=y.createElement("div"),b.innerHTML="  <link/><table></table><a href='/a'>a</a><input type='checkbox'/>",d=b.getElementsByTagName("a")[0],c=d&&d.style){c.cssText="float:left;opacity:.5",k.opacity="0.5"===c.opacity,k.cssFloat=!!c.cssFloat,b.style.backgroundClip="content-box",b.cloneNode(!0).style.backgroundClip="",k.clearCloneStyle="content-box"===b.style.backgroundClip,k.boxSizing=""===c.boxSizing||""===c.MozBoxSizing||""===c.WebkitBoxSizing,m.extend(k,{reliableHiddenOffsets:function(){return null==g&&i(),g},boxSizingReliable:function(){return null==f&&i(),f},pixelPosition:function(){return null==e&&i(),e},reliableMarginRight:function(){return null==h&&i(),h}});function i(){var b,c,d,i;c=y.getElementsByTagName("body")[0],c&&c.style&&(b=y.createElement("div"),d=y.createElement("div"),d.style.cssText="position:absolute;border:0;width:0;height:0;top:0;left:-9999px",c.appendChild(d).appendChild(b),b.style.cssText="-webkit-box-sizing:border-box;-moz-box-sizing:border-box;box-sizing:border-box;display:block;margin-top:1%;top:1%;border:1px;padding:1px;width:4px;position:absolute",e=f=!1,h=!0,a.getComputedStyle&&(e="1%"!==(a.getComputedStyle(b,null)||{}).top,f="4px"===(a.getComputedStyle(b,null)||{width:"4px"}).width,i=b.appendChild(y.createElement("div")),i.style.cssText=b.style.cssText="-webkit-box-sizing:content-box;-moz-box-sizing:content-box;box-sizing:content-box;display:block;margin:0;border:0;padding:0",i.style.marginRight=i.style.width="0",b.style.width="1px",h=!parseFloat((a.getComputedStyle(i,null)||{}).marginRight),b.removeChild(i)),b.innerHTML="<table><tr><td></td><td>t</td></tr></table>",i=b.getElementsByTagName("td"),i[0].style.cssText="margin:0;border:0;padding:0;display:none",g=0===i[0].offsetHeight,g&&(i[0].style.display="",i[1].style.display="none",g=0===i[0].offsetHeight),c.removeChild(d))}}}(),m.swap=function(a,b,c,d){var e,f,g={};for(f in b)g[f]=a.style[f],a.style[f]=b[f];e=c.apply(a,d||[]);for(f in b)a.style[f]=g[f];return e};var Ma=/alpha\([^)]*\)/i,Na=/opacity\s*=\s*([^)]*)/,Oa=/^(none|table(?!-c[ea]).+)/,Pa=new RegExp("^("+S+")(.*)$","i"),Qa=new RegExp("^([+-])=("+S+")","i"),Ra={position:"absolute",visibility:"hidden",display:"block"},Sa={letterSpacing:"0",fontWeight:"400"},Ta=["Webkit","O","Moz","ms"];function Ua(a,b){if(b in a)return b;var c=b.charAt(0).toUpperCase()+b.slice(1),d=b,e=Ta.length;while(e--)if(b=Ta[e]+c,b in a)return b;return d}function Va(a,b){for(var c,d,e,f=[],g=0,h=a.length;h>g;g++)d=a[g],d.style&&(f[g]=m._data(d,"olddisplay"),c=d.style.display,b?(f[g]||"none"!==c||(d.style.display=""),""===d.style.display&&U(d)&&(f[g]=m._data(d,"olddisplay",Fa(d.nodeName)))):(e=U(d),(c&&"none"!==c||!e)&&m._data(d,"olddisplay",e?c:m.css(d,"display"))));for(g=0;h>g;g++)d=a[g],d.style&&(b&&"none"!==d.style.display&&""!==d.style.display||(d.style.display=b?f[g]||"":"none"));return a}function Wa(a,b,c){var d=Pa.exec(b);return d?Math.max(0,d[1]-(c||0))+(d[2]||"px"):b}function Xa(a,b,c,d,e){for(var f=c===(d?"border":"content")?4:"width"===b?1:0,g=0;4>f;f+=2)"margin"===c&&(g+=m.css(a,c+T[f],!0,e)),d?("content"===c&&(g-=m.css(a,"padding"+T[f],!0,e)),"margin"!==c&&(g-=m.css(a,"border"+T[f]+"Width",!0,e))):(g+=m.css(a,"padding"+T[f],!0,e),"padding"!==c&&(g+=m.css(a,"border"+T[f]+"Width",!0,e)));return g}function Ya(a,b,c){var d=!0,e="width"===b?a.offsetWidth:a.offsetHeight,f=Ia(a),g=k.boxSizing&&"border-box"===m.css(a,"boxSizing",!1,f);if(0>=e||null==e){if(e=Ja(a,b,f),(0>e||null==e)&&(e=a.style[b]),Ha.test(e))return e;d=g&&(k.boxSizingReliable()||e===a.style[b]),e=parseFloat(e)||0}return e+Xa(a,b,c||(g?"border":"content"),d,f)+"px"}m.extend({cssHooks:{opacity:{get:function(a,b){if(b){var c=Ja(a,"opacity");return""===c?"1":c}}}},cssNumber:{columnCount:!0,fillOpacity:!0,flexGrow:!0,flexShrink:!0,fontWeight:!0,lineHeight:!0,opacity:!0,order:!0,orphans:!0,widows:!0,zIndex:!0,zoom:!0},cssProps:{"float":k.cssFloat?"cssFloat":"styleFloat"},style:function(a,b,c,d){if(a&&3!==a.nodeType&&8!==a.nodeType&&a.style){var e,f,g,h=m.camelCase(b),i=a.style;if(b=m.cssProps[h]||(m.cssProps[h]=Ua(i,h)),g=m.cssHooks[b]||m.cssHooks[h],void 0===c)return g&&"get"in g&&void 0!==(e=g.get(a,!1,d))?e:i[b];if(f=typeof c,"string"===f&&(e=Qa.exec(c))&&(c=(e[1]+1)*e[2]+parseFloat(m.css(a,b)),f="number"),null!=c&&c===c&&("number"!==f||m.cssNumber[h]||(c+="px"),k.clearCloneStyle||""!==c||0!==b.indexOf("background")||(i[b]="inherit"),!(g&&"set"in g&&void 0===(c=g.set(a,c,d)))))try{i[b]=c}catch(j){}}},css:function(a,b,c,d){var e,f,g,h=m.camelCase(b);return b=m.cssProps[h]||(m.cssProps[h]=Ua(a.style,h)),g=m.cssHooks[b]||m.cssHooks[h],g&&"get"in g&&(f=g.get(a,!0,c)),void 0===f&&(f=Ja(a,b,d)),"normal"===f&&b in Sa&&(f=Sa[b]),""===c||c?(e=parseFloat(f),c===!0||m.isNumeric(e)?e||0:f):f}}),m.each(["height","width"],function(a,b){m.cssHooks[b]={get:function(a,c,d){return c?Oa.test(m.css(a,"display"))&&0===a.offsetWidth?m.swap(a,Ra,function(){return Ya(a,b,d)}):Ya(a,b,d):void 0},set:function(a,c,d){var e=d&&Ia(a);return Wa(a,c,d?Xa(a,b,d,k.boxSizing&&"border-box"===m.css(a,"boxSizing",!1,e),e):0)}}}),k.opacity||(m.cssHooks.opacity={get:function(a,b){return Na.test((b&&a.currentStyle?a.currentStyle.filter:a.style.filter)||"")?.01*parseFloat(RegExp.$1)+"":b?"1":""},set:function(a,b){var c=a.style,d=a.currentStyle,e=m.isNumeric(b)?"alpha(opacity="+100*b+")":"",f=d&&d.filter||c.filter||"";c.zoom=1,(b>=1||""===b)&&""===m.trim(f.replace(Ma,""))&&c.removeAttribute&&(c.removeAttribute("filter"),""===b||d&&!d.filter)||(c.filter=Ma.test(f)?f.replace(Ma,e):f+" "+e)}}),m.cssHooks.marginRight=La(k.reliableMarginRight,function(a,b){return b?m.swap(a,{display:"inline-block"},Ja,[a,"marginRight"]):void 0}),m.each({margin:"",padding:"",border:"Width"},function(a,b){m.cssHooks[a+b]={expand:function(c){for(var d=0,e={},f="string"==typeof c?c.split(" "):[c];4>d;d++)e[a+T[d]+b]=f[d]||f[d-2]||f[0];return e}},Ga.test(a)||(m.cssHooks[a+b].set=Wa)}),m.fn.extend({css:function(a,b){return V(this,function(a,b,c){var d,e,f={},g=0;if(m.isArray(b)){for(d=Ia(a),e=b.length;e>g;g++)f[b[g]]=m.css(a,b[g],!1,d);return f}return void 0!==c?m.style(a,b,c):m.css(a,b)},a,b,arguments.length>1)},show:function(){return Va(this,!0)},hide:function(){return Va(this)},toggle:function(a){return"boolean"==typeof a?a?this.show():this.hide():this.each(function(){U(this)?m(this).show():m(this).hide()})}});function Za(a,b,c,d,e){
return new Za.prototype.init(a,b,c,d,e)}m.Tween=Za,Za.prototype={constructor:Za,init:function(a,b,c,d,e,f){this.elem=a,this.prop=c,this.easing=e||"swing",this.options=b,this.start=this.now=this.cur(),this.end=d,this.unit=f||(m.cssNumber[c]?"":"px")},cur:function(){var a=Za.propHooks[this.prop];return a&&a.get?a.get(this):Za.propHooks._default.get(this)},run:function(a){var b,c=Za.propHooks[this.prop];return this.options.duration?this.pos=b=m.easing[this.easing](a,this.options.duration*a,0,1,this.options.duration):this.pos=b=a,this.now=(this.end-this.start)*b+this.start,this.options.step&&this.options.step.call(this.elem,this.now,this),c&&c.set?c.set(this):Za.propHooks._default.set(this),this}},Za.prototype.init.prototype=Za.prototype,Za.propHooks={_default:{get:function(a){var b;return null==a.elem[a.prop]||a.elem.style&&null!=a.elem.style[a.prop]?(b=m.css(a.elem,a.prop,""),b&&"auto"!==b?b:0):a.elem[a.prop]},set:function(a){m.fx.step[a.prop]?m.fx.step[a.prop](a):a.elem.style&&(null!=a.elem.style[m.cssProps[a.prop]]||m.cssHooks[a.prop])?m.style(a.elem,a.prop,a.now+a.unit):a.elem[a.prop]=a.now}}},Za.propHooks.scrollTop=Za.propHooks.scrollLeft={set:function(a){a.elem.nodeType&&a.elem.parentNode&&(a.elem[a.prop]=a.now)}},m.easing={linear:function(a){return a},swing:function(a){return.5-Math.cos(a*Math.PI)/2}},m.fx=Za.prototype.init,m.fx.step={};var $a,_a,ab=/^(?:toggle|show|hide)$/,bb=new RegExp("^(?:([+-])=|)("+S+")([a-z%]*)$","i"),cb=/queueHooks$/,db=[ib],eb={"*":[function(a,b){var c=this.createTween(a,b),d=c.cur(),e=bb.exec(b),f=e&&e[3]||(m.cssNumber[a]?"":"px"),g=(m.cssNumber[a]||"px"!==f&&+d)&&bb.exec(m.css(c.elem,a)),h=1,i=20;if(g&&g[3]!==f){f=f||g[3],e=e||[],g=+d||1;do h=h||".5",g/=h,m.style(c.elem,a,g+f);while(h!==(h=c.cur()/d)&&1!==h&&--i)}return e&&(g=c.start=+g||+d||0,c.unit=f,c.end=e[1]?g+(e[1]+1)*e[2]:+e[2]),c}]};function fb(){return setTimeout(function(){$a=void 0}),$a=m.now()}function gb(a,b){var c,d={height:a},e=0;for(b=b?1:0;4>e;e+=2-b)c=T[e],d["margin"+c]=d["padding"+c]=a;return b&&(d.opacity=d.width=a),d}function hb(a,b,c){for(var d,e=(eb[b]||[]).concat(eb["*"]),f=0,g=e.length;g>f;f++)if(d=e[f].call(c,b,a))return d}function ib(a,b,c){var d,e,f,g,h,i,j,l,n=this,o={},p=a.style,q=a.nodeType&&U(a),r=m._data(a,"fxshow");c.queue||(h=m._queueHooks(a,"fx"),null==h.unqueued&&(h.unqueued=0,i=h.empty.fire,h.empty.fire=function(){h.unqueued||i()}),h.unqueued++,n.always(function(){n.always(function(){h.unqueued--,m.queue(a,"fx").length||h.empty.fire()})})),1===a.nodeType&&("height"in b||"width"in b)&&(c.overflow=[p.overflow,p.overflowX,p.overflowY],j=m.css(a,"display"),l="none"===j?m._data(a,"olddisplay")||Fa(a.nodeName):j,"inline"===l&&"none"===m.css(a,"float")&&(k.inlineBlockNeedsLayout&&"inline"!==Fa(a.nodeName)?p.zoom=1:p.display="inline-block")),c.overflow&&(p.overflow="hidden",k.shrinkWrapBlocks()||n.always(function(){p.overflow=c.overflow[0],p.overflowX=c.overflow[1],p.overflowY=c.overflow[2]}));for(d in b)if(e=b[d],ab.exec(e)){if(delete b[d],f=f||"toggle"===e,e===(q?"hide":"show")){if("show"!==e||!r||void 0===r[d])continue;q=!0}o[d]=r&&r[d]||m.style(a,d)}else j=void 0;if(m.isEmptyObject(o))"inline"===("none"===j?Fa(a.nodeName):j)&&(p.display=j);else{r?"hidden"in r&&(q=r.hidden):r=m._data(a,"fxshow",{}),f&&(r.hidden=!q),q?m(a).show():n.done(function(){m(a).hide()}),n.done(function(){var b;m._removeData(a,"fxshow");for(b in o)m.style(a,b,o[b])});for(d in o)g=hb(q?r[d]:0,d,n),d in r||(r[d]=g.start,q&&(g.end=g.start,g.start="width"===d||"height"===d?1:0))}}function jb(a,b){var c,d,e,f,g;for(c in a)if(d=m.camelCase(c),e=b[d],f=a[c],m.isArray(f)&&(e=f[1],f=a[c]=f[0]),c!==d&&(a[d]=f,delete a[c]),g=m.cssHooks[d],g&&"expand"in g){f=g.expand(f),delete a[d];for(c in f)c in a||(a[c]=f[c],b[c]=e)}else b[d]=e}function kb(a,b,c){var d,e,f=0,g=db.length,h=m.Deferred().always(function(){delete i.elem}),i=function(){if(e)return!1;for(var b=$a||fb(),c=Math.max(0,j.startTime+j.duration-b),d=c/j.duration||0,f=1-d,g=0,i=j.tweens.length;i>g;g++)j.tweens[g].run(f);return h.notifyWith(a,[j,f,c]),1>f&&i?c:(h.resolveWith(a,[j]),!1)},j=h.promise({elem:a,props:m.extend({},b),opts:m.extend(!0,{specialEasing:{}},c),originalProperties:b,originalOptions:c,startTime:$a||fb(),duration:c.duration,tweens:[],createTween:function(b,c){var d=m.Tween(a,j.opts,b,c,j.opts.specialEasing[b]||j.opts.easing);return j.tweens.push(d),d},stop:function(b){var c=0,d=b?j.tweens.length:0;if(e)return this;for(e=!0;d>c;c++)j.tweens[c].run(1);return b?h.resolveWith(a,[j,b]):h.rejectWith(a,[j,b]),this}}),k=j.props;for(jb(k,j.opts.specialEasing);g>f;f++)if(d=db[f].call(j,a,k,j.opts))return d;return m.map(k,hb,j),m.isFunction(j.opts.start)&&j.opts.start.call(a,j),m.fx.timer(m.extend(i,{elem:a,anim:j,queue:j.opts.queue})),j.progress(j.opts.progress).done(j.opts.done,j.opts.complete).fail(j.opts.fail).always(j.opts.always)}m.Animation=m.extend(kb,{tweener:function(a,b){m.isFunction(a)?(b=a,a=["*"]):a=a.split(" ");for(var c,d=0,e=a.length;e>d;d++)c=a[d],eb[c]=eb[c]||[],eb[c].unshift(b)},prefilter:function(a,b){b?db.unshift(a):db.push(a)}}),m.speed=function(a,b,c){var d=a&&"object"==typeof a?m.extend({},a):{complete:c||!c&&b||m.isFunction(a)&&a,duration:a,easing:c&&b||b&&!m.isFunction(b)&&b};return d.duration=m.fx.off?0:"number"==typeof d.duration?d.duration:d.duration in m.fx.speeds?m.fx.speeds[d.duration]:m.fx.speeds._default,(null==d.queue||d.queue===!0)&&(d.queue="fx"),d.old=d.complete,d.complete=function(){m.isFunction(d.old)&&d.old.call(this),d.queue&&m.dequeue(this,d.queue)},d},m.fn.extend({fadeTo:function(a,b,c,d){return this.filter(U).css("opacity",0).show().end().animate({opacity:b},a,c,d)},animate:function(a,b,c,d){var e=m.isEmptyObject(a),f=m.speed(b,c,d),g=function(){var b=kb(this,m.extend({},a),f);(e||m._data(this,"finish"))&&b.stop(!0)};return g.finish=g,e||f.queue===!1?this.each(g):this.queue(f.queue,g)},stop:function(a,b,c){var d=function(a){var b=a.stop;delete a.stop,b(c)};return"string"!=typeof a&&(c=b,b=a,a=void 0),b&&a!==!1&&this.queue(a||"fx",[]),this.each(function(){var b=!0,e=null!=a&&a+"queueHooks",f=m.timers,g=m._data(this);if(e)g[e]&&g[e].stop&&d(g[e]);else for(e in g)g[e]&&g[e].stop&&cb.test(e)&&d(g[e]);for(e=f.length;e--;)f[e].elem!==this||null!=a&&f[e].queue!==a||(f[e].anim.stop(c),b=!1,f.splice(e,1));(b||!c)&&m.dequeue(this,a)})},finish:function(a){return a!==!1&&(a=a||"fx"),this.each(function(){var b,c=m._data(this),d=c[a+"queue"],e=c[a+"queueHooks"],f=m.timers,g=d?d.length:0;for(c.finish=!0,m.queue(this,a,[]),e&&e.stop&&e.stop.call(this,!0),b=f.length;b--;)f[b].elem===this&&f[b].queue===a&&(f[b].anim.stop(!0),f.splice(b,1));for(b=0;g>b;b++)d[b]&&d[b].finish&&d[b].finish.call(this);delete c.finish})}}),m.each(["toggle","show","hide"],function(a,b){var c=m.fn[b];m.fn[b]=function(a,d,e){return null==a||"boolean"==typeof a?c.apply(this,arguments):this.animate(gb(b,!0),a,d,e)}}),m.each({slideDown:gb("show"),slideUp:gb("hide"),slideToggle:gb("toggle"),fadeIn:{opacity:"show"},fadeOut:{opacity:"hide"},fadeToggle:{opacity:"toggle"}},function(a,b){m.fn[a]=function(a,c,d){return this.animate(b,a,c,d)}}),m.timers=[],m.fx.tick=function(){var a,b=m.timers,c=0;for($a=m.now();c<b.length;c++)a=b[c],a()||b[c]!==a||b.splice(c--,1);b.length||m.fx.stop(),$a=void 0},m.fx.timer=function(a){m.timers.push(a),a()?m.fx.start():m.timers.pop()},m.fx.interval=13,m.fx.start=function(){_a||(_a=setInterval(m.fx.tick,m.fx.interval))},m.fx.stop=function(){clearInterval(_a),_a=null},m.fx.speeds={slow:600,fast:200,_default:400},m.fn.delay=function(a,b){return a=m.fx?m.fx.speeds[a]||a:a,b=b||"fx",this.queue(b,function(b,c){var d=setTimeout(b,a);c.stop=function(){clearTimeout(d)}})},function(){var a,b,c,d,e;b=y.createElement("div"),b.setAttribute("className","t"),b.innerHTML="  <link/><table></table><a href='/a'>a</a><input type='checkbox'/>",d=b.getElementsByTagName("a")[0],c=y.createElement("select"),e=c.appendChild(y.createElement("option")),a=b.getElementsByTagName("input")[0],d.style.cssText="top:1px",k.getSetAttribute="t"!==b.className,k.style=/top/.test(d.getAttribute("style")),k.hrefNormalized="/a"===d.getAttribute("href"),k.checkOn=!!a.value,k.optSelected=e.selected,k.enctype=!!y.createElement("form").enctype,c.disabled=!0,k.optDisabled=!e.disabled,a=y.createElement("input"),a.setAttribute("value",""),k.input=""===a.getAttribute("value"),a.value="t",a.setAttribute("type","radio"),k.radioValue="t"===a.value}();var lb=/\r/g;m.fn.extend({val:function(a){var b,c,d,e=this[0];{if(arguments.length)return d=m.isFunction(a),this.each(function(c){var e;1===this.nodeType&&(e=d?a.call(this,c,m(this).val()):a,null==e?e="":"number"==typeof e?e+="":m.isArray(e)&&(e=m.map(e,function(a){return null==a?"":a+""})),b=m.valHooks[this.type]||m.valHooks[this.nodeName.toLowerCase()],b&&"set"in b&&void 0!==b.set(this,e,"value")||(this.value=e))});if(e)return b=m.valHooks[e.type]||m.valHooks[e.nodeName.toLowerCase()],b&&"get"in b&&void 0!==(c=b.get(e,"value"))?c:(c=e.value,"string"==typeof c?c.replace(lb,""):null==c?"":c)}}}),m.extend({valHooks:{option:{get:function(a){var b=m.find.attr(a,"value");return null!=b?b:m.trim(m.text(a))}},select:{get:function(a){for(var b,c,d=a.options,e=a.selectedIndex,f="select-one"===a.type||0>e,g=f?null:[],h=f?e+1:d.length,i=0>e?h:f?e:0;h>i;i++)if(c=d[i],!(!c.selected&&i!==e||(k.optDisabled?c.disabled:null!==c.getAttribute("disabled"))||c.parentNode.disabled&&m.nodeName(c.parentNode,"optgroup"))){if(b=m(c).val(),f)return b;g.push(b)}return g},set:function(a,b){var c,d,e=a.options,f=m.makeArray(b),g=e.length;while(g--)if(d=e[g],m.inArray(m.valHooks.option.get(d),f)>=0)try{d.selected=c=!0}catch(h){d.scrollHeight}else d.selected=!1;return c||(a.selectedIndex=-1),e}}}}),m.each(["radio","checkbox"],function(){m.valHooks[this]={set:function(a,b){return m.isArray(b)?a.checked=m.inArray(m(a).val(),b)>=0:void 0}},k.checkOn||(m.valHooks[this].get=function(a){return null===a.getAttribute("value")?"on":a.value})});var mb,nb,ob=m.expr.attrHandle,pb=/^(?:checked|selected)$/i,qb=k.getSetAttribute,rb=k.input;m.fn.extend({attr:function(a,b){return V(this,m.attr,a,b,arguments.length>1)},removeAttr:function(a){return this.each(function(){m.removeAttr(this,a)})}}),m.extend({attr:function(a,b,c){var d,e,f=a.nodeType;if(a&&3!==f&&8!==f&&2!==f)return typeof a.getAttribute===K?m.prop(a,b,c):(1===f&&m.isXMLDoc(a)||(b=b.toLowerCase(),d=m.attrHooks[b]||(m.expr.match.bool.test(b)?nb:mb)),void 0===c?d&&"get"in d&&null!==(e=d.get(a,b))?e:(e=m.find.attr(a,b),null==e?void 0:e):null!==c?d&&"set"in d&&void 0!==(e=d.set(a,c,b))?e:(a.setAttribute(b,c+""),c):void m.removeAttr(a,b))},removeAttr:function(a,b){var c,d,e=0,f=b&&b.match(E);if(f&&1===a.nodeType)while(c=f[e++])d=m.propFix[c]||c,m.expr.match.bool.test(c)?rb&&qb||!pb.test(c)?a[d]=!1:a[m.camelCase("default-"+c)]=a[d]=!1:m.attr(a,c,""),a.removeAttribute(qb?c:d)},attrHooks:{type:{set:function(a,b){if(!k.radioValue&&"radio"===b&&m.nodeName(a,"input")){var c=a.value;return a.setAttribute("type",b),c&&(a.value=c),b}}}}}),nb={set:function(a,b,c){return b===!1?m.removeAttr(a,c):rb&&qb||!pb.test(c)?a.setAttribute(!qb&&m.propFix[c]||c,c):a[m.camelCase("default-"+c)]=a[c]=!0,c}},m.each(m.expr.match.bool.source.match(/\w+/g),function(a,b){var c=ob[b]||m.find.attr;ob[b]=rb&&qb||!pb.test(b)?function(a,b,d){var e,f;return d||(f=ob[b],ob[b]=e,e=null!=c(a,b,d)?b.toLowerCase():null,ob[b]=f),e}:function(a,b,c){return c?void 0:a[m.camelCase("default-"+b)]?b.toLowerCase():null}}),rb&&qb||(m.attrHooks.value={set:function(a,b,c){return m.nodeName(a,"input")?void(a.defaultValue=b):mb&&mb.set(a,b,c)}}),qb||(mb={set:function(a,b,c){var d=a.getAttributeNode(c);return d||a.setAttributeNode(d=a.ownerDocument.createAttribute(c)),d.value=b+="","value"===c||b===a.getAttribute(c)?b:void 0}},ob.id=ob.name=ob.coords=function(a,b,c){var d;return c?void 0:(d=a.getAttributeNode(b))&&""!==d.value?d.value:null},m.valHooks.button={get:function(a,b){var c=a.getAttributeNode(b);return c&&c.specified?c.value:void 0},set:mb.set},m.attrHooks.contenteditable={set:function(a,b,c){mb.set(a,""===b?!1:b,c)}},m.each(["width","height"],function(a,b){m.attrHooks[b]={set:function(a,c){return""===c?(a.setAttribute(b,"auto"),c):void 0}}})),k.style||(m.attrHooks.style={get:function(a){return a.style.cssText||void 0},set:function(a,b){return a.style.cssText=b+""}});var sb=/^(?:input|select|textarea|button|object)$/i,tb=/^(?:a|area)$/i;m.fn.extend({prop:function(a,b){return V(this,m.prop,a,b,arguments.length>1)},removeProp:function(a){return a=m.propFix[a]||a,this.each(function(){try{this[a]=void 0,delete this[a]}catch(b){}})}}),m.extend({propFix:{"for":"htmlFor","class":"className"},prop:function(a,b,c){var d,e,f,g=a.nodeType;if(a&&3!==g&&8!==g&&2!==g)return f=1!==g||!m.isXMLDoc(a),f&&(b=m.propFix[b]||b,e=m.propHooks[b]),void 0!==c?e&&"set"in e&&void 0!==(d=e.set(a,c,b))?d:a[b]=c:e&&"get"in e&&null!==(d=e.get(a,b))?d:a[b]},propHooks:{tabIndex:{get:function(a){var b=m.find.attr(a,"tabindex");return b?parseInt(b,10):sb.test(a.nodeName)||tb.test(a.nodeName)&&a.href?0:-1}}}}),k.hrefNormalized||m.each(["href","src"],function(a,b){m.propHooks[b]={get:function(a){return a.getAttribute(b,4)}}}),k.optSelected||(m.propHooks.selected={get:function(a){var b=a.parentNode;return b&&(b.selectedIndex,b.parentNode&&b.parentNode.selectedIndex),null}}),m.each(["tabIndex","readOnly","maxLength","cellSpacing","cellPadding","rowSpan","colSpan","useMap","frameBorder","contentEditable"],function(){m.propFix[this.toLowerCase()]=this}),k.enctype||(m.propFix.enctype="encoding");var ub=/[\t\r\n\f]/g;m.fn.extend({addClass:function(a){var b,c,d,e,f,g,h=0,i=this.length,j="string"==typeof a&&a;if(m.isFunction(a))return this.each(function(b){m(this).addClass(a.call(this,b,this.className))});if(j)for(b=(a||"").match(E)||[];i>h;h++)if(c=this[h],d=1===c.nodeType&&(c.className?(" "+c.className+" ").replace(ub," "):" ")){f=0;while(e=b[f++])d.indexOf(" "+e+" ")<0&&(d+=e+" ");g=m.trim(d),c.className!==g&&(c.className=g)}return this},removeClass:function(a){var b,c,d,e,f,g,h=0,i=this.length,j=0===arguments.length||"string"==typeof a&&a;if(m.isFunction(a))return this.each(function(b){m(this).removeClass(a.call(this,b,this.className))});if(j)for(b=(a||"").match(E)||[];i>h;h++)if(c=this[h],d=1===c.nodeType&&(c.className?(" "+c.className+" ").replace(ub," "):"")){f=0;while(e=b[f++])while(d.indexOf(" "+e+" ")>=0)d=d.replace(" "+e+" "," ");g=a?m.trim(d):"",c.className!==g&&(c.className=g)}return this},toggleClass:function(a,b){var c=typeof a;return"boolean"==typeof b&&"string"===c?b?this.addClass(a):this.removeClass(a):this.each(m.isFunction(a)?function(c){m(this).toggleClass(a.call(this,c,this.className,b),b)}:function(){if("string"===c){var b,d=0,e=m(this),f=a.match(E)||[];while(b=f[d++])e.hasClass(b)?e.removeClass(b):e.addClass(b)}else(c===K||"boolean"===c)&&(this.className&&m._data(this,"__className__",this.className),this.className=this.className||a===!1?"":m._data(this,"__className__")||"")})},hasClass:function(a){for(var b=" "+a+" ",c=0,d=this.length;d>c;c++)if(1===this[c].nodeType&&(" "+this[c].className+" ").replace(ub," ").indexOf(b)>=0)return!0;return!1}}),m.each("blur focus focusin focusout load resize scroll unload click dblclick mousedown mouseup mousemove mouseover mouseout mouseenter mouseleave change select submit keydown keypress keyup error contextmenu".split(" "),function(a,b){m.fn[b]=function(a,c){return arguments.length>0?this.on(b,null,a,c):this.trigger(b)}}),m.fn.extend({hover:function(a,b){return this.mouseenter(a).mouseleave(b||a)},bind:function(a,b,c){return this.on(a,null,b,c)},unbind:function(a,b){return this.off(a,null,b)},delegate:function(a,b,c,d){return this.on(b,a,c,d)},undelegate:function(a,b,c){return 1===arguments.length?this.off(a,"**"):this.off(b,a||"**",c)}});var vb=m.now(),wb=/\?/,xb=/(,)|(\[|{)|(}|])|"(?:[^"\\\r\n]|\\["\\\/bfnrt]|\\u[\da-fA-F]{4})*"\s*:?|true|false|null|-?(?!0\d)\d+(?:\.\d+|)(?:[eE][+-]?\d+|)/g;m.parseJSON=function(b){if(a.JSON&&a.JSON.parse)return a.JSON.parse(b+"");var c,d=null,e=m.trim(b+"");return e&&!m.trim(e.replace(xb,function(a,b,e,f){return c&&b&&(d=0),0===d?a:(c=e||b,d+=!f-!e,"")}))?Function("return "+e)():m.error("Invalid JSON: "+b)},m.parseXML=function(b){var c,d;if(!b||"string"!=typeof b)return null;try{a.DOMParser?(d=new DOMParser,c=d.parseFromString(b,"text/xml")):(c=new ActiveXObject("Microsoft.XMLDOM"),c.async="false",c.loadXML(b))}catch(e){c=void 0}return c&&c.documentElement&&!c.getElementsByTagName("parsererror").length||m.error("Invalid XML: "+b),c};var yb,zb,Ab=/#.*$/,Bb=/([?&])_=[^&]*/,Cb=/^(.*?):[ \t]*([^\r\n]*)\r?$/gm,Db=/^(?:about|app|app-storage|.+-extension|file|res|widget):$/,Eb=/^(?:GET|HEAD)$/,Fb=/^\/\//,Gb=/^([\w.+-]+:)(?:\/\/(?:[^\/?#]*@|)([^\/?#:]*)(?::(\d+)|)|)/,Hb={},Ib={},Jb="*/".concat("*");try{zb=location.href}catch(Kb){zb=y.createElement("a"),zb.href="",zb=zb.href}yb=Gb.exec(zb.toLowerCase())||[];function Lb(a){return function(b,c){"string"!=typeof b&&(c=b,b="*");var d,e=0,f=b.toLowerCase().match(E)||[];if(m.isFunction(c))while(d=f[e++])"+"===d.charAt(0)?(d=d.slice(1)||"*",(a[d]=a[d]||[]).unshift(c)):(a[d]=a[d]||[]).push(c)}}function Mb(a,b,c,d){var e={},f=a===Ib;function g(h){var i;return e[h]=!0,m.each(a[h]||[],function(a,h){var j=h(b,c,d);return"string"!=typeof j||f||e[j]?f?!(i=j):void 0:(b.dataTypes.unshift(j),g(j),!1)}),i}return g(b.dataTypes[0])||!e["*"]&&g("*")}function Nb(a,b){var c,d,e=m.ajaxSettings.flatOptions||{};for(d in b)void 0!==b[d]&&((e[d]?a:c||(c={}))[d]=b[d]);return c&&m.extend(!0,a,c),a}function Ob(a,b,c){var d,e,f,g,h=a.contents,i=a.dataTypes;while("*"===i[0])i.shift(),void 0===e&&(e=a.mimeType||b.getResponseHeader("Content-Type"));if(e)for(g in h)if(h[g]&&h[g].test(e)){i.unshift(g);break}if(i[0]in c)f=i[0];else{for(g in c){if(!i[0]||a.converters[g+" "+i[0]]){f=g;break}d||(d=g)}f=f||d}return f?(f!==i[0]&&i.unshift(f),c[f]):void 0}function Pb(a,b,c,d){var e,f,g,h,i,j={},k=a.dataTypes.slice();if(k[1])for(g in a.converters)j[g.toLowerCase()]=a.converters[g];f=k.shift();while(f)if(a.responseFields[f]&&(c[a.responseFields[f]]=b),!i&&d&&a.dataFilter&&(b=a.dataFilter(b,a.dataType)),i=f,f=k.shift())if("*"===f)f=i;else if("*"!==i&&i!==f){if(g=j[i+" "+f]||j["* "+f],!g)for(e in j)if(h=e.split(" "),h[1]===f&&(g=j[i+" "+h[0]]||j["* "+h[0]])){g===!0?g=j[e]:j[e]!==!0&&(f=h[0],k.unshift(h[1]));break}if(g!==!0)if(g&&a["throws"])b=g(b);else try{b=g(b)}catch(l){return{state:"parsererror",error:g?l:"No conversion from "+i+" to "+f}}}return{state:"success",data:b}}m.extend({active:0,lastModified:{},etag:{},ajaxSettings:{url:zb,type:"GET",isLocal:Db.test(yb[1]),global:!0,processData:!0,async:!0,contentType:"application/x-www-form-urlencoded; charset=UTF-8",accepts:{"*":Jb,text:"text/plain",html:"text/html",xml:"application/xml, text/xml",json:"application/json, text/javascript"},contents:{xml:/xml/,html:/html/,json:/json/},responseFields:{xml:"responseXML",text:"responseText",json:"responseJSON"},converters:{"* text":String,"text html":!0,"text json":m.parseJSON,"text xml":m.parseXML},flatOptions:{url:!0,context:!0}},ajaxSetup:function(a,b){return b?Nb(Nb(a,m.ajaxSettings),b):Nb(m.ajaxSettings,a)},ajaxPrefilter:Lb(Hb),ajaxTransport:Lb(Ib),ajax:function(a,b){"object"==typeof a&&(b=a,a=void 0),b=b||{};var c,d,e,f,g,h,i,j,k=m.ajaxSetup({},b),l=k.context||k,n=k.context&&(l.nodeType||l.jquery)?m(l):m.event,o=m.Deferred(),p=m.Callbacks("once memory"),q=k.statusCode||{},r={},s={},t=0,u="canceled",v={readyState:0,getResponseHeader:function(a){var b;if(2===t){if(!j){j={};while(b=Cb.exec(f))j[b[1].toLowerCase()]=b[2]}b=j[a.toLowerCase()]}return null==b?null:b},getAllResponseHeaders:function(){return 2===t?f:null},setRequestHeader:function(a,b){var c=a.toLowerCase();return t||(a=s[c]=s[c]||a,r[a]=b),this},overrideMimeType:function(a){return t||(k.mimeType=a),this},statusCode:function(a){var b;if(a)if(2>t)for(b in a)q[b]=[q[b],a[b]];else v.always(a[v.status]);return this},abort:function(a){var b=a||u;return i&&i.abort(b),x(0,b),this}};if(o.promise(v).complete=p.add,v.success=v.done,v.error=v.fail,k.url=((a||k.url||zb)+"").replace(Ab,"").replace(Fb,yb[1]+"//"),k.type=b.method||b.type||k.method||k.type,k.dataTypes=m.trim(k.dataType||"*").toLowerCase().match(E)||[""],null==k.crossDomain&&(c=Gb.exec(k.url.toLowerCase()),k.crossDomain=!(!c||c[1]===yb[1]&&c[2]===yb[2]&&(c[3]||("http:"===c[1]?"80":"443"))===(yb[3]||("http:"===yb[1]?"80":"443")))),k.data&&k.processData&&"string"!=typeof k.data&&(k.data=m.param(k.data,k.traditional)),Mb(Hb,k,b,v),2===t)return v;h=m.event&&k.global,h&&0===m.active++&&m.event.trigger("ajaxStart"),k.type=k.type.toUpperCase(),k.hasContent=!Eb.test(k.type),e=k.url,k.hasContent||(k.data&&(e=k.url+=(wb.test(e)?"&":"?")+k.data,delete k.data),k.cache===!1&&(k.url=Bb.test(e)?e.replace(Bb,"$1_="+vb++):e+(wb.test(e)?"&":"?")+"_="+vb++)),k.ifModified&&(m.lastModified[e]&&v.setRequestHeader("If-Modified-Since",m.lastModified[e]),m.etag[e]&&v.setRequestHeader("If-None-Match",m.etag[e])),(k.data&&k.hasContent&&k.contentType!==!1||b.contentType)&&v.setRequestHeader("Content-Type",k.contentType),v.setRequestHeader("Accept",k.dataTypes[0]&&k.accepts[k.dataTypes[0]]?k.accepts[k.dataTypes[0]]+("*"!==k.dataTypes[0]?", "+Jb+"; q=0.01":""):k.accepts["*"]);for(d in k.headers)v.setRequestHeader(d,k.headers[d]);if(k.beforeSend&&(k.beforeSend.call(l,v,k)===!1||2===t))return v.abort();u="abort";for(d in{success:1,error:1,complete:1})v[d](k[d]);if(i=Mb(Ib,k,b,v)){v.readyState=1,h&&n.trigger("ajaxSend",[v,k]),k.async&&k.timeout>0&&(g=setTimeout(function(){v.abort("timeout")},k.timeout));try{t=1,i.send(r,x)}catch(w){if(!(2>t))throw w;x(-1,w)}}else x(-1,"No Transport");function x(a,b,c,d){var j,r,s,u,w,x=b;2!==t&&(t=2,g&&clearTimeout(g),i=void 0,f=d||"",v.readyState=a>0?4:0,j=a>=200&&300>a||304===a,c&&(u=Ob(k,v,c)),u=Pb(k,u,v,j),j?(k.ifModified&&(w=v.getResponseHeader("Last-Modified"),w&&(m.lastModified[e]=w),w=v.getResponseHeader("etag"),w&&(m.etag[e]=w)),204===a||"HEAD"===k.type?x="nocontent":304===a?x="notmodified":(x=u.state,r=u.data,s=u.error,j=!s)):(s=x,(a||!x)&&(x="error",0>a&&(a=0))),v.status=a,v.statusText=(b||x)+"",j?o.resolveWith(l,[r,x,v]):o.rejectWith(l,[v,x,s]),v.statusCode(q),q=void 0,h&&n.trigger(j?"ajaxSuccess":"ajaxError",[v,k,j?r:s]),p.fireWith(l,[v,x]),h&&(n.trigger("ajaxComplete",[v,k]),--m.active||m.event.trigger("ajaxStop")))}return v},getJSON:function(a,b,c){return m.get(a,b,c,"json")},getScript:function(a,b){return m.get(a,void 0,b,"script")}}),m.each(["get","post"],function(a,b){m[b]=function(a,c,d,e){return m.isFunction(c)&&(e=e||d,d=c,c=void 0),m.ajax({url:a,type:b,dataType:e,data:c,success:d})}}),m._evalUrl=function(a){return m.ajax({url:a,type:"GET",dataType:"script",async:!1,global:!1,"throws":!0})},m.fn.extend({wrapAll:function(a){if(m.isFunction(a))return this.each(function(b){m(this).wrapAll(a.call(this,b))});if(this[0]){var b=m(a,this[0].ownerDocument).eq(0).clone(!0);this[0].parentNode&&b.insertBefore(this[0]),b.map(function(){var a=this;while(a.firstChild&&1===a.firstChild.nodeType)a=a.firstChild;return a}).append(this)}return this},wrapInner:function(a){return this.each(m.isFunction(a)?function(b){m(this).wrapInner(a.call(this,b))}:function(){var b=m(this),c=b.contents();c.length?c.wrapAll(a):b.append(a)})},wrap:function(a){var b=m.isFunction(a);return this.each(function(c){m(this).wrapAll(b?a.call(this,c):a)})},unwrap:function(){return this.parent().each(function(){m.nodeName(this,"body")||m(this).replaceWith(this.childNodes)}).end()}}),m.expr.filters.hidden=function(a){return a.offsetWidth<=0&&a.offsetHeight<=0||!k.reliableHiddenOffsets()&&"none"===(a.style&&a.style.display||m.css(a,"display"))},m.expr.filters.visible=function(a){return!m.expr.filters.hidden(a)};var Qb=/%20/g,Rb=/\[\]$/,Sb=/\r?\n/g,Tb=/^(?:submit|button|image|reset|file)$/i,Ub=/^(?:input|select|textarea|keygen)/i;function Vb(a,b,c,d){var e;if(m.isArray(b))m.each(b,function(b,e){c||Rb.test(a)?d(a,e):Vb(a+"["+("object"==typeof e?b:"")+"]",e,c,d)});else if(c||"object"!==m.type(b))d(a,b);else for(e in b)Vb(a+"["+e+"]",b[e],c,d)}m.param=function(a,b){var c,d=[],e=function(a,b){b=m.isFunction(b)?b():null==b?"":b,d[d.length]=encodeURIComponent(a)+"="+encodeURIComponent(b)};if(void 0===b&&(b=m.ajaxSettings&&m.ajaxSettings.traditional),m.isArray(a)||a.jquery&&!m.isPlainObject(a))m.each(a,function(){e(this.name,this.value)});else for(c in a)Vb(c,a[c],b,e);return d.join("&").replace(Qb,"+")},m.fn.extend({serialize:function(){return m.param(this.serializeArray())},serializeArray:function(){return this.map(function(){var a=m.prop(this,"elements");return a?m.makeArray(a):this}).filter(function(){var a=this.type;return this.name&&!m(this).is(":disabled")&&Ub.test(this.nodeName)&&!Tb.test(a)&&(this.checked||!W.test(a))}).map(function(a,b){var c=m(this).val();return null==c?null:m.isArray(c)?m.map(c,function(a){return{name:b.name,value:a.replace(Sb,"\r\n")}}):{name:b.name,value:c.replace(Sb,"\r\n")}}).get()}}),m.ajaxSettings.xhr=void 0!==a.ActiveXObject?function(){return!this.isLocal&&/^(get|post|head|put|delete|options)$/i.test(this.type)&&Zb()||$b()}:Zb;var Wb=0,Xb={},Yb=m.ajaxSettings.xhr();a.attachEvent&&a.attachEvent("onunload",function(){for(var a in Xb)Xb[a](void 0,!0)}),k.cors=!!Yb&&"withCredentials"in Yb,Yb=k.ajax=!!Yb,Yb&&m.ajaxTransport(function(a){if(!a.crossDomain||k.cors){var b;return{send:function(c,d){var e,f=a.xhr(),g=++Wb;if(f.open(a.type,a.url,a.async,a.username,a.password),a.xhrFields)for(e in a.xhrFields)f[e]=a.xhrFields[e];a.mimeType&&f.overrideMimeType&&f.overrideMimeType(a.mimeType),a.crossDomain||c["X-Requested-With"]||(c["X-Requested-With"]="XMLHttpRequest");for(e in c)void 0!==c[e]&&f.setRequestHeader(e,c[e]+"");f.send(a.hasContent&&a.data||null),b=function(c,e){var h,i,j;if(b&&(e||4===f.readyState))if(delete Xb[g],b=void 0,f.onreadystatechange=m.noop,e)4!==f.readyState&&f.abort();else{j={},h=f.status,"string"==typeof f.responseText&&(j.text=f.responseText);try{i=f.statusText}catch(k){i=""}h||!a.isLocal||a.crossDomain?1223===h&&(h=204):h=j.text?200:404}j&&d(h,i,j,f.getAllResponseHeaders())},a.async?4===f.readyState?setTimeout(b):f.onreadystatechange=Xb[g]=b:b()},abort:function(){b&&b(void 0,!0)}}}});function Zb(){try{return new a.XMLHttpRequest}catch(b){}}function $b(){try{return new a.ActiveXObject("Microsoft.XMLHTTP")}catch(b){}}m.ajaxSetup({accepts:{script:"text/javascript, application/javascript, application/ecmascript, application/x-ecmascript"},contents:{script:/(?:java|ecma)script/},converters:{"text script":function(a){return m.globalEval(a),a}}}),m.ajaxPrefilter("script",function(a){void 0===a.cache&&(a.cache=!1),a.crossDomain&&(a.type="GET",a.global=!1)}),m.ajaxTransport("script",function(a){if(a.crossDomain){var b,c=y.head||m("head")[0]||y.documentElement;return{send:function(d,e){b=y.createElement("script"),b.async=!0,a.scriptCharset&&(b.charset=a.scriptCharset),b.src=a.url,b.onload=b.onreadystatechange=function(a,c){(c||!b.readyState||/loaded|complete/.test(b.readyState))&&(b.onload=b.onreadystatechange=null,b.parentNode&&b.parentNode.removeChild(b),b=null,c||e(200,"success"))},c.insertBefore(b,c.firstChild)},abort:function(){b&&b.onload(void 0,!0)}}}});var _b=[],ac=/(=)\?(?=&|$)|\?\?/;m.ajaxSetup({jsonp:"callback",jsonpCallback:function(){var a=_b.pop()||m.expando+"_"+vb++;return this[a]=!0,a}}),m.ajaxPrefilter("json jsonp",function(b,c,d){var e,f,g,h=b.jsonp!==!1&&(ac.test(b.url)?"url":"string"==typeof b.data&&!(b.contentType||"").indexOf("application/x-www-form-urlencoded")&&ac.test(b.data)&&"data");return h||"jsonp"===b.dataTypes[0]?(e=b.jsonpCallback=m.isFunction(b.jsonpCallback)?b.jsonpCallback():b.jsonpCallback,h?b[h]=b[h].replace(ac,"$1"+e):b.jsonp!==!1&&(b.url+=(wb.test(b.url)?"&":"?")+b.jsonp+"="+e),b.converters["script json"]=function(){return g||m.error(e+" was not called"),g[0]},b.dataTypes[0]="json",f=a[e],a[e]=function(){g=arguments},d.always(function(){a[e]=f,b[e]&&(b.jsonpCallback=c.jsonpCallback,_b.push(e)),g&&m.isFunction(f)&&f(g[0]),g=f=void 0}),"script"):void 0}),m.parseHTML=function(a,b,c){if(!a||"string"!=typeof a)return null;"boolean"==typeof b&&(c=b,b=!1),b=b||y;var d=u.exec(a),e=!c&&[];return d?[b.createElement(d[1])]:(d=m.buildFragment([a],b,e),e&&e.length&&m(e).remove(),m.merge([],d.childNodes))};var bc=m.fn.load;m.fn.load=function(a,b,c){if("string"!=typeof a&&bc)return bc.apply(this,arguments);var d,e,f,g=this,h=a.indexOf(" ");return h>=0&&(d=m.trim(a.slice(h,a.length)),a=a.slice(0,h)),m.isFunction(b)?(c=b,b=void 0):b&&"object"==typeof b&&(f="POST"),g.length>0&&m.ajax({url:a,type:f,dataType:"html",data:b}).done(function(a){e=arguments,g.html(d?m("<div>").append(m.parseHTML(a)).find(d):a)}).complete(c&&function(a,b){g.each(c,e||[a.responseText,b,a])}),this},m.each(["ajaxStart","ajaxStop","ajaxComplete","ajaxError","ajaxSuccess","ajaxSend"],function(a,b){m.fn[b]=function(a){return this.on(b,a)}}),m.expr.filters.animated=function(a){return m.grep(m.timers,function(b){return a===b.elem}).length};var cc=a.document.documentElement;function dc(a){return m.isWindow(a)?a:9===a.nodeType?a.defaultView||a.parentWindow:!1}m.offset={setOffset:function(a,b,c){var d,e,f,g,h,i,j,k=m.css(a,"position"),l=m(a),n={};"static"===k&&(a.style.position="relative"),h=l.offset(),f=m.css(a,"top"),i=m.css(a,"left"),j=("absolute"===k||"fixed"===k)&&m.inArray("auto",[f,i])>-1,j?(d=l.position(),g=d.top,e=d.left):(g=parseFloat(f)||0,e=parseFloat(i)||0),m.isFunction(b)&&(b=b.call(a,c,h)),null!=b.top&&(n.top=b.top-h.top+g),null!=b.left&&(n.left=b.left-h.left+e),"using"in b?b.using.call(a,n):l.css(n)}},m.fn.extend({offset:function(a){if(arguments.length)return void 0===a?this:this.each(function(b){m.offset.setOffset(this,a,b)});var b,c,d={top:0,left:0},e=this[0],f=e&&e.ownerDocument;if(f)return b=f.documentElement,m.contains(b,e)?(typeof e.getBoundingClientRect!==K&&(d=e.getBoundingClientRect()),c=dc(f),{top:d.top+(c.pageYOffset||b.scrollTop)-(b.clientTop||0),left:d.left+(c.pageXOffset||b.scrollLeft)-(b.clientLeft||0)}):d},position:function(){if(this[0]){var a,b,c={top:0,left:0},d=this[0];return"fixed"===m.css(d,"position")?b=d.getBoundingClientRect():(a=this.offsetParent(),b=this.offset(),m.nodeName(a[0],"html")||(c=a.offset()),c.top+=m.css(a[0],"borderTopWidth",!0),c.left+=m.css(a[0],"borderLeftWidth",!0)),{top:b.top-c.top-m.css(d,"marginTop",!0),left:b.left-c.left-m.css(d,"marginLeft",!0)}}},offsetParent:function(){return this.map(function(){var a=this.offsetParent||cc;while(a&&!m.nodeName(a,"html")&&"static"===m.css(a,"position"))a=a.offsetParent;return a||cc})}}),m.each({scrollLeft:"pageXOffset",scrollTop:"pageYOffset"},function(a,b){var c=/Y/.test(b);m.fn[a]=function(d){return V(this,function(a,d,e){var f=dc(a);return void 0===e?f?b in f?f[b]:f.document.documentElement[d]:a[d]:void(f?f.scrollTo(c?m(f).scrollLeft():e,c?e:m(f).scrollTop()):a[d]=e)},a,d,arguments.length,null)}}),m.each(["top","left"],function(a,b){m.cssHooks[b]=La(k.pixelPosition,function(a,c){return c?(c=Ja(a,b),Ha.test(c)?m(a).position()[b]+"px":c):void 0})}),m.each({Height:"height",Width:"width"},function(a,b){m.each({padding:"inner"+a,content:b,"":"outer"+a},function(c,d){m.fn[d]=function(d,e){var f=arguments.length&&(c||"boolean"!=typeof d),g=c||(d===!0||e===!0?"margin":"border");return V(this,function(b,c,d){var e;return m.isWindow(b)?b.document.documentElement["client"+a]:9===b.nodeType?(e=b.documentElement,Math.max(b.body["scroll"+a],e["scroll"+a],b.body["offset"+a],e["offset"+a],e["client"+a])):void 0===d?m.css(b,c,g):m.style(b,c,d,g)},b,f?d:void 0,f,null)}})}),m.fn.size=function(){return this.length},m.fn.andSelf=m.fn.addBack,"function"==typeof define&&define.amd&&define("jquery",[],function(){return m});var ec=a.jQuery,fc=a.$;return m.noConflict=function(b){return a.$===m&&(a.$=fc),b&&a.jQuery===m&&(a.jQuery=ec),m},typeof b===K&&(a.jQuery=a.$=m),m});
</script>
<meta name="viewport" content="width=device-width, initial-scale=1" />
<style type="text/css">@font-face {
font-family: 'Roboto';
font-style: normal;
font-weight: 300;
src: url(data:application/x-font-truetype;base64,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) format('truetype');
}
@font-face {
font-family: 'Roboto';
font-style: normal;
font-weight: 400;
src: url(data:application/x-font-truetype;base64,AAEAAAASAQAABAAgR0RFRgUwBPIAAHGoAAAATEdQT1PO9uRJAABx9AAADQ5HU1VClCaeUgAAfwQAAACIT1MvMqCnsaYAAGkIAAAAYGNtYXDigyFaAABqUAAAAzhjdnQgJEEG5QAAcCAAAABMZnBnbWf0XKsAAG2IAAABvGdhc3AACAATAABxnAAAAAxnbHlmCBgu+gAAASwAAGImaGRteAQC+OIAAGloAAAA6GhlYWT4RqsOAABlNAAAADZoaGVhCroGfQAAaOQAAAAkaG10eIFaUZ8AAGVsAAADdmxvY2E6/CGoAABjdAAAAb5tYXhwAw4C+QAAY1QAAAAgbmFtZRBvLKkAAHBsAAABEHBvc3T/bQBkAABxfAAAACBwcmVwdKCP7AAAb0QAAADbAAUAZAAAAygFsAADAAYACQAMAA8AcbIMEBEREjmwDBCwANCwDBCwBtCwDBCwCdCwDBCwDdAAsABFWLACLxuxAhw+WbAARViwAC8bsQAQPlmyBAIAERI5sgUCABESObIHAgAREjmyCAIAERI5sQoM9LIMAgAREjmyDQIAERI5sAIQsQ4M9DAxISERIQMRAQERAQMhATUBIQMo/TwCxDb+7v66AQzkAgP+/gEC/f0FsPqkBQf9fQJ3+xECeP1eAl6IAl4AAgCg//UBewWwAAMADAAvALAARViwAi8bsQIcPlmwAEVYsAsvG7ELED5ZsgYFCitYIdgb9FmyAQYCERI5MDEBIwMzAzQ2MhYUBiImAVunDcLJN2w4OGw3AZsEFfqtLT09Wjs7AAIAiAQSAiMGAAAEAAkAGQCwAy+yAgoDERI5sAIvsAfQsAMQsAjQMDEBAyMTMwUDIxMzARUebwGMAQ4ebwGMBXj+mgHuiP6aAe4AAgB3AAAE0wWwABsAHwCPALAARViwDC8bsQwcPlmwAEVYsBAvG7EQHD5ZsABFWLACLxuxAhA+WbAARViwGi8bsRoQPlmyHQwCERI5fLAdLxiyAAMKK1gh2Bv0WbAE0LAdELAG0LAdELAL0LALL7IIAworWCHYG/RZsAsQsA7QsAsQsBLQsAgQsBTQsB0QsBbQsAAQsBjQsAgQsB7QMDEBIQMjEyM1IRMhNSETMwMhEzMDMxUjAzMVIwMjAyETIQL9/vhQj1DvAQlF/v4BHVKPUgEIUpBSzOdF4ftQkJ4BCEX++AGa/mYBmokBYosBoP5gAaD+YIv+non+ZgIjAWIAAAEAbv8wBBEGnAArAGYAsABFWLAJLxuxCRw+WbAARViwIi8bsSIQPlmyAiIJERI5sAkQsAzQsAkQsBDQsAkQshMBCitYIdgb9FmwAhCyGQEKK1gh2Bv0WbAiELAf0LAiELAm0LAiELIpAQorWCHYG/RZMDEBNCYnJiY1NDY3NTMVFhYVIzQmIyIGFRQWBBYWFRQGBxUjNSYmNTMUFjMyNgNYgZnVw7+nlai7uIZyd36FATGrUcu3lLrTuZKGg5YBd1x+M0HRoaTSFNvcF+zNjaZ7bmZ5Y3eeaqnOE7+/EefGi5Z+AAUAaf/rBYMFxQANABoAJgA0ADgAeACwAEVYsAMvG7EDHD5ZsABFWLAjLxuxIxA+WbADELAK0LAKL7IRBAorWCHYG/RZsAMQshgECitYIdgb9FmwIxCwHdCwHS+wIxCyKgQKK1gh2Bv0WbAdELIxBAorWCHYG/RZsjUjAxESObA1L7I3AyMREjmwNy8wMRM0NjMyFhUVFAYjIiY1FxQWMzI2NTU0JiIGFQE0NiAWFRUUBiAmNRcUFjMyNjU1NCYjIgYVBScBF2mng4Wlp4GCqopYSkdXVpRWAjunAQaop/78qopYSkhWV0lHWf4HaQLHaQSYg6qriEeEp6eLB05lYlVJTmZmUvzRg6moi0eDqaeLBk9lY1VKT2RjVPNCBHJCAAMAZf/sBPMFxAAeACcAMwCFALAARViwCS8bsQkcPlmwAEVYsBwvG7EcED5ZsABFWLAYLxuxGBA+WbIiHAkREjmyKgkcERI5sgMiKhESObIQKiIREjmyEQkcERI5shMcCRESObIZHAkREjmyFhEZERI5sBwQsh8BCitYIdgb9FmyIR8RERI5sAkQsjEBCitYIdgb9FkwMRM0NjcmJjU0NjMyFhUUBgcHATY1MxQHFyMnBgYjIiQFMjcBBwYVFBYDFBc3NjY1NCYjIgZldaVhQsSolsRZb2sBRESne9DeYUrHZ9X+/gHXk3r+nSGnmSJ2dkQyZExSYAGHabB1dpBHpryvhViVUk/+fYKf/6j5c0JF4ktwAakYe4J2jgPlYJBTMFc+Q1lvAAEAZwQhAP0GAAAEABAAsAMvsgIFAxESObACLzAxEwMjEzP9FYEBlQWR/pAB3wABAIX+KgKVBmsAEQAJALAOL7AELzAxEzQSEjcXBgIDBxATFhcHJicChXnwgSaSuwkBjVV1JoV57AJP4gGgAVRGenD+NP7jVf5+/uSqYHFKrgFUAAABACb+KgI3BmsAEQAJALAOL7AELzAxARQCAgcnNhITNTQCAic3FhISAjd18YQnmrsCWJ1iJ4TvdwJF3/5n/qZJcXYB8QEvINIBaQEeUHFJ/qr+ZAABABwCYQNVBbAADgAgALAARViwBC8bsQQcPlmwANAZsAAvGLAJ0BmwCS8YMDEBJTcFAzMDJRcFEwcDAycBSv7SLgEuCZkKASku/s3GfLq0fQPXWpdwAVj+o26YW/7xXgEg/udbAAABAE4AkgQ0BLYACwAaALAJL7AA0LAJELIGAQorWCHYG/RZsAPQMDEBIRUhESMRITUhETMCngGW/mq6/moBlroDDa/+NAHMrwGpAAEAHf7eATQA2wAIABcAsAkvsgQFCitYIdgb9FmwANCwAC8wMRMnNjc1MxUUBoZpXgS1Y/7eSIOLp5FlygAAAQAlAh8CDQK2AAMAEQCwAi+yAQEKK1gh2Bv0WTAxASE1IQIN/hgB6AIflwABAJD/9QF2ANEACQAbALAARViwBy8bsQcQPlmyAgUKK1gh2Bv0WTAxNzQ2MhYVFAYiJpA5cjs7cjlhMEBAMC4+PgABABL/gwMQBbAAAwATALAAL7AARViwAi8bsQIcPlkwMRcjATOxnwJgnn0GLQAAAgBz/+wECgXEAA0AGwA5ALAARViwCi8bsQocPlmwAEVYsAMvG7EDED5ZsAoQshEBCitYIdgb9FmwAxCyGAEKK1gh2Bv0WTAxARACIyICAzUQEjMyEhMnNCYjIgYHERQWMzI2NwQK3uzp4ATe7eveA7mEj46CAomLiYUDAm3+u/7EATUBM/cBQQE4/tP+xg3r19be/tjs4dTkAAEAqgAAAtkFtwAGADkAsABFWLAFLxuxBRw+WbAARViwAC8bsQAQPlmyBAAFERI5sAQvsgMBCitYIdgb9FmyAgMFERI5MDEhIxEFNSUzAtm6/osCEh0E0YmoxwAAAQBdAAAEMwXEABcATQCwAEVYsBAvG7EQHD5ZsABFWLAALxuxABA+WbIXAQorWCHYG/RZsALQsgMQFxESObAQELIJAQorWCHYG/RZsBAQsAzQshUXEBESOTAxISE1ATY2NTQmIyIGFSM0JDMyFhUUAQEhBDP8RgH4cFWKc4qZuQED2cvs/u7+egLbhQIwf59VcpKdjMn41bHX/tf+WQABAF7/7AP5BcQAJgB4ALAARViwDS8bsQ0cPlmwAEVYsBkvG7EZED5ZsgANGRESObAAL7LPAAFdsp8AAXGyLwABXbJfAAFysA0QsgYBCitYIdgb9FmwDRCwCdCwABCyJgEKK1gh2Bv0WbITJgAREjmwGRCwHNCwGRCyHwEKK1gh2Bv0WTAxATM2NjUQIyIGFSM0NjMyFhUUBgcWFhUUBCAkNTMUFjMyNjU0JicjAYaLg5b/eI+5/cPO6ntqeIP/AP5m/v+6ln6GjpyTiwMyAoZyAQCJca3l2sJfsiwmsH/E5t62c4qMg3+IAgACADUAAARQBbAACgAOAEkAsABFWLAJLxuxCRw+WbAARViwBC8bsQQQPlmyAQkEERI5sAEvsgIBCitYIdgb9FmwBtCwARCwC9CyCAYLERI5sg0JBBESOTAxATMVIxEjESE1ATMBIREHA4bKyrr9aQKMxf2BAcUWAemX/q4BUm0D8fw5AsooAAEAmv/sBC0FsAAdAGEAsABFWLABLxuxARw+WbAARViwDS8bsQ0QPlmwARCyBAEKK1gh2Bv0WbIHDQEREjmwBy+yGgEKK1gh2Bv0WbIFBxoREjmwDRCwEdCwDRCyFAEKK1gh2Bv0WbAHELAd0DAxExMhFSEDNjMyEhUUAiMiJiczFhYzMjY1NCYjIgcHzkoC6v2zLGuIx+rz2sH0Ea8RkHaBk5+EeUUxAtoC1qv+cz/++eDh/v3WvX1/sJuSsTUoAAIAhP/sBBwFsQAUACEATgCwAEVYsAAvG7EAHD5ZsABFWLANLxuxDRA+WbAAELIBAQorWCHYG/RZsgcNABESObAHL7IVAQorWCHYG/RZsA0QshwBCitYIdgb9FkwMQEVIwYEBzYzMhIVFAIjIgA1NRAAJQMiBgcVFBYzMjY1NCYDTyLY/wAUc8e+4/XO0f78AVcBU9JfoB+ieX2PkQWxnQT44YT+9NTh/vIBQf1HAZIBqQX9cHJWRLTcuJWWuQABAE0AAAQlBbAABgAyALAARViwBS8bsQUcPlmwAEVYsAEvG7EBED5ZsAUQsgMBCitYIdgb9FmyAAMFERI5MDEBASMBITUhBCX9pcICWfzsA9gFSPq4BRiYAAADAHD/7AQOBcQAFwAhACsAYQCwAEVYsBUvG7EVHD5ZsABFWLAJLxuxCRA+WbInCRUREjmwJy+yzycBXbIaAQorWCHYG/RZsgMaJxESObIPJxoREjmwCRCyHwEKK1gh2Bv0WbAVELIiAQorWCHYG/RZMDEBFAYHFhYVFAYjIiY1NDY3JiY1NDYzMhYDNCYiBhQWMzI2ASIGFRQWMjY0JgPsc2Jyhf/Q0v2BcmFw7MHA7Zeb+peTg4KU/upth4XehYoENG2qMDG8d73g4bx2vjEwqmy42Nj8oXqamPiOjwQah3RviYnejAAAAgBk//8D+AXEABcAJABYALAARViwCy8bsQscPlmwAEVYsBMvG7ETED5ZsgMTCxESObADL7IAAwsREjmwExCyFAEKK1gh2Bv0WbADELIYAQorWCHYG/RZsAsQsh8BCitYIdgb9FkwMQEGBiMiJiY1NDY2MzISERUQAAUjNTM2NiUyNjc1NCYjIgYVFBYDPjqhYH67Zm/MiNj5/rD+rSQn5fb+7l2dJJ55epSPAoBFVHzhiJLqfP69/uk2/lf+eQWcBOf6clRKtuS7mZXBAP//AIb/9QFtBEQAJgAS9gABBwAS//cDcwAQALAARViwDS8bsQ0YPlkwMf//ACn+3gFVBEQAJwAS/98DcwEGABAMAAAQALAARViwAy8bsQMYPlkwMQABAEgAwwN6BEoABgAWALAARViwBS8bsQUYPlmwAtCwAi8wMQEFFQE1ARUBCAJy/M4DMgKE/cQBe5IBesQAAAIAmAGPA9oDzwADAAcAJQCwBy+wA9CwAy+yAAEKK1gh2Bv0WbAHELIEAQorWCHYG/RZMDEBITUhESE1IQPa/L4DQvy+A0IDLqH9wKAAAAEAhgDEA9wESwAGABYAsABFWLACLxuxAhg+WbAF0LAFLzAxAQE1ARUBNQMb/WsDVvyqAooBA77+hpL+hcAAAgBL//UDdgXEABgAIQBRALAARViwEC8bsRAcPlmwAEVYsCAvG7EgED5ZshsFCitYIdgb9FmyABsQERI5sgQQABESObAQELIJAQorWCHYG/RZsBAQsAzQshUAEBESOTAxATY2Nzc2NTQmIyIGFSM2NjMyFhUUBwcGFQM0NjIWFAYiJgFlAjJNg1RuaWZ8uQLjtr3Tom1JwTdsODhsNwGad4pUh19taXdsW6LHy7GvqmxRmP7DLT09Wjs7AAACAGr+OwbWBZcANQBCAGgAsDIvsABFWLAILxuxCBA+WbAD0LIPMggREjmwDy+yBQgPERI5sAgQsjkCCitYIdgb9FmwFdCwMhCyGwIKK1gh2Bv0WbAIELAq0LAqL7IjAgorWCHYG/RZsA8QskACCitYIdgb9FkwMQEGAiMiJwYGIyImNzYSNjMyFhcDBjMyNjcSACEiBAIHBhIEMzI2NxcGBiMiJAITEhIkMzIEEgEGFjMyNjc3EyYjIgYGygzYtbs1NotKjpITD3m/aVGAUDQTk3GMBhP+uf6yyf7ItAsMkAEn0Vq1PCU+zWn6/pizDAzeAXzv+QFkrvvyDlFYPG8kAS44QHWZAfby/uioVVPozaUBA5QrP/3W5+C0AYUBmMf+iPb4/pPBLCNzJzLhAacBGwETAbfv4P5a/pCOmGZfCQH3He4AAAIAHAAABR0FsAAHAAoARgCwAEVYsAQvG7EEHD5ZsABFWLACLxuxAhA+WbAARViwBi8bsQYQPlmyCQQCERI5sAkvsgABCitYIdgb9FmyCgQCERI5MDEBIQMjATMBIwEhAwPN/Z6JxgIsqAItxf1NAe/4AXz+hAWw+lACGgKpAAMAqQAABIgFsAAOABYAHwBVALAARViwAS8bsQEcPlmwAEVYsAAvG7EAED5ZshcAARESObAXL7IPAQorWCHYG/RZsggPFxESObAAELIQAQorWCHYG/RZsAEQsh8BCitYIdgb9FkwMTMRITIWFRQGBxYWFRQGIwERITI2NRAhJSEyNjU0JiMhqQHc7e90ZHaJ/uj+xwE9hpv+4v7AASJ+l4yP/uQFsMTAZp0rIbmAxOACqf30i3oBB5p+bHhtAAABAHf/7ATYBcQAHABFALAARViwCy8bsQscPlmwAEVYsAMvG7EDED5ZsAsQsA/QsAsQshIBCitYIdgb9FmwAxCyGQEKK1gh2Bv0WbADELAc0DAxAQYEIyAAETU0EiQzMgAXIyYmIyICFRUUEjMyNjcE2Bv+4e7+/v7JkQEKr+gBGBfBGaeWuNHGsqCrHAHO5/sBcgE2jMsBNKX+/eWunP7w+43t/uiRtAACAKkAAATGBbAACwAVADkAsABFWLABLxuxARw+WbAARViwAC8bsQAQPlmwARCyDAEKK1gh2Bv0WbAAELINAQorWCHYG/RZMDEzESEyBBIXFRQCBAcDETMyEjU1NAInqQGbvgEknwGf/tnE08re9+nWBbCo/srJXc7+yqYCBRL7iwEU/1X4ARMCAAABAKkAAARGBbAACwBOALAARViwBi8bsQYcPlmwAEVYsAQvG7EEED5ZsgsEBhESObALL7IAAQorWCHYG/RZsAQQsgIBCitYIdgb9FmwBhCyCAEKK1gh2Bv0WTAxASERIRUhESEVIREhA+D9iQLd/GMDk/0tAncCof38nQWwnv4sAAEAqQAABC8FsAAJAEAAsABFWLAELxuxBBw+WbAARViwAi8bsQIQPlmyCQIEERI5sAkvsgABCitYIdgb9FmwBBCyBgEKK1gh2Bv0WTAxASERIxEhFSERIQPM/Z3AA4b9OgJjAoP9fQWwnv4OAAEAev/sBNwFxAAfAGIAsABFWLALLxuxCxw+WbAARViwAy8bsQMQPlmwCxCwD9CwCxCyEQEKK1gh2Bv0WbADELIYAQorWCHYG/RZsh4DCxESObAeL7QPHh8eAl20Px5PHgJdsh0BCitYIdgb9FkwMSUGBCMiJAInNRAAITIEFyMCISICAxUUEjMyNjcRITUhBNxK/vewsv7slwIBMwEW5AEWH8A2/t7BxwHgv2yiNf6vAhC/ammnATTLfwFJAWrp1gEh/vH+/3f1/t8wOQFHnAABAKkAAAUIBbAACwBVALAARViwBi8bsQYcPlmwAEVYsAovG7EKHD5ZsABFWLAALxuxABA+WbAARViwBC8bsQQQPlmwABCwCdCwCS+ynwkBcrIvCQFdsgIBCitYIdgb9FkwMSEjESERIxEzESERMwUIwf0iwMAC3sECof1fBbD9jgJyAAABALcAAAF3BbAAAwAdALAARViwAi8bsQIcPlmwAEVYsAAvG7EAED5ZMDEhIxEzAXfAwAWwAAABADX/7APMBbAADwAuALAARViwAC8bsQAcPlmwAEVYsAUvG7EFED5ZsAnQsAUQsgwBCitYIdgb9FkwMQEzERQGIyImNTMUFjMyNjcDC8H70dnywImCd5MBBbD7+dHs3sh9jJaHAAABAKkAAAUFBbAACwB0ALAARViwBS8bsQUcPlmwAEVYsAcvG7EHHD5ZsABFWLACLxuxAhA+WbAARViwCy8bsQsQPlmyAAIFERI5QBFKAFoAagB6AIoAmgCqALoACF2yOQABXbIGBQIREjlAEzYGRgZWBmYGdgaGBpYGpga2BgldMDEBBxEjETMRATMBASMCG7LAwAKH6P3DAmrmAqW5/hQFsP0wAtD9ffzTAAEAqQAABBwFsAAFACgAsABFWLAELxuxBBw+WbAARViwAi8bsQIQPlmyAAEKK1gh2Bv0WTAxJSEVIREzAWoCsvyNwZ2dBbAAAAEAqQAABlIFsAAOAFkAsABFWLAALxuxABw+WbAARViwAi8bsQIcPlmwAEVYsAQvG7EEED5ZsABFWLAILxuxCBA+WbAARViwDC8bsQwQPlmyAQAEERI5sgcABBESObIKAAQREjkwMQkCMxEjERMBIwETESMRAaEB3AHc+cAS/iKT/iMTwAWw+1wEpPpQAjcCZPtlBJj9n/3JBbAAAAEAqQAABQgFsAAJAEyyAQoLERI5ALAARViwBS8bsQUcPlmwAEVYsAgvG7EIHD5ZsABFWLAALxuxABA+WbAARViwAy8bsQMQPlmyAgUAERI5sgcFABESOTAxISMBESMRMwERMwUIwf0jwcEC378EYvueBbD7mQRnAAIAdv/sBQkFxAARAB8AOQCwAEVYsA0vG7ENHD5ZsABFWLAELxuxBBA+WbANELIVAQorWCHYG/RZsAQQshwBCitYIdgb9FkwMQEUAgQjIiQCJzU0EiQzMgQSFScQAiMiAgcVFBIzMhI3BQmQ/viwrP72kwKSAQusrwELkL/Qu7bRA9O5uswDAqnW/sGoqQE5zmnSAUKrqf6/1QIBAwEV/uv2a/v+4QEP/QAAAgCpAAAEwAWwAAoAEwBNsgoUFRESObAKELAM0ACwAEVYsAMvG7EDHD5ZsABFWLABLxuxARA+WbILAwEREjmwCy+yAAEKK1gh2Bv0WbADELISAQorWCHYG/RZMDEBESMRITIEFRQEIyUhMjY1NCYnIQFpwAIZ7wEP/vf3/qkBWZqkpI/+nAI6/cYFsPTJ1OWdkYmCnAMAAgBt/woFBgXEABUAIgBNsggjJBESObAIELAZ0ACwAEVYsBEvG7ERHD5ZsABFWLAILxuxCBA+WbIDCBEREjmwERCyGQEKK1gh2Bv0WbAIELIgAQorWCHYG/RZMDEBFAIHBQclBiMiJAInNTQSJDMyBBIVJxACIyICBxUUEiASNwUBhnkBBIP+zUhQrP72kwKSAQussAELkMDNvrXRA9EBdMwDAqnT/s9WzHn0EqkBOc5p0gFCq6r+wdUBAQEBF/7r9mv6/uABD/0AAAIAqAAABMkFsAAOABcAYbIFGBkREjmwBRCwFtAAsABFWLAELxuxBBw+WbAARViwAi8bsQIQPlmwAEVYsA0vG7ENED5ZshAEAhESObAQL7IAAQorWCHYG/RZsgsABBESObAEELIWAQorWCHYG/RZMDEBIREjESEyBBUUBgcBFSMBITI2NTQmJyECv/6qwQHi9gEJk4MBVs79bgEnj6mhmP7aAk39swWw4NaIyjL9lgwC6pR8h5ABAAABAFD/7ARyBcQAJgBhsgAnKBESOQCwAEVYsAYvG7EGHD5ZsABFWLAaLxuxGhA+WbAGELAL0LAGELIOAQorWCHYG/RZsiYaBhESObAmELIUAQorWCHYG/RZsBoQsB/QsBoQsiIBCitYIdgb9FkwMQEmJjU0JDMyFhYVIzQmIyIGFRQWBBYWFRQEIyIkJjUzFBYzMjY0JgJW9+EBE9yW64HBqJmOn5cBa81j/uznlv78jcHDo5iilgKJR8+YrOF0zHmEl31vWXtme6RvsdVzyH+EmXzWdQAAAQAxAAAElwWwAAcALgCwAEVYsAYvG7EGHD5ZsABFWLACLxuxAhA+WbAGELIAAQorWCHYG/RZsATQMDEBIREjESE1IQSX/iy//i0EZgUS+u4FEp4AAQCM/+wEqgWwABIAPLIFExQREjkAsABFWLAALxuxABw+WbAARViwCS8bsQkcPlmwAEVYsAUvG7EFED5Zsg4BCitYIdgb9FkwMQERBgAHByIAJxEzERQWMzI2NREEqgH+/9wz7/7kAr6uoaOtBbD8Is7++hACAQLiA+D8Jp6vrp4D2wAAAQAcAAAE/QWwAAYAOLIABwgREjkAsABFWLABLxuxARw+WbAARViwBS8bsQUcPlmwAEVYsAMvG7EDED5ZsgABAxESOTAxJQEzASMBMwKLAaDS/eSq/eXR/wSx+lAFsAAAAQA9AAAG7QWwABIAWQCwAEVYsAMvG7EDHD5ZsABFWLAILxuxCBw+WbAARViwES8bsREcPlmwAEVYsAovG7EKED5ZsABFWLAPLxuxDxA+WbIBAwoREjmyBgMKERI5sg0DChESOTAxARc3ATMBFzcTMwEjAScHASMBMwHjHCkBIKIBGSgf4sH+n6/+1BcX/smv/qDAAcvArQP4/AiwxAPk+lAEJW9v+9sFsAABADkAAATOBbAACwBrALAARViwAS8bsQEcPlmwAEVYsAovG7EKHD5ZsABFWLAELxuxBBA+WbAARViwBy8bsQcQPlmyAAEEERI5QAmGAJYApgC2AARdsgYBBBESOUAJiQaZBqkGuQYEXbIDAAYREjmyCQYAERI5MDEBATMBASMBASMBATMChAFd4v40Adfk/pr+mOMB2P4z4QOCAi79Lv0iAjj9yALeAtIAAAEADwAABLsFsAAIADEAsABFWLABLxuxARw+WbAARViwBy8bsQccPlmwAEVYsAQvG7EEED5ZsgABBBESOTAxAQEzAREjEQEzAmUBfNr+CsD+CtwC1QLb/G/94QIfA5EAAAEAVgAABHoFsAAJAEQAsABFWLAHLxuxBxw+WbAARViwAi8bsQIQPlmyAAEKK1gh2Bv0WbIEAAIREjmwBxCyBQEKK1gh2Bv0WbIJBQcREjkwMSUhFSE1ASE1IRUBOQNB+9wDHvzvA/ednZAEgp6NAAABAJL+yAILBoAABwAiALAEL7AHL7IAAQorWCHYG/RZsAQQsgMBCitYIdgb9FkwMQEjETMVIREhAgu/v/6HAXkF6Pl4mAe4AAABACj/gwM4BbAAAwATALACL7AARViwAC8bsQAcPlkwMRMzASMosAJgsAWw+dMAAQAJ/sgBgwaAAAcAJQCwAi+wAS+wAhCyBQEKK1gh2Bv0WbABELIGAQorWCHYG/RZMDETIREhNTMRIwkBev6GwcEGgPhImAaIAAABAEAC2QMUBbAABgAnsgAHCBESOQCwAEVYsAMvG7EDHD5ZsADQsgEHAxESObABL7AF0DAxAQMjATMBIwGqvqwBK38BKqsEu/4eAtf9KQABAAT/aQOYAAAAAwAbALAARViwAy8bsQMQPlmyAAEKK1gh2Bv0WTAxBSE1IQOY/GwDlJeXAAABADkE2AHaBf4AAwAjALABL7IPAQFdsADQGbAALxiwARCwAtCwAi+0DwIfAgJdMDEBIwEzAdqf/v7fBNgBJgAAAgBt/+wD6gROAB4AKAB5shcpKhESObAXELAg0ACwAEVYsBcvG7EXGD5ZsABFWLAELxuxBBA+WbAARViwAC8bsQAQPlmyAhcEERI5sgsXBBESObALL7AXELIPAQorWCHYG/RZshILFxESObAEELIfAQorWCHYG/RZsAsQsiMBCitYIdgb9FkwMSEmJwYjIiY1NCQzMzU0JiMiBhUjNDY2MzIWFxEUFxUlMjY3NSMgFRQWAygQCoGzoM0BAem0dHFjhrpzxXa71AQm/gtXnCOR/qx0IFKGtYupu1Vhc2RHUZdYu6T+DpVYEI1aSN7HV2IAAgCM/+wEIAYAAA4AGQBkshIaGxESObASELAD0ACwCC+wAEVYsAwvG7EMGD5ZsABFWLADLxuxAxA+WbAARViwBi8bsQYQPlmyBQgDERI5sgoMAxESObAMELISAQorWCHYG/RZsAMQshcBCitYIdgb9FkwMQEUAiMiJwcjETMRNiASESc0JiMiBxEWMzI2BCDkwM1wCaq5cAGK4bmSibdQVbSFlAIR+P7TkX0GAP3Di/7W/v0Fvc6q/iyqzgABAFz/7APsBE4AHQBJshAeHxESOQCwAEVYsBAvG7EQGD5ZsABFWLAILxuxCBA+WbIAAQorWCHYG/RZsAgQsAPQsBAQsBTQsBAQshcBCitYIdgb9FkwMSUyNjczDgIjIgARNTQ2NjMyFhcjJiYjIgYVFRQWAj5jlAivBXbFbt3++3TZlLbxCK8Ij2mNm5qDeFpdqGQBJwEAH572iNquaYfLwCO7ygAAAgBf/+wD8AYAAA8AGgBkshgbHBESObAYELAD0ACwBi+wAEVYsAMvG7EDGD5ZsABFWLAMLxuxDBA+WbAARViwCC8bsQgQPlmyBQMMERI5sgoDDBESObAMELITAQorWCHYG/RZsAMQshgBCitYIdgb9FkwMRM0EjMyFxEzESMnBiMiAjUXFBYzMjcRJiMiBl/sv75vuaoJb8a87bmYhrBRU6yImAIm+QEvggI0+gB0iAE0+Ae40J4B8ZnSAAACAF3/7APzBE4AFQAdAGmyCB4fERI5sAgQsBbQALAARViwCC8bsQgYPlmwAEVYsAAvG7EAED5ZshoIABESObAaL7S/Gs8aAl2yDAEKK1gh2Bv0WbAAELIQAQorWCHYG/RZshMIABESObAIELIWAQorWCHYG/RZMDEFIgA1NTQ2NjMyEhEVIRYWMzI2NxcGASIGByE1JiYCTdz+7HvdgdPq/SMEs4piiDNxiP7ZcJgSAh4IiBQBIfIiof2P/ur+/U2gxVBCWNEDyqOTDo2bAAEAPAAAAsoGFQAVAGOyDxYXERI5ALAARViwCC8bsQgePlmwAEVYsAMvG7EDGD5ZsABFWLARLxuxERg+WbAARViwAC8bsQAQPlmwAxCyAQEKK1gh2Bv0WbAIELINAQorWCHYG/RZsAEQsBPQsBTQMDEzESM1MzU0NjMyFwcmIyIGFRUzFSMR56uruqpAPwovNVpi5+cDq49vrr4RlglpYnKP/FUAAgBg/lYD8gROABkAJACDsiIlJhESObAiELAL0ACwAEVYsAMvG7EDGD5ZsABFWLAGLxuxBhg+WbAARViwCy8bsQsSPlmwAEVYsBcvG7EXED5ZsgUDFxESObIPFwsREjmwCxCyEQEKK1gh2Bv0WbIVAxcREjmwFxCyHQEKK1gh2Bv0WbADELIiAQorWCHYG/RZMDETNBIzMhc3MxEUBiMiJic3FjMyNjU1BiMiAjcUFjMyNxEmIyIGYOrBxm8JqfnSdeA7YHesh5dvwL7rupaHr1JVqoeYAib9ASuMePvg0vJkV2+TmIpdgAEy87fRnwHum9IAAAEAjAAAA98GAAARAEmyChITERI5ALAQL7AARViwAi8bsQIYPlmwAEVYsAUvG7EFED5ZsABFWLAOLxuxDhA+WbIAAgUREjmwAhCyCgEKK1gh2Bv0WTAxATYzIBMRIxEmJiMiBgcRIxEzAUV7xQFXA7kBaW9aiCa5uQO3l/59/TUCzHVwYE78/QYAAAIAjQAAAWgFxAADAAwAPrIGDQ4REjmwBhCwAdAAsABFWLACLxuxAhg+WbAARViwAC8bsQAQPlmwAhCwCtCwCi+yBgUKK1gh2Bv0WTAxISMRMwM0NjIWFAYiJgFVubnIN2w4OGw3BDoBHy0+Plo8PAAC/7/+SwFZBcQADAAWAEmyEBcYERI5sBAQsADQALAARViwDC8bsQwYPlmwAEVYsAMvG7EDEj5ZsggBCitYIdgb9FmwDBCwFdCwFS+yEAUKK1gh2Bv0WTAxAREQISInNRYzMjY1EQM0NjMyFhQGIiYBS/7lPTQgND5BEzc1Njg4bDYEOvtJ/sgSlAhDUwS7AR8sPz5aPDwAAAEAjQAABAwGAAAMAHUAsABFWLAELxuxBB4+WbAARViwCC8bsQgYPlmwAEVYsAIvG7ECED5ZsABFWLALLxuxCxA+WbIACAIREjlAFToASgBaAGoAegCKAJoAqgC6AMoACl2yBggCERI5QBU2BkYGVgZmBnYGhgaWBqYGtgbGBgpdMDEBBxEjETMRNwEzAQEjAbp0ubljAVHh/lsB1tkB9Xn+hAYA/F93AWT+PP2KAAEAnAAAAVUGAAADAB0AsABFWLACLxuxAh4+WbAARViwAC8bsQAQPlkwMSEjETMBVbm5BgAAAAEAiwAABngETgAdAHeyBB4fERI5ALAARViwAy8bsQMYPlmwAEVYsAgvG7EIGD5ZsABFWLAALxuxABg+WbAARViwCy8bsQsQPlmwAEVYsBQvG7EUED5ZsABFWLAbLxuxGxA+WbIBCAsREjmyBQgLERI5sAgQshABCitYIdgb9FmwGNAwMQEXNjMyFzY2MyATESMRNCYjIgYHESMRNCMiBxEjEQE6BXfK41I2rXYBZAa5an1niAu657ZDuQQ6eIyuTmD+h/0rAsp0c3to/TICxeyb/OoEOgABAIwAAAPfBE4AEQBTsgsSExESOQCwAEVYsAMvG7EDGD5ZsABFWLAALxuxABg+WbAARViwBi8bsQYQPlmwAEVYsA8vG7EPED5ZsgEDBhESObADELILAQorWCHYG/RZMDEBFzYzIBMRIxEmJiMiBgcRIxEBOwZ8yAFXA7kBaW9aiCa5BDqInP59/TUCzHVwYE78/QQ6AAACAFv/7AQ0BE4ADwAbAEOyDBwdERI5sAwQsBPQALAARViwBC8bsQQYPlmwAEVYsAwvG7EMED5ZshMBCitYIdgb9FmwBBCyGQEKK1gh2Bv0WTAxEzQ2NjMyABUVFAYGIyIANRcUFjMyNjU0JiMiBlt934/dARF54ZLc/u+6p4yNpqmMiagCJ5/+iv7O/g2e+4wBMvwJtNrdx7Ld2gACAIz+YAQeBE4ADwAaAG6yExscERI5sBMQsAzQALAARViwDC8bsQwYPlmwAEVYsAkvG7EJGD5ZsABFWLAGLxuxBhI+WbAARViwAy8bsQMQPlmyBQwDERI5sgoMAxESObAMELITAQorWCHYG/RZsAMQshgBCitYIdgb9FkwMQEUAiMiJxEjETMXNjMyEhEnNCYjIgcRFjMyNgQe4sHFcbmpCXHJw+O5nIioVFOrhZ0CEff+0n399wXaeIz+2v76BLfUlf37lNMAAAIAX/5gA+8ETgAPABoAa7IYGxwREjmwGBCwA9AAsABFWLADLxuxAxg+WbAARViwBi8bsQYYPlmwAEVYsAgvG7EIEj5ZsABFWLAMLxuxDBA+WbIFAwwREjmyCgMMERI5shMBCitYIdgb9FmwAxCyGAEKK1gh2Bv0WTAxEzQSMzIXNzMRIxEGIyICNRcUFjMyNxEmIyIGX+rFwG8IqrlwusTpuZ2FpVdYooaeAib/ASmBbfomAgR4ATH8CLrUkgISj9UAAQCMAAAClwROAA0ARrIEDg8REjkAsABFWLALLxuxCxg+WbAARViwCC8bsQgYPlmwAEVYsAUvG7EFED5ZsAsQsgIBCitYIdgb9FmyCQsFERI5MDEBJiMiBxEjETMXNjMyFwKXKjG2Qbm0A1unNhwDlAeb/QAEOn2RDgABAF//7AO7BE4AJgBhsgknKBESOQCwAEVYsAkvG7EJGD5ZsABFWLAcLxuxHBA+WbIDHAkREjmwCRCwDdCwCRCyEAEKK1gh2Bv0WbADELIVAQorWCHYG/RZsBwQsCHQsBwQsiQBCitYIdgb9FkwMQE0JiQmJjU0NjMyFhUjNCYjIgYVFBYEFhYVFAYjIiYmNTMWFjMyNgMCcf7npU/hr7jluoFiZXJqARWsU+i5gshxuQWLcml/AR9LUzxUdFCFuL6UTG5YR0NEPlZ5V5GvXKVgXW1VAAEACf/sAlYFQAAVAF+yDhYXERI5ALAARViwAS8bsQEYPlmwAEVYsBMvG7ETGD5ZsABFWLANLxuxDRA+WbABELAA0LAAL7ABELIDAQorWCHYG/RZsA0QsggBCitYIdgb9FmwAxCwEdCwEtAwMQERMxUjERQWMzI3FQYjIiY1ESM1MxEBh8rKNkEgOElFfH7FxQVA/vqP/WFBQQyWFJaKAp+PAQYAAQCI/+wD3AQ6ABAAU7IKERIREjkAsABFWLAGLxuxBhg+WbAARViwDS8bsQ0YPlmwAEVYsAIvG7ECED5ZsABFWLAQLxuxEBA+WbIADQIREjmwAhCyCgEKK1gh2Bv0WTAxJQYjIiYnETMRFDMyNxEzESMDKGzRrbUBucjURrmwa3/JxQLA/UX2ngMT+8YAAAEAIQAAA7oEOgAGADiyAAcIERI5ALAARViwAS8bsQEYPlmwAEVYsAUvG7EFGD5ZsABFWLADLxuxAxA+WbIABQMREjkwMSUBMwEjATMB8QEMvf58jf54vfsDP/vGBDoAAAEAKwAABdMEOgAMAGCyBQ0OERI5ALAARViwAS8bsQEYPlmwAEVYsAgvG7EIGD5ZsABFWLALLxuxCxg+WbAARViwAy8bsQMQPlmwAEVYsAYvG7EGED5ZsgALAxESObIFCwMREjmyCgsDERI5MDElEzMBIwEBIwEzExMzBErQuf7Flv75/wCW/sa41fyV/wM7+8YDNPzMBDr81gMqAAEAKQAAA8oEOgALAFMAsABFWLABLxuxARg+WbAARViwCi8bsQoYPlmwAEVYsAQvG7EEED5ZsABFWLAHLxuxBxA+WbIACgQREjmyBgoEERI5sgMABhESObIJBgAREjkwMQETMwEBIwMDIwEBMwH38Nj+ngFt1vr61wFt/p7WAq8Bi/3p/d0Blf5rAiMCFwABABb+SwOwBDoADwBJsgAQERESOQCwAEVYsAEvG7EBGD5ZsABFWLAOLxuxDhg+WbAARViwBS8bsQUSPlmyAA4FERI5sgkBCitYIdgb9FmwABCwDdAwMQETMwECIycnNRcyNjc3ATMB7vzG/k1l3CNFMl5pIin+fsoBDwMr+x/+8gMNlgRMZW4ELgABAFgAAAOzBDoACQBEALAARViwBy8bsQcYPlmwAEVYsAIvG7ECED5ZsgABCitYIdgb9FmyBAACERI5sAcQsgUBCitYIdgb9FmyCQUHERI5MDElIRUhNQEhNSEVAToCefylAlX9tAM0l5eIAxmZgwAAAQBA/pICngY9ABgAMbITGRoREjkAsA0vsAAvsgcNABESObAHL7IfBwFdsgYDCitYIdgb9FmyEwYHERI5MDEBJiY1NTQjNTI1NTY2NxcGERUUBxYVFRIXAnixs9TUAq+zJtGnpwPO/pIy5bzH85Hy0LfhM3ND/ubK41la5c7+7UIAAAEAr/7yAUQFsAADABMAsAAvsABFWLACLxuxAhw+WTAxASMRMwFElZX+8ga+AAABABP+kgJyBj0AGAAxsgUZGhESOQCwCy+wGC+yEQsYERI5sBEvsh8RAV2yEgMKK1gh2Bv0WbIFEhEREjkwMRc2EzU0NyY1NRAnNxYWFxUUMxUiFRUUBgcTywe1tdEmsbIB1NS1r/tBAQrc51RS6csBGkNzMuG50u+R88q84jIAAAEAgwGSBO8DIgAXAEKyERgZERI5ALAARViwDy8bsQ8WPlmwANCwDxCwFNCwFC+yAwEKK1gh2Bv0WbAPELIIAQorWCHYG/RZsAMQsAvQMDEBFAYjIi4CIyIGFQc0NjMyFhYXFzI2NQTvu4lIgKlKKk5UobiLTIywQB1MXwMJntk1lCRrXgKgzkChCgJ0XwACAIv+mAFmBE0AAwAMADKyBg0OERI5sAYQsADQALACL7AARViwCy8bsQsYPlmyBgUKK1gh2Bv0WbIBAgYREjkwMRMzEyMTFAYiJjQ2MhaqqA3CyTdsODhsNwKs++wFTC0+Plo8PAABAGn/CwP5BSYAIQBSsgAiIxESOQCwAEVYsBQvG7EUGD5ZsABFWLAKLxuxChA+WbAH0LIAAQorWCHYG/RZsAoQsAPQsBQQsBHQsBQQsBjQsBQQshsBCitYIdgb9FkwMSUyNjczBgYHFSM1JgI1NTQSNzUzFRYWFyMmJiMiBhUVFBYCSmSUCK8GxpC5s8jKsbmWwAavCI9pjZubg3lZfska6eoiARzcI9QBHSHi3xfUlmmHy8Aju8oAAQBbAAAEaAXEACEAfLIcIiMREjkAsABFWLAULxuxFBw+WbAARViwBS8bsQUQPlmyHxQFERI5sB8vsl8fAXKyjx8BcbK/HwFdsgABCitYIdgb9FmwBRCyAwEKK1gh2Bv0WbAH0LAI0LAAELAN0LAfELAP0LAUELAY0LAUELIbAQorWCHYG/RZMDEBFxQHIQchNTM2Njc1JyM1MwM0NjMyFhUjNCYjIgYVEyEVAcEIPgLdAfv4TSgyAgiloAn1yL7ev39vaYIJAT8CbtyaW52dCYNgCN2dAQTH7tSxa3yaff78nQAAAgBp/+UFWwTxABsAKgA/sgIrLBESObACELAn0ACwAEVYsAIvG7ECED5ZsBDQsBAvsAIQsh8BCitYIdgb9FmwEBCyJwEKK1gh2Bv0WTAxJQYjIicHJzcmNTQ3JzcXNjMyFzcXBxYVFAcXBwEUFhYyNjY1NCYmIyIGBgRPn9HPn4aCi2hwk4KTnsPEn5WEl25mj4T8YHPE4sRxccVwccRzcISCiIeNnMrOo5eIlnh5mImao8vEn5CIAnt71Hp703t603l41AAAAQAfAAAErQWwABYAawCwAEVYsBYvG7EWHD5ZsABFWLABLxuxARw+WbAARViwDC8bsQwQPlmyDxMDK7IADBYREjm0DxMfEwJdsBMQsAPQsBMQshICCitYIdgb9FmwBtCwDxCwB9CwDxCyDgIKK1gh2Bv0WbAK0DAxAQEzASEVIRUhFSERIxEhNSE1ITUhATMCZgFs2/5eATj+gAGA/oDB/oYBev6GATn+XtwDDgKi/TB9pXz+vgFCfKV9AtAAAAIAk/7yAU0FsAADAAcAGACwAC+wAEVYsAYvG7EGHD5ZsgUBAyswMRMRMxERIxEzk7q6uv7yAxf86QPIAvYAAgBa/hEEeQXEADQARACAsiNFRhESObAjELA10ACwCC+wAEVYsCMvG7EjHD5ZshYIIxESObAWELI/AQorWCHYG/RZsgIWPxESObAIELAO0LAIELIRAQorWCHYG/RZsjAjCBESObAwELI3AQorWCHYG/RZsh03MBESObAjELAn0LAjELIqAQorWCHYG/RZMDEBFAcWFhUUBCMiJicmNTcUFjMyNjU0JicuAjU0NyYmNTQkMzIEFSM0JiMiBhUUFhYEHgIlJicGBhUUFhYEFzY2NTQmBHm6RUj+/ORwyUaLurSciKaO0bbAXbZCRwEL3ugBBLmoi46hOIcBH6lxOv3hWktQSzaFARwsTlSLAa+9VTGIZKjHODlxzQKCl3VgWWk+MG+bb7pYMYhkpsjizX2bc2JFUEFQSGGBqxgbE2VFRlBCUhEUZUVYbQAAAgBmBPAC7wXFAAgAEQAdALAHL7ICBQorWCHYG/RZsAvQsAcQsBDQsBAvMDETNDYyFhQGIiYlNDYyFhQGIiZmN2w4OGw3Aa43bDg4bDcFWy09PVo8PCstPj5aPDwAAAMAW//rBeYFxAAbACoAOQCVsic6OxESObAnELAD0LAnELA20ACwAEVYsC4vG7EuHD5ZsABFWLA2LxuxNhA+WbIDNi4REjmwAy+0DwMfAwJdsgouNhESObAKL7QAChAKAl2yDgoDERI5shECCitYIdgb9FmwAxCyGAIKK1gh2Bv0WbIbAwoREjmwNhCyIAQKK1gh2Bv0WbAuELInBAorWCHYG/RZMDEBFAYjIiY1NTQ2MzIWFSM0JiMiBhUVFBYzMjY1JRQSBCAkEjU0AiQjIgQCBzQSJCAEEhUUAgQjIiQCBF+tnp29v5ugrJJfW15sbF5cXf0BoAETAUABEqCe/u2hoP7sn3O7AUsBgAFKu7T+tcbF/rW2AlWZodO2brDTpJVjVYp7cXiKVGWErP7bpqYBJayqASKnpf7cqsoBWsfH/qbKxf6o0c8BWAAAAgCTArMDDwXEABsAJQBssg4mJxESObAOELAd0ACwAEVYsBUvG7EVHD5ZsgQmFRESObAEL7AA0LICBBUREjmyCwQVERI5sAsvsBUQsg4DCitYIdgb9FmyEQsVERI5sAQQshwDCitYIdgb9FmwCxCyIAQKK1gh2Bv0WTAxASYnBiMiJjU0NjMzNTQjIgYVJzQ2MzIWFREUFyUyNjc1IwYGFRQCagwGTIB3gqesbHxFT6GsiYWaGv6kK1gccFNZAsEiJlZ8Z294NIc2Mwxngo+G/sRhUXsoG44BPzNe//8AZgCXA2QDswAmAJr6/gAHAJoBRP/+AAEAfwF3A74DIAAFABoAsAQvsAHQsAEvsAQQsgIBCitYIdgb9FkwMQEjESE1IQO+uv17Az8BdwEIoQAEAFr/6wXlBcQADgAeADQAPQCpsjY+PxESObA2ELAL0LA2ELAT0LA2ELAj0ACwAEVYsAMvG7EDHD5ZsABFWLALLxuxCxA+WbITBAorWCHYG/RZsAMQshsECitYIdgb9FmyIAsDERI5sCAvsiIDCxESObAiL7QAIhAiAl2yNSAiERI5sDUvsr81AV20ADUQNQJdsh8CCitYIdgb9FmyKB81ERI5sCAQsC/QsC8vsCIQsj0CCitYIdgb9FkwMRM0EiQgBBIVFAIEIyIkAjcUEgQzMiQSNTQCJCMiBAIFESMRITIWFRQHFhcVFBcVIyY0JyYnJzM2NjU0JiMjWrsBSwGAAUq7tP61xsX+tbZzoAEToKEBFJ2d/uyhoP7snwHAjQEUmamAegERkQ4DEHOwnEhYTmSKAtnKAVrHx/6mysX+qNHPAVjHrP7bpqkBIqyrASGnpf7c9f6uA1GDfXtBMpo9ViYQJLkRYASAAkI2ST0AAAEAeAUhA0IFsAADABEAsAEvsgIDCitYIdgb9FkwMQEhNSEDQv02AsoFIY8AAgCCA8ACfAXEAAsAFgAvALAARViwAy8bsQMcPlmwDNCwDC+yCQIKK1gh2Bv0WbADELISAgorWCHYG/RZMDETNDYzMhYVFAYjIiYXMjY1NCYjIgYUFoKVamiTk2hplv82Sko2N0tLBMBonJtpapaWFkc5OktPbEoAAgBhAAAD9QTzAAsADwBGALAJL7AARViwDS8bsQ0QPlmwCRCwANCwCRCyBgEKK1gh2Bv0WbAD0LANELIOAQorWCHYG/RZsgUOBhESObQLBRsFAl0wMQEhFSERIxEhNSERMwEhNSECiQFs/pSn/n8BgacBQfy9A0MDVpf+YgGelwGd+w2YAAABAEICmwKrBbsAFgBUsggXGBESOQCwAEVYsA4vG7EOHD5ZsABFWLAALxuxABQ+WbIWAgorWCHYG/RZsALQsgMOFhESObAOELIIAgorWCHYG/RZsA4QsAvQshQWDhESOTAxASE1ATY1NCYjIgYVIzQ2IBYVFA8CIQKr/akBLG1APEtHnacBCJprVLABjwKbbAEaZkUxPUw5cpR/bmhrT5EAAQA+Ao8CmgW6ACYAibIgJygREjkAsABFWLAOLxuxDhw+WbAARViwGS8bsRkUPlmyABkOERI5sAAvtm8AfwCPAANdsj8AAXG2DwAfAC8AA12yXwABcrAOELIHAgorWCHYG/RZsgoOGRESObAAELImBAorWCHYG/RZshQmABESObIdGQ4REjmwGRCyIAIKK1gh2Bv0WTAxATMyNjU0JiMiBhUjNDYzMhYVFAYHFhUUBiMiJjUzFBYzMjY1NCcjAQlUSkg/RjlLnaN8iZxGQpWqiISmnk9DRkmcWARlPTAtOjMpYnt5aDdbGSmPan1+ay08PDNxAgAAAQB7BNgCHAX+AAMAIwCwAi+yDwIBXbAA0LAAL7QPAB8AAl2wAhCwA9AZsAMvGDAxATMBIwE84P70lQX+/toAAAEAmv5gA+4EOgASAFCyDRMUERI5ALAARViwAC8bsQAYPlmwAEVYsAcvG7EHGD5ZsABFWLAQLxuxEBI+WbAARViwDS8bsQ0QPlmyBAEKK1gh2Bv0WbILBw0REjkwMQERFhYzMjcRMxEjJwYjIicRIxEBUwFndMc+uqcJXaqTUbkEOv2Ho5yYAyD7xnOHSf4rBdoAAQBDAAADQAWwAAoAK7ICCwwREjkAsABFWLAILxuxCBw+WbAARViwAC8bsQAQPlmyAQAIERI5MDEhESMiJDU0JDMhEQKGVOb+9wEK5gENAgj+1tX/+lAAAAEAkwJrAXkDSQAJABayAwoLERI5ALACL7EICitY2BvcWTAxEzQ2MhYVFAYiJpM5cjs7cjkC2TBAQDAvPz8AAQB0/k0BqgAAAA4AQbIFDxAREjkAsABFWLAALxuxABA+WbAARViwBi8bsQYSPlm0EwYjBgJdsgEGABESObEHCitY2BvcWbABELAN0DAxIQcWFRQGIycyNjU0Jic3AR0MmaCPB09XQGIgNBuSYXFrNC8sKgmGAAEAegKiAe8FtwAGAECyAQcIERI5ALAARViwBS8bsQUcPlmwAEVYsAAvG7EAFD5ZsgQABRESObAEL7IDAgorWCHYG/RZsgIDBRESOTAxASMRBzUlMwHvndgBYxICogJZOYB1AAACAHoCsgMnBcQADAAaAECyAxscERI5sAMQsBDQALAARViwAy8bsQMcPlmyChsDERI5sAovshADCitYIdgb9FmwAxCyFwMKK1gh2Bv0WTAxEzQ2MzIWFRUUBiAmNRcUFjMyNjU1NCYjIgYHeryam7y7/sy+o2FUU19hU1FgAgRjnsPBpkqfwsKlBmRyc2VOY3JuYQD//wBmAJgDeAO1ACYAmw0AAAcAmwFqAAD//wBVAAAFkQWtACcAov/bApgAJwCcARgACAEHAKUC1gAAABAAsABFWLAFLxuxBRw+WTAx//8AUAAABckFrQAnAJwA7AAIACcAov/WApgBBwCjAx4AAAAQALAARViwCS8bsQkcPlkwMf//AG8AAAXtBbsAJwCcAZcACAAnAKUDMgAAAQcApAAxApsAEACwAEVYsCEvG7EhHD5ZMDEAAgBE/n8DeARNABgAIgBXsgkjJBESObAJELAc0ACwEC+wAEVYsCEvG7EhGD5ZsgAQIRESObIDEAAREjmwEBCyCQEKK1gh2Bv0WbAQELAM0LIVABAREjmwIRCyGwUKK1gh2Bv0WTAxAQ4DBwcUFjMyNjUzBgYjIiY1NDc3NjUTFAYiJjU0NjIWAkwBKWC4CwJ0bWR9uQLht8TWoG1CwTdsODhsNwKoan92wWMlbXNxW6HMybOtr3FOkgE9LT4+LSw8PAAC//IAAAdXBbAADwASAHcAsABFWLAGLxuxBhw+WbAARViwAC8bsQAQPlmwAEVYsAQvG7EEED5ZshEGABESObARL7ICAQorWCHYG/RZsAYQsggBCitYIdgb9FmyCwAGERI5sAsvsgwBCitYIdgb9FmwABCyDgEKK1gh2Bv0WbISBgAREjkwMSEhAyEDIwEhFSETIRUhEyEBIQMHV/yND/3MzeIDcAO3/U0UAk79uBYCwfqvAcgfAWH+nwWwmP4pl/3tAXgC3QABAFkAzgPdBGMACwA4ALADL7IJDAMREjmwCS+yCgkDERI5sgQDCRESObIBCgQREjmwAxCwBdCyBwQKERI5sAkQsAvQMDETAQE3AQEXAQEHAQFZAUr+uHcBSQFJd/64AUp3/rX+tQFJAVABT3v+sQFPe/6x/rB7AVH+rwAAAwB2/6MFHQXsABcAIAApAGayBCorERI5sAQQsB3QsAQQsCbQALAARViwEC8bsRAcPlmwAEVYsAQvG7EEED5ZshoQBBESObIjEAQREjmwIxCwG9CwEBCyHQEKK1gh2Bv0WbAaELAk0LAEELImAQorWCHYG/RZMDEBFAIEIyInByM3JhE1NBIkMzIXNzMHFhMFFBcBJiMiAgcFNCcBFjMyEjcFCZD++LCrg2GOkL6SAQus1pRnjZ+JAvwsYgI0Zqa20QMDFTj921t5uswDAqnW/sGoUpvnwAFoU9IBQqt9pf+7/tpj9I0DiG/+6/YNtoP8j0ABD/0AAgCmAAAEXQWwAA0AFgBXsgkXGBESObAJELAQ0ACwAEVYsAAvG7EAHD5ZsABFWLALLxuxCxA+WbIBAAsREjmwAS+yEAALERI5sBAvsgkBCitYIdgb9FmwARCyDgEKK1gh2Bv0WTAxAREhMhYWFRQEIyERIxETESEyNjU0JicBYAEXk9x3/vjj/u66ugEVjqCgiAWw/ttpwn7C5/7HBbD+Q/3el3h7lwEAAQCL/+wEagYSACoAabIhKywREjkAsABFWLAFLxuxBR4+WbAARViwEy8bsRMQPlmwAEVYsAAvG7EAED5ZsgoTBRESObIOBRMREjmwExCyGgEKK1gh2Bv0WbIgEwUREjmyIwUTERI5sAUQsigBCitYIdgb9FkwMSEjETQ2MzIWFRQGFRQeAhUUBiMiJic3FhYzMjY1NC4CNTQ2NTQmIyIRAUS5z7q0xYBLvFbLtlG1JisxhzVrcUq9V4toWNoEV9Drs599y0UzX5CITJ+yLBybICxeUjRgk4pRWc9UXmv+2wADAE7/7AZ8BE4AKgA1AD0AxrICPj8REjmwAhCwLtCwAhCwOdAAsABFWLAXLxuxFxg+WbAARViwHS8bsR0YPlmwAEVYsAAvG7EAED5ZsABFWLAFLxuxBRA+WbICHQAREjmyDAUXERI5sAwvtL8MzwwCXbAXELIQAQorWCHYG/RZshMMFxESObIaHQAREjmyOh0AERI5sDovtL86zzoCXbIhAQorWCHYG/RZsAAQsiUBCitYIdgb9FmyKB0AERI5sCvQsAwQsi8BCitYIdgb9FmwEBCwNtAwMQUgJwYGIyImNTQ2MzM1NCYjIgYVJzQ2MzIWFzY2MzISFRUhFhYzMjc3FwYlMjY3NSMGBhUUFgEiBgchNTQmBO7++4hB4o2nvOPd325oaYy48rtzsDI/rmnS6P0oB66VlHkvQJ78CUieMuR1jGoDUHOVEQIahhS0Vl6tl52uVWt7blETj7VTU09X/v/pc7C/TB+IeZZKNu0CblNNXQM0q4sfhJMAAAIAfv/sBC0GLAAdACsAVLIHLC0REjmwBxCwKNAAsABFWLAZLxuxGR4+WbAARViwBy8bsQcQPlmyDxkHERI5sA8vshEZBxESObIiAQorWCHYG/RZsAcQsigBCitYIdgb9FkwMQESERUUBgYjIiYmNTQ2NjMyFyYnByc3Jic3Fhc3FwMnJiYjIgYVFBYzMjY1AzT5ddiGh9x5cM+Bo3kwjdpJwIS3Oe+vvUloAiGLXJGip4B9mQUV/vj+Z12e/ZCB4IaT6YJyw42UY4NbMZ82i4Fk/PM4PUm/p4zE4rgAAAMARwCsBC0EugADAA0AFwBOsgcYGRESObAHELAA0LAHELAR0ACwAi+yAQEKK1gh2Bv0WbACELEMCitY2BvcWbEGCitY2BvcWbABELEQCitY2BvcWbEWCitY2BvcWTAxASE1IQE0NjIWFRQGIiYRNDYyFhUUBiImBC38GgPm/aA5cjs7cjk5cjs7cjkCWLgBOjBAQDAvPj78/jBAQDAuPz8AAAMAW/96BDQEuAAVAB0AJgBjsgQnKBESObAEELAb0LAEELAj0ACwAEVYsAQvG7EEGD5ZsABFWLAPLxuxDxA+WbIjAQorWCHYG/RZsiEjBBESObAhELAY0LAEELIbAQorWCHYG/RZshkbDxESObAZELAg0DAxEzQ2NjMyFzczBxYRFAYGIyInByM3JhMUFwEmIyIGBTQnARYzMjY1W3vhj25eSXxmw3zgkGhWSnxkzblhAVc+SIqoAmZX/qw3QounAief/YsqlM2a/sCe/okjlcuVATfCbwK2INq1tm/9UBnbuQACAJX+YAQnBgAADwAaAGSyGBscERI5sBgQsAzQALAIL7AARViwDC8bsQwYPlmwAEVYsAYvG7EGEj5ZsABFWLADLxuxAxA+WbIFDAMREjmyCgwDERI5sAwQshMBCitYIdgb9FmwAxCyGAEKK1gh2Bv0WTAxARQCIyInESMRMxE2MzISESc0JiMiBxEWMzI2BCfiwcVxublxwsPjuZyIqFRTq4WdAhH3/tJ9/fcHoP3KhP7a/voEt9SV/fuU0wAAAQCbAAABVQQ6AAMAHQCwAEVYsAIvG7ECGD5ZsABFWLAALxuxABA+WTAxISMRMwFVuroEOgAAAgBo/+sHCQXEABcAIwCRsgEkJRESObABELAa0ACwAEVYsAwvG7EMHD5ZsABFWLAOLxuxDhw+WbAARViwAC8bsQAQPlmwAEVYsAMvG7EDED5ZsA4QshABCitYIdgb9FmyEwAOERI5sBMvshQBCitYIdgb9FmwABCyFgEKK1gh2Bv0WbADELIYAQorWCHYG/RZsAwQsh0BCitYIdgb9FkwMSEhBiMiJgInETQSNjMyFyEVIREhFSERIQUyNxEmIyIGBxEUFgcJ/LCycqL+jAGL/qJ8qgNG/S0Cd/2JAt37jHFmbWytwgLDFZYBD6sBNawBEZcUnv4snf38Gw4Ejg/lz/7H0+sAAAMAYf/sBwAETgAgACwANACWsgY1NhESObAGELAm0LAGELAw0ACwAEVYsAQvG7EEGD5ZsABFWLAKLxuxChg+WbAARViwFy8bsRcQPlmwAEVYsB0vG7EdED5ZsgcKFxESObIxChcREjmwMS+yDgEKK1gh2Bv0WbAXELISAQorWCHYG/RZshQKFxESObIaChcREjmwJNCwBBCyKgEKK1gh2Bv0WbAt0DAxEzQ2NjMyFhc2NjMyFhUVIRYWMzI3FwYjIiYnBgYjIgA1FxQWMzI2NTQmIyIGJSIGByE1NCZheduOick9QcRwz+r9Mgekhrx4Son1h80/PseG3P74uaCLiaChioeiBC1jlhYCDokCJ6D+iXVkZnP+63SqxWx+hHBkY3EBMP4Jt9jXzrbZ1tajihp9lgAAAQCpBOQDBgYAAAgANACwBC+wB9CwBy+0DwcfBwJdsgUEBxESORmwBS8YsAHQGbABLxiwBBCwAtCyAwQHERI5MDEBFSMnByM1EzMDBpmWlZn2cATuCqqqDAEQAAACAHkEtAInBlAACQAUACqyAxUWERI5sAMQsA3QALADL7AH0LAHL7I/BwFdsAMQsA3QsAcQsBLQMDEBFAYjIiY0NjIWBRQWMzI2NCYjIgYCJ3xbXHt7uHv+tUMxMERDMTJCBYBXdXasenpWL0RCYkVGAAABAHsE2QM+BegAFwA+ALADL7AI0LAIL7QPCB8IAl2wAxCwC9CwCy+wCBCyDwMKK1gh2Bv0WbADELIUAworWCHYG/RZsA8QsBfQMDEBFAYjIi4CIyIGFSc0NjMyHgIzMjY1Az57XCk8YSscKTp8eV0jOGAzHys5BdxshhQ+DT8xB2uMFDoSRC3//wCiAosEjQMiAEYAn9kATM1AAP//AJACiwXJAyIARgCfhABmZkAAAAEAYAQxAXgGEwAIACGyCAkKERI5ALAARViwAC8bsQAePlmyBQkAERI5sAUvMDEBFwYHFSM1NDYBDmpdA7hhBhNIf5OIdGbIAAEAMAQWAUcGAAAIACGyCAkKERI5ALAARViwBC8bsQQePlmyAAkEERI5sAAvMDETJzY3NTMVBgaZaV0DtwFhBBZIgpCQgmTHAAEAJP7lATsAtQAIAB6yCAkKERI5ALAJL7IEBQorWCHYG/RZsADQsAAvMDETJzY3NTMVFAaNaVsDuWP+5Ul/knZkZcr//wBoBDECuwYTACYAkwgAAAcAkwFDAAD//wA8BBYChgYAACYAlAwAAAcAlAE/AAAAAgAk/tMCZAD2AAgAEQAwsgoSExESObAKELAF0ACwEi+yBAUKK1gh2Bv0WbAA0LAAL7AJ0LAJL7AEELAN0DAxEyc2NzUzFRQGFyc2NzUzFRQGjWlbA7lj3WlbA7ph/tNIiZm5pGzTQEiJmbmka9EAAAEAigIXAiIDywANABayCg4PERI5ALADL7EKCitY2BvcWTAxEzQ2MzIWFRUUBiMiJjWKb1xbcm5eXW8DBFdwbV0lV25vWAABAGwAmQIgA7UABgAQALAFL7ICBwUREjmwAi8wMQEBIwE1ATMBHgECjf7ZASeNAib+cwGEEwGFAAEAWQCYAg4DtQAGABAAsAAvsgMHABESObADLzAxEwEVASMBAecBJ/7ZjgEC/v4Dtf57E/57AY4BjwABADsAbgNqBSIAAwAJALAAL7ACLzAxNycBF6NoAsdobkIEckIA//8ANgKQArsFpQMHAKUAAAKQABMAsABFWLAJLxuxCRw+WbAN0DAxAAABAF//7AQcBcQAIwCHshUkJRESOQCwAEVYsBYvG7EWHD5ZsABFWLAJLxuxCRA+WbIjCRYREjmwIy+yAAIKK1gh2Bv0WbAJELIEAQorWCHYG/RZsAAQsAzQsCMQsA/QsCMQsB/QsB8vtg8fHx8vHwNdsiACCitYIdgb9FmwENCwHxCwE9CwFhCyGwEKK1gh2Bv0WTAxASEWFjMyNxcGIyIAAyM1MzUjNTMSADMyFwcmIyIGByEVIRUhA1H+gAS0pXRmFHh4+P7jBrKysrIKAR3zaocUbW6ksQYBf/6AAYACHcPSIqAeASUBDHyJfQEGAR8foiPLvH2JAAEAqAKLA+sDIgADABsAsABFWLACLxuxAhY+WbIBAQorWCHYG/RZMDEBITUhA+v8vQNDAouXAAIAHwAAA80GFQAVABkAg7IIGhsREjmwCBCwF9AAsABFWLAILxuxCB4+WbAARViwAy8bsQMYPlmwAEVYsBEvG7ERGD5ZsABFWLAYLxuxGBg+WbAARViwAC8bsQAQPlmwAEVYsBYvG7EWED5ZsAMQsgEBCitYIdgb9FmwCBCyDQEKK1gh2Bv0WbABELAT0LAU0DAxMxEjNTM1NDYzMhcHJiMiBhUVMxUjESEjETPKq6vPvXCrH31xd2nd3QJJuroDq49ctco9nDJra16P/FUEOgABADwAAAPpBhUAFgBcALAARViwEi8bsRIePlmwAEVYsAYvG7EGGD5ZsABFWLAJLxuxCRA+WbAARViwFi8bsRYQPlmwEhCyAgEKK1gh2Bv0WbAGELIHAQorWCHYG/RZsAvQsAYQsA7QMDEBJiMiFRUzFSMRIxEjNTM1NjYzMgURIwMwfEzI5+e5q6sBwLFlASu5BWMU0muP/FUDq492rbg9+igAAAEAegAAAe8DFQAGADUAsABFWLAFLxuxBRY+WbAARViwAS8bsQEQPlmyBAUBERI5sAQvsgMCCitYIdgb9FmwAtAwMSEjEQc1JTMB753YAWMSAlk5gHUAAQBCAAACqwMgABYAVLIIFxgREjkAsABFWLAOLxuxDhY+WbAARViwAC8bsQAQPlmyFQIKK1gh2Bv0WbAC0LIUFQ4REjmyAw4UERI5sA4QsggCCitYIdgb9FmwDhCwC9AwMSEhNQE2NTQmIyIGFSM0NiAWFRQPAiECq/2pASxtQDxLR52nAQiaa1SwAY9sARpmRTE9TDlylH9uaGtPkQABAD7/9QKaAyAAJgBxALAARViwDi8bsQ4WPlmwAEVYsBkvG7EZED5ZsgAZDhESOXywAC8YtoAAkACgAANdsA4QsgcCCitYIdgb9FmyCgAHERI5sAAQsiYCCitYIdgb9FmyFCYAERI5sBkQsiACCitYIdgb9FmyHSYgERI5MDEBMzI2NTQmIyIGFSM0NjMyFhUUBgcWFRQGIyImNTMUFjMyNjU0JyMBCVRKSD9GOUudo3yJnEZClaqIhKaeT0NGSZxYAcs9MC06Mylie3loN1sZKY9qfX5rLTw8M3ECAAACADYAAAK7AxUACgAOAEkAsABFWLAJLxuxCRY+WbAARViwBC8bsQQQPlmyAQkEERI5sAEvsgICCitYIdgb9FmwBtCwARCwC9CyCAsGERI5sg0JBBESOTAxATMVIxUjNSEnATMBMxEHAlBra53+iQYBeaH+hN8RASuCqalmAgb+FgEhHP//ACUCHwINArYCBgARAAAAAgAlAAAE5AWwAA8AHQBmALAARViwBS8bsQUcPlmwAEVYsAAvG7EAED5ZsgQABRESObAEL7LPBAFdsi8EAV2ynwQBcbIBAQorWCHYG/RZsBHQsAAQshIBCitYIdgb9FmwBRCyGwEKK1gh2Bv0WbAEELAc0DAxMxEjNTMRITIEEhcVFAIEBxMhETMyEjc1NAInIxEhx6KiAZu+ASSfAZ/+2cRH/ubJ3vcB6dbgARoCmpcCf6j+ysldzv7KpgICmv4DARL5XfgBEwL+HwD//wAcAAAFHQc0AiYAJQAAAQcARAEwATYAFACwAEVYsAQvG7EEHD5ZsQwI9DAx//8AHAAABR0HNAImACUAAAEHAHUBvwE2ABQAsABFWLAFLxuxBRw+WbENCPQwMf//ABwAAAUdBzYCJgAlAAABBwCOAMkBNgAUALAARViwBC8bsQQcPlmxDwb0MDH//wAcAAAFHQciAiYAJQAAAQcAkADFAToAFACwAEVYsAUvG7EFHD5ZsQ4E9DAx//8AHAAABR0G+wImACUAAAEHAGoA+QE2ABcAsABFWLAELxuxBBw+WbERBPSwG9AwMQD//wAcAAAFHQeRAiYAJQAAAQcAjwFQAUEAFwCwAEVYsAQvG7EEHD5ZsQ4G9LAY0DAxAP//AHf+RATYBcQCJgAnAAAABwB5AdL/9///AKkAAARGB0ACJgApAAABBwBEAPsBQgAUALAARViwBi8bsQYcPlmxDQj0MDH//wCpAAAERgdAAiYAKQAAAQcAdQGKAUIAFACwAEVYsAYvG7EGHD5ZsQ4I9DAx//8AqQAABEYHQgImACkAAAEHAI4AlAFCABQAsABFWLAGLxuxBhw+WbEQBvQwMf//AKkAAARGBwcCJgApAAABBwBqAMQBQgAXALAARViwBi8bsQYcPlmxEgT0sBvQMDEA////4AAAAYEHQAImAC0AAAEHAET/pwFCABQAsABFWLACLxuxAhw+WbEFCPQwMf//ALAAAAJRB0ACJgAtAAABBwB1ADUBQgAUALAARViwAy8bsQMcPlmxBgj0MDH////pAAACRgdCAiYALQAAAQcAjv9AAUIAFACwAEVYsAIvG7ECHD5ZsQgG9DAx////1gAAAl8HBwImAC0AAAEHAGr/cAFCABcAsABFWLACLxuxAhw+WbEKBPSwFNAwMQD//wCpAAAFCAciAiYAMgAAAQcAkAD7AToAFACwAEVYsAYvG7EGHD5ZsQ0E9DAx//8Adv/sBQkHNgImADMAAAEHAEQBUgE4ABQAsABFWLANLxuxDRw+WbEhCPQwMf//AHb/7AUJBzYCJgAzAAABBwB1AeEBOAAUALAARViwDS8bsQ0cPlmxIgj0MDH//wB2/+wFCQc4AiYAMwAAAQcAjgDrATgAFACwAEVYsA0vG7ENHD5ZsSIG9DAx//8Adv/sBQkHJAImADMAAAEHAJAA5wE8ABQAsABFWLANLxuxDRw+WbEjBPQwMf//AHb/7AUJBv0CJgAzAAABBwBqARsBOAAXALAARViwDS8bsQ0cPlmxJwT0sDDQMDEA//8AjP/sBKoHNAImADkAAAEHAEQBKwE2ABQAsABFWLAKLxuxChw+WbEUCPQwMf//AIz/7ASqBzQCJgA5AAABBwB1AboBNgAUALAARViwEi8bsRIcPlmxFQj0MDH//wCM/+wEqgc2AiYAOQAAAQcAjgDEATYAFACwAEVYsAovG7EKHD5ZsRcG9DAx//8AjP/sBKoG+wImADkAAAEHAGoA9AE2ABcAsABFWLAKLxuxChw+WbEZBPSwI9AwMQD//wAPAAAEuwc0AiYAPQAAAQcAdQGIATYAFACwAEVYsAEvG7EBHD5ZsQsI9DAx//8Abf/sA+oF/gImAEUAAAEHAEQA1QAAABQAsABFWLAXLxuxFxg+WbEqCfQwMf//AG3/7APqBf4CJgBFAAABBwB1AWQAAAAUALAARViwFy8bsRcYPlmxKwn0MDH//wBt/+wD6gYAAiYARQAAAQYAjm4AABQAsABFWLAXLxuxFxg+WbErAfQwMf//AG3/7APqBewCJgBFAAABBgCQagQAFACwAEVYsBcvG7EXGD5ZsSwB9DAx//8Abf/sA+oFxQImAEUAAAEHAGoAngAAABcAsABFWLAXLxuxFxg+WbEwAfSwOdAwMQD//wBt/+wD6gZbAiYARQAAAQcAjwD1AAsAFwCwAEVYsBcvG7EXGD5ZsSwE9LA20DAxAP//AFz+RAPsBE4CJgBHAAAABwB5AT//9///AF3/7APzBf4CJgBJAAABBwBEAMUAAAAUALAARViwCC8bsQgYPlmxHwn0MDH//wBd/+wD8wX+AiYASQAAAQcAdQFUAAAAFACwAEVYsAgvG7EIGD5ZsSAJ9DAx//8AXf/sA/MGAAImAEkAAAEGAI5eAAAUALAARViwCC8bsQgYPlmxIAH0MDH//wBd/+wD8wXFAiYASQAAAQcAagCOAAAAFwCwAEVYsAgvG7EIGD5ZsSUB9LAu0DAxAP///8YAAAFnBf0CJgCLAAABBgBEjf8AFACwAEVYsAIvG7ECGD5ZsQUJ9DAx//8AlgAAAjcF/QImAIsAAAEGAHUb/wAUALAARViwAy8bsQMYPlmxBgn0MDH////PAAACLAX/AiYAiwAAAQcAjv8m//8AFACwAEVYsAIvG7ECGD5ZsQgB9DAx////vAAAAkUFxAImAIsAAAEHAGr/Vv//ABcAsABFWLACLxuxAhg+WbELAfSwFNAwMQD//wCMAAAD3wXsAiYAUgAAAQYAkGEEABQAsABFWLADLxuxAxg+WbEVAfQwMf//AFv/7AQ0Bf4CJgBTAAABBwBEAM8AAAAUALAARViwBC8bsQQYPlmxHQn0MDH//wBb/+wENAX+AiYAUwAAAQcAdQFeAAAAFACwAEVYsAQvG7EEGD5ZsR4J9DAx//8AW//sBDQGAAImAFMAAAEGAI5oAAAUALAARViwBC8bsQQYPlmxHgH0MDH//wBb/+wENAXsAiYAUwAAAQYAkGQEABQAsABFWLAELxuxBBg+WbEfAfQwMf//AFv/7AQ0BcUCJgBTAAABBwBqAJgAAAAXALAARViwBC8bsQQYPlmxIwH0sCzQMDEA//8AiP/sA9wF/gImAFkAAAEHAEQAxwAAABQAsABFWLAHLxuxBxg+WbESCfQwMf//AIj/7APcBf4CJgBZAAABBwB1AVYAAAAUALAARViwDS8bsQ0YPlmxEwn0MDH//wCI/+wD3AYAAiYAWQAAAQYAjmAAABQAsABFWLAHLxuxBxg+WbEVAfQwMf//AIj/7APcBcUCJgBZAAABBwBqAJAAAAAXALAARViwBy8bsQcYPlmxGAH0sCHQMDEA//8AFv5LA7AF/gImAF0AAAEHAHUBGwAAABQAsABFWLABLxuxARg+WbESCfQwMf//ABb+SwOwBcUCJgBdAAABBgBqVQAAFwCwAEVYsA8vG7EPGD5ZsRcB9LAg0DAxAAAAAAEAAADeAI8AFgBUAAUAAQAAAAAADgAAAgACFAAGAAEAAABhAGEAYQBhAGEAkwC4ATgBqgI6As0C5AMOAzgDawOQA68DxQPmA/0ESgR4BMcFPAV/Bd8GPgZrBt8HRgdbB3AHjwe2B9UIMwjWCRUJdAnICg0KTQqDCusLLQtIC3sL0Av0DEIMfgzTDR4Ngw3fDkoOdA62DuYPOw+QD8AP+BAcEDMQWBB/EJoQuhEyEZAR4xJBEqgS+hN0E7kT8RQ9FJQUrxUaFWUVsxYXFngWtRcfF3EXuBfoGDYYfRjCGPoZOxlSGZIZ2RoMGmga2hs9G5wbuxxgHI8dNR2jHa8dzB6EHpoe1h8ZH2kf5CAEIE0geSCYINMhBSFPIVshdSGPIakiCiJtIqsjJiN6I+okqCUXJWgl2SY4JlMm1idwJ54n1ygbKCUoLyhTKHcomSilKLEo6SkMKSgpRSlYKWwp6CoDKmsqvSroKzcrpivoK+gr8CxWLG0shCybLLIsyyzkLPAtBy0eLTUtTi1lLXwtky2sLcMt2i3xLgguHy44Lk8uZi59LpYurS7ELtsu8S8HLyAvOS9FL1wvcy+JL6IvuC/OL+Uv/jAUMCswQjBYMG4whzCeMLUwyzDkMPsxEwAAAAEAAAACAAAwG1GuXw889QAbCAAAAAAAxPARLgAAAADQ206a+hv91QkwCHMAAAAJAAIAAAAAAAADjABkAAAAAAAAAAAB+wAAAfsAAAIPAKACjwCIBO0AdwR+AG4F3ABpBPkAZQFlAGcCvACFAsgAJgNyABwEiQBOAZIAHQI1ACUCGwCQA0wAEgR+AHMEfgCqBH4AXQR+AF4EfgA1BH4AmgR+AIQEfgBNBH4AcAR+AGQB8ACGAbEAKQQRAEgEZACYBC4AhgPHAEsHLwBqBTgAHAT7AKkFNQB3BT8AqQSMAKkEbACpBXMAegW0AKkCLQC3BGoANQUEAKkETgCpBvwAqQW0AKkFgAB2BQwAqQWAAG0E7QCoBL8AUATGADEFMACMBRcAHAcZAD0FBAA5BM4ADwTKAFYCHwCSA0gAKAIfAAkDWABAA5wABAJ5ADkEWgBtBH0AjAQwAFwEgwBfBD0AXQLHADwEfQBgBGgAjAHxAI0B6f+/BA4AjQHxAJwHAwCLBGoAjASQAFsEfQCMBIwAXwK1AIwEIABfAp0ACQRpAIgD4AAhBgMAKwP3ACkDyQAWA/cAWAK1AEAB8wCvArUAEwVxAIMB8wCLBGAAaQSmAFsFtABpBNgAHwHrAJME6ABaA1gAZgZJAFsDkwCTA8EAZgRuAH8GSgBaA6oAeAL9AIIERgBhAu8AQgLvAD4CggB7BIgAmgPpAEMCFgCTAfsAdALvAHoDowB6A8AAZgXcAFUGNQBQBjkAbwPJAEQHev/yBEQAWQWAAHYEugCmBMIAiwbBAE4EsAB+BJEARwSIAFsEnACVAfoAmwehAGgHRABhA8QAqQKtAHkDxgB7BUAAogY/AJABmQBgAZkAMAGXACQC1ABoAtsAPALBACQCsgCKAmYAbAJmAFkDowA7Au8ANgR+AF8EkgCoBG4AHwSLADwC7wB6Au8AQgLvAD4C7wA2AfsAAAI1ACUFXQAlBTgAHAU4ABwFOAAcBTgAHAU4ABwFOAAcBTUAdwSMAKkEjACpBIwAqQSMAKkCLf/gAi0AsAIt/+kCLf/WBbQAqQWAAHYFgAB2BYAAdgWAAHYFgAB2BTAAjAUwAIwFMACMBTAAjATOAA8EWgBtBFoAbQRaAG0EWgBtBFoAbQRaAG0EMABcBD0AXQQ9AF0EPQBdBD0AXQH6/8YB+gCWAfr/zwH6/7wEagCMBJAAWwSQAFsEkABbBJAAWwSQAFsEaQCIBGkAiARpAIgEaQCIA8kAFgAWAAAAAQAAB2z+DAAACUn6G/5KCTAAAQAAAAAAAAAAAAAAAAAAAN0AAwSFAZAABQAABZoFMwAAAR8FmgUzAAAD0QBmAgAAAAIAAAAAAAAAAADgAAr/UAAhfwAAACEAAAAAR09PRwBAAAD//QYA/gAAZgeaAgAgAAGfAAAAAAQ6BbAAIAAgAAIAAAABAAAA4AkJBAAAAgICAwYFBwYCAwMEBQICAgQFBQUFBQUFBQUFAgIFBQUECAYGBgYFBQYGAgUGBQgGBgYGBgUFBgYIBgUFAgQCBAQDBQUFBQUDBQUCAgUCCAUFBQUDBQMFBAcEBAQDAgMGAgUFBgUCBgQHBAQFBwQDBQMDAwUEAgIDBAQHBwcECAUGBQUIBQUFBQIJCAQDBAYHAgICAwMDAwMDBAMFBQUFAwMDAwICBgYGBgYGBgYFBQUFAgICAgYGBgYGBgYGBgYFBQUFBQUFBQUFBQUCAgICBQUFBQUFBQUFBQQEAAAAAwAAAAMAAAAcAAMAAQAAABwAAwAKAAABYAAEAUQAAAA2ACAABAAWAAAADQB+AKAArACtAL8AxgDPAOYA7wD/ATEBUwLGAtoC3CAUIBogHiAiIDogRCB0IKwiEv//AAAAAAANACAAoAChAK0ArgDAAMcA0ADnAPABMQFSAsYC2gLcIBMgGCAcICIgOSBEIHQgrCIS//8AAf/2/+QABv/C//r/wQAA/+gAAP/iAAD/Wv86/cj9tf204H7ge+B64HfgYeBY4Cnf8t6NAAEAAAAAAAAAAAAAAAAAAAAoAAAAMgAAAFwAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAqQCqAKsArACtAK4AgQCoALgAuQC6ALsAvAC9AIIAgwC+AL8AwADBAMIAhACFAMMAxADFAMYAxwDIAIYAhwDSANMA1ADVANYA1wCIAIkA2ADZANoA2wDcAIoA3QAMAAAAAAHYAAAAAAAAACYAAAAAAAAAAAAAAAEAAAANAAAADQAAAAMAAAAgAAAAfgAAAAQAAACgAAAAoAAAAKYAAAChAAAArAAAAGMAAACtAAAArQAAAKcAAACuAAAAvwAAAG8AAADAAAAAxQAAAKkAAADGAAAAxgAAAIEAAADHAAAAzwAAAK8AAADQAAAA0AAAAKgAAADRAAAA1gAAALgAAADXAAAA2AAAAIIAAADZAAAA3QAAAL4AAADeAAAA3wAAAIQAAADgAAAA5QAAAMMAAADmAAAA5gAAAIYAAADnAAAA7wAAAMkAAADwAAAA8AAAAIcAAADxAAAA9gAAANIAAAD3AAAA+AAAAIgAAAD5AAAA/QAAANgAAAD+AAAA/gAAAIoAAAD/AAAA/wAAAN0AAAExAAABMQAAAIsAAAFSAAABUwAAAIwAAALGAAACxgAAAI4AAALaAAAC2gAAAI8AAALcAAAC3AAAAJAAACATAAAgFAAAAJEAACAYAAAgGgAAAJMAACAcAAAgHgAAAJYAACAiAAAgIgAAAJkAACA5AAAgOgAAAJoAACBEAAAgRAAAAJwAACB0AAAgdAAAAJ0AACCsAAAgrAAAAJ4AACISAAAiEgAAAJ+wACxLsAlQWLEBAY5ZuAH/hbCEHbEJA19eLbABLCAgRWlEsAFgLbACLLABKiEtsAMsIEawAyVGUlgjWSCKIIpJZIogRiBoYWSwBCVGIGhhZFJYI2WKWS8gsABTWGkgsABUWCGwQFkbaSCwAFRYIbBAZVlZOi2wBCwgRrAEJUZSWCOKWSBGIGphZLAEJUYgamFkUlgjilkv/S2wBSxLILADJlBYUViwgEQbsEBEWRshISBFsMBQWLDARBshWVktsAYsICBFaUSwAWAgIEV9aRhEsAFgLbAHLLAGKi2wCCxLILADJlNYsEAbsABZioogsAMmU1gjIbCAioobiiNZILADJlNYIyGwwIqKG4ojWSCwAyZTWCMhuAEAioobiiNZILADJlNYIyG4AUCKihuKI1kgsAMmU1iwAyVFuAGAUFgjIbgBgCMhG7ADJUUjISMhWRshWUQtsAksS1NYRUQbISFZLbAKLLAkRS2wCyywJUUtsAwssScBiCCKU1i5QAAEAGO4CACIVFi5ACQD6HBZG7AjU1iwIIi4EABUWLkAJAPocFlZWS2wDSywQIi4IABaWLElAEQbuQAlA+hEWS2wDCuwACsAsgEOAisBsg8BAisBtw86MCUbEAAIKwC3AUg7LiEUAAgrtwJYSDgoFAAIK7cDUkM0JRYACCu3BF5NPCsZAAgrtwU2LCIZDwAIK7cGcV1GMhsACCu3B5F3XDojAAgrtwh+Z1A5GgAIK7cJVEU2JhcACCu3CnZgSzYdAAgrtwuDZE46IwAIK7cM2bKKYzwACCu3DRQRDQkGAAgrtw48MiccEQAIKwCyEAoHK7AAIEV9aRhEsjASAXOysBQBc7JQFAF0soAUAXSycBQBdbIPHAFzsm8cAXUAACoAnQCAAIoAeADUAGQATgBaAIcAYABWADQCPAC8AMQAAAAU/mAAFAKbACADIQALBDoAFASNABAFsAAUBhgAFQGmABEGwAAOAAAAAAAAAAcAWgADAAEECQABAAwAAAADAAEECQACAA4ADAADAAEECQADAAwAAAADAAEECQAEAAwAAAADAAEECQAFACwAGgADAAEECQAGABwARgADAAEECQAOAFQAYgBSAG8AYgBvAHQAbwBSAGUAZwB1AGwAYQByAFYAZQByAHMAaQBvAG4AIAAyAC4AMAAwADEAMQAwADEAOwAgADIAMAAxADQAUgBvAGIAbwB0AG8ALQBSAGUAZwB1AGwAYQByAGgAdAB0AHAAOgAvAC8AdwB3AHcALgBhAHAAYQBjAGgAZQAuAG8AcgBnAC8AbABpAGMAZQBuAHMAZQBzAC8ATABJAEMARQBOAFMARQAtADIALgAwAAMAAAAAAAD/agBkAAAAAAAAAAAAAAAAAAAAAAAAAAAAAQACAAgAAv//AA8AAQAAAAwAAAAAAAAAAgAKACUAPgABAEUAXgABAHkAeQADAIEAgQABAIMAgwABAIYAhgABAIkAiQABAIsAjQABAKAAoQACAKgA3QABAAEAAAAKAFQAdAAEREZMVAAaY3lybAAmZ3JlawAybGF0bgA+AAQAAAAA//8AAQAAAAQAAAAA//8AAQABAAQAAAAA//8AAQACAAQAAAAA//8AAQADAARrZXJuABprZXJuABprZXJuABprZXJuABoAAAABAAAAAQAEAAIAAAAEAA4CDgOSBFIAAQCCAAQAAAA8AYgBiAD+AY4BnAG0AaoBBAEKARABtAEWASABQgFUAboBZgH0AWwB9AH0AfQB9AF6AfoB+gGIAYgBiAGIAbQBjgGOAY4BjgGOAY4BnAGqAaoBqgGqAbQBtAG0AbQBtAG6AfQB9AH0AfQB9AH0AfQB9AH0AfQB+gH6AAEAPAAGAAsAEwAlACcAKAApACoALwAwADMANAA4ADoAOwA9AD4ASQBKAEwAUQBSAFMAVgBaAF0AkwCUAJYAlwCoAKkAqgCrAKwArQCuAK8AsACxALIAswC5ALoAuwC8AL0AwgDKAMsAzADNANIA0wDUANUA1gDXANwA3QABABP/IAABAFb/5gABAFv/wQABAFv/pAACAFgADgCB/58ACAAE/9gAVv+1AFv/xwBt/rgAfP8oAIH/TQCG/44Aif+hAAQADQAUAEEAEQBW/+IAYQATAAQADQAPAEEADABW/+sAYQAOAAEAW//lAAMADQAUAEEAEgBhABMAAwBKAA8AWAAyAFsAEQABAFsACwADACP/wwBY/+8AW//fAAMADf/mAEH/9ABh/+8AAgBK/+4AW//qAAEAgf/fAA4ACv/iAA0AFAAO/88AQQASAEr/6gBW/9gAWP/qAGEAEwBt/64AfP/NAIH/oACG/8EAif/AAJn/0wABAJT/sAABAEoADQABABgABAAAAAcAKgAwAEIA/AESASQBPgABAAcABAAMACoANQA2AD8ASgABADj/2AAEADoAFAA7ABIAPQAWAMIAFgAuABD/FgAS/xYAJf9WAC7++AA4ABQARf/eAEf/6wBI/+sASf/rAEv/6wBT/+sAVf/rAFn/6gBa/+gAXf/oAI3/6wCV/xYAmP8WAKn/VgCq/1YAq/9WAKz/VgCt/1YArv9WAMP/3gDE/94Axf/eAMb/3gDH/94AyP/eAMn/6wDK/+sAy//rAMz/6wDN/+sA0//rANT/6wDV/+sA1v/rANf/6wDY/+oA2f/qANr/6gDb/+oA3P/oAN3/6AAFADj/1QA6/+QAO//sAD3/3QDC/90ABAA4/7AAOv/tAD3/0ADC/9AABgAu/+4AOf/uAL7/7gC//+4AwP/uAMH/7gARAAYAEAALABAAR//oAEj/6ABJ/+gAS//oAFX/6ACN/+gAkwAQAJQAEACWABAAlwAQAMn/6ADK/+gAy//oAMz/6ADN/+gAAQAUAAQAAAAFACIAUABqAHwAlgABAAUATwBYAFsAXwCUAAsAR//sAEj/7ABJ/+wAS//sAFX/7ACN/+wAyf/sAMr/7ADL/+wAzP/sAM3/7AAGAFP/7ADT/+wA1P/sANX/7ADW/+wA1//sAAQAEP+EABL/hACV/4QAmP+EAAYALv/sADn/7AC+/+wAv//sAMD/7ADB/+wACgBMACAATwAgAFAAIABT/4AAV/+QANP/gADU/4AA1f+AANb/gADX/4AAAgVQAAQAAAXGBwgAHAAYAAD/zv/1/+//iP/0/7v/f//1AAz/qf+iAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAD/5QAAAAD/6P/JAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAD/4wAAAAAAAP/kABIAEQAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAD/5QAAAAD/6v/V/+v/6v+a/+kAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAD/4wAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAD/5gAAAAAAAP/tAAAAFP/vAAAAAAAAAAAAAAAAAAD/7QAAAAAAAAAAAAAAAAAAAAD/uP/kAAAAAP+dAA8AEP+h/8QAEAAQ/7EAAP8mAAD/nf+z/xj/k//w/4//jP8QAAD/2P/hAAAAAP/lAAAAAP/pAAAAAAAAAAAAAAAAAAD/5gAA/8D/6QAAAAAAAAAAAAD/e/+//8r+sAAA/3H+7f/UAAD/Uf8RABMAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAADwAAAAAAAP/zAAAAAAAAAAAAAAAA/3b/4f68/+b/8wAAAAAAAAAA//UAAP84AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA/+oAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAD/9f/zAAAAAP/SAAAAAP/kAAAAAAAA/7UAAP8fAAD/1AAA/9sAAAAA/9IAAAAAAAD/4f/nAAAAAP/rAAAAAP/rAAAADgAAAAAAAAAAAAD/5gAA/9IAAAAAAAAAAAAAAAD/7P/j/6AAAP+/ABEAEf/Z/+IAEgAS/6IADf8tAAD/v//p/8z/2P/w/7f/xv+gAAAAAAAAAAAAAP/hAAAADv/tAAAAAAAA/9UAAP+FAAD/4QAA/8QAAAAA/98AAAAAAAD/5f/mAAAAAP/rAAAAAP/tAAAAAAAAAA0AAAAAAAD/6wAAAAAAAAAAAAAAAAAAAAD/8QAAAAD/vQAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAD/9QAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAD/9QAAAAD/4wAAAAAAAAAA//EAAAAAAAAAAAAAAAAAAP/xAAAAAAAAAAAAAAAAAAD/8wAAAAD/8gAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAD/mAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAD/8QAAAAD/eAAAAAAAAAAA//AAAAAAAAAAAAAAAAAAAP/rAAAAAAAAAAAAAAAAAAAAAAAAAAAAD//xAAAAAAAAAAAAAAAAAAAAAP+VAAD/8wAAAAAAAAAA//EAAAAAAAAAEgAAAAAAEP/sAAAAAAAAAAAAAAAAAAAAAP+FAAD/7QAAAAAAAAAA/9gAAAAAAAAAAAAAAAAAAP/sAAAAAAAAAAAAAAAAAAAAAAAAAAD/7AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAP/wAAAAAAAAAAAAAAAAAAAAAAAAAAD/8AAAAAAAAAAAAAAAAAAAAAAAAAAAAAD/lf/DAAAAAAAAAAAAAAAA/4gAAAAAAAD/xQAAAAD/7AAA/87/sAAAAAAAAAAAAAD/VgAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAIAEwAGAAYAAAALAAsAAQAQABAAAgASABIAAwAlACkABAAsADQACQA4AD4AEgBFAEcAGQBJAEkAHABMAEwAHQBRAFQAHgBWAFYAIgBaAFoAIwBcAF4AJACKAIoAJwCTAJgAKACoAM0ALgDSANcAVADcAN0AWgACADUABgAGABoACwALABoAEAAQABsAEgASABsAJgAmAAEAJwAnAAQAKAAoAAMAKQApAAUALAAtAAIALgAuAAoALwAvAAcAMAAwAAgAMQAyAAIAMwAzAAMANAA0AAkAOAA4AAYAOQA5AAoAOgA6AAsAOwA7AA4APAA8AAwAPQA9AA0APgA+AA8ARQBFABAARgBGABIARwBHABEASQBJABMATABMABQAUQBSABQAUwBTABUAVABUABIAVgBWABcAWgBaABYAXABcABgAXQBdABYAXgBeABkAigCKABIAkwCUABoAlQCVABsAlgCXABoAmACYABsAqACoAAMArwCvAAQAsACzAAUAtAC4AAIAuQC9AAMAvgDBAAoAwgDCAA0AwwDIABAAyQDJABEAygDNABMA0gDSABQA0wDXABUA3ADdABYAAgA0AAYABgAEAAsACwAEABAAEAAOABEAEQASABIAEgAOACUAJQAMACcAJwACACsAKwACAC4ALgAXADMAMwACADUANQACADcANwAUADgAOAAHADkAOQADADoAOgAKADsAOwAGADwAPAANAD0APQALAD4APgAPAEUARQAVAEcASQAQAEsASwAQAFEAUgATAFMAUwAFAFQAVAATAFUAVQAQAFcAVwAWAFkAWQAIAFoAWgABAFwAXAARAF0AXQABAF4AXgAJAIMAgwACAIwAjAACAI0AjQAQAJEAkgASAJMAlAAEAJUAlQAOAJYAlwAEAJgAmAAOAKcApwASAKkArgAMAK8ArwACALkAvQACAL4AwQADAMIAwgALAMMAyAAVAMkAzQAQANIA0gATANMA1wAFANgA2wAIANwA3QABAAAAAQAAAAoALABIAAFsYXRuAAgACgABVFVSIAASAAD//wABAAAAAP//AAEAAQACbGlnYQAObGlnYQAWAAAAAgAAAAEAAAABAAEAAgAGACAABAAAAAEACAABACwAAQAIAAEABACgAAIATQAEAAAAAQAIAAEAEgABAAgAAQAEAKEAAgBQAAEAAQBK) format('truetype');
}
@font-face {
font-family: 'Roboto';
font-style: normal;
font-weight: 500;
src: url(data:application/x-font-truetype;base64,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) format('truetype');
}
@font-face {
font-family: 'Roboto';
font-style: normal;
font-weight: 700;
src: url(data:application/x-font-truetype;base64,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) format('truetype');
}
html{font-family:sans-serif;-ms-text-size-adjust:100%;-webkit-text-size-adjust:100%}body{margin:0}article,aside,details,figcaption,figure,footer,header,hgroup,main,menu,nav,section,summary{display:block}audio,canvas,progress,video{display:inline-block;vertical-align:baseline}audio:not([controls]){display:none;height:0}[hidden],template{display:none}a{background-color:transparent}a:active,a:hover{outline:0}abbr[title]{border-bottom:1px dotted}b,strong{font-weight:bold}dfn{font-style:italic}h1{font-size:2em;margin:0.67em 0}mark{background:#ff0;color:#000}small{font-size:80%}sub,sup{font-size:75%;line-height:0;position:relative;vertical-align:baseline}sup{top:-0.5em}sub{bottom:-0.25em}img{border:0}svg:not(:root){overflow:hidden}figure{margin:1em 40px}hr{-webkit-box-sizing:content-box;-moz-box-sizing:content-box;box-sizing:content-box;height:0}pre{overflow:auto}code,kbd,pre,samp{font-family:monospace, monospace;font-size:1em}button,input,optgroup,select,textarea{color:inherit;font:inherit;margin:0}button{overflow:visible}button,select{text-transform:none}button,html input[type="button"],input[type="reset"],input[type="submit"]{-webkit-appearance:button;cursor:pointer}button[disabled],html input[disabled]{cursor:default}button::-moz-focus-inner,input::-moz-focus-inner{border:0;padding:0}input{line-height:normal}input[type="checkbox"],input[type="radio"]{-webkit-box-sizing:border-box;-moz-box-sizing:border-box;box-sizing:border-box;padding:0}input[type="number"]::-webkit-inner-spin-button,input[type="number"]::-webkit-outer-spin-button{height:auto}input[type="search"]{-webkit-appearance:textfield;-webkit-box-sizing:content-box;-moz-box-sizing:content-box;box-sizing:content-box}input[type="search"]::-webkit-search-cancel-button,input[type="search"]::-webkit-search-decoration{-webkit-appearance:none}fieldset{border:1px solid #c0c0c0;margin:0 2px;padding:0.35em 0.625em 0.75em}legend{border:0;padding:0}textarea{overflow:auto}optgroup{font-weight:bold}table{border-collapse:collapse;border-spacing:0}td,th{padding:0}@media print{*,*:before,*:after{background:transparent !important;color:#000 !important;-webkit-box-shadow:none !important;box-shadow:none !important;text-shadow:none !important}a,a:visited{text-decoration:underline}a[href]:after{content:" (" attr(href) ")"}abbr[title]:after{content:" (" attr(title) ")"}a[href^="#"]:after,a[href^="javascript:"]:after{content:""}pre,blockquote{border:1px solid #999;page-break-inside:avoid}thead{display:table-header-group}tr,img{page-break-inside:avoid}img{max-width:100% !important}p,h2,h3{orphans:3;widows:3}h2,h3{page-break-after:avoid}.navbar{display:none}.btn>.caret,.dropup>.btn>.caret{border-top-color:#000 !important}.label{border:1px solid #000}.table{border-collapse:collapse !important}.table td,.table th{background-color:#fff !important}.table-bordered th,.table-bordered td{border:1px solid #ddd !important}}@font-face{font-family:'Glyphicons Halflings';src:url(data:application/vnd.ms-fontobject;base64,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);src:url(data:application/vnd.ms-fontobject;base64,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) format('embedded-opentype'),url(data:application/font-woff;base64,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) format('woff'),url(data:application/x-font-truetype;base64,AAEAAAAPAIAAAwBwRkZUTW0ql9wAAAD8AAAAHEdERUYBRAAEAAABGAAAACBPUy8yZ7lriQAAATgAAABgY21hcNqt44EAAAGYAAAGcmN2dCAAKAL4AAAIDAAAAARnYXNw//8AAwAACBAAAAAIZ2x5Zn1dwm8AAAgYAACUpGhlYWQFTS/YAACcvAAAADZoaGVhCkQEEQAAnPQAAAAkaG10eNLHIGAAAJ0YAAADdGxvY2Fv+5XOAACgjAAAAjBtYXhwAWoA2AAAorwAAAAgbmFtZbMsoJsAAKLcAAADonBvc3S6o+U1AACmgAAACtF3ZWJmwxhUUAAAsVQAAAAGAAAAAQAAAADMPaLPAAAAANB2gXUAAAAA0HZzlwABAAAADgAAABgAAAAAAAIAAQABARYAAQAEAAAAAgAAAAMEiwGQAAUABAMMAtAAAABaAwwC0AAAAaQAMgK4AAAAAAUAAAAAAAAAAAAAAAIAAAAAAAAAAAAAAFVLV04AQAAg//8DwP8QAAAFFAB7AAAAAQAAAAAAAAAAAAAAIAABAAAABQAAAAMAAAAsAAAACgAAAdwAAQAAAAAEaAADAAEAAAAsAAMACgAAAdwABAGwAAAAaABAAAUAKAAgACsAoAClIAogLyBfIKwgvSISIxsl/CYBJvonCScP4APgCeAZ4CngOeBJ4FngYOBp4HngieCX4QnhGeEp4TnhRuFJ4VnhaeF54YnhleGZ4gbiCeIW4hniIeIn4jniSeJZ4mD4////AAAAIAAqAKAApSAAIC8gXyCsIL0iEiMbJfwmASb6JwknD+AB4AXgEOAg4DDgQOBQ4GDgYuBw4IDgkOEB4RDhIOEw4UDhSOFQ4WDhcOGA4ZDhl+IA4gniEOIY4iHiI+Iw4kDiUOJg+P/////j/9r/Zv9i4Ajf5N+132nfWd4F3P3aHdoZ2SHZE9kOIB0gHCAWIBAgCiAEH/4f+B/3H/Ef6x/lH3wfdh9wH2ofZB9jH10fVx9RH0sfRR9EHt4e3B7WHtUezh7NHsUevx65HrMIFQABAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAADAAAAAACjAAAAAAAAAA1AAAAIAAAACAAAAADAAAAKgAAACsAAAAEAAAAoAAAAKAAAAAGAAAApQAAAKUAAAAHAAAgAAAAIAoAAAAIAAAgLwAAIC8AAAATAAAgXwAAIF8AAAAUAAAgrAAAIKwAAAAVAAAgvQAAIL0AAAAWAAAiEgAAIhIAAAAXAAAjGwAAIxsAAAAYAAAl/AAAJfwAAAAZAAAmAQAAJgEAAAAaAAAm+gAAJvoAAAAbAAAnCQAAJwkAAAAcAAAnDwAAJw8AAAAdAADgAQAA4AMAAAAeAADgBQAA4AkAAAAhAADgEAAA4BkAAAAmAADgIAAA4CkAAAAwAADgMAAA4DkAAAA6AADgQAAA4EkAAABEAADgUAAA4FkAAABOAADgYAAA4GAAAABYAADgYgAA4GkAAABZAADgcAAA4HkAAABhAADggAAA4IkAAABrAADgkAAA4JcAAAB1AADhAQAA4QkAAAB9AADhEAAA4RkAAACGAADhIAAA4SkAAACQAADhMAAA4TkAAACaAADhQAAA4UYAAACkAADhSAAA4UkAAACrAADhUAAA4VkAAACtAADhYAAA4WkAAAC3AADhcAAA4XkAAADBAADhgAAA4YkAAADLAADhkAAA4ZUAAADVAADhlwAA4ZkAAADbAADiAAAA4gYAAADeAADiCQAA4gkAAADlAADiEAAA4hYAAADmAADiGAAA4hkAAADtAADiIQAA4iEAAADvAADiIwAA4icAAADwAADiMAAA4jkAAAD1AADiQAAA4kkAAAD/AADiUAAA4lkAAAEJAADiYAAA4mAAAAETAAD4/wAA+P8AAAEUAAH1EQAB9REAAAEVAAH2qgAB9qoAAAEWAAYCCgAAAAABAAABAAAAAAAAAAAAAAAAAAAAAQACAAAAAAAAAAIAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAQAAAAAAAwAAAAAAAAAAAAAAAAAAAAAAAAAEAAUAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAHAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAYAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAVAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAEUAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAKAL4AAAAAf//AAIAAgAoAAABaAMgAAMABwAusQEALzyyBwQA7TKxBgXcPLIDAgDtMgCxAwAvPLIFBADtMrIHBgH8PLIBAgDtMjMRIRElMxEjKAFA/ujw8AMg/OAoAtAAAQBkAGQETARMAFsAAAEyFh8BHgEdATc+AR8BFgYPATMyFhcWFRQGDwEOASsBFx4BDwEGJi8BFRQGBwYjIiYvAS4BPQEHDgEvASY2PwEjIiYnJjU0Nj8BPgE7AScuAT8BNhYfATU0Njc2AlgPJgsLCg+eBxYIagcCB57gChECBgMCAQIRCuCeBwIHaggWB54PCikiDyYLCwoPngcWCGoHAgee4AoRAgYDAgECEQrgngcCB2oIFgeeDwopBEwDAgECEQrgngcCB2oIFgeeDwopIg8mCwsKD54HFghqBwIHnuAKEQIGAwIBAhEK4J4HAgdqCBYHng8KKSIPJgsLCg+eBxYIagcCB57gChECBgAAAAABAAAAAARMBEwAIwAAATMyFhURITIWHQEUBiMhERQGKwEiJjURISImPQE0NjMhETQ2AcLIFR0BXhUdHRX+oh0VyBUd/qIVHR0VAV4dBEwdFf6iHRXIFR3+ohUdHRUBXh0VyBUdAV4VHQAAAAABAHAAAARABEwARQAAATMyFgcBBgchMhYPAQ4BKwEVITIWDwEOASsBFRQGKwEiJj0BISImPwE+ATsBNSEiJj8BPgE7ASYnASY2OwEyHwEWMj8BNgM5+goFCP6UBgUBDAoGBngGGAp9ARMKBgZ4BhgKfQ8LlAsP/u0KBgZ4BhgKff7tCgYGeAYYCnYFBv6UCAUK+hkSpAgUCKQSBEwKCP6UBgwMCKAIDGQMCKAIDK4LDw8LrgwIoAgMZAwIoAgMDAYBbAgKEqQICKQSAAABAGQABQSMBK4AOwAAATIXFhcjNC4DIyIOAwchByEGFSEHIR4EMzI+AzUzBgcGIyInLgEnIzczNjcjNzM+ATc2AujycDwGtSM0QDkXEys4MjAPAXtk/tQGAZZk/tQJMDlCNBUWOUA0I64eYmunznYkQgzZZHABBdpkhhQ+H3UErr1oaS1LMCEPCx4uTzJkMjJkSnRCKw8PIjBKK6trdZ4wqndkLzVkV4UljQAAAgB7AAAETASwAD4ARwAAASEyHgUVHAEVFA4FKwEHITIWDwEOASsBFRQGKwEiJj0BISImPwE+ATsBNSEiJj8BPgE7ARE0NhcRMzI2NTQmIwGsAV5DakIwFgwBAQwWMEJqQ7ICASAKBgZ4BhgKigsKlQoP/vUKBgZ4BhgKdf71CgYGeAYYCnUPtstALS1ABLAaJD8yTyokCwsLJCpQMkAlGmQMCKAIDK8LDg8KrwwIoAgMZAwIoAgMAdsKD8j+1EJWVEAAAAEAyAGQBEwCvAAPAAATITIWHQEUBiMhIiY9ATQ2+gMgFR0dFfzgFR0dArwdFcgVHR0VyBUdAAAAAgDIAAAD6ASwACUAQQAAARUUBisBFRQGBx4BHQEzMhYdASE1NDY7ATU0NjcuAT0BIyImPQEXFRQWFx4BFAYHDgEdASE1NCYnLgE0Njc+AT0BA+gdFTJjUVFjMhUd/OAdFTJjUVFjMhUdyEE3HCAgHDdBAZBBNxwgIBw3QQSwlhUdZFuVIyOVW5YdFZaWFR2WW5UjI5VbZB0VlshkPGMYDDI8MgwYYzyWljxjGAwyPDIMGGM8ZAAAAAEAAAAAAAAAAAAAAAAxAAAB//IBLATCBEEAFgAAATIWFzYzMhYVFAYjISImNTQ2NyY1NDYB9261LCwueKqqeP0ST3FVQgLYBEF3YQ6teHmtclBFaw4MGZnXAAAAAgAAAGQEsASvABoAHgAAAB4BDwEBMzIWHQEhNTQ2OwEBJyY+ARYfATc2AyEnAwL2IAkKiAHTHhQe+1AeFB4B1IcKCSAkCm9wCXoBebbDBLMTIxC7/RYlFSoqFSUC6rcQJBQJEJSWEPwecAIWAAAAAAQAAABkBLAETAALABcAIwA3AAATITIWBwEGIicBJjYXARYUBwEGJjURNDYJATYWFREUBicBJjQHARYGIyEiJjcBNjIfARYyPwE2MhkEfgoFCP3MCBQI/cwIBQMBCAgI/vgICgoDjAEICAoKCP74CFwBbAgFCvuCCgUIAWwIFAikCBQIpAgUBEwKCP3JCAgCNwgK2v74CBQI/vgIBQoCJgoF/vABCAgFCv3aCgUIAQgIFID+lAgKCggBbAgIpAgIpAgAAAAD//D/8AS6BLoACQANABAAAAAyHwEWFA8BJzcTAScJAQUTA+AmDpkNDWPWXyL9mdYCZv4f/rNuBLoNmQ4mDlzWYP50/ZrWAmb8anABTwAAAAEAAAAABLAEsAAPAAABETMyFh0BITU0NjsBEQEhArz6FR384B0V+v4MBLACiv3aHRUyMhUdAiYCJgAAAAEADgAIBEwEnAAfAAABJTYWFREUBgcGLgE2NzYXEQURFAYHBi4BNjc2FxE0NgFwAoUnMFNGT4gkV09IQv2oWEFPiCRXT0hCHQP5ow8eIvzBN1EXGSltchkYEAIJm/2iKmAVGilucRoYEQJ/JioAAAACAAn/+AS7BKcAHQApAAAAMh4CFQcXFAcBFgYPAQYiJwEGIycHIi4CND4BBCIOARQeATI+ATQmAZDItoNOAQFOARMXARY7GikT/u13jgUCZLaDTk6DAXKwlFZWlLCUVlYEp06DtmQCBY15/u4aJRg6FBQBEk0BAU6Dtsi2g1tWlLCUVlaUsJQAAQBkAFgErwREABkAAAE+Ah4CFRQOAwcuBDU0PgIeAQKJMHt4dVg2Q3mEqD4+p4V4Qzhadnh5A7VESAUtU3ZAOXmAf7JVVbJ/gHk5QHZTLQVIAAAAAf/TAF4EewSUABgAAAETNjIXEyEyFgcFExYGJyUFBiY3EyUmNjMBl4MHFQeBAaUVBhH+qoIHDxH+qf6qEQ8Hgv6lEQYUAyABYRMT/p8RDPn+bxQLDPb3DAsUAZD7DBEAAv/TAF4EewSUABgAIgAAARM2MhcTITIWBwUTFgYnJQUGJjcTJSY2MwUjFwc3Fyc3IycBl4MHFQeBAaUVBhH+qoIHDxH+qf6qEQ8Hgv6lEQYUAfPwxUrBw0rA6k4DIAFhExP+nxEM+f5vFAsM9vcMCxQBkPsMEWSO4ouM5YzTAAABAAAAAASwBLAAJgAAATIWHQEUBiMVFBYXBR4BHQEUBiMhIiY9ATQ2NyU+AT0BIiY9ATQ2Alh8sD4mDAkBZgkMDwr7ggoPDAkBZgkMJj6wBLCwfPouaEsKFwbmBRcKXQoPDwpdChcF5gYXCktoLvp8sAAAAA0AAAAABLAETAAPABMAIwAnACsALwAzADcARwBLAE8AUwBXAAATITIWFREUBiMhIiY1ETQ2FxUzNSkBIgYVERQWMyEyNjURNCYzFTM1BRUzNSEVMzUFFTM1IRUzNQchIgYVERQWMyEyNjURNCYFFTM1IRUzNQUVMzUhFTM1GQR+Cg8PCvuCCg8PVWQCo/3aCg8PCgImCg8Pc2T8GGQDIGT8GGQDIGTh/doKDw8KAiYKDw/872QDIGT8GGQDIGQETA8K++YKDw8KBBoKD2RkZA8K/qIKDw8KAV4KD2RkyGRkZGTIZGRkZGQPCv6iCg8PCgFeCg9kZGRkZMhkZGRkAAAEAAAAAARMBEwADwAfAC8APwAAEyEyFhURFAYjISImNRE0NikBMhYVERQGIyEiJjURNDYBITIWFREUBiMhIiY1ETQ2KQEyFhURFAYjISImNRE0NjIBkBUdHRX+cBUdHQJtAZAVHR0V/nAVHR39vQGQFR0dFf5wFR0dAm0BkBUdHRX+cBUdHQRMHRX+cBUdHRUBkBUdHRX+cBUdHRUBkBUd/agdFf5wFR0dFQGQFR0dFf5wFR0dFQGQFR0AAAkAAAAABEwETAAPAB8ALwA/AE8AXwBvAH8AjwAAEzMyFh0BFAYrASImPQE0NiEzMhYdARQGKwEiJj0BNDYhMzIWHQEUBisBIiY9ATQ2ATMyFh0BFAYrASImPQE0NiEzMhYdARQGKwEiJj0BNDYhMzIWHQEUBisBIiY9ATQ2ATMyFh0BFAYrASImPQE0NiEzMhYdARQGKwEiJj0BNDYhMzIWHQEUBisBIiY9ATQ2MsgVHR0VyBUdHQGlyBUdHRXIFR0dAaXIFR0dFcgVHR389cgVHR0VyBUdHQGlyBUdHRXIFR0dAaXIFR0dFcgVHR389cgVHR0VyBUdHQGlyBUdHRXIFR0dAaXIFR0dFcgVHR0ETB0VyBUdHRXIFR0dFcgVHR0VyBUdHRXIFR0dFcgVHf5wHRXIFR0dFcgVHR0VyBUdHRXIFR0dFcgVHR0VyBUd/nAdFcgVHR0VyBUdHRXIFR0dFcgVHR0VyBUdHRXIFR0ABgAAAAAEsARMAA8AHwAvAD8ATwBfAAATMzIWHQEUBisBIiY9ATQ2KQEyFh0BFAYjISImPQE0NgEzMhYdARQGKwEiJj0BNDYpATIWHQEUBiMhIiY9ATQ2ATMyFh0BFAYrASImPQE0NikBMhYdARQGIyEiJj0BNDYyyBUdHRXIFR0dAaUCvBUdHRX9RBUdHf6FyBUdHRXIFR0dAaUCvBUdHRX9RBUdHf6FyBUdHRXIFR0dAaUCvBUdHRX9RBUdHQRMHRXIFR0dFcgVHR0VyBUdHRXIFR3+cB0VyBUdHRXIFR0dFcgVHR0VyBUd/nAdFcgVHR0VyBUdHRXIFR0dFcgVHQAAAAABACYALAToBCAAFwAACQE2Mh8BFhQHAQYiJwEmND8BNjIfARYyAdECOwgUB7EICPzxBxUH/oAICLEHFAirBxYB3QI7CAixBxQI/PAICAGACBQHsQgIqwcAAQBuAG4EQgRCACMAAAEXFhQHCQEWFA8BBiInCQEGIi8BJjQ3CQEmND8BNjIXCQE2MgOIsggI/vUBCwgIsggVB/70/vQHFQiyCAgBC/71CAiyCBUHAQwBDAcVBDuzCBUH/vT+9AcVCLIICAEL/vUICLIIFQcBDAEMBxUIsggI/vUBDAcAAwAX/+sExQSZABkAJQBJAAAAMh4CFRQHARYUDwEGIicBBiMiLgI0PgEEIg4BFB4BMj4BNCYFMzIWHQEzMhYdARQGKwEVFAYrASImPQEjIiY9ATQ2OwE1NDYBmcSzgk1OASwICG0HFQj+1HeOYrSBTU2BAW+zmFhYmLOZWFj+vJYKD0sKDw8KSw8KlgoPSwoPDwpLDwSZTYKzYo15/tUIFQhsCAgBK01NgbTEs4JNWJmzmFhYmLOZIw8KSw8KlgoPSwoPDwpLDwqWCg9LCg8AAAMAF//rBMUEmQAZACUANQAAADIeAhUUBwEWFA8BBiInAQYjIi4CND4BBCIOARQeATI+ATQmBSEyFh0BFAYjISImPQE0NgGZxLOCTU4BLAgIbQcVCP7Ud45itIFNTYEBb7OYWFiYs5lYWP5YAV4KDw8K/qIKDw8EmU2Cs2KNef7VCBUIbAgIAStNTYG0xLOCTViZs5hYWJizmYcPCpYKDw8KlgoPAAAAAAIAFwAXBJkEsAAPAC0AAAEzMhYVERQGKwEiJjURNDYFNRYSFRQOAiIuAjU0EjcVDgEVFB4BMj4BNTQmAiZkFR0dFWQVHR0BD6fSW5vW6tabW9KnZ3xyxejFcnwEsB0V/nAVHR0VAZAVHeGmPv7ZuHXWm1tbm9Z1uAEnPqY3yHh0xXJyxXR4yAAEAGQAAASwBLAADwAfAC8APwAAATMyFhURFAYrASImNRE0NgEzMhYVERQGKwEiJjURNDYBMzIWFREUBisBIiY1ETQ2BTMyFh0BFAYrASImPQE0NgQBlgoPDwqWCg8P/t6WCg8PCpYKDw/+3pYKDw8KlgoPD/7elgoPDwqWCg8PBLAPCvuCCg8PCgR+Cg/+cA8K/RIKDw8KAu4KD/7UDwr+PgoPDwoBwgoPyA8K+goPDwr6Cg8AAAAAAgAaABsElgSWAEcATwAAATIfAhYfATcWFwcXFh8CFhUUDwIGDwEXBgcnBwYPAgYjIi8CJi8BByYnNycmLwImNTQ/AjY/ASc2Nxc3Nj8CNhIiBhQWMjY0AlghKSYFMS0Fhj0rUAMZDgGYBQWYAQ8YA1AwOIYFLDIFJisfISkmBTEtBYY8LFADGQ0ClwYGlwINGQNQLzqFBS0xBSYreLJ+frJ+BJYFmAEOGQJQMDmGBSwxBiYrHiIoJgYxLAWGPSxRAxkOApcFBZcCDhkDUTA5hgUtMAYmKiAhKCYGMC0Fhj0sUAIZDgGYBf6ZfrF+frEABwBkAAAEsAUUABMAFwAhACUAKQAtADEAAAEhMhYdASEyFh0BITU0NjMhNTQ2FxUhNQERFAYjISImNREXETMRMxEzETMRMxEzETMRAfQBLCk7ARMKD/u0DwoBEzspASwBLDsp/UQpO2RkZGRkZGRkBRQ7KWQPCktLCg9kKTtkZGT+1PzgKTs7KQMgZP1EArz9RAK8/UQCvP1EArwAAQAMAAAFCATRAB8AABMBNjIXARYGKwERFAYrASImNREhERQGKwEiJjURIyImEgJsCBUHAmAIBQqvDwr6Cg/+1A8K+goPrwoFAmoCYAcH/aAICv3BCg8PCgF3/okKDw8KAj8KAAIAZAAAA+gEsAARABcAAAERFBYzIREUBiMhIiY1ETQ2MwEjIiY9AQJYOykBLB0V/OAVHR0VA1L6FR0EsP5wKTv9dhUdHRUETBUd/nAdFfoAAwAXABcEmQSZAA8AGwAwAAAAMh4CFA4CIi4CND4BBCIOARQeATI+ATQmBTMyFhURMzIWHQEUBisBIiY1ETQ2AePq1ptbW5vW6tabW1ubAb/oxXJyxejFcnL+fDIKD68KDw8K+goPDwSZW5vW6tabW1ub1urWmztyxejFcnLF6MUNDwr+7Q8KMgoPDwoBXgoPAAAAAAL/nAAABRQEsAALAA8AACkBAyMDIQEzAzMDMwEDMwMFFP3mKfIp/eYBr9EVohTQ/p4b4BsBkP5wBLD+1AEs/nD+1AEsAAAAAAIAZAAABLAEsAAVAC8AAAEzMhYVETMyFgcBBiInASY2OwERNDYBMzIWFREUBiMhIiY1ETQ2OwEyFh0BITU0NgImyBUdvxQLDf65DSYN/rkNCxS/HQJUMgoPDwr75goPDwoyCg8DhA8EsB0V/j4XEP5wEBABkBAXAcIVHfzgDwr+ogoPDwoBXgoPDwqvrwoPAAMAFwAXBJkEmQAPABsAMQAAADIeAhQOAiIuAjQ+AQQiDgEUHgEyPgE0JgUzMhYVETMyFgcDBiInAyY2OwERNDYB4+rWm1tbm9bq1ptbW5sBv+jFcnLF6MVycv58lgoPiRUKDd8NJg3fDQoViQ8EmVub1urWm1tbm9bq1ps7csXoxXJyxejFDQ8K/u0XEP7tEBABExAXARMKDwAAAAMAFwAXBJkEmQAPABsAMQAAADIeAhQOAiIuAjQ+AQQiDgEUHgEyPgE0JiUTFgYrAREUBisBIiY1ESMiJjcTNjIB4+rWm1tbm9bq1ptbW5sBv+jFcnLF6MVycv7n3w0KFYkPCpYKD4kVCg3fDSYEmVub1urWm1tbm9bq1ps7csXoxXJyxejFAf7tEBf+7QoPDwoBExcQARMQAAAAAAIAAAAABLAEsAAZADkAABMhMhYXExYVERQGBwYjISImJyY1EzQ3Ez4BBSEiBgcDBhY7ATIWHwEeATsBMjY/AT4BOwEyNicDLgHhAu4KEwO6BwgFDBn7tAweAgYBB7kDEwKX/dQKEgJXAgwKlgoTAiYCEwr6ChMCJgITCpYKDAJXAhIEsA4K/XQYGf5XDB4CBggEDRkBqRkYAowKDsgOC/4+Cw4OCpgKDg4KmAoODgsBwgsOAAMAFwAXBJkEmQAPABsAJwAAADIeAhQOAiIuAjQ+AQQiDgEUHgEyPgE0JgUXFhQPAQYmNRE0NgHj6tabW1ub1urWm1tbmwG/6MVycsXoxXJy/ov9ERH9EBgYBJlbm9bq1ptbW5vW6tabO3LF6MVycsXoxV2+DCQMvgwLFQGQFQsAAQAXABcEmQSwACgAAAE3NhYVERQGIyEiJj8BJiMiDgEUHgEyPgE1MxQOAiIuAjQ+AjMyA7OHBwsPCv6WCwQHhW2BdMVycsXoxXKWW5vW6tabW1ub1nXABCSHBwQL/pYKDwsHhUxyxejFcnLFdHXWm1tbm9bq1ptbAAAAAAIAFwABBJkEsAAaADUAAAE3NhYVERQGIyEiJj8BJiMiDgEVIzQ+AjMyEzMUDgIjIicHBiY1ETQ2MyEyFg8BFjMyPgEDs4cHCw8L/pcLBAeGboF0xXKWW5vWdcDrllub1nXAnIYHCw8LAWgKBQiFboJ0xXIEJIcHBAv+lwsPCweGS3LFdHXWm1v9v3XWm1t2hggFCgFoCw8LB4VMcsUAAAAKAGQAAASwBLAADwAfAC8APwBPAF8AbwB/AI8AnwAAEyEyFhURFAYjISImNRE0NgUhIgYVERQWMyEyNjURNCYFMzIWHQEUBisBIiY9ATQ2MyEyFh0BFAYjISImPQE0NgczMhYdARQGKwEiJj0BNDYzITIWHQEUBiMhIiY9ATQ2BzMyFh0BFAYrASImPQE0NjMhMhYdARQGIyEiJj0BNDYHMzIWHQEUBisBIiY9ATQ2MyEyFh0BFAYjISImPQE0Nn0EGgoPDwr75goPDwPA/K4KDw8KA1IKDw/9CDIKDw8KMgoPD9IBwgoPDwr+PgoPD74yCg8PCjIKDw/SAcIKDw8K/j4KDw++MgoPDwoyCg8P0gHCCg8PCv4+Cg8PvjIKDw8KMgoPD9IBwgoPDwr+PgoPDwSwDwr7ggoPDwoEfgoPyA8K/K4KDw8KA1IKD2QPCjIKDw8KMgoPDwoyCg8PCjIKD8gPCjIKDw8KMgoPDwoyCg8PCjIKD8gPCjIKDw8KMgoPDwoyCg8PCjIKD8gPCjIKDw8KMgoPDwoyCg8PCjIKDwAAAAACAAAAAARMBLAAGQAjAAABNTQmIyEiBh0BIyIGFREUFjMhMjY1ETQmIyE1NDY7ATIWHQEDhHVT/tRSdmQpOzspA4QpOzsp/ageFMgUHgMgyFN1dlLIOyn9qCk7OykCWCk7lhUdHRWWAAIAZAAABEwETAAJADcAABMzMhYVESMRNDYFMhcWFREUBw4DIyIuAScuAiMiBwYjIicmNRE+ATc2HgMXHgIzMjc2fTIKD2QPA8AEBRADIUNAMRwaPyonKSxHHlVLBwgGBQ4WeDsXKC4TOQQpLUUdZ1AHBEwPCvvNBDMKDzACBhH+WwYGO1AkDQ0ODg8PDzkFAwcPAbY3VwMCAwsGFAEODg5XCAAAAwAAAAAEsASXACEAMQBBAAAAMh4CFREUBisBIiY1ETQuASAOARURFAYrASImNRE0PgEDMzIWFREUBisBIiY1ETQ2ITMyFhURFAYrASImNRE0NgHk6N6jYw8KMgoPjeT++uSNDwoyCg9joyqgCAwMCKAIDAwCYKAIDAwIoAgMDASXY6PedP7UCg8PCgEsf9FyctF//tQKDw8KASx03qP9wAwI/jQIDAwIAcwIDAwI/jQIDAwIAcwIDAAAAAACAAAA0wRHA90AFQA5AAABJTYWFREUBiclJisBIiY1ETQ2OwEyBTc2Mh8BFhQPARcWFA8BBiIvAQcGIi8BJjQ/AScmND8BNjIXAUEBAgkMDAn+/hUZ+goPDwr6GQJYeAcUByIHB3h4BwciBxQHeHgHFAciBwd3dwcHIgcUBwMurAYHCv0SCgcGrA4PCgFeCg+EeAcHIgcUB3h4BxQHIgcHd3cHByIHFAd4eAcUByIICAAAAAACAAAA0wNyA90AFQAvAAABJTYWFREUBiclJisBIiY1ETQ2OwEyJTMWFxYVFAcGDwEiLwEuATc2NTQnJjY/ATYBQQECCQwMCf7+FRn6Cg8PCvoZAdIECgZgWgYLAwkHHQcDBkhOBgMIHQcDLqwGBwr9EgoHBqwODwoBXgoPZAEJgaGafwkBAQYXBxMIZ36EaggUBxYFAAAAAAMAAADEBGID7AAbADEASwAAATMWFxYVFAYHBgcjIi8BLgE3NjU0JicmNj8BNgUlNhYVERQGJyUmKwEiJjURNDY7ATIlMxYXFhUUBwYPASIvAS4BNzY1NCcmNj8BNgPHAwsGh0RABwoDCQcqCAIGbzs3BgIJKgf9ggECCQwMCf7+FRn6Cg8PCvoZAdIECgZgWgYLAwkHHQcDBkhOBgMIHQcD7AEJs9lpy1QJAQYiBhQIlrJarEcJFAYhBb6sBgcK/RIKBwasDg8KAV4KD2QBCYGhmn8JAQEGFwcTCGd+hGoIFQYWBQAAAAANAAAAAASwBLAACQAVABkAHQAhACUALQA7AD8AQwBHAEsATwAAATMVIxUhFSMRIQEjFTMVIREjESM1IQURIREhESERBSM1MwUjNTMBMxEhETM1MwEzFSMVIzUjNTM1IzUhBREhEQcjNTMFIzUzASM1MwUhNSEB9GRk/nBkAfQCvMjI/tTIZAJY+7QBLAGQASz84GRkArxkZP1EyP4MyGQB9MhkyGRkyAEs/UQBLGRkZAOEZGT+DGRkAfT+1AEsA4RkZGQCWP4MZMgBLAEsyGT+1AEs/tQBLMhkZGT+DP4MAfRk/tRkZGRkyGTI/tQBLMhkZGT+1GRkZAAAAAAJAAAAAASwBLAAAwAHAAsADwATABcAGwAfACMAADcjETMTIxEzASMRMxMjETMBIxEzASE1IRcjNTMXIzUzBSM1M2RkZMhkZAGQyMjIZGQBLMjI/OD+1AEsyGRkyGRkASzIyMgD6PwYA+j8GAPo/BgD6PwYA+j7UGRkW1tbW1sAAAIAAAAKBKYEsAANABUAAAkBFhQHAQYiJwETNDYzBCYiBhQWMjYB9AKqCAj+MAgUCP1WAQ8KAUM7Uzs7UzsEsP1WCBQI/jAICAKqAdsKD807O1Q7OwAAAAADAAAACgXSBLAADQAZACEAAAkBFhQHAQYiJwETNDYzIQEWFAcBBiIvAQkBBCYiBhQWMjYB9AKqCAj+MAgUCP1WAQ8KAwYCqggI/jAIFAg4Aaj9RP7TO1M7O1M7BLD9VggUCP4wCAgCqgHbCg/9VggUCP4wCAg4AaoCvM07O1Q7OwAAAAABAGQAAASwBLAAJgAAASEyFREUDwEGJjURNCYjISIPAQYWMyEyFhURFAYjISImNRE0PwE2ASwDOUsSQAgKDwr9RBkSQAgFCgK8Cg8PCvyuCg8SixIEsEv8fBkSQAgFCgO2Cg8SQAgKDwr8SgoPDwoDzxkSixIAAAABAMj//wRMBLAACgAAEyEyFhURCQERNDb6AyAVHf4+/j4dBLAdFfuCAbz+QwR/FR0AAAAAAwAAAAAEsASwABUARQBVAAABISIGBwMGHwEeATMhMjY/ATYnAy4BASMiBg8BDgEjISImLwEuASsBIgYVERQWOwEyNj0BNDYzITIWHQEUFjsBMjY1ETQmASEiBg8BBhYzITI2LwEuAQM2/kQLEAFOBw45BhcKAcIKFwY+DgdTARABVpYKFgROBBYK/doKFgROBBYKlgoPDwqWCg8PCgLuCg8PCpYKDw/+sf4MChMCJgILCgJYCgsCJgITBLAPCv7TGBVsCQwMCWwVGAEtCg/+cA0JnAkNDQmcCQ0PCv12Cg8PCpYKDw8KlgoPDwoCigoP/agOCpgKDg4KmAoOAAAAAAQAAABkBLAETAAdACEAKQAxAAABMzIeAh8BMzIWFREUBiMhIiY1ETQ2OwE+BAEVMzUEIgYUFjI2NCQyFhQGIiY0AfTIOF00JAcGlik7Oyn8GCk7OymWAgknM10ByGT+z76Hh76H/u9WPDxWPARMKTs7FRQ7Kf2oKTs7KQJYKTsIG0U1K/7UZGRGh76Hh74IPFY8PFYAAAAAAgA1AAAEsASvACAAIwAACQEWFx4BHwEVITUyNi8BIQYHBh4CMxUhNTY3PgE/AQEDIQMCqQGBFCgSJQkK/l81LBFS/nk6IgsJKjIe/pM4HAwaBwcBj6wBVKIEr/waMioTFQECQkJXLd6RWSIuHAxCQhgcDCUNDQPu/VoByQAAAAADAGQAAAPwBLAAJwAyADsAAAEeBhUUDgMjITU+ATURNC4EJzUFMh4CFRQOAgclMzI2NTQuAisBETMyNjU0JisBAvEFEzUwOyodN1htbDD+DCk7AQYLFyEaAdc5dWM+Hy0tEP6Pi05pESpTPnbYUFJ9Xp8CgQEHGB0zOlIuQ3VONxpZBzMoAzsYFBwLEAkHRwEpSXNDM1s6KwkxYUopOzQb/K5lUFqBAAABAMgAAANvBLAAGQAAARcOAQcDBhYXFSE1NjcTNjQuBCcmJzUDbQJTQgeECSxK/gy6Dq0DAw8MHxUXDQYEsDkTNSj8uTEoBmFhEFIDQBEaExAJCwYHAwI5AAAAAAL/tQAABRQEsAAlAC8AAAEjNC4FKwERFBYfARUhNTI+AzURIyIOBRUjESEFIxEzByczESM3BRQyCAsZEyYYGcgyGRn+cAQOIhoWyBkYJhMZCwgyA+j7m0tLfX1LS30DhBUgFQ4IAwH8rhYZAQJkZAEFCRUOA1IBAwgOFSAVASzI/OCnpwMgpwACACH/tQSPBLAAJQAvAAABIzQuBSsBERQWHwEVITUyPgM1ESMiDgUVIxEhEwc1IRUnNxUhNQRMMggLGRMmGBnIMhkZ/nAEDiIaFsgZGCYTGQsIMgPoQ6f84KenAyADhBUgFQ4IAwH9dhYZAQJkZAEFCRUOAooBAwgOFSAVASz7gn1LS319S0sABAAAAAAEsARMAA8AHwAvAD8AABMhMhYdARQGIyEiJj0BNDYTITIWHQEUBiMhIiY9ATQ2EyEyFh0BFAYjISImPQE0NhMhMhYdARQGIyEiJj0BNDYyAlgVHR0V/agVHR0VA+gVHR0V/BgVHR0VAyAVHR0V/OAVHR0VBEwVHR0V+7QVHR0ETB0VZBUdHRVkFR3+1B0VZBUdHRVkFR3+1B0VZBUdHRVkFR3+1B0VZBUdHRVkFR0ABAAAAAAEsARMAA8AHwAvAD8AABMhMhYdARQGIyEiJj0BNDYDITIWHQEUBiMhIiY9ATQ2EyEyFh0BFAYjISImPQE0NgMhMhYdARQGIyEiJj0BNDb6ArwVHR0V/UQVHR2zBEwVHR0V+7QVHR3dArwVHR0V/UQVHR2zBEwVHR0V+7QVHR0ETB0VZBUdHRVkFR3+1B0VZBUdHRVkFR3+1B0VZBUdHRVkFR3+1B0VZBUdHRVkFR0ABAAAAAAEsARMAA8AHwAvAD8AAAE1NDYzITIWHQEUBiMhIiYBNTQ2MyEyFh0BFAYjISImEzU0NjMhMhYdARQGIyEiJgE1NDYzITIWHQEUBiMhIiYB9B0VAlgVHR0V/agVHf5wHRUD6BUdHRX8GBUdyB0VAyAVHR0V/OAVHf7UHRUETBUdHRX7tBUdA7ZkFR0dFWQVHR3+6WQVHR0VZBUdHf7pZBUdHRVkFR0d/ulkFR0dFWQVHR0AAAQAAAAABLAETAAPAB8ALwA/AAATITIWHQEUBiMhIiY9ATQ2EyEyFh0BFAYjISImPQE0NhMhMhYdARQGIyEiJj0BNDYTITIWHQEUBiMhIiY9ATQ2MgRMFR0dFfu0FR0dFQRMFR0dFfu0FR0dFQRMFR0dFfu0FR0dFQRMFR0dFfu0FR0dBEwdFWQVHR0VZBUd/tQdFWQVHR0VZBUd/tQdFWQVHR0VZBUd/tQdFWQVHR0VZBUdAAgAAAAABLAETAAPAB8ALwA/AE8AXwBvAH8AABMzMhYdARQGKwEiJj0BNDYpATIWHQEUBiMhIiY9ATQ2ATMyFh0BFAYrASImPQE0NikBMhYdARQGIyEiJj0BNDYBMzIWHQEUBisBIiY9ATQ2KQEyFh0BFAYjISImPQE0NgEzMhYdARQGKwEiJj0BNDYpATIWHQEUBiMhIiY9ATQ2MmQVHR0VZBUdHQFBAyAVHR0V/OAVHR3+6WQVHR0VZBUdHQFBAyAVHR0V/OAVHR3+6WQVHR0VZBUdHQFBAyAVHR0V/OAVHR3+6WQVHR0VZBUdHQFBAyAVHR0V/OAVHR0ETB0VZBUdHRVkFR0dFWQVHR0VZBUd/tQdFWQVHR0VZBUdHRVkFR0dFWQVHf7UHRVkFR0dFWQVHR0VZBUdHRVkFR3+1B0VZBUdHRVkFR0dFWQVHR0VZBUdAAAG/5wAAASwBEwAAwATACMAKgA6AEoAACEjETsCMhYdARQGKwEiJj0BNDYTITIWHQEUBiMhIiY9ATQ2BQc1IzUzNQUhMhYdARQGIyEiJj0BNDYTITIWHQEUBiMhIiY9ATQ2AZBkZJZkFR0dFWQVHR0VAfQVHR0V/gwVHR3++qfIyAHCASwVHR0V/tQVHR0VAlgVHR0V/agVHR0ETB0VZBUdHRVkFR3+1B0VZBUdHRVkFR36fUtkS68dFWQVHR0VZBUd/tQdFWQVHR0VZBUdAAAABgAAAAAFFARMAA8AEwAjACoAOgBKAAATMzIWHQEUBisBIiY9ATQ2ASMRMwEhMhYdARQGIyEiJj0BNDYFMxUjFSc3BSEyFh0BFAYjISImPQE0NhMhMhYdARQGIyEiJj0BNDYyZBUdHRVkFR0dA2dkZPyuAfQVHR0V/gwVHR0EL8jIp6f75gEsFR0dFf7UFR0dFQJYFR0dFf2oFR0dBEwdFWQVHR0VZBUd+7QETP7UHRVkFR0dFWQVHchkS319rx0VZBUdHRVkFR3+1B0VZBUdHRVkFR0AAAAAAgAAAMgEsAPoAA8AEgAAEyEyFhURFAYjISImNRE0NgkCSwLuHywsH/0SHywsBIT+1AEsA+gsH/12HywsHwKKHyz9RAEsASwAAwAAAAAEsARMAA8AFwAfAAATITIWFREUBiMhIiY1ETQ2FxE3BScBExEEMhYUBiImNCwEWBIaGhL7qBIaGkr3ASpKASXs/NJwTk5wTgRMGhL8DBIaGhID9BIaZP0ftoOcAT7+4AH0dE5vT09vAAAAAAIA2wAFBDYEkQAWAB4AAAEyHgEVFAcOAQ8BLgQnJjU0PgIWIgYUFjI2NAKIdcZzRkWyNjYJIV5YbSk8RHOft7eCgreCBJF4ynVzj23pPz4IIWZomEiEdVijeUjDgriBgbgAAAACABcAFwSZBJkADwAXAAAAMh4CFA4CIi4CND4BAREiDgEUHgEB4+rWm1tbm9bq1ptbW5sBS3TFcnLFBJlbm9bq1ptbW5vW6tab/G8DVnLF6MVyAAACAHUAAwPfBQ8AGgA1AAABHgYVFA4DBy4DNTQ+BQMOAhceBBcWNj8BNiYnLgInJjc2IyYCKhVJT1dOPiUzVnB9P1SbfEokP0xXUEm8FykoAwEbITEcExUWAgYCCQkFEikMGiACCAgFD0iPdXdzdYdFR4BeRiYEBTpjl1lFh3ZzeHaQ/f4hS4I6JUEnIw4IBwwQIgoYBwQQQSlZtgsBAAAAAwAAAAAEywRsAAwAKgAvAAABNz4CHgEXHgEPAiUhMhcHISIGFREUFjMhMjY9ATcRFAYjISImNRE0NgkBBzcBA+hsAgYUFR0OFgoFBmz9BQGQMje7/pApOzspAfQpO8i7o/5wpbm5Azj+lqE3AWMD9XMBAgIEDw4WKgsKc8gNuzsp/gwpOzsptsj+tKW5uaUBkKW5/tf+ljKqAWMAAgAAAAAEkwRMABsANgAAASEGByMiBhURFBYzITI2NTcVFAYjISImNRE0NgUBFhQHAQYmJzUmDgMHPgY3NT4BAV4BaaQ0wyk7OykB9Ck7yLml/nClubkCfwFTCAj+rAcLARo5ZFRYGgouOUlARioTAQsETJI2Oyn+DCk7OymZZ6W5uaUBkKW5G/7TBxUH/s4GBAnLAQINFjAhO2JBNB0UBwHSCgUAAAAAAgAAAAAEnQRMAB0ANQAAASEyFwchIgYVERQWMyEyNj0BNxUUBiMhIiY1ETQ2CQE2Mh8BFhQHAQYiLwEmND8BNjIfARYyAV4BXjxDsv6jKTs7KQH0KTvIuaX+cKW5uQHKAYsHFQdlBwf97QcVB/gHB2UHFQdvCBQETBexOyn+DCk7OylFyNulubmlAZCluf4zAYsHB2UHFQf97AcH+AcVB2UHB28HAAAAAQAKAAoEpgSmADsAAAkBNjIXARYGKwEVMzU0NhcBFhQHAQYmPQEjFTMyFgcBBiInASY2OwE1IxUUBicBJjQ3ATYWHQEzNSMiJgE+AQgIFAgBBAcFCqrICggBCAgI/vgICsiqCgUH/vwIFAj++AgFCq/ICgj++AgIAQgICsivCgUDlgEICAj++AgKyK0KBAf+/AcVB/73BwQKrcgKCP74CAgBCAgKyK0KBAcBCQcVBwEEBwQKrcgKAAEAyAAAA4QETAAZAAATMzIWFREBNhYVERQGJwERFAYrASImNRE0NvpkFR0B0A8VFQ/+MB0VZBUdHQRMHRX+SgHFDggV/BgVCA4Bxf5KFR0dFQPoFR0AAAABAAAAAASwBEwAIwAAEzMyFhURATYWFREBNhYVERQGJwERFAYnAREUBisBIiY1ETQ2MmQVHQHQDxUB0A8VFQ/+MBUP/jAdFWQVHR0ETB0V/koBxQ4IFf5KAcUOCBX8GBUIDgHF/koVCA4Bxf5KFR0dFQPoFR0AAAABAJ0AGQSwBDMAFQAAAREUBicBERQGJwEmNDcBNhYVEQE2FgSwFQ/+MBUP/hQPDwHsDxUB0A8VBBr8GBUIDgHF/koVCA4B4A4qDgHgDggV/koBxQ4IAAAAAQDIABYEMwQ2AAsAABMBFhQHAQYmNRE0NvMDLhIS/NISGRkEMv4OCx4L/g4LDhUD6BUOAAIAyABkA4QD6AAPAB8AABMzMhYVERQGKwEiJjURNDYhMzIWFREUBisBIiY1ETQ2+sgVHR0VyBUdHQGlyBUdHRXIFR0dA+gdFfzgFR0dFQMgFR0dFfzgFR0dFQMgFR0AAAEAyABkBEwD6AAPAAABERQGIyEiJjURNDYzITIWBEwdFfzgFR0dFQMgFR0DtvzgFR0dFQMgFR0dAAAAAAEAAAAZBBMEMwAVAAABETQ2FwEWFAcBBiY1EQEGJjURNDYXAfQVDwHsDw/+FA8V/jAPFRUPAmQBthUIDv4gDioO/iAOCBUBtv47DggVA+gVCA4AAAH//gACBLMETwAjAAABNzIWFRMUBiMHIiY1AwEGJjUDAQYmNQM0NhcBAzQ2FwEDNDYEGGQUHgUdFWQVHQL+MQ4VAv4yDxUFFQ8B0gIVDwHSAh0ETgEdFfwYFR0BHRUBtf46DwkVAbX+OQ4JFAPoFQkP/j4BthQJDv49AbYVHQAAAQEsAAAD6ARMABkAAAEzMhYVERQGKwEiJjURAQYmNRE0NhcBETQ2A1JkFR0dFWQVHf4wDxUVDwHQHQRMHRX8GBUdHRUBtv47DggVA+gVCA7+OwG2FR0AAAIAZADIBLAESAALABsAAAkBFgYjISImNwE2MgEhMhYdARQGIyEiJj0BNDYCrgH1DwkW++4WCQ8B9Q8q/fcD6BUdHRX8GBUdHQQ5/eQPFhYPAhwP/UgdFWQVHR0VZBUdAAEAiP/8A3UESgAFAAAJAgcJAQN1/qABYMX92AIoA4T+n/6fxgIoAiYAAAAAAQE7//wEKARKAAUAAAkBJwkBNwQo/dnGAWH+n8YCI/3ZxgFhAWHGAAIAFwAXBJkEmQAPADMAAAAyHgIUDgIiLgI0PgEFIyIGHQEjIgYdARQWOwEVFBY7ATI2PQEzMjY9ATQmKwE1NCYB4+rWm1tbm9bq1ptbW5sBfWQVHZYVHR0Vlh0VZBUdlhUdHRWWHQSZW5vW6tabW1ub1urWm7odFZYdFWQVHZYVHR0Vlh0VZBUdlhUdAAAAAAIAFwAXBJkEmQAPAB8AAAAyHgIUDgIiLgI0PgEBISIGHQEUFjMhMjY9ATQmAePq1ptbW5vW6tabW1ubAkX+DBUdHRUB9BUdHQSZW5vW6tabW1ub1urWm/5+HRVkFR0dFWQVHQACABcAFwSZBJkADwAzAAAAMh4CFA4CIi4CND4BBCIPAScmIg8BBhQfAQcGFB8BFjI/ARcWMj8BNjQvATc2NC8BAePq1ptbW5vW6tabW1ubAeUZCXh4CRkJjQkJeHgJCY0JGQl4eAkZCY0JCXh4CQmNBJlbm9bq1ptbW5vW6tabrQl4eAkJjQkZCXh4CRkJjQkJeHgJCY0JGQl4eAkZCY0AAgAXABcEmQSZAA8AJAAAADIeAhQOAiIuAjQ+AQEnJiIPAQYUHwEWMjcBNjQvASYiBwHj6tabW1ub1urWm1tbmwEVVAcVCIsHB/IHFQcBdwcHiwcVBwSZW5vW6tabW1ub1urWm/4xVQcHiwgUCPEICAF3BxUIiwcHAAAAAAMAFwAXBJkEmQAPADsASwAAADIeAhQOAiIuAjQ+AQUiDgMVFDsBFjc+ATMyFhUUBgciDgUHBhY7ATI+AzU0LgMTIyIGHQEUFjsBMjY9ATQmAePq1ptbW5vW6tabW1ubAT8dPEIyIRSDHgUGHR8UFw4TARkOGhITDAIBDQ6tBx4oIxgiM0Q8OpYKDw8KlgoPDwSZW5vW6tabW1ub1urWm5ELHi9PMhkFEBQQFRIXFgcIBw4UHCoZCBEQKDhcNi9IKhsJ/eMPCpYKDw8KlgoPAAADABcAFwSZBJkADwAfAD4AAAAyHgIUDgIiLgI0PgEFIyIGHQEUFjsBMjY9ATQmAyMiBh0BFBY7ARUjIgYdARQWMyEyNj0BNCYrARE0JgHj6tabW1ub1urWm1tbmwGWlgoPDwqWCg8PCvoKDw8KS0sKDw8KAV4KDw8KSw8EmVub1urWm1tbm9bq1ptWDwqWCg8PCpYKD/7UDwoyCg/IDwoyCg8PCjIKDwETCg8AAgAAAAAEsASwAC8AXwAAATMyFh0BHgEXMzIWHQEUBisBDgEHFRQGKwEiJj0BLgEnIyImPQE0NjsBPgE3NTQ2ExUUBisBIiY9AQ4BBzMyFh0BFAYrAR4BFzU0NjsBMhYdAT4BNyMiJj0BNDY7AS4BAg2WCg9nlxvCCg8PCsIbl2cPCpYKD2eXG8IKDw8KwhuXZw+5DwqWCg9EZheoCg8PCqgXZkQPCpYKD0RmF6gKDw8KqBdmBLAPCsIbl2cPCpYKD2eXG8IKDw8KwhuXZw8KlgoPZ5cbwgoP/s2oCg8PCqgXZkQPCpYKD0RmF6gKDw8KqBdmRA8KlgoPRGYAAwAXABcEmQSZAA8AGwA/AAAAMh4CFA4CIi4CND4BBCIOARQeATI+ATQmBxcWFA8BFxYUDwEGIi8BBwYiLwEmND8BJyY0PwE2Mh8BNzYyAePq1ptbW5vW6tabW1ubAb/oxXJyxejFcnKaQAcHfHwHB0AHFQd8fAcVB0AHB3x8BwdABxUHfHwHFQSZW5vW6tabW1ub1urWmztyxejFcnLF6MVaQAcVB3x8BxUHQAcHfHwHB0AHFQd8fAcVB0AHB3x8BwAAAAMAFwAXBJkEmQAPABsAMAAAADIeAhQOAiIuAjQ+AQQiDgEUHgEyPgE0JgcXFhQHAQYiLwEmND8BNjIfATc2MgHj6tabW1ub1urWm1tbmwG/6MVycsXoxXJyg2oHB/7ACBQIyggIagcVB0/FBxUEmVub1urWm1tbm9bq1ps7csXoxXJyxejFfWoHFQf+vwcHywcVB2oICE/FBwAAAAMAFwAXBJkEmQAPABgAIQAAADIeAhQOAiIuAjQ+AQUiDgEVFBcBJhcBFjMyPgE1NAHj6tabW1ub1urWm1tbmwFLdMVyQQJLafX9uGhzdMVyBJlbm9bq1ptbW5vW6tabO3LFdHhpAktB0P24PnLFdHMAAAAAAQAXAFMEsAP5ABUAABMBNhYVESEyFh0BFAYjIREUBicBJjQnAgoQFwImFR0dFf3aFxD99hACRgGrDQoV/t0dFcgVHf7dFQoNAasNJgAAAAABAAAAUwSZA/kAFQAACQEWFAcBBiY1ESEiJj0BNDYzIRE0NgJ/AgoQEP32EBf92hUdHRUCJhcD8f5VDSYN/lUNChUBIx0VyBUdASMVCgAAAAEAtwAABF0EmQAVAAAJARYGIyERFAYrASImNREhIiY3ATYyAqoBqw0KFf7dHRXIFR3+3RUKDQGrDSYEif32EBf92hUdHRUCJhcQAgoQAAAAAQC3ABcEXQSwABUAAAEzMhYVESEyFgcBBiInASY2MyERNDYCJsgVHQEjFQoN/lUNJg3+VQ0KFQEjHQSwHRX92hcQ/fYQEAIKEBcCJhUdAAABAAAAtwSZBF0AFwAACQEWFAcBBiY1EQ4DBz4ENxE0NgJ/AgoQEP32EBdesKWBJAUsW4fHfhcEVf5VDSYN/lUNChUBIwIkRHVNabGdcUYHAQYVCgACAAAAAASwBLAAFQArAAABITIWFREUBi8BBwYiLwEmND8BJyY2ASEiJjURNDYfATc2Mh8BFhQPARcWBgNSASwVHRUOXvkIFAhqBwf5Xg4I/iH+1BUdFQ5e+QgUCGoHB/leDggEsB0V/tQVCA5e+QcHaggUCPleDhX7UB0VASwVCA5e+QcHaggUCPleDhUAAAACAEkASQRnBGcAFQArAAABFxYUDwEXFgYjISImNRE0Nh8BNzYyASEyFhURFAYvAQcGIi8BJjQ/AScmNgP2agcH+V4OCBX+1BUdFQ5e+QgU/QwBLBUdFQ5e+QgUCGoHB/leDggEYGoIFAj5Xg4VHRUBLBUIDl75B/3xHRX+1BUIDl75BwdqCBQI+V4OFQAAAAADABcAFwSZBJkADwAfAC8AAAAyHgIUDgIiLgI0PgEFIyIGFxMeATsBMjY3EzYmAyMiBh0BFBY7ATI2PQE0JgHj6tabW1ub1urWm1tbmwGz0BQYBDoEIxQ2FCMEOgQYMZYKDw8KlgoPDwSZW5vW6tabW1ub1urWm7odFP7SFB0dFAEuFB3+DA8KlgoPDwqWCg8AAAAABQAAAAAEsASwAEkAVQBhAGgAbwAAATIWHwEWHwEWFxY3Nj8BNjc2MzIWHwEWHwIeATsBMhYdARQGKwEiBh0BIREjESE1NCYrASImPQE0NjsBMjY1ND8BNjc+BAUHBhY7ATI2LwEuAQUnJgYPAQYWOwEyNhMhIiY1ESkBERQGIyERAQQJFAUFFhbEFQ8dCAsmxBYXERUXMA0NDgQZCAEPCj0KDw8KMgoP/nDI/nAPCjIKDw8KPQsOCRkFDgIGFRYfAp2mBwQK2woKAzMDEP41sQgQAzMDCgrnCwMe/okKDwGQAlgPCv6JBLAEAgIKDXYNCxUJDRZ2DQoHIREQFRh7LAkLDwoyCg8PCq8BLP7UrwoPDwoyCg8GBQQwgBkUAwgWEQ55ogcKDgqVCgSqnQcECo8KDgr8cg8KAXf+iQoPAZAAAAAAAgAAAAwErwSmACsASQAAATYWFQYCDgQuAScmByYOAQ8BBiY1NDc+ATc+AScuAT4BNz4GFyYGBw4BDwEOBAcOARY2Nz4CNz4DNz4BBI0IGgItQmxhi2KORDg9EQQRMxuZGhYqCFUYEyADCQIQOjEnUmFch3vAJQgdHyaiPT44XHRZUhcYDhItIRmKcVtGYWtbKRYEBKYDEwiy/t3IlVgxEQgLCwwBAQIbG5kYEyJAJghKFRE8Hzdff4U/M0o1JSMbL0QJGCYvcSEhHjZST2c1ODwEJygeW0AxJUBff1UyFAABAF0AHgRyBM8ATwAAAQ4BHgQXLgc+ATceAwYHDgQHBicmNzY3PgQuAScWDgMmJy4BJyY+BDcGHgM3PgEuAicmPgMCjScfCic4R0IgBBsKGAoQAwEJEg5gikggBhANPkpTPhZINx8SBgsNJysiCRZOQQoVNU1bYC9QZwICBAUWITsoCAYdJzIYHw8YIiYHDyJJYlkEz0OAZVxEOSQMBzgXOB42IzElKRIqg5Gnl0o3Z0c6IAYWCwYNAwQFIDhHXGF1OWiqb0sdBxUknF0XNTQ8PEUiNWNROBYJDS5AQVUhVZloUSkAAAAAA//cAGoE1ARGABsAPwBRAAAAMh4FFA4FIi4FND4EBSYGFxYVFAYiJjU0NzYmBwYHDgEXHgQyPgM3NiYnJgUHDgEXFhcWNj8BNiYnJicuAQIGpJ17bk85HBw6T257naKde25POhwcOU9uewIPDwYIGbD4sBcIBw5GWg0ECxYyWl+DiINfWjIWCwQMWv3/Iw8JCSU4EC0OIw4DDywtCyIERi1JXGJcSSpJXGJcSS0tSVxiXEkqSVxiXEncDwYTOT58sLB8OzcTBg9FcxAxEiRGXkQxMEVeRSQSMRF1HiQPLxJEMA0EDyIPJQ8sSRIEAAAABP/cAAAE1ASwABQAJwA7AEwAACEjNy4ENTQ+BTMyFzczEzceARUUDgMHNz4BNzYmJyYlBgcOARceBBc3LgE1NDc2JhcHDgEXFhcWNj8CJyYnLgECUJQfW6l2WSwcOU9ue51SPUEglCYvbIknUGqYUi5NdiYLBAw2/VFGWg0ECxIqSExoNSlrjxcIB3wjDwkJJTgQLQ4MFgMsLQsieBRhdHpiGxVJXGJcSS0Pef5StVXWNBpacm5jGq0xiD8SMRFGckVzEDESHjxRQTkNmhKnbjs3EwZwJA8vEkQwDQQPC1YELEkSBAAAAAP/ngAABRIEqwALABgAKAAAJwE2FhcBFgYjISImJSE1NDY7ATIWHQEhAQczMhYPAQ4BKwEiJi8BJjZaAoIUOBQCghUbJfryJRsBCgFZDwqWCg8BWf5DaNAUGAQ6BCMUNhQjBDoEGGQEKh8FIfvgIEdEhEsKDw8KSwLT3x0U/BQdHRT8FB0AAAABAGQAFQSwBLAAKAAAADIWFREBHgEdARQGJyURFh0BFAYvAQcGJj0BNDcRBQYmPQE0NjcBETQCTHxYAWsPFhgR/plkGhPNzRMaZP6ZERgWDwFrBLBYPv6t/rsOMRQpFA0M+f75XRRAFRAJgIAJEBVAFF0BB/kMDRQpFDEOAUUBUz4AAAARAAAAAARMBLAAHQAnACsALwAzADcAOwA/AEMARwBLAE8AUwBXAFsAXwBjAAABMzIWHQEzMhYdASE1NDY7ATU0NjsBMhYdASE1NDYBERQGIyEiJjURFxUzNTMVMzUzFTM1MxUzNTMVMzUFFTM1MxUzNTMVMzUzFTM1MxUzNQUVMzUzFTM1MxUzNTMVMzUzFTM1A1JkFR0yFR37tB0VMh0VZBUdAfQdAQ8dFfwYFR1kZGRkZGRkZGRk/HxkZGRkZGRkZGT8fGRkZGRkZGRkZASwHRUyHRWWlhUdMhUdHRUyMhUd/nD9EhUdHRUC7shkZGRkZGRkZGRkyGRkZGRkZGRkZGTIZGRkZGRkZGRkZAAAAAMAAAAZBXcElwAZACUANwAAARcWFA8BBiY9ASMBISImPQE0NjsBATM1NDYBBycjIiY9ATQ2MyEBFxYUDwEGJj0BIyc3FzM1NDYEb/kPD/kOFZ/9qP7dFR0dFdECWPEV/amNetEVHR0VASMDGvkPD/kOFfG1jXqfFQSN5g4qDuYOCBWW/agdFWQVHQJYlhUI/piNeh0VZBUd/k3mDioO5g4IFZa1jXqWFQgAAAABAAAAAASwBEwAEgAAEyEyFhURFAYjIQERIyImNRE0NmQD6Ck7Oyn9rP7QZCk7OwRMOyn9qCk7/tQBLDspAlgpOwAAAAMAZAAABEwEsAAJABMAPwAAEzMyFh0BITU0NiEzMhYdASE1NDYBERQOBSIuBTURIRUUFRwBHgYyPgYmNTQ9AZbIFR3+1B0C0cgVHf7UHQEPBhgoTGacwJxmTCgYBgEsAwcNFB8nNkI2Jx8TDwUFAQSwHRX6+hUdHRX6+hUd/nD+1ClJalZcPigoPlxWakkpASz6CRIVKyclIRsWEAgJEBccISUnKhURCPoAAAAB//8A1ARMA8IABQAAAQcJAScBBEzG/p/+n8UCJwGbxwFh/p/HAicAAQAAAO4ETQPcAAUAAAkCNwkBBE392v3ZxgFhAWEDFf3ZAifH/p8BYQAAAAAC/1EAZAVfA+gAFAApAAABITIWFREzMhYPAQYiLwEmNjsBESElFxYGKwERIRchIiY1ESMiJj8BNjIBlALqFR2WFQgO5g4qDuYOCBWW/oP+HOYOCBWWAYHX/RIVHZYVCA7mDioD6B0V/dkVDvkPD/kOFQGRuPkOFf5wyB0VAiYVDvkPAAABAAYAAASeBLAAMAAAEzMyFh8BITIWBwMOASMhFyEyFhQGKwEVFAYiJj0BIRUUBiImPQEjIiYvAQMjIiY0NjheERwEJgOAGB4FZAUsIf2HMAIXFR0dFTIdKh3+1B0qHR8SHQYFyTYUHh4EsBYQoiUY/iUVK8gdKh0yFR0dFTIyFR0dFTIUCQoDwR0qHQAAAAACAAAAAASwBEwACwAPAAABFSE1MzQ2MyEyFhUFIREhBLD7UMg7KQEsKTv9RASw+1AD6GRkKTs7Kcj84AACAAAAAAXcBEwADAAQAAATAxEzNDYzITIWFSEVBQEhAcjIyDspASwqOgH0ASz+1PtQASwDIP5wAlgpOzspyGT9RAK8AAEBRQAAA2sErwAbAAABFxYGKwERMzIWDwEGIi8BJjY7AREjIiY/ATYyAnvmDggVlpYVCA7mDioO5g4IFZaWFQgO5g4qBKD5DhX9pxUO+Q8P+Q4VAlkVDvkPAAAAAQABAUQErwNrABsAAAEXFhQPAQYmPQEhFRQGLwEmND8BNhYdASE1NDYDqPkODvkPFf2oFQ/5Dg75DxUCWBUDYOUPKQ/lDwkUl5cUCQ/lDykP5Q8JFZWVFQkAAAAEAAAAAASwBLAACQAZAB0AIQAAAQMuASMhIgYHAwUhIgYdARQWMyEyNj0BNCYFNTMVMzUzFQSRrAUkFP1gFCQFrAQt/BgpOzspA+gpOzv+q2RkZAGQAtwXLSgV/R1kOylkKTs7KWQpO8hkZGRkAAAAA/+cAGQEsARMAAsAIwAxAAAAMhYVERQGIiY1ETQDJSMTFgYjIisBIiYnAj0BNDU0PgE7ASUBFSIuAz0BND4CNwRpKh0dKh1k/V0mLwMRFQUCVBQdBDcCCwzIAqP8GAQOIhoWFR0dCwRMHRX8rhUdHRUDUhX8mcj+7BAIHBUBUQ76AgQQDw36/tT6AQsTKRwyGigUDAEAAAACAEoAAARmBLAALAA1AAABMzIWDwEeARcTFzMyFhQGBw4EIyIuBC8BLgE0NjsBNxM+ATcnJjYDFjMyNw4BIiYCKV4UEgYSU3oPP3YRExwaEggeZGqfTzl0XFU+LwwLEhocExF2Pw96UxIGEyQyNDUxDDdGOASwFRMlE39N/rmtHSkoBwQLHBYSCg4REg4FBAgoKR2tAUdNfhQgExr7vgYGMT09AAEAFAAUBJwEnAAXAAABNwcXBxcHFycHJwcnBzcnNyc3Jxc3FzcDIOBO6rS06k7gLZubLeBO6rS06k7gLZubA7JO4C2bmy3gTuq0tOpO4C2bmy3gTuq0tAADAAAAZASwBLAAIQAtAD0AAAEzMhYdAQchMhYdARQHAw4BKwEiJi8BIyImNRE0PwI+ARcPAREzFzMTNSE3NQEzMhYVERQGKwEiJjURNDYCijIoPBwBSCg8He4QLBf6B0YfHz0tNxSRYA0xG2SWZIjW+v4+Mv12ZBUdHRVkFR0dBLBRLJZ9USxkLR3+qBghMhkZJCcBkCQbxMYcKGTU1f6JZAF3feGv/tQdFf4MFR0dFQH0FR0AAAAAAwAAAAAEsARMACAAMAA8AAABMzIWFxMWHQEUBiMhFh0BFAYrASImLwImNRE0NjsBNgUzMhYVERQGKwEiJjURNDYhByMRHwEzNSchNQMCWPoXLBDuHTwo/rgcPCgyGzENYJEUNy09fP3pZBUdHRVkFR0dAl+IZJZkMjIBwvoETCEY/qgdLWQsUXYHlixRKBzGxBskAZAnJGRkHRX+DBUdHRUB9BUdZP6J1dSv4X0BdwADAAAAZAUOBE8AGwA3AEcAAAElNh8BHgEPASEyFhQGKwEDDgEjISImNRE0NjcXERchEz4BOwEyNiYjISoDLgQnJj8BJwUzMhYVERQGKwEiJjURNDYBZAFrHxZuDQEMVAEuVGxuVGqDBhsP/qoHphwOOmQBJYMGGw/LFRMSFv44AgoCCQMHAwUDAQwRklb9T2QVHR0VZBUdHQNp5hAWcA0mD3lMkE7+rRUoog0CDRElCkj+CVkBUxUoMjIBAgIDBQIZFrdT5B0V/gwVHR0VAfQVHQAAAAP/nABkBLAETwAdADYARgAAAQUeBBURFAYjISImJwMjIiY0NjMhJyY2PwE2BxcWBw4FKgIjIRUzMhYXEyE3ESUFMzIWFREUBisBIiY1ETQ2AdsBbgIIFBANrAf+qg8bBoNqVW1sVAEuVQsBDW4WSpIRDAIDBQMHAwkDCgH+Jd0PHAaCASZq/qoCUGQVHR0VZBUdHQRP5gEFEBEXC/3zDaIoFQFTTpBMeQ8mDXAWrrcWGQIFAwICAWQoFf6tWQH37OQdFf4MFR0dFQH0FR0AAAADAGEAAARMBQ4AGwA3AEcAAAAyFh0BBR4BFREUBiMhIiYvAQMmPwE+AR8BETQXNTQmBhURHAMOBAcGLwEHEyE3ESUuAQMhMhYdARQGIyEiJj0BNDYB3pBOAVMVKKIN/fMRJQoJ5hAWcA0mD3nGMjIBAgIDBQIZFrdT7AH3Wf6tFSiWAfQVHR0V/gwVHR0FDm5UaoMGGw/+qgemHA4OAWsfFm4NAQxUAS5U1ssVExIW/jgCCgIJAwcDBQMBDBGSVv6tZAElgwYb/QsdFWQVHR0VZBUdAAP//QAGA+gFFAAPAC0ASQAAASEyNj0BNCYjISIGHQEUFgEVFAYiJjURBwYmLwEmNxM+BDMhMhYVERQGBwEDFzc2Fx4FHAIVERQWNj0BNDY3JREnAV4B9BUdHRX+DBUdHQEPTpBMeQ8mDXAWEOYBBRARFwsCDQ2iKBX9iexTtxYZAgUDAgIBMjIoFQFTWQRMHRVkFR0dFWQVHfzmalRubFQBLlQMAQ1uFh8BawIIEw8Mpgf+qg8bBgHP/q1WkhEMAQMFAwcDCQIKAv44FhITFcsPGwaDASVkAAIAFgAWBJoEmgAPACUAAAAyHgIUDgIiLgI0PgEBJSYGHQEhIgYdARQWMyEVFBY3JTY0AeLs1ptbW5vW7NabW1ubAob+7RAX/u0KDw8KARMXEAETEASaW5vW7NabW1ub1uzWm/453w0KFYkPCpYKD4kVCg3fDSYAAAIAFgAWBJoEmgAPACUAAAAyHgIUDgIiLgI0PgENAQYUFwUWNj0BITI2PQE0JiMhNTQmAeLs1ptbW5vW7NabW1ubASX+7RAQARMQFwETCg8PCv7tFwSaW5vW7NabW1ub1uzWm+jfDSYN3w0KFYkPCpYKD4kVCgAAAAIAFgAWBJoEmgAPACUAAAAyHgIUDgIiLgI0PgEBAyYiBwMGFjsBERQWOwEyNjURMzI2AeLs1ptbW5vW7NabW1ubAkvfDSYN3w0KFYkPCpYKD4kVCgSaW5vW7NabW1ub1uzWm/5AARMQEP7tEBf+7QoPDwoBExcAAAIAFgAWBJoEmgAPACUAAAAyHgIUDgIiLgI0PgEFIyIGFREjIgYXExYyNxM2JisBETQmAeLs1ptbW5vW7NabW1ubAZeWCg+JFQoN3w0mDd8NChWJDwSaW5vW7NabW1ub1uzWm7sPCv7tFxD+7RAQARMQFwETCg8AAAMAGAAYBJgEmAAPAJYApgAAADIeAhQOAiIuAjQ+ASUOAwcGJgcOAQcGFgcOAQcGFgcUFgcyHgEXHgIXHgI3Fg4BFx4CFxQGFBcWNz4CNy4BJy4BJyIOAgcGJyY2NS4BJzYuAQYHBicmNzY3HgIXHgMfAT4CJyY+ATc+AzcmNzIWMjY3LgMnND4CJiceAT8BNi4CJwYHFB4BFS4CJz4BNxYyPgEB5OjVm1xcm9Xo1ZtcXJsBZA8rHDoKDz0PFD8DAxMBAzEFCRwGIgEMFhkHECIvCxU/OR0HFBkDDRQjEwcFaHUeISQDDTAMD0UREi4oLBAzDwQBBikEAQMLGhIXExMLBhAGKBsGBxYVEwYFAgsFAwMNFwQGCQcYFgYQCCARFwkKKiFBCwQCAQMDHzcLDAUdLDgNEiEQEgg/KhADGgMKEgoRBJhcm9Xo1ZtcXJvV6NWbEQwRBwkCAwYFBycPCxcHInIWInYcCUcYChQECA4QBAkuHgQPJioRFRscBAcSCgwCch0kPiAIAQcHEAsBAgsLIxcBMQENCQIPHxkCFBkdHB4QBgEBBwoMGBENBAMMJSAQEhYXDQ4qFBkKEhIDCQsXJxQiBgEOCQwHAQ0DBAUcJAwSCwRnETIoAwEJCwsLJQcKDBEAAAAAAQAAAAIErwSFABYAAAE2FwUXNxYGBw4BJwEGIi8BJjQ3ASY2AvSkjv79kfsGUE08hjv9rA8rD28PDwJYIk8EhVxliuh+WYcrIgsW/awQEG4PKxACV2XJAAYAAABgBLAErAAPABMAIwAnADcAOwAAEyEyFh0BFAYjISImPQE0NgUjFTMFITIWHQEUBiMhIiY9ATQ2BSEVIQUhMhYdARQGIyEiJj0BNDYFIRUhZAPoKTs7KfwYKTs7BBHIyPwYA+gpOzsp/BgpOzsEEf4MAfT8GAPoKTs7KfwYKTs7BBH+1AEsBKw7KWQpOzspZCk7ZGTIOylkKTs7KWQpO2RkyDspZCk7OylkKTtkZAAAAAIAZAAABEwEsAALABEAABMhMhYUBiMhIiY0NgERBxEBIZYDhBUdHRX8fBUdHQI7yP6iA4QEsB0qHR0qHf1E/tTIAfQB9AAAAAMAAABkBLAEsAAXABsAJQAAATMyFh0BITIWFREhNSMVIRE0NjMhNTQ2FxUzNQEVFAYjISImPQEB9MgpOwEsKTv+DMj+DDspASw7KcgB9Dsp/BgpOwSwOylkOyn+cGRkAZApO2QpO2RkZP1EyCk7OynIAAAABAAAAAAEsASwABUAKwBBAFcAABMhMhYPARcWFA8BBiIvAQcGJjURNDYpATIWFREUBi8BBwYiLwEmND8BJyY2ARcWFA8BFxYGIyEiJjURNDYfATc2MgU3NhYVERQGIyEiJj8BJyY0PwE2MhcyASwVCA5exwcHaggUCMdeDhUdAzUBLBUdFQ5exwgUCGoHB8deDgj+L2oHB8deDggV/tQVHRUOXscIFALLXg4VHRX+1BUIDl7HBwdqCBQIBLAVDl7HCBQIagcHx14OCBUBLBUdHRX+1BUIDl7HBwdqCBQIx14OFf0maggUCMdeDhUdFQEsFQgOXscHzl4OCBX+1BUdFQ5exwgUCGoHBwAAAAYAAAAABKgEqAAPABsAIwA7AEMASwAAADIeAhQOAiIuAjQ+AQQiDgEUHgEyPgE0JiQyFhQGIiY0JDIWFAYjIicHFhUUBiImNTQ2PwImNTQEMhYUBiImNCQyFhQGIiY0Advy3Z9fX5/d8t2gXl6gAcbgv29vv+C/b2/+LS0gIC0gAUwtICAWDg83ETNIMykfegEJ/octICAtIAIdLSAgLSAEqF+f3fLdoF5eoN3y3Z9Xb7/gv29vv+C/BiAtISEtICAtIQqRFxwkMzMkIDEFfgEODhekIC0gIC0gIC0gIC0AAf/YAFoEuQS8AFsAACUBNjc2JicmIyIOAwcABw4EFx4BMzI3ATYnLgEjIgcGBwEOASY0NwA3PgEzMhceARcWBgcOBgcGIyImJyY2NwE2NzYzMhceARcWBgcBDgEnLgECIgHVWwgHdl8WGSJBMD8hIP6IDx4eLRMNBQlZN0ozAiQkEAcdEhoYDRr+qw8pHA4BRyIjQS4ODyw9DQ4YIwwod26La1YOOEBGdiIwGkQB/0coW2tQSE5nDxE4Qv4eDyoQEAOtAdZbZWKbEQQUGjIhH/6JDxsdNSg3HT5CMwIkJCcQFBcMGv6uDwEcKQ4BTSIjIQEINykvYyMLKnhuiWZMBxtAOU6+RAH/SBg3ISSGV121Qv4kDwIPDyYAAAACAGQAWASvBEQAGQBEAAABPgIeAhUUDgMHLgQ1ND4CHgEFIg4DIi4DIyIGFRQeAhcWFx4EMj4DNzY3PgQ1NCYCiTB7eHVYNkN5hKg+PqeFeEM4WnZ4eQEjIT8yLSohJyktPyJDbxtBMjMPBw86KzEhDSIzKUAMBAgrKT8dF2oDtURIBS1TdkA5eYB/slVVsn+AeTlAdlMtBUgtJjY1JiY1NiZvTRc4SjQxDwcOPCouGBgwKEALBAkpKkQqMhNPbQACADn/8gR3BL4AFwAuAAAAMh8BFhUUBg8BJi8BNycBFwcvASY0NwEDNxYfARYUBwEGIi8BJjQ/ARYfAQcXAQKru0KNQjgiHR8uEl/3/nvUaRONQkIBGxJpCgmNQkL+5UK6Qo1CQjcdLhJf9wGFBL5CjUJeKmsiHTUuEl/4/nvUahKNQrpCARv+RmkICY1CukL+5UJCjUK7Qjc3LxFf+AGFAAAAAAMAyAAAA+gEsAARABUAHQAAADIeAhURFAYjISImNRE0PgEHESERACIGFBYyNjQCBqqaZDo7Kf2oKTs8Zj4CWP7/Vj09Vj0EsB4uMhX8Ryk7OykDuRUzLar9RAK8/RY9Vj09VgABAAAAAASwBLAAFgAACQEWFAYiLwEBEScBBRMBJyEBJyY0NjIDhgEbDx0qDiT+6dT+zP7oywEz0gEsAQsjDx0qBKH+5g8qHQ8j/vX+1NL+zcsBGAE01AEXJA4qHQAAAAADAScAEQQJBOAAMgBAAEsAAAEVHgQXIy4DJxEXHgQVFAYHFSM1JicuASczHgEXEScuBDU0PgI3NRkBDgMVFB4DFxYXET4ENC4CArwmRVI8LAKfBA0dMydAIjxQNyiym2SWVygZA4sFV0obLkJOMCAyVWg6HSoqFQ4TJhkZCWgWKTEiGBkzNwTgTgUTLD9pQiQuLBsH/s0NBxMtPGQ+i6oMTU8QVyhrVk1iEAFPCA4ZLzlYNkZwSCoGTf4SARIEDh02Jh0rGRQIBgPQ/soCCRYgNEM0JRkAAAABAGQAZgOUBK0ASgAAATIeARUjNC4CIyIGBwYVFB4BFxYXMxUjFgYHBgc+ATM2FjMyNxcOAyMiLgEHDgEPASc+BTc+AScjNTMmJy4CPgE3NgIxVJlemSc8OxolVBQpGxoYBgPxxQgVFS02ImIWIIwiUzUyHzY4HCAXanQmJ1YYFzcEGAcTDBEJMAwk3aYXFQcKAg4tJGEErVCLTig/IhIdFSw5GkowKgkFZDKCHj4yCg8BIh6TExcIASIfBAMaDAuRAxAFDQsRCjePR2QvORQrREFMIVgAAAACABn//wSXBLAADwAfAAABMzIWDwEGIi8BJjY7AREzBRcWBisBESMRIyImPwE2MgGQlhUIDuYOKg7mDggVlsgCF+YOCBWWyJYVCA7mDioBLBYO+g8P+g4WA4QQ+Q4V/HwDhBUO+Q8AAAQAGf//A+gEsAAHABcAGwAlAAABIzUjFSMRIQEzMhYPAQYiLwEmNjsBETMFFTM1EwczFSE1NyM1IQPoZGRkASz9qJYVCA7mDioO5g4IFZbIAZFkY8jI/tTIyAEsArxkZAH0/HwWDvoPD/oOFgOEZMjI/RL6ZJb6ZAAAAAAEABn//wPoBLAADwAZACEAJQAAATMyFg8BBiIvASY2OwERMwUHMxUhNTcjNSERIzUjFSMRIQcVMzUBkJYVCA7mDioO5g4IFZbIAljIyP7UyMgBLGRkZAEsx2QBLBYO+g8P+g4WA4SW+mSW+mT7UGRkAfRkyMgAAAAEABn//wRMBLAADwAVABsAHwAAATMyFg8BBiIvASY2OwERMwEjESM1MxMjNSMRIQcVMzUBkJYVCA7mDioO5g4IFZbIAlhkZMhkZMgBLMdkASwWDvoPD/oOFgOE/gwBkGT7UGQBkGTIyAAAAAAEABn//wRMBLAADwAVABkAHwAAATMyFg8BBiIvASY2OwERMwEjNSMRIQcVMzUDIxEjNTMBkJYVCA7mDioO5g4IFZbIArxkyAEsx2QBZGTIASwWDvoPD/oOFgOE/gxkAZBkyMj7tAGQZAAAAAAFABn//wSwBLAADwATABcAGwAfAAABMzIWDwEGIi8BJjY7AREzBSM1MxMhNSETITUhEyE1IQGQlhUIDuYOKg7mDggVlsgB9MjIZP7UASxk/nABkGT+DAH0ASwWDvoPD/oOFgOEyMj+DMj+DMj+DMgABQAZ//8EsASwAA8AEwAXABsAHwAAATMyFg8BBiIvASY2OwERMwUhNSEDITUhAyE1IQMjNTMBkJYVCA7mDioO5g4IFZbIAyD+DAH0ZP5wAZBk/tQBLGTIyAEsFg76Dw/6DhYDhMjI/gzI/gzI/gzIAAIAAAAABEwETAAPAB8AAAEhMhYVERQGIyEiJjURNDYFISIGFREUFjMhMjY1ETQmAV4BkKK8u6P+cKW5uQJn/gwpOzspAfQpOzsETLuj/nClubmlAZClucg7Kf4MKTs7KQH0KTsAAAAAAwAAAAAETARMAA8AHwArAAABITIWFREUBiMhIiY1ETQ2BSEiBhURFBYzITI2NRE0JgUXFhQPAQYmNRE0NgFeAZClubml/nCju7wCZP4MKTs7KQH0KTs7/m/9ERH9EBgYBEy5pf5wpbm5pQGQo7vIOyn+DCk7OykB9Ck7gr4MJAy+DAsVAZAVCwAAAAADAAAAAARMBEwADwAfACsAAAEhMhYVERQGIyEiJjURNDYFISIGFREUFjMhMjY1ETQmBSEyFg8BBiIvASY2AV4BkKO7uaX+cKW5uQJn/gwpOzspAfQpOzv+FQGQFQsMvgwkDL4MCwRMvKL+cKW5uaUBkKO7yDsp/gwpOzspAfQpO8gYEP0REf0QGAAAAAMAAAAABEwETAAPAB8AKwAAASEyFhURFAYjISImNRE0NgUhIgYVERQWMyEyNjURNCYFFxYGIyEiJj8BNjIBXgGQpbm5pf5wo7u5Amf+DCk7OykB9Ck7O/77vgwLFf5wFQsMvgwkBEy5pf5wo7u8ogGQpbnIOyn+DCk7OykB9Ck7z/0QGBgQ/REAAAAAAgAAAAAFFARMAB8ANQAAASEyFhURFAYjISImPQE0NjMhMjY1ETQmIyEiJj0BNDYHARYUBwEGJj0BIyImPQE0NjsBNTQ2AiYBkKW5uaX+cBUdHRUBwik7Oyn+PhUdHb8BRBAQ/rwQFvoVHR0V+hYETLml/nCluR0VZBUdOykB9Ck7HRVkFR3p/uQOJg7+5A4KFZYdFcgVHZYVCgAAAQDZAAID1wSeACMAAAEXFgcGAgclMhYHIggBBwYrAScmNz4BPwEhIicmNzYANjc2MwMZCQgDA5gCASwYEQ4B/vf+8wQMDgkJCQUCUCcn/tIXCAoQSwENuwUJEASeCQoRC/5TBwEjEv7K/sUFDwgLFQnlbm4TFRRWAS/TBhAAAAACAAAAAAT+BEwAHwA1AAABITIWHQEUBiMhIgYVERQWMyEyFh0BFAYjISImNRE0NgUBFhQHAQYmPQEjIiY9ATQ2OwE1NDYBXgGQFR0dFf4+KTs7KQHCFR0dFf5wpbm5AvEBRBAQ/rwQFvoVHR0V+hYETB0VZBUdOyn+DCk7HRVkFR25pQGQpbnp/uQOJg7+5A4KFZYdFcgVHZYVCgACAAAAAASwBLAAFQAxAAABITIWFREUBi8BAQYiLwEmNDcBJyY2ASMiBhURFBYzITI2PQE3ERQGIyEiJjURNDYzIQLuAZAVHRUObf7IDykPjQ8PAThtDgj+75wpOzspAfQpO8i7o/5wpbm5pQEsBLAdFf5wFQgObf7IDw+NDykPAThtDhX+1Dsp/gwpOzsplMj+1qW5uaUBkKW5AAADAA4ADgSiBKIADwAbACMAAAAyHgIUDgIiLgI0PgEEIg4BFB4BMj4BNCYEMhYUBiImNAHh7tmdXV2d2e7ZnV1dnQHD5sJxccLmwnFx/nugcnKgcgSiXZ3Z7tmdXV2d2e7ZnUdxwubCcXHC5sJzcqBycqAAAAMAAAAABEwEsAAVAB8AIwAAATMyFhURMzIWBwEGIicBJjY7ARE0NgEhMhYdASE1NDYFFTM1AcLIFR31FAoO/oEOJw3+hQ0JFfod/oUD6BUd+7QdA2dkBLAdFf6iFg/+Vg8PAaoPFgFeFR38fB0V+voVHWQyMgAAAAMAAAAABEwErAAVAB8AIwAACQEWBisBFRQGKwEiJj0BIyImNwE+AQEhMhYdASE1NDYFFTM1AkcBeg4KFfQiFsgUGPoUCw4Bfw4n/fkD6BUd+7QdA2dkBJ7+TQ8g+hQeHRX6IQ8BrxAC/H8dFfr6FR1kMjIAAwAAAAAETARLABQAHgAiAAAJATYyHwEWFAcBBiInASY0PwE2MhcDITIWHQEhNTQ2BRUzNQGMAXEHFQeLBwf98wcVB/7cBweLCBUH1APoFR37tB0DZ2QC0wFxBweLCBUH/fMICAEjCBQIiwcH/dIdFfr6FR1kMjIABAAAAAAETASbAAkAGQAjACcAABM3NjIfAQcnJjQFNzYWFQMOASMFIiY/ASc3ASEyFh0BITU0NgUVMzWHjg4qDk3UTQ4CFtIOFQIBHRX9qxUIDtCa1P49A+gVHfu0HQNnZAP/jg4OTdRMDyqa0g4IFf2pFB4BFQ7Qm9T9Oh0V+voVHWQyMgAAAAQAAAAABEwEsAAPABkAIwAnAAABBR4BFRMUBi8BByc3JyY2EwcGIi8BJjQ/AQEhMhYdASE1NDYFFTM1AV4CVxQeARUO0JvUm9IOCMNMDyoOjg4OTf76A+gVHfu0HQNnZASwAgEdFf2rFQgO0JrUmtIOFf1QTQ4Ojg4qDk3+WB0V+voVHWQyMgACAAT/7ASwBK8ABQAIAAAlCQERIQkBFQEEsP4d/sb+cQSs/TMCq2cBFP5xAacDHPz55gO5AAAAAAIAAABkBEwEsAAVABkAAAERFAYrAREhESMiJjURNDY7AREhETMHIzUzBEwdFZb9RJYVHR0V+gH0ZMhkZAPo/K4VHQGQ/nAdFQPoFB7+1AEsyMgAAAMAAABFBN0EsAAWABoALwAAAQcBJyYiDwEhESMiJjURNDY7AREhETMHIzUzARcWFAcBBiIvASY0PwE2Mh8BATYyBEwC/tVfCRkJlf7IlhUdHRX6AfRkyGRkAbBqBwf+XAgUCMoICGoHFQdPASkHFQPolf7VXwkJk/5wHRUD6BQe/tQBLMjI/c5qBxUH/lsHB8sHFQdqCAhPASkHAAMAAAANBQcEsAAWABoAPgAAAREHJy4BBwEhESMiJjURNDY7AREhETMHIzUzARcWFA8BFxYUDwEGIi8BBwYiLwEmND8BJyY0PwE2Mh8BNzYyBExnhg8lEP72/reWFR0dFfoB9GTIZGQB9kYPD4ODDw9GDykPg4MPKQ9GDw+Dgw8PRg8pD4ODDykD6P7zZ4YPAw7+9v5wHRUD6BQe/tQBLMjI/YxGDykPg4MPKQ9GDw+Dgw8PRg8pD4ODDykPRg8Pg4MPAAADAAAAFQSXBLAAFQAZAC8AAAERISIGHQEhESMiJjURNDY7AREhETMHIzUzEzMyFh0BMzIWDwEGIi8BJjY7ATU0NgRM/qIVHf4MlhUdHRX6AfRkyGRklmQVHZYVCA7mDioO5g4IFZYdA+j+1B0Vlv5wHRUD6BQe/tQBLMjI/agdFfoVDuYODuYOFfoVHQAAAAADAAAAAASXBLAAFQAZAC8AAAERJyYiBwEhESMiJjURNDY7AREhETMHIzUzExcWBisBFRQGKwEiJj0BIyImPwE2MgRMpQ4qDv75/m6WFR0dFfoB9GTIZGTr5g4IFZYdFWQVHZYVCA7mDioD6P5wpQ8P/vf+cB0VA+gUHv7UASzIyP2F5Q8V+hQeHhT6FQ/lDwADAAAAyASwBEwACQATABcAABMhMhYdASE1NDYBERQGIyEiJjURExUhNTIETBUd+1AdBJMdFfu0FR1kAZAETB0VlpYVHf7U/doVHR0VAib+1MjIAAAGAAMAfQStBJcADwAZAB0ALQAxADsAAAEXFhQPAQYmPQEhNSE1NDYBIyImPQE0NjsBFyM1MwE3NhYdASEVIRUUBi8BJjQFIzU7AjIWHQEUBisBA6f4Dg74DhX+cAGQFf0vMhUdHRUyyGRk/oL3DhUBkP5wFQ73DwOBZGRkMxQdHRQzBI3mDioO5g4IFZbIlhUI/oUdFWQVHcjI/cvmDggVlsiWFQgO5g4qecgdFWQVHQAAAAACAGQAAASwBLAAFgBRAAABJTYWFREUBisBIiY1ES4ENRE0NiUyFh8BERQOAg8BERQGKwEiJjURLgQ1ETQ+AzMyFh8BETMRPAE+AjMyFh8BETMRND4DA14BFBklHRXIFR0EDiIaFiX+4RYZAgEVHR0LCh0VyBUdBA4iGhYBBwoTDRQZAgNkBQkVDxcZAQFkAQUJFQQxdBIUH/uuFR0dFQGNAQgbHzUeAWcfRJEZDA3+Phw/MSkLC/5BFR0dFQG/BA8uLkAcAcICBxENCxkMDf6iAV4CBxENCxkMDf6iAV4CBxENCwABAGQAAASwBEwAMwAAARUiDgMVERQWHwEVITUyNjURIREUFjMVITUyPgM1ETQmLwE1IRUiBhURIRE0JiM1BLAEDiIaFjIZGf5wSxn+DBlL/nAEDiIaFjIZGQGQSxkB9BlLBEw4AQUKFA78iBYZAQI4OA0lAYr+diUNODgBBQoUDgN4FhkBAjg4DSX+dgGKJQ04AAAABgAAAAAETARMAAwAHAAgACQAKAA0AAABITIWHQEjBTUnITchBSEyFhURFAYjISImNRE0NhcVITUBBTUlBRUhNQUVFAYjIQchJyE3MwKjAXcVHWn+2cj+cGQBd/4lASwpOzsp/tQpOzspASwCvP5wAZD8GAEsArwdFf6JZP6JZAGQyGkD6B0VlmJiyGTIOyn+DCk7OykB9Ck7ZMjI/veFo4XGyMhm+BUdZGTIAAEAEAAQBJ8EnwAmAAATNzYWHwEWBg8BHgEXNz4BHwEeAQ8BBiIuBicuBTcRohEuDosOBhF3ZvyNdxEzE8ATBxGjAw0uMUxPZWZ4O0p3RjITCwED76IRBhPCFDERdo78ZXYRBA6IDi8RogEECBUgNUNjO0qZfHNVQBAAAAACAAAAAASwBEwAIwBBAAAAMh4EHwEVFAYvAS4BPQEmIAcVFAYPAQYmPQE+BRIyHgIfARUBHgEdARQGIyEiJj0BNDY3ATU0PgIB/LimdWQ/LAkJHRTKFB2N/sKNHRTKFB0DDTE7ZnTKcFImFgEBAW0OFR0V+7QVHRUOAW0CFiYETBUhKCgiCgrIFRgDIgMiFZIYGJIVIgMiAxgVyAQNJyQrIP7kExwcCgoy/tEPMhTUFR0dFdQUMg8BLzIEDSEZAAADAAAAAASwBLAADQAdACcAAAEHIScRMxUzNTMVMzUzASEyFhQGKwEXITcjIiY0NgMhMhYdASE1NDYETMj9qMjIyMjIyPyuArwVHR0VDIn8SokMFR0dswRMFR37UB0CvMjIAfTIyMjI/OAdKh1kZB0qHf7UHRUyMhUdAAAAAwBkAAAEsARMAAkAEwAdAAABIyIGFREhETQmASMiBhURIRE0JgEhETQ2OwEyFhUCvGQpOwEsOwFnZCk7ASw7/Rv+1DspZCk7BEw7KfwYA+gpO/7UOyn9RAK8KTv84AGQKTs7KQAAAAAF/5wAAASwBEwADwATAB8AJQApAAATITIWFREUBiMhIiY1ETQ2FxEhEQUjFTMRITUzNSMRIQURByMRMwcRMxHIArx8sLB8/UR8sLAYA4T+DMjI/tTIyAEsAZBkyMhkZARMsHz+DHywsHwB9HywyP1EArzIZP7UZGQBLGT+1GQB9GT+1AEsAAAABf+cAAAEsARMAA8AEwAfACUAKQAAEyEyFhURFAYjISImNRE0NhcRIREBIzUjFSMRMxUzNTMFEQcjETMHETMRyAK8fLCwfP1EfLCwGAOE/gxkZGRkZGQBkGTIyGRkBEywfP4MfLCwfAH0fLDI/UQCvP2oyMgB9MjIZP7UZAH0ZP7UASwABP+cAAAEsARMAA8AEwAbACMAABMhMhYVERQGIyEiJjURNDYXESERBSMRMxUhESEFIxEzFSERIcgCvHywsHz9RHywsBgDhP4MyMj+1AEsAZDIyP7UASwETLB8/gx8sLB8AfR8sMj9RAK8yP7UZAH0ZP7UZAH0AAAABP+cAAAEsARMAA8AEwAWABkAABMhMhYVERQGIyEiJjURNDYXESERAS0BDQERyAK8fLCwfP1EfLCwGAOE/gz+1AEsAZD+1ARMsHz+DHywsHwB9HywyP1EArz+DJaWlpYBLAAAAAX/nAAABLAETAAPABMAFwAgACkAABMhMhYVERQGIyEiJjURNDYXESERAyERIQcjIgYVFBY7AQERMzI2NTQmI8gCvHywsHz9RHywsBgDhGT9RAK8ZIImOTYpgv4Mgik2OSYETLB8/gx8sLB8AfR8sMj9RAK8/agB9GRWQUFUASz+1FRBQVYAAAAF/5wAAASwBEwADwATAB8AJQApAAATITIWFREUBiMhIiY1ETQ2FxEhEQUjFTMRITUzNSMRIQEjESM1MwMjNTPIArx8sLB8/UR8sLAYA4T+DMjI/tTIyAEsAZBkZMjIZGQETLB8/gx8sLB8AfR8sMj9RAK8yGT+1GRkASz+DAGQZP4MZAAG/5wAAASwBEwADwATABkAHwAjACcAABMhMhYVERQGIyEiJjURNDYXESERBTMRIREzASMRIzUzBRUzNQEjNTPIArx8sLB8/UR8sLAYA4T9RMj+1GQCWGRkyP2oZAEsZGQETLB8/gx8sLB8AfR8sMj9RAK8yP5wAfT+DAGQZMjIyP7UZAAF/5wAAASwBEwADwATABwAIgAmAAATITIWFREUBiMhIiY1ETQ2FxEhEQEHIzU3NSM1IQEjESM1MwMjNTPIArx8sLB8/UR8sLAYA4T+DMdkx8gBLAGQZGTIx2RkBEywfP4MfLCwfAH0fLDI/UQCvP5wyDLIlmT+DAGQZP4MZAAAAAMACQAJBKcEpwAPABsAJQAAADIeAhQOAiIuAjQ+AQQiDgEUHgEyPgE0JgchFSEVISc1NyEB4PDbnl5entvw255eXp4BxeTCcXHC5MJxcWz+1AEs/tRkZAEsBKdentvw255eXp7b8NueTHHC5MJxccLkwtDIZGTIZAAAAAAEAAkACQSnBKcADwAbACcAKwAAADIeAhQOAiIuAjQ+AQQiDgEUHgEyPgE0JgcVBxcVIycjFSMRIQcVMzUB4PDbnl5entvw255eXp4BxeTCcXHC5MJxcWwyZGRklmQBLMjIBKdentvw255eXp7b8NueTHHC5MJxccLkwtBkMmQyZGQBkGRkZAAAAv/y/50EwgRBACAANgAAATIWFzYzMhYUBisBNTQmIyEiBh0BIyImNTQ2NyY1ND4BEzMyFhURMzIWDwEGIi8BJjY7ARE0NgH3brUsLC54qqp4gB0V/tQVHd5QcFZBAmKqepYKD4kVCg3fDSYN3w0KFYkPBEF3YQ6t8a36FR0dFfpzT0VrDhMSZKpi/bMPCv7tFxD0EBD0EBcBEwoPAAAAAAL/8v+cBMMEQQAcADMAAAEyFhc2MzIWFxQGBwEmIgcBIyImNTQ2NyY1ND4BExcWBisBERQGKwEiJjURIyImNzY3NjIB9m62LCsueaoBeFr+hg0lDf6DCU9xVkECYqnm3w0KFYkPCpYKD4kVCg3HGBMZBEF3YQ+teGOkHAFoEBD+k3NPRWsOExNkqWP9kuQQF/7tCg8PCgETFxDMGBMAAAABAGQAAARMBG0AGAAAJTUhATMBMwkBMwEzASEVIyIGHQEhNTQmIwK8AZD+8qr+8qr+1P7Uqv7yqv7yAZAyFR0BkB0VZGQBLAEsAU3+s/7U/tRkHRUyMhUdAAAAAAEAeQAABDcEmwAvAAABMhYXHgEVFAYHFhUUBiMiJxUyFh0BITU0NjM1BiMiJjU0Ny4BNTQ2MzIXNCY1NDYCWF6TGll7OzIJaUo3LRUd/tQdFS03SmkELzlpSgUSAqMEm3FZBoNaPWcfHRpKaR77HRUyMhUd+x5pShIUFVg1SmkCAhAFdKMAAAAGACcAFASJBJwAEQAqAEIASgBiAHsAAAEWEgIHDgEiJicmAhI3PgEyFgUiBw4BBwYWHwEWMzI3Njc2Nz4BLwEmJyYXIgcOAQcGFh8BFjMyNz4BNz4BLwEmJyYWJiIGFBYyNjciBw4BBw4BHwEWFxYzMjc+ATc2Ji8BJhciBwYHBgcOAR8BFhcWMzI3PgE3NiYvASYD8m9PT29T2dzZU29PT29T2dzZ/j0EBHmxIgQNDCQDBBcGG0dGYAsNAwkDCwccBAVQdRgEDA0iBAQWBhJROQwMAwkDCwf5Y4xjY4xjVhYGElE6CwwDCQMLBwgEBVB1GAQNDCIEjRcGG0dGYAsNAwkDCwcIBAR5sSIEDQwkAwPyb/7V/tVvU1dXU28BKwErb1NXVxwBIrF5DBYDCQEWYEZHGwMVDCMNBgSRAhh1UA0WAwkBFTpREgMVCyMMBwT6Y2OMY2MVFTpREQQVCyMMBwQCGHVQDRYDCQEkFmBGRxsDFQwjDQYEASKxeQwWAwkBAAAABQBkAAAD6ASwAAwADwAWABwAIgAAASERIzUhFSERNDYzIQEjNQMzByczNTMDISImNREFFRQGKwECvAEstP6s/oQPCgI/ASzIZKLU1KJktP51Cg8DhA8KwwMg/oTIyALzCg/+1Mj84NTUyP4MDwoBi8jDCg8AAAAABQBkAAAD6ASwAAkADAATABoAIQAAASERCQERNDYzIQEjNRMjFSM1IzcDISImPQEpARUUBisBNQK8ASz+ov3aDwoCPwEsyD6iZKLUqv6dCg8BfAIIDwqbAyD9+AFe/doERwoP/tTI/HzIyNT+ZA8KNzcKD1AAAAAAAwAAAAAEsAP0AAgAGQAfAAABIxUzFyERIzcFMzIeAhUhFSEDETM0PgIBMwMhASEEiqJkZP7UotT9EsgbGiEOASz9qMhkDiEaAnPw8PzgASwB9AMgyGQBLNTUBBErJGT+ogHCJCsRBP5w/nAB9AAAAAMAAAAABEwETAAZADIAOQAAATMyFh0BMzIWHQEUBiMhIiY9ATQ2OwE1NDYFNTIWFREUBiMhIic3ARE0NjMVFBYzITI2AQc1IzUzNQKKZBUdMhUdHRX+1BUdHRUyHQFzKTs7Kf2oARP2/ro7KVg+ASw+WP201MjIBEwdFTIdFWQVHR0VZBUdMhUd+pY7KfzgKTsE9gFGAUQpO5Y+WFj95tSiZKIAAwBkAAAEvARMABkANgA9AAABMzIWHQEzMhYdARQGIyEiJj0BNDY7ATU0NgU1MhYVESMRMxQOAiMhIiY1ETQ2MxUUFjMhMjYBBzUjNTM1AcJkFR0yFR0dFf7UFR0dFTIdAXMpO8jIDiEaG/2oKTs7KVg+ASw+WAGc1MjIBEwdFTIdFWQVHR0VZBUdMhUd+pY7Kf4M/tQkKxEEOykDICk7lj5YWP3m1KJkogAAAAP/ogAABRYE1AALABsAHwAACQEWBiMhIiY3ATYyEyMiBhcTHgE7ATI2NxM2JgMVMzUCkgJ9FyAs+wQsIBcCfRZARNAUGAQ6BCMUNhQjBDoEGODIBK37sCY3NyYEUCf+TB0U/tIUHR0UAS4UHf4MZGQAAAAACQAAAAAETARMAA8AHwAvAD8ATwBfAG8AfwCPAAABMzIWHQEUBisBIiY9ATQ2EzMyFh0BFAYrASImPQE0NiEzMhYdARQGKwEiJj0BNDYBMzIWHQEUBisBIiY9ATQ2ITMyFh0BFAYrASImPQE0NiEzMhYdARQGKwEiJj0BNDYBMzIWHQEUBisBIiY9ATQ2ITMyFh0BFAYrASImPQE0NiEzMhYdARQGKwEiJj0BNDYBqfoKDw8K+goPDwr6Cg8PCvoKDw8BmvoKDw8K+goPD/zq+goPDwr6Cg8PAZr6Cg8PCvoKDw8BmvoKDw8K+goPD/zq+goPDwr6Cg8PAZr6Cg8PCvoKDw8BmvoKDw8K+goPDwRMDwqWCg8PCpYKD/7UDwqWCg8PCpYKDw8KlgoPDwqWCg/+1A8KlgoPDwqWCg8PCpYKDw8KlgoPDwqWCg8PCpYKD/7UDwqWCg8PCpYKDw8KlgoPDwqWCg8PCpYKDw8KlgoPAAAAAwAAAAAEsAUUABkAKQAzAAABMxUjFSEyFg8BBgchJi8BJjYzITUjNTM1MwEhMhYUBisBFyE3IyImNDYDITIWHQEhNTQ2ArxkZAFePjEcQiko/PwoKUIcMT4BXmRkyP4+ArwVHR0VDIn8SooNFR0dswRMFR37UB0EsMhkTzeEUzMzU4Q3T2TIZPx8HSodZGQdKh3+1B0VMjIVHQAABAAAAAAEsAUUAAUAGQArADUAAAAyFhUjNAchFhUUByEyFg8BIScmNjMhJjU0AyEyFhQGKwEVBSElNSMiJjQ2AyEyFh0BITU0NgIwUDnCPAE6EgMBSCkHIq/9WrIiCikBSAOvArwVHR0VlgET/EoBE5YVHR2zBEwVHftQHQUUOykpjSUmCBEhFpGRFiERCCb+lR0qHcjIyMgdKh39qB0VMjIVHQAEAAAAAASwBJ0ABwAUACQALgAAADIWFAYiJjQTMzIWFRQXITY1NDYzASEyFhQGKwEXITcjIiY0NgMhMhYdASE1NDYCDZZqapZqty4iKyf+vCcrI/7NArwVHR0VDYr8SokMFR0dswRMFR37UB0EnWqWamqW/us5Okxra0w6Of5yHSodZGQdKh3+1B0VMjIVHQAEAAAAAASwBRQADwAcACwANgAAATIeARUUBiImNTQ3FzcnNhMzMhYVFBchNjU0NjMBITIWFAYrARchNyMiJjQ2AyEyFh0BITU0NgJYL1szb5xvIpBvoyIfLiIrJ/68Jysj/s0CvBUdHRUNivxKiQwVHR2zBEwVHftQHQUUa4s2Tm9vTj5Rj2+jGv4KOTpMa2tMOjn+ch0qHWRkHSod/tQdFTIyFR0AAAADAAAAAASwBRIAEgAiACwAAAEFFSEUHgMXIS4BNTQ+AjcBITIWFAYrARchNyMiJjQ2AyEyFh0BITU0NgJYASz+1CU/P00T/e48PUJtj0r+ogK8FR0dFQ2K/EqJDBUdHbMETBUd+1AdBLChizlmUT9IGVO9VFShdksE/H4dKh1kZB0qHf7UHRUyMhUdAAIAyAAAA+gFFAAPACkAAAAyFh0BHgEdASE1NDY3NTQDITIWFyMVMxUjFTMVIxUzFAYjISImNRE0NgIvUjsuNv5wNi5kAZA2XBqsyMjIyMh1U/5wU3V1BRQ7KU4aXDYyMjZcGk4p/kc2LmRkZGRkU3V1UwGQU3UAAAMAZP//BEwETAAPAC8AMwAAEyEyFhURFAYjISImNRE0NgMhMhYdARQGIyEXFhQGIi8BIQcGIiY0PwEhIiY9ATQ2BQchJ5YDhBUdHRX8fBUdHQQDtgoPDwr+5eANGiUNWP30Vw0mGg3g/t8KDw8BqmQBRGQETB0V/gwVHR0VAfQVHf1EDwoyCg/gDSUbDVhYDRslDeAPCjIKD2RkZAAAAAAEAAAAAASwBEwAGQAjAC0ANwAAEyEyFh0BIzQmKwEiBhUjNCYrASIGFSM1NDYDITIWFREhETQ2ExUUBisBIiY9ASEVFAYrASImPQHIAyBTdWQ7KfopO2Q7KfopO2R1EQPoKTv7UDvxHRVkFR0D6B0VZBUdBEx1U8gpOzspKTs7KchTdf4MOyn+1AEsKTv+DDIVHR0VMjIVHR0VMgADAAEAAASpBKwADQARABsAAAkBFhQPASEBJjQ3ATYyCQMDITIWHQEhNTQ2AeACqh8fg/4f/fsgIAEnH1n+rAFWAS/+q6IDIBUd/HwdBI39VR9ZH4MCBh9ZHwEoH/5u/qoBMAFV/BsdFTIyFR0AAAAAAgCPAAAEIQSwABcALwAAAQMuASMhIgYHAwYWMyEVFBYyNj0BMzI2AyE1NDY7ATU0NjsBETMRMzIWHQEzMhYVBCG9CCcV/nAVJwi9CBMVAnEdKh19FROo/a0dFTIdFTDILxUdMhUdAocB+hMcHBP+BhMclhUdHRWWHP2MMhUdMhUdASz+1B0VMh0VAAAEAAAAAASwBLAADQAQAB8AIgAAASERFAYjIREBNTQ2MyEBIzUBIREUBiMhIiY1ETQ2MyEBIzUDhAEsDwr+if7UDwoBdwEsyP2oASwPCv12Cg8PCgF3ASzIAyD9wQoPAk8BLFQKD/7UyP4M/cEKDw8KA7YKD/7UyAAC/5wAZAUUBEcARgBWAAABMzIeAhcWFxY2NzYnJjc+ARYXFgcOASsBDgEPAQ4BKwEiJj8BBisBIicHDgErASImPwEmLwEuAT0BNDY7ATY3JyY2OwE2BSMiBh0BFBY7ATI2PQE0JgHkw0uOakkMEhEfQwoKGRMKBQ8XDCkCA1Y9Pgc4HCcDIhVkFRgDDDEqwxgpCwMiFWQVGAMaVCyfExwdFXwLLW8QBxXLdAFF+goPDwr6Cg8PBEdBa4pJDgYKISAiJRsQCAYIDCw9P1c3fCbqFB0dFEYOCEAUHR0UnUplNQcmFTIVHVdPXw4TZV8PCjIKDw8KMgoPAAb/nP/mBRQEfgAJACQANAA8AFIAYgAAASU2Fh8BFgYPASUzMhYfASEyFh0BFAYHBQYmJyYjISImPQE0NhcjIgYdARQ7ATI2NTQmJyYEIgYUFjI2NAE3PgEeARceAT8BFxYGDwEGJi8BJjYlBwYfAR4BPwE2Jy4BJy4BAoEBpxMuDiAOAxCL/CtqQ0geZgM3FR0cE/0fFyIJKjr+1D5YWLlQExIqhhALIAsSAYBALS1ALf4PmBIgHhMQHC0aPzANITNQL3wpgigJASlmHyElDR0RPRMFAhQHCxADhPcICxAmDyoNeMgiNtQdFTIVJgeEBBQPQ1g+yD5YrBwVODMQEAtEERzJLUAtLUD+24ITChESEyMgAwWzPUkrRSgJL5cvfRxYGyYrDwkLNRAhFEgJDAQAAAAAAwBkAAAEOQSwAFEAYABvAAABMzIWHQEeARcWDgIPATIeBRUUDgUjFRQGKwEiJj0BIxUUBisBIiY9ASMiJj0BNDY7AREjIiY9ATQ2OwE1NDY7ATIWHQEzNTQ2AxUhMj4CNTc0LgMjARUhMj4CNTc0LgMjAnGWCg9PaAEBIC4uEBEGEjQwOiodFyI2LUAjGg8KlgoPZA8KlgoPrwoPDwpLSwoPDwqvDwqWCg9kD9cBBxwpEwsBAQsTKRz++QFrHCkTCwEBCxMpHASwDwptIW1KLk0tHwYGAw8UKDJOLTtdPCoVCwJLCg8PCktLCg8PCksPCpYKDwJYDwqWCg9LCg8PCktLCg/+1MgVHR0LCgQOIhoW/nDIFR0dCwoEDiIaFgAAAwAEAAIEsASuABcAKQAsAAATITIWFREUBg8BDgEjISImJy4CNRE0NgQiDgQPARchNy4FAyMT1AMMVnokEhIdgVL9xFKCHAgYKHoCIIx9VkcrHQYGnAIwnAIIIClJVSGdwwSuelb+YDO3QkJXd3ZYHFrFMwGgVnqZFyYtLSUMDPPzBQ8sKDEj/sIBBQACAMgAAAOEBRQADwAZAAABMzIWFREUBiMhIiY1ETQ2ARUUBisBIiY9AQHblmesVCn+PilUrAFINhWWFTYFFKxn/gwpVFQpAfRnrPwY4RU2NhXhAAACAMgAAAOEBRQADwAZAAABMxQWMxEUBiMhIiY1ETQ2ARUUBisBIiY9AQHbYLOWVCn+PilUrAFINhWWFTYFFJaz/kIpVFQpAfRnrPwY4RU2NhXhAAACAAAAFAUOBBoAFAAaAAAJASUHFRcVJwc1NzU0Jj4CPwEnCQEFJTUFJQUO/YL+hk5klpZkAQEBBQQvkwKCAVz+ov6iAV4BXgL//uWqPOCWx5SVyJb6BA0GCgYDKEEBG/1ipqaTpaUAAAMAZAH0BLADIAAHAA8AFwAAEjIWFAYiJjQkMhYUBiImNCQyFhQGIiY0vHxYWHxYAeh8WFh8WAHofFhYfFgDIFh8WFh8WFh8WFh8WFh8WFh8AAAAAAMBkAAAArwETAAHAA8AFwAAADIWFAYiJjQSMhYUBiImNBIyFhQGIiY0Aeh8WFh8WFh8WFh8WFh8WFh8WARMWHxYWHz+yFh8WFh8/shYfFhYfAAAAAMAZABkBEwETAAPAB8ALwAAEyEyFh0BFAYjISImPQE0NhMhMhYdARQGIyEiJj0BNDYTITIWHQEUBiMhIiY9ATQ2fQO2Cg8PCvxKCg8PCgO2Cg8PCvxKCg8PCgO2Cg8PCvxKCg8PBEwPCpYKDw8KlgoP/nAPCpYKDw8KlgoP/nAPCpYKDw8KlgoPAAAABAAAAAAEsASwAA8AHwAvADMAAAEhMhYVERQGIyEiJjURNDYFISIGFREUFjMhMjY1ETQmBSEyFhURFAYjISImNRE0NhcVITUBXgH0ory7o/4Mpbm5Asv9qCk7OykCWCk7O/2xAfQVHR0V/gwVHR1HAZAEsLuj/gylubmlAfSlucg7Kf2oKTs7KQJYKTtkHRX+1BUdHRUBLBUdZMjIAAAAAAEAZABkBLAETAA7AAATITIWFAYrARUzMhYUBisBFTMyFhQGKwEVMzIWFAYjISImNDY7ATUjIiY0NjsBNSMiJjQ2OwE1IyImNDaWA+gVHR0VMjIVHR0VMjIVHR0VMjIVHR0V/BgVHR0VMjIVHR0VMjIVHR0VMjIVHR0ETB0qHcgdKh3IHSodyB0qHR0qHcgdKh3IHSodyB0qHQAAAAYBLAAFA+gEowAHAA0AEwAZAB8AKgAAAR4BBgcuATYBMhYVIiYlFAYjNDYBMhYVIiYlFAYjNDYDFRQGIiY9ARYzMgKKVz8/V1c/P/75fLB8sAK8sHyw/cB8sHywArywfLCwHSodKAMRBKNDsrJCQrKy/sCwfLB8fLB8sP7UsHywfHywfLD+05AVHR0VjgQAAAH/tQDIBJQDgQBCAAABNzYXAR4BBw4BKwEyFRQOBCsBIhE0NyYiBxYVECsBIi4DNTQzIyImJyY2NwE2HwEeAQ4BLwEHIScHBi4BNgLpRRkUASoLCAYFGg8IAQQNGyc/KZK4ChRUFQu4jjBJJxkHAgcPGQYGCAsBKhQaTBQVCiMUM7YDe7YsFCMKFgNuEwYS/tkLHw8OEw0dNkY4MhwBIBgXBAQYF/7gKjxTQyMNEw4PHwoBKBIHEwUjKBYGDMHBDAUWKCMAAAAAAgAAAAAEsASwACUAQwAAASM0LgUrAREUFh8BFSE1Mj4DNREjIg4FFSMRIQEjNC4DKwERFBYXMxUjNTI1ESMiDgMVIzUhBLAyCAsZEyYYGcgyGRn+cAQOIhoWyBkYJhMZCwgyA+j9RBkIChgQEWQZDQzIMmQREBgKCBkB9AOEFSAVDggDAfyuFhkBAmRkAQUJFQ4DUgEDCA4VIBUBLP0SDxMKBQH+VwsNATIyGQGpAQUKEw+WAAAAAAMAAAAABEwErgAdACAAMAAAATUiJy4BLwEBIwEGBw4BDwEVITUiJj8BIRcWBiMVARsBARUUBiMhIiY9ATQ2MyEyFgPoGR4OFgUE/t9F/tQSFQkfCwsBETE7EkUBJT0NISf+7IZ5AbEdFfwYFR0dFQPoFR0BLDIgDiIKCwLr/Q4jFQkTBQUyMisusKYiQTIBhwFW/qr942QVHR0VZBUdHQADAAAAAASwBLAADwBHAEoAABMhMhYVERQGIyEiJjURNDYFIyIHAQYHBgcGHQEUFjMhMjY9ATQmIyInJj8BIRcWBwYjIgYdARQWMyEyNj0BNCYnIicmJyMBJhMjEzIETBUdHRX7tBUdHQJGRg0F/tUREhImDAsJAREIDAwINxAKCj8BCjkLEQwYCAwMCAE5CAwLCBEZGQ8B/uAFDsVnBLAdFfu0FR0dFQRMFR1SDP0PIBMSEAUNMggMDAgyCAwXDhmjmR8YEQwIMggMDAgyBwwBGRskAuwM/gUBCAAABAAAAAAEsASwAAMAEwAjACcAAAEhNSEFITIWFREUBiMhIiY1ETQ2KQEyFhURFAYjISImNRE0NhcRIREEsPtQBLD7ggGQFR0dFf5wFR0dAm0BkBUdHRX+cBUdHUcBLARMZMgdFfx8FR0dFQOEFR0dFf5wFR0dFQGQFR1k/tQBLAAEAAAAAASwBLAADwAfACMAJwAAEyEyFhURFAYjISImNRE0NgEhMhYVERQGIyEiJjURNDYXESEREyE1ITIBkBUdHRX+cBUdHQJtAZAVHR0V/nAVHR1HASzI+1AEsASwHRX8fBUdHRUDhBUd/gwdFf5wFR0dFQGQFR1k/tQBLP2oZAAAAAACAAAAZASwA+gAJwArAAATITIWFREzNTQ2MyEyFh0BMxUjFRQGIyEiJj0BIxEUBiMhIiY1ETQ2AREhETIBkBUdZB0VAZAVHWRkHRX+cBUdZB0V/nAVHR0CnwEsA+gdFf6ilhUdHRWWZJYVHR0Vlv6iFR0dFQMgFR3+1P7UASwAAAQAAAAABLAEsAADABMAFwAnAAAzIxEzFyEyFhURFAYjISImNRE0NhcRIREBITIWFREUBiMhIiY1ETQ2ZGRklgGQFR0dFf5wFR0dRwEs/qIDhBUdHRX8fBUdHQSwZB0V/nAVHR0VAZAVHWT+1AEs/gwdFf5wFR0dFQGQFR0AAAAAAgBkAAAETASwACcAKwAAATMyFhURFAYrARUhMhYVERQGIyEiJjURNDYzITUjIiY1ETQ2OwE1MwcRIRECWJYVHR0VlgHCFR0dFfx8FR0dFQFelhUdHRWWZMgBLARMHRX+cBUdZB0V/nAVHR0VAZAVHWQdFQGQFR1kyP7UASwAAAAEAAAAAASwBLAAAwATABcAJwAAISMRMwUhMhYVERQGIyEiJjURNDYXESERASEyFhURFAYjISImNRE0NgSwZGT9dgGQFR0dFf5wFR0dRwEs/K4DhBUdHRX8fBUdHQSwZB0V/nAVHR0VAZAVHWT+1AEs/gwdFf5wFR0dFQGQFR0AAAEBLAAwA28EgAAPAAAJAQYjIiY1ETQ2MzIXARYUA2H+EhcSDhAQDhIXAe4OAjX+EhcbGQPoGRsX/hIOKgAAAAABAUEAMgOEBH4ACwAACQE2FhURFAYnASY0AU8B7h0qKh3+Eg4CewHuHREp/BgpER0B7g4qAAAAAAEAMgFBBH4DhAALAAATITIWBwEGIicBJjZkA+gpER3+Eg4qDv4SHREDhCod/hIODgHuHSoAAAAAAQAyASwEfgNvAAsAAAkBFgYjISImNwE2MgJ7Ae4dESn8GCkRHQHuDioDYf4SHSoqHQHuDgAAAAACAAgAAASwBCgABgAKAAABFQE1LQE1ASE1IQK8/UwBnf5jBKj84AMgAuW2/r3dwcHd+9jIAAAAAAIAAABkBLAEsAALADEAAAEjFTMVIREzNSM1IQEzND4FOwERFAYPARUhNSIuAzURMzIeBRUzESEEsMjI/tTIyAEs+1AyCAsZEyYYGWQyGRkBkAQOIhoWZBkYJhMZCwgy/OADhGRkASxkZP4MFSAVDggDAf3aFhkBAmRkAQUJFQ4CJgEDCA4VIBUBLAAAAgAAAAAETAPoACUAMQAAASM0LgUrAREUFh8BFSE1Mj4DNREjIg4FFSMRIQEjFTMVIREzNSM1IQMgMggLGRMmGBlkMhkZ/nAEDiIaFmQZGCYTGQsIMgMgASzIyP7UyMgBLAK8FSAVDggDAf3aFhkCAWRkAQUJFQ4CJgEDCA4VIBUBLPzgZGQBLGRkAAABAMgAZgNyBEoAEgAAATMyFgcJARYGKwEiJwEmNDcBNgK9oBAKDP4wAdAMChCgDQr+KQcHAdcKBEoWDP4w/jAMFgkB1wgUCAHXCQAAAQE+AGYD6ARKABIAAAEzMhcBFhQHAQYrASImNwkBJjYBU6ANCgHXBwf+KQoNoBAKDAHQ/jAMCgRKCf4pCBQI/ikJFgwB0AHQDBYAAAEAZgDIBEoDcgASAAAAFh0BFAcBBiInASY9ATQ2FwkBBDQWCf4pCBQI/ikJFgwB0AHQA3cKEKANCv4pBwcB1woNoBAKDP4wAdAAAAABAGYBPgRKA+gAEgAACQEWHQEUBicJAQYmPQE0NwE2MgJqAdcJFgz+MP4wDBYJAdcIFAPh/ikKDaAQCgwB0P4wDAoQoA0KAdcHAAAAAgDZ//kEPQSwAAUAOgAAARQGIzQ2BTMyFh8BNjc+Ah4EBgcOBgcGIiYjIgYiJy4DLwEuAT4EHgEXJyY2A+iwfLD+VmQVJgdPBQsiKFAzRyorDwURAQQSFyozTSwNOkkLDkc3EDlfNyYHBw8GDyUqPjdGMR+TDA0EsHywfLDIHBPCAQIGBwcFDx81S21DBxlLR1xKQhEFBQcHGWt0bCQjP2hJNyATBwMGBcASGAAAAAACAMgAFQOEBLAAFgAaAAATITIWFREUBisBEQcGJjURIyImNRE0NhcVITX6AlgVHR0Vlv8TGpYVHR2rASwEsB0V/nAVHf4MsgkQFQKKHRUBkBUdZGRkAAAAAgDIABkETASwAA4AEgAAEyEyFhURBRElIREjETQ2ARU3NfoC7ic9/UQCWP1EZB8BDWQEsFEs/Ft1A7Z9/BgEARc0/V1kFGQAAQAAAAECTW/DBF9fDzz1AB8EsAAAAADQdnOXAAAAANB2c5f/Uf+cBdwFFAAAAAgAAgAAAAAAAAABAAAFFP+FAAAFFP9R/tQF3AABAAAAAAAAAAAAAAAAAAAAowG4ACgAAAAAAZAAAASwAAAEsABkBLAAAASwAAAEsABwAooAAAUUAAACigAABRQAAAGxAAABRQAAANgAAADYAAAAogAAAQQAAABIAAABBAAAAUUAAASwAGQEsAB7BLAAyASwAMgB9AAABLD/8gSwAAAEsAAABLD/8ASwAAAEsAAOBLAACQSwAGQEsP/TBLD/0wSwAAAEsAAABLAAAASwAAAEsAAABLAAJgSwAG4EsAAXBLAAFwSwABcEsABkBLAAGgSwAGQEsAAMBLAAZASwABcEsP+cBLAAZASwABcEsAAXBLAAAASwABcEsAAXBLAAFwSwAGQEsAAABLAAZASwAAAEsAAABLAAAASwAAAEsAAABLAAAASwAAAEsAAABLAAZASwAMgEsAAABLAAAASwADUEsABkBLAAyASw/7UEsAAhBLAAAASwAAAEsAAABLAAAASwAAAEsP+cBLAAAASwAAAEsAAABLAA2wSwABcEsAB1BLAAAASwAAAEsAAABLAACgSwAMgEsAAABLAAnQSwAMgEsADIBLAAyASwAAAEsP/+BLABLASwAGQEsACIBLABOwSwABcEsAAXBLAAFwSwABcEsAAXBLAAFwSwAAAEsAAXBLAAFwSwABcEsAAXBLAAAASwALcEsAC3BLAAAASwAAAEsABJBLAAFwSwAAAEsAAABLAAXQSw/9wEsP/cBLD/nwSwAGQEsAAABLAAAASwAAAEsABkBLD//wSwAAAEsP9RBLAABgSwAAAEsAAABLABRQSwAAEEsAAABLD/nASwAEoEsAAUBLAAAASwAAAEsAAABLD/nASwAGEEsP/9BLAAFgSwABYEsAAWBLAAFgSwABgEsAAABMQAAASwAGQAAAAAAAD/2ABkADkAyAAAAScAZAAZABkAGQAZABkAGQAZAAAAAAAAAAAAAADZAAAAAAAOAAAAAAAAAAAAAAAEAAAAAAAAAAAAAAAAAAMAZABkAAAAEAAAAAAAZP+c/5z/nP+c/5z/nP+c/5wACQAJ//L/8gBkAHkAJwBkAGQAAAAAAGT/ogAAAAAAAAAAAAAAAADIAGQAAAABAI8AAP+c/5wAZAAEAMgAyAAAAGQBkABkAAAAZAEs/7UAAAAAAAAAAAAAAAAAAABkAAABLAFBADIAMgAIAAAAAADIAT4AZgBmANkAyADIAAAAKgAqACoAKgCyAOgA6AFOAU4BTgFOAU4BTgFOAU4BTgFOAU4BTgFOAU4BpAIGAiICfgKGAqwC5ANGA24DjAPEBAgEMgRiBKIE3AVcBboGcgb0ByAHYgfKCB4IYgi+CTYJhAm2Cd4KKApMCpQK4gswC4oLygwIDFgNKg1eDbAODg5oDrQPKA+mD+YQEhBUEJAQqhEqEXYRthIKEjgSfBLAExoTdBPQFCoU1BU8FagVzBYEFjYWYBawFv4XUhemGAIYLhhqGJYYsBjgGP4ZKBloGZQZxBnaGe4aNhpoGrga9hteG7QcMhyUHOIdHB1EHWwdlB28HeYeLh52HsAfYh/SIEYgviEyIXYhuCJAIpYiuCMOIyIjOCN6I8Ij4CQCJDAkXiSWJOIlNCVgJbwmFCZ+JuYnUCe8J/goNChwKKwpoCnMKiYqSiqEKworeiwILGgsuizsLRwtiC30LiguZi6iLtgvDi9GL34vsi/4MD4whDDSMRIxYDGuMegyJDJeMpoy3jMiMz4zaDO2NBg0YDSoNNI1LDWeNeg2PjZ8Ntw3GjdON5I31DgQOEI4hjjIOQo5SjmIOcw6HDpsOpo63jugO9w8GDxQPKI8+D0yPew+Oj6MPtQ/KD9uP6o/+kBIQIBAxkECQX5CGEKoQu5DGENCQ3ZDoEPKRBBEYESuRPZFWkW2RgZGdEa0RvZHNkd2R7ZH9kgWSDJITkhqSIZIzEkSSThJXkmESapKAkouSlIAAQAAARcApwARAAAAAAACAAAAAQABAAAAQAAuAAAAAAAAABAAxgABAAAAAAATABIAAAADAAEECQAAAGoAEgADAAEECQABACgAfAADAAEECQACAA4ApAADAAEECQADAEwAsgADAAEECQAEADgA/gADAAEECQAFAHgBNgADAAEECQAGADYBrgADAAEECQAIABYB5AADAAEECQAJABYB+gADAAEECQALACQCEAADAAEECQAMACQCNAADAAEECQATACQCWAADAAEECQDIABYCfAADAAEECQDJADACkgADAAEECdkDABoCwnd3dy5nbHlwaGljb25zLmNvbQBDAG8AcAB5AHIAaQBnAGgAdAAgAKkAIAAyADAAMQA0ACAAYgB5ACAASgBhAG4AIABLAG8AdgBhAHIAaQBrAC4AIABBAGwAbAAgAHIAaQBnAGgAdABzACAAcgBlAHMAZQByAHYAZQBkAC4ARwBMAFkAUABIAEkAQwBPAE4AUwAgAEgAYQBsAGYAbABpAG4AZwBzAFIAZQBnAHUAbABhAHIAMQAuADAAMAA5ADsAVQBLAFcATgA7AEcATABZAFAASABJAEMATwBOAFMASABhAGwAZgBsAGkAbgBnAHMALQBSAGUAZwB1AGwAYQByAEcATABZAFAASABJAEMATwBOAFMAIABIAGEAbABmAGwAaQBuAGcAcwAgAFIAZQBnAHUAbABhAHIAVgBlAHIAcwBpAG8AbgAgADEALgAwADAAOQA7AFAAUwAgADAAMAAxAC4AMAAwADkAOwBoAG8AdABjAG8AbgB2ACAAMQAuADAALgA3ADAAOwBtAGEAawBlAG8AdABmAC4AbABpAGIAMgAuADUALgA1ADgAMwAyADkARwBMAFkAUABIAEkAQwBPAE4AUwBIAGEAbABmAGwAaQBuAGcAcwAtAFIAZQBnAHUAbABhAHIASgBhAG4AIABLAG8AdgBhAHIAaQBrAEoAYQBuACAASwBvAHYAYQByAGkAawB3AHcAdwAuAGcAbAB5AHAAaABpAGMAbwBuAHMALgBjAG8AbQB3AHcAdwAuAGcAbAB5AHAAaABpAGMAbwBuAHMALgBjAG8AbQB3AHcAdwAuAGcAbAB5AHAAaABpAGMAbwBuAHMALgBjAG8AbQBXAGUAYgBmAG8AbgB0ACAAMQAuADAAVwBlAGQAIABPAGMAdAAgADIAOQAgADAANgA6ADMANgA6ADAANwAgADIAMAAxADQARgBvAG4AdAAgAFMAcQB1AGkAcgByAGUAbAAAAAIAAAAAAAD/tQAyAAAAAAAAAAAAAAAAAAAAAAAAAAABFwAAAQIBAwADAA0ADgEEAJYBBQEGAQcBCAEJAQoBCwEMAQ0BDgEPARABEQESARMA7wEUARUBFgEXARgBGQEaARsBHAEdAR4BHwEgASEBIgEjASQBJQEmAScBKAEpASoBKwEsAS0BLgEvATABMQEyATMBNAE1ATYBNwE4ATkBOgE7ATwBPQE+AT8BQAFBAUIBQwFEAUUBRgFHAUgBSQFKAUsBTAFNAU4BTwFQAVEBUgFTAVQBVQFWAVcBWAFZAVoBWwFcAV0BXgFfAWABYQFiAWMBZAFlAWYBZwFoAWkBagFrAWwBbQFuAW8BcAFxAXIBcwF0AXUBdgF3AXgBeQF6AXsBfAF9AX4BfwGAAYEBggGDAYQBhQGGAYcBiAGJAYoBiwGMAY0BjgGPAZABkQGSAZMBlAGVAZYBlwGYAZkBmgGbAZwBnQGeAZ8BoAGhAaIBowGkAaUBpgGnAagBqQGqAasBrAGtAa4BrwGwAbEBsgGzAbQBtQG2AbcBuAG5AboBuwG8Ab0BvgG/AcABwQHCAcMBxAHFAcYBxwHIAckBygHLAcwBzQHOAc8B0AHRAdIB0wHUAdUB1gHXAdgB2QHaAdsB3AHdAd4B3wHgAeEB4gHjAeQB5QHmAecB6AHpAeoB6wHsAe0B7gHvAfAB8QHyAfMB9AH1AfYB9wH4AfkB+gH7AfwB/QH+Af8CAAIBAgICAwIEAgUCBgIHAggCCQIKAgsCDAINAg4CDwIQAhECEgZnbHlwaDEGZ2x5cGgyB3VuaTAwQTAHdW5pMjAwMAd1bmkyMDAxB3VuaTIwMDIHdW5pMjAwMwd1bmkyMDA0B3VuaTIwMDUHdW5pMjAwNgd1bmkyMDA3B3VuaTIwMDgHdW5pMjAwOQd1bmkyMDBBB3VuaTIwMkYHdW5pMjA1RgRFdXJvB3VuaTIwQkQHdW5pMjMxQgd1bmkyNUZDB3VuaTI2MDEHdW5pMjZGQQd1bmkyNzA5B3VuaTI3MEYHdW5pRTAwMQd1bmlFMDAyB3VuaUUwMDMHdW5pRTAwNQd1bmlFMDA2B3VuaUUwMDcHdW5pRTAwOAd1bmlFMDA5B3VuaUUwMTAHdW5pRTAxMQd1bmlFMDEyB3VuaUUwMTMHdW5pRTAxNAd1bmlFMDE1B3VuaUUwMTYHdW5pRTAxNwd1bmlFMDE4B3VuaUUwMTkHdW5pRTAyMAd1bmlFMDIxB3VuaUUwMjIHdW5pRTAyMwd1bmlFMDI0B3VuaUUwMjUHdW5pRTAyNgd1bmlFMDI3B3VuaUUwMjgHdW5pRTAyOQd1bmlFMDMwB3VuaUUwMzEHdW5pRTAzMgd1bmlFMDMzB3VuaUUwMzQHdW5pRTAzNQd1bmlFMDM2B3VuaUUwMzcHdW5pRTAzOAd1bmlFMDM5B3VuaUUwNDAHdW5pRTA0MQd1bmlFMDQyB3VuaUUwNDMHdW5pRTA0NAd1bmlFMDQ1B3VuaUUwNDYHdW5pRTA0Nwd1bmlFMDQ4B3VuaUUwNDkHdW5pRTA1MAd1bmlFMDUxB3VuaUUwNTIHdW5pRTA1Mwd1bmlFMDU0B3VuaUUwNTUHdW5pRTA1Ngd1bmlFMDU3B3VuaUUwNTgHdW5pRTA1OQd1bmlFMDYwB3VuaUUwNjIHdW5pRTA2Mwd1bmlFMDY0B3VuaUUwNjUHdW5pRTA2Ngd1bmlFMDY3B3VuaUUwNjgHdW5pRTA2OQd1bmlFMDcwB3VuaUUwNzEHdW5pRTA3Mgd1bmlFMDczB3VuaUUwNzQHdW5pRTA3NQd1bmlFMDc2B3VuaUUwNzcHdW5pRTA3OAd1bmlFMDc5B3VuaUUwODAHdW5pRTA4MQd1bmlFMDgyB3VuaUUwODMHdW5pRTA4NAd1bmlFMDg1B3VuaUUwODYHdW5pRTA4Nwd1bmlFMDg4B3VuaUUwODkHdW5pRTA5MAd1bmlFMDkxB3VuaUUwOTIHdW5pRTA5Mwd1bmlFMDk0B3VuaUUwOTUHdW5pRTA5Ngd1bmlFMDk3B3VuaUUxMDEHdW5pRTEwMgd1bmlFMTAzB3VuaUUxMDQHdW5pRTEwNQd1bmlFMTA2B3VuaUUxMDcHdW5pRTEwOAd1bmlFMTA5B3VuaUUxMTAHdW5pRTExMQd1bmlFMTEyB3VuaUUxMTMHdW5pRTExNAd1bmlFMTE1B3VuaUUxMTYHdW5pRTExNwd1bmlFMTE4B3VuaUUxMTkHdW5pRTEyMAd1bmlFMTIxB3VuaUUxMjIHdW5pRTEyMwd1bmlFMTI0B3VuaUUxMjUHdW5pRTEyNgd1bmlFMTI3B3VuaUUxMjgHdW5pRTEyOQd1bmlFMTMwB3VuaUUxMzEHdW5pRTEzMgd1bmlFMTMzB3VuaUUxMzQHdW5pRTEzNQd1bmlFMTM2B3VuaUUxMzcHdW5pRTEzOAd1bmlFMTM5B3VuaUUxNDAHdW5pRTE0MQd1bmlFMTQyB3VuaUUxNDMHdW5pRTE0NAd1bmlFMTQ1B3VuaUUxNDYHdW5pRTE0OAd1bmlFMTQ5B3VuaUUxNTAHdW5pRTE1MQd1bmlFMTUyB3VuaUUxNTMHdW5pRTE1NAd1bmlFMTU1B3VuaUUxNTYHdW5pRTE1Nwd1bmlFMTU4B3VuaUUxNTkHdW5pRTE2MAd1bmlFMTYxB3VuaUUxNjIHdW5pRTE2Mwd1bmlFMTY0B3VuaUUxNjUHdW5pRTE2Ngd1bmlFMTY3B3VuaUUxNjgHdW5pRTE2OQd1bmlFMTcwB3VuaUUxNzEHdW5pRTE3Mgd1bmlFMTczB3VuaUUxNzQHdW5pRTE3NQd1bmlFMTc2B3VuaUUxNzcHdW5pRTE3OAd1bmlFMTc5B3VuaUUxODAHdW5pRTE4MQd1bmlFMTgyB3VuaUUxODMHdW5pRTE4NAd1bmlFMTg1B3VuaUUxODYHdW5pRTE4Nwd1bmlFMTg4B3VuaUUxODkHdW5pRTE5MAd1bmlFMTkxB3VuaUUxOTIHdW5pRTE5Mwd1bmlFMTk0B3VuaUUxOTUHdW5pRTE5Nwd1bmlFMTk4B3VuaUUxOTkHdW5pRTIwMAd1bmlFMjAxB3VuaUUyMDIHdW5pRTIwMwd1bmlFMjA0B3VuaUUyMDUHdW5pRTIwNgd1bmlFMjA5B3VuaUUyMTAHdW5pRTIxMQd1bmlFMjEyB3VuaUUyMTMHdW5pRTIxNAd1bmlFMjE1B3VuaUUyMTYHdW5pRTIxOAd1bmlFMjE5B3VuaUUyMjEHdW5pRTIyMwd1bmlFMjI0B3VuaUUyMjUHdW5pRTIyNgd1bmlFMjI3B3VuaUUyMzAHdW5pRTIzMQd1bmlFMjMyB3VuaUUyMzMHdW5pRTIzNAd1bmlFMjM1B3VuaUUyMzYHdW5pRTIzNwd1bmlFMjM4B3VuaUUyMzkHdW5pRTI0MAd1bmlFMjQxB3VuaUUyNDIHdW5pRTI0Mwd1bmlFMjQ0B3VuaUUyNDUHdW5pRTI0Ngd1bmlFMjQ3B3VuaUUyNDgHdW5pRTI0OQd1bmlFMjUwB3VuaUUyNTEHdW5pRTI1Mgd1bmlFMjUzB3VuaUUyNTQHdW5pRTI1NQd1bmlFMjU2B3VuaUUyNTcHdW5pRTI1OAd1bmlFMjU5B3VuaUUyNjAHdW5pRjhGRgZ1MUY1MTEGdTFGNkFBAAAAAAFUUMMXAAA=) format('truetype'),url(data:image/svg+xml;base64,<?xml version="1.0" standalone="no"?>
<!DOCTYPE svg PUBLIC "-//W3C//DTD SVG 1.1//EN" "http://www.w3.org/Graphics/SVG/1.1/DTD/svg11.dtd" >
<svg xmlns="http://www.w3.org/2000/svg">
<metadata></metadata>
<defs>
<font id="glyphicons_halflingsregular" horiz-adv-x="1200" >
<font-face units-per-em="1200" ascent="960" descent="-240" />
<missing-glyph horiz-adv-x="500" />
<glyph horiz-adv-x="0" />
<glyph horiz-adv-x="400" />
<glyph unicode=" " />
<glyph unicode="*" d="M600 1100q15 0 34 -1.5t30 -3.5l11 -1q10 -2 17.5 -10.5t7.5 -18.5v-224l158 158q7 7 18 8t19 -6l106 -106q7 -8 6 -19t-8 -18l-158 -158h224q10 0 18.5 -7.5t10.5 -17.5q6 -41 6 -75q0 -15 -1.5 -34t-3.5 -30l-1 -11q-2 -10 -10.5 -17.5t-18.5 -7.5h-224l158 -158 q7 -7 8 -18t-6 -19l-106 -106q-8 -7 -19 -6t-18 8l-158 158v-224q0 -10 -7.5 -18.5t-17.5 -10.5q-41 -6 -75 -6q-15 0 -34 1.5t-30 3.5l-11 1q-10 2 -17.5 10.5t-7.5 18.5v224l-158 -158q-7 -7 -18 -8t-19 6l-106 106q-7 8 -6 19t8 18l158 158h-224q-10 0 -18.5 7.5 t-10.5 17.5q-6 41 -6 75q0 15 1.5 34t3.5 30l1 11q2 10 10.5 17.5t18.5 7.5h224l-158 158q-7 7 -8 18t6 19l106 106q8 7 19 6t18 -8l158 -158v224q0 10 7.5 18.5t17.5 10.5q41 6 75 6z" />
<glyph unicode="+" d="M450 1100h200q21 0 35.5 -14.5t14.5 -35.5v-350h350q21 0 35.5 -14.5t14.5 -35.5v-200q0 -21 -14.5 -35.5t-35.5 -14.5h-350v-350q0 -21 -14.5 -35.5t-35.5 -14.5h-200q-21 0 -35.5 14.5t-14.5 35.5v350h-350q-21 0 -35.5 14.5t-14.5 35.5v200q0 21 14.5 35.5t35.5 14.5 h350v350q0 21 14.5 35.5t35.5 14.5z" />
<glyph unicode="&#xa0;" />
<glyph unicode="&#xa5;" d="M825 1100h250q10 0 12.5 -5t-5.5 -13l-364 -364q-6 -6 -11 -18h268q10 0 13 -6t-3 -14l-120 -160q-6 -8 -18 -14t-22 -6h-125v-100h275q10 0 13 -6t-3 -14l-120 -160q-6 -8 -18 -14t-22 -6h-125v-174q0 -11 -7.5 -18.5t-18.5 -7.5h-148q-11 0 -18.5 7.5t-7.5 18.5v174 h-275q-10 0 -13 6t3 14l120 160q6 8 18 14t22 6h125v100h-275q-10 0 -13 6t3 14l120 160q6 8 18 14t22 6h118q-5 12 -11 18l-364 364q-8 8 -5.5 13t12.5 5h250q25 0 43 -18l164 -164q8 -8 18 -8t18 8l164 164q18 18 43 18z" />
<glyph unicode="&#x2000;" horiz-adv-x="650" />
<glyph unicode="&#x2001;" horiz-adv-x="1300" />
<glyph unicode="&#x2002;" horiz-adv-x="650" />
<glyph unicode="&#x2003;" horiz-adv-x="1300" />
<glyph unicode="&#x2004;" horiz-adv-x="433" />
<glyph unicode="&#x2005;" horiz-adv-x="325" />
<glyph unicode="&#x2006;" horiz-adv-x="216" />
<glyph unicode="&#x2007;" horiz-adv-x="216" />
<glyph unicode="&#x2008;" horiz-adv-x="162" />
<glyph unicode="&#x2009;" horiz-adv-x="260" />
<glyph unicode="&#x200a;" horiz-adv-x="72" />
<glyph unicode="&#x202f;" horiz-adv-x="260" />
<glyph unicode="&#x205f;" horiz-adv-x="325" />
<glyph unicode="&#x20ac;" d="M744 1198q242 0 354 -189q60 -104 66 -209h-181q0 45 -17.5 82.5t-43.5 61.5t-58 40.5t-60.5 24t-51.5 7.5q-19 0 -40.5 -5.5t-49.5 -20.5t-53 -38t-49 -62.5t-39 -89.5h379l-100 -100h-300q-6 -50 -6 -100h406l-100 -100h-300q9 -74 33 -132t52.5 -91t61.5 -54.5t59 -29 t47 -7.5q22 0 50.5 7.5t60.5 24.5t58 41t43.5 61t17.5 80h174q-30 -171 -128 -278q-107 -117 -274 -117q-206 0 -324 158q-36 48 -69 133t-45 204h-217l100 100h112q1 47 6 100h-218l100 100h134q20 87 51 153.5t62 103.5q117 141 297 141z" />
<glyph unicode="&#x20bd;" d="M428 1200h350q67 0 120 -13t86 -31t57 -49.5t35 -56.5t17 -64.5t6.5 -60.5t0.5 -57v-16.5v-16.5q0 -36 -0.5 -57t-6.5 -61t-17 -65t-35 -57t-57 -50.5t-86 -31.5t-120 -13h-178l-2 -100h288q10 0 13 -6t-3 -14l-120 -160q-6 -8 -18 -14t-22 -6h-138v-175q0 -11 -5.5 -18 t-15.5 -7h-149q-10 0 -17.5 7.5t-7.5 17.5v175h-267q-10 0 -13 6t3 14l120 160q6 8 18 14t22 6h117v100h-267q-10 0 -13 6t3 14l120 160q6 8 18 14t22 6h117v475q0 10 7.5 17.5t17.5 7.5zM600 1000v-300h203q64 0 86.5 33t22.5 119q0 84 -22.5 116t-86.5 32h-203z" />
<glyph unicode="&#x2212;" d="M250 700h800q21 0 35.5 -14.5t14.5 -35.5v-200q0 -21 -14.5 -35.5t-35.5 -14.5h-800q-21 0 -35.5 14.5t-14.5 35.5v200q0 21 14.5 35.5t35.5 14.5z" />
<glyph unicode="&#x231b;" d="M1000 1200v-150q0 -21 -14.5 -35.5t-35.5 -14.5h-50v-100q0 -91 -49.5 -165.5t-130.5 -109.5q81 -35 130.5 -109.5t49.5 -165.5v-150h50q21 0 35.5 -14.5t14.5 -35.5v-150h-800v150q0 21 14.5 35.5t35.5 14.5h50v150q0 91 49.5 165.5t130.5 109.5q-81 35 -130.5 109.5 t-49.5 165.5v100h-50q-21 0 -35.5 14.5t-14.5 35.5v150h800zM400 1000v-100q0 -60 32.5 -109.5t87.5 -73.5q28 -12 44 -37t16 -55t-16 -55t-44 -37q-55 -24 -87.5 -73.5t-32.5 -109.5v-150h400v150q0 60 -32.5 109.5t-87.5 73.5q-28 12 -44 37t-16 55t16 55t44 37 q55 24 87.5 73.5t32.5 109.5v100h-400z" />
<glyph unicode="&#x25fc;" horiz-adv-x="500" d="M0 0z" />
<glyph unicode="&#x2601;" d="M503 1089q110 0 200.5 -59.5t134.5 -156.5q44 14 90 14q120 0 205 -86.5t85 -206.5q0 -121 -85 -207.5t-205 -86.5h-750q-79 0 -135.5 57t-56.5 137q0 69 42.5 122.5t108.5 67.5q-2 12 -2 37q0 153 108 260.5t260 107.5z" />
<glyph unicode="&#x26fa;" d="M774 1193.5q16 -9.5 20.5 -27t-5.5 -33.5l-136 -187l467 -746h30q20 0 35 -18.5t15 -39.5v-42h-1200v42q0 21 15 39.5t35 18.5h30l468 746l-135 183q-10 16 -5.5 34t20.5 28t34 5.5t28 -20.5l111 -148l112 150q9 16 27 20.5t34 -5zM600 200h377l-182 112l-195 534v-646z " />
<glyph unicode="&#x2709;" d="M25 1100h1150q10 0 12.5 -5t-5.5 -13l-564 -567q-8 -8 -18 -8t-18 8l-564 567q-8 8 -5.5 13t12.5 5zM18 882l264 -264q8 -8 8 -18t-8 -18l-264 -264q-8 -8 -13 -5.5t-5 12.5v550q0 10 5 12.5t13 -5.5zM918 618l264 264q8 8 13 5.5t5 -12.5v-550q0 -10 -5 -12.5t-13 5.5 l-264 264q-8 8 -8 18t8 18zM818 482l364 -364q8 -8 5.5 -13t-12.5 -5h-1150q-10 0 -12.5 5t5.5 13l364 364q8 8 18 8t18 -8l164 -164q8 -8 18 -8t18 8l164 164q8 8 18 8t18 -8z" />
<glyph unicode="&#x270f;" d="M1011 1210q19 0 33 -13l153 -153q13 -14 13 -33t-13 -33l-99 -92l-214 214l95 96q13 14 32 14zM1013 800l-615 -614l-214 214l614 614zM317 96l-333 -112l110 335z" />
<glyph unicode="&#xe001;" d="M700 650v-550h250q21 0 35.5 -14.5t14.5 -35.5v-50h-800v50q0 21 14.5 35.5t35.5 14.5h250v550l-500 550h1200z" />
<glyph unicode="&#xe002;" d="M368 1017l645 163q39 15 63 0t24 -49v-831q0 -55 -41.5 -95.5t-111.5 -63.5q-79 -25 -147 -4.5t-86 75t25.5 111.5t122.5 82q72 24 138 8v521l-600 -155v-606q0 -42 -44 -90t-109 -69q-79 -26 -147 -5.5t-86 75.5t25.5 111.5t122.5 82.5q72 24 138 7v639q0 38 14.5 59 t53.5 34z" />
<glyph unicode="&#xe003;" d="M500 1191q100 0 191 -39t156.5 -104.5t104.5 -156.5t39 -191l-1 -2l1 -5q0 -141 -78 -262l275 -274q23 -26 22.5 -44.5t-22.5 -42.5l-59 -58q-26 -20 -46.5 -20t-39.5 20l-275 274q-119 -77 -261 -77l-5 1l-2 -1q-100 0 -191 39t-156.5 104.5t-104.5 156.5t-39 191 t39 191t104.5 156.5t156.5 104.5t191 39zM500 1022q-88 0 -162 -43t-117 -117t-43 -162t43 -162t117 -117t162 -43t162 43t117 117t43 162t-43 162t-117 117t-162 43z" />
<glyph unicode="&#xe005;" d="M649 949q48 68 109.5 104t121.5 38.5t118.5 -20t102.5 -64t71 -100.5t27 -123q0 -57 -33.5 -117.5t-94 -124.5t-126.5 -127.5t-150 -152.5t-146 -174q-62 85 -145.5 174t-150 152.5t-126.5 127.5t-93.5 124.5t-33.5 117.5q0 64 28 123t73 100.5t104 64t119 20 t120.5 -38.5t104.5 -104z" />
<glyph unicode="&#xe006;" d="M407 800l131 353q7 19 17.5 19t17.5 -19l129 -353h421q21 0 24 -8.5t-14 -20.5l-342 -249l130 -401q7 -20 -0.5 -25.5t-24.5 6.5l-343 246l-342 -247q-17 -12 -24.5 -6.5t-0.5 25.5l130 400l-347 251q-17 12 -14 20.5t23 8.5h429z" />
<glyph unicode="&#xe007;" d="M407 800l131 353q7 19 17.5 19t17.5 -19l129 -353h421q21 0 24 -8.5t-14 -20.5l-342 -249l130 -401q7 -20 -0.5 -25.5t-24.5 6.5l-343 246l-342 -247q-17 -12 -24.5 -6.5t-0.5 25.5l130 400l-347 251q-17 12 -14 20.5t23 8.5h429zM477 700h-240l197 -142l-74 -226 l193 139l195 -140l-74 229l192 140h-234l-78 211z" />
<glyph unicode="&#xe008;" d="M600 1200q124 0 212 -88t88 -212v-250q0 -46 -31 -98t-69 -52v-75q0 -10 6 -21.5t15 -17.5l358 -230q9 -5 15 -16.5t6 -21.5v-93q0 -10 -7.5 -17.5t-17.5 -7.5h-1150q-10 0 -17.5 7.5t-7.5 17.5v93q0 10 6 21.5t15 16.5l358 230q9 6 15 17.5t6 21.5v75q-38 0 -69 52 t-31 98v250q0 124 88 212t212 88z" />
<glyph unicode="&#xe009;" d="M25 1100h1150q10 0 17.5 -7.5t7.5 -17.5v-1050q0 -10 -7.5 -17.5t-17.5 -7.5h-1150q-10 0 -17.5 7.5t-7.5 17.5v1050q0 10 7.5 17.5t17.5 7.5zM100 1000v-100h100v100h-100zM875 1000h-550q-10 0 -17.5 -7.5t-7.5 -17.5v-350q0 -10 7.5 -17.5t17.5 -7.5h550 q10 0 17.5 7.5t7.5 17.5v350q0 10 -7.5 17.5t-17.5 7.5zM1000 1000v-100h100v100h-100zM100 800v-100h100v100h-100zM1000 800v-100h100v100h-100zM100 600v-100h100v100h-100zM1000 600v-100h100v100h-100zM875 500h-550q-10 0 -17.5 -7.5t-7.5 -17.5v-350q0 -10 7.5 -17.5 t17.5 -7.5h550q10 0 17.5 7.5t7.5 17.5v350q0 10 -7.5 17.5t-17.5 7.5zM100 400v-100h100v100h-100zM1000 400v-100h100v100h-100zM100 200v-100h100v100h-100zM1000 200v-100h100v100h-100z" />
<glyph unicode="&#xe010;" d="M50 1100h400q21 0 35.5 -14.5t14.5 -35.5v-400q0 -21 -14.5 -35.5t-35.5 -14.5h-400q-21 0 -35.5 14.5t-14.5 35.5v400q0 21 14.5 35.5t35.5 14.5zM650 1100h400q21 0 35.5 -14.5t14.5 -35.5v-400q0 -21 -14.5 -35.5t-35.5 -14.5h-400q-21 0 -35.5 14.5t-14.5 35.5v400 q0 21 14.5 35.5t35.5 14.5zM50 500h400q21 0 35.5 -14.5t14.5 -35.5v-400q0 -21 -14.5 -35.5t-35.5 -14.5h-400q-21 0 -35.5 14.5t-14.5 35.5v400q0 21 14.5 35.5t35.5 14.5zM650 500h400q21 0 35.5 -14.5t14.5 -35.5v-400q0 -21 -14.5 -35.5t-35.5 -14.5h-400 q-21 0 -35.5 14.5t-14.5 35.5v400q0 21 14.5 35.5t35.5 14.5z" />
<glyph unicode="&#xe011;" d="M50 1100h200q21 0 35.5 -14.5t14.5 -35.5v-200q0 -21 -14.5 -35.5t-35.5 -14.5h-200q-21 0 -35.5 14.5t-14.5 35.5v200q0 21 14.5 35.5t35.5 14.5zM450 1100h200q21 0 35.5 -14.5t14.5 -35.5v-200q0 -21 -14.5 -35.5t-35.5 -14.5h-200q-21 0 -35.5 14.5t-14.5 35.5v200 q0 21 14.5 35.5t35.5 14.5zM850 1100h200q21 0 35.5 -14.5t14.5 -35.5v-200q0 -21 -14.5 -35.5t-35.5 -14.5h-200q-21 0 -35.5 14.5t-14.5 35.5v200q0 21 14.5 35.5t35.5 14.5zM50 700h200q21 0 35.5 -14.5t14.5 -35.5v-200q0 -21 -14.5 -35.5t-35.5 -14.5h-200 q-21 0 -35.5 14.5t-14.5 35.5v200q0 21 14.5 35.5t35.5 14.5zM450 700h200q21 0 35.5 -14.5t14.5 -35.5v-200q0 -21 -14.5 -35.5t-35.5 -14.5h-200q-21 0 -35.5 14.5t-14.5 35.5v200q0 21 14.5 35.5t35.5 14.5zM850 700h200q21 0 35.5 -14.5t14.5 -35.5v-200 q0 -21 -14.5 -35.5t-35.5 -14.5h-200q-21 0 -35.5 14.5t-14.5 35.5v200q0 21 14.5 35.5t35.5 14.5zM50 300h200q21 0 35.5 -14.5t14.5 -35.5v-200q0 -21 -14.5 -35.5t-35.5 -14.5h-200q-21 0 -35.5 14.5t-14.5 35.5v200q0 21 14.5 35.5t35.5 14.5zM450 300h200 q21 0 35.5 -14.5t14.5 -35.5v-200q0 -21 -14.5 -35.5t-35.5 -14.5h-200q-21 0 -35.5 14.5t-14.5 35.5v200q0 21 14.5 35.5t35.5 14.5zM850 300h200q21 0 35.5 -14.5t14.5 -35.5v-200q0 -21 -14.5 -35.5t-35.5 -14.5h-200q-21 0 -35.5 14.5t-14.5 35.5v200q0 21 14.5 35.5 t35.5 14.5z" />
<glyph unicode="&#xe012;" d="M50 1100h200q21 0 35.5 -14.5t14.5 -35.5v-200q0 -21 -14.5 -35.5t-35.5 -14.5h-200q-21 0 -35.5 14.5t-14.5 35.5v200q0 21 14.5 35.5t35.5 14.5zM450 1100h700q21 0 35.5 -14.5t14.5 -35.5v-200q0 -21 -14.5 -35.5t-35.5 -14.5h-700q-21 0 -35.5 14.5t-14.5 35.5v200 q0 21 14.5 35.5t35.5 14.5zM50 700h200q21 0 35.5 -14.5t14.5 -35.5v-200q0 -21 -14.5 -35.5t-35.5 -14.5h-200q-21 0 -35.5 14.5t-14.5 35.5v200q0 21 14.5 35.5t35.5 14.5zM450 700h700q21 0 35.5 -14.5t14.5 -35.5v-200q0 -21 -14.5 -35.5t-35.5 -14.5h-700 q-21 0 -35.5 14.5t-14.5 35.5v200q0 21 14.5 35.5t35.5 14.5zM50 300h200q21 0 35.5 -14.5t14.5 -35.5v-200q0 -21 -14.5 -35.5t-35.5 -14.5h-200q-21 0 -35.5 14.5t-14.5 35.5v200q0 21 14.5 35.5t35.5 14.5zM450 300h700q21 0 35.5 -14.5t14.5 -35.5v-200 q0 -21 -14.5 -35.5t-35.5 -14.5h-700q-21 0 -35.5 14.5t-14.5 35.5v200q0 21 14.5 35.5t35.5 14.5z" />
<glyph unicode="&#xe013;" d="M465 477l571 571q8 8 18 8t17 -8l177 -177q8 -7 8 -17t-8 -18l-783 -784q-7 -8 -17.5 -8t-17.5 8l-384 384q-8 8 -8 18t8 17l177 177q7 8 17 8t18 -8l171 -171q7 -7 18 -7t18 7z" />
<glyph unicode="&#xe014;" d="M904 1083l178 -179q8 -8 8 -18.5t-8 -17.5l-267 -268l267 -268q8 -7 8 -17.5t-8 -18.5l-178 -178q-8 -8 -18.5 -8t-17.5 8l-268 267l-268 -267q-7 -8 -17.5 -8t-18.5 8l-178 178q-8 8 -8 18.5t8 17.5l267 268l-267 268q-8 7 -8 17.5t8 18.5l178 178q8 8 18.5 8t17.5 -8 l268 -267l268 268q7 7 17.5 7t18.5 -7z" />
<glyph unicode="&#xe015;" d="M507 1177q98 0 187.5 -38.5t154.5 -103.5t103.5 -154.5t38.5 -187.5q0 -141 -78 -262l300 -299q8 -8 8 -18.5t-8 -18.5l-109 -108q-7 -8 -17.5 -8t-18.5 8l-300 299q-119 -77 -261 -77q-98 0 -188 38.5t-154.5 103t-103 154.5t-38.5 188t38.5 187.5t103 154.5 t154.5 103.5t188 38.5zM506.5 1023q-89.5 0 -165.5 -44t-120 -120.5t-44 -166t44 -165.5t120 -120t165.5 -44t166 44t120.5 120t44 165.5t-44 166t-120.5 120.5t-166 44zM425 900h150q10 0 17.5 -7.5t7.5 -17.5v-75h75q10 0 17.5 -7.5t7.5 -17.5v-150q0 -10 -7.5 -17.5 t-17.5 -7.5h-75v-75q0 -10 -7.5 -17.5t-17.5 -7.5h-150q-10 0 -17.5 7.5t-7.5 17.5v75h-75q-10 0 -17.5 7.5t-7.5 17.5v150q0 10 7.5 17.5t17.5 7.5h75v75q0 10 7.5 17.5t17.5 7.5z" />
<glyph unicode="&#xe016;" d="M507 1177q98 0 187.5 -38.5t154.5 -103.5t103.5 -154.5t38.5 -187.5q0 -141 -78 -262l300 -299q8 -8 8 -18.5t-8 -18.5l-109 -108q-7 -8 -17.5 -8t-18.5 8l-300 299q-119 -77 -261 -77q-98 0 -188 38.5t-154.5 103t-103 154.5t-38.5 188t38.5 187.5t103 154.5 t154.5 103.5t188 38.5zM506.5 1023q-89.5 0 -165.5 -44t-120 -120.5t-44 -166t44 -165.5t120 -120t165.5 -44t166 44t120.5 120t44 165.5t-44 166t-120.5 120.5t-166 44zM325 800h350q10 0 17.5 -7.5t7.5 -17.5v-150q0 -10 -7.5 -17.5t-17.5 -7.5h-350q-10 0 -17.5 7.5 t-7.5 17.5v150q0 10 7.5 17.5t17.5 7.5z" />
<glyph unicode="&#xe017;" d="M550 1200h100q21 0 35.5 -14.5t14.5 -35.5v-400q0 -21 -14.5 -35.5t-35.5 -14.5h-100q-21 0 -35.5 14.5t-14.5 35.5v400q0 21 14.5 35.5t35.5 14.5zM800 975v166q167 -62 272 -209.5t105 -331.5q0 -117 -45.5 -224t-123 -184.5t-184.5 -123t-224 -45.5t-224 45.5 t-184.5 123t-123 184.5t-45.5 224q0 184 105 331.5t272 209.5v-166q-103 -55 -165 -155t-62 -220q0 -116 57 -214.5t155.5 -155.5t214.5 -57t214.5 57t155.5 155.5t57 214.5q0 120 -62 220t-165 155z" />
<glyph unicode="&#xe018;" d="M1025 1200h150q10 0 17.5 -7.5t7.5 -17.5v-1150q0 -10 -7.5 -17.5t-17.5 -7.5h-150q-10 0 -17.5 7.5t-7.5 17.5v1150q0 10 7.5 17.5t17.5 7.5zM725 800h150q10 0 17.5 -7.5t7.5 -17.5v-750q0 -10 -7.5 -17.5t-17.5 -7.5h-150q-10 0 -17.5 7.5t-7.5 17.5v750 q0 10 7.5 17.5t17.5 7.5zM425 500h150q10 0 17.5 -7.5t7.5 -17.5v-450q0 -10 -7.5 -17.5t-17.5 -7.5h-150q-10 0 -17.5 7.5t-7.5 17.5v450q0 10 7.5 17.5t17.5 7.5zM125 300h150q10 0 17.5 -7.5t7.5 -17.5v-250q0 -10 -7.5 -17.5t-17.5 -7.5h-150q-10 0 -17.5 7.5t-7.5 17.5 v250q0 10 7.5 17.5t17.5 7.5z" />
<glyph unicode="&#xe019;" d="M600 1174q33 0 74 -5l38 -152l5 -1q49 -14 94 -39l5 -2l134 80q61 -48 104 -105l-80 -134l3 -5q25 -44 39 -93l1 -6l152 -38q5 -43 5 -73q0 -34 -5 -74l-152 -38l-1 -6q-15 -49 -39 -93l-3 -5l80 -134q-48 -61 -104 -105l-134 81l-5 -3q-44 -25 -94 -39l-5 -2l-38 -151 q-43 -5 -74 -5q-33 0 -74 5l-38 151l-5 2q-49 14 -94 39l-5 3l-134 -81q-60 48 -104 105l80 134l-3 5q-25 45 -38 93l-2 6l-151 38q-6 42 -6 74q0 33 6 73l151 38l2 6q13 48 38 93l3 5l-80 134q47 61 105 105l133 -80l5 2q45 25 94 39l5 1l38 152q43 5 74 5zM600 815 q-89 0 -152 -63t-63 -151.5t63 -151.5t152 -63t152 63t63 151.5t-63 151.5t-152 63z" />
<glyph unicode="&#xe020;" d="M500 1300h300q41 0 70.5 -29.5t29.5 -70.5v-100h275q10 0 17.5 -7.5t7.5 -17.5v-75h-1100v75q0 10 7.5 17.5t17.5 7.5h275v100q0 41 29.5 70.5t70.5 29.5zM500 1200v-100h300v100h-300zM1100 900v-800q0 -41 -29.5 -70.5t-70.5 -29.5h-700q-41 0 -70.5 29.5t-29.5 70.5 v800h900zM300 800v-700h100v700h-100zM500 800v-700h100v700h-100zM700 800v-700h100v700h-100zM900 800v-700h100v700h-100z" />
<glyph unicode="&#xe021;" d="M18 618l620 608q8 7 18.5 7t17.5 -7l608 -608q8 -8 5.5 -13t-12.5 -5h-175v-575q0 -10 -7.5 -17.5t-17.5 -7.5h-250q-10 0 -17.5 7.5t-7.5 17.5v375h-300v-375q0 -10 -7.5 -17.5t-17.5 -7.5h-250q-10 0 -17.5 7.5t-7.5 17.5v575h-175q-10 0 -12.5 5t5.5 13z" />
<glyph unicode="&#xe022;" d="M600 1200v-400q0 -41 29.5 -70.5t70.5 -29.5h300v-650q0 -21 -14.5 -35.5t-35.5 -14.5h-800q-21 0 -35.5 14.5t-14.5 35.5v1100q0 21 14.5 35.5t35.5 14.5h450zM1000 800h-250q-21 0 -35.5 14.5t-14.5 35.5v250z" />
<glyph unicode="&#xe023;" d="M600 1177q117 0 224 -45.5t184.5 -123t123 -184.5t45.5 -224t-45.5 -224t-123 -184.5t-184.5 -123t-224 -45.5t-224 45.5t-184.5 123t-123 184.5t-45.5 224t45.5 224t123 184.5t184.5 123t224 45.5zM600 1027q-116 0 -214.5 -57t-155.5 -155.5t-57 -214.5t57 -214.5 t155.5 -155.5t214.5 -57t214.5 57t155.5 155.5t57 214.5t-57 214.5t-155.5 155.5t-214.5 57zM525 900h50q10 0 17.5 -7.5t7.5 -17.5v-275h175q10 0 17.5 -7.5t7.5 -17.5v-50q0 -10 -7.5 -17.5t-17.5 -7.5h-250q-10 0 -17.5 7.5t-7.5 17.5v350q0 10 7.5 17.5t17.5 7.5z" />
<glyph unicode="&#xe024;" d="M1300 0h-538l-41 400h-242l-41 -400h-538l431 1200h209l-21 -300h162l-20 300h208zM515 800l-27 -300h224l-27 300h-170z" />
<glyph unicode="&#xe025;" d="M550 1200h200q21 0 35.5 -14.5t14.5 -35.5v-450h191q20 0 25.5 -11.5t-7.5 -27.5l-327 -400q-13 -16 -32 -16t-32 16l-327 400q-13 16 -7.5 27.5t25.5 11.5h191v450q0 21 14.5 35.5t35.5 14.5zM1125 400h50q10 0 17.5 -7.5t7.5 -17.5v-350q0 -10 -7.5 -17.5t-17.5 -7.5 h-1050q-10 0 -17.5 7.5t-7.5 17.5v350q0 10 7.5 17.5t17.5 7.5h50q10 0 17.5 -7.5t7.5 -17.5v-175h900v175q0 10 7.5 17.5t17.5 7.5z" />
<glyph unicode="&#xe026;" d="M600 1177q117 0 224 -45.5t184.5 -123t123 -184.5t45.5 -224t-45.5 -224t-123 -184.5t-184.5 -123t-224 -45.5t-224 45.5t-184.5 123t-123 184.5t-45.5 224t45.5 224t123 184.5t184.5 123t224 45.5zM600 1027q-116 0 -214.5 -57t-155.5 -155.5t-57 -214.5t57 -214.5 t155.5 -155.5t214.5 -57t214.5 57t155.5 155.5t57 214.5t-57 214.5t-155.5 155.5t-214.5 57zM525 900h150q10 0 17.5 -7.5t7.5 -17.5v-275h137q21 0 26 -11.5t-8 -27.5l-223 -275q-13 -16 -32 -16t-32 16l-223 275q-13 16 -8 27.5t26 11.5h137v275q0 10 7.5 17.5t17.5 7.5z " />
<glyph unicode="&#xe027;" d="M600 1177q117 0 224 -45.5t184.5 -123t123 -184.5t45.5 -224t-45.5 -224t-123 -184.5t-184.5 -123t-224 -45.5t-224 45.5t-184.5 123t-123 184.5t-45.5 224t45.5 224t123 184.5t184.5 123t224 45.5zM600 1027q-116 0 -214.5 -57t-155.5 -155.5t-57 -214.5t57 -214.5 t155.5 -155.5t214.5 -57t214.5 57t155.5 155.5t57 214.5t-57 214.5t-155.5 155.5t-214.5 57zM632 914l223 -275q13 -16 8 -27.5t-26 -11.5h-137v-275q0 -10 -7.5 -17.5t-17.5 -7.5h-150q-10 0 -17.5 7.5t-7.5 17.5v275h-137q-21 0 -26 11.5t8 27.5l223 275q13 16 32 16 t32 -16z" />
<glyph unicode="&#xe028;" d="M225 1200h750q10 0 19.5 -7t12.5 -17l186 -652q7 -24 7 -49v-425q0 -12 -4 -27t-9 -17q-12 -6 -37 -6h-1100q-12 0 -27 4t-17 8q-6 13 -6 38l1 425q0 25 7 49l185 652q3 10 12.5 17t19.5 7zM878 1000h-556q-10 0 -19 -7t-11 -18l-87 -450q-2 -11 4 -18t16 -7h150 q10 0 19.5 -7t11.5 -17l38 -152q2 -10 11.5 -17t19.5 -7h250q10 0 19.5 7t11.5 17l38 152q2 10 11.5 17t19.5 7h150q10 0 16 7t4 18l-87 450q-2 11 -11 18t-19 7z" />
<glyph unicode="&#xe029;" d="M600 1177q117 0 224 -45.5t184.5 -123t123 -184.5t45.5 -224t-45.5 -224t-123 -184.5t-184.5 -123t-224 -45.5t-224 45.5t-184.5 123t-123 184.5t-45.5 224t45.5 224t123 184.5t184.5 123t224 45.5zM600 1027q-116 0 -214.5 -57t-155.5 -155.5t-57 -214.5t57 -214.5 t155.5 -155.5t214.5 -57t214.5 57t155.5 155.5t57 214.5t-57 214.5t-155.5 155.5t-214.5 57zM540 820l253 -190q17 -12 17 -30t-17 -30l-253 -190q-16 -12 -28 -6.5t-12 26.5v400q0 21 12 26.5t28 -6.5z" />
<glyph unicode="&#xe030;" d="M947 1060l135 135q7 7 12.5 5t5.5 -13v-362q0 -10 -7.5 -17.5t-17.5 -7.5h-362q-11 0 -13 5.5t5 12.5l133 133q-109 76 -238 76q-116 0 -214.5 -57t-155.5 -155.5t-57 -214.5t57 -214.5t155.5 -155.5t214.5 -57t214.5 57t155.5 155.5t57 214.5h150q0 -117 -45.5 -224 t-123 -184.5t-184.5 -123t-224 -45.5t-224 45.5t-184.5 123t-123 184.5t-45.5 224t45.5 224t123 184.5t184.5 123t224 45.5q192 0 347 -117z" />
<glyph unicode="&#xe031;" d="M947 1060l135 135q7 7 12.5 5t5.5 -13v-361q0 -11 -7.5 -18.5t-18.5 -7.5h-361q-11 0 -13 5.5t5 12.5l134 134q-110 75 -239 75q-116 0 -214.5 -57t-155.5 -155.5t-57 -214.5h-150q0 117 45.5 224t123 184.5t184.5 123t224 45.5q192 0 347 -117zM1027 600h150 q0 -117 -45.5 -224t-123 -184.5t-184.5 -123t-224 -45.5q-192 0 -348 118l-134 -134q-7 -8 -12.5 -5.5t-5.5 12.5v360q0 11 7.5 18.5t18.5 7.5h360q10 0 12.5 -5.5t-5.5 -12.5l-133 -133q110 -76 240 -76q116 0 214.5 57t155.5 155.5t57 214.5z" />
<glyph unicode="&#xe032;" d="M125 1200h1050q10 0 17.5 -7.5t7.5 -17.5v-1150q0 -10 -7.5 -17.5t-17.5 -7.5h-1050q-10 0 -17.5 7.5t-7.5 17.5v1150q0 10 7.5 17.5t17.5 7.5zM1075 1000h-850q-10 0 -17.5 -7.5t-7.5 -17.5v-850q0 -10 7.5 -17.5t17.5 -7.5h850q10 0 17.5 7.5t7.5 17.5v850 q0 10 -7.5 17.5t-17.5 7.5zM325 900h50q10 0 17.5 -7.5t7.5 -17.5v-50q0 -10 -7.5 -17.5t-17.5 -7.5h-50q-10 0 -17.5 7.5t-7.5 17.5v50q0 10 7.5 17.5t17.5 7.5zM525 900h450q10 0 17.5 -7.5t7.5 -17.5v-50q0 -10 -7.5 -17.5t-17.5 -7.5h-450q-10 0 -17.5 7.5t-7.5 17.5v50 q0 10 7.5 17.5t17.5 7.5zM325 700h50q10 0 17.5 -7.5t7.5 -17.5v-50q0 -10 -7.5 -17.5t-17.5 -7.5h-50q-10 0 -17.5 7.5t-7.5 17.5v50q0 10 7.5 17.5t17.5 7.5zM525 700h450q10 0 17.5 -7.5t7.5 -17.5v-50q0 -10 -7.5 -17.5t-17.5 -7.5h-450q-10 0 -17.5 7.5t-7.5 17.5v50 q0 10 7.5 17.5t17.5 7.5zM325 500h50q10 0 17.5 -7.5t7.5 -17.5v-50q0 -10 -7.5 -17.5t-17.5 -7.5h-50q-10 0 -17.5 7.5t-7.5 17.5v50q0 10 7.5 17.5t17.5 7.5zM525 500h450q10 0 17.5 -7.5t7.5 -17.5v-50q0 -10 -7.5 -17.5t-17.5 -7.5h-450q-10 0 -17.5 7.5t-7.5 17.5v50 q0 10 7.5 17.5t17.5 7.5zM325 300h50q10 0 17.5 -7.5t7.5 -17.5v-50q0 -10 -7.5 -17.5t-17.5 -7.5h-50q-10 0 -17.5 7.5t-7.5 17.5v50q0 10 7.5 17.5t17.5 7.5zM525 300h450q10 0 17.5 -7.5t7.5 -17.5v-50q0 -10 -7.5 -17.5t-17.5 -7.5h-450q-10 0 -17.5 7.5t-7.5 17.5v50 q0 10 7.5 17.5t17.5 7.5z" />
<glyph unicode="&#xe033;" d="M900 800v200q0 83 -58.5 141.5t-141.5 58.5h-300q-82 0 -141 -59t-59 -141v-200h-100q-41 0 -70.5 -29.5t-29.5 -70.5v-600q0 -41 29.5 -70.5t70.5 -29.5h900q41 0 70.5 29.5t29.5 70.5v600q0 41 -29.5 70.5t-70.5 29.5h-100zM400 800v150q0 21 15 35.5t35 14.5h200 q20 0 35 -14.5t15 -35.5v-150h-300z" />
<glyph unicode="&#xe034;" d="M125 1100h50q10 0 17.5 -7.5t7.5 -17.5v-1075h-100v1075q0 10 7.5 17.5t17.5 7.5zM1075 1052q4 0 9 -2q16 -6 16 -23v-421q0 -6 -3 -12q-33 -59 -66.5 -99t-65.5 -58t-56.5 -24.5t-52.5 -6.5q-26 0 -57.5 6.5t-52.5 13.5t-60 21q-41 15 -63 22.5t-57.5 15t-65.5 7.5 q-85 0 -160 -57q-7 -5 -15 -5q-6 0 -11 3q-14 7 -14 22v438q22 55 82 98.5t119 46.5q23 2 43 0.5t43 -7t32.5 -8.5t38 -13t32.5 -11q41 -14 63.5 -21t57 -14t63.5 -7q103 0 183 87q7 8 18 8z" />
<glyph unicode="&#xe035;" d="M600 1175q116 0 227 -49.5t192.5 -131t131 -192.5t49.5 -227v-300q0 -10 -7.5 -17.5t-17.5 -7.5h-50q-10 0 -17.5 7.5t-7.5 17.5v300q0 127 -70.5 231.5t-184.5 161.5t-245 57t-245 -57t-184.5 -161.5t-70.5 -231.5v-300q0 -10 -7.5 -17.5t-17.5 -7.5h-50 q-10 0 -17.5 7.5t-7.5 17.5v300q0 116 49.5 227t131 192.5t192.5 131t227 49.5zM220 500h160q8 0 14 -6t6 -14v-460q0 -8 -6 -14t-14 -6h-160q-8 0 -14 6t-6 14v460q0 8 6 14t14 6zM820 500h160q8 0 14 -6t6 -14v-460q0 -8 -6 -14t-14 -6h-160q-8 0 -14 6t-6 14v460 q0 8 6 14t14 6z" />
<glyph unicode="&#xe036;" d="M321 814l258 172q9 6 15 2.5t6 -13.5v-750q0 -10 -6 -13.5t-15 2.5l-258 172q-21 14 -46 14h-250q-10 0 -17.5 7.5t-7.5 17.5v350q0 10 7.5 17.5t17.5 7.5h250q25 0 46 14zM900 668l120 120q7 7 17 7t17 -7l34 -34q7 -7 7 -17t-7 -17l-120 -120l120 -120q7 -7 7 -17 t-7 -17l-34 -34q-7 -7 -17 -7t-17 7l-120 119l-120 -119q-7 -7 -17 -7t-17 7l-34 34q-7 7 -7 17t7 17l119 120l-119 120q-7 7 -7 17t7 17l34 34q7 8 17 8t17 -8z" />
<glyph unicode="&#xe037;" d="M321 814l258 172q9 6 15 2.5t6 -13.5v-750q0 -10 -6 -13.5t-15 2.5l-258 172q-21 14 -46 14h-250q-10 0 -17.5 7.5t-7.5 17.5v350q0 10 7.5 17.5t17.5 7.5h250q25 0 46 14zM766 900h4q10 -1 16 -10q96 -129 96 -290q0 -154 -90 -281q-6 -9 -17 -10l-3 -1q-9 0 -16 6 l-29 23q-7 7 -8.5 16.5t4.5 17.5q72 103 72 229q0 132 -78 238q-6 8 -4.5 18t9.5 17l29 22q7 5 15 5z" />
<glyph unicode="&#xe038;" d="M967 1004h3q11 -1 17 -10q135 -179 135 -396q0 -105 -34 -206.5t-98 -185.5q-7 -9 -17 -10h-3q-9 0 -16 6l-42 34q-8 6 -9 16t5 18q111 150 111 328q0 90 -29.5 176t-84.5 157q-6 9 -5 19t10 16l42 33q7 5 15 5zM321 814l258 172q9 6 15 2.5t6 -13.5v-750q0 -10 -6 -13.5 t-15 2.5l-258 172q-21 14 -46 14h-250q-10 0 -17.5 7.5t-7.5 17.5v350q0 10 7.5 17.5t17.5 7.5h250q25 0 46 14zM766 900h4q10 -1 16 -10q96 -129 96 -290q0 -154 -90 -281q-6 -9 -17 -10l-3 -1q-9 0 -16 6l-29 23q-7 7 -8.5 16.5t4.5 17.5q72 103 72 229q0 132 -78 238 q-6 8 -4.5 18.5t9.5 16.5l29 22q7 5 15 5z" />
<glyph unicode="&#xe039;" d="M500 900h100v-100h-100v-100h-400v-100h-100v600h500v-300zM1200 700h-200v-100h200v-200h-300v300h-200v300h-100v200h600v-500zM100 1100v-300h300v300h-300zM800 1100v-300h300v300h-300zM300 900h-100v100h100v-100zM1000 900h-100v100h100v-100zM300 500h200v-500 h-500v500h200v100h100v-100zM800 300h200v-100h-100v-100h-200v100h-100v100h100v200h-200v100h300v-300zM100 400v-300h300v300h-300zM300 200h-100v100h100v-100zM1200 200h-100v100h100v-100zM700 0h-100v100h100v-100zM1200 0h-300v100h300v-100z" />
<glyph unicode="&#xe040;" d="M100 200h-100v1000h100v-1000zM300 200h-100v1000h100v-1000zM700 200h-200v1000h200v-1000zM900 200h-100v1000h100v-1000zM1200 200h-200v1000h200v-1000zM400 0h-300v100h300v-100zM600 0h-100v91h100v-91zM800 0h-100v91h100v-91zM1100 0h-200v91h200v-91z" />
<glyph unicode="&#xe041;" d="M500 1200l682 -682q8 -8 8 -18t-8 -18l-464 -464q-8 -8 -18 -8t-18 8l-682 682l1 475q0 10 7.5 17.5t17.5 7.5h474zM319.5 1024.5q-29.5 29.5 -71 29.5t-71 -29.5t-29.5 -71.5t29.5 -71.5t71 -29.5t71 29.5t29.5 71.5t-29.5 71.5z" />
<glyph unicode="&#xe042;" d="M500 1200l682 -682q8 -8 8 -18t-8 -18l-464 -464q-8 -8 -18 -8t-18 8l-682 682l1 475q0 10 7.5 17.5t17.5 7.5h474zM800 1200l682 -682q8 -8 8 -18t-8 -18l-464 -464q-8 -8 -18 -8t-18 8l-56 56l424 426l-700 700h150zM319.5 1024.5q-29.5 29.5 -71 29.5t-71 -29.5 t-29.5 -71.5t29.5 -71.5t71 -29.5t71 29.5t29.5 71.5t-29.5 71.5z" />
<glyph unicode="&#xe043;" d="M300 1200h825q75 0 75 -75v-900q0 -25 -18 -43l-64 -64q-8 -8 -13 -5.5t-5 12.5v950q0 10 -7.5 17.5t-17.5 7.5h-700q-25 0 -43 -18l-64 -64q-8 -8 -5.5 -13t12.5 -5h700q10 0 17.5 -7.5t7.5 -17.5v-950q0 -10 -7.5 -17.5t-17.5 -7.5h-850q-10 0 -17.5 7.5t-7.5 17.5v975 q0 25 18 43l139 139q18 18 43 18z" />
<glyph unicode="&#xe044;" d="M250 1200h800q21 0 35.5 -14.5t14.5 -35.5v-1150l-450 444l-450 -445v1151q0 21 14.5 35.5t35.5 14.5z" />
<glyph unicode="&#xe045;" d="M822 1200h-444q-11 0 -19 -7.5t-9 -17.5l-78 -301q-7 -24 7 -45l57 -108q6 -9 17.5 -15t21.5 -6h450q10 0 21.5 6t17.5 15l62 108q14 21 7 45l-83 301q-1 10 -9 17.5t-19 7.5zM1175 800h-150q-10 0 -21 -6.5t-15 -15.5l-78 -156q-4 -9 -15 -15.5t-21 -6.5h-550 q-10 0 -21 6.5t-15 15.5l-78 156q-4 9 -15 15.5t-21 6.5h-150q-10 0 -17.5 -7.5t-7.5 -17.5v-650q0 -10 7.5 -17.5t17.5 -7.5h150q10 0 17.5 7.5t7.5 17.5v150q0 10 7.5 17.5t17.5 7.5h750q10 0 17.5 -7.5t7.5 -17.5v-150q0 -10 7.5 -17.5t17.5 -7.5h150q10 0 17.5 7.5 t7.5 17.5v650q0 10 -7.5 17.5t-17.5 7.5zM850 200h-500q-10 0 -19.5 -7t-11.5 -17l-38 -152q-2 -10 3.5 -17t15.5 -7h600q10 0 15.5 7t3.5 17l-38 152q-2 10 -11.5 17t-19.5 7z" />
<glyph unicode="&#xe046;" d="M500 1100h200q56 0 102.5 -20.5t72.5 -50t44 -59t25 -50.5l6 -20h150q41 0 70.5 -29.5t29.5 -70.5v-600q0 -41 -29.5 -70.5t-70.5 -29.5h-1000q-41 0 -70.5 29.5t-29.5 70.5v600q0 41 29.5 70.5t70.5 29.5h150q2 8 6.5 21.5t24 48t45 61t72 48t102.5 21.5zM900 800v-100 h100v100h-100zM600 730q-95 0 -162.5 -67.5t-67.5 -162.5t67.5 -162.5t162.5 -67.5t162.5 67.5t67.5 162.5t-67.5 162.5t-162.5 67.5zM600 603q43 0 73 -30t30 -73t-30 -73t-73 -30t-73 30t-30 73t30 73t73 30z" />
<glyph unicode="&#xe047;" d="M681 1199l385 -998q20 -50 60 -92q18 -19 36.5 -29.5t27.5 -11.5l10 -2v-66h-417v66q53 0 75 43.5t5 88.5l-82 222h-391q-58 -145 -92 -234q-11 -34 -6.5 -57t25.5 -37t46 -20t55 -6v-66h-365v66q56 24 84 52q12 12 25 30.5t20 31.5l7 13l399 1006h93zM416 521h340 l-162 457z" />
<glyph unicode="&#xe048;" d="M753 641q5 -1 14.5 -4.5t36 -15.5t50.5 -26.5t53.5 -40t50.5 -54.5t35.5 -70t14.5 -87q0 -67 -27.5 -125.5t-71.5 -97.5t-98.5 -66.5t-108.5 -40.5t-102 -13h-500v89q41 7 70.5 32.5t29.5 65.5v827q0 24 -0.5 34t-3.5 24t-8.5 19.5t-17 13.5t-28 12.5t-42.5 11.5v71 l471 -1q57 0 115.5 -20.5t108 -57t80.5 -94t31 -124.5q0 -51 -15.5 -96.5t-38 -74.5t-45 -50.5t-38.5 -30.5zM400 700h139q78 0 130.5 48.5t52.5 122.5q0 41 -8.5 70.5t-29.5 55.5t-62.5 39.5t-103.5 13.5h-118v-350zM400 200h216q80 0 121 50.5t41 130.5q0 90 -62.5 154.5 t-156.5 64.5h-159v-400z" />
<glyph unicode="&#xe049;" d="M877 1200l2 -57q-83 -19 -116 -45.5t-40 -66.5l-132 -839q-9 -49 13 -69t96 -26v-97h-500v97q186 16 200 98l173 832q3 17 3 30t-1.5 22.5t-9 17.5t-13.5 12.5t-21.5 10t-26 8.5t-33.5 10q-13 3 -19 5v57h425z" />
<glyph unicode="&#xe050;" d="M1300 900h-50q0 21 -4 37t-9.5 26.5t-18 17.5t-22 11t-28.5 5.5t-31 2t-37 0.5h-200v-850q0 -22 25 -34.5t50 -13.5l25 -2v-100h-400v100q4 0 11 0.5t24 3t30 7t24 15t11 24.5v850h-200q-25 0 -37 -0.5t-31 -2t-28.5 -5.5t-22 -11t-18 -17.5t-9.5 -26.5t-4 -37h-50v300 h1000v-300zM175 1000h-75v-800h75l-125 -167l-125 167h75v800h-75l125 167z" />
<glyph unicode="&#xe051;" d="M1100 900h-50q0 21 -4 37t-9.5 26.5t-18 17.5t-22 11t-28.5 5.5t-31 2t-37 0.5h-200v-650q0 -22 25 -34.5t50 -13.5l25 -2v-100h-400v100q4 0 11 0.5t24 3t30 7t24 15t11 24.5v650h-200q-25 0 -37 -0.5t-31 -2t-28.5 -5.5t-22 -11t-18 -17.5t-9.5 -26.5t-4 -37h-50v300 h1000v-300zM1167 50l-167 -125v75h-800v-75l-167 125l167 125v-75h800v75z" />
<glyph unicode="&#xe052;" d="M50 1100h600q21 0 35.5 -14.5t14.5 -35.5v-100q0 -21 -14.5 -35.5t-35.5 -14.5h-600q-21 0 -35.5 14.5t-14.5 35.5v100q0 21 14.5 35.5t35.5 14.5zM50 800h1000q21 0 35.5 -14.5t14.5 -35.5v-100q0 -21 -14.5 -35.5t-35.5 -14.5h-1000q-21 0 -35.5 14.5t-14.5 35.5v100 q0 21 14.5 35.5t35.5 14.5zM50 500h800q21 0 35.5 -14.5t14.5 -35.5v-100q0 -21 -14.5 -35.5t-35.5 -14.5h-800q-21 0 -35.5 14.5t-14.5 35.5v100q0 21 14.5 35.5t35.5 14.5zM50 200h1100q21 0 35.5 -14.5t14.5 -35.5v-100q0 -21 -14.5 -35.5t-35.5 -14.5h-1100 q-21 0 -35.5 14.5t-14.5 35.5v100q0 21 14.5 35.5t35.5 14.5z" />
<glyph unicode="&#xe053;" d="M250 1100h700q21 0 35.5 -14.5t14.5 -35.5v-100q0 -21 -14.5 -35.5t-35.5 -14.5h-700q-21 0 -35.5 14.5t-14.5 35.5v100q0 21 14.5 35.5t35.5 14.5zM50 800h1100q21 0 35.5 -14.5t14.5 -35.5v-100q0 -21 -14.5 -35.5t-35.5 -14.5h-1100q-21 0 -35.5 14.5t-14.5 35.5v100 q0 21 14.5 35.5t35.5 14.5zM250 500h700q21 0 35.5 -14.5t14.5 -35.5v-100q0 -21 -14.5 -35.5t-35.5 -14.5h-700q-21 0 -35.5 14.5t-14.5 35.5v100q0 21 14.5 35.5t35.5 14.5zM50 200h1100q21 0 35.5 -14.5t14.5 -35.5v-100q0 -21 -14.5 -35.5t-35.5 -14.5h-1100 q-21 0 -35.5 14.5t-14.5 35.5v100q0 21 14.5 35.5t35.5 14.5z" />
<glyph unicode="&#xe054;" d="M500 950v100q0 21 14.5 35.5t35.5 14.5h600q21 0 35.5 -14.5t14.5 -35.5v-100q0 -21 -14.5 -35.5t-35.5 -14.5h-600q-21 0 -35.5 14.5t-14.5 35.5zM100 650v100q0 21 14.5 35.5t35.5 14.5h1000q21 0 35.5 -14.5t14.5 -35.5v-100q0 -21 -14.5 -35.5t-35.5 -14.5h-1000 q-21 0 -35.5 14.5t-14.5 35.5zM300 350v100q0 21 14.5 35.5t35.5 14.5h800q21 0 35.5 -14.5t14.5 -35.5v-100q0 -21 -14.5 -35.5t-35.5 -14.5h-800q-21 0 -35.5 14.5t-14.5 35.5zM0 50v100q0 21 14.5 35.5t35.5 14.5h1100q21 0 35.5 -14.5t14.5 -35.5v-100 q0 -21 -14.5 -35.5t-35.5 -14.5h-1100q-21 0 -35.5 14.5t-14.5 35.5z" />
<glyph unicode="&#xe055;" d="M50 1100h1100q21 0 35.5 -14.5t14.5 -35.5v-100q0 -21 -14.5 -35.5t-35.5 -14.5h-1100q-21 0 -35.5 14.5t-14.5 35.5v100q0 21 14.5 35.5t35.5 14.5zM50 800h1100q21 0 35.5 -14.5t14.5 -35.5v-100q0 -21 -14.5 -35.5t-35.5 -14.5h-1100q-21 0 -35.5 14.5t-14.5 35.5v100 q0 21 14.5 35.5t35.5 14.5zM50 500h1100q21 0 35.5 -14.5t14.5 -35.5v-100q0 -21 -14.5 -35.5t-35.5 -14.5h-1100q-21 0 -35.5 14.5t-14.5 35.5v100q0 21 14.5 35.5t35.5 14.5zM50 200h1100q21 0 35.5 -14.5t14.5 -35.5v-100q0 -21 -14.5 -35.5t-35.5 -14.5h-1100 q-21 0 -35.5 14.5t-14.5 35.5v100q0 21 14.5 35.5t35.5 14.5z" />
<glyph unicode="&#xe056;" d="M50 1100h100q21 0 35.5 -14.5t14.5 -35.5v-100q0 -21 -14.5 -35.5t-35.5 -14.5h-100q-21 0 -35.5 14.5t-14.5 35.5v100q0 21 14.5 35.5t35.5 14.5zM350 1100h800q21 0 35.5 -14.5t14.5 -35.5v-100q0 -21 -14.5 -35.5t-35.5 -14.5h-800q-21 0 -35.5 14.5t-14.5 35.5v100 q0 21 14.5 35.5t35.5 14.5zM50 800h100q21 0 35.5 -14.5t14.5 -35.5v-100q0 -21 -14.5 -35.5t-35.5 -14.5h-100q-21 0 -35.5 14.5t-14.5 35.5v100q0 21 14.5 35.5t35.5 14.5zM350 800h800q21 0 35.5 -14.5t14.5 -35.5v-100q0 -21 -14.5 -35.5t-35.5 -14.5h-800 q-21 0 -35.5 14.5t-14.5 35.5v100q0 21 14.5 35.5t35.5 14.5zM50 500h100q21 0 35.5 -14.5t14.5 -35.5v-100q0 -21 -14.5 -35.5t-35.5 -14.5h-100q-21 0 -35.5 14.5t-14.5 35.5v100q0 21 14.5 35.5t35.5 14.5zM350 500h800q21 0 35.5 -14.5t14.5 -35.5v-100 q0 -21 -14.5 -35.5t-35.5 -14.5h-800q-21 0 -35.5 14.5t-14.5 35.5v100q0 21 14.5 35.5t35.5 14.5zM50 200h100q21 0 35.5 -14.5t14.5 -35.5v-100q0 -21 -14.5 -35.5t-35.5 -14.5h-100q-21 0 -35.5 14.5t-14.5 35.5v100q0 21 14.5 35.5t35.5 14.5zM350 200h800 q21 0 35.5 -14.5t14.5 -35.5v-100q0 -21 -14.5 -35.5t-35.5 -14.5h-800q-21 0 -35.5 14.5t-14.5 35.5v100q0 21 14.5 35.5t35.5 14.5z" />
<glyph unicode="&#xe057;" d="M400 0h-100v1100h100v-1100zM550 1100h100q21 0 35.5 -14.5t14.5 -35.5v-100q0 -21 -14.5 -35.5t-35.5 -14.5h-100q-21 0 -35.5 14.5t-14.5 35.5v100q0 21 14.5 35.5t35.5 14.5zM550 800h500q21 0 35.5 -14.5t14.5 -35.5v-100q0 -21 -14.5 -35.5t-35.5 -14.5h-500 q-21 0 -35.5 14.5t-14.5 35.5v100q0 21 14.5 35.5t35.5 14.5zM267 550l-167 -125v75h-200v100h200v75zM550 500h300q21 0 35.5 -14.5t14.5 -35.5v-100q0 -21 -14.5 -35.5t-35.5 -14.5h-300q-21 0 -35.5 14.5t-14.5 35.5v100q0 21 14.5 35.5t35.5 14.5zM550 200h600 q21 0 35.5 -14.5t14.5 -35.5v-100q0 -21 -14.5 -35.5t-35.5 -14.5h-600q-21 0 -35.5 14.5t-14.5 35.5v100q0 21 14.5 35.5t35.5 14.5z" />
<glyph unicode="&#xe058;" d="M50 1100h100q21 0 35.5 -14.5t14.5 -35.5v-100q0 -21 -14.5 -35.5t-35.5 -14.5h-100q-21 0 -35.5 14.5t-14.5 35.5v100q0 21 14.5 35.5t35.5 14.5zM900 0h-100v1100h100v-1100zM50 800h500q21 0 35.5 -14.5t14.5 -35.5v-100q0 -21 -14.5 -35.5t-35.5 -14.5h-500 q-21 0 -35.5 14.5t-14.5 35.5v100q0 21 14.5 35.5t35.5 14.5zM1100 600h200v-100h-200v-75l-167 125l167 125v-75zM50 500h300q21 0 35.5 -14.5t14.5 -35.5v-100q0 -21 -14.5 -35.5t-35.5 -14.5h-300q-21 0 -35.5 14.5t-14.5 35.5v100q0 21 14.5 35.5t35.5 14.5zM50 200h600 q21 0 35.5 -14.5t14.5 -35.5v-100q0 -21 -14.5 -35.5t-35.5 -14.5h-600q-21 0 -35.5 14.5t-14.5 35.5v100q0 21 14.5 35.5t35.5 14.5z" />
<glyph unicode="&#xe059;" d="M75 1000h750q31 0 53 -22t22 -53v-650q0 -31 -22 -53t-53 -22h-750q-31 0 -53 22t-22 53v650q0 31 22 53t53 22zM1200 300l-300 300l300 300v-600z" />
<glyph unicode="&#xe060;" d="M44 1100h1112q18 0 31 -13t13 -31v-1012q0 -18 -13 -31t-31 -13h-1112q-18 0 -31 13t-13 31v1012q0 18 13 31t31 13zM100 1000v-737l247 182l298 -131l-74 156l293 318l236 -288v500h-1000zM342 884q56 0 95 -39t39 -94.5t-39 -95t-95 -39.5t-95 39.5t-39 95t39 94.5 t95 39z" />
<glyph unicode="&#xe062;" d="M648 1169q117 0 216 -60t156.5 -161t57.5 -218q0 -115 -70 -258q-69 -109 -158 -225.5t-143 -179.5l-54 -62q-9 8 -25.5 24.5t-63.5 67.5t-91 103t-98.5 128t-95.5 148q-60 132 -60 249q0 88 34 169.5t91.5 142t137 96.5t166.5 36zM652.5 974q-91.5 0 -156.5 -65 t-65 -157t65 -156.5t156.5 -64.5t156.5 64.5t65 156.5t-65 157t-156.5 65z" />
<glyph unicode="&#xe063;" d="M600 1177q117 0 224 -45.5t184.5 -123t123 -184.5t45.5 -224t-45.5 -224t-123 -184.5t-184.5 -123t-224 -45.5t-224 45.5t-184.5 123t-123 184.5t-45.5 224t45.5 224t123 184.5t184.5 123t224 45.5zM600 173v854q-116 0 -214.5 -57t-155.5 -155.5t-57 -214.5t57 -214.5 t155.5 -155.5t214.5 -57z" />
<glyph unicode="&#xe064;" d="M554 1295q21 -72 57.5 -143.5t76 -130t83 -118t82.5 -117t70 -116t49.5 -126t18.5 -136.5q0 -71 -25.5 -135t-68.5 -111t-99 -82t-118.5 -54t-125.5 -23q-84 5 -161.5 34t-139.5 78.5t-99 125t-37 164.5q0 69 18 136.5t49.5 126.5t69.5 116.5t81.5 117.5t83.5 119 t76.5 131t58.5 143zM344 710q-23 -33 -43.5 -70.5t-40.5 -102.5t-17 -123q1 -37 14.5 -69.5t30 -52t41 -37t38.5 -24.5t33 -15q21 -7 32 -1t13 22l6 34q2 10 -2.5 22t-13.5 19q-5 4 -14 12t-29.5 40.5t-32.5 73.5q-26 89 6 271q2 11 -6 11q-8 1 -15 -10z" />
<glyph unicode="&#xe065;" d="M1000 1013l108 115q2 1 5 2t13 2t20.5 -1t25 -9.5t28.5 -21.5q22 -22 27 -43t0 -32l-6 -10l-108 -115zM350 1100h400q50 0 105 -13l-187 -187h-368q-41 0 -70.5 -29.5t-29.5 -70.5v-500q0 -41 29.5 -70.5t70.5 -29.5h500q41 0 70.5 29.5t29.5 70.5v182l200 200v-332 q0 -165 -93.5 -257.5t-256.5 -92.5h-400q-165 0 -257.5 92.5t-92.5 257.5v400q0 165 92.5 257.5t257.5 92.5zM1009 803l-362 -362l-161 -50l55 170l355 355z" />
<glyph unicode="&#xe066;" d="M350 1100h361q-164 -146 -216 -200h-195q-41 0 -70.5 -29.5t-29.5 -70.5v-500q0 -41 29.5 -70.5t70.5 -29.5h500q41 0 70.5 29.5t29.5 70.5l200 153v-103q0 -165 -92.5 -257.5t-257.5 -92.5h-400q-165 0 -257.5 92.5t-92.5 257.5v400q0 165 92.5 257.5t257.5 92.5z M824 1073l339 -301q8 -7 8 -17.5t-8 -17.5l-340 -306q-7 -6 -12.5 -4t-6.5 11v203q-26 1 -54.5 0t-78.5 -7.5t-92 -17.5t-86 -35t-70 -57q10 59 33 108t51.5 81.5t65 58.5t68.5 40.5t67 24.5t56 13.5t40 4.5v210q1 10 6.5 12.5t13.5 -4.5z" />
<glyph unicode="&#xe067;" d="M350 1100h350q60 0 127 -23l-178 -177h-349q-41 0 -70.5 -29.5t-29.5 -70.5v-500q0 -41 29.5 -70.5t70.5 -29.5h500q41 0 70.5 29.5t29.5 70.5v69l200 200v-219q0 -165 -92.5 -257.5t-257.5 -92.5h-400q-165 0 -257.5 92.5t-92.5 257.5v400q0 165 92.5 257.5t257.5 92.5z M643 639l395 395q7 7 17.5 7t17.5 -7l101 -101q7 -7 7 -17.5t-7 -17.5l-531 -532q-7 -7 -17.5 -7t-17.5 7l-248 248q-7 7 -7 17.5t7 17.5l101 101q7 7 17.5 7t17.5 -7l111 -111q8 -7 18 -7t18 7z" />
<glyph unicode="&#xe068;" d="M318 918l264 264q8 8 18 8t18 -8l260 -264q7 -8 4.5 -13t-12.5 -5h-170v-200h200v173q0 10 5 12t13 -5l264 -260q8 -7 8 -17.5t-8 -17.5l-264 -265q-8 -7 -13 -5t-5 12v173h-200v-200h170q10 0 12.5 -5t-4.5 -13l-260 -264q-8 -8 -18 -8t-18 8l-264 264q-8 8 -5.5 13 t12.5 5h175v200h-200v-173q0 -10 -5 -12t-13 5l-264 265q-8 7 -8 17.5t8 17.5l264 260q8 7 13 5t5 -12v-173h200v200h-175q-10 0 -12.5 5t5.5 13z" />
<glyph unicode="&#xe069;" d="M250 1100h100q21 0 35.5 -14.5t14.5 -35.5v-438l464 453q15 14 25.5 10t10.5 -25v-1000q0 -21 -10.5 -25t-25.5 10l-464 453v-438q0 -21 -14.5 -35.5t-35.5 -14.5h-100q-21 0 -35.5 14.5t-14.5 35.5v1000q0 21 14.5 35.5t35.5 14.5z" />
<glyph unicode="&#xe070;" d="M50 1100h100q21 0 35.5 -14.5t14.5 -35.5v-438l464 453q15 14 25.5 10t10.5 -25v-438l464 453q15 14 25.5 10t10.5 -25v-1000q0 -21 -10.5 -25t-25.5 10l-464 453v-438q0 -21 -10.5 -25t-25.5 10l-464 453v-438q0 -21 -14.5 -35.5t-35.5 -14.5h-100q-21 0 -35.5 14.5 t-14.5 35.5v1000q0 21 14.5 35.5t35.5 14.5z" />
<glyph unicode="&#xe071;" d="M1200 1050v-1000q0 -21 -10.5 -25t-25.5 10l-464 453v-438q0 -21 -10.5 -25t-25.5 10l-492 480q-15 14 -15 35t15 35l492 480q15 14 25.5 10t10.5 -25v-438l464 453q15 14 25.5 10t10.5 -25z" />
<glyph unicode="&#xe072;" d="M243 1074l814 -498q18 -11 18 -26t-18 -26l-814 -498q-18 -11 -30.5 -4t-12.5 28v1000q0 21 12.5 28t30.5 -4z" />
<glyph unicode="&#xe073;" d="M250 1000h200q21 0 35.5 -14.5t14.5 -35.5v-800q0 -21 -14.5 -35.5t-35.5 -14.5h-200q-21 0 -35.5 14.5t-14.5 35.5v800q0 21 14.5 35.5t35.5 14.5zM650 1000h200q21 0 35.5 -14.5t14.5 -35.5v-800q0 -21 -14.5 -35.5t-35.5 -14.5h-200q-21 0 -35.5 14.5t-14.5 35.5v800 q0 21 14.5 35.5t35.5 14.5z" />
<glyph unicode="&#xe074;" d="M1100 950v-800q0 -21 -14.5 -35.5t-35.5 -14.5h-800q-21 0 -35.5 14.5t-14.5 35.5v800q0 21 14.5 35.5t35.5 14.5h800q21 0 35.5 -14.5t14.5 -35.5z" />
<glyph unicode="&#xe075;" d="M500 612v438q0 21 10.5 25t25.5 -10l492 -480q15 -14 15 -35t-15 -35l-492 -480q-15 -14 -25.5 -10t-10.5 25v438l-464 -453q-15 -14 -25.5 -10t-10.5 25v1000q0 21 10.5 25t25.5 -10z" />
<glyph unicode="&#xe076;" d="M1048 1102l100 1q20 0 35 -14.5t15 -35.5l5 -1000q0 -21 -14.5 -35.5t-35.5 -14.5l-100 -1q-21 0 -35.5 14.5t-14.5 35.5l-2 437l-463 -454q-14 -15 -24.5 -10.5t-10.5 25.5l-2 437l-462 -455q-15 -14 -25.5 -9.5t-10.5 24.5l-5 1000q0 21 10.5 25.5t25.5 -10.5l466 -450 l-2 438q0 20 10.5 24.5t25.5 -9.5l466 -451l-2 438q0 21 14.5 35.5t35.5 14.5z" />
<glyph unicode="&#xe077;" d="M850 1100h100q21 0 35.5 -14.5t14.5 -35.5v-1000q0 -21 -14.5 -35.5t-35.5 -14.5h-100q-21 0 -35.5 14.5t-14.5 35.5v438l-464 -453q-15 -14 -25.5 -10t-10.5 25v1000q0 21 10.5 25t25.5 -10l464 -453v438q0 21 14.5 35.5t35.5 14.5z" />
<glyph unicode="&#xe078;" d="M686 1081l501 -540q15 -15 10.5 -26t-26.5 -11h-1042q-22 0 -26.5 11t10.5 26l501 540q15 15 36 15t36 -15zM150 400h1000q21 0 35.5 -14.5t14.5 -35.5v-100q0 -21 -14.5 -35.5t-35.5 -14.5h-1000q-21 0 -35.5 14.5t-14.5 35.5v100q0 21 14.5 35.5t35.5 14.5z" />
<glyph unicode="&#xe079;" d="M885 900l-352 -353l352 -353l-197 -198l-552 552l552 550z" />
<glyph unicode="&#xe080;" d="M1064 547l-551 -551l-198 198l353 353l-353 353l198 198z" />
<glyph unicode="&#xe081;" d="M600 1177q117 0 224 -45.5t184.5 -123t123 -184.5t45.5 -224t-45.5 -224t-123 -184.5t-184.5 -123t-224 -45.5t-224 45.5t-184.5 123t-123 184.5t-45.5 224t45.5 224t123 184.5t184.5 123t224 45.5zM650 900h-100q-21 0 -35.5 -14.5t-14.5 -35.5v-150h-150 q-21 0 -35.5 -14.5t-14.5 -35.5v-100q0 -21 14.5 -35.5t35.5 -14.5h150v-150q0 -21 14.5 -35.5t35.5 -14.5h100q21 0 35.5 14.5t14.5 35.5v150h150q21 0 35.5 14.5t14.5 35.5v100q0 21 -14.5 35.5t-35.5 14.5h-150v150q0 21 -14.5 35.5t-35.5 14.5z" />
<glyph unicode="&#xe082;" d="M600 1177q117 0 224 -45.5t184.5 -123t123 -184.5t45.5 -224t-45.5 -224t-123 -184.5t-184.5 -123t-224 -45.5t-224 45.5t-184.5 123t-123 184.5t-45.5 224t45.5 224t123 184.5t184.5 123t224 45.5zM850 700h-500q-21 0 -35.5 -14.5t-14.5 -35.5v-100q0 -21 14.5 -35.5 t35.5 -14.5h500q21 0 35.5 14.5t14.5 35.5v100q0 21 -14.5 35.5t-35.5 14.5z" />
<glyph unicode="&#xe083;" d="M600 1177q117 0 224 -45.5t184.5 -123t123 -184.5t45.5 -224t-45.5 -224t-123 -184.5t-184.5 -123t-224 -45.5t-224 45.5t-184.5 123t-123 184.5t-45.5 224t45.5 224t123 184.5t184.5 123t224 45.5zM741.5 913q-12.5 0 -21.5 -9l-120 -120l-120 120q-9 9 -21.5 9 t-21.5 -9l-141 -141q-9 -9 -9 -21.5t9 -21.5l120 -120l-120 -120q-9 -9 -9 -21.5t9 -21.5l141 -141q9 -9 21.5 -9t21.5 9l120 120l120 -120q9 -9 21.5 -9t21.5 9l141 141q9 9 9 21.5t-9 21.5l-120 120l120 120q9 9 9 21.5t-9 21.5l-141 141q-9 9 -21.5 9z" />
<glyph unicode="&#xe084;" d="M600 1177q117 0 224 -45.5t184.5 -123t123 -184.5t45.5 -224t-45.5 -224t-123 -184.5t-184.5 -123t-224 -45.5t-224 45.5t-184.5 123t-123 184.5t-45.5 224t45.5 224t123 184.5t184.5 123t224 45.5zM546 623l-84 85q-7 7 -17.5 7t-18.5 -7l-139 -139q-7 -8 -7 -18t7 -18 l242 -241q7 -8 17.5 -8t17.5 8l375 375q7 7 7 17.5t-7 18.5l-139 139q-7 7 -17.5 7t-17.5 -7z" />
<glyph unicode="&#xe085;" d="M600 1177q117 0 224 -45.5t184.5 -123t123 -184.5t45.5 -224t-45.5 -224t-123 -184.5t-184.5 -123t-224 -45.5t-224 45.5t-184.5 123t-123 184.5t-45.5 224t45.5 224t123 184.5t184.5 123t224 45.5zM588 941q-29 0 -59 -5.5t-63 -20.5t-58 -38.5t-41.5 -63t-16.5 -89.5 q0 -25 20 -25h131q30 -5 35 11q6 20 20.5 28t45.5 8q20 0 31.5 -10.5t11.5 -28.5q0 -23 -7 -34t-26 -18q-1 0 -13.5 -4t-19.5 -7.5t-20 -10.5t-22 -17t-18.5 -24t-15.5 -35t-8 -46q-1 -8 5.5 -16.5t20.5 -8.5h173q7 0 22 8t35 28t37.5 48t29.5 74t12 100q0 47 -17 83 t-42.5 57t-59.5 34.5t-64 18t-59 4.5zM675 400h-150q-10 0 -17.5 -7.5t-7.5 -17.5v-150q0 -10 7.5 -17.5t17.5 -7.5h150q10 0 17.5 7.5t7.5 17.5v150q0 10 -7.5 17.5t-17.5 7.5z" />
<glyph unicode="&#xe086;" d="M600 1177q117 0 224 -45.5t184.5 -123t123 -184.5t45.5 -224t-45.5 -224t-123 -184.5t-184.5 -123t-224 -45.5t-224 45.5t-184.5 123t-123 184.5t-45.5 224t45.5 224t123 184.5t184.5 123t224 45.5zM675 1000h-150q-10 0 -17.5 -7.5t-7.5 -17.5v-150q0 -10 7.5 -17.5 t17.5 -7.5h150q10 0 17.5 7.5t7.5 17.5v150q0 10 -7.5 17.5t-17.5 7.5zM675 700h-250q-10 0 -17.5 -7.5t-7.5 -17.5v-50q0 -10 7.5 -17.5t17.5 -7.5h75v-200h-75q-10 0 -17.5 -7.5t-7.5 -17.5v-50q0 -10 7.5 -17.5t17.5 -7.5h350q10 0 17.5 7.5t7.5 17.5v50q0 10 -7.5 17.5 t-17.5 7.5h-75v275q0 10 -7.5 17.5t-17.5 7.5z" />
<glyph unicode="&#xe087;" d="M525 1200h150q10 0 17.5 -7.5t7.5 -17.5v-194q103 -27 178.5 -102.5t102.5 -178.5h194q10 0 17.5 -7.5t7.5 -17.5v-150q0 -10 -7.5 -17.5t-17.5 -7.5h-194q-27 -103 -102.5 -178.5t-178.5 -102.5v-194q0 -10 -7.5 -17.5t-17.5 -7.5h-150q-10 0 -17.5 7.5t-7.5 17.5v194 q-103 27 -178.5 102.5t-102.5 178.5h-194q-10 0 -17.5 7.5t-7.5 17.5v150q0 10 7.5 17.5t17.5 7.5h194q27 103 102.5 178.5t178.5 102.5v194q0 10 7.5 17.5t17.5 7.5zM700 893v-168q0 -10 -7.5 -17.5t-17.5 -7.5h-150q-10 0 -17.5 7.5t-7.5 17.5v168q-68 -23 -119 -74 t-74 -119h168q10 0 17.5 -7.5t7.5 -17.5v-150q0 -10 -7.5 -17.5t-17.5 -7.5h-168q23 -68 74 -119t119 -74v168q0 10 7.5 17.5t17.5 7.5h150q10 0 17.5 -7.5t7.5 -17.5v-168q68 23 119 74t74 119h-168q-10 0 -17.5 7.5t-7.5 17.5v150q0 10 7.5 17.5t17.5 7.5h168 q-23 68 -74 119t-119 74z" />
<glyph unicode="&#xe088;" d="M600 1177q117 0 224 -45.5t184.5 -123t123 -184.5t45.5 -224t-45.5 -224t-123 -184.5t-184.5 -123t-224 -45.5t-224 45.5t-184.5 123t-123 184.5t-45.5 224t45.5 224t123 184.5t184.5 123t224 45.5zM600 1027q-116 0 -214.5 -57t-155.5 -155.5t-57 -214.5t57 -214.5 t155.5 -155.5t214.5 -57t214.5 57t155.5 155.5t57 214.5t-57 214.5t-155.5 155.5t-214.5 57zM759 823l64 -64q7 -7 7 -17.5t-7 -17.5l-124 -124l124 -124q7 -7 7 -17.5t-7 -17.5l-64 -64q-7 -7 -17.5 -7t-17.5 7l-124 124l-124 -124q-7 -7 -17.5 -7t-17.5 7l-64 64 q-7 7 -7 17.5t7 17.5l124 124l-124 124q-7 7 -7 17.5t7 17.5l64 64q7 7 17.5 7t17.5 -7l124 -124l124 124q7 7 17.5 7t17.5 -7z" />
<glyph unicode="&#xe089;" d="M600 1177q117 0 224 -45.5t184.5 -123t123 -184.5t45.5 -224t-45.5 -224t-123 -184.5t-184.5 -123t-224 -45.5t-224 45.5t-184.5 123t-123 184.5t-45.5 224t45.5 224t123 184.5t184.5 123t224 45.5zM600 1027q-116 0 -214.5 -57t-155.5 -155.5t-57 -214.5t57 -214.5 t155.5 -155.5t214.5 -57t214.5 57t155.5 155.5t57 214.5t-57 214.5t-155.5 155.5t-214.5 57zM782 788l106 -106q7 -7 7 -17.5t-7 -17.5l-320 -321q-8 -7 -18 -7t-18 7l-202 203q-8 7 -8 17.5t8 17.5l106 106q7 8 17.5 8t17.5 -8l79 -79l197 197q7 7 17.5 7t17.5 -7z" />
<glyph unicode="&#xe090;" d="M600 1177q117 0 224 -45.5t184.5 -123t123 -184.5t45.5 -224t-45.5 -224t-123 -184.5t-184.5 -123t-224 -45.5t-224 45.5t-184.5 123t-123 184.5t-45.5 224t45.5 224t123 184.5t184.5 123t224 45.5zM600 1027q-116 0 -214.5 -57t-155.5 -155.5t-57 -214.5q0 -120 65 -225 l587 587q-105 65 -225 65zM965 819l-584 -584q104 -62 219 -62q116 0 214.5 57t155.5 155.5t57 214.5q0 115 -62 219z" />
<glyph unicode="&#xe091;" d="M39 582l522 427q16 13 27.5 8t11.5 -26v-291h550q21 0 35.5 -14.5t14.5 -35.5v-200q0 -21 -14.5 -35.5t-35.5 -14.5h-550v-291q0 -21 -11.5 -26t-27.5 8l-522 427q-16 13 -16 32t16 32z" />
<glyph unicode="&#xe092;" d="M639 1009l522 -427q16 -13 16 -32t-16 -32l-522 -427q-16 -13 -27.5 -8t-11.5 26v291h-550q-21 0 -35.5 14.5t-14.5 35.5v200q0 21 14.5 35.5t35.5 14.5h550v291q0 21 11.5 26t27.5 -8z" />
<glyph unicode="&#xe093;" d="M682 1161l427 -522q13 -16 8 -27.5t-26 -11.5h-291v-550q0 -21 -14.5 -35.5t-35.5 -14.5h-200q-21 0 -35.5 14.5t-14.5 35.5v550h-291q-21 0 -26 11.5t8 27.5l427 522q13 16 32 16t32 -16z" />
<glyph unicode="&#xe094;" d="M550 1200h200q21 0 35.5 -14.5t14.5 -35.5v-550h291q21 0 26 -11.5t-8 -27.5l-427 -522q-13 -16 -32 -16t-32 16l-427 522q-13 16 -8 27.5t26 11.5h291v550q0 21 14.5 35.5t35.5 14.5z" />
<glyph unicode="&#xe095;" d="M639 1109l522 -427q16 -13 16 -32t-16 -32l-522 -427q-16 -13 -27.5 -8t-11.5 26v291q-94 -2 -182 -20t-170.5 -52t-147 -92.5t-100.5 -135.5q5 105 27 193.5t67.5 167t113 135t167 91.5t225.5 42v262q0 21 11.5 26t27.5 -8z" />
<glyph unicode="&#xe096;" d="M850 1200h300q21 0 35.5 -14.5t14.5 -35.5v-300q0 -21 -10.5 -25t-24.5 10l-94 94l-249 -249q-8 -7 -18 -7t-18 7l-106 106q-7 8 -7 18t7 18l249 249l-94 94q-14 14 -10 24.5t25 10.5zM350 0h-300q-21 0 -35.5 14.5t-14.5 35.5v300q0 21 10.5 25t24.5 -10l94 -94l249 249 q8 7 18 7t18 -7l106 -106q7 -8 7 -18t-7 -18l-249 -249l94 -94q14 -14 10 -24.5t-25 -10.5z" />
<glyph unicode="&#xe097;" d="M1014 1120l106 -106q7 -8 7 -18t-7 -18l-249 -249l94 -94q14 -14 10 -24.5t-25 -10.5h-300q-21 0 -35.5 14.5t-14.5 35.5v300q0 21 10.5 25t24.5 -10l94 -94l249 249q8 7 18 7t18 -7zM250 600h300q21 0 35.5 -14.5t14.5 -35.5v-300q0 -21 -10.5 -25t-24.5 10l-94 94 l-249 -249q-8 -7 -18 -7t-18 7l-106 106q-7 8 -7 18t7 18l249 249l-94 94q-14 14 -10 24.5t25 10.5z" />
<glyph unicode="&#xe101;" d="M600 1177q117 0 224 -45.5t184.5 -123t123 -184.5t45.5 -224t-45.5 -224t-123 -184.5t-184.5 -123t-224 -45.5t-224 45.5t-184.5 123t-123 184.5t-45.5 224t45.5 224t123 184.5t184.5 123t224 45.5zM704 900h-208q-20 0 -32 -14.5t-8 -34.5l58 -302q4 -20 21.5 -34.5 t37.5 -14.5h54q20 0 37.5 14.5t21.5 34.5l58 302q4 20 -8 34.5t-32 14.5zM675 400h-150q-10 0 -17.5 -7.5t-7.5 -17.5v-150q0 -10 7.5 -17.5t17.5 -7.5h150q10 0 17.5 7.5t7.5 17.5v150q0 10 -7.5 17.5t-17.5 7.5z" />
<glyph unicode="&#xe102;" d="M260 1200q9 0 19 -2t15 -4l5 -2q22 -10 44 -23l196 -118q21 -13 36 -24q29 -21 37 -12q11 13 49 35l196 118q22 13 45 23q17 7 38 7q23 0 47 -16.5t37 -33.5l13 -16q14 -21 18 -45l25 -123l8 -44q1 -9 8.5 -14.5t17.5 -5.5h61q10 0 17.5 -7.5t7.5 -17.5v-50 q0 -10 -7.5 -17.5t-17.5 -7.5h-50q-10 0 -17.5 -7.5t-7.5 -17.5v-175h-400v300h-200v-300h-400v175q0 10 -7.5 17.5t-17.5 7.5h-50q-10 0 -17.5 7.5t-7.5 17.5v50q0 10 7.5 17.5t17.5 7.5h61q11 0 18 3t7 8q0 4 9 52l25 128q5 25 19 45q2 3 5 7t13.5 15t21.5 19.5t26.5 15.5 t29.5 7zM915 1079l-166 -162q-7 -7 -5 -12t12 -5h219q10 0 15 7t2 17l-51 149q-3 10 -11 12t-15 -6zM463 917l-177 157q-8 7 -16 5t-11 -12l-51 -143q-3 -10 2 -17t15 -7h231q11 0 12.5 5t-5.5 12zM500 0h-375q-10 0 -17.5 7.5t-7.5 17.5v375h400v-400zM1100 400v-375 q0 -10 -7.5 -17.5t-17.5 -7.5h-375v400h400z" />
<glyph unicode="&#xe103;" d="M1165 1190q8 3 21 -6.5t13 -17.5q-2 -178 -24.5 -323.5t-55.5 -245.5t-87 -174.5t-102.5 -118.5t-118 -68.5t-118.5 -33t-120 -4.5t-105 9.5t-90 16.5q-61 12 -78 11q-4 1 -12.5 0t-34 -14.5t-52.5 -40.5l-153 -153q-26 -24 -37 -14.5t-11 43.5q0 64 42 102q8 8 50.5 45 t66.5 58q19 17 35 47t13 61q-9 55 -10 102.5t7 111t37 130t78 129.5q39 51 80 88t89.5 63.5t94.5 45t113.5 36t129 31t157.5 37t182 47.5zM1116 1098q-8 9 -22.5 -3t-45.5 -50q-38 -47 -119 -103.5t-142 -89.5l-62 -33q-56 -30 -102 -57t-104 -68t-102.5 -80.5t-85.5 -91 t-64 -104.5q-24 -56 -31 -86t2 -32t31.5 17.5t55.5 59.5q25 30 94 75.5t125.5 77.5t147.5 81q70 37 118.5 69t102 79.5t99 111t86.5 148.5q22 50 24 60t-6 19z" />
<glyph unicode="&#xe104;" d="M653 1231q-39 -67 -54.5 -131t-10.5 -114.5t24.5 -96.5t47.5 -80t63.5 -62.5t68.5 -46.5t65 -30q-4 7 -17.5 35t-18.5 39.5t-17 39.5t-17 43t-13 42t-9.5 44.5t-2 42t4 43t13.5 39t23 38.5q96 -42 165 -107.5t105 -138t52 -156t13 -159t-19 -149.5q-13 -55 -44 -106.5 t-68 -87t-78.5 -64.5t-72.5 -45t-53 -22q-72 -22 -127 -11q-31 6 -13 19q6 3 17 7q13 5 32.5 21t41 44t38.5 63.5t21.5 81.5t-6.5 94.5t-50 107t-104 115.5q10 -104 -0.5 -189t-37 -140.5t-65 -93t-84 -52t-93.5 -11t-95 24.5q-80 36 -131.5 114t-53.5 171q-2 23 0 49.5 t4.5 52.5t13.5 56t27.5 60t46 64.5t69.5 68.5q-8 -53 -5 -102.5t17.5 -90t34 -68.5t44.5 -39t49 -2q31 13 38.5 36t-4.5 55t-29 64.5t-36 75t-26 75.5q-15 85 2 161.5t53.5 128.5t85.5 92.5t93.5 61t81.5 25.5z" />
<glyph unicode="&#xe105;" d="M600 1094q82 0 160.5 -22.5t140 -59t116.5 -82.5t94.5 -95t68 -95t42.5 -82.5t14 -57.5t-14 -57.5t-43 -82.5t-68.5 -95t-94.5 -95t-116.5 -82.5t-140 -59t-159.5 -22.5t-159.5 22.5t-140 59t-116.5 82.5t-94.5 95t-68.5 95t-43 82.5t-14 57.5t14 57.5t42.5 82.5t68 95 t94.5 95t116.5 82.5t140 59t160.5 22.5zM888 829q-15 15 -18 12t5 -22q25 -57 25 -119q0 -124 -88 -212t-212 -88t-212 88t-88 212q0 59 23 114q8 19 4.5 22t-17.5 -12q-70 -69 -160 -184q-13 -16 -15 -40.5t9 -42.5q22 -36 47 -71t70 -82t92.5 -81t113 -58.5t133.5 -24.5 t133.5 24t113 58.5t92.5 81.5t70 81.5t47 70.5q11 18 9 42.5t-14 41.5q-90 117 -163 189zM448 727l-35 -36q-15 -15 -19.5 -38.5t4.5 -41.5q37 -68 93 -116q16 -13 38.5 -11t36.5 17l35 34q14 15 12.5 33.5t-16.5 33.5q-44 44 -89 117q-11 18 -28 20t-32 -12z" />
<glyph unicode="&#xe106;" d="M592 0h-148l31 120q-91 20 -175.5 68.5t-143.5 106.5t-103.5 119t-66.5 110t-22 76q0 21 14 57.5t42.5 82.5t68 95t94.5 95t116.5 82.5t140 59t160.5 22.5q61 0 126 -15l32 121h148zM944 770l47 181q108 -85 176.5 -192t68.5 -159q0 -26 -19.5 -71t-59.5 -102t-93 -112 t-129 -104.5t-158 -75.5l46 173q77 49 136 117t97 131q11 18 9 42.5t-14 41.5q-54 70 -107 130zM310 824q-70 -69 -160 -184q-13 -16 -15 -40.5t9 -42.5q18 -30 39 -60t57 -70.5t74 -73t90 -61t105 -41.5l41 154q-107 18 -178.5 101.5t-71.5 193.5q0 59 23 114q8 19 4.5 22 t-17.5 -12zM448 727l-35 -36q-15 -15 -19.5 -38.5t4.5 -41.5q37 -68 93 -116q16 -13 38.5 -11t36.5 17l12 11l22 86l-3 4q-44 44 -89 117q-11 18 -28 20t-32 -12z" />
<glyph unicode="&#xe107;" d="M-90 100l642 1066q20 31 48 28.5t48 -35.5l642 -1056q21 -32 7.5 -67.5t-50.5 -35.5h-1294q-37 0 -50.5 34t7.5 66zM155 200h345v75q0 10 7.5 17.5t17.5 7.5h150q10 0 17.5 -7.5t7.5 -17.5v-75h345l-445 723zM496 700h208q20 0 32 -14.5t8 -34.5l-58 -252 q-4 -20 -21.5 -34.5t-37.5 -14.5h-54q-20 0 -37.5 14.5t-21.5 34.5l-58 252q-4 20 8 34.5t32 14.5z" />
<glyph unicode="&#xe108;" d="M650 1200q62 0 106 -44t44 -106v-339l363 -325q15 -14 26 -38.5t11 -44.5v-41q0 -20 -12 -26.5t-29 5.5l-359 249v-263q100 -93 100 -113v-64q0 -21 -13 -29t-32 1l-205 128l-205 -128q-19 -9 -32 -1t-13 29v64q0 20 100 113v263l-359 -249q-17 -12 -29 -5.5t-12 26.5v41 q0 20 11 44.5t26 38.5l363 325v339q0 62 44 106t106 44z" />
<glyph unicode="&#xe109;" d="M850 1200h100q21 0 35.5 -14.5t14.5 -35.5v-50h50q21 0 35.5 -14.5t14.5 -35.5v-150h-1100v150q0 21 14.5 35.5t35.5 14.5h50v50q0 21 14.5 35.5t35.5 14.5h100q21 0 35.5 -14.5t14.5 -35.5v-50h500v50q0 21 14.5 35.5t35.5 14.5zM1100 800v-750q0 -21 -14.5 -35.5 t-35.5 -14.5h-1000q-21 0 -35.5 14.5t-14.5 35.5v750h1100zM100 600v-100h100v100h-100zM300 600v-100h100v100h-100zM500 600v-100h100v100h-100zM700 600v-100h100v100h-100zM900 600v-100h100v100h-100zM100 400v-100h100v100h-100zM300 400v-100h100v100h-100zM500 400 v-100h100v100h-100zM700 400v-100h100v100h-100zM900 400v-100h100v100h-100zM100 200v-100h100v100h-100zM300 200v-100h100v100h-100zM500 200v-100h100v100h-100zM700 200v-100h100v100h-100zM900 200v-100h100v100h-100z" />
<glyph unicode="&#xe110;" d="M1135 1165l249 -230q15 -14 15 -35t-15 -35l-249 -230q-14 -14 -24.5 -10t-10.5 25v150h-159l-600 -600h-291q-21 0 -35.5 14.5t-14.5 35.5v100q0 21 14.5 35.5t35.5 14.5h209l600 600h241v150q0 21 10.5 25t24.5 -10zM522 819l-141 -141l-122 122h-209q-21 0 -35.5 14.5 t-14.5 35.5v100q0 21 14.5 35.5t35.5 14.5h291zM1135 565l249 -230q15 -14 15 -35t-15 -35l-249 -230q-14 -14 -24.5 -10t-10.5 25v150h-241l-181 181l141 141l122 -122h159v150q0 21 10.5 25t24.5 -10z" />
<glyph unicode="&#xe111;" d="M100 1100h1000q41 0 70.5 -29.5t29.5 -70.5v-600q0 -41 -29.5 -70.5t-70.5 -29.5h-596l-304 -300v300h-100q-41 0 -70.5 29.5t-29.5 70.5v600q0 41 29.5 70.5t70.5 29.5z" />
<glyph unicode="&#xe112;" d="M150 1200h200q21 0 35.5 -14.5t14.5 -35.5v-250h-300v250q0 21 14.5 35.5t35.5 14.5zM850 1200h200q21 0 35.5 -14.5t14.5 -35.5v-250h-300v250q0 21 14.5 35.5t35.5 14.5zM1100 800v-300q0 -41 -3 -77.5t-15 -89.5t-32 -96t-58 -89t-89 -77t-129 -51t-174 -20t-174 20 t-129 51t-89 77t-58 89t-32 96t-15 89.5t-3 77.5v300h300v-250v-27v-42.5t1.5 -41t5 -38t10 -35t16.5 -30t25.5 -24.5t35 -19t46.5 -12t60 -4t60 4.5t46.5 12.5t35 19.5t25 25.5t17 30.5t10 35t5 38t2 40.5t-0.5 42v25v250h300z" />
<glyph unicode="&#xe113;" d="M1100 411l-198 -199l-353 353l-353 -353l-197 199l551 551z" />
<glyph unicode="&#xe114;" d="M1101 789l-550 -551l-551 551l198 199l353 -353l353 353z" />
<glyph unicode="&#xe115;" d="M404 1000h746q21 0 35.5 -14.5t14.5 -35.5v-551h150q21 0 25 -10.5t-10 -24.5l-230 -249q-14 -15 -35 -15t-35 15l-230 249q-14 14 -10 24.5t25 10.5h150v401h-381zM135 984l230 -249q14 -14 10 -24.5t-25 -10.5h-150v-400h385l215 -200h-750q-21 0 -35.5 14.5 t-14.5 35.5v550h-150q-21 0 -25 10.5t10 24.5l230 249q14 15 35 15t35 -15z" />
<glyph unicode="&#xe116;" d="M56 1200h94q17 0 31 -11t18 -27l38 -162h896q24 0 39 -18.5t10 -42.5l-100 -475q-5 -21 -27 -42.5t-55 -21.5h-633l48 -200h535q21 0 35.5 -14.5t14.5 -35.5t-14.5 -35.5t-35.5 -14.5h-50v-50q0 -21 -14.5 -35.5t-35.5 -14.5t-35.5 14.5t-14.5 35.5v50h-300v-50 q0 -21 -14.5 -35.5t-35.5 -14.5t-35.5 14.5t-14.5 35.5v50h-31q-18 0 -32.5 10t-20.5 19l-5 10l-201 961h-54q-20 0 -35 14.5t-15 35.5t15 35.5t35 14.5z" />
<glyph unicode="&#xe117;" d="M1200 1000v-100h-1200v100h200q0 41 29.5 70.5t70.5 29.5h300q41 0 70.5 -29.5t29.5 -70.5h500zM0 800h1200v-800h-1200v800z" />
<glyph unicode="&#xe118;" d="M200 800l-200 -400v600h200q0 41 29.5 70.5t70.5 29.5h300q42 0 71 -29.5t29 -70.5h500v-200h-1000zM1500 700l-300 -700h-1200l300 700h1200z" />
<glyph unicode="&#xe119;" d="M635 1184l230 -249q14 -14 10 -24.5t-25 -10.5h-150v-601h150q21 0 25 -10.5t-10 -24.5l-230 -249q-14 -15 -35 -15t-35 15l-230 249q-14 14 -10 24.5t25 10.5h150v601h-150q-21 0 -25 10.5t10 24.5l230 249q14 15 35 15t35 -15z" />
<glyph unicode="&#xe120;" d="M936 864l249 -229q14 -15 14 -35.5t-14 -35.5l-249 -229q-15 -15 -25.5 -10.5t-10.5 24.5v151h-600v-151q0 -20 -10.5 -24.5t-25.5 10.5l-249 229q-14 15 -14 35.5t14 35.5l249 229q15 15 25.5 10.5t10.5 -25.5v-149h600v149q0 21 10.5 25.5t25.5 -10.5z" />
<glyph unicode="&#xe121;" d="M1169 400l-172 732q-5 23 -23 45.5t-38 22.5h-672q-20 0 -38 -20t-23 -41l-172 -739h1138zM1100 300h-1000q-41 0 -70.5 -29.5t-29.5 -70.5v-100q0 -41 29.5 -70.5t70.5 -29.5h1000q41 0 70.5 29.5t29.5 70.5v100q0 41 -29.5 70.5t-70.5 29.5zM800 100v100h100v-100h-100 zM1000 100v100h100v-100h-100z" />
<glyph unicode="&#xe122;" d="M1150 1100q21 0 35.5 -14.5t14.5 -35.5v-850q0 -21 -14.5 -35.5t-35.5 -14.5t-35.5 14.5t-14.5 35.5v850q0 21 14.5 35.5t35.5 14.5zM1000 200l-675 200h-38l47 -276q3 -16 -5.5 -20t-29.5 -4h-7h-84q-20 0 -34.5 14t-18.5 35q-55 337 -55 351v250v6q0 16 1 23.5t6.5 14 t17.5 6.5h200l675 250v-850zM0 750v-250q-4 0 -11 0.5t-24 6t-30 15t-24 30t-11 48.5v50q0 26 10.5 46t25 30t29 16t25.5 7z" />
<glyph unicode="&#xe123;" d="M553 1200h94q20 0 29 -10.5t3 -29.5l-18 -37q83 -19 144 -82.5t76 -140.5l63 -327l118 -173h17q19 0 33 -14.5t14 -35t-13 -40.5t-31 -27q-8 -4 -23 -9.5t-65 -19.5t-103 -25t-132.5 -20t-158.5 -9q-57 0 -115 5t-104 12t-88.5 15.5t-73.5 17.5t-54.5 16t-35.5 12l-11 4 q-18 8 -31 28t-13 40.5t14 35t33 14.5h17l118 173l63 327q15 77 76 140t144 83l-18 32q-6 19 3.5 32t28.5 13zM498 110q50 -6 102 -6q53 0 102 6q-12 -49 -39.5 -79.5t-62.5 -30.5t-63 30.5t-39 79.5z" />
<glyph unicode="&#xe124;" d="M800 946l224 78l-78 -224l234 -45l-180 -155l180 -155l-234 -45l78 -224l-224 78l-45 -234l-155 180l-155 -180l-45 234l-224 -78l78 224l-234 45l180 155l-180 155l234 45l-78 224l224 -78l45 234l155 -180l155 180z" />
<glyph unicode="&#xe125;" d="M650 1200h50q40 0 70 -40.5t30 -84.5v-150l-28 -125h328q40 0 70 -40.5t30 -84.5v-100q0 -45 -29 -74l-238 -344q-16 -24 -38 -40.5t-45 -16.5h-250q-7 0 -42 25t-66 50l-31 25h-61q-45 0 -72.5 18t-27.5 57v400q0 36 20 63l145 196l96 198q13 28 37.5 48t51.5 20z M650 1100l-100 -212l-150 -213v-375h100l136 -100h214l250 375v125h-450l50 225v175h-50zM50 800h100q21 0 35.5 -14.5t14.5 -35.5v-500q0 -21 -14.5 -35.5t-35.5 -14.5h-100q-21 0 -35.5 14.5t-14.5 35.5v500q0 21 14.5 35.5t35.5 14.5z" />
<glyph unicode="&#xe126;" d="M600 1100h250q23 0 45 -16.5t38 -40.5l238 -344q29 -29 29 -74v-100q0 -44 -30 -84.5t-70 -40.5h-328q28 -118 28 -125v-150q0 -44 -30 -84.5t-70 -40.5h-50q-27 0 -51.5 20t-37.5 48l-96 198l-145 196q-20 27 -20 63v400q0 39 27.5 57t72.5 18h61q124 100 139 100z M50 1000h100q21 0 35.5 -14.5t14.5 -35.5v-500q0 -21 -14.5 -35.5t-35.5 -14.5h-100q-21 0 -35.5 14.5t-14.5 35.5v500q0 21 14.5 35.5t35.5 14.5zM636 1000l-136 -100h-100v-375l150 -213l100 -212h50v175l-50 225h450v125l-250 375h-214z" />
<glyph unicode="&#xe127;" d="M356 873l363 230q31 16 53 -6l110 -112q13 -13 13.5 -32t-11.5 -34l-84 -121h302q84 0 138 -38t54 -110t-55 -111t-139 -39h-106l-131 -339q-6 -21 -19.5 -41t-28.5 -20h-342q-7 0 -90 81t-83 94v525q0 17 14 35.5t28 28.5zM400 792v-503l100 -89h293l131 339 q6 21 19.5 41t28.5 20h203q21 0 30.5 25t0.5 50t-31 25h-456h-7h-6h-5.5t-6 0.5t-5 1.5t-5 2t-4 2.5t-4 4t-2.5 4.5q-12 25 5 47l146 183l-86 83zM50 800h100q21 0 35.5 -14.5t14.5 -35.5v-500q0 -21 -14.5 -35.5t-35.5 -14.5h-100q-21 0 -35.5 14.5t-14.5 35.5v500 q0 21 14.5 35.5t35.5 14.5z" />
<glyph unicode="&#xe128;" d="M475 1103l366 -230q2 -1 6 -3.5t14 -10.5t18 -16.5t14.5 -20t6.5 -22.5v-525q0 -13 -86 -94t-93 -81h-342q-15 0 -28.5 20t-19.5 41l-131 339h-106q-85 0 -139.5 39t-54.5 111t54 110t138 38h302l-85 121q-11 15 -10.5 34t13.5 32l110 112q22 22 53 6zM370 945l146 -183 q17 -22 5 -47q-2 -2 -3.5 -4.5t-4 -4t-4 -2.5t-5 -2t-5 -1.5t-6 -0.5h-6h-6.5h-6h-475v-100h221q15 0 29 -20t20 -41l130 -339h294l106 89v503l-342 236zM1050 800h100q21 0 35.5 -14.5t14.5 -35.5v-500q0 -21 -14.5 -35.5t-35.5 -14.5h-100q-21 0 -35.5 14.5t-14.5 35.5 v500q0 21 14.5 35.5t35.5 14.5z" />
<glyph unicode="&#xe129;" d="M550 1294q72 0 111 -55t39 -139v-106l339 -131q21 -6 41 -19.5t20 -28.5v-342q0 -7 -81 -90t-94 -83h-525q-17 0 -35.5 14t-28.5 28l-9 14l-230 363q-16 31 6 53l112 110q13 13 32 13.5t34 -11.5l121 -84v302q0 84 38 138t110 54zM600 972v203q0 21 -25 30.5t-50 0.5 t-25 -31v-456v-7v-6v-5.5t-0.5 -6t-1.5 -5t-2 -5t-2.5 -4t-4 -4t-4.5 -2.5q-25 -12 -47 5l-183 146l-83 -86l236 -339h503l89 100v293l-339 131q-21 6 -41 19.5t-20 28.5zM450 200h500q21 0 35.5 -14.5t14.5 -35.5v-100q0 -21 -14.5 -35.5t-35.5 -14.5h-500 q-21 0 -35.5 14.5t-14.5 35.5v100q0 21 14.5 35.5t35.5 14.5z" />
<glyph unicode="&#xe130;" d="M350 1100h500q21 0 35.5 14.5t14.5 35.5v100q0 21 -14.5 35.5t-35.5 14.5h-500q-21 0 -35.5 -14.5t-14.5 -35.5v-100q0 -21 14.5 -35.5t35.5 -14.5zM600 306v-106q0 -84 -39 -139t-111 -55t-110 54t-38 138v302l-121 -84q-15 -12 -34 -11.5t-32 13.5l-112 110 q-22 22 -6 53l230 363q1 2 3.5 6t10.5 13.5t16.5 17t20 13.5t22.5 6h525q13 0 94 -83t81 -90v-342q0 -15 -20 -28.5t-41 -19.5zM308 900l-236 -339l83 -86l183 146q22 17 47 5q2 -1 4.5 -2.5t4 -4t2.5 -4t2 -5t1.5 -5t0.5 -6v-5.5v-6v-7v-456q0 -22 25 -31t50 0.5t25 30.5 v203q0 15 20 28.5t41 19.5l339 131v293l-89 100h-503z" />
<glyph unicode="&#xe131;" d="M600 1178q118 0 225 -45.5t184.5 -123t123 -184.5t45.5 -225t-45.5 -225t-123 -184.5t-184.5 -123t-225 -45.5t-225 45.5t-184.5 123t-123 184.5t-45.5 225t45.5 225t123 184.5t184.5 123t225 45.5zM914 632l-275 223q-16 13 -27.5 8t-11.5 -26v-137h-275 q-10 0 -17.5 -7.5t-7.5 -17.5v-150q0 -10 7.5 -17.5t17.5 -7.5h275v-137q0 -21 11.5 -26t27.5 8l275 223q16 13 16 32t-16 32z" />
<glyph unicode="&#xe132;" d="M600 1178q118 0 225 -45.5t184.5 -123t123 -184.5t45.5 -225t-45.5 -225t-123 -184.5t-184.5 -123t-225 -45.5t-225 45.5t-184.5 123t-123 184.5t-45.5 225t45.5 225t123 184.5t184.5 123t225 45.5zM561 855l-275 -223q-16 -13 -16 -32t16 -32l275 -223q16 -13 27.5 -8 t11.5 26v137h275q10 0 17.5 7.5t7.5 17.5v150q0 10 -7.5 17.5t-17.5 7.5h-275v137q0 21 -11.5 26t-27.5 -8z" />
<glyph unicode="&#xe133;" d="M600 1178q118 0 225 -45.5t184.5 -123t123 -184.5t45.5 -225t-45.5 -225t-123 -184.5t-184.5 -123t-225 -45.5t-225 45.5t-184.5 123t-123 184.5t-45.5 225t45.5 225t123 184.5t184.5 123t225 45.5zM855 639l-223 275q-13 16 -32 16t-32 -16l-223 -275q-13 -16 -8 -27.5 t26 -11.5h137v-275q0 -10 7.5 -17.5t17.5 -7.5h150q10 0 17.5 7.5t7.5 17.5v275h137q21 0 26 11.5t-8 27.5z" />
<glyph unicode="&#xe134;" d="M600 1178q118 0 225 -45.5t184.5 -123t123 -184.5t45.5 -225t-45.5 -225t-123 -184.5t-184.5 -123t-225 -45.5t-225 45.5t-184.5 123t-123 184.5t-45.5 225t45.5 225t123 184.5t184.5 123t225 45.5zM675 900h-150q-10 0 -17.5 -7.5t-7.5 -17.5v-275h-137q-21 0 -26 -11.5 t8 -27.5l223 -275q13 -16 32 -16t32 16l223 275q13 16 8 27.5t-26 11.5h-137v275q0 10 -7.5 17.5t-17.5 7.5z" />
<glyph unicode="&#xe135;" d="M600 1176q116 0 222.5 -46t184 -123.5t123.5 -184t46 -222.5t-46 -222.5t-123.5 -184t-184 -123.5t-222.5 -46t-222.5 46t-184 123.5t-123.5 184t-46 222.5t46 222.5t123.5 184t184 123.5t222.5 46zM627 1101q-15 -12 -36.5 -20.5t-35.5 -12t-43 -8t-39 -6.5 q-15 -3 -45.5 0t-45.5 -2q-20 -7 -51.5 -26.5t-34.5 -34.5q-3 -11 6.5 -22.5t8.5 -18.5q-3 -34 -27.5 -91t-29.5 -79q-9 -34 5 -93t8 -87q0 -9 17 -44.5t16 -59.5q12 0 23 -5t23.5 -15t19.5 -14q16 -8 33 -15t40.5 -15t34.5 -12q21 -9 52.5 -32t60 -38t57.5 -11 q7 -15 -3 -34t-22.5 -40t-9.5 -38q13 -21 23 -34.5t27.5 -27.5t36.5 -18q0 -7 -3.5 -16t-3.5 -14t5 -17q104 -2 221 112q30 29 46.5 47t34.5 49t21 63q-13 8 -37 8.5t-36 7.5q-15 7 -49.5 15t-51.5 19q-18 0 -41 -0.5t-43 -1.5t-42 -6.5t-38 -16.5q-51 -35 -66 -12 q-4 1 -3.5 25.5t0.5 25.5q-6 13 -26.5 17.5t-24.5 6.5q1 15 -0.5 30.5t-7 28t-18.5 11.5t-31 -21q-23 -25 -42 4q-19 28 -8 58q6 16 22 22q6 -1 26 -1.5t33.5 -4t19.5 -13.5q7 -12 18 -24t21.5 -20.5t20 -15t15.5 -10.5l5 -3q2 12 7.5 30.5t8 34.5t-0.5 32q-3 18 3.5 29 t18 22.5t15.5 24.5q6 14 10.5 35t8 31t15.5 22.5t34 22.5q-6 18 10 36q8 0 24 -1.5t24.5 -1.5t20 4.5t20.5 15.5q-10 23 -31 42.5t-37.5 29.5t-49 27t-43.5 23q0 1 2 8t3 11.5t1.5 10.5t-1 9.5t-4.5 4.5q31 -13 58.5 -14.5t38.5 2.5l12 5q5 28 -9.5 46t-36.5 24t-50 15 t-41 20q-18 -4 -37 0zM613 994q0 -17 8 -42t17 -45t9 -23q-8 1 -39.5 5.5t-52.5 10t-37 16.5q3 11 16 29.5t16 25.5q10 -10 19 -10t14 6t13.5 14.5t16.5 12.5z" />
<glyph unicode="&#xe136;" d="M756 1157q164 92 306 -9l-259 -138l145 -232l251 126q6 -89 -34 -156.5t-117 -110.5q-60 -34 -127 -39.5t-126 16.5l-596 -596q-15 -16 -36.5 -16t-36.5 16l-111 110q-15 15 -15 36.5t15 37.5l600 599q-34 101 5.5 201.5t135.5 154.5z" />
<glyph unicode="&#xe137;" horiz-adv-x="1220" d="M100 1196h1000q41 0 70.5 -29.5t29.5 -70.5v-100q0 -41 -29.5 -70.5t-70.5 -29.5h-1000q-41 0 -70.5 29.5t-29.5 70.5v100q0 41 29.5 70.5t70.5 29.5zM1100 1096h-200v-100h200v100zM100 796h1000q41 0 70.5 -29.5t29.5 -70.5v-100q0 -41 -29.5 -70.5t-70.5 -29.5h-1000 q-41 0 -70.5 29.5t-29.5 70.5v100q0 41 29.5 70.5t70.5 29.5zM1100 696h-500v-100h500v100zM100 396h1000q41 0 70.5 -29.5t29.5 -70.5v-100q0 -41 -29.5 -70.5t-70.5 -29.5h-1000q-41 0 -70.5 29.5t-29.5 70.5v100q0 41 29.5 70.5t70.5 29.5zM1100 296h-300v-100h300v100z " />
<glyph unicode="&#xe138;" d="M150 1200h900q21 0 35.5 -14.5t14.5 -35.5t-14.5 -35.5t-35.5 -14.5h-900q-21 0 -35.5 14.5t-14.5 35.5t14.5 35.5t35.5 14.5zM700 500v-300l-200 -200v500l-350 500h900z" />
<glyph unicode="&#xe139;" d="M500 1200h200q41 0 70.5 -29.5t29.5 -70.5v-100h300q41 0 70.5 -29.5t29.5 -70.5v-400h-500v100h-200v-100h-500v400q0 41 29.5 70.5t70.5 29.5h300v100q0 41 29.5 70.5t70.5 29.5zM500 1100v-100h200v100h-200zM1200 400v-200q0 -41 -29.5 -70.5t-70.5 -29.5h-1000 q-41 0 -70.5 29.5t-29.5 70.5v200h1200z" />
<glyph unicode="&#xe140;" d="M50 1200h300q21 0 25 -10.5t-10 -24.5l-94 -94l199 -199q7 -8 7 -18t-7 -18l-106 -106q-8 -7 -18 -7t-18 7l-199 199l-94 -94q-14 -14 -24.5 -10t-10.5 25v300q0 21 14.5 35.5t35.5 14.5zM850 1200h300q21 0 35.5 -14.5t14.5 -35.5v-300q0 -21 -10.5 -25t-24.5 10l-94 94 l-199 -199q-8 -7 -18 -7t-18 7l-106 106q-7 8 -7 18t7 18l199 199l-94 94q-14 14 -10 24.5t25 10.5zM364 470l106 -106q7 -8 7 -18t-7 -18l-199 -199l94 -94q14 -14 10 -24.5t-25 -10.5h-300q-21 0 -35.5 14.5t-14.5 35.5v300q0 21 10.5 25t24.5 -10l94 -94l199 199 q8 7 18 7t18 -7zM1071 271l94 94q14 14 24.5 10t10.5 -25v-300q0 -21 -14.5 -35.5t-35.5 -14.5h-300q-21 0 -25 10.5t10 24.5l94 94l-199 199q-7 8 -7 18t7 18l106 106q8 7 18 7t18 -7z" />
<glyph unicode="&#xe141;" d="M596 1192q121 0 231.5 -47.5t190 -127t127 -190t47.5 -231.5t-47.5 -231.5t-127 -190.5t-190 -127t-231.5 -47t-231.5 47t-190.5 127t-127 190.5t-47 231.5t47 231.5t127 190t190.5 127t231.5 47.5zM596 1010q-112 0 -207.5 -55.5t-151 -151t-55.5 -207.5t55.5 -207.5 t151 -151t207.5 -55.5t207.5 55.5t151 151t55.5 207.5t-55.5 207.5t-151 151t-207.5 55.5zM454.5 905q22.5 0 38.5 -16t16 -38.5t-16 -39t-38.5 -16.5t-38.5 16.5t-16 39t16 38.5t38.5 16zM754.5 905q22.5 0 38.5 -16t16 -38.5t-16 -39t-38 -16.5q-14 0 -29 10l-55 -145 q17 -23 17 -51q0 -36 -25.5 -61.5t-61.5 -25.5t-61.5 25.5t-25.5 61.5q0 32 20.5 56.5t51.5 29.5l122 126l1 1q-9 14 -9 28q0 23 16 39t38.5 16zM345.5 709q22.5 0 38.5 -16t16 -38.5t-16 -38.5t-38.5 -16t-38.5 16t-16 38.5t16 38.5t38.5 16zM854.5 709q22.5 0 38.5 -16 t16 -38.5t-16 -38.5t-38.5 -16t-38.5 16t-16 38.5t16 38.5t38.5 16z" />
<glyph unicode="&#xe142;" d="M546 173l469 470q91 91 99 192q7 98 -52 175.5t-154 94.5q-22 4 -47 4q-34 0 -66.5 -10t-56.5 -23t-55.5 -38t-48 -41.5t-48.5 -47.5q-376 -375 -391 -390q-30 -27 -45 -41.5t-37.5 -41t-32 -46.5t-16 -47.5t-1.5 -56.5q9 -62 53.5 -95t99.5 -33q74 0 125 51l548 548 q36 36 20 75q-7 16 -21.5 26t-32.5 10q-26 0 -50 -23q-13 -12 -39 -38l-341 -338q-15 -15 -35.5 -15.5t-34.5 13.5t-14 34.5t14 34.5q327 333 361 367q35 35 67.5 51.5t78.5 16.5q14 0 29 -1q44 -8 74.5 -35.5t43.5 -68.5q14 -47 2 -96.5t-47 -84.5q-12 -11 -32 -32 t-79.5 -81t-114.5 -115t-124.5 -123.5t-123 -119.5t-96.5 -89t-57 -45q-56 -27 -120 -27q-70 0 -129 32t-93 89q-48 78 -35 173t81 163l511 511q71 72 111 96q91 55 198 55q80 0 152 -33q78 -36 129.5 -103t66.5 -154q17 -93 -11 -183.5t-94 -156.5l-482 -476 q-15 -15 -36 -16t-37 14t-17.5 34t14.5 35z" />
<glyph unicode="&#xe143;" d="M649 949q48 68 109.5 104t121.5 38.5t118.5 -20t102.5 -64t71 -100.5t27 -123q0 -57 -33.5 -117.5t-94 -124.5t-126.5 -127.5t-150 -152.5t-146 -174q-62 85 -145.5 174t-150 152.5t-126.5 127.5t-93.5 124.5t-33.5 117.5q0 64 28 123t73 100.5t104 64t119 20 t120.5 -38.5t104.5 -104zM896 972q-33 0 -64.5 -19t-56.5 -46t-47.5 -53.5t-43.5 -45.5t-37.5 -19t-36 19t-40 45.5t-43 53.5t-54 46t-65.5 19q-67 0 -122.5 -55.5t-55.5 -132.5q0 -23 13.5 -51t46 -65t57.5 -63t76 -75l22 -22q15 -14 44 -44t50.5 -51t46 -44t41 -35t23 -12 t23.5 12t42.5 36t46 44t52.5 52t44 43q4 4 12 13q43 41 63.5 62t52 55t46 55t26 46t11.5 44q0 79 -53 133.5t-120 54.5z" />
<glyph unicode="&#xe144;" d="M776.5 1214q93.5 0 159.5 -66l141 -141q66 -66 66 -160q0 -42 -28 -95.5t-62 -87.5l-29 -29q-31 53 -77 99l-18 18l95 95l-247 248l-389 -389l212 -212l-105 -106l-19 18l-141 141q-66 66 -66 159t66 159l283 283q65 66 158.5 66zM600 706l105 105q10 -8 19 -17l141 -141 q66 -66 66 -159t-66 -159l-283 -283q-66 -66 -159 -66t-159 66l-141 141q-66 66 -66 159.5t66 159.5l55 55q29 -55 75 -102l18 -17l-95 -95l247 -248l389 389z" />
<glyph unicode="&#xe145;" d="M603 1200q85 0 162 -15t127 -38t79 -48t29 -46v-953q0 -41 -29.5 -70.5t-70.5 -29.5h-600q-41 0 -70.5 29.5t-29.5 70.5v953q0 21 30 46.5t81 48t129 37.5t163 15zM300 1000v-700h600v700h-600zM600 254q-43 0 -73.5 -30.5t-30.5 -73.5t30.5 -73.5t73.5 -30.5t73.5 30.5 t30.5 73.5t-30.5 73.5t-73.5 30.5z" />
<glyph unicode="&#xe146;" d="M902 1185l283 -282q15 -15 15 -36t-14.5 -35.5t-35.5 -14.5t-35 15l-36 35l-279 -267v-300l-212 210l-308 -307l-280 -203l203 280l307 308l-210 212h300l267 279l-35 36q-15 14 -15 35t14.5 35.5t35.5 14.5t35 -15z" />
<glyph unicode="&#xe148;" d="M700 1248v-78q38 -5 72.5 -14.5t75.5 -31.5t71 -53.5t52 -84t24 -118.5h-159q-4 36 -10.5 59t-21 45t-40 35.5t-64.5 20.5v-307l64 -13q34 -7 64 -16.5t70 -32t67.5 -52.5t47.5 -80t20 -112q0 -139 -89 -224t-244 -97v-77h-100v79q-150 16 -237 103q-40 40 -52.5 93.5 t-15.5 139.5h139q5 -77 48.5 -126t117.5 -65v335l-27 8q-46 14 -79 26.5t-72 36t-63 52t-40 72.5t-16 98q0 70 25 126t67.5 92t94.5 57t110 27v77h100zM600 754v274q-29 -4 -50 -11t-42 -21.5t-31.5 -41.5t-10.5 -65q0 -29 7 -50.5t16.5 -34t28.5 -22.5t31.5 -14t37.5 -10 q9 -3 13 -4zM700 547v-310q22 2 42.5 6.5t45 15.5t41.5 27t29 42t12 59.5t-12.5 59.5t-38 44.5t-53 31t-66.5 24.5z" />
<glyph unicode="&#xe149;" d="M561 1197q84 0 160.5 -40t123.5 -109.5t47 -147.5h-153q0 40 -19.5 71.5t-49.5 48.5t-59.5 26t-55.5 9q-37 0 -79 -14.5t-62 -35.5q-41 -44 -41 -101q0 -26 13.5 -63t26.5 -61t37 -66q6 -9 9 -14h241v-100h-197q8 -50 -2.5 -115t-31.5 -95q-45 -62 -99 -112 q34 10 83 17.5t71 7.5q32 1 102 -16t104 -17q83 0 136 30l50 -147q-31 -19 -58 -30.5t-55 -15.5t-42 -4.5t-46 -0.5q-23 0 -76 17t-111 32.5t-96 11.5q-39 -3 -82 -16t-67 -25l-23 -11l-55 145q4 3 16 11t15.5 10.5t13 9t15.5 12t14.5 14t17.5 18.5q48 55 54 126.5 t-30 142.5h-221v100h166q-23 47 -44 104q-7 20 -12 41.5t-6 55.5t6 66.5t29.5 70.5t58.5 71q97 88 263 88z" />
<glyph unicode="&#xe150;" d="M400 300h150q21 0 25 -11t-10 -25l-230 -250q-14 -15 -35 -15t-35 15l-230 250q-14 14 -10 25t25 11h150v900h200v-900zM935 1184l230 -249q14 -14 10 -24.5t-25 -10.5h-150v-900h-200v900h-150q-21 0 -25 10.5t10 24.5l230 249q14 15 35 15t35 -15z" />
<glyph unicode="&#xe151;" d="M1000 700h-100v100h-100v-100h-100v500h300v-500zM400 300h150q21 0 25 -11t-10 -25l-230 -250q-14 -15 -35 -15t-35 15l-230 250q-14 14 -10 25t25 11h150v900h200v-900zM801 1100v-200h100v200h-100zM1000 350l-200 -250h200v-100h-300v150l200 250h-200v100h300v-150z " />
<glyph unicode="&#xe152;" d="M400 300h150q21 0 25 -11t-10 -25l-230 -250q-14 -15 -35 -15t-35 15l-230 250q-14 14 -10 25t25 11h150v900h200v-900zM1000 1050l-200 -250h200v-100h-300v150l200 250h-200v100h300v-150zM1000 0h-100v100h-100v-100h-100v500h300v-500zM801 400v-200h100v200h-100z " />
<glyph unicode="&#xe153;" d="M400 300h150q21 0 25 -11t-10 -25l-230 -250q-14 -15 -35 -15t-35 15l-230 250q-14 14 -10 25t25 11h150v900h200v-900zM1000 700h-100v400h-100v100h200v-500zM1100 0h-100v100h-200v400h300v-500zM901 400v-200h100v200h-100z" />
<glyph unicode="&#xe154;" d="M400 300h150q21 0 25 -11t-10 -25l-230 -250q-14 -15 -35 -15t-35 15l-230 250q-14 14 -10 25t25 11h150v900h200v-900zM1100 700h-100v100h-200v400h300v-500zM901 1100v-200h100v200h-100zM1000 0h-100v400h-100v100h200v-500z" />
<glyph unicode="&#xe155;" d="M400 300h150q21 0 25 -11t-10 -25l-230 -250q-14 -15 -35 -15t-35 15l-230 250q-14 14 -10 25t25 11h150v900h200v-900zM900 1000h-200v200h200v-200zM1000 700h-300v200h300v-200zM1100 400h-400v200h400v-200zM1200 100h-500v200h500v-200z" />
<glyph unicode="&#xe156;" d="M400 300h150q21 0 25 -11t-10 -25l-230 -250q-14 -15 -35 -15t-35 15l-230 250q-14 14 -10 25t25 11h150v900h200v-900zM1200 1000h-500v200h500v-200zM1100 700h-400v200h400v-200zM1000 400h-300v200h300v-200zM900 100h-200v200h200v-200z" />
<glyph unicode="&#xe157;" d="M350 1100h400q162 0 256 -93.5t94 -256.5v-400q0 -165 -93.5 -257.5t-256.5 -92.5h-400q-165 0 -257.5 92.5t-92.5 257.5v400q0 165 92.5 257.5t257.5 92.5zM800 900h-500q-41 0 -70.5 -29.5t-29.5 -70.5v-500q0 -41 29.5 -70.5t70.5 -29.5h500q41 0 70.5 29.5t29.5 70.5 v500q0 41 -29.5 70.5t-70.5 29.5z" />
<glyph unicode="&#xe158;" d="M350 1100h400q165 0 257.5 -92.5t92.5 -257.5v-400q0 -165 -92.5 -257.5t-257.5 -92.5h-400q-163 0 -256.5 92.5t-93.5 257.5v400q0 163 94 256.5t256 93.5zM800 900h-500q-41 0 -70.5 -29.5t-29.5 -70.5v-500q0 -41 29.5 -70.5t70.5 -29.5h500q41 0 70.5 29.5t29.5 70.5 v500q0 41 -29.5 70.5t-70.5 29.5zM440 770l253 -190q17 -12 17 -30t-17 -30l-253 -190q-16 -12 -28 -6.5t-12 26.5v400q0 21 12 26.5t28 -6.5z" />
<glyph unicode="&#xe159;" d="M350 1100h400q163 0 256.5 -94t93.5 -256v-400q0 -165 -92.5 -257.5t-257.5 -92.5h-400q-165 0 -257.5 92.5t-92.5 257.5v400q0 163 92.5 256.5t257.5 93.5zM800 900h-500q-41 0 -70.5 -29.5t-29.5 -70.5v-500q0 -41 29.5 -70.5t70.5 -29.5h500q41 0 70.5 29.5t29.5 70.5 v500q0 41 -29.5 70.5t-70.5 29.5zM350 700h400q21 0 26.5 -12t-6.5 -28l-190 -253q-12 -17 -30 -17t-30 17l-190 253q-12 16 -6.5 28t26.5 12z" />
<glyph unicode="&#xe160;" d="M350 1100h400q165 0 257.5 -92.5t92.5 -257.5v-400q0 -163 -92.5 -256.5t-257.5 -93.5h-400q-163 0 -256.5 94t-93.5 256v400q0 165 92.5 257.5t257.5 92.5zM800 900h-500q-41 0 -70.5 -29.5t-29.5 -70.5v-500q0 -41 29.5 -70.5t70.5 -29.5h500q41 0 70.5 29.5t29.5 70.5 v500q0 41 -29.5 70.5t-70.5 29.5zM580 693l190 -253q12 -16 6.5 -28t-26.5 -12h-400q-21 0 -26.5 12t6.5 28l190 253q12 17 30 17t30 -17z" />
<glyph unicode="&#xe161;" d="M550 1100h400q165 0 257.5 -92.5t92.5 -257.5v-400q0 -165 -92.5 -257.5t-257.5 -92.5h-400q-21 0 -35.5 14.5t-14.5 35.5v100q0 21 14.5 35.5t35.5 14.5h450q41 0 70.5 29.5t29.5 70.5v500q0 41 -29.5 70.5t-70.5 29.5h-450q-21 0 -35.5 14.5t-14.5 35.5v100 q0 21 14.5 35.5t35.5 14.5zM338 867l324 -284q16 -14 16 -33t-16 -33l-324 -284q-16 -14 -27 -9t-11 26v150h-250q-21 0 -35.5 14.5t-14.5 35.5v200q0 21 14.5 35.5t35.5 14.5h250v150q0 21 11 26t27 -9z" />
<glyph unicode="&#xe162;" d="M793 1182l9 -9q8 -10 5 -27q-3 -11 -79 -225.5t-78 -221.5l300 1q24 0 32.5 -17.5t-5.5 -35.5q-1 0 -133.5 -155t-267 -312.5t-138.5 -162.5q-12 -15 -26 -15h-9l-9 8q-9 11 -4 32q2 9 42 123.5t79 224.5l39 110h-302q-23 0 -31 19q-10 21 6 41q75 86 209.5 237.5 t228 257t98.5 111.5q9 16 25 16h9z" />
<glyph unicode="&#xe163;" d="M350 1100h400q21 0 35.5 -14.5t14.5 -35.5v-100q0 -21 -14.5 -35.5t-35.5 -14.5h-450q-41 0 -70.5 -29.5t-29.5 -70.5v-500q0 -41 29.5 -70.5t70.5 -29.5h450q21 0 35.5 -14.5t14.5 -35.5v-100q0 -21 -14.5 -35.5t-35.5 -14.5h-400q-165 0 -257.5 92.5t-92.5 257.5v400 q0 165 92.5 257.5t257.5 92.5zM938 867l324 -284q16 -14 16 -33t-16 -33l-324 -284q-16 -14 -27 -9t-11 26v150h-250q-21 0 -35.5 14.5t-14.5 35.5v200q0 21 14.5 35.5t35.5 14.5h250v150q0 21 11 26t27 -9z" />
<glyph unicode="&#xe164;" d="M750 1200h400q21 0 35.5 -14.5t14.5 -35.5v-400q0 -21 -10.5 -25t-24.5 10l-109 109l-312 -312q-15 -15 -35.5 -15t-35.5 15l-141 141q-15 15 -15 35.5t15 35.5l312 312l-109 109q-14 14 -10 24.5t25 10.5zM456 900h-156q-41 0 -70.5 -29.5t-29.5 -70.5v-500 q0 -41 29.5 -70.5t70.5 -29.5h500q41 0 70.5 29.5t29.5 70.5v148l200 200v-298q0 -165 -93.5 -257.5t-256.5 -92.5h-400q-165 0 -257.5 92.5t-92.5 257.5v400q0 165 92.5 257.5t257.5 92.5h300z" />
<glyph unicode="&#xe165;" d="M600 1186q119 0 227.5 -46.5t187 -125t125 -187t46.5 -227.5t-46.5 -227.5t-125 -187t-187 -125t-227.5 -46.5t-227.5 46.5t-187 125t-125 187t-46.5 227.5t46.5 227.5t125 187t187 125t227.5 46.5zM600 1022q-115 0 -212 -56.5t-153.5 -153.5t-56.5 -212t56.5 -212 t153.5 -153.5t212 -56.5t212 56.5t153.5 153.5t56.5 212t-56.5 212t-153.5 153.5t-212 56.5zM600 794q80 0 137 -57t57 -137t-57 -137t-137 -57t-137 57t-57 137t57 137t137 57z" />
<glyph unicode="&#xe166;" d="M450 1200h200q21 0 35.5 -14.5t14.5 -35.5v-350h245q20 0 25 -11t-9 -26l-383 -426q-14 -15 -33.5 -15t-32.5 15l-379 426q-13 15 -8.5 26t25.5 11h250v350q0 21 14.5 35.5t35.5 14.5zM50 300h1000q21 0 35.5 -14.5t14.5 -35.5v-250h-1100v250q0 21 14.5 35.5t35.5 14.5z M900 200v-50h100v50h-100z" />
<glyph unicode="&#xe167;" d="M583 1182l378 -435q14 -15 9 -31t-26 -16h-244v-250q0 -20 -17 -35t-39 -15h-200q-20 0 -32 14.5t-12 35.5v250h-250q-20 0 -25.5 16.5t8.5 31.5l383 431q14 16 33.5 17t33.5 -14zM50 300h1000q21 0 35.5 -14.5t14.5 -35.5v-250h-1100v250q0 21 14.5 35.5t35.5 14.5z M900 200v-50h100v50h-100z" />
<glyph unicode="&#xe168;" d="M396 723l369 369q7 7 17.5 7t17.5 -7l139 -139q7 -8 7 -18.5t-7 -17.5l-525 -525q-7 -8 -17.5 -8t-17.5 8l-292 291q-7 8 -7 18t7 18l139 139q8 7 18.5 7t17.5 -7zM50 300h1000q21 0 35.5 -14.5t14.5 -35.5v-250h-1100v250q0 21 14.5 35.5t35.5 14.5zM900 200v-50h100v50 h-100z" />
<glyph unicode="&#xe169;" d="M135 1023l142 142q14 14 35 14t35 -14l77 -77l-212 -212l-77 76q-14 15 -14 36t14 35zM655 855l210 210q14 14 24.5 10t10.5 -25l-2 -599q-1 -20 -15.5 -35t-35.5 -15l-597 -1q-21 0 -25 10.5t10 24.5l208 208l-154 155l212 212zM50 300h1000q21 0 35.5 -14.5t14.5 -35.5 v-250h-1100v250q0 21 14.5 35.5t35.5 14.5zM900 200v-50h100v50h-100z" />
<glyph unicode="&#xe170;" d="M350 1200l599 -2q20 -1 35 -15.5t15 -35.5l1 -597q0 -21 -10.5 -25t-24.5 10l-208 208l-155 -154l-212 212l155 154l-210 210q-14 14 -10 24.5t25 10.5zM524 512l-76 -77q-15 -14 -36 -14t-35 14l-142 142q-14 14 -14 35t14 35l77 77zM50 300h1000q21 0 35.5 -14.5 t14.5 -35.5v-250h-1100v250q0 21 14.5 35.5t35.5 14.5zM900 200v-50h100v50h-100z" />
<glyph unicode="&#xe171;" d="M1200 103l-483 276l-314 -399v423h-399l1196 796v-1096zM483 424v-230l683 953z" />
<glyph unicode="&#xe172;" d="M1100 1000v-850q0 -21 -14.5 -35.5t-35.5 -14.5h-150v400h-700v-400h-150q-21 0 -35.5 14.5t-14.5 35.5v1000q0 20 14.5 35t35.5 15h250v-300h500v300h100zM700 1000h-100v200h100v-200z" />
<glyph unicode="&#xe173;" d="M1100 1000l-2 -149l-299 -299l-95 95q-9 9 -21.5 9t-21.5 -9l-149 -147h-312v-400h-150q-21 0 -35.5 14.5t-14.5 35.5v1000q0 20 14.5 35t35.5 15h250v-300h500v300h100zM700 1000h-100v200h100v-200zM1132 638l106 -106q7 -7 7 -17.5t-7 -17.5l-420 -421q-8 -7 -18 -7 t-18 7l-202 203q-8 7 -8 17.5t8 17.5l106 106q7 8 17.5 8t17.5 -8l79 -79l297 297q7 7 17.5 7t17.5 -7z" />
<glyph unicode="&#xe174;" d="M1100 1000v-269l-103 -103l-134 134q-15 15 -33.5 16.5t-34.5 -12.5l-266 -266h-329v-400h-150q-21 0 -35.5 14.5t-14.5 35.5v1000q0 20 14.5 35t35.5 15h250v-300h500v300h100zM700 1000h-100v200h100v-200zM1202 572l70 -70q15 -15 15 -35.5t-15 -35.5l-131 -131 l131 -131q15 -15 15 -35.5t-15 -35.5l-70 -70q-15 -15 -35.5 -15t-35.5 15l-131 131l-131 -131q-15 -15 -35.5 -15t-35.5 15l-70 70q-15 15 -15 35.5t15 35.5l131 131l-131 131q-15 15 -15 35.5t15 35.5l70 70q15 15 35.5 15t35.5 -15l131 -131l131 131q15 15 35.5 15 t35.5 -15z" />
<glyph unicode="&#xe175;" d="M1100 1000v-300h-350q-21 0 -35.5 -14.5t-14.5 -35.5v-150h-500v-400h-150q-21 0 -35.5 14.5t-14.5 35.5v1000q0 20 14.5 35t35.5 15h250v-300h500v300h100zM700 1000h-100v200h100v-200zM850 600h100q21 0 35.5 -14.5t14.5 -35.5v-250h150q21 0 25 -10.5t-10 -24.5 l-230 -230q-14 -14 -35 -14t-35 14l-230 230q-14 14 -10 24.5t25 10.5h150v250q0 21 14.5 35.5t35.5 14.5z" />
<glyph unicode="&#xe176;" d="M1100 1000v-400l-165 165q-14 15 -35 15t-35 -15l-263 -265h-402v-400h-150q-21 0 -35.5 14.5t-14.5 35.5v1000q0 20 14.5 35t35.5 15h250v-300h500v300h100zM700 1000h-100v200h100v-200zM935 565l230 -229q14 -15 10 -25.5t-25 -10.5h-150v-250q0 -20 -14.5 -35 t-35.5 -15h-100q-21 0 -35.5 15t-14.5 35v250h-150q-21 0 -25 10.5t10 25.5l230 229q14 15 35 15t35 -15z" />
<glyph unicode="&#xe177;" d="M50 1100h1100q21 0 35.5 -14.5t14.5 -35.5v-150h-1200v150q0 21 14.5 35.5t35.5 14.5zM1200 800v-550q0 -21 -14.5 -35.5t-35.5 -14.5h-1100q-21 0 -35.5 14.5t-14.5 35.5v550h1200zM100 500v-200h400v200h-400z" />
<glyph unicode="&#xe178;" d="M935 1165l248 -230q14 -14 14 -35t-14 -35l-248 -230q-14 -14 -24.5 -10t-10.5 25v150h-400v200h400v150q0 21 10.5 25t24.5 -10zM200 800h-50q-21 0 -35.5 14.5t-14.5 35.5v100q0 21 14.5 35.5t35.5 14.5h50v-200zM400 800h-100v200h100v-200zM18 435l247 230 q14 14 24.5 10t10.5 -25v-150h400v-200h-400v-150q0 -21 -10.5 -25t-24.5 10l-247 230q-15 14 -15 35t15 35zM900 300h-100v200h100v-200zM1000 500h51q20 0 34.5 -14.5t14.5 -35.5v-100q0 -21 -14.5 -35.5t-34.5 -14.5h-51v200z" />
<glyph unicode="&#xe179;" d="M862 1073l276 116q25 18 43.5 8t18.5 -41v-1106q0 -21 -14.5 -35.5t-35.5 -14.5h-200q-21 0 -35.5 14.5t-14.5 35.5v397q-4 1 -11 5t-24 17.5t-30 29t-24 42t-11 56.5v359q0 31 18.5 65t43.5 52zM550 1200q22 0 34.5 -12.5t14.5 -24.5l1 -13v-450q0 -28 -10.5 -59.5 t-25 -56t-29 -45t-25.5 -31.5l-10 -11v-447q0 -21 -14.5 -35.5t-35.5 -14.5h-200q-21 0 -35.5 14.5t-14.5 35.5v447q-4 4 -11 11.5t-24 30.5t-30 46t-24 55t-11 60v450q0 2 0.5 5.5t4 12t8.5 15t14.5 12t22.5 5.5q20 0 32.5 -12.5t14.5 -24.5l3 -13v-350h100v350v5.5t2.5 12 t7 15t15 12t25.5 5.5q23 0 35.5 -12.5t13.5 -24.5l1 -13v-350h100v350q0 2 0.5 5.5t3 12t7 15t15 12t24.5 5.5z" />
<glyph unicode="&#xe180;" d="M1200 1100v-56q-4 0 -11 -0.5t-24 -3t-30 -7.5t-24 -15t-11 -24v-888q0 -22 25 -34.5t50 -13.5l25 -2v-56h-400v56q75 0 87.5 6.5t12.5 43.5v394h-500v-394q0 -37 12.5 -43.5t87.5 -6.5v-56h-400v56q4 0 11 0.5t24 3t30 7.5t24 15t11 24v888q0 22 -25 34.5t-50 13.5 l-25 2v56h400v-56q-75 0 -87.5 -6.5t-12.5 -43.5v-394h500v394q0 37 -12.5 43.5t-87.5 6.5v56h400z" />
<glyph unicode="&#xe181;" d="M675 1000h375q21 0 35.5 -14.5t14.5 -35.5v-150h-105l-295 -98v98l-200 200h-400l100 100h375zM100 900h300q41 0 70.5 -29.5t29.5 -70.5v-500q0 -41 -29.5 -70.5t-70.5 -29.5h-300q-41 0 -70.5 29.5t-29.5 70.5v500q0 41 29.5 70.5t70.5 29.5zM100 800v-200h300v200 h-300zM1100 535l-400 -133v163l400 133v-163zM100 500v-200h300v200h-300zM1100 398v-248q0 -21 -14.5 -35.5t-35.5 -14.5h-375l-100 -100h-375l-100 100h400l200 200h105z" />
<glyph unicode="&#xe182;" d="M17 1007l162 162q17 17 40 14t37 -22l139 -194q14 -20 11 -44.5t-20 -41.5l-119 -118q102 -142 228 -268t267 -227l119 118q17 17 42.5 19t44.5 -12l192 -136q19 -14 22.5 -37.5t-13.5 -40.5l-163 -162q-3 -1 -9.5 -1t-29.5 2t-47.5 6t-62.5 14.5t-77.5 26.5t-90 42.5 t-101.5 60t-111 83t-119 108.5q-74 74 -133.5 150.5t-94.5 138.5t-60 119.5t-34.5 100t-15 74.5t-4.5 48z" />
<glyph unicode="&#xe183;" d="M600 1100q92 0 175 -10.5t141.5 -27t108.5 -36.5t81.5 -40t53.5 -37t31 -27l9 -10v-200q0 -21 -14.5 -33t-34.5 -9l-202 34q-20 3 -34.5 20t-14.5 38v146q-141 24 -300 24t-300 -24v-146q0 -21 -14.5 -38t-34.5 -20l-202 -34q-20 -3 -34.5 9t-14.5 33v200q3 4 9.5 10.5 t31 26t54 37.5t80.5 39.5t109 37.5t141 26.5t175 10.5zM600 795q56 0 97 -9.5t60 -23.5t30 -28t12 -24l1 -10v-50l365 -303q14 -15 24.5 -40t10.5 -45v-212q0 -21 -14.5 -35.5t-35.5 -14.5h-1100q-21 0 -35.5 14.5t-14.5 35.5v212q0 20 10.5 45t24.5 40l365 303v50 q0 4 1 10.5t12 23t30 29t60 22.5t97 10z" />
<glyph unicode="&#xe184;" d="M1100 700l-200 -200h-600l-200 200v500h200v-200h200v200h200v-200h200v200h200v-500zM250 400h700q21 0 35.5 -14.5t14.5 -35.5t-14.5 -35.5t-35.5 -14.5h-12l137 -100h-950l137 100h-12q-21 0 -35.5 14.5t-14.5 35.5t14.5 35.5t35.5 14.5zM50 100h1100q21 0 35.5 -14.5 t14.5 -35.5v-50h-1200v50q0 21 14.5 35.5t35.5 14.5z" />
<glyph unicode="&#xe185;" d="M700 1100h-100q-41 0 -70.5 -29.5t-29.5 -70.5v-1000h300v1000q0 41 -29.5 70.5t-70.5 29.5zM1100 800h-100q-41 0 -70.5 -29.5t-29.5 -70.5v-700h300v700q0 41 -29.5 70.5t-70.5 29.5zM400 0h-300v400q0 41 29.5 70.5t70.5 29.5h100q41 0 70.5 -29.5t29.5 -70.5v-400z " />
<glyph unicode="&#xe186;" d="M200 1100h700q124 0 212 -88t88 -212v-500q0 -124 -88 -212t-212 -88h-700q-124 0 -212 88t-88 212v500q0 124 88 212t212 88zM100 900v-700h900v700h-900zM500 700h-200v-100h200v-300h-300v100h200v100h-200v300h300v-100zM900 700v-300l-100 -100h-200v500h200z M700 700v-300h100v300h-100z" />
<glyph unicode="&#xe187;" d="M200 1100h700q124 0 212 -88t88 -212v-500q0 -124 -88 -212t-212 -88h-700q-124 0 -212 88t-88 212v500q0 124 88 212t212 88zM100 900v-700h900v700h-900zM500 300h-100v200h-100v-200h-100v500h100v-200h100v200h100v-500zM900 700v-300l-100 -100h-200v500h200z M700 700v-300h100v300h-100z" />
<glyph unicode="&#xe188;" d="M200 1100h700q124 0 212 -88t88 -212v-500q0 -124 -88 -212t-212 -88h-700q-124 0 -212 88t-88 212v500q0 124 88 212t212 88zM100 900v-700h900v700h-900zM500 700h-200v-300h200v-100h-300v500h300v-100zM900 700h-200v-300h200v-100h-300v500h300v-100z" />
<glyph unicode="&#xe189;" d="M200 1100h700q124 0 212 -88t88 -212v-500q0 -124 -88 -212t-212 -88h-700q-124 0 -212 88t-88 212v500q0 124 88 212t212 88zM100 900v-700h900v700h-900zM500 400l-300 150l300 150v-300zM900 550l-300 -150v300z" />
<glyph unicode="&#xe190;" d="M200 1100h700q124 0 212 -88t88 -212v-500q0 -124 -88 -212t-212 -88h-700q-124 0 -212 88t-88 212v500q0 124 88 212t212 88zM100 900v-700h900v700h-900zM900 300h-700v500h700v-500zM800 700h-130q-38 0 -66.5 -43t-28.5 -108t27 -107t68 -42h130v300zM300 700v-300 h130q41 0 68 42t27 107t-28.5 108t-66.5 43h-130z" />
<glyph unicode="&#xe191;" d="M200 1100h700q124 0 212 -88t88 -212v-500q0 -124 -88 -212t-212 -88h-700q-124 0 -212 88t-88 212v500q0 124 88 212t212 88zM100 900v-700h900v700h-900zM500 700h-200v-100h200v-300h-300v100h200v100h-200v300h300v-100zM900 300h-100v400h-100v100h200v-500z M700 300h-100v100h100v-100z" />
<glyph unicode="&#xe192;" d="M200 1100h700q124 0 212 -88t88 -212v-500q0 -124 -88 -212t-212 -88h-700q-124 0 -212 88t-88 212v500q0 124 88 212t212 88zM100 900v-700h900v700h-900zM300 700h200v-400h-300v500h100v-100zM900 300h-100v400h-100v100h200v-500zM300 600v-200h100v200h-100z M700 300h-100v100h100v-100z" />
<glyph unicode="&#xe193;" d="M200 1100h700q124 0 212 -88t88 -212v-500q0 -124 -88 -212t-212 -88h-700q-124 0 -212 88t-88 212v500q0 124 88 212t212 88zM100 900v-700h900v700h-900zM500 500l-199 -200h-100v50l199 200v150h-200v100h300v-300zM900 300h-100v400h-100v100h200v-500zM701 300h-100 v100h100v-100z" />
<glyph unicode="&#xe194;" d="M600 1191q120 0 229.5 -47t188.5 -126t126 -188.5t47 -229.5t-47 -229.5t-126 -188.5t-188.5 -126t-229.5 -47t-229.5 47t-188.5 126t-126 188.5t-47 229.5t47 229.5t126 188.5t188.5 126t229.5 47zM600 1021q-114 0 -211 -56.5t-153.5 -153.5t-56.5 -211t56.5 -211 t153.5 -153.5t211 -56.5t211 56.5t153.5 153.5t56.5 211t-56.5 211t-153.5 153.5t-211 56.5zM800 700h-300v-200h300v-100h-300l-100 100v200l100 100h300v-100z" />
<glyph unicode="&#xe195;" d="M600 1191q120 0 229.5 -47t188.5 -126t126 -188.5t47 -229.5t-47 -229.5t-126 -188.5t-188.5 -126t-229.5 -47t-229.5 47t-188.5 126t-126 188.5t-47 229.5t47 229.5t126 188.5t188.5 126t229.5 47zM600 1021q-114 0 -211 -56.5t-153.5 -153.5t-56.5 -211t56.5 -211 t153.5 -153.5t211 -56.5t211 56.5t153.5 153.5t56.5 211t-56.5 211t-153.5 153.5t-211 56.5zM800 700v-100l-50 -50l100 -100v-50h-100l-100 100h-150v-100h-100v400h300zM500 700v-100h200v100h-200z" />
<glyph unicode="&#xe197;" d="M503 1089q110 0 200.5 -59.5t134.5 -156.5q44 14 90 14q120 0 205 -86.5t85 -207t-85 -207t-205 -86.5h-128v250q0 21 -14.5 35.5t-35.5 14.5h-300q-21 0 -35.5 -14.5t-14.5 -35.5v-250h-222q-80 0 -136 57.5t-56 136.5q0 69 43 122.5t108 67.5q-2 19 -2 37q0 100 49 185 t134 134t185 49zM525 500h150q10 0 17.5 -7.5t7.5 -17.5v-275h137q21 0 26 -11.5t-8 -27.5l-223 -244q-13 -16 -32 -16t-32 16l-223 244q-13 16 -8 27.5t26 11.5h137v275q0 10 7.5 17.5t17.5 7.5z" />
<glyph unicode="&#xe198;" d="M502 1089q110 0 201 -59.5t135 -156.5q43 15 89 15q121 0 206 -86.5t86 -206.5q0 -99 -60 -181t-150 -110l-378 360q-13 16 -31.5 16t-31.5 -16l-381 -365h-9q-79 0 -135.5 57.5t-56.5 136.5q0 69 43 122.5t108 67.5q-2 19 -2 38q0 100 49 184.5t133.5 134t184.5 49.5z M632 467l223 -228q13 -16 8 -27.5t-26 -11.5h-137v-275q0 -10 -7.5 -17.5t-17.5 -7.5h-150q-10 0 -17.5 7.5t-7.5 17.5v275h-137q-21 0 -26 11.5t8 27.5q199 204 223 228q19 19 31.5 19t32.5 -19z" />
<glyph unicode="&#xe199;" d="M700 100v100h400l-270 300h170l-270 300h170l-300 333l-300 -333h170l-270 -300h170l-270 -300h400v-100h-50q-21 0 -35.5 -14.5t-14.5 -35.5v-50h400v50q0 21 -14.5 35.5t-35.5 14.5h-50z" />
<glyph unicode="&#xe200;" d="M600 1179q94 0 167.5 -56.5t99.5 -145.5q89 -6 150.5 -71.5t61.5 -155.5q0 -61 -29.5 -112.5t-79.5 -82.5q9 -29 9 -55q0 -74 -52.5 -126.5t-126.5 -52.5q-55 0 -100 30v-251q21 0 35.5 -14.5t14.5 -35.5v-50h-300v50q0 21 14.5 35.5t35.5 14.5v251q-45 -30 -100 -30 q-74 0 -126.5 52.5t-52.5 126.5q0 18 4 38q-47 21 -75.5 65t-28.5 97q0 74 52.5 126.5t126.5 52.5q5 0 23 -2q0 2 -1 10t-1 13q0 116 81.5 197.5t197.5 81.5z" />
<glyph unicode="&#xe201;" d="M1010 1010q111 -111 150.5 -260.5t0 -299t-150.5 -260.5q-83 -83 -191.5 -126.5t-218.5 -43.5t-218.5 43.5t-191.5 126.5q-111 111 -150.5 260.5t0 299t150.5 260.5q83 83 191.5 126.5t218.5 43.5t218.5 -43.5t191.5 -126.5zM476 1065q-4 0 -8 -1q-121 -34 -209.5 -122.5 t-122.5 -209.5q-4 -12 2.5 -23t18.5 -14l36 -9q3 -1 7 -1q23 0 29 22q27 96 98 166q70 71 166 98q11 3 17.5 13.5t3.5 22.5l-9 35q-3 13 -14 19q-7 4 -15 4zM512 920q-4 0 -9 -2q-80 -24 -138.5 -82.5t-82.5 -138.5q-4 -13 2 -24t19 -14l34 -9q4 -1 8 -1q22 0 28 21 q18 58 58.5 98.5t97.5 58.5q12 3 18 13.5t3 21.5l-9 35q-3 12 -14 19q-7 4 -15 4zM719.5 719.5q-49.5 49.5 -119.5 49.5t-119.5 -49.5t-49.5 -119.5t49.5 -119.5t119.5 -49.5t119.5 49.5t49.5 119.5t-49.5 119.5zM855 551q-22 0 -28 -21q-18 -58 -58.5 -98.5t-98.5 -57.5 q-11 -4 -17 -14.5t-3 -21.5l9 -35q3 -12 14 -19q7 -4 15 -4q4 0 9 2q80 24 138.5 82.5t82.5 138.5q4 13 -2.5 24t-18.5 14l-34 9q-4 1 -8 1zM1000 515q-23 0 -29 -22q-27 -96 -98 -166q-70 -71 -166 -98q-11 -3 -17.5 -13.5t-3.5 -22.5l9 -35q3 -13 14 -19q7 -4 15 -4 q4 0 8 1q121 34 209.5 122.5t122.5 209.5q4 12 -2.5 23t-18.5 14l-36 9q-3 1 -7 1z" />
<glyph unicode="&#xe202;" d="M700 800h300v-380h-180v200h-340v-200h-380v755q0 10 7.5 17.5t17.5 7.5h575v-400zM1000 900h-200v200zM700 300h162l-212 -212l-212 212h162v200h100v-200zM520 0h-395q-10 0 -17.5 7.5t-7.5 17.5v395zM1000 220v-195q0 -10 -7.5 -17.5t-17.5 -7.5h-195z" />
<glyph unicode="&#xe203;" d="M700 800h300v-520l-350 350l-550 -550v1095q0 10 7.5 17.5t17.5 7.5h575v-400zM1000 900h-200v200zM862 200h-162v-200h-100v200h-162l212 212zM480 0h-355q-10 0 -17.5 7.5t-7.5 17.5v55h380v-80zM1000 80v-55q0 -10 -7.5 -17.5t-17.5 -7.5h-155v80h180z" />
<glyph unicode="&#xe204;" d="M1162 800h-162v-200h100l100 -100h-300v300h-162l212 212zM200 800h200q27 0 40 -2t29.5 -10.5t23.5 -30t7 -57.5h300v-100h-600l-200 -350v450h100q0 36 7 57.5t23.5 30t29.5 10.5t40 2zM800 400h240l-240 -400h-800l300 500h500v-100z" />
<glyph unicode="&#xe205;" d="M650 1100h100q21 0 35.5 -14.5t14.5 -35.5v-50h50q21 0 35.5 -14.5t14.5 -35.5v-100q0 -21 -14.5 -35.5t-35.5 -14.5h-300q-21 0 -35.5 14.5t-14.5 35.5v100q0 21 14.5 35.5t35.5 14.5h50v50q0 21 14.5 35.5t35.5 14.5zM1000 850v150q41 0 70.5 -29.5t29.5 -70.5v-800 q0 -41 -29.5 -70.5t-70.5 -29.5h-600q-1 0 -20 4l246 246l-326 326v324q0 41 29.5 70.5t70.5 29.5v-150q0 -62 44 -106t106 -44h300q62 0 106 44t44 106zM412 250l-212 -212v162h-200v100h200v162z" />
<glyph unicode="&#xe206;" d="M450 1100h100q21 0 35.5 -14.5t14.5 -35.5v-50h50q21 0 35.5 -14.5t14.5 -35.5v-100q0 -21 -14.5 -35.5t-35.5 -14.5h-300q-21 0 -35.5 14.5t-14.5 35.5v100q0 21 14.5 35.5t35.5 14.5h50v50q0 21 14.5 35.5t35.5 14.5zM800 850v150q41 0 70.5 -29.5t29.5 -70.5v-500 h-200v-300h200q0 -36 -7 -57.5t-23.5 -30t-29.5 -10.5t-40 -2h-600q-41 0 -70.5 29.5t-29.5 70.5v800q0 41 29.5 70.5t70.5 29.5v-150q0 -62 44 -106t106 -44h300q62 0 106 44t44 106zM1212 250l-212 -212v162h-200v100h200v162z" />
<glyph unicode="&#xe209;" d="M658 1197l637 -1104q23 -38 7 -65.5t-60 -27.5h-1276q-44 0 -60 27.5t7 65.5l637 1104q22 39 54 39t54 -39zM704 800h-208q-20 0 -32 -14.5t-8 -34.5l58 -302q4 -20 21.5 -34.5t37.5 -14.5h54q20 0 37.5 14.5t21.5 34.5l58 302q4 20 -8 34.5t-32 14.5zM500 300v-100h200 v100h-200z" />
<glyph unicode="&#xe210;" d="M425 1100h250q10 0 17.5 -7.5t7.5 -17.5v-150q0 -10 -7.5 -17.5t-17.5 -7.5h-250q-10 0 -17.5 7.5t-7.5 17.5v150q0 10 7.5 17.5t17.5 7.5zM425 800h250q10 0 17.5 -7.5t7.5 -17.5v-150q0 -10 -7.5 -17.5t-17.5 -7.5h-250q-10 0 -17.5 7.5t-7.5 17.5v150q0 10 7.5 17.5 t17.5 7.5zM825 800h250q10 0 17.5 -7.5t7.5 -17.5v-150q0 -10 -7.5 -17.5t-17.5 -7.5h-250q-10 0 -17.5 7.5t-7.5 17.5v150q0 10 7.5 17.5t17.5 7.5zM25 500h250q10 0 17.5 -7.5t7.5 -17.5v-150q0 -10 -7.5 -17.5t-17.5 -7.5h-250q-10 0 -17.5 7.5t-7.5 17.5v150 q0 10 7.5 17.5t17.5 7.5zM425 500h250q10 0 17.5 -7.5t7.5 -17.5v-150q0 -10 -7.5 -17.5t-17.5 -7.5h-250q-10 0 -17.5 7.5t-7.5 17.5v150q0 10 7.5 17.5t17.5 7.5zM825 500h250q10 0 17.5 -7.5t7.5 -17.5v-150q0 -10 -7.5 -17.5t-17.5 -7.5h-250q-10 0 -17.5 7.5t-7.5 17.5 v150q0 10 7.5 17.5t17.5 7.5zM25 200h250q10 0 17.5 -7.5t7.5 -17.5v-150q0 -10 -7.5 -17.5t-17.5 -7.5h-250q-10 0 -17.5 7.5t-7.5 17.5v150q0 10 7.5 17.5t17.5 7.5zM425 200h250q10 0 17.5 -7.5t7.5 -17.5v-150q0 -10 -7.5 -17.5t-17.5 -7.5h-250q-10 0 -17.5 7.5 t-7.5 17.5v150q0 10 7.5 17.5t17.5 7.5zM825 200h250q10 0 17.5 -7.5t7.5 -17.5v-150q0 -10 -7.5 -17.5t-17.5 -7.5h-250q-10 0 -17.5 7.5t-7.5 17.5v150q0 10 7.5 17.5t17.5 7.5z" />
<glyph unicode="&#xe211;" d="M700 1200h100v-200h-100v-100h350q62 0 86.5 -39.5t-3.5 -94.5l-66 -132q-41 -83 -81 -134h-772q-40 51 -81 134l-66 132q-28 55 -3.5 94.5t86.5 39.5h350v100h-100v200h100v100h200v-100zM250 400h700q21 0 35.5 -14.5t14.5 -35.5t-14.5 -35.5t-35.5 -14.5h-12l137 -100 h-950l138 100h-13q-21 0 -35.5 14.5t-14.5 35.5t14.5 35.5t35.5 14.5zM50 100h1100q21 0 35.5 -14.5t14.5 -35.5v-50h-1200v50q0 21 14.5 35.5t35.5 14.5z" />
<glyph unicode="&#xe212;" d="M600 1300q40 0 68.5 -29.5t28.5 -70.5h-194q0 41 28.5 70.5t68.5 29.5zM443 1100h314q18 -37 18 -75q0 -8 -3 -25h328q41 0 44.5 -16.5t-30.5 -38.5l-175 -145h-678l-178 145q-34 22 -29 38.5t46 16.5h328q-3 17 -3 25q0 38 18 75zM250 700h700q21 0 35.5 -14.5 t14.5 -35.5t-14.5 -35.5t-35.5 -14.5h-150v-200l275 -200h-950l275 200v200h-150q-21 0 -35.5 14.5t-14.5 35.5t14.5 35.5t35.5 14.5zM50 100h1100q21 0 35.5 -14.5t14.5 -35.5v-50h-1200v50q0 21 14.5 35.5t35.5 14.5z" />
<glyph unicode="&#xe213;" d="M600 1181q75 0 128 -53t53 -128t-53 -128t-128 -53t-128 53t-53 128t53 128t128 53zM602 798h46q34 0 55.5 -28.5t21.5 -86.5q0 -76 39 -183h-324q39 107 39 183q0 58 21.5 86.5t56.5 28.5h45zM250 400h700q21 0 35.5 -14.5t14.5 -35.5t-14.5 -35.5t-35.5 -14.5h-13 l138 -100h-950l137 100h-12q-21 0 -35.5 14.5t-14.5 35.5t14.5 35.5t35.5 14.5zM50 100h1100q21 0 35.5 -14.5t14.5 -35.5v-50h-1200v50q0 21 14.5 35.5t35.5 14.5z" />
<glyph unicode="&#xe214;" d="M600 1300q47 0 92.5 -53.5t71 -123t25.5 -123.5q0 -78 -55.5 -133.5t-133.5 -55.5t-133.5 55.5t-55.5 133.5q0 62 34 143l144 -143l111 111l-163 163q34 26 63 26zM602 798h46q34 0 55.5 -28.5t21.5 -86.5q0 -76 39 -183h-324q39 107 39 183q0 58 21.5 86.5t56.5 28.5h45 zM250 400h700q21 0 35.5 -14.5t14.5 -35.5t-14.5 -35.5t-35.5 -14.5h-13l138 -100h-950l137 100h-12q-21 0 -35.5 14.5t-14.5 35.5t14.5 35.5t35.5 14.5zM50 100h1100q21 0 35.5 -14.5t14.5 -35.5v-50h-1200v50q0 21 14.5 35.5t35.5 14.5z" />
<glyph unicode="&#xe215;" d="M600 1200l300 -161v-139h-300q0 -57 18.5 -108t50 -91.5t63 -72t70 -67.5t57.5 -61h-530q-60 83 -90.5 177.5t-30.5 178.5t33 164.5t87.5 139.5t126 96.5t145.5 41.5v-98zM250 400h700q21 0 35.5 -14.5t14.5 -35.5t-14.5 -35.5t-35.5 -14.5h-13l138 -100h-950l137 100 h-12q-21 0 -35.5 14.5t-14.5 35.5t14.5 35.5t35.5 14.5zM50 100h1100q21 0 35.5 -14.5t14.5 -35.5v-50h-1200v50q0 21 14.5 35.5t35.5 14.5z" />
<glyph unicode="&#xe216;" d="M600 1300q41 0 70.5 -29.5t29.5 -70.5v-78q46 -26 73 -72t27 -100v-50h-400v50q0 54 27 100t73 72v78q0 41 29.5 70.5t70.5 29.5zM400 800h400q54 0 100 -27t72 -73h-172v-100h200v-100h-200v-100h200v-100h-200v-100h200q0 -83 -58.5 -141.5t-141.5 -58.5h-400 q-83 0 -141.5 58.5t-58.5 141.5v400q0 83 58.5 141.5t141.5 58.5z" />
<glyph unicode="&#xe218;" d="M150 1100h900q21 0 35.5 -14.5t14.5 -35.5v-500q0 -21 -14.5 -35.5t-35.5 -14.5h-900q-21 0 -35.5 14.5t-14.5 35.5v500q0 21 14.5 35.5t35.5 14.5zM125 400h950q10 0 17.5 -7.5t7.5 -17.5v-50q0 -10 -7.5 -17.5t-17.5 -7.5h-283l224 -224q13 -13 13 -31.5t-13 -32 t-31.5 -13.5t-31.5 13l-88 88h-524l-87 -88q-13 -13 -32 -13t-32 13.5t-13 32t13 31.5l224 224h-289q-10 0 -17.5 7.5t-7.5 17.5v50q0 10 7.5 17.5t17.5 7.5zM541 300l-100 -100h324l-100 100h-124z" />
<glyph unicode="&#xe219;" d="M200 1100h800q83 0 141.5 -58.5t58.5 -141.5v-200h-100q0 41 -29.5 70.5t-70.5 29.5h-250q-41 0 -70.5 -29.5t-29.5 -70.5h-100q0 41 -29.5 70.5t-70.5 29.5h-250q-41 0 -70.5 -29.5t-29.5 -70.5h-100v200q0 83 58.5 141.5t141.5 58.5zM100 600h1000q41 0 70.5 -29.5 t29.5 -70.5v-300h-1200v300q0 41 29.5 70.5t70.5 29.5zM300 100v-50q0 -21 -14.5 -35.5t-35.5 -14.5h-100q-21 0 -35.5 14.5t-14.5 35.5v50h200zM1100 100v-50q0 -21 -14.5 -35.5t-35.5 -14.5h-100q-21 0 -35.5 14.5t-14.5 35.5v50h200z" />
<glyph unicode="&#xe221;" d="M480 1165l682 -683q31 -31 31 -75.5t-31 -75.5l-131 -131h-481l-517 518q-32 31 -32 75.5t32 75.5l295 296q31 31 75.5 31t76.5 -31zM108 794l342 -342l303 304l-341 341zM250 100h800q21 0 35.5 -14.5t14.5 -35.5v-50h-900v50q0 21 14.5 35.5t35.5 14.5z" />
<glyph unicode="&#xe223;" d="M1057 647l-189 506q-8 19 -27.5 33t-40.5 14h-400q-21 0 -40.5 -14t-27.5 -33l-189 -506q-8 -19 1.5 -33t30.5 -14h625v-150q0 -21 14.5 -35.5t35.5 -14.5t35.5 14.5t14.5 35.5v150h125q21 0 30.5 14t1.5 33zM897 0h-595v50q0 21 14.5 35.5t35.5 14.5h50v50 q0 21 14.5 35.5t35.5 14.5h48v300h200v-300h47q21 0 35.5 -14.5t14.5 -35.5v-50h50q21 0 35.5 -14.5t14.5 -35.5v-50z" />
<glyph unicode="&#xe224;" d="M900 800h300v-575q0 -10 -7.5 -17.5t-17.5 -7.5h-375v591l-300 300v84q0 10 7.5 17.5t17.5 7.5h375v-400zM1200 900h-200v200zM400 600h300v-575q0 -10 -7.5 -17.5t-17.5 -7.5h-650q-10 0 -17.5 7.5t-7.5 17.5v950q0 10 7.5 17.5t17.5 7.5h375v-400zM700 700h-200v200z " />
<glyph unicode="&#xe225;" d="M484 1095h195q75 0 146 -32.5t124 -86t89.5 -122.5t48.5 -142q18 -14 35 -20q31 -10 64.5 6.5t43.5 48.5q10 34 -15 71q-19 27 -9 43q5 8 12.5 11t19 -1t23.5 -16q41 -44 39 -105q-3 -63 -46 -106.5t-104 -43.5h-62q-7 -55 -35 -117t-56 -100l-39 -234q-3 -20 -20 -34.5 t-38 -14.5h-100q-21 0 -33 14.5t-9 34.5l12 70q-49 -14 -91 -14h-195q-24 0 -65 8l-11 -64q-3 -20 -20 -34.5t-38 -14.5h-100q-21 0 -33 14.5t-9 34.5l26 157q-84 74 -128 175l-159 53q-19 7 -33 26t-14 40v50q0 21 14.5 35.5t35.5 14.5h124q11 87 56 166l-111 95 q-16 14 -12.5 23.5t24.5 9.5h203q116 101 250 101zM675 1000h-250q-10 0 -17.5 -7.5t-7.5 -17.5v-50q0 -10 7.5 -17.5t17.5 -7.5h250q10 0 17.5 7.5t7.5 17.5v50q0 10 -7.5 17.5t-17.5 7.5z" />
<glyph unicode="&#xe226;" d="M641 900l423 247q19 8 42 2.5t37 -21.5l32 -38q14 -15 12.5 -36t-17.5 -34l-139 -120h-390zM50 1100h106q67 0 103 -17t66 -71l102 -212h823q21 0 35.5 -14.5t14.5 -35.5v-50q0 -21 -14 -40t-33 -26l-737 -132q-23 -4 -40 6t-26 25q-42 67 -100 67h-300q-62 0 -106 44 t-44 106v200q0 62 44 106t106 44zM173 928h-80q-19 0 -28 -14t-9 -35v-56q0 -51 42 -51h134q16 0 21.5 8t5.5 24q0 11 -16 45t-27 51q-18 28 -43 28zM550 727q-32 0 -54.5 -22.5t-22.5 -54.5t22.5 -54.5t54.5 -22.5t54.5 22.5t22.5 54.5t-22.5 54.5t-54.5 22.5zM130 389 l152 130q18 19 34 24t31 -3.5t24.5 -17.5t25.5 -28q28 -35 50.5 -51t48.5 -13l63 5l48 -179q13 -61 -3.5 -97.5t-67.5 -79.5l-80 -69q-47 -40 -109 -35.5t-103 51.5l-130 151q-40 47 -35.5 109.5t51.5 102.5zM380 377l-102 -88q-31 -27 2 -65l37 -43q13 -15 27.5 -19.5 t31.5 6.5l61 53q19 16 14 49q-2 20 -12 56t-17 45q-11 12 -19 14t-23 -8z" />
<glyph unicode="&#xe227;" d="M625 1200h150q10 0 17.5 -7.5t7.5 -17.5v-109q79 -33 131 -87.5t53 -128.5q1 -46 -15 -84.5t-39 -61t-46 -38t-39 -21.5l-17 -6q6 0 15 -1.5t35 -9t50 -17.5t53 -30t50 -45t35.5 -64t14.5 -84q0 -59 -11.5 -105.5t-28.5 -76.5t-44 -51t-49.5 -31.5t-54.5 -16t-49.5 -6.5 t-43.5 -1v-75q0 -10 -7.5 -17.5t-17.5 -7.5h-150q-10 0 -17.5 7.5t-7.5 17.5v75h-100v-75q0 -10 -7.5 -17.5t-17.5 -7.5h-150q-10 0 -17.5 7.5t-7.5 17.5v75h-175q-10 0 -17.5 7.5t-7.5 17.5v150q0 10 7.5 17.5t17.5 7.5h75v600h-75q-10 0 -17.5 7.5t-7.5 17.5v150 q0 10 7.5 17.5t17.5 7.5h175v75q0 10 7.5 17.5t17.5 7.5h150q10 0 17.5 -7.5t7.5 -17.5v-75h100v75q0 10 7.5 17.5t17.5 7.5zM400 900v-200h263q28 0 48.5 10.5t30 25t15 29t5.5 25.5l1 10q0 4 -0.5 11t-6 24t-15 30t-30 24t-48.5 11h-263zM400 500v-200h363q28 0 48.5 10.5 t30 25t15 29t5.5 25.5l1 10q0 4 -0.5 11t-6 24t-15 30t-30 24t-48.5 11h-363z" />
<glyph unicode="&#xe230;" d="M212 1198h780q86 0 147 -61t61 -147v-416q0 -51 -18 -142.5t-36 -157.5l-18 -66q-29 -87 -93.5 -146.5t-146.5 -59.5h-572q-82 0 -147 59t-93 147q-8 28 -20 73t-32 143.5t-20 149.5v416q0 86 61 147t147 61zM600 1045q-70 0 -132.5 -11.5t-105.5 -30.5t-78.5 -41.5 t-57 -45t-36 -41t-20.5 -30.5l-6 -12l156 -243h560l156 243q-2 5 -6 12.5t-20 29.5t-36.5 42t-57 44.5t-79 42t-105 29.5t-132.5 12zM762 703h-157l195 261z" />
<glyph unicode="&#xe231;" d="M475 1300h150q103 0 189 -86t86 -189v-500q0 -41 -42 -83t-83 -42h-450q-41 0 -83 42t-42 83v500q0 103 86 189t189 86zM700 300v-225q0 -21 -27 -48t-48 -27h-150q-21 0 -48 27t-27 48v225h300z" />
<glyph unicode="&#xe232;" d="M475 1300h96q0 -150 89.5 -239.5t239.5 -89.5v-446q0 -41 -42 -83t-83 -42h-450q-41 0 -83 42t-42 83v500q0 103 86 189t189 86zM700 300v-225q0 -21 -27 -48t-48 -27h-150q-21 0 -48 27t-27 48v225h300z" />
<glyph unicode="&#xe233;" d="M1294 767l-638 -283l-378 170l-78 -60v-224l100 -150v-199l-150 148l-150 -149v200l100 150v250q0 4 -0.5 10.5t0 9.5t1 8t3 8t6.5 6l47 40l-147 65l642 283zM1000 380l-350 -166l-350 166v147l350 -165l350 165v-147z" />
<glyph unicode="&#xe234;" d="M250 800q62 0 106 -44t44 -106t-44 -106t-106 -44t-106 44t-44 106t44 106t106 44zM650 800q62 0 106 -44t44 -106t-44 -106t-106 -44t-106 44t-44 106t44 106t106 44zM1050 800q62 0 106 -44t44 -106t-44 -106t-106 -44t-106 44t-44 106t44 106t106 44z" />
<glyph unicode="&#xe235;" d="M550 1100q62 0 106 -44t44 -106t-44 -106t-106 -44t-106 44t-44 106t44 106t106 44zM550 700q62 0 106 -44t44 -106t-44 -106t-106 -44t-106 44t-44 106t44 106t106 44zM550 300q62 0 106 -44t44 -106t-44 -106t-106 -44t-106 44t-44 106t44 106t106 44z" />
<glyph unicode="&#xe236;" d="M125 1100h950q10 0 17.5 -7.5t7.5 -17.5v-150q0 -10 -7.5 -17.5t-17.5 -7.5h-950q-10 0 -17.5 7.5t-7.5 17.5v150q0 10 7.5 17.5t17.5 7.5zM125 700h950q10 0 17.5 -7.5t7.5 -17.5v-150q0 -10 -7.5 -17.5t-17.5 -7.5h-950q-10 0 -17.5 7.5t-7.5 17.5v150q0 10 7.5 17.5 t17.5 7.5zM125 300h950q10 0 17.5 -7.5t7.5 -17.5v-150q0 -10 -7.5 -17.5t-17.5 -7.5h-950q-10 0 -17.5 7.5t-7.5 17.5v150q0 10 7.5 17.5t17.5 7.5z" />
<glyph unicode="&#xe237;" d="M350 1200h500q162 0 256 -93.5t94 -256.5v-500q0 -165 -93.5 -257.5t-256.5 -92.5h-500q-165 0 -257.5 92.5t-92.5 257.5v500q0 165 92.5 257.5t257.5 92.5zM900 1000h-600q-41 0 -70.5 -29.5t-29.5 -70.5v-600q0 -41 29.5 -70.5t70.5 -29.5h600q41 0 70.5 29.5 t29.5 70.5v600q0 41 -29.5 70.5t-70.5 29.5zM350 900h500q21 0 35.5 -14.5t14.5 -35.5v-300q0 -21 -14.5 -35.5t-35.5 -14.5h-500q-21 0 -35.5 14.5t-14.5 35.5v300q0 21 14.5 35.5t35.5 14.5zM400 800v-200h400v200h-400z" />
<glyph unicode="&#xe238;" d="M150 1100h1000q21 0 35.5 -14.5t14.5 -35.5t-14.5 -35.5t-35.5 -14.5h-50v-200h50q21 0 35.5 -14.5t14.5 -35.5t-14.5 -35.5t-35.5 -14.5h-50v-200h50q21 0 35.5 -14.5t14.5 -35.5t-14.5 -35.5t-35.5 -14.5h-50v-200h50q21 0 35.5 -14.5t14.5 -35.5t-14.5 -35.5 t-35.5 -14.5h-1000q-21 0 -35.5 14.5t-14.5 35.5t14.5 35.5t35.5 14.5h50v200h-50q-21 0 -35.5 14.5t-14.5 35.5t14.5 35.5t35.5 14.5h50v200h-50q-21 0 -35.5 14.5t-14.5 35.5t14.5 35.5t35.5 14.5h50v200h-50q-21 0 -35.5 14.5t-14.5 35.5t14.5 35.5t35.5 14.5z" />
<glyph unicode="&#xe239;" d="M650 1187q87 -67 118.5 -156t0 -178t-118.5 -155q-87 66 -118.5 155t0 178t118.5 156zM300 800q124 0 212 -88t88 -212q-124 0 -212 88t-88 212zM1000 800q0 -124 -88 -212t-212 -88q0 124 88 212t212 88zM300 500q124 0 212 -88t88 -212q-124 0 -212 88t-88 212z M1000 500q0 -124 -88 -212t-212 -88q0 124 88 212t212 88zM700 199v-144q0 -21 -14.5 -35.5t-35.5 -14.5t-35.5 14.5t-14.5 35.5v142q40 -4 43 -4q17 0 57 6z" />
<glyph unicode="&#xe240;" d="M745 878l69 19q25 6 45 -12l298 -295q11 -11 15 -26.5t-2 -30.5q-5 -14 -18 -23.5t-28 -9.5h-8q1 0 1 -13q0 -29 -2 -56t-8.5 -62t-20 -63t-33 -53t-51 -39t-72.5 -14h-146q-184 0 -184 288q0 24 10 47q-20 4 -62 4t-63 -4q11 -24 11 -47q0 -288 -184 -288h-142 q-48 0 -84.5 21t-56 51t-32 71.5t-16 75t-3.5 68.5q0 13 2 13h-7q-15 0 -27.5 9.5t-18.5 23.5q-6 15 -2 30.5t15 25.5l298 296q20 18 46 11l76 -19q20 -5 30.5 -22.5t5.5 -37.5t-22.5 -31t-37.5 -5l-51 12l-182 -193h891l-182 193l-44 -12q-20 -5 -37.5 6t-22.5 31t6 37.5 t31 22.5z" />
<glyph unicode="&#xe241;" d="M1200 900h-50q0 21 -4 37t-9.5 26.5t-18 17.5t-22 11t-28.5 5.5t-31 2t-37 0.5h-200v-850q0 -22 25 -34.5t50 -13.5l25 -2v-100h-400v100q4 0 11 0.5t24 3t30 7t24 15t11 24.5v850h-200q-25 0 -37 -0.5t-31 -2t-28.5 -5.5t-22 -11t-18 -17.5t-9.5 -26.5t-4 -37h-50v300 h1000v-300zM500 450h-25q0 15 -4 24.5t-9 14.5t-17 7.5t-20 3t-25 0.5h-100v-425q0 -11 12.5 -17.5t25.5 -7.5h12v-50h-200v50q50 0 50 25v425h-100q-17 0 -25 -0.5t-20 -3t-17 -7.5t-9 -14.5t-4 -24.5h-25v150h500v-150z" />
<glyph unicode="&#xe242;" d="M1000 300v50q-25 0 -55 32q-14 14 -25 31t-16 27l-4 11l-289 747h-69l-300 -754q-18 -35 -39 -56q-9 -9 -24.5 -18.5t-26.5 -14.5l-11 -5v-50h273v50q-49 0 -78.5 21.5t-11.5 67.5l69 176h293l61 -166q13 -34 -3.5 -66.5t-55.5 -32.5v-50h312zM412 691l134 342l121 -342 h-255zM1100 150v-100q0 -21 -14.5 -35.5t-35.5 -14.5h-1000q-21 0 -35.5 14.5t-14.5 35.5v100q0 21 14.5 35.5t35.5 14.5h1000q21 0 35.5 -14.5t14.5 -35.5z" />
<glyph unicode="&#xe243;" d="M50 1200h1100q21 0 35.5 -14.5t14.5 -35.5v-1100q0 -21 -14.5 -35.5t-35.5 -14.5h-1100q-21 0 -35.5 14.5t-14.5 35.5v1100q0 21 14.5 35.5t35.5 14.5zM611 1118h-70q-13 0 -18 -12l-299 -753q-17 -32 -35 -51q-18 -18 -56 -34q-12 -5 -12 -18v-50q0 -8 5.5 -14t14.5 -6 h273q8 0 14 6t6 14v50q0 8 -6 14t-14 6q-55 0 -71 23q-10 14 0 39l63 163h266l57 -153q11 -31 -6 -55q-12 -17 -36 -17q-8 0 -14 -6t-6 -14v-50q0 -8 6 -14t14 -6h313q8 0 14 6t6 14v50q0 7 -5.5 13t-13.5 7q-17 0 -42 25q-25 27 -40 63h-1l-288 748q-5 12 -19 12zM639 611 h-197l103 264z" />
<glyph unicode="&#xe244;" d="M1200 1100h-1200v100h1200v-100zM50 1000h400q21 0 35.5 -14.5t14.5 -35.5v-900q0 -21 -14.5 -35.5t-35.5 -14.5h-400q-21 0 -35.5 14.5t-14.5 35.5v900q0 21 14.5 35.5t35.5 14.5zM650 1000h400q21 0 35.5 -14.5t14.5 -35.5v-400q0 -21 -14.5 -35.5t-35.5 -14.5h-400 q-21 0 -35.5 14.5t-14.5 35.5v400q0 21 14.5 35.5t35.5 14.5zM700 900v-300h300v300h-300z" />
<glyph unicode="&#xe245;" d="M50 1200h400q21 0 35.5 -14.5t14.5 -35.5v-900q0 -21 -14.5 -35.5t-35.5 -14.5h-400q-21 0 -35.5 14.5t-14.5 35.5v900q0 21 14.5 35.5t35.5 14.5zM650 700h400q21 0 35.5 -14.5t14.5 -35.5v-400q0 -21 -14.5 -35.5t-35.5 -14.5h-400q-21 0 -35.5 14.5t-14.5 35.5v400 q0 21 14.5 35.5t35.5 14.5zM700 600v-300h300v300h-300zM1200 0h-1200v100h1200v-100z" />
<glyph unicode="&#xe246;" d="M50 1000h400q21 0 35.5 -14.5t14.5 -35.5v-350h100v150q0 21 14.5 35.5t35.5 14.5h400q21 0 35.5 -14.5t14.5 -35.5v-150h100v-100h-100v-150q0 -21 -14.5 -35.5t-35.5 -14.5h-400q-21 0 -35.5 14.5t-14.5 35.5v150h-100v-350q0 -21 -14.5 -35.5t-35.5 -14.5h-400 q-21 0 -35.5 14.5t-14.5 35.5v800q0 21 14.5 35.5t35.5 14.5zM700 700v-300h300v300h-300z" />
<glyph unicode="&#xe247;" d="M100 0h-100v1200h100v-1200zM250 1100h400q21 0 35.5 -14.5t14.5 -35.5v-400q0 -21 -14.5 -35.5t-35.5 -14.5h-400q-21 0 -35.5 14.5t-14.5 35.5v400q0 21 14.5 35.5t35.5 14.5zM300 1000v-300h300v300h-300zM250 500h900q21 0 35.5 -14.5t14.5 -35.5v-400 q0 -21 -14.5 -35.5t-35.5 -14.5h-900q-21 0 -35.5 14.5t-14.5 35.5v400q0 21 14.5 35.5t35.5 14.5z" />
<glyph unicode="&#xe248;" d="M600 1100h150q21 0 35.5 -14.5t14.5 -35.5v-400q0 -21 -14.5 -35.5t-35.5 -14.5h-150v-100h450q21 0 35.5 -14.5t14.5 -35.5v-400q0 -21 -14.5 -35.5t-35.5 -14.5h-900q-21 0 -35.5 14.5t-14.5 35.5v400q0 21 14.5 35.5t35.5 14.5h350v100h-150q-21 0 -35.5 14.5 t-14.5 35.5v400q0 21 14.5 35.5t35.5 14.5h150v100h100v-100zM400 1000v-300h300v300h-300z" />
<glyph unicode="&#xe249;" d="M1200 0h-100v1200h100v-1200zM550 1100h400q21 0 35.5 -14.5t14.5 -35.5v-400q0 -21 -14.5 -35.5t-35.5 -14.5h-400q-21 0 -35.5 14.5t-14.5 35.5v400q0 21 14.5 35.5t35.5 14.5zM600 1000v-300h300v300h-300zM50 500h900q21 0 35.5 -14.5t14.5 -35.5v-400 q0 -21 -14.5 -35.5t-35.5 -14.5h-900q-21 0 -35.5 14.5t-14.5 35.5v400q0 21 14.5 35.5t35.5 14.5z" />
<glyph unicode="&#xe250;" d="M865 565l-494 -494q-23 -23 -41 -23q-14 0 -22 13.5t-8 38.5v1000q0 25 8 38.5t22 13.5q18 0 41 -23l494 -494q14 -14 14 -35t-14 -35z" />
<glyph unicode="&#xe251;" d="M335 635l494 494q29 29 50 20.5t21 -49.5v-1000q0 -41 -21 -49.5t-50 20.5l-494 494q-14 14 -14 35t14 35z" />
<glyph unicode="&#xe252;" d="M100 900h1000q41 0 49.5 -21t-20.5 -50l-494 -494q-14 -14 -35 -14t-35 14l-494 494q-29 29 -20.5 50t49.5 21z" />
<glyph unicode="&#xe253;" d="M635 865l494 -494q29 -29 20.5 -50t-49.5 -21h-1000q-41 0 -49.5 21t20.5 50l494 494q14 14 35 14t35 -14z" />
<glyph unicode="&#xe254;" d="M700 741v-182l-692 -323v221l413 193l-413 193v221zM1200 0h-800v200h800v-200z" />
<glyph unicode="&#xe255;" d="M1200 900h-200v-100h200v-100h-300v300h200v100h-200v100h300v-300zM0 700h50q0 21 4 37t9.5 26.5t18 17.5t22 11t28.5 5.5t31 2t37 0.5h100v-550q0 -22 -25 -34.5t-50 -13.5l-25 -2v-100h400v100q-4 0 -11 0.5t-24 3t-30 7t-24 15t-11 24.5v550h100q25 0 37 -0.5t31 -2 t28.5 -5.5t22 -11t18 -17.5t9.5 -26.5t4 -37h50v300h-800v-300z" />
<glyph unicode="&#xe256;" d="M800 700h-50q0 21 -4 37t-9.5 26.5t-18 17.5t-22 11t-28.5 5.5t-31 2t-37 0.5h-100v-550q0 -22 25 -34.5t50 -14.5l25 -1v-100h-400v100q4 0 11 0.5t24 3t30 7t24 15t11 24.5v550h-100q-25 0 -37 -0.5t-31 -2t-28.5 -5.5t-22 -11t-18 -17.5t-9.5 -26.5t-4 -37h-50v300 h800v-300zM1100 200h-200v-100h200v-100h-300v300h200v100h-200v100h300v-300z" />
<glyph unicode="&#xe257;" d="M701 1098h160q16 0 21 -11t-7 -23l-464 -464l464 -464q12 -12 7 -23t-21 -11h-160q-13 0 -23 9l-471 471q-7 8 -7 18t7 18l471 471q10 9 23 9z" />
<glyph unicode="&#xe258;" d="M339 1098h160q13 0 23 -9l471 -471q7 -8 7 -18t-7 -18l-471 -471q-10 -9 -23 -9h-160q-16 0 -21 11t7 23l464 464l-464 464q-12 12 -7 23t21 11z" />
<glyph unicode="&#xe259;" d="M1087 882q11 -5 11 -21v-160q0 -13 -9 -23l-471 -471q-8 -7 -18 -7t-18 7l-471 471q-9 10 -9 23v160q0 16 11 21t23 -7l464 -464l464 464q12 12 23 7z" />
<glyph unicode="&#xe260;" d="M618 993l471 -471q9 -10 9 -23v-160q0 -16 -11 -21t-23 7l-464 464l-464 -464q-12 -12 -23 -7t-11 21v160q0 13 9 23l471 471q8 7 18 7t18 -7z" />
<glyph unicode="&#xf8ff;" d="M1000 1200q0 -124 -88 -212t-212 -88q0 124 88 212t212 88zM450 1000h100q21 0 40 -14t26 -33l79 -194q5 1 16 3q34 6 54 9.5t60 7t65.5 1t61 -10t56.5 -23t42.5 -42t29 -64t5 -92t-19.5 -121.5q-1 -7 -3 -19.5t-11 -50t-20.5 -73t-32.5 -81.5t-46.5 -83t-64 -70 t-82.5 -50q-13 -5 -42 -5t-65.5 2.5t-47.5 2.5q-14 0 -49.5 -3.5t-63 -3.5t-43.5 7q-57 25 -104.5 78.5t-75 111.5t-46.5 112t-26 90l-7 35q-15 63 -18 115t4.5 88.5t26 64t39.5 43.5t52 25.5t58.5 13t62.5 2t59.5 -4.5t55.5 -8l-147 192q-12 18 -5.5 30t27.5 12z" />
<glyph unicode="&#x1f511;" d="M250 1200h600q21 0 35.5 -14.5t14.5 -35.5v-400q0 -21 -14.5 -35.5t-35.5 -14.5h-150v-500l-255 -178q-19 -9 -32 -1t-13 29v650h-150q-21 0 -35.5 14.5t-14.5 35.5v400q0 21 14.5 35.5t35.5 14.5zM400 1100v-100h300v100h-300z" />
<glyph unicode="&#x1f6aa;" d="M250 1200h750q39 0 69.5 -40.5t30.5 -84.5v-933l-700 -117v950l600 125h-700v-1000h-100v1025q0 23 15.5 49t34.5 26zM500 525v-100l100 20v100z" />
</font>
</defs></svg> ) format('svg')}.glyphicon{position:relative;top:1px;display:inline-block;font-family:'Glyphicons Halflings';font-style:normal;font-weight:normal;line-height:1;-webkit-font-smoothing:antialiased;-moz-osx-font-smoothing:grayscale}.glyphicon-asterisk:before{content:"\002a"}.glyphicon-plus:before{content:"\002b"}.glyphicon-euro:before,.glyphicon-eur:before{content:"\20ac"}.glyphicon-minus:before{content:"\2212"}.glyphicon-cloud:before{content:"\2601"}.glyphicon-envelope:before{content:"\2709"}.glyphicon-pencil:before{content:"\270f"}.glyphicon-glass:before{content:"\e001"}.glyphicon-music:before{content:"\e002"}.glyphicon-search:before{content:"\e003"}.glyphicon-heart:before{content:"\e005"}.glyphicon-star:before{content:"\e006"}.glyphicon-star-empty:before{content:"\e007"}.glyphicon-user:before{content:"\e008"}.glyphicon-film:before{content:"\e009"}.glyphicon-th-large:before{content:"\e010"}.glyphicon-th:before{content:"\e011"}.glyphicon-th-list:before{content:"\e012"}.glyphicon-ok:before{content:"\e013"}.glyphicon-remove:before{content:"\e014"}.glyphicon-zoom-in:before{content:"\e015"}.glyphicon-zoom-out:before{content:"\e016"}.glyphicon-off:before{content:"\e017"}.glyphicon-signal:before{content:"\e018"}.glyphicon-cog:before{content:"\e019"}.glyphicon-trash:before{content:"\e020"}.glyphicon-home:before{content:"\e021"}.glyphicon-file:before{content:"\e022"}.glyphicon-time:before{content:"\e023"}.glyphicon-road:before{content:"\e024"}.glyphicon-download-alt:before{content:"\e025"}.glyphicon-download:before{content:"\e026"}.glyphicon-upload:before{content:"\e027"}.glyphicon-inbox:before{content:"\e028"}.glyphicon-play-circle:before{content:"\e029"}.glyphicon-repeat:before{content:"\e030"}.glyphicon-refresh:before{content:"\e031"}.glyphicon-list-alt:before{content:"\e032"}.glyphicon-lock:before{content:"\e033"}.glyphicon-flag:before{content:"\e034"}.glyphicon-headphones:before{content:"\e035"}.glyphicon-volume-off:before{content:"\e036"}.glyphicon-volume-down:before{content:"\e037"}.glyphicon-volume-up:before{content:"\e038"}.glyphicon-qrcode:before{content:"\e039"}.glyphicon-barcode:before{content:"\e040"}.glyphicon-tag:before{content:"\e041"}.glyphicon-tags:before{content:"\e042"}.glyphicon-book:before{content:"\e043"}.glyphicon-bookmark:before{content:"\e044"}.glyphicon-print:before{content:"\e045"}.glyphicon-camera:before{content:"\e046"}.glyphicon-font:before{content:"\e047"}.glyphicon-bold:before{content:"\e048"}.glyphicon-italic:before{content:"\e049"}.glyphicon-text-height:before{content:"\e050"}.glyphicon-text-width:before{content:"\e051"}.glyphicon-align-left:before{content:"\e052"}.glyphicon-align-center:before{content:"\e053"}.glyphicon-align-right:before{content:"\e054"}.glyphicon-align-justify:before{content:"\e055"}.glyphicon-list:before{content:"\e056"}.glyphicon-indent-left:before{content:"\e057"}.glyphicon-indent-right:before{content:"\e058"}.glyphicon-facetime-video:before{content:"\e059"}.glyphicon-picture:before{content:"\e060"}.glyphicon-map-marker:before{content:"\e062"}.glyphicon-adjust:before{content:"\e063"}.glyphicon-tint:before{content:"\e064"}.glyphicon-edit:before{content:"\e065"}.glyphicon-share:before{content:"\e066"}.glyphicon-check:before{content:"\e067"}.glyphicon-move:before{content:"\e068"}.glyphicon-step-backward:before{content:"\e069"}.glyphicon-fast-backward:before{content:"\e070"}.glyphicon-backward:before{content:"\e071"}.glyphicon-play:before{content:"\e072"}.glyphicon-pause:before{content:"\e073"}.glyphicon-stop:before{content:"\e074"}.glyphicon-forward:before{content:"\e075"}.glyphicon-fast-forward:before{content:"\e076"}.glyphicon-step-forward:before{content:"\e077"}.glyphicon-eject:before{content:"\e078"}.glyphicon-chevron-left:before{content:"\e079"}.glyphicon-chevron-right:before{content:"\e080"}.glyphicon-plus-sign:before{content:"\e081"}.glyphicon-minus-sign:before{content:"\e082"}.glyphicon-remove-sign:before{content:"\e083"}.glyphicon-ok-sign:before{content:"\e084"}.glyphicon-question-sign:before{content:"\e085"}.glyphicon-info-sign:before{content:"\e086"}.glyphicon-screenshot:before{content:"\e087"}.glyphicon-remove-circle:before{content:"\e088"}.glyphicon-ok-circle:before{content:"\e089"}.glyphicon-ban-circle:before{content:"\e090"}.glyphicon-arrow-left:before{content:"\e091"}.glyphicon-arrow-right:before{content:"\e092"}.glyphicon-arrow-up:before{content:"\e093"}.glyphicon-arrow-down:before{content:"\e094"}.glyphicon-share-alt:before{content:"\e095"}.glyphicon-resize-full:before{content:"\e096"}.glyphicon-resize-small:before{content:"\e097"}.glyphicon-exclamation-sign:before{content:"\e101"}.glyphicon-gift:before{content:"\e102"}.glyphicon-leaf:before{content:"\e103"}.glyphicon-fire:before{content:"\e104"}.glyphicon-eye-open:before{content:"\e105"}.glyphicon-eye-close:before{content:"\e106"}.glyphicon-warning-sign:before{content:"\e107"}.glyphicon-plane:before{content:"\e108"}.glyphicon-calendar:before{content:"\e109"}.glyphicon-random:before{content:"\e110"}.glyphicon-comment:before{content:"\e111"}.glyphicon-magnet:before{content:"\e112"}.glyphicon-chevron-up:before{content:"\e113"}.glyphicon-chevron-down:before{content:"\e114"}.glyphicon-retweet:before{content:"\e115"}.glyphicon-shopping-cart:before{content:"\e116"}.glyphicon-folder-close:before{content:"\e117"}.glyphicon-folder-open:before{content:"\e118"}.glyphicon-resize-vertical:before{content:"\e119"}.glyphicon-resize-horizontal:before{content:"\e120"}.glyphicon-hdd:before{content:"\e121"}.glyphicon-bullhorn:before{content:"\e122"}.glyphicon-bell:before{content:"\e123"}.glyphicon-certificate:before{content:"\e124"}.glyphicon-thumbs-up:before{content:"\e125"}.glyphicon-thumbs-down:before{content:"\e126"}.glyphicon-hand-right:before{content:"\e127"}.glyphicon-hand-left:before{content:"\e128"}.glyphicon-hand-up:before{content:"\e129"}.glyphicon-hand-down:before{content:"\e130"}.glyphicon-circle-arrow-right:before{content:"\e131"}.glyphicon-circle-arrow-left:before{content:"\e132"}.glyphicon-circle-arrow-up:before{content:"\e133"}.glyphicon-circle-arrow-down:before{content:"\e134"}.glyphicon-globe:before{content:"\e135"}.glyphicon-wrench:before{content:"\e136"}.glyphicon-tasks:before{content:"\e137"}.glyphicon-filter:before{content:"\e138"}.glyphicon-briefcase:before{content:"\e139"}.glyphicon-fullscreen:before{content:"\e140"}.glyphicon-dashboard:before{content:"\e141"}.glyphicon-paperclip:before{content:"\e142"}.glyphicon-heart-empty:before{content:"\e143"}.glyphicon-link:before{content:"\e144"}.glyphicon-phone:before{content:"\e145"}.glyphicon-pushpin:before{content:"\e146"}.glyphicon-usd:before{content:"\e148"}.glyphicon-gbp:before{content:"\e149"}.glyphicon-sort:before{content:"\e150"}.glyphicon-sort-by-alphabet:before{content:"\e151"}.glyphicon-sort-by-alphabet-alt:before{content:"\e152"}.glyphicon-sort-by-order:before{content:"\e153"}.glyphicon-sort-by-order-alt:before{content:"\e154"}.glyphicon-sort-by-attributes:before{content:"\e155"}.glyphicon-sort-by-attributes-alt:before{content:"\e156"}.glyphicon-unchecked:before{content:"\e157"}.glyphicon-expand:before{content:"\e158"}.glyphicon-collapse-down:before{content:"\e159"}.glyphicon-collapse-up:before{content:"\e160"}.glyphicon-log-in:before{content:"\e161"}.glyphicon-flash:before{content:"\e162"}.glyphicon-log-out:before{content:"\e163"}.glyphicon-new-window:before{content:"\e164"}.glyphicon-record:before{content:"\e165"}.glyphicon-save:before{content:"\e166"}.glyphicon-open:before{content:"\e167"}.glyphicon-saved:before{content:"\e168"}.glyphicon-import:before{content:"\e169"}.glyphicon-export:before{content:"\e170"}.glyphicon-send:before{content:"\e171"}.glyphicon-floppy-disk:before{content:"\e172"}.glyphicon-floppy-saved:before{content:"\e173"}.glyphicon-floppy-remove:before{content:"\e174"}.glyphicon-floppy-save:before{content:"\e175"}.glyphicon-floppy-open:before{content:"\e176"}.glyphicon-credit-card:before{content:"\e177"}.glyphicon-transfer:before{content:"\e178"}.glyphicon-cutlery:before{content:"\e179"}.glyphicon-header:before{content:"\e180"}.glyphicon-compressed:before{content:"\e181"}.glyphicon-earphone:before{content:"\e182"}.glyphicon-phone-alt:before{content:"\e183"}.glyphicon-tower:before{content:"\e184"}.glyphicon-stats:before{content:"\e185"}.glyphicon-sd-video:before{content:"\e186"}.glyphicon-hd-video:before{content:"\e187"}.glyphicon-subtitles:before{content:"\e188"}.glyphicon-sound-stereo:before{content:"\e189"}.glyphicon-sound-dolby:before{content:"\e190"}.glyphicon-sound-5-1:before{content:"\e191"}.glyphicon-sound-6-1:before{content:"\e192"}.glyphicon-sound-7-1:before{content:"\e193"}.glyphicon-copyright-mark:before{content:"\e194"}.glyphicon-registration-mark:before{content:"\e195"}.glyphicon-cloud-download:before{content:"\e197"}.glyphicon-cloud-upload:before{content:"\e198"}.glyphicon-tree-conifer:before{content:"\e199"}.glyphicon-tree-deciduous:before{content:"\e200"}.glyphicon-cd:before{content:"\e201"}.glyphicon-save-file:before{content:"\e202"}.glyphicon-open-file:before{content:"\e203"}.glyphicon-level-up:before{content:"\e204"}.glyphicon-copy:before{content:"\e205"}.glyphicon-paste:before{content:"\e206"}.glyphicon-alert:before{content:"\e209"}.glyphicon-equalizer:before{content:"\e210"}.glyphicon-king:before{content:"\e211"}.glyphicon-queen:before{content:"\e212"}.glyphicon-pawn:before{content:"\e213"}.glyphicon-bishop:before{content:"\e214"}.glyphicon-knight:before{content:"\e215"}.glyphicon-baby-formula:before{content:"\e216"}.glyphicon-tent:before{content:"\26fa"}.glyphicon-blackboard:before{content:"\e218"}.glyphicon-bed:before{content:"\e219"}.glyphicon-apple:before{content:"\f8ff"}.glyphicon-erase:before{content:"\e221"}.glyphicon-hourglass:before{content:"\231b"}.glyphicon-lamp:before{content:"\e223"}.glyphicon-duplicate:before{content:"\e224"}.glyphicon-piggy-bank:before{content:"\e225"}.glyphicon-scissors:before{content:"\e226"}.glyphicon-bitcoin:before{content:"\e227"}.glyphicon-btc:before{content:"\e227"}.glyphicon-xbt:before{content:"\e227"}.glyphicon-yen:before{content:"\00a5"}.glyphicon-jpy:before{content:"\00a5"}.glyphicon-ruble:before{content:"\20bd"}.glyphicon-rub:before{content:"\20bd"}.glyphicon-scale:before{content:"\e230"}.glyphicon-ice-lolly:before{content:"\e231"}.glyphicon-ice-lolly-tasted:before{content:"\e232"}.glyphicon-education:before{content:"\e233"}.glyphicon-option-horizontal:before{content:"\e234"}.glyphicon-option-vertical:before{content:"\e235"}.glyphicon-menu-hamburger:before{content:"\e236"}.glyphicon-modal-window:before{content:"\e237"}.glyphicon-oil:before{content:"\e238"}.glyphicon-grain:before{content:"\e239"}.glyphicon-sunglasses:before{content:"\e240"}.glyphicon-text-size:before{content:"\e241"}.glyphicon-text-color:before{content:"\e242"}.glyphicon-text-background:before{content:"\e243"}.glyphicon-object-align-top:before{content:"\e244"}.glyphicon-object-align-bottom:before{content:"\e245"}.glyphicon-object-align-horizontal:before{content:"\e246"}.glyphicon-object-align-left:before{content:"\e247"}.glyphicon-object-align-vertical:before{content:"\e248"}.glyphicon-object-align-right:before{content:"\e249"}.glyphicon-triangle-right:before{content:"\e250"}.glyphicon-triangle-left:before{content:"\e251"}.glyphicon-triangle-bottom:before{content:"\e252"}.glyphicon-triangle-top:before{content:"\e253"}.glyphicon-console:before{content:"\e254"}.glyphicon-superscript:before{content:"\e255"}.glyphicon-subscript:before{content:"\e256"}.glyphicon-menu-left:before{content:"\e257"}.glyphicon-menu-right:before{content:"\e258"}.glyphicon-menu-down:before{content:"\e259"}.glyphicon-menu-up:before{content:"\e260"}*{-webkit-box-sizing:border-box;-moz-box-sizing:border-box;box-sizing:border-box}*:before,*:after{-webkit-box-sizing:border-box;-moz-box-sizing:border-box;box-sizing:border-box}html{font-size:10px;-webkit-tap-highlight-color:rgba(0,0,0,0)}body{font-family:"Roboto","Helvetica Neue",Helvetica,Arial,sans-serif;font-size:13px;line-height:1.846;color:#666666;background-color:#ffffff}input,button,select,textarea{font-family:inherit;font-size:inherit;line-height:inherit}a{color:#2196f3;text-decoration:none}a:hover,a:focus{color:#0a6ebd;text-decoration:underline}a:focus{outline:thin dotted;outline:5px auto -webkit-focus-ring-color;outline-offset:-2px}figure{margin:0}img{vertical-align:middle}.img-responsive,.thumbnail>img,.thumbnail a>img,.carousel-inner>.item>img,.carousel-inner>.item>a>img{display:block;max-width:100%;height:auto}.img-rounded{border-radius:3px}.img-thumbnail{padding:4px;line-height:1.846;background-color:#ffffff;border:1px solid #dddddd;border-radius:3px;-webkit-transition:all .2s ease-in-out;-o-transition:all .2s ease-in-out;transition:all .2s ease-in-out;display:inline-block;max-width:100%;height:auto}.img-circle{border-radius:50%}hr{margin-top:23px;margin-bottom:23px;border:0;border-top:1px solid #eeeeee}.sr-only{position:absolute;width:1px;height:1px;margin:-1px;padding:0;overflow:hidden;clip:rect(0, 0, 0, 0);border:0}.sr-only-focusable:active,.sr-only-focusable:focus{position:static;width:auto;height:auto;margin:0;overflow:visible;clip:auto}[role="button"]{cursor:pointer}h1,h2,h3,h4,h5,h6,.h1,.h2,.h3,.h4,.h5,.h6{font-family:inherit;font-weight:400;line-height:1.1;color:#444444}h1 small,h2 small,h3 small,h4 small,h5 small,h6 small,.h1 small,.h2 small,.h3 small,.h4 small,.h5 small,.h6 small,h1 .small,h2 .small,h3 .small,h4 .small,h5 .small,h6 .small,.h1 .small,.h2 .small,.h3 .small,.h4 .small,.h5 .small,.h6 .small{font-weight:normal;line-height:1;color:#bbbbbb}h1,.h1,h2,.h2,h3,.h3{margin-top:23px;margin-bottom:11.5px}h1 small,.h1 small,h2 small,.h2 small,h3 small,.h3 small,h1 .small,.h1 .small,h2 .small,.h2 .small,h3 .small,.h3 .small{font-size:65%}h4,.h4,h5,.h5,h6,.h6{margin-top:11.5px;margin-bottom:11.5px}h4 small,.h4 small,h5 small,.h5 small,h6 small,.h6 small,h4 .small,.h4 .small,h5 .small,.h5 .small,h6 .small,.h6 .small{font-size:75%}h1,.h1{font-size:56px}h2,.h2{font-size:45px}h3,.h3{font-size:34px}h4,.h4{font-size:24px}h5,.h5{font-size:20px}h6,.h6{font-size:14px}p{margin:0 0 11.5px}.lead{margin-bottom:23px;font-size:14px;font-weight:300;line-height:1.4}@media (min-width:768px){.lead{font-size:19.5px}}small,.small{font-size:92%}mark,.mark{background-color:#ffe0b2;padding:.2em}.text-left{text-align:left}.text-right{text-align:right}.text-center{text-align:center}.text-justify{text-align:justify}.text-nowrap{white-space:nowrap}.text-lowercase{text-transform:lowercase}.text-uppercase{text-transform:uppercase}.text-capitalize{text-transform:capitalize}.text-muted{color:#bbbbbb}.text-primary{color:#2196f3}a.text-primary:hover,a.text-primary:focus{color:#0c7cd5}.text-success{color:#4caf50}a.text-success:hover,a.text-success:focus{color:#3d8b40}.text-info{color:#9c27b0}a.text-info:hover,a.text-info:focus{color:#771e86}.text-warning{color:#ff9800}a.text-warning:hover,a.text-warning:focus{color:#cc7a00}.text-danger{color:#e51c23}a.text-danger:hover,a.text-danger:focus{color:#b9151b}.bg-primary{color:#fff;background-color:#2196f3}a.bg-primary:hover,a.bg-primary:focus{background-color:#0c7cd5}.bg-success{background-color:#dff0d8}a.bg-success:hover,a.bg-success:focus{background-color:#c1e2b3}.bg-info{background-color:#e1bee7}a.bg-info:hover,a.bg-info:focus{background-color:#d099d9}.bg-warning{background-color:#ffe0b2}a.bg-warning:hover,a.bg-warning:focus{background-color:#ffcb7f}.bg-danger{background-color:#f9bdbb}a.bg-danger:hover,a.bg-danger:focus{background-color:#f5908c}.page-header{padding-bottom:10.5px;margin:46px 0 23px;border-bottom:1px solid #eeeeee}ul,ol{margin-top:0;margin-bottom:11.5px}ul ul,ol ul,ul ol,ol ol{margin-bottom:0}.list-unstyled{padding-left:0;list-style:none}.list-inline{padding-left:0;list-style:none;margin-left:-5px}.list-inline>li{display:inline-block;padding-left:5px;padding-right:5px}dl{margin-top:0;margin-bottom:23px}dt,dd{line-height:1.846}dt{font-weight:bold}dd{margin-left:0}@media (min-width:768px){.dl-horizontal dt{float:left;width:160px;clear:left;text-align:right;overflow:hidden;text-overflow:ellipsis;white-space:nowrap}.dl-horizontal dd{margin-left:180px}}abbr[title],abbr[data-original-title]{cursor:help;border-bottom:1px dotted #bbbbbb}.initialism{font-size:90%;text-transform:uppercase}blockquote{padding:11.5px 23px;margin:0 0 23px;font-size:16.25px;border-left:5px solid #eeeeee}blockquote p:last-child,blockquote ul:last-child,blockquote ol:last-child{margin-bottom:0}blockquote footer,blockquote small,blockquote .small{display:block;font-size:80%;line-height:1.846;color:#bbbbbb}blockquote footer:before,blockquote small:before,blockquote .small:before{content:'\2014 \00A0'}.blockquote-reverse,blockquote.pull-right{padding-right:15px;padding-left:0;border-right:5px solid #eeeeee;border-left:0;text-align:right}.blockquote-reverse footer:before,blockquote.pull-right footer:before,.blockquote-reverse small:before,blockquote.pull-right small:before,.blockquote-reverse .small:before,blockquote.pull-right .small:before{content:''}.blockquote-reverse footer:after,blockquote.pull-right footer:after,.blockquote-reverse small:after,blockquote.pull-right small:after,.blockquote-reverse .small:after,blockquote.pull-right .small:after{content:'\00A0 \2014'}address{margin-bottom:23px;font-style:normal;line-height:1.846}code,kbd,pre,samp{font-family:monospace}code{padding:2px 4px;font-size:90%;color:#c7254e;background-color:#f9f2f4;border-radius:3px}kbd{padding:2px 4px;font-size:90%;color:#ffffff;background-color:#333333;border-radius:3px;-webkit-box-shadow:inset 0 -1px 0 rgba(0,0,0,0.25);box-shadow:inset 0 -1px 0 rgba(0,0,0,0.25)}kbd kbd{padding:0;font-size:100%;font-weight:bold;-webkit-box-shadow:none;box-shadow:none}pre{display:block;padding:11px;margin:0 0 11.5px;font-size:12px;line-height:1.846;word-break:break-all;word-wrap:break-word;color:#212121;background-color:#f5f5f5;border:1px solid #cccccc;border-radius:3px}pre code{padding:0;font-size:inherit;color:inherit;white-space:pre-wrap;background-color:transparent;border-radius:0}.pre-scrollable{max-height:340px;overflow-y:scroll}.container{margin-right:auto;margin-left:auto;padding-left:15px;padding-right:15px}@media (min-width:768px){.container{width:750px}}@media (min-width:992px){.container{width:970px}}@media (min-width:1200px){.container{width:1170px}}.container-fluid{margin-right:auto;margin-left:auto;padding-left:15px;padding-right:15px}.row{margin-left:-15px;margin-right:-15px}.col-xs-1,.col-sm-1,.col-md-1,.col-lg-1,.col-xs-2,.col-sm-2,.col-md-2,.col-lg-2,.col-xs-3,.col-sm-3,.col-md-3,.col-lg-3,.col-xs-4,.col-sm-4,.col-md-4,.col-lg-4,.col-xs-5,.col-sm-5,.col-md-5,.col-lg-5,.col-xs-6,.col-sm-6,.col-md-6,.col-lg-6,.col-xs-7,.col-sm-7,.col-md-7,.col-lg-7,.col-xs-8,.col-sm-8,.col-md-8,.col-lg-8,.col-xs-9,.col-sm-9,.col-md-9,.col-lg-9,.col-xs-10,.col-sm-10,.col-md-10,.col-lg-10,.col-xs-11,.col-sm-11,.col-md-11,.col-lg-11,.col-xs-12,.col-sm-12,.col-md-12,.col-lg-12{position:relative;min-height:1px;padding-left:15px;padding-right:15px}.col-xs-1,.col-xs-2,.col-xs-3,.col-xs-4,.col-xs-5,.col-xs-6,.col-xs-7,.col-xs-8,.col-xs-9,.col-xs-10,.col-xs-11,.col-xs-12{float:left}.col-xs-12{width:100%}.col-xs-11{width:91.66666667%}.col-xs-10{width:83.33333333%}.col-xs-9{width:75%}.col-xs-8{width:66.66666667%}.col-xs-7{width:58.33333333%}.col-xs-6{width:50%}.col-xs-5{width:41.66666667%}.col-xs-4{width:33.33333333%}.col-xs-3{width:25%}.col-xs-2{width:16.66666667%}.col-xs-1{width:8.33333333%}.col-xs-pull-12{right:100%}.col-xs-pull-11{right:91.66666667%}.col-xs-pull-10{right:83.33333333%}.col-xs-pull-9{right:75%}.col-xs-pull-8{right:66.66666667%}.col-xs-pull-7{right:58.33333333%}.col-xs-pull-6{right:50%}.col-xs-pull-5{right:41.66666667%}.col-xs-pull-4{right:33.33333333%}.col-xs-pull-3{right:25%}.col-xs-pull-2{right:16.66666667%}.col-xs-pull-1{right:8.33333333%}.col-xs-pull-0{right:auto}.col-xs-push-12{left:100%}.col-xs-push-11{left:91.66666667%}.col-xs-push-10{left:83.33333333%}.col-xs-push-9{left:75%}.col-xs-push-8{left:66.66666667%}.col-xs-push-7{left:58.33333333%}.col-xs-push-6{left:50%}.col-xs-push-5{left:41.66666667%}.col-xs-push-4{left:33.33333333%}.col-xs-push-3{left:25%}.col-xs-push-2{left:16.66666667%}.col-xs-push-1{left:8.33333333%}.col-xs-push-0{left:auto}.col-xs-offset-12{margin-left:100%}.col-xs-offset-11{margin-left:91.66666667%}.col-xs-offset-10{margin-left:83.33333333%}.col-xs-offset-9{margin-left:75%}.col-xs-offset-8{margin-left:66.66666667%}.col-xs-offset-7{margin-left:58.33333333%}.col-xs-offset-6{margin-left:50%}.col-xs-offset-5{margin-left:41.66666667%}.col-xs-offset-4{margin-left:33.33333333%}.col-xs-offset-3{margin-left:25%}.col-xs-offset-2{margin-left:16.66666667%}.col-xs-offset-1{margin-left:8.33333333%}.col-xs-offset-0{margin-left:0%}@media (min-width:768px){.col-sm-1,.col-sm-2,.col-sm-3,.col-sm-4,.col-sm-5,.col-sm-6,.col-sm-7,.col-sm-8,.col-sm-9,.col-sm-10,.col-sm-11,.col-sm-12{float:left}.col-sm-12{width:100%}.col-sm-11{width:91.66666667%}.col-sm-10{width:83.33333333%}.col-sm-9{width:75%}.col-sm-8{width:66.66666667%}.col-sm-7{width:58.33333333%}.col-sm-6{width:50%}.col-sm-5{width:41.66666667%}.col-sm-4{width:33.33333333%}.col-sm-3{width:25%}.col-sm-2{width:16.66666667%}.col-sm-1{width:8.33333333%}.col-sm-pull-12{right:100%}.col-sm-pull-11{right:91.66666667%}.col-sm-pull-10{right:83.33333333%}.col-sm-pull-9{right:75%}.col-sm-pull-8{right:66.66666667%}.col-sm-pull-7{right:58.33333333%}.col-sm-pull-6{right:50%}.col-sm-pull-5{right:41.66666667%}.col-sm-pull-4{right:33.33333333%}.col-sm-pull-3{right:25%}.col-sm-pull-2{right:16.66666667%}.col-sm-pull-1{right:8.33333333%}.col-sm-pull-0{right:auto}.col-sm-push-12{left:100%}.col-sm-push-11{left:91.66666667%}.col-sm-push-10{left:83.33333333%}.col-sm-push-9{left:75%}.col-sm-push-8{left:66.66666667%}.col-sm-push-7{left:58.33333333%}.col-sm-push-6{left:50%}.col-sm-push-5{left:41.66666667%}.col-sm-push-4{left:33.33333333%}.col-sm-push-3{left:25%}.col-sm-push-2{left:16.66666667%}.col-sm-push-1{left:8.33333333%}.col-sm-push-0{left:auto}.col-sm-offset-12{margin-left:100%}.col-sm-offset-11{margin-left:91.66666667%}.col-sm-offset-10{margin-left:83.33333333%}.col-sm-offset-9{margin-left:75%}.col-sm-offset-8{margin-left:66.66666667%}.col-sm-offset-7{margin-left:58.33333333%}.col-sm-offset-6{margin-left:50%}.col-sm-offset-5{margin-left:41.66666667%}.col-sm-offset-4{margin-left:33.33333333%}.col-sm-offset-3{margin-left:25%}.col-sm-offset-2{margin-left:16.66666667%}.col-sm-offset-1{margin-left:8.33333333%}.col-sm-offset-0{margin-left:0%}}@media (min-width:992px){.col-md-1,.col-md-2,.col-md-3,.col-md-4,.col-md-5,.col-md-6,.col-md-7,.col-md-8,.col-md-9,.col-md-10,.col-md-11,.col-md-12{float:left}.col-md-12{width:100%}.col-md-11{width:91.66666667%}.col-md-10{width:83.33333333%}.col-md-9{width:75%}.col-md-8{width:66.66666667%}.col-md-7{width:58.33333333%}.col-md-6{width:50%}.col-md-5{width:41.66666667%}.col-md-4{width:33.33333333%}.col-md-3{width:25%}.col-md-2{width:16.66666667%}.col-md-1{width:8.33333333%}.col-md-pull-12{right:100%}.col-md-pull-11{right:91.66666667%}.col-md-pull-10{right:83.33333333%}.col-md-pull-9{right:75%}.col-md-pull-8{right:66.66666667%}.col-md-pull-7{right:58.33333333%}.col-md-pull-6{right:50%}.col-md-pull-5{right:41.66666667%}.col-md-pull-4{right:33.33333333%}.col-md-pull-3{right:25%}.col-md-pull-2{right:16.66666667%}.col-md-pull-1{right:8.33333333%}.col-md-pull-0{right:auto}.col-md-push-12{left:100%}.col-md-push-11{left:91.66666667%}.col-md-push-10{left:83.33333333%}.col-md-push-9{left:75%}.col-md-push-8{left:66.66666667%}.col-md-push-7{left:58.33333333%}.col-md-push-6{left:50%}.col-md-push-5{left:41.66666667%}.col-md-push-4{left:33.33333333%}.col-md-push-3{left:25%}.col-md-push-2{left:16.66666667%}.col-md-push-1{left:8.33333333%}.col-md-push-0{left:auto}.col-md-offset-12{margin-left:100%}.col-md-offset-11{margin-left:91.66666667%}.col-md-offset-10{margin-left:83.33333333%}.col-md-offset-9{margin-left:75%}.col-md-offset-8{margin-left:66.66666667%}.col-md-offset-7{margin-left:58.33333333%}.col-md-offset-6{margin-left:50%}.col-md-offset-5{margin-left:41.66666667%}.col-md-offset-4{margin-left:33.33333333%}.col-md-offset-3{margin-left:25%}.col-md-offset-2{margin-left:16.66666667%}.col-md-offset-1{margin-left:8.33333333%}.col-md-offset-0{margin-left:0%}}@media (min-width:1200px){.col-lg-1,.col-lg-2,.col-lg-3,.col-lg-4,.col-lg-5,.col-lg-6,.col-lg-7,.col-lg-8,.col-lg-9,.col-lg-10,.col-lg-11,.col-lg-12{float:left}.col-lg-12{width:100%}.col-lg-11{width:91.66666667%}.col-lg-10{width:83.33333333%}.col-lg-9{width:75%}.col-lg-8{width:66.66666667%}.col-lg-7{width:58.33333333%}.col-lg-6{width:50%}.col-lg-5{width:41.66666667%}.col-lg-4{width:33.33333333%}.col-lg-3{width:25%}.col-lg-2{width:16.66666667%}.col-lg-1{width:8.33333333%}.col-lg-pull-12{right:100%}.col-lg-pull-11{right:91.66666667%}.col-lg-pull-10{right:83.33333333%}.col-lg-pull-9{right:75%}.col-lg-pull-8{right:66.66666667%}.col-lg-pull-7{right:58.33333333%}.col-lg-pull-6{right:50%}.col-lg-pull-5{right:41.66666667%}.col-lg-pull-4{right:33.33333333%}.col-lg-pull-3{right:25%}.col-lg-pull-2{right:16.66666667%}.col-lg-pull-1{right:8.33333333%}.col-lg-pull-0{right:auto}.col-lg-push-12{left:100%}.col-lg-push-11{left:91.66666667%}.col-lg-push-10{left:83.33333333%}.col-lg-push-9{left:75%}.col-lg-push-8{left:66.66666667%}.col-lg-push-7{left:58.33333333%}.col-lg-push-6{left:50%}.col-lg-push-5{left:41.66666667%}.col-lg-push-4{left:33.33333333%}.col-lg-push-3{left:25%}.col-lg-push-2{left:16.66666667%}.col-lg-push-1{left:8.33333333%}.col-lg-push-0{left:auto}.col-lg-offset-12{margin-left:100%}.col-lg-offset-11{margin-left:91.66666667%}.col-lg-offset-10{margin-left:83.33333333%}.col-lg-offset-9{margin-left:75%}.col-lg-offset-8{margin-left:66.66666667%}.col-lg-offset-7{margin-left:58.33333333%}.col-lg-offset-6{margin-left:50%}.col-lg-offset-5{margin-left:41.66666667%}.col-lg-offset-4{margin-left:33.33333333%}.col-lg-offset-3{margin-left:25%}.col-lg-offset-2{margin-left:16.66666667%}.col-lg-offset-1{margin-left:8.33333333%}.col-lg-offset-0{margin-left:0%}}table{background-color:transparent}caption{padding-top:8px;padding-bottom:8px;color:#bbbbbb;text-align:left}th{}.table{width:100%;max-width:100%;margin-bottom:23px}.table>thead>tr>th,.table>tbody>tr>th,.table>tfoot>tr>th,.table>thead>tr>td,.table>tbody>tr>td,.table>tfoot>tr>td{padding:8px;line-height:1.846;vertical-align:top;border-top:1px solid #dddddd}.table>thead>tr>th{vertical-align:bottom;border-bottom:2px solid #dddddd}.table>caption+thead>tr:first-child>th,.table>colgroup+thead>tr:first-child>th,.table>thead:first-child>tr:first-child>th,.table>caption+thead>tr:first-child>td,.table>colgroup+thead>tr:first-child>td,.table>thead:first-child>tr:first-child>td{border-top:0}.table>tbody+tbody{border-top:2px solid #dddddd}.table .table{background-color:#ffffff}.table-condensed>thead>tr>th,.table-condensed>tbody>tr>th,.table-condensed>tfoot>tr>th,.table-condensed>thead>tr>td,.table-condensed>tbody>tr>td,.table-condensed>tfoot>tr>td{padding:5px}.table-bordered{border:1px solid #dddddd}.table-bordered>thead>tr>th,.table-bordered>tbody>tr>th,.table-bordered>tfoot>tr>th,.table-bordered>thead>tr>td,.table-bordered>tbody>tr>td,.table-bordered>tfoot>tr>td{border:1px solid #dddddd}.table-bordered>thead>tr>th,.table-bordered>thead>tr>td{border-bottom-width:2px}.table-striped>tbody>tr:nth-of-type(odd){background-color:#f9f9f9}.table-hover>tbody>tr:hover{background-color:#f5f5f5}table col[class*="col-"]{position:static;float:none;display:table-column}table td[class*="col-"],table th[class*="col-"]{position:static;float:none;display:table-cell}.table>thead>tr>td.active,.table>tbody>tr>td.active,.table>tfoot>tr>td.active,.table>thead>tr>th.active,.table>tbody>tr>th.active,.table>tfoot>tr>th.active,.table>thead>tr.active>td,.table>tbody>tr.active>td,.table>tfoot>tr.active>td,.table>thead>tr.active>th,.table>tbody>tr.active>th,.table>tfoot>tr.active>th{background-color:#f5f5f5}.table-hover>tbody>tr>td.active:hover,.table-hover>tbody>tr>th.active:hover,.table-hover>tbody>tr.active:hover>td,.table-hover>tbody>tr:hover>.active,.table-hover>tbody>tr.active:hover>th{background-color:#e8e8e8}.table>thead>tr>td.success,.table>tbody>tr>td.success,.table>tfoot>tr>td.success,.table>thead>tr>th.success,.table>tbody>tr>th.success,.table>tfoot>tr>th.success,.table>thead>tr.success>td,.table>tbody>tr.success>td,.table>tfoot>tr.success>td,.table>thead>tr.success>th,.table>tbody>tr.success>th,.table>tfoot>tr.success>th{background-color:#dff0d8}.table-hover>tbody>tr>td.success:hover,.table-hover>tbody>tr>th.success:hover,.table-hover>tbody>tr.success:hover>td,.table-hover>tbody>tr:hover>.success,.table-hover>tbody>tr.success:hover>th{background-color:#d0e9c6}.table>thead>tr>td.info,.table>tbody>tr>td.info,.table>tfoot>tr>td.info,.table>thead>tr>th.info,.table>tbody>tr>th.info,.table>tfoot>tr>th.info,.table>thead>tr.info>td,.table>tbody>tr.info>td,.table>tfoot>tr.info>td,.table>thead>tr.info>th,.table>tbody>tr.info>th,.table>tfoot>tr.info>th{background-color:#e1bee7}.table-hover>tbody>tr>td.info:hover,.table-hover>tbody>tr>th.info:hover,.table-hover>tbody>tr.info:hover>td,.table-hover>tbody>tr:hover>.info,.table-hover>tbody>tr.info:hover>th{background-color:#d8abe0}.table>thead>tr>td.warning,.table>tbody>tr>td.warning,.table>tfoot>tr>td.warning,.table>thead>tr>th.warning,.table>tbody>tr>th.warning,.table>tfoot>tr>th.warning,.table>thead>tr.warning>td,.table>tbody>tr.warning>td,.table>tfoot>tr.warning>td,.table>thead>tr.warning>th,.table>tbody>tr.warning>th,.table>tfoot>tr.warning>th{background-color:#ffe0b2}.table-hover>tbody>tr>td.warning:hover,.table-hover>tbody>tr>th.warning:hover,.table-hover>tbody>tr.warning:hover>td,.table-hover>tbody>tr:hover>.warning,.table-hover>tbody>tr.warning:hover>th{background-color:#ffd699}.table>thead>tr>td.danger,.table>tbody>tr>td.danger,.table>tfoot>tr>td.danger,.table>thead>tr>th.danger,.table>tbody>tr>th.danger,.table>tfoot>tr>th.danger,.table>thead>tr.danger>td,.table>tbody>tr.danger>td,.table>tfoot>tr.danger>td,.table>thead>tr.danger>th,.table>tbody>tr.danger>th,.table>tfoot>tr.danger>th{background-color:#f9bdbb}.table-hover>tbody>tr>td.danger:hover,.table-hover>tbody>tr>th.danger:hover,.table-hover>tbody>tr.danger:hover>td,.table-hover>tbody>tr:hover>.danger,.table-hover>tbody>tr.danger:hover>th{background-color:#f7a6a4}.table-responsive{overflow-x:auto;min-height:0.01%}@media screen and (max-width:767px){.table-responsive{width:100%;margin-bottom:17.25px;overflow-y:hidden;-ms-overflow-style:-ms-autohiding-scrollbar;border:1px solid #dddddd}.table-responsive>.table{margin-bottom:0}.table-responsive>.table>thead>tr>th,.table-responsive>.table>tbody>tr>th,.table-responsive>.table>tfoot>tr>th,.table-responsive>.table>thead>tr>td,.table-responsive>.table>tbody>tr>td,.table-responsive>.table>tfoot>tr>td{white-space:nowrap}.table-responsive>.table-bordered{border:0}.table-responsive>.table-bordered>thead>tr>th:first-child,.table-responsive>.table-bordered>tbody>tr>th:first-child,.table-responsive>.table-bordered>tfoot>tr>th:first-child,.table-responsive>.table-bordered>thead>tr>td:first-child,.table-responsive>.table-bordered>tbody>tr>td:first-child,.table-responsive>.table-bordered>tfoot>tr>td:first-child{border-left:0}.table-responsive>.table-bordered>thead>tr>th:last-child,.table-responsive>.table-bordered>tbody>tr>th:last-child,.table-responsive>.table-bordered>tfoot>tr>th:last-child,.table-responsive>.table-bordered>thead>tr>td:last-child,.table-responsive>.table-bordered>tbody>tr>td:last-child,.table-responsive>.table-bordered>tfoot>tr>td:last-child{border-right:0}.table-responsive>.table-bordered>tbody>tr:last-child>th,.table-responsive>.table-bordered>tfoot>tr:last-child>th,.table-responsive>.table-bordered>tbody>tr:last-child>td,.table-responsive>.table-bordered>tfoot>tr:last-child>td{border-bottom:0}}fieldset{padding:0;margin:0;border:0;min-width:0}legend{display:block;width:100%;padding:0;margin-bottom:23px;font-size:19.5px;line-height:inherit;color:#212121;border:0;border-bottom:1px solid #e5e5e5}label{display:inline-block;max-width:100%;margin-bottom:5px;font-weight:bold}input[type="search"]{-webkit-box-sizing:border-box;-moz-box-sizing:border-box;box-sizing:border-box}input[type="radio"],input[type="checkbox"]{margin:4px 0 0;margin-top:1px \9;line-height:normal}input[type="file"]{display:block}input[type="range"]{display:block;width:100%}select[multiple],select[size]{height:auto}input[type="file"]:focus,input[type="radio"]:focus,input[type="checkbox"]:focus{outline:thin dotted;outline:5px auto -webkit-focus-ring-color;outline-offset:-2px}output{display:block;padding-top:7px;font-size:13px;line-height:1.846;color:#666666}.form-control{display:block;width:100%;height:37px;padding:6px 16px;font-size:13px;line-height:1.846;color:#666666;background-color:transparent;background-image:none;border:1px solid transparent;border-radius:3px;-webkit-box-shadow:inset 0 1px 1px rgba(0,0,0,0.075);box-shadow:inset 0 1px 1px rgba(0,0,0,0.075);-webkit-transition:border-color ease-in-out .15s,-webkit-box-shadow ease-in-out .15s;-o-transition:border-color ease-in-out .15s,box-shadow ease-in-out .15s;transition:border-color ease-in-out .15s,box-shadow ease-in-out .15s}.form-control:focus{border-color:#66afe9;outline:0;-webkit-box-shadow:inset 0 1px 1px rgba(0,0,0,0.075),0 0 8px rgba(102,175,233,0.6);box-shadow:inset 0 1px 1px rgba(0,0,0,0.075),0 0 8px rgba(102,175,233,0.6)}.form-control::-moz-placeholder{color:#bbbbbb;opacity:1}.form-control:-ms-input-placeholder{color:#bbbbbb}.form-control::-webkit-input-placeholder{color:#bbbbbb}.form-control::-ms-expand{border:0;background-color:transparent}.form-control[disabled],.form-control[readonly],fieldset[disabled] .form-control{background-color:transparent;opacity:1}.form-control[disabled],fieldset[disabled] .form-control{cursor:not-allowed}textarea.form-control{height:auto}input[type="search"]{-webkit-appearance:none}@media screen and (-webkit-min-device-pixel-ratio:0){input[type="date"].form-control,input[type="time"].form-control,input[type="datetime-local"].form-control,input[type="month"].form-control{line-height:37px}input[type="date"].input-sm,input[type="time"].input-sm,input[type="datetime-local"].input-sm,input[type="month"].input-sm,.input-group-sm input[type="date"],.input-group-sm input[type="time"],.input-group-sm input[type="datetime-local"],.input-group-sm input[type="month"]{line-height:30px}input[type="date"].input-lg,input[type="time"].input-lg,input[type="datetime-local"].input-lg,input[type="month"].input-lg,.input-group-lg input[type="date"],.input-group-lg input[type="time"],.input-group-lg input[type="datetime-local"],.input-group-lg input[type="month"]{line-height:45px}}.form-group{margin-bottom:15px}.radio,.checkbox{position:relative;display:block;margin-top:10px;margin-bottom:10px}.radio label,.checkbox label{min-height:23px;padding-left:20px;margin-bottom:0;font-weight:normal;cursor:pointer}.radio input[type="radio"],.radio-inline input[type="radio"],.checkbox input[type="checkbox"],.checkbox-inline input[type="checkbox"]{position:absolute;margin-left:-20px;margin-top:4px \9}.radio+.radio,.checkbox+.checkbox{margin-top:-5px}.radio-inline,.checkbox-inline{position:relative;display:inline-block;padding-left:20px;margin-bottom:0;vertical-align:middle;font-weight:normal;cursor:pointer}.radio-inline+.radio-inline,.checkbox-inline+.checkbox-inline{margin-top:0;margin-left:10px}input[type="radio"][disabled],input[type="checkbox"][disabled],input[type="radio"].disabled,input[type="checkbox"].disabled,fieldset[disabled] input[type="radio"],fieldset[disabled] input[type="checkbox"]{cursor:not-allowed}.radio-inline.disabled,.checkbox-inline.disabled,fieldset[disabled] .radio-inline,fieldset[disabled] .checkbox-inline{cursor:not-allowed}.radio.disabled label,.checkbox.disabled label,fieldset[disabled] .radio label,fieldset[disabled] .checkbox label{cursor:not-allowed}.form-control-static{padding-top:7px;padding-bottom:7px;margin-bottom:0;min-height:36px}.form-control-static.input-lg,.form-control-static.input-sm{padding-left:0;padding-right:0}.input-sm{height:30px;padding:5px 10px;font-size:12px;line-height:1.5;border-radius:3px}select.input-sm{height:30px;line-height:30px}textarea.input-sm,select[multiple].input-sm{height:auto}.form-group-sm .form-control{height:30px;padding:5px 10px;font-size:12px;line-height:1.5;border-radius:3px}.form-group-sm select.form-control{height:30px;line-height:30px}.form-group-sm textarea.form-control,.form-group-sm select[multiple].form-control{height:auto}.form-group-sm .form-control-static{height:30px;min-height:35px;padding:6px 10px;font-size:12px;line-height:1.5}.input-lg{height:45px;padding:10px 16px;font-size:17px;line-height:1.3333333;border-radius:3px}select.input-lg{height:45px;line-height:45px}textarea.input-lg,select[multiple].input-lg{height:auto}.form-group-lg .form-control{height:45px;padding:10px 16px;font-size:17px;line-height:1.3333333;border-radius:3px}.form-group-lg select.form-control{height:45px;line-height:45px}.form-group-lg textarea.form-control,.form-group-lg select[multiple].form-control{height:auto}.form-group-lg .form-control-static{height:45px;min-height:40px;padding:11px 16px;font-size:17px;line-height:1.3333333}.has-feedback{position:relative}.has-feedback .form-control{padding-right:46.25px}.form-control-feedback{position:absolute;top:0;right:0;z-index:2;display:block;width:37px;height:37px;line-height:37px;text-align:center;pointer-events:none}.input-lg+.form-control-feedback,.input-group-lg+.form-control-feedback,.form-group-lg .form-control+.form-control-feedback{width:45px;height:45px;line-height:45px}.input-sm+.form-control-feedback,.input-group-sm+.form-control-feedback,.form-group-sm .form-control+.form-control-feedback{width:30px;height:30px;line-height:30px}.has-success .help-block,.has-success .control-label,.has-success .radio,.has-success .checkbox,.has-success .radio-inline,.has-success .checkbox-inline,.has-success.radio label,.has-success.checkbox label,.has-success.radio-inline label,.has-success.checkbox-inline label{color:#4caf50}.has-success .form-control{border-color:#4caf50;-webkit-box-shadow:inset 0 1px 1px rgba(0,0,0,0.075);box-shadow:inset 0 1px 1px rgba(0,0,0,0.075)}.has-success .form-control:focus{border-color:#3d8b40;-webkit-box-shadow:inset 0 1px 1px rgba(0,0,0,0.075),0 0 6px #92cf94;box-shadow:inset 0 1px 1px rgba(0,0,0,0.075),0 0 6px #92cf94}.has-success .input-group-addon{color:#4caf50;border-color:#4caf50;background-color:#dff0d8}.has-success .form-control-feedback{color:#4caf50}.has-warning .help-block,.has-warning .control-label,.has-warning .radio,.has-warning .checkbox,.has-warning .radio-inline,.has-warning .checkbox-inline,.has-warning.radio label,.has-warning.checkbox label,.has-warning.radio-inline label,.has-warning.checkbox-inline label{color:#ff9800}.has-warning .form-control{border-color:#ff9800;-webkit-box-shadow:inset 0 1px 1px rgba(0,0,0,0.075);box-shadow:inset 0 1px 1px rgba(0,0,0,0.075)}.has-warning .form-control:focus{border-color:#cc7a00;-webkit-box-shadow:inset 0 1px 1px rgba(0,0,0,0.075),0 0 6px #ffc166;box-shadow:inset 0 1px 1px rgba(0,0,0,0.075),0 0 6px #ffc166}.has-warning .input-group-addon{color:#ff9800;border-color:#ff9800;background-color:#ffe0b2}.has-warning .form-control-feedback{color:#ff9800}.has-error .help-block,.has-error .control-label,.has-error .radio,.has-error .checkbox,.has-error .radio-inline,.has-error .checkbox-inline,.has-error.radio label,.has-error.checkbox label,.has-error.radio-inline label,.has-error.checkbox-inline label{color:#e51c23}.has-error .form-control{border-color:#e51c23;-webkit-box-shadow:inset 0 1px 1px rgba(0,0,0,0.075);box-shadow:inset 0 1px 1px rgba(0,0,0,0.075)}.has-error .form-control:focus{border-color:#b9151b;-webkit-box-shadow:inset 0 1px 1px rgba(0,0,0,0.075),0 0 6px #ef787c;box-shadow:inset 0 1px 1px rgba(0,0,0,0.075),0 0 6px #ef787c}.has-error .input-group-addon{color:#e51c23;border-color:#e51c23;background-color:#f9bdbb}.has-error .form-control-feedback{color:#e51c23}.has-feedback label~.form-control-feedback{top:28px}.has-feedback label.sr-only~.form-control-feedback{top:0}.help-block{display:block;margin-top:5px;margin-bottom:10px;color:#a6a6a6}@media (min-width:768px){.form-inline .form-group{display:inline-block;margin-bottom:0;vertical-align:middle}.form-inline .form-control{display:inline-block;width:auto;vertical-align:middle}.form-inline .form-control-static{display:inline-block}.form-inline .input-group{display:inline-table;vertical-align:middle}.form-inline .input-group .input-group-addon,.form-inline .input-group .input-group-btn,.form-inline .input-group .form-control{width:auto}.form-inline .input-group>.form-control{width:100%}.form-inline .control-label{margin-bottom:0;vertical-align:middle}.form-inline .radio,.form-inline .checkbox{display:inline-block;margin-top:0;margin-bottom:0;vertical-align:middle}.form-inline .radio label,.form-inline .checkbox label{padding-left:0}.form-inline .radio input[type="radio"],.form-inline .checkbox input[type="checkbox"]{position:relative;margin-left:0}.form-inline .has-feedback .form-control-feedback{top:0}}.form-horizontal .radio,.form-horizontal .checkbox,.form-horizontal .radio-inline,.form-horizontal .checkbox-inline{margin-top:0;margin-bottom:0;padding-top:7px}.form-horizontal .radio,.form-horizontal .checkbox{min-height:30px}.form-horizontal .form-group{margin-left:-15px;margin-right:-15px}@media (min-width:768px){.form-horizontal .control-label{text-align:right;margin-bottom:0;padding-top:7px}}.form-horizontal .has-feedback .form-control-feedback{right:15px}@media (min-width:768px){.form-horizontal .form-group-lg .control-label{padding-top:11px;font-size:17px}}@media (min-width:768px){.form-horizontal .form-group-sm .control-label{padding-top:6px;font-size:12px}}.btn{display:inline-block;margin-bottom:0;font-weight:normal;text-align:center;vertical-align:middle;-ms-touch-action:manipulation;touch-action:manipulation;cursor:pointer;background-image:none;border:1px solid transparent;white-space:nowrap;padding:6px 16px;font-size:13px;line-height:1.846;border-radius:3px;-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none}.btn:focus,.btn:active:focus,.btn.active:focus,.btn.focus,.btn:active.focus,.btn.active.focus{outline:thin dotted;outline:5px auto -webkit-focus-ring-color;outline-offset:-2px}.btn:hover,.btn:focus,.btn.focus{color:#444444;text-decoration:none}.btn:active,.btn.active{outline:0;background-image:none;-webkit-box-shadow:inset 0 3px 5px rgba(0,0,0,0.125);box-shadow:inset 0 3px 5px rgba(0,0,0,0.125)}.btn.disabled,.btn[disabled],fieldset[disabled] .btn{cursor:not-allowed;opacity:0.65;filter:alpha(opacity=65);-webkit-box-shadow:none;box-shadow:none}a.btn.disabled,fieldset[disabled] a.btn{pointer-events:none}.btn-default{color:#444444;background-color:#ffffff;border-color:transparent}.btn-default:focus,.btn-default.focus{color:#444444;background-color:#e6e6e6;border-color:rgba(0,0,0,0)}.btn-default:hover{color:#444444;background-color:#e6e6e6;border-color:rgba(0,0,0,0)}.btn-default:active,.btn-default.active,.open>.dropdown-toggle.btn-default{color:#444444;background-color:#e6e6e6;border-color:rgba(0,0,0,0)}.btn-default:active:hover,.btn-default.active:hover,.open>.dropdown-toggle.btn-default:hover,.btn-default:active:focus,.btn-default.active:focus,.open>.dropdown-toggle.btn-default:focus,.btn-default:active.focus,.btn-default.active.focus,.open>.dropdown-toggle.btn-default.focus{color:#444444;background-color:#d4d4d4;border-color:rgba(0,0,0,0)}.btn-default:active,.btn-default.active,.open>.dropdown-toggle.btn-default{background-image:none}.btn-default.disabled:hover,.btn-default[disabled]:hover,fieldset[disabled] .btn-default:hover,.btn-default.disabled:focus,.btn-default[disabled]:focus,fieldset[disabled] .btn-default:focus,.btn-default.disabled.focus,.btn-default[disabled].focus,fieldset[disabled] .btn-default.focus{background-color:#ffffff;border-color:transparent}.btn-default .badge{color:#ffffff;background-color:#444444}.btn-primary{color:#ffffff;background-color:#2196f3;border-color:transparent}.btn-primary:focus,.btn-primary.focus{color:#ffffff;background-color:#0c7cd5;border-color:rgba(0,0,0,0)}.btn-primary:hover{color:#ffffff;background-color:#0c7cd5;border-color:rgba(0,0,0,0)}.btn-primary:active,.btn-primary.active,.open>.dropdown-toggle.btn-primary{color:#ffffff;background-color:#0c7cd5;border-color:rgba(0,0,0,0)}.btn-primary:active:hover,.btn-primary.active:hover,.open>.dropdown-toggle.btn-primary:hover,.btn-primary:active:focus,.btn-primary.active:focus,.open>.dropdown-toggle.btn-primary:focus,.btn-primary:active.focus,.btn-primary.active.focus,.open>.dropdown-toggle.btn-primary.focus{color:#ffffff;background-color:#0a68b4;border-color:rgba(0,0,0,0)}.btn-primary:active,.btn-primary.active,.open>.dropdown-toggle.btn-primary{background-image:none}.btn-primary.disabled:hover,.btn-primary[disabled]:hover,fieldset[disabled] .btn-primary:hover,.btn-primary.disabled:focus,.btn-primary[disabled]:focus,fieldset[disabled] .btn-primary:focus,.btn-primary.disabled.focus,.btn-primary[disabled].focus,fieldset[disabled] .btn-primary.focus{background-color:#2196f3;border-color:transparent}.btn-primary .badge{color:#2196f3;background-color:#ffffff}.btn-success{color:#ffffff;background-color:#4caf50;border-color:transparent}.btn-success:focus,.btn-success.focus{color:#ffffff;background-color:#3d8b40;border-color:rgba(0,0,0,0)}.btn-success:hover{color:#ffffff;background-color:#3d8b40;border-color:rgba(0,0,0,0)}.btn-success:active,.btn-success.active,.open>.dropdown-toggle.btn-success{color:#ffffff;background-color:#3d8b40;border-color:rgba(0,0,0,0)}.btn-success:active:hover,.btn-success.active:hover,.open>.dropdown-toggle.btn-success:hover,.btn-success:active:focus,.btn-success.active:focus,.open>.dropdown-toggle.btn-success:focus,.btn-success:active.focus,.btn-success.active.focus,.open>.dropdown-toggle.btn-success.focus{color:#ffffff;background-color:#327334;border-color:rgba(0,0,0,0)}.btn-success:active,.btn-success.active,.open>.dropdown-toggle.btn-success{background-image:none}.btn-success.disabled:hover,.btn-success[disabled]:hover,fieldset[disabled] .btn-success:hover,.btn-success.disabled:focus,.btn-success[disabled]:focus,fieldset[disabled] .btn-success:focus,.btn-success.disabled.focus,.btn-success[disabled].focus,fieldset[disabled] .btn-success.focus{background-color:#4caf50;border-color:transparent}.btn-success .badge{color:#4caf50;background-color:#ffffff}.btn-info{color:#ffffff;background-color:#9c27b0;border-color:transparent}.btn-info:focus,.btn-info.focus{color:#ffffff;background-color:#771e86;border-color:rgba(0,0,0,0)}.btn-info:hover{color:#ffffff;background-color:#771e86;border-color:rgba(0,0,0,0)}.btn-info:active,.btn-info.active,.open>.dropdown-toggle.btn-info{color:#ffffff;background-color:#771e86;border-color:rgba(0,0,0,0)}.btn-info:active:hover,.btn-info.active:hover,.open>.dropdown-toggle.btn-info:hover,.btn-info:active:focus,.btn-info.active:focus,.open>.dropdown-toggle.btn-info:focus,.btn-info:active.focus,.btn-info.active.focus,.open>.dropdown-toggle.btn-info.focus{color:#ffffff;background-color:#5d1769;border-color:rgba(0,0,0,0)}.btn-info:active,.btn-info.active,.open>.dropdown-toggle.btn-info{background-image:none}.btn-info.disabled:hover,.btn-info[disabled]:hover,fieldset[disabled] .btn-info:hover,.btn-info.disabled:focus,.btn-info[disabled]:focus,fieldset[disabled] .btn-info:focus,.btn-info.disabled.focus,.btn-info[disabled].focus,fieldset[disabled] .btn-info.focus{background-color:#9c27b0;border-color:transparent}.btn-info .badge{color:#9c27b0;background-color:#ffffff}.btn-warning{color:#ffffff;background-color:#ff9800;border-color:transparent}.btn-warning:focus,.btn-warning.focus{color:#ffffff;background-color:#cc7a00;border-color:rgba(0,0,0,0)}.btn-warning:hover{color:#ffffff;background-color:#cc7a00;border-color:rgba(0,0,0,0)}.btn-warning:active,.btn-warning.active,.open>.dropdown-toggle.btn-warning{color:#ffffff;background-color:#cc7a00;border-color:rgba(0,0,0,0)}.btn-warning:active:hover,.btn-warning.active:hover,.open>.dropdown-toggle.btn-warning:hover,.btn-warning:active:focus,.btn-warning.active:focus,.open>.dropdown-toggle.btn-warning:focus,.btn-warning:active.focus,.btn-warning.active.focus,.open>.dropdown-toggle.btn-warning.focus{color:#ffffff;background-color:#a86400;border-color:rgba(0,0,0,0)}.btn-warning:active,.btn-warning.active,.open>.dropdown-toggle.btn-warning{background-image:none}.btn-warning.disabled:hover,.btn-warning[disabled]:hover,fieldset[disabled] .btn-warning:hover,.btn-warning.disabled:focus,.btn-warning[disabled]:focus,fieldset[disabled] .btn-warning:focus,.btn-warning.disabled.focus,.btn-warning[disabled].focus,fieldset[disabled] .btn-warning.focus{background-color:#ff9800;border-color:transparent}.btn-warning .badge{color:#ff9800;background-color:#ffffff}.btn-danger{color:#ffffff;background-color:#e51c23;border-color:transparent}.btn-danger:focus,.btn-danger.focus{color:#ffffff;background-color:#b9151b;border-color:rgba(0,0,0,0)}.btn-danger:hover{color:#ffffff;background-color:#b9151b;border-color:rgba(0,0,0,0)}.btn-danger:active,.btn-danger.active,.open>.dropdown-toggle.btn-danger{color:#ffffff;background-color:#b9151b;border-color:rgba(0,0,0,0)}.btn-danger:active:hover,.btn-danger.active:hover,.open>.dropdown-toggle.btn-danger:hover,.btn-danger:active:focus,.btn-danger.active:focus,.open>.dropdown-toggle.btn-danger:focus,.btn-danger:active.focus,.btn-danger.active.focus,.open>.dropdown-toggle.btn-danger.focus{color:#ffffff;background-color:#991216;border-color:rgba(0,0,0,0)}.btn-danger:active,.btn-danger.active,.open>.dropdown-toggle.btn-danger{background-image:none}.btn-danger.disabled:hover,.btn-danger[disabled]:hover,fieldset[disabled] .btn-danger:hover,.btn-danger.disabled:focus,.btn-danger[disabled]:focus,fieldset[disabled] .btn-danger:focus,.btn-danger.disabled.focus,.btn-danger[disabled].focus,fieldset[disabled] .btn-danger.focus{background-color:#e51c23;border-color:transparent}.btn-danger .badge{color:#e51c23;background-color:#ffffff}.btn-link{color:#2196f3;font-weight:normal;border-radius:0}.btn-link,.btn-link:active,.btn-link.active,.btn-link[disabled],fieldset[disabled] .btn-link{background-color:transparent;-webkit-box-shadow:none;box-shadow:none}.btn-link,.btn-link:hover,.btn-link:focus,.btn-link:active{border-color:transparent}.btn-link:hover,.btn-link:focus{color:#0a6ebd;text-decoration:underline;background-color:transparent}.btn-link[disabled]:hover,fieldset[disabled] .btn-link:hover,.btn-link[disabled]:focus,fieldset[disabled] .btn-link:focus{color:#bbbbbb;text-decoration:none}.btn-lg,.btn-group-lg>.btn{padding:10px 16px;font-size:17px;line-height:1.3333333;border-radius:3px}.btn-sm,.btn-group-sm>.btn{padding:5px 10px;font-size:12px;line-height:1.5;border-radius:3px}.btn-xs,.btn-group-xs>.btn{padding:1px 5px;font-size:12px;line-height:1.5;border-radius:3px}.btn-block{display:block;width:100%}.btn-block+.btn-block{margin-top:5px}input[type="submit"].btn-block,input[type="reset"].btn-block,input[type="button"].btn-block{width:100%}.fade{opacity:0;-webkit-transition:opacity 0.15s linear;-o-transition:opacity 0.15s linear;transition:opacity 0.15s linear}.fade.in{opacity:1}.collapse{display:none}.collapse.in{display:block}tr.collapse.in{display:table-row}tbody.collapse.in{display:table-row-group}.collapsing{position:relative;height:0;overflow:hidden;-webkit-transition-property:height, visibility;-o-transition-property:height, visibility;transition-property:height, visibility;-webkit-transition-duration:0.35s;-o-transition-duration:0.35s;transition-duration:0.35s;-webkit-transition-timing-function:ease;-o-transition-timing-function:ease;transition-timing-function:ease}.caret{display:inline-block;width:0;height:0;margin-left:2px;vertical-align:middle;border-top:4px dashed;border-top:4px solid \9;border-right:4px solid transparent;border-left:4px solid transparent}.dropup,.dropdown{position:relative}.dropdown-toggle:focus{outline:0}.dropdown-menu{position:absolute;top:100%;left:0;z-index:1000;display:none;float:left;min-width:160px;padding:5px 0;margin:2px 0 0;list-style:none;font-size:13px;text-align:left;background-color:#ffffff;border:1px solid #cccccc;border:1px solid rgba(0,0,0,0.15);border-radius:3px;-webkit-box-shadow:0 6px 12px rgba(0,0,0,0.175);box-shadow:0 6px 12px rgba(0,0,0,0.175);-webkit-background-clip:padding-box;background-clip:padding-box}.dropdown-menu.pull-right{right:0;left:auto}.dropdown-menu .divider{height:1px;margin:10.5px 0;overflow:hidden;background-color:#e5e5e5}.dropdown-menu>li>a{display:block;padding:3px 20px;clear:both;font-weight:normal;line-height:1.846;color:#666666;white-space:nowrap}.dropdown-menu>li>a:hover,.dropdown-menu>li>a:focus{text-decoration:none;color:#141414;background-color:#eeeeee}.dropdown-menu>.active>a,.dropdown-menu>.active>a:hover,.dropdown-menu>.active>a:focus{color:#ffffff;text-decoration:none;outline:0;background-color:#2196f3}.dropdown-menu>.disabled>a,.dropdown-menu>.disabled>a:hover,.dropdown-menu>.disabled>a:focus{color:#bbbbbb}.dropdown-menu>.disabled>a:hover,.dropdown-menu>.disabled>a:focus{text-decoration:none;background-color:transparent;background-image:none;filter:progid:DXImageTransform.Microsoft.gradient(enabled=false);cursor:not-allowed}.open>.dropdown-menu{display:block}.open>a{outline:0}.dropdown-menu-right{left:auto;right:0}.dropdown-menu-left{left:0;right:auto}.dropdown-header{display:block;padding:3px 20px;font-size:12px;line-height:1.846;color:#bbbbbb;white-space:nowrap}.dropdown-backdrop{position:fixed;left:0;right:0;bottom:0;top:0;z-index:990}.pull-right>.dropdown-menu{right:0;left:auto}.dropup .caret,.navbar-fixed-bottom .dropdown .caret{border-top:0;border-bottom:4px dashed;border-bottom:4px solid \9;content:""}.dropup .dropdown-menu,.navbar-fixed-bottom .dropdown .dropdown-menu{top:auto;bottom:100%;margin-bottom:2px}@media (min-width:768px){.navbar-right .dropdown-menu{left:auto;right:0}.navbar-right .dropdown-menu-left{left:0;right:auto}}.btn-group,.btn-group-vertical{position:relative;display:inline-block;vertical-align:middle}.btn-group>.btn,.btn-group-vertical>.btn{position:relative;float:left}.btn-group>.btn:hover,.btn-group-vertical>.btn:hover,.btn-group>.btn:focus,.btn-group-vertical>.btn:focus,.btn-group>.btn:active,.btn-group-vertical>.btn:active,.btn-group>.btn.active,.btn-group-vertical>.btn.active{z-index:2}.btn-group .btn+.btn,.btn-group .btn+.btn-group,.btn-group .btn-group+.btn,.btn-group .btn-group+.btn-group{margin-left:-1px}.btn-toolbar{margin-left:-5px}.btn-toolbar .btn,.btn-toolbar .btn-group,.btn-toolbar .input-group{float:left}.btn-toolbar>.btn,.btn-toolbar>.btn-group,.btn-toolbar>.input-group{margin-left:5px}.btn-group>.btn:not(:first-child):not(:last-child):not(.dropdown-toggle){border-radius:0}.btn-group>.btn:first-child{margin-left:0}.btn-group>.btn:first-child:not(:last-child):not(.dropdown-toggle){border-bottom-right-radius:0;border-top-right-radius:0}.btn-group>.btn:last-child:not(:first-child),.btn-group>.dropdown-toggle:not(:first-child){border-bottom-left-radius:0;border-top-left-radius:0}.btn-group>.btn-group{float:left}.btn-group>.btn-group:not(:first-child):not(:last-child)>.btn{border-radius:0}.btn-group>.btn-group:first-child:not(:last-child)>.btn:last-child,.btn-group>.btn-group:first-child:not(:last-child)>.dropdown-toggle{border-bottom-right-radius:0;border-top-right-radius:0}.btn-group>.btn-group:last-child:not(:first-child)>.btn:first-child{border-bottom-left-radius:0;border-top-left-radius:0}.btn-group .dropdown-toggle:active,.btn-group.open .dropdown-toggle{outline:0}.btn-group>.btn+.dropdown-toggle{padding-left:8px;padding-right:8px}.btn-group>.btn-lg+.dropdown-toggle{padding-left:12px;padding-right:12px}.btn-group.open .dropdown-toggle{-webkit-box-shadow:inset 0 3px 5px rgba(0,0,0,0.125);box-shadow:inset 0 3px 5px rgba(0,0,0,0.125)}.btn-group.open .dropdown-toggle.btn-link{-webkit-box-shadow:none;box-shadow:none}.btn .caret{margin-left:0}.btn-lg .caret{border-width:5px 5px 0;border-bottom-width:0}.dropup .btn-lg .caret{border-width:0 5px 5px}.btn-group-vertical>.btn,.btn-group-vertical>.btn-group,.btn-group-vertical>.btn-group>.btn{display:block;float:none;width:100%;max-width:100%}.btn-group-vertical>.btn-group>.btn{float:none}.btn-group-vertical>.btn+.btn,.btn-group-vertical>.btn+.btn-group,.btn-group-vertical>.btn-group+.btn,.btn-group-vertical>.btn-group+.btn-group{margin-top:-1px;margin-left:0}.btn-group-vertical>.btn:not(:first-child):not(:last-child){border-radius:0}.btn-group-vertical>.btn:first-child:not(:last-child){border-top-right-radius:3px;border-top-left-radius:3px;border-bottom-right-radius:0;border-bottom-left-radius:0}.btn-group-vertical>.btn:last-child:not(:first-child){border-top-right-radius:0;border-top-left-radius:0;border-bottom-right-radius:3px;border-bottom-left-radius:3px}.btn-group-vertical>.btn-group:not(:first-child):not(:last-child)>.btn{border-radius:0}.btn-group-vertical>.btn-group:first-child:not(:last-child)>.btn:last-child,.btn-group-vertical>.btn-group:first-child:not(:last-child)>.dropdown-toggle{border-bottom-right-radius:0;border-bottom-left-radius:0}.btn-group-vertical>.btn-group:last-child:not(:first-child)>.btn:first-child{border-top-right-radius:0;border-top-left-radius:0}.btn-group-justified{display:table;width:100%;table-layout:fixed;border-collapse:separate}.btn-group-justified>.btn,.btn-group-justified>.btn-group{float:none;display:table-cell;width:1%}.btn-group-justified>.btn-group .btn{width:100%}.btn-group-justified>.btn-group .dropdown-menu{left:auto}[data-toggle="buttons"]>.btn input[type="radio"],[data-toggle="buttons"]>.btn-group>.btn input[type="radio"],[data-toggle="buttons"]>.btn input[type="checkbox"],[data-toggle="buttons"]>.btn-group>.btn input[type="checkbox"]{position:absolute;clip:rect(0, 0, 0, 0);pointer-events:none}.input-group{position:relative;display:table;border-collapse:separate}.input-group[class*="col-"]{float:none;padding-left:0;padding-right:0}.input-group .form-control{position:relative;z-index:2;float:left;width:100%;margin-bottom:0}.input-group .form-control:focus{z-index:3}.input-group-lg>.form-control,.input-group-lg>.input-group-addon,.input-group-lg>.input-group-btn>.btn{height:45px;padding:10px 16px;font-size:17px;line-height:1.3333333;border-radius:3px}select.input-group-lg>.form-control,select.input-group-lg>.input-group-addon,select.input-group-lg>.input-group-btn>.btn{height:45px;line-height:45px}textarea.input-group-lg>.form-control,textarea.input-group-lg>.input-group-addon,textarea.input-group-lg>.input-group-btn>.btn,select[multiple].input-group-lg>.form-control,select[multiple].input-group-lg>.input-group-addon,select[multiple].input-group-lg>.input-group-btn>.btn{height:auto}.input-group-sm>.form-control,.input-group-sm>.input-group-addon,.input-group-sm>.input-group-btn>.btn{height:30px;padding:5px 10px;font-size:12px;line-height:1.5;border-radius:3px}select.input-group-sm>.form-control,select.input-group-sm>.input-group-addon,select.input-group-sm>.input-group-btn>.btn{height:30px;line-height:30px}textarea.input-group-sm>.form-control,textarea.input-group-sm>.input-group-addon,textarea.input-group-sm>.input-group-btn>.btn,select[multiple].input-group-sm>.form-control,select[multiple].input-group-sm>.input-group-addon,select[multiple].input-group-sm>.input-group-btn>.btn{height:auto}.input-group-addon,.input-group-btn,.input-group .form-control{display:table-cell}.input-group-addon:not(:first-child):not(:last-child),.input-group-btn:not(:first-child):not(:last-child),.input-group .form-control:not(:first-child):not(:last-child){border-radius:0}.input-group-addon,.input-group-btn{width:1%;white-space:nowrap;vertical-align:middle}.input-group-addon{padding:6px 16px;font-size:13px;font-weight:normal;line-height:1;color:#666666;text-align:center;background-color:transparent;border:1px solid transparent;border-radius:3px}.input-group-addon.input-sm{padding:5px 10px;font-size:12px;border-radius:3px}.input-group-addon.input-lg{padding:10px 16px;font-size:17px;border-radius:3px}.input-group-addon input[type="radio"],.input-group-addon input[type="checkbox"]{margin-top:0}.input-group .form-control:first-child,.input-group-addon:first-child,.input-group-btn:first-child>.btn,.input-group-btn:first-child>.btn-group>.btn,.input-group-btn:first-child>.dropdown-toggle,.input-group-btn:last-child>.btn:not(:last-child):not(.dropdown-toggle),.input-group-btn:last-child>.btn-group:not(:last-child)>.btn{border-bottom-right-radius:0;border-top-right-radius:0}.input-group-addon:first-child{border-right:0}.input-group .form-control:last-child,.input-group-addon:last-child,.input-group-btn:last-child>.btn,.input-group-btn:last-child>.btn-group>.btn,.input-group-btn:last-child>.dropdown-toggle,.input-group-btn:first-child>.btn:not(:first-child),.input-group-btn:first-child>.btn-group:not(:first-child)>.btn{border-bottom-left-radius:0;border-top-left-radius:0}.input-group-addon:last-child{border-left:0}.input-group-btn{position:relative;font-size:0;white-space:nowrap}.input-group-btn>.btn{position:relative}.input-group-btn>.btn+.btn{margin-left:-1px}.input-group-btn>.btn:hover,.input-group-btn>.btn:focus,.input-group-btn>.btn:active{z-index:2}.input-group-btn:first-child>.btn,.input-group-btn:first-child>.btn-group{margin-right:-1px}.input-group-btn:last-child>.btn,.input-group-btn:last-child>.btn-group{z-index:2;margin-left:-1px}.nav{margin-bottom:0;padding-left:0;list-style:none}.nav>li{position:relative;display:block}.nav>li>a{position:relative;display:block;padding:10px 15px}.nav>li>a:hover,.nav>li>a:focus{text-decoration:none;background-color:#eeeeee}.nav>li.disabled>a{color:#bbbbbb}.nav>li.disabled>a:hover,.nav>li.disabled>a:focus{color:#bbbbbb;text-decoration:none;background-color:transparent;cursor:not-allowed}.nav .open>a,.nav .open>a:hover,.nav .open>a:focus{background-color:#eeeeee;border-color:#2196f3}.nav .nav-divider{height:1px;margin:10.5px 0;overflow:hidden;background-color:#e5e5e5}.nav>li>a>img{max-width:none}.nav-tabs{border-bottom:1px solid transparent}.nav-tabs>li{float:left;margin-bottom:-1px}.nav-tabs>li>a{margin-right:2px;line-height:1.846;border:1px solid transparent;border-radius:3px 3px 0 0}.nav-tabs>li>a:hover{border-color:#eeeeee #eeeeee transparent}.nav-tabs>li.active>a,.nav-tabs>li.active>a:hover,.nav-tabs>li.active>a:focus{color:#666666;background-color:transparent;border:1px solid transparent;border-bottom-color:transparent;cursor:default}.nav-tabs.nav-justified{width:100%;border-bottom:0}.nav-tabs.nav-justified>li{float:none}.nav-tabs.nav-justified>li>a{text-align:center;margin-bottom:5px}.nav-tabs.nav-justified>.dropdown .dropdown-menu{top:auto;left:auto}@media (min-width:768px){.nav-tabs.nav-justified>li{display:table-cell;width:1%}.nav-tabs.nav-justified>li>a{margin-bottom:0}}.nav-tabs.nav-justified>li>a{margin-right:0;border-radius:3px}.nav-tabs.nav-justified>.active>a,.nav-tabs.nav-justified>.active>a:hover,.nav-tabs.nav-justified>.active>a:focus{border:1px solid transparent}@media (min-width:768px){.nav-tabs.nav-justified>li>a{border-bottom:1px solid transparent;border-radius:3px 3px 0 0}.nav-tabs.nav-justified>.active>a,.nav-tabs.nav-justified>.active>a:hover,.nav-tabs.nav-justified>.active>a:focus{border-bottom-color:#ffffff}}.nav-pills>li{float:left}.nav-pills>li>a{border-radius:3px}.nav-pills>li+li{margin-left:2px}.nav-pills>li.active>a,.nav-pills>li.active>a:hover,.nav-pills>li.active>a:focus{color:#ffffff;background-color:#2196f3}.nav-stacked>li{float:none}.nav-stacked>li+li{margin-top:2px;margin-left:0}.nav-justified{width:100%}.nav-justified>li{float:none}.nav-justified>li>a{text-align:center;margin-bottom:5px}.nav-justified>.dropdown .dropdown-menu{top:auto;left:auto}@media (min-width:768px){.nav-justified>li{display:table-cell;width:1%}.nav-justified>li>a{margin-bottom:0}}.nav-tabs-justified{border-bottom:0}.nav-tabs-justified>li>a{margin-right:0;border-radius:3px}.nav-tabs-justified>.active>a,.nav-tabs-justified>.active>a:hover,.nav-tabs-justified>.active>a:focus{border:1px solid transparent}@media (min-width:768px){.nav-tabs-justified>li>a{border-bottom:1px solid transparent;border-radius:3px 3px 0 0}.nav-tabs-justified>.active>a,.nav-tabs-justified>.active>a:hover,.nav-tabs-justified>.active>a:focus{border-bottom-color:#ffffff}}.tab-content>.tab-pane{display:none}.tab-content>.active{display:block}.nav-tabs .dropdown-menu{margin-top:-1px;border-top-right-radius:0;border-top-left-radius:0}.navbar{position:relative;min-height:64px;margin-bottom:23px;border:1px solid transparent}@media (min-width:768px){.navbar{border-radius:3px}}@media (min-width:768px){.navbar-header{float:left}}.navbar-collapse{overflow-x:visible;padding-right:15px;padding-left:15px;border-top:1px solid transparent;-webkit-box-shadow:inset 0 1px 0 rgba(255,255,255,0.1);box-shadow:inset 0 1px 0 rgba(255,255,255,0.1);-webkit-overflow-scrolling:touch}.navbar-collapse.in{overflow-y:auto}@media (min-width:768px){.navbar-collapse{width:auto;border-top:0;-webkit-box-shadow:none;box-shadow:none}.navbar-collapse.collapse{display:block !important;height:auto !important;padding-bottom:0;overflow:visible !important}.navbar-collapse.in{overflow-y:visible}.navbar-fixed-top .navbar-collapse,.navbar-static-top .navbar-collapse,.navbar-fixed-bottom .navbar-collapse{padding-left:0;padding-right:0}}.navbar-fixed-top .navbar-collapse,.navbar-fixed-bottom .navbar-collapse{max-height:340px}@media (max-device-width:480px) and (orientation:landscape){.navbar-fixed-top .navbar-collapse,.navbar-fixed-bottom .navbar-collapse{max-height:200px}}.container>.navbar-header,.container-fluid>.navbar-header,.container>.navbar-collapse,.container-fluid>.navbar-collapse{margin-right:-15px;margin-left:-15px}@media (min-width:768px){.container>.navbar-header,.container-fluid>.navbar-header,.container>.navbar-collapse,.container-fluid>.navbar-collapse{margin-right:0;margin-left:0}}.navbar-static-top{z-index:1000;border-width:0 0 1px}@media (min-width:768px){.navbar-static-top{border-radius:0}}.navbar-fixed-top,.navbar-fixed-bottom{position:fixed;right:0;left:0;z-index:1030}@media (min-width:768px){.navbar-fixed-top,.navbar-fixed-bottom{border-radius:0}}.navbar-fixed-top{top:0;border-width:0 0 1px}.navbar-fixed-bottom{bottom:0;margin-bottom:0;border-width:1px 0 0}.navbar-brand{float:left;padding:20.5px 15px;font-size:17px;line-height:23px;height:64px}.navbar-brand:hover,.navbar-brand:focus{text-decoration:none}.navbar-brand>img{display:block}@media (min-width:768px){.navbar>.container .navbar-brand,.navbar>.container-fluid .navbar-brand{margin-left:-15px}}.navbar-toggle{position:relative;float:right;margin-right:15px;padding:9px 10px;margin-top:15px;margin-bottom:15px;background-color:transparent;background-image:none;border:1px solid transparent;border-radius:3px}.navbar-toggle:focus{outline:0}.navbar-toggle .icon-bar{display:block;width:22px;height:2px;border-radius:1px}.navbar-toggle .icon-bar+.icon-bar{margin-top:4px}@media (min-width:768px){.navbar-toggle{display:none}}.navbar-nav{margin:10.25px -15px}.navbar-nav>li>a{padding-top:10px;padding-bottom:10px;line-height:23px}@media (max-width:767px){.navbar-nav .open .dropdown-menu{position:static;float:none;width:auto;margin-top:0;background-color:transparent;border:0;-webkit-box-shadow:none;box-shadow:none}.navbar-nav .open .dropdown-menu>li>a,.navbar-nav .open .dropdown-menu .dropdown-header{padding:5px 15px 5px 25px}.navbar-nav .open .dropdown-menu>li>a{line-height:23px}.navbar-nav .open .dropdown-menu>li>a:hover,.navbar-nav .open .dropdown-menu>li>a:focus{background-image:none}}@media (min-width:768px){.navbar-nav{float:left;margin:0}.navbar-nav>li{float:left}.navbar-nav>li>a{padding-top:20.5px;padding-bottom:20.5px}}.navbar-form{margin-left:-15px;margin-right:-15px;padding:10px 15px;border-top:1px solid transparent;border-bottom:1px solid transparent;-webkit-box-shadow:inset 0 1px 0 rgba(255,255,255,0.1),0 1px 0 rgba(255,255,255,0.1);box-shadow:inset 0 1px 0 rgba(255,255,255,0.1),0 1px 0 rgba(255,255,255,0.1);margin-top:13.5px;margin-bottom:13.5px}@media (min-width:768px){.navbar-form .form-group{display:inline-block;margin-bottom:0;vertical-align:middle}.navbar-form .form-control{display:inline-block;width:auto;vertical-align:middle}.navbar-form .form-control-static{display:inline-block}.navbar-form .input-group{display:inline-table;vertical-align:middle}.navbar-form .input-group .input-group-addon,.navbar-form .input-group .input-group-btn,.navbar-form .input-group .form-control{width:auto}.navbar-form .input-group>.form-control{width:100%}.navbar-form .control-label{margin-bottom:0;vertical-align:middle}.navbar-form .radio,.navbar-form .checkbox{display:inline-block;margin-top:0;margin-bottom:0;vertical-align:middle}.navbar-form .radio label,.navbar-form .checkbox label{padding-left:0}.navbar-form .radio input[type="radio"],.navbar-form .checkbox input[type="checkbox"]{position:relative;margin-left:0}.navbar-form .has-feedback .form-control-feedback{top:0}}@media (max-width:767px){.navbar-form .form-group{margin-bottom:5px}.navbar-form .form-group:last-child{margin-bottom:0}}@media (min-width:768px){.navbar-form{width:auto;border:0;margin-left:0;margin-right:0;padding-top:0;padding-bottom:0;-webkit-box-shadow:none;box-shadow:none}}.navbar-nav>li>.dropdown-menu{margin-top:0;border-top-right-radius:0;border-top-left-radius:0}.navbar-fixed-bottom .navbar-nav>li>.dropdown-menu{margin-bottom:0;border-top-right-radius:3px;border-top-left-radius:3px;border-bottom-right-radius:0;border-bottom-left-radius:0}.navbar-btn{margin-top:13.5px;margin-bottom:13.5px}.navbar-btn.btn-sm{margin-top:17px;margin-bottom:17px}.navbar-btn.btn-xs{margin-top:21px;margin-bottom:21px}.navbar-text{margin-top:20.5px;margin-bottom:20.5px}@media (min-width:768px){.navbar-text{float:left;margin-left:15px;margin-right:15px}}@media (min-width:768px){.navbar-left{float:left !important}.navbar-right{float:right !important;margin-right:-15px}.navbar-right~.navbar-right{margin-right:0}}.navbar-default{background-color:#ffffff;border-color:transparent}.navbar-default .navbar-brand{color:#666666}.navbar-default .navbar-brand:hover,.navbar-default .navbar-brand:focus{color:#212121;background-color:transparent}.navbar-default .navbar-text{color:#bbbbbb}.navbar-default .navbar-nav>li>a{color:#666666}.navbar-default .navbar-nav>li>a:hover,.navbar-default .navbar-nav>li>a:focus{color:#212121;background-color:transparent}.navbar-default .navbar-nav>.active>a,.navbar-default .navbar-nav>.active>a:hover,.navbar-default .navbar-nav>.active>a:focus{color:#212121;background-color:#eeeeee}.navbar-default .navbar-nav>.disabled>a,.navbar-default .navbar-nav>.disabled>a:hover,.navbar-default .navbar-nav>.disabled>a:focus{color:#cccccc;background-color:transparent}.navbar-default .navbar-toggle{border-color:transparent}.navbar-default .navbar-toggle:hover,.navbar-default .navbar-toggle:focus{background-color:transparent}.navbar-default .navbar-toggle .icon-bar{background-color:rgba(0,0,0,0.5)}.navbar-default .navbar-collapse,.navbar-default .navbar-form{border-color:transparent}.navbar-default .navbar-nav>.open>a,.navbar-default .navbar-nav>.open>a:hover,.navbar-default .navbar-nav>.open>a:focus{background-color:#eeeeee;color:#212121}@media (max-width:767px){.navbar-default .navbar-nav .open .dropdown-menu>li>a{color:#666666}.navbar-default .navbar-nav .open .dropdown-menu>li>a:hover,.navbar-default .navbar-nav .open .dropdown-menu>li>a:focus{color:#212121;background-color:transparent}.navbar-default .navbar-nav .open .dropdown-menu>.active>a,.navbar-default .navbar-nav .open .dropdown-menu>.active>a:hover,.navbar-default .navbar-nav .open .dropdown-menu>.active>a:focus{color:#212121;background-color:#eeeeee}.navbar-default .navbar-nav .open .dropdown-menu>.disabled>a,.navbar-default .navbar-nav .open .dropdown-menu>.disabled>a:hover,.navbar-default .navbar-nav .open .dropdown-menu>.disabled>a:focus{color:#cccccc;background-color:transparent}}.navbar-default .navbar-link{color:#666666}.navbar-default .navbar-link:hover{color:#212121}.navbar-default .btn-link{color:#666666}.navbar-default .btn-link:hover,.navbar-default .btn-link:focus{color:#212121}.navbar-default .btn-link[disabled]:hover,fieldset[disabled] .navbar-default .btn-link:hover,.navbar-default .btn-link[disabled]:focus,fieldset[disabled] .navbar-default .btn-link:focus{color:#cccccc}.navbar-inverse{background-color:#2196f3;border-color:transparent}.navbar-inverse .navbar-brand{color:#b2dbfb}.navbar-inverse .navbar-brand:hover,.navbar-inverse .navbar-brand:focus{color:#ffffff;background-color:transparent}.navbar-inverse .navbar-text{color:#bbbbbb}.navbar-inverse .navbar-nav>li>a{color:#b2dbfb}.navbar-inverse .navbar-nav>li>a:hover,.navbar-inverse .navbar-nav>li>a:focus{color:#ffffff;background-color:transparent}.navbar-inverse .navbar-nav>.active>a,.navbar-inverse .navbar-nav>.active>a:hover,.navbar-inverse .navbar-nav>.active>a:focus{color:#ffffff;background-color:#0c7cd5}.navbar-inverse .navbar-nav>.disabled>a,.navbar-inverse .navbar-nav>.disabled>a:hover,.navbar-inverse .navbar-nav>.disabled>a:focus{color:#444444;background-color:transparent}.navbar-inverse .navbar-toggle{border-color:transparent}.navbar-inverse .navbar-toggle:hover,.navbar-inverse .navbar-toggle:focus{background-color:transparent}.navbar-inverse .navbar-toggle .icon-bar{background-color:rgba(0,0,0,0.5)}.navbar-inverse .navbar-collapse,.navbar-inverse .navbar-form{border-color:#0c84e4}.navbar-inverse .navbar-nav>.open>a,.navbar-inverse .navbar-nav>.open>a:hover,.navbar-inverse .navbar-nav>.open>a:focus{background-color:#0c7cd5;color:#ffffff}@media (max-width:767px){.navbar-inverse .navbar-nav .open .dropdown-menu>.dropdown-header{border-color:transparent}.navbar-inverse .navbar-nav .open .dropdown-menu .divider{background-color:transparent}.navbar-inverse .navbar-nav .open .dropdown-menu>li>a{color:#b2dbfb}.navbar-inverse .navbar-nav .open .dropdown-menu>li>a:hover,.navbar-inverse .navbar-nav .open .dropdown-menu>li>a:focus{color:#ffffff;background-color:transparent}.navbar-inverse .navbar-nav .open .dropdown-menu>.active>a,.navbar-inverse .navbar-nav .open .dropdown-menu>.active>a:hover,.navbar-inverse .navbar-nav .open .dropdown-menu>.active>a:focus{color:#ffffff;background-color:#0c7cd5}.navbar-inverse .navbar-nav .open .dropdown-menu>.disabled>a,.navbar-inverse .navbar-nav .open .dropdown-menu>.disabled>a:hover,.navbar-inverse .navbar-nav .open .dropdown-menu>.disabled>a:focus{color:#444444;background-color:transparent}}.navbar-inverse .navbar-link{color:#b2dbfb}.navbar-inverse .navbar-link:hover{color:#ffffff}.navbar-inverse .btn-link{color:#b2dbfb}.navbar-inverse .btn-link:hover,.navbar-inverse .btn-link:focus{color:#ffffff}.navbar-inverse .btn-link[disabled]:hover,fieldset[disabled] .navbar-inverse .btn-link:hover,.navbar-inverse .btn-link[disabled]:focus,fieldset[disabled] .navbar-inverse .btn-link:focus{color:#444444}.breadcrumb{padding:8px 15px;margin-bottom:23px;list-style:none;background-color:#f5f5f5;border-radius:3px}.breadcrumb>li{display:inline-block}.breadcrumb>li+li:before{content:"/\00a0";padding:0 5px;color:#cccccc}.breadcrumb>.active{color:#bbbbbb}.pagination{display:inline-block;padding-left:0;margin:23px 0;border-radius:3px}.pagination>li{display:inline}.pagination>li>a,.pagination>li>span{position:relative;float:left;padding:6px 16px;line-height:1.846;text-decoration:none;color:#2196f3;background-color:#ffffff;border:1px solid #dddddd;margin-left:-1px}.pagination>li:first-child>a,.pagination>li:first-child>span{margin-left:0;border-bottom-left-radius:3px;border-top-left-radius:3px}.pagination>li:last-child>a,.pagination>li:last-child>span{border-bottom-right-radius:3px;border-top-right-radius:3px}.pagination>li>a:hover,.pagination>li>span:hover,.pagination>li>a:focus,.pagination>li>span:focus{z-index:2;color:#0a6ebd;background-color:#eeeeee;border-color:#dddddd}.pagination>.active>a,.pagination>.active>span,.pagination>.active>a:hover,.pagination>.active>span:hover,.pagination>.active>a:focus,.pagination>.active>span:focus{z-index:3;color:#ffffff;background-color:#2196f3;border-color:#2196f3;cursor:default}.pagination>.disabled>span,.pagination>.disabled>span:hover,.pagination>.disabled>span:focus,.pagination>.disabled>a,.pagination>.disabled>a:hover,.pagination>.disabled>a:focus{color:#bbbbbb;background-color:#ffffff;border-color:#dddddd;cursor:not-allowed}.pagination-lg>li>a,.pagination-lg>li>span{padding:10px 16px;font-size:17px;line-height:1.3333333}.pagination-lg>li:first-child>a,.pagination-lg>li:first-child>span{border-bottom-left-radius:3px;border-top-left-radius:3px}.pagination-lg>li:last-child>a,.pagination-lg>li:last-child>span{border-bottom-right-radius:3px;border-top-right-radius:3px}.pagination-sm>li>a,.pagination-sm>li>span{padding:5px 10px;font-size:12px;line-height:1.5}.pagination-sm>li:first-child>a,.pagination-sm>li:first-child>span{border-bottom-left-radius:3px;border-top-left-radius:3px}.pagination-sm>li:last-child>a,.pagination-sm>li:last-child>span{border-bottom-right-radius:3px;border-top-right-radius:3px}.pager{padding-left:0;margin:23px 0;list-style:none;text-align:center}.pager li{display:inline}.pager li>a,.pager li>span{display:inline-block;padding:5px 14px;background-color:#ffffff;border:1px solid #dddddd;border-radius:15px}.pager li>a:hover,.pager li>a:focus{text-decoration:none;background-color:#eeeeee}.pager .next>a,.pager .next>span{float:right}.pager .previous>a,.pager .previous>span{float:left}.pager .disabled>a,.pager .disabled>a:hover,.pager .disabled>a:focus,.pager .disabled>span{color:#bbbbbb;background-color:#ffffff;cursor:not-allowed}.label{display:inline;padding:.2em .6em .3em;font-size:75%;font-weight:bold;line-height:1;color:#ffffff;text-align:center;white-space:nowrap;vertical-align:baseline;border-radius:.25em}a.label:hover,a.label:focus{color:#ffffff;text-decoration:none;cursor:pointer}.label:empty{display:none}.btn .label{position:relative;top:-1px}.label-default{background-color:#bbbbbb}.label-default[href]:hover,.label-default[href]:focus{background-color:#a2a2a2}.label-primary{background-color:#2196f3}.label-primary[href]:hover,.label-primary[href]:focus{background-color:#0c7cd5}.label-success{background-color:#4caf50}.label-success[href]:hover,.label-success[href]:focus{background-color:#3d8b40}.label-info{background-color:#9c27b0}.label-info[href]:hover,.label-info[href]:focus{background-color:#771e86}.label-warning{background-color:#ff9800}.label-warning[href]:hover,.label-warning[href]:focus{background-color:#cc7a00}.label-danger{background-color:#e51c23}.label-danger[href]:hover,.label-danger[href]:focus{background-color:#b9151b}.badge{display:inline-block;min-width:10px;padding:3px 7px;font-size:12px;font-weight:normal;color:#ffffff;line-height:1;vertical-align:middle;white-space:nowrap;text-align:center;background-color:#bbbbbb;border-radius:10px}.badge:empty{display:none}.btn .badge{position:relative;top:-1px}.btn-xs .badge,.btn-group-xs>.btn .badge{top:0;padding:1px 5px}a.badge:hover,a.badge:focus{color:#ffffff;text-decoration:none;cursor:pointer}.list-group-item.active>.badge,.nav-pills>.active>a>.badge{color:#2196f3;background-color:#ffffff}.list-group-item>.badge{float:right}.list-group-item>.badge+.badge{margin-right:5px}.nav-pills>li>a>.badge{margin-left:3px}.jumbotron{padding-top:30px;padding-bottom:30px;margin-bottom:30px;color:inherit;background-color:#f9f9f9}.jumbotron h1,.jumbotron .h1{color:#444444}.jumbotron p{margin-bottom:15px;font-size:20px;font-weight:200}.jumbotron>hr{border-top-color:#e0e0e0}.container .jumbotron,.container-fluid .jumbotron{border-radius:3px;padding-left:15px;padding-right:15px}.jumbotron .container{max-width:100%}@media screen and (min-width:768px){.jumbotron{padding-top:48px;padding-bottom:48px}.container .jumbotron,.container-fluid .jumbotron{padding-left:60px;padding-right:60px}.jumbotron h1,.jumbotron .h1{font-size:59px}}.thumbnail{display:block;padding:4px;margin-bottom:23px;line-height:1.846;background-color:#ffffff;border:1px solid #dddddd;border-radius:3px;-webkit-transition:border .2s ease-in-out;-o-transition:border .2s ease-in-out;transition:border .2s ease-in-out}.thumbnail>img,.thumbnail a>img{margin-left:auto;margin-right:auto}a.thumbnail:hover,a.thumbnail:focus,a.thumbnail.active{border-color:#2196f3}.thumbnail .caption{padding:9px;color:#666666}.alert{padding:15px;margin-bottom:23px;border:1px solid transparent;border-radius:3px}.alert h4{margin-top:0;color:inherit}.alert .alert-link{font-weight:bold}.alert>p,.alert>ul{margin-bottom:0}.alert>p+p{margin-top:5px}.alert-dismissable,.alert-dismissible{padding-right:35px}.alert-dismissable .close,.alert-dismissible .close{position:relative;top:-2px;right:-21px;color:inherit}.alert-success{background-color:#dff0d8;border-color:#d6e9c6;color:#4caf50}.alert-success hr{border-top-color:#c9e2b3}.alert-success .alert-link{color:#3d8b40}.alert-info{background-color:#e1bee7;border-color:#cba4dd;color:#9c27b0}.alert-info hr{border-top-color:#c191d6}.alert-info .alert-link{color:#771e86}.alert-warning{background-color:#ffe0b2;border-color:#ffc599;color:#ff9800}.alert-warning hr{border-top-color:#ffb67f}.alert-warning .alert-link{color:#cc7a00}.alert-danger{background-color:#f9bdbb;border-color:#f7a4af;color:#e51c23}.alert-danger hr{border-top-color:#f58c9a}.alert-danger .alert-link{color:#b9151b}@-webkit-keyframes progress-bar-stripes{from{background-position:40px 0}to{background-position:0 0}}@-o-keyframes progress-bar-stripes{from{background-position:40px 0}to{background-position:0 0}}@keyframes progress-bar-stripes{from{background-position:40px 0}to{background-position:0 0}}.progress{overflow:hidden;height:23px;margin-bottom:23px;background-color:#f5f5f5;border-radius:3px;-webkit-box-shadow:inset 0 1px 2px rgba(0,0,0,0.1);box-shadow:inset 0 1px 2px rgba(0,0,0,0.1)}.progress-bar{float:left;width:0%;height:100%;font-size:12px;line-height:23px;color:#ffffff;text-align:center;background-color:#2196f3;-webkit-box-shadow:inset 0 -1px 0 rgba(0,0,0,0.15);box-shadow:inset 0 -1px 0 rgba(0,0,0,0.15);-webkit-transition:width 0.6s ease;-o-transition:width 0.6s ease;transition:width 0.6s ease}.progress-striped .progress-bar,.progress-bar-striped{background-image:-webkit-linear-gradient(45deg, rgba(255,255,255,0.15) 25%, transparent 25%, transparent 50%, rgba(255,255,255,0.15) 50%, rgba(255,255,255,0.15) 75%, transparent 75%, transparent);background-image:-o-linear-gradient(45deg, rgba(255,255,255,0.15) 25%, transparent 25%, transparent 50%, rgba(255,255,255,0.15) 50%, rgba(255,255,255,0.15) 75%, transparent 75%, transparent);background-image:linear-gradient(45deg, rgba(255,255,255,0.15) 25%, transparent 25%, transparent 50%, rgba(255,255,255,0.15) 50%, rgba(255,255,255,0.15) 75%, transparent 75%, transparent);-webkit-background-size:40px 40px;background-size:40px 40px}.progress.active .progress-bar,.progress-bar.active{-webkit-animation:progress-bar-stripes 2s linear infinite;-o-animation:progress-bar-stripes 2s linear infinite;animation:progress-bar-stripes 2s linear infinite}.progress-bar-success{background-color:#4caf50}.progress-striped .progress-bar-success{background-image:-webkit-linear-gradient(45deg, rgba(255,255,255,0.15) 25%, transparent 25%, transparent 50%, rgba(255,255,255,0.15) 50%, rgba(255,255,255,0.15) 75%, transparent 75%, transparent);background-image:-o-linear-gradient(45deg, rgba(255,255,255,0.15) 25%, transparent 25%, transparent 50%, rgba(255,255,255,0.15) 50%, rgba(255,255,255,0.15) 75%, transparent 75%, transparent);background-image:linear-gradient(45deg, rgba(255,255,255,0.15) 25%, transparent 25%, transparent 50%, rgba(255,255,255,0.15) 50%, rgba(255,255,255,0.15) 75%, transparent 75%, transparent)}.progress-bar-info{background-color:#9c27b0}.progress-striped .progress-bar-info{background-image:-webkit-linear-gradient(45deg, rgba(255,255,255,0.15) 25%, transparent 25%, transparent 50%, rgba(255,255,255,0.15) 50%, rgba(255,255,255,0.15) 75%, transparent 75%, transparent);background-image:-o-linear-gradient(45deg, rgba(255,255,255,0.15) 25%, transparent 25%, transparent 50%, rgba(255,255,255,0.15) 50%, rgba(255,255,255,0.15) 75%, transparent 75%, transparent);background-image:linear-gradient(45deg, rgba(255,255,255,0.15) 25%, transparent 25%, transparent 50%, rgba(255,255,255,0.15) 50%, rgba(255,255,255,0.15) 75%, transparent 75%, transparent)}.progress-bar-warning{background-color:#ff9800}.progress-striped .progress-bar-warning{background-image:-webkit-linear-gradient(45deg, rgba(255,255,255,0.15) 25%, transparent 25%, transparent 50%, rgba(255,255,255,0.15) 50%, rgba(255,255,255,0.15) 75%, transparent 75%, transparent);background-image:-o-linear-gradient(45deg, rgba(255,255,255,0.15) 25%, transparent 25%, transparent 50%, rgba(255,255,255,0.15) 50%, rgba(255,255,255,0.15) 75%, transparent 75%, transparent);background-image:linear-gradient(45deg, rgba(255,255,255,0.15) 25%, transparent 25%, transparent 50%, rgba(255,255,255,0.15) 50%, rgba(255,255,255,0.15) 75%, transparent 75%, transparent)}.progress-bar-danger{background-color:#e51c23}.progress-striped .progress-bar-danger{background-image:-webkit-linear-gradient(45deg, rgba(255,255,255,0.15) 25%, transparent 25%, transparent 50%, rgba(255,255,255,0.15) 50%, rgba(255,255,255,0.15) 75%, transparent 75%, transparent);background-image:-o-linear-gradient(45deg, rgba(255,255,255,0.15) 25%, transparent 25%, transparent 50%, rgba(255,255,255,0.15) 50%, rgba(255,255,255,0.15) 75%, transparent 75%, transparent);background-image:linear-gradient(45deg, rgba(255,255,255,0.15) 25%, transparent 25%, transparent 50%, rgba(255,255,255,0.15) 50%, rgba(255,255,255,0.15) 75%, transparent 75%, transparent)}.media{margin-top:15px}.media:first-child{margin-top:0}.media,.media-body{zoom:1;overflow:hidden}.media-body{width:10000px}.media-object{display:block}.media-object.img-thumbnail{max-width:none}.media-right,.media>.pull-right{padding-left:10px}.media-left,.media>.pull-left{padding-right:10px}.media-left,.media-right,.media-body{display:table-cell;vertical-align:top}.media-middle{vertical-align:middle}.media-bottom{vertical-align:bottom}.media-heading{margin-top:0;margin-bottom:5px}.media-list{padding-left:0;list-style:none}.list-group{margin-bottom:20px;padding-left:0}.list-group-item{position:relative;display:block;padding:10px 15px;margin-bottom:-1px;background-color:#ffffff;border:1px solid #dddddd}.list-group-item:first-child{border-top-right-radius:3px;border-top-left-radius:3px}.list-group-item:last-child{margin-bottom:0;border-bottom-right-radius:3px;border-bottom-left-radius:3px}a.list-group-item,button.list-group-item{color:#555555}a.list-group-item .list-group-item-heading,button.list-group-item .list-group-item-heading{color:#333333}a.list-group-item:hover,button.list-group-item:hover,a.list-group-item:focus,button.list-group-item:focus{text-decoration:none;color:#555555;background-color:#f5f5f5}button.list-group-item{width:100%;text-align:left}.list-group-item.disabled,.list-group-item.disabled:hover,.list-group-item.disabled:focus{background-color:#eeeeee;color:#bbbbbb;cursor:not-allowed}.list-group-item.disabled .list-group-item-heading,.list-group-item.disabled:hover .list-group-item-heading,.list-group-item.disabled:focus .list-group-item-heading{color:inherit}.list-group-item.disabled .list-group-item-text,.list-group-item.disabled:hover .list-group-item-text,.list-group-item.disabled:focus .list-group-item-text{color:#bbbbbb}.list-group-item.active,.list-group-item.active:hover,.list-group-item.active:focus{z-index:2;color:#ffffff;background-color:#2196f3;border-color:#2196f3}.list-group-item.active .list-group-item-heading,.list-group-item.active:hover .list-group-item-heading,.list-group-item.active:focus .list-group-item-heading,.list-group-item.active .list-group-item-heading>small,.list-group-item.active:hover .list-group-item-heading>small,.list-group-item.active:focus .list-group-item-heading>small,.list-group-item.active .list-group-item-heading>.small,.list-group-item.active:hover .list-group-item-heading>.small,.list-group-item.active:focus .list-group-item-heading>.small{color:inherit}.list-group-item.active .list-group-item-text,.list-group-item.active:hover .list-group-item-text,.list-group-item.active:focus .list-group-item-text{color:#e3f2fd}.list-group-item-success{color:#4caf50;background-color:#dff0d8}a.list-group-item-success,button.list-group-item-success{color:#4caf50}a.list-group-item-success .list-group-item-heading,button.list-group-item-success .list-group-item-heading{color:inherit}a.list-group-item-success:hover,button.list-group-item-success:hover,a.list-group-item-success:focus,button.list-group-item-success:focus{color:#4caf50;background-color:#d0e9c6}a.list-group-item-success.active,button.list-group-item-success.active,a.list-group-item-success.active:hover,button.list-group-item-success.active:hover,a.list-group-item-success.active:focus,button.list-group-item-success.active:focus{color:#fff;background-color:#4caf50;border-color:#4caf50}.list-group-item-info{color:#9c27b0;background-color:#e1bee7}a.list-group-item-info,button.list-group-item-info{color:#9c27b0}a.list-group-item-info .list-group-item-heading,button.list-group-item-info .list-group-item-heading{color:inherit}a.list-group-item-info:hover,button.list-group-item-info:hover,a.list-group-item-info:focus,button.list-group-item-info:focus{color:#9c27b0;background-color:#d8abe0}a.list-group-item-info.active,button.list-group-item-info.active,a.list-group-item-info.active:hover,button.list-group-item-info.active:hover,a.list-group-item-info.active:focus,button.list-group-item-info.active:focus{color:#fff;background-color:#9c27b0;border-color:#9c27b0}.list-group-item-warning{color:#ff9800;background-color:#ffe0b2}a.list-group-item-warning,button.list-group-item-warning{color:#ff9800}a.list-group-item-warning .list-group-item-heading,button.list-group-item-warning .list-group-item-heading{color:inherit}a.list-group-item-warning:hover,button.list-group-item-warning:hover,a.list-group-item-warning:focus,button.list-group-item-warning:focus{color:#ff9800;background-color:#ffd699}a.list-group-item-warning.active,button.list-group-item-warning.active,a.list-group-item-warning.active:hover,button.list-group-item-warning.active:hover,a.list-group-item-warning.active:focus,button.list-group-item-warning.active:focus{color:#fff;background-color:#ff9800;border-color:#ff9800}.list-group-item-danger{color:#e51c23;background-color:#f9bdbb}a.list-group-item-danger,button.list-group-item-danger{color:#e51c23}a.list-group-item-danger .list-group-item-heading,button.list-group-item-danger .list-group-item-heading{color:inherit}a.list-group-item-danger:hover,button.list-group-item-danger:hover,a.list-group-item-danger:focus,button.list-group-item-danger:focus{color:#e51c23;background-color:#f7a6a4}a.list-group-item-danger.active,button.list-group-item-danger.active,a.list-group-item-danger.active:hover,button.list-group-item-danger.active:hover,a.list-group-item-danger.active:focus,button.list-group-item-danger.active:focus{color:#fff;background-color:#e51c23;border-color:#e51c23}.list-group-item-heading{margin-top:0;margin-bottom:5px}.list-group-item-text{margin-bottom:0;line-height:1.3}.panel{margin-bottom:23px;background-color:#ffffff;border:1px solid transparent;border-radius:3px;-webkit-box-shadow:0 1px 1px rgba(0,0,0,0.05);box-shadow:0 1px 1px rgba(0,0,0,0.05)}.panel-body{padding:15px}.panel-heading{padding:10px 15px;border-bottom:1px solid transparent;border-top-right-radius:2px;border-top-left-radius:2px}.panel-heading>.dropdown .dropdown-toggle{color:inherit}.panel-title{margin-top:0;margin-bottom:0;font-size:15px;color:inherit}.panel-title>a,.panel-title>small,.panel-title>.small,.panel-title>small>a,.panel-title>.small>a{color:inherit}.panel-footer{padding:10px 15px;background-color:#f5f5f5;border-top:1px solid #dddddd;border-bottom-right-radius:2px;border-bottom-left-radius:2px}.panel>.list-group,.panel>.panel-collapse>.list-group{margin-bottom:0}.panel>.list-group .list-group-item,.panel>.panel-collapse>.list-group .list-group-item{border-width:1px 0;border-radius:0}.panel>.list-group:first-child .list-group-item:first-child,.panel>.panel-collapse>.list-group:first-child .list-group-item:first-child{border-top:0;border-top-right-radius:2px;border-top-left-radius:2px}.panel>.list-group:last-child .list-group-item:last-child,.panel>.panel-collapse>.list-group:last-child .list-group-item:last-child{border-bottom:0;border-bottom-right-radius:2px;border-bottom-left-radius:2px}.panel>.panel-heading+.panel-collapse>.list-group .list-group-item:first-child{border-top-right-radius:0;border-top-left-radius:0}.panel-heading+.list-group .list-group-item:first-child{border-top-width:0}.list-group+.panel-footer{border-top-width:0}.panel>.table,.panel>.table-responsive>.table,.panel>.panel-collapse>.table{margin-bottom:0}.panel>.table caption,.panel>.table-responsive>.table caption,.panel>.panel-collapse>.table caption{padding-left:15px;padding-right:15px}.panel>.table:first-child,.panel>.table-responsive:first-child>.table:first-child{border-top-right-radius:2px;border-top-left-radius:2px}.panel>.table:first-child>thead:first-child>tr:first-child,.panel>.table-responsive:first-child>.table:first-child>thead:first-child>tr:first-child,.panel>.table:first-child>tbody:first-child>tr:first-child,.panel>.table-responsive:first-child>.table:first-child>tbody:first-child>tr:first-child{border-top-left-radius:2px;border-top-right-radius:2px}.panel>.table:first-child>thead:first-child>tr:first-child td:first-child,.panel>.table-responsive:first-child>.table:first-child>thead:first-child>tr:first-child td:first-child,.panel>.table:first-child>tbody:first-child>tr:first-child td:first-child,.panel>.table-responsive:first-child>.table:first-child>tbody:first-child>tr:first-child td:first-child,.panel>.table:first-child>thead:first-child>tr:first-child th:first-child,.panel>.table-responsive:first-child>.table:first-child>thead:first-child>tr:first-child th:first-child,.panel>.table:first-child>tbody:first-child>tr:first-child th:first-child,.panel>.table-responsive:first-child>.table:first-child>tbody:first-child>tr:first-child th:first-child{border-top-left-radius:2px}.panel>.table:first-child>thead:first-child>tr:first-child td:last-child,.panel>.table-responsive:first-child>.table:first-child>thead:first-child>tr:first-child td:last-child,.panel>.table:first-child>tbody:first-child>tr:first-child td:last-child,.panel>.table-responsive:first-child>.table:first-child>tbody:first-child>tr:first-child td:last-child,.panel>.table:first-child>thead:first-child>tr:first-child th:last-child,.panel>.table-responsive:first-child>.table:first-child>thead:first-child>tr:first-child th:last-child,.panel>.table:first-child>tbody:first-child>tr:first-child th:last-child,.panel>.table-responsive:first-child>.table:first-child>tbody:first-child>tr:first-child th:last-child{border-top-right-radius:2px}.panel>.table:last-child,.panel>.table-responsive:last-child>.table:last-child{border-bottom-right-radius:2px;border-bottom-left-radius:2px}.panel>.table:last-child>tbody:last-child>tr:last-child,.panel>.table-responsive:last-child>.table:last-child>tbody:last-child>tr:last-child,.panel>.table:last-child>tfoot:last-child>tr:last-child,.panel>.table-responsive:last-child>.table:last-child>tfoot:last-child>tr:last-child{border-bottom-left-radius:2px;border-bottom-right-radius:2px}.panel>.table:last-child>tbody:last-child>tr:last-child td:first-child,.panel>.table-responsive:last-child>.table:last-child>tbody:last-child>tr:last-child td:first-child,.panel>.table:last-child>tfoot:last-child>tr:last-child td:first-child,.panel>.table-responsive:last-child>.table:last-child>tfoot:last-child>tr:last-child td:first-child,.panel>.table:last-child>tbody:last-child>tr:last-child th:first-child,.panel>.table-responsive:last-child>.table:last-child>tbody:last-child>tr:last-child th:first-child,.panel>.table:last-child>tfoot:last-child>tr:last-child th:first-child,.panel>.table-responsive:last-child>.table:last-child>tfoot:last-child>tr:last-child th:first-child{border-bottom-left-radius:2px}.panel>.table:last-child>tbody:last-child>tr:last-child td:last-child,.panel>.table-responsive:last-child>.table:last-child>tbody:last-child>tr:last-child td:last-child,.panel>.table:last-child>tfoot:last-child>tr:last-child td:last-child,.panel>.table-responsive:last-child>.table:last-child>tfoot:last-child>tr:last-child td:last-child,.panel>.table:last-child>tbody:last-child>tr:last-child th:last-child,.panel>.table-responsive:last-child>.table:last-child>tbody:last-child>tr:last-child th:last-child,.panel>.table:last-child>tfoot:last-child>tr:last-child th:last-child,.panel>.table-responsive:last-child>.table:last-child>tfoot:last-child>tr:last-child th:last-child{border-bottom-right-radius:2px}.panel>.panel-body+.table,.panel>.panel-body+.table-responsive,.panel>.table+.panel-body,.panel>.table-responsive+.panel-body{border-top:1px solid #dddddd}.panel>.table>tbody:first-child>tr:first-child th,.panel>.table>tbody:first-child>tr:first-child td{border-top:0}.panel>.table-bordered,.panel>.table-responsive>.table-bordered{border:0}.panel>.table-bordered>thead>tr>th:first-child,.panel>.table-responsive>.table-bordered>thead>tr>th:first-child,.panel>.table-bordered>tbody>tr>th:first-child,.panel>.table-responsive>.table-bordered>tbody>tr>th:first-child,.panel>.table-bordered>tfoot>tr>th:first-child,.panel>.table-responsive>.table-bordered>tfoot>tr>th:first-child,.panel>.table-bordered>thead>tr>td:first-child,.panel>.table-responsive>.table-bordered>thead>tr>td:first-child,.panel>.table-bordered>tbody>tr>td:first-child,.panel>.table-responsive>.table-bordered>tbody>tr>td:first-child,.panel>.table-bordered>tfoot>tr>td:first-child,.panel>.table-responsive>.table-bordered>tfoot>tr>td:first-child{border-left:0}.panel>.table-bordered>thead>tr>th:last-child,.panel>.table-responsive>.table-bordered>thead>tr>th:last-child,.panel>.table-bordered>tbody>tr>th:last-child,.panel>.table-responsive>.table-bordered>tbody>tr>th:last-child,.panel>.table-bordered>tfoot>tr>th:last-child,.panel>.table-responsive>.table-bordered>tfoot>tr>th:last-child,.panel>.table-bordered>thead>tr>td:last-child,.panel>.table-responsive>.table-bordered>thead>tr>td:last-child,.panel>.table-bordered>tbody>tr>td:last-child,.panel>.table-responsive>.table-bordered>tbody>tr>td:last-child,.panel>.table-bordered>tfoot>tr>td:last-child,.panel>.table-responsive>.table-bordered>tfoot>tr>td:last-child{border-right:0}.panel>.table-bordered>thead>tr:first-child>td,.panel>.table-responsive>.table-bordered>thead>tr:first-child>td,.panel>.table-bordered>tbody>tr:first-child>td,.panel>.table-responsive>.table-bordered>tbody>tr:first-child>td,.panel>.table-bordered>thead>tr:first-child>th,.panel>.table-responsive>.table-bordered>thead>tr:first-child>th,.panel>.table-bordered>tbody>tr:first-child>th,.panel>.table-responsive>.table-bordered>tbody>tr:first-child>th{border-bottom:0}.panel>.table-bordered>tbody>tr:last-child>td,.panel>.table-responsive>.table-bordered>tbody>tr:last-child>td,.panel>.table-bordered>tfoot>tr:last-child>td,.panel>.table-responsive>.table-bordered>tfoot>tr:last-child>td,.panel>.table-bordered>tbody>tr:last-child>th,.panel>.table-responsive>.table-bordered>tbody>tr:last-child>th,.panel>.table-bordered>tfoot>tr:last-child>th,.panel>.table-responsive>.table-bordered>tfoot>tr:last-child>th{border-bottom:0}.panel>.table-responsive{border:0;margin-bottom:0}.panel-group{margin-bottom:23px}.panel-group .panel{margin-bottom:0;border-radius:3px}.panel-group .panel+.panel{margin-top:5px}.panel-group .panel-heading{border-bottom:0}.panel-group .panel-heading+.panel-collapse>.panel-body,.panel-group .panel-heading+.panel-collapse>.list-group{border-top:1px solid #dddddd}.panel-group .panel-footer{border-top:0}.panel-group .panel-footer+.panel-collapse .panel-body{border-bottom:1px solid #dddddd}.panel-default{border-color:#dddddd}.panel-default>.panel-heading{color:#212121;background-color:#f5f5f5;border-color:#dddddd}.panel-default>.panel-heading+.panel-collapse>.panel-body{border-top-color:#dddddd}.panel-default>.panel-heading .badge{color:#f5f5f5;background-color:#212121}.panel-default>.panel-footer+.panel-collapse>.panel-body{border-bottom-color:#dddddd}.panel-primary{border-color:#2196f3}.panel-primary>.panel-heading{color:#ffffff;background-color:#2196f3;border-color:#2196f3}.panel-primary>.panel-heading+.panel-collapse>.panel-body{border-top-color:#2196f3}.panel-primary>.panel-heading .badge{color:#2196f3;background-color:#ffffff}.panel-primary>.panel-footer+.panel-collapse>.panel-body{border-bottom-color:#2196f3}.panel-success{border-color:#d6e9c6}.panel-success>.panel-heading{color:#ffffff;background-color:#4caf50;border-color:#d6e9c6}.panel-success>.panel-heading+.panel-collapse>.panel-body{border-top-color:#d6e9c6}.panel-success>.panel-heading .badge{color:#4caf50;background-color:#ffffff}.panel-success>.panel-footer+.panel-collapse>.panel-body{border-bottom-color:#d6e9c6}.panel-info{border-color:#cba4dd}.panel-info>.panel-heading{color:#ffffff;background-color:#9c27b0;border-color:#cba4dd}.panel-info>.panel-heading+.panel-collapse>.panel-body{border-top-color:#cba4dd}.panel-info>.panel-heading .badge{color:#9c27b0;background-color:#ffffff}.panel-info>.panel-footer+.panel-collapse>.panel-body{border-bottom-color:#cba4dd}.panel-warning{border-color:#ffc599}.panel-warning>.panel-heading{color:#ffffff;background-color:#ff9800;border-color:#ffc599}.panel-warning>.panel-heading+.panel-collapse>.panel-body{border-top-color:#ffc599}.panel-warning>.panel-heading .badge{color:#ff9800;background-color:#ffffff}.panel-warning>.panel-footer+.panel-collapse>.panel-body{border-bottom-color:#ffc599}.panel-danger{border-color:#f7a4af}.panel-danger>.panel-heading{color:#ffffff;background-color:#e51c23;border-color:#f7a4af}.panel-danger>.panel-heading+.panel-collapse>.panel-body{border-top-color:#f7a4af}.panel-danger>.panel-heading .badge{color:#e51c23;background-color:#ffffff}.panel-danger>.panel-footer+.panel-collapse>.panel-body{border-bottom-color:#f7a4af}.embed-responsive{position:relative;display:block;height:0;padding:0;overflow:hidden}.embed-responsive .embed-responsive-item,.embed-responsive iframe,.embed-responsive embed,.embed-responsive object,.embed-responsive video{position:absolute;top:0;left:0;bottom:0;height:100%;width:100%;border:0}.embed-responsive-16by9{padding-bottom:56.25%}.embed-responsive-4by3{padding-bottom:75%}.well{min-height:20px;padding:19px;margin-bottom:20px;background-color:#f9f9f9;border:1px solid transparent;border-radius:3px;-webkit-box-shadow:inset 0 1px 1px rgba(0,0,0,0.05);box-shadow:inset 0 1px 1px rgba(0,0,0,0.05)}.well blockquote{border-color:#ddd;border-color:rgba(0,0,0,0.15)}.well-lg{padding:24px;border-radius:3px}.well-sm{padding:9px;border-radius:3px}.close{float:right;font-size:19.5px;font-weight:normal;line-height:1;color:#000000;text-shadow:none;opacity:0.2;filter:alpha(opacity=20)}.close:hover,.close:focus{color:#000000;text-decoration:none;cursor:pointer;opacity:0.5;filter:alpha(opacity=50)}button.close{padding:0;cursor:pointer;background:transparent;border:0;-webkit-appearance:none}.modal-open{overflow:hidden}.modal{display:none;overflow:hidden;position:fixed;top:0;right:0;bottom:0;left:0;z-index:1050;-webkit-overflow-scrolling:touch;outline:0}.modal.fade .modal-dialog{-webkit-transform:translate(0, -25%);-ms-transform:translate(0, -25%);-o-transform:translate(0, -25%);transform:translate(0, -25%);-webkit-transition:-webkit-transform .3s ease-out;-o-transition:-o-transform .3s ease-out;transition:transform .3s ease-out}.modal.in .modal-dialog{-webkit-transform:translate(0, 0);-ms-transform:translate(0, 0);-o-transform:translate(0, 0);transform:translate(0, 0)}.modal-open .modal{overflow-x:hidden;overflow-y:auto}.modal-dialog{position:relative;width:auto;margin:10px}.modal-content{position:relative;background-color:#ffffff;border:1px solid #999999;border:1px solid transparent;border-radius:3px;-webkit-box-shadow:0 3px 9px rgba(0,0,0,0.5);box-shadow:0 3px 9px rgba(0,0,0,0.5);-webkit-background-clip:padding-box;background-clip:padding-box;outline:0}.modal-backdrop{position:fixed;top:0;right:0;bottom:0;left:0;z-index:1040;background-color:#000000}.modal-backdrop.fade{opacity:0;filter:alpha(opacity=0)}.modal-backdrop.in{opacity:0.5;filter:alpha(opacity=50)}.modal-header{padding:15px;border-bottom:1px solid transparent}.modal-header .close{margin-top:-2px}.modal-title{margin:0;line-height:1.846}.modal-body{position:relative;padding:15px}.modal-footer{padding:15px;text-align:right;border-top:1px solid transparent}.modal-footer .btn+.btn{margin-left:5px;margin-bottom:0}.modal-footer .btn-group .btn+.btn{margin-left:-1px}.modal-footer .btn-block+.btn-block{margin-left:0}.modal-scrollbar-measure{position:absolute;top:-9999px;width:50px;height:50px;overflow:scroll}@media (min-width:768px){.modal-dialog{width:600px;margin:30px auto}.modal-content{-webkit-box-shadow:0 5px 15px rgba(0,0,0,0.5);box-shadow:0 5px 15px rgba(0,0,0,0.5)}.modal-sm{width:300px}}@media (min-width:992px){.modal-lg{width:900px}}.tooltip{position:absolute;z-index:1070;display:block;font-family:"Roboto","Helvetica Neue",Helvetica,Arial,sans-serif;font-style:normal;font-weight:normal;letter-spacing:normal;line-break:auto;line-height:1.846;text-align:left;text-align:start;text-decoration:none;text-shadow:none;text-transform:none;white-space:normal;word-break:normal;word-spacing:normal;word-wrap:normal;font-size:12px;opacity:0;filter:alpha(opacity=0)}.tooltip.in{opacity:0.9;filter:alpha(opacity=90)}.tooltip.top{margin-top:-3px;padding:5px 0}.tooltip.right{margin-left:3px;padding:0 5px}.tooltip.bottom{margin-top:3px;padding:5px 0}.tooltip.left{margin-left:-3px;padding:0 5px}.tooltip-inner{max-width:200px;padding:3px 8px;color:#ffffff;text-align:center;background-color:#727272;border-radius:3px}.tooltip-arrow{position:absolute;width:0;height:0;border-color:transparent;border-style:solid}.tooltip.top .tooltip-arrow{bottom:0;left:50%;margin-left:-5px;border-width:5px 5px 0;border-top-color:#727272}.tooltip.top-left .tooltip-arrow{bottom:0;right:5px;margin-bottom:-5px;border-width:5px 5px 0;border-top-color:#727272}.tooltip.top-right .tooltip-arrow{bottom:0;left:5px;margin-bottom:-5px;border-width:5px 5px 0;border-top-color:#727272}.tooltip.right .tooltip-arrow{top:50%;left:0;margin-top:-5px;border-width:5px 5px 5px 0;border-right-color:#727272}.tooltip.left .tooltip-arrow{top:50%;right:0;margin-top:-5px;border-width:5px 0 5px 5px;border-left-color:#727272}.tooltip.bottom .tooltip-arrow{top:0;left:50%;margin-left:-5px;border-width:0 5px 5px;border-bottom-color:#727272}.tooltip.bottom-left .tooltip-arrow{top:0;right:5px;margin-top:-5px;border-width:0 5px 5px;border-bottom-color:#727272}.tooltip.bottom-right .tooltip-arrow{top:0;left:5px;margin-top:-5px;border-width:0 5px 5px;border-bottom-color:#727272}.popover{position:absolute;top:0;left:0;z-index:1060;display:none;max-width:276px;padding:1px;font-family:"Roboto","Helvetica Neue",Helvetica,Arial,sans-serif;font-style:normal;font-weight:normal;letter-spacing:normal;line-break:auto;line-height:1.846;text-align:left;text-align:start;text-decoration:none;text-shadow:none;text-transform:none;white-space:normal;word-break:normal;word-spacing:normal;word-wrap:normal;font-size:13px;background-color:#ffffff;-webkit-background-clip:padding-box;background-clip:padding-box;border:1px solid transparent;border-radius:3px;-webkit-box-shadow:0 5px 10px rgba(0,0,0,0.2);box-shadow:0 5px 10px rgba(0,0,0,0.2)}.popover.top{margin-top:-10px}.popover.right{margin-left:10px}.popover.bottom{margin-top:10px}.popover.left{margin-left:-10px}.popover-title{margin:0;padding:8px 14px;font-size:13px;background-color:#f7f7f7;border-bottom:1px solid #ebebeb;border-radius:2px 2px 0 0}.popover-content{padding:9px 14px}.popover>.arrow,.popover>.arrow:after{position:absolute;display:block;width:0;height:0;border-color:transparent;border-style:solid}.popover>.arrow{border-width:11px}.popover>.arrow:after{border-width:10px;content:""}.popover.top>.arrow{left:50%;margin-left:-11px;border-bottom-width:0;border-top-color:rgba(0,0,0,0);border-top-color:rgba(0,0,0,0.075);bottom:-11px}.popover.top>.arrow:after{content:" ";bottom:1px;margin-left:-10px;border-bottom-width:0;border-top-color:#ffffff}.popover.right>.arrow{top:50%;left:-11px;margin-top:-11px;border-left-width:0;border-right-color:rgba(0,0,0,0);border-right-color:rgba(0,0,0,0.075)}.popover.right>.arrow:after{content:" ";left:1px;bottom:-10px;border-left-width:0;border-right-color:#ffffff}.popover.bottom>.arrow{left:50%;margin-left:-11px;border-top-width:0;border-bottom-color:rgba(0,0,0,0);border-bottom-color:rgba(0,0,0,0.075);top:-11px}.popover.bottom>.arrow:after{content:" ";top:1px;margin-left:-10px;border-top-width:0;border-bottom-color:#ffffff}.popover.left>.arrow{top:50%;right:-11px;margin-top:-11px;border-right-width:0;border-left-color:rgba(0,0,0,0);border-left-color:rgba(0,0,0,0.075)}.popover.left>.arrow:after{content:" ";right:1px;border-right-width:0;border-left-color:#ffffff;bottom:-10px}.carousel{position:relative}.carousel-inner{position:relative;overflow:hidden;width:100%}.carousel-inner>.item{display:none;position:relative;-webkit-transition:.6s ease-in-out left;-o-transition:.6s ease-in-out left;transition:.6s ease-in-out left}.carousel-inner>.item>img,.carousel-inner>.item>a>img{line-height:1}@media all and (transform-3d),(-webkit-transform-3d){.carousel-inner>.item{-webkit-transition:-webkit-transform .6s ease-in-out;-o-transition:-o-transform .6s ease-in-out;transition:transform .6s ease-in-out;-webkit-backface-visibility:hidden;backface-visibility:hidden;-webkit-perspective:1000px;perspective:1000px}.carousel-inner>.item.next,.carousel-inner>.item.active.right{-webkit-transform:translate3d(100%, 0, 0);transform:translate3d(100%, 0, 0);left:0}.carousel-inner>.item.prev,.carousel-inner>.item.active.left{-webkit-transform:translate3d(-100%, 0, 0);transform:translate3d(-100%, 0, 0);left:0}.carousel-inner>.item.next.left,.carousel-inner>.item.prev.right,.carousel-inner>.item.active{-webkit-transform:translate3d(0, 0, 0);transform:translate3d(0, 0, 0);left:0}}.carousel-inner>.active,.carousel-inner>.next,.carousel-inner>.prev{display:block}.carousel-inner>.active{left:0}.carousel-inner>.next,.carousel-inner>.prev{position:absolute;top:0;width:100%}.carousel-inner>.next{left:100%}.carousel-inner>.prev{left:-100%}.carousel-inner>.next.left,.carousel-inner>.prev.right{left:0}.carousel-inner>.active.left{left:-100%}.carousel-inner>.active.right{left:100%}.carousel-control{position:absolute;top:0;left:0;bottom:0;width:15%;opacity:0.5;filter:alpha(opacity=50);font-size:20px;color:#ffffff;text-align:center;text-shadow:0 1px 2px rgba(0,0,0,0.6);background-color:rgba(0,0,0,0)}.carousel-control.left{background-image:-webkit-linear-gradient(left, rgba(0,0,0,0.5) 0, rgba(0,0,0,0.0001) 100%);background-image:-o-linear-gradient(left, rgba(0,0,0,0.5) 0, rgba(0,0,0,0.0001) 100%);background-image:-webkit-gradient(linear, left top, right top, from(rgba(0,0,0,0.5)), to(rgba(0,0,0,0.0001)));background-image:linear-gradient(to right, rgba(0,0,0,0.5) 0, rgba(0,0,0,0.0001) 100%);background-repeat:repeat-x;filter:progid:DXImageTransform.Microsoft.gradient(startColorstr='#80000000', endColorstr='#00000000', GradientType=1)}.carousel-control.right{left:auto;right:0;background-image:-webkit-linear-gradient(left, rgba(0,0,0,0.0001) 0, rgba(0,0,0,0.5) 100%);background-image:-o-linear-gradient(left, rgba(0,0,0,0.0001) 0, rgba(0,0,0,0.5) 100%);background-image:-webkit-gradient(linear, left top, right top, from(rgba(0,0,0,0.0001)), to(rgba(0,0,0,0.5)));background-image:linear-gradient(to right, rgba(0,0,0,0.0001) 0, rgba(0,0,0,0.5) 100%);background-repeat:repeat-x;filter:progid:DXImageTransform.Microsoft.gradient(startColorstr='#00000000', endColorstr='#80000000', GradientType=1)}.carousel-control:hover,.carousel-control:focus{outline:0;color:#ffffff;text-decoration:none;opacity:0.9;filter:alpha(opacity=90)}.carousel-control .icon-prev,.carousel-control .icon-next,.carousel-control .glyphicon-chevron-left,.carousel-control .glyphicon-chevron-right{position:absolute;top:50%;margin-top:-10px;z-index:5;display:inline-block}.carousel-control .icon-prev,.carousel-control .glyphicon-chevron-left{left:50%;margin-left:-10px}.carousel-control .icon-next,.carousel-control .glyphicon-chevron-right{right:50%;margin-right:-10px}.carousel-control .icon-prev,.carousel-control .icon-next{width:20px;height:20px;line-height:1;font-family:serif}.carousel-control .icon-prev:before{content:'\2039'}.carousel-control .icon-next:before{content:'\203a'}.carousel-indicators{position:absolute;bottom:10px;left:50%;z-index:15;width:60%;margin-left:-30%;padding-left:0;list-style:none;text-align:center}.carousel-indicators li{display:inline-block;width:10px;height:10px;margin:1px;text-indent:-999px;border:1px solid #ffffff;border-radius:10px;cursor:pointer;background-color:#000 \9;background-color:rgba(0,0,0,0)}.carousel-indicators .active{margin:0;width:12px;height:12px;background-color:#ffffff}.carousel-caption{position:absolute;left:15%;right:15%;bottom:20px;z-index:10;padding-top:20px;padding-bottom:20px;color:#ffffff;text-align:center;text-shadow:0 1px 2px rgba(0,0,0,0.6)}.carousel-caption .btn{text-shadow:none}@media screen and (min-width:768px){.carousel-control .glyphicon-chevron-left,.carousel-control .glyphicon-chevron-right,.carousel-control .icon-prev,.carousel-control .icon-next{width:30px;height:30px;margin-top:-10px;font-size:30px}.carousel-control .glyphicon-chevron-left,.carousel-control .icon-prev{margin-left:-10px}.carousel-control .glyphicon-chevron-right,.carousel-control .icon-next{margin-right:-10px}.carousel-caption{left:20%;right:20%;padding-bottom:30px}.carousel-indicators{bottom:20px}}.clearfix:before,.clearfix:after,.dl-horizontal dd:before,.dl-horizontal dd:after,.container:before,.container:after,.container-fluid:before,.container-fluid:after,.row:before,.row:after,.form-horizontal .form-group:before,.form-horizontal .form-group:after,.btn-toolbar:before,.btn-toolbar:after,.btn-group-vertical>.btn-group:before,.btn-group-vertical>.btn-group:after,.nav:before,.nav:after,.navbar:before,.navbar:after,.navbar-header:before,.navbar-header:after,.navbar-collapse:before,.navbar-collapse:after,.pager:before,.pager:after,.panel-body:before,.panel-body:after,.modal-header:before,.modal-header:after,.modal-footer:before,.modal-footer:after{content:" ";display:table}.clearfix:after,.dl-horizontal dd:after,.container:after,.container-fluid:after,.row:after,.form-horizontal .form-group:after,.btn-toolbar:after,.btn-group-vertical>.btn-group:after,.nav:after,.navbar:after,.navbar-header:after,.navbar-collapse:after,.pager:after,.panel-body:after,.modal-header:after,.modal-footer:after{clear:both}.center-block{display:block;margin-left:auto;margin-right:auto}.pull-right{float:right !important}.pull-left{float:left !important}.hide{display:none !important}.show{display:block !important}.invisible{visibility:hidden}.text-hide{font:0/0 a;color:transparent;text-shadow:none;background-color:transparent;border:0}.hidden{display:none !important}.affix{position:fixed}@-ms-viewport{width:device-width}.visible-xs,.visible-sm,.visible-md,.visible-lg{display:none !important}.visible-xs-block,.visible-xs-inline,.visible-xs-inline-block,.visible-sm-block,.visible-sm-inline,.visible-sm-inline-block,.visible-md-block,.visible-md-inline,.visible-md-inline-block,.visible-lg-block,.visible-lg-inline,.visible-lg-inline-block{display:none !important}@media (max-width:767px){.visible-xs{display:block !important}table.visible-xs{display:table !important}tr.visible-xs{display:table-row !important}th.visible-xs,td.visible-xs{display:table-cell !important}}@media (max-width:767px){.visible-xs-block{display:block !important}}@media (max-width:767px){.visible-xs-inline{display:inline !important}}@media (max-width:767px){.visible-xs-inline-block{display:inline-block !important}}@media (min-width:768px) and (max-width:991px){.visible-sm{display:block !important}table.visible-sm{display:table !important}tr.visible-sm{display:table-row !important}th.visible-sm,td.visible-sm{display:table-cell !important}}@media (min-width:768px) and (max-width:991px){.visible-sm-block{display:block !important}}@media (min-width:768px) and (max-width:991px){.visible-sm-inline{display:inline !important}}@media (min-width:768px) and (max-width:991px){.visible-sm-inline-block{display:inline-block !important}}@media (min-width:992px) and (max-width:1199px){.visible-md{display:block !important}table.visible-md{display:table !important}tr.visible-md{display:table-row !important}th.visible-md,td.visible-md{display:table-cell !important}}@media (min-width:992px) and (max-width:1199px){.visible-md-block{display:block !important}}@media (min-width:992px) and (max-width:1199px){.visible-md-inline{display:inline !important}}@media (min-width:992px) and (max-width:1199px){.visible-md-inline-block{display:inline-block !important}}@media (min-width:1200px){.visible-lg{display:block !important}table.visible-lg{display:table !important}tr.visible-lg{display:table-row !important}th.visible-lg,td.visible-lg{display:table-cell !important}}@media (min-width:1200px){.visible-lg-block{display:block !important}}@media (min-width:1200px){.visible-lg-inline{display:inline !important}}@media (min-width:1200px){.visible-lg-inline-block{display:inline-block !important}}@media (max-width:767px){.hidden-xs{display:none !important}}@media (min-width:768px) and (max-width:991px){.hidden-sm{display:none !important}}@media (min-width:992px) and (max-width:1199px){.hidden-md{display:none !important}}@media (min-width:1200px){.hidden-lg{display:none !important}}.visible-print{display:none !important}@media print{.visible-print{display:block !important}table.visible-print{display:table !important}tr.visible-print{display:table-row !important}th.visible-print,td.visible-print{display:table-cell !important}}.visible-print-block{display:none !important}@media print{.visible-print-block{display:block !important}}.visible-print-inline{display:none !important}@media print{.visible-print-inline{display:inline !important}}.visible-print-inline-block{display:none !important}@media print{.visible-print-inline-block{display:inline-block !important}}@media print{.hidden-print{display:none !important}}.navbar{border:none;-webkit-box-shadow:0 1px 2px rgba(0,0,0,0.3);box-shadow:0 1px 2px rgba(0,0,0,0.3)}.navbar-brand{font-size:24px}.navbar-inverse .navbar-form input[type=text],.navbar-inverse .navbar-form input[type=password]{color:#fff;-webkit-box-shadow:inset 0 -1px 0 #b2dbfb;box-shadow:inset 0 -1px 0 #b2dbfb}.navbar-inverse .navbar-form input[type=text]::-moz-placeholder,.navbar-inverse .navbar-form input[type=password]::-moz-placeholder{color:#b2dbfb;opacity:1}.navbar-inverse .navbar-form input[type=text]:-ms-input-placeholder,.navbar-inverse .navbar-form input[type=password]:-ms-input-placeholder{color:#b2dbfb}.navbar-inverse .navbar-form input[type=text]::-webkit-input-placeholder,.navbar-inverse .navbar-form input[type=password]::-webkit-input-placeholder{color:#b2dbfb}.navbar-inverse .navbar-form input[type=text]:focus,.navbar-inverse .navbar-form input[type=password]:focus{-webkit-box-shadow:inset 0 -2px 0 #fff;box-shadow:inset 0 -2px 0 #fff}.btn-default{-webkit-background-size:200% 200%;background-size:200%;background-position:50%}.btn-default:focus{background-color:#ffffff}.btn-default:hover,.btn-default:active:hover{background-color:#f0f0f0}.btn-default:active{background-color:#e0e0e0;background-image:-webkit-radial-gradient(circle, #e0e0e0 10%, #fff 11%);background-image:-o-radial-gradient(circle, #e0e0e0 10%, #fff 11%);background-image:radial-gradient(circle, #e0e0e0 10%, #fff 11%);background-repeat:no-repeat;-webkit-background-size:1000% 1000%;background-size:1000%;-webkit-box-shadow:2px 2px 4px rgba(0,0,0,0.4);box-shadow:2px 2px 4px rgba(0,0,0,0.4)}.btn-primary{-webkit-background-size:200% 200%;background-size:200%;background-position:50%}.btn-primary:focus{background-color:#2196f3}.btn-primary:hover,.btn-primary:active:hover{background-color:#0d87e9}.btn-primary:active{background-color:#0b76cc;background-image:-webkit-radial-gradient(circle, #0b76cc 10%, #2196f3 11%);background-image:-o-radial-gradient(circle, #0b76cc 10%, #2196f3 11%);background-image:radial-gradient(circle, #0b76cc 10%, #2196f3 11%);background-repeat:no-repeat;-webkit-background-size:1000% 1000%;background-size:1000%;-webkit-box-shadow:2px 2px 4px rgba(0,0,0,0.4);box-shadow:2px 2px 4px rgba(0,0,0,0.4)}.btn-success{-webkit-background-size:200% 200%;background-size:200%;background-position:50%}.btn-success:focus{background-color:#4caf50}.btn-success:hover,.btn-success:active:hover{background-color:#439a46}.btn-success:active{background-color:#39843c;background-image:-webkit-radial-gradient(circle, #39843c 10%, #4caf50 11%);background-image:-o-radial-gradient(circle, #39843c 10%, #4caf50 11%);background-image:radial-gradient(circle, #39843c 10%, #4caf50 11%);background-repeat:no-repeat;-webkit-background-size:1000% 1000%;background-size:1000%;-webkit-box-shadow:2px 2px 4px rgba(0,0,0,0.4);box-shadow:2px 2px 4px rgba(0,0,0,0.4)}.btn-info{-webkit-background-size:200% 200%;background-size:200%;background-position:50%}.btn-info:focus{background-color:#9c27b0}.btn-info:hover,.btn-info:active:hover{background-color:#862197}.btn-info:active{background-color:#701c7e;background-image:-webkit-radial-gradient(circle, #701c7e 10%, #9c27b0 11%);background-image:-o-radial-gradient(circle, #701c7e 10%, #9c27b0 11%);background-image:radial-gradient(circle, #701c7e 10%, #9c27b0 11%);background-repeat:no-repeat;-webkit-background-size:1000% 1000%;background-size:1000%;-webkit-box-shadow:2px 2px 4px rgba(0,0,0,0.4);box-shadow:2px 2px 4px rgba(0,0,0,0.4)}.btn-warning{-webkit-background-size:200% 200%;background-size:200%;background-position:50%}.btn-warning:focus{background-color:#ff9800}.btn-warning:hover,.btn-warning:active:hover{background-color:#e08600}.btn-warning:active{background-color:#c27400;background-image:-webkit-radial-gradient(circle, #c27400 10%, #ff9800 11%);background-image:-o-radial-gradient(circle, #c27400 10%, #ff9800 11%);background-image:radial-gradient(circle, #c27400 10%, #ff9800 11%);background-repeat:no-repeat;-webkit-background-size:1000% 1000%;background-size:1000%;-webkit-box-shadow:2px 2px 4px rgba(0,0,0,0.4);box-shadow:2px 2px 4px rgba(0,0,0,0.4)}.btn-danger{-webkit-background-size:200% 200%;background-size:200%;background-position:50%}.btn-danger:focus{background-color:#e51c23}.btn-danger:hover,.btn-danger:active:hover{background-color:#cb171e}.btn-danger:active{background-color:#b0141a;background-image:-webkit-radial-gradient(circle, #b0141a 10%, #e51c23 11%);background-image:-o-radial-gradient(circle, #b0141a 10%, #e51c23 11%);background-image:radial-gradient(circle, #b0141a 10%, #e51c23 11%);background-repeat:no-repeat;-webkit-background-size:1000% 1000%;background-size:1000%;-webkit-box-shadow:2px 2px 4px rgba(0,0,0,0.4);box-shadow:2px 2px 4px rgba(0,0,0,0.4)}.btn-link{-webkit-background-size:200% 200%;background-size:200%;background-position:50%}.btn-link:focus{background-color:#ffffff}.btn-link:hover,.btn-link:active:hover{background-color:#f0f0f0}.btn-link:active{background-color:#e0e0e0;background-image:-webkit-radial-gradient(circle, #e0e0e0 10%, #fff 11%);background-image:-o-radial-gradient(circle, #e0e0e0 10%, #fff 11%);background-image:radial-gradient(circle, #e0e0e0 10%, #fff 11%);background-repeat:no-repeat;-webkit-background-size:1000% 1000%;background-size:1000%;-webkit-box-shadow:2px 2px 4px rgba(0,0,0,0.4);box-shadow:2px 2px 4px rgba(0,0,0,0.4)}.btn{text-transform:uppercase;border:none;-webkit-box-shadow:1px 1px 4px rgba(0,0,0,0.4);box-shadow:1px 1px 4px rgba(0,0,0,0.4);-webkit-transition:all 0.4s;-o-transition:all 0.4s;transition:all 0.4s}.btn-link{border-radius:3px;-webkit-box-shadow:none;box-shadow:none;color:#444444}.btn-link:hover,.btn-link:focus{-webkit-box-shadow:none;box-shadow:none;color:#444444;text-decoration:none}.btn-default.disabled{background-color:rgba(0,0,0,0.1);color:rgba(0,0,0,0.4);opacity:1}.btn-group .btn+.btn,.btn-group .btn+.btn-group,.btn-group .btn-group+.btn,.btn-group .btn-group+.btn-group{margin-left:0}.btn-group-vertical>.btn+.btn,.btn-group-vertical>.btn+.btn-group,.btn-group-vertical>.btn-group+.btn,.btn-group-vertical>.btn-group+.btn-group{margin-top:0}body{-webkit-font-smoothing:antialiased;letter-spacing:.1px}p{margin:0 0 1em}input,button{-webkit-font-smoothing:antialiased;letter-spacing:.1px}a{-webkit-transition:all 0.2s;-o-transition:all 0.2s;transition:all 0.2s}.table-hover>tbody>tr,.table-hover>tbody>tr>th,.table-hover>tbody>tr>td{-webkit-transition:all 0.2s;-o-transition:all 0.2s;transition:all 0.2s}label{font-weight:normal}textarea,textarea.form-control,input.form-control,input[type=text],input[type=password],input[type=email],input[type=number],[type=text].form-control,[type=password].form-control,[type=email].form-control,[type=tel].form-control,[contenteditable].form-control{padding:0;border:none;border-radius:0;-webkit-appearance:none;-webkit-box-shadow:inset 0 -1px 0 #ddd;box-shadow:inset 0 -1px 0 #ddd;font-size:16px}textarea:focus,textarea.form-control:focus,input.form-control:focus,input[type=text]:focus,input[type=password]:focus,input[type=email]:focus,input[type=number]:focus,[type=text].form-control:focus,[type=password].form-control:focus,[type=email].form-control:focus,[type=tel].form-control:focus,[contenteditable].form-control:focus{-webkit-box-shadow:inset 0 -2px 0 #2196f3;box-shadow:inset 0 -2px 0 #2196f3}textarea[disabled],textarea.form-control[disabled],input.form-control[disabled],input[type=text][disabled],input[type=password][disabled],input[type=email][disabled],input[type=number][disabled],[type=text].form-control[disabled],[type=password].form-control[disabled],[type=email].form-control[disabled],[type=tel].form-control[disabled],[contenteditable].form-control[disabled],textarea[readonly],textarea.form-control[readonly],input.form-control[readonly],input[type=text][readonly],input[type=password][readonly],input[type=email][readonly],input[type=number][readonly],[type=text].form-control[readonly],[type=password].form-control[readonly],[type=email].form-control[readonly],[type=tel].form-control[readonly],[contenteditable].form-control[readonly]{-webkit-box-shadow:none;box-shadow:none;border-bottom:1px dotted #ddd}textarea.input-sm,textarea.form-control.input-sm,input.form-control.input-sm,input[type=text].input-sm,input[type=password].input-sm,input[type=email].input-sm,input[type=number].input-sm,[type=text].form-control.input-sm,[type=password].form-control.input-sm,[type=email].form-control.input-sm,[type=tel].form-control.input-sm,[contenteditable].form-control.input-sm{font-size:12px}textarea.input-lg,textarea.form-control.input-lg,input.form-control.input-lg,input[type=text].input-lg,input[type=password].input-lg,input[type=email].input-lg,input[type=number].input-lg,[type=text].form-control.input-lg,[type=password].form-control.input-lg,[type=email].form-control.input-lg,[type=tel].form-control.input-lg,[contenteditable].form-control.input-lg{font-size:17px}select,select.form-control{border:0;border-radius:0;-webkit-appearance:none;-moz-appearance:none;appearance:none;padding-left:0;padding-right:0\9;background-image:url(data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAABoAAAAaCAMAAACelLz8AAAAJ1BMVEVmZmZmZmZmZmZmZmZmZmZmZmZmZmZmZmZmZmZmZmZmZmZmZmZmZmaP/QSjAAAADHRSTlMAAgMJC0uWpKa6wMxMdjkoAAAANUlEQVR4AeXJyQEAERAAsNl7Hf3X6xt0QL6JpZWq30pdvdadme+0PMdzvHm8YThHcT1H7K0BtOMDniZhWOgAAAAASUVORK5CYII=);-webkit-background-size:13px 13px;background-size:13px;background-repeat:no-repeat;background-position:right center;-webkit-box-shadow:inset 0 -1px 0 #ddd;box-shadow:inset 0 -1px 0 #ddd;font-size:16px;line-height:1.5}select::-ms-expand,select.form-control::-ms-expand{display:none}select.input-sm,select.form-control.input-sm{font-size:12px}select.input-lg,select.form-control.input-lg{font-size:17px}select:focus,select.form-control:focus{-webkit-box-shadow:inset 0 -2px 0 #2196f3;box-shadow:inset 0 -2px 0 #2196f3;background-image:url(data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAABoAAAAaCAMAAACelLz8AAAAJ1BMVEUhISEhISEhISEhISEhISEhISEhISEhISEhISEhISEhISEhISEhISF8S9ewAAAADHRSTlMAAgMJC0uWpKa6wMxMdjkoAAAANUlEQVR4AeXJyQEAERAAsNl7Hf3X6xt0QL6JpZWq30pdvdadme+0PMdzvHm8YThHcT1H7K0BtOMDniZhWOgAAAAASUVORK5CYII=)}select[multiple],select.form-control[multiple]{background:none}.radio label,.radio-inline label,.checkbox label,.checkbox-inline label{padding-left:25px}.radio input[type="radio"],.radio-inline input[type="radio"],.checkbox input[type="radio"],.checkbox-inline input[type="radio"],.radio input[type="checkbox"],.radio-inline input[type="checkbox"],.checkbox input[type="checkbox"],.checkbox-inline input[type="checkbox"]{margin-left:-25px}input[type="radio"],.radio input[type="radio"],.radio-inline input[type="radio"]{position:relative;margin-top:6px;margin-right:4px;vertical-align:top;border:none;background-color:transparent;-webkit-appearance:none;appearance:none;cursor:pointer}input[type="radio"]:focus,.radio input[type="radio"]:focus,.radio-inline input[type="radio"]:focus{outline:none}input[type="radio"]:before,.radio input[type="radio"]:before,.radio-inline input[type="radio"]:before,input[type="radio"]:after,.radio input[type="radio"]:after,.radio-inline input[type="radio"]:after{content:"";display:block;width:18px;height:18px;border-radius:50%;-webkit-transition:240ms;-o-transition:240ms;transition:240ms}input[type="radio"]:before,.radio input[type="radio"]:before,.radio-inline input[type="radio"]:before{position:absolute;left:0;top:-3px;background-color:#2196f3;-webkit-transform:scale(0);-ms-transform:scale(0);-o-transform:scale(0);transform:scale(0)}input[type="radio"]:after,.radio input[type="radio"]:after,.radio-inline input[type="radio"]:after{position:relative;top:-3px;border:2px solid #666666}input[type="radio"]:checked:before,.radio input[type="radio"]:checked:before,.radio-inline input[type="radio"]:checked:before{-webkit-transform:scale(.5);-ms-transform:scale(.5);-o-transform:scale(.5);transform:scale(.5)}input[type="radio"]:disabled:checked:before,.radio input[type="radio"]:disabled:checked:before,.radio-inline input[type="radio"]:disabled:checked:before{background-color:#bbbbbb}input[type="radio"]:checked:after,.radio input[type="radio"]:checked:after,.radio-inline input[type="radio"]:checked:after{border-color:#2196f3}input[type="radio"]:disabled:after,.radio input[type="radio"]:disabled:after,.radio-inline input[type="radio"]:disabled:after,input[type="radio"]:disabled:checked:after,.radio input[type="radio"]:disabled:checked:after,.radio-inline input[type="radio"]:disabled:checked:after{border-color:#bbbbbb}input[type="checkbox"],.checkbox input[type="checkbox"],.checkbox-inline input[type="checkbox"]{position:relative;border:none;margin-bottom:-4px;-webkit-appearance:none;appearance:none;cursor:pointer}input[type="checkbox"]:focus,.checkbox input[type="checkbox"]:focus,.checkbox-inline input[type="checkbox"]:focus{outline:none}input[type="checkbox"]:focus:after,.checkbox input[type="checkbox"]:focus:after,.checkbox-inline input[type="checkbox"]:focus:after{border-color:#2196f3}input[type="checkbox"]:after,.checkbox input[type="checkbox"]:after,.checkbox-inline input[type="checkbox"]:after{content:"";display:block;width:18px;height:18px;margin-top:-2px;margin-right:5px;border:2px solid #666666;border-radius:2px;-webkit-transition:240ms;-o-transition:240ms;transition:240ms}input[type="checkbox"]:checked:before,.checkbox input[type="checkbox"]:checked:before,.checkbox-inline input[type="checkbox"]:checked:before{content:"";position:absolute;top:0;left:6px;display:table;width:6px;height:12px;border:2px solid #fff;border-top-width:0;border-left-width:0;-webkit-transform:rotate(45deg);-ms-transform:rotate(45deg);-o-transform:rotate(45deg);transform:rotate(45deg)}input[type="checkbox"]:checked:after,.checkbox input[type="checkbox"]:checked:after,.checkbox-inline input[type="checkbox"]:checked:after{background-color:#2196f3;border-color:#2196f3}input[type="checkbox"]:disabled:after,.checkbox input[type="checkbox"]:disabled:after,.checkbox-inline input[type="checkbox"]:disabled:after{border-color:#bbbbbb}input[type="checkbox"]:disabled:checked:after,.checkbox input[type="checkbox"]:disabled:checked:after,.checkbox-inline input[type="checkbox"]:disabled:checked:after{background-color:#bbbbbb;border-color:transparent}.has-warning input:not([type=checkbox]),.has-warning .form-control,.has-warning input.form-control[readonly],.has-warning input[type=text][readonly],.has-warning [type=text].form-control[readonly],.has-warning input:not([type=checkbox]):focus,.has-warning .form-control:focus{border-bottom:none;-webkit-box-shadow:inset 0 -2px 0 #ff9800;box-shadow:inset 0 -2px 0 #ff9800}.has-error input:not([type=checkbox]),.has-error .form-control,.has-error input.form-control[readonly],.has-error input[type=text][readonly],.has-error [type=text].form-control[readonly],.has-error input:not([type=checkbox]):focus,.has-error .form-control:focus{border-bottom:none;-webkit-box-shadow:inset 0 -2px 0 #e51c23;box-shadow:inset 0 -2px 0 #e51c23}.has-success input:not([type=checkbox]),.has-success .form-control,.has-success input.form-control[readonly],.has-success input[type=text][readonly],.has-success [type=text].form-control[readonly],.has-success input:not([type=checkbox]):focus,.has-success .form-control:focus{border-bottom:none;-webkit-box-shadow:inset 0 -2px 0 #4caf50;box-shadow:inset 0 -2px 0 #4caf50}.has-warning .input-group-addon,.has-error .input-group-addon,.has-success .input-group-addon{color:#666666;border-color:transparent;background-color:transparent}.nav-tabs>li>a,.nav-tabs>li>a:focus{margin-right:0;background-color:transparent;border:none;color:#666666;-webkit-box-shadow:inset 0 -1px 0 #ddd;box-shadow:inset 0 -1px 0 #ddd;-webkit-transition:all 0.2s;-o-transition:all 0.2s;transition:all 0.2s}.nav-tabs>li>a:hover,.nav-tabs>li>a:focus:hover{background-color:transparent;-webkit-box-shadow:inset 0 -2px 0 #2196f3;box-shadow:inset 0 -2px 0 #2196f3;color:#2196f3}.nav-tabs>li.active>a,.nav-tabs>li.active>a:focus{border:none;-webkit-box-shadow:inset 0 -2px 0 #2196f3;box-shadow:inset 0 -2px 0 #2196f3;color:#2196f3}.nav-tabs>li.active>a:hover,.nav-tabs>li.active>a:focus:hover{border:none;color:#2196f3}.nav-tabs>li.disabled>a{-webkit-box-shadow:inset 0 -1px 0 #ddd;box-shadow:inset 0 -1px 0 #ddd}.nav-tabs.nav-justified>li>a,.nav-tabs.nav-justified>li>a:hover,.nav-tabs.nav-justified>li>a:focus,.nav-tabs.nav-justified>.active>a,.nav-tabs.nav-justified>.active>a:hover,.nav-tabs.nav-justified>.active>a:focus{border:none}.nav-tabs .dropdown-menu{margin-top:0}.dropdown-menu{margin-top:0;border:none;-webkit-box-shadow:0 1px 4px rgba(0,0,0,0.3);box-shadow:0 1px 4px rgba(0,0,0,0.3)}.alert{border:none;color:#fff}.alert-success{background-color:#4caf50}.alert-info{background-color:#9c27b0}.alert-warning{background-color:#ff9800}.alert-danger{background-color:#e51c23}.alert a:not(.close),.alert .alert-link{color:#fff;font-weight:bold}.alert .close{color:#fff}.badge{padding:4px 6px 4px}.progress{position:relative;z-index:1;height:6px;border-radius:0;-webkit-box-shadow:none;box-shadow:none}.progress-bar{-webkit-box-shadow:none;box-shadow:none}.progress-bar:last-child{border-radius:0 3px 3px 0}.progress-bar:last-child:before{display:block;content:"";position:absolute;width:100%;height:100%;left:0;right:0;z-index:-1;background-color:#cae6fc}.progress-bar-success:last-child.progress-bar:before{background-color:#c7e7c8}.progress-bar-info:last-child.progress-bar:before{background-color:#edc9f3}.progress-bar-warning:last-child.progress-bar:before{background-color:#ffe0b3}.progress-bar-danger:last-child.progress-bar:before{background-color:#f28e92}.close{font-size:34px;font-weight:300;line-height:24px;opacity:0.6;-webkit-transition:all 0.2s;-o-transition:all 0.2s;transition:all 0.2s}.close:hover{opacity:1}.list-group-item{padding:15px}.list-group-item-text{color:#bbbbbb}.well{border-radius:0;-webkit-box-shadow:none;box-shadow:none}.panel{border:none;border-radius:2px;-webkit-box-shadow:0 1px 4px rgba(0,0,0,0.3);box-shadow:0 1px 4px rgba(0,0,0,0.3)}.panel-heading{border-bottom:none}.panel-footer{border-top:none}.popover{border:none;-webkit-box-shadow:0 1px 4px rgba(0,0,0,0.3);box-shadow:0 1px 4px rgba(0,0,0,0.3)}.carousel-caption h1,.carousel-caption h2,.carousel-caption h3,.carousel-caption h4,.carousel-caption h5,.carousel-caption h6{color:inherit}
</style>
<script>/*!
 * Bootstrap v3.3.5 (http://getbootstrap.com)
 * Copyright 2011-2015 Twitter, Inc.
 * Licensed under the MIT license
 */
if("undefined"==typeof jQuery)throw new Error("Bootstrap's JavaScript requires jQuery");+function(a){"use strict";var b=a.fn.jquery.split(" ")[0].split(".");if(b[0]<2&&b[1]<9||1==b[0]&&9==b[1]&&b[2]<1)throw new Error("Bootstrap's JavaScript requires jQuery version 1.9.1 or higher")}(jQuery),+function(a){"use strict";function b(){var a=document.createElement("bootstrap"),b={WebkitTransition:"webkitTransitionEnd",MozTransition:"transitionend",OTransition:"oTransitionEnd otransitionend",transition:"transitionend"};for(var c in b)if(void 0!==a.style[c])return{end:b[c]};return!1}a.fn.emulateTransitionEnd=function(b){var c=!1,d=this;a(this).one("bsTransitionEnd",function(){c=!0});var e=function(){c||a(d).trigger(a.support.transition.end)};return setTimeout(e,b),this},a(function(){a.support.transition=b(),a.support.transition&&(a.event.special.bsTransitionEnd={bindType:a.support.transition.end,delegateType:a.support.transition.end,handle:function(b){return a(b.target).is(this)?b.handleObj.handler.apply(this,arguments):void 0}})})}(jQuery),+function(a){"use strict";function b(b){return this.each(function(){var c=a(this),e=c.data("bs.alert");e||c.data("bs.alert",e=new d(this)),"string"==typeof b&&e[b].call(c)})}var c='[data-dismiss="alert"]',d=function(b){a(b).on("click",c,this.close)};d.VERSION="3.3.5",d.TRANSITION_DURATION=150,d.prototype.close=function(b){function c(){g.detach().trigger("closed.bs.alert").remove()}var e=a(this),f=e.attr("data-target");f||(f=e.attr("href"),f=f&&f.replace(/.*(?=#[^\s]*$)/,""));var g=a(f);b&&b.preventDefault(),g.length||(g=e.closest(".alert")),g.trigger(b=a.Event("close.bs.alert")),b.isDefaultPrevented()||(g.removeClass("in"),a.support.transition&&g.hasClass("fade")?g.one("bsTransitionEnd",c).emulateTransitionEnd(d.TRANSITION_DURATION):c())};var e=a.fn.alert;a.fn.alert=b,a.fn.alert.Constructor=d,a.fn.alert.noConflict=function(){return a.fn.alert=e,this},a(document).on("click.bs.alert.data-api",c,d.prototype.close)}(jQuery),+function(a){"use strict";function b(b){return this.each(function(){var d=a(this),e=d.data("bs.button"),f="object"==typeof b&&b;e||d.data("bs.button",e=new c(this,f)),"toggle"==b?e.toggle():b&&e.setState(b)})}var c=function(b,d){this.$element=a(b),this.options=a.extend({},c.DEFAULTS,d),this.isLoading=!1};c.VERSION="3.3.5",c.DEFAULTS={loadingText:"loading..."},c.prototype.setState=function(b){var c="disabled",d=this.$element,e=d.is("input")?"val":"html",f=d.data();b+="Text",null==f.resetText&&d.data("resetText",d[e]()),setTimeout(a.proxy(function(){d[e](null==f[b]?this.options[b]:f[b]),"loadingText"==b?(this.isLoading=!0,d.addClass(c).attr(c,c)):this.isLoading&&(this.isLoading=!1,d.removeClass(c).removeAttr(c))},this),0)},c.prototype.toggle=function(){var a=!0,b=this.$element.closest('[data-toggle="buttons"]');if(b.length){var c=this.$element.find("input");"radio"==c.prop("type")?(c.prop("checked")&&(a=!1),b.find(".active").removeClass("active"),this.$element.addClass("active")):"checkbox"==c.prop("type")&&(c.prop("checked")!==this.$element.hasClass("active")&&(a=!1),this.$element.toggleClass("active")),c.prop("checked",this.$element.hasClass("active")),a&&c.trigger("change")}else this.$element.attr("aria-pressed",!this.$element.hasClass("active")),this.$element.toggleClass("active")};var d=a.fn.button;a.fn.button=b,a.fn.button.Constructor=c,a.fn.button.noConflict=function(){return a.fn.button=d,this},a(document).on("click.bs.button.data-api",'[data-toggle^="button"]',function(c){var d=a(c.target);d.hasClass("btn")||(d=d.closest(".btn")),b.call(d,"toggle"),a(c.target).is('input[type="radio"]')||a(c.target).is('input[type="checkbox"]')||c.preventDefault()}).on("focus.bs.button.data-api blur.bs.button.data-api",'[data-toggle^="button"]',function(b){a(b.target).closest(".btn").toggleClass("focus",/^focus(in)?$/.test(b.type))})}(jQuery),+function(a){"use strict";function b(b){return this.each(function(){var d=a(this),e=d.data("bs.carousel"),f=a.extend({},c.DEFAULTS,d.data(),"object"==typeof b&&b),g="string"==typeof b?b:f.slide;e||d.data("bs.carousel",e=new c(this,f)),"number"==typeof b?e.to(b):g?e[g]():f.interval&&e.pause().cycle()})}var c=function(b,c){this.$element=a(b),this.$indicators=this.$element.find(".carousel-indicators"),this.options=c,this.paused=null,this.sliding=null,this.interval=null,this.$active=null,this.$items=null,this.options.keyboard&&this.$element.on("keydown.bs.carousel",a.proxy(this.keydown,this)),"hover"==this.options.pause&&!("ontouchstart"in document.documentElement)&&this.$element.on("mouseenter.bs.carousel",a.proxy(this.pause,this)).on("mouseleave.bs.carousel",a.proxy(this.cycle,this))};c.VERSION="3.3.5",c.TRANSITION_DURATION=600,c.DEFAULTS={interval:5e3,pause:"hover",wrap:!0,keyboard:!0},c.prototype.keydown=function(a){if(!/input|textarea/i.test(a.target.tagName)){switch(a.which){case 37:this.prev();break;case 39:this.next();break;default:return}a.preventDefault()}},c.prototype.cycle=function(b){return b||(this.paused=!1),this.interval&&clearInterval(this.interval),this.options.interval&&!this.paused&&(this.interval=setInterval(a.proxy(this.next,this),this.options.interval)),this},c.prototype.getItemIndex=function(a){return this.$items=a.parent().children(".item"),this.$items.index(a||this.$active)},c.prototype.getItemForDirection=function(a,b){var c=this.getItemIndex(b),d="prev"==a&&0===c||"next"==a&&c==this.$items.length-1;if(d&&!this.options.wrap)return b;var e="prev"==a?-1:1,f=(c+e)%this.$items.length;return this.$items.eq(f)},c.prototype.to=function(a){var b=this,c=this.getItemIndex(this.$active=this.$element.find(".item.active"));return a>this.$items.length-1||0>a?void 0:this.sliding?this.$element.one("slid.bs.carousel",function(){b.to(a)}):c==a?this.pause().cycle():this.slide(a>c?"next":"prev",this.$items.eq(a))},c.prototype.pause=function(b){return b||(this.paused=!0),this.$element.find(".next, .prev").length&&a.support.transition&&(this.$element.trigger(a.support.transition.end),this.cycle(!0)),this.interval=clearInterval(this.interval),this},c.prototype.next=function(){return this.sliding?void 0:this.slide("next")},c.prototype.prev=function(){return this.sliding?void 0:this.slide("prev")},c.prototype.slide=function(b,d){var e=this.$element.find(".item.active"),f=d||this.getItemForDirection(b,e),g=this.interval,h="next"==b?"left":"right",i=this;if(f.hasClass("active"))return this.sliding=!1;var j=f[0],k=a.Event("slide.bs.carousel",{relatedTarget:j,direction:h});if(this.$element.trigger(k),!k.isDefaultPrevented()){if(this.sliding=!0,g&&this.pause(),this.$indicators.length){this.$indicators.find(".active").removeClass("active");var l=a(this.$indicators.children()[this.getItemIndex(f)]);l&&l.addClass("active")}var m=a.Event("slid.bs.carousel",{relatedTarget:j,direction:h});return a.support.transition&&this.$element.hasClass("slide")?(f.addClass(b),f[0].offsetWidth,e.addClass(h),f.addClass(h),e.one("bsTransitionEnd",function(){f.removeClass([b,h].join(" ")).addClass("active"),e.removeClass(["active",h].join(" ")),i.sliding=!1,setTimeout(function(){i.$element.trigger(m)},0)}).emulateTransitionEnd(c.TRANSITION_DURATION)):(e.removeClass("active"),f.addClass("active"),this.sliding=!1,this.$element.trigger(m)),g&&this.cycle(),this}};var d=a.fn.carousel;a.fn.carousel=b,a.fn.carousel.Constructor=c,a.fn.carousel.noConflict=function(){return a.fn.carousel=d,this};var e=function(c){var d,e=a(this),f=a(e.attr("data-target")||(d=e.attr("href"))&&d.replace(/.*(?=#[^\s]+$)/,""));if(f.hasClass("carousel")){var g=a.extend({},f.data(),e.data()),h=e.attr("data-slide-to");h&&(g.interval=!1),b.call(f,g),h&&f.data("bs.carousel").to(h),c.preventDefault()}};a(document).on("click.bs.carousel.data-api","[data-slide]",e).on("click.bs.carousel.data-api","[data-slide-to]",e),a(window).on("load",function(){a('[data-ride="carousel"]').each(function(){var c=a(this);b.call(c,c.data())})})}(jQuery),+function(a){"use strict";function b(b){var c,d=b.attr("data-target")||(c=b.attr("href"))&&c.replace(/.*(?=#[^\s]+$)/,"");return a(d)}function c(b){return this.each(function(){var c=a(this),e=c.data("bs.collapse"),f=a.extend({},d.DEFAULTS,c.data(),"object"==typeof b&&b);!e&&f.toggle&&/show|hide/.test(b)&&(f.toggle=!1),e||c.data("bs.collapse",e=new d(this,f)),"string"==typeof b&&e[b]()})}var d=function(b,c){this.$element=a(b),this.options=a.extend({},d.DEFAULTS,c),this.$trigger=a('[data-toggle="collapse"][href="#'+b.id+'"],[data-toggle="collapse"][data-target="#'+b.id+'"]'),this.transitioning=null,this.options.parent?this.$parent=this.getParent():this.addAriaAndCollapsedClass(this.$element,this.$trigger),this.options.toggle&&this.toggle()};d.VERSION="3.3.5",d.TRANSITION_DURATION=350,d.DEFAULTS={toggle:!0},d.prototype.dimension=function(){var a=this.$element.hasClass("width");return a?"width":"height"},d.prototype.show=function(){if(!this.transitioning&&!this.$element.hasClass("in")){var b,e=this.$parent&&this.$parent.children(".panel").children(".in, .collapsing");if(!(e&&e.length&&(b=e.data("bs.collapse"),b&&b.transitioning))){var f=a.Event("show.bs.collapse");if(this.$element.trigger(f),!f.isDefaultPrevented()){e&&e.length&&(c.call(e,"hide"),b||e.data("bs.collapse",null));var g=this.dimension();this.$element.removeClass("collapse").addClass("collapsing")[g](0).attr("aria-expanded",!0),this.$trigger.removeClass("collapsed").attr("aria-expanded",!0),this.transitioning=1;var h=function(){this.$element.removeClass("collapsing").addClass("collapse in")[g](""),this.transitioning=0,this.$element.trigger("shown.bs.collapse")};if(!a.support.transition)return h.call(this);var i=a.camelCase(["scroll",g].join("-"));this.$element.one("bsTransitionEnd",a.proxy(h,this)).emulateTransitionEnd(d.TRANSITION_DURATION)[g](this.$element[0][i])}}}},d.prototype.hide=function(){if(!this.transitioning&&this.$element.hasClass("in")){var b=a.Event("hide.bs.collapse");if(this.$element.trigger(b),!b.isDefaultPrevented()){var c=this.dimension();this.$element[c](this.$element[c]())[0].offsetHeight,this.$element.addClass("collapsing").removeClass("collapse in").attr("aria-expanded",!1),this.$trigger.addClass("collapsed").attr("aria-expanded",!1),this.transitioning=1;var e=function(){this.transitioning=0,this.$element.removeClass("collapsing").addClass("collapse").trigger("hidden.bs.collapse")};return a.support.transition?void this.$element[c](0).one("bsTransitionEnd",a.proxy(e,this)).emulateTransitionEnd(d.TRANSITION_DURATION):e.call(this)}}},d.prototype.toggle=function(){this[this.$element.hasClass("in")?"hide":"show"]()},d.prototype.getParent=function(){return a(this.options.parent).find('[data-toggle="collapse"][data-parent="'+this.options.parent+'"]').each(a.proxy(function(c,d){var e=a(d);this.addAriaAndCollapsedClass(b(e),e)},this)).end()},d.prototype.addAriaAndCollapsedClass=function(a,b){var c=a.hasClass("in");a.attr("aria-expanded",c),b.toggleClass("collapsed",!c).attr("aria-expanded",c)};var e=a.fn.collapse;a.fn.collapse=c,a.fn.collapse.Constructor=d,a.fn.collapse.noConflict=function(){return a.fn.collapse=e,this},a(document).on("click.bs.collapse.data-api",'[data-toggle="collapse"]',function(d){var e=a(this);e.attr("data-target")||d.preventDefault();var f=b(e),g=f.data("bs.collapse"),h=g?"toggle":e.data();c.call(f,h)})}(jQuery),+function(a){"use strict";function b(b){var c=b.attr("data-target");c||(c=b.attr("href"),c=c&&/#[A-Za-z]/.test(c)&&c.replace(/.*(?=#[^\s]*$)/,""));var d=c&&a(c);return d&&d.length?d:b.parent()}function c(c){c&&3===c.which||(a(e).remove(),a(f).each(function(){var d=a(this),e=b(d),f={relatedTarget:this};e.hasClass("open")&&(c&&"click"==c.type&&/input|textarea/i.test(c.target.tagName)&&a.contains(e[0],c.target)||(e.trigger(c=a.Event("hide.bs.dropdown",f)),c.isDefaultPrevented()||(d.attr("aria-expanded","false"),e.removeClass("open").trigger("hidden.bs.dropdown",f))))}))}function d(b){return this.each(function(){var c=a(this),d=c.data("bs.dropdown");d||c.data("bs.dropdown",d=new g(this)),"string"==typeof b&&d[b].call(c)})}var e=".dropdown-backdrop",f='[data-toggle="dropdown"]',g=function(b){a(b).on("click.bs.dropdown",this.toggle)};g.VERSION="3.3.5",g.prototype.toggle=function(d){var e=a(this);if(!e.is(".disabled, :disabled")){var f=b(e),g=f.hasClass("open");if(c(),!g){"ontouchstart"in document.documentElement&&!f.closest(".navbar-nav").length&&a(document.createElement("div")).addClass("dropdown-backdrop").insertAfter(a(this)).on("click",c);var h={relatedTarget:this};if(f.trigger(d=a.Event("show.bs.dropdown",h)),d.isDefaultPrevented())return;e.trigger("focus").attr("aria-expanded","true"),f.toggleClass("open").trigger("shown.bs.dropdown",h)}return!1}},g.prototype.keydown=function(c){if(/(38|40|27|32)/.test(c.which)&&!/input|textarea/i.test(c.target.tagName)){var d=a(this);if(c.preventDefault(),c.stopPropagation(),!d.is(".disabled, :disabled")){var e=b(d),g=e.hasClass("open");if(!g&&27!=c.which||g&&27==c.which)return 27==c.which&&e.find(f).trigger("focus"),d.trigger("click");var h=" li:not(.disabled):visible a",i=e.find(".dropdown-menu"+h);if(i.length){var j=i.index(c.target);38==c.which&&j>0&&j--,40==c.which&&j<i.length-1&&j++,~j||(j=0),i.eq(j).trigger("focus")}}}};var h=a.fn.dropdown;a.fn.dropdown=d,a.fn.dropdown.Constructor=g,a.fn.dropdown.noConflict=function(){return a.fn.dropdown=h,this},a(document).on("click.bs.dropdown.data-api",c).on("click.bs.dropdown.data-api",".dropdown form",function(a){a.stopPropagation()}).on("click.bs.dropdown.data-api",f,g.prototype.toggle).on("keydown.bs.dropdown.data-api",f,g.prototype.keydown).on("keydown.bs.dropdown.data-api",".dropdown-menu",g.prototype.keydown)}(jQuery),+function(a){"use strict";function b(b,d){return this.each(function(){var e=a(this),f=e.data("bs.modal"),g=a.extend({},c.DEFAULTS,e.data(),"object"==typeof b&&b);f||e.data("bs.modal",f=new c(this,g)),"string"==typeof b?f[b](d):g.show&&f.show(d)})}var c=function(b,c){this.options=c,this.$body=a(document.body),this.$element=a(b),this.$dialog=this.$element.find(".modal-dialog"),this.$backdrop=null,this.isShown=null,this.originalBodyPad=null,this.scrollbarWidth=0,this.ignoreBackdropClick=!1,this.options.remote&&this.$element.find(".modal-content").load(this.options.remote,a.proxy(function(){this.$element.trigger("loaded.bs.modal")},this))};c.VERSION="3.3.5",c.TRANSITION_DURATION=300,c.BACKDROP_TRANSITION_DURATION=150,c.DEFAULTS={backdrop:!0,keyboard:!0,show:!0},c.prototype.toggle=function(a){return this.isShown?this.hide():this.show(a)},c.prototype.show=function(b){var d=this,e=a.Event("show.bs.modal",{relatedTarget:b});this.$element.trigger(e),this.isShown||e.isDefaultPrevented()||(this.isShown=!0,this.checkScrollbar(),this.setScrollbar(),this.$body.addClass("modal-open"),this.escape(),this.resize(),this.$element.on("click.dismiss.bs.modal",'[data-dismiss="modal"]',a.proxy(this.hide,this)),this.$dialog.on("mousedown.dismiss.bs.modal",function(){d.$element.one("mouseup.dismiss.bs.modal",function(b){a(b.target).is(d.$element)&&(d.ignoreBackdropClick=!0)})}),this.backdrop(function(){var e=a.support.transition&&d.$element.hasClass("fade");d.$element.parent().length||d.$element.appendTo(d.$body),d.$element.show().scrollTop(0),d.adjustDialog(),e&&d.$element[0].offsetWidth,d.$element.addClass("in"),d.enforceFocus();var f=a.Event("shown.bs.modal",{relatedTarget:b});e?d.$dialog.one("bsTransitionEnd",function(){d.$element.trigger("focus").trigger(f)}).emulateTransitionEnd(c.TRANSITION_DURATION):d.$element.trigger("focus").trigger(f)}))},c.prototype.hide=function(b){b&&b.preventDefault(),b=a.Event("hide.bs.modal"),this.$element.trigger(b),this.isShown&&!b.isDefaultPrevented()&&(this.isShown=!1,this.escape(),this.resize(),a(document).off("focusin.bs.modal"),this.$element.removeClass("in").off("click.dismiss.bs.modal").off("mouseup.dismiss.bs.modal"),this.$dialog.off("mousedown.dismiss.bs.modal"),a.support.transition&&this.$element.hasClass("fade")?this.$element.one("bsTransitionEnd",a.proxy(this.hideModal,this)).emulateTransitionEnd(c.TRANSITION_DURATION):this.hideModal())},c.prototype.enforceFocus=function(){a(document).off("focusin.bs.modal").on("focusin.bs.modal",a.proxy(function(a){this.$element[0]===a.target||this.$element.has(a.target).length||this.$element.trigger("focus")},this))},c.prototype.escape=function(){this.isShown&&this.options.keyboard?this.$element.on("keydown.dismiss.bs.modal",a.proxy(function(a){27==a.which&&this.hide()},this)):this.isShown||this.$element.off("keydown.dismiss.bs.modal")},c.prototype.resize=function(){this.isShown?a(window).on("resize.bs.modal",a.proxy(this.handleUpdate,this)):a(window).off("resize.bs.modal")},c.prototype.hideModal=function(){var a=this;this.$element.hide(),this.backdrop(function(){a.$body.removeClass("modal-open"),a.resetAdjustments(),a.resetScrollbar(),a.$element.trigger("hidden.bs.modal")})},c.prototype.removeBackdrop=function(){this.$backdrop&&this.$backdrop.remove(),this.$backdrop=null},c.prototype.backdrop=function(b){var d=this,e=this.$element.hasClass("fade")?"fade":"";if(this.isShown&&this.options.backdrop){var f=a.support.transition&&e;if(this.$backdrop=a(document.createElement("div")).addClass("modal-backdrop "+e).appendTo(this.$body),this.$element.on("click.dismiss.bs.modal",a.proxy(function(a){return this.ignoreBackdropClick?void(this.ignoreBackdropClick=!1):void(a.target===a.currentTarget&&("static"==this.options.backdrop?this.$element[0].focus():this.hide()))},this)),f&&this.$backdrop[0].offsetWidth,this.$backdrop.addClass("in"),!b)return;f?this.$backdrop.one("bsTransitionEnd",b).emulateTransitionEnd(c.BACKDROP_TRANSITION_DURATION):b()}else if(!this.isShown&&this.$backdrop){this.$backdrop.removeClass("in");var g=function(){d.removeBackdrop(),b&&b()};a.support.transition&&this.$element.hasClass("fade")?this.$backdrop.one("bsTransitionEnd",g).emulateTransitionEnd(c.BACKDROP_TRANSITION_DURATION):g()}else b&&b()},c.prototype.handleUpdate=function(){this.adjustDialog()},c.prototype.adjustDialog=function(){var a=this.$element[0].scrollHeight>document.documentElement.clientHeight;this.$element.css({paddingLeft:!this.bodyIsOverflowing&&a?this.scrollbarWidth:"",paddingRight:this.bodyIsOverflowing&&!a?this.scrollbarWidth:""})},c.prototype.resetAdjustments=function(){this.$element.css({paddingLeft:"",paddingRight:""})},c.prototype.checkScrollbar=function(){var a=window.innerWidth;if(!a){var b=document.documentElement.getBoundingClientRect();a=b.right-Math.abs(b.left)}this.bodyIsOverflowing=document.body.clientWidth<a,this.scrollbarWidth=this.measureScrollbar()},c.prototype.setScrollbar=function(){var a=parseInt(this.$body.css("padding-right")||0,10);this.originalBodyPad=document.body.style.paddingRight||"",this.bodyIsOverflowing&&this.$body.css("padding-right",a+this.scrollbarWidth)},c.prototype.resetScrollbar=function(){this.$body.css("padding-right",this.originalBodyPad)},c.prototype.measureScrollbar=function(){var a=document.createElement("div");a.className="modal-scrollbar-measure",this.$body.append(a);var b=a.offsetWidth-a.clientWidth;return this.$body[0].removeChild(a),b};var d=a.fn.modal;a.fn.modal=b,a.fn.modal.Constructor=c,a.fn.modal.noConflict=function(){return a.fn.modal=d,this},a(document).on("click.bs.modal.data-api",'[data-toggle="modal"]',function(c){var d=a(this),e=d.attr("href"),f=a(d.attr("data-target")||e&&e.replace(/.*(?=#[^\s]+$)/,"")),g=f.data("bs.modal")?"toggle":a.extend({remote:!/#/.test(e)&&e},f.data(),d.data());d.is("a")&&c.preventDefault(),f.one("show.bs.modal",function(a){a.isDefaultPrevented()||f.one("hidden.bs.modal",function(){d.is(":visible")&&d.trigger("focus")})}),b.call(f,g,this)})}(jQuery),+function(a){"use strict";function b(b){return this.each(function(){var d=a(this),e=d.data("bs.tooltip"),f="object"==typeof b&&b;(e||!/destroy|hide/.test(b))&&(e||d.data("bs.tooltip",e=new c(this,f)),"string"==typeof b&&e[b]())})}var c=function(a,b){this.type=null,this.options=null,this.enabled=null,this.timeout=null,this.hoverState=null,this.$element=null,this.inState=null,this.init("tooltip",a,b)};c.VERSION="3.3.5",c.TRANSITION_DURATION=150,c.DEFAULTS={animation:!0,placement:"top",selector:!1,template:'<div class="tooltip" role="tooltip"><div class="tooltip-arrow"></div><div class="tooltip-inner"></div></div>',trigger:"hover focus",title:"",delay:0,html:!1,container:!1,viewport:{selector:"body",padding:0}},c.prototype.init=function(b,c,d){if(this.enabled=!0,this.type=b,this.$element=a(c),this.options=this.getOptions(d),this.$viewport=this.options.viewport&&a(a.isFunction(this.options.viewport)?this.options.viewport.call(this,this.$element):this.options.viewport.selector||this.options.viewport),this.inState={click:!1,hover:!1,focus:!1},this.$element[0]instanceof document.constructor&&!this.options.selector)throw new Error("`selector` option must be specified when initializing "+this.type+" on the window.document object!");for(var e=this.options.trigger.split(" "),f=e.length;f--;){var g=e[f];if("click"==g)this.$element.on("click."+this.type,this.options.selector,a.proxy(this.toggle,this));else if("manual"!=g){var h="hover"==g?"mouseenter":"focusin",i="hover"==g?"mouseleave":"focusout";this.$element.on(h+"."+this.type,this.options.selector,a.proxy(this.enter,this)),this.$element.on(i+"."+this.type,this.options.selector,a.proxy(this.leave,this))}}this.options.selector?this._options=a.extend({},this.options,{trigger:"manual",selector:""}):this.fixTitle()},c.prototype.getDefaults=function(){return c.DEFAULTS},c.prototype.getOptions=function(b){return b=a.extend({},this.getDefaults(),this.$element.data(),b),b.delay&&"number"==typeof b.delay&&(b.delay={show:b.delay,hide:b.delay}),b},c.prototype.getDelegateOptions=function(){var b={},c=this.getDefaults();return this._options&&a.each(this._options,function(a,d){c[a]!=d&&(b[a]=d)}),b},c.prototype.enter=function(b){var c=b instanceof this.constructor?b:a(b.currentTarget).data("bs."+this.type);return c||(c=new this.constructor(b.currentTarget,this.getDelegateOptions()),a(b.currentTarget).data("bs."+this.type,c)),b instanceof a.Event&&(c.inState["focusin"==b.type?"focus":"hover"]=!0),c.tip().hasClass("in")||"in"==c.hoverState?void(c.hoverState="in"):(clearTimeout(c.timeout),c.hoverState="in",c.options.delay&&c.options.delay.show?void(c.timeout=setTimeout(function(){"in"==c.hoverState&&c.show()},c.options.delay.show)):c.show())},c.prototype.isInStateTrue=function(){for(var a in this.inState)if(this.inState[a])return!0;return!1},c.prototype.leave=function(b){var c=b instanceof this.constructor?b:a(b.currentTarget).data("bs."+this.type);return c||(c=new this.constructor(b.currentTarget,this.getDelegateOptions()),a(b.currentTarget).data("bs."+this.type,c)),b instanceof a.Event&&(c.inState["focusout"==b.type?"focus":"hover"]=!1),c.isInStateTrue()?void 0:(clearTimeout(c.timeout),c.hoverState="out",c.options.delay&&c.options.delay.hide?void(c.timeout=setTimeout(function(){"out"==c.hoverState&&c.hide()},c.options.delay.hide)):c.hide())},c.prototype.show=function(){var b=a.Event("show.bs."+this.type);if(this.hasContent()&&this.enabled){this.$element.trigger(b);var d=a.contains(this.$element[0].ownerDocument.documentElement,this.$element[0]);if(b.isDefaultPrevented()||!d)return;var e=this,f=this.tip(),g=this.getUID(this.type);this.setContent(),f.attr("id",g),this.$element.attr("aria-describedby",g),this.options.animation&&f.addClass("fade");var h="function"==typeof this.options.placement?this.options.placement.call(this,f[0],this.$element[0]):this.options.placement,i=/\s?auto?\s?/i,j=i.test(h);j&&(h=h.replace(i,"")||"top"),f.detach().css({top:0,left:0,display:"block"}).addClass(h).data("bs."+this.type,this),this.options.container?f.appendTo(this.options.container):f.insertAfter(this.$element),this.$element.trigger("inserted.bs."+this.type);var k=this.getPosition(),l=f[0].offsetWidth,m=f[0].offsetHeight;if(j){var n=h,o=this.getPosition(this.$viewport);h="bottom"==h&&k.bottom+m>o.bottom?"top":"top"==h&&k.top-m<o.top?"bottom":"right"==h&&k.right+l>o.width?"left":"left"==h&&k.left-l<o.left?"right":h,f.removeClass(n).addClass(h)}var p=this.getCalculatedOffset(h,k,l,m);this.applyPlacement(p,h);var q=function(){var a=e.hoverState;e.$element.trigger("shown.bs."+e.type),e.hoverState=null,"out"==a&&e.leave(e)};a.support.transition&&this.$tip.hasClass("fade")?f.one("bsTransitionEnd",q).emulateTransitionEnd(c.TRANSITION_DURATION):q()}},c.prototype.applyPlacement=function(b,c){var d=this.tip(),e=d[0].offsetWidth,f=d[0].offsetHeight,g=parseInt(d.css("margin-top"),10),h=parseInt(d.css("margin-left"),10);isNaN(g)&&(g=0),isNaN(h)&&(h=0),b.top+=g,b.left+=h,a.offset.setOffset(d[0],a.extend({using:function(a){d.css({top:Math.round(a.top),left:Math.round(a.left)})}},b),0),d.addClass("in");var i=d[0].offsetWidth,j=d[0].offsetHeight;"top"==c&&j!=f&&(b.top=b.top+f-j);var k=this.getViewportAdjustedDelta(c,b,i,j);k.left?b.left+=k.left:b.top+=k.top;var l=/top|bottom/.test(c),m=l?2*k.left-e+i:2*k.top-f+j,n=l?"offsetWidth":"offsetHeight";d.offset(b),this.replaceArrow(m,d[0][n],l)},c.prototype.replaceArrow=function(a,b,c){this.arrow().css(c?"left":"top",50*(1-a/b)+"%").css(c?"top":"left","")},c.prototype.setContent=function(){var a=this.tip(),b=this.getTitle();a.find(".tooltip-inner")[this.options.html?"html":"text"](b),a.removeClass("fade in top bottom left right")},c.prototype.hide=function(b){function d(){"in"!=e.hoverState&&f.detach(),e.$element.removeAttr("aria-describedby").trigger("hidden.bs."+e.type),b&&b()}var e=this,f=a(this.$tip),g=a.Event("hide.bs."+this.type);return this.$element.trigger(g),g.isDefaultPrevented()?void 0:(f.removeClass("in"),a.support.transition&&f.hasClass("fade")?f.one("bsTransitionEnd",d).emulateTransitionEnd(c.TRANSITION_DURATION):d(),this.hoverState=null,this)},c.prototype.fixTitle=function(){var a=this.$element;(a.attr("title")||"string"!=typeof a.attr("data-original-title"))&&a.attr("data-original-title",a.attr("title")||"").attr("title","")},c.prototype.hasContent=function(){return this.getTitle()},c.prototype.getPosition=function(b){b=b||this.$element;var c=b[0],d="BODY"==c.tagName,e=c.getBoundingClientRect();null==e.width&&(e=a.extend({},e,{width:e.right-e.left,height:e.bottom-e.top}));var f=d?{top:0,left:0}:b.offset(),g={scroll:d?document.documentElement.scrollTop||document.body.scrollTop:b.scrollTop()},h=d?{width:a(window).width(),height:a(window).height()}:null;return a.extend({},e,g,h,f)},c.prototype.getCalculatedOffset=function(a,b,c,d){return"bottom"==a?{top:b.top+b.height,left:b.left+b.width/2-c/2}:"top"==a?{top:b.top-d,left:b.left+b.width/2-c/2}:"left"==a?{top:b.top+b.height/2-d/2,left:b.left-c}:{top:b.top+b.height/2-d/2,left:b.left+b.width}},c.prototype.getViewportAdjustedDelta=function(a,b,c,d){var e={top:0,left:0};if(!this.$viewport)return e;var f=this.options.viewport&&this.options.viewport.padding||0,g=this.getPosition(this.$viewport);if(/right|left/.test(a)){var h=b.top-f-g.scroll,i=b.top+f-g.scroll+d;h<g.top?e.top=g.top-h:i>g.top+g.height&&(e.top=g.top+g.height-i)}else{var j=b.left-f,k=b.left+f+c;j<g.left?e.left=g.left-j:k>g.right&&(e.left=g.left+g.width-k)}return e},c.prototype.getTitle=function(){var a,b=this.$element,c=this.options;return a=b.attr("data-original-title")||("function"==typeof c.title?c.title.call(b[0]):c.title)},c.prototype.getUID=function(a){do a+=~~(1e6*Math.random());while(document.getElementById(a));return a},c.prototype.tip=function(){if(!this.$tip&&(this.$tip=a(this.options.template),1!=this.$tip.length))throw new Error(this.type+" `template` option must consist of exactly 1 top-level element!");return this.$tip},c.prototype.arrow=function(){return this.$arrow=this.$arrow||this.tip().find(".tooltip-arrow")},c.prototype.enable=function(){this.enabled=!0},c.prototype.disable=function(){this.enabled=!1},c.prototype.toggleEnabled=function(){this.enabled=!this.enabled},c.prototype.toggle=function(b){var c=this;b&&(c=a(b.currentTarget).data("bs."+this.type),c||(c=new this.constructor(b.currentTarget,this.getDelegateOptions()),a(b.currentTarget).data("bs."+this.type,c))),b?(c.inState.click=!c.inState.click,c.isInStateTrue()?c.enter(c):c.leave(c)):c.tip().hasClass("in")?c.leave(c):c.enter(c)},c.prototype.destroy=function(){var a=this;clearTimeout(this.timeout),this.hide(function(){a.$element.off("."+a.type).removeData("bs."+a.type),a.$tip&&a.$tip.detach(),a.$tip=null,a.$arrow=null,a.$viewport=null})};var d=a.fn.tooltip;a.fn.tooltip=b,a.fn.tooltip.Constructor=c,a.fn.tooltip.noConflict=function(){return a.fn.tooltip=d,this}}(jQuery),+function(a){"use strict";function b(b){return this.each(function(){var d=a(this),e=d.data("bs.popover"),f="object"==typeof b&&b;(e||!/destroy|hide/.test(b))&&(e||d.data("bs.popover",e=new c(this,f)),"string"==typeof b&&e[b]())})}var c=function(a,b){this.init("popover",a,b)};if(!a.fn.tooltip)throw new Error("Popover requires tooltip.js");c.VERSION="3.3.5",c.DEFAULTS=a.extend({},a.fn.tooltip.Constructor.DEFAULTS,{placement:"right",trigger:"click",content:"",template:'<div class="popover" role="tooltip"><div class="arrow"></div><h3 class="popover-title"></h3><div class="popover-content"></div></div>'}),c.prototype=a.extend({},a.fn.tooltip.Constructor.prototype),c.prototype.constructor=c,c.prototype.getDefaults=function(){return c.DEFAULTS},c.prototype.setContent=function(){var a=this.tip(),b=this.getTitle(),c=this.getContent();a.find(".popover-title")[this.options.html?"html":"text"](b),a.find(".popover-content").children().detach().end()[this.options.html?"string"==typeof c?"html":"append":"text"](c),a.removeClass("fade top bottom left right in"),a.find(".popover-title").html()||a.find(".popover-title").hide()},c.prototype.hasContent=function(){return this.getTitle()||this.getContent()},c.prototype.getContent=function(){var a=this.$element,b=this.options;return a.attr("data-content")||("function"==typeof b.content?b.content.call(a[0]):b.content)},c.prototype.arrow=function(){return this.$arrow=this.$arrow||this.tip().find(".arrow")};var d=a.fn.popover;a.fn.popover=b,a.fn.popover.Constructor=c,a.fn.popover.noConflict=function(){return a.fn.popover=d,this}}(jQuery),+function(a){"use strict";function b(c,d){this.$body=a(document.body),this.$scrollElement=a(a(c).is(document.body)?window:c),this.options=a.extend({},b.DEFAULTS,d),this.selector=(this.options.target||"")+" .nav li > a",this.offsets=[],this.targets=[],this.activeTarget=null,this.scrollHeight=0,this.$scrollElement.on("scroll.bs.scrollspy",a.proxy(this.process,this)),this.refresh(),this.process()}function c(c){return this.each(function(){var d=a(this),e=d.data("bs.scrollspy"),f="object"==typeof c&&c;e||d.data("bs.scrollspy",e=new b(this,f)),"string"==typeof c&&e[c]()})}b.VERSION="3.3.5",b.DEFAULTS={offset:10},b.prototype.getScrollHeight=function(){return this.$scrollElement[0].scrollHeight||Math.max(this.$body[0].scrollHeight,document.documentElement.scrollHeight)},b.prototype.refresh=function(){var b=this,c="offset",d=0;this.offsets=[],this.targets=[],this.scrollHeight=this.getScrollHeight(),a.isWindow(this.$scrollElement[0])||(c="position",d=this.$scrollElement.scrollTop()),this.$body.find(this.selector).map(function(){var b=a(this),e=b.data("target")||b.attr("href"),f=/^#./.test(e)&&a(e);return f&&f.length&&f.is(":visible")&&[[f[c]().top+d,e]]||null}).sort(function(a,b){return a[0]-b[0]}).each(function(){b.offsets.push(this[0]),b.targets.push(this[1])})},b.prototype.process=function(){var a,b=this.$scrollElement.scrollTop()+this.options.offset,c=this.getScrollHeight(),d=this.options.offset+c-this.$scrollElement.height(),e=this.offsets,f=this.targets,g=this.activeTarget;if(this.scrollHeight!=c&&this.refresh(),b>=d)return g!=(a=f[f.length-1])&&this.activate(a);if(g&&b<e[0])return this.activeTarget=null,this.clear();for(a=e.length;a--;)g!=f[a]&&b>=e[a]&&(void 0===e[a+1]||b<e[a+1])&&this.activate(f[a])},b.prototype.activate=function(b){this.activeTarget=b,this.clear();var c=this.selector+'[data-target="'+b+'"],'+this.selector+'[href="'+b+'"]',d=a(c).parents("li").addClass("active");d.parent(".dropdown-menu").length&&(d=d.closest("li.dropdown").addClass("active")),
d.trigger("activate.bs.scrollspy")},b.prototype.clear=function(){a(this.selector).parentsUntil(this.options.target,".active").removeClass("active")};var d=a.fn.scrollspy;a.fn.scrollspy=c,a.fn.scrollspy.Constructor=b,a.fn.scrollspy.noConflict=function(){return a.fn.scrollspy=d,this},a(window).on("load.bs.scrollspy.data-api",function(){a('[data-spy="scroll"]').each(function(){var b=a(this);c.call(b,b.data())})})}(jQuery),+function(a){"use strict";function b(b){return this.each(function(){var d=a(this),e=d.data("bs.tab");e||d.data("bs.tab",e=new c(this)),"string"==typeof b&&e[b]()})}var c=function(b){this.element=a(b)};c.VERSION="3.3.5",c.TRANSITION_DURATION=150,c.prototype.show=function(){var b=this.element,c=b.closest("ul:not(.dropdown-menu)"),d=b.data("target");if(d||(d=b.attr("href"),d=d&&d.replace(/.*(?=#[^\s]*$)/,"")),!b.parent("li").hasClass("active")){var e=c.find(".active:last a"),f=a.Event("hide.bs.tab",{relatedTarget:b[0]}),g=a.Event("show.bs.tab",{relatedTarget:e[0]});if(e.trigger(f),b.trigger(g),!g.isDefaultPrevented()&&!f.isDefaultPrevented()){var h=a(d);this.activate(b.closest("li"),c),this.activate(h,h.parent(),function(){e.trigger({type:"hidden.bs.tab",relatedTarget:b[0]}),b.trigger({type:"shown.bs.tab",relatedTarget:e[0]})})}}},c.prototype.activate=function(b,d,e){function f(){g.removeClass("active").find("> .dropdown-menu > .active").removeClass("active").end().find('[data-toggle="tab"]').attr("aria-expanded",!1),b.addClass("active").find('[data-toggle="tab"]').attr("aria-expanded",!0),h?(b[0].offsetWidth,b.addClass("in")):b.removeClass("fade"),b.parent(".dropdown-menu").length&&b.closest("li.dropdown").addClass("active").end().find('[data-toggle="tab"]').attr("aria-expanded",!0),e&&e()}var g=d.find("> .active"),h=e&&a.support.transition&&(g.length&&g.hasClass("fade")||!!d.find("> .fade").length);g.length&&h?g.one("bsTransitionEnd",f).emulateTransitionEnd(c.TRANSITION_DURATION):f(),g.removeClass("in")};var d=a.fn.tab;a.fn.tab=b,a.fn.tab.Constructor=c,a.fn.tab.noConflict=function(){return a.fn.tab=d,this};var e=function(c){c.preventDefault(),b.call(a(this),"show")};a(document).on("click.bs.tab.data-api",'[data-toggle="tab"]',e).on("click.bs.tab.data-api",'[data-toggle="pill"]',e)}(jQuery),+function(a){"use strict";function b(b){return this.each(function(){var d=a(this),e=d.data("bs.affix"),f="object"==typeof b&&b;e||d.data("bs.affix",e=new c(this,f)),"string"==typeof b&&e[b]()})}var c=function(b,d){this.options=a.extend({},c.DEFAULTS,d),this.$target=a(this.options.target).on("scroll.bs.affix.data-api",a.proxy(this.checkPosition,this)).on("click.bs.affix.data-api",a.proxy(this.checkPositionWithEventLoop,this)),this.$element=a(b),this.affixed=null,this.unpin=null,this.pinnedOffset=null,this.checkPosition()};c.VERSION="3.3.5",c.RESET="affix affix-top affix-bottom",c.DEFAULTS={offset:0,target:window},c.prototype.getState=function(a,b,c,d){var e=this.$target.scrollTop(),f=this.$element.offset(),g=this.$target.height();if(null!=c&&"top"==this.affixed)return c>e?"top":!1;if("bottom"==this.affixed)return null!=c?e+this.unpin<=f.top?!1:"bottom":a-d>=e+g?!1:"bottom";var h=null==this.affixed,i=h?e:f.top,j=h?g:b;return null!=c&&c>=e?"top":null!=d&&i+j>=a-d?"bottom":!1},c.prototype.getPinnedOffset=function(){if(this.pinnedOffset)return this.pinnedOffset;this.$element.removeClass(c.RESET).addClass("affix");var a=this.$target.scrollTop(),b=this.$element.offset();return this.pinnedOffset=b.top-a},c.prototype.checkPositionWithEventLoop=function(){setTimeout(a.proxy(this.checkPosition,this),1)},c.prototype.checkPosition=function(){if(this.$element.is(":visible")){var b=this.$element.height(),d=this.options.offset,e=d.top,f=d.bottom,g=Math.max(a(document).height(),a(document.body).height());"object"!=typeof d&&(f=e=d),"function"==typeof e&&(e=d.top(this.$element)),"function"==typeof f&&(f=d.bottom(this.$element));var h=this.getState(g,b,e,f);if(this.affixed!=h){null!=this.unpin&&this.$element.css("top","");var i="affix"+(h?"-"+h:""),j=a.Event(i+".bs.affix");if(this.$element.trigger(j),j.isDefaultPrevented())return;this.affixed=h,this.unpin="bottom"==h?this.getPinnedOffset():null,this.$element.removeClass(c.RESET).addClass(i).trigger(i.replace("affix","affixed")+".bs.affix")}"bottom"==h&&this.$element.offset({top:g-b-f})}};var d=a.fn.affix;a.fn.affix=b,a.fn.affix.Constructor=c,a.fn.affix.noConflict=function(){return a.fn.affix=d,this},a(window).on("load",function(){a('[data-spy="affix"]').each(function(){var c=a(this),d=c.data();d.offset=d.offset||{},null!=d.offsetBottom&&(d.offset.bottom=d.offsetBottom),null!=d.offsetTop&&(d.offset.top=d.offsetTop),b.call(c,d)})})}(jQuery);</script>
<script>/**
* @preserve HTML5 Shiv 3.7.2 | @afarkas @jdalton @jon_neal @rem | MIT/GPL2 Licensed
*/
// Only run this code in IE 8
if (!!window.navigator.userAgent.match("MSIE 8")) {
!function(a,b){function c(a,b){var c=a.createElement("p"),d=a.getElementsByTagName("head")[0]||a.documentElement;return c.innerHTML="x<style>"+b+"</style>",d.insertBefore(c.lastChild,d.firstChild)}function d(){var a=t.elements;return"string"==typeof a?a.split(" "):a}function e(a,b){var c=t.elements;"string"!=typeof c&&(c=c.join(" ")),"string"!=typeof a&&(a=a.join(" ")),t.elements=c+" "+a,j(b)}function f(a){var b=s[a[q]];return b||(b={},r++,a[q]=r,s[r]=b),b}function g(a,c,d){if(c||(c=b),l)return c.createElement(a);d||(d=f(c));var e;return e=d.cache[a]?d.cache[a].cloneNode():p.test(a)?(d.cache[a]=d.createElem(a)).cloneNode():d.createElem(a),!e.canHaveChildren||o.test(a)||e.tagUrn?e:d.frag.appendChild(e)}function h(a,c){if(a||(a=b),l)return a.createDocumentFragment();c=c||f(a);for(var e=c.frag.cloneNode(),g=0,h=d(),i=h.length;i>g;g++)e.createElement(h[g]);return e}function i(a,b){b.cache||(b.cache={},b.createElem=a.createElement,b.createFrag=a.createDocumentFragment,b.frag=b.createFrag()),a.createElement=function(c){return t.shivMethods?g(c,a,b):b.createElem(c)},a.createDocumentFragment=Function("h,f","return function(){var n=f.cloneNode(),c=n.createElement;h.shivMethods&&("+d().join().replace(/[\w\-:]+/g,function(a){return b.createElem(a),b.frag.createElement(a),'c("'+a+'")'})+");return n}")(t,b.frag)}function j(a){a||(a=b);var d=f(a);return!t.shivCSS||k||d.hasCSS||(d.hasCSS=!!c(a,"article,aside,dialog,figcaption,figure,footer,header,hgroup,main,nav,section{display:block}mark{background:#FF0;color:#000}template{display:none}")),l||i(a,d),a}var k,l,m="3.7.2",n=a.html5||{},o=/^<|^(?:button|map|select|textarea|object|iframe|option|optgroup)$/i,p=/^(?:a|b|code|div|fieldset|h1|h2|h3|h4|h5|h6|i|label|li|ol|p|q|span|strong|style|table|tbody|td|th|tr|ul)$/i,q="_html5shiv",r=0,s={};!function(){try{var a=b.createElement("a");a.innerHTML="<xyz></xyz>",k="hidden"in a,l=1==a.childNodes.length||function(){b.createElement("a");var a=b.createDocumentFragment();return"undefined"==typeof a.cloneNode||"undefined"==typeof a.createDocumentFragment||"undefined"==typeof a.createElement}()}catch(c){k=!0,l=!0}}();var t={elements:n.elements||"abbr article aside audio bdi canvas data datalist details dialog figcaption figure footer header hgroup main mark meter nav output picture progress section summary template time video",version:m,shivCSS:n.shivCSS!==!1,supportsUnknownElements:l,shivMethods:n.shivMethods!==!1,type:"default",shivDocument:j,createElement:g,createDocumentFragment:h,addElements:e};a.html5=t,j(b)}(this,document);
};
</script>
<script>/*! Respond.js v1.4.2: min/max-width media query polyfill * Copyright 2013 Scott Jehl
 * Licensed under https://github.com/scottjehl/Respond/blob/master/LICENSE-MIT
 *  */

// Only run this code in IE 8
if (!!window.navigator.userAgent.match("MSIE 8")) {
!function(a){"use strict";a.matchMedia=a.matchMedia||function(a){var b,c=a.documentElement,d=c.firstElementChild||c.firstChild,e=a.createElement("body"),f=a.createElement("div");return f.id="mq-test-1",f.style.cssText="position:absolute;top:-100em",e.style.background="none",e.appendChild(f),function(a){return f.innerHTML='&shy;<style media="'+a+'"> #mq-test-1 { width: 42px; }</style>',c.insertBefore(e,d),b=42===f.offsetWidth,c.removeChild(e),{matches:b,media:a}}}(a.document)}(this),function(a){"use strict";function b(){u(!0)}var c={};a.respond=c,c.update=function(){};var d=[],e=function(){var b=!1;try{b=new a.XMLHttpRequest}catch(c){b=new a.ActiveXObject("Microsoft.XMLHTTP")}return function(){return b}}(),f=function(a,b){var c=e();c&&(c.open("GET",a,!0),c.onreadystatechange=function(){4!==c.readyState||200!==c.status&&304!==c.status||b(c.responseText)},4!==c.readyState&&c.send(null))};if(c.ajax=f,c.queue=d,c.regex={media:/@media[^\{]+\{([^\{\}]*\{[^\}\{]*\})+/gi,keyframes:/@(?:\-(?:o|moz|webkit)\-)?keyframes[^\{]+\{(?:[^\{\}]*\{[^\}\{]*\})+[^\}]*\}/gi,urls:/(url\()['"]?([^\/\)'"][^:\)'"]+)['"]?(\))/g,findStyles:/@media *([^\{]+)\{([\S\s]+?)$/,only:/(only\s+)?([a-zA-Z]+)\s?/,minw:/\([\s]*min\-width\s*:[\s]*([\s]*[0-9\.]+)(px|em)[\s]*\)/,maxw:/\([\s]*max\-width\s*:[\s]*([\s]*[0-9\.]+)(px|em)[\s]*\)/},c.mediaQueriesSupported=a.matchMedia&&null!==a.matchMedia("only all")&&a.matchMedia("only all").matches,!c.mediaQueriesSupported){var g,h,i,j=a.document,k=j.documentElement,l=[],m=[],n=[],o={},p=30,q=j.getElementsByTagName("head")[0]||k,r=j.getElementsByTagName("base")[0],s=q.getElementsByTagName("link"),t=function(){var a,b=j.createElement("div"),c=j.body,d=k.style.fontSize,e=c&&c.style.fontSize,f=!1;return b.style.cssText="position:absolute;font-size:1em;width:1em",c||(c=f=j.createElement("body"),c.style.background="none"),k.style.fontSize="100%",c.style.fontSize="100%",c.appendChild(b),f&&k.insertBefore(c,k.firstChild),a=b.offsetWidth,f?k.removeChild(c):c.removeChild(b),k.style.fontSize=d,e&&(c.style.fontSize=e),a=i=parseFloat(a)},u=function(b){var c="clientWidth",d=k[c],e="CSS1Compat"===j.compatMode&&d||j.body[c]||d,f={},o=s[s.length-1],r=(new Date).getTime();if(b&&g&&p>r-g)return a.clearTimeout(h),h=a.setTimeout(u,p),void 0;g=r;for(var v in l)if(l.hasOwnProperty(v)){var w=l[v],x=w.minw,y=w.maxw,z=null===x,A=null===y,B="em";x&&(x=parseFloat(x)*(x.indexOf(B)>-1?i||t():1)),y&&(y=parseFloat(y)*(y.indexOf(B)>-1?i||t():1)),w.hasquery&&(z&&A||!(z||e>=x)||!(A||y>=e))||(f[w.media]||(f[w.media]=[]),f[w.media].push(m[w.rules]))}for(var C in n)n.hasOwnProperty(C)&&n[C]&&n[C].parentNode===q&&q.removeChild(n[C]);n.length=0;for(var D in f)if(f.hasOwnProperty(D)){var E=j.createElement("style"),F=f[D].join("\n");E.type="text/css",E.media=D,q.insertBefore(E,o.nextSibling),E.styleSheet?E.styleSheet.cssText=F:E.appendChild(j.createTextNode(F)),n.push(E)}},v=function(a,b,d){var e=a.replace(c.regex.keyframes,"").match(c.regex.media),f=e&&e.length||0;b=b.substring(0,b.lastIndexOf("/"));var g=function(a){return a.replace(c.regex.urls,"$1"+b+"$2$3")},h=!f&&d;b.length&&(b+="/"),h&&(f=1);for(var i=0;f>i;i++){var j,k,n,o;h?(j=d,m.push(g(a))):(j=e[i].match(c.regex.findStyles)&&RegExp.$1,m.push(RegExp.$2&&g(RegExp.$2))),n=j.split(","),o=n.length;for(var p=0;o>p;p++)k=n[p],l.push({media:k.split("(")[0].match(c.regex.only)&&RegExp.$2||"all",rules:m.length-1,hasquery:k.indexOf("(")>-1,minw:k.match(c.regex.minw)&&parseFloat(RegExp.$1)+(RegExp.$2||""),maxw:k.match(c.regex.maxw)&&parseFloat(RegExp.$1)+(RegExp.$2||"")})}u()},w=function(){if(d.length){var b=d.shift();f(b.href,function(c){v(c,b.href,b.media),o[b.href]=!0,a.setTimeout(function(){w()},0)})}},x=function(){for(var b=0;b<s.length;b++){var c=s[b],e=c.href,f=c.media,g=c.rel&&"stylesheet"===c.rel.toLowerCase();e&&g&&!o[e]&&(c.styleSheet&&c.styleSheet.rawCssText?(v(c.styleSheet.rawCssText,e,f),o[e]=!0):(!/^([a-zA-Z:]*\/\/)/.test(e)&&!r||e.replace(RegExp.$1,"").split("/")[0]===a.location.host)&&("//"===e.substring(0,2)&&(e=a.location.protocol+e),d.push({href:e,media:f})))}w()};x(),c.update=x,c.getEmValue=t,a.addEventListener?a.addEventListener("resize",b,!1):a.attachEvent&&a.attachEvent("onresize",b)}}(this);
};
</script>
<style type="text/css">.pagedtable {
overflow: auto;
padding-left: 8px;
padding-right: 8px;
}
.pagedtable-wrapper {
border: 1px solid #ccc;
border-radius: 4px;
margin-bottom: 10px;
}
.pagedtable table {
width: 100%;
max-width: 100%;
margin: 0;
}
.pagedtable th {
padding: 0 5px 0 5px;
border: none;
border-bottom: 2px solid #dddddd;
min-width: 45px;
}
.pagedtable-empty th {
display: none;
}
.pagedtable td {
padding: 0 4px 0 4px;
}
.pagedtable .even {
background-color: rgba(140, 140, 140, 0.1);
}
.pagedtable-padding-col {
display: none;
}
.pagedtable a {
-webkit-touch-callout: none;
-webkit-user-select: none;
-khtml-user-select: none;
-moz-user-select: none;
-ms-user-select: none;
user-select: none;
}
.pagedtable-index-nav {
cursor: pointer;
padding: 0 5px 0 5px;
float: right;
border: 0;
}
.pagedtable-index-nav-disabled {
cursor: default;
text-decoration: none;
color: #999;
}
a.pagedtable-index-nav-disabled:hover {
text-decoration: none;
color: #999;
}
.pagedtable-indexes {
cursor: pointer;
float: right;
border: 0;
}
.pagedtable-index-current {
cursor: default;
text-decoration: none;
font-weight: bold;
color: #333;
border: 0;
}
a.pagedtable-index-current:hover {
text-decoration: none;
font-weight: bold;
color: #333;
}
.pagedtable-index {
width: 30px;
display: inline-block;
text-align: center;
border: 0;
}
.pagedtable-index-separator-left {
display: inline-block;
color: #333;
font-size: 9px;
padding: 0 0 0 0;
cursor: default;
}
.pagedtable-index-separator-right {
display: inline-block;
color: #333;
font-size: 9px;
padding: 0 4px 0 0;
cursor: default;
}
.pagedtable-footer {
padding-top: 4px;
padding-bottom: 5px;
}
.pagedtable-not-empty .pagedtable-footer {
border-top: 2px solid #dddddd;
}
.pagedtable-info {
overflow: hidden;
color: #999;
white-space: nowrap;
text-overflow: ellipsis;
}
.pagedtable-header-name {
overflow: hidden;
text-overflow: ellipsis;
}
.pagedtable-header-type {
color: #999;
font-weight: 400;
}
.pagedtable-na-cell {
font-style: italic;
opacity: 0.3;
}
</style>
<script>// Production steps of ECMA-262, Edition 5, 15.4.4.18
// Reference: http://es5.github.io/#x15.4.4.18
if (!Array.prototype.forEach) {

  Array.prototype.forEach = function(callback, thisArg) {

    var T, k;

    if (this === null) {
      throw new TypeError(' this is null or not defined');
    }

    // 1. Let O be the result of calling toObject() passing the
    // |this| value as the argument.
    var O = Object(this);

    // 2. Let lenValue be the result of calling the Get() internal
    // method of O with the argument "length".
    // 3. Let len be toUint32(lenValue).
    var len = O.length >>> 0;

    // 4. If isCallable(callback) is false, throw a TypeError exception.
    // See: http://es5.github.com/#x9.11
    if (typeof callback !== "function") {
      throw new TypeError(callback + ' is not a function');
    }

    // 5. If thisArg was supplied, let T be thisArg; else let
    // T be undefined.
    if (arguments.length > 1) {
      T = thisArg;
    }

    // 6. Let k be 0
    k = 0;

    // 7. Repeat, while k < len
    while (k < len) {

      var kValue;

      // a. Let Pk be ToString(k).
      //    This is implicit for LHS operands of the in operator
      // b. Let kPresent be the result of calling the HasProperty
      //    internal method of O with argument Pk.
      //    This step can be combined with c
      // c. If kPresent is true, then
      if (k in O) {

        // i. Let kValue be the result of calling the Get internal
        // method of O with argument Pk.
        kValue = O[k];

        // ii. Call the Call internal method of callback with T as
        // the this value and argument list containing kValue, k, and O.
        callback.call(T, kValue, k, O);
      }
      // d. Increase k by 1.
      k++;
    }
    // 8. return undefined
  };
}

// Production steps of ECMA-262, Edition 5, 15.4.4.19
// Reference: http://es5.github.io/#x15.4.4.19
if (!Array.prototype.map) {

  Array.prototype.map = function(callback, thisArg) {

    var T, A, k;

    if (this == null) {
      throw new TypeError(' this is null or not defined');
    }

    // 1. Let O be the result of calling ToObject passing the |this|
    //    value as the argument.
    var O = Object(this);

    // 2. Let lenValue be the result of calling the Get internal
    //    method of O with the argument "length".
    // 3. Let len be ToUint32(lenValue).
    var len = O.length >>> 0;

    // 4. If IsCallable(callback) is false, throw a TypeError exception.
    // See: http://es5.github.com/#x9.11
    if (typeof callback !== 'function') {
      throw new TypeError(callback + ' is not a function');
    }

    // 5. If thisArg was supplied, let T be thisArg; else let T be undefined.
    if (arguments.length > 1) {
      T = thisArg;
    }

    // 6. Let A be a new array created as if by the expression new Array(len)
    //    where Array is the standard built-in constructor with that name and
    //    len is the value of len.
    A = new Array(len);

    // 7. Let k be 0
    k = 0;

    // 8. Repeat, while k < len
    while (k < len) {

      var kValue, mappedValue;

      // a. Let Pk be ToString(k).
      //   This is implicit for LHS operands of the in operator
      // b. Let kPresent be the result of calling the HasProperty internal
      //    method of O with argument Pk.
      //   This step can be combined with c
      // c. If kPresent is true, then
      if (k in O) {

        // i. Let kValue be the result of calling the Get internal
        //    method of O with argument Pk.
        kValue = O[k];

        // ii. Let mappedValue be the result of calling the Call internal
        //     method of callback with T as the this value and argument
        //     list containing kValue, k, and O.
        mappedValue = callback.call(T, kValue, k, O);

        // iii. Call the DefineOwnProperty internal method of A with arguments
        // Pk, Property Descriptor
        // { Value: mappedValue,
        //   Writable: true,
        //   Enumerable: true,
        //   Configurable: true },
        // and false.

        // In browsers that support Object.defineProperty, use the following:
        // Object.defineProperty(A, k, {
        //   value: mappedValue,
        //   writable: true,
        //   enumerable: true,
        //   configurable: true
        // });

        // For best browser support, use the following:
        A[k] = mappedValue;
      }
      // d. Increase k by 1.
      k++;
    }

    // 9. return A
    return A;
  };
}

var PagedTable = function (pagedTable) {
  var me = this;

  var source = function(pagedTable) {
    var sourceElems = [].slice.call(pagedTable.children).filter(function(e) {
      return e.hasAttribute("data-pagedtable-source");
    });

    if (sourceElems === null || sourceElems.length !== 1) {
      throw("A single data-pagedtable-source was not found");
    }

    return JSON.parse(sourceElems[0].innerHTML);
  }(pagedTable);

  var options = function(source) {
    var options = typeof(source.options) !== "undefined" &&
      source.options !== null ? source.options : {};

    var columns = typeof(options.columns) !== "undefined" ? options.columns : {};
    var rows = typeof(options.rows) !== "undefined" ? options.rows : {};

    var positiveIntOrNull = function(value) {
      return parseInt(value) >= 0 ? parseInt(value) : null;
    };

    return {
      pages: positiveIntOrNull(options.pages),
      rows: {
        min: positiveIntOrNull(rows.min),
        max: positiveIntOrNull(rows.max),
        total: positiveIntOrNull(rows.total)
      },
      columns: {
        min: positiveIntOrNull(columns.min),
        max: positiveIntOrNull(columns.max),
        total: positiveIntOrNull(columns.total)
      }
    };
  }(source);

  var Measurer = function() {

    // set some default initial values that will get adjusted in runtime
    me.measures = {
      padding: 12,
      character: 8,
      height: 15,
      defaults: true
    };

    me.calculate = function(measuresCell) {
      if (!me.measures.defaults)
        return;

      var measuresCellStyle = window.getComputedStyle(measuresCell, null);

      var newPadding = parsePadding(measuresCellStyle.paddingLeft) +
            parsePadding(measuresCellStyle.paddingRight);

      var sampleString = "ABCDEFGHIJ0123456789";
      var newCharacter = Math.ceil(measuresCell.clientWidth / sampleString.length);

      if (newPadding <= 0 || newCharacter <= 0)
        return;

      me.measures.padding = newPadding;
      me.measures.character = newCharacter;
      me.measures.height = measuresCell.clientHeight;
      me.measures.defaults = false;
    };

    return me;
  };

  var Page = function(data, options) {
    var me = this;

    var defaults = {
      max: 7,
      rows: 10
    };

    var totalPages = function() {
      return Math.ceil(data.length / me.rows);
    };

    me.number = 0;
    me.max = options.pages !== null ? options.pages : defaults.max;
    me.visible = me.max;
    me.rows = options.rows.min !== null ? options.rows.min : defaults.rows;
    me.total = totalPages();

    me.setRows = function(newRows) {
      me.rows = newRows;
      me.total = totalPages();
    };

    me.setPageNumber = function(newPageNumber) {
      if (newPageNumber < 0) newPageNumber = 0;
      if (newPageNumber >= me.total) newPageNumber = me.total - 1;

      me.number = newPageNumber;
    };

    me.setVisiblePages = function(visiblePages) {
      me.visible = Math.min(me.max, visiblePages);
      me.setPageNumber(me.number);
    };

    me.getVisiblePageRange = function() {
      var start = me.number - Math.max(Math.floor((me.visible - 1) / 2), 0);
      var end = me.number + Math.floor(me.visible / 2) + 1;
      var pageCount = me.total;

      if (start < 0) {
        var diffToStart = 0 - start;
        start += diffToStart;
        end += diffToStart;
      }

      if (end > pageCount) {
        var diffToEnd = end - pageCount;
        start -= diffToEnd;
        end -= diffToEnd;
      }

      start = start < 0 ? 0 : start;
      end = end >= pageCount ? pageCount : end;

      var first = false;
      var last = false;

      if (start > 0 && me.visible > 1) {
        start = start + 1;
        first = true;
      }

      if (end < pageCount && me.visible > 2) {
        end = end - 1;
        last = true;
      }

      return {
        first: first,
        start: start,
        end: end,
        last: last
      };
    };

    me.getRowStart = function() {
      var rowStart = page.number * page.rows;
      if (rowStart < 0)
        rowStart = 0;

      return rowStart;
    };

    me.getRowEnd = function() {
      var rowStart = me.getRowStart();
      return Math.min(rowStart + me.rows, data.length);
    };

    me.getPaddingRows = function() {
      var rowStart = me.getRowStart();
      var rowEnd = me.getRowEnd();
      return data.length > me.rows ? me.rows - (rowEnd - rowStart) : 0;
    };
  };

  var Columns = function(data, columns, options) {
    var me = this;

    me.defaults = {
      min: 5
    };

    me.number = 0;
    me.visible = 0;
    me.total = columns.length;
    me.subset = [];
    me.padding = 0;
    me.min = options.columns.min !== null ? options.columns.min : me.defaults.min;
    me.max = options.columns.max !== null ? options.columns.max : null;
    me.widths = {};

    var widthsLookAhead = Math.max(100, options.rows.min);
    var paddingColChars = 10;

    me.emptyNames = function() {
      columns.forEach(function(column) {
        if (columns.label !== null && columns.label !== "")
          return false;
      });

      return true;
    };

    var parsePadding = function(value) {
      return parseInt(value) >= 0 ? parseInt(value) : 0;
    };

    me.calculateWidths = function(measures) {
      columns.forEach(function(column) {
        var maxChars = Math.max(
          column.label.toString().length,
          column.type.toString().length
        );

        for (var idxRow = 0; idxRow < Math.min(widthsLookAhead, data.length); idxRow++) {
          maxChars = Math.max(maxChars, data[idxRow][column.name.toString()].length);
        }

        me.widths[column.name] = {
          // width in characters
          chars: maxChars,
          // width for the inner html columns
          inner: maxChars * measures.character,
          // width adding outer styles like padding
          outer: maxChars * measures.character + measures.padding
        };
      });
    };

    me.getWidth = function() {
      var widthOuter = 0;
      for (var idxCol = 0; idxCol < me.subset.length; idxCol++) {
        var columnName = me.subset[idxCol].name;
        widthOuter = widthOuter + me.widths[columnName].outer;
      }

      widthOuter = widthOuter + me.padding * paddingColChars * measurer.measures.character;

      if (me.hasMoreLeftColumns()) {
        widthOuter = widthOuter + columnNavigationWidthPX + measurer.measures.padding;
      }

      if (me.hasMoreRightColumns()) {
        widthOuter = widthOuter + columnNavigationWidthPX + measurer.measures.padding;
      }

      return widthOuter;
    };

    me.updateSlice = function() {
      if (me.number + me.visible >= me.total)
        me.number = me.total - me.visible;

      if (me.number < 0) me.number = 0;

      me.subset = columns.slice(me.number, Math.min(me.number + me.visible, me.total));

      me.subset = me.subset.map(function(column) {
        Object.keys(column).forEach(function(colKey) {
          column[colKey] = column[colKey] === null ? "" : column[colKey].toString();
        });

        column.width = null;
        return column;
      });
    };

    me.setVisibleColumns = function(columnNumber, newVisibleColumns, paddingCount) {
      me.number = columnNumber;
      me.visible = newVisibleColumns;
      me.padding = paddingCount;

      me.updateSlice();
    };

    me.incColumnNumber = function(increment) {
      me.number = me.number + increment;
    };

    me.setColumnNumber = function(newNumber) {
      me.number = newNumber;
    };

    me.setPaddingCount = function(newPadding) {
      me.padding = newPadding;
    };

    me.getPaddingCount = function() {
      return me.padding;
    };

    me.hasMoreLeftColumns = function() {
      return me.number > 0;
    };

    me.hasMoreRightColumns = function() {
      return me.number + me.visible < me.total;
    };

    me.updateSlice(0);
    return me;
  };

  var data = source.data;
  var page = new Page(data, options);
  var measurer = new Measurer(data, options);
  var columns = new Columns(data, source.columns, options);

  var table = null;
  var tableDiv = null;
  var header = null;
  var footer = null;
  var tbody = null;

  // Caches pagedTable.clientWidth, specially for webkit
  var cachedPagedTableClientWidth = null;

  var onChangeCallbacks = [];

  var clearSelection = function() {
    if(document.selection && document.selection.empty) {
      document.selection.empty();
    } else if(window.getSelection) {
      var sel = window.getSelection();
      sel.removeAllRanges();
    }
  };

  var columnNavigationWidthPX = 5;

  var renderColumnNavigation = function(increment, backwards) {
    var arrow = document.createElement("div");
    arrow.setAttribute("style",
      "border-top: " + columnNavigationWidthPX + "px solid transparent;" +
      "border-bottom: " + columnNavigationWidthPX + "px solid transparent;" +
      "border-" + (backwards ? "right" : "left") + ": " + columnNavigationWidthPX + "px solid;");

    var header = document.createElement("th");
    header.appendChild(arrow);
    header.setAttribute("style",
      "cursor: pointer;" +
      "vertical-align: middle;" +
      "min-width: " + columnNavigationWidthPX + "px;" +
      "width: " + columnNavigationWidthPX + "px;");

    header.onclick = function() {
      columns.incColumnNumber(backwards ? -1 : increment);

      me.animateColumns(backwards);
      renderFooter();

      clearSelection();
      triggerOnChange();
    };

    return header;
  };

  var maxColumnWidth = function(width) {
    var padding = 80;
    var columnMax = Math.max(cachedPagedTableClientWidth - padding, 0);

    return parseInt(width) > 0 ?
      Math.min(columnMax, parseInt(width)) + "px" :
      columnMax + "px";
  };

  var clearHeader = function() {
    var thead = pagedTable.querySelectorAll("thead")[0];
    thead.innerHTML = "";
  };

  var renderHeader = function(clear) {
    cachedPagedTableClientWidth = pagedTable.clientWidth;

    var fragment = document.createDocumentFragment();

    header = document.createElement("tr");
    fragment.appendChild(header);

    if (columns.number > 0)
      header.appendChild(renderColumnNavigation(-columns.visible, true));

    columns.subset = columns.subset.map(function(columnData) {
      var column = document.createElement("th");
      column.setAttribute("align", columnData.align);
      column.style.textAlign = columnData.align;

      column.style.maxWidth = maxColumnWidth(null);
      if (columnData.width) {
        column.style.minWidth =
          column.style.maxWidth = maxColumnWidth(columnData.width);
      }

      var columnName = document.createElement("div");
      columnName.setAttribute("class", "pagedtable-header-name");
      if (columnData.label === "") {
        columnName.innerHTML = "&nbsp;";
      }
      else {
        columnName.appendChild(document.createTextNode(columnData.label));
      }
      column.appendChild(columnName);

      var columnType = document.createElement("div");
      columnType.setAttribute("class", "pagedtable-header-type");
      if (columnData.type === "") {
        columnType.innerHTML = "&nbsp;";
      }
      else {
        columnType.appendChild(document.createTextNode("<" + columnData.type + ">"));
      }
      column.appendChild(columnType);

      header.appendChild(column);

      columnData.element = column;

      return columnData;
    });

    for (var idx = 0; idx < columns.getPaddingCount(); idx++) {
      var paddingCol = document.createElement("th");
      paddingCol.setAttribute("class", "pagedtable-padding-col");
      header.appendChild(paddingCol);
    }

    if (columns.number + columns.visible < columns.total)
      header.appendChild(renderColumnNavigation(columns.visible, false));

    if (typeof(clear) == "undefined" || clear) clearHeader();
    var thead = pagedTable.querySelectorAll("thead")[0];
    thead.appendChild(fragment);
  };

  me.animateColumns = function(backwards) {
    var thead = pagedTable.querySelectorAll("thead")[0];

    var headerOld = thead.querySelectorAll("tr")[0];
    var tbodyOld = table.querySelectorAll("tbody")[0];

    me.fitColumns(backwards);

    renderHeader(false);

    header.style.opacity = "0";
    header.style.transform = backwards ? "translateX(-30px)" : "translateX(30px)";
    header.style.transition = "transform 200ms linear, opacity 200ms";
    header.style.transitionDelay = "0";

    renderBody(false);

    if (headerOld) {
      headerOld.style.position = "absolute";
      headerOld.style.transform = "translateX(0px)";
      headerOld.style.opacity = "1";
      headerOld.style.transition = "transform 100ms linear, opacity 100ms";
      headerOld.setAttribute("class", "pagedtable-remove-head");
      if (headerOld.style.transitionEnd) {
        headerOld.addEventListener("transitionend", function() {
          var headerOldByClass = thead.querySelector(".pagedtable-remove-head");
          if (headerOldByClass) thead.removeChild(headerOldByClass);
        });
      }
      else {
        thead.removeChild(headerOld);
      }
    }

    if (tbodyOld) table.removeChild(tbodyOld);

    tbody.style.opacity = "0";
    tbody.style.transition = "transform 200ms linear, opacity 200ms";
    tbody.style.transitionDelay = "0ms";

    // force relayout
    window.getComputedStyle(header).opacity;
    window.getComputedStyle(tbody).opacity;

    if (headerOld) {
      headerOld.style.transform = backwards ? "translateX(20px)" : "translateX(-30px)";
      headerOld.style.opacity = "0";
    }

    header.style.transform = "translateX(0px)";
    header.style.opacity = "1";

    tbody.style.opacity = "1";
  }

  me.onChange = function(callback) {
    onChangeCallbacks.push(callback);
  };

  var triggerOnChange = function() {
    onChangeCallbacks.forEach(function(onChange) {
      onChange();
    });
  };

  var clearBody = function() {
    if (tbody) {
      table.removeChild(tbody);
      tbody = null;
    }
  };

  var renderBody = function(clear) {
    cachedPagedTableClientWidth = pagedTable.clientWidth

    var fragment = document.createDocumentFragment();

    var pageData = data.slice(page.getRowStart(), page.getRowEnd());

    pageData.forEach(function(dataRow, idxRow) {
      var htmlRow = document.createElement("tr");
      htmlRow.setAttribute("class", (idxRow % 2 !==0) ? "even" : "odd");

      if (columns.hasMoreLeftColumns())
        htmlRow.appendChild(document.createElement("td"));

      columns.subset.forEach(function(columnData) {
        var cellName = columnData.name;
        var dataCell = dataRow[cellName];
        var htmlCell = document.createElement("td");

        if (dataCell === "NA") htmlCell.setAttribute("class", "pagedtable-na-cell");
        if (dataCell === "__NA__") dataCell = "NA";

        var cellText = document.createTextNode(dataCell);
        htmlCell.appendChild(cellText);
        if (dataCell.length > 50) {
          htmlCell.setAttribute("title", dataCell);
        }
        htmlCell.setAttribute("align", columnData.align);
        htmlCell.style.textAlign = columnData.align;
        htmlCell.style.maxWidth = maxColumnWidth(null);
        if (columnData.width) {
          htmlCell.style.minWidth = htmlCell.style.maxWidth = maxColumnWidth(columnData.width);
        }
        htmlRow.appendChild(htmlCell);
      });

      for (var idx = 0; idx < columns.getPaddingCount(); idx++) {
        var paddingCol = document.createElement("td");
        paddingCol.setAttribute("class", "pagedtable-padding-col");
        htmlRow.appendChild(paddingCol);
      }

      if (columns.hasMoreRightColumns())
        htmlRow.appendChild(document.createElement("td"));

      fragment.appendChild(htmlRow);
    });

    for (var idxPadding = 0; idxPadding < page.getPaddingRows(); idxPadding++) {
      var paddingRow = document.createElement("tr");

      var paddingCellRow = document.createElement("td");
      paddingCellRow.innerHTML = "&nbsp;";
      paddingCellRow.setAttribute("colspan", "100%");
      paddingRow.appendChild(paddingCellRow);

      fragment.appendChild(paddingRow);
    }

    if (typeof(clear) == "undefined" || clear) clearBody();
    tbody = document.createElement("tbody");
    tbody.appendChild(fragment);

    table.appendChild(tbody);
  };

  var getLabelInfo = function() {
    var pageStart = page.getRowStart();
    var pageEnd = page.getRowEnd();
    var totalRows = data.length;

    var totalRowsLabel = options.rows.total ? options.rows.total : totalRows;
    var totalRowsLabelFormat = totalRowsLabel.toString().replace(/(\d)(?=(\d\d\d)+(?!\d))/g, '$1,');

    var infoText = (pageStart + 1) + "-" + pageEnd + " of " + totalRowsLabelFormat + " rows";
    if (totalRows < page.rows) {
      infoText = totalRowsLabel + " row" + (totalRows != 1 ? "s" : "");
    }
    if (columns.total > columns.visible) {
      var totalColumnsLabel = options.columns.total ? options.columns.total : columns.total;

      infoText = infoText + " | " + (columns.number + 1) + "-" +
        (Math.min(columns.number + columns.visible, columns.total)) +
        " of " + totalColumnsLabel + " columns";
    }

    return infoText;
  };

  var clearFooter = function() {
    footer = pagedTable.querySelectorAll("div.pagedtable-footer")[0];
    footer.innerHTML = "";

    return footer;
  };

  var createPageLink = function(idxPage) {
    var pageLink = document.createElement("a");
    pageLinkClass = idxPage === page.number ? "pagedtable-index pagedtable-index-current" : "pagedtable-index";
    pageLink.setAttribute("class", pageLinkClass);
    pageLink.setAttribute("data-page-index", idxPage);
    pageLink.onclick = function() {
      page.setPageNumber(parseInt(this.getAttribute("data-page-index")));
      renderBody();
      renderFooter();

      triggerOnChange();
    };

    pageLink.appendChild(document.createTextNode(idxPage + 1));

    return pageLink;
  }

  var renderFooter = function() {
    footer = clearFooter();

    var next = document.createElement("a");
    next.appendChild(document.createTextNode("Next"));
    next.onclick = function() {
      page.setPageNumber(page.number + 1);
      renderBody();
      renderFooter();

      triggerOnChange();
    };
    if (data.length > page.rows) footer.appendChild(next);

    var pageNumbers = document.createElement("div");
    pageNumbers.setAttribute("class", "pagedtable-indexes");

    var pageRange = page.getVisiblePageRange();

    if (pageRange.first) {
      var pageLink = createPageLink(0);
      pageNumbers.appendChild(pageLink);

      var pageSeparator = document.createElement("div");
      pageSeparator.setAttribute("class", "pagedtable-index-separator-left");
      pageSeparator.appendChild(document.createTextNode("..."))
      pageNumbers.appendChild(pageSeparator);
    }

    for (var idxPage = pageRange.start; idxPage < pageRange.end; idxPage++) {
      var pageLink = createPageLink(idxPage);

      pageNumbers.appendChild(pageLink);
    }

    if (pageRange.last) {
      var pageSeparator = document.createElement("div");
      pageSeparator.setAttribute("class", "pagedtable-index-separator-right");
      pageSeparator.appendChild(document.createTextNode("..."))
      pageNumbers.appendChild(pageSeparator);

      var pageLink = createPageLink(page.total - 1);
      pageNumbers.appendChild(pageLink);
    }

    if (data.length > page.rows) footer.appendChild(pageNumbers);

    var previous = document.createElement("a");
    previous.appendChild(document.createTextNode("Previous"));
    previous.onclick = function() {
      page.setPageNumber(page.number - 1);
      renderBody();
      renderFooter();

      triggerOnChange();
    };
    if (data.length > page.rows) footer.appendChild(previous);

    var infoLabel = document.createElement("div");
    infoLabel.setAttribute("class", "pagedtable-info");
    infoLabel.setAttribute("title", getLabelInfo());
    infoLabel.appendChild(document.createTextNode(getLabelInfo()));
    footer.appendChild(infoLabel);

    var enabledClass = "pagedtable-index-nav";
    var disabledClass = "pagedtable-index-nav pagedtable-index-nav-disabled";
    previous.setAttribute("class", page.number <= 0 ? disabledClass : enabledClass);
    next.setAttribute("class", (page.number + 1) * page.rows >= data.length ? disabledClass : enabledClass);
  };

  var measuresCell = null;

  var renderMeasures = function() {
    var measuresTable = document.createElement("table");
    measuresTable.style.visibility = "hidden";
    measuresTable.style.position = "absolute";
    measuresTable.style.whiteSpace = "nowrap";
    measuresTable.style.height = "auto";
    measuresTable.style.width = "auto";

    var measuresRow = document.createElement("tr");
    measuresTable.appendChild(measuresRow);

    measuresCell = document.createElement("td");
    var sampleString = "ABCDEFGHIJ0123456789";
    measuresCell.appendChild(document.createTextNode(sampleString));

    measuresRow.appendChild(measuresCell);

    tableDiv.appendChild(measuresTable);
  }

  me.init = function() {
    tableDiv = document.createElement("div");
    pagedTable.appendChild(tableDiv);
    var pagedTableClass = data.length > 0 ?
      "pagedtable pagedtable-not-empty" :
      "pagedtable pagedtable-empty";

    if (columns.total == 0 || (columns.emptyNames() && data.length == 0)) {
      pagedTableClass = pagedTableClass + " pagedtable-empty-columns";
    }

    tableDiv.setAttribute("class", pagedTableClass);

    renderMeasures();
    measurer.calculate(measuresCell);
    columns.calculateWidths(measurer.measures);

    table = document.createElement("table");
    table.setAttribute("cellspacing", "0");
    table.setAttribute("class", "table table-condensed");
    tableDiv.appendChild(table);

    table.appendChild(document.createElement("thead"));

    var footerDiv = document.createElement("div");
    footerDiv.setAttribute("class", "pagedtable-footer");
    tableDiv.appendChild(footerDiv);

    // if the host has not yet provided horizontal space, render hidden
    if (tableDiv.clientWidth <= 0) {
      tableDiv.style.opacity = "0";
    }

    me.render();

    // retry seizing columns later if the host has not provided space
    function retryFit() {
      if (tableDiv.clientWidth <= 0) {
        setTimeout(retryFit, 100);
      } else {
        me.render();
        triggerOnChange();
      }
    }
    if (tableDiv.clientWidth <= 0) {
      retryFit();
    }
  };

  var registerWidths = function() {
    columns.subset = columns.subset.map(function(column) {
      column.width = columns.widths[column.name].inner;
      return column;
    });
  };

  var parsePadding = function(value) {
    return parseInt(value) >= 0 ? parseInt(value) : 0;
  };

  me.fixedHeight = function() {
    return options.rows.max != null;
  }

  me.fitRows = function() {
    if (me.fixedHeight())
      return;

    measurer.calculate(measuresCell);

    var rows = options.rows.min !== null ? options.rows.min : 0;
    var headerHeight = header !== null && header.offsetHeight > 0 ? header.offsetHeight : 0;
    var footerHeight = footer !== null && footer.offsetHeight > 0 ? footer.offsetHeight : 0;

    if (pagedTable.offsetHeight > 0) {
      var availableHeight = pagedTable.offsetHeight - headerHeight - footerHeight;
      rows = Math.floor((availableHeight) / measurer.measures.height);
    }

    rows = options.rows.min !== null ? Math.max(options.rows.min, rows) : rows;

    page.setRows(rows);
  }

  // The goal of this function is to add as many columns as possible
  // starting from left-to-right, when the right most limit is reached
  // it tries to add columns from the left as well.
  //
  // When startBackwards is true columns are added from right-to-left
  me.fitColumns = function(startBackwards) {
    measurer.calculate(measuresCell);
    columns.calculateWidths(measurer.measures);

    if (tableDiv.clientWidth > 0) {
      tableDiv.style.opacity = 1;
    }

    var visibleColumns = tableDiv.clientWidth <= 0 ? Math.max(columns.min, 1) : 1;
    var columnNumber = columns.number;
    var paddingCount = 0;

    // track a list of added columns as we build the visible ones to allow us
    // to remove columns when they don't fit anymore.
    var columnHistory = [];

    var lastTableHeight = 0;
    var backwards = startBackwards;

    var tableDivStyle = window.getComputedStyle(tableDiv, null);
    var tableDivPadding = parsePadding(tableDivStyle.paddingLeft) +
      parsePadding(tableDivStyle.paddingRight);

    var addPaddingCol = false;
    var currentWidth = 0;

    while (true) {
      columns.setVisibleColumns(columnNumber, visibleColumns, paddingCount);
      currentWidth = columns.getWidth();

      if (tableDiv.clientWidth - tableDivPadding < currentWidth) {
        break;
      }

      columnHistory.push({
        columnNumber: columnNumber,
        visibleColumns: visibleColumns,
        paddingCount: paddingCount
      });

      if (columnHistory.length > 100) {
        console.error("More than 100 tries to fit columns, aborting");
        break;
      }

      if (columns.max !== null &&
        columns.visible + columns.getPaddingCount() >= columns.max) {
        break;
      }

      // if we run out of right-columns
      if (!backwards && columnNumber + columns.visible >= columns.total) {
        // if we started adding right-columns, try adding left-columns
        if (!startBackwards && columnNumber > 0) {
          backwards = true;
        }
        else if (columns.min === null || visibleColumns + columns.getPaddingCount() >= columns.min) {
          break;
        }
        else {
          paddingCount = paddingCount + 1;
        }
      }

      // if we run out of left-columns
      if (backwards && columnNumber == 0) {
        // if we started adding left-columns, try adding right-columns
        if (startBackwards && columnNumber + columns.visible < columns.total) {
          backwards = false;
        }
        else if (columns.min === null || visibleColumns + columns.getPaddingCount() >= columns.min) {
          break;
        }
        else {
          paddingCount = paddingCount + 1;
        }
      }

      // when moving backwards try fitting left columns first
      if (backwards && columnNumber > 0) {
        columnNumber = columnNumber - 1;
      }

      if (columnNumber + visibleColumns < columns.total) {
        visibleColumns = visibleColumns + 1;
      }
    }

    var lastRenderableColumn = {
        columnNumber: columnNumber,
        visibleColumns: visibleColumns,
        paddingCount: paddingCount
    };

    if (columnHistory.length > 0) {
      lastRenderableColumn = columnHistory[columnHistory.length - 1];
    }

    columns.setVisibleColumns(
      lastRenderableColumn.columnNumber,
      lastRenderableColumn.visibleColumns,
      lastRenderableColumn.paddingCount);

    if (pagedTable.offsetWidth > 0) {
      page.setVisiblePages(Math.max(Math.ceil(1.0 * (pagedTable.offsetWidth - 250) / 40), 2));
    }

    registerWidths();
  };

  me.fit = function(startBackwards) {
    me.fitRows();
    me.fitColumns(startBackwards);
  }

  me.render = function() {
    me.fitColumns(false);

    // render header/footer to measure height accurately
    renderHeader();
    renderFooter();

    me.fitRows();
    renderBody();

    // re-render footer to match new rows
    renderFooter();
  }

  var resizeLastWidth = -1;
  var resizeLastHeight = -1;
  var resizeNewWidth = -1;
  var resizeNewHeight = -1;
  var resizePending = false;

  me.resize = function(newWidth, newHeight) {

    function resizeDelayed() {
      resizePending = false;

      if (
        (resizeNewWidth !== resizeLastWidth) ||
        (!me.fixedHeight() && resizeNewHeight !== resizeLastHeight)
      ) {
        resizeLastWidth = resizeNewWidth;
        resizeLastHeight = resizeNewHeight;

        setTimeout(resizeDelayed, 200);
        resizePending = true;
      } else {
        me.render();
        triggerOnChange();

        resizeLastWidth = -1;
        resizeLastHeight = -1;
      }
    }

    resizeNewWidth = newWidth;
    resizeNewHeight = newHeight;

    if (!resizePending) resizeDelayed();
  };
};

var PagedTableDoc;
(function (PagedTableDoc) {
  var allPagedTables = [];

  PagedTableDoc.initAll = function() {
    allPagedTables = [];

    var pagedTables = [].slice.call(document.querySelectorAll('[data-pagedtable="false"],[data-pagedtable=""]'));
    pagedTables.forEach(function(pagedTable, idx) {
      pagedTable.setAttribute("data-pagedtable", "true");
      pagedTable.setAttribute("pagedtable-page", 0);
      pagedTable.setAttribute("class", "pagedtable-wrapper");

      var pagedTableInstance = new PagedTable(pagedTable);
      pagedTableInstance.init();

      allPagedTables.push(pagedTableInstance);
    });
  };

  PagedTableDoc.resizeAll = function() {
    allPagedTables.forEach(function(pagedTable) {
      pagedTable.render();
    });
  };

  window.addEventListener("resize", PagedTableDoc.resizeAll);

  return PagedTableDoc;
})(PagedTableDoc || (PagedTableDoc = {}));

window.onload = function() {
  PagedTableDoc.initAll();
};
</script>
<script>

/**
 * jQuery Plugin: Sticky Tabs
 *
 * @author Aidan Lister <aidan@php.net>
 * adapted by Ruben Arslan to activate parent tabs too
 * http://www.aidanlister.com/2014/03/persisting-the-tab-state-in-bootstrap/
 */
(function($) {
  "use strict";
  $.fn.rmarkdownStickyTabs = function() {
    var context = this;
    // Show the tab corresponding with the hash in the URL, or the first tab
    var showStuffFromHash = function() {
      var hash = window.location.hash;
      var selector = hash ? 'a[href="' + hash + '"]' : 'li.active > a';
      var $selector = $(selector, context);
      if($selector.data('toggle') === "tab") {
        $selector.tab('show');
        // walk up the ancestors of this element, show any hidden tabs
        $selector.parents('.section.tabset').each(function(i, elm) {
          var link = $('a[href="#' + $(elm).attr('id') + '"]');
          if(link.data('toggle') === "tab") {
            link.tab("show");
          }
        });
      }
    };


    // Set the correct tab when the page loads
    showStuffFromHash(context);

    // Set the correct tab when a user uses their back/forward button
    $(window).on('hashchange', function() {
      showStuffFromHash(context);
    });

    // Change the URL when tabs are clicked
    $('a', context).on('click', function(e) {
      history.pushState(null, null, this.href);
      showStuffFromHash(context);
    });

    return this;
  };
}(jQuery));

window.buildTabsets = function(tocID) {

  // build a tabset from a section div with the .tabset class
  function buildTabset(tabset) {

    // check for fade and pills options
    var fade = tabset.hasClass("tabset-fade");
    var pills = tabset.hasClass("tabset-pills");
    var navClass = pills ? "nav-pills" : "nav-tabs";

    // determine the heading level of the tabset and tabs
    var match = tabset.attr('class').match(/level(\d) /);
    if (match === null)
      return;
    var tabsetLevel = Number(match[1]);
    var tabLevel = tabsetLevel + 1;

    // find all subheadings immediately below
    var tabs = tabset.find("div.section.level" + tabLevel);
    if (!tabs.length)
      return;

    // create tablist and tab-content elements
    var tabList = $('<ul class="nav ' + navClass + '" role="tablist"></ul>');
    $(tabs[0]).before(tabList);
    var tabContent = $('<div class="tab-content"></div>');
    $(tabs[0]).before(tabContent);

    // build the tabset
    var activeTab = 0;
    tabs.each(function(i) {

      // get the tab div
      var tab = $(tabs[i]);

      // get the id then sanitize it for use with bootstrap tabs
      var id = tab.attr('id');

      // see if this is marked as the active tab
      if (tab.hasClass('active'))
        activeTab = i;

      // remove any table of contents entries associated with
      // this ID (since we'll be removing the heading element)
      $("div#" + tocID + " li a[href='#" + id + "']").parent().remove();

      // sanitize the id for use with bootstrap tabs
      id = id.replace(/[.\/?&!#<>]/g, '').replace(/\s/g, '_');
      tab.attr('id', id);

      // get the heading element within it, grab it's text, then remove it
      var heading = tab.find('h' + tabLevel + ':first');
      var headingText = heading.html();
      heading.remove();

      // build and append the tab list item
      var a = $('<a role="tab" data-toggle="tab">' + headingText + '</a>');
      a.attr('href', '#' + id);
      a.attr('aria-controls', id);
      var li = $('<li role="presentation"></li>');
      li.append(a);
      tabList.append(li);

      // set it's attributes
      tab.attr('role', 'tabpanel');
      tab.addClass('tab-pane');
      tab.addClass('tabbed-pane');
      if (fade)
        tab.addClass('fade');

      // move it into the tab content div
      tab.detach().appendTo(tabContent);
    });

    // set active tab
    $(tabList.children('li')[activeTab]).addClass('active');
    var active = $(tabContent.children('div.section')[activeTab]);
    active.addClass('active');
    if (fade)
      active.addClass('in');

    if (tabset.hasClass("tabset-sticky"))
      tabset.rmarkdownStickyTabs();
  }

  // convert section divs with the .tabset class to tabsets
  var tabsets = $("div.section.tabset");
  tabsets.each(function(i) {
    buildTabset($(tabsets[i]));
  });
};

</script>
<script>
window.initializeCodeFolding = function(show) {

  // handlers for show-all and hide all
  $("#rmd-show-all-code").click(function() {
    $('div.r-code-collapse').each(function() {
      $(this).collapse('show');
    });
  });
  $("#rmd-hide-all-code").click(function() {
    $('div.r-code-collapse').each(function() {
      $(this).collapse('hide');
    });
  });

  // index for unique code element ids
  var currentIndex = 1;

  // select all R code blocks
  var rCodeBlocks = $('pre.r, pre.python, pre.bash, pre.sql, pre.cpp, pre.stan, pre.julia');
  rCodeBlocks.each(function() {

    // create a collapsable div to wrap the code in
    var div = $('<div class="collapse r-code-collapse"></div>');
    if (show || $(this)[0].classList.contains('fold-show'))
      div.addClass('in');
    var id = 'rcode-643E0F36' + currentIndex++;
    div.attr('id', id);
    $(this).before(div);
    $(this).detach().appendTo(div);

    // add a show code button right above
    var showCodeText = $('<span>' + (show ? 'Hide' : 'Code') + '</span>');
    var showCodeButton = $('<button type="button" class="btn btn-default btn-xs code-folding-btn pull-right"></button>');
    showCodeButton.append(showCodeText);
    showCodeButton
        .attr('data-toggle', 'collapse')
        .attr('data-target', '#' + id)
        .attr('aria-expanded', show)
        .attr('aria-controls', id);

    var buttonRow = $('<div class="row"></div>');
    var buttonCol = $('<div class="col-md-12"></div>');

    buttonCol.append(showCodeButton);
    buttonRow.append(buttonCol);

    div.before(buttonRow);

    // update state of button on show/hide
    div.on('hidden.bs.collapse', function () {
      showCodeText.text('Code');
    });
    div.on('show.bs.collapse', function () {
      showCodeText.text('Hide');
    });
  });

}
</script>
<script>
window.initializeSourceEmbed = function(filename) {
  $("#rmd-download-source").click(function() {
    var src = $("#rmd-source-code").html();
    var a = document.createElement('a');
    a.href = "data:text/x-r-markdown;base64," + src;
    a.download = filename;
    document.body.appendChild(a);
    a.click();
    document.body.removeChild(a);
  });
};
</script>




<style type="text/css">
h1 {
  font-size: 34px;
}
h1.title {
  font-size: 38px;
}
h2 {
  font-size: 30px;
}
h3 {
  font-size: 24px;
}
h4 {
  font-size: 18px;
}
h5 {
  font-size: 16px;
}
h6 {
  font-size: 12px;
}
.table th:not([align]) {
  text-align: left;
}
#rmd-source-code {
  display: none;
}
</style>




<style type="text/css">
.main-container {
  max-width: 940px;
  margin-left: auto;
  margin-right: auto;
}
code {
  color: inherit;
  background-color: rgba(0, 0, 0, 0.04);
}
img {
  max-width:100%;
}
.tabbed-pane {
  padding-top: 12px;
}
.html-widget {
  margin-bottom: 20px;
}
button.code-folding-btn:focus {
  outline: none;
}
summary {
  display: list-item;
}
</style>

<style type="text/css">
.kable-table {
  border: 1px solid #ccc;
  border-radius: 4px;
  overflow: auto;
  padding-left: 8px;
  padding-right: 8px;
  margin-bottom: 20px;
  max-height: 350px;
}

.kable-table table {
  margin-bottom: 0px;
}

.kable-table table>thead>tr>th {
  border: none;
  border-bottom: 2px solid #dddddd;
}

.kable-table table>thead {
  background-color: #fff;
}
</style>


<!-- tabsets -->

<style type="text/css">
.tabset-dropdown > .nav-tabs {
  display: inline-table;
  max-height: 500px;
  min-height: 44px;
  overflow-y: auto;
  background: white;
  border: 1px solid #ddd;
  border-radius: 4px;
}

.tabset-dropdown > .nav-tabs > li.active:before {
  content: "";
  font-family: 'Glyphicons Halflings';
  display: inline-block;
  padding: 10px;
  border-right: 1px solid #ddd;
}

.tabset-dropdown > .nav-tabs.nav-tabs-open > li.active:before {
  content: "";
  border: none;
}

.tabset-dropdown > .nav-tabs.nav-tabs-open:before {
  content: "";
  font-family: 'Glyphicons Halflings';
  display: inline-block;
  padding: 10px;
  border-right: 1px solid #ddd;
}

.tabset-dropdown > .nav-tabs > li.active {
  display: block;
}

.tabset-dropdown > .nav-tabs > li > a,
.tabset-dropdown > .nav-tabs > li > a:focus,
.tabset-dropdown > .nav-tabs > li > a:hover {
  border: none;
  display: inline-block;
  border-radius: 4px;
  background-color: transparent;
}

.tabset-dropdown > .nav-tabs.nav-tabs-open > li {
  display: block;
  float: none;
}

.tabset-dropdown > .nav-tabs > li {
  display: none;
}
</style>

<!-- code folding -->
<style type="text/css">
.code-folding-btn { margin-bottom: 4px; }
</style>




</head>

<body>


<div class="container-fluid main-container">




<div class="fluid-row" id="header">

<div class="btn-group pull-right">
<button type="button" class="btn btn-default btn-xs dropdown-toggle" data-toggle="dropdown" aria-haspopup="true" aria-expanded="false"><span>Code</span> <span class="caret"></span></button>
<ul class="dropdown-menu" style="min-width: 50px;">
<li><a id="rmd-download-source" href="#">Download Rmd</a></li>
</ul>
</div>



<h1 class="title toc-ignore">Pancreatobiliary Pathology Society Journal Watch</h1>
<h3 class="subtitle">Recent Articles that will be Selected</h3>
<h4 class="date">Last Update on 2020-06-18</h4>

</div>


<!-- rnb-text-begin -->
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<style type="text/css">

h1{
  text-align: center;
}
h2{
  text-align: center;
}
h3{
  text-align: center;
}
h4{
  text-align: center;
}
h4.date{
  text-align: center;
}

</style>
<!-- Open all links in new tab-->
<p><base target="_blank"></base></p>
<hr />
<div id="pbpath_jw" class="section level1 tabset tabset-fade tabset-pills">
<h1 class="tabset tabset-fade tabset-pills">PBPath Journal Watch Articles</h1>
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<hr />
<p><strong>Welcome to the PBPath Journal Watch!</strong></p>
<p>This bi-monthly journal watch features exciting recently published pancreas and biliary pathology articles that will provide up to date medical knowledge in our field. These articles will be showcased in several convenient categories, including surgical pathology, cytopathology, molecular pathology, pancreas, gallbladder, bile ducts, and ampulla among others. The articles in each category are in no particular order. See the list of journals we search regularly <a href="http://pbpath.org/pbpath-journal-watch/">here</a>. Previous months’ issues may be found in our <em><a href="http://pbpath.org/journal-watch-archive/">archive</a></em> and you may see <a href="http://pbpath.org/journal-watch-upcoming-issue/">drafts of the upcoming issue here</a>.</p>
<p>We encourage members to actively participate by recommending new articles and providing feedback using the <a href="#feedback" target="_self">forms provided below.</a></p>
<p><strong>We hope that you will enjoy the new PBPath Journal Watch!</strong></p>
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details>
<p><summary> Click here to see these articles and graphical summaries in other databases </summary></p>
<p>The <em>journal watch</em> articles are collected in <a href="https://doi.org/10.5281/zenodo.3635440">zenodo</a> and <a href="https://osf.io/3d67y/">OSF</a>.<br />
<a href="https://doi.org/10.5281/zenodo.3635440"><img src="data:image/svg+xml; charset=utf-8;base64,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" alt="DOI" /></a></p>
<p>To see these selected articles in <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=32548755[uid] OR 32541639[uid] OR 32541638[uid] OR 32541637[uid] OR 32541637[uid] OR 32541636[uid] OR 32541635[uid] OR 32541633[uid] OR 32541631[uid] OR 32541630[uid] OR 32541629[uid] OR 32541628[uid] OR 32541227[uid] OR 32538222[uid] OR 32535975[uid] OR 32526166[uid] OR 32525623[uid] OR 32515558[uid] OR 32513848[uid] OR 32511899[uid] OR 32511134[uid] OR 32506819[uid] OR 32506441[uid] OR 32506156[uid] OR 32506156[uid] OR 32488621[uid] OR 32476131[uid] OR 32473032[uid] OR 32472717[uid] OR 32472097[uid] OR 32470391[uid] OR 32468246[uid] OR 32460791[uid] OR 32457409[uid] OR 32457408[uid] OR 32451945[uid] OR 32451945[uid] OR 32450151[uid] OR 32447492[uid] OR 32447492[uid] OR 32433409[uid] OR 32433407[uid] OR 32433400[uid] OR 32424767[uid] OR 32424583[uid] OR 32414657[uid] OR 32413172[uid] OR 32401429[uid] OR 32399832[uid] OR 32398486[uid] OR 32393543[uid] OR 32388775[uid] OR 32380013[uid] OR 32376951[uid] OR 32376474[uid] OR 32376411[uid] OR 32376198[uid] OR 32375666[uid] OR 32375666[uid] OR 32371200[uid] OR 32367668[uid] OR 32367502[uid] OR 32366671[uid] OR 32364613[uid] OR 32363511[uid] OR 32361926[uid] OR 32360551[uid] OR 32360245[uid] OR 32360002[uid] OR 32360001[uid] OR 32360000[uid] OR 32358589[uid] OR 32356271[uid] OR 32354994[uid] OR 32354626[uid] OR 32353313[uid] OR 32350971[uid] OR 32350416[uid] OR 32350415[uid] OR 32350089[uid] OR 32342296[uid] OR 32341034[uid] OR 32340876[uid] OR 32339496[uid] OR 32338534[uid] OR 32334515[uid] OR 32332003[uid] OR 32330476[uid] OR 32328982[uid] OR 32327527[uid] OR 32326889[uid] OR 32323087[uid] OR 32321542[uid] OR 32321466[uid] OR 32320048[uid] OR 32319130[uid] OR 32318949[uid] OR 32317534[uid] OR 32315514[uid] OR 32314163[uid]"> PubMed click here </a></p>
<p>To see these selected articles in <a href="https://www.lens.org/lens/scholar/search/results?q=pmid:32548755%20OR%20pmid:32541639%20OR%20pmid:32541638%20OR%20pmid:32541637%20OR%20pmid:32541637%20OR%20pmid:32541636%20OR%20pmid:32541635%20OR%20pmid:32541633%20OR%20pmid:32541631%20OR%20pmid:32541630%20OR%20pmid:32541629%20OR%20pmid:32541628%20OR%20pmid:32541227%20OR%20pmid:32538222%20OR%20pmid:32535975%20OR%20pmid:32526166%20OR%20pmid:32525623%20OR%20pmid:32515558%20OR%20pmid:32513848%20OR%20pmid:32511899%20OR%20pmid:32511134%20OR%20pmid:32506819%20OR%20pmid:32506441%20OR%20pmid:32506156%20OR%20pmid:32506156%20OR%20pmid:32488621%20OR%20pmid:32476131%20OR%20pmid:32473032%20OR%20pmid:32472717%20OR%20pmid:32472097%20OR%20pmid:32470391%20OR%20pmid:32468246%20OR%20pmid:32460791%20OR%20pmid:32457409%20OR%20pmid:32457408%20OR%20pmid:32451945%20OR%20pmid:32451945%20OR%20pmid:32450151%20OR%20pmid:32447492%20OR%20pmid:32447492%20OR%20pmid:32433409%20OR%20pmid:32433407%20OR%20pmid:32433400%20OR%20pmid:32424767%20OR%20pmid:32424583%20OR%20pmid:32414657%20OR%20pmid:32413172%20OR%20pmid:32401429%20OR%20pmid:32399832%20OR%20pmid:32398486%20OR%20pmid:32393543%20OR%20pmid:32388775%20OR%20pmid:32380013%20OR%20pmid:32376951%20OR%20pmid:32376474%20OR%20pmid:32376411%20OR%20pmid:32376198%20OR%20pmid:32375666%20OR%20pmid:32375666%20OR%20pmid:32371200%20OR%20pmid:32367668%20OR%20pmid:32367502%20OR%20pmid:32366671%20OR%20pmid:32364613%20OR%20pmid:32363511%20OR%20pmid:32361926%20OR%20pmid:32360551%20OR%20pmid:32360245%20OR%20pmid:32360002%20OR%20pmid:32360001%20OR%20pmid:32360000%20OR%20pmid:32358589%20OR%20pmid:32356271%20OR%20pmid:32354994%20OR%20pmid:32354626%20OR%20pmid:32353313%20OR%20pmid:32350971%20OR%20pmid:32350416%20OR%20pmid:32350415%20OR%20pmid:32350089%20OR%20pmid:32342296%20OR%20pmid:32341034%20OR%20pmid:32340876%20OR%20pmid:32339496%20OR%20pmid:32338534%20OR%20pmid:32334515%20OR%20pmid:32332003%20OR%20pmid:32330476%20OR%20pmid:32328982%20OR%20pmid:32327527%20OR%20pmid:32326889%20OR%20pmid:32323087%20OR%20pmid:32321542%20OR%20pmid:32321466%20OR%20pmid:32320048%20OR%20pmid:32319130%20OR%20pmid:32318949%20OR%20pmid:32317534%20OR%20pmid:32315514%20OR%20pmid:32314163&amp;toYear=2020&amp;fromYear=1950&amp;dateFilterField=year_published&amp;filterMap=%7B%7D&amp;preview=true"> Lens.org click here </a></p>
</details>
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<div style="page-break-after: always;"></div>
<div id="pancreas" class="section level2">
<h2>Pancreas</h2>
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Interactions Between Neutrophils and Platelets in the Progression of Acute Pancreatitis</strong> </summary></p>
<p><em>Pancreas 2020 Jun;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=32541639" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=32541639</a></p>
<p>OBJECTIVE: Severe acute pancreatitis is a serious disease, but its detailed mechanism has not yet been elucidated. We aimed to clarify the interaction between neutrophils and platelets in the pathogenesis of acute pancreatitis. METHODS: We induced acute pancreatitis in rats by injection of sodium taurocholate into the biliopancreatic duct and killed them over time. We observed the histological changes in pancreatic tissue with special attention to the dynamics of neutrophils and platelets. We also measured the concentrations of neutrophil- and platelet-derived factors in pancreatic tissue and blood samples. RESULTS: Neutrophils and platelets in the pancreatic tissue showed a similar pattern of migration. They initially spread in the interlobular connective tissue and finally into the lobules. The concentration of myeloperoxidase gradually increased in the inflamed pancreas until 24 hours and the concentration of thromboxane B2, plasminogen activator inhibitor 1, and CD41 also increased with time. Finally, the concentration of serum myeloperoxidase, citrullinated histone H3, and high-mobility group box 1 increased over time. CONCLUSIONS: The interaction between neutrophils and platelets in pancreatic tissue plays an important role in the mechanism of advancing severity in acute pancreatitis. Circulating damage-associated molecular patterns induced by excessive local inflammation may lead to other organ injuries.</p>
<p>doi: <a href="https://doi.org/10.1097/MPA.0000000000001585" class="uri">https://doi.org/10.1097/MPA.0000000000001585</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Radiation as a Single-Modality Treatment in Localized Pancreatic Cancer</strong> </summary></p>
<p><em>Pancreas 2020 Jun;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=32541638" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=32541638</a></p>
<p>OBJECTIVES: Locally advanced pancreatic cancer (LAPC) is managed with multimodality therapy. We aim to evaluate the outcome of single-modality radiation therapy for LAPC. METHODS: Locally advanced pancreatic cancer patients were identified between 2004 and 2013 using the National Cancer Database excluding patients who received chemotherapy or surgery. RESULTS: A total of 6590 patients were included. The mean age was 73.5 (range, 28-90) years, 83.2% were white, and 54.4% were female. Tumors of 4 cm or greater (&gt;T3 stage) accounted for 52.7%. The median radiation dose was 39.6 Gy. Stereotactic body radiation (SBRT) delivered to 64 patients and external-beam/intensity modulated radiotherapy in 416 patients. Radiation therapy was associated with improved overall survival (OS) compared with no treatment in univariate and multivariable analyses. The medians OS for patients who received SBRT, external-beam/intensity modulated radiotherapy, or no radiation were 8.6, 6.7, and 3.4 months, respectively (P &lt; 0.001). There is a significant difference in 12-month OS for the SBRT cohort (31.9%; 95% confidence interval [CI], 20.9%-43.5%) compared with patients who received no radiation (15.1%; 95% CI, 14.2%-16.0%), and on multivariable analysis (hazard ratio, 0.50; 95% CI, 0.38-0.65; P &lt; 0.001). CONCLUSIONS: The current study suggests potential benefit for radiation therapy alone in comparison with no treatment in LAPC.</p>
<p>doi: <a href="https://doi.org/10.1097/MPA.0000000000001584" class="uri">https://doi.org/10.1097/MPA.0000000000001584</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Alterations in Enteroendocrine Hormones After Total Pancreatectomy With Islet Autotransplantation</strong> </summary></p>
<p><em>Pancreas 2020 Jun;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=32541637" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=32541637</a></p>
<p>OBJECTIVE: When total pancreatectomy with islet autotransplantation (TPIAT) is performed for chronic pancreatitis, the pancreas and most of the duodenum are removed, with Roux-en-Y reconstruction of the gastrointestinal tract. Enteroendocrine cells in the intestines and pancreas secrete hormones coordinating digestion and motility, but anatomic reconstruction alters transit of nutrients to these cells. We hypothesized that TPIAT leads to changes in enteroendocrine hormones. METHODS: Glucagon-like peptide 1 (GLP-1), peptide YY (PYY), and pancreatic polypeptide (PP) were measured from mixed-meal tolerance tests of 34 clinical trial participants before and 18 months after TPIAT. Area under the curve of GLP-1 and PYY-stimulated responses were calculated by trapezoidal method, and the PP response was measured as the stimulated max minus baseline (ΔPP). RESULTS: Area under the curve of GLP-1 and PYY increased significantly after TPIAT (GLP-1 average +553.1 pg/mL per minute, P = 0.004; PYY average +4647.9 pg/mL per minute, P = 0.02). ΔPP trended toward lower after TPIAT (average, -52.2 pg/mL, P = 0.06). CONCLUSIONS: In this novel study of enteroendocrine hormones in TPIAT patients, stimulated levels of GLP-1 and PYY were significantly higher after versus before TPIAT. ΔPP was lower after TPIAT, but not significantly. These hormone changes have potential clinical implications that warrant further research.</p>
<p>doi: <a href="https://doi.org/10.1097/MPA.0000000000001582" class="uri">https://doi.org/10.1097/MPA.0000000000001582</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>The Applicability of a Checklist for the Diagnosis and Treatment of Exocrine Pancreatic Insufficiency: Results of the Italian Exocrine Pancreatic Insufficiency Registry</strong> </summary></p>
<p><em>Pancreas 2020 Jun;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=32541636" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=32541636</a></p>
<p>OBJECTIVE: To evaluate a rapid checklist capable of identifying exocrine pancreatic insufficiency in outpatients. METHODS: Prospective observational study of a multicenter cohort. RESULTS: One hundred and two patients were enrolled; 61.8% of the patients had medically-treated benign or malignant pancreatic disease, and 38.2% had a pancreatic resection. Visual examination of the feces was evaluated in 84 patients and it was related to steatorrhea in 51 patients (50.0%). Receiver operating characteristic curves were evaluated for each symptom or clinical sign and four of them (ie, increase in daily bowel movements, number of bowel movements, fatty stools, &gt;10% weight loss) had a satisfactory area under the curve. At multivariate analysis, fatty stools and &gt;10% weight loss entered into this analysis having an area under the curve of 0.916 (95% confidence interval, 0.851-0.981). At 1 month and at one year of follow-up, the pancreatic enzyme replacement therapy administered showed that pancreatic extracts were able to significantly improve the increase in daily bowel movements, the number of bowel movements, fatty and bulky stools and &gt;10% weight loss. CONCLUSION: Both fatty stools and &gt;10% weight loss were able to clinically evaluate steatorrhea, and their improvement was sufficient to evaluate substitution therapy.</p>
<p>doi: <a href="https://doi.org/10.1097/MPA.0000000000001575" class="uri">https://doi.org/10.1097/MPA.0000000000001575</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Intraoperative Ultrasound Elastography Is Useful for Determining the Pancreatic Texture and Predicting Pancreatic Fistula After Pancreaticoduodenectomy</strong> </summary></p>
<p><em>Pancreas 2020 Jun;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=32541635" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=32541635</a></p>
<p>OBJECTIVES: Pancreatic fistula (PF) is one of the most common complications after pancreaticoduodenectomy (PD). The soft pancreatic texture is known to be an important predictive factor for PF after PD. However, its evaluation is depending on the sense of touch by the operator during operation, thus not objective. The aim of this study was to investigate the relationship between mean elasticity via intraoperative ultrasound elastography and histological pancreatic hardness, as well as predictive factor of PF after PD. METHODS: Forty-eight patients who underwent ultrasound elastography during PD and had pancreatic parenchyma histologically evaluated were included. RESULTS: Pancreatic fistula was noted in 20 patients. There were significant differences in the histological pancreatic fibrosis rate between soft pancreas group (8.2%) and hard pancreas group (28.4%, P &lt; 0.05) and in the mean elasticity between soft pancreas group (1.94 m/s) and hard pancreas group (3.17 m/s, P &lt; 0.05). The mean elasticity was significantly correlated with pancreatic fibrosis rate (P &lt; 0.05). A multivariate analysis revealed that the mean elasticity of less than 2.2 m/s was a significant predictor of PF after PD (P = 0.003). CONCLUSIONS: Intraoperative ultrasound elastography could predict pancreatic texture objectively. The mean elasticity of less than 2.2 m/s was a significant predictor of PF after PD.</p>
<p>doi: <a href="https://doi.org/10.1097/MPA.0000000000001576" class="uri">https://doi.org/10.1097/MPA.0000000000001576</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Patients With Acinar Cell Carcinoma of the Pancreas After 2005: A Large Population Study</strong> </summary></p>
<p><em>Pancreas 2020 Jun;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=32541633" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=32541633</a></p>
<p>OBJECTIVES: Acinar cell carcinoma of the pancreas is a rare tumor with limited data. The objective of our study was to evaluate the characteristics, treatments, and outcomes of patients with pancreatic acinar cell carcinoma after 2005. METHODS: We retrospectively reviewed patients with pancreatic acinar cell carcinoma treated in Peking University Cancer Hospital and Institute (2005-2018) and also identified cases using the Surveillance, Epidemiology, and End Results database (2005-2015). The characteristics, treatments, response, and survival time were evaluated. RESULTS: A total of 306 cases in our institute (n = 11) and the Surveillance, Epidemiology, and End Results database (n = 295) were identified. The median age was 67 years, and 73.5% were male. The 5-year survival was 36.8% for all patients (median, 27 months). About 37% underwent surgical resection. The 5-year survival was 65.6% for resected patients as compared with 16.9% for unresected ones (P &lt; 0.0001). Among locoregional and metastatic diseases, surgery significantly prolonged survival as well (P = 0.0003). Stage IV patients who received chemotherapy had a better survival than those without it (median, 16 vs 3 months; P = 0.0019). Aging, stage IV, and no surgery were independent predictors of poor overall survival. CONCLUSIONS: For pancreatic acinar cell carcinoma, surgery is a potentially curative treatment contributing to long-term survival and suggested even in advanced diseases. Chemotherapy improved survival for metastatic patients.</p>
<p>doi: <a href="https://doi.org/10.1097/MPA.0000000000001573" class="uri">https://doi.org/10.1097/MPA.0000000000001573</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Serum Anti-p53 Antibody Can Serve as a Predictive Marker for Histological Grade of Intraductal Papillary Mucinous Neoplasms of the Pancreas</strong> </summary></p>
<p><em>Pancreas 2020 Jun;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=32541631" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=32541631</a></p>
<p>OBJECTIVE: The aim of the study was to clarify the diagnostic impact of measuring serum anti-p53 antibody (S-p53Ab) in predicting the histological grades of intraductal papillary mucinous neoplasms (IPMNs) of the pancreas. METHODS: We compared the measured values and positive prevalence of S-p53Ab across the different histological grades of 111 resected IPMN cases. We also evaluated the TP53 alterations using immunohistochemistry and next-generation sequencing. RESULTS: Serum anti-p53 antibody were detected in 6 of 111 cases, all of their histological grades were high-grade dysplasia (HGD) and invasive carcinoma (INV). Positive prevalence of S-p53Ab was higher in cases with INV (4/35 cases, 11.4%) than those with HGD (2/38 cases, 5.3%), whereas S-p53Abs were undetectable in cases with low-grade dysplasia. Measured S-p53Ab values were not correlated with either carcinoembryonic antigen (CEA) or carbohydrate antigen 19-9 (CA 19-9). In 4 of 6 S-p53Ab-positive cases, the TP53 alterations-somatic pathogenic mutations or aberrant immunoreactivity-were identified in their IPMN lesions. A combination assay of S-p53Ab, CEA, and CA 19-9 revealed a 38.4% sensitivity and 81.6% specificity for predicting HGD/INV. CONCLUSIONS: Serum anti-p53 antibody can serve as a surrogate marker for TP53 alterations and help predict the presence of HGD/INV in cases with IPMN, in combination with CEA and CA 19-9.</p>
<p>doi: <a href="https://doi.org/10.1097/MPA.0000000000001570" class="uri">https://doi.org/10.1097/MPA.0000000000001570</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Nomogram for Estimating Overall Survival in Patients With Metastatic Pancreatic Cancer</strong> </summary></p>
<p><em>Pancreas 2020 Jun;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=32541630" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=32541630</a></p>
<p>OBJECTIVES: This analysis investigated nomogram use to evaluate metastatic pancreatic cancer prognosis. METHODS: Thirty-four baseline factors were examined in the Metastatic Pancreatic Adenocarcinoma Clinical Trial (MPACT) (nab-paclitaxel plus gemcitabine vs gemcitabine) data set. Factors significantly (P &lt; 0.1) associated with overall survival (OS) in a univariable model or with known clinical relevance were tested further. In a multivariable model, factors associated with OS (P &lt; 0.1) were selected to generate the primary nomogram, which was internally validated using bootstrapping, a concordance index, and calibration plots. RESULTS: Using data from 861 patients, 6 factors were retained (multivariable analysis): neutrophil-lymphocyte ratio, albumin level, Karnofsky performance status, sum of longest diameter of target lesions, presence of liver metastases, and previous Whipple procedure. The nomogram distinguished low-, medium-, and high-risk groups (concordance index, 0.67; 95% confidence interval, 0.65-0.69; median OS, 11.7, 8.0, and 3.3 months, respectively). CONCLUSIONS: This nomogram may guide estimates of the range of OS outcomes and contribute to patient stratification in future prospective metastatic pancreatic cancer trials; however, external validation is required to improve estimate reliability and applicability to a general patient population. Caution should be exercised in interpreting these results for treatment decisions: patient characteristics could differ from those included in the nomogram development.</p>
<p>doi: <a href="https://doi.org/10.1097/MPA.0000000000001563" class="uri">https://doi.org/10.1097/MPA.0000000000001563</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Diabetes Is Associated With the Metastasis of Pancreatic Neuroendocrine Tumors</strong> </summary></p>
<p><em>Pancreas 2020 Jun;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=32541629" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=32541629</a></p>
<p>OBJECTIVES: Type 2 diabetes mellitus (T2DM) has been associated with several types of cancers, but the role of T2DM in pancreatic neuroendocrine tumors (pNETs) has not been systematically studied. METHODS: In this study, 299 patients with pNETs were recruited, and the clinicopathologic characteristics and prognosis of the diabetic and nondiabetic patients were compared. The association between metformin use and survival was assessed to examine whether metformin impacts the prognosis of pNETs patients. RESULTS: The prevalence of T2DM in the cohort was 20.7% (n = 62). The proportions of grade 3 tumors, distant metastases, and nerve invasion in pNET patients with T2DM were higher than those in patients without T2DM, and as a result, the survival was worse in patients with T2DM. After adjusting for the tumor stage, diabetic status was not associated with poor survival in the univariate analysis. The results of logistic regression showed that pNET patients with T2DM were at high risk for tumor metastasis (odds ratio [OR], 2.81; P = 0.001), nerve invasion (OR, 2.43; P = 0.029), and grade 3 tumors (OR, 4.97; P = 0.010). CONCLUSIONS: Type 2 diabetes mellitus is associated with pNET metastasis and not an independent risk factor for poor prognosis in pNETs.</p>
<p>doi: <a href="https://doi.org/10.1097/MPA.0000000000001564" class="uri">https://doi.org/10.1097/MPA.0000000000001564</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>A Multimodal Approach for the First-Line Treatment of Infected Pancreatic Necrosis</strong> </summary></p>
<p><em>Pancreas 2020 Jun;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=32541628" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=32541628</a></p>
<p>OBJECTIVES: Because infected pancreatic necrosis (IPN) has multiple presentations, not all patients are likely to benefit from the same first-line treatment. Our objective was to evaluate morbidity and mortality in a series of patients treated with a multimodal therapeutic approach. METHODS: Between May 2012 and May 2019, 51 patients diagnosed with IPN were treated. The 5 initial treatment alternatives were as follows: percutaneous drainage, minimally invasive necrosectomy, antibiotics alone, transgastric necrosectomy, and temporizing percutaneous/endoscopic drainage. Initial treatment selection depended on evolution, clinical condition, and extension of pancreatic necrosis. Success, morbidity, and mortality rates were determined. RESULTS: In terms of determinant-based classification, 37 were classified as severe, and 14 as critical. Percutaneous, temporizing drainage, minimally invasive necrosectomy, antibiotics alone and transgastric necrosectomy approaches were used in 21, 10, 11, 4, and 5 patients, respectively. Necrosectomy was not required in 18 patients (35%). There were no significant differences in mortality among the different treatment approaches (P &lt; 0.45). Overall success, morbidity, and mortality rates were 68.6%, 52.9%, and 7.8%, respectively. CONCLUSIONS: The multimodal approach seems to be a rational and efficient strategy for the initial treatment of IPN.</p>
<p>doi: <a href="https://doi.org/10.1097/MPA.0000000000001568" class="uri">https://doi.org/10.1097/MPA.0000000000001568</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>The Fistula Risk Score Catalog: Toward Precision Medicine for Pancreatic Fistula After Pancreatoduodenectomy</strong> </summary></p>
<p><em>Annals of surgery 2020 Jun;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=32541227" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=32541227</a></p>
<p>OBJECTIVE: This study aims to present a full spectrum of individual patient presentations of pancreatic fistula risk, and to define the utility of mitigation strategies amongst some of the most prevalent, and vulnerable scenarios surgeons encounter. BACKGROUND: The FRS has been utilized to identify technical strategies associated with reduced CR-POPF incidence across various risk strata. However, risk-stratification using the FRS has never been investigated with greater granularity. By deriving all possible combinations of FRS elements, individualized risk assessment could be utilized for precision medicine purposes. METHODS: FRS profiles and outcomes of 5533 PDs were accrued from 17 international institutions (2003-2019). The FRS was used to derive 80 unique combinations of patient “scenarios.” Risk-matched analyses were conducted using a Bonferroni adjustment to identify scenarios with increased vulnerability for CR-POPF occurrence. Subsequently, these scenarios were analyzed using multivariable regression to explore optimal mitigation approaches. RESULTS: The overall CR-POPF rate was 13.6%. All 80 possible scenarios were encountered, with the most frequent being scenario #1 (8.1%) - the only negligible-risk scenario (CR-POPF rate = 0.7%). The moderate-risk zone had the most scenarios (50), patients (N = 3246), CR-POPFs (65.2%), and greatest non-zero discrepancy in CR-POPF rates between scenarios (18-fold). In the risk-matched analysis, 2 scenarios (#59 and 60) displayed increased vulnerability for CR-POPF relative to the moderate-risk zone (both P &lt; 0.001). Multivariable analysis revealed factors associated with CR-POPF in these scenarios: pancreaticogastrostomy reconstruction [odds ratio (OR) 4.67], omission of drain placement (OR 5.51), and prophylactic octreotide (OR 3.09). When comparing the utilization of best practice strategies to patients who did not have these conjointly utilized, there was a significant decrease in CR-POPF (10.7% vs 35.5%, P &lt; 0.001; OR 0.20, 95% confidence interval 0.12-0.33). CONCLUSION: Through this data, a comprehensive fistula risk catalog has been created and the most clinically-impactful scenarios have been discerned. Focusing on individual scenarios provides a practical way to approach precision medicine, allowing for more directed and efficient management of CR-POPF.</p>
<p>doi: <a href="https://doi.org/10.1097/SLA.0000000000004068" class="uri">https://doi.org/10.1097/SLA.0000000000004068</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Pancreatic Endocrine Heterotopia Involving Meckel’s Diverticulum: A Potential Mimic of Neuroendocrine Tumor</strong> </summary></p>
<p><em>International journal of surgical pathology 2020 Jun;():1066896920934009</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=32538222" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=32538222</a></p>
<p>Pancreatic heterotopia most commonly occurs in the upper gastrointestinal tract, but can occur in other sites, including Meckel’s diverticulum. When multiple histologic elements of the pancreatic tissue (acini, ducts, and endocrine cells) are present, the diagnosis is typically straightforward. In this article, we report a rare case of pure endocrine pancreatic heterotopia involving a Meckel’s diverticulum, a potential mimic of a well-differentiated neuroendocrine tumor. Several features were useful in making the distinction, including lack of desmoplasia and mass forming lesion, and immunohistochemical staining in a physiological pattern similar to that of islets of Langerhans. It is important for pathologists to be aware of this entity and its features to avoid misdiagnosis of a neuroendocrine tumor.</p>
<p>doi: <a href="https://doi.org/10.1177/1066896920934009" class="uri">https://doi.org/10.1177/1066896920934009</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>The applicability of Papanicolaou Society of Cytopathology system on reporting endoscopic ultrasound guided fine needle aspiration cytology specimens of pancreatic lesions in situations with limited availability of ancillary tests. Experience at a single laboratory</strong> </summary></p>
<p><em>Cytopathology : official journal of the British Society for Clinical Cytology 2020 Jun;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=32535975" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=32535975</a></p>
<p>OBJECTIVE: The Papanicolaou Society of Cytopathology (PSC) system of reporting pancreatobiliary cytology is a standardized reporting nomenclature which uses a six-tiered scheme of diagnostic categories utilizing routine microscopy and ancillary tests such as biochemical and molecular analysis of cyst fluids and immunochemistry. The objective of this study was to determine the applicability of the PSC system on endoscopic ultrasound guided fine needle aspiration cytology (EUS-FNAC) samples reported at the cytopathology laboratory, Mubarak Al Kabeer Hospital, in Kuwait with special emphasis on situations with limited availability of ancillary tests. METHODS: 132 cases of EUS-FNAC samples from pancreatic lesions were categorized according to PSC system guidelines after examining the glass slides and reviewing the clinical, imaging and ancillary test findings. These review diagnoses were compared with the diagnoses rendered during initial reporting. Correlation with histopathology reports was done wherever available. RESULTS: In 23 (17.42 %) of 132 cases, recategorization was necessary between initial and reviewed diagnoses. In 16 cases, recategorizations were because of non-analogous categories between initial and reviewed diagnosis. In the remaining seven, they were due to identification of newer cytomorphological and imaging findings or because of issues arising from unavailability of sufficient material for ancillary investigations. CONCLUSION: All cases could be categorized using the PSC system with a moderate number of recategorizations between initial and reviewed diagnoses. In certain circumstances, limited availability of ancillary tests, resulted in non-diagnostic categories whereas in other such circumstances, diagnostic categories could be assigned with certain conceptual modifications to the PSC guidelines.</p>
<p>doi: <a href="https://doi.org/10.1111/cyt.12873" class="uri">https://doi.org/10.1111/cyt.12873</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>The membrane protein sortilin can be targeted to inhibit pancreatic cancer cell invasion</strong> </summary></p>
<p><em>The American journal of pathology 2020 Jun;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=32526166" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=32526166</a></p>
<p>Pancreatic cancer has a dismal prognosis and there is no targeted therapy against this malignancy. The neuronal membrane protein sortilin is emerging as a regulator of cancer cell development, but its expression and impact in pancreatic cancer is unknown. In this study, we found that sortilin expression was higher in pancreatic cell lines vs normal pancreatic ductal epithelial cells, as demonstrated by Western blot and mass spectrometry. The increased sortilin level in pancreatic cancer cells was confirmed by immunohistochemistry in a series of 99 human pancreatic adenocarcinomas vs 48 normal pancreatic tissues (p=0.0014). Sortilin inhibition by siRNA and the pharmacological inhibitor AF38469 strongly reduced the adhesion and invasion of pancreatic cancer cells without affecting cell survival and viability. Sortilin inhibition also decreased the phosphorylation of the focal adhesion kinase (FAK) in Tyr925. Together, these data reveal that sortilin contributes to pancreatic cancer invasion and could eventually be targeted in therapy.</p>
<p>doi: <a href="https://doi.org/10.1016/j.ajpath.2020.05.018" class="uri">https://doi.org/10.1016/j.ajpath.2020.05.018</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Nondiagnostic fine needle aspirates of the pancreas: A root cause analysis</strong> </summary></p>
<p><em>Cancer cytopathology 2020 Jun;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=32525623" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=32525623</a></p>
<p>BACKGROUND: Fine needle aspiration (FNA) of the pancreas is considered the primary and least invasive diagnostic method in the evaluation of pancreatic lesions. A nondiagnostic sample may trigger repeat FNA or a more invasive diagnostic procedure. The goal of this study was to identify the root causes of nondiagnostic samples. METHODS: We performed a retrospective review of FNAs of the pancreas categorized as nondiagnostic at our institution between 2008 and 2019. Medical records and slides were reviewed to identify the features described by imaging, rapid on-site evaluation, fluid chemistry, final cytology diagnosis, and final histology. A root cause analysis was performed using the Ishikawa (or fishbone) diagram and the 5 Whys method. RESULTS: A total of 30 cases were identified: 11 adenocarcinomas, 6 cases of pancreatitis, 4 intraductal papillary mucinous neoplasms, 3 serous cystadenomas, 3 neuroendocrine tumors, 1 mucinous cystic neoplasm, 1 retention cyst, and 1 case of Brunner gland hyperplasia. The root causes identified were: man in 8 cases, machine in 1 case, method in 17 cases, and material in 18 cases. In many cases, more than 1 root cause contributed to the problem. CONCLUSION: Material related errors contributed to the majority of nondiagnostic results and were primarily related to fibrotic cancers, chronic pancreatitis, absence of diagnostic criteria of cystic lesions, and technically challenging cases. Only 1 major interpretation error was identified. Sampling and interpretive errors contributed equally to man-related causes. For mucinous cysts, neoplastic mucin was difficult to identify in liquid-based preparations. Pathologists tended to issue a nondiagnostic categorization when epithelial cells are lacking and particularly when the nature and radiological impression of the cyst was not communicated.</p>
<p>doi: <a href="https://doi.org/10.1002/cncy.22301" class="uri">https://doi.org/10.1002/cncy.22301</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>EUS-FNA, ancillary studies and their clinical utility in patients with mediastinal, pancreatic, and other abdominal lesions</strong> </summary></p>
<p><em>Diagnostic cytopathology 2020 Jun;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=32515558" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=32515558</a></p>
<p>BACKGROUND: Endoscopic ultrasound-guided fine-needle aspiration (EUS-FNA) is an important modality to obtain tissue diagnosis from mediastinal, pancreatic, and intra-abdominal lesions in close proximity to the pulmonary and gastrointestinal tract. It is considered to be a relatively safe, rapid, and minimally invasive technique with low complication rates. AIMS: To determine the diagnostic accuracy, sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), and outcome of EUS-FNA, with histological correlation where applicable. METHODS: Data of all 1059 consecutive patients who underwent EUS-FNA from 1 January 2005 to 31 December 2017 at Shaukat Khanum Memorial Cancer Hospital and Research Centre, Lahore was reviewed in this retrospective study. The major sites that were targeted for EUS-FNA were pancreatic (423), mediastinal (376), and other abdominal lesions (260). RESULTS: The average number of passes per patient was 2.22. Rapid on-site evaluation (ROSE) was adequate in 969 patients (91.4%). Concordance between ROSE and final cytology was 99.5%. Follow-up was available in 810 patients (76.4%). The overall diagnostic yield was 94.3%. Ancillary studies, including immunohistochemical stains and flow cytometry, helped to increase the diagnostic yield from 78.1% to 94.3%. The overall sensitivity, specificity, PPV, NPV, and diagnostic accuracy for EUS-FNA were 94.8%, 98.6%, 99.9%, 65.5%, and 95.1%, respectively. Seven of 1059 patients (0.6%) developed complications. CONCLUSION: EUS-FNA is a very sensitive and specific diagnostic tool with a minimal complication rate. Ancillary studies helped to increase the sensitivity, as well as the diagnostic yield.</p>
<p>doi: <a href="https://doi.org/10.1002/dc.24523" class="uri">https://doi.org/10.1002/dc.24523</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Detection of microsatellite instability in a panel of solid tumours with the Idylla MSI Test using extracted DNA</strong> </summary></p>
<p><em>Journal of clinical pathology 2020 Jun;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=32513848" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=32513848</a></p>
<p>AIM: During the last few years, determination of microstatellite instability (MSI) status has become a routine part of clinical practice, essentially to detect Lynch syndrome. Recently, MSI testing has increased with the development of immunotherapy and has expanded to a large panel of solid tumours. The aim of our work was to evaluate a fully automated system developed by Biocartis, the Idylla MSI Test, which performs an MSI analysis within 150 min. METHODS: A comparison between pentaplex PCR, immunohistochemistry and Idylla MSI Test was performed in 53 colorectal carcinoma samples, 7 small intestine adenocarcinomas, 15 duodenal and pancreatic adenocarcinomas, 16 gastric tumours, 15 endometrial adenocarcinomas, 5 ovarian carcinomas and 4 cases of urinary tract tumours using extracted DNA. Limit-of-detection (LOD) experiment was also done using a commercial DNA known to harbour MSI phenotype. RESULTS: The overall sensitivity was 94% and the overall specificity was 100%. Two invalid and three false-negative results were observed. Our experiments showed that the amount of DNA loaded into the cartridge was decisive and should be superior to 25 ng. LOD comprised between 4% and 8%. CONCLUSION: Overall, we have demonstrated that the Idylla MSI Test is a rapid and valid option to detect MSI phenotype which can be used in a large panel of solid tumours.</p>
<p>doi: <a href="https://doi.org/10.1136/jclinpath-2020-206581" class="uri">https://doi.org/10.1136/jclinpath-2020-206581</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Next-generation sequencing in residual liquid-based cytology specimens for cancer genome analysis</strong> </summary></p>
<p><em>Diagnostic cytopathology 2020 Jun;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=32511899" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=32511899</a></p>
<p>BACKGROUND: Cancer genome profiling of cytology specimens using next-generation sequencing (NGS) requires adequate and good-quality DNA. Genomic examination of cytology samples was conventionally performed on cell block (CB) or smear specimens than on residual liquid-based cytology (LBC) specimens, which are high-quality DNA sources even after long-term storage. METHODS: We estimated tumor fractions of 37 residual LBC specimens, including 30 fine needle aspiration (FNA) samples from the thyroid (12 papillary thyroid carcinomas and two malignant lymphomas), lymph node (13 metastatic carcinomas and one malignant lymphoma), and breast cancer (one phyllodes tumor and one invasive ductal carcinoma), two pancreatic carcinoma samples, and five liquid (ascites, pleural effusion, and cerebrospinal fluid) samples. The DNA was extracted from all samples and subjected to NGS using a customized cancer gene panel comprising 28 cancer-related genes. RESULTS: NGS analysis revealed somatic mutations corresponding to pathological diagnosis with adequate variant allele frequency (VAF) in 24 LBC specimens, which had significantly higher tumor fraction (72.5% ± 4.9%). Ten cases, including the five fluid samples, had very small tumor fractions (7.5% ± 2.3%) to obtain sufficient VAF. Other two samples had high tumor fractions but showed very low VAF, indicating the presence of fusion genes. The remaining one sample yielded no DNA recovery. CONCLUSION: The residual LBC specimens collected by FNA from the thyroid gland and lymph node were verified to carry high tumor fraction and could serve as an alternate source for molecular testing to screen and diagnose cancers without the use of CB or smears.</p>
<p>doi: <a href="https://doi.org/10.1002/dc.24511" class="uri">https://doi.org/10.1002/dc.24511</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Development and Validation of a Modified Eighth AJCC Staging System for Primary Pancreatic Neuroendocrine Tumors</strong> </summary></p>
<p><em>Annals of surgery 2020 Jun;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=32511134" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=32511134</a></p>
<p>OBJECTIVE: To improve the prognostic accuracy of the eighth edition of AJCC staging system for pNETs with establishment and validation of a new staging system. BACKGROUND: Validation of the updated eighth AJCC staging system for pNETs has been limited and controversial. METHODS: Data from the SEER registry (1975-2016) (n = 3303) and a multi-institutional database (2000-2016) (n = 825) was used as development and validation cohorts, respectively. A mTNM was proposed by maintaining the eighth AJCC T and M definitions, and the recently proposed N status as N0 (no LNM), N1 (1-3 LNM), and N2 (≥4 LNM), but adopting a new stage classification. RESULTS: The eighth TNM staging system failed to stratify patients with stage I versus IIA, stage IIB versus IIIA, and overall stage I versus II relative to long-term OS in both database. There was a monotonic decrement in survival based on the proposed mTNM staging classification among patients derived from both the SEER (5-year OS, stage I 87.0% vs stage II 80.3% vs stage III 72.9% vs stage IV 57.2%, all P &lt; 0.001), and multi-institutional (5-year OS, stage I 97.6% vs stage II 82.7% vs stage III 78.4% vs stage IV 50.0%, all P &lt; 0.05) datasets. On multivariable analysis, mTNM staging remained strongly associated with prognosis, as the hazard of death incrementally increased with each stage among patients in the 2 cohorts. CONCLUSION: A mTNM pNETs clinical staging system using N0, N1, N2 nodal categories was better at stratifying patients relative to long-term OS than the eighth AJCC staging.</p>
<p>doi: <a href="https://doi.org/10.1097/SLA.0000000000004039" class="uri">https://doi.org/10.1097/SLA.0000000000004039</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Stat2 loss disrupts damage signalling and is protective in acute pancreatitis</strong> </summary></p>
<p><em>The Journal of pathology 2020 Jun;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=32506441" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=32506441</a></p>
<p>The severity of sterile inflammation, as seen in acute pancreatitis, is determined by damage-sensing receptors, signalling cascades and cytokine production. Stat2 is a type I interferon signalling mediator that also has interferon-independent roles in murine lipopolysaccharide-induced NF-κB-mediated sepsis. However, its role in sterile inflammation is unknown. We hypothesised that Stat2 determines the severity of non-infective inflammation in the pancreas. Wild type (WT) and Stat2-/- mice were injected intraperitoneally with caerulein or L-arginine. Specific cytokine-blocking antibodies were used in some experiments. Pancreata and blood were harvested 1 h and 24 h after the final dose of caerulein and up to 96 h post L-arginine. Whole-tissue phosphoproteomic changes were assessed using label-free mass spectrometry. Tissue-specific Stat2 effects were studied in WT/Stat2-/- bone-marrow chimera and using Cre-lox recombination to delete Stat2 in pancreatic and duodenal homeobox 1(Pdx1)-expressing cells. Stat2-/- mice were protected from caerulein- and L-arginine-induced pancreatitis. Protection was independent of type I interferon signalling. Stat2-/- mice had lower cytokine levels including TNFα and IL-10 and reduced NF-kB nuclear localisation in pancreatic tissue compared to WT. Inhibition of TNFα improved (inhibition of IL-10 worsened) caerulein-induced pancreatitis in WT but not Stat2-/- mice. Phosphoproteomics showed down-regulation of mitogen-activated protein kinase (MAPK) mediators but accumulation of Ser412-phosphorylated Tak1. Stat2 deletion in Pdx1-expressing acinar cells (Stat2flox/Pdx1-cre ) reduced pancreatic TNFα expression, but not histological injury or serum amylase. WT/Stat2-/- bone-marrow chimera mice were protected from pancreatitis irrespective of host or recipient genotype. Stat2 loss results in disrupted signalling in pancreatitis, upstream of NF-κB in non-acinar and/or bone marrow derived cells. This article is protected by copyright. All rights reserved.</p>
<p>doi: <a href="https://doi.org/10.1002/path.5481" class="uri">https://doi.org/10.1002/path.5481</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Peribiliary glands pathology in a large series of end-stage alcohol-related liver disease</strong> </summary></p>
<p><em>Virchows Archiv : an international journal of pathology 2020 Jun;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=32506156" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=32506156</a></p>
<p>The peribiliary glands are intramural or extramural structures with multiple functions related to bile secretion. The peribiliary glands can develop cystic alterations in several conditions, such as alcohol addiction. Peribiliary cysts can enlarge till being radiologically visible and mimic cancer. We studied 217 consecutive explanted livers for end-stage alcohol-related liver disease from the Pathology Unit of the Liver Unit at the King’s College Hospital in Denmark Hill, with particular focus on peribiliary glands. Our cohort consisted of 31 females and 186 males, with a median age of 51 and of 56 years respectively. 92,2% had established cirrhosis, 73,3% had only alcohol-induced liver disease, whilst 26,7% had other co-morbidities. We found a mild ectasia of the peribiliary glands (&lt;2 mm) in 37,8% and peribiliary cysts (&gt; = 2 mm) in 22,6% of cases. The diameter of the peribiliary glands varied from 1 mm to 8 mm. Inflammation of the peribiliary glands was found in the majority of cases with dilatation (p value = 0,000). 4,6% of the peribiliary cysts had low-grade intraductal papillary neoplasm of the bile ducts confined to the peribiliary glands. Pancreatic heterotopia was found in 10,6% and associated with the presence of ectasia. Our findings fit with what is reported in literature, such as the alcohol-induced damage at the peribiliary glands. Moreover these results underline the possible role of peribiliary glands in the development of the intraductal papillary neoplasm of the bile ducts, the biliary counterpart of the branch type intraductal mucinous neoplasm of the pancreas.</p>
<p>doi: <a href="https://doi.org/10.1007/s00428-020-02851-3" class="uri">https://doi.org/10.1007/s00428-020-02851-3</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Morphologic Variants of Pancreatic Neuroendocrine Tumors: Clinicopathologic Analysis and Prognostic Stratification</strong> </summary></p>
<p><em>Endocrine pathology 2020 Jun;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=32488621" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=32488621</a></p>
<p>Better prognostication/stratification of pancreatic neuroendocrine tumors (PanNETs) is needed. In this detailed morpheomic study of 163 resected PanNETs, 11 unusual variants, some of which were not previously recognized, and others scarcely documented in the literature, were identified, and their pathologic characteristics were further analyzed. By behavior and clinicopathologic associations, these variants could be grouped into three prognostically different categories. I. More aggressive (20%). Included in this group were the variants that in average showed higher grade and stage and adverse outcome including oncocytic, plasmacytoid, lipid-rich and previously unrecognized hepatoid variants, which often had a more diffuse/broad-band growth pattern, with some also displaying discohesiveness. They were characterized by abundant cytoplasm and often had prominent nucleoli (as seen in metabolically active cells), thus the provisional name “metabolic cell phenotype.” Because of their diversion from classical neuroendocrine cytomorphology, these variants created challenges on original diagnostic workup, particularly hepatoid examples, which revealed Arginase 1/Hep Par-1 expression in 50%. II. Less aggressive (10%). These cases either showed signs of maturation, including nested growth, paraganglioid pattern (which was previously unrecognized), and organoid PanNETs such as “ductulo-insular” growth, or showed symplastic/degenerative changes, and despite their paradoxically disconcerting histology, were more benevolent in behavior. III. Undetermined. There were other variants including mammary tubulolobular-like, pseudoglandular, peliotic, and sclerotic PanNETs, which although diagnostically challenging, their biologic significance could not be determined because of rarity or heterogeneous characteristics. Prognostic associations: Features that were significantly different in the more aggressive group than the less aggressive group were median size (5.0 vs 1.6 cm, p &lt; 0.001), percentage of pT3+T4 cases (72% vs 12%, p &lt; 0.001), Ki67 index (5.3% vs 2.3%, p = 0.001), % G2 and G3 cases (77% vs 27%, p &lt; 0.001), and rate of lymph node and distant metastasis (96% vs 27%, p &lt; 0.001). In stepwise logistic regression model using the 3 established prognosticators of T stage, size, and grade along with morphology, only aggressive-morphology (metabolic cell phenotype) was found to be associated with metastatic behavior with an odds ratio of 5.9 with 95% confidence interval (C.I.) 1.688 to 22.945 and p value 0.007. In conclusion, PanNETs display various morphologic patterns that are not only challenging and important diagnostically but appear to have biologic significance. Tumors with more diffuse growth of cells with nucleoli and abundant cytoplasm and/or discohesion (oncocytic, hepatoid, lipid-rich, plasmacytoid PanNETs), provisionally termed “metabolic cell phenotype,” show aggressive characteristics and are an independent determinant of adverse outcome and thus may require closer post-surgical follow-up, whereas variants with more degenerative or mature features (ductuloinsular, pleomorphic, paraganglioma-like) appear to be more benevolent despite their more atypical and worrisome morphology.</p>
<p>doi: <a href="https://doi.org/10.1007/s12022-020-09628-z" class="uri">https://doi.org/10.1007/s12022-020-09628-z</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Cancer-associated fibroblasts are a useful cytological finding for diagnosing pancreatic ductal adenocarcinoma</strong> </summary></p>
<p><em>Cytopathology : official journal of the British Society for Clinical Cytology 2020 May;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=32472717" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=32472717</a></p>
<p>BACKGROUND: Cancer-associated fibroblasts (CAFs) are activated fibroblasts or myofibroblaststhatplay a crucial role in the invasiveness of pancreatic ductal adenocarcinoma (PDAC). In this study, the cytological features and diagnostic significance of CAFsbased on pancreatic duct brushing cytology (PDBC) were evaluated. METHODS: The prevalence of fibrous stroma (FS) including CAFs on PDBC in 42 PDAC cases and 33 benign cases was retrospectively investigated. The average nuclear size of fibroblasts was compared between PDAC and benign cases to distinguish CAFs from normal FS. RESULTS: Overall, FSwas observed in 25 PDAC cases (60%) and 8 benign cases (24%). The average nuclear size of FS in PDAC cases was significantly larger than that in benign cases. From the receiver operating characteristics analysis, the cut-off value of the nuclear size of FS for the diagnosis of PDAC was defined as 10.22µm. FS with nuclei over 10.22µmin size in PDAC cases had clear prominent nucleoli. In contrast, FS in benign cases had no clear nucleoli. Thus, CAFs on PDBC were considered to be FS with nuclei over 10.22µmin size and prominent nucleoli. The presence of CAFs on PDBC had 100% positive predictive value and specificity for the diagnosis of PDAC. CONCLUSIONS: This study suggested that CAFs on PDBC could be distinguished from normal FS by large nuclear size (over 10.22µm) and prominent nucleoli and that CAFs on PDBC may be used for the diagnosis of PDAC.</p>
<p>doi: <a href="https://doi.org/10.1111/cyt.12868" class="uri">https://doi.org/10.1111/cyt.12868</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Angiotensin-converting enzyme 2 influences pancreatic and renal function in diabetic mice</strong> </summary></p>
<p><em>Laboratory investigation; a journal of technical methods and pathology 2020 May;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=32472097" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=32472097</a></p>
<p>Type 1 diabetes is a T-cell mediated autoimmune disease characterized by pancreatic beta cells destruction. Angiotensin-converting enzyme 2 (ACE2), a component of renin-angiotensin system (RAS) has been identified in pancreas from type 2 diabetic mice and its overexpression prevents beta cell dysfunction. We studied the effect of ACE2 deletion on pancreatic and renal function in the nonobese diabetic mice, a model that mimics type 1 diabetes. ACE2-deficient NOD mice and the respective controls were generated. Pancreas function and immunohistochemistry studies were performed. Renal function and RAS gene expression were also analyzed. Renal proximal tubular cells were obtained from these animals to dissect the effect of ACE2 deficiency in these cells. In NOD mice, ACE2 deletion significantly worsened glucose homeostasis, decreased islet insulin content, increased beta cell oxidative stress, and RIPK1-positive islets as compared with control mice. Angiotensin-converting enzyme and angiotensin II type 1 receptor (AT1R) were also increased in ACE2-deficient mice. In kidneys of 30-day diabetic mice, ACE2 deletion decreased podocyte number within the glomeruli, and altered renal RAS gene expression in tubules. ACE2 deletion influenced the expression of fibrosis-related genes in isolated primary renal proximal tubular cells before diabetes onset in NOD mice. Our findings suggest that ACE2 deletion may have a deleterious impact on beta cell and renal function, by promoting oxidative stress and increasing necroptosis mediators. In addition, this effect is accompanied by RAS alterations in both pancreas and renal proximal tubular cells, indicating that ACE2 may exert a renopancreatic protective effect on type 1 diabetes, which is activated before diabetes starts.</p>
<p>doi: <a href="https://doi.org/10.1038/s41374-020-0440-5" class="uri">https://doi.org/10.1038/s41374-020-0440-5</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Seeking Cellular Fitness and Immune Evasion: Autophagy in Pancreatic Carcinoma</strong> </summary></p>
<p><em>Cancer cell 2020 May;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=32470391" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=32470391</a></p>
<p>In a recent Nature paper, Yamamoto et al. demonstrate that, in the particular context of pancreatic carcinoma, autophagy causes the continuous destruction of major histocompatibility complex class I (MHC-I) proteins. Suppression of autophagy favors MHC-I re-appearance on the surface of malignant cells, facilitating their clearance by cytotoxic T lymphocytes.</p>
<p>doi: <a href="https://doi.org/10.1016/j.ccell.2020.05.009" class="uri">https://doi.org/10.1016/j.ccell.2020.05.009</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Chronic inflammatory changes and oxidative stress in the background of “pancreatic ductal adenocarcinoma concomitant with intraductal papillary mucinous neoplasm”</strong> </summary></p>
<p><em>Virchows Archiv : an international journal of pathology 2020 May;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=32468246" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=32468246</a></p>
<p>Cases of “pancreatic ductal adenocarcinoma (PDAC) concomitant with intraductal papillary mucinous neoplasm” (IPMN) have multiple PDAC lesions more frequently than cases of “PDAC without IPMN”. However, the mechanism of carcinogenesis in this former disease category remains unknown. The main objective of this work was thus to investigate the effects of chronic inflammation on carcinogenesis in PDAC cases. We selected 31 “PDAC concomitant with IPMN” patients and 58 “PDAC without IPMN” patients and pathologically evaluated their background pancreatic parenchyma. Fibrosis and inflammation scores of background pancreas were higher in “PDAC concomitant with IPMN” than in “PDAC without IPMN” (P &lt; 0.0001 and P &lt; 0.0001, respectively), whereas the fatty infiltration score of background pancreas was high in “PDAC without IPMN” (P = 0.0024). Immunohistochemically, the expression of 8-hydroxy-2’-deoxyguanosine (8-OHDG), an oxidative stress marker, in the background pancreas was high in “PDAC concomitant with IPMN” compared with that in “PDAC without IPMN” (P &lt; 0.0001). Chronic inflammation activates oxidative stress in tissue throughout the pancreas and probably confers susceptibility to tumorigenesis in “PDAC concomitant with IPMN”.</p>
<p>doi: <a href="https://doi.org/10.1007/s00428-020-02844-2" class="uri">https://doi.org/10.1007/s00428-020-02844-2</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Intraductal pancreatic cancer is less responsive than cancer in the stroma to neoadjuvant chemotherapy</strong> </summary></p>
<p><em>Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc 2020 May;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=32457408" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=32457408</a></p>
<p>Neoadjuvant chemotherapy (NAC) is often the treatment of choice for borderline resectable and locally advanced invasive pancreatic ductal adenocarcinoma (PDAC); however, most cancers only partially respond to therapy. We hypothesized that the location of residual neoplastic cells in resected specimens following NAC could provide a clue as to the mechanisms of resistance. PDAC cells invade the stroma but can also invade back into and spread via the pancreatic ducts, which has been referred to as “cancerization of ducts” (COD). We compared the responsiveness to chemotherapy between PDAC cells in the stroma and PDAC cells in the duct. Pancreatic resections from a total of 174 PDAC patients (NAC, n = 97; immediate surgery, n = 77) were reviewed. On hematoxylin and eosin sections, COD was identified at the same prevalence in both groups (NAC: 50/97 cases, 52%; immediate surgery: 39/77 cases, 51%; p = 0.879, Fisher’s exact test). However, using quantitative image analysis of CK19 immunohistochemistry, we found that the proportion of cancer cells that were intraductal was significantly different between the NAC and immediate surgery groups (median; 12.7% vs. 1.99%, p &lt; 0.0001, Mann-Whitney U test). This proportion was highest in patients with marked therapy responses (36.2%) compared with patients with moderate or poor responses (7.21 &amp; 7.91%). In summary, our data suggest that intraductal components in PDAC are less responsive to chemotherapy than the remainder of the tumor, which could have important implications for therapeutic resistance.</p>
<p>doi: <a href="https://doi.org/10.1038/s41379-020-0572-6" class="uri">https://doi.org/10.1038/s41379-020-0572-6</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Detailed Analysis of Margin Positivity and the Site of Local Recurrence After Pancreaticoduodenectomy</strong> </summary></p>
<p><em>Annals of surgical oncology 2020 May;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=32451945" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=32451945</a></p>
<p>BACKGROUND: The association between a positive surgical margin and local recurrence after resection of pancreatic adenocarcinoma (PDAC) has been reported. Assessment of the location of the a positive margin and the specific site of local recurrence has not been well described. METHODS: A prospectively maintained database was queried for patients who underwent R0/R1 pancreaticoduodenectomy for PDAC between 2000 and 2015. The pancreatic, posterior, gastric/duodenal, anterior peritoneal, and bile duct margins were routinely assessed. Postoperative imaging was reviewed for the site of first recurrence, and local recurrence was defined as recurrence located in the remnant pancreas, surgical bed, or retroperitoneal site outside the surgical bed. RESULTS: During the study period, 891 patients underwent pancreaticoduodenectomy, and 390 patients had an initial local recurrence with or without distant metastases. The 5-year cumulative incidence of local recurrence by site included the remnant pancreas (4%; 95% confidence interval [CI], 3-5%), the surgical bed (35%; 95% CI, 32-39%), and other regional retroperitoneal site (4%; 95% CI, 3-6%). In the univariate analysis, positive posterior margin (hazard ratio [HR], 1.50; 95% CI, 1.17-1.91; p = 0.001) and positive lymph nodes (HR, 1.36; 95% CI, 1.06-1.75; p = 0.017) were associated with surgical bed recurrence, and in the multivariate analysis, positive posterior margin remained significant (HR, 1.40; 95% CI, 1.09-1.81; p = 0.009). An isolated local recurrence was found in 197 patients, and a positive posterior margin was associated with surgical bed recurrence in this subgroup (HR, 1.51; 95% CI, 1.08-2.10; p = 0.016). CONCLUSION: In this study, the primary association between site of margin positivity and site of local recurrence was between the posterior margin and surgical bed recurrence. Given this association and the limited ability to modify this margin intraoperatively, preoperative assessment should be emphasized.</p>
<p>doi: <a href="https://doi.org/10.1245/s10434-020-08600-9" class="uri">https://doi.org/10.1245/s10434-020-08600-9</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Beyond stiffness: collagen signaling in pancreatic cancer and pancreas regeneration</strong> </summary></p>
<p><em>The American journal of pathology 2020 May;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=32450151" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=32450151</a></p>
<p>This commentary highlights the article by Ruggeri et al that reports the importance of discoidin domain receptor 1 (DDR1) in tissue homeostasis in pancreatic injury and pancreatic ductal adenocarcinoma pathogenesis.</p>
<p>doi: <a href="https://doi.org/10.1016/j.ajpath.2020.05.005" class="uri">https://doi.org/10.1016/j.ajpath.2020.05.005</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Characteristics of Lung Metastasis as an Initial Recurrence Pattern After Curative Resection of Pancreatic Cancer</strong> </summary></p>
<p><em>Pancreas 2020 5;49(5):699-705</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=32433409" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=32433409</a></p>
<p>OBJECTIVES: Understanding the disparity in clinical course because of differences in initial recurrence patterns could lead to a more accurate estimation of prognosis and optimal treatment. METHODS: Patients who underwent resection for pancreatic cancer between January 2003 and December 2016 were identified from a prospective database. We analyzed the association between clinicopathological information or survival outcomes and initial recurrence patterns. RESULTS: The most frequent recurrence pattern was locoregional recurrence (n = 84, 31.3%), followed by simultaneous multiple recurrences (n = 65, 24.2%), liver metastasis (n = 53, 19.8%), peritoneal dissemination (n = 41, 15.3%), and lung metastasis (n = 20, 7.5%). In addition, survival outcomes were significantly longer in the lung metastasis group than in the other recurrence pattern group (recurrence-free survival, 18.2 vs 8.2 months, P &lt; 0.001; overall survival, 86.4 vs 21.0 months, P &lt; 0.001; and survival after recurrence, 37.1 vs 9.3 months, P &lt; 0.001). The lung metastasis group had a significantly higher proportion of pancreatic body and tail cancer (P &lt; 0.002) and arterial invasion (P = 0.006) than the other recurrence pattern group. CONCLUSIONS: Lung metastasis as an initial recurrence pattern frequently occurred in patients with body and tail cancer and patients with arterial invasion.</p>
<p>doi: <a href="https://doi.org/10.1097/MPA.0000000000001559" class="uri">https://doi.org/10.1097/MPA.0000000000001559</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Adenosquamous Carcinoma of the Pancreas Comprise a Heterogeneous Group of Tumors With the Worst Outcome: A Clinicopathological Analysis of 25 Cases Identified in 562 Pancreatic Carcinomas Resected With Curative Intent</strong> </summary></p>
<p><em>Pancreas 2020 5;49(5):683-691</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=32433407" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=32433407</a></p>
<p>OBJECTIVES: Information of the clinicopathological characteristics and outcome data of patients with adenosquamous carcinoma of the pancreas (ASCAP) remains limited. This study’s aim is to describe the clinical, pathological, and molecular characteristics of 25 resected ASCAPs. METHODS: Of all 25 cases, patient characteristics, follow-up data, and pathological/immunohistological features were reviewed and analyzed. RESULTS: In this 3-institutional retrospective analysis of 562 pancreatic cancer patients, we identified 25 cases with histologically confirmed ASCAP (4.4%). Follow-up was available in 21 ASCAP and 50 pancreatic ductal adenocarcinoma control patients with a median overall survival of 8.2 and 21 months, respectively. Age, tumor size, localization in the tail, lymph node status, and resection margin seem to be the most significant factors of survival in our ASCAP cohort. In contrast to pancreatic ductal adenocarcinoma, positive expression of p63, keratins K5/14, and the epidermal growth factor receptor are a robust marker profile of these tumors. CONCLUSIONS: Adenosquamous carcinoma of the pancreas comprises a group of neoplasms in which stage and adverse morphological features contribute to its bad prognosis. Further work must be pursued to improve detection and treatment options to reduce mortality. Specifically, differences in biology might become a target for the development of possible therapies.</p>
<p>doi: <a href="https://doi.org/10.1097/MPA.0000000000001548" class="uri">https://doi.org/10.1097/MPA.0000000000001548</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Clinical Utility of Histological and Radiological Evaluations of Tumor Necrosis for Predicting Prognosis in Pancreatic Cancer</strong> </summary></p>
<p><em>Pancreas 2020 5;49(5):634-641</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=32433400" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=32433400</a></p>
<p>OBJECTIVES: Tumor necrosis is often found in pancreatic ductal adenocarcinoma (PDAC). Objective histological assessment and adequate radiological detection of necrosis could be used as biomarkers for therapeutic decision. However, standardized clinical utility of necrosis remains unknown. Here, we aimed to determine the prognostic potential of histological and radiological evaluations of necrosis. METHODS: We investigated histological necrosis in 221 patients, who underwent surgery for PDAC, and classified its size as small (≤5 mm) or large (&gt;5 mm). We also evaluated poorly enhanced areas on preoperative computed tomography to assess their ability for predicting histological necrosis and postoperative prognosis. RESULTS: Tumor necrosis was found in 115 patients (52%) and was related to tumor area, lymph node metastasis, and lymphovascular invasion. Size of necrosis was significantly associated with tumor area, perimeter of necrosis, circularity of necrosis, number of ruptured cancer glands, and presence of collagen bundle (P &lt; 0.05 for all). Both presence of necrosis and their size were strongly correlated to postoperative prognosis. Patients with poorly enhanced areas showed worse prognosis (P &lt; 0.01). CONCLUSIONS: Our findings underline the capacity of histological and radiological assessment of tumor necrosis for prognosis prediction in PDAC.</p>
<p>doi: <a href="https://doi.org/10.1097/MPA.0000000000001539" class="uri">https://doi.org/10.1097/MPA.0000000000001539</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Negative prognostic impact of PD-L1 expression in tumor cells of undifferentiated (anaplastic) carcinoma with osteoclast-like giant cells of the pancreas: study of 13 cases comparing ductal pancreatic carcinoma and review of the literature</strong> </summary></p>
<p><em>Virchows Archiv : an international journal of pathology 2020 May;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=32424767" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=32424767</a></p>
<p>Pancreatic carcinoma remains one of the leading cancer-related causes of death worldwide and is generally characterized by a dismal prognosis and limited potential for oncologic treatment. A rare subvariant of pancreatic cancer, undifferentiated carcinoma with osteoclast-like giant cells (UCOGC), has an unpredictable prognosis according to many previous studies, with unexpectedly long survival in individual cases. In this study, we collected, retrospectively, 13 cases of well-documented UCOGCs and performed immunohistochemistry focused on the expression of the programmed death-ligand 1 (PD-L1) and several other potential therapeutic and predictive markers (PanTRK, p53, MSH2, PMS2, and the number of tumor-infiltrating lymphocytes), to explore their correlation with the follow-up of the patients. As a control group, we examined 24 cases of conventional pancreatic ductal adenocarcinoma (PDAC). In our results, PanTRK was negative in all 24 cases. P53 did not show any significant differences between UCOGCs and PDACs, and the entire cohort was MSH2, MLH1, PMS2, and MSH6 positive. Significant differences were present in the analysis of PD-L1: UCOGCs were found to express PD-L1 significantly more frequently and have a higher number of tumor-infiltrating lymphocytes than PDAC. The expression of PD-L1 was related to significantly shorter survival in patients with UCOGC and in the entire cohort. Patients with PD-L1 negative UCOGCs displayed surprisingly long survival in comparison to PD-L1 positive UCOGCs and PDACs (both PD-L1+ and PD-L1-). We compared our results with previously published data, and, after statistical analysis, we were able to identify PD-L1 as an effective prognostic marker of UCOGC and suggest a strong need for a clinical trial of immune checkpoint immunotherapy in patients with advanced PD-L1 positive UCOGC.</p>
<p>doi: <a href="https://doi.org/10.1007/s00428-020-02830-8" class="uri">https://doi.org/10.1007/s00428-020-02830-8</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Grading Solid Pseudopapillary Tumors of the Pancreas: the Fudan Prognostic Index</strong> </summary></p>
<p><em>Annals of surgical oncology 2020 May;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=32424583" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=32424583</a></p>
<p>BACKGROUND: Ki-67 has been shown to predict outcome of patients with solid pseudopapillary tumor of the pancreas (SPTP) but has not been incorporated into a formal classification system to predict recurrence-free survival (RFS). METHODS: This is a retrospective cohort study of patients with histologically confirmed diagnosis of SPTP who had at least 1 year of follow-up at two tertiary academic centers. Survival data were assessed by Kaplan-Meier method and multivariable Cox regression model. Prognostic performance was compared among various systems. RESULTS: A total of 193 consecutive patients were included, ranging in age from 12 to 70 years (median 33 years). Seven patients (3.6%) developed tumor recurrence. The 3-, 5-, and 10-year RFS rates were estimated at 96.9%, 96.1%, and 94.8%, respectively. For the AJCC staging system, patients with stage I had similar prognosis to those with stage II. For the ENETS staging system, patients with stage I to III had similar prognosis. Grade based on Ki-67 was superior to both the AJCC and ENETS systems for predicting survival. Multivariate analysis revealed that large tumor size [&gt; 10 cm; hazard ratio (HR), 6.177 95% confidence interval (CI), 1.289-29.603; P = 0.023] and Ki-67 (HR, 17.199 95% CI, 4.001-73.930; P &lt; 0.001) were independent predictors for RFS. The Fudan Prognostic Index based on the combination of Ki-67 and tumor size showed excellent discrimination for RFS and was more accurate and informative than other grading/staging systems. CONCLUSION: The Fudan Prognostic Index better predicts RFS compared with either Ki-67 alone or the current AJCC and ENETS TNM-based staging systems.</p>
<p>doi: <a href="https://doi.org/10.1245/s10434-020-08626-z" class="uri">https://doi.org/10.1245/s10434-020-08626-z</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Guidelines on the histopathology of chronic pancreatitis. Recommendations from the working group for the international consensus guidelines for chronic pancreatitis in collaboration with the International Association of Pancreatology, the American Pancreatic Association, the Japan Pancreas Society, and the European Pancreatic Club</strong> </summary></p>
<p><em>Pancreatology : official journal of the International Association of Pancreatology (IAP) … [et al.] 2020 Apr;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=32414657" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=32414657</a></p>
<p>BACKGROUND: Chronic pancreatitis is a complex multifactorial fibro-inflammatory disease. Consensus guidelines are needed for the histopathological evaluation of non-autoimmune chronic pancreatitis (CP). METHODS: An international working group with experts on the histopathology of CP evaluated 15 statements generated from evidence on seven key clinically relevant questions. The Grading of Recommendations Assessment, Development, and Evaluation (GRADE) approach was used to evaluate the level of evidence available for each statement. To determine the level of agreement, the working group voted on the statements for strength of agreement, using a nine-point Likert scale, and Cronbach’s alpha reliability coefficients were calculated. RESULTS: Strong consensus was obtained for 12 statements relating to all seven key questions including that: the cardinal features of CP are the triad of fibrosis, loss of acinar tissue and duct changes; there are no unique histopathological features that distinguish the different aetiologies of CP; clinical history and laboratory investigations, including genetic testing, are important in establishing the aetiology of CP; there is no reproducible and universally accepted histological grading system for assessing severity of CP, although classification as “mild”, “moderate” and “severe” is usually applied; scoring systems for fibrosis are not validated for clinical use; asymptomatic fibrosis is a common finding associated with ageing, and not necessarily evidence of CP; there are no obvious diagnostic macroscopic features of early CP; histopathology is not the gold standard for the diagnosis of CP; and cytology alone is not a reliable method for the diagnosis of CP. CONCLUSIONS: Cardinal histopathological features of CP are well-defined and internationally accepted and pathological assessment is relevant for the purpose of differential diagnosis with other pancreatic diseases, especially cancer. However, a reliable diagnosis of CP requires integration of clinical, laboratory and imaging features and cannot be made by histology alone.</p>
<p>doi: <a href="https://doi.org/10.1016/j.pan.2020.04.009" class="uri">https://doi.org/10.1016/j.pan.2020.04.009</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Loss of switch/sucrose non-fermenting complex protein expression in undifferentiated gastrointestinal and pancreatic carcinomas</strong> </summary></p>
<p><em>Histopathology 2020 May;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=32413172" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=32413172</a></p>
<p>AIMS: Undifferentiated carcinoma refers to an epithelial malignancy that lacks morphological evidence of differentiation. Recent studies have implicated the loss of constitutively expressed switch/sucrose non-fermenting (SWI/SNF) complex subunits in undifferentiated carcinomas of the gastrointestinal tract and other sites. In this study we examine the expression of SWI/SNF and mismatch repair (MMR) proteins in a series of undifferentiated carcinomas from the gastrointestinal tract and the pancreas. METHODS AND RESULTS: We searched pathology databases from four Canadian health centres for primary undifferentiated carcinoma from gastrointestinal and pancreatic resection specimens. Upon review of 31 cases, 19 were confirmed to be undifferentiated carcinomas (eight colonic, six gastric, three pancreatic, one appendiceal and one duodenal). Immunohistochemical analysis of SMARCA4, SMARCA2, SMARCB1, ARID1A, ARID1B, MSH2, MSH6, MLH1 and PMS2 was performed on whole sections. Five of 19 (26%) showed loss of core SWI/SNF proteins (two loss of SMARCA4, one loss of SMARCB1 and two concurrent loss of ARID1A and ARID1B). SMARCA4, SMARCB1, or ARID1A/ARID1B-deficient undifferentiated carcinoma consistently exhibited sheet-like growth pattern, with cellular discohesion and rhabdoid morphology. Nine of 17 undifferentiated carcinomas tested were MMR-deficient by immunohistochemistry. In comparison, none of the 12 poorly differentiated carcinomas that were originally diagnosed as undifferentiated carcinomas showed loss of SMARCA4, SMARCA2, SMARCB1 or ARID1B. CONCLUSIONS: Undifferentiated gastrointestinal/pancreatic carcinomas show frequent loss of expression of SWI/SNF complex proteins. The loss of these core components of SWI/SNF complex may contribute to the arrest of cellular differentiation, resulting in the undifferentiated histology and aggressive clinical behaviour.</p>
<p>doi: <a href="https://doi.org/10.1111/his.14096" class="uri">https://doi.org/10.1111/his.14096</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Ki-67 proliferation index in neuroendocrine tumors: Can augmented reality microscopy with image analysis improve scoring?</strong> </summary></p>
<p><em>Cancer cytopathology 2020 May;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=32401429" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=32401429</a></p>
<p>BACKGROUND: The Ki-67 index is important for grading neuroendocrine tumors (NETs) in cytology. However, different counting methods exist. Recently, augmented reality microscopy (ARM) has enabled real-time image analysis using glass slides. The objective of the current study was to compare different traditional Ki-67 scoring methods in cell block material with newer methods such as ARM. METHODS: Ki-67 immunostained slides from 50 NETs of varying grades were retrieved (39 from the pancreas and 11 metastases). Methods with which to quantify the Ki-67 index in up to 3 hot spots included: 1) “eyeball” estimation (EE); 2) printed image manual counting (PIMC); 3) ARM with live image analysis; and 4) image analysis using whole-slide images (WSI) (field of view [FOV] and the entire slide). RESULTS: The Ki-67 index obtained using the different methods varied. The pairwise kappa results varied from no agreement for image analysis using digital image analysis WSI (FOV) and histology to near-perfect agreement for ARM and PIMC. Using surgical pathology as the gold standard, the EE method was found to have the highest concordance rate (84.2%), followed by WSI analysis of the entire slide (73.7%) and then both the ARM and PIMC methods (63.2% for both). The PIMC method was the most time-consuming whereas image analysis using WSI (FOV) was the fastest method followed by ARM. CONCLUSIONS: The Ki-67 index for NETs in cell block material varied by the method used for scoring, which may affect grade. PIMC was the most time-consuming method, and EE had the highest concordance rate. Although real-time automated counting using image analysis demonstrated inaccuracies, ARM streamlined and hastened the task of Ki-67 quantification in NETs.</p>
<p>doi: <a href="https://doi.org/10.1002/cncy.22272" class="uri">https://doi.org/10.1002/cncy.22272</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Amyloid-Rich Pancreatic Neuroendocrine Tumors: a Potential Diagnostic Pitfall in Endoscopic Ultrasound-Guided Fine Needle Aspiration Cytology (EUS-FNAC)</strong> </summary></p>
<p><em>Endocrine pathology 2020 May;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=32399832" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=32399832</a></p>
<p>Pancreatic neuroendocrine tumors (PanNETs) are rare neoplasms that include even rarer variants that may pose different diagnostic problems, especially in fine needle aspiration cytology (FNAC). We describe the diagnostic clues of the amyloid-rich variant of PanNETs in endoscopic ultrasound (EUS)-guided fine needle aspiration cytology (EUS-FNAC). Three cases of PanNETs with an amyloid-rich stromal component were retrieved and retrospectively reviewed. For every case, the pancreatic lesion was investigated by a EUS-FNAC procedure. The final diagnosis was supported by immunocytochemistry and Congo red staining. All cases had similar EUS-FNAC features: neoplastic cells were entrapped in an eosinophilic, homogeneous dense and amorphous matrix. The neuroendocrine nature was confirmed by immunoexpression of synaptophysin and chromogranin A, while the amorphous stroma was characterized as amyloid based on positive Congo red staining. Regarding the hormonal profile, no insulin or proinsulin reactivity was observed, but all cases were diffusely positive for amylin. The diagnosis of uncommon variants of PanNETs, such as the amyloid-rich, is challenging especially in EUS-FNAC procedures because of a unique and misleading morphology, potentially mimicking fibrotic conditions and amyloid deposition within systemic amyloidosis. In cytology specimens, the presence of amorphous material requires amyloid deposition to be considered in the differential diagnosis of pancreatic neoplasms with neuroendocrine phenotype.</p>
<p>doi: <a href="https://doi.org/10.1007/s12022-020-09625-2" class="uri">https://doi.org/10.1007/s12022-020-09625-2</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Identification of Serum miRNA Signature and Establishment of a Nomogram for Risk Stratification in Patients With Pancreatic Ductal Adenocarcinoma</strong> </summary></p>
<p><em>Annals of surgery 2020 May;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=32398486" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=32398486</a></p>
<p>OBJECTIVE: The aim of the study was to perform mRNA-miRNA regulatory network analyses to identify a miRNA panel for molecular subtype identification and stratification of high-risk patients with pancreatic ductal adenocarcinoma (PDAC). BACKGROUND: Recent transcriptional profiling effort in PDAC has led to the identification of molecular subtypes that associate with poor survival; however, their clinical significance for risk stratification in patients with PDAC has been challenging. METHODS: By performing a systematic analysis in The Cancer Genome Atlas and International Cancer Genome Consortium cohorts, we discovered a panel of miRNAs that associated with squamous and other poor molecular subtypes in PDAC. Subsequently, we used logistic regression analysis to develop models for risk stratification and Cox proportional hazard analysis to determine survival prediction probability of this signature in multiple cohorts of 433 patients with PDAC, including a tissue cohort (n = 199) and a preoperative serum cohort (n = 51). RESULTS: We identified a panel of 9 miRNAs that were significantly upregulated (miR-205-5p and -934) or downregulated (miR-192-5p, 194-5p, 194-3p, 215-5p, 375-3p, 552-3p, and 1251-5p) in PDAC molecular subtypes with poor survival [squamous, area under the receiver operating characteristic curve (AUC) = 0.90; basal, AUC = 0.89; and quasimesenchymal, AUC = 0.83]. The validation of this miRNA panel in a tissue clinical cohort was a significant predictor of overall survival (hazard ratio = 2.48, P &lt; 0.0001), and this predictive accuracy improved further in a risk nomogram which included key clinicopathological factors. Finally, we were able to successfully translate this miRNA predictive signature into a liquid biopsy-based assay in preoperative serum specimens from PDAC patients (hazard ratio: 2.85, P = 0.02). CONCLUSION: We report a novel miRNA risk-stratification signature that can be used as a noninvasive assay for the identification of high-risk patients and potential disease monitoring in patients with PDAC.</p>
<p>doi: <a href="https://doi.org/10.1097/SLA.0000000000003945" class="uri">https://doi.org/10.1097/SLA.0000000000003945</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Interleukin-1��-induced pancreatitis promotes pancreatic ductal adenocarcinoma via B lymphocyte-mediated immune suppression</strong> </summary></p>
<p><em>Gut 2020 May;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=32393543" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=32393543</a></p>
<p>OBJECTIVE: Long-standing chronic pancreatitis is an established risk factor for pancreatic ductal adenocarcinoma (PDAC). Interleukin-1β (IL-1β) has been associated in PDAC with shorter survival. We employed murine models to investigate the mechanisms by which IL-1β and chronic pancreatitis might contribute to PDAC progression. DESIGN: We crossed LSL-Kras+/G12D;Pdx1-Cre (KC) mice with transgenic mice overexpressing IL-1β to generate KC-IL1β mice, and followed them longitudinally. We used pancreatic 3D in vitro culture to assess acinar-to-ductal metaplasia formation. Immune cells were analysed by flow cytometry and immunohistochemical staining. B lymphocytes were adoptively transferred or depleted in Kras-mutant mice. B-cell infiltration was analysed in human PDAC samples. RESULTS: KC-IL1β mice developed PDAC with liver metastases. IL-1β treatment increased Kras+/G12D pancreatic spheroid formation. CXCL13 expression and B lymphocyte infiltration were increased in KC-IL1β pancreata. Adoptive transfer of B lymphocytes from KC-IL1β mice promoted tumour formation, while depletion of B cells prevented tumour progression in KC-IL1β mice. B cells isolated from KC-IL1β mice had much higher expression of PD-L1, more regulatory B cells, impaired CD8+ T cell activity and promoted tumorigenesis. IL-35 was increased in the KC-IL1β pancreata, and depletion of IL-35 decreased the number of PD-L1+ B cells. Finally, in human PDAC samples, patients with PDAC with higher B-cell infiltration within tumours showed significantly shorter survival. CONCLUSION: We show here that IL-1β promotes tumorigenesis in part by inducing an expansion of immune-suppressive B cells. These findings point to the growing significance of B suppressor cells in pancreatic tumorigenesis.</p>
<p>doi: <a href="https://doi.org/10.1136/gutjnl-2019-319912" class="uri">https://doi.org/10.1136/gutjnl-2019-319912</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Long Survival and Prolonged Remission after Surgery and Chemotherapy in a Metastatic Mismatch Repair Deficient Pancreatic Neuroendocrine Carcinoma with MLH1/PMS2 Immunodeficiency and Minimal Microsatellite Shift</strong> </summary></p>
<p><em>Endocrine pathology 2020 May;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=32388775" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=32388775</a></p>
<p>Pancreatic neuroendocrine carcinomas (NECs) are rare and very aggressive neoplasms with dismal prognosis, especially when metastatic or with negative prognostic factors, such as vascular invasion. To the best of our knowledge, no case of pancreatic NEC with mismatch repair deficiency has been reported to date. We describe a 62-year-old patient who underwent pancreaticoduodenectomy for a NEC located in the pancreatic head, with peripancreatic lymph node metastases. Tumor necrosis was prominent and the Ki67 proliferative index was 60%. One year after the diagnosis, the patient experienced recurrence with a left supraclavicular lymph node metastasis, which was surgically removed, followed by standard cisplatin-etoposide chemotherapy. Neoplastic cells showed combined loss of expression of MLH1 and PMS2 in both primary tumor and lymph node metastasis. Microsatellite instability (MSI) test using a mononucleotide repeats pentaplex PCR (BAT-25, BAT-26, NR-21, NR-22, and NR-24) revealed minimal mononucleotide shifts showing deletion of less than 3 bp at NR-21, BAT-26, NR-24, and NR-22 loci. MLH1 methylation analysis revealed absence of the gene promoter methylation. BRAF and KRAS mutations were not detected. In gut, NECs’ mismatch repair deficiency phenotype has been reported in about 10% of cases, and it represents an independent factor of more favorable outcome. Likewise, our patient is currently alive with a follow-up of more than 12 years after pancreaticoduodenectomy, by itself an unexpected finding for such an aggressive neoplasm.</p>
<p>doi: <a href="https://doi.org/10.1007/s12022-020-09622-5" class="uri">https://doi.org/10.1007/s12022-020-09622-5</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Simple mucinous cysts of the pancreas have heterogeneous somatic mutations</strong> </summary></p>
<p><em>Human pathology 2020 May;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=32380013" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=32380013</a></p>
<p>Simple mucinous cysts of the pancreas have an epithelial lining resembling pancreatic intraepithelial neoplasia but may have a clinical presentation similar to pre-malignant mucinous neoplasms such as intraductal papillary mucinous neoplasms. Whether the epithelial lining shares genomic alterations with other pancreatic preinvasive neoplasms such as PanIN and intraductal papillary mucinous neoplasm has not been determined. We performed targeted sequencing analysis using a custom designed MiSeq panel including the full coding regions of 18 pancreatic cancer genes on 13 clinically and pathologically well characterized simple mucinous cysts. We detected 59 mutations in 15 genes in the cohort, with a median of 4 mutations per cyst (range=0-16 mutations per cyst). The mutated genes and rate of detected mutations were: KMT2C (MLL3) (62%), KRAS (15%), BRAF (8%), RNF43 (8%), CDKN2a (8%), TP53 (15%), and SMAD4 (8%). No GNAS mutations were detected. Four cases (31%) had no mutations detected. These findings place the majority of simple mucinous cysts of the pancreas in the spectrum of early, low grade mucinous neoplasia, albeit with an different spectrum of genomic alterations than PanIN and intraductal papillary mucinous neoplasm.</p>
<p>doi: <a href="https://doi.org/10.1016/j.humpath.2020.04.006" class="uri">https://doi.org/10.1016/j.humpath.2020.04.006</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Autophagy promotes immune evasion of pancreatic cancer by degrading MHC-I</strong> </summary></p>
<p><em>Nature 2020 May;581(7806):100-105</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=32376951" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=32376951</a></p>
<p>Immune evasion is a major obstacle for cancer treatment. Common mechanisms of evasion include impaired antigen presentation caused by mutations or loss of heterozygosity of the major histocompatibility complex class I (MHC-I), which has been implicated in resistance to immune checkpoint blockade (ICB) therapy1-3. However, in pancreatic ductal adenocarcinoma (PDAC), which is resistant to most therapies including ICB4, mutations that cause loss of MHC-I are rarely found5 despite the frequent downregulation of MHC-I expression6-8. Here we show that, in PDAC, MHC-I molecules are selectively targeted for lysosomal degradation by an autophagy-dependent mechanism that involves the autophagy cargo receptor NBR1. PDAC cells display reduced expression of MHC-I at the cell surface and instead demonstrate predominant localization within autophagosomes and lysosomes. Notably, inhibition of autophagy restores surface levels of MHC-I and leads to improved antigen presentation, enhanced anti-tumour T cell responses and reduced tumour growth in syngeneic host mice. Accordingly, the anti-tumour effects of autophagy inhibition are reversed by depleting CD8+ T cells or reducing surface expression of MHC-I. Inhibition of autophagy, either genetically or pharmacologically with chloroquine, synergizes with dual ICB therapy (anti-PD1 and anti-CTLA4 antibodies), and leads to an enhanced anti-tumour immune response. Our findings demonstrate a role for enhanced autophagy or lysosome function in immune evasion by selective targeting of MHC-I molecules for degradation, and provide a rationale for the combination of autophagy inhibition and dual ICB therapy as a therapeutic strategy against PDAC.</p>
<p>doi: <a href="https://doi.org/10.1038/s41586-020-2229-5" class="uri">https://doi.org/10.1038/s41586-020-2229-5</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Development and clinical validation of discriminatory multi-target digital droplet PCR assays for the detection of hot spot KRAS and NRAS mutations in cell-free DNA</strong> </summary></p>
<p><em>The Journal of molecular diagnostics : JMD 2020 May;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=32376474" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=32376474</a></p>
<p>Detection and quantification of tumor-derived KRAS and NRAS mutations in cell-free plasma DNA (cfDNA) holds great potential for cancer diagnostics and treatment response monitoring. Because of high sensitivity, specificity, robustness and affordability, digital droplet PCR (ddPCR) is ideally suited for this application but requires discriminatory multiplexing when used as screening assay. We therefore designed, optimized and clinically validated mutation-specific locked nucleic acid (LNA)-based ddPCR assays for 14 commonly occurring KRAS and NRAS mutations and assembled these assays into 7 discriminatory multi-target screening assays covering 2-6 SNVs each. Limit of detection (LOD), limit of blank (LOB) and inter-assay accuracy were determined. Assay performance and suitability for screening in cell-free DNA were validated with plasma samples from a clinically fully characterized cohort of pancreatic cancer patients and healthy controls. LODs for single-target assays were between 0.0015 and 0.069 % variant allele fraction (VAF), and between 0.022 and 0.16 % for multi-target assays. Dilution linearity and inter-assay accuracy were excellent throughout (r2&gt;0.99). Multi-target assay screening of cfDNA extracted from pancreatic cancer patients with unknown KRAS mutational status correctly identified SNV in 45/45 (100%) of ctDNA-positive samples. In summary, we here present and clinically validate generic single- and discriminatory multi-target ddPCR assays for KRAS and NRAS hot spot mutations with broad applicability for clinical and translational research.</p>
<p>doi: <a href="https://doi.org/10.1016/j.jmoldx.2020.04.206" class="uri">https://doi.org/10.1016/j.jmoldx.2020.04.206</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>A microRNA Signature Identifies Pancreatic Ductal Adenocarcinoma Patients at Risk for Lymph Node Metastases</strong> </summary></p>
<p><em>Gastroenterology 2020 May;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=32376411" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=32376411</a></p>
<p>BACKGROUND &amp; AIMS: Pancreatic ductal adenocarcinomas (PDACs) frequently metastasize to the lymph nodes; strategies are needed to identify patients at highest risk for lymph node metastases. We performed genome-wide expression profile analyses of PDAC specimens, collected during surgery or endoscopic ultrasound fine-need aspiration (EUS-FNA), to identify a microRNA (miRNA) signature associated with metastasis to lymph nodes. METHODS: For biomarker discovery, we analyzed miRNA expression profiles of primary pancreatic tumors from 3 public datasets (TCGA, GSE24279, and GSE32688). We then analyzed 157 PDAC specimens (83 from patients with lymph node metastases and 74 without) from Japan, collected from 2001 through 2017, for the training cohort and a 107 PDAC specimens (63 from patients with lymph node metastases and 44 without) from a different medical center in Japan, from 2002 through 2016, for the validation cohort. We also analyzed samples collected by EUS-FNA before surgery from 47 patients (22 patients with lymph node metastases and 25 without; 17 for the training cohort and 30 from the validation cohort), and 62 specimens prior to any treatment from patients who received neoadjuvant chemotherapy (9 patients with lymph node metastasis and 53 without) for additional validation. Multivariate logistic regression analyses were used to evaluate the statistical differences in miRNA expression between patients with vs without metastases. RESULTS: We identified a miRNA expression pattern associated with diagnosis of PDAC metastasis to lymph nodes. Using logistic regression analysis, we optimized and trained a 6-miRNA risk prediction model for training cohort; this model discriminated patients with vs without lymph node metastases with an area under the curve (AUC) of 0.84 (95% CI. 0.77-0.89). In the validation cohort, the model identified patients with vs without lymph node metastases with an AUC of 0.73 (95% CI. 0.64-0.81). In EUS-FNA biopsies, the model identified patients with vs without lymph node metastases with an AUC of 0.78 (95% CI. 0.63-0.89). The miRNA expression pattern was an independent predictor of PDAC metastasis to lymph node in the validation cohort (odds ratio, 17.05; 95% CI. 2.43-119.57), and in the EUS-FNA cohort (95% CI. 0.65-0.87). CONCLUSIONS: Using data and tumor samples from 3 independent cohorts, we identified a miRNA signature that identifies patients at risk for PDAC metastasis to lymph nodes. The signature has similar levels of accuracy in analysis of resected tumor specimens and EUS-FNA biopsies. This model might be used to select treatment and management strategies for patients with PDAC.</p>
<p>doi: <a href="https://doi.org/10.1053/j.gastro.2020.04.057" class="uri">https://doi.org/10.1053/j.gastro.2020.04.057</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>International Consensus Guidelines for Risk Factors in Chronic Pancreatitis. Recommendations from the working group for the international consensus guidelines for chronic pancreatitis in collaboration with the International Association of Pancreatology, the American Pancreatic Association, the Japan Pancreas Society, and European Pancreatic Club</strong> </summary></p>
<p><em>Pancreatology : official journal of the International Association of Pancreatology (IAP) … [et al.] 2020 Jun;20(4):579-585</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=32376198" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=32376198</a></p>
<p>BACKGROUND: Chronic pancreatitis (CP) is a complex inflammatory disease with remarkably impaired quality of life and permanent damage of the pancreas. This paper is part of the international consensus guidelines on CP and presents the consensus on factors elevating the risk for CP. METHODS: An international working group with 20 experts on CP from the major pancreas societies (IAP, APA, JPS, and EPC) evaluated 14 statements generated from evidence on four questions deemed to be the most clinically relevant in CP. The Grading of Recommendations Assessment, Development, and Evaluation (GRADE) approach was used to evaluate the level of evidence available per statement. To determine the level of agreement, the working group voted on the 14 statements for strength of agreement, using a nine-point Likert scale in order to calculate Cronbach’s alpha reliability coefficient. RESULTS: Strong consensus and agreement were obtained for the following statements: Alcohol, smoking, and certain genetic alterations are risk factors for CP. Past history, family history, onset of symptoms, and life-style factors including alcohol intake and smoking history should be determined. Alcohol consumption dose-dependently elevates the risk of CP up to 4-fold. Ever smokers, even smoking less than a pack of cigarettes per day, have an increased risk for CP, as compared to never smokers. CONCLUSIONS: Both genetic and environmental factors can markedly elevate the risk for CP. Therefore, health-promoting lifestyle education and in certain cases genetic counselling should be employed to reduce the incidence of CP.</p>
<p>doi: <a href="https://doi.org/10.1016/j.pan.2020.03.014" class="uri">https://doi.org/10.1016/j.pan.2020.03.014</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Exosomal miRNA signatures of pancreatic lesions</strong> </summary></p>
<p><em>BMC gastroenterology 2020 May;20(1):137</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=32375666" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=32375666</a></p>
<p>BACKGROUND: Pancreatic and peri-pancreatic neoplasms encompass a variety of histotypes characterized by a heterogeneous prognostic impact. miRNAs are considered efficient candidate biomarkers due to their high stability in tissues and body fluids. We applied Nanostring profiling of circulating exosomal miRNAs to distinct pancreatic lesions in order to establish a source for biomarker development. METHODS: A series of 140 plasma samples obtained from patients affected by pancreatic ductal adenocarcinoma (PDAC, n = 58), pancreatic neuroendocrine tumors (PanNET, n = 42), intraductal papillary mucinous neoplasms (IPMN, n = 20), and ampulla of Vater carcinomas (AVC, n = 20) were analyzed. Comprehensive miRNA profiling was performed on plasma-derived exosomes. Relevant miRNAs were validated by qRT-PCR and in situ hybridization (ISH). RESULTS: Lesion specific miRNAs were identified through multiple disease comparisons. Selected miRNAs were validated in the plasma by qRT-PCR and at tissue level by ISH. We leveraged the presence of clinical subtypes with each disease cohort to identify miRNAs that are differentially enriched in aggressive phenotypes. CONCLUSIONS: This study shows that pancreatic lesions are characterized by specific exosomal-miRNA signatures. We also provide the basis for further explorations in order to better understand the relevance of these signatures in pancreatic neoplasms.</p>
<p>doi: <a href="https://doi.org/10.1186/s12876-020-01287-y" class="uri">https://doi.org/10.1186/s12876-020-01287-y</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Magnetic resonance cholangiopancreatography findings in early chronic pancreatitis diagnosed according to the Japanese Diagnostic Criteria</strong> </summary></p>
<p><em>Pancreatology : official journal of the International Association of Pancreatology (IAP) … [et al.] 2020 Apr;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=32371200" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=32371200</a></p>
<p>OBJECTIVES: It is important for diagnosing early chronic pancreatitis (CP), which may be improved by therapeutic intervention. We aimed to examine the pancreatic ductal changes on magnetic resonance cholangiopancreatography (MRCP) in patients with early CP defined by the Japanese Diagnostic Criteria. METHODS: This retrospective study included patients suspected early CP and performed both endoscopic ultrasonography (EUS) and MRCP from January 2010 to August 2018. We assessed the diameter of the main pancreatic duct (MPD) and the number of irregularly dilated duct branches using MRCP imaging in early CP. RESULTS: We enrolled 165 patients and 25 patients (15%) fulfilled the diagnostic criteria for early CP. Irregular dilatation of ≥ 3 duct branches on MRCP was more often observed in early CP compared to non-early CP (P = 0.004), although MPD diameter was comparable (2.06 mm in early CP vs. 1.96 in non-early CP, P = 0.698). The sensitivity and specificity were 45% and 74%, respectively. The prevalence of positive MRCP findings in patients with ≥ 2 positive EUS findings was higher than that in patients with 1 positive EUS finding (P = 0.08) and in patients without an EUS finding (P &lt; 0.001). There was no difference in the average diameter of MPD. CONCLUSION: Patients with early CP often exhibit alteration in duct branches and not in MPD in addition to parenchymal alteration. Both pancreatic parenchyma and duct branches might need to be evaluated by EUS and MRCP.</p>
<p>doi: <a href="https://doi.org/10.1016/j.pan.2020.04.008" class="uri">https://doi.org/10.1016/j.pan.2020.04.008</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Prognostic Impact of Pancreatic Invasion in Duodenal Carcinoma: A Single-Center Experience</strong> </summary></p>
<p><em>Annals of surgical oncology 2020 May;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=32367502" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=32367502</a></p>
<p>BACKGROUND: The prognostic factors for duodenal carcinoma (DC) remain unclear because of its rarity. This study aimed to investigate the prognostic impact of pancreatic invasion (PI) on postoperative survival for patients with DC. METHODS: This study retrospectively analyzed 86 patients with DC, including 18 patients with PI, who underwent surgical resection between October 2002 and March 2018. The clinicopathologic features and survival outcomes of these patients were investigated to identify the prognostic factors in DC. The long-term survival for the DC patients with PI was compared with that for the patients who underwent resection for resectable pancreatic head carcinoma (RPHC) during the same period. RESULTS: The median survival time (MST) for the DC patients with PI was 25.7 months, which was significantly worse than for the patients with T2 or deeper DC without PI (p = 0.010). The multivariate analysis showed that the independent prognostic factors were PI (hazard ratio [HR] 7.59; p = 0.019) and lymph node metastasis (LNM) (HR 5.01; p = 0.026). The MST for the DC patients with PI did not differ significantly from that for the RPHC patients treated without adjuvant chemotherapy (p = 0.135). Comparable rates of microscopic venous invasion and hematogenous metastasis were observed for the DC patients with PI and the RPHC patients. CONCLUSIONS: Pancreatic invasion was an independent prognostic factor in DC. The survival outcomes for the DC patients with PI did not differ from those for the patients with RPHC, which was associated with a high rate of hematogenous recurrence.</p>
<p>doi: <a href="https://doi.org/10.1245/s10434-020-08512-8" class="uri">https://doi.org/10.1245/s10434-020-08512-8</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>First-in-Human Trial of Epichaperome-Targeted Positron Emission Tomography in Cancer Patients</strong> </summary></p>
<p><em>Clinical cancer research : an official journal of the American Association for Cancer Research 2020 May;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=32366671" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=32366671</a></p>
<p>PURPOSE: 124I-PU-H71 is an investigational first-in-class radiologic agent specific for imaging tumor epichaperome formations. The intracellular epichaperome forms under cellular stress and is a clinically validated oncotherapeutic target. We conducted a first-in-human study of microdose 124I-PU-H71 for positron emission tomography (PET) to study in vivo biodistribution, pharmacokinetics, metabolism, and safety; and the feasibility of epichaperome-targeted tumor imaging. EXPERIMENTAL DESIGN: Adult patients with cancer (n=30) received 124I-PU-H71 tracer (201±12 MBq, &lt;25 μg) IV bolus followed by PET/CT scans and blood radioassays. RESULTS: 124I-PU-H71 PET detected tumors of different cancer types (breast, lymphoma, neuroblastoma, genitourinary, gynecologic, sarcoma, and pancreas). 124I-PU-H71 was retained by tumors for several days while it cleared rapidly from bones, healthy soft tissues, and blood. Radiation dosimetry is favorable and patients suffered no adverse effects. CONCLUSIONS: Our first-in-human results demonstrate the safety and feasibility of non-invasive in vivo detection of tumor epichaperomes using 124I-PU-H71 PET, supporting clinical development of PU-H71 and other epichaperome-targeted therapeutics.</p>
<p>doi: <a href="https://doi.org/10.1158/1078-0432.CCR-19-3704" class="uri">https://doi.org/10.1158/1078-0432.CCR-19-3704</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Histopathological and Immunophenotypic Changes of Pancreatic Neuroendocrine Tumors after Neoadjuvant Peptide Receptor Radionuclide Therapy (PRRT)</strong> </summary></p>
<p><em>Endocrine pathology 2020 May;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=32361926" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=32361926</a></p>
<p>Peptide Receptor Radionuclide Therapy (PRRT) is an emerging therapeutic option for pancreatic neuroendocrine tumors (PanNETs). A possible role for PRRT as a neoadjuvant agent is still largely undetermined, explored only in case reports or small case series. Likewise, the histopathological and immunophenotypic changes induced by PRRT are poorly characterized. In the present study, 24 patients who underwent neoadjuvant PRRT on the basis of their disease’s characteristics were retrospectively matched with 24 patients who underwent upfront surgery. A comprehensive morphological and immunohistochemical evaluation was conducted to identify the differences in the two groups. The most significant findings were that the total percentage of stroma increased significantly in patients who underwent PRRT (p &lt; 0.0001) and the characteristics of the stroma were different in the two groups. The somatostatin receptors type 2A (SSTR2A) were retained in most patients (87%) after PRRT. The density of CD163+ M2-polarized macrophages was greater in the PRRT group (p = 0.022), and M2-polarized macrophages tended to assume an epithelioid morphology (p = 0.043). In the neoadjuvant PRRT group, none of the histological parameters considered were associated with progression-free survival (PFS). Neoadjuvant PRRT in PanNETs is associated with reduced tumor diameter, an increased percentage of stroma, preserved SSTR2A expression in most of the cases, and an increased CD163+ M2-polarized macrophages density.</p>
<p>doi: <a href="https://doi.org/10.1007/s12022-020-09623-4" class="uri">https://doi.org/10.1007/s12022-020-09623-4</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>SETDB1 Inhibits p53-Mediated Apoptosis and is Required for Formation of Pancreatic Ductal Adenocarcinomas in Mice</strong> </summary></p>
<p><em>Gastroenterology 2020 Apr;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=32360551" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=32360551</a></p>
<p>BACKGROUND &amp; AIMS: SETDB1, a histone methyltransferase that trimethylates histone H3 on lysine 9, promotes development of several tumor types. We investigated whether SETDB1 contributes to development of pancreatic ductal adenocarcinoma (PDAC). METHODS: We performed studies with Ptf1aCre; KrasG12D; Setdb1f/f, Ptf1aCre; KrasG12D; Trp53f/+; Setdb1f/f, and Ptf1aCre; KrasG12D; Trp53f/f; Setdb1f/f mice to investigate the effects of disruption of Setdb1 in mice with activated KRAS-induced pancreatic tumorigenesis, with heterozygous or homozygous disruption of Trp53. We performed microarray analyses of whole-pancreas tissues from Ptf1aCre; KrasG12D; Setdb1f/f and Ptf1aCre; KrasG12D mice and compared their gene expression patterns. Chromatin immunoprecipitation assays were performed using acinar cells isolated from pancreata with and without disruption of Setdb1. We used human PDAC cells for SETDB1 knockdown and inhibitor experiments. RESULTS: Loss of SETDB1 from pancreas accelerated formation of premalignant lesions in mice with pancreata that express activated KRAS. Microarray analysis revealed upregulated expression of genes in the apoptotic pathway and genes regulated by p53 in SETDB1-deficient pancreata. Deletion of SETDB1 from pancreas prevented formation of PDACs, concomitant with increased apoptosis and upregulated expression of Trp53 in mice heterozygous for disruption of Trp53. In contrast, pancreata of mice with homozygous disruption of Trp53 had no increased apoptosis, and PDACs developed. Chromatin immunoprecipitation revealed that SETDB1 bound to the Trp53 promoter to regulate its expression. Expression of an inactivated form of SETDB1 in human PDAC cells with wild type TP53 resulted in TP53-induced apoptosis. CONCLUSIONS: We found that the histone methyltransferase SETDB1 is required for development of PDACs, induced by activated KRAS, in mice. SETDB1 inhibits apoptosis by regulating expression of p53. SETDB1 might be a therapeutic target for PDACs that retain p53 function.</p>
<p>doi: <a href="https://doi.org/10.1053/j.gastro.2020.04.047" class="uri">https://doi.org/10.1053/j.gastro.2020.04.047</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Frequency of mismatch repair deficiency in pancreatic ductal adenocarcinoma</strong> </summary></p>
<p><em>Pathology, research and practice 2020 Apr;():152985</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=32360245" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=32360245</a></p>
<p>Pancreatic ductal adenocarcinoma (PDAC) has an ominous prognosis and there are only few treatment options. It is therefore crucial to investigate possible predictive markers that may improve the treatment of this disease. Mismatch repair (MMR) deficiency (d-MMR), meaning MMR protein loss (l-MMR) and/or microsatellite instability (MSI), is predictive of response to immunotherapy, but its frequency has to our knowledge not been elucidated in Scandinavian PDACs. Our aims were to examine the frequency of d-MMR in a Danish cohort of PDACs. We constructed multi-punch tissue microarrays (TMAs) using primary tumor tissue. Immunohistochemistry (IHC) for the DNA MMR proteins MLH1, MSH2, MSH6 and PMS2 was performed, and their expression was evaluated using a scoring system from 0 to 4. If the overall score was between 0-2 or if IHC was inconclusive for technical reasons, IHC on whole-tissue sections and MSI using PCR was performed. A final score of 0, 1-2 or 3-4 defined the tumor as l-MMR, MMR reduced (r-MMR) or MMR proficient. In total, 4/164 (2.4 %), 2/164 (1.2 %) and 3/164 (1.8 %) were l-MMR, r-MMR, or inconclusive based on IHC. MSI testing of these specimens showed that two of the four l-MMR tumors were MSI-high, while the remaining cases were microsatellite stable (MSS). In conclusion, in this study of Danish PDACss, d-MMR was found in a small proportion of the tumors. For these patients, individualized treatment using immunotherapy could be considered.</p>
<p>doi: <a href="https://doi.org/10.1016/j.prp.2020.152985" class="uri">https://doi.org/10.1016/j.prp.2020.152985</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Pancreatic cancer cells show lower oleic acid oxidation and their conditioned medium inhibits oleic acid oxidation in human myotubes</strong> </summary></p>
<p><em>Pancreatology : official journal of the International Association of Pancreatology (IAP) … [et al.] 2020 Apr;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=32360002" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=32360002</a></p>
<p>BACKGROUND: /Objectives: We aimed to metabolically compare healthy primary human pancreatic epithelial cells (hPEC) to a pancreatic cancer cell line (PANC-1) and explore the effect on energy metabolism of exposing primary human myotubes to conditioned medium from hPEC and PANC-1 cells. METHODS: Differences in metabolism were examined with radiolabeled glucose, oleic acid and lactic acid, and by qPCR. Mass spectrometry-based proteomics was used to study global protein secretion from the two cell types. Pathway analyses were performed. RESULTS: PANC-1 cells tended to have higher glucose uptake, production of lactic acid, and glucose oxidation compared to hPEC cells. PANC-1 cells had higher uptake but lower oxidation of oleic acid, and mitochondrial reserve capacity from oleic acid was lower in PANC-1 cells. These differences in energy metabolism were reflected by differences in gene expressions and pathway analyses of the secretome. Conditioned medium from PANC-1 cells attenuated oleic acid oxidation in primary human myotubes. CONCLUSIONS: Metabolic characterization of the PANC-1 cells revealed a glycolytic phenotype since they had an active glucose oxidation. Furthermore, PANC-1 cells showed a lower oleic acid oxidation and secreted a high amount of proteins into conditioned medium that also induced a reduced oleic acid oxidation in myotubes.</p>
<p>doi: <a href="https://doi.org/10.1016/j.pan.2020.04.014" class="uri">https://doi.org/10.1016/j.pan.2020.04.014</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Natural history and clinical outcomes of pancreatic neuroendocrine neoplasms based on the WHO 2017 classification; a single-center experience of 30 years</strong> </summary></p>
<p><em>Pancreatology : official journal of the International Association of Pancreatology (IAP) … [et al.] 2020 Apr;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=32360001" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=32360001</a></p>
<p>BACKGROUND/OBJECTIVES: This single-center study aimed to evaluate treatment outcomes and long-term prognosis of patients with pancreatic neuroendocrine neoplasms (PanNENs) based on the World Health Organization (WHO) 2017 classification. METHODS: We enrolled 245 patients with PanNENs treated at Kyushu University Hospital between January 1987 and March 2018. PanNENs were categorized according to the WHO 2017 classification or further subdivisions of Ki-67 index. Clinicopathological features, median survival time (MST), and prognostic factors were retrospectively analyzed. RESULTS: The number of PanNENs, especially non-functioning PanNENs, has increased over the last decade. The mean MST of all patients was 202 months; which was longest in patients with NET G1 (n = 145, MST = 261 months) relative to NET G2 (n = 72, 132 months), NET G3 (n = 3, 34 months) and NEC G3 (n = 17, 9 months). Prognosis in patients with surgery as the first-line treatment was significantly better than in those with drug therapy. However, 26% of patients who underwent curative resection developed recurrence after a median time of 28.7 months. In unresectable PanNENs (n = 97), the MST and 5-year survival rate were 78 months and 55.8%, respectively. Poor differentiation, Ki-67 index of &gt;10% and presence of liver metastasis were significant unfavorable predictors. Response to first-line therapy (stable disease/partial response) and three or more treatment regimens were significant favorable predictors for unresectable PanNENs according to multivariate analyses (p &lt; 0.01). CONCLUSIONS: We demonstrated the utility of the WHO 2017 classification for PanNENs in the real clinical setting. For better prognosis in PanNENs, the use of three or more regimens should be considered.</p>
<p>doi: <a href="https://doi.org/10.1016/j.pan.2020.04.003" class="uri">https://doi.org/10.1016/j.pan.2020.04.003</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Reduction of intra-abdominal pressure after percutaneous catheter drainage of pancreatic fluid collection predicts survival</strong> </summary></p>
<p><em>Pancreatology : official journal of the International Association of Pancreatology (IAP) … [et al.] 2020 Apr;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=32360000" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=32360000</a></p>
<p>OBJECTIVE: Intra-abdominal hypertension (IAH) can adversely affect the outcome in patients of acute pancreatitis (AP). Effect of percutaneous drainage (PCD) on IAH has not been studied. We studied the effect of PCD on IAH in patients with acute fluid collections. MATERIAL AND METHODS: Consecutive patients of AP undergoing PCD between Jan 2016 and May 2018 were evaluated for severity markers, clinical course, hospital and ICU stay, and mortality. Patients were divided into two groups: with IAH and with no IAH (NIAH). The two groups were compared for severity scores, organ failure, hospital and ICU stay, reduction in IAP and mortality. RESULTS: Of the 105 patients, IAH was present in 48 (45.7%) patients. Patients with IAH had more often severe disease, BISAP ≥2, higher APACHE II scores and computed tomography severity index (CTSI). IAH group had more often OF (87.5% vs. 70.2%, p = 0.033), prolonged ICU stay (12.5 vs. 6.75 days, p = 0.007) and higher mortality (52.1% vs. 15.8%, p &lt; 0.001). After PCD, IAP decreased significantly more in the IAH group (21.85 ± 4.53 mmHg to 12.5 ± 4.42 mmHg) than in the NIAH group (12.68 ± 2.72 mmHg to 8.32 ± 3.18 mmHg), p = &lt;0.001. Reduction of IAP in patients with IAH by &gt;40% at 48 h after PCD was associated with better survival (63.3% vs. 36.7%, p = 0.006). CONCLUSION: We observed that patients with IAH have poor outcome. PCD decreases IAP and a fall in IAP &gt;40% of baseline value predicts a better outcome after PCD in patients with acute fluid collections.</p>
<p>doi: <a href="https://doi.org/10.1016/j.pan.2020.04.012" class="uri">https://doi.org/10.1016/j.pan.2020.04.012</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>RAF1 rearrangements are common in pancreatic acinar cell carcinomas</strong> </summary></p>
<p><em>Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc 2020 May;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=32358589" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=32358589</a></p>
<p>There is now evidence that gene fusions activating the MAPK pathway are relatively common in pancreatic acinar cell carcinoma with potentially actionable BRAF or RET fusions being found in ~30%. We sought to investigate the incidence of RAF1 fusions in pancreatic malignancies with acinar cell differentiation. FISH testing for RAF1 was undertaken on 30 tumors comprising 25 ‘pure’ acinar cell carcinomas, 2 mixed pancreatic acinar-neuroendocrine carcinomas, 1 mixed acinar cell-low grade neuroendocrine tumor and 2 pancreatoblastomas. RAF1 rearrangements were identified in 5 cases and confirmed by DNA and RNA sequencing to represent oncogenic fusions (GATM-RAF1, GOLGA4-RAF1, PDZRN3-RAF1, HERPUD1-RAF1 and TRIM33-RAF1) and to be mutually exclusive with BRAF and RET fusions, as well as KRAS mutations. Large genome-wide copy number changes were common and included 1q gain and/or 1p loss in all five RAF1 FISH-positive acinar cell carcinomas. RAF1 expression by immunohistochemistry was found in 3 of 5 (60%) of fusion-positive cases and no FISH-negative cases. Phospho-ERK1/2 expression was found in 4 of 5 RAF1-fusion-positive cases. Expression of both RAF1 and phospho-ERK1/2 was heterogeneous and often only detected at the tumor-stroma interface, thus limiting their clinical utility. We conclude that RAF1 gene rearrangements are relatively common in pancreatic acinar cell carcinomas (14.3% to 18.5% of cases) and can be effectively identified by FISH with follow up molecular testing. The combined results of several studies now indicate that BRAF, RET or RAF1 fusions occur in between one third and one-half of these tumors but are extremely rare in other pancreatic malignancies. As these fusions are potentially actionable with currently available therapies, a strong argument can be made to perform FISH or molecular testing on all pancreatic acinar cell carcinomas.</p>
<p>doi: <a href="https://doi.org/10.1038/s41379-020-0545-9" class="uri">https://doi.org/10.1038/s41379-020-0545-9</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Diagnosis of Depression is Associated with Readmission Following Elective Pancreatectomy</strong> </summary></p>
<p><em>Annals of surgical oncology 2020 Apr;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=32356271" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=32356271</a></p>
<p>BACKGROUND: Diagnosis of depression may be associated with adverse outcomes following surgery. The aim of this study is to investigate whether depression is associated with an increased readmission rate following elective pancreatectomy, which is currently unknown. METHODS: The 2014 Nationwide Readmissions Database was used to evaluate whether diagnosis of depression was associated with 30-day readmission following elective pancreatectomy in adult patients. Univariate and multivariate logistic regression models were adjusted for clustering by facility. A secondary analysis was performed to evaluate whether the risk of diagnosis of depression on 30-day readmission rates was modified by length of stay (median 8 days). All multivariate models were adjusted for patient-level characteristics. RESULTS: There were an estimated 11,992 patients who underwent elective pancreatectomy. Mean age was 63 years, and 48.9% were male. Approximately 10.2% (n = 1223) had diagnosis of depression. Depression was associated with higher odds of 30-day readmission following elective pancreatectomy on univariate [odds ratio (OR) 1.26, 95% confidence interval (CI) 1.01-1.59; P = 0.043] and multivariate analyses (OR 1.29, 95% CI 1.01-1.65; P = 0.039). Although length of stay &gt; 8 days was independently associated with higher odds of 30-day readmission (P = 0.005), length of stay did not alter the association between diagnosis of depression and odds of readmission (P = 0.90). CONCLUSIONS: Diagnosis of depression was associated with higher odds of 30-day readmission following pancreatectomy, regardless of length of stay. Enhanced focus on evaluation and optimization of perioperative mental health is warranted to identify patients at high risk for readmission and reduce the burden related to readmission following pancreatic surgery.</p>
<p>doi: <a href="https://doi.org/10.1245/s10434-020-08522-6" class="uri">https://doi.org/10.1245/s10434-020-08522-6</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Single-cell resolution analysis of the human pancreatic ductal progenitor cell niche</strong> </summary></p>
<p><em>Proceedings of the National Academy of Sciences of the United States of America 2020 Apr;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=32354994" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=32354994</a></p>
<p>We have described multipotent progenitor-like cells within the major pancreatic ducts (MPDs) of the human pancreas. They express PDX1, its surrogate surface marker P2RY1, and the bone morphogenetic protein (BMP) receptor 1A (BMPR1A)/activin-like kinase 3 (ALK3), but not carbonic anhydrase II (CAII). Here we report the single-cell RNA sequencing (scRNA-seq) of ALK3bright+-sorted ductal cells, a fraction that harbors BMP-responsive progenitor-like cells. Our analysis unveiled the existence of multiple subpopulations along two major axes, one that encompasses a gradient of ductal cell differentiation stages, and another featuring cells with transitional phenotypes toward acinar tissue. A third potential ducto-endocrine axis is revealed upon integration of the ALK3bright+ dataset with a single-cell whole-pancreas transcriptome. When transplanted into immunodeficient mice, P2RY1+/ALK3bright+ populations (enriched in PDX1+/ALK3+/CAII- cells) differentiate into all pancreatic lineages, including functional β-cells. This process is accelerated when hosts are treated systemically with an ALK3 agonist. We found PDX1+/ALK3+/CAII- progenitor-like cells in the MPDs of types 1 and 2 diabetes donors, regardless of the duration of the disease. Our findings open the door to the pharmacological activation of progenitor cells in situ.</p>
<p>doi: <a href="https://doi.org/10.1073/pnas.1918314117" class="uri">https://doi.org/10.1073/pnas.1918314117</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Nicotine promotes tumor progression and epithelial-mesenchymal transition by regulating the miR-155-5p/NDFIP1 axis in pancreatic ductal adenocarcinoma</strong> </summary></p>
<p><em>Pancreatology : official journal of the International Association of Pancreatology (IAP) … [et al.] 2020 Apr;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=32354626" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=32354626</a></p>
<p>BACKGROUND: Nicotine, the major component of cigarette smoke, has been reported to promote pancreatic ductal adenocarcinoma (PDAC) growth and invasion. Deregulation of microRNA (miRNA) expression is found in many cancers, including PDAC. The effects of nicotine on miRNAs change in PDAC progression remain unknown. METHODS: The effects of cigarette smoking/nicotine exposure on PDAC cell lines and tissues were evaluated. Quantitative real-time PCR and in situ hybridization assays were used to determine miR-155-5p expression in human PDAC tissue and cell lines upon cigarette smoking/nicotine exposure. Bioinformatics, loss-of-function experiments, luciferase reporter assay were performed to validate Nedd4 family interacting protein 1 (NDFIP1) as a direct target of miR-155-5p. The potentials of systemic miR-155-5p inhibitor-based therapy in overcoming nicotine exposure were evaluated in tumor xenograft model. RESULTS: Nicotine promoted PDAC cells proliferation, migration, invasion and epithelial-mesenchymal transition (EMT) in a dose-response manner. MiR-155-5p was found to be highly expressed in PDAC cell lines and tissues upon cigarette smoking/nicotine exposure. Functional studies showed that miR-155-5p knockdown could override the enhancement of oncogenic activity due to nicotine exposure in vitro and in vivo by directly interacting with the 3’ untranslated regions (UTRs) of NDFIP1. CONCLUSIONS: These data demonstrate that nicotine-regulated miR-155-5p/NDFIP1 promotes tumor progression and EMT of PDAC.</p>
<p>doi: <a href="https://doi.org/10.1016/j.pan.2020.04.004" class="uri">https://doi.org/10.1016/j.pan.2020.04.004</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Opium use and subsequent incidence of cancer: results from the Golestan Cohort Study</strong> </summary></p>
<p><em>The Lancet. Global health 2020 May;8(5):e649-e660</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=32353313" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=32353313</a></p>
<p>BACKGROUND: Evidence is emerging for a role of opiates in various cancers. In this study, we aimed to investigate the association between regular opium use and cancer incidence. METHODS: This study was done in a population-based cohort of 50 045 individuals aged 40-75 years from northeast Iran. Data on participant demographics, diet, lifestyle, opium use, and different exposures were collected upon enrolment using validated questionnaires. We used proportional hazards regression models to estimate hazard ratios (HRs) and corresponding 95% CIs for the association between opium use and different cancer types. FINDINGS: During a median 10 years of follow-up, 1833 participants were diagnosed with cancer. Use of opium was associated with an increased risk of developing all cancers combined (HR 1·40, 95% CI 1·24-1·58), gastrointestinal cancers (1·31, 1·11-1·55), and respiratory cancers (2·28, 1·58-3·30) in a dose-dependent manner (ptrend&lt;0·001). For site-specific cancers, use of opium was associated with an increased risk of developing oesophageal (1·38, 1·06-1·80), gastric (1·36, 1·03-1·79), lung (2·21, 1·44-3·39), bladder (2·86, 1·47-5·55), and laryngeal (2·53, 1·21-5·29) cancers in a dose-dependent manner (ptrend&lt;0·05). Only high-dose opium use was associated with pancreatic cancer (2·66, 1·23-5·74). Ingestion of opium (but not smoking opium) was associated with brain (2·15, 1·00-4·63) and liver (2·46, 1·23-4·95) cancers in a dose-dependent manner (prend&lt;0·01). We observed consistent associations among ever and never tobacco users, men and women, and individuals with lower and higher socioeconomic status. INTERPRETATION: Opium users have a significantly higher risk of developing cancers in different organs of the respiratory, digestive, and urinary systems and the CNS. The results of this analysis show that regular use of opiates might increase the risk of a range of cancer types. FUNDING: World Cancer Research Fund International, Cancer Research UK, Tehran University of Medical Sciences, US National Cancer Institute, International Agency for Research on Cancer.</p>
<p>doi: <a href="https://doi.org/10.1016/S2214-109X(20)30059-0" class="uri">https://doi.org/10.1016/S2214-109X(20)30059-0</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Evaluation of glucocorticoid-induced TNF receptor (GITR) expression in breast cancer and across multiple tumor types</strong> </summary></p>
<p><em>Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc 2020 Apr;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=32350416" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=32350416</a></p>
<p>Glucocorticoid-induced TNF receptor (GITR) is an emerging immunotherapy target that is expressed at high levels on regulatory T cells. Agonistic anti-GITR antibodies have anti-tumor activity in cancer mouse models, and recent phase 1 trials have demonstrated their safe pharmacological profile. However, there is limited knowledge on the relationship between GITR expression and the tumor microenvironment. GITR protein expression was assayed by immunohistochemistry on 3992 breast cancer surgical excision specimens assembled into tissue microarrays and scored visually by a pathologist for GITR expression on tumor-infiltrating lymphocytes and on carcinoma cells. GITR expression by the malignant cells was further surveyed in gastrointestinal stromal tumor (N = 713), lung carcinoma (N = 705), pancreatic cancer (N = 486), ovarian cancer (N = 445), bladder cancer (N = 88), prostate cancer (N = 88), testicular cancer (N = 76), melanoma (N = 75), renal cell carcinoma (N = 68),  epithelioid sarcoma (N = 53), and neuroendocrine tumors (N = 41). In breast cancer, GITR expression on tumor-infiltrating lymphocytes (12.4%) correlated with other immune response biomarkers (PD-L1+ on tumor cells, and PD-1+, LAG-3+, TIM-3+ lymphocytes; p &lt; 0.001), and T-cell markers (CD8+, FOXP3+; p &lt; 0.001). GITR+ carcinoma cells were observed in 6.0% of breast cancer cases and correlated with worse relapse-free survival (p = 0.015). Among the additional tumor types examined, cancers with GITR+ malignant cells included bladder cancer (5.7%), primary (but not metastatic) melanoma (4.5%), and ovarian cancer (3.2%); no expression was identified among examined sarcomas. To our knowledge, this is the first immunohistochemistry study to report the frequency and pattern of GITR expression in a large breast cancer cohort, or to report membranous GITR expression on malignant cells. The co-infiltration of GITR with other immune biomarkers and T-cell markers supports a potential role for anti-GITR agents in combination immunotherapies. In addition, GITR expression on carcinoma cells could imply the existence of a novel cancer immune evasion strategy worthy of further investigation.</p>
<p>doi: <a href="https://doi.org/10.1038/s41379-020-0550-z" class="uri">https://doi.org/10.1038/s41379-020-0550-z</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Genetic and clinical correlates of entosis in pancreatic ductal adenocarcinoma</strong> </summary></p>
<p><em>Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc 2020 Apr;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=32350415" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=32350415</a></p>
<p>Entosis is a type of regulated cell death that promotes cancer cell competition. Though several studies have revealed the molecular mechanisms that govern entosis, the clinical and genetic correlates of entosis in human tumors is less well understood. Here we reviewed entotic cell-in-cell (CIC) patterns in a large single institution sequencing cohort (MSK IMPACT clinical sequencing cohort) of more than 1600 human pancreatic ductal adenocarcinoma (PDAC) samples to identify the genetic and clinical correlates of this cellular feature. After case selection, 516 conventional PDACs and 21 ASCs entered this study and ~45,000 HPFs (median 80 HPFs per sample) were reviewed; 549 entotic-CICs were detected through our cohort. We observed that entotic-CIC occurred more frequently in liver metastasis compared with primary in PDAC. Moreover, poorly differentiated adenocarcinoma or adenosquamous carcinoma had more entotic-CIC than well or moderately differentiated adenocarcinoma. With respect to genetic features TP53 mutations, KRAS amplification, and MYC amplification were significantly associated with entosis in PDAC tissues. From a clinical standpoint entotic CICs were independently associated with a poor prognosis by multivariate Cox regression analysis when considering all cases or primary PDACs specifically. These results provide a contextual basis for understanding entosis in PDAC, a highly aggressive cancer for which molecular insights are needed to improve survival.</p>
<p>doi: <a href="https://doi.org/10.1038/s41379-020-0549-5" class="uri">https://doi.org/10.1038/s41379-020-0549-5</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Comprehensive characterisation of pancreatic ductal adenocarcinoma with microsatellite instability: histology, molecular pathology and clinical implications</strong> </summary></p>
<p><em>Gut 2020 Apr;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=32350089" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=32350089</a></p>
<p>OBJECTIVE: Recently, tumours with microsatellite instability (MSI)/defective DNA mismatch repair (dMMR) have gained considerable interest due to the success of immunotherapy in this molecular setting. Here, we aim to clarify clinical-pathological and/or molecular features of this tumour subgroup through a systematic review coupled with a comparative analysis with existing databases, also providing indications for a correct approach to the clinical identification of MSI/dMMR pancreatic ductal adenocarcinoma (PDAC). DESIGN: PubMed, SCOPUS and Embase were searched for studies reporting data on MSI/dMMR in PDAC up to 30 November 2019. Histological and molecular data of MSI/dMMR PDAC were compared with non-MSI/dMMR PDAC and with PDAC reference cohorts (including SEER database and The Cancer Genome Atlas Research Network - TCGA project). RESULTS: Overall, 34 studies with 8323 patients with PDAC were included in the systematic review. MSI/dMMR demonstrated a very low prevalence in PDAC (around 1%-2%). Compared with conventional PDAC, MSI/dMMR PDAC resulted strongly associated with medullary and mucinous/colloid histology (p&lt;0.01) and with a KRAS/TP53 wild-type molecular background (p&lt;0.01), with more common JAK genes mutations. Data on survival are still unclear. CONCLUSION: PDAC showing typical medullary or mucinous/colloid histology should be routinely examined for MSI/dMMR status using specific tests (immunohistochemistry, followed by MSI-PCR in cases with doubtful results). Next-generation sequencing (NGS) should be adopted either where there is limited tissue or as part of NGS tumour profiling in the context of precision oncology, acknowledging that conventional histology of PDAC may rarely harbour MSI/dMMR.</p>
<p>doi: <a href="https://doi.org/10.1136/gutjnl-2020-320726" class="uri">https://doi.org/10.1136/gutjnl-2020-320726</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Correction to: Trends in the Number of Lymph Nodes Evaluated Among Patients with Pancreatic Neuroendocrine Tumors in the United States: A Multi-Institutional and National Database Analysis</strong> </summary></p>
<p><em>Annals of surgical oncology 2020 Apr;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=32342296" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=32342296</a></p>
<p>In the original article, Ryan C. Fields’ middle initial is missing.</p>
<p>doi: <a href="https://doi.org/10.1245/s10434-020-08397-7" class="uri">https://doi.org/10.1245/s10434-020-08397-7</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Theranostic targeting of CUB domain containing protein 1 (CDCP1) in pancreatic cancer</strong> </summary></p>
<p><em>Clinical cancer research : an official journal of the American Association for Cancer Research 2020 Apr;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=32341034" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=32341034</a></p>
<p>PURPOSE: The recent emergence of radioligand therapies for cancer treatment has increased enthusiasm for developing new theranostic strategies coupling both imaging and cytotoxicity in the same entity. We evaluated if CUB domain containing protein 1 (CDCP1), a transmembrane protein highly overexpressed in human cancers, is a target for cancer theranostics. EXPERIMENTAL DESIGN: The ectodomain of CDCP1 was targeted using radiolabeled forms of 4A06, a potent and specific recombinant human antibody that we developed. Imaging and antitumor assessment studies were performed in animal models of pancreatic cancer, including two PDX models we developed for this study. For antitumor assessment studies, the endpoints were death due to tumor volume &gt;3000 mm3 or ≥20% loss in body weight. Specific tracer binding or antitumor effects were assessed with an unpaired, two-tailed Student’s t test and survival advantages were assessed with a log rank (Mantel Cox) test. RESULTS: 89Zr-4A06 detected a broad dynamic range of full length or cleaved CDCP1 expression on seven human pancreatic cancer tumors (n = 4/tumor). Treating mice with single or fractionated doses of 177Lu-4A06 significantly reduced pancreatic cancer tumor volume compared to mice receiving vehicle or unlabeled 4A06 (n = 8, P&lt;0.01). A single dose of 225Ac-4A06 also inhibited tumor growth, although the effect was less profound compared to 177Lu-4A06 (n = 8, P&lt;0.01). A significant survival advantage was imparted by 225Ac-4A06 (HR = 2.56, P &lt;0.05). CONCLUSIONS: These data establish that CDCP1 can be exploited for theranostics, a finding with widespread implications given its breadth of overexpression in cancer.</p>
<p>doi: <a href="https://doi.org/10.1158/1078-0432.CCR-20-0268" class="uri">https://doi.org/10.1158/1078-0432.CCR-20-0268</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>External validation and comparison of the original, alternative and updated-alternative fistula risk scores for the prediction of postoperative pancreatic fistula after pancreatoduodenectomy</strong> </summary></p>
<p><em>Pancreatology : official journal of the International Association of Pancreatology (IAP) … [et al.] 2020 Apr;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=32340876" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=32340876</a></p>
<p>BACKGROUND: Many postoperative pancreatic fistula (POPF) predictions models were developed and validated in western populations. Direct use of these models in the large Indian/Asian population, however, requires proper validation. OBJECTIVE: To validate the original, alternative and updated alternative fistula risk score (FRS) models. METHODS: A validation study was performed in consecutive patients undergoing pancreatoduodenectomy (PD) from January 2011 to March 2018. The area under the receiver operating curve (ROC) and calibration plots were used to assess the performance of original-FRS (o-FRS), alternative FRS (a-FRS) and updated alternative FRS (ua-FRS) models. RESULTS: This cohort consisted of 825 patients of which 66% were males with a median age of 55 years and mean body mass index of 22.6. The majority of tumors (61.8%) were of periampullary origin. Clinically relevant POPF was observed in 16.8% patients. Area under curve (AUC) of ROC for the o-FRS was 0.65, 0.69 for a-FRS and 0.70 for ua-FRS, respectively (p = 0.006). CONCLUSIONS: In this large Indian cohort of predominantly periampullary tumors, the ua-FRS performed better than the a-FRS and o-FRS, although differences were small. Since the AUC value of the ua-FRS is at the accepted threshold there might be room for improvement for a FRS.</p>
<p>doi: <a href="https://doi.org/10.1016/j.pan.2020.04.006" class="uri">https://doi.org/10.1016/j.pan.2020.04.006</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Discoidin Domain Receptor 1 (DDR1) is Necessary for Tissue Homeostasis in Pancreatic Injury and Pathogenesis of Pancreatic Ductal Adenocarcinoma</strong> </summary></p>
<p><em>The American journal of pathology 2020 Apr;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=32339496" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=32339496</a></p>
<p>Pancreatic ductal adenocarcinoma (PDA) and chronic pancreatitis (CP) are characterized by a dense collagen-rich desmoplastic reaction. Discoidin domain receptor 1 (DDR1) is a receptor tyrosine kinase activated by collagens that can regulate cell proliferation, migration, adhesion, and remodeling of the extracellular matrix (ECM). To address the role of DDR1 in PDA, we crossed DDR1-null (DDR1-/-) mice into the KrasG12D/+; Trp53R172H/+; Ptf1aCre/+(KPC) model of metastatic PDA. We found that DDR1-/-; KPC mice progress to differentiated PDA, but resist progression to poorly-differentiated cancer, compared to KPC control mice. Strikingly, severe pancreatic atrophy accompanied tumor progression in DDR1-/-; KPC mice. To further explore the effects of DDR1 ablation, we crossed the DDR1-/- mice into the KrasG12D/+; Ptf1aCre/+(KC) neoplasia model and also subjected them to cerulein-induced experimental pancreatitis. Similar to KPC mice, tissue atrophy was a hallmark of both neoplasia and pancreatitis models in the absence of DDR1. Compared to controls, DDR1-/- models showed increased acinar cell drop-out and reduced proliferation with no difference in apoptotic cell death between control and DDR1-/- animals. In most models, organ atrophy was accompanied by increased fibrillar collagen deposition, suggesting a compensatory response in the absence of this collagen receptor. Overall, our data suggest that DDR1 regulates tissue homeostasis in the neoplastic and injured pancreas.</p>
<p>doi: <a href="https://doi.org/10.1016/j.ajpath.2020.03.020" class="uri">https://doi.org/10.1016/j.ajpath.2020.03.020</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Efficacy of gastric decompression after pancreatic surgery: a systematic review and meta-analysis</strong> </summary></p>
<p><em>BMC gastroenterology 2020 Apr;20(1):126</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=32334515" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=32334515</a></p>
<p>BACKGROUND: Gastric decompression after pancreatic surgery has been a routine procedure for many years. However, this procedure has often been waived in non-pancreatic abdominal surgeries. The aim of this meta-analysis was to determine the necessity of routine gastric decompression (RGD) following pancreatic surgery. METHODS: PubMed, the Cochrane Library, EMBASE, and Web of Science were systematically searched to identify relevant studies comparing outcomes of RGD and no gastric decompression (NGD) after pancreatic surgery. The overall complications, major complications, mortality, delayed gastric emptying (DGE); clinically relevant DGE (CR-DGE), postoperative pancreatic fistula (POPF), clinically relevant POPF (CR-POPF), secondary gastric decompression, and the length of hospital stay were evaluated. RESULTS: A total of six comparative studies with a total of 940 patients were included. There were no differences between RGD and NGD groups in terms of the overall complications (OR = 1.73, 95% CI: 0.60-5.00; p = 0.31), major complications (OR = 2.22, 95% CI: 1.00-4.91; p = 0.05), incidence of secondary gastric decompression (OR = 1.19, 95% CI: 0.60-2.02; p = 0.61), incidence of overall DGE (OR = 2.74; 95% CI: 0.88-8.56; p = 0.08; I2 = 88%), incidence of CR-POPF (OR = 1.28, 95% CI: 0.76-2.15; p = 0.36), and incidence of POPF (OR = 1.31, 95% CI: 0.81-2.14; p = 0.27). However, RGD was associated with a higher incidence of CR-DGE (OR = 5.45; 95% CI: 2.68-11.09; p &lt; 0.001, I2 = 35%), a higher rate of mortality (OR = 1.53; 95% CI: 1.05-2.24; p = 0.03; I2 = 83%), and a longer length of hospital stay (WMD = 5.43, 95% CI: 0.30 to 10.56; p = 0.04; I2 = 93%). CONCLUSIONS: Routine gastric decompression in patients after pancreatic surgery was not associated with a better recovery, and may be unnecessary after pancreatic surgery.</p>
<p>doi: <a href="https://doi.org/10.1186/s12876-020-01265-4" class="uri">https://doi.org/10.1186/s12876-020-01265-4</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>An elevated CA 19-9 is associated with invasive cancer and worse survival in IPMN</strong> </summary></p>
<p><em>Pancreatology : official journal of the International Association of Pancreatology (IAP) … [et al.] 2020 Apr;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=32332003" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=32332003</a></p>
<p>BACKGROUND: Current guidelines for IPMN include an elevated serum carbohydrate antigen (CA) 19-9 among the worrisome features. However, the correlation of CA 19-9 with histological malignant features and survival is unclear. Serum CEA is also currently used for preoperative management of IPMN, although its measurement is not evidence-based. Accordingly, we aimed to assess the role of these tumor markers as predictors of malignancy in IPMN. METHODS: IPMN resected between 1998 and 2018 at Massachusetts General Hospital were analyzed. Clinical, pathological and survival data were collected and compared to preoperative levels of CA 19-9 and CEA. Receiver operating characteristic (ROC) and Cox regression analyses were performed considering cut-offs of 37 U/ml (CA 19-9) and 5 μg/l (CEA). RESULTS: Analysis of 594 patients showed that preoperative CA 19-9 levels &gt; 37 U/ml (n = 128) were associated with an increased likelihood of invasive carcinoma when compared to normal levels (45.3% vs. 18.0%, P &lt; 0.001), while there was no difference with respect to high-grade dysplasia (32.9% vs 31.9%, P = 0.88). The proportion of concurrent pancreatic cancer was higher in patients with CA 19-9 &gt; 37 U/ml (17.2% vs 4.9%, P &lt; 0.001). An elevated CA 19-9 was also associated with worse overall and disease-free survival (HR = 1.943, P = 0.007 and HR = 2.484, P &lt; 0.001 respectively). CEA levels did not correlate with malignancy. CONCLUSION: In patients with IPMN, serum CA19-9 &gt; 37 U/ml is associated with invasive IPMN and concurrent pancreatic cancer as well as worse survival, but not with high-grade dysplasia. Serum CEA appears to have minimal utility in the management of these patients.</p>
<p>doi: <a href="https://doi.org/10.1016/j.pan.2020.04.002" class="uri">https://doi.org/10.1016/j.pan.2020.04.002</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>CXCL10 and CCL21 Promote Migration of Pancreatic Cancer Cells Toward Sensory Neurons and Neural Remodeling in Tumors in Mice, Associated With Pain in Patients</strong> </summary></p>
<p><em>Gastroenterology 2020 Apr;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=32330476" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=32330476</a></p>
<p>BACKGROUND &amp; AIMS: Pancreatic ductal adenocarcinoma (PDAC) is frequently accompanied by excruciating pain, which has been associated with attraction of cancer cells and their invasion of intrapancreatic sensory nerves. Neutralization of the chemokine CCL2 reduced cancer-associated pain in a clinical trial, but there have been no systematic analyses of the highly diverse chemokine families and their receptors in PDAC. METHODS: We performed an open, unbiased RNA-interference screen of mammalian chemokines in co-cultures of mouse PDAC cells (K8484) and mouse peripheral sensory neurons, and confirmed findings in studies of DT8082 PDAC cells. We studied the effects of chemokines on migration of PDAC cell lines. Orthotopic tumors were grown from K8484 cells in mice, and mice were given injections of neutralizing antibodies against chemokines, antagonists, or control antibodies. We analyzed abdominal mechanical hypersensitivity and collected tumors and analyzed them by histology and immunohistochemistry to assess neural remodeling. We collected PDAC samples and information on pain levels from 74 patients undergoing resection and measured levels of CXCR3 and CCR7 by immunohistochemistry and immunoblotting. RESULTS: Knockdown of 9 chemokines in DRG neurons significantly reduced migration of PDAC cells towards sensory neurons. Sensory neuron-derived CCL21 and CXCL10 promoted migration of PDAC cells via their receptors CCR7 and CXCR3, respectively, which were expressed by cells in orthotopic tumors and PDAC specimens from patients. Neutralization of CCL21 or CXCL10, or their receptors, in mice with orthotopic tumors significantly reduced nociceptive hypersensitivity and nerve fiber hypertrophy and improved behavioral parameters without affecting tumor infiltration by T cells or neutrophils. Increased levels of CXCR3 and CCR7 in human PDAC specimens were associated with increased frequency of cancer-associated pain, determined from patient questionnaires. CONCLUSIONS: In an unbiased screen of chemokines, we identified CCL21 and CXCL10 as proteins that promote migration of pancreatic cancer cells toward sensory neurons. Inhibition of these chemokines or their receptors reduce hypersensitivity in mice with orthotopic tumors, and patients with PDACs with high levels of the chemokine receptors of CXCR3 and CCR7 had increased frequency of cancer-associated pain.</p>
<p>doi: <a href="https://doi.org/10.1053/j.gastro.2020.04.037" class="uri">https://doi.org/10.1053/j.gastro.2020.04.037</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Specific Growth Rate as a Predictor of Survival in Pancreatic Neuroendocrine Tumors: A Multi-institutional Study from the United States Neuroendocrine Study Group</strong> </summary></p>
<p><em>Annals of surgical oncology 2020 Apr;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=32328982" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=32328982</a></p>
<p>BACKGROUND: Pancreatic neuroendocrine tumors (PNETs) are often indolent; however, identifying patients at risk for rapidly progressing variants is critical, particularly for those with small tumors who may be candidates for expectant management. Specific growth rate (SGR) has been predictive of survival in other malignancies but has not been examined in PNETs. METHODS: A retrospective cohort study of adult patients who underwent PNET resection from 2000 to 2016 was performed utilizing the multi-institutional United States Neuroendocrine Study Group database. Patients with ≥ 2 preoperative cross-sectional imaging studies at least 30 days apart were included in our analysis (N = 288). Patients were grouped as “high SGR” or “low SGR.” Demographic and clinical factors were compared between the groups. Kaplan-Meier and log-rank analysis were used for survival analysis. Cox proportional hazard analysis was used to assess the impact of various clinical factors on overall survival (OS). RESULTS: High SGR was associated with higher T stage at resection, shorter doubling time, and elevated HbA1c (all P ≤ 0.01). Patients with high SGR had significantly decreased 5-year OS (63 vs 80%, P = 0.01) and disease-specific survival (72 vs 91%, P = 0.03) compared to those with low SGR. In patients with small (≤ 2 cm) tumors (N = 106), high SGR predicted lower 5-year OS (79 vs 96%, P = 0.01). On multivariate analysis, high SGR was independently associated with worse OS (hazard ratio 2.67, 95% confidence interval 1.05-6.84, P = 0.04). CONCLUSION: High SGR is associated with worse survival in PNET patients. Evaluating PNET SGR may enhance clinical decision-making, particularly when weighing expectant management versus surgery in patients with small tumors.</p>
<p>doi: <a href="https://doi.org/10.1245/s10434-020-08497-4" class="uri">https://doi.org/10.1245/s10434-020-08497-4</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Reduced risk of post ERCP pancreatitis in statin users</strong> </summary></p>
<p><em>BMC gastroenterology 2020 Apr;20(1):125</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=32326889" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=32326889</a></p>
<p>BACKGROUND: One of the most feared complications of endoscopic retrograde cholangiopancreatography (ERCP), with an incidence of 3.5 to 15%, is post ERCP pancreatitis (PEP). Given the role of statins in the reduction of systemic and pancreatic intraluminal inflammation, we hypothesized that the use of statins may lower the risk of PEP. METHODS: A retrospective cohort study of all patients undergoing ERCP at West Virginia University during the years 2016 and 2017 was performed. Possible association of collected variables with PEP was assessed with Univariate tests and multivariable logistic regression analyses. RESULTS: A total of 1162 ERCPs were included. Mean age was 60.12 years (SD: 17.5). 51.3% of the participants were female. Two hundred and sixty-three participants underwent more than one ERCP during the study period. Seven hundred and ninety-nine ERCPs (78.8%) were conducted in participants who were not taking a statin medication at the time of ERCP, while 363 participants were on statin medications at the time of ERCP; 118 and 245 participants were taking high dose statins (atorvastatin 40-80 mg or rosuvastatin 20 mg), and low/medium dose statins (all other statin regimens) at the time of the procedure, respectively. The overall incidence of PEP in the cohort was 7.3%. In the non-statin and statin groups, 9.5 and 3.4% of participants developed PEP, respectively. On univariate analysis, young age, no statin use, history of PEP, and endoscopic sphincterotomy were found to be significantly associated with the development of PEP. In a binary logistic regression model, young age (P = 0.033), history of PEP (P = 0.0001, OR 2.41, 95% CI: 1.05-5.51) and endoscopic sphincterotomy (P = 0.038, OR 2.85, 95% CI: 1.7-4.78) were found to be associated with increased risk of PEP. Statin usage was found to be protective against PEP, (OR 0.35, 95% CI: 0.18-0.69). CONCLUSION: Chronic statin usage is protective against post ERCP pancreatitis, and our findings suggest a potential role of these drugs as prophylactic agents. Randomized controlled trials are needed to establish any potential clinical application.</p>
<p>doi: <a href="https://doi.org/10.1186/s12876-020-01264-5" class="uri">https://doi.org/10.1186/s12876-020-01264-5</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Laparoscopic Radical Antegrade Modular Pancreatosplenectomy with Venous Tangential Resection: Focus on Periadventitial Dissection of the Superior Mesenteric Artery for Obtaining Negative Margin and a Safe Vascular Resection</strong> </summary></p>
<p><em>Annals of surgical oncology 2020 Apr;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=32323087" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=32323087</a></p>
<p>BACKGROUND: Due to its technical complexity, laparoscopic (L-) radical antegrade modular pancreatosplenectomy (RAMPS) for left-sided pancreatic ductal adenocarcinoma (PDAC) has been described in a few series.1-4 In addition, splenomesenteric junction tumor involvement is considered a formal contraindication to L-RAMPS. METHODS: The video shows posterior L-RAMPS with a left approach to the superior mesenteric artery (SMA) for a left-sided PDAC with suspected involvement of the splenomesenteric junction. RESULTS: The patient was a 61-year-old woman affected by a cT3N0M0 pancreatic body PDAC. Following dissection of the superior mesenteric vein (SMV), proper/common hepatic artery, and gastroduodenal artery, the pancreatic neck is encircled and the celiac trunk (CT) skeletonized. The treitz ligament is opened, and the SMA is identified and dissected on its left anterior margin. Pancreatic mobilization en bloc with the Gerota fascia and left adrenal gland is followed by splenic artery transection and suprapancreatic lymphadenectomy completion. The mesopancreas is dissected from the right margin of the SMA and CT and the pancreas is transected. The portal vein and SMV are cross-clamped and a venous tangential resection/closure is performed. Cryostate histological examination of the venous and pancreatic stumps showed absence of tumor cells. Final pathology revealed a pT2N0(0+/42)R0G2 PDAC of the pancreatic body. CONCLUSION: During L-RAMPS, periadvential SMA dissection through the left-anterior approach, specular to the right posterior SMA approach described for laparoscopic pancreatoduodenectomy,5,6 has a primary role in maximizing the vascular surgical margin and, allowing for complete mobilization of the specimen before vein resection, may make a splenomesenteric junction tangential resection/closure easier and safer in case of tumor involvement of the splenomesenteric venous axis.</p>
<p>doi: <a href="https://doi.org/10.1245/s10434-020-08271-6" class="uri">https://doi.org/10.1245/s10434-020-08271-6</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Broadening risk profile in familial colorectal cancer type X; increased risk for five cancer types in the national Danish cohort</strong> </summary></p>
<p><em>BMC cancer 2020 Apr;20(1):345</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=32321466" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=32321466</a></p>
<p>BACKGROUND: Familial colorectal cancer type X (FCCTX) is a phenotypically defined subset of hereditary colorectal cancer with unknown and potentially heterogeneous genetic aetiology. FCCTX has been characterized as a colorectal cancer-specific syndrome, which we herein challenge by estimating the risk for extra-colorectal cancer in the Danish FCCTX cohort. METHODS: Through the national hereditary non-polyposis colorectal cancer (HNPCC) register, 213 families fulfilling the Amsterdam I criteria and showing retained mismatch repair (MMR) function were identified. In here, sex and age-specific incidence rate ratios (IRR) were calculated for 30 extra-colorectal cancer types in comparison with the general Danish population. RESULTS: In total, 494 extra-colorectal cancers developed with significantly increased risks for cancers of the urinary tract, breast, stomach, pancreas, and eye tumours. The age groups at increased risks were 30-49 years for gastric cancer, 30-69 years for female breast cancer, 50-69 years for ocular melanoma and above age 70 for pancreatic cancer and urothelial cancer. CONCLUSIONS: Danish FCCTX families show an increased risk of several extra-colorectal cancer types. This observation may indicate unidentified disease-predisposing genetic variants in this phenotypically defined subset of hereditary colorectal cancer and calls for awareness during genetic counselling and follow-up.</p>
<p>doi: <a href="https://doi.org/10.1186/s12885-020-06859-5" class="uri">https://doi.org/10.1186/s12885-020-06859-5</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Pembrolizumab for the treatment of programmed death-ligand 1-positive advanced carcinoid or pancreatic neuroendocrine tumors: Results from the KEYNOTE-028 study</strong> </summary></p>
<p><em>Cancer 2020 Apr;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=32320048" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=32320048</a></p>
<p>BACKGROUND: Despite a protracted disease course and multiple available therapies, patients with well-differentiated neuroendocrine tumors (NETs) inevitably experience disease progression. Programmed death-ligand 1 (PD-L1) has been associated with NET progression and prognosis. The multicohort, phase 1 KEYNOTE-028 study (ClinicalTrials.gov identifier NCT02054806) evaluated the activity and safety of the anti-programmed cell death protein 1 immunotherapy pembrolizumab in patients with well-differentiated or moderately-differentiated NETs. METHODS: Patients with PD-L1-positive, locally advanced or metastatic carcinoid or well-differentiated or moderately-differentiated pancreatic NETs (pNETs) were enrolled into separate cohorts and received pembrolizumab at a dose of 10 mg/kg every 2 weeks for up to 2 years. The objective response rate was the primary endpoint (as per Response Evaluation Criteria in Solid Tumors version 1.1, by investigator review). Safety was a secondary endpoint. RESULTS: Of 170 and 106 patients, respectively, who had evaluable samples among those screened for the carcinoid and pNET cohorts, 21% and 25%, respectively, had PD-L1-positive tumors; of these, 25 and 16 patients, respectively, were eligible and treated. The median follow-up was 20 months (range, 2-35 months) and 21 months (range, 5-32 months), respectively. The objective response rate was 12.0% (95% CI, 2.5%-31.2%) and 6.3% (95% CI, 0.2%-30.2%), respectively; 3 partial responses occurred among the carcinoid cohort and 1 among the pNET cohort. The median duration of response in the carcinoid cohort was 9.2 months (range, 6.9-11.1 months), and was not reached in the pNET cohort. No complete responses occurred. Treatment-related adverse events occurred in 68% and 69% of patients, respectively, most often diarrhea (7 patients in the carcinoid cohort and 4 patients in the pNET cohort) and fatigue (6 patients in each cohort). Hypothyroidism was the most common immune-mediated adverse event (5 patients in the carcinoid cohort and 2 patients in the pNET cohort). CONCLUSIONS: Pembrolizumab demonstrated antitumor activity in a subset of patients with NETs and was well-tolerated.</p>
<p>doi: <a href="https://doi.org/10.1002/cncr.32883" class="uri">https://doi.org/10.1002/cncr.32883</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Fine needle aspiration cytology with the aid of immunochemistry on cell block confirms the diagnosis of solid pseudopapillary neoplasm of the pancreas</strong> </summary></p>
<p><em>Cytopathology : official journal of the British Society for Clinical Cytology 2020 Apr;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=32319130" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=32319130</a></p>
<p>AIMS AND OBJECTIVE: To determine the diagnostic efficacy of fine needle aspiration cytology (FNAC) in cases of pancreatic solid pseudopapillary neoplasm (PSPN) with emphasis on the cytomorphologic features and to evaluate the contribution of immunochemistry on FNAC cell block (CB) in cases of PSPN. MATERIAL AND METHOD: It is a retrospective study in which ultrasound-guided FNAC (USG-FNAC) of pancreatic lesions diagnosed as PSPN between years 2009- July 2019 were reviewed along with cytohistological correlation. Immunochemistry on CB was performed, wherever required. RESULTS: A total of 16 patients with a cytological diagnosis of PSPN of the pancreas were identified. The most common cytological findings are characteristic branching pseudopapillary fragments with central thin, delicate capillaries associated with the amorphous myxoid substance, surrounded by tumor cells with mild pleomorphism. Immunochemistry was performed on CB of six cases. The tumor cells revealed nucleocytoplasmic positivity for beta-catenin, cytoplasmic positivity for vimentin, membranocytoplasmic positivity for CD10, and nuclear positivity for PR in all the cases while were negative for chromogranin, CD56, pan-cytokeratin and EMA. The resected histopathological specimen was available in ten cases, and all turned out PSPN. CONCLUSION: Although PSPN has a characteristic cytomorphology, cell block immunocytochemistry on FNA material confirms the diagnosis in enigmatic cases and excludes other pancreatic tumors, thus helping in appropriate management.</p>
<p>doi: <a href="https://doi.org/10.1111/cyt.12838" class="uri">https://doi.org/10.1111/cyt.12838</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>CA19-9 Change During Neoadjuvant Therapy May Guide the Need for Additional Adjuvant Therapy Following Resected Pancreatic Cancer</strong> </summary></p>
<p><em>Annals of surgical oncology 2020 Apr;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=32318949" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=32318949</a></p>
<p>BACKGROUND: Neoadjuvant therapy (NAT) is increasingly utilized for pancreatic cancer, however the added benefit of adjuvant therapy (AT) in this setting is unknown. We hypothesized that the magnitude of CA19-9 response to NAT can guide the need for further AT in resected pancreatic cancer. METHODS: CA19-9 secretors who received NAT for pancreatic cancer during 2008-2016 at a single institution were analyzed and CA19-9 response (difference between pre- and post-NAT values) was measured. Kaplan-Meier estimators and Cox proportional hazard ratio models were used to determine the optimal CA19-9 response at which AT ceases to confer any additional survival benefit after NAT. RESULTS: A total of 241 patients (mean age 65.4 years, 50% female) with complete CA19-9 data who underwent NAT followed by resection were analyzed. In a cohort of patients (n = 78) in whom CA19-9 normalized with a decrease &gt; 50% after NAT (optimal responders), AT was not associated with additional survival benefit (40.6 vs. 39.0 months, p = 0.815). Conversely, in the cohort of patients (n = 163) in whom NAT was not associated with normalization and a decrease of ≤ 50% in CA19-9 (suboptimal responders), receipt of AT was associated with a survival benefit (34.5 vs. 19.1 months, p &lt; 0.001) following NAT. A Cox proportional hazards model confirmed CA19-9 normalization and decrease &gt; 50% during NAT to predict no additional survival benefit from AT. CONCLUSIONS: The magnitude of CA19-9 response to NAT may predict the need for further AT in resected pancreatic cancer. Prospective studies are needed to elucidate the optimal interplay of NAT and AT in pancreatic cancer.</p>
<p>doi: <a href="https://doi.org/10.1245/s10434-020-08468-9" class="uri">https://doi.org/10.1245/s10434-020-08468-9</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Does IgG4 level evaluation in pancreatic mass play role in avoiding major surgery in uncertain presentation: A case report</strong> </summary></p>
<p><em>Indian journal of pathology &amp; microbiology 2020 4;63(2):282-285</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=32317534" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=32317534</a></p>
<p>A 66-year-old male presented with chief complaints of anorexia associated with mild dull, intermittent epigastric pain for 6 months. The patient was a known diabetic on oral hypoglycemic and on routine checkup was found to have deranged liver function profile. On radiology, an ill-defined hypoechoic enhancing lesion involving head, neck, and uncinate process of pancreas was noted. Whipple’s pancreaticodudenectomy was done and reported as IgG4-related autoimmune pancreatitis. Later, IgG (slightly) and IgG4 were found to be markedly raised. We report this case to highlight the importance of IgG4 evaluation prior to major surgery in uncertain pancreatic mass.</p>
<p>doi: <a href="https://doi.org/10.4103/IJPM.IJPM_289_19" class="uri">https://doi.org/10.4103/IJPM.IJPM_289_19</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Endoscopic ultrasound-guided fine needle aspiration of accessory spleen: Cytomorphologic features and diagnostic considerations</strong> </summary></p>
<p><em>Diagnostic cytopathology 2020 Apr;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=32315514" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=32315514</a></p>
<p>BACKGROUND: Accessory spleen/or splenule (AS) can involve pancreas/or peripancreatic tissue and present as a mass-forming lesion, and on imaging studies, it stimulates concern for a neoplastic process. The current study reported the largest cohort of AS cases evaluated by endoscopic ultrasound-guided fine needle aspiration (EUS-FNA). METHODS: We retrospectively reviewed our data base system for cases underwent EUS-FNA for pancreatic/or peripancreatic lesions, with “AS” in diagnosis or in note/or with a clinical concern in the history, from January 2010 to August 2019. Corresponding cytology slides were re-reviewed to identify the key cytomorphologic features. RESULTS: We identified 25 AS cases from 15 female and 10 male patients with a mean age of 55 years. Most patients presented with non-specific clinical symptoms or were identified as an incidental mass lesion. Majority of the lesions were located in or around the pancreatic tail region (68%) while the remainder in perisplenic region (32%). Rapid on-site evaluation (ROSE) was performed in nearly half of the cases (48%). Cytologically, AS shows a mixed population of medium to small-sized lymphocytes, clusters of lymphoid cells (LC), prominent vascularity (PV), scattered mixed inflammatory cells including eosinophils, and large platelet aggregates (LPAs). Among them, LC (P = .0079), PV and LPAs were the most helpful features for cytological diagnosis. CONCLUSION: AS is a benign entity and may pose a diagnostic challenge due to its resemblance to a neoplastic process on imaging studies. EUS-FNA is an important tool to recognize AS by identifying its key cytologic features, thus may help to avoid unnecessary surgical management.</p>
<p>doi: <a href="https://doi.org/10.1002/dc.24434" class="uri">https://doi.org/10.1002/dc.24434</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Increased Rate of Complete Pathologic Response After Neoadjuvant FOLFIRINOX for BRCA Mutation Carriers with Borderline Resectable Pancreatic Cancer</strong> </summary></p>
<p><em>Annals of surgical oncology 2020 Apr;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=32314163" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=32314163</a></p>
<p>BACKGROUND: Neoadjuvant FOLFIRINOX is a standard-of-care treatment for BRPC patients. Patients with gBRCAm who have demonstrated improved response to platinum-based chemotherapy may have impaired homologous repair deficiency. This study aimed to describe the pathologic complete response rate and long-term survival for patients with germline BRCA1 or BRCA2 mutation (gBRCAm) and borderline resectable pancreatic cancer (BRPC) treated with neoadjuvant FOLFIRINOX. METHODS: A dual-center retrospective analysis was performed. Patients who had BRPC treated with neoadjuvant FOLFIRINOX followed by curative resection were identified from clinical databases. Pathologic complete response was defined as no viable tumor cells present in the specimen. Common founder Jewish germline BRCA1 or BRCA2 mutation was determined for available patients. RESULTS: The 61 BRPC patients in this study underwent resection after neoadjuvant FOLFIRINOX. Analysis of BRCA mutation was performed for 39 patients, and 9 patients were found to be BRCA2 germline mutation carriers. The pathologic complete response rate was 44.4% for the gBRCAm patients and 10% for the BRCA non-carriers (p = 0.009). The median disease-free survival was not reached for the gBRCAm patients and was 7 months for the BRCA non-carriers (p = 0.03). The median overall survival was not reached for the gBRCAm patients and was 32 months for the BRCA non-carriers (p = 0.2). After a mean follow-up period of 33.7 months, all eight patients with pathologic complete response were disease-free. CONCLUSIONS: The study showed that gBRCAm patients with BRPC have an increased chance for pathologic complete response and prolonged survival after neoadjuvant FOLFIRINOX. The results support the benefit of exposing gBRCAm patients to platinum-based chemotherapy early in the course of the disease. Neoadjuvant FOLFIRINOX should be considered for BRCA carriers who have resectable pancreatic cancer.</p>
<p>doi: <a href="https://doi.org/10.1245/s10434-020-08469-8" class="uri">https://doi.org/10.1245/s10434-020-08469-8</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>N6-methyladenosine mRNA methylation of PIK3CB regulates AKT signalling to promote PTEN-deficient pancreatic cancer progression</strong> </summary></p>
<p><em>Gut 2020 Apr;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=32312789" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=32312789</a></p>
<p>OBJECTIVE: Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal cancers worldwide. Thus far, most drugs have failed to significantly improve patient survival. N6-methyladenosine (m6A) plays an important role in the progression of PDAC, but its aberrant regulation driven by germline variants in human diseases remains unclear. DESIGN: We first performed an exome-wide association analysis in 518 PDAC patients with overall survival and replicated in an independent population containing 552 PDAC patients. Then, a series of biochemical experiments in vitro and in vivo were conducted to investigate potential mechanisms of the candidate variant and its target gene PIK3CB underlying the PDAC progression. Moreover, the PIK3CB-selective inhibitor KIN-193 was used to block PDAC tumour growth. RESULTS: We identified a missense variant rs142933486 in PIK3CB that is significantly associated with the overall survival of PDAC by reducing the PIK3CB m6A level, which facilitated its mRNA and protein expression levels mediated by the m6A ‘writer’ complex (METTL13/METTL14/WTAP) and the m6A ‘reader’ YTHDF2. The upregulation of PIK3CB is widely found in PDAC tumour tissues and significantly correlated with the poor prognosis of PDAC, especially in PTEN-deficient patients. We further demonstrated that PIK3CB overexpression substantially enhanced the proliferation and migration abilities of PTEN-deficient PDAC cells and activated AKT signalling pathway. Remarkably, KIN-193, a PIK3CB-selective inhibitor, is shown to serve as an effective anticancer agent for blocking PTEN-deficient PDAC. CONCLUSIONS: These findings demonstrate aberrant m6A homoeostasis as an oncogenic mechanism in PDAC and highlight the potential of PIK3CB as a therapeutic target for this disease.</p>
<p>doi: <a href="https://doi.org/10.1136/gutjnl-2019-320179" class="uri">https://doi.org/10.1136/gutjnl-2019-320179</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Computerized Medical Evidence-Based Decision Assistance System “MEBDAS®” improves in-hospital outcome after pancreatoduodenectomy for pancreatic cancer</strong> </summary></p>
<p><em>Pancreatology : official journal of the International Association of Pancreatology (IAP) … [et al.] 2020 Apr;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=32312611" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=32312611</a></p>
<p>BACKGROUND: Indication for pancreatoduodenectomy for pancreatic cancer can be challenging. Wrong decisions in indication processes lead to significant health impairments. Computerized decision support systems can take over parts of decision-making processes, making them more accurate. MEBDAS® is a decision-supporting software that predicts outcomes of proposed treatments. AIM: to determine the decision concordance between MEBDAS® and multidisciplinary tumour board (MTB) and the impact of MEBDAS® on in-hospital outcome at different indication thresholds. METHODS: 126 patients with pancreatoduodenectomy from a high-volume university hospital were included. Outcome indicators were in-hospital mortality, Comprehensive Complication Index (CCI®), therapy-related loss of “Quality-Adjusted-Life-Day” (QALD-loss) and prognostic gain of treatment-related “Quality-Adjusted-Life-Year” (QALY-gain). RESULTS: The concordance of decisions was 94.4% at the indication threshold of 0. By raising the indication threshold to 1 year, the concordance decreased to 0%, the in-hospital-mortality dropped from 2.52% to 0%, the CCI® decreased from 26.47 to 13.90, the therapy-related QALD-loss declined from 21.53 to 16.22 days and the prognostic QALY-gain increased from 0.374 to 0.906 years. At IT = 0.250 years, the concordance was 61.11% and differences between MTB and MEBDAS®-group were highly significant (p &lt; 0.001) for all outcome parameters: mortality (3.97% vs. 1.30%), CCI® (28.96 vs. 18.29), therapy-related QALD-loss (24.41 vs. 15.19 days) and QALY-gain (0.351 vs. 0.501 years). CONCLUSION: MEBDAS® decisions are superior to those of MTB in terms of in-hospital-outcome. The inclusion of MEBDAS® in decision procedure makes the indication more accurate and reduces morbidity and mortality. In addition, MEBDAS® can increase patients’ competence by involving them in decision-making process.</p>
<p>doi: <a href="https://doi.org/10.1016/j.pan.2020.04.007" class="uri">https://doi.org/10.1016/j.pan.2020.04.007</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Does Site Matter? Impact of Tumor Location on Pathologic Characteristics, Recurrence, and Survival of Resected Pancreatic Ductal Adenocarcinoma</strong> </summary></p>
<p><em>Annals of surgical oncology 2020 Apr;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=32307617" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=32307617</a></p>
<p>BACKGROUND: The authors hypothesized that in resected pancreatic adenocarcinoma (PDAC), pathologic characteristics, oncologic outcomes, prognostic factors, and the accuracy of the American Joint Committee on Cancer (AJCC) staging system might differ based on tumor location. METHODS: Patients undergoing pancreatectomy for PDAC at two academic institutions from 2000 to 2015 were retrieved. A comparative analysis between head (H-PDAC) and body-tail (BT-PDAC) tumors was performed using uni- and multivariable models. The accuracy of the eighth AJCC staging system was analyzed using C-statistics. RESULTS: Among 1466 patients, 264 (18%) had BT-PDAC, which displayed greater tumor size but significantly lower rates of perineural invasion and G3/4 grading. Furthermore, BT-PDAC was associated with a lower frequency of nodal involvement and a greater representation of earlier stages. The recurrence-free survival and disease-specific survival times were longer for BT-PDAC (16 vs 14 months [p = 0.020] and 33 vs 26 months [p = 0.026], respectively), but tumor location was not an independent predictor of recurrence or survival in the multivariable analyses. The recurrence patterns did not differ. Certain prognostic factors (i.e., CA 19.9, grading, R-status, and adjuvant treatment) were common, whereas others were site-specific (i.e., preoperative pain, diabetes, and multivisceral resection). The performances of the AJCC staging system were similar (C-statistics of 0.573 for H-PDAC and 0.597 for BT-PDAC, respectively). CONCLUSIONS: Despite differences in pathologic profile found to be in favor of BT-PDAC, tumor location was not an independent predictor of recurrence or survival after pancreatectomy. An array of site-specific prognostic factors was identified, but the AJCC staging system displayed similar prognostic power regardless of primary tumor location.</p>
<p>doi: <a href="https://doi.org/10.1245/s10434-020-08354-4" class="uri">https://doi.org/10.1245/s10434-020-08354-4</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Pasireotide administration after pancreaticoduodenectomy may decrease clinically relevant postoperative pancreatic fistula in high-risk patients with small pancreatic ducts, soft pancreatic parenchyma and cystic or neuroendocrine neoplasia</strong> </summary></p>
<p><em>Pancreatology : official journal of the International Association of Pancreatology (IAP) … [et al.] 2020 Jun;20(4):757-761</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=32307251" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=32307251</a></p>
<p>OBJECTIVES: Post-operative pancreatic fistula (POPF) is a feared complication after a pancreaticoduodenectomy. Previously in a randomized trial found fewer clinically relevant fistulas (CR-POPF) accompanying administration of perioperative pasireotide. Our hospital previously found that the risk for CR-POPF reached 7% in pancreaticoduodenectomy patients. Here, we aimed to determine the CR-POPF rate accompanying prophylactic pasireotide in patients with a normal pancreas at resection level. METHODS: In this clinical study, perioperative pasireotide was administered to pancreaticoduodenectomy patients treated between 1 July 2014 and 30 April 2016. High-risk individuals were defined preoperatively by the surgeon based on the following: no dilatation of the pancreatic duct, suspected soft pancreas and a cystic or neuroendocrine tumor at the head of the pancreas. If the pancreas was considered hard at surgery, thereby carrying a lower risk for fistula, pasireotide was discontinued following one preoperative 900-μg dose. Among high-risk patients, pasireotide was continued for one week or until discharge from the hospital. RESULTS: During the study period, 153/215 pancreatic operations were pancreaticoduodenectomies, 58 (38%) of which were considered high risk for developing clinically significant pancreatic fistula. Among these, 4 (2.6%) developed a grade B or C fistula: 2 in the pasireotide group [3.5%, 95% confidence interval (CI) 0.4-11.9%], 1 in the low-risk group (1.2%, 95% CI 0.0-6.4%; difference: 2.3%, 95% CI -6.4-17.3%) and 1 in the discontinued group (10%). CONCLUSION: We found similar rates of CR-POPF among high- and low-risk patients undergoing pancreaticoduodenectomy when using prophylactic perioperative pasireotide in high-risk patients.</p>
<p>doi: <a href="https://doi.org/10.1016/j.pan.2020.03.010" class="uri">https://doi.org/10.1016/j.pan.2020.03.010</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Prognostic value of long non-coding RNA ATB in digestive system cancers: A meta-analysis</strong> </summary></p>
<p><em>Pathology, research and practice 2020 Apr;():152949</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=32307201" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=32307201</a></p>
<p>BACKGROUND: The present meta-analysis has evaluated the association between lncRNA ATB, prognosis and clinicopathological parameters in patients with digestive cancers. METHODS: Eligible studies were gathered from Web of Science, PubMed, Embase, Cochrane Library, WanFang databases and China National Knowledge Infrastructure (up to October 15, 2019). Hazard ratios (HRs) and 95 % confidence intervals (CIs) were calculated to estimate the prognosis and clinicopathological parameters of lncRNA ATB in patients with digestive cancers. RESULT: We divided this study into two groups, pancreatic cancer (PC, downregulation) and non-pancreatic cancer (non-PC, upregulation). In the non-PC group, high expression levels of lncRNA ATB were significantly related to poor OS (pooled HR = 2.19, 95 % CI 1.68-2.85, P＜0.00001). In contrast, increased levels of lncRNA ATB in pancreatic cancer tissue were favorable factors in OS (HR = 0.47, 95 % CI 0.32-0.69, P = 0.0001). The pooled data suggested that high expression levels of lncRNA ATB predicted a poor DFS in CRC and a poor RFS in HCC. Increased expression of lncRNA ATB was correlated with negative lymph node metastasis and TNM stage in the non-PC group. In contrast, lncRNA ATB were favorable factors for LNM and TNM stages in pancreatic cancer. CONCLUSION: LncRNA ATBs, whether cancer promoters or suppressors, were potential biomarkers and therapeutic targets for digestive system cancers.</p>
<p>doi: <a href="https://doi.org/10.1016/j.prp.2020.152949" class="uri">https://doi.org/10.1016/j.prp.2020.152949</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Three-hour post-ERCP amylase level: a useful indicator for early prediction of post-ERCP pancreatitis</strong> </summary></p>
<p><em>BMC gastroenterology 2020 Apr;20(1):118</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=32306904" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=32306904</a></p>
<p>BACKGROUND: To evaluate the value of the 3-h post-ERCP serum amylase level for early prediction of post-ERCP pancreatitis (PEP). METHOD: A study of 206 patients performed ERCP (Encoscopic Retrograde Cholangio-Pancreatography) at a single centre was done from Jan. 2011 to Nov. 2016. The serum amylase or lipase level was measured at 3 h after ERCP. The patients with PEP were recorded. ROC curves were used to statistically analyze the data: The enrolled patients were divided into two groups according to gender, then we analyzed the data respectively. We comprehensively evaluated the predictive value of PEP by 3-h post-ERCP serum amylase level based on the results above. RESULTS: Two hundred six patients (92 males, 114 females) were enrolled. PEP occurred in 21 patients (10.19%) among them. The median time to discharge was 7 days (min = 1d, max = 13d) after the procedure. In the 206 patients, the 3-h post-ERCP pancreatic amylase level was used as the test variable, and the PEP occurrence as the state variable to plot the ROC curve. The area under the curve (AUC) was 0.816, and was statistically significant (P &lt; 0.001). The standard error (SE) was 0.0507, the 95% confidence interval (CI) was 0.756-0.866, and the optimal cut-off value was 351 U/L (sensitivity 76.19%, specificity 83.24%, positive likelihood ratio 4.55, negative likelihood ratio 0.29, Youden index 59.43%). Of the 206 patients, there were 83 patients with both 3-h post-ERCP amylase level and lipase level detected, and the ROC curves were plotted for both serum amylase and lipase respectively. The ROC curve matched-pair testing was carried out: The areas under the ROC curves were statistically significant. (P &lt; 0.001) The area under the ROC curve for the 3-h post-ERCP lipase was 0.778, the 95% confidence interval was 0.673-0.862, and optimal cut-off value was 1834 U/L. The area under the ROC curve for the 3-h post-ERCP serum amylase was 0.780, and the 95% confidence interval was 0.676-0.864. The optimal cut-off is 380 U/L, and there was no statistically significant difference between the two for diagnostic accuracy. According to gender, 206 patients were divided into 2 groups, and the ROC curves were drawn respectively. Based on statistical analysis, there was no statistically significant difference in the diagnostic accuracy of the two groups. In the male group, 436 U/L serum amylase provided the greatest diagnostic accuracy with sensitivity (SE) of 70.5%, specificity (SP) of 89.2%, positive predictive value (PPV) 87.5%, and negative predictive value (NPV) 78.1%. Whereas, in the female group, 357 U/L serum amylase provided the greatest diagnostic accuracy with sensitivity of 76.9%, specificity of 81.2%, positive predictive value of 80.4%, negative predictive value of 77.9%. CONCLUSIONS: 1. The 3-h post-ERCP serum amylase level is a useful measurement for predicting post-ERCP pancreatitis. 2. There was no significant difference between serum amylase and lipase 3-h post-ERCP for predicting PEP. 3. There was no statistically significant difference between male and female using the 3-h post-ERCP serum amylase level to predict PEP. For female, the optimal cut-off value was 357 U/L, whereas male 436 U/L .</p>
<p>doi: <a href="https://doi.org/10.1186/s12876-020-01254-7" class="uri">https://doi.org/10.1186/s12876-020-01254-7</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Initially elevated arterial lactate as an independent predictor of poor outcomes in severe acute pancreatitis</strong> </summary></p>
<p><em>BMC gastroenterology 2020 Apr;20(1):116</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=32306903" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=32306903</a></p>
<p>BACKGROUND: The present study aimed to investigate the relationships between arterial lactate levels and outcomes in severe acute pancreatitis. METHODS: The study retrospectively analyzed the medical data of 329 patients with severe acute pancreatitis from January 2014 to February 2019. We compared baseline characteristics, laboratory data, severity scores, types of persistent organ failure, and primary and secondary outcomes of patients with and without elevated arterial lactate levels at admission. A multivariate logistic regression analysis model and receiver operating characteristic curve were adopted to evaluate the value of arterial lactate ≥4 mmol/L for identifying high-risk patients. Trends in arterial lactate levels were compared between patients in the survivor and nonsurvivor groups over a period of 7 days. RESULTS: Compared to normal arterial lactate levels, patients with elevated arterial lactate levels show significantly higher incidences of multiple persistent organ failure (3% vs 30%, P &lt; 0.01), death (2% vs 11%, P &lt; 0.01), septic shock (4% vs 24%, P &lt; 0.01), pancreatic infection (12% vs 37%, P &lt; 0.01), abdominal compartment syndrome (3% vs 20%, P &lt; 0.01), pancreatic necrosis (41% vs 63%, P &lt; 0.01), and a need for ventilator support (26% vs 54%, P &lt; 0.01). For predicting mortality, arterial lactate levels ≥4 mmol/L had a high hazard ratio (10, 95% CI; 3.7-27; P &lt; 0.01) and the highest area under the curve (0.78). CONCLUSIONS: Our results indicate that initially elevated arterial lactate is independently associated with poor outcomes and death in patients with severe acute pancreatitis and may serve as an early high-risk stratification indicator.</p>
<p>doi: <a href="https://doi.org/10.1186/s12876-020-01268-1" class="uri">https://doi.org/10.1186/s12876-020-01268-1</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Endocrine-Exocrine Signaling Drives Obesity-Associated Pancreatic Ductal Adenocarcinoma</strong> </summary></p>
<p><em>Cell 2020 Apr;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=32304665" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=32304665</a></p>
<p>Obesity is a major modifiable risk factor for pancreatic ductal adenocarcinoma (PDAC), yet how and when obesity contributes to PDAC progression is not well understood. Leveraging an autochthonous mouse model, we demonstrate a causal and reversible role for obesity in early PDAC progression, showing that obesity markedly enhances tumorigenesis, while genetic or dietary induction of weight loss intercepts cancer development. Molecular analyses of human and murine samples define microenvironmental consequences of obesity that foster tumorigenesis rather than new driver gene mutations, including significant pancreatic islet cell adaptation in obesity-associated tumors. Specifically, we identify aberrant beta cell expression of the peptide hormone cholecystokinin (Cck) in response to obesity and show that islet Cck promotes oncogenic Kras-driven pancreatic ductal tumorigenesis. Our studies argue that PDAC progression is driven by local obesity-associated changes in the tumor microenvironment and implicate endocrine-exocrine signaling beyond insulin in PDAC development.</p>
<p>doi: <a href="https://doi.org/10.1016/j.cell.2020.03.062" class="uri">https://doi.org/10.1016/j.cell.2020.03.062</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>The outcome of ex vivo TIL expansion is highly influenced by spatial heterogeneity of the tumor T-cell repertoire and differences in intrinsic in vitro growth capacity between T-cell clones</strong> </summary></p>
<p><em>Clinical cancer research : an official journal of the American Association for Cancer Research 2020 Apr;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=32303540" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=32303540</a></p>
<p>PURPOSE: During our efforts to develop TIL therapy to counter the devastating recurrence rate in patients with primary resectable pancreatic ductal adenocarcinoma (PDA), we found that PDA TILs can readily be expanded in vitro and that the majority of resulting TIL cultures show reactivity against the autologous tumor. However, the fraction of tumor-reactive T-cells is low. We investigated to which extent this was related to the in vitro expansion. EXPERIMENTAL DESIGN: We compared the clonal composition of TIL preparations before and after in vitro expansion using T-cell receptor (TCR) deep-sequencing. Our findings for PDA were benchmarked to experiments with melanoma TILs. RESULTS: We found that the TIL TCR repertoire changes dramatically during in vitro expansion, leading to loss of tumor-dominant T-cell clones and overgrowth by newly emerging T-cell clones that are barely detectable in the tumor. These changes are primarily driven by differences in the intrinsic in vitro expansion capacity of T-cell clones. Single cell experiments showed an association between poor proliferative capacity and expression of markers related to antigen experience and dysfunction. Furthermore, we found that spatial heterogeneity of the TIL repertoire resulted in TCR repertoires that are greatly divergent between TIL cultures derived from distant tumor samples of the same patient. CONCLUSIONS: Culture-induced changes in clonal composition are likely to affect tumor-reactivity of TIL preparations. TCR deep-sequencing provides important insights into the factors that govern the outcome of in vitro TIL expansion and thereby a path towards optimization of the production of TIL preparations with high therapeutic efficacy.</p>
<p>doi: <a href="https://doi.org/10.1158/1078-0432.CCR-19-3845" class="uri">https://doi.org/10.1158/1078-0432.CCR-19-3845</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>A multi-analyte panel consisting of extracellular vesicle miRNAs and mRNAs, cfDNA, and CA19-9 shows utility for diagnosis and staging of pancreatic adenocarcinoma</strong> </summary></p>
<p><em>Clinical cancer research : an official journal of the American Association for Cancer Research 2020 Apr;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=32299821" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=32299821</a></p>
<p>PURPOSE: To determine whether a multi-analyte liquid biopsy can improve the detection and staging of pancreatic adenocarcinoma (PDAC). EXPERIMENTAL DESIGN: We analyzed plasma from 204 subjects (71 healthy, 44 non-PDAC pancreatic disease, and 89 PDAC) for the following biomarkers: Tumor-associated extra-cellular vesicle (EV) miRNA and mRNA isolated on a nanomagnetic platform that we developed and measured by next-generation sequencing or qPCR, circulating cell-free DNA (ccfDNA) concentration measured by qPCR, ccfDNA KRASG12D/V/R mutations detected by droplet digital PCR, and CA19-9 measured by ECLIA. We applied machine learning to training sets and subsequently evaluated model performance in independent, user-blinded test sets. RESULTS: To identify patients with PDAC versus those without, we generated a classification model using a training set of 47 subjects (20 PDAC and 27 non-cancer). When applied to a blinded test set (N = 136), the model achieved an area under the curve (AUC)of 0.95 and accuracy of 92%, superior to the best individual biomarker, CA19-9 (89%). We next used a cohort of 20 PDAC patients to train our model for disease staging and applied it to a blinded test set of 25 patients clinically staged by imaging as metastasis-free, including 9 subsequently determined to have had occult metastasis. Our workflow achieved significantly higher accuracy for disease staging (84%) than imaging alone (accuracy = 64%; P &lt;0.05). CONCLUSIONS: Algorithmically combining blood-based biomarkers may improve PDAC diagnostic accuracy and pre-operative identification of non-metastatic patients best suited for surgery, although larger validation studies are necessary.</p>
<p>doi: <a href="https://doi.org/10.1158/1078-0432.CCR-19-3313" class="uri">https://doi.org/10.1158/1078-0432.CCR-19-3313</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Choice of first line systemic treatment in pancreatic cancer among national experts</strong> </summary></p>
<p><em>Pancreatology : official journal of the International Association of Pancreatology (IAP) … [et al.] 2020 Mar;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=32299764" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=32299764</a></p>
<p>BACKGROUND: Treatment options for patients with metastatic pancreatic cancer depend on various factors, including performance status, tumor burden and patient preferences. Metastatic pancreatic cancer is incurable and many systemic treatment options have been investigated over the past decades. This analysis of patterns of practice was performed to identify decision criteria and their impact on the choice of first-line management of metastatic pancreatic cancer. MATERIALS AND METHODS: Members of the Swiss Group for Clinical Cancer Research (SAKK) Gastrointestinal Cancer Group were contacted and agreed to participate in this analysis. Decision trees for the first line treatment of metastatic pancreatic cancer from 9 centers in Switzerland were collected and analyzed based on the objective consensus methodology to identify consensus and discrepancies in clinical decision-making. RESULTS: The final treatment algorithms included 3 decision criteria (comorbidities, performance status and age) and 5 treatment options: FOLFIRINOX, FOLFOX, gemcitabine + nab-paclitaxel, gemcitabine mono and best supportive care. CONCLUSION: We identified multiple decision criteria relevant to all participating centers. We found consensus for the treatment of young (age below 65) patients with good performance status with FOLFIRINOX. For patients with increasing age and reducing performance status there was a decreasing trend to use gemcitabine + nab-paclitaxel. Gemcitabine monotherapy was typically offered to patients in the presence of comorbidities. For patients with ECOG 3-4, most of the experts recommended BSC.</p>
<p>doi: <a href="https://doi.org/10.1016/j.pan.2020.03.012" class="uri">https://doi.org/10.1016/j.pan.2020.03.012</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Comment on ‘comparison of overall survival and perioperative outcomes of laparoscopic pancreaticoduodenectomy and open pancreaticoduodenectomy for pancreatic ductal adenocarcinoma: a systematic review and meta-analysis’</strong> </summary></p>
<p><em>BMC cancer 2020 Apr;20(1):327</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=32299368" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=32299368</a></p>
<p>BACKGROUND: To discuss some inaccurate parts of a published systematic review and meta-analysis which was about comparison of laparoscopic pancreaticoduodenectomy and open pancreaticoduodenectomy for pancreatic ductal adenocarcinoma in overall survival and perioperative outcomes. METHODS: Not applicable. RESULTS: The study enrolled overlapping patient cohorts and patients with a variety of disease histologies, not specific for pancreatic ductal adenocarcinoma. They also reported different conclusion for R0 resection of 2 approaches in result and discussion part. Some data should be revised through statistical method, which could be polled to analysis. CONCLUSION: The conclusion of this published systematic review and meta-analysis was not objective; therefor, the study may mislead readers, especially for those who just read the abstract of this study or not analysis this article in detail.</p>
<p>doi: <a href="https://doi.org/10.1186/s12885-020-06830-4" class="uri">https://doi.org/10.1186/s12885-020-06830-4</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Pancreatic Neuroendocrine Neoplasms: Landscape and Horizon</strong> </summary></p>
<p><em>Archives of pathology &amp; laboratory medicine 2020 Apr;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=32298138" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=32298138</a></p>
<p>CONTEXT.—: Since the initial description of pancreatic endocrine physiology and the recognition of islet cell tumors in the 1800s, there have been noteworthy advances in the pathobiology of pancreatic neuroendocrine neoplasms (PanNENs), and definition of the important distinction between well-differentiated neuroendocrine tumor (PanNET) and poorly differentiated neuroendocrine carcinoma (PanNEC). The evolving knowledge has resulted in a continuous update in terminology, classification, and grading system for this group of neoplasms. Pancreatic neuroendocrine tumors associated with hereditary conditions have been linked to unique molecular and genetic events, and sporadic PanNETs have specific gene signatures. Based on accumulative experience and knowledge, therapeutic strategies have been defined for this group of neoplasms. OBJECTIVE.—: To review the evolution and description of the pathologic-genomic evolution of PanNENs, and to facilitate accurate pathologic interpretation for the corresponding clinical management. DATA SOURCES.—: Literature review of published studies and author’s own work. CONCLUSIONS.—: Evolving experience and knowledge have established subtypes of pancreatic neuroendocrine neoplasms, based on their genotype and phenotype. Accurate pathologic interpretation of the specific neoplasm has significant implications for therapy and prognosis.</p>
<p>doi: <a href="https://doi.org/10.5858/arpa.2019-0654-RA" class="uri">https://doi.org/10.5858/arpa.2019-0654-RA</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Gastrointestinal peptides in children before and after hematopoietic stem cell transplantation</strong> </summary></p>
<p><em>BMC cancer 2020 Apr;20(1):306</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=32293354" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=32293354</a></p>
<p>BACKGROUND: Gastrointestinal tract function and it’s integrity are controlled by a number of peptides whose secretion is influenced by severe inflammation. In stomach the main regulatory peptide is ghrelin. For upper small intestine cholecystokinin and lower small intestine glucagon-like peptide- 1 are secreted, while fibroblast growth factor-21 is secreted by several organs, including the liver, pancreas, and adipose tissue [12]. Hematopoietic stem cell transplantation causes serious mucosal damage, which can reflect on this peptides. METHODS: The aim of the study was to determine fasting plasma concentrations of ghrelin, cholecystokinin, glucagon- like peptide-1, and fibroblast growth factor-21, and their gene expressions, before and 6 months after hematopoietic stem cell transplantation.27 children were studied, control group included 26 healthy children. RESULTS: Acute graft versus host disease was diagnosed in 11 patients (41%, n = 27). Median pre-transplantation concentrations of gastrointestinal peptides, as well as their gene expressions, were significantly lower in studied group compared with the control group. Only median of fibroblast growth factor-21 concentration was near-significantly higher before stem cell transplantation than in the control group. The post-hematopoietic transplant results revealed significantly higher concentrations of the studied peptides (except fibroblast growth factor-21) and respective gene expressions as compare to pre transplant results. Median glucagone like peptide-1 concentrations were significantly decreased in patients with features of acute graft versus host disease. Moreover, negative correlation between glucagone like peptide-1 concentrations and acute graft versus host disease severity was found. CONCLUSIONS: Increased concentrations and gene expressions of gastrointestinal tract regulation peptides can be caused by stimulation of regeneration in the severe injured organ. Measurement of these parameters may be a useful method of assessment of severity of gastrointestinal tract complications of hematopoietic stem cell transplantation.</p>
<p>doi: <a href="https://doi.org/10.1186/s12885-020-06790-9" class="uri">https://doi.org/10.1186/s12885-020-06790-9</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Chemotherapy, host response and molecular dynamics in periampullary cancer: the CHAMP study</strong> </summary></p>
<p><em>BMC cancer 2020 Apr;20(1):308</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=32293352" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=32293352</a></p>
<p>BACKGROUND: Pancreatic cancer is a devastating disease with a dismal prognosis. Despite profound medical advances in systemic therapies for other types of aggressive tumours during recent years, a diagnosis of pancreatic cancer is still often synonymous with a fatal outcome. The term periampullary cancer includes pancreatic cancer and applies to the group of tumours found in proximity to the ampulla of Vater. Molecular events and immune response in the host during chemotherapy remain largely unexplored in this group of tumours. Therefore, the “Chemotherapy, Host Response and Molecular Dynamics in Periampullary Cancer (CHAMP)” study aims to monitor these processes to gain new insight into this perplexing disease. METHODS: The CHAMP study is a prospective, single-arm observational study. All patients diagnosed with pancreatic or other periampullary adenocarcinoma undergoing adjuvant or palliative chemotherapy treatment in the Department of Oncology, Skåne University Hospital, are invited to participate. Clinical and pathological data will be compiled at study entry. A single tissue microarray (TMA) block is constructed for each patient with a resected tumour and blood samples are drawn before, during and after chemotherapy in order to sample peripheral blood mononuclear cells (PBMC), cytokines and circulating tumour DNA (ctDNA). Next generation sequencing will be performed on tumour tissue and ctDNA to detect changes in the clonal landscape over space and time. DISCUSSION: Despite the recent emergence of some promising biomarkers for periampullary cancer, there has been a lack of success in clinical implementation. Cancer cells continuously adapt and become resistant to treatment during chemotherapy. To be able to keep pace with and hopefully overtake this rapid evolution we must, with the help of new diagnostic tools, be ready to adapt and alter treatment accordingly. It seems to us that the only way forward is to gain a better understanding of the dynamics of the disease during treatment. With insights gained from the CHAMP study we hope to find answers to key questions in this largely unexplored territory. TRIAL REGISTRATION: This study has been registered 30th October 2018 at clinicaltrials.gov as NCT03724994.</p>
<p>doi: <a href="https://doi.org/10.1186/s12885-020-06807-3" class="uri">https://doi.org/10.1186/s12885-020-06807-3</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Unexpected response to palliative radiotherapy for subcutaneous metastases of an advanced small cell pancreatic neuroendocrine carcinoma: a case report of two different radiation schedules</strong> </summary></p>
<p><em>BMC cancer 2020 Apr;20(1):311</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=32293342" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=32293342</a></p>
<p>BACKGROUND: Skin metastases from pancreatic neuroendocrine carcinoma (PNEC) are rare and their palliative treatment is challenging. We report our experience in the multimodal management of one of the few reported cases of metastatic PNEC with multiple visceral and subcutaneous secondary lesions, focusing on the effectiveness of palliative radiotherapy for skin metastases. CASE PRESENTATION: A 61-years old woman affected by a metastatic PNEC - with subcutaneous growing and bleeding secondary lesions (at the scalp, right scapular region and at the back of the left thoracic wall, respectively) - obtained a successful control of visceral metastases with the use of chemotherapy and an unexpected local response of her skin metastases with palliative radiotherapy. In particular, two subsequent radiation treatments were performed using different fractionation schedules (30 Gy in 10 fractions and 20 Gy in 5 fractions, respectively). Both radiation treatments were well-tolerated and patient’s quality of life was improved. Local response was maintained until patient’s death - that occurred due to cachexia. CONCLUSIONS: The presented case highlights the effectiveness and the good tolerance of radiotherapy in the treatment of subcutaneous metastases; nevertheless, further knowledge of the optimal local palliative approach for PNEC metastatic sites is necessary. The experience gained in this work is the occasion to encourage a routine integrated multidisciplinary team management of metastatic PNECs because of their clinical complexity. The aim is to guarantee the optimization of the care with personalized and more effective systemic and local treatments - also including supportive cares and treatment-related side effects management.</p>
<p>doi: <a href="https://doi.org/10.1186/s12885-020-06845-x" class="uri">https://doi.org/10.1186/s12885-020-06845-x</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>How does intestinal-type intraductal papillary mucinous neoplasm emerge? CDX2 plays a critical role in the process of intestinal differentiation and progression</strong> </summary></p>
<p><em>Virchows Archiv : an international journal of pathology 2020 Apr;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=32291497" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=32291497</a></p>
<p>Intestinal-type intraductal papillary mucinous neoplasm (IPMN) of the pancreas is clinicopathologically distinctive. Our research aimed to elucidate the molecular mechanism of the development and progression of the intestinal-type IPMN. In 60 intestinal-type IPMN specimens, histological transitions from gastric-type epithelia to intestinal-type epithelia were observed in 48 cases (80%). CDX2/MUC2/alcian blue triple staining indicated that CDX2 appeared to precede MUC2 expression and subsequent alcian blue-positive mucin production. Expression of p21 and Ki-67 seemed to be accelerated by CDX2 expression (p = 6.02e-13 and p = 3.1e-09, respectively). p21/Ki-67 double staining revealed that p21 was mostly expressed in differentiated cells in the apex of papillae, while Ki-67 was expressed in proliferative cells in the base of papillae. This clear cellular arrangement seemed to break down with the progression of atypical grade and development of invasion (p = 0.00197). Intestinal-type IPMNs harbored frequent GNAS mutations (100%, 25/25) and RNF43 mutations (57%, 8/14) and shared identical GNAS and KRAS mutations with concurrent gastric-type IPMNs or incipient gastric-type neoplasia (100%, 25/25). RNF43 mutations showed emerging or being selected in intestinal-type neoplasms along with ß-catenin aberration. Activation of protein kinase A and extracellular-regulated kinase was observed in CDX2-positive intestinal-type neoplasm. These results suggest that gastric-type epithelia that acquire GNAS mutations together with induction of intrinsic CDX2 expression may evolve with clonal selection and additional molecular aberrations including RNF43 and ß-catenin into intestinal-type IPMNs, which may further progress with complex villous growth due to disoriented cell cycle regulation, acceleration of atypical grade, and advance to show an invasive phenotype.</p>
<p>doi: <a href="https://doi.org/10.1007/s00428-020-02806-8" class="uri">https://doi.org/10.1007/s00428-020-02806-8</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Targeting the MAPK Pathway in KRAS-Driven Tumors</strong> </summary></p>
<p><em>Cancer cell 2020 Apr;37(4):543-550</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=32289276" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=32289276</a></p>
<p>KRAS mutations occur in a quarter of all of human cancers, yet no selective drug has been approved to treat these tumors. Despite the recent development of drugs that block KRASG12C, the majority of KRAS oncoproteins remain undruggable. Here, we review recent efforts to validate individual components of the mitogen-activated protein kinase (MAPK) pathway as targets to treat KRAS-mutant cancers by comparing genetic information derived from experimental mouse models of KRAS-driven lung and pancreatic tumors with the outcome of selective MAPK inhibitors in clinical trials. We also review the potential of RAF1 as a key target to block KRAS-mutant cancers.</p>
<p>doi: <a href="https://doi.org/10.1016/j.ccell.2020.03.013" class="uri">https://doi.org/10.1016/j.ccell.2020.03.013</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>The T1D-associated lncRNA Lnc13 modulates human pancreatic β cell inflammation by allele-specific stabilization of STAT1 mRNA</strong> </summary></p>
<p><em>Proceedings of the National Academy of Sciences of the United States of America 2020 Apr;117(16):9022-9031</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=32284404" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=32284404</a></p>
<p>The vast majority of type 1 diabetes (T1D) genetic association signals lie in noncoding regions of the human genome. Many have been predicted to affect the expression and secondary structure of long noncoding RNAs (lncRNAs), but the contribution of these lncRNAs to the pathogenesis of T1D remains to be clarified. Here, we performed a complete functional characterization of a lncRNA that harbors a single nucleotide polymorphism (SNP) associated with T1D, namely, Lnc13 Human pancreatic islets harboring the T1D-associated SNP risk genotype in Lnc13 (rs917997<em>CC) showed higher STAT1 expression than islets harboring the heterozygous genotype (rs917997</em>CT). Up-regulation of Lnc13 in pancreatic β-cells increased activation of the proinflammatory STAT1 pathway, which correlated with increased production of chemokines in an allele-specific manner. In a mirror image, Lnc13 gene disruption in β-cells partially counteracts polyinosinic-polycytidylic acid (PIC)-induced STAT1 and proinflammatory chemokine expression. Furthermore, we observed that PIC, a viral mimetic, induces Lnc13 translocation from the nucleus to the cytoplasm promoting the interaction of STAT1 mRNA with (poly[rC] binding protein 2) (PCBP2). Interestingly, Lnc13-PCBP2 interaction regulates the stability of the STAT1 mRNA, sustaining inflammation in β-cells in an allele-specific manner. Our results show that the T1D-associated Lnc13 may contribute to the pathogenesis of T1D by increasing pancreatic β-cell inflammation. These findings provide information on the molecular mechanisms by which disease-associated SNPs in lncRNAs influence disease pathogenesis and open the door to the development of diagnostic and therapeutic approaches based on lncRNA targeting.</p>
<p>doi: <a href="https://doi.org/10.1073/pnas.1914353117" class="uri">https://doi.org/10.1073/pnas.1914353117</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>The assessment of pancreatic exocrine function in patients with inoperable pancreatic cancer: In need of a new gold-standard</strong> </summary></p>
<p><em>Pancreatology : official journal of the International Association of Pancreatology (IAP) … [et al.] 2020 Apr;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=32284260" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=32284260</a></p>
<p>BACKGROUND: Pancreatic exocrine insufficiency is commonplace in patients with pancreatic cancer, adversely impacting on quality of life and survival. Whilst the management of exocrine insufficiency is well established, diagnosis remains challenging in clinical practice. A plethora of diagnostic tests exist. Nevertheless, a lack of consensus remains about the optimal diagnostic method, specifically in patients with pancreatic cancer. Research, to date, has primarily been undertaken in patients with chronic pancreatitis and cystic fibrosis. This manuscript will review the current literature and will examine the evidence around the diagnostic tests available for pancreatic exocrine insufficiency and whether any exists specifically for pancreatic cancer cohorts. FINDINGS: Evidence to recommend an individual test for the diagnosis of pancreatic exocrine insufficiency in clinical practice is lacking. Direct testing (by direct sampling of pancreatic secretions) has the highest specificity and sensitivity but is no longer routinely deployed or feasible in practice. Indirect testing, such as faecal elastase, is less accurate with high false-positive rates, but is routinely available in clinical practice. The 13C-mixed triglyceride breath test and the gold-standard 72-h faecal fat test have high specificity for indirect tests, but are not routinely available and cumbersome to undertake. A combination approach including nutritional markers and faecal elastase has more recently been proposed. CONCLUSION: Further research is required to identify the most optimal and accurate diagnostic tool to diagnose pancreatic exocrine insufficiency in patients with pancreatic cancer in clinical practice.</p>
<p>doi: <a href="https://doi.org/10.1016/j.pan.2020.03.020" class="uri">https://doi.org/10.1016/j.pan.2020.03.020</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Acute Pancreatitis in Patients With a Medical History of Type 2 Diabetes Mellitus: Clinical Findings and Magnetic Resonance Imaging Characteristics</strong> </summary></p>
<p><em>Pancreas 2020 Apr;49(4):591-597</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=32282775" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=32282775</a></p>
<p>OBJECTIVE: To determine the characteristics of type 2 diabetes mellitus (T2DM)-related acute pancreatitis (AP) on magnetic resonance imaging (MRI). METHODS: Retrospectively studied 262 patients with AP were admitted to our institution and underwent MRI. Diagnosis of T2DM-related AP was based on clinical manifestations, laboratory tests, and MRI. Pancreatic/peripancreatic changes were assessed on MRI. RESULTS: Fifty-three (20.2%) patients with T2DM-related AP and 209 (79.8%) with nondiabetic AP were enrolled. On MRI, a higher prevalence of necrotizing pancreatitis (P &lt; 0.001), pancreatic necrosis &gt;30% (57.5% vs 29.2%; P = 0.006), hemorrhage (35.8% vs 19.1%; P = 0.009), abdominal wall edema (67.9% vs 46.8%; P = 0.006), walled-off necrosis (43.2% vs 14.6%; P &lt; 0.001), and infected collections (P &lt; 0.001) were registered in T2DM with AP. T2DM-related AP sustained greater magnetic resonance severity index (mean, 5.1 [range, 2-10] vs 3.4 [range, 1-10]; P &lt; 0.001), higher incidence of moderate and severe pancreatitis (69.8% vs 40.2%; P &lt; 0.001), higher organ failure (45.3% vs 22%; P = 0.001), and prolonged hospitalization (mean, 25.2 [range, 10-63] vs 16 [range, 5-48] days; P &lt; 0.001). CONCLUSIONS: Type 2 diabetes mellitus-related AP is more moderate-to-severe pancreatitis, and it correlates with MRI characteristics of the pancreas itself, hemorrhage, abdominal wall, and infected collections.</p>
<p>doi: <a href="https://doi.org/10.1097/MPA.0000000000001530" class="uri">https://doi.org/10.1097/MPA.0000000000001530</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Endoscopic Ultrasound-Guided Fine-Needle Aspiration Microhistology in Asymptomatic and Symptomatic Pancreatic Cystic Lesions</strong> </summary></p>
<p><em>Pancreas 2020 Apr;49(4):584-590</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=32282774" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=32282774</a></p>
<p>OBJECTIVE: This study aimed to analyze the usefulness of endoscopic ultrasound-guided fine-needle aspiration (EUS-FNA) microhistology to detect malignancy in pancreatic cystic lesions (PCLs). METHODS: Patients with PCLs were identified and submitted to EUS-FNA from January 2010 to January 2017. The percentage of samples suitable for diagnostic classification by microhistology and the positive and negative likelihood ratios to detect malignancy in asymptomatic (APC) and symptomatic (SPC) PCLs were determined. RESULTS: Endoscopic ultrasound-guided fine-needle aspiration was performed in 510 patients. The resulting material was processed by microhistology and useful for diagnosis in 432 (84.2%). Clinical characteristics of APC (341) and SPC (169) revealed that APC patients were younger (P = 0.004) and had smaller PCLs (23 vs 35 mm; P &lt; 0.001). In APC, we found more preneoplastic (38.7% vs 30.2%; P = 0.0016) and a lower number of malignant PCLs (8.2% vs 24.3%; P &lt; 0.001). In APC and SPC, the sensitivity, specificity, positive predictive value, negative predictive value, and accuracy of microhistology to detect malignancy were 71.4%, 99.7%, 95.2%, 97.5%, and 97.4% (k = 0.80) and 58.5%, 96.9%, 85.7%, 87.9%, and 87.6%, respectively. CONCLUSIONS: Endoscopic ultrasound-guided fine-needle aspiration was technically feasible. Microhistology was especially useful to detect neoplastic or malignant PCLs in APC patients.</p>
<p>doi: <a href="https://doi.org/10.1097/MPA.0000000000001525" class="uri">https://doi.org/10.1097/MPA.0000000000001525</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Nonaggressive Versus Aggressive Intravenous Fluid Therapy in Acute Pancreatitis With More Than 24 Hours From Disease Onset: A Randomized Controlled Trial</strong> </summary></p>
<p><em>Pancreas 2020 Apr;49(4):579-583</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=32282773" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=32282773</a></p>
<p>OBJECTIVE: This study aimed to compare a “nonaggressive” hydration versus an “aggressive” hydration using Hartmann’s solution in patients with acute pancreatitis (AP) with more than 24 hours from disease onset. METHODS: We included 88 patients with AP with more than 24 hours from disease onset, and were randomized into 2 groups. Group I (n = 45) received a nonaggressive hydration (Hartmann’s solution at 1.5 mL kg h for the first 24 hours and 30 mL kg during the next 24 hours), and group II (n = 43) received an aggressive hydration (bolus of Hartmann’s solution 20 mL kg, followed by an infusion of 3 mL kg h for the first 24 hours and then 30 mL kg for the next 24 hours). RESULTS: The mean volume of fluid administered was greater in group II (P &lt; 0.001). We did not find differences when comparing both groups in reference to persistent systemic inflammatory response syndrome (P = 0.528), pancreatic necrosis (P = 0.710), respiratory complications (P = 0.999), acute kidney injury (P = 0.714), or length of hospital stay (P = 0.892). CONCLUSIONS: Our study suggests that the clinical evolution of patients with AP with more than 24 hours from disease onset is similar using an aggressive or nonaggressive hydration.</p>
<p>doi: <a href="https://doi.org/10.1097/MPA.0000000000001528" class="uri">https://doi.org/10.1097/MPA.0000000000001528</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>FOLFIRINOX for Advanced Pancreatic Cancer Patients After Nab-Paclitaxel Plus Gemcitabine Failure</strong> </summary></p>
<p><em>Pancreas 2020 Apr;49(4):574-578</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=32282772" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=32282772</a></p>
<p>OBJECTIVES: There is no standard chemotherapy for advanced pancreatic cancer (APC) after gemcitabine plus nab-paclitaxel (GP) failure. The aim of this study was to evaluate the efficacy and safety of FOLFIRINOX (5-Fluorouracil, leucovorin, irinotecan, and oxaliplatin) (5-Fluorouracil, leucovorin, irinotecan, and oxaliplatin) (FFX) and modified FFX (mFFX) for APC patients after GP failure. METHODS: We retrospectively evaluated the efficacy and safety of FFX in APC patients who were refractory or intolerant of GP. RESULTS: Between July 2014 and October 2018, 23 patients received FFX after failure of GP. The overall response rate (RR) was 23%, and the disease control rate (DCR) was 68%. The median progression-free survival (PFS) was 5.3 months (95% confidence interval, 2.5-8.9), and the median overall survival (OS) was 12.1 months (95% confidence interval, 4.0-14.2). Twelve patients received FFX, and 11 patients received mFFX. In the FFX group, the RR was 9%, the DCR was 73%, the PFS was 5.3 months, and the OS was 6.9 months. In the mFFX group, the RR was 23%, the DCR was 64%, the PFS was 4.3 months, and the OS was 12.8 months. There was no significant difference between the groups. CONCLUSIONS: FOLFIRINOX has potential activity for patients with APC in whom GP failed.</p>
<p>doi: <a href="https://doi.org/10.1097/MPA.0000000000001534" class="uri">https://doi.org/10.1097/MPA.0000000000001534</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Comparative Effectiveness of Pylorus-Preserving Versus Standard Pancreaticoduodenectomy in Clinical Practice</strong> </summary></p>
<p><em>Pancreas 2020 Apr;49(4):568-573</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=32282771" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=32282771</a></p>
<p>OBJECTIVES: We compared risk-adjusted short- and long-term outcomes between standard pancreaticoduodenectomy (SPD) and a pylorus-preserving pancreaticoduodenectomy (PPPD). METHODS: The National Cancer Database was queried for the years 2004 to 2014 to identify patients with adenocarcinoma of the pancreatic head undergoing SPD and PPD. Margin status, lymph node yield, length of stay (LOS), 30- and 90-day mortality, and overall survival were compared. RESULTS: A total of 11,172 patients were identified, of whom 9332 (83.5%) underwent SPD and 1840 (16.5%) PPPD. There was no difference in patient age, sex, stage, tumor grade, radiation treatment, and chemotherapy treatment between the 2 groups. Total number of regional lymph nodes was examined, and surgical margin status and overall survival were also comparable. However, patients undergoing PPPD had a shorter LOS (11.3 vs 12.3 days, P &lt; 0.001), lower 30-day mortality (2.5% vs 3.7%, P = 0.02), and 90-day mortality (5.5% vs 6.9%, P = 0.03). On multivariate analyses, patients undergoing SPD were at higher risk for 30-day mortality compared with PPPD (odds ratio, 1.51; 95% confidence interval, 1.07-2.13). CONCLUSIONS: Standard pancreaticoduodenectomy and PPPD are oncologically equivalent, yet PPPD is associated with a reduction in postoperative mortality and shorter LOS.</p>
<p>doi: <a href="https://doi.org/10.1097/MPA.0000000000001524" class="uri">https://doi.org/10.1097/MPA.0000000000001524</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Endoscopic Ultrasound Criteria for Arterial Invasion in Pancreatic Cancer of the Body and Tail</strong> </summary></p>
<p><em>Pancreas 2020 Apr;49(4):561-567</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=32282770" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=32282770</a></p>
<p>OBJECTIVES: We aimed to determine the difference in endoscopic ultrasonography (EUS) images between portal vein (PV) and arterial invasion of pancreatic cancer and to develop criteria for arterial involvement. METHODS: We reviewed EUS data of consecutive patients who underwent distal pancreatectomy from December 2010 to May 2017. We categorized the tumor-vessel relationship into 4 and 5 types, respectively, for the PV and arteries: (a) clear separation between tumor and vessel; (b) tumor border at vessel, echo-rich vessel wall uninterrupted; (c) echo-rich vessel wall interrupted; (d) vessel contour irregularity; and (e) arterial wall thickening or echogenic band surrounding the artery. We compared EUS outcomes with surgical and pathological results. RESULTS: Overall, 56 patients underwent distal pancreatectomy, of whom 22 received en bloc celiac axis resection. The pathological invasion rates of PVs and arteries were 46.2% and 0% in (c), and 72.5% and 42.4% in (d) (P = 0.046, P = 0.016), respectively. The overall sensitivity and specificity were 92.1% and 83.2%, respectively, for diagnosing venous invasion and 70.0% and 84.4%, respectively, for arterial invasion. CONCLUSIONS: Different EUS criteria may be necessary for diagnosing arterial and portal venous invasions. Criterion (d) might be appropriate for diagnosing arterial invasion.</p>
<p>doi: <a href="https://doi.org/10.1097/MPA.0000000000001523" class="uri">https://doi.org/10.1097/MPA.0000000000001523</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Risk Factors for Pancreatic Cancer and the Necessity of Long-Term Surveillance in Patients With Pancreatic Cystic Lesions</strong> </summary></p>
<p><em>Pancreas 2020 Apr;49(4):552-560</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=32282769" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=32282769</a></p>
<p>OBJECTIVES: Pancreatic cystic lesions (PCLs) are a risk factor for pancreatic cancer (PC). Which PCLs should be surveilled and necessity of long-term observation are still controversial. METHODS: From January 2000 to March 2016, we enrolled 1137 patients with PCLs observed for 1 year. We defined PCLs with cyst size of greater than 30 mm, main pancreatic duct (MPD) of greater than 5 mm or mural nodule as high-risk group, and others as low-risk group (LRG). Kaplan-Meier method and Cox proportional hazard model were applied to assess incidence and risk factors of PC. RESULTS: In 107 high-risk group and 1030 LRG patients, mean observation period was 4.3 years and 5.0 years, respectively, and 5-year PC incidence was 12.0% and 2.8%, respectively. In LRG, MPD of greater than 3 mm, diabetes mellitus, and presumed branch-duct intraductal papillary mucinous neoplasia (BD-IPMN), defined as PCLs fulfilling any of multilocular formation, multiplicity, or MPD communication, were independent risk factors for PC. In 450 LRG observed for 5 years, 10-year PC incidence was higher in PCLs with our identified risk factors. There was no PC occurrence in PCLs not presumed BD-IPMN after 5-year observation. CONCLUSIONS: Continuous surveillance is needed after 5-year observation, especially in LRG with our identified risk factors. For discontinuing surveillance, PCLs not presumed BD-IPMN at fifth year could be candidates.</p>
<p>doi: <a href="https://doi.org/10.1097/MPA.0000000000001521" class="uri">https://doi.org/10.1097/MPA.0000000000001521</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>miR-375 Inhibits Autophagy and Further Promotes Inflammation and Apoptosis of Acinar Cells by Targeting ATG7</strong> </summary></p>
<p><em>Pancreas 2020 Apr;49(4):543-551</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=32282768" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=32282768</a></p>
<p>OBJECTIVES: MicroRNAs have been considered to be closely related with the development of severe acute pancreatitis (SAP), and microRNA-375 (miR-375) was believed to be a marker of SAP. We aim to investigate the role of miR-375 in regulating SP. METHODS: Cerulein and lipopolysaccharide were used to establish the models of SAP. AR42J cell line was chosen for study in vitro. Flow cytometry was applied for assessing apoptosis. The contents of inflammatory factors were detected with related enzyme-linked immunosorbent assay and quantitative real-time polymerase chain reaction assays. Hematoxylin and eosin staining was applied to observe the pathological changes of pancreatic tissues. Immunohistochemistry analysis was conducted for investigating the expression of light chain 3. RESULTS: The level of miR-375 in pancreatitis tissues and cell lines was upregulated. Overexpression of miR-375 promoted inflammation and the apoptosis of acinar cells through inhibiting autophagy. The binding site between miR-375 and ATG7 was identified, and miR-375 could directly regulate the ATG7. microRNA-375 suppressed autophagy and promoted inflammation and the apoptosis of acinar cells via targeting ATG7. CONCLUSIONS: We proved that miR-375 could inhibit autophagy and promote inflammation and the apoptosis of acinar cells through regulating ATG7. This study first proves that miR-375 modulates the development of SAP through targeting ATG7.</p>
<p>doi: <a href="https://doi.org/10.1097/MPA.0000000000001536" class="uri">https://doi.org/10.1097/MPA.0000000000001536</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Alteration of Transforming Growth Factor β Signaling Pathway Predicts Worse Prognosis in Pancreatic Ductal Adenocarcinoma</strong> </summary></p>
<p><em>Pancreas 2020 Apr;49(4):534-542</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=32282767" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=32282767</a></p>
<p>OBJECTIVES: Transforming growth factor β (TGF-β) signaling pathway is one of the core pathways in pancreatic ductal adenocarcinoma (PDAC). Prognostic value of TGF-β pathway genes as a functionally related group in PDAC is rarely studied. METHODS: Seventy-two PDAC patients who underwent surgery between November 30, 2015, and September 13, 2017, in West China Hospital, Sichuan University, were identified and included in this study. Whole-exome sequencing or targeted next-generation sequencing was performed with tumor tissue. Clinicopathologic characteristics and survival data were retrospectively collected and analyzed. RESULTS: Genetic alterations were detected in 71 patients (98.6%). Although 1 patient (1.4%) had one genetic alteration, 33 patients (45.8%) had 2 to 4 alterations and 37 patients (51.4%) had 5 or more alterations. Twenty-five patients with TGF-β pathway alteration were identified as TGF-βm+ group. Other 47 patients were TGF-βm- group. Mutation of TGF-β pathway was independently associated with inferior survival (hazard ratio, 2.22, 95% confidence interval, 1.05-4.70, P = 0.04), especially in patients accepting radical surgery (hazard ratio, 3.25, 95% confidence interval, 1.01-10.49, P = 0.04). CONCLUSIONS: Inferior prognosis was observed in PDACs with mutations of TGF-β pathway. Genomic information could help screen out patients at risk after surgery, and adjuvant therapy might benefit this subgroup of PDACs.</p>
<p>doi: <a href="https://doi.org/10.1097/MPA.0000000000001522" class="uri">https://doi.org/10.1097/MPA.0000000000001522</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Aberration of ARID1A Is Associated With the Tumorigenesis and Prognosis of Sporadic Nonfunctional Pancreatic Neuroendocrine Tumors</strong> </summary></p>
<p><em>Pancreas 2020 Apr;49(4):514-523</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=32282764" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=32282764</a></p>
<p>OBJECTIVE: The genetic aberrations that underlie chromatin remodeling in sporadic nonfunctional pancreatic neuroendocrine tumors (NF-pNETs) remain largely unknown. Here, we investigated the dysregulation of the switch/sucrose nonfermentable (SWI/SNF) component ARID1A and its correlation with clinicopathological features and prognosis. METHODS: We sequenced the exomes of sporadic NF-pNETs. Quantitative real-time polymerase chain reaction and immunohistochemistry were used to determine messenger RNA level and protein expression. RESULTS: The sporadic NF-pNETs harbored 264 somatic mutations in 228 different genes, most commonly affecting the SWI/SNF components ARID1B (57.1%) and ARID1A (42.9%). The expression of ARID1A was remarkably downregulated in NF-pNETs and corresponding liver metastases compared with that in normal pancreatic islet tissue. Reduced expression of ARID1A was associated with malignant clinicopathological features (P &lt; 0.05). The loss of ARID1A was related to a high Ki-67 index (P &lt; 0.05). Patients with ARID1A-negative expression had a significantly worse overall survival rate than those with ARID1A-positive expression (P &lt; 0.05). The ARID1A status was an independent predictor of overall survival, and a nomogram integrating ARID1A with clinicopathological features was proposed. CONCLUSIONS: The loss of SWI/SNF components ARID1A may be associated with malignant behaviors and an unfavorable prognosis. Aberrations of ARID1A may contribute to tumorigenesis and metastasis in sporadic NF-pNETs.</p>
<p>doi: <a href="https://doi.org/10.1097/MPA.0000000000001535" class="uri">https://doi.org/10.1097/MPA.0000000000001535</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Efficacy of Recombinant Human-Soluble Thrombomodulin for Severe Acute Pancreatitis in a Rat Experimental Model</strong> </summary></p>
<p><em>Pancreas 2020 Apr;49(4):503-508</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=32282763" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=32282763</a></p>
<p>OBJECTIVES: Early death in severe acute pancreatitis (SAP) is caused by pancreatic necrosis and multiple-organ failure due to microcirculation disorder. The aim of this study was to prove that recombinant human-soluble thrombomodulin (rTM) has therapeutic effects on SAP by preventing pancreatic necrosis and organ failure. METHODS: Male Wister rats were used. Cerulein was administered intraperitoneally 4 times every 1 hour, and lipopolysaccharide was administered intraperitoneally 3 hours after. One hour after administration of lipopolysaccharide, rTM was injected intravenously. Rats were observed for 24 hours after starting the experiment, and the survival rate was evaluated. All surviving rats were killed, and the blood sample, liver, and pancreas were excised. Serum amylase, aspartate aminotransferase, alanine aminotransferase, and high mobility group box 1 were measured, and the liver and pancreas were examined histologically. For the evaluation of microcirculation, von Willebrand factor staining was performed. RESULTS: Serum amylase, aspartate aminotransferase, and alanine aminotransferase were significantly decreased. The survival rate was significantly improved to 100%. Moreover, serum high mobility group box 1 was decreased. Liver injury and pancreatic necrosis became less severe, and microcirculation was preserved histologically. CONCLUSIONS: Early administration of rTM prevents organ failure by maintenance of microcirculation and improves prognoses of SAP.</p>
<p>doi: <a href="https://doi.org/10.1097/MPA.0000000000001527" class="uri">https://doi.org/10.1097/MPA.0000000000001527</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Intraductal Tubulopapillary Neoplasm of the Pancreas and Bile Duct: A Review</strong> </summary></p>
<p><em>Pancreas 2020 Apr;49(4):498-502</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=32282762" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=32282762</a></p>
<p>Intraductal tubulopapillary neoplasms (ITPNs) of the pancreas and bile duct are contemporary entities. It is unclear on how to best manage patients with this diagnosis because little is known about its progression to cancer. This review provides an update on the current knowledge of ITPN of the pancreas and bile duct with an overview of clinical, radiological, histopathological, and molecular features, as well as the prognosis and management. Embase and Medline databases search were performed to identify studies that evaluated ITPN of the pancreas and bile duct. The infrequent exposure to this variant poses a diagnostic challenge. The diagnosis of ITPN is almost always made postoperatively because there are no characteristics on radiological studies to distinguish it from other cystic neoplasms of the pancreas. As ITPN has a favorable prognosis, it is crucial to establish an accurate diagnosis and differentiate it from other pancreatic and biliary variants. These neoplasms are considered to be precursor lesions to carcinomas, hence, surgery and close clinical surveillance are recommended. Further studies are essential to elucidate the natural history of ITPN, guide best treatment strategy and determine disease recurrence and survival.</p>
<p>doi: <a href="https://doi.org/10.1097/MPA.0000000000001518" class="uri">https://doi.org/10.1097/MPA.0000000000001518</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Roles of Autophagy and Pancreatic Secretory Trypsin Inhibitor in Trypsinogen Activation in Acute Pancreatitis</strong> </summary></p>
<p><em>Pancreas 2020 Apr;49(4):493-497</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=32282761" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=32282761</a></p>
<p>The focus of the review is on roles of autophagy and pancreatic secretory trypsin inhibitor (PSTI), an endogenous trypsin inhibitor, in trypsinogen activation in acute pancreatitis. Acute pancreatitis is a disease in which tissues in and around the pancreas are autodigested by pancreatic digestive enzymes. This reaction is triggered by the intrapancreatic activation of trypsinogen. Autophagy causes trypsinogen and cathepsin B, a trypsinogen activator, to colocalize within the autolysosomes. Consequently, if the resultant trypsin activity exceeds the inhibitory activity of PSTI, the pancreatic digestive enzymes are activated, and they cause autodigestion of the acinar cells. Thus, autophagy and PSTI play important roles in the development and suppression of acute pancreatitis, respectively.</p>
<p>doi: <a href="https://doi.org/10.1097/MPA.0000000000001519" class="uri">https://doi.org/10.1097/MPA.0000000000001519</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>DNA Flow Cytometric Analysis of Paraffin-Embedded Tissue for the Diagnosis of Malignancy in Bile Duct Biopsies</strong> </summary></p>
<p><em>Human pathology 2020 Apr;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=32272125" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=32272125</a></p>
<p>Differentiation of reactive versus neoplastic epithelial changes can be challenging in bile duct biopsies. The samples are often scant, distorted, and mixed with significant inflammation, ulceration, and/or debris. Histological confirmation of malignancy is often required before the initiation of surgical therapy, while an erroneous diagnosis of malignancy can lead to unnecessary clinical management. Aneuploidy assessment by DNA flow cytometry was performed on formalin-fixed paraffin-embedded (FFPE) tissue from 63 bile duct biopsies: 10 with a malignant diagnosis (7 adenocarcinoma and 3 at least high-grade dysplasia [HGD]); 3 with an “atypical” diagnosis showing rare atypical glands/cells, concerning but not definite for malignancy; 28 likely “reactive” biopsies with acute/chronic inflammation, ulceration, and/or mild nuclear atypia; and 22 additional benign biopsies without significant inflammation, ulceration, or nuclear atypia. Aneuploidy was detected in 7 (70%) of the 10 biopsies with definite neoplasia (5 of 7 adenocarcinoma and 2 of 3 at least HGD), all 3 (100%) “atypical” biopsies, and none of the 50 benign biopsies. All 3 “atypical” cases with aneuploidy were subsequently found to have adenocarcinoma (n = 2) or HGD (n = 1). Among the 2 cases of at least HGD with aneuploidy, 1 case developed adenocarcinoma, but no follow-up information was available in the other case. The remaining 1 case of at least HGD, despite having normal DNA content, was found to have adenocarcinoma on follow-up. None of the 50 benign cases (further supported by normal DNA content) developed adenocarcinoma within a mean follow-up time of 37 months (range: 0-282 months). The estimated sensitivity of aneuploidy as a diagnostic marker of malignancy (adenocarcinoma and HGD) was 70% with the specificity of 100%, positive predictive value of 100%, and negative predictive value of 94%. In conclusion, DNA flow cytometry using FFPE tissue from bile duct biopsies demonstrates a high rate of aneuploidy (70%) in malignant cases, and normal DNA content in all benign biopsies. Although the sample size is small, the results indicate that this assay can be potentially useful in challenging “atypical” cases, where morphological evaluation is limited by scarcity of atypical glands/cells, inflammation, and/or ulceration.</p>
<p>doi: <a href="https://doi.org/10.1016/j.humpath.2020.04.002" class="uri">https://doi.org/10.1016/j.humpath.2020.04.002</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>A 15-gene immune, stromal and proliferation gene signature that significantly associates with poor survival in patients with pancreatic ductal adenocarcinoma</strong> </summary></p>
<p><em>Clinical cancer research : an official journal of the American Association for Cancer Research 2020 Mar;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=32234757" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=32234757</a></p>
<p>PURPOSE: Pancreatic ductal adenocarcinoma (PDAC) is a lethal disease with dismal survival rates. Tumor microenvironment (TME), comprising of immune cells and cancer-associated fibroblasts, plays a key role in driving poor prognosis and resistance to chemotherapy. Herein, we aimed to identify a TME-associated, risk-stratification gene biomarker signature in PDAC. EXPERIMENTAL DESIGN: The initial biomarker discovery was performed in The Cancer Genome Atlas (TCGA, n=163) transcriptomic data. This was followed by independent validation of the gene signature in The International Cancer Genome Consortium (ICGC, n=95), E-MTAB-6134 (n=288), and GSE71729 (n=123) datasets for predicting overall survival (OS), and for its ability to detect poor molecular subtypes. Clinical validation and nomogram establishment was undertaken by performing multivariate cox regression analysis. RESULTS: Our biomarker discovery effort identified a 15-gene immune, stromal and proliferation (ISP) gene signature that significantly associated with poor OS (HR: 3.90, 95% CI, 2.36-6.41, p&lt;0.0001). This signature also robustly predicted survival in 3 independent validation cohorts ICGC (HR:2.63 [1.56-4.41], p&lt;0.0001), E-MTAB-6134 (HR:1.53 [1.14-2.04], p=0.004), and GSE71729 (HR:2.33 [1.49-3.63], p&lt;0.0001). Interestingly, the ISP signature also permitted identification of poor molecular PDAC subtypes with excellent accuracy in all 4 cohorts; TCGA (AUC=0.94), ICGC (AUC=0.91), E-MTAB-6134 (AUC=0.80), and GSE71729 (AUC=0.83). The ISP-derived high-risk patients exhibited significantly poor OS in a clinical validation cohort (n=119; HR:2.62 [1.50-4.56], p=0.0004). A nomogram was established which included the ISP, CA19-9, T and N-stage for eventual clinical translation. CONCLUSIONS: We report a novel gene signature for risk-stratification and robust identification of PDAC patients with poor molecular subtypes.</p>
<p>doi: <a href="https://doi.org/10.1158/1078-0432.CCR-19-4044" class="uri">https://doi.org/10.1158/1078-0432.CCR-19-4044</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Primary biliary adenosarcoma of the liver-a special and new entity</strong> </summary></p>
<p><em>Virchows Archiv : an international journal of pathology 2020 Mar;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=32219513" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=32219513</a></p>
<p>Primary sarcoma of the liver (PSL) is a rare entity accounting for less than 1% of all liver cancers, with unknown aetiology. Several subtypes have been recognized, with histology playing an essential role in patient tailoring and management. We are about to report a case of an unusual PSL, with peculiar morphologic and immunohistochemical properties. A 65-year-old female with a multicystic hepatic lesion underwent surgery due to spontaneous rupture. Pathology revealed dilated bile duct-like structures lined by benign cuboidal/columnar epithelium surrounded by neoplastic proliferation of spindle and epithelioid cells with interspersed osteoclast-like multinucleated giant cells, loosely arranged in a storiform pattern, positive for CD10. The conjugation of morphology and immunohistochemistry results provided the diagnosis of primary biliary adenosarcoma of the liver, biliary type. The patient experienced tumour relapse and died of disease 2 years and 7 months later.</p>
<p>doi: <a href="https://doi.org/10.1007/s00428-020-02783-y" class="uri">https://doi.org/10.1007/s00428-020-02783-y</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Expression Patterns and Prognostic Value of DNA Damage Repair Proteins in Resected Pancreatic Neuroendocrine Neoplasms</strong> </summary></p>
<p><em>Annals of surgery 2020 Mar;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=32209898" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=32209898</a></p>
<p>OBJECTIVE: This study aimed to examine the expression profiles and prognostic value of multiple DDR proteins in resected PanNENs. BACKGROUND: DDR proteins play important roles in various cancers, including pancreatic ductal adenocarcinoma. However, the expression patterns and prognostic value of DDR proteins in PanNENs remain unclear. METHODS: This retrospective analysis included PanNEN patients who underwent resection at the Fudan University Shanghai Cancer Center from 2012 to 2018. Immunohistochemical staining was performed for 12 DDR proteins in tissue microarrays. The associations of DDR protein expression and clinicopathological features with recurrence-free survival (RFS) were examined via a Cox regression model and random survival forest. A recurrence signature was constructed using recursive partitioning analysis. RESULTS: In total, 131 PanNEN patients were included, with 32 (24.4%) cases of recurrence. Among the 12 DDR proteins, low checkpoint kinase 2 (CHK2) expression (P = 0.020) and loss of ataxia-telangiectasia-mutated (ATM) (P = 0.0007) significantly correlated with recurrence. Multivariable Cox regression analysis identified tumor size ≥3 cm, lymph node (LN) metastasis, high tumor grade, low CHK2 expression, and ATM loss as independent risk factors for recurrence. A recurrence signature was established based on the importance of recurrence-specific risk factors; patients with the LNnegTumorSize&lt;3cm signature had a 5-year RFS rate of 96.8%, whereas patients with the LNposCHK2low signature had the worst 5-year RFS rate (0%). Discrimination (concordance index: 0.770) and calibration plots indicated that the recurrence signature had a good ability to identify patients at risk for recurrence. CONCLUSIONS: By analyzing large-scale tissue microarrays of PanNENs, we evaluated 12 DDR protein expression profiles. We developed a recurrence signature that can identify distinct subpopulations according to RFS, which may help refine individual follow-up.</p>
<p>doi: <a href="https://doi.org/10.1097/SLA.0000000000003884" class="uri">https://doi.org/10.1097/SLA.0000000000003884</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>DETECTION OF CIRCULATING TUMOR DNA IN PATIENTS WITH PANCREATIC CANCER USING DIGITAL NEXT-GENERATION SEQUENCING</strong> </summary></p>
<p><em>The Journal of molecular diagnostics : JMD 2020 Mar;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=32205290" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=32205290</a></p>
<p>Circulating tumor DNA (ctDNA) measurements can be used to estimate tumor burden, but avoiding false-positives is a challenge. We evaluated digital next-generation sequencing (NGS) as a ctDNA detection method. Plasma KRAS and GNAS hotspot mutation levels were measured in 140 subjects including 67 with pancreatic ductal adenocarcinoma, and 73 healthy and disease controls. To limit chemical modifications of DNA that yield false-positive mutation calls, plasma DNA was enzymatically pre-treated, after which DNA was aliquoted for digital detection of mutations (up to 384 aliquots/sample) by PCR and NGS. A digital NGS score of two standard deviations above the mean in controls was considered positive. 37% of patients with pancreatic cancer, including 31% of patients with Stage I/II disease had positive KRAS codon 12 ctDNA scores; only one patient had a positive GNAS mutation score. Two disease control patients had positive ctDNA scores. Low normal-range digital NGS scores at mutation hot-spots were found at similar levels in healthy and disease controls, usually at sites of cytosine deamination, and were likely the result of chemical modification of plasma DNA and NGS error, rather than true mutations. Digital NGS detects mutated ctDNA in patients with pancreatic cancer with similar yield to other methods. The detection of low-level, true-positive ctDNA is limited by frequent low-level detection of false-positive mutation cells in plasma DNA from controls.</p>
<p>doi: <a href="https://doi.org/10.1016/j.jmoldx.2020.02.010" class="uri">https://doi.org/10.1016/j.jmoldx.2020.02.010</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Validation of the T category for distal cholangiocarcinoma: Measuring the depth of invasion is complex but correlates with survival</strong> </summary></p>
<p><em>Annals of diagnostic pathology 2020 Mar;46():151489</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=32169826" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=32169826</a></p>
<p>According to the current 8th edition of the American Joint Committee of Cancer (AJCC), the T category of distal cholangiocarcinomas is classified based on the depth of invasion (DOI) (T1, &lt; 5 mm; T2, between 5 and 12 mm; T3, &gt; 12 mm). In consideration of the discrepancies between previous studies about the prognostic significance, we aimed to validate the current AJCC T staging system of distal cholangiocarcinomas. DOI was measured using three different methods: DOI1, DOI2, and DOI3. DOI1 was defined and stratified according to the AJCC 8th edition. DOI2 was measured as the distance from an imaginary curved line approximated along the distorted mucosal surface to the deepest invasive tumor cells. DOI3 was defined as the total tumor thickness. DOI2 and DOI3 were also divided into three categories using the same cut-off points as in the AJCC 8th edition. We compared these three DOI methods to the AJCC 7th edition as well. In contrast with the AJCC 7th edition, all three groups showed a correlation with patients’ overall survival. Above all, the DOI2 group demonstrated the best significance in multivariate analysis. However, when the C indices were compared between these groups, differential significance proved to be negligible (DOI1 vs DOI2, p = 0.915; DOI2 vs DOI3, p = 0.057). Therefore, the measurement of DOI does not need to be rigorously and stringently performed. In conclusion, we showed that the current T classification system better correlates with the overall survival of patients with distal cholangiocarcinomas than the previous system.</p>
<p>doi: <a href="https://doi.org/10.1016/j.anndiagpath.2020.151489" class="uri">https://doi.org/10.1016/j.anndiagpath.2020.151489</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>GATA6 expression distinguishes classical and basal-like subtypes in advanced pancreatic cancer</strong> </summary></p>
<p><em>Clinical cancer research : an official journal of the American Association for Cancer Research 2020 Mar;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=32156747" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=32156747</a></p>
<p>PURPOSE: To determine the impact of basal-like and classical subtypes in advanced PDAC and to explore GATA6 expression as a surrogate biomarker. EXPERIMENTAL DESIGN: Within the COMPASS trial patients proceeding to chemotherapy for advanced PDAC undergo tumour biopsy for RNA sequencing. Overall response rate (ORR) and overall survival (OS) were stratified by subtypes and according to chemotherapy received. Correlation of GATA6 with the subtypes using gene expression profiling, in situ hybridization (ISH) were explored. RESULTS: Between December 2015-May 2019, 195 patients (95%) had enough tissue for RNA sequencing; 39 (20%) were classified as basal-like and 156 (80%) as classical. RECIST response data were available for 157 patients; 29 basal-like and 128 classical where the ORR was 10% vs. 33% respectively (p=0.02). In patients with basal-like tumours treated with modified FOLFIRINOX (mFFX) (n=22) the progression rate was 60% compared to 15% in classical PDAC (p= 0.0002). Median OS in the intention to treat population (n=195) was 9.3 months for classical vs. 5.9 months for basal-like PDAC (HR 0.47 95% CI 0.32-0.69, p=0.0001). GATA6 expression by RNAseq highly correlated with the classifier (p&lt;0.001) and ISH predicted the subtypes with sensitivity of 89% and specificity of 83%. In a multivariable analysis, GATA6 expression was prognostic (p=0.02). In exploratory analyses, basal-like tumours, could be identified by keratin 5, were more hypoxic and enriched for a T cell inflamed gene expression signature. CONCLUSIONS: The basal-like subtype is chemoresistant and can be distinguished from classical PDAC by GATA6 expression.</p>
<p>doi: <a href="https://doi.org/10.1158/1078-0432.CCR-19-3724" class="uri">https://doi.org/10.1158/1078-0432.CCR-19-3724</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Validation and modification of staging Systems for Poorly Differentiated Pancreatic Neuroendocrine Carcinoma</strong> </summary></p>
<p><em>BMC cancer 2020 Mar;20(1):188</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=32138704" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=32138704</a></p>
<p>BACKGROUND: The American Joint Committee on Cancer (AJCC) and the European Neuroendocrine Tumor Society (ENETS) staging classifications are two broadly used systems for pancreatic neuroendocrine tumors. This study aims to identify the most accurate and useful tumor-node-metastasis (TNM) staging system for poorly differentiated pancreatic neuroendocrine carcinomas (pNECs). METHODS: An analysis was performed to evaluate the application of the ENETS, 7th edition (7th) AJCC and 8th edition (8th) AJCC staging classifications using the Surveillance, Epidemiology, and End Results (SEER) registry (N = 568 patients), and a modified system based on the analysis of the 7th AJCC classification was proposed. RESULTS: In multivariable analyses, only the 7th AJCC staging system allocated patients into four different risk groups, although there was no significant difference. We modified the staging classification by maintaining the T and M definitions of the 7th AJCC staging and adopting new staging definitions. An increased hazard ratio (HR) of death was also observed from class I to class IV for the modified 7th (m7th) staging system (compared with stage I disease; HR for stage II =1.23, 95% confidence interval (CI) = 0.73-2.06, P = 0.44; HR for stage III =2.20, 95% CI =1.06-4.56, P = 0.03; HR for stage IV =4.95, 95% CI =3.20-7.65, P &lt; 0.001). The concordance index (C-index) was higher for local disease with the m7th AJCC staging system than with the 7th AJCC staging system. CONCLUSIONS: The m7th AJCC staging system for pNECs proposed in this study provides improvements and may be assessed for potential adoption in the next edition.</p>
<p>doi: <a href="https://doi.org/10.1186/s12885-020-6634-9" class="uri">https://doi.org/10.1186/s12885-020-6634-9</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Global trends in intrahepatic and extrahepatic cholangiocarcinoma incidence from 1993 to 2012</strong> </summary></p>
<p><em>Cancer 2020 Mar;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=32129902" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=32129902</a></p>
<p>BACKGROUND: Intrahepatic cholangiocarcinomas (ICCs) and extrahepatic cholangiocarcinomas (ECCs) are highly lethal bile duct tumors. Their incidence can be difficult to estimate because of changes in cancer coding over time. No studies to date have examined their global incidence and trends with high-quality topography- and histology-specific cancer registry data. Therefore, this study examined ICC and ECC incidence with the Cancer Incidence in Five Continents Plus database. METHODS: Regional and national cancer registry data were used to estimate age-standardized incidence rates (ASRs) per 100,000 person-years, 95% confidence intervals, and average annual percent changes (AAPCs) for ICC in 38 countries and for ECC in 33 countries from 1993 to 2012. ICC and ECC trends were tabulated and plotted by country. Rates versus birth cohort by age were plotted, and an age-period-cohort analysis was performed to assess age and cohort incidence rate ratios. RESULTS: The highest rates of ICC and ECC were in Asia, specifically South Korea (ASR for ICC, 2.80; ASR for ECC, 2.24), Thailand (ASR for ICC, 2.19; ASR for ECC, 0.71), and Japan (ASR for ICC, 0.95; ASR for ECC, 0.83). Between 1993 and 2012, incidence rates of both ICC and ECC increased in most countries. The largest ASR increases over the study period occurred in Latvia (AAPC, 20.1%) and China (AAPC, 11.1%) for ICC and in Thailand (AAPC, 8.8%) and Colombia (AAPC, 8.5%) for ECC. CONCLUSIONS: In the 20 years examined, ICC and ECC incidence increased in the majority of countries worldwide. ICC and ECC incidence may continue to increase because of metabolic and infectious etiologic factors. Efforts to further elucidate risk factors contributing to these increases in incidence are warranted.</p>
<p>doi: <a href="https://doi.org/10.1002/cncr.32803" class="uri">https://doi.org/10.1002/cncr.32803</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>INSM1 Is a Highly Specific Marker of Neuroendocrine Differentiation in Primary Neoplasms of the Gastrointestinal Tract, Appendix, and Pancreas</strong> </summary></p>
<p><em>American journal of clinical pathology 2020 Mar;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=32128564" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=32128564</a></p>
<p>OBJECTIVES: INSM1 has been described as a sensitive and specific neuroendocrine marker. This study aims to compare INSM1 with traditional neuroendocrine markers in gastrointestinal neuroendocrine neoplasms. METHODS: Retrospective review (2008-2018) was used to retrieve paraffin-embedded tissue from 110 gastrointestinal neuroendocrine neoplasms and controls that was subsequently stained with INSM1, synaptophysin, chromogranin, CD56, and Ki-67. RESULTS: INSM1 was positive in 16 of 17 (94.1%) gastric, 17 of 18 (94.4%) pancreatic, 13 of 18 (72.2%) small bowel, 17 of 21 (81.0%) colonic, and 26 of 36 (72.2%) appendiceal tumors. INSM1 was positive in 58 of 70 (82.9%) well-differentiated neuroendocrine tumors, 17 of 20 (85.0%) poorly differentiated neuroendocrine carcinomas, 8 of 11 (72.7%) low-grade goblet cell adenocarcinomas (grade 1), and 6 of 9 (66.7%) high-grade goblet cell adenocarcinomas (grade 2/3). INSM1 sensitivity for neuroendocrine neoplasms (80.9%) was less than that of synaptophysin (99.1%), chromogranin (88%), and CD56 (95.3%); specificity was higher (95.7% vs 86.0%, 87.3%, and 86.0%, respectively). CONCLUSIONS: INSM1 is a useful marker of neuroendocrine differentiation in gastrointestinal neuroendocrine and mixed neuroendocrine neoplasms. Compared with traditional neuroendocrine markers, INSM1 is less sensitive but more specific.</p>
<p>doi: <a href="https://doi.org/10.1093/ajcp/aqaa014" class="uri">https://doi.org/10.1093/ajcp/aqaa014</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Global, regional and national burden of pancreatic cancer, 1990 to 2017: Results from the Global Burden of Disease Study 2017</strong> </summary></p>
<p><em>Pancreatology : official journal of the International Association of Pancreatology (IAP) … [et al.] 2020 Apr;20(3):462-469</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=32113937" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=32113937</a></p>
<p>BACKGROUND: The global burden of pancreatic cancer (PCa) continues to grow. Detailed data on PCa epidemiology are essential for policy-making and appropriate healthcare resource allocation. METHODS: Estimates of incidence, death and disability-adjusted life years (DALYs) of PCa from 1990 to 2017 were collected from the Global Burden of Disease Study 2017. Decomposition analysis was conducted to detect the contributing factors related to PCa incidence variation. The estimated annual percentage change (EAPC) was calculated to quantify the PCa epidemiology trends over a specified interval. RESULTS: Globally, the incidence of PCa cases increased by 129.1% to 447 664 664 (95% uncertainty interval (UI) 438 597-456 295), death increased by 125.2% to 441 082 082 (95% UI 448 960-432 833), and DALYs increased by 107.3% to 9 080 004 (95% UI 8 894 128-9 256 346) between 1990 and 2017. Relatively higher sociodemographic index (SDI) regions were observed with greater incidences, more deaths and a greater number of DALYs of PCa, but relatively lower SDI regions experienced a sharply increasing trend in these measures. Decomposition analysis indicated that the global increase in PCa incidence was driven by the aging population from 2007 to 2017, especially in higher SDI regions. In addition, a significant negative correlation was found between EAPC and ASIR (in 1990) (r = -0.56, P &lt; 0.001). CONCLUSIONS: PCa remains a major public health burden globally. The unfavorable trend in PCa suggesting that further study for prevention should be conducted to forestall the increase in pancreatic cancer.</p>
<p>doi: <a href="https://doi.org/10.1016/j.pan.2020.02.011" class="uri">https://doi.org/10.1016/j.pan.2020.02.011</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>TRAIL receptors are differentially regulated and clinically significant in gallbladder cancer</strong> </summary></p>
<p><em>Pathology 2020 Apr;52(3):348-358</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=32111400" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=32111400</a></p>
<p>Deregulation of the receptors of TNF-related apoptosis inducing ligand (TRAIL) has been reported in various cancers. In an effort to define the role of these receptors we profiled their expression in gallbladder cancer (GBC) and explored their clinical significance. Expression of TRAIL receptors’ mRNA in GBC was analysed through reverse transcriptase polymerase chain reaction (RT-PCR), and protein through western blotting, immunohistochemistry and enzyme-linked immunosorbent assay (ELISA). mRNA data show frequent higher expression of TRAIL receptors in GBC samples. Death receptors DR4 and DR5 showed significant negative correlation with tumour stage, T stage and tumour grade; DcR1 transcript showed positive correlation with tumour stage, N stage, M stage and tumour grade. Similarly, IHC showed frequent positive staining for DR4, DR5 and DcR1in GBC samples. Cytoplasmic and nuclear DR4 protein showed negative correlation with T stage and tumour grade, whereas cytoplasmic DcR1 protein showed positive correlation with tumour stage and N stage. Nuclear DcR1 showed positive correlation with N stage. ELISA results showed significantly higher expression of secretory DcR1 in GBC patients. Kaplan-Meier analysis demonstrated significantly decreased mean survival of patients with positive staining of cytoplasmic DcR1. High level of death receptors identified the patients with early gallbladder cancer, whereas high DcR1 expression served as a prognostic factor for poor outcome.</p>
<p>doi: <a href="https://doi.org/10.1016/j.pathol.2019.12.001" class="uri">https://doi.org/10.1016/j.pathol.2019.12.001</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Pancreatic acinar cell carcinomas and mixed acinar-neuroendocrine carcinomas are more clinically aggressive than grade 1 pancreatic neuroendocrine tumours</strong> </summary></p>
<p><em>Pathology 2020 Apr;52(3):336-347</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=32111396" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=32111396</a></p>
<p>Acinar cell carcinomas (ACCs) and mixed acinar-neuroendocrine carcinomas (MAcNECs) of the pancreas are extremely rare carcinomas with a significant component with acinar differentiation. To date, the clinicopathological behaviours of these neoplasms remain unclear. In this study, we evaluated the histopathological and molecular characteristics of 20 ACCs and 13 MAcNECs and compared them to a cohort of 269 well-differentiated pancreatic neuroendocrine tumours (PanNETs). Compared to PanNETs, both ACCs and MAcNECs had an advanced pT classification (p&lt;0.001), as well as more prevalent lymphovascular and perineural invasion (p=0.002) and lymph node and distant metastases (p&lt;0.001). Patients with MAcNECs had worse overall (p&lt;0.001) and recurrence-free survival (p&lt;0.001) than those with PanNETs, but no significant difference with those with ACCs. Subgroup analyses revealed that patients with ACCs and MAcNECs had significantly worse recurrence-free survival than those with grade 1 PanNET (p&lt;0.001), and patients with MAcNECs also had worse overall survival than those with grade 1 and 2 PanNETs (p&lt;0.001, and p=0.001). ACCs presented more commonly with intraductal growth (p=0.014) than MAcNECs, while MAcNECs more often had lymph node metastasis (p=0.012) than ACCs. The telomere maintenance mechanism Alternative Lengthening of Telomeres (ALT) was assessed by telomere-specific FISH, and ALT was detected in 1 of 20 ACCs and in three of the 13 MAcNECs. Patients with MAcNECs and ACCs had worse survival and more aggressive behaviour than those with grade 1 PanNETs; thus, the clinicopathological behaviour of MAcNECs resembles ACCs rather than PanNETs. Combined neuroendocrine and acinar cell immunohistochemical markers are helpful for differentiating these different tumour types.</p>
<p>doi: <a href="https://doi.org/10.1016/j.pathol.2020.01.437" class="uri">https://doi.org/10.1016/j.pathol.2020.01.437</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>MMR Deficiency is Homogeneous in Pancreatic Carcinoma and Associated with High Density of Cd8-Positive Lymphocytes</strong> </summary></p>
<p><em>Annals of surgical oncology 2020 Feb;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=32108923" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=32108923</a></p>
<p>BACKGROUND: Microsatellite instability (MSI) has emerged as a predictive biomarker for immune checkpoint inhibitor therapy. Cancer heterogeneity represents a potential obstacle for the analysis of predicitive biomarkers. MSI has been reported in pancreatic cancer, but data on the possible extent of intratumoral heterogeneity are lacking. METHODS: To study MSI heterogeneity in pancreatic cancer, a tissue microarray (TMA) comprising 597 tumors was screened by immunohistochemistry with antibodies for the mismatch repair (MMR) proteins MLH1, PMS2, MSH2, and MSH6. RESULTS: In six suspicious cases, large section immunohistochemistry and microsatellite analysis (Bethesda panel) resulted in the identification of 4 (0.8%) validated MSI cases out of 480 interpretable pancreatic ductal adenocarcinomas. MSI was absent in 55 adenocarcinomas of the ampulla of Vater and 7 acinar cell carcinomas. MMR deficiency always involved MSH6 loss, in three cases with additional loss of MSH2 expression. Three cancers were MSI-high and one case with isolated MSH6 loss was MSS in PCR analysis. The analysis of 44 cancer-containing tumor blocks revealed that the loss of MMR protein expression was always homogeneous in affected tumors. Automated digital image analysis of CD8 immunostaining demonstrated markedly higher CD8 + tumor infiltrating lymphocytes in tumors with (mean = 685, median = 626) than without (mean = 227; median = 124) MMR deficiency (p &lt; 0.0001), suggesting a role of MSI for immune response. CONCLUSIONS: Our data suggest that MSI occurs early in a small subset of ductal adenocarcinomas of the pancreas and that immunohistochemical MMR analysis on limited biopsy or cytology material may be sufficient to estimate MMR status of the entire cancer mass.</p>
<p>doi: <a href="https://doi.org/10.1245/s10434-020-08209-y" class="uri">https://doi.org/10.1245/s10434-020-08209-y</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Intraductal papillary neoplasms of the bile duct consist of two distinct types specifically associated with clinicopathological features and molecular phenotypes</strong> </summary></p>
<p><em>The Journal of pathology 2020 Feb;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=32100878" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=32100878</a></p>
<p>Intraductal papillary neoplasm of the bile duct (IPNB) is a grossly visible papillary biliary neoplasm with morphological variations and occasional invasion. Recently a new classification of IPNB into type 1 and type 2 was proposed in which the type 1 IPNBs consist of fine papillary neoplastic glands and the type 2 IPNBs consist of complex branching glands, seldom with foci of solid-tubular components. However, clinicopathological and molecular characteristics of these types of IPNBs are yet to be identified. We aimed to uncover clinicopathological and molecular characteristics of the types of IPNBs. Thirty-six IPNBs were studied retrospectively. Clinicopathological features as well as molecular alterations of 31 genes were evaluated by means of targeted next-generation sequencing and immunohistochemical examination of expression of mucin and cancer-associated molecules. The 36 IPNBs were classified into 22 of type 1 and 14 of type 2. The type 1 IPNBs were associated with a non-invasive phenotype, intestinal and oncocytic subtypes, development in the intrahepatic bile duct, overt mucin production, and a relatively good prognosis. The type 2 IPNBs were associated with an invasive phenotype, the pancreatobiliary subtype, development within the extrahepatic bile duct, and worse prognosis compared with the type 1 IPNBs. In the molecular analysis, recurrent mutations were found in TP53 (34.3%), KRAS (31.4%), STK11 (25.7%), CTNNB1 (17.1%), APC (14.3%), SMAD4 (14.3%), GNAS (11.4%), PBRM1 (11.4%), ELF3 (8.6%), KMT2C (8.6%), NF1 (8.6%), PIK3CA (8.6%), ARID1A (5.7%), ARID2 (5.7%), BAP1 (5.7%), BRAF (5.7%), EPHA6 (5.7%), ERBB2 (5.7%), ERBB3 (5.7%), KMT2D (5.7%), and RNF43 (5.7%). Mutations in KRAS and GNAS were enriched in the type 1 IPNBs, whereas mutations in TP53, SMAD4, and KMT2C were enriched in the type 2 IPNBs. These results indicate that IPNBs consist of two distinct types of neoplasms specifically associated with clinicopathological features and molecular phenotypes. © 2020 Pathological Society of Great Britain and Ireland. Published by John Wiley &amp; Sons, Ltd.</p>
<p>doi: <a href="https://doi.org/10.1002/path.5398" class="uri">https://doi.org/10.1002/path.5398</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Tumor-Insular Complex in Neoadjuvant Treated Pancreatic Ductal Adenocarcinoma Is Associated With Higher Residual Tumor</strong> </summary></p>
<p><em>The American journal of surgical pathology 2020 Feb;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=32091434" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=32091434</a></p>
<p>The tumor microenvironment in pancreatic ductal adenocarcinoma (PDAC) plays a vital role in treatment response, and therefore, patient survival. We and others have observed an intimate association of neoplastic ductal cells with non-neoplastic islet cells, recapitulating the ductoinsular complex. We define this phenomenon as tumor-insular complex (TIC). Herein, we describe the clinicopathologic characteristics of TIC in neoadjuvant treated PDAC cases for the first time. We retrospectively reviewed the pathology of 105 cases of neoadjuvant treated PDAC resected at our institution. TIC was noted in 35 cases (33.3%), the mean tumor bed size was 2.7±1.0 cm, mean percentage of residual tumor 40±28% and mean Residual Tumor Index (RTI) (an index previously established as a prognostic parameter by our group) was 1.1±1.0. TIC was significantly associated with perineural invasion (P=0.001), higher tumor bed size (P=0.007), percentage of residual tumor (P=0.009), RTI (P=0.001), ypT stage (P=0.045), and poor treatment response, grouped by a previously established criteria (P=0.010). Using our prior binary reported prognostic cutoff for RTI of ≤0.35 and &gt;0.35, TIC was associated with a RTI &gt;0.35 (P=0.002). Moreover, patients who did not receive neoadjuvant radiation were associated with a higher frequency of TIC (P=0.003). In this cohort, RTI but not TIC was also shown to be a significant independent prognosticator for recurrence-free survival and overall survival on multivariate analysis. In conclusion, TIC is significantly associated with a more aggressive neoplasm which shows a poor treatment response. Further studies will be needed to better understand the tumor biology of TICs.</p>
<p>doi: <a href="https://doi.org/10.1097/PAS.0000000000001454" class="uri">https://doi.org/10.1097/PAS.0000000000001454</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Clinical Significance of CBS and CCL21 in Gallbladder Adenocarcinomas and Squamous Cell/Adenosquamous Carcinomas</strong> </summary></p>
<p><em>Applied immunohistochemistry &amp; molecular morphology : AIMM 2020 02;28(2):103-110</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=32044878" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=32044878</a></p>
<p>Gallbladder cancer (GBC) is a rare disease with high mortality. However, no biomarkers for the carcinogenesis, progression, prognosis, and early diagnosis are clinically available. This study investigated the expressions of cystathionine-β-synthase (CBS) and C-C chemokine receptor 7 (CCR7) protein and their clinical and pathologic significances in gallbladder squamous cell/adenosquamous carcinomas (SC/ASC) and adenocarcinomas (AC). CBS and chemokine ligand 21 (CCL21) expression was measured using immunohistochemistry in 69 SC/ASCs and 146 ACs. A significantly high percentage of patients with an age above 45 years, lymph node metastasis, and invasion was observed in the SCs/ASCs compared with ACs (P&lt;0.05). Both AC and SC/ASC patients with positive CBS and CCL21 expression exhibited a high tumor-lymph node-metastasis stage, lymph node metastasis, and invasion compared with patients with negative CBS and CCL21 expression (P&lt;0.05 or P&lt;0.01). SC/ASC patients with positive CBS expression was prone to have a larger tumor size than those with negative expression (P&lt;0.05). Positive CBS and CCL21 expression correlated with poor differentiation and larger tumor size in AC patients. Positive CBS and CCL21 are closely associated with a decreased overall survival in SC/ASC and AC patients (P&lt;0.05 or P&lt;0.01) and were independent factors for a poor-prognosis. Both CBS and CCL21 showed a good overall diagnostic performance for SC/ASC (AUC=0.742 and AUC=0.764, respectively) and AC (AUC=0.734 and AUC=0.718, respectively). In conclusion, positive CBS and CCL21 expression are closely associated with the clinical severity and poor prognosis in GBC, and can be a marker for the diagnosis of AC and SC/ASC type of GBC.</p>
<p>doi: <a href="https://doi.org/10.1097/PAI.0000000000000705" class="uri">https://doi.org/10.1097/PAI.0000000000000705</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Germline alterations in patients with biliary tract cancers: A spectrum of significant and previously underappreciated findings</strong> </summary></p>
<p><em>Cancer 2020 Jan;126(9):1995-2002</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=32012241" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=32012241</a></p>
<p>BACKGROUND: With limited information on germline mutations in biliary tract cancers, this study performed somatic and germline testing for patients at Memorial Sloan Kettering Cancer Center with known biliary tract carcinoma with the aim of determining the frequency and range of pathogenic germline alterations (PGAs). METHODS: Patients with biliary tract carcinoma were consented for somatic tumor and matched blood testing of up to 468 genes via the Memorial Sloan Kettering Cancer Center Integrated Mutation Profiling of Actionable Cancer Targets next-generation sequencing platform. A germline variant analysis was performed on a panel of up to 88 genes associated with an increased predisposition for cancer. Demographic and diagnostic details were collected. RESULTS: Germline mutations were tested in 131 patients. Intrahepatic cholangiocarcinoma was the most common cancer (63.4%), and it was followed by gallbladder adenocarcinoma (16.8%), extrahepatic cholangiocarcinoma (16%), and otherwise unspecified biliary tract cancer (3.8%). Known and likely PGAs were present in 21 patients (16.0%), with 9.9% harboring a PGA in a high/moderate-penetrance cancer predisposition gene. Among high-penetrance cancer susceptibility genes, PGAs were most commonly observed in BRCA1 and BRCA2 (33.3%), which made up 5.3% of the entire cohort, and they were followed by PALB2, BAP1, and PMS2. Mutations in ATM, MITF, and NBN, moderate-penetrance cancer susceptibility genes, were identified in 1 patient each. There was no observed difference in the types of mutations among the subtypes of biliary tract cancer. CONCLUSIONS: The frequency of PGAs found was comparable to existing data on the prevalence of germline mutations in other solid tumor types with matched tumor analysis. This provides support for the role of the BRCA1/2, ATM, and BAP1 genes in biliary tract cancer susceptibility.</p>
<p>doi: <a href="https://doi.org/10.1002/cncr.32740" class="uri">https://doi.org/10.1002/cncr.32740</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Smooth Muscle Distribution Patterns of Choledochal Cysts and Their Implications for Pathogenesis and Postoperative Complications</strong> </summary></p>
<p><em>American journal of clinical pathology 2020 Feb;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=32010932" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=32010932</a></p>
<p>OBJECTIVES: Histopathologic characteristics of choledochal cysts and their clinical implications have not been previously comprehensively studied. METHODS: Smooth muscle distribution patterns and other histologic findings (inflammation, metaplasia, dysplasia, and heterotopia) in 233 surgically resected choledochal cysts were evaluated. RESULTS: Mean patient age was 23.3 ± 19.8 years, with male:female ratio of 0.3. Most cases were Todani type I (175 cases, 75.1%) or IVa (56 cases, 24.1%). Choledochal cysts with thin scattered/no muscle fiber (175 cases, 75.1%) were the predominant pattern and were associated with more frequent postoperative biliary stricture (P = .031), less frequent pyloric metaplasia (P = .016), and mucosal smooth muscle aggregates (P &lt; .001) compared to cysts with thick muscle bundles. Severe chronic cholangitis (P = .049), pyloric metaplasia (P = .019), mucosal smooth muscle aggregates (P &lt; .001), biliary intraepithelial neoplasia (P = .021), and associated bile duct (P = .021) and gallbladder carcinomas (P = .03) were more common in adults (age &gt;20 years vs ≤20 years), suggesting that chronic irritation in association with developmental anomalies involves tumorigenesis from choledochal cysts. CONCLUSION: Smooth muscle distribution pattern of choledochal cyst may predict postoperative complication, raising clinical implications of smooth muscle patterns in postoperative management of choledochal cysts.</p>
<p>doi: <a href="https://doi.org/10.1093/ajcp/aqaa002" class="uri">https://doi.org/10.1093/ajcp/aqaa002</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Innervation of the proximal human biliary tree</strong> </summary></p>
<p><em>Virchows Archiv : an international journal of pathology 2020 Jan;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31993770" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31993770</a></p>
<p>The autonomic nervous system plays a role in a variety of liver regenerative and metabolic functions, including modulating bile secretion and cholangiocyte and hepatobiliary progenitors of the canals of Hering. However, the nature and location of nerves which link to the proximal biliary tree have remained uncertain. We investigate the anatomic relationship of nerves to the proximal biliary tree including the putative stem/progenitor cell niche of the canal of Hering. Using double immunostaining (fluorescence, histochemistry) to highlight markers of cholangiocytes (biliary-type keratins), nerves (S100, neurofilament protein, PGP9.5, tyrosine hydroxylase), and stellate cells (CRBP-1), we examined sections from normal adult livers from autopsy or surgical resections. There is extensive contact between nerves and interlobular bile ducts, bile ductules, and canals of Hering (CoH). In multiple serial sections from 4 normal livers, biliary-nerve contacts were seen in all of these structures and were more common in the interlobular bile ducts (78/137; 57%) than in the ductules and CoH (95/294; 33%) (p &lt; 0.001). Contacts appear to consist of nerves in juxtaposition to the biliary basement membrane, though crossing through basement membrane to interface directly with cholangiocytes is also present. These nerves are positive for tyrosine hydroxylase and are, thus, predominately adrenergic. Electron microscopy confirms nerves closely approximating ductules. Nerve fiber-hepatic stellate cell juxtaposition is observed but without stellate cell approximation to cholangiocytes. We present novel findings of biliary innervation, perhaps mediated in part, by direct cholangiocyte-nerve interactions. The implications of these findings are protean for studies of neuromodulation of biliary physiology and hepatic stem/progenitor cells.</p>
<p>doi: <a href="https://doi.org/10.1007/s00428-020-02761-4" class="uri">https://doi.org/10.1007/s00428-020-02761-4</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Luschka Ducts of the Gallbladder in Adults: Case Series Report and Review of the Medical Literature</strong> </summary></p>
<p><em>International journal of surgical pathology 2020 Jan;():1066896920901334</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31983263" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31983263</a></p>
<p>Luschka ducts (LD) of the gallbladder (GB) are rare congenital lesions. They are defined as bile ducts that connect directly the hepatic bile duct system to the GB. We aimed to present the characteristics of 55 cases of GB LDs as diagnosed on cholecystectomy specimens. Surgically resected GBs (55) were analyzed for LD morphological features (length, morphological pattern, and epithelial lesions) as well as for immunohistochemical features. The age varied between 24 and 88 years. The gender ratio was 30:25 (female-male). The diagnosis was acute and subacute/chronic cholecystitis (21 and 34 cases, respectively). GB abnormalities of Rokitansky-Aschoff sinus, adenomyoma, septate, and subserosal-liver types were present in 36, 6, 22, and 12 GBs, respectively, while adenocarcinoma was present in 2 GBs. A history of renal cyst, pancreatitis, and colon diverticulosis was observed in 8, 11, and 4 cases, respectively. The LDs were detected at subserosal, resection, or both sites (25, 4, and 26 cases, respectively). The length varied between &lt;1 and 36 mm. Duct-type LDs were observed in 17 cases, complex-type LDs in 5 cases, and mixed-type LDs in 33 cases. Mucosecretion was seen in 12 LDs and cystic dilatation in 8 cases. Epithelial atypia was observed in 2 cases and meganucleoli in 15 cases. Presence of LD-angulation correlated with chronic cholecystitis, while LD-nuclear atypia correlated with acute cholecystitis. In conclusion, LDs may harbor varied aspects, from duct-like or cystic, to nodular, biliary adenoma-like complexes. GB abnormalities of Rokitansky-Aschoff sinus, septa, or subserosal-liver types and extra-GB lesions such as renal cysts, pancreatitis, and colon diverticulosis were associated.</p>
<p>doi: <a href="https://doi.org/10.1177/1066896920901334" class="uri">https://doi.org/10.1177/1066896920901334</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Gallbladder Mixed Neuroendocrine-Non-neuroendocrine Neoplasm (MiNEN) Arising in Intracholecystic Papillary Neoplasm: Clinicopathologic and Molecular Analysis of a Case and Review of the Literature</strong> </summary></p>
<p><em>Endocrine pathology 2020 Mar;31(1):84-93</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31981075" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31981075</a></p>
<p>Mixed neuroendocrine-non-neuroendocrine neoplasms (MiNENs) of the gallbladder are generally composed of adenocarcinoma and neuroendocrine carcinoma (NEC). Rare cases associated with intracholecystic papillary neoplasm (ICPN) have been reported. Although recent molecular data suggest that the different components of digestive MiNENs originate from a common precursor stem cell, this aspect has been poorly investigated in gallbladder MiNENs. We describe the clinicopathologic and molecular features of a MiNEN composed of ICPN, adenocarcinoma, and NEC. A 66-year-old woman presented with severe abdominal pain. She underwent radical cholecystectomy and an intracholecystic mass was found. Histologically, it was composed of ICPN associated with adenocarcinoma and large cell neuroendocrine carcinoma (LCNEC). The three components were positive for DNA repair proteins and p53. EMA was positive in the ICPN and adenocarcinoma components, while it was negative in the LCNEC. Heterogeneous expression of Muc5AC, cytokeratin 20, and CDX2 was only observed in the ICPN component. Cytokeratin 7 was diffusely positive in both adenocarcinoma and LCNEC components, while it was heterogeneously expressed in the ICPN. The copy number variation analysis showed overlapping results between the adenocarcinoma and LCNEC components with some minor differences with the ICPN component. The three tumor components showed the same mutation profile including TP53 mutation c.700T &gt; C (p. Tyr234His), without mutations in other 51 genes known to be frequently altered in cancer pathogenesis and growth. This finding may support the hypothesis of a monoclonal origin of the different tumor components. We have also performed a review of the literature on gallbladder MiNENs.</p>
<p>doi: <a href="https://doi.org/10.1007/s12022-020-09605-6" class="uri">https://doi.org/10.1007/s12022-020-09605-6</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Insulinoma-associated protein 1 (INSM1) is a robust marker for identifying and grading pancreatic neuroendocrine tumors</strong> </summary></p>
<p><em>Cancer cytopathology 2020 Apr;128(4):269-277</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31977134" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31977134</a></p>
<p>BACKGROUND: Pancreatic neuroendocrine tumor (PNET) is a diagnostic challenge with limited samples in not only identification but grading. Prior studies have shown insulinoma-associated protein 1 (INSM1) to be a robust marker in identifying PNETs from other solid pancreatic tumors on resection specimens. In this study, we investigated the utility of INSM1 not only for identifying PNETs but also for grading in cell blocks (CBs) and surgical resections (SRs). METHODS: A search for PNET cases between 2000 and 2019 identified 55 samples (26 CBs and 29 SRs) that were further separated into high (2 CBs, 3 SRs), intermediate (4 CBs, 7 SRs), and low (20 CBs, 19 SRs) grades based on their final pathology report and Ki-67 level. Immunohistochemical (IHC) staining for INSM1 (C-8, Santa Cruz Biotechnology [1:100]) was performed and quantified using an H score of 0 to 300. Non-PNET solid pancreatic tumors were compared and included acinar cell carcinoma, solid pseudopapillary neoplasm, and ductal adenocarcinoma. RESULTS: All 55 cases of PNET demonstrated nuclear INSM1 staining. The average H scores for INSM1 staining of PNET were 254 and 252 in CB and SR, respectively. The H scores decreased with increasing tumor grade, with low-grade (G1), intermediate-grade (G2), and high-grade (G3) tumors showing average INSM1 H scores of 229 and 253, 266 and 253, and 30 and 33 in both CB and SR, respectively. CONCLUSION: IHC with INSM1 plays a role in identifying and potentially grading PNETs.</p>
<p>doi: <a href="https://doi.org/10.1002/cncy.22242" class="uri">https://doi.org/10.1002/cncy.22242</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Microscopic Size Measurements Predict Outcomes in Post-Neoadjuvant Resections of Pancreatic Ductal Adenocarcinoma (PDAC)</strong> </summary></p>
<p><em>Histopathology 2020 Jan;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31965618" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31965618</a></p>
<p>BACKGROUND: Pancreatic ductal adenocarcinomas (PDACs) are increasingly treated with neoadjuvant therapy. However, the American Joint Committee on Cancer (AJCC) 8th Edition T staging based on tumor size does not reflect treatment effect, which often results in multiple, small foci of residual tumor in a background of mass-forming fibrosis. Thus, we evaluated the performance of AJCC 8th Edition T staging in predicting patient outcomes using a microscopic tumor size measurement method. METHODS AND RESULTS: 106 post-neoadjuvant therapy pancreatectomies were reviewed, and all individual tumor foci were measured. T stages based on gross size (GS) and the largest single microscopic focus size (MFS) were examined in association with clinicopathologic variables and patient outcomes. 63/106 (59%) were locally advanced; 78% received FOLFIRINOX treatment. Average GS and MFS were 2.5cm and 1.1cm, respectively; 9 cases each were classified as T0, 35 and 85 cases as T1, 42 and 12 cases as T2, and 20 and 0 cases as T3, based on the GS and MFS, respectively. Higher GS- and MFS-based T stages were significantly associated with higher tumor regression grade, lymphovascular and perineural invasion, and higher N stage. Furthermore, higher MFS-based T stage was significantly associated with shorter disease-free survival (DFS) (p&lt;0.001) and shorter overall survival (OS) (p=0.002). GS was significantly associated with OS (p=0.046), but not with DFS. CONCLUSIONS: In post-neoadjuvant PDAC resections, MFS-based T staging is superior to GS-based T staging for predicting patient outcomes, suggesting that microscopic measurements have clinical utility beyond the conventional use of GS measurements alone.</p>
<p>doi: <a href="https://doi.org/10.1111/his.14067" class="uri">https://doi.org/10.1111/his.14067</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Gallbladder and extrahepatic bile duct cancers in the Americas: Incidence and mortality patterns and trends</strong> </summary></p>
<p><em>International journal of cancer 2020 Jan;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31922259" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31922259</a></p>
<p>Trends in gallbladder cancer incidence and mortality in populations across the Americas can provide insight into shifting epidemiologic patterns and the current and potential impact of preventative and curative programs. Estimates of gallbladder and extrahepatic bile duct cancer incidence and mortality for the year 2018 were extracted from International Agency for Research on Cancer (IARC) GLOBOCAN database for 185 countries. Recorded registry-based incidence from 13 countries was extracted from IARCs Cancer Incidence in Five Continents series and corresponding national deaths from the WHO mortality database. Among females, the highest estimated incidence for gallbladder and extrahepatic bile duct cancer in the Americas were found in Bolivia (21.0 per 100,000), Chile (11.7) and Peru (6.0). In the US, the highest incidence rates were observed among Hispanics (1.8). In the Chilean population, gallbladder cancer rates declined in both females and males between 1998 and 2012. Rates dropped slightly in Canada, Costa Rica, US Whites and Hispanics in Los Angeles. Gallbladder cancer mortality rates also decreased across the studied countries, although rising trends were observed in Colombia and Canada after 2010. Countries within Southern and Central America tended to have a higher proportion of unspecified biliary tract cancers. In public health terms, the decline in gallbladder cancer incidence and mortality rates is encouraging. However, the slight increase in mortality rates during recent years in Colombia and Canada warrant further attention. Higher proportions of unspecified biliary tract cancers (with correspondingly higher mortality rates) suggest more rigorous pathology procedures may be needed after surgery.</p>
<p>doi: <a href="https://doi.org/10.1002/ijc.32863" class="uri">https://doi.org/10.1002/ijc.32863</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Long-term outcomes of surgical resection for T1b gallbladder cancer: an institutional evaluation</strong> </summary></p>
<p><em>BMC cancer 2020 Jan;20(1):20</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31907021" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31907021</a></p>
<p>BACKGROUND: There is no comprehensive agreement concerning the overall performance of radical resection for T1b gallbladder cancer (GBC). This research focused on addressing whether T1b GBC may spread loco-regionally and whether radical resection is necessary. METHODS: A retrospective analysis was conducted of 1032 patients with GBC who underwent surgical resection at our centre and its affiliated institutions between January 1982 and December 2018. A total of 47 patients with T1b GBC, 29 (62%) of whom underwent simple cholecystectomy and 18 (38%) of whom underwent radical resection with regional lymph node dissection, were enrolled in the study. RESULTS: GBC was diagnosed pre-operatively in 16 patients (34%), whereas 31 patients (66%) had incidental GBC. There was no blood venous or perineural invasion in any patient on histology evaluation, except for lymphatic vessel invasion in a single patient. There were no metastases in any analysed lymph nodes. The open surgical approach was more prevalent among the 18 patients who underwent radical resection (open in all 18 patients) than among the 29 patients who underwent simple cholecystectomy (open in 21; laparoscopic in 8) (P = 0.017). The cumulative 10- and 20-year overall survival rates were 65 and 25%, respectively. The outcome following simple cholecystectomy (10-year overall survival rate of 66%) was akin to that following radical resection (64%, P = 0.618). The cumulative 10- and 20-year disease-specific survival rates were 93 and 93%, respectively. The outcome following simple cholecystectomy (10-year disease-specific survival rate of 100%) was equivalent to that following radical resection (that of 86%, P = 0.151). While age (&gt; 70 years, hazard ratio 5.285, P = 0.003) and gender (female, hazard ratio 0.272, P = 0.007) had a strong effect on patient overall survival, surgical procedure (simple cholecystectomy vs. radical resection) and surgical approach (open vs. laparoscopic) did not. CONCLUSIONS: Most T1b GBCs represent local disease. As pre-operative diagnosis, including tumour penetration of T1b GBC, is difficult, the decision of radical resection is justified. Additional radical resection is not required following simple cholecystectomy provided that the penetration depth is restricted towards the muscular layer and that surgical margins are uninvolved.</p>
<p>doi: <a href="https://doi.org/10.1186/s12885-019-6507-2" class="uri">https://doi.org/10.1186/s12885-019-6507-2</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - **** </summary></p>
<ul>
<li>;():*</li>
</ul>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=</a></p>
<p>doi: <a href="https://doi.org/" class="uri">https://doi.org/</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>The North American Neuroendocrine Tumor Society Consensus Paper on the Surgical Management of Pancreatic Neuroendocrine Tumors</strong> </summary></p>
<p><em>Pancreas 2020 01;49(1):1-33</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31856076" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31856076</a></p>
<p>This manuscript is the result of the North American Neuroendocrine Tumor Society consensus conference on the surgical management of pancreatic neuroendocrine tumors from July 19 to 20, 2018. The group reviewed a series of questions of specific interest to surgeons taking care of patients with pancreatic neuroendocrine tumors, and for each, the available literature was reviewed. What follows are these reviews for each question followed by recommendations of the panel.</p>
<p>doi: <a href="https://doi.org/10.1097/MPA.0000000000001454" class="uri">https://doi.org/10.1097/MPA.0000000000001454</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Pathologic Evaluation of Endoscopically Resected Non-Ampullary Duodenal Lesions: A Single Center Experience</strong> </summary></p>
<p><em>Turk patoloji dergisi 2019 Dec;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31825518" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31825518</a></p>
<p>OBJECTIVE: Endoscopic resections are increasingly being used for superficial gastrointestinal lesions. However, application of these techniques in the duodenum remains challenging, due to the technical difficulties and high complication rates. This study projects a western tertiary center’s experience in the endoscopic treatment and diagnostic workup of 19 cases of non-ampullary duodenal lesions. MATERIAL AND METHOD: Specimens (12 endoscopic mucosal resections, 6 endoscopic submucosal dissections, and one endoscopic full-thickness resection) were processed following a strict protocol (photographed, mapped digitally and submitted totally) for histopathologic examination. Clinicopathologic characteristics, margin status and follow-up information were analyzed. RESULTS: The mean age of the 16 patients was 52 years (range: 22-81). Mean lesion size was 1.4 cm (range: 0.3-3.6 cm) for all cases, 2 cm for endoscopic submucosal dissections and 1.1 cm for endoscopic mucosal resections. Mean number of blocks submitted was 4/case. Seven neuroendocrine tumors, 3 tubulovillous adenomas were diagnosed along with nine benign lesions. For endoscopic submucosal dissections, en-bloc and R0 resection rates were 100% (n=6/6) and 83% (n=5/6); for endoscopic mucosal resections, they were 92% (n=11/12) and 83% (n=10/12), respectively. Only one patient had procedure-related late perforation that was managed endoscopically. No mortality was encountered. CONCLUSION: Duodenal endoscopic resections proved successful, safe and feasible methods in a tertiary center. The pathologist’s role is to designate the accurate diagnosis, related histopathologic parameters and margin status. The gross protocol was found to be essential in evaluating specimen margins and orientation, as well as in size measurement. We recommend following a standardized approach including gross photography and digital mapping when handling these specimens, for both diagnostic and data collection purposes.</p>
<p>doi: <a href="https://doi.org/10.5146/tjpath.2019.01474" class="uri">https://doi.org/10.5146/tjpath.2019.01474</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Intracholecystic Papillary-Tubular Neoplasms (ICPN) of the Gallbladder: A Short Review of Literature</strong> </summary></p>
<p><em>Applied immunohistochemistry &amp; molecular morphology : AIMM 2020 01;28(1):57-61</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31815746" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31815746</a></p>
<p>Increasing use of radiographic studies of the hepatobiliary system has led to a growing diagnostic rate of many asymptomatic polyps of the gallbladder which would have gone undiagnosed otherwise. Neoplastic polyps of the gallbladder are 5% of the total number of polyps of this organ. However, due to their malignant potential, the correct diagnosis and classification become of crucial importance. Lack of unified terminology and reporting criteria have led to a limited body of scientific evidence regarding their classification and management. Therefore in 2012 the novel and unified terminology, Intracholecystic papillary-tubular neoplasm was proposed for these lesions when they measure &gt;1 cm. Smaller lesions are usually of no adverse outcome. Intracholecystic papillary-tubular neoplasms show 5 histologic subcategories: (1) pyloric gland subtype which is the most commonly encountered neoplastic polyp in the gallbladder and has the lowest rate of harboring high-grade dysplasia and invasive carcinoma and it shows diffuse cytoplasmic positivity with MUC6, a specific pyloric marker; (2) biliary subtype which is diffusely positive for MUC1 and has the highest risk of concurrent adenocarcinoma; (3) gastric foveolar subtype which is MUC5AC positive in all the cases. Most of the cases in this category are associated with some extent of high-grade dysplasia; (4) intestinal subtype which is the easiest one to recognize as it mimics tubular adenomas of the gastrointestinal tract and show MUC2 and CDX2 positivity; and (5) oncocytic subtype which is the least common.</p>
<p>doi: <a href="https://doi.org/10.1097/PAI.0000000000000711" class="uri">https://doi.org/10.1097/PAI.0000000000000711</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Clinicopathologic and Prognostic Significance of Gallbladder and Cystic Duct Invasion in Distal Bile Duct Carcinoma</strong> </summary></p>
<p><em>Archives of pathology &amp; laboratory medicine 2019 Nov;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31755778" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31755778</a></p>
<p>CONTEXT.—: The roles of the gallbladder and cystic duct (CD) invasions in distal bile duct carcinoma (DBDC) have not been well elucidated. OBJECTIVE.—: To define the characteristics and prognostic significance of gallbladder or CD invasions in patients with DBDC. DESIGN.—: Organ invasion patterns with clinicopathologic features were assessed in 258 resected DBDCs. RESULTS.—: CD invasions (N = 31) were associated with frequent concomitant pancreatic and/or duodenal invasions (23 of 31, 74%) and showed stromal infiltration (16 of 31, 52%) and intraductal cancerization (15 of 31, 48%) patterns. In only 2 cases, invasions with intraductal cancerization were observed in the gallbladder neck. Conversely, all pancreatic (N = 175) and duodenal (83) invasions developed through stromal infiltration. CD invasions were associated with larger tumor size (P = .001), bile duct margin positivity (P = .001), perineural invasions (P = .04), and higher N categories (P = .007). Patients with pancreatic or duodenal invasions had significantly lower survival rates than those without pancreatic (median, 31.0 versus 93.9 months) or duodenal (27.5 versus 56.8 months, P &lt; .001, both) invasions. However, those with gallbladder or CD invasions did not have different survival times (P = .13). Patients with concomitant gallbladder/CD and pancreatic/duodenal invasions demonstrated significantly lower survival rates than those without organ invasions (P &lt; .001). CONCLUSIONS.—: Gallbladder invasions were rare in DBDCs as neck invasions with intraductal cancerization. CD invasions occurred by stromal infiltrations and intraductal cancerization, whereas all pancreatic and duodenal invasions had stromal infiltration patterns. Gallbladder and/or CD invasions did not affect survival rates of patients with DBDC, while pancreatic and duodenal invasions affected survival rates. Therefore, these differences in survival rates may originate from the different invasive patterns of DBDCs.</p>
<p>doi: <a href="https://doi.org/10.5858/arpa.2019-0218-OA" class="uri">https://doi.org/10.5858/arpa.2019-0218-OA</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Re-resection in Incidental Gallbladder Cancer: Survival and the Incidence of Residual Disease</strong> </summary></p>
<p><em>Annals of surgical oncology 2020 Apr;27(4):1132-1142</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31741109" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31741109</a></p>
<p>BACKGROUND: Re-resection for incidental gallbladder cancer (iGBC) is associated with improved survival but little is known about residual disease (RD) and prognostic factors. In this study, survival after re-resection, RD, and prognostic factors are analyzed. METHODS: Patients with iGBC were identified from the Netherlands Cancer Registry, and pathology reports of re-resected patients were reviewed. Survival and prognostic factors were analyzed. RESULTS: Overall, 463 patients were included; 24% (n = 110) underwent re-resection after a median interval of 66 days. RD was present in 35% of patients and was most frequently found in the lymph nodes (23%). R0 resection was achieved in 93 patients (92%). Median overall survival (OS) of patients without re-resection was 13.7 (95% confidence interval [CI] 11.6-15.6), compared with 52.6 months (95% CI 36.3-68.8) in re-resected patients (p &lt; 0.001). After re-resection, median OS was superior in patients without RD versus patients with RD (not reached vs. 23.1 months; p &lt; 0.001). In patients who underwent re-resection, RD in the liver (hazard ratio [HR] 5.54; p &lt; 0.001) and lymph nodes (HR 2.35; p = 0.005) were the only significant prognostic factors in multivariable analysis. Predictive factors for the presence of RD were pT3 stage (HR 25.3; p = 0.003) and pN1 stage (HR 23.0; p = 0.022). CONCLUSION: Re-resection for iGBC is associated with improved survival but remains infrequently used and is often performed after the optimal timing interval. RD is the only significant prognostic factor for survival after re-resection and can be predicted by pT and pN stages.</p>
<p>doi: <a href="https://doi.org/10.1245/s10434-019-08074-4" class="uri">https://doi.org/10.1245/s10434-019-08074-4</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Non-neoplastic Polyps of the Gallbladder: A Clinicopathologic Analysis of 447 Cases</strong> </summary></p>
<p><em>The American journal of surgical pathology 2020 Apr;44(4):467-476</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31725469" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31725469</a></p>
<p>There is no systematic histopathologic analysis of non-neoplastic polyps in the gallbladder. In this study, in addition to a computer search for cases designated as “polyp,” a systematic review of 2533 consecutive routinely sampled archival and 203 totally submitted prospective cholecystectomies were analyzed for &gt;2 mm polyps (cut-off was based on radiologic sensitivity). A total of 447 non-neoplastic polyps were identified. The frequency was 3% in archival cases and 5% in totally submitted cases. Only 21 (5%) were ≥1 cm. The average age was 52 years, and the female to male ratio was 3.1. Two distinct categories were delineated: (1) injury-related polyps (n=273): (a) Fibro(myo)glandular polyps (n=214) were small (mean=0.4 cm), broad-based, often multiple (45%), almost always (98%) gallstone-associated, and were composed of a mixture of (myo)fibroblastic tissue/lobular glandular units with chronic cholecystitis. Dysplasia seen in 9% seemed to be secondary involvement. (b) Metaplastic pyloric glands forming polypoid collections (n=42). (c) Inflammatory-type polyps associated with acute/subacute injury (11 granulation tissue, 3 xanthogranulomatous, 3 lymphoid). (2) Cholesterol polyps (n=174) occurred in uninjured gallbladders, revealing a very thin stalk, edematous cores devoid of glands but with cholesterol-laden macrophages in 85%, and cholesterolosis in the uninvolved mucosa in 60%. Focal low-grade dysplasia was seen in 3%, always confined to the polyp, unaccompanied by carcinoma. In conclusion, non-neoplastic polyps are seen in 3% of cholecystectomies and are often small. Injury-related fibromyoglandular polyps are the most common. Cholesterol polyps have distinctive cauliflower architecture, often in a background of uninjured gallbladders with cholesterolosis and may lack the cholesterol-laden macrophages in the polyp itself. Although dysplastic changes can involve non-neoplastic polyps, they do not seem to be the cause of invasive carcinoma by themselves.</p>
<p>doi: <a href="https://doi.org/10.1097/PAS.0000000000001405" class="uri">https://doi.org/10.1097/PAS.0000000000001405</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Main Pancreatic Duct to Parenchymal Thickness Ratio at Preoperative Imaging is Associated with Overall Survival in Upfront Resected Pancreatic Cancer</strong> </summary></p>
<p><em>Annals of surgical oncology 2020 May;27(5):1606-1612</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31722071" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31722071</a></p>
<p>BACKGROUND: Pancreatic cancer induces parenchymal atrophy and duct dilation. The aim of this study was to evaluate whether these radiologic modifications are associated with outcomes. METHODS: Upfront pancreaticoduodenectomy patients with available preoperative contrast enhanced CT scan imaging were retrospectively analyzed. Thickness of the pancreas, size of the main pancreatic duct (MPD), and distance of the tumor from the ampulla were assessed. A training cohort was selected, including short- (3-12 months following surgery) and long-term (≥ 36 months) survivors. Identified survival determinants were validated in the overall cohort. RESULTS: Two-hundred-sixteen patients were analyzed. In the training cohort (N = 118), 68 patients (57.6%) were in the short-term and 50 (42.4%) in the long-term survival group. The short-term survival group had significantly higher CA 19-9 levels (p = 0.027), larger tumors (32.6 ± 12.1 mm vs. 26.5 ± 11.6 mm, p = 0.007), poorer differentiation (p = 0.003), higher rate of R &lt; 1 mm resections (54% vs. 32%, p = 0.008), and reduced receipt of adjuvant chemotherapy (p = 0.020). The MPD-to-pancreatic thickness ratio was significantly lower in the short-term survivors (3.6 ± 6.2 vs. 8.2 ± 12.0, p = 0.016). In the entire cohort, an MPD-to-pancreatic thickness ratio ≥ 3.5 was associated with improved OS [median 33.0 months IQR (19.7-48.1) versus 17 months IQR (14.8-19.2), p = 0.004], and confirmed by a Cox-proportional hazards model independently associated with OS (HR = 0.58; p = 0.009), together with tumor size (HR = 1.02; p =0.012), R1/R2 status (HR = 1.53; p = 0.029), and receipt of adjuvant treatment (HR = 0.61; p = 0.021). CONCLUSIONS: High MPD-to-pancreatic thickness ratio was associated with improved long-term survival in pancreaticoduodenectomy for cancer. Whether these features are related to tumor chronicity, indolent biology, or local growth over metastasis remains to be determined.</p>
<p>doi: <a href="https://doi.org/10.1245/s10434-019-08040-0" class="uri">https://doi.org/10.1245/s10434-019-08040-0</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Recurrent Rearrangements in PRKACA and PRKACB in Intraductal Oncocytic Papillary Neoplasms of the Pancreas and Bile Duct</strong> </summary></p>
<p><em>Gastroenterology 2020 02;158(3):573-582.e2</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31678302" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31678302</a></p>
<p>BACKGROUND &amp; AIMS: Intraductal oncocytic papillary neoplasms (IOPNs) of the pancreas and bile duct contain epithelial cells with numerous, large mitochondria and are cystic precursors to pancreatic ductal adenocarcinoma (PDAC) and cholangiocarcinoma (CCA), respectively. However, IOPNs do not have the genomic alterations found in other pancreatobiliary neoplasms. In fact, no recurrent genomic alterations have been described in IOPNs. PDACs without activating mutations in KRAS contain gene rearrangements, so we investigated whether IOPNs have recurrent fusions in genes. METHODS: We analyzed 20 resected pancreatic IOPNs and 3 resected biliary IOPNs using a broad RNA-based targeted sequencing panel to detect cancer-related fusion genes. Four invasive PDACs and 2 intrahepatic CCAs from the same patients as the IOPNs, were also available for analysis. Samples of pancreatic cyst fluid (n = 5, collected before surgery) and bile duct brushings (n = 2) were analyzed for translocations. For comparison, we analyzed pancreatobiliary lesions from 126 patients without IOPN (controls). RESULTS: All IOPNs evaluated were found to have recurring fusions of ATP1B1-PRKACB (n = 13), DNAJB1-PRKACA (n = 6), or ATP1B1-PRKACA (n = 4). These fusions also were found in corresponding invasive PDACs and intrahepatic CCAs, as well as in matched pancreatic cyst fluid and bile duct brushings. These gene rearrangements were absent from all 126 control pancreatobiliary lesions. CONCLUSIONS: We identified fusions in PRKACA and PRKACB genes in pancreatic and biliary IOPNs, as well as in PDACs and pancreatic cyst fluid and bile duct cells from the same patients. We did not identify these gene fusions in 126 control pancreatobiliary lesions. These fusions might be used to identify patients at risk for IOPNs and their associated invasive carcinomas.</p>
<p>doi: <a href="https://doi.org/10.1053/j.gastro.2019.10.028" class="uri">https://doi.org/10.1053/j.gastro.2019.10.028</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>DNAJB1-PRKACA fusions occur in oncocytic pancreatic and biliary neoplasms and are not specific for fibrolamellar hepatocellular carcinoma</strong> </summary></p>
<p><em>Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc 2020 04;33(4):648-656</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31676785" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31676785</a></p>
<p>Recently discovered DNAJB1-PRKACA oncogenic fusions have been considered diagnostic for fibrolamellar hepatocellular carcinoma. In this study, we describe six pancreatobiliary neoplasms with PRKACA fusions, five of which harbor the DNAJB1-PRKACA fusion. All neoplasms were subjected to a hybridization capture-based next-generation sequencing assay (MSK-IMPACT), which enables the identification of sequence mutations, copy number alterations, and selected structural rearrangements involving ≥410 genes (n = 6) and/or to a custom targeted, RNA-based panel (MSK-Fusion) that utilizes Archer Anchored Multiplex PCR technology and next-generation sequencing to detect gene fusions in 62 genes (n = 2). Selected neoplasms also underwent FISH analysis, albumin mRNA in-situ hybridization, and arginase-1 immunohistochemical labeling (n = 3). Five neoplasms were pancreatic, and one arose in the intrahepatic bile ducts. All revealed at least focal oncocytic morphology: three cases were diagnosed as intraductal oncocytic papillary neoplasms, and three as intraductal papillary mucinous neoplasms with mixed oncocytic and pancreatobiliary or gastric features. Four cases had an invasive carcinoma component composed of oncocytic cells. Five cases revealed DNAJB1-PRKACA fusions and one revealed an ATP1B1-PRKACA fusion. None of the cases tested were positive for albumin or arginase-1. Our data prove that DNAJB1-PRKACA fusion is neither exclusive nor diagnostic for fibrolamellar hepatocellular carcinoma, and caution should be exercised in diagnosing liver tumors with DNAJB1-PRKACA fusions as fibrolamellar hepatocellular carcinoma, particularly if a pancreatic lesion is present. Moreover, considering DNAJB1-PRKACA fusions lead to upregulated protein kinase activity and that this upregulated protein kinase activity has a significant role in tumorigenesis of fibrolamellar hepatocellular carcinoma, protein kinase inhibition could have therapeutic potential in the treatment of these pancreatobiliary neoplasms as well, once a suitable drug is developed.</p>
<p>doi: <a href="https://doi.org/10.1038/s41379-019-0398-2" class="uri">https://doi.org/10.1038/s41379-019-0398-2</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Clinicopathologic Characteristics of Gallbladder Adenomyomas and the Contribution of Macroscopic Sampling in Adenomyoma Diagnosis</strong> </summary></p>
<p><em>Turk patoloji dergisi 2020 10;36(1):11-16</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31633192" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31633192</a></p>
<p>OBJECTIVE: Adenomyoma, a reactive and hamartomatous lesion of the gallbladder, is included in the differential diagnosis of several benign and malignant lesions. Macroscopic sampling is very important in the determination of these lesions. The agreed macroscopy protocol in recent years has been prepared by the Hepatopancreatobiliary Pathology Working Group. We aimed to evaluate the clinicopathologic properties of adenomyoma cases in the gallbladder and the contribution of new macroscopy techniques to the diagnosis of adenomyoma in the pre-protocol and post-protocol parts of a one-year period. MATERIAL AND METHOD: Two institutes were included in the study. Adenomyoma cases diagnosed in the pre-protocol and post-protocol periods of one year duration were included in the study. Slides and demographic properties of the cases were reexamined. RESULTS: While adenomyoma was present in 22 of 1879 gallbladder before the protocol, it was observed in 32 of 1781 gallbladders in the post-protocol period. 17 of the cases were male and 37 were female. The mean age of the cases was 51.8. 52% of the lesions were located in the fundus. A gallstone was observed in 37 cases, and cholesterolosis in 14 cases. In the comparison of the two periods, the number of cases was lower in the post-protocol period but a 0.6% increase in the diagnosis of adenomyoma was found. CONCLUSION: Adenomyoma is one of the lesions of the gallbladder that should be recognized but can be easily overlooked macroscopically. When we conducted the sampling according to the last protocol, the increase in the diagnosis of adenomyoma showed that adequate and accurate sampling was very useful for the detection of adenomyoma in the gallbladder.</p>
<p>doi: <a href="https://doi.org/10.5146/tjpath.2019.01471" class="uri">https://doi.org/10.5146/tjpath.2019.01471</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Exome sequencing of 22 genes using tissue from patients with biliary tract cancer</strong> </summary></p>
<p><em>APMIS : acta pathologica, microbiologica, et immunologica Scandinavica 2020 Jan;128(1):3-9</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31628675" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31628675</a></p>
<p>Biliary tract cancers (BTC) are a rare heterogeneous disease group with a dismal prognosis and limited treatment options. The mutational landscape consists of genetic aberrations both shared by and characteristic for anatomical location. Here, we present exome sequencing data on 22 genes from a phase 2 trial using a clinically validated panel used in patients with colorectal cancer. A total of 56 patients were included in a one-armed phase 2 trial investigating the treatment combination of capecitabine, gemcitabine, oxaliplatin, and cetuximab. Tissue DNA yield and quality allowed analysis of 30 patients on our panel including 22 genes. ARID1A (33%) and TP53 (33%) were found to be most frequently mutated followed by KRAS mutations found in 20% of the patients. Mutational aberrations in ARID1A were found more prevalent than expected, whereas TP53 and KRAS were in concordance with earlier reported data. Mutation in CTNNB1 was significantly associated with poor prognosis. Our panel is clinically validated and suitable for a high volume of samples to detect mutations in patients with BTC. However, it is reasonable to assume that the clinical utility could be optimized in this patient group by extending the panel to include BTC specific mutations with potential therapeutic consequences such as IDH1/2, FGFR fusions, ERBB3, and BRCA1/2.</p>
<p>doi: <a href="https://doi.org/10.1111/apm.13003" class="uri">https://doi.org/10.1111/apm.13003</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Brain-to-pancreas signalling axis links nicotine and diabetes</strong> </summary></p>
<p><em>Nature 2019 10;574(7778):336-337</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31619783" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31619783</a></p>
<p>doi: <a href="https://doi.org/10.1038/d41586-019-02975-w" class="uri">https://doi.org/10.1038/d41586-019-02975-w</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Ultrastructural Characteristics of Gallbladder Epithelial Inclusions Mimicking Cystoisospora</strong> </summary></p>
<p><em>American journal of clinical pathology 2020 01;153(1):88-93</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31600399" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31600399</a></p>
<p>OBJECTIVES: There is recently reported increased prevalence of Isospora organisms in cholecystectomy specimens from immunocompetent patients, especially in acalculous cholecystectomies. We performed an ultrastructural and molecular evaluation of these specimens. METHODS: From 28 gallbladders with intraepithelial inclusions, two specimens with diffuse involvement of the gallbladder epithelium were analyzed by electron microscopy. Polymerase chain reaction was performed on five samples for the ITS2 region of C belli and eukaryotic 18S region. The 18S products were sequenced by next-generation sequencing. RESULTS: Electron microscopic analysis showed cytoplasmic condensations leading to vacuole formation. In contrast with true C belli, there were no identifiable organelles or organization. None of these cases showed amplified products other than human on molecular analysis. CONCLUSIONS: Electron microscopic analysis demonstrates that the inclusions are condensed cytoplasmic material and not true organisms.</p>
<p>doi: <a href="https://doi.org/10.1093/ajcp/aqz137" class="uri">https://doi.org/10.1093/ajcp/aqz137</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Elucidating the roles of ASPM isoforms reveals a novel prognostic marker for pancreatic cancer</strong> </summary></p>
<p><em>The Journal of pathology 2020 Feb;250(2):123-125</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31595972" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31595972</a></p>
<p>Pancreatic ductal adenocarcinoma (PDAC) is one of the deadliest cancers worldwide. Late diagnosis, desmoplastic tissue and intrinsic resistance to therapy are among the main reasons for its aggressive phenotype. In addition, it is now appreciated that cancer stem cells - a rare subpopulation of tumor cells highly resistant to therapy - are crucial players in PDAC initiation, progression and resistance to therapy. In a recent article in The Journal of Pathology, Hsu et al elucidated the specific roles of abnormal spindle-like, microcephaly-associated protein (ASPM) isoforms in PDAC. The authors reported that ASPM isoform I (ASPM-iI) is mainly expressed in the cytoplasm of PDAC cells. Its expression is associated with the Wnt signaling pathway, which promotes stemness and maintains the cancer stem cell niche. Clinically, expression of ASPM-iI correlates with poor survival in PDAC patients. Thus, this study revealed a novel prognostic marker as well as a potential therapeutic target for PDAC. © 2019 Pathological Society of Great Britain and Ireland. Published by John Wiley &amp; Sons, Ltd.</p>
<p>doi: <a href="https://doi.org/10.1002/path.5355" class="uri">https://doi.org/10.1002/path.5355</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Is Centralization Needed for Patients Undergoing Distal Pancreatectomy?: A Nationwide Study of 3314 Patients</strong> </summary></p>
<p><em>Pancreas 2019 10;48(9):1188-1194</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31593018" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31593018</a></p>
<p>OBJECTIVE: The centralization of complex surgical procedures is associated with better postoperative outcomes. However, little is known about the impact of hospital volume on the outcome after distal pancreatectomy. METHODS: Using the French national hospital discharge database, we identified all patients having undergone distal pancreatectomy in France between 2012 and 2015. A spline model was applied to determine the caseload cut-off in annual distal pancreatectomy that influenced 90-day postoperative mortality. RESULTS: A total of 3314 patients were identified. Use of a spline model did not reveal a cut-off in the annual distal pancreatectomy caseload. By taking the median number of distal pancreatectomy (n = 5) and the third quartile (n = 15), we stratified centers into low, intermediate, and high hospital volume groups. The overall postoperative mortality rate was 3.0% and did not differ significantly between these groups. In a multivariable analysis, age, Charlson comorbidity score, septic complications, hemorrhage, shock, and reoperation were independently associated with a greater overall risk of death. However, hospital volume had no impact on mortality after distal pancreatectomy (odds ratio, 0.954; 95% confidence interval, 0.552-1.651, P = 0.867). CONCLUSIONS: Hospital volume does not seem to influence mortality after distal pancreatectomy in France, and centralization may not necessarily improve outcomes.</p>
<p>doi: <a href="https://doi.org/10.1097/MPA.0000000000001410" class="uri">https://doi.org/10.1097/MPA.0000000000001410</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Acupuncture for Acute Pancreatitis: A Systematic Review and Meta-analysis</strong> </summary></p>
<p><em>Pancreas 2019 10;48(9):1136-1147</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31593017" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31593017</a></p>
<p>OBJECTIVE: The objective of this study was to assess the efficacy and safety of acupuncture plus routine treatment (RT) for acute pancreatitis (AP). METHODS: Literature searches were performed in 8 databases up to October 31, 2018. Randomized controlled trials comparing acupuncture plus RT with RT alone for AP were included. RESULTS: Twelve eligible studies were included finally. The meta-analysis showed that acupuncture plus RT compared with RT alone could significantly improve the total effective rate and gastrointestinal function and reduce the Acute Physiology, Age, Chronic Health Evaluation II score, tumor necrosis factor α count, the time of resuming to diets, and the length of hospital stay. Only 3 of the studies reported adverse events or reactions. CONCLUSIONS: This study suggested that acupuncture combined with RT may be effective for AP. However, more rigorously designed randomized controlled trials are warranted to confirm the current findings.</p>
<p>doi: <a href="https://doi.org/10.1097/MPA.0000000000001399" class="uri">https://doi.org/10.1097/MPA.0000000000001399</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Predrainage and Postdrainage Prognostic Nomograms to Predict Outcome of Percutaneous Drainage for Infected Pancreatic and Peripancreatic Necrotic Collections</strong> </summary></p>
<p><em>Pancreas 2019 10;48(9):1212-1219</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31593016" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31593016</a></p>
<p>OBJECTIVES: This study aimed to identify factors affecting outcome of percutaneous catheter drainage (PCD) in management of infected pancreatic necrosis treated with step-up approach. METHODS: This was a single-center retrospective cohort study that included patients with infected necrosis undergoing PCD as initial intervention. Patients who did not respond underwent necrosectomy. Predictors of PCD failure (ie, mortality or need for necrosectomy) were analyzed. Models were constructed for predrainage and postdrainage use and were internally validated. RESULTS: Of 304 patients included, catheter drainage was successful in 59.8%, with overall mortality of 22%. Predrainage model consisted of Acute Physiologic and Chronic Health Evaluation II score at admission, early organ failure, and pancreatic necrosis of greater than 50%. Postdrainage model consisted of Acute Physiologic and Chronic Health Evaluation II at first PCD, early organ failure, pancreatic necrosis of greater than 50%, sepsis reversal within 1 week of PCD and Escherichia coli in PCD culture. Both models were internally validated with area under receiver operating characteristics curve of 71.2% for pre-PCD and 81.2% for post-PCD model. Prognostic nomograms were constructed using the models. CONCLUSIONS: Percutaneous catheter drainage alone was successful in 59.8% with mortality of 22%. The nomograms can help in guiding treatment strategy and referral of high-risk cases.</p>
<p>doi: <a href="https://doi.org/10.1097/MPA.0000000000001395" class="uri">https://doi.org/10.1097/MPA.0000000000001395</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Lowest Case Fatality Rate for Patients With Acute Pancreatitis Admitted in Gastroenterology Units in Veneto Region, Italy</strong> </summary></p>
<p><em>Pancreas 2019 10;48(9):1175-1181</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31593015" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31593015</a></p>
<p>OBJECTIVES: This study aimed to evaluate trends in hospitalizations and outcomes of acute pancreatitis (AP) according to first admitting hospital unit and hospital volumes. METHODS: Hospital discharge records of patients with AP admitted in the Veneto Region (Northeast Italy) during the period 2001-2015 were examined. RESULTS: A total of 23,389 patients (54% males; mean age, 62.2 years; standard deviation, 19.3 years) were admitted for AP. Both hospitalization (32.4 to 29.5/100,000 inhabitants per year; P &lt; 0.05) and in-hospital mortality (1.41 to 0.79/100,000 inhabitants per year; P &lt; 0.05) decreased over the study period. Case fatality rate was altogether 3.2%. The percentages of patients admitted in surgery, nongastroenterology medical units, gastroenterology, and intensive care were 52%, 30%, 16%, and 2%, respectively. Fewer fatalities were observed in gastroenterology units (1.7%) compared with nongastroenterology medical units (4.3%; odds ratio, 0.37; 95% confidence interval, 0.28-0.49) and surgical units (2.7%; odds ratio, 0.61; 95% confidence interval, 0.47-0.80). Fatalities decreased progressively with increasing hospital volumes from 3.7% to 2.9% (P &lt; 0.05). CONCLUSION: In the Veneto Region, both hospitalizations and in-hospital mortality for AP significantly decreased over the last 15 years. Case fatality rate was lowest for patients admitted in gastroenterology units.</p>
<p>doi: <a href="https://doi.org/10.1097/MPA.0000000000001397" class="uri">https://doi.org/10.1097/MPA.0000000000001397</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Parecoxib Improves the Outcomes of Acute Mild and Moderate Pancreatitis: A 3-Year Matched Cohort Study Based on a Prospective Database</strong> </summary></p>
<p><em>Pancreas 2019 10;48(9):1148-1154</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31593014" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31593014</a></p>
<p>OBJECTIVES: The aim of this study was to evaluate the role of parecoxib in patients with different severities of acute pancreatitis (AP). METHODS: A total of 772 eligible patients with AP were divided into 4 groups: mild and moderately AP (MAP) treated with parecoxib (group A, n = 236), MAP without parecoxib treatment (group B, n = 453), severe AP (SAP) treated with parecoxib (group C, n = 28), and SAP without parecoxib treatment (group D, n = 55). Patients in group A were exactly matched with patients in group B by propensity score matching, similar to the matching between group C and group D. RESULTS: The morbidity of abdominal infection in group A was significantly lower as compared with that in group B (P &lt; 0.050). The progression of MAP to SAP significantly decreased in group A than group B (P &lt; 0.050). No significant differences were observed between group C and group D. The risk factors independently related to the progression of MAP included alcoholic/high-fat dietary (P = 0.028) and parecoxib administration (P = 0.011). CONCLUSIONS: Early administration of parecoxib could reduce the morbidity of complications among patients with MAP. Parecoxib may prevent the progression of MAP to SAP and improve its outcomes.</p>
<p>doi: <a href="https://doi.org/10.1097/MPA.0000000000001393" class="uri">https://doi.org/10.1097/MPA.0000000000001393</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Risk Factors Associated With Progression Toward Endocrine Insufficiency in Chronic Pancreatitis</strong> </summary></p>
<p><em>Pancreas 2019 10;48(9):1160-1166</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31593013" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31593013</a></p>
<p>OBJECTIVE: Little data exist describing the change over time in islet function and glycemic control in patients with chronic pancreatitis (CP). METHODS: In 325 CP patients who underwent 2 mixed meal tolerance tests and/or glycated hemoglobin (HbA1c) levels, we estimated the rate of change in metabolic measures per 6 months and assessed the association between potential risk factors for diabetes and rate of change using multivariate regression models. RESULTS: Per 6-month time, HbA1c increased by 0.062% with a standard error of 0.029% (P = 0.037) and the ratio (area under the curve (AUC) C-peptide to AUC glucose from mixed meal tolerance testing) decreased by 0.0028 with a standard error of 0.0011 (P = 0.014). We observed more rapid decline in smokers (AUC C-peptide, P = 0.043) and patients with surgical drainage (AUC glucose, P = 0.001; ratio, P = 0.03) or with calcific pancreatitis (HbA1c, P = 0.003). In multivariate models, AUC C-peptide and ratio declined at a greater rate in smokers and HbA1c in those with pancreatic calcifications (both P &lt; 0.05). CONCLUSIONS: We observed a measurable decline in β-cell function and glycemic control in patients with CP. Patients with a history of tobacco smoking, surgical drainage, or pancreatic calcification may be at highest risk.</p>
<p>doi: <a href="https://doi.org/10.1097/MPA.0000000000001394" class="uri">https://doi.org/10.1097/MPA.0000000000001394</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>The Prevalence of Nonalcoholic Fatty Pancreas by Endoscopic Ultrasonography</strong> </summary></p>
<p><em>Pancreas 2019 10;48(9):1220-1224</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31593012" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31593012</a></p>
<p>OBJECTIVES: Pancreatic steatosis or fatty pancreas refers to the fat accumulation in the pancreas, which can lead to inflammation and fibrosis, β-cell dysfunction, fibrosis, and, possibly, pancreatic cancer. This study aimed to study the prevalence of fatty pancreas and its risk factors in patients referred to an endosonography center. METHODS: During 18 months, 228 patients who were referred to our endosonography center for various reasons were evaluated for fatty pancreas. Fatty pancreas was defined as hyperechoic pancreas echotexture compared with spleen echotexture. Demographic characteristics, past medical history, and laboratory measurements were compared between groups with and without fatty pancreas to determine the risk factors for fatty pancreas. RESULTS: The prevalence of fatty pancreas was 25.9%. Patients with fatty pancreas had a significantly higher mean level of uric acid (P = 0.04), frequency of ischemic heart disease (P = 0.03), hyperlipidemia (P = 0.04), frequency of fatty liver (P &lt; 0.001), and aortic intima thickness (P = 0.01). There was no significant difference in age, sex, body mass index, smoking status, substance abuse, and use of oral contraceptives in the 2 groups. CONCLUSIONS: Fatty pancreas is a common disorder. There are meaningful relationships between coronary artery disease, nonalcoholic fatty liver, and atherosclerosis with fatty pancreas.</p>
<p>doi: <a href="https://doi.org/10.1097/MPA.0000000000001396" class="uri">https://doi.org/10.1097/MPA.0000000000001396</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Long-Term Functional Outcome After Pancreatoduodenectomy for Periampullary Carcinoma With Morphological Correlation</strong> </summary></p>
<p><em>Pancreas 2019 10;48(9):1182-1187</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31593011" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31593011</a></p>
<p>OBJECTIVE: The aim of the study was to evaluate the long-term functional outcome (exocrine and endocrine) and morphological changes in remnant pancreas after pancreatoduodenectomy and its clinical impact. METHODS: Periampullary carcinoma patients with minimum follow-up of 2 years and without recurrence were included (N = 102). Exocrine insufficiency includes clinical steatorrhea and fecal elastase-1 (FE-1) levels; endocrine insufficiency, glucose levels and glycated hemoglobin; and morphological changes, main pancreatic duct (MPD) diameter and thickness of remnant pancreas. RESULTS: The mean (standard deviation) follow-up period was 59 (26) months. Of the 102 patients, 81 (80%) had severely deficient FE-1 (0-100 μg/g). The preoperative MPD was significantly more and thickness of remnant pancreas was significantly less in patients with severely deficient FE-1. Overall, 15.6% (16/102) developed steatorrhea and improved on enzyme replacement therapy. The presence of MPD stricture (P = 0.008) and weight loss (P = 0.001) were significantly associated with steatorrhea. New-onset diabetes was seen in 17% (15/90) patients, of whom 3 of 5 developed it after 4 years (range, 4-7 years). The blood glucose was controlled on oral hypoglycemics in 2 (10/15) of 3 patients. CONCLUSIONS: The assessment by FE-1 indicates loss of exocrine function in more than 90%, whereas only 1 of 6 developed steatorrhea and new-onset diabetes. Morphological changes especially MPD stricture affect the functional status of remnant pancreas.</p>
<p>doi: <a href="https://doi.org/10.1097/MPA.0000000000001392" class="uri">https://doi.org/10.1097/MPA.0000000000001392</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Biphenotypic Differentiation of Pancreatic Cancer in 3-Dimensional Culture</strong> </summary></p>
<p><em>Pancreas 2019 10;48(9):1225-1231</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31593010" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31593010</a></p>
<p>OBJECTIVE: Pancreatic ductal adenocarcinoma (PDAC) is the third most common cause of cancer death in the United States. Improved characterized models of PDAC are needed for drug screening. METHODS: We grew 4 established pancreatic cancer cell lines in hanging drop cultures to produce spheroids. We also grew organoids from explanted xenografted PDAC and surgically resected primary PDAC. We performed transmission and scanning electron microscopy and compared findings with those of the normal pancreatic duct. We also performed single-cell cloning to determine the potential options for differentiation. RESULTS: Spheroids contained tight junctions and desmosomes but lacked zymogen granules, as expected. The former features were present in normal pancreatic duct but absent from PDAC cell lines grown in standard 2-dimensional culture. Spheroids functionally excluded macromolecules in whole mounts. Cells on the surface of PDAC spheroids were carpeted by microvilli except for rare cells with prominent stereocilia. Carpets of microvilli were also seen in low passage organoids produced from xenografts and surgically resected human PDAC, in addition to normal human pancreatic duct. We performed single-cell cloning and resulting spheroids produced both cell phenotypes at the same approximate ratios as those from bulk cultures. CONCLUSIONS: Pancreatic cancer spheroids/organoids are capable of biphenotypic differentiation.</p>
<p>doi: <a href="https://doi.org/10.1097/MPA.0000000000001390" class="uri">https://doi.org/10.1097/MPA.0000000000001390</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>What is the Outcome of Patients Affected by Intraductal Papillary Mucinous Neoplasms Without High-Risk Stigmata?: A Single-Center Retrospective Study</strong> </summary></p>
<p><em>Pancreas 2019 10;48(9):1167-1174</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31593009" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31593009</a></p>
<p>OBJECTIVES: The objectives of the study were to define the natural history of intraductal papillary mucinous neoplasms (IPMNs) without high-risk stigmata (HRS) and to identify factors capable of influencing outcome and management. METHODS: This is a retrospective study of patients affected by IPMNs without HRS. Survival analyses included overall survival, disease-specific survival, and years of life lost. Uni- and multivariate analyses were carried out to identify factors capable of predicting years of life lost. RESULTS: Three hundred fifty-six patients were analyzed. Fifty-three patients (14.9%) died: no postoperative mortality, 6 (1.7%) patients from pancreatic cancer and 47 (13.2%) from reasons not related to the disease. Mean overall survival and disease-specific survival were 199.4 (SD, 16.6) and 281 months (SD, 6.9), respectively. The years of life lost of the sample observed with respect to the general population were 2 years and 3 months (15 years and 3 months vs 17 years and 6 months). Younger age, length of follow-up more than 3 years, and surgery significantly increased the years of life lost. CONCLUSIONS: The patients affected by IPMNs without HRS rarely died from the disease. Young age (&lt;65 years) and follow-up more than 3 years seemed to be the only factors capable of influencing the outcome and management.</p>
<p>doi: <a href="https://doi.org/10.1097/MPA.0000000000001388" class="uri">https://doi.org/10.1097/MPA.0000000000001388</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Fungi accelerate pancreatic cancer</strong> </summary></p>
<p><em>Nature 2019 10;574(7777):184-185</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31591542" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31591542</a></p>
<p>doi: <a href="https://doi.org/10.1038/d41586-019-02892-y" class="uri">https://doi.org/10.1038/d41586-019-02892-y</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Cell Type Purification by Single-Cell Transcriptome-Trained Sorting</strong> </summary></p>
<p><em>Cell 2019 Oct;179(2):527-542.e19</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31585086" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31585086</a></p>
<p>Much of current molecular and cell biology research relies on the ability to purify cell types by fluorescence-activated cell sorting (FACS). FACS typically relies on the ability to label cell types of interest with antibodies or fluorescent transgenic constructs. However, antibody availability is often limited, and genetic manipulation is labor intensive or impossible in the case of primary human tissue. To date, no systematic method exists to enrich for cell types without a priori knowledge of cell-type markers. Here, we propose GateID, a computational method that combines single-cell transcriptomics with FACS index sorting to purify cell types of choice using only native cellular properties such as cell size, granularity, and mitochondrial content. We validate GateID by purifying various cell types from zebrafish kidney marrow and the human pancreas to high purity without resorting to specific antibodies or transgenes.</p>
<p>doi: <a href="https://doi.org/10.1016/j.cell.2019.08.006" class="uri">https://doi.org/10.1016/j.cell.2019.08.006</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Targeting tumour microenvironment, a FAKtual challenge in pancreatic cancer</strong> </summary></p>
<p><em>Gut 2020 01;69(1):1-2</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31582402" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31582402</a></p>
<p>doi: <a href="https://doi.org/10.1136/gutjnl-2019-318962" class="uri">https://doi.org/10.1136/gutjnl-2019-318962</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Cathepsin E expression and activity: Role in the detection and treatment of pancreatic cancer</strong> </summary></p>
<p><em>Pancreatology : official journal of the International Association of Pancreatology (IAP) … [et al.] 2019 Oct;19(7):951-956</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31582345" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31582345</a></p>
<p>Cathepsin E (CTSE) is an intracellular, hydrolytic aspartic protease found to be expressed in cells of the immune and gastrointestinal systems, lymphoid tissues, erythrocytes, and cancer cells. The precise functions are not fully understood; however, various studies have investigated its numerous cell-type specific roles. CTSE expression has been shown to be a potential early biomarker for pancreatic ductal adenocarcinoma (PDAC). PDAC patients have low survival rates mostly due to the lack of early detection methods. CTSE-specific activity probes have been developed and tested to assist in tumor imaging and functional studies investigating the role of CTSE expression in PDAC tumors. Furthermore, a CTSE protease-specific, photodynamic therapy pro-drug was developed to explore its potential use to treat tumors that express CTSE. Since CTSE is expressed in pancreatic diseases that are risk factors for PDAC, such as pancreatic cysts and chronic pancreatitis, learning about its function in these disease types could assist in early PDAC detection and in understanding the biology of PDAC progression. Overall, CTSE expression and activity shows potential to detect PDAC and other pancreatic diseases. Further research is needed to fully understand its functions and potential translational applicability.</p>
<p>doi: <a href="https://doi.org/10.1016/j.pan.2019.09.009" class="uri">https://doi.org/10.1016/j.pan.2019.09.009</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>The fungal mycobiome promotes pancreatic oncogenesis via activation of MBL</strong> </summary></p>
<p><em>Nature 2019 10;574(7777):264-267</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31578522" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31578522</a></p>
<p>Bacterial dysbiosis accompanies carcinogenesis in malignancies such as colon and liver cancer, and has recently been implicated in the pathogenesis of pancreatic ductal adenocarcinoma (PDA)1. However, the mycobiome has not been clearly implicated in tumorigenesis. Here we show that fungi migrate from the gut lumen to the pancreas, and that this is implicated in the pathogenesis of PDA. PDA tumours in humans and mouse models of this cancer displayed an increase in fungi of about 3,000-fold compared to normal pancreatic tissue. The composition of the mycobiome of PDA tumours was distinct from that of the gut or normal pancreas on the basis of alpha- and beta-diversity indices. Specifically, the fungal community that infiltrated PDA tumours was markedly enriched for Malassezia spp. in both mice and humans. Ablation of the mycobiome was protective against tumour growth in slowly progressive and invasive models of PDA, and repopulation with a Malassezia species-but not species in the genera Candida, Saccharomyces or Aspergillus-accelerated oncogenesis. We also discovered that ligation of mannose-binding lectin (MBL), which binds to glycans of the fungal wall to activate the complement cascade, was required for oncogenic progression, whereas deletion of MBL or C3 in the extratumoral compartment-or knockdown of C3aR in tumour cells-were both protective against tumour growth. In addition, reprogramming of the mycobiome did not alter the progression of PDA in Mbl- (also known as Mbl2) or C3-deficient mice. Collectively, our work shows that pathogenic fungi promote PDA by driving the complement cascade through the activation of MBL.</p>
<p>doi: <a href="https://doi.org/10.1038/s41586-019-1608-2" class="uri">https://doi.org/10.1038/s41586-019-1608-2</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Multi-institutional Development and External Validation of a Nomogram to Predict Recurrence After Curative Resection of Pancreatic Neuroendocrine Tumors</strong> </summary></p>
<p><em>Annals of surgery 2019 Sep;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31567347" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31567347</a></p>
<p>OBJECTIVE: To develop a nomogram estimating the probability of recurrence free at 5 years after resection for localized grade 1 (G1)/ grade 2 (G2) pancreatic neuroendocrine tumors (PanNETs). BACKGROUND: Among patients undergoing resection of PanNETs, approximately 17% experience recurrence. It is not established which patients are at risk, with no consensus on optimal follow-up. METHOD: A multi-institutional database of patients with G1/G2 PanNETs treated at 2 institutions was used to develop a nomogram estimating the rate of freedom from recurrence at 5 years after curative resection. A second cohort of patients from 3 additional institutions was used to validate the nomogram. Prognostic factors were assessed by univariate analysis using Cox regression model. The nomogram was internally validated using bootstrap resampling method and on the external cohort. Performance was assessed by concordance index (c-index) and a calibration curve. RESULTS: The nomogram was constructed using a cohort of 632 patients. Overall, 68% of PanNETs were G1, the median follow-up was 51 months, and we observed 74 recurrences. Variables included in the nomogram were the number of positive nodes, tumor diameter, Ki-67, and vascular/perineural invasion. The model bias-corrected c-index from the internal validation was 0.85, which was higher than European Neuroendocrine Tumors Society/American Joint Committee on Cancer 8th staging scheme (c-index 0.76, P = &lt;0.001). On the external cohort of 328 patients, the nomogram c-index was 0.84 (95% confidence interval 0.79-0.88). CONCLUSION: Our externally validated nomogram predicts the probability of recurrence-free survival at 5 years after PanNETs curative resection, with improved accuracy over current staging systems. Estimating individual recurrence risk will guide the development of personalized surveillance programs after surgery.</p>
<p>doi: <a href="https://doi.org/10.1097/SLA.0000000000003579" class="uri">https://doi.org/10.1097/SLA.0000000000003579</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>The impact of preoperative biliary stenting in pancreatic cancer: A case-matched study from the German nationwide pancreatic surgery registry (DGAV StuDoQ|Pancreas)</strong> </summary></p>
<p><em>Pancreatology : official journal of the International Association of Pancreatology (IAP) … [et al.] 2019 Oct;19(7):985-993</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31563328" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31563328</a></p>
<p>BACKGROUND/OBJECTIVE: The impact of preoperative biliary stenting (PBS) before pancreatoduodenectomy (PD) for pancreatic ductal adenocarcinoma (PDAC) is controversial. METHODS: Patients undergoing PD with or without PBS for PDAC were identified from the German DGAV-StuDoQlPancreas registry. The impact of PBS on perioperative complications was analyzed. RESULTS: 1133 patients undergoing PD for PDAC were identified from the registry. After matching, 480 PBS patients vs. 480 patients without PBS were analyzed. Postoperative complications Clavien-Dindo classification (CDC) grade IIIa-IVb were higher in PBS patients (PBS 27% vs. no PBS 22%, p = 0.027). 320 PBS patients (66%) had no history of jaundice. In these patients, PBS was associated with higher morbidity. In contrast, PBS was not associated with higher complication rates in patients with history of jaundice. Serum bilirubin levels of 15 mg/dl and higher lead to more CDC IIIa-IVb (24% vs. 28%, p = 0.053) and higher mortality (3% vs. 7%, p &lt; 0.001). PBS in patients with serum bilirubin levels of &gt;15 mg/dl increased CDC IIa-IVb complications (21% vs. 50%, p = 0.001), mortality was equivalent. CONCLUSION: Most PBS procedures were performed in patients with no history of jaundice and increased morbidity. Serum bilirubin levels &gt;15 mg/dl lead to higher morbidity and mortality. PBS correlated with higher complication rates in these patients.</p>
<p>doi: <a href="https://doi.org/10.1016/j.pan.2019.09.007" class="uri">https://doi.org/10.1016/j.pan.2019.09.007</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Impact of Endocrine and Exocrine Insufficiency on Quality of Life After Total Pancreatectomy</strong> </summary></p>
<p><em>Annals of surgical oncology 2020 Feb;27(2):587-596</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31562603" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31562603</a></p>
<p>BACKGROUND: Total pancreatectomy (TP) is rarely performed due to concerns for endocrine and exocrine insufficiency and decreased quality of life (QoL). Renewed interest is seen in recent years, but large cohort studies remain scarce. This study was designed to evaluate endocrine and exocrine insufficiency after TP and its impact on QoL. METHODS: Adult patients (age ≥ 18 years) who underwent TP between 2008 and 2017 at Karolinska University Hospital with at least 6 months follow-up were included. Endocrine and exocrine insufficiency and QoL were assessed using validated questionnaires (EORTC QLQ-C30, QLQ-PAN26, PAID20, and DTSQs). Both pre- and postoperative questionnaires were available in a subgroup. RESULTS: Of 145 TP, 60 patients were eligible of whom 53 (88.3%) with a median of 21 months (interquartile range [IQR] 13-54) follow-up were included. Symptomatic hypoglycemia occurred in 90.6% (48/53) of patients, and 25% (12/48) experienced ≥ 1 episodes of loss of consciousness. The PAID20 revealed emotional burnout in seven patients (13.2%), whereas a high satisfaction score of diabetes treatment (median 28, IQR 24-32) was measured according to the DTSQs. Overall, 27 patients (50.9%) reported to have steatorrhea during a median of 2 days (IQR 0-4) in the past week. Overall QoL was reduced compared with a general population (66.7% vs. 76.4%; Δ9.7%) but did not differ with preoperative outcomes (n = 39, 66.7%; IQR 41.7-83.3 vs. 66.7%, IQR 50.0-83.3; P = 0.553) according to the EORTC QLQ-C30. CONCLUSIONS: Although the impact of endocrine and exocrine insufficiency on QoL after TP seems acceptable, the management of both insufficiencies should be further improved.</p>
<p>doi: <a href="https://doi.org/10.1245/s10434-019-07853-3" class="uri">https://doi.org/10.1245/s10434-019-07853-3</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Plasma extracellular vesicle long RNA profiling identifies a diagnostic signature for the detection of pancreatic ductal adenocarcinoma</strong> </summary></p>
<p><em>Gut 2020 03;69(3):540-550</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31562239" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31562239</a></p>
<p>OBJECTIVE: Pancreatic ductal adenocarcinoma (PDAC) is difficult to diagnose at resectable stage. Recent studies have suggested that extracellular vesicles (EVs) contain long RNAs. The aim of this study was to develop a diagnostic (d-)signature for the detection of PDAC based on EV long RNA (exLR) profiling. DESIGN: We conducted a case-control study with 501 participants, including 284 patients with PDAC, 100 patients with chronic pancreatitis (CP) and 117 healthy subjects. The exLR profile of plasma samples was analysed by exLR sequencing. The d-signature was identified using a support vector machine algorithm and a training cohort (n=188) and was validated using an internal validation cohort (n=135) and an external validation cohort (n=178). RESULTS: We developed a d-signature that comprised eight exLRs, including FGA, KRT19, HIST1H2BK, ITIH2, MARCH2, CLDN1, MAL2 and TIMP1, for PDAC detection. The d-signature showed high accuracy, with an area under the receiver operating characteristic curve (AUC) of 0.960, 0.950 and 0.936 in the training, internal validation and external validation cohort, respectively. The d-signature was able to identify resectable stage I/II cancer with an AUC of 0.949 in the combined three cohorts. In addition, the d-signature showed superior performance to carbohydrate antigen 19-9 in distinguishing PDAC from CP (AUC 0.931 vs 0.873, p=0.028). CONCLUSION: This study is the first to characterise the plasma exLR profile in PDAC and to report an exLR signature for the detection of pancreatic cancer. This signature may improve the prognosis of patients who would have otherwise missed the curative treatment window.</p>
<p>doi: <a href="https://doi.org/10.1136/gutjnl-2019-318860" class="uri">https://doi.org/10.1136/gutjnl-2019-318860</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Unilateral Scrotal Swelling After Acute Pancreatitis of Pancreas Transplant Graft</strong> </summary></p>
<p><em>Gastroenterology 2020 02;158(3):e6-e7</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31560896" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31560896</a></p>
<p>doi: <a href="https://doi.org/10.1053/j.gastro.2019.09.014" class="uri">https://doi.org/10.1053/j.gastro.2019.09.014</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>RET gene rearrangements occur in a subset of pancreatic acinar cell carcinomas</strong> </summary></p>
<p><em>Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc 2020 04;33(4):657-664</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31558784" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31558784</a></p>
<p>Pancreatic acinar cell carcinoma is relatively rare (1 to 2% of pancreatic malignancies) but may be under-recognized. In contrast to pancreatic ductal adenocarcinoma, most acinar cell carcinomas lack mutations in KRAS, DPC, CDKN2A or TP53, but appear to have a high incidence of gene rearrangements, with up to 20% reported to be driven by BRAF fusions. With the development of a new class of RET-specific tyrosine kinase inhibitors, which appear to have particularly strong activity against RET gene rearranged tumours, there is now considerable interest in identifying RET gene rearrangements across a wide range of cancers. RET rearrangements have been reported to occur at a very low incidence (&lt;1%) in all pancreatic carcinomas. We postulated that given its unique molecular profile, RET gene rearrangements may be common in acinar cell carcinomas. We performed fluorescent in-situ hybridization (FISH) studies on a cohort of 40 acinar cell spectrum tumours comprising 36 pure acinar cell carcinomas, three pancreatoblastomas and one mixed acinar-pancreatic neuroendocrine tumour. RET gene rearrangements were identified in 3 (7.5%) cases and BRAF gene rearrangements in 5 (12.5%). All gene rearranged tumours were pure acinar cell carcinomas. Our findings indicate that amongst all pancreatic carcinomas, acinar carcinomas are highly enriched for potentially actionable gene rearrangements in RET or BRAF. FISH testing is inexpensive and readily available in the routine clinical setting and may have a role in the assessment of all acinar cell carcinomas-at this stage to recruit patients for clinical trials of new targeted therapies, but perhaps in the near future as part of routine care.</p>
<p>doi: <a href="https://doi.org/10.1038/s41379-019-0373-y" class="uri">https://doi.org/10.1038/s41379-019-0373-y</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Adverse clinical outcomes associated with multidrug-resistant organisms in patients with infected pancreatic necrosis</strong> </summary></p>
<p><em>Pancreatology : official journal of the International Association of Pancreatology (IAP) … [et al.] 2019 Oct;19(7):935-940</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31558390" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31558390</a></p>
<p>BACKGROUND: Multidrug-resistant organisms (MDROs) is becoming a serious worldwide threat to public health. However, the impact of MDROs on the outcomes of the patients with infected pancreatic necrosis (IPN) remains unclear. This study aims to evaluate the roles of MDROs in IPN. METHODS: A prospectively maintained database of 188 patients with IPN between January 2010 and May 2019 was analyzed. The microbiology profile of organisms isolated from wall-off necrosis (WON) was specifically investigated to correlate with the outcomes of the patients. RESULTS: Of the 188 patients with IPN, 108 patients (57.4%) had MDROs detected in aspirates from WON. Carbapenem-resistant Klebsiella pneumoniae (CRKP) accounted for 43.5% of the MDROs isolated (60/138), followed by Carbapenem-resistant Acinetobacter baumanii (CRAB) (34.8%, 48/138) and Escherichia coli producing an extended-spectrum beta-lactamase (ESBLp) (6.5%, 9/138). MDROs infection was associated with higher mortality (35.2% vs 11.3%, P &lt; 0.001), higher rate of hemorrhage (36.1% vs 11.3%, P &lt; 0.001), longer intensive care unit (ICU) stay (23 vs 12 days, P &lt; 0.001), longer hospital stay (68 vs 51 days, P = 0.001) and more hospitalization expenses (45,190 ± 31,680 vs 26,965 ± 17,167 $, P &lt; 0.001). Multivariate analysis of predictors of mortality indicated that MDROs infection (OR = 2.6; 95% confidence interval [CI], 1.0-6.5; P = 0.042), age ≥ 50 years (OR = 2.6; 95% CI, 1.2-5.8; P = 0.016), severe category (OR = 2.9; 95% CI, 1.1-8.0; P = 0.035), bloodstream infection (OR = 3.4; 95% CI, 1.5-7.6; P = 0.049), step-down surgical approach (OR = 2.7; 95% CI, 1.1-6.2; P = 0.023) were significant factors. CONCLUSIONS: MDROs infection was prevalent among patients with IPN and associated with adverse clinical outcomes and increased mortality.</p>
<p>doi: <a href="https://doi.org/10.1016/j.pan.2019.09.008" class="uri">https://doi.org/10.1016/j.pan.2019.09.008</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Modelling human hepato-biliary-pancreatic organogenesis from the foregut-midgut boundary</strong> </summary></p>
<p><em>Nature 2019 10;574(7776):112-116</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31554966" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31554966</a></p>
<p>Organogenesis is a complex and interconnected process that is orchestrated by multiple boundary tissue interactions1-7. However, it remains unclear how individual, neighbouring components coordinate to establish an integral multi-organ structure. Here we report the continuous patterning and dynamic morphogenesis of hepatic, biliary and pancreatic structures, invaginating from a three-dimensional culture of human pluripotent stem cells. The boundary interactions between anterior and posterior gut spheroids differentiated from human pluripotent stem cells enables retinoic acid-dependent emergence of hepato-biliary-pancreatic organ domains specified at the foregut-midgut boundary organoids in the absence of extrinsic factors. Whereas transplant-derived tissues are dominated by midgut derivatives, long-term-cultured microdissected hepato-biliary-pancreatic organoids develop into segregated multi-organ anlages, which then recapitulate early morphogenetic events including the invagination and branching of three different and interconnected organ structures, reminiscent of tissues derived from mouse explanted foregut-midgut culture. Mis-segregation of multi-organ domains caused by a genetic mutation in HES1 abolishes the biliary specification potential in culture, as seen in vivo8,9. In sum, we demonstrate that the experimental multi-organ integrated model can be established by the juxtapositioning of foregut and midgut tissues, and potentially serves as a tractable, manipulatable and easily accessible model for the study of complex human endoderm organogenesis.</p>
<p>doi: <a href="https://doi.org/10.1038/s41586-019-1598-0" class="uri">https://doi.org/10.1038/s41586-019-1598-0</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>ASO Author Reflections: What Will Be the Future of IPMN Management?</strong> </summary></p>
<p><em>Annals of surgical oncology 2019 Dec;26(Suppl 3):743-744</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31552617" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31552617</a></p>
<p>doi: <a href="https://doi.org/10.1245/s10434-019-07858-y" class="uri">https://doi.org/10.1245/s10434-019-07858-y</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Percutaneous stenting and chemotherapy for unresectable pancreatic cancer: Comparison of irradiation stents vs conventional metal stents</strong> </summary></p>
<p><em>Pancreatology : official journal of the International Association of Pancreatology (IAP) … [et al.] 2019 Oct;19(7):957-962</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31551162" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31551162</a></p>
<p>OBJECTIVES: Percutaneous stenting is a palliative method to relieve obstructive jaundice caused by unresectable pancreatic carcinoma. In this study, we aimed to compare the safety and efficacy of irradiation stents and conventional metal stents. METHODS: A total of 32 patients who received irradiation stents or conventional metal stents to treat obstructive jaundice caused by locally advanced pancreatic cancer were included in this retrospective study. Chemotherapy using gemcitabine was performed after jaundice subsided. Stent patency, technical success, survival, and complications were compared between groups. RESULTS: Seventeen patients were enrolled in the irradiation stent group (ISG), and 15 patients were enrolled in the uncovered stent group (USG). Median and mean stent patency time were 9.8 months (95% CI, 7.682-11.981) and 9.506 months (95% CI, 8.0-11.012) in the ISG, respectively, vs 8.8 months (95% CI, 6.528-11.072) and 7.62 months (95% CI, 5.917-9.323) in the USG, respectively (P = 0.019). Median and mean overall survival were 10.4 months (95% CI, 8.383-12.417) and 9.953 months (95% CI, 8.408-11.498), respectively, in the ISG vs 9.7 months (95% CI, 7.901-11.499) and 8.14 months (95% CI, 6.44-9.84), respectively, in the USG (P = 0.027). CONCLUSIONS: Irradiation stents extend stent patency and overall survival compared with conventional biliary stents for the treatment of pancreatic carcinoma complicated by obstructive jaundice. Irradiation stents combined with chemotherapy may be a better choice for the treatment of obstructive jaundice caused by unresectable pancreatic carcinoma.</p>
<p>doi: <a href="https://doi.org/10.1016/j.pan.2019.09.006" class="uri">https://doi.org/10.1016/j.pan.2019.09.006</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Brush Cytology Performance for the Assessment of Biliopancreatic Strictures</strong> </summary></p>
<p><em>Acta cytologica 2019 Sep;():1-8</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31550713" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31550713</a></p>
<p>INTRODUCTION: Brush cytology is commonly used during endoscopic retrograde cholangiopancreatography for the diagnostic evaluation of biliopancreatic strictures. However, since the overall sensitivity of brush cytology is poor, the exclusion of malignancy is difficult. Recognition of factors related to the patient, technique or lesion may help improve the diagnostic yield of brush cytology. The objective of this study was to evaluate the diagnostic yield of brush cytology in the assessment of biliopancreatic strictures and identify predictive factors associated with a positive diagnosis of malignancy. METHODS: Retrospective study that evaluated all consecutive patients that underwent brush cytology for the investigation of biliopancreatic strictures in a tertiary center, between January 2012 and January 2018. RESULTS: One hundred and sixty-five patients that underwent 182 procedures were included. A diagnosis of malignancy was confirmed in 110 patients (66.7%), of whom 62 had positive brush cytology (sensitivity 53.7%, specificity 98.5%, accuracy 69.8%). On the multivariate analysis, age ≥68 years (OR 4.83, 95% CI 1.04-22.37) and lesions suspicious of metastasis on cross-sectional imaging (OR 8.58, 95% CI 1.70-43.38) were independently associated with a positive result. Subanalysis of the patients presenting with these two factors (n = 26) revealed an increase in the diagnostic yield (sensitivity 80.8%). CONCLUSION: Age ≥68 years and lesions suspicious of metastasis on cross-sectional imaging are independent factors associated with a positive result. Patient selection taking these factors into account may increase the diagnostic yield of brush cytology.</p>
<p>doi: <a href="https://doi.org/10.1159/000502791" class="uri">https://doi.org/10.1159/000502791</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Immunohistochemical profiling of liver metastases and matched-pair analysis in patients with metastatic pancreatic ductal adenocarcinoma</strong> </summary></p>
<p><em>Pancreatology : official journal of the International Association of Pancreatology (IAP) … [et al.] 2019 Oct;19(7):963-970</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31542399" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31542399</a></p>
<p>BACKGROUND: The purpose of the current study was to investigate the immunohistochemical (IHC) profile of liver metastases (LM) in patients with pancreatic ductal adenocarcinoma (PDAC). METHODS: Expression of 15 IHC markers in liver biopsies from 77 patients with PDAC, who were diagnosed between 2010 and 2014, were evaluated. In a separate subgroup analysis (n = 12), paired samples (LM and primary tumor) from the same patient were investigated for IHC profile differences. RESULTS: LM samples were classified as pancreatobiliary-type (PB-type) in 72 patients (93.5%), intestinal-type (INT-type) in four patients (5.2%), and squamous in one patient (1.3%). There was no significant difference in overall survival (OS) between LM of the PB-type or INT-type (p = 0.097). In a multivariate analysis, age &lt;70 years (p = 0.047), absence of SMAD4 mutation (p = 0.026), absence of CDX2 expression (p = 0.003), and well to moderate differentiation were significant prognostic factors for better OS in patients with LM (p = 0.031). Analysis of paired tissue samples from LM and the primary tumor revealed a difference in CDX2 (50% increase, p = 0.125) and SMAD4 (33% loss of SMAD4, p = 0.375). CONCLUSIONS: CDX2 expression and SMAD4 mutation indicate a poor outcome in patients with LM of PDAC. Matched-pair analysis revealed differences in distinct IHC marker expression.</p>
<p>doi: <a href="https://doi.org/10.1016/j.pan.2019.09.005" class="uri">https://doi.org/10.1016/j.pan.2019.09.005</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>ASO Author Reflections: Impact of Neoadjuvant Chemotherapy with Gemcitabine Plus Nab-Paclitaxel for Borderline Resectable Pancreatic Cancer on Surgical Outcomes</strong> </summary></p>
<p><em>Annals of surgical oncology 2019 Dec;26(Suppl 3):739-740</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31538287" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31538287</a></p>
<p>doi: <a href="https://doi.org/10.1245/s10434-019-07857-z" class="uri">https://doi.org/10.1245/s10434-019-07857-z</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>α-Ketoglutarate links p53 to cell fate during tumour suppression</strong> </summary></p>
<p><em>Nature 2019 09;573(7775):595-599</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31534224" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31534224</a></p>
<p>The tumour suppressor TP53 is mutated in the majority of human cancers, and in over 70% of pancreatic ductal adenocarcinoma (PDAC)1,2. Wild-type p53 accumulates in response to cellular stress, and regulates gene expression to alter cell fate and prevent tumour development2. Wild-type p53 is also known to modulate cellular metabolic pathways3, although p53-dependent metabolic alterations that constrain cancer progression remain poorly understood. Here we find that p53 remodels cancer-cell metabolism to enforce changes in chromatin and gene expression that favour a premalignant cell fate. Restoring p53 function in cancer cells derived from KRAS-mutant mouse models of PDAC leads to the accumulation of α-ketoglutarate (αKG, also known as 2-oxoglutarate), a metabolite that also serves as an obligate substrate for a subset of chromatin-modifying enzymes. p53 induces transcriptional programs that are characteristic of premalignant differentiation, and this effect can be partially recapitulated by the addition of cell-permeable αKG. Increased levels of the αKG-dependent chromatin modification 5-hydroxymethylcytosine (5hmC) accompany the tumour-cell differentiation that is triggered by p53, whereas decreased 5hmC characterizes the transition from premalignant to de-differentiated malignant lesions that is associated with mutations in Trp53. Enforcing the accumulation of αKG in p53-deficient PDAC cells through the inhibition of oxoglutarate dehydrogenase-an enzyme of the tricarboxylic acid cycle-specifically results in increased 5hmC, tumour-cell differentiation and decreased tumour-cell fitness. Conversely, increasing the intracellular levels of succinate (a competitive inhibitor of αKG-dependent dioxygenases) blunts p53-driven tumour suppression. These data suggest that αKG is an effector of p53-mediated tumour suppression, and that the accumulation of αKG in p53-deficient tumours can drive tumour-cell differentiation and antagonize malignant progression.</p>
<p>doi: <a href="https://doi.org/10.1038/s41586-019-1577-5" class="uri">https://doi.org/10.1038/s41586-019-1577-5</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Psychometric performance of the PAncreatic CAncer disease impact (PACADI) score</strong> </summary></p>
<p><em>Pancreatology : official journal of the International Association of Pancreatology (IAP) … [et al.] 2019 Oct;19(7):971-978</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31530448" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31530448</a></p>
<p>BACKGROUND/OBJECTIVE: Pancreatic Cancer Disease Impact (PACADI) score measures the impact of pancreatic cancer (PC) on important health dimensions, selected by patients. The aim of this single center study was to test the psychometric performance of the Pancreatic Cancer Disease Impact (PACADI) score. METHODS: Patients with suspected pancreatic cancer (PC) completed PACADI, the EuroQol-5D (EQ-5D index) and Edmonton Symptom Assessment System (ESAS) in this longitudinal observational study. Measures were compared across patients with PC (n = 210), other malignant lesions (OML) (n = 109) and non-malignant lesions (NML) (n = 41). Associations, test-retest and internal consistency reliability, longitudinal changes, sensitivity to change and prediction of mortality during the first year were examined in patients with PC. RESULTS: The three measures discriminated between PC and OML. The PACADI score correlated strongly at baseline (n = 199)/after three months (n = 85) with the EQ-5D index and ESAS “sense of well-being” (0.64 and 0.66/0.73 and 0.69, p &lt; 0.001, respectively), showed high test-retest reliability (ICC 0.84) and very good internal consistency reliability (Cronbach’s alpha 0.81-0.85) across all visits. Scores improved over time at 3, 6, 9 and 12 months for survivors, and standardized response mean (SRM) for improvement between 2 and 3 months (n = 44) was 0.80 (PACADI), -0.59 (EQ-5D index) and 0.69 (ESAS “sense of well-being”). The PACADI score significantly predicted mortality within the first year (p = 0.02) in contrast to the EQ-5D index and ESAS “sense of well-being”. CONCLUSION: This study showed satisfactory psychometric performance of the PACADI score. The results support its use in clinical practice and intervention trials.</p>
<p>doi: <a href="https://doi.org/10.1016/j.pan.2019.09.001" class="uri">https://doi.org/10.1016/j.pan.2019.09.001</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Clinicopathological features of pyloric gland adenomas of the duodenum: a multicentre study of 57 cases</strong> </summary></p>
<p><em>Histopathology 2020 Feb;76(3):404-410</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31529725" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31529725</a></p>
<p>AIMS: To determine the clinicopathological features of pyloric gland adenomas (PGA) that arise in the duodenum. METHODS AND RESULTS: Fifty-seven cases of duodenal PGA were identified and analysed from 56 patients. Clinicopathological and immunohistochemical analyses were performed. PGA tend to occur in older individuals (median age = 73.5), with a slight female predominance (25 males, 31 females). PGA arise more commonly in the proximal duodenum (68.75% in D1, 25% in D2 and 6.25% in D3) and usually present as mucosal nodules (98.2%) or plaques (1.8%), with a mean size of 14.8 mm. There is associated gastric heterotopia in 22.8% of cases. PGA showing features of high-grade dysplasia were significantly larger in size than PGA, showing only low-grade dysplasia (23.1 versus 8.7 mm; P = 0.0001) and more likely to show a tubulovillous rather than a pure tubular architecture (P = 0.025). In our series, 10 of 56 patients had intramucosal or invasive carcinoma associated with the duodenal PGA (17.9%). Three of these carcinomas showed lymph node metastasis. Following definitive treatment, local recurrence occurred in only three patients. CONCLUSIONS: Duodenal PGA tend to occur in the proximal duodenum of older individuals. Larger size and tubulovillous architecture correlates with high-grade dysplasia and associated adenocarcinoma. The low recurrence rate of these lesions would suggest that endoscopic management is appropriate, provided that the lesion can be completely resected.</p>
<p>doi: <a href="https://doi.org/10.1111/his.13996" class="uri">https://doi.org/10.1111/his.13996</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Atp6ap2 deletion causes extensive vacuolation that consumes the insulin content of pancreatic β cells</strong> </summary></p>
<p><em>Proceedings of the National Academy of Sciences of the United States of America 2019 10;116(40):19983-19988</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31527264" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31527264</a></p>
<p>Pancreatic β cells store insulin within secretory granules which undergo exocytosis upon elevation of blood glucose levels. Crinophagy and autophagy are instead responsible to deliver damaged or old granules to acidic lysosomes for intracellular degradation. However, excessive consumption of insulin granules can impair β cell function and cause diabetes. Atp6ap2 is an essential accessory component of the vacuolar ATPase required for lysosomal degradative functions and autophagy. Here, we show that Cre recombinase-mediated conditional deletion of Atp6ap2 in mouse β cells causes a dramatic accumulation of large, multigranular vacuoles in the cytoplasm, with reduction of insulin content and compromised glucose homeostasis. Loss of insulin stores and gigantic vacuoles were also observed in cultured insulinoma INS-1 cells upon CRISPR/Cas9-mediated removal of Atp6ap2. Remarkably, these phenotypic alterations could not be attributed to a deficiency in autophagy or acidification of lysosomes. Together, these data indicate that Atp6ap2 is critical for regulating the stored insulin pool and that a balanced regulation of granule turnover is key to maintaining β cell function and diabetes prevention.</p>
<p>doi: <a href="https://doi.org/10.1073/pnas.1903678116" class="uri">https://doi.org/10.1073/pnas.1903678116</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Incidental pulmonary embolism in pancreatic ductal adenocarcinoma: Impact of tumor and AJCC stages at initial staging CT</strong> </summary></p>
<p><em>Pancreatology : official journal of the International Association of Pancreatology (IAP) … [et al.] 2019 Oct;19(7):979-984</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31522961" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31522961</a></p>
<p>BACKGROUND/OBJECTIVES: To determine the prevalence of incidental pulmonary embolism (PE) detected during initial staging CT among patients with newly diagnosed pancreatic ductal adenocarcinoma (PDAC) and assess their association with underlying tumor burden. MATERIALS AND METHODS: This retrospective cohort study evaluated staging chest CT scans (2013-2017) to identify PE among patients with treatment naïve, biopsy-proven PDAC. Data included age, sex, T stage, AJCC stage, presence/absence of metastases and their location at diagnosis. The association of PE with tumor (T1-T4) and AJCC stage were assessed using Pearson Chi-square and Fischer’s exact test. A threshold p-value of &lt;0.05 indicated statistical significance. RESULTS: A total of 174 patients (90 female, mean age, 68 years; range: 34-93) were identified, of which 10 patients harbored incidental PE (prevalence, 5.7%). In the PE group, two patients presented with distant metastasis (liver, 20%), while eight patients had T4 tumors (80%). No statistical association was detected between PE and age, sex, and the presence/absence or location of distant metastasis (p = 0.065, p = 0.59, p = 0.687 and p = 0.933, respectively). Patients with T4 tumors and higher AJCC stages (stage III/IV) were significantly more likely to present with PE than those with lower T stage (p = 0.045) and AJCC stage (stage I/II; p = 0.017). CONCLUSION: The prevalence of incidental PE among PDAC patients undergoing initial CT staging is 5.7%. Patients with T4 and AJCC stages III/IV are at higher risk of PE. Caution should be exercised during radiographic interpretation of initial staging chest CTs, as incidental PE may be lurking and require treatment.</p>
<p>doi: <a href="https://doi.org/10.1016/j.pan.2019.09.002" class="uri">https://doi.org/10.1016/j.pan.2019.09.002</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Lavage through percutaneous catheter drains in severe acute pancreatitis: Does it help?A randomized control trial</strong> </summary></p>
<p><em>Pancreatology : official journal of the International Association of Pancreatology (IAP) … [et al.] 2019 Oct;19(7):929-934</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31521496" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31521496</a></p>
<p>AIMS: There is no study comparing large volume lavage through image guided percutaneously placed drains in severe acute pancreatitis. METHODS: Of the 114 randomized patients, 60 eligible candidates were randomly allocated to - Lavage Treatment (LT) group (28 patients) and Dependent Drainage (DD) group (32 patients). Primary end point was reversal of pre-existing organ failure, development of new onset organ failure, need for surgery, mortality and hospital stay. RESULTS: Both the groups were comparable in terms of demographic data, onset and severity of pancreatitis. LT group had higher infected pancreatic necrosis (75% vs 50%,p = 0.047). On intention to treat analysis, lavage treatment group showed a significant reversal of persistent organ failure (84% vs 50%, p = 0.23), reduction in APACHEII scores (3.5 ± 3.405 vs 1.16 ± 3.811 p = 0.012), as measured at the time of placement of PCD to cessation of intervention. There was no difference in development of new onset organ failure in the two groups (25% vs37.5% p=.290). 75% in LT group and 69% in DD group improved with PCD alone. There was no difference in the catheter related complications and number of catheters used. The need for surgical intervention was comparable in two groups (18.8% vs 14.3% p=.737). There was a trend toward decreased mortality in group A (18.8% vs 28.8% p=.370). CONCLUSION: Large volume lavage trough PCD improves organ failure and this translates into trend towards reduced mortality.</p>
<p>doi: <a href="https://doi.org/10.1016/j.pan.2019.09.003" class="uri">https://doi.org/10.1016/j.pan.2019.09.003</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Preoperative chemotherapy and carbon ions therapy for treatment of resectable and borderline resectable pancreatic adenocarcinoma: a prospective, phase II, multicentre, single-arm study</strong> </summary></p>
<p><em>BMC cancer 2019 Sep;19(1):922</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31521134" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31521134</a></p>
<p>BACKGROUND: Pancreatic adenocarcinoma is a high-mortality neoplasm with a documented 5-years-overall survival around 5%. In the last decades, a real breakthrough in the treatment of the disease has not been achieved. Here we propose a prospective, phase II, multicentre, single-arm study aiming to assess the efficacy and the feasibility of a therapeutic protocol combining chemotherapy, carbon ion therapy and surgery for resectable and borderline resectable pancreatic adenocarcinoma. METHOD: The purpose of this trial (PIOPPO Protocol) is to assess the efficacy and the feasibility of 3 cycles of FOLFIRINOX neoadjuvant chemotherapy followed by a short-course of carbon ion radiotherapy (CIRT) for resectable or borderline resectable pancreatic adenocarcinoma patients. Primary outcome of this study is the assessment of local progression free survival (L-PFS). The calculation of sample size is based on the analysis of the primary endpoint “progression free survival” according to Fleming’s Procedure. DISCUSSION: Very preliminary results provide initial evidence of the feasibility of the combined chemotherapy and CIRT in the neoadjuvant setting for resectable or borderline resectable pancreatic cancer. Completion of the accrual and long term results are awaited to see if this combination of treatment is advisable and will provide the expected benefits. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03822936 registered on January 2019.</p>
<p>doi: <a href="https://doi.org/10.1186/s12885-019-6108-0" class="uri">https://doi.org/10.1186/s12885-019-6108-0</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Precision medicine in pancreatic cancer: treating every patient as an exception</strong> </summary></p>
<p><em>The lancet. Gastroenterology &amp; hepatology 2019 Oct;4(10):805-810</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31511204" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31511204</a></p>
<p>Patients with pancreatic cancer have not benefited from recent improvements in overall survival brought about by precision medicine in other malignancies. This failure is not due to a dearth of precision-medicine research in pancreatic ductal adenocarcinoma (PDAC), the main type of pancreatic cancer. In fact, the stalled progress in precision therapies for this type of cancer is due to the absence of agents that are able to target the common genetic alterations in PDAC. Several studies have attempted to phenotypically stratify PDAC at the transcriptional level. However, the value of such classifications will only be revealed through prospective studies and, crucially, only after development of new treatment options for this disease. Therefore, it is essential to learn from breakthrough discoveries in other cancer types that could benefit subpopulations of patients with PDAC and convert them from ordinary to exceptional responders. Identifying these exceptional patients will help to bring PDAC in line with other cancer types in terms of availability of precision therapies. Thus, the true challenge to precision medicine for PDAC might be the poor consensus on which genetic and phenotypic alterations across the spectrum of this disease are actionable; not the absence of actionable variables themselves. To reach consensus, knowledge and tools must be developed and disseminated for individuals who provide pancreatic cancer care, to enable the real-time identification of exceptional patients, more precise subgroup classifications, and effective disease management strategies; all informed by immediate feedback from clinical outcome data.</p>
<p>doi: <a href="https://doi.org/10.1016/S2468-1253(19)30175-X" class="uri">https://doi.org/10.1016/S2468-1253(19)30175-X</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Two cases of lung neuroendocrine carcinoma with carcinoid morphology</strong> </summary></p>
<p><em>Diagnostic pathology 2019 Sep;14(1):104</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31511024" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31511024</a></p>
<p>BACKGROUND: The category of grade 3 neuroendocrine tumor (NET G3) was newly introduced in the 2017 World Health Organization (WHO 2017) classification of neuroendocrine neoplasms of the pancreas. Pancreatic NET G3 shows a carcinoid-like morphology with high proliferative activity and the prognosis is intermediate between NET G2 and neuroendocrine carcinoma. There is no category corresponding to NET G3 in the current WHO 2015 classification of lung tumors. Herein, we report two cases of lung neuroendocrine carcinoma with carcinoid morphology that correspond to NET G3. CASE PRESENTATION: Case 1: An abnormal chest shadow was detected in a 78-year-old female never-smoker during a routine medical examination. She was asymptomatic. The radiological assessment revealed a mass in the peripheral S4 segment of the right lung. She underwent right middle lobectomy for the mass preoperatively diagnosed as non-small cell lung carcinoma. Postoperative histological examination revealed a neuroendocrine tumor with carcinoid morphology and a mitotic count of 15/2 mm2. Case 2: An abnormal chest shadow was detected in a 74-year-old female never-smoker undergoing follow-up for another disease. She was asymptomatic. The radiological assessment revealed a mass in the peripheral S3 segment of the right lung. She underwent right upper lobectomy for the mass suspected to be lung carcinoma. Postoperative histological examination revealed a neuroendocrine tumor with carcinoid morphology with mitotic count of 13/2 mm2. Both of these tumors showed carcinoid morphology but with a mitotic count exceeding 10/2 mm2; thus, we diagnosed them as small cell lung carcinomas according to the current WHO 2015 classification. CONCLUSIONS: Our tumors occurred in female never-smokers and their histology showed carcinoid morphology without extensive necrosis. Moreover, proliferative abilities of them were extremely low compared to small cell lung carcinoma. The clinical and pathological features of our tumors appeared to be different from those of small cell lung carcinoma. Although there is no category corresponding to NET G3 in the current classification of lung tumors, we consider that our tumors may correspond to NET G3 and identification of this subset is relevant for therapeutic management.</p>
<p>doi: <a href="https://doi.org/10.1186/s13000-019-0886-1" class="uri">https://doi.org/10.1186/s13000-019-0886-1</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Risk evaluation of splenic hilar or splenic artery lymph node metastasis and survival analysis for patients with proximal gastric cancer after curative gastrectomy: a retrospective study</strong> </summary></p>
<p><em>BMC cancer 2019 Sep;19(1):905</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31510966" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31510966</a></p>
<p>BACKGROUND: As splenectomy and spleen-preserving lymphadenectomy are performed only in some proximal gastric cancer patients, it is difficult to identify patients who have undergone radical gastrectomy with or without splenic hilar (No.10) or splenic artery (No.11) lymph node metastases. We aimed to determine the risk factors for No.10 and No.11 lymph node metastases and evaluate the survival significance of No.10 and No.11 lymph node dissection in advanced proximal gastric cancer patients. METHODS: A total of 873 advanced proximal gastric cancer patients who underwent curative gastrectomy with or without splenectomy or pancreaticosplenectomy were analyzed retrospectively. The clinicopathological characteristics of 152 patients who underwent splenectomy or pancreaticosplenectomy were analyzed to determine the risk factors for No.10 and No.11 lymph node metastases. The survival difference between patients with No.10 and No.11 lymph node dissections and those who did not undergo these dissections were compared. RESULTS: Patients with No.10 and No.11 lymph node metastases had very poor prognoses. Tumor invasion of the greater curvature and No.2 and No.4 lymph node metastases were independent risk factors for No.10 and No.11 lymph node metastases. No survival differences were evident between patients with No.10 and No.11 lymph node metastases who underwent No.10 and No.11 lymph node dissections and those who did not undergo these dissections but were at high risks of No.10 and No.11 lymph node metastases. CONCLUSIONS: Splenic hilar or splenic artery lymph node dissection was not associated with increased survival, in proximal gastric cancer patients without direct cancer invasion of the spleen and pancreas, regardless of whether splenectomy, pancreaticosplenectomy, or spleen-preserving lymphadenectomy was performed.</p>
<p>doi: <a href="https://doi.org/10.1186/s12885-019-6112-4" class="uri">https://doi.org/10.1186/s12885-019-6112-4</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Role of Ancillary Testing on Endoscopic US-Guided Fine Needle Aspiration Samples from Cystic Pancreatic Neoplasms</strong> </summary></p>
<p><em>Acta cytologica 2020 09;64(1-2):124-135</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31509835" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31509835</a></p>
<p>Pancreatic cysts are increasingly detected on imaging studies. Accurate determination of the cyst type is important to provide appropriate care for the patients. It is also very clear that not one single modality can provide adequate diagnostic information. A multidisciplinary approach is the key to the diagnosis of pancreatic cysts. In this setting, the role of ancillary testing, which includes biochemical testing (carcinoembryonic antigen and amylase levels in the cyst), molecular testing (e.g., KRAS, GNAS, VHL, and CTNB1), and/or immunohistochemical tests are very important to obtain an accurate diagnosis. This review will discuss helpful ancillary tests in common pancreatic cyst neoplasms and how to approach the diagnosis of pancreatic cysts.</p>
<p>doi: <a href="https://doi.org/10.1159/000502372" class="uri">https://doi.org/10.1159/000502372</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Alcohol-dependent effect of PRSS1-PRSS2 haplotype in chronic pancreatitis</strong> </summary></p>
<p><em>Gut 2019 Sep;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31506327" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31506327</a></p>
<p>doi: <a href="https://doi.org/10.1136/gutjnl-2019-319729" class="uri">https://doi.org/10.1136/gutjnl-2019-319729</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Risk analysis of extended pancreas donor selection criteria</strong> </summary></p>
<p><em>Pancreatology : official journal of the International Association of Pancreatology (IAP) … [et al.] 2019 Oct;19(7):994-999</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31495709" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31495709</a></p>
<p>INTRODUCTION: The success of pancreas transplantation, in combination with a stable number of available allografts has resulted in an increasing waiting list. This study investigated donor potential by expanding age and Body Mass Index (BMI) criteria. METHODS: All reported donors in the Netherlands between 2013 and 2017 were analysed. Risk assessment of extended criteria donors was done by in-depth analysis of donor reports and calculation of the Pancreas Donor Risk Index (PDRI). The PDRI of these extended criteria donors was compared to standard criteria donors to evaluate the increased risk on graft failure. RESULTS: A total of 1273 donors were reported. Of these donors, 405 donors were reported as pancreas donor, of which 93 (23%) pancreata were transplanted. Extending age criterion with 5 years could result in additional 40 Donation after Brain Death donors and 37 Donation after Circulatory Death donors reported. In 24 (31%) extended age criteria donors the PDRI was below the upper limit of currently transplanted pancreata. Extending BMI criteria to 35 kg/m2 could result in an additional 19 (6%) donors reported. CONCLUSIONS: Extending BMI criteria could result in a slight increase of reported donors. Extending age criteria increased significantly the number of reported donors. In 24 (31%) of the older donors the PDRI showed a reduced risk compared to currently transplanted pancreata. This study suggest that, if other risk factors are absent, pancreata of extended age and/or BMI criteria donors should be considered for transplantation.</p>
<p>doi: <a href="https://doi.org/10.1016/j.pan.2019.08.010" class="uri">https://doi.org/10.1016/j.pan.2019.08.010</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Proteomic analyses of ECM during pancreatic ductal adenocarcinoma progression reveal different contributions by tumor and stromal cells</strong> </summary></p>
<p><em>Proceedings of the National Academy of Sciences of the United States of America 2019 09;116(39):19609-19618</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31484774" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31484774</a></p>
<p>Pancreatic ductal adenocarcinoma (PDAC) has prominent extracellular matrix (ECM) that compromises treatments yet cannot be nonselectively disrupted without adverse consequences. ECM of PDAC, despite the recognition of its importance, has not been comprehensively studied in patients. In this study, we used quantitative mass spectrometry (MS)-based proteomics to characterize ECM proteins in normal pancreas and pancreatic intraepithelial neoplasia (PanIN)- and PDAC-bearing pancreas from both human patients and mouse genetic models, as well as chronic pancreatitis patient samples. We describe detailed changes in both abundance and complexity of matrisome proteins in the course of PDAC progression. We reveal an early up-regulated group of matrisome proteins in PanIN, which are further up-regulated in PDAC, and we uncover notable similarities in matrix changes between pancreatitis and PDAC. We further assigned cellular origins to matrisome proteins by performing MS on multiple lines of human-to-mouse xenograft tumors. We found that, although stromal cells produce over 90% of the ECM mass, elevated levels of ECM proteins derived from the tumor cells, but not those produced exclusively by stromal cells, tend to correlate with poor patient survival. Furthermore, distinct pathways were implicated in regulating expression of matrisome proteins in cancer cells and stromal cells. We suggest that, rather than global suppression of ECM production, more precise ECM manipulations, such as targeting tumor-promoting ECM proteins and their regulators in cancer cells, could be more effective therapeutically.</p>
<p>doi: <a href="https://doi.org/10.1073/pnas.1908626116" class="uri">https://doi.org/10.1073/pnas.1908626116</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Comment on “Deleterious Effect of RAS and Evolutionary High-risk TP53 Double Mutation in Colorectal Liver Metastases”</strong> </summary></p>
<p><em>Annals of surgery 2020 Feb;271(2):e15-e16</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31478983" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31478983</a></p>
<p>doi: <a href="https://doi.org/10.1097/SLA.0000000000003600" class="uri">https://doi.org/10.1097/SLA.0000000000003600</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Comparison of the clinicopathological features of pancreatic solid pseudopapillary neoplasms between males and females: gender does matter</strong> </summary></p>
<p><em>Histology and histopathology 2020 Mar;35(3):257-268</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31478554" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31478554</a></p>
<p>BACKGROUND: Solid pseudopapillary neoplasms (SPN) of the pancreas are a rare and low-grade malignant entity with a female predominance. However, it also occurs in males, but the rarity and lack of concern makes its clinicopathological features unclarified. METHODS: The morphological, immunohistochemical, prognostic features and CTNNB1 exon 3 mutation status of SPN were compared semi-quantitively between 9 male and 21 female patients. RESULTS: SPN in males grew in a distinctive solid pattern, with abundant fibrotic stroma and clear cells. Collagen tended to be the main component of tumor stroma in males, while hyaluronan composed a considerable proportion in females. A much stronger expression of androgen receptor (AR) was found in males, and CD56 and/or synaptophysin (Syn) was expressed frequently in both genders. All patients survived. One male patient had post-operational liver nodules and accepted interventional therapy without biopsy. Mutations of CTNNB1 exon 3 were observed in all cases, distributed at codon 32, 33 and 37 in both genders, as well as 34, 41 and 62 in females. CONCLUSION: SPN in males presented with significantly different morphological features from that in females, which might be helpful in differential diagnosis, especially when with extensive positivity for CD56 and/or Syn. The stronger expression of AR in males might be a clue to explore the underlying mechanism of the gender difference.</p>
<p>doi: <a href="https://doi.org/10.14670/HH-18-156" class="uri">https://doi.org/10.14670/HH-18-156</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Serotonin and Dopamine Receptor Expression in Solid Tumours Including Rare Cancers</strong> </summary></p>
<p><em>Pathology oncology research : POR 2019 Sep;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31478179" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31478179</a></p>
<p>In preclinical studies serotonin stimulates and dopamine inhibits tumour growth and angiogenesis. Information regarding serotonin and dopamine receptor (5-HTR and DRD) expression in human cancers is limited. Therefore, we screened a large tumour set for receptor mRNA overexpression using functional genomic mRNA (FGmRNA) profiling, and we analysed protein expression and location of 5-HTR1B, 5-HTR2B, DRD1, and DRD2 with immunohistochemistry in different tumour types. With FGmRNA profiling 11,756 samples representing 43 tumour types were compared to 3,520 normal tissue samples to analyse receptor overexpression. 5-HTR2B overexpression was present in many tumour types, most frequently in uveal melanomas (56%). Receptor overexpression in rare cancers included 5-HTR1B in nasopharyngeal carcinoma (17%), DRD1 in ependymoma (30%) and synovial sarcoma (21%), and DRD2 in astrocytoma (13%). Immunohistochemistry demonstrated high 5-HTR2B protein expression on melanoma and gastro-intestinal stromal tumour cells and endothelial cells of colon, ovarian, breast, renal and pancreatic tumours. 5-HTR1B expression was predominantly low. High DRD2 protein expression on tumour cells was observed in 48% of pheochromocytomas, and DRD1 expression ranged from 14% in melanoma to 57% in renal cell carcinoma. In conclusion, 5-HTR1B, 5-HTR2B, DRD1, and DRD2 show mRNA overexpression in a broad spectrum of common and rare cancers. 5-HTR2B protein is frequently highly expressed in human cancers, especially on endothelial cells. These findings support further investigation of especially 5HTR2B as a potential treatment target.</p>
<p>doi: <a href="https://doi.org/10.1007/s12253-019-00734-w" class="uri">https://doi.org/10.1007/s12253-019-00734-w</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Treatment of disrupted and disconnected pancreatic duct in necrotizing pancreatitis: A systematic review and meta-analysis</strong> </summary></p>
<p><em>Pancreatology : official journal of the International Association of Pancreatology (IAP) … [et al.] 2019 Oct;19(7):905-915</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31473083" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31473083</a></p>
<p>BACKGROUND: Necrotizing pancreatitis may lead to loss of integrity of the pancreatic duct, resulting in leakage of pancreatic fluid. Pancreatic duct disruption or disconnection is associated with a prolonged disease course and particular complications. Since a standard treatment for this condition is currently lacking, we performed a systematic review of the literature to compare outcomes of various treatment strategies. METHODS: A systematic review was performed according to the PRISMA guidelines in the PubMed, EMBASE and Cochrane databases. Included were articles considering the treatment of patients with disrupted or disconnected pancreatic duct resulting from acute necrotizing pancreatitis. RESULTS: Overall, 21 observational cohort studies were included comprising a total of 583 relevant patients. The most frequently used treatment strategies included endoscopic transpapillary drainage, endoscopic transluminal drainage, surgical drainage or resection, or combined procedures. Pooled analysis showed success rates of 81% (95%-CI: 60-92%) for transpapillary and 92% (95%-CI: 77-98%) for transluminal drainage, 80% (95%-CI: 67-89%) for distal pancreatectomy and 84% (95%-CI: 73-91%) for cyst-jejunostomy. Success rates did not differ between surgical procedures (cyst-jejunostomy and distal pancreatectomy (risk ratio = 1.06, p = .26)) but distal pancreatectomy was associated with a higher incidence of endocrine pancreatic insufficiency (risk ratio = 3.06, p = .01). The success rate of conservative treatment is unknown. DISCUSSION: Different treatment strategies for pancreatic duct disruption and duct disconnection after necrotizing pancreatitis show high success rates but various sources of bias in the available studies are likely. High-quality prospective, studies, including unselected patients, are needed to establish the most effective treatment in specific subgroups of patients, including timing of treatment and long-term follow-up.</p>
<p>doi: <a href="https://doi.org/10.1016/j.pan.2019.08.006" class="uri">https://doi.org/10.1016/j.pan.2019.08.006</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Modulation of all-trans retinoic acid-induced MiRNA expression in neoplastic cell lines: a systematic review</strong> </summary></p>
<p><em>BMC cancer 2019 Aug;19(1):866</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31470825" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31470825</a></p>
<p>BACKGROUND: Cancer is a genetic and epigenetic disease that involves inactivation of tumor suppressor genes and activation of proto-oncogenes. All-trans retinoic acid (ATRA) is an isomer of retinoic acid involved in the onset of differentiation and apoptosis of a number of normal and cancer cells, functioning as an anti-cancer agent in several neoplasms. Ectopic changes in the expression of certain microRNAs (miRNAs) occur in response to ATRA, leading to phenotypic alterations in neoplastic cell lines. Moreover, the modulation of miRNA patterns upon ATRA-treatment may represent an effective chemopreventive and anti-cancer therapy strategy. The present systematic review was performed to provide an overview of the modulation of ATRA-induced miRNA expression in different types of neoplastic cells and identify the efficacy of intervention factors (i.e., concentration and duration of treatment) and how they influence expression profiles of oncogenesis-targeting miRNAs. METHODS: A systematic search was conducted according to the PRISMA statement via the US National Library of Medicine MEDLINE/PubMed bibliographic search engine. RESULTS: The search identified 31 experimental studies involving human cell lines from nine different cancer types (neuroblastoma, acute myeloid leukemia, breast cancer, lung cancer, pancreatic cancer, glioma, glioblastoma, embryonal carcinoma, and colorectal cancer) treated with ATRA at concentrations ranging from 10- 3 μmol/L to 102 μmol mol/L for 24 h to 21 days. CONCLUSION: The concentrations used and the duration of treatment of cancer cells with ATRA varied widely. The presence of ATRA in the culture medium of cancer cells was able to modulate the expression of more than 300 miRNAs, and inhibit invasive behavior and deregulated growth of cancer cells, resulting in total tumor remission in some cases. ATRA may thus be broadly effective for neoplasm treatment and prevention, although these studies may not accurately represent in vivo conditions. Additional studies are required to elucidate ATRA-induced miRNA modulation during neoplasm treatment.</p>
<p>doi: <a href="https://doi.org/10.1186/s12885-019-6081-7" class="uri">https://doi.org/10.1186/s12885-019-6081-7</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>CA19-9 decrease and survival according to platelet level in patients with advanced pancreatic cancer</strong> </summary></p>
<p><em>BMC cancer 2019 Aug;19(1):860</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31470818" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31470818</a></p>
<p>BACKGROUND: CA19-9 decrease during treatment has been associated with superior survival of pancreatic cancer in several studies. The evidence to show the correlation of high platelet level with inferior survival is insufficient in pancreatic cancer. It also remains unclear whether the association between CA19-9 decrease and survival was corresponded to different levels of platelet in metastatic pancreatic cancer. METHODS: We measured CA19-9 serum concentration and platelet level at baseline and after the second cycle of chemotherapy for 200 advanced pancreatic cancer patients. A Cox proportional hazards model was used to compute mortality hazard ratios (HRs) for CA19-9 decrease, adjusting for potential confounders, including age, sex, KPS, prediagnosis body mass index, Diabetes Mellitus, tumor location, first-line chemotherapy regimen, and radiotherapy. RESULTS: We found that the association of CA19-9 decrease with superior overall survival was stronger in advanced pancreatic cancer with a low level of platelet (Pinteraction &lt;  0.001) compared with intermediate and high level of platelet. Multivariable-adjusted hazard ratios per unit decrease of CA19-9 change was 0.45 [95% confidence interval (CI), 0.33 to 0.62] in cases with low platelet level, 0.74 (95% CI, 0.50 to 1.09) in cases with intermediate platelet level, and 0.94 (95% CI, 0.74 to 1.10) in cases with high platelet level. A similar differential association was found between CA19-9 decrease and progression-free survival in strata of platelet level (Pinteraction = 0.034). CONCLUSION: The association of CA19-9 decrease with superior pancreatic cancer survival appeared to be pronounced in patients with a low platelet level. This finding could provide supports for the underlying mechanisms of CA19-9 involved in platelet / tumor cell interaction.</p>
<p>doi: <a href="https://doi.org/10.1186/s12885-019-6078-2" class="uri">https://doi.org/10.1186/s12885-019-6078-2</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Higher IL-6 peri-tumoural expression is associated with gastro-intestinal neuroendocrine tumour progression</strong> </summary></p>
<p><em>Pathology 2019 Oct;51(6):593-599</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31466863" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31466863</a></p>
<p>An association of well-differentiated gastroenteropancreatic neuroendocrine tumours (WD GEP NETs) with metabolic syndrome (MetS) was recently described. Yet no molecular mechanisms linking the two conditions are known. This study’s aim was to identify putative molecular signatures linking WD GEP NETs and MetS to gain further insight into potential mechanisms for this association. Patients with WD GEP NETs (n=39), pancreatic (panNET) and gastro-intestinal (GI-NET), were clinically evaluated for presence of MetS. WD GEP NETs immunohistochemistry staining for Forkhead box protein M1 (FOXM1), insulin growth factor 1 receptor (IGF1R), Ki-67 and interleukin 6 (IL-6) was performed and quantified by computerised morphometric analysis. FOXM1, Ki-67, IGF1R or IL-6 expression in WD GEP NETs was not influenced by the presence of MetS. IL-6 peritumoural expression was higher in GI-NETs of patients with low HDL cholesterol (0.018±0.005% vs 0.030±0.005%, p=0.02). In GI-NETs, a higher IL-6 expression was also associated with disease progression (0.026±0.004% vs 0.016±0.002%, p=0.03). In WD GEP-NETs, MetS did not influence FOXM1, IGF1R and IL-6 expression. In GI-NETs, IL-6 expression was influenced by the MetS feature low HDL, and positively associated with disease progression. These data suggest that local and systemic inflammatory status can potentially modulate GI-NET behaviour.</p>
<p>doi: <a href="https://doi.org/10.1016/j.pathol.2019.07.001" class="uri">https://doi.org/10.1016/j.pathol.2019.07.001</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Chronic inflammation markers are associated with risk of pancreatic cancer in the Swedish AMORIS cohort study</strong> </summary></p>
<p><em>BMC cancer 2019 Aug;19(1):858</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31464604" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31464604</a></p>
<p>BACKGROUND: Nested case-control studies examining the association between serum markers of chronic inflammation, focused on three specific biomarkers (CRP, IL-8 and TNF-α), and risk of pancreatic cancer have reported no associations. In this study, we evaluated associations between standard pre-diagnostic serum markers of chronic inflammation (CRP, albumin, haptoglobin and leukocytes) and pancreatic cancer risk in the Swedish Apolipoprotein-related MORtality RISk (AMORIS) prospective cohort study. METHODS: We selected all participants (≥20 years old) with baseline measurements of CRP, albumin, haptoglobin and leukocytes between 1985 and 1996 (n = 61,597). Participants were excluded if they had a history of chronic pancreatitis and all individuals were free from pancreatic cancer at baseline. Cox proportional multivariable hazards regression analysis was carried out for medical cut-offs of CRP, albumin, haptoglobin and leukocytes. RESULTS: We observed an increased risk of pancreatic cancer for those individuals with higher levels of serum haptoglobin (≥1.4 g/L), CRP (≥10 mg/L) and leukocytes (≥10 × 109 cells/L) compared to those with haptoglobin levels &lt; 1.4 g/L, CRP levels &lt; 10 mg/L and Leukocyte levels &lt; 10 × 109 cells/L [haptoglobin HR: 2.23 (95% CI 1.72-2.88), CRP HR: 1.32 (95% CI 1.00-1.74), leukocytes HR: 2.20 (95% CI 1.52-3.18)]. No associations were noted for serum albumin. CONCLUSIONS: We found an increased risk of pancreatic cancer associated with pre-diagnostic serum levels of haptoglobin, CRP and leukocytes. Our finding suggests a possible role of chronic inflammation in the aetiology of pancreatic cancer and highlight the need to further investigate this association.</p>
<p>doi: <a href="https://doi.org/10.1186/s12885-019-6082-6" class="uri">https://doi.org/10.1186/s12885-019-6082-6</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>ASO Author Reflections: Formalization of Robotic Central Pancreatectomy Focusing on the Reconstruction of Pancreatic Digestive Continuity</strong> </summary></p>
<p><em>Annals of surgical oncology 2019 Dec;26(Suppl 3):707-708</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31463694" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31463694</a></p>
<p>doi: <a href="https://doi.org/10.1245/s10434-019-07774-1" class="uri">https://doi.org/10.1245/s10434-019-07774-1</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Whole-genome sequencing reveals distinct genetic bases for insulinomas and non-functional pancreatic neuroendocrine tumours: leading to a new classification system</strong> </summary></p>
<p><em>Gut 2020 May;69(5):877-887</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31462556" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31462556</a></p>
<p>OBJECTIVE: Insulinomas and non-functional pancreatic neuroendocrine tumours (NF-PanNETs) have distinctive clinical presentations but share similar pathological features. Their genetic bases have not been comprehensively compared. Herein, we used whole-genome/whole-exome sequencing (WGS/WES) to identify genetic differences between insulinomas and NF-PanNETs. DESIGN: The mutational profiles and copy-number variation (CNV) patterns of 211 PanNETs, including 84 insulinomas and 127 NF-PanNETs, were obtained from WGS/WES data provided by Peking Union Medical College Hospital and the International Cancer Genome Consortium. Insulinoma RNA sequencing and immunohistochemistry data were assayed. RESULTS: PanNETs were categorised based on CNV patterns: amplification, copy neutral and deletion. Insulinomas had CNV amplifications and copy neutral and lacked CNV deletions. CNV-neutral insulinomas exhibited an elevated rate of YY1 mutations. In contrast, NF-PanNETs had all three CNV patterns, and NF-PanNETs with CNV deletions had a high rate of loss-of-function mutations of tumour suppressor genes. NF-PanNETs with CNV alterations (amplification and deletion) had an elevated risk of relapse, and additional DAXX/ATRX mutations could predict an increased relapse risk in the first 2-year period. CONCLUSION: These WGS/WES data allowed a comprehensive assessment of genetic differences between insulinomas and NF-PanNETs, reclassifying these tumours into novel molecular subtypes. We also proposed a novel relapse risk stratification system using CNV patterns and DAXX/ATRX mutations.</p>
<p>doi: <a href="https://doi.org/10.1136/gutjnl-2018-317233" class="uri">https://doi.org/10.1136/gutjnl-2018-317233</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Cell block processing is optimal for assessing endoscopic ultrasound fine needle aspiration specimens of pancreatic mucinous cysts</strong> </summary></p>
<p><em>Journal of clinical pathology 2020 Feb;73(2):102-106</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31462450" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31462450</a></p>
<p>AIMS: The cell block technique for assessing endoscopic ultrasound-guided fine needle aspiration (EUS-FNA) specimens from pancreatic mucinous cystic lesions (MCLs) was systematically evaluated for the first time, including comparisons with three traditional methods of assessing such specimens. METHODS: The prospective arm comprised EUS-FNA specimens from EUS-suspected pancreatic MCLs. The retrospective arm comprised EUS-FNA specimens from pancreatic MCLs surgically resected before the study start. For each specimen, these data points were collected: macroscopic likelihood of mucin, cyst fluid carcinoembryonic antigen (CEA) level and presence of mucin in air-dried, direct smears and in cell block preparations. RESULTS: The prospective and retrospective arms of the study comprised 80 and 30 EUS-FNA specimens, respectively. Seven prospective cases led to surgical resections during the study, and therefore, 37 EUS-FNA specimens were confirmed to have originated from MCLs. In the prospective arm, macroscopic mucin was suspected, cyst fluid CEA level exceeded 192 ng/mL, mucin was detected in direct smears and cell block preparations in 78%, 30%, 39% and 73% of cases, respectively. Of the 37 specimens confirmed to originate from MCLs, macroscopic mucin assessment, cyst fluid CEA level, direct smear mucin assessment and cell block mucin assessment had sensitivities for diagnosing MCL of 87%, 45%, 45% and 81%, respectively. CONCLUSIONS: Cell block preparations are as likely to identify mucin from pancreatic MCLs as macroscopic assessment but are twice as likely to diagnose MCL than direct smears and fluid CEA biochemistry. The cell block technique is easy for sample collection and processing especially because these are identical for solid and cystic pancreatic lesions.</p>
<p>doi: <a href="https://doi.org/10.1136/jclinpath-2019-206079" class="uri">https://doi.org/10.1136/jclinpath-2019-206079</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Pancreatic calcifications associate with diverse aetiological risk factors in patients with chronic pancreatitis: A multicentre study of 1500 cases</strong> </summary></p>
<p><em>Pancreatology : official journal of the International Association of Pancreatology (IAP) … [et al.] 2019 Oct;19(7):922-928</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31462382" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31462382</a></p>
<p>BACKGROUND: Pancreatic calcifications is a common finding in patients with chronic pancreatitis (CP), but the underlying pathophysiology is incompletely understood. Past studies for risk factors of calcifications have generally been focused on single parameters or limited by small sample sizes. The aim of this study was to explore several patient and disease characteristics and their associations with pancreatic calcifications in a large cohort of CP patients with diverse aetiological risk factors. METHODS: This was a multicentre, cross-sectional study including 1509 patients with CP. Patient and disease characteristics were compared for patients with calcifications (n = 912) vs. without calcifications (n = 597). Multivariable logistic regression was performed to assess the parameters independently associated with calcifications. RESULTS: The mean age of patients was 53.9 ± 14.5 years and 1006 (67%) were men. The prevalence of calcifications was 60.4% in the overall patient cohort, but highly variable between patients with different aetiological risk factors (range: 2-69%). On multivariate analysis, alcoholic aetiology (OR 1.76 [95% CI, 1.39-2.24]; p &lt; 0.001) and smoking aetiology (OR 1.77 [95% CI, 1.39-2.26], p &lt; 0.001) were positively associated with the presence of calcifications, while an autoimmune aetiology was negatively associated with calcifications (OR 0.15 [95% CI, 0.08-0.27], p &lt; 0.001). Patients with pancreatic calcifications were more likely to have undergone pancreatic duct stenting (OR 1.59 [95%CI, 1.16-2.19], p = 0.004). CONCLUSION: The presence of pancreatic calcifications is associated with diverse aetiological risk factors in patients with CP. This observation attest to the understanding of CP as a complex disease and may have implications for disease classification.</p>
<p>doi: <a href="https://doi.org/10.1016/j.pan.2019.08.009" class="uri">https://doi.org/10.1016/j.pan.2019.08.009</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Comparative efficacy and tolerability of front-line treatments for newly diagnosed chronic-phase chronic myeloid leukemia: an update network meta-analysis</strong> </summary></p>
<p><em>BMC cancer 2019 Aug;19(1):849</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31462241" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31462241</a></p>
<p>BACKGROUND: Recent years have witnessed the rapid evolution of therapies in chronic-phase chronic myeloid leukemia (CP-CML). To assess the efficacy and tolerability of all reported front-line treatments for patients with newly diagnosed CML, a multiple-treatments meta-analysis was performed, which accounted for both direct and indirect comparisons among those treatments. METHODS: Primary outcomes were the percentage of patients achieving major molecular response (MMR) and complete cytogenetic response (CCyR) within 12 months. Secondary outcomes included the percentage of progression to accelerated phase (AP), serious adverse effects (AEs), overall discontinuation and discontinuation for drug-related AEs. Direct pairwise meta-analysis and indirect multi-comparison meta-analysis among those treatments in each outcome were both conducted. The surface under the cumulative ranking curve (SUCRA) was calculated for all treatments in each outcome. Cluster analysis demonstrated the division of treatments into distinct groupings according to efficacy and tolerability profiles. RESULTS: A total of 21 randomized controlled trials (RCTs, including 10,187 patients) comparing 15 different interventions for CP-CML patients were included in this study. SUCRA analysis suggested that all tyrosine kinase inhibitors (TKIs) are highly effective in newly diagnosed CP-CML when compared to traditional drugs. Newer TKIs and higher-dose imatinib generally resulted in faster cytogenetic and molecular responses when compared with standard-dose imatinib and traditional drugs. Furthermore, traditional drugs, higher-dose imatinib and newer TKIs demonstrated lower acceptability than standard-dose imatinib. One cluster of interventions, which included nilotinib (300/400 mg BID), dasatinib (100 mg QD) and radotinib (300 mg BID), demonstrated higher efficacy and tolerability than other treatments. CONCLUSIONS: Nilotinib (300/400 mg BID), dasatinib (100 mg QD) and radotinib (300 mg BID) prove to be the most recommended front-line treatments of the greatest efficacy and tolerability for CP-CML patients. High-dose therapies are recommended only for patients in accelerated phase/blast phase or with suboptimal CML-CP response, and management of adverse events should be carried out to avoid compromising the clinical efficacy.</p>
<p>doi: <a href="https://doi.org/10.1186/s12885-019-6039-9" class="uri">https://doi.org/10.1186/s12885-019-6039-9</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Preoperative Risk Assessment for Loss of Independence Following Hepatic Resection in Elderly Patients: A Prospective Multicenter Study</strong> </summary></p>
<p><em>Annals of surgery 2019 Aug;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31460876" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31460876</a></p>
<p>OBJECTIVE: To establish a preoperative risk assessment method for loss of independence after hepatic resection. SUMMARY BACKGROUND DATA: Hepatic resection often results in loss of independence in preoperatively self-sufficient elderly people. Elderly patients should therefore be carefully selected for surgery. METHODS: In this prospective, multicenter study, 347 independently-living patients aged ≥65 years, scheduled for hepatic resection, were divided into study (n = 232) and validation (n = 115) cohorts. We investigated the risk factors for postoperative loss of independence in the study cohort and verified our findings with the validation cohort. Loss of independence was defined as transfer to a rehabilitation facility, discharge to residence with home-based healthcare, 30-day readmission for poor functionality, and 90-day mortality (except for cancer-related deaths). RESULTS: In the study cohort, univariate and multivariate analyses indicated that frailty, age ≥ 76 years, and open surgery were independent risk factors for postoperative loss of independence. Proportions of patients with postoperative loss of independence in the study and validation cohorts were respectively 3.0% and 0% among those with no applicable risk factors, 8.1% and 12.5% among those with 1 applicable risk factor, 25.5% and 25.0% among those with 2 applicable risk factors, and 56.3% and 50.0% among those with all 3 factors applicable (P &lt; 0.001 for both cohorts). Areas under the receiver operating characteristic curves for the study and validation groups were 0.777 and 0.783, respectively. CONCLUSIONS: Preoperative risk assessments using these 3 factors may be effective in predicting and planning for postoperative loss of independence after hepatic resection in elderly patients.</p>
<p>doi: <a href="https://doi.org/10.1097/SLA.0000000000003585" class="uri">https://doi.org/10.1097/SLA.0000000000003585</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Allosteric modulation of β-cell M3 muscarinic acetylcholine receptors greatly improves glucose homeostasis in lean and obese mice</strong> </summary></p>
<p><em>Proceedings of the National Academy of Sciences of the United States of America 2019 09;116(37):18684-18690</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31451647" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31451647</a></p>
<p>Given the global epidemic in type 2 diabetes, novel antidiabetic drugs with increased efficacy and reduced side effects are urgently needed. Previous work has shown that M3 muscarinic acetylcholine (ACh) receptors (M3Rs) expressed by pancreatic β cells play key roles in stimulating insulin secretion and maintaining physiological blood glucose levels. In the present study, we tested the hypothesis that a positive allosteric modulator (PAM) of M3R function can improve glucose homeostasis in mice by promoting insulin release. One major advantage of this approach is that allosteric agents respect the ACh-dependent spatiotemporal control of M3R activity. In this study, we first demonstrated that VU0119498, a drug known to act as a PAM at M3Rs, significantly augmented ACh-induced insulin release from cultured β cells and mouse and human pancreatic islets. This stimulatory effect was absent in islets prepared from mice lacking M3Rs, indicative of the involvement of M3Rs. VU0119498 treatment of wild-type mice caused a significant increase in plasma insulin levels, accompanied by a striking improvement in glucose tolerance. These effects were mediated by β-cell M3Rs, since they were absent in mutant mice selectively lacking M3Rs in β cells. Moreover, acute VU0119498 treatment of obese, glucose-intolerant mice triggered enhanced insulin release and restored normal glucose tolerance. Interestingly, doses of VU0119498 that led to pronounced improvements in glucose homeostasis did not cause any significant side effects due to activation of M3Rs expressed by other peripheral cell types. Taken together, the data from this proof-of-concept study strongly suggest that M3R PAMs may become clinically useful as novel antidiabetic agents.</p>
<p>doi: <a href="https://doi.org/10.1073/pnas.1904943116" class="uri">https://doi.org/10.1073/pnas.1904943116</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>“Trivial” Cysts Redefine the Risk of Cancer in Presumed Branch-Duct Intraductal Papillary Mucinous Neoplasms of the Pancreas: A Potential Target for Follow-Up Discontinuation?</strong> </summary></p>
<p><em>The American journal of gastroenterology 2019 10;114(10):1678-1684</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31449158" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31449158</a></p>
<p>OBJECTIVES: The management of small and incidental branch duct intraductal papillary mucinous neoplasms (BD-IPMNs) still is of concern. The aim is assessing the safety of a surveillance protocol through the evaluation of their progression to malignancy. METHODS: All presumed BD-IPMNs observed from 2000 to 2016 were included. Only patients presenting without worrisome features (WFs) and high-risk stigmata (HRS) at diagnosis were included. Development of WF, HRS, pancreatic cancer (PC), and survival were analyzed. BD-IPMNs were defined as trivial in the continuing absence of WF/HRS after 5 years of surveillance. The age-specific standardized incidence ratio of PC in the general population was used for comparison. RESULTS: A total of 1,036 BD-IPMNs without WF/HRS at diagnosis were included, 4.2% developed WF or HRS, and 1.1% developed PC after a median of 62 months. The median cyst growth rate was 0 mm/yr. A growth rate ≥2.5 mm/yr and the development of WF resulted independent predictors of PC. The standardized incidence ratio of PC for trivial BD-IPMN (n = 378) was 22.45 (95% confidence interval 8.19-48.86), but considering only patients aged &gt;65 years (n = 198), it decreased to 3.84 (95% confidence interval 0.77-11.20). DISCUSSION: Surveillance of the vast majority of presumed BD-IPMNs is safe, as the risk of PC is comparable to postoperative mortality of pancreatic surgery. A growth rate ≥2.5 mm/yr is the main predictor of PC, reinforcing the role of repeated observations. A trivial BD-IPMN in patients aged &gt;65 years might not increase the risk of developing PC compared with general population, identifying potential targets for follow-up discontinuation.</p>
<p>doi: <a href="https://doi.org/10.14309/ajg.0000000000000378" class="uri">https://doi.org/10.14309/ajg.0000000000000378</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Management of Locally Advanced Pancreatic Cancer: Results of an International Survey of Current Practice</strong> </summary></p>
<p><em>Annals of surgery 2019 Aug;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31449138" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31449138</a></p>
<p>MINI: An international survey of high-volume pancreas cancer surgeons revealed wide variations in management preferences, attitudes regarding contraindications to surgery, and the propensity to offer exploration. When presented with 6 hypothetical clinical vignettes using details from real patients that have received R0 resection, only 14% to 53% of participating surgeons were willing to offer exploration following neoadjuvant therapy. The aim of this study was to investigate surgeon preferences for the management of patients with locally advanced pancreatic cancer (LAPC). Select patients with LAPC may become candidates for curative resection following neoadjuvant therapy, and recent reports of survival are encouraging. Yet the optimal management approach remains unclear. An extensive electronic survey was systematically distributed by email to an international cohort of pancreas surgeons. Data collected included practice characteristics, management preferences, attitudes regarding contraindications to surgery, and 6 clinical vignettes of patients that ultimately received a margin negative resection (with detailed videos of post-neoadjuvant imaging) to assess propensity for surgical exploration if resection status is not known. A total of 153 eligible responses were received from 4 continents. Median duration of practice is 12 years (interquartile range 6-20) and 77% work in a university setting. Most surgeons (86%) are considered high volume (&gt;10 resections/yr), 33% offer a minimally-invasive approach, and 50% offer arterial resections in select patients. Most (72%) always recommend neoadjuvant chemotherapy, and 65% prefer FOLFIRINOX. Preferences for the duration of chemotherapy varied widely: 39% prefer ≥2 months, 43% prefer ≥4 months, and 11% prefer ≥6 months. Forty-one percent frequently recommend neoadjuvant radiotherapy, and 53% prefer 5 to 6 weeks of chemoradiation. The proportion of surgeons favoring exploration following neoadjuvant varied extensively across 5 vignettes of LAPC, from 14% to 53%. In a vignette of oligometastatic liver metastases, 31% would offer exploration if a favorable therapy response is observed. In an international cohort of pancreas surgeons, there is substantial variation in management preferences, perceived contraindications to surgery, and the propensity to consider exploration in LAPC. These results emphasize the importance of a robust and nuanced multidisciplinary discussion for each patient, and suggest an evolving concept of “resectability.”</p>
<p>doi: <a href="https://doi.org/10.1097/SLA.0000000000003568" class="uri">https://doi.org/10.1097/SLA.0000000000003568</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Obesity and pancreatic cancer: An update of epidemiological evidence and molecular mechanisms</strong> </summary></p>
<p><em>Pancreatology : official journal of the International Association of Pancreatology (IAP) … [et al.] 2019 Oct;19(7):941-950</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31447281" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31447281</a></p>
<p>Despite advances in therapy and achievements in translational research, pancreatic cancer (PC) remains an invariably fatal malignancy. Risk factors that affect the incidence of PC include diabetes, smoking, obesity, chronic pancreatitis, and diet. The growing worldwide obesity epidemic is associated with an increased risk of the most common cancers, including PC. Chronic inflammation, hormonal effects, circulating adipokines, and adipocyte-mediated inflammatory and immunosuppressive microenvironment are involved in the association of obesity with PC. Herein, we systematically review the epidemiology of PC and the biological mechanisms that may account for this association. Included in this review is a discussion of adipokine-mediated inflammation, lipid metabolism, and the interactions of adipocytes with cancer cells. We consider the influence of bariatric surgery on the risk of PC risk as well as potential molecular targets of therapy. Our review leads us to conclude that targeting adipose tissue to achieve weight loss may represent a new therapeutic strategy for preventing and treating PC.</p>
<p>doi: <a href="https://doi.org/10.1016/j.pan.2019.08.008" class="uri">https://doi.org/10.1016/j.pan.2019.08.008</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>ESWL for large pancreatic calculi: Report of over 5000 patients</strong> </summary></p>
<p><em>Pancreatology : official journal of the International Association of Pancreatology (IAP) … [et al.] 2019 Oct;19(7):916-921</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31447280" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31447280</a></p>
<p>INTRODUCTION: The primary aim of this study was to evaluate efficacy, safety and short-term pain relief after ESWL for large pancreatic calculi in over 5000 patients at a single center. METHODS: This is a retrospective analysis of prospectively collected data. Patients with painful calculi &gt;5 mm, located in the head, neck and body region in the MPD, who were not amenable for extraction by the standard procedure of endoscopic pancreatic sphincterotomy were subjected to ESWL using a third generation dual focus lithotripter. Patients were followed up at 6 months for outcome evaluation. RESULTS: A total of 5124 patients (66% males) were subjected to ESWL. Majority of stones (79.2%) were radiopaque. Single calculi were seen in 3851 (75.1%).The majority of stones were located in head region of MPD in 2824 (55.1%) patients. 4386 (85.5%) patients required 3 or less sessions for fragmentation and complete stone clearance was achieved in 3722 (72.6%). EPS was performed in 5022 (98%) while PD stenting was required in 3536 (69%) patients. Of the 4280 patients followed up for 6 months, 3529 (82.6%) patients were pain free. Another 512 (11.9%) patients had significant reduction in VAS score. In 229 (5.3%) there was no decrease in pain intensity. Minor and self-limiting complications were reported in 1153 (22.5%). DISCUSSION: Our study confirms the safety and efficacy and short-term pain relief of ESWL for large calculi in the MPD. In properly selected patients, this should be offered as the first line of therapy for all large MPD calculi not amenable to the standard techniques of stone extraction.</p>
<p>doi: <a href="https://doi.org/10.1016/j.pan.2019.08.001" class="uri">https://doi.org/10.1016/j.pan.2019.08.001</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>A rational approach to postoperative surveillance for resected non-functional pancreatic neuro-endocrine tumours</strong> </summary></p>
<p><em>Pancreatology : official journal of the International Association of Pancreatology (IAP) … [et al.] 2019 Oct;19(7):1000-1007</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31445889" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31445889</a></p>
<p>BACKGROUND: Non-functional pancreatic neuroendocrine tumours (NF-PNETs) are rare and have highly variable outcomes. Current guidelines recommend surveillance for NF-PNETs &lt;2 cm. Patients who ultimately have surgical resection are at risk of disease recurrence, and data to support postoperative surveillance protocols are lacking. The aims of this study were to i) identify post-operative predictors of recurrence and ii) risk stratify patients at risk of recurrence. METHODS: Consecutive patients who underwent surgery for NF-PNETs between 2002 and 2015 were identified retrospectively. Data were collected on demographics, pre-operative laboratory results and histopathological tumour characteristics. Statistical analyses were based on penalised Cox-regression modelling and a decision-tree model. Comparison of the variables identified was performed using ROC curves to identify the most sensitive and specific variable associated with disease recurrence. RESULTS: We identified 73 patients (38 males) with a median age of 61.5 years (range: 31-79). The median period of follow-up was 49 months (5-131). During follow up, 10 deaths (13.9%) were recorded and disease recurrence occurred in 12 patients (16.4%). The Kaplan-Meier predicted 1-,3- and 5-year recurrence-free survival rates were 98.6% (95% CI = 95.9, 100%), 85.4% (76.9-94.8%) and 72% (58.7-88.2%) respectively. Cox multivariate analysis identified poor tumour differentiation (WHO G3 grade) and lymph node ratio (LNR) as independent predictors for recurrence (p &lt; 0.05). A simple criterion of ‘tumour grade G3 or LNR ≥0.1’ was found to be sensitive and specific in detecting disease recurrence. CONCLUSION: Our results have identified a simple and sensitive criterion for risk stratifying post-resection surveillance. Prospective validation in larger patient cohort is now warranted.</p>
<p>doi: <a href="https://doi.org/10.1016/j.pan.2019.08.005" class="uri">https://doi.org/10.1016/j.pan.2019.08.005</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Design of an immunohistochemistry biomarker panel for diagnosis of pancreatic adenocarcinoma</strong> </summary></p>
<p><em>Pancreatology : official journal of the International Association of Pancreatology (IAP) … [et al.] 2019 Sep;19(6):842-849</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31445888" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31445888</a></p>
<p>BACKGROUND: Challenges still exist in differentiating pancreatic adenocarcinoma from benign disease. The use of adjuvant testing of tissue biopsies has demonstrated potential diagnostic value. We designed a proof of concept study to first validate four individual immunohistochemistry biomarkers and then combine them into a panel to boost overall diagnostic sensitivity. METHODS: Malignant and benign pancreas from 27 pancreaticoduodenectomy specimens underwent immunohistochemistry staining with VHL, IMP3, S100A4, S100P. Using ROC curve analysis, threshold criteria for number of cells staining were chosen for each biomarker. Biomarkers were then evaluated as a panel for their ability to discriminate malignant from benign specimens. RESULTS: Diagnostic sensitivity of VHL, IMP3, S100A4, and S100P were 75.0%, 79.2%, 45.8%, and 0%. When VHL, IMP3, and S100A4 were grouped into a panel, they were able to distinguish cancer from normal tissue with a sensitivity of 100% and a specificity of 96%. CONCLUSIONS: The high diagnostic value of an IHC panel consisting of VHL, IMP3, and S100A4 on surgical specimens suggests the need for future prospective studies of these biomarkers on biopsy specimens.</p>
<p>doi: <a href="https://doi.org/10.1016/j.pan.2019.08.007" class="uri">https://doi.org/10.1016/j.pan.2019.08.007</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Medium and long-term risks of specific cardiovascular diseases in survivors of 20 adult cancers: a population-based cohort study using multiple linked UK electronic health records databases</strong> </summary></p>
<p><em>Lancet (London, England) 2019 09;394(10203):1041-1054</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31443926" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31443926</a></p>
<p>BACKGROUND: The past few decades have seen substantial improvements in cancer survival, but concerns exist about long-term cardiovascular disease risk in survivors. Evidence is scarce on the risks of specific cardiovascular diseases in survivors of a wide range of cancers to inform prevention and management. In this study, we used large-scale electronic health records data from multiple linked UK databases to address these evidence gaps. METHODS: For this population-based cohort study, we used linked primary care, hospital, and cancer registry data from the UK Clinical Practice Research Datalink to identify cohorts of survivors of the 20 most common cancers who were 18 years or older and alive 12 months after diagnosis and controls without history of cancer, matched for age, sex, and general practice. We compared risks for a range of cardiovascular disease outcomes using crude and adjusted Cox models. We fitted interactions to investigate effect modification, and flexible parametric survival models to estimate absolute excess risks over time. FINDINGS: Between Jan 1, 1990, and Dec 31, 2015, 126 120 individuals with a diagnosis of a cancer of interest still being followed up at least 1 year later were identified and matched to 630 144 controls. After exclusions, 108 215 cancer survivors and 523 541 controls were included in the main analyses. Venous thromboembolism risk was elevated in survivors of 18 of 20 site-specific cancers compared with that of controls; adjusted hazard ratios (HRs) ranged from 1·72 (95% CI 1·57-1·89) in patients after prostate cancer to 9·72 (5·50-17·18) after pancreatic cancer. HRs decreased over time, but remained elevated more than 5 years after diagnosis. We observed increased risks of heart failure or cardiomyopathy in patients after ten of 20 cancers, including haematological (adjusted HR 1·94, 1·66-2·25, with non-Hodgkin lymphoma; 1·77, 1·50-2·09, with leukaemia; and 3·29, 2·59-4·18, with multiple myeloma), oesophageal (1·96, 1·46-2·64), lung (1·82, 1·52-2·17) kidney (1·73, 1·38-2·17) and ovarian (1·59, 1·19-2·12). Elevated risks of arrhythmia, pericarditis, coronary artery disease, stroke, and valvular heart disease were also observed for multiple cancers, including haematological malignancies. HRs for heart failure or cardiomyopathy and venous thromboembolism were greater in patients without previous cardiovascular disease and in younger patients. However, absolute excess risks were generally greater with increasing age. Increased risks of these outcomes seemed most pronounced in patients who had received chemotherapy. INTERPRETATION: Survivors of most site-specific cancers had increased medium-term to long-term risk for one or more cardiovascular diseases compared with that for the general population, with substantial variations between cancer sites. FUNDING: Wellcome Trust and Royal Society.</p>
<p>doi: <a href="https://doi.org/10.1016/S0140-6736(19)31674-5" class="uri">https://doi.org/10.1016/S0140-6736(19)31674-5</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>ASO Author Reflections: Lymph Node Metastasis and the Role for Lymphadenectomy During Surgery for Nonfunctional Pancreatic Neuroendocrine Tumors</strong> </summary></p>
<p><em>Annals of surgical oncology 2019 Dec;26(Suppl 3):700-701</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31440924" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31440924</a></p>
<p>doi: <a href="https://doi.org/10.1245/s10434-019-07746-5" class="uri">https://doi.org/10.1245/s10434-019-07746-5</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Regulation of PRMT5-MDM4 axis is critical in the response to CDK4/6 inhibitors in melanoma</strong> </summary></p>
<p><em>Proceedings of the National Academy of Sciences of the United States of America 2019 09;116(36):17990-18000</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31439820" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31439820</a></p>
<p>Cyclin-dependent kinase 4/6 (CDK4/6) inhibitors are an established treatment in estrogen receptor-positive breast cancer and are currently in clinical development in melanoma, a tumor that exhibits high rates of CDK4 activation. We analyzed melanoma cells with acquired resistance to the CDK4/6 inhibitor palbociclib and demonstrate that the activity of PRMT5, a protein arginine methyltransferase and indirect target of CDK4, is essential for CDK4/6 inhibitor sensitivity. By indirectly suppressing PRMT5 activity, palbociclib alters the pre-mRNA splicing of MDM4, a negative regulator of p53, leading to decreased MDM4 protein expression and subsequent p53 activation. In turn, p53 induces p21, leading to inhibition of CDK2, the main kinase substituting for CDK4/6 and a key driver of resistance to palbociclib. Loss of the ability of palbociclib to regulate the PRMT5-MDM4 axis leads to resistance. Importantly, combining palbociclib with the PRMT5 inhibitor GSK3326595 enhances the efficacy of palbociclib in treating naive and resistant models and also delays the emergence of resistance. Our studies have uncovered a mechanism of action of CDK4/6 inhibitors in regulating the MDM4 oncogene and the tumor suppressor, p53. Furthermore, we have established that palbociclib inhibition of the PRMT5-MDM4 axis is essential for robust melanoma cell sensitivity and provide preclinical evidence that coinhibition of CDK4/6 and PRMT5 is an effective and well-tolerated therapeutic strategy. Overall, our data provide a strong rationale for further investigation of novel combinations of CDK4/6 and PRMT5 inhibitors, not only in melanoma but other tumor types, including breast, pancreatic, and esophageal carcinoma.</p>
<p>doi: <a href="https://doi.org/10.1073/pnas.1901323116" class="uri">https://doi.org/10.1073/pnas.1901323116</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Ovarian Steroid Cell Tumor in an Adolescent With Von Hippel-Lindau Syndrome: A Case Report and Review of the Literature</strong> </summary></p>
<p><em>International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists 2019 Aug;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31433374" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31433374</a></p>
<p>Von Hippel-Lindau (VHL) syndrome is an autosomal dominant genetic disorder caused by germline mutation of the VHL gene. It is associated with multiple neoplasias including hemangioblastoma, clear cell renal cell carcinoma, pheochromocytoma, and neuroendocrine tumors. Ovarian tumors are extremely rare in this syndrome. We describe the case of a 16-yr-old girl with a previous diagnosis of bilateral pheochromocytoma and several pancreatic neuroendocrine tumors in VHL syndrome context. Follow-up abdominal-pelvic magnetic resonance imaging revealed a 33 mm, well-circumscribed nodule in the right ovary. The patient was submitted to laparoscopic right salpingo-oophorectomy. Microscopically, the tumor consisted of polygonal cells with abundant microvacuolized clear cytoplasm arranged in a solid pattern. The neoplastic cells were immunohistochemically positive for inhibin and calretinin. A diagnosis of ovarian steroid cell tumor was made. Only 4 cases with this association have been reported to date. Of the previously described cases, only one concerns a child; the others were all adult women. All of them had a previous diagnosis of VHL syndrome and presented with secondary amenorrhea and/or hirsutism due to testosterone-secreting ovarian steroid cell tumors. Although extremely rare, the association between VHL syndrome and ovarian steroid cell tumor has been reported, and our case suggests there is a link between the 2 entities.</p>
<p>doi: <a href="https://doi.org/10.1097/PGP.0000000000000628" class="uri">https://doi.org/10.1097/PGP.0000000000000628</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Expression of fatty-acid-binding protein 5 in intrahepatic and extrahepatic cholangiocarcinoma: the possibility of different energy metabolisms in anatomical location</strong> </summary></p>
<p><em>Medical molecular morphology 2020 Mar;53(1):42-49</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31432248" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31432248</a></p>
<p>The biliary tract cancer (BTC) covers a range of carcinomas, including intrahepatic cholangiocarcinoma (ICC), cholangiolocellular carcinoma (CoCC), perihilar cholangiocarcinoma (perihilar CC), extrahepatic cholangiocarcinoma (ECC), and gallbladder cancer (GBC), defined according to the anatomical location. These adenocarcinomas mostly comprise biliary epithelial cell-derived malignant cells. In addition to anatomical differences, there are morphological and biological differences in BTC starting from embryonic development of the tissues extending to physiological differences. Fatty acid-binding proteins (FABPs) are closely associated with the energy metabolism. Using surgical specimens from 74 BTCs, we performed immunohistochemistry for FABP5 and its associated molecules, including peroxisome proliferator-activated receptor γ (PPARγ), PPARγ coactivator 1 (PGC-1), and estrogen-related receptor α (ERRα). We found that the expression patterns of small BTCs (ICC and CoCC) considerably differed from those of large BTCs (perihilar CC, ECC, and GBC). Expression of FABP5 and PGC-1 in large BTCs was high compared with those of small BTCs, but no difference in the expression of PPARγ and ERRα was observed. FABP5 appears to play a role in malignant progression in large BTCs. Small and large BTCs possess different energy metabolism systems owing to their different anatomical locations and course of carcinogenesis, although all BTCs originate from biliary epithelial cells.</p>
<p>doi: <a href="https://doi.org/10.1007/s00795-019-00230-9" class="uri">https://doi.org/10.1007/s00795-019-00230-9</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>ASO Author Reflections: Resection for Metastasis to the Pancreas-Worthwhile for Selected Patients</strong> </summary></p>
<p><em>Annals of surgical oncology 2019 Dec;26(Suppl 3):696-697</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31429018" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31429018</a></p>
<p>doi: <a href="https://doi.org/10.1245/s10434-019-07621-3" class="uri">https://doi.org/10.1245/s10434-019-07621-3</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>AZD1775 plus chemoradiotherapy for pancreatic cancer</strong> </summary></p>
<p><em>The Lancet. Oncology 2019 Sep;20(9):e472</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31427207" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31427207</a></p>
<p>doi: <a href="https://doi.org/10.1016/S1470-2045(19)30537-6" class="uri">https://doi.org/10.1016/S1470-2045(19)30537-6</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Acute Pancreatitis Associated With Myotonic Dystrophy Type I</strong> </summary></p>
<p><em>Pancreas 2019 09;48(8):e63-e64</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31425487" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31425487</a></p>
<p>doi: <a href="https://doi.org/10.1097/MPA.0000000000001366" class="uri">https://doi.org/10.1097/MPA.0000000000001366</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Minimally Invasive Treatment for Severe Acute Pancreatitis With Superior Mesenteric Vein and Common Bile Duct Stenosis: A Case Report and Review of the Literature</strong> </summary></p>
<p><em>Pancreas 2019 09;48(8):e61-e63</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31425486" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31425486</a></p>
<p>doi: <a href="https://doi.org/10.1097/MPA.0000000000001379" class="uri">https://doi.org/10.1097/MPA.0000000000001379</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Clinical Utility of Cytokine Biomarker Analysis of Pancreatic Cyst Fluid Obtained by Endoscopic Ultrasound Fine Needle Aspiration: A Pilot Study</strong> </summary></p>
<p><em>Pancreas 2019 09;48(8):e60-e61</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31425485" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31425485</a></p>
<p>doi: <a href="https://doi.org/10.1097/MPA.0000000000001365" class="uri">https://doi.org/10.1097/MPA.0000000000001365</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Cigarette Smoking and Mortality in Patients With Pancreatic Cancer: A Systematic Review and Meta-analysis</strong> </summary></p>
<p><em>Pancreas 2019 09;48(8):985-995</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31425484" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31425484</a></p>
<p>Current evidence on cigarette smoking associated with pancreatic cancer mortality is limited. We searched MEDLINE, Web of Science, and Embase databases to identify relevant studies published through January 31, 2018. A random-effects model was used to estimate summary hazard ratios (HRs) and 95% confidence intervals (CIs). A total of 20 studies were retrieved, involving 2,517,623 participants. Of these, more than 15,341 patients with pancreatic cancer died. Compared with never smokers, current (summary HR, 1.56; 95% CI, 1.34-1.83) and former (summary HR, 1.15; 95% CI, 1.06-1.26) smokers had elevated risk of total mortality in patients diagnosed with pancreatic cancer. This effect of cigarette smoking is observed both in the Western regions and the Asia-Pacific regions. This effect of smoking is independent of alcohol use, body mass index, and history of diabetes but is modified by tumor stage and study settings. Dose-response associations between smoking and pancreatic cancer mortality were revealed for smoking intensity, cumulative amount of cigarettes smoked, and duration of smoking. Cigarette smoking was associated with an increase in total mortality for patients with pancreatic cancer. Future studies should further clarify the role of smoking as an effect modifier in treatment trials of pancreatic cancer.</p>
<p>doi: <a href="https://doi.org/10.1097/MPA.0000000000001383" class="uri">https://doi.org/10.1097/MPA.0000000000001383</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>A Qualitative Review of Neoadjuvant Chemotherapy in Resectable Pancreatic Adenocarcinoma</strong> </summary></p>
<p><em>Pancreas 2019 09;48(8):973-984</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31425483" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31425483</a></p>
<p>The aim of this study was to evaluate outcomes of patients with resectable pancreatic adenocarcinoma (PDAC) who underwent neoadjuvant chemotherapy. The MEDLINE and PubMed databases were searched to identify relevant original articles investigating neoadjuvant therapy in resectable PDAC. Qualitative analyses were performed to investigate patient selection, disease stage, impact on perioperative outcomes, and cost-effectiveness. Forty-three studies met inclusion criteria for this review. Neoadjuvant chemotherapy for upfront resectable PDAC is cost-effective, safe, may result in lower stage disease and has potential survival advantages. With proper patient selection, neoadjuvant chemotherapy is an appropriate approach for upfront resectable PDAC. Nevertheless, the risk for disease progression and losing a curative surgical window highlights the need for appropriate patient identification, further discovery of superior biomarkers or molecular profiles representative of positive treatment response, and additional prospective comparative study.</p>
<p>doi: <a href="https://doi.org/10.1097/MPA.0000000000001376" class="uri">https://doi.org/10.1097/MPA.0000000000001376</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Management of Diarrhea in Patients With Carcinoid Syndrome</strong> </summary></p>
<p><em>Pancreas 2019 09;48(8):961-972</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31425482" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31425482</a></p>
<p>Neuroendocrine tumors (NETs) arise from enterochromaffin cells found in neuroendocrine tissues, with most occurring in the gastrointestinal tract. The global incidence of NETs has increased in the past 15 years, likely due to better diagnostic methods. Small-bowel NETs are frequently associated with carcinoid syndrome (CS). Carcinoid syndrome diarrhea occurs in 80% of CS patients and poses a substantial symptomatic and economic burden. Patients with CS diarrhea frequently suffer from diarrhea and flushing and report corresponding impairment in quality of life, requiring substantial changes in daily activities and lifestyle. Treatment paradigms range from surgical debulking to liver-directed therapies to treatment with somatostatin analogs, nonspecific anti-diarrheal agents, and a tryptophan hydroxylase inhibitor. Other causes of diarrhea, including steatorrhea, short bowel syndrome, and bile acid malabsorption, should be considered in NET patients with refractory diarrhea. More therapeutic options are needed for symptomatic management of patients with NETs, and better understanding of the pathophysiology can empower clinicians with improved patient care.</p>
<p>doi: <a href="https://doi.org/10.1097/MPA.0000000000001384" class="uri">https://doi.org/10.1097/MPA.0000000000001384</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Significance of Examined Lymph Node Number in Accurate Staging and Long-term Survival in Resected Stage I-II Pancreatic Cancer-More is Better? A Large International Population-based Cohort Study</strong> </summary></p>
<p><em>Annals of surgery 2019 Aug;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31425290" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31425290</a></p>
<p>OBJECTIVE: This large international cohort study aimed to investigate the associations of examined lymph node (ELN) number with accurate staging and long-term survival in pancreatic adenocarcinoma (PaC) and to robustly determine the minimal and optimal ELN thresholds. SUMMARY BACKGROUND DATA: ELN number is an important quality metric in cancer care. The recommended minimal ELN number in PaC to accurately stage cancer varies greatly across guidelines, and the optimal number especially to adequately stratify patient survival has not yet been established. METHODS: Population-based data on patients with stage I to II PaC resected in 2003 to 2015 from the US Surveillance, Epidemiology, and End Results (SEER)-18 Program and Netherlands National Cancer Registry (NCR) were analyzed. Associations of ELN number with stage migration and survival were evaluated using multivariable-adjusted logistic and Cox regression models, respectively. The series of odds ratios (ORs) for negative-to-positive node stage migration and hazard ratios (HRs) for survival with more ELNs were fitted using a LOWESS smoother, and structural breakpoints were determined by Chow test. RESULTS: Overall 16,241 patients were analyzed. With increasing ELN number, both cohorts exhibited significant proportional increases from node-negative to node-positive disease [ORSEER-18=1.05, 95% confidence interval (CI) = 1.04-1.05; ORNCR = 1.10, 95% CI = 1.08-1.12] and serial improvements in survival (HRSEER-18 = 0.98, 95% CI = 0.98-0.99; HRNCR = 0.98, 95% CI = 0.97-0.99) per additional ELN after controlling for confounders. Associations for stage migration and survival remained significant in most stratifications by patient, tumor, and treatment factors. Cut-point analyses suggested a minimal threshold ELN number of 11 and an optimal number of 19, which were validated both internally in the derivative US cohort and externally in the Dutch cohort with the ability to well discriminate different probabilities of both survival and stage migration. CONCLUSIONS: In stage I to II PaC, more ELNs are associated with more precise nodal staging, which might largely explain the survival association. Our observational study does not suggest causality, and does not encourage more extended lymphadenectomy before further randomized evidence is obtained. Our results robustly conclude 11 ELNs as the minimal and suggest 19 ELNs as the optimal cut-points, for evaluating quality of lymph node examination and possibly for stratifying postoperative prognosis.</p>
<p>doi: <a href="https://doi.org/10.1097/SLA.0000000000003558" class="uri">https://doi.org/10.1097/SLA.0000000000003558</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Cholangiolar pattern and albumin in situ hybridisation enable a diagnosis of intrahepatic cholangiocarcinoma</strong> </summary></p>
<p><em>Journal of clinical pathology 2020 Jan;73(1):23-29</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31422372" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31422372</a></p>
<p>AIMS: The histological distinction of intrahepatic cholangiocarcinoma (ICC) from metastatic adenocarcinoma remains a challenge. The primary goal was to evaluate the diagnostic value of morphology and albumin expression in the diagnosis of ICC. METHODS: We evaluated morphological patterns in 120 ICCs and 677 non-hepatic adenocarcinomas and performed in situ hybridisation (ISH) stain for albumin in the former cohort (retrospective cohort). We also identified 119 samples from primary and metastatic lesions, the validation cohort, in which albumin ISH was performed as part of the diagnostic workup. Targeted sequencing was performed on selected cases. We also mined existing expression profiling data including cases from The Cancer Genome Atlas (TCGA) (41 760 unique samples). RESULTS: In the retrospective cohort, 45% of ICCs and &lt;1% of non-hepatic adenocarcinomas showed a cholangiolar pattern; albumin ISH was positive in 93% of ICCs with significant intratumorous heterogeneity. In the validation cohort, 29% of ICCs showed a cholangiolar pattern and 88% expressed albumin, while all metastatic non-hepatic neoplasms were negative (n=37) (sensitivity 88% and specificity 100%). Targetable genetic alterations (IDH mutations and FGFR2 fusions) were identified in 31% of ICCs (10 of 32). An analysis of the TCGA data validated the specificity of the albumin assay. CONCLUSIONS: The cholangiolar pattern and albumin RNA ISH distinguishes ICC from metastatic adenocarcinoma with high specificity. Given the high prevalence of targetable mutations in ICC, albumin RNA ISH is an essential component in the workup of tumours of uncertain origin. A specific diagnosis of ICC could trigger molecular testing and uncover targetable genetic alterations.</p>
<p>doi: <a href="https://doi.org/10.1136/jclinpath-2019-206055" class="uri">https://doi.org/10.1136/jclinpath-2019-206055</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials</strong> </summary></p>
<p><em>The lancet. Diabetes &amp; endocrinology 2019 Oct;7(10):776-785</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31422062" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31422062</a></p>
<p>BACKGROUND: Glucagon-like peptide-1 (GLP-1) receptor agonists differ in their structure and duration of action and have been studied in trials of varying sizes and with different patient populations, with inconsistent effects on cardiovascular outcomes reported. We aimed to synthesise the available evidence by doing a systematic review and meta-analysis of cardiovascular outcome trials of these drugs. METHODS: We searched MEDLINE (via PubMed) and the Cochrane Central Register of Controlled Trials for eligible placebo-controlled trials reporting major adverse cardiovascular events (MACE; ie, cardiovascular death, stroke, or myocardial infarction) up to June 15, 2019. We did a meta-analysis using a random-effects model to estimate overall hazard ratios (HRs) for MACE, its components, death from any cause, hospital admission for heart failure, kidney outcomes, and key safety outcomes (severe hypoglycaemia, pancreatitis, and pancreatic cancer). We also examined MACE in several subgroups based on patient characteristics (history of cardiovascular disease, BMI, age, baseline HbA1c, and baseline estimated glomerular filtration rate), trial duration, treatment dosing interval, and structural homology. FINDINGS: Of 27 publications screened, seven trials, with a combined total of 56 004 participants, were included: ELIXA (lixisenatide), LEADER (liraglutide), SUSTAIN-6 (semaglutide), EXSCEL (exenatide), Harmony Outcomes (albiglutide), REWIND (dulaglutide), and PIONEER 6 (oral semaglutide). Overall, GLP-1 receptor agonist treatment reduced MACE by 12% (HR 0·88, 95% CI 0·82-0·94; p&lt;0·0001). There was no statistically significant heterogeneity across the subgroups examined. HRs were 0·88 (95% CI 0·81-0·96; p=0·003) for death from cardiovascular causes, 0·84 (0·76-0·93; p&lt;0·0001) for fatal or non-fatal stroke, and 0·91 (0·84-1·00; p=0·043) for fatal or non-fatal myocardial infarction. GLP-1 receptor agonist treatment reduced all-cause mortality by 12% (0·88, 0·83-0·95; p=0·001), hospital admission for heart failure by 9% (0·91, 0·83-0·99; p=0·028), and a broad composite kidney outcome (development of new-onset macroalbuminuria, decline in estimated glomerular filtration rate [or increase in creatinine], progression to end-stage kidney disease, or death attributable to kidney causes) by 17% (0·83, 0·78-0·89; p&lt;0·0001), mainly due to a reduction in urinary albumin excretion. There was no increase in risk of severe hypoglycaemia, pancreatitis, or pancreatic cancer. INTERPRETATION: Treatment with GLP-1 receptor agonists has beneficial effects on cardiovascular, mortality, and kidney outcomes in patients with type 2 diabetes. FUNDING: None.</p>
<p>doi: <a href="https://doi.org/10.1016/S2213-8587(19)30249-9" class="uri">https://doi.org/10.1016/S2213-8587(19)30249-9</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Long-term outcomes of therapeutic ERCP in pediatric patients with pancreas divisum presenting with acute recurrent or chronic pancreatitis</strong> </summary></p>
<p><em>Pancreatology : official journal of the International Association of Pancreatology (IAP) … [et al.] 2019 Sep;19(6):834-841</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31421974" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31421974</a></p>
<p>OBJECTIVES: The aim of this study was to evaluate the long-term outcomes of therapeutic endoscopic retrograde cholangiopancreatography (ERCP) for pediatric patients with pancreas divisum (PD) presenting with acute recurrent pancreatitis (ARP) or chronic pancreatitis (CP). METHODS: Between May 2008 and August 2017, pediatric patients with PD who received endotherapy at Ruijin Hospital were identified and grouped according to clinical presentation, namely ARP and CP. Primary success was defined as patients’ improvement in symptoms after index ERCPs, without further intervention or any analgesic. RESULTS: A total of 74 ERCPs were performed in 38 pediatric patients. The frequency of at least 1 genetic mutation identified in patients with ARP and CP was 44.4% and 68.4%, respectively. Patients with CP required more ERCPs than those with ARP (2.4 ± 1.7 vs. 1.1 ± 0.4, P = 0.005). The incidence of post-ERCP complications was 14.9%, including pancreatitis of 13.5% and hemorrhage of 1.4%. During a median follow-up duration of 41 months (range, 12-123 months), the frequency of pancreatitis episodes decreased significantly from 2.31 to 0.45 (P &lt; 0.0001). The 25% recurrence and reintervention rates were estimated at 25 and 48 months, respectively, without significant difference between patients with ARP or CP. There was a nonsignificant trend towards a higher rate of primary success in patients with ARP than those with CP (92.9% vs. 69.6%, P = 0.123). After further endotherapy, 91.3% patients with CP improved clinically. CONCLUSIONS: Therapeutic ERCP is an effective and safe intervention for pediatric patients with symptomatic PD. Patients presenting with CP seem to achieve improvement after additional ERCPs.</p>
<p>doi: <a href="https://doi.org/10.1016/j.pan.2019.08.004" class="uri">https://doi.org/10.1016/j.pan.2019.08.004</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Pancreatic tumor in type 1 autoimmune pancreatitis: a diagnostic challenge</strong> </summary></p>
<p><em>BMC cancer 2019 Aug;19(1):814</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31419961" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31419961</a></p>
<p>BACKGROUND: The co-occurrence of type 1 autoimmune pancreatitis (AIP) and pancreatic tumor (PaT) has been previously reported. Pure AIP cases have favorable prognosis and are primarily treated with steroids, while AIP cases with PaT are associated with poor prognosis where the primary management is pancreatic resection. However, it’s a challenge to timely identify the concurrent PaT in AIP because of their similar clinical and radiological manifestations. METHODS: We retrospectively reviewed the data in two medical centers from January 2010 to April 2019. The inclusion criteria were as follows: 1) completion of abdominal CT imaging before invasive procedures to the pancreas, 2) a final diagnosis of type 1 AIP using the 2011 international consensus diagnostic criteria, 3) follow-up duration of at least one month unless AIP and PaT were identified simultaneously. The presence of PaT in AIP was made based on histopathological confirmation, and the absence of PaT in AIP was defined as no pathological or radiological evidence of concurrent PaT. Clinical and radiological characteristics including gender, age, surveillance period, serum IgG4 and Ca-199 levels, biopsy, extrapancreatic involvement, CT and MR (if performed) imaging characteristics were compared between AIP with and without PaT. The Fisher’s exact test was used for qualitative variables, and nonparametric Mann-Whitney test for quantitative variables. A p value ≤0.05 was considered statistically significant. RESULTS: A total of 74 patients with type 1 AIP were included, of which 5 (6.7%) had the concurrent PaT. The subtypes were pancreatic ductal adenocarcinoma (3/5), solitary extramedullary plasmacytoma in the pancreas (1/5) and cholangiocarcinoma in the pancreatic segment (1/5), respectively. Gender (p = 0.044), the pattern of pancreatic enlargement (p = 0.003), heterogeneity (p = 0.015), low-density (p = 0.004) on CT and rim enhancement on MRI (p = 0.050) differed significantly between AIP with and without PaT. None of the low-density characteristics on CT or other assessed MRI characteristics could significantly differentiate the two groups (p&gt;0.05). CONCLUSIONS: Female, focal pancreatic enlargement, pancreatic heterogeneity, low-density on CT and rim enhancement on MRI are suggestive of the concurrent PaT in type 1 AIP. The characteristics of low-density on CT or other MRI characteristics did not provide further diagnostic values.</p>
<p>doi: <a href="https://doi.org/10.1186/s12885-019-6027-0" class="uri">https://doi.org/10.1186/s12885-019-6027-0</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Cell phenotypic plasticity requires autophagic flux driven by YAP/TAZ mechanotransduction</strong> </summary></p>
<p><em>Proceedings of the National Academy of Sciences of the United States of America 2019 09;116(36):17848-17857</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31416916" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31416916</a></p>
<p>Autophagy, besides ensuring energy metabolism and organelle renewal, is crucial for the biology of adult normal and cancer stem cells. However, it remains incompletely understood how autophagy connects to stemness factors and the nature of the microenvironmental signals that pattern autophagy in different cell types. Here we advance in these directions by reporting that YAP/TAZ transcriptionally control autophagy, being critical for autophagosomal degradation into autolysosomes. YAP/TAZ are downstream effectors of cellular mechanotransduction and indeed we found that cell mechanics, dictated by the physical property of the ECM and cytoskeletal tension, profoundly impact on autophagic flux in a YAP/TAZ-mediated manner. Functionally, by using pancreatic and mammary organoid cultures, we found that YAP/TAZ-regulated autophagy is essential in normal cells for YAP/TAZ-mediated dedifferentiation and acquisition of self-renewing properties. In tumor cells, the YAP/TAZ-autophagy connection is key to sustain transformed traits and for acquisition of a cancer stem cell state by otherwise more benign cells. Mechanistically, YAP/TAZ promote autophagic flux by directly promoting the expression of Armus, a RAB7-GAP required for autophagosome turnover and whose add-back rescues autophagy in YAP/TAZ-depleted cells. These findings expand the influence of YAP/TAZ mechanotransduction to the control of autophagy and, vice versa, the role of autophagy in YAP/TAZ biology, and suggest a mechanism to coordinate transcriptional rewiring with cytoplasmic restructuring during cell reprogramming.</p>
<p>doi: <a href="https://doi.org/10.1073/pnas.1908228116" class="uri">https://doi.org/10.1073/pnas.1908228116</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Grading Pancreatic Neuroendocrine Tumors by Ki-67 Index Evaluated on Fine-Needle Aspiration Cell Block Material</strong> </summary></p>
<p><em>American journal of clinical pathology 2020 01;153(1):74-81</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31415691" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31415691</a></p>
<p>OBJECTIVES: This study aimed to determine whether Ki-67 index evaluated on cytologic material could reliably grade pancreatic neuroendocrine tumors (PanNETs). METHODS: Cases with adequate cell block and available surgical specimens were included. Ki-67 index was calculated using “eyeballing,” “hot spot,” and “complete” counting methods. RESULTS: The overall concordance rates between cytology and surgical specimens were 71%, 73%, and 59%, respectively, by using eyeballing, hot spot, and complete counting approaches. All grade 1 tumors were correctly graded on cytology, but in grade 2 tumors concordance rates were only 36%, 41%, and 9%, respectively. All grade 2 tumors were undergraded when cell blocks contained fewer than 1,000 cells, while concordance rate increased to 57%, 64%, and 14%, respectively, in cases with 1,000 cells or more. CONCLUSIONS: Grade 2 PanNETs can be significantly undergraded when Ki-67 index is evaluated on cell block material. In cases with 1,000 or more cells, the hot spot counting method has better correlation with surgical specimens.</p>
<p>doi: <a href="https://doi.org/10.1093/ajcp/aqz110" class="uri">https://doi.org/10.1093/ajcp/aqz110</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Randomized Comparison of Gastric Tube Reconstruction With and Without Duodenal Diversion Plus Roux-en-Y Anastomosis After Esophagectomy</strong> </summary></p>
<p><em>Annals of surgery 2019 Aug;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31415003" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31415003</a></p>
<p>OBJECTIVE: This prospective randomized phase-II trial examined whether gastric reconstruction with duodenal diversion plus Roux-en-Y anastomosis(RY) minimized gastroduodenal reflux and delayed gastric emptying compared with standard gastric reconstruction. SUMMARY BACKGROUND DATA: There is no established standard surgical procedure to prevent both gastroduodenal reflux and delayed gastric emptying simultaneously. METHODS: Sixty patients with thoracic esophageal cancer scheduled to undergo esophagectomy with retrosternal gastric tube reconstruction were randomly allocated to standard gastric reconstruction (non-RY, n = 31) or gastric reconstruction with duodenal diversion plus RY (n = 29) groups. Primary endpoint was quality of life assessed by DAUGS-32 score 1 year after surgery. Secondary endpoints were the extent of postoperative duodenal juice reflux into the gastric tube, postoperative morbidity, endoscopic findings, body weight changes, and nutritional status. RESULTS: Preoperative clinicopathological characteristics and postoperative morbidity did not differ significantly between groups. However, operation time and blood loss volume were significantly higher in the RY group. Pancreatic amylase concentrations in the gastric conduit on postoperative days 2, 3, and 7 were higher in the non-RY group. Postoperative endoscopic examination showed residual gastric content in 7 of 17 patients in the non-RY group but in none in the RY group (P = 0.012). Quality of life was significantly favorable in the RY group with regard to reflux symptoms and food passage dysfunction. Postoperative body weight changes, serum albumin levels, and peripheral blood lymphocyte counts were not significantly different between groups. CONCLUSION: Gastric reconstruction with duodenal diversion plus RY is effective in improving both gastroduodenal reflux and delayed gastric emptying.</p>
<p>doi: <a href="https://doi.org/10.1097/SLA.0000000000003557" class="uri">https://doi.org/10.1097/SLA.0000000000003557</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>The applications of metabolomics in the molecular diagnostics of cancer</strong> </summary></p>
<p><em>Expert review of molecular diagnostics 2019 09;19(9):785-793</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31414918" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31414918</a></p>
<p>Introduction: Metabolomics, the study of metabolites, is a promising research field for cancers. The metabolic pathway in a tumor cell is different from a normal tissue cell. There are two approaches to study the metabolism, targeted and untargeted. The general approach is that metabolomic data are interpreted by bioinformatics tools correlating with metabolomic databases to obtain significant findings. With the use of specific analysis tools, such as nuclear magnetic resonance (NMR) and mass spectrometer (MS) combined with chromatography, metabolic profile or metabolic fingerprint of various biological specimens could be obtained. The applications of metabolomics are used to discover potential cancer biomarkers and monitor the metastatic state, therapeutic and drug response for better patient management. Areas covered: In this review, the author introduce metabolomics and discuss the use of metabolomics approaches in different cancers, including the study of colorectal cancer, prostate cancer, liver cancer, pancreatic cancer and breast cancer using NMR and MS. Expert opinion: Knowledge on the molecular basis of cancer metabolism and its potential clinical applications has been improving recently. However, there are still many challenges for the technological development and integration of metabolomics with other omics spaces such as genomics. In the near future, it is expected that metabolomics will play an important role in cancer molecular diagnostics.</p>
<p>doi: <a href="https://doi.org/10.1080/14737159.2019.1656530" class="uri">https://doi.org/10.1080/14737159.2019.1656530</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Prognostic significance of neutrophil-lymphocyte ratio in resectable pancreatic neuroendocrine tumors with special reference to tumor-associated macrophages</strong> </summary></p>
<p><em>Pancreatology : official journal of the International Association of Pancreatology (IAP) … [et al.] 2019 Sep;19(6):897-902</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31409525" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31409525</a></p>
<p>BACKGROUND: Recent studies have shown that the systemic inflammatory response induced by cancer leads to cancer progression. Neutrophil-to-lymphocyte ratio (NLR) is the most reliable marker to detect systemic inflammation. In this study, we investigated the significance of NLR in patients with well-differentiated pancreatic neuroendocrine tumors (PanNETs) according to the World Health Organization 2017 classification. METHODS: We retrospectively collected data for patients with PanNET who underwent pancreatic resection with curative intent between January 2008 and December 2017 at six institutions. Clinicopathological factors, recurrence, and immunohistochemical staining of tumor-associated macrophages (TAMs) were analyzed in a total of 55 patients in this study. RESULTS: High NLR (&gt;3.41) in patients was significantly associated with higher white blood cell count, higher Ki-67 index, higher mitotic count, higher grade, higher incidence of lymph node metastasis, higher incidence of lymphatic and neural invasion, massive blood loss, and a large number of CD163-expressing TAMs. Recurrence-free survival of patients with high NLR was significantly poorer than that of patients with low NLR. Multivariate analysis identified high NLR, NET Grade 2 (G2) or Grade 3 (G3), and synchronous hepatic resection as independent risk factors for recurrence after curative resection. CONCLUSIONS: NLR is a promising predictor of recurrence after pancreatectomy that needs to be further investigated and that accumulation of TAMs in the tumor could be one of the causes of NLR elevation.</p>
<p>doi: <a href="https://doi.org/10.1016/j.pan.2019.08.003" class="uri">https://doi.org/10.1016/j.pan.2019.08.003</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Extended Laparoscopic Central Pancreatectomy with Clamping of the Mesentericoportal Vein and Resection of the Splenic Vessels for a Large Solid Pseudopapillary Tumor</strong> </summary></p>
<p><em>Annals of surgical oncology 2019 Oct;26(11):3709-3710</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31407182" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31407182</a></p>
<p>BACKGROUND: Solid pseudopapillary tumors (SPPTs) are low malignant potential entities found mainly in young females.1,2 Pancreatectomy without tumor rupture is the treatment of choice, and the laparoscopic approach is indicated.3,4 Limited pancreatectomy is possible due to the low risk of malignancy (&lt; 10%) based on the low risk of lymph node invasion or true vascular invasion.1,2 Centrally located large SPPTs can be treated by extended central pancreatectomy with or without vascular resection to avoid pancreatoduodenectomy or distal pancreatectomy. METHODS: A 24-year-old woman was admitted with abdominal pain. A 6-cm SPPT was discovered at the neck-body junction in close contact with the anterior aspect of the mesentericoportal vein (MPV) and the splenic vessels, with signs of segmental portal hypertension. To avoid an extended pancreatectomy for this young patient, an extended central pancreatectomy was performed, with resection of the splenic vessels, and the MPV was freed from the tumor under clamping for 10 min, with no need for vascular reconstruction. The duration of the surgery was 260 min, with 200 ml of blood loss and no transfusion. RESULTS: The woman’s postoperative course was uneventful, with a hospital stay of 16 days. Histology confirmed the diagnosis of a 6-cm SPPT tumor (R0 and N0). The patient was asymptomatic 1 year later, with no tumor recurrence and no pancreatic insufficiency. Between 2011 and 2018 the authors performed 72 laparoscopic central pancreatectomies, with SPPT performed for 13 patients (18%). Laparoscopic central pancreatectomy was extended (n = 5) or standard (n = 8) with no conversion, no recurrence, and no pancreatic insufficiency. CONCLUSION: An SPPT tumor is a good indication for the laparoscopic approach because this entity is found in young patients with a low risk of malignancy. Large centrally located tumors can be treated by extended central pancreatectomy to avoid a large pancreatectomy with greater early and long-term disadvantages.</p>
<p>doi: <a href="https://doi.org/10.1245/s10434-019-07689-x" class="uri">https://doi.org/10.1245/s10434-019-07689-x</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Robotic Extended Right Hemicolectomy with Complete Mesocolic Excision and D3 Lymph Node Dissection</strong> </summary></p>
<p><em>Annals of surgical oncology 2019 Nov;26(12):3990-3991</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31407176" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31407176</a></p>
<p>BACKGROUND: Recent studies have shown the benefits of complete mesocolic excision and extended lymphadenectomy (D3 lymph node dissection) in patients with colon cancer.1-3 METHODS: We present the case of a 62-year-old male with hepatic flexure adenocarcinoma. No metastatic disease was identified by computed tomography. A robot-assisted extended right hemicolectomy with complete mesocolic excision, D3 lymph node dissection, and resection of the mesentery with intact visceral peritoneum was performed. RESULTS: The trocars are placed in the right lower (8 mm), lower midline (8 mm), and left upper (12 mm) quadrants. The camera port is placed superior to the umbilicus, and the assistant port is placed in the left lower quadrant. The robotic right lower port is used to place the cecum on tension in order to outline the ileocolic pedicle. The assistant retracts the transverse colon cephalad to outline the superior mesenteric artery and vein. Using two robotic arms, the surgeon begins dissection over the superior mesenteric vein inferior to the ileocolic pedicle. Cephalad dissection along the superior mesenteric vein proceeds with reflection of the mesentery and D3 lymph nodes laterally to allow en bloc resection. The ileocolic and middle colic vessels are identified, ligated and divided at their origins. The plane is then developed between the right colon mesentery and the retroperitoneum, including Gerota’s fascia, duodenum, and head of the pancreas, in a medial-to-lateral fashion, with care taken to ensure an intact visceral peritoneum is maintained. The proximal transverse colon, hepatic flexure, and ascending colon are mobilized by taking down lateral attachments. The intervening mesentery is transected, and perfusion is assessed with indocyanine green fluorescence imaging. An intracorporeal, isoperistaltic, side-to-side anastomosis is performed using the 45-mm robotic stapler. The common enterotomy is sewn closed in two layers. Pathology showed T3N0 adenocarcinoma with all negative margins. CONCLUSION: Extended right hemicolectomy with complete mesocolic excision and D3 lymph node dissection is facilitated by a robotic approach, which improves visualization and instrument dexterity.</p>
<p>doi: <a href="https://doi.org/10.1245/s10434-019-07692-2" class="uri">https://doi.org/10.1245/s10434-019-07692-2</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Inflammation Promotes Progression of Pancreatic Cancer Through WNT/β-Catenin Pathway-Dependent Manner</strong> </summary></p>
<p><em>Pancreas 2019 09;48(8):1003-1014</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31404031" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31404031</a></p>
<p>OBJECTIVE: Identify the molecular mechanism of inflammatory stimuli induced pancreatic cancer progression. METHODS: RNA-seq, microarray assay and bioinformatics analyses were used to identify differentially expressed genes. Immunohistochemical staining was performed to evaluate CD68, CD163, β-catenin, CD103, CCL3 markers. Quantitative real-time polymerase chain reaction (qRT-PCR), luciferase reporter assay, apoptosis assay, wound healing assay and immunofluorescence were performed to study the relationship of inflammatory stimuli and WNT/β-catenin pathway. RESULTS: Differentially expressed genes of macrophage-conditioned medium-treated pancreatic cancer cells were related with WNT/β-catenin pathway. Inflammatory stimuli could activate WNT/β-catenin signaling pathway. In 106 pancreatic cancer patients, nuclear β-catenin expression of CD68-high group was much higher than CD68-low group (P &lt; 0.05), as same as CD163 (P &lt; 0.05). Inflammatory stimuli downregulated the expression of CCL3 via WNT/β-catenin pathway and inhibited the chemotaxis of CD103 dendritic cells. Six pancreatic cancer prognosis associating genes were upregulated by inflammatory stimuli via WNT/β-catenin pathway. Transforming growth factor-β promoted malignant biological behavior of pancreatic cancer cells through WNT/β-catenin pathway-dependent mechanism. CONCLUSIONS: Our present study provided a novel mechanism involved in the inflammation-driven cancer progression through tumor immune escape and downstream gene regulation of WNT/β-catenin pathway-dependent manner.</p>
<p>doi: <a href="https://doi.org/10.1097/MPA.0000000000001386" class="uri">https://doi.org/10.1097/MPA.0000000000001386</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Detection of Reg3γ by Immunohistochemistry in Cerulein-Induced Model of Acute Pancreatic Injury in Mice and Rats</strong> </summary></p>
<p><em>Pancreas 2019 09;48(8):1015-1025</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31404030" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31404030</a></p>
<p>OBJECTIVE: In a continuation of previous work, Reg3γ protein was further evaluated as a biomarker of pancreatic injury using immunohistochemistry in an additional species. METHODS: Mice and rats were treated with intraperitoneal cerulein injections, creating acute pancreatic injury. Mice received 2, 4, or 6 doses, and rats received 1, 2, or 3 doses of cerulein creating low, medium, and high treatment groups. Control animals were dosed with phosphate-buffered saline at corresponding volumes and intervals. Groups of 6 animals were killed 1, 3, 6, 24, and 48 hours after final treatments. Reg3γ immunohistochemical staining and image analysis were performed on pancreatic tissue obtained 6, 24, or 48 hours after control or cerulein treatment. Staining was quantified using image analysis software to calculate area of positivity as a percentage of total tissue area. RESULTS: Percent positivity of Reg3γ in both species rose by 6 hours, peaked by 24 hours across all 3 cerulein doses, and dropped significantly by 48 hours. In high-dose rats with accompanying gene expression data, Reg3γ gene expression corresponded temporally with quantitative staining data. CONCLUSIONS: Reg3γ staining quantified through image analysis showed a time- and dose-response in cerulein-treated mice and rats.</p>
<p>doi: <a href="https://doi.org/10.1097/MPA.0000000000001382" class="uri">https://doi.org/10.1097/MPA.0000000000001382</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Pancreatic Function in Chronic Pancreatitis: A Cohort Study Comparing 3 Methods of Detecting Fat Malabsorption and the Impact of Short-term Pancreatic Enzyme Replacement Therapy</strong> </summary></p>
<p><em>Pancreas 2019 09;48(8):1068-1078</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31404029" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31404029</a></p>
<p>OBJECTIVES: Reliable pancreatic function tests in patients with chronic pancreatitis (CP) are needed. This cohort study identified malabsorption in people with CP compared with healthy people and then investigated short-term pancreatic enzyme replacement therapy (PERT) and fat malabsorption, nutritional status, and quality of life (QOL). METHODS: Subjects with CP were evaluated before and after PERT and compared with the healthy cohort using coefficient of fat absorption (CFA), stool bomb calorimetry, and the malabsorption blood test (MBT). Anthropometrics, micronutrients, and QOL data were collected. Group means at baseline and after PERT were analyzed. RESULTS: The 24 subjects with CP had greater stool energy loss (5668 cal/g [standard deviation {SD}, 753] vs 5152 cal/g [SD, 418], P &lt; 0.01), reduced triglyceride absorption (MBT, 8.3 mg·h/dL [SD, 4.3] vs 17.7 mg·h/dL [SD, 10.3], P &lt; 0.001), lower fat intake, and poorer QOL. Differences in CFA were not significant (90.9% [SD, 12.8] vs 95.4% [SD, 9.3]). After PERT, triglyceride absorption (Δ = 1.7 [SD, 3], P &lt; 0.05) and QOL increased. CONCLUSIONS: The MBT detected changes in triglyceride absorption in the absence of CFA changes. The MBT may be helpful in guiding PERT initiation in patients with CP before significant morbidity.</p>
<p>doi: <a href="https://doi.org/10.1097/MPA.0000000000001381" class="uri">https://doi.org/10.1097/MPA.0000000000001381</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Risk and Outcomes of Clostridium difficile Infection With Chronic Pancreatitis</strong> </summary></p>
<p><em>Pancreas 2019 09;48(8):1041-1049</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31404028" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31404028</a></p>
<p>OBJECTIVES: Chronic pancreatitis (CP) is associated with high rates of recurrent hospitalizations, which predisposes to Clostridium difficile infection (CDI). We investigate the burden of CDI in CP. METHODS: We identified records of patients with CP from the Nationwide Inpatient Sample (NIS) 2012-2014 and estimated the impact of CDI on their outcomes. We calculated the adjusted odds ratio (AOR) of CP on having CDI (NIS 2014). From NIS 2007-2014, we plotted the trends of CDI and its interaction with CP. RESULTS: From 2012 to 2014, 886 (2.72%) of the 32,614 CP patients had concomitant CDI, which was associated with poorer outcomes: acute kidney injury (AOR, 2.57 [95% confidence interval {CI}, 2.11-3.13]), length of stay (13.3 vs 7.4 days), and charges (US $127,496 vs US $72,767), but not mortality (AOR, 0.93 [95% CI, 0.28-3.05]). In 2014, CP was associated with an increased risk of CDI (crude odds ratio, 2.10 [95% CI, 1.95-2.26]), which persisted after multivariate adjustment (AOR, 2.03 [95% CI, 1.87-2.19]). From 2007 to 2014, the annual prevalence of CDI was 106.4 cases per 10,000 hospitalizations, increasing from 2007 (95.5/10,000) to 2014 (118.4/10,000), with a 3.7 times higher annual rate of increase among CP versus no-CP patients (13.4/10,000 vs 3.7/10,000 population/year). CONCLUSIONS: Chronic pancreatitis patients have high burden of CDI and may benefit from CDI prophylaxis.</p>
<p>doi: <a href="https://doi.org/10.1097/MPA.0000000000001380" class="uri">https://doi.org/10.1097/MPA.0000000000001380</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Microbial Contamination, Infection, and Antimicrobial Use During Total Pancreatectomy With Islet Autotransplantation</strong> </summary></p>
<p><em>Pancreas 2019 09;48(8):1050-1055</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31404027" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31404027</a></p>
<p>OBJECTIVES: Total pancreatectomy with islet autotransplantation can relieve pain associated with chronic pancreatitis while preserving islet function. Islet preparations are often contaminated by enteric flora. We assessed the impact of contaminated islet preparations on the prevalence of postoperative infection. METHODS: Electronic health records for patients who underwent total pancreatectomy with islet autotransplantation from August 1, 2011, to November 15, 2017 were retrospectively reviewed to compare the prevalence of postoperative infection in patients with a positive islet culture and islet culture negative patients. RESULTS: Sixty-one patients were included. Twenty-nine patients (47.5%) had a positive islet culture, and 23 (79.3%) of these patients received antimicrobial prophylaxis. The prevalence of postoperative infection did not differ between the islet culture positive and islet culture negative groups (41% vs 34%, P = 0.57). No infections occurred in the 6 islet culture positive patients who did not receive prophylaxis. No difference in intensive care unit or hospital length of stay or in 30-day or 90-day readmission rates were observed. CONCLUSIONS: Despite the common use of postoperative systemic antimicrobials, we observed no difference in the prevalence of postoperative infection, length of stay, or hospital readmission in patients receiving a contaminated islet preparation. If prophylactic antimicrobials are used, the duration should be minimized.</p>
<p>doi: <a href="https://doi.org/10.1097/MPA.0000000000001378" class="uri">https://doi.org/10.1097/MPA.0000000000001378</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Association Between Pancreatic Cystic Lesions and High-grade Intraepithelial Neoplasia and Aging: An Autopsy Study</strong> </summary></p>
<p><em>Pancreas 2019 09;48(8):1079-1085</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31404026" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31404026</a></p>
<p>OBJECTIVES: This study aimed to clarify clinicopathological features of pancreatic cysts. METHODS: Pancreata from 280 autopsies (median, 83 years; male, 146; female, 134) were sectioned every 5 mm. Cysts (&lt;10 mm) were diagnosed as a simple cyst or low-grade, intermediate-grade, or high-grade dysplasia. RESULTS: We found 236 cysts in 93 patients (33.2%). The number and diameter of cysts increased according to the age. Of the 236 cysts, 9 (3.8%) were with high-grade dysplasia. Cysts with high-grade dysplasia arose in the pancreata of older patients with larger numbers of cysts. In contrast, 15 noncystic lesions with high-grade dysplasia were also detected. Hence, in total, 24 high-grade dysplastic lesions in 15 patients (5.4%) were noted. Of the 15 patients with high-grade dysplastic lesions, in 10 patients, the condition was accompanied by pancreatic cysts, whereas 5 patients did not have any cysts in the pancreas; therefore, patients with cyst showed higher incidence of high-grade dysplasia (10.8%; P = 0.0047) than patients without cyst (2.7%). All cysts with high-grade dysplasia were located in the branch duct of the pancreatic head/body, whereas 20% of noncystic lesions with high-grade dysplasia were located in the main pancreatic duct. CONCLUSIONS: Cystic lesions with high-grade dysplasia may have different characteristics compared with noncystic high-grade dysplasia.</p>
<p>doi: <a href="https://doi.org/10.1097/MPA.0000000000001374" class="uri">https://doi.org/10.1097/MPA.0000000000001374</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>18F-Fluorodeoxyglucose Positron Emission Tomography Predicts Treatment Efficacy and Clinical Outcome for Patients With Pancreatic Carcinoma: A Meta-analysis</strong> </summary></p>
<p><em>Pancreas 2019 09;48(8):996-1002</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31404025" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31404025</a></p>
<p>OBJECTIVES: F-Fluorodeoxyglucose positron emission tomography (FDG-PET) has been an important modality for detecting malignancies. Recently, an increasing number of studies reported the utility of FDG-PET parameters in predicting clinical outcomes and treatment assessment in variety of cancers. We aimed at clarifying both the prognostic role and assessment value of FDG-PET in pancreatic carcinoma. METHODS: We systematically searched electronic databases of PubMed, Embase, Cochrane Library, and Web of Science to identify relevant studies to conduct this meta-analysis. Comparative analyses of the pooled hazard ratio (HR) for overall survival were performed to assess the utility of FDG-PET parameters in prognosis evaluation and treatment assessment by random-effect model. RESULTS: Twenty-three studies with 1762 patients met the inclusion criteria of this meta-analysis. The pooled results revealed that greater maximum standardized uptake value of the primary tumor was significantly correlated with poorer overall survival (HR, 1.31; 95% confidence interval, 1.15-1.50; P &lt; 0.001). Besides, greater reduction of maximum standardized uptake value after treatments indicated significant better overall survival (HR, 0.68; 95% confidence interval, 0.47-0.98; P = 0.037). CONCLUSIONS: F-Fluorodeoxyglucose positron emission tomography parameters might be helpful not only for predicting survival outcome but also for selecting potentially efficacious treatments in patients with pancreatic carcinoma.</p>
<p>doi: <a href="https://doi.org/10.1097/MPA.0000000000001375" class="uri">https://doi.org/10.1097/MPA.0000000000001375</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Time to Adjuvant Systemic Therapy Following Pancreatic Cancer Resection and Effect on Outcome</strong> </summary></p>
<p><em>Pancreas 2019 09;48(8):1086-1091</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31404024" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31404024</a></p>
<p>OBJECTIVES: The appropriate timing of chemotherapy following surgery for resectable pancreatic adenocarcinoma is controversial. Using the National Cancer Database we evaluated time to initiation of chemotherapy postresection and correlated with outcome. METHODS: We identified stage I-III pancreatic adenocarcinoma treated surgically with adjuvant chemoradiotherapy. Receiver operator curve analysis identified an interval of 66 days as the a priori value for largest discrepancy in outcome. Multivariable logistic regression analysis identified variables associated with increased time to chemotherapy postoperatively (&gt;66 days). Propensity matching was performed to account for indication bias. RESULTS: In total, 6873 and 3348 patients received chemotherapy before and after the 66-day cutoff, respectively. Predictors of expedited chemotherapy included lower comorbidity, treatment outside a community program in an urban location, having insurance, white race, and treatment after 2009. Propensity-matched median survival was 21.8 months for all patients, and of these, 6462 were stage 1. Five-year survival was 20% in patients receiving chemotherapy within 66 days and 18% in those not (P = 0.0266). In stage 1 patients, 5-year survival was 23% versus 21% (P = 0.0116) in favor of expedited chemotherapy. CONCLUSIONS: The present propensity-matched analysis showed a significant association with survival for earlier delivery of chemotherapy in the adjuvant setting.</p>
<p>doi: <a href="https://doi.org/10.1097/MPA.0000000000001373" class="uri">https://doi.org/10.1097/MPA.0000000000001373</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Pancreatic Fluid Interleukin-1�� Complements Prostaglandin E2 and Serum Carbohydrate Antigen 19-9 in Prediction of Intraductal Papillary Mucinous Neoplasm Dysplasia</strong> </summary></p>
<p><em>Pancreas 2019 09;48(8):1026-1031</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31404023" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31404023</a></p>
<p>OBJECTIVES: We sought to determine if interleukin (IL)-1β and prostaglandin E2 (PGE2) (inflammatory mediators in pancreatic fluid) together with serum carbohydrate antigen (CA) 19-9 could better predict intraductal papillary mucinous neoplasm (IPMN) dysplasia than individual biomarkers alone. METHODS: Pancreatic cyst fluid (n = 92) collected via endoscopy or surgery (2003-2016) was analyzed for PGE2 and IL-1β (enzyme-linked immunosorbent assay). Patients had surgical pathology-proven IPMN. Threshold values (PGE2 [&gt;1100 pg/mL], IL-1β [&gt;20 pg/mL], and serum CA 19-9 [&gt;36 U/mL]) were determined. RESULTS: Levels of IL-1β were higher in high-grade dysplasia (HGD)/invasive-IPMN (n = 42) compared with low/moderate IPMN (n = 37) (median [range], 54.6 [0-2671] vs 5.9 [0-797] pg/mL; P &lt; 0.001; area under curve [AUC], 0.766). Similarly, PGE2 was higher in HGD/invasive IPMN (n = 45) compared with low/moderate IPMN (n = 47) (median [range], 1790 [20-15,180] vs. 140 [10-14,630] pg/mL; P &lt; 0.001; AUC, 0.748). Presence of elevated PGE2 and IL-1β (AUC, 0.789) provided 89% specificity and 82% positive predictive value (PPV) for HGD/invasive IPMN. Elevated levels of all 3 provided 100% specificity and PPV for HGD/invasive IPMN. CONCLUSIONS: Cyst fluid PGE2, IL-1β, and serum CA 19-9 in combination optimize specificity and PPV for HGD/invasive IPMN and may help build a panel of markers to predict IPMN dysplasia.</p>
<p>doi: <a href="https://doi.org/10.1097/MPA.0000000000001377" class="uri">https://doi.org/10.1097/MPA.0000000000001377</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Etiologic Distribution of Pancreatic Cystic Lesions Identified on Computed Tomography/Magnetic Resonance Imaging</strong> </summary></p>
<p><em>Pancreas 2019 09;48(8):1092-1097</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31404022" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31404022</a></p>
<p>OBJECTIVES: This study aimed to determine the distribution of etiology of pancreatic cysts using established criteria/markers from cyst fluid analysis and cytology that have been reported to have high specificity in published literature. METHODS: A retrospective study of pancreatic cysts using an endoscopic database from March 2002 and May 2013 was conducted. Pancreatic cysts &lt;10 mm and cysts with a history of pancreatic cancer were excluded. RESULTS: In our cohort of 758 patients with pancreatic cyst(s), the cyst etiology was as follows: mucinous cyst/side-branch intraductal papillary mucinous neoplasms (SB-IPMNs)/mucinous cystic neoplasms (MCN; 48.2%), pseudocyst (27.6%), serous cystadenoma (11%), simple cysts (6.4%), mucinous cystadenocarcinoma (5.1%), and other (1%). Approximately 41% (n = 310) of the cysts were ≥3 cm in size and included the following: pseudocyst (39.7%), mucinous cysts/SB-IPMN/MCN (28.1%), serous cystadenoma (16.7%), mucinous cyst adenocarcinoma (9.7%), and simple cyst (4.8%). In 118 patients with a known history of acute pancreatitis, the cyst diagnoses included pseudocyst (68.7%), mucinous cyst/SB-IPMN/MCN (18.6%), benign/simple cyst (7.6%), and mucinous cystadenocarcinoma (2.5%). CONCLUSIONS: In patients with cystic pancreatic lesion noted on cross-sectional imaging, approximately half of the patients have lesions without malignancy or malignant potential and therefore not requiring surveillance. Endoscopic ultrasound/endoscopic ultrasound-guided fine-needle aspiration evaluation of the pancreatic cysts can help optimize their further management.</p>
<p>doi: <a href="https://doi.org/10.1097/MPA.0000000000001372" class="uri">https://doi.org/10.1097/MPA.0000000000001372</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Mutational Patterns in Pancreatic Juice of Intraductal Papillary Mucinous Neoplasms and Concomitant Pancreatic Cancer</strong> </summary></p>
<p><em>Pancreas 2019 09;48(8):1032-1040</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31404021" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31404021</a></p>
<p>OBJECTIVES: The aims of this study were to identify genetic characteristics of intraductal papillary mucinous neoplasm (IPMN)-associated pancreatic ductal carcinoma (PDC) and to detect these markers using pancreatic juice. METHODS: From 76 cases, 102 tissues were obtained: 29 cases were noninvasive IPMN, 18 were PDC derived from IPMN (D-PDC; noninvasive part, n = 16; invasive part, n = 18), and 29 were PDC concomitant with IPMN (C-PDC; IPMN part, n = 10; PDC part, n = 29). Moreover, pancreatic juice samples from 28 cases were obtained (noninvasive IPMN, n = 13; D-PDC, n = 7; C-PDC, n = 8). Fifty-one cancer-related genes were analyzed by next-generation sequencing. RESULTS: TP53 mutation rates in D-PDC, C-PDC, and noninvasive IPMN were 67%, 66%, and 10%, respectively. Moreover, KRAS mutational patterns between 2 simultaneous tumors differed in 1 (6.3%) of the 16 D-PDC cases and in 8 (80%) of the 10 C-PDC cases (P = 0.0006). TP53 or multiple KRAS mutations were detected using pancreatic juice more frequently in C-PDC cases than in noninvasive IPMN cases (75% and 23%, respectively, P = 0.03). CONCLUSIONS: Multiple KRAS mutations along with TP53 mutation are genetic markers for C-PDC, which could be detected using pancreatic juice preoperatively.</p>
<p>doi: <a href="https://doi.org/10.1097/MPA.0000000000001371" class="uri">https://doi.org/10.1097/MPA.0000000000001371</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>SpHincterotomy for Acute Recurrent Pancreatitis Randomized Trial: Rationale, Methodology, and Potential Implications</strong> </summary></p>
<p><em>Pancreas 2019 09;48(8):1061-1067</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31404020" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31404020</a></p>
<p>OBJECTIVES: In patients with acute recurrent pancreatitis (ARP), pancreas divisum, and no other etiologic factors, endoscopic retrograde cholangiopancreatography (ERCP) with minor papilla endoscopic sphincterotomy (miES) is often performed to enlarge the minor papillary orifice, based on limited data. The aims of this study are to describe the rationale and methodology of a sham-controlled clinical trial designed to test the hypothesis that miES reduces the risk of acute pancreatitis. METHODS: The SpHincterotomy for Acute Recurrent Pancreatitis (SHARP) trial is a multicenter, international, sham-controlled, randomized trial comparing endoscopic ultrasound + ERCP with miES versus endoscopic ultrasound + sham for the management of ARP. A total of 234 consented patients having 2 or more discrete episodes of acute pancreatitis, pancreas divisum confirmed by magnetic resonance cholangiopancreatography, and no other clear etiology for acute pancreatitis will be randomized. Both cohorts will be followed for a minimum of 6 months and a maximum of 48 months. RESULTS: The trial is powered to detect a 33% risk reduction of acute pancreatitis frequency. CONCLUSIONS: The SHARP trial will determine whether ERCP with miES benefits patients with idiopathic ARP and pancreas divisum. Trial planning has informed the importance of blinded outcome assessors and long-term follow-up.</p>
<p>doi: <a href="https://doi.org/10.1097/MPA.0000000000001370" class="uri">https://doi.org/10.1097/MPA.0000000000001370</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Expression of Monocarboxylate Transporter 1 Is Associated With Better Prognosis and Reduced Nodal Metastasis in Pancreatic Ductal Adenocarcinoma</strong> </summary></p>
<p><em>Pancreas 2019 09;48(8):1102-1110</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31404019" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31404019</a></p>
<p>OBJECTIVES: Because lactate is believed to support tumor growth, monocarboxylate transporters (MCTs), which transport lactate, have been investigated in multiple tumors. However, the significance of MCTs in pancreatic cancer is unclear. METHODS: A retrospective survey was conducted on 240 patients who underwent surgical resection for pancreatic ductal adenocarcinoma without preoperative treatment. The expression of MCT1, MCT2, MCT3, MCT4, and the glucose transporter 1 (GLUT1) was assessed in tumor cells and cancer-associated fibroblasts (CAFs) by tissue microarrays and immunohistochemistry. The impact of their expression on patient outcome and clinicopathological characteristics was also analyzed. RESULTS: In tumor cells, MCT1, MCT2, MCT3, MCT4, and GLUT1 were detected in 52 (22%), 31 (13%), 149 (62%), 204 (85%), and 235 (98%) cases, respectively. In CAFs, MCT2, MCT4, and GLUT1 were detected in 9 (3.8%), 178 (74%), and 36 (15%) cases, respectively. In tumor cells, MCT1 expression was associated with extended overall and progression-free survival and decreased nodal metastasis. Conversely, MCT4 expression in CAFs was associated with shortened survival. CONCLUSIONS: In tumor cells, MCT1 expression is associated with better prognosis and reduced nodal metastasis in pancreatic cancer, contrary to findings of past in vitro studies. Conversely, MCT4 expression in CAFs is indicative of worse prognosis.</p>
<p>doi: <a href="https://doi.org/10.1097/MPA.0000000000001369" class="uri">https://doi.org/10.1097/MPA.0000000000001369</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Prevention of Infectious Complications in Acute Pancreatitis: Results of a Single-Center, Randomized, Controlled Trial</strong> </summary></p>
<p><em>Pancreas 2019 09;48(8):1056-1060</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31404018" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31404018</a></p>
<p>OBJECTIVES: This study aimed to investigate the efficiency of imipenem to prevent infectious complications in predicted severe acute pancreatitis (AP). METHODS: Consecutive AP patients were randomized to imipenem 3 × 500 mg intravenously daily or an identical placebo. Exclusion criteria were prior AP, chronic pancreatitis, active malignancy, immune deficiency, active infection, concomitant antibiotic treatment, pregnancy, and patients younger than 18 years. Infectious complications including infected pancreatic necrosis, pneumonia, urinary tract infection, positive blood cultures, sepsis, and other infections were assessed as the primary outcome. Secondary outcomes included mortality, persistent organ failure, systemic inflammatory response syndrome, local complications, serious adverse events, and need for surgical intervention. RESULTS: Forty-nine patients were randomized to each group. Infectious complications were present in 10 versus 12 of 49 patients (relative risk [RR], 0.833; 95% confidence interval [CI], 0.398-1.747). There were no significant differences in infected pancreatic necrosis (RR, 1.5; 95% CI, 0.262-8.588), pneumonia (RR, 1.5; 95% CI, 0.262-8.588), urinary tract infection (RR, 0.6; 95% CI, 0.152-2.374), positive blood cultures (RR, 0.5; 95% CI, 0.047-5.336), sepsis (RR, 0.333; 95% CI, 0.036-3.095), and other (RR, 1.333; 95% CI, 0.315-5.648). We found no significant differences in secondary outcomes. CONCLUSIONS: Concordantly to available evidence, there is currently no ground to support prophylactic use of antibiotics in predicted severe AP.</p>
<p>doi: <a href="https://doi.org/10.1097/MPA.0000000000001368" class="uri">https://doi.org/10.1097/MPA.0000000000001368</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Defining Pancreatitis as a Risk Factor for Pancreatic Cancer: The Role, Incidence, and Timeline of Development</strong> </summary></p>
<p><em>Pancreas 2019 09;48(8):1098-1101</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31404017" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31404017</a></p>
<p>OBJECTIVES: Acute and/or chronic pancreatitis has been implicated as an important risk factor for pancreatic cancer; however, the incidence and temporal relationship of pancreatitis before pancreatic cancer diagnosis are unclear. We aim to understand the role and incidence of pancreatitis temporally with the development of pancreatic cancer. METHODS: A population-based study was used to investigate a temporal relationship between pancreatitis and pancreatic cancer diagnoses. Intervals of 3, 6, 12, 24, and 36 months were developed. Demographical data including age, sex, and race were also recorded and analyzed. RESULTS: A total of 50,080 patients were found to have a diagnosis of pancreatic cancer, of which 7420 (14.8%) had prior diagnoses of pancreatitis. Of those, 92% were between the ages of 40 and 89 years. African Americans had a higher rate of pancreatitis before cancer diagnosis when compared with whites (21.2% vs 14.8%, P &lt; 0.0001). Further analysis revealed that pancreatitis occurred in 81.3% of patients 3 months before a diagnosis of pancreas cancer and 98.9% had established diagnoses of pancreatic cancer within 3 years. CONCLUSIONS: Screening of patients older than 40 years who have pancreatitis and unclear etiology of pancreatitis may be warranted, especially in African Americans and male individuals.</p>
<p>doi: <a href="https://doi.org/10.1097/MPA.0000000000001367" class="uri">https://doi.org/10.1097/MPA.0000000000001367</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Intraductal Papillary Mucinous Neoplasms: Attack of the Clones</strong> </summary></p>
<p><em>Gastroenterology 2019 10;157(4):929-932</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31400367" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31400367</a></p>
<p>doi: <a href="https://doi.org/10.1053/j.gastro.2019.08.007" class="uri">https://doi.org/10.1053/j.gastro.2019.08.007</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Pancreas FNA</strong> </summary></p>
<p><em>Cytopathology : official journal of the British Society for Clinical Cytology 2020 Mar;31(2):161-162</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31400170" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31400170</a></p>
<p>doi: <a href="https://doi.org/10.1111/cyt.12767" class="uri">https://doi.org/10.1111/cyt.12767</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>ARF6 and AMAP1 are major targets of KRAS and TP53 mutations to promote invasion, PD-L1 dynamics, and immune evasion of pancreatic cancer</strong> </summary></p>
<p><em>Proceedings of the National Academy of Sciences of the United States of America 2019 08;116(35):17450-17459</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31399545" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31399545</a></p>
<p>Although KRAS and TP53 mutations are major drivers of pancreatic ductal adenocarcinoma (PDAC), the incurable nature of this cancer still remains largely elusive. ARF6 and its effector AMAP1 are often overexpressed in different cancers and regulate the intracellular dynamics of integrins and E-cadherin, thus promoting tumor invasion and metastasis when ARF6 is activated. Here we show that the ARF6-AMAP1 pathway is a major target by which KRAS and TP53 cooperatively promote malignancy. KRAS was identified to promote eIF4A-dependent ARF6 mRNA translation, which contains a quadruplex structure at its 5’-untranslated region, by inducing TEAD3 and ETV4 to suppress PDCD4; and also eIF4E-dependent AMAP1 mRNA translation, which contains a 5’-terminal oligopyrimidine-like sequence, via up-regulating mTORC1. TP53 facilitated ARF6 activation by platelet-derived growth factor (PDGF), via its known function to promote the expression of PDGF receptor β (PDGFRβ) and enzymes of the mevalonate pathway (MVP). The ARF6-AMAP1 pathway was moreover essential for PDGF-driven recycling of PD-L1, in which KRAS, TP53, eIF4A/4E-dependent translation, mTOR, and MVP were all integral. We moreover demonstrated that the mouse PDAC model KPC cells, bearing KRAS/TP53 mutations, express ARF6 and AMAP1 at high levels and that the ARF6-based pathway is closely associated with immune evasion of KPC cells. Expression of ARF6 pathway components statistically correlated with poor patient outcomes. Thus, the cooperation among eIF4A/4E-dependent mRNA translation and MVP has emerged as a link by which pancreatic driver mutations may promote tumor cell motility, PD-L1 dynamics, and immune evasion, via empowering the ARF6-based pathway and its activation by external ligands.</p>
<p>doi: <a href="https://doi.org/10.1073/pnas.1901765116" class="uri">https://doi.org/10.1073/pnas.1901765116</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Second harmonic generation detection of Ras conformational changes and discovery of a small molecule binder</strong> </summary></p>
<p><em>Proceedings of the National Academy of Sciences of the United States of America 2019 08;116(35):17290-17297</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31399543" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31399543</a></p>
<p>Second harmonic generation (SHG) is an emergent biophysical method that sensitively measures real-time conformational change of biomolecules in the presence of biological ligands and small molecules. This study describes the successful implementation of SHG as a primary screening platform to identify fragment ligands to oncogenic Kirsten rat sarcoma (KRas). KRas is the most frequently mutated driver of pancreatic, colon, and lung cancers; however, there are few well-characterized small molecule ligands due to a lack of deep binding pockets. Using SHG, we identified a fragment binder to KRasG12D and used 1H 15N transverse relaxation optimized spectroscopy (TROSY) heteronuclear single-quantum coherence (HSQC) NMR to characterize its binding site as a pocket adjacent to the switch 2 region. The unique sensitivity of SHG furthered our study by revealing distinct conformations induced by our hit fragment compared with 4,6-dichloro-2-methyl-3-aminoethyl-indole (DCAI), a Ras ligand previously described to bind the same pocket. This study highlights SHG as a high-throughput screening platform that reveals structural insights in addition to ligand binding.</p>
<p>doi: <a href="https://doi.org/10.1073/pnas.1905516116" class="uri">https://doi.org/10.1073/pnas.1905516116</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Tumor Microbiome Diversity and Composition Influence Pancreatic Cancer Outcomes</strong> </summary></p>
<p><em>Cell 2019 08;178(4):795-806.e12</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31398337" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31398337</a></p>
<p>Most patients diagnosed with resected pancreatic adenocarcinoma (PDAC) survive less than 5 years, but a minor subset survives longer. Here, we dissect the role of the tumor microbiota and the immune system in influencing long-term survival. Using 16S rRNA gene sequencing, we analyzed the tumor microbiome composition in PDAC patients with short-term survival (STS) and long-term survival (LTS). We found higher alpha-diversity in the tumor microbiome of LTS patients and identified an intra-tumoral microbiome signature (Pseudoxanthomonas-Streptomyces-Saccharopolyspora-Bacillus clausii) highly predictive of long-term survivorship in both discovery and validation cohorts. Through human-into-mice fecal microbiota transplantation (FMT) experiments from STS, LTS, or control donors, we were able to differentially modulate the tumor microbiome and affect tumor growth as well as tumor immune infiltration. Our study demonstrates that PDAC microbiome composition, which cross-talks to the gut microbiome, influences the host immune response and natural history of the disease.</p>
<p>doi: <a href="https://doi.org/10.1016/j.cell.2019.07.008" class="uri">https://doi.org/10.1016/j.cell.2019.07.008</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Variation in use of open and laparoscopic distal pancreatectomy and associated outcome metrics in a universal health care system</strong> </summary></p>
<p><em>Pancreatology : official journal of the International Association of Pancreatology (IAP) … [et al.] 2019 Sep;19(6):880-887</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31395453" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31395453</a></p>
<p>BACKGROUND: Universal health care (UHC) should ensure equal access to and use of surgery, but few studies have explored variation in UHC systems. The objective was to describe practice of distal pancreatectomy in Norway covered exclusively by an UHC. METHODS: Data on all patients undergoing distal pancreatectomy from the Norwegian Patient Register over a 5-year period. Age- and gender-adjusted population-based resection rates (adj. per million/yr) for distal pancreatectomy were analysed across 4 regions and outcomes related to splenic salvage rate, hospital stay, reoperation, readmissions and 90-day mortality risk between regions. Risk is reported as odds ratio (OR) with 95% confidence interval (c.i.). RESULTS: Regional difference exist in terms of absolute numbers, with the majority of procedures done in one region (n = 331; 59.7%). Regional variation persisted for age- and gender-adjusted population-rates, with highest rate at 23.8/million/yr and lowest rate at 13.5/mill/yr (for a 176% relative difference; or an absolute difference of +10.3 resections/million/yr). Overall, a lapDP instead of an open DP was 3.5 times more likely in SouthEast compared to all other regions combined (lapDP rate: 83% vrs 24%, respectively; OR 15.4, 95% c.i. 10.1-23.5; P &lt; 0.001). The splenic salvage rate was lower in SouthEast (19.9%) compared to all other regions (average 26.5%; highest in Central-region at 37.0%; P = 0.010 for trend). Controlled for other factors in multivariate regression, ‘region’ of surgery remained significantly associated with laparoscopic access. CONCLUSION: Despite a universal health care system, considerable variation exists in resection rates, use of laparoscopy and splenic salvage rates across regions.</p>
<p>doi: <a href="https://doi.org/10.1016/j.pan.2019.07.047" class="uri">https://doi.org/10.1016/j.pan.2019.07.047</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Comparison of overall survival and perioperative outcomes of laparoscopic pancreaticoduodenectomy and open pancreaticoduodenectomy for pancreatic ductal adenocarcinoma: a systematic review and meta-analysis</strong> </summary></p>
<p><em>BMC cancer 2019 Aug;19(1):781</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31391085" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31391085</a></p>
<p>BACKGROUND: The aim of this study was to compare the oncological outcomes and clinical efficacy of laparoscopic pancreaticoduodenectomy (LPD) and open pancreaticoduodenectomy (OPD) in patients with pancreatic ductal adenocarcinoma (PDAC). METHODS: We systematically searched PubMed, EMBASE, Web of Science, ClinicalTrials.gov and the Cochrane Central Register for studies published between May 1998 and May 2018. The included studies compared LPD and OPD for the treatment of PDAC. The oncological outcomes and perioperative data were analyzed. RESULTS: Eight studies involving 15,278 patients were included in our meta-analysis. No significant difference was found in the 5-year overall survival (OS) between patients undergoing the two types of surgery (HR: 0.97, 95% CI 0.82-1.15, p = 0.76). LPD resulted in a higher rate of R0 resection than OPD (OR: 1.16, 95% CI 0.85-1.57, p &gt; 0.05). This study showed that compared with OPD, LPD resulted in comparable rates of postoperative pancreatic fistulas (POPFs) (OR: 1.07, 95% CI: 0.68-1.68, p = 0.77) and postoperative hemorrhage (OR: 1.74, 95% CI 0.96-3.71, p = 0.07), more harvested lymph nodes (WMD: 1.84, 95% CI: 0.95-2.72, p &lt; 0.05), shorter hospital stays (WMD: -2.45, 95% CI: - 3.33- -1.56, p &lt; 0.05), and less estimated blood loss (WMD: -374.30, 95% CI: - 513.06- -235.54, p &lt; 0.05). CONCLUSIONS: LPD is equivalent to OPD with respect to 5-year OS and results in better perioperative clinical outcomes for patients with PDAC.</p>
<p>doi: <a href="https://doi.org/10.1186/s12885-019-6001-x" class="uri">https://doi.org/10.1186/s12885-019-6001-x</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>A 12-year trend analysis of the incidence of gastrointestinal cancers in East Azerbaijan: last updated results of an ongoing population-based cancer registry</strong> </summary></p>
<p><em>BMC cancer 2019 Aug;19(1):782</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31391032" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31391032</a></p>
<p>BACKGROUND: The most recent results of Global Cancer Statistics indicated that gastrointestinal cancers, including gastric, colorectal, esophageal, and liver cancers, are among the most commonly diagnosed cancers worldwide. Previous reports from cancer registries in East Azerbaijan have shown that there is a high incidence of gastrointestinal cancer in this region, so we performed a trend analysis to determine the pattern of change over the last decade. METHODS: In total, 12 years of cancer registry data were collected from different sources in East Azerbaijan, and a data quality check was performed to ensure clean data. Using the 2000 World Health Organization standard population, we then generated age-standardized incidence rates (ASRs) for different cancers, and for each year from 1383 to 1394 of the Persian calendar (i.e., 19 March 2004 to 20 March 2015). Annual percent changes (APCs) and Average annual percent changes (AAPCs) in the ASRs for esophageal, gastric, small intestine, colorectal, anal, liver, gallbladder, and pancreatic cancers were calculated using Joinpoint Software (Version 4.5.0.1, June 2017). RESULTS: An increase in most types of cancer was observed during the study period. The ASR for colorectal cancer increased from 2.9 to 13.6 per 100,000 women (APC, 9.7%) and from 2.2 to 17.8 per 100,000 men (APC, 10.2%). The ASR for gastric cancer showed a slight increasing trend from 10.5 to 13.5 per 100,000 women (APC, 1.3%) and from 3.1 to 29.9 per 100,000 men (APC, 3.2%). However, trend analysis showed a decreasing pattern for the ASR of esophageal cancer in both genders (APC,- 3%), with APCs of - 1.1% in females and - 0.4% in males. CONCLUSIONS: The latest results of the East Azerbaijan Population-Based Cancer Registry indicate that gastrointestinal cancers remain common, with significant increasing trends in their ASRs. Improved screening and early detection are needed in this region.</p>
<p>doi: <a href="https://doi.org/10.1186/s12885-019-6008-3" class="uri">https://doi.org/10.1186/s12885-019-6008-3</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>The prognostic value of lncRNA SNHG1 in cancer patients: a meta-analysis</strong> </summary></p>
<p><em>BMC cancer 2019 Aug;19(1):780</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31391030" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31391030</a></p>
<p>BACKGROUND: Increasing evidence revealed that high expression level of lncRNA SNHG1 was associated with the unfavorable prognosis of cancer and maybe used as a valuable biomarker for cancer patients. The present meta-&gt;analysis is to analyze existing data to reveal potential clinical application of SNHG1 on cancer prognosis and tumor progression. All of the included studies were collected through a variety of retrieval strategies. And the articles were qualified by MOOSE and PRISMA checklists. METHODS: Up to Mar 20, 2018, literature collection was performed by comprehensive search through electronic databases, including the Cochrane library, PubMed, Embase, Web of science, Springer, Science direct, and three Chinese databases: CNKI, Weipu, and Wanfang. We analyzed 14 studies that met the criteria, and concluded that the increased SHNG1 level was correlated with poor OS and tumor progression. RESULTS: The combined results indicated that elevated SNHG1 expression level was significantly associated with poor OS (HR = 2.06, 95% CI: 1.69-2.52, P &lt; 0.01) and PFS (HR = 2.78, 95% CI: 1.69-4.55, P &lt; 0.01) in various cancers. Moreover, the promoted SNHG1 expression was also associated with tumor progression ((III/IV vs. I/II: HR = 1.89, 95% CI: 1.53-2.34, P &lt; 0.01). In stratified analyses, a significantly unfavorable association of elevated lncRNA SNHG1 and OS was observed in both digestive system (HR = 2.04, 95% CI: 1.56-2.68, P &lt; 0.01) and non-digestive system (HR = 2.09, 95% CI: 1.55-2.83, P &lt; 0.01) cancer patients. CONCLUSIONS: The present analysis indicated that the increased SNHG1 is associated with poor OS in patients with general tumors and may be served as a useful prognostic biomarker.</p>
<p>doi: <a href="https://doi.org/10.1186/s12885-019-5987-4" class="uri">https://doi.org/10.1186/s12885-019-5987-4</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Dynamic serum alkaline phosphatase is an indicator of overall survival in pancreatic cancer</strong> </summary></p>
<p><em>BMC cancer 2019 Aug;19(1):785</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31391026" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31391026</a></p>
<p>BACKGROUND: The prognostic role of serum alkaline phosphatase (ALP) has been found in several kinds of solid malignant tumor, but has never been extensively discussed in pancreatic cancer, especially through the application of dynamic survival model which incorporates the varying nature of ALP measurements. METHODS: We conducted a retrospective study which successfully collected 551 histopathologically confirmed pancreatic ductal adenocarcinoma (PDAC) patients from a cancer specialized hospital in southwest China. The association between variant ALP which measured during the whole survival period and the overall survival (OS) of PDAC patients was evaluated by using dynamic Anderson-Gill (AG) model. Exhaustive sensitivity analysis was performed by adopting continuous cut-offs of ALP. RESULTS: After adjusted for possible confounding of serum albumin, total bilirubin and leukocyte counts, AG model revealed that, serum ALP during the survival period was nonlinearly associated with the OS of PDAC: for resected patients, compared with those whose ALP results ranged within the first quartile (&lt;P25), patients whose ALP measurements belonged to the second (P25-P50), the third (P50-P75), and the forth (&gt;P75) quartiles were observed 1.14 (95% CI: 0.29-4.56), 3.93 (95% CI: 1.23-12.60), 3.87 (95% CI: 1.32-11.36) folds of death hazard; whereas in un-resected PDAC patients, the hazard ratios (HRs) were 1.15 (95% CI: 0.79-1.68), 1.92 (95% CI: 1.32-2.78), and 1.97 (95% CI: 1.30-2.98), respectively. Sensitivity analysis revealed that, for both resected and un-resected patients, the results of AG model were robust with regard to various cut-offs of ALP, and an increased ALP was in general associated with significantly increased hazard of death. CONCLUSION: Serum ALP during the survival period was significantly associated with the OS of PDAC patients, especially for resected early stage PDAC patients. Future studies with expanded sample size and refined prospective design should be implemented to corroborate our major findings. Besides, the underlying mechanism for this possible hazardous role of ALP should also be investigated.</p>
<p>doi: <a href="https://doi.org/10.1186/s12885-019-6004-7" class="uri">https://doi.org/10.1186/s12885-019-6004-7</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Corrigendum to “Cystic pancreatic neuroendocrine tumors: A more favorable lesion?” [Pancreatology 19 (2) (March 2019) 372-376]</strong> </summary></p>
<p><em>Pancreatology : official journal of the International Association of Pancreatology (IAP) … [et al.] 2019 Sep;19(6):903</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31387834" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31387834</a></p>
<p>doi: <a href="https://doi.org/10.1016/j.pan.2019.07.043" class="uri">https://doi.org/10.1016/j.pan.2019.07.043</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>The harms of early cessation of trials on systematic reviews - Authors’ reply</strong> </summary></p>
<p><em>The lancet. Gastroenterology &amp; hepatology 2019 Sep;4(9):667-668</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31387729" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31387729</a></p>
<p>doi: <a href="https://doi.org/10.1016/S2468-1253(19)30228-6" class="uri">https://doi.org/10.1016/S2468-1253(19)30228-6</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Classification of Complication Clusters Might Vary in Different Populations With Chronic Pancreatitis</strong> </summary></p>
<p><em>The American journal of gastroenterology 2019 08;114(8):1351-1352</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31386633" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31386633</a></p>
<p>doi: <a href="https://doi.org/10.14309/ajg.0000000000000292" class="uri">https://doi.org/10.14309/ajg.0000000000000292</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Sclerosing epithelioid mesenchymal neoplasm of the pancreas��-��a proposed new entity</strong> </summary></p>
<p><em>Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc 2020 03;33(3):456-467</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31383964" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31383964</a></p>
<p>We have encountered pancreatic tumors with unique histologic features, which do not conform to any of the known tumors of the pancreas or other anatomical sites. We aimed to define their clinicopathologic features and whether they are characterized by recurrent molecular signatures. Eight cases were identified; studied histologically and by immunohistochemistry. Selected cases were also subjected to whole-exome sequencing (WES; n = 4), RNA-sequencing (n = 6), Archer FusionPlex assay (n = 5), methylation profiling using the Illumina MethylationEPIC (850k) array platform (n = 6), and TERT promoter sequencing (n = 5). Six neoplasms occurred in females. The mean age was 43 years (range: 26-75). Five occurred in the head/neck of the pancreas. All patients were treated surgically; none received neoadjuvant/adjuvant therapy. All patients are free of disease after 53 months of median follow-up (range: 8-94). The tumors were well-circumscribed, and the median size was 1.8 cm (range: 1.3-5.8). Microscopically, the unencapsulated tumors had a geographic pattern of epithelioid cell nests alternating with spindle cell fascicles. Some areas showed dense fibrosis, in which enmeshed tumor cells imparted a slit-like pattern. The predominant epithelioid cells had scant cytoplasm and round-oval nuclei with open chromatin. The spindle cells displayed irregular, hyperchromatic nuclei. Mitoses were rare. No lymph node metastases were identified. All tumors were positive for vimentin, CD99 and cytokeratin (patchy), while negative for markers of solid pseudopapillary neoplasm, neuroendocrine, acinar, myogenic/rhabdoid, vascular, melanocytic, or lymphoid differentiation, gastrointestinal stromal tumor as well as MUC4. Whole-exome sequencing revealed no recurrent somatic mutations or amplifications/homozygous deletions in any known oncogenes or tumor suppressor genes. RNA-sequencing and the Archer FusionPlex assay did not detect any recurrent likely pathogenic gene fusions. Single sample gene set enrichment analysis revealed that these tumors display a likely mesenchymal transcriptomic program. Unsupervised analysis (t-SNE) of their methylation profiles against a set of different mesenchymal neoplasms demonstrated a distinct methylation pattern. Here, we describe pancreatic neoplasms with unique morphologic/immunophenotypic features and a distinct methylation pattern, along with a lack of abnormalities in any of key genetic drivers, supporting that these neoplasms represent a novel entity with an indolent clinical course. Given their mesenchymal transcriptomic features, we propose the designation of “sclerosing epithelioid mesenchymal neoplasm” of the pancreas.</p>
<p>doi: <a href="https://doi.org/10.1038/s41379-019-0334-5" class="uri">https://doi.org/10.1038/s41379-019-0334-5</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>The cost of endoscopic treatment for walled-off pancreatic necrosis</strong> </summary></p>
<p><em>Pancreatology : official journal of the International Association of Pancreatology (IAP) … [et al.] 2019 Sep;19(6):828-833</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31383574" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31383574</a></p>
<p>BACKGROUND: Use of minimally invasive techniques has reduced mortality in walled-off pancreatic necrosis (WON) but may be costly. The aim of this study was to evaluate the actual costs associated with the endoscopic management of patients with WON. METHODS: We included a retrospective cohort of WON patients treated with endoscopic, transgastric drainage and necrosectomy (ETDN) during 2013-2014. Costs were calculated for six sub-areas based on a micro-costing model. Students T-test and non-parametric analysis of variance were performed to evaluate costs in relation to disease etiology and outcome. RESULTS: We included 58 patients (50% men, median age 57 years). The most common etiologies were gallstones (57%) and alcohol (19%). Nine patients (16%) died during admission. The median length of stay was 50 days (IQR 31 days). Eighteen patients (31%) needed treatment in our intensive care unit with a median length of stay of 16 days (IQR 31 days). The mean costs and standard deviation of costs (SD) per patient were: diagnostic imaging $2,431 ($2,301), laboratory tests $3,579 ($2,477), blood products $982 ($1,734), endoscopic treatment $3,794 ($1,777), medicine $5,440 ($6,656), and ward cost $41,260 ($35,854). The mean total cost was $57,486 ($46,739). Post-ERCP pancreatitis and mortality predicted higher costs. CONCLUSIONS: This study sheds light on the different costs associated with endoscopic treatment of WON. As nearly three quarters of the costs are related to ward care, initiatives aimed at reducing the length of hospital stay may have a great impact on making endoscopic treatment more cost effective.</p>
<p>doi: <a href="https://doi.org/10.1016/j.pan.2019.07.042" class="uri">https://doi.org/10.1016/j.pan.2019.07.042</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Coexisting pancreatic serous cystadenoma and pancreatic ductal adenocarcinoma: A cytological-pathologic correlation with literature review</strong> </summary></p>
<p><em>Annals of diagnostic pathology 2019 Oct;42():87-91</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31382079" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31382079</a></p>
<p>Pancreatic serous cystadenoma (SCA) is a benign neoplastic lesion with a distinctive gross and microscopic appearance consisting of numerous thin-walled cysts lined by uniform epithelial cells with clear cytoplasm and small nuclei. The vast majority of serous cystadenomas are benign. Pancreatic SCA has rarely been reported in association with other pancreatic lesions. We present a challenging case in which a cystic and solid pancreatic mass was identified on imaging studies. FNA was performed and showed clusters of atypical cells with significant nuclear pleomorphism (&gt;4:1), disorganized, overlapping nuclei, and prominent nucleoli. The FNA diagnosis was positive for malignancy, consistent with adenocarcinoma. The patient underwent neoadjuvant therapy and pancreaticoduodenectomy. Final pathology showed a serous cystadenoma associated with small foci of high-grade PanIN. The lack of invasive adenocarcinoma in the resection specimen was most likely due to complete response of the tumor to neoadjuvant chemoradiation therapy, but it is also possible that only high-grade PanIN was present initially. To our knowledge, this is the first reported case of SCA and high grade PanIN/PDAC that was assessed by FNA. We discuss the cytologic differential diagnosis and how to avoid potential pitfalls highlighted by this case.</p>
<p>doi: <a href="https://doi.org/10.1016/j.anndiagpath.2019.07.006" class="uri">https://doi.org/10.1016/j.anndiagpath.2019.07.006</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>The role of abdominal drainage in pancreatic resection - A multicenter validation study for early drain removal</strong> </summary></p>
<p><em>Pancreatology : official journal of the International Association of Pancreatology (IAP) … [et al.] 2019 Sep;19(6):888-896</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31378583" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31378583</a></p>
<p>BACKGROUND: Abdominal drainage and the timing of drain removal in patients undergoing pancreatic resection are under debate. Early drain removal after pancreatic resection has been reported to be safe with a low risk for clinical relevant postoperative pancreatic fistula (CR-POPF) when drain amylase on POD1 is &lt; 5000U/L. The aim of this study was to validate this algorithm in a large national cohort. METHODS: Patients registered in the Dutch Pancreatic Cancer Audit (2014-2016) who underwent pancreatoduodenectomy, distal pancreatectomy or enucleation were analysed. Data on post-operative drain amylase levels, drain removal, postoperative pancreatic fistulae were collected. Univariate and multivariate analysis using a logistic regression model were performed. The primary outcome measure was grade B/C pancreatic fistula (CR-POPF). RESULTS: Among 1402 included patients, 433 patients with a drain fluid amylase level of &lt;5000U/L on POD1, 7% developed a CR-POPF. For patients with an amylase level &gt;5000U/L the CR-POPF rate was 28%. When using a cut-off point of 2000U/L or 1000U/L during POD1-3, the CR-POPF rates were 6% and 5% respectively. For patients with an amylase level of &gt;2000U/L and &gt;1000UL during POD 1-3 the CR-POPF rates were 26% and 22% respectively (n = 223). Drain removal on POD4 or thereafter was associated with more complications (p = 0.004). Drain amylase level was shown to be the most statistically significant predicting factor for CR-POPF (Wald = 49.7; p &lt; 0.001). CONCLUSION: Our data support early drain removal after pancreatic resection. However, a cut-off of 5000U/L drain amylase on POD1 was associated with a relatively high CR-POPF rate of 7%. A cut-off point of 1000U/L during POD1-3 resulted in 5% CR-POPF and might be a safer alternative.</p>
<p>doi: <a href="https://doi.org/10.1016/j.pan.2019.07.041" class="uri">https://doi.org/10.1016/j.pan.2019.07.041</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Factors predicting readmission within 30 days of acute pancreatitis attack: A prospective study</strong> </summary></p>
<p><em>Pancreatology : official journal of the International Association of Pancreatology (IAP) … [et al.] 2019 Sep;19(6):805-806</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31378581" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31378581</a></p>
<p>doi: <a href="https://doi.org/10.1016/j.pan.2019.07.044" class="uri">https://doi.org/10.1016/j.pan.2019.07.044</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Intraductal oncocytic papillary neoplasm of the pancreas: A systematic review</strong> </summary></p>
<p><em>Pancreatology : official journal of the International Association of Pancreatology (IAP) … [et al.] 2019 Sep;19(6):858-865</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31375434" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31375434</a></p>
<p>BACKGROUND: Intraductal oncocytic papillary neoplasm of the pancreas (IOPN-P) is a rare subtype of intraductal papillary mucinous neoplasm (IPMN). This study was performed to summarize the clinicopathological features and management of IOPN-P. METHODS: English-language articles were searched from MEDLINE and EMBASE from the first report of IOPN-P in 1996 until 1 May 2019 following the methodology in the PRISMA guidelines. RESULTS: In total, 66 patients from 24 full articles were included in the final data analysis. The patients’ average age was 61 years, and the male/female ratio was 1. Most lesions were large (average size, 5.50 cm), located in the pancreatic head, and found either incidentally or by uncharacteristic abdominal symptoms. IOPN-P was usually a cystic and solid lesion with or without mural nodules on radiological examination. A definitive diagnosis was often acquired from fine needle aspiration biopsy or postoperative pathology. All tumors were diagnosed as carcinoma in situ or minimally invasive carcinoma, necessitating surgical resection. The prognosis of IOPN-P was better than that of other IPMN subtypes, even when metastasis occurred. Recurrence after surgical resection of IOPN-P was rare. CONCLUSIONS: IOPN-P is rare among IPMN subtypes with unique pathological characteristics. Because of the nontypical symptoms and radiological findings, a definitive preoperative diagnosis usually depends on multimodal examinations. Management and surveillance of IOPN-P after surgical resection should be differentiated from those of other pancreatic benign cystic lesions because of its relative malignancy, but IOPN-P should also be differentiated from other IPMN subtypes and malignant cystic tumors because of its favorable prognosis.</p>
<p>doi: <a href="https://doi.org/10.1016/j.pan.2019.07.040" class="uri">https://doi.org/10.1016/j.pan.2019.07.040</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Response to repeat echoendoscopic celiac plexus neurolysis in pancreatic cancer patients: A machine learning approach</strong> </summary></p>
<p><em>Pancreatology : official journal of the International Association of Pancreatology (IAP) … [et al.] 2019 Sep;19(6):866-872</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31375433" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31375433</a></p>
<p>BACKGROUND: /Objectives: Efficacy of repeat echoendoscopic celiac plexus neurolysis is still unclear. Aim of the study was to assess the efficacy of repeat celiac plexus neurolysis and to build an artificial neural network model able to predict pain response. METHODS: Data regarding 156 patients treated with repeat celiac plexus neurolysis between 2004 and 2019 were reviewed. Artificial neural network and logistic regression models were built to predict pain response after treatment. Performance of the models was expressed in terms of accuracy, positive predictive value, and positive likelihood ratio. RESULTS: Median age was 62 years (range 39-86) and most patients were male (66%) with pre-procedural visual analogue score 7. Fifty-one patients (32.6%) experienced treatment response, of which 6 (3.8%) complete pain suppression. Median duration of pain relief was 6 (2-8) weeks. Tumoral stage, interval from initial to repeat treatment, response to initial neurolysis, and tumor progression between the two treatments resulted as significant predictors of pain response. The performance of the artificial neural network in predicting treatment response was higher than regression model (area under the curve: 0.94, 0.89-0.97 versus 0.85, 0.78-0.89; p &lt; 0.001). Positive predictive value and positive likelihood ratio resulted 90.3% and 19.35, respectively. Classification error rate was 5.7% with the artificial neural network compared to 14.7% of regression model (p &lt; 0.001). These findings were confirmed through ten-fold cross validation. CONCLUSIONS: Pain response following repeat neurolysis is generally less pronounced than after initial treatment. Artificial neural network may help to identify those subjects likely to benefit from repeat neurolysis.</p>
<p>doi: <a href="https://doi.org/10.1016/j.pan.2019.07.038" class="uri">https://doi.org/10.1016/j.pan.2019.07.038</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Disruption of IRE1�� through its kinase domain attenuates multiple myeloma</strong> </summary></p>
<p><em>Proceedings of the National Academy of Sciences of the United States of America 2019 08;116(33):16420-16429</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31371506" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31371506</a></p>
<p>Multiple myeloma (MM) arises from malignant immunoglobulin (Ig)-secreting plasma cells and remains an incurable, often lethal disease despite therapeutic advances. The unfolded-protein response sensor IRE1α supports protein secretion by deploying a kinase-endoribonuclease module to activate the transcription factor XBP1s. MM cells may co-opt the IRE1α-XBP1s pathway; however, the validity of IRE1α as a potential MM therapeutic target is controversial. Genetic disruption of IRE1α or XBP1s, or pharmacologic IRE1α kinase inhibition, attenuated subcutaneous or orthometastatic growth of MM tumors in mice and augmented efficacy of two established frontline antimyeloma agents, bortezomib and lenalidomide. Mechanistically, IRE1α perturbation inhibited expression of key components of the endoplasmic reticulum-associated degradation machinery, as well as secretion of Ig light chains and of cytokines and chemokines known to promote MM growth. Selective IRE1α kinase inhibition reduced viability of CD138+ plasma cells while sparing CD138- cells derived from bone marrows of newly diagnosed or posttreatment-relapsed MM patients, in both US- and European Union-based cohorts. Effective IRE1α inhibition preserved glucose-induced insulin secretion by pancreatic microislets and viability of primary hepatocytes in vitro, as well as normal tissue homeostasis in mice. These results establish a strong rationale for developing kinase-directed inhibitors of IRE1α for MM therapy.</p>
<p>doi: <a href="https://doi.org/10.1073/pnas.1906999116" class="uri">https://doi.org/10.1073/pnas.1906999116</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Comparative effectiveness of primary tumor resection in patients with stage III pancreatic adenocarcinoma</strong> </summary></p>
<p><em>BMC cancer 2019 Aug;19(1):761</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31370893" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31370893</a></p>
<p>BACKGROUND: Previous studies comparing primary tumor resection (PTR) to palliative treatment for advanced-stage pancreatic ductal adenocarcinoma (PDA) were limited by strong selection bias. We used multiple methods to control for confounding and selection bias to estimate the effect of PTR on survival for late-stage PDA. METHODS: Surveillance, Epidemiology, and End Results (SEER) 18 registry database for 2004 through 2014 was retrieved for the present study. A total of 4322 patients with stage III (AJCC, 6th) PDA were included in this study. Propensity score matching (PSM) was performed to eliminate possible bias. In addition, instrumental variable (IV) analysis was utilized to adjust for both measured and unmeasured confounders. RESULTS: A total of 4322 patients with stage III PDA including 552 (12.8%) who underwent PTR, 3770 (87.2%) without PTR, were identified. In the multivariable cohort, a clear prognostic advantage of PTR was observed in overall survival (OS) (P &lt; 0.001) and disease-specific survival (DSS) (P &lt; 0.001) compared to patients after non-surgery therapy. In the PSM cohort, patients in PTR group showed a better OS and DSS (both P values &lt; 0.001) compared to patients in non-surgery group. The survival benefit of PTR for stage III PDA was not observed in the two-stage residual inclusion (2SRI) model. Estimates based on this instrument indicated that patients treated with PTR had similar OS (P = 0.448) and DSS (P = 0.719). In IV analyses stratified by chemotherapy and tumor location, patients undergoing PTR had similar OS and DSS compared to patients in non-surgery group across all subgroups. CONCLUSIONS: Survival with PTR did not differ significantly from palliative treatment in marginal patients with stage III pancreatic adenocarcinoma. High-quality randomized trials are needed to validate these results.</p>
<p>doi: <a href="https://doi.org/10.1186/s12885-019-5966-9" class="uri">https://doi.org/10.1186/s12885-019-5966-9</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Characterising the impact of body composition change during neoadjuvant chemotherapy for pancreatic cancer</strong> </summary></p>
<p><em>Pancreatology : official journal of the International Association of Pancreatology (IAP) … [et al.] 2019 Sep;19(6):850-857</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31362865" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31362865</a></p>
<p>BACKGROUND: Pancreatic Cancer remains a lethal disease for the majority of patients. New chemotherapy agents such as Folfirinox offer therapeutic potential for patients who present with Borderline Resectable disease (BRPC). However, results to date are inconsistent, with factors such as malnutrition limiting successful drug delivery. We sought to determine the prevalence of sarcopenia in BRPC patients at diagnosis, and to quantify body composition change during chemotherapy. METHODS: The diagnostic/restaging CT scans of BRPC patients were analysed. Body composition was measured at L3 using Tomovision Slice-O-Matic™. Total muscle and adipose tissue mass were estimated using validated regression equations. Sarcopenia was defined as per gender- and body mass index (BMI)-specific lumbar skeletal muscle index (LSMI) and muscle attenuation reference values. RESULTS: Seventy-eight patients received neo-adjuvant chemotherapy, and 67 patients underwent restaging CT, at which point a third were deemed resectable. Half were sarcopenic at diagnosis, and sarcopenia was equally prevalent across all BMI categories.. Skeletal muscle and adipose tissue (intra-muscular, visceral and sub-cutaneous) area decreased during chemotherapy (p &lt; 0.0001). Low muscle attenuation was observed in half of patients at diagnosis, and was associated with increased mortality risk. Loss of lean tissue parameters during chemotherapy was associated with an increased mortality risk; specifically fat-free mass, HR 1.1 (95% CI 1.03-1.17, p = 0.003) and skeletal muscle mass, HR 1.21 (95%CI 1.08-1.35, p = 0.001). CONCLUSIONS: Sarcopenia was prevalent in half of patients at the time of diagnosis with BRPC. Low muscle attenuation at diagnosis, coupled with lean tissue loss during chemotherapy, independently increased mortality risk.</p>
<p>doi: <a href="https://doi.org/10.1016/j.pan.2019.07.039" class="uri">https://doi.org/10.1016/j.pan.2019.07.039</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Fungal sinusitis in simultaneous pancreas-kidney transplant</strong> </summary></p>
<p><em>Journal of clinical pathology 2019 10;72(10):720</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31358535" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31358535</a></p>
<p>doi: <a href="https://doi.org/10.1136/jclinpath-2018-205258" class="uri">https://doi.org/10.1136/jclinpath-2018-205258</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>New Nodal Staging for Primary Pancreatic Neuroendocrine Tumors: A Multi-institutional and National Data Analysis</strong> </summary></p>
<p><em>Annals of surgery 2019 Jul;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31356277" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31356277</a></p>
<p>OBJECTIVE: To determine the prognostic role of metastatic lymph node (LN) number and the minimal number of LNs for optimal staging of patients with pancreatic neuroendocrine tumors (pNETs). BACKGROUND: Prognosis relative to number of LN metastasis (LNM), and minimal number of LNs needed to evaluate for accurate staging, have been poorly defined for pNETs. METHODS: Number of LNM and total number of LN evaluated (TNLE) were assessed relative to recurrence-free survival (RFS) and overall survival (OS) in a multi-institutional database. External validation was performed using Surveillance, Epidemiology and End Results (SEER) registry. RESULTS: Among 854 patients who underwent resection, 233 (27.3%) had at least 1 LNM. Patients with 1, 2, or 3 LNM had a comparable worse RFS versus patients with no nodal metastasis (5-year RFS, 1 LNM 65.6%, 2 LNM 68.2%, 3 LNM 63.2% vs 0 LNM 82.6%; all P &lt; 0.001). In contrast, patients with ≥4 LNM (proposed N2) had a worse RFS versus patients who either had 1 to 3 LNM (proposed N1) or node-negative disease (5-year RFS, ≥4 LNM 43.5% vs 1-3 LNM 66.3%, 0 LNM 82.6%; all P &lt; 0.05) [C-statistics area under the curve (AUC) 0.650]. TNLE ≥8 had the highest discriminatory power relative to RFS (AUC 0.713) and OS (AUC 0.726) among patients who had 1 to 3 LNM, and patients who had ≥4 LNM in the multi-institutional and SEER database (n = 2764). CONCLUSIONS: Regional lymphadenectomy of at least 8 lymph nodes was necessary to stage patients accurately. The proposed nodal staging of N0, N1, and N2 optimally staged patients.</p>
<p>doi: <a href="https://doi.org/10.1097/SLA.0000000000003478" class="uri">https://doi.org/10.1097/SLA.0000000000003478</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Left-sided Portal Hypertension After Pancreaticoduodenectomy With Resection of the Portal Vein/Superior Mesenteric Vein Confluence in Patients With Pancreatic Cancer: A Project Study by the Japanese Society of Hepato-Biliary-Pancreatic Surgery</strong> </summary></p>
<p><em>Annals of surgery 2019 Jul;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31356273" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31356273</a></p>
<p>OBJECTIVE: The aim of this study was to evaluate how often left-sided portal hypertension (LPH) develops and how LPH affects the long-term outcomes of patients with pancreatic cancer treated with pancreaticoduodenectomy (PD) and resection of the portal vein (PV)/superior mesenteric vein (SMV) confluence. SUMMARY BACKGROUND DATA: Little is known about LPH after PD with resection of the PV/SMV confluence. METHODS: Overall, 536 patients who underwent PD with PV/SMV resection were enrolled. Among them, we mainly compared the SVp group [n=285; the splenic vein (SV) was preserved] and the SVr group (n = 227; the SV was divided and not reconstructed). RESULTS: The incidence of variceal formation in the SVr group increased until 3 years after PD compared with that in the SVp group (38.7% vs 8.3%, P &lt; 0.001). Variceal bleeding occurred in the SVr group (n = 9: 4.0%) but not in the SVp group (P &lt; 0.001). In the multivariate analysis, the risk factors for variceal formation were liver disease, N factor, conventional PD, middle colic artery resection, and SV division. The only risk factor for variceal bleeding was SV division. The platelet count ratio at 6 months after PD was significantly lower in the SVr group than in the SVp group (0.97 vs 0.82, P &lt; 0.001), and the spleen-volume ratios at 6 and 12 months were significantly higher in the SVr group than in the SVp group (1.38 vs 1.00 and 1.54 vs 1.09; P &lt; 0.001 and P &lt; 0.001, respectively). CONCLUSIONS: PD with SV division causes variceal formation, bleeding, and thrombocytopenia.</p>
<p>doi: <a href="https://doi.org/10.1097/SLA.0000000000003487" class="uri">https://doi.org/10.1097/SLA.0000000000003487</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>African American women with gum disease and tooth loss face higher pancreatic cancer risk</strong> </summary></p>
<p><em>Cancer 2019 08;125(16):2719</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31355935" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31355935</a></p>
<p>doi: <a href="https://doi.org/10.1002/cncr.32413" class="uri">https://doi.org/10.1002/cncr.32413</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Silibinin inhibited autophagy and mitochondrial apoptosis in pancreatic carcinoma by activating JNK/SAPK signaling</strong> </summary></p>
<p><em>Pathology, research and practice 2019 Sep;215(9):152530</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31351801" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31351801</a></p>
<p>BACKGROUND: Previous investigation have indicated Silibinin induces apoptosis and JNK/SAPK in human pancreatic cancer cells. This study aims to evaluate the further mechanism of Silibinin in pancreatic cancer treatment. MATERIALS AND METHODS: Human pancreatic cancer cell lines SW1990 was treated with Silibinin and/or JNK/SAPK inhibitor SP600125 followed by measurement of cell viability, apoptosis, autophagy, ROS and ATP, and western blotting. RESULTS: Silibinin promoted cell viability and promoted cell apoptosis. The expression of ROS and ATP associated with mitochondrial function was also promoted by the treatment of silibinin. Silibinin also promoted autophagy in pancreatic cancer cells. All these biological effects of Silibinin can be reversed by JNK/SAPK inhibitor. CONCLUSIONS: The biological effects regulated by Silibinin can be mediated by JNK/SAPK signaling. This provides a solid theoretical basis for the role of Silibinin in the treatment of pancreatic cancer.</p>
<p>doi: <a href="https://doi.org/10.1016/j.prp.2019.152530" class="uri">https://doi.org/10.1016/j.prp.2019.152530</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Fine-needle aspiration of the liver: a 10-year single institution retrospective review</strong> </summary></p>
<p><em>Human pathology 2019 Oct;92():25-31</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31351156" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31351156</a></p>
<p>Fine-needle aspiration (FNA) of liver masses is a minimally invasive means of evaluation, with diagnostic accuracy over 85%. Given that most of the recent literature on sampling hepatic tumors was published by radiologists and gastroenterologists, we herein conduct a 10-year retrospective review of a single institution’s cytopathology experience with the diagnosis of liver lesions. Electronic record review of the cytopathology files (CoPathPlus; Cerner Corp) was conducted for the 10-year interval January 2007 through December 2016. All cytology specimens designated as “liver” and “FNA” were included. Associated concurrent and subsequent surgical pathology and cytopathology cases were identified. All FNA cases were organized into four diagnostic categories: positive for malignancy, atypical, negative for malignancy, and non-diagnostic. There were 713 hepatic FNAs that were categorized as follows: positive for malignancy 467 (65.5%), atypical 49 (6.9%), negative 171 (24.0%) and non-diagnostic 26 (3.6%). Metastatic tumors (95.7%) were more common that primary (4.3%). The top two metastatic primary sites were pancreas (30.1%) and colon (12.7%). A total of 166 (23.2%) cases had concurrent core needle biopsies (CNB). 111 (66.9%) were concordant with the FNA diagnosis. Of the 55 discordant cases, 43 (25.9%) had diagnostic material only on CNB and 12 (7.2%) had diagnostic material only on FNA. The sensitivity, specificity, positive predictive value, negative predictive value, and diagnostic accuracy were 93.4%, 96.7%, 98.2%, 84.3%, and 89.3% respectively. Irrespective of endoscopic versus percutaneous approach, hepatic FNA is a sensitive and specific means of identifying metastatic and primary malignancies of the liver.</p>
<p>doi: <a href="https://doi.org/10.1016/j.humpath.2019.07.007" class="uri">https://doi.org/10.1016/j.humpath.2019.07.007</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Period prevalence of chronic pancreatitis diagnosis from 2001-2013 in the commercially insured population of the United States</strong> </summary></p>
<p><em>Pancreatology : official journal of the International Association of Pancreatology (IAP) … [et al.] 2019 Sep;19(6):813-818</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31350077" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31350077</a></p>
<p>BACKGROUND: Prevalence estimates of chronic pancreatitis (CP) in the US are scarce. We aimed to determine the prevalence of CP in the commercially insured population of the US. METHODS: We analyzed the IQVIA Legacy PharMetrics database to calculate the period prevalence of CP from 2001 to 2013 among individuals with ≥1 year of enrollment. CP was defined as ≥1 healthcare contacts associated with a non-ancillary claim for a primary diagnosis of CP (ICD-9-CM 577.1). Prevalence estimates were age- and sex- adjusted to the 2010 US population. Sensitivity analysis was performed by using more stringent criteria: a) 1 claim of CP + [≥1 claims of acute pancreatitis (AP), CP or pancreatic cyst/pseudocyst]; b) 1 claim of CP + [≥1 claims for AP, CP or pancreatic cyst/pseudocyst in ≥3 months before or after the index CP claim]; c) ≥2 claims for CP; and d) ≥2 claims for CP separated by ≥ 6 months. RESULTS: Of 48.67 million eligible enrollees, 37,061 received the diagnosis of CP (mean age, 51.2 ± 15.2 years; 49% male). The age- and sex- adjusted period prevalence of CP per 100,000 was 73.4 (95% CI, 72.6-74.1), 98.7 (95% CI, 97.7-99.7) for adults and 8.3 (95% CI, 7.8-8.8) for children. Prevalence of CP was slightly higher in males (sex ratio, 1.05) and highest in the age group of 46-55 years (135/100,000). On sensitivity analysis, the prevalence of CP per 100,000 decreased to 60.2, 39.7, 38.8, and 18.8 with each of the alternative definitions. CONCLUSION: Prevalence estimates reported in our study provide an insight into the population burden of CP in the US.</p>
<p>doi: <a href="https://doi.org/10.1016/j.pan.2019.07.003" class="uri">https://doi.org/10.1016/j.pan.2019.07.003</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Morphologic Factors Predict Pain Relief Following Pancreatic Head Resection in Chronic Pancreatitis Description of the Chronic Pancreatitis Pain Relief (CPPR) Score</strong> </summary></p>
<p><em>Annals of surgery 2019 Jul;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31348039" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31348039</a></p>
<p>OBJECTIVE: This study analyzes the clinicopathologic findings and their impact on outcome of patients so as to identify which patients benefit most from surgical treatment in chronic pancreatitis, especially in regard to pain relief. SUMMARY BACKGROUND DATA: The predominant symptom of chronic pancreatitis is chronic pain resulting in reduced quality of life. It is well known that the main reason for development of the disease is abuse of alcohol and nicotine, but only little data on factors influencing outcome are available. METHODS: One thousand one hundred forty-six consecutive patients who underwent surgery for chronic pancreatitis were included. Clinicopathologic data, including morphology of the pancreas in preoperative diagnostics and the histopathologic results, were evaluated. A long-term follow-up including Quality of Life and pain scores was performed. Additionally, we describe the novel Chronic Pancreatitis Pain Relief Score (CPPR-Score) as a tool for prediction of pain relief. RESULTS: Overall the rate of pain relief was 79.8% after surgery. The presence of an inflammatory mass in the pancreatic head larger than 4 cm (P &lt; 0.001), presence of a dilated main pancreatic duct of over 4 mm (P &lt; 0.001), histopathologically detected severe calcifications (P = 0.001) and severe fibrosis (P &lt; 0.001) as well as ethanol induced disease (P &lt; 0.001) found to be strong independent prognostic factors for pain relief. The CPPR-Score (0-5 points) proved to be a very good predictive score for pain-relief (P &lt; 0.001). CONCLUSIONS: The rate of pain relief after surgical treatment in chronic pancreatitis is high and the commonly used procedures can be performed with acceptable morbidity and mortality. The Chronic Pancreatitis Pain Relief Score allows identifying patients who will benefit most from surgery.</p>
<p>doi: <a href="https://doi.org/10.1097/SLA.0000000000003439" class="uri">https://doi.org/10.1097/SLA.0000000000003439</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Reappraisal of a 2-Cm Cut-Off Size for the Management of Cystic Pancreatic Neuroendocrine Neoplasms: A Multicenter International Study</strong> </summary></p>
<p><em>Annals of surgery 2019 Jul;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31348038" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31348038</a></p>
<p>MINI: The characteristics of cystic pancreatic neuroendocrine neoplasms (cPanNENs) are largely unknown, and their clinical management remains unclear; specifically, an observational strategy for asymptomatic cPanNENs ≤2 cm has been proposed by recent guidelines, but evidence is scarce and limited to single institutional series. In this international cohort study of 263 resected cPanNENs from 16 institutions worldwide, a preoperative size &gt;2 cm was independently associated with aggressive behavior both in the whole cohort and in the subset of asymptomatic patients; notably, only 1 of 61 asymptomatic cPanNENs ≤2 cm was aggressive. Based on these results, a watch-and-wait policy for sporadic asymptomatic cPanNENs ≤2 cm seems justified and safe. The aim of this study was to characterize an international cohort of resected cystic pancreatic neuroendocrine neoplasms (cPanNENs) and identify preoperative predictors of aggressive behavior. The characteristics of cPanNENs are unknown and their clinical management remains unclear. An observational strategy for asymptomatic cPanNENs ≤2 cm has been proposed by recent guidelines, but evidence is scarce and limited to single-institutional series. Resected cPanNENs (1995-2017) from 16 institutions worldwide were included. Solid lesions (&gt;50% solid component), functional tumors, and MEN-1 patients were excluded. Aggressiveness was defined as lymph node (LN) involvement, G3 grading, distant metastases, and/or recurrence. Overall, 263 resected cPanNENs were included, among which 177 (63.5%) were &gt;2 cm preoperatively. A preoperative diagnosis of cPanNEN was established in 162 cases (61.6%) and was more frequent when patients underwent endoscopic ultrasound [EUS, odds ratio (OR) 2.69, 95% confidence interval (CI) 1.52-4.77] and somatostatin-receptor imaging (OR 3.681, 95% CI 1.809-7.490), and for those managed in specialized institutions (OR 3.12, 95% CI 1.57-6.21). Forty-one cPanNENs (15.6%) were considered aggressive. In the whole cohort, LN involvement on imaging, age &gt;65 years, preoperative size &gt;2 cm, and pancreatic duct dilation were independently associated with aggressive behavior. In asymptomatic patients, older age and a preoperative size &gt;2 cm remained independently associated with aggressiveness. Only 1 of 61 asymptomatic cPanNENs ≤2 cm displayed an aggressive behavior. The diagnostic accuracy of cPanNENs is increased by the use of EUS and somatostatin-receptor imaging and is higher in specialized institutions. Preoperative size &gt;2 cm is independently associated with aggressive behavior. Consequently, a watch-and-wait policy for sporadic asymptomatic cPanNENs ≤2 cm seems justified and safe for most patients.</p>
<p>doi: <a href="https://doi.org/10.1097/SLA.0000000000003508" class="uri">https://doi.org/10.1097/SLA.0000000000003508</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Long non-coding RNA PTTG3P functions as an oncogene by sponging miR-383 and up-regulating CCND1 and PARP2 in hepatocellular carcinoma</strong> </summary></p>
<p><em>BMC cancer 2019 Jul;19(1):731</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31340767" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31340767</a></p>
<p>BACKGROUND: Emerging evidence indicates that Long non-coding RNAs (LncRNAs) and microRNAs (miRNAs) play crucial roles in tumor progression, including hepatocellular carcinoma (HCC). However, whether there is a crosstalk between LncRNA pituitary tumor-transforming 3 (PTTG3P) and miR-383 in HCC remains unknown. This study is designed to explore the underlying mechanism by which LncRNA PTTG3P sponges miR-383 during HCC progression. METHODS: qPCR and Western blot were used to analyze LncRNA PTTG3P, miR-383 and other target genes’ expression. CCK-8 assay was performed to examine cell proliferation. Annexin V-PE/PI and PI staining were used to analyze cell apoptosis and cell cycle distribution by flow cytometry, respectively. Transwell migration and invasion assays were used to examine cell migration and invasion abilities. An in vivo xenograft study was performed to detect tumor growth. Luciferase reporter assay and RNA pull-down assay were carried out to detect the interaction between miR-383 and LncRNA PTTG3P. RIP was carried out to detect whether PTTG3P and miR-383 were enriched in Ago2-immunoprecipitated complex. RESULTS: In this study, we found that PTTG3P was up-regulated in HCC tissues and cells. Functional experiments demonstrated that knockdown of PTTG3P inhibited cell proliferation, migration and invasion, and promoted cell apoptosis, acting as an oncogene. Mechanistically, PTTG3P upregulated the expression of miR-383 targets Cyclin D1 (CCND1) and poly ADP-ribose polymerase 2 (PARP2) by sponging miR-383, acting as a competing endogenous RNA (ceRNA). The PTTG3P-miR-383-CCND1/PARP2 axis modulated HCC phenotypes. Moreover, PTTG3P also affected the PI3K/Akt signaling pathway. CONCLUSION: The data indicate a novel PTTG3P-miR-383-CCND1/PARP2 axis in HCC tumorigenesis, suggesting that PTTG3P may be used as a potential therapeutic target in HCC.</p>
<p>doi: <a href="https://doi.org/10.1186/s12885-019-5936-2" class="uri">https://doi.org/10.1186/s12885-019-5936-2</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Age-related morphological changes in the pancreas and their association with pancreatic carcinogenesis</strong> </summary></p>
<p><em>Pathology international 2019 Aug;69(8):450-462</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31339204" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31339204</a></p>
<p>Age-related pathological changes in the pancreas have been unclear because they are often minor and nonspecific. However, recent studies have shown that they are closely related to various pathological conditions such as pancreatic cancer and diabetes mellitus. Knowledge of age-related changes is important to determine appropriate prevention, detection, and treatment strategies for various diseases observed in elderly patients. We present a review of the pathological age-related non-neoplastic changes in the exocrine pancreas such as pancreatic fatty replacement, lobulocentric pancreatic atrophy, pancreatic duct ectasia, and metaplasia of exocrine pancreas, as well as changes in islet cells. We have discussed common pancreatic neoplasms in elderly patients, such as pancreatic intraepithelial neoplasia (PanIN), intraductal papillary mucinous neoplasms (IPMNs), and pancreatic ductal adenocarcinoma (PDAC). Age-related pathological changes play a key role in pancreatic carcinogenesis via telomere dysfunction. Further studies are warranted to clarify molecular mechanisms of pancreatic carcinogenesis in elderly patients.</p>
<p>doi: <a href="https://doi.org/10.1111/pin.12837" class="uri">https://doi.org/10.1111/pin.12837</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Overall survival in patients over 40 years old with surgically resected pancreatic carcinoma: a SEER-based nomogram analysis</strong> </summary></p>
<p><em>BMC cancer 2019 Jul;19(1):726</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31337369" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31337369</a></p>
<p>BACKGROUND: The aim of this study was to identify the determinants of overall survival (OS) within patients over 40 years old with surgically resected pancreatic carcinoma (PC), and to develop a nomogram with the intention of OS predicting. METHODS: A total of 6341 patients of 40 years of age or later with surgically resected PC between 2010 and 2015 were enrolled from the Surveillance, Epidemiology, and End Results (SEER) program and randomly assigned into training set (4242 cases) and validation set (2099 cases). A nomogram was constructed for predicting 1-, 2- and 3-years OS based on univairate and multivariate Cox regression. The C-index and calibration plot were adopted to assess the nomogram performance. RESULTS: Our analysis showed that age, location of carcinoma in pancreas, tumor grade, TNM stage, size of carcinoma together with lymph node ratio (LNR) were considered to be independent overall survival predictors. A nomogram based on these six factors was developed with C-index being 0.680 (95%CI: 0.667-0.693). All calibration curves of OS fitted well. The OS curves stratified by nomogram-predicted probability score (≥20, 10-19 and &lt; 10) demonstrated statistically significant difference not only within training set but also in validation set. CONCLUSIONS: The present nomogram for OS predicting can serve as the efficacious survival-predicting model and assist in accurate decision-making for patients over 40 years old with surgically resected PC.</p>
<p>doi: <a href="https://doi.org/10.1186/s12885-019-5958-9" class="uri">https://doi.org/10.1186/s12885-019-5958-9</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Tumor Budding in Intrahepatic Cholangiocarcinoma: A Predictor of Postsurgery Outcomes</strong> </summary></p>
<p><em>The American journal of surgical pathology 2019 09;43(9):1180-1190</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31335353" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31335353</a></p>
<p>Intrahepatic cholangiocarcinoma (ICC) is an extremely aggressive carcinoma. Useful predictors for the patients’ prognosis after surgery have not been fully established. From the University of Tokyo Hospital pathology archives, we reviewed 107 cases of ICC, 54 cases of perihilar cholangiocarcinoma, and 40 cases of extrahepatic cholangiocarcinoma (ECC); we also investigated the significance of tumor budding in ICC, in comparison with perihilar cholangiocarcinoma and ECC. The tumor-budding frequencies were different by tumor location: 40.2% (43/107) in ICC, 70.4% (38/54) in perihilar cholangiocarcinoma, and 60.0% (24/40) in ECC. Tumor budding in ICC was associated with many pathologic indicators associated with invasion, such as major vascular invasion (P=0.012) and Union for International Cancer Control stage (P=0.007). Univariate and multivariate Cox regression analyses revealed tumor budding as a powerful prognostic factor for both recurrence-free survival (RFS) and overall survival (OS) in ICC by univariate (RFS: hazard ratio [HR]: 2.666; 95% confidence interval [CI]: 1.517-4.683, OS: HR: 4.206; 95% CI: 2.447-7.230) and by multivariate analyses (RFS: HR: 3.038; 95% CI: 1.591-5.973, OS: HR: 4.547, 95% CI: 2.348-8.805). Tumor budding was also a significant prognostic factor of perihilar cholangiocarcinoma, but not of ECC. When ICC was divided into 2 subtypes, type 1 (hilar) and type 2 (peripheral), tumor budding was the strong prognostic factor in type 2 ICC, but not in type 1 ICC, suggesting that some differences in biological behavior exist between type 1 ICC and perihilar cholangiocarcinoma. Tumor budding is prognostically important in ICC, and its pathogenetic role in biliary tract carcinomas might be different by anatomic location.</p>
<p>doi: <a href="https://doi.org/10.1097/PAS.0000000000001332" class="uri">https://doi.org/10.1097/PAS.0000000000001332</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Vaccination for Pancreatic Ductal Adenocarcinoma: A Hard Nut to Crack</strong> </summary></p>
<p><em>Clinical cancer research : an official journal of the American Association for Cancer Research 2019 Sep;25(18):5435-5437</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31315885" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31315885</a></p>
<p>No immunotherapy strategy is yet offering consistent results against pancreatic ductal adenocarcinoma. A randomized clinical trial testing repeated immunization with a Listeria monocytogenes-based vaccine encoding for mesothelin in combination with a GM-CSF-transfected allogeneic pancreatic cell vaccine reports no survival benefit for the vaccinated patients.See related article by Le et al., p. 5493.</p>
<p>doi: <a href="https://doi.org/10.1158/1078-0432.CCR-19-1753" class="uri">https://doi.org/10.1158/1078-0432.CCR-19-1753</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>The Presence of Pericholedochal Hyaline Cartilage in Biliary Atresia: A Report and A Review</strong> </summary></p>
<p><em>Fetal and pediatric pathology 2020 Apr;39(2):156-162</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31314631" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31314631</a></p>
<p>Background: The presence of cartilage in extra hepatic biliary tree is an unusual finding. An isolated presence of the cartilage is possibly heterotopic or occurs as a metaplastic response to the inflammatory insult.Material and methods: We had examined the liver biopsy and the resected specimen of a biliary atresia (BA) after Kasai procedure.Results: There was hyaline cartilage around the common hepatic and common bile duct in a 3-months-old male infant with distal obstructive cholangiopathy on liver biopsy and had positive serum IgM for cytomegalovirus (CMV). Similar findings could not be documented in the pericholedochal tissue of any of the 25 other pediatric cases operated for BA or choledochal cyst and three neonatal autopsies performed for liver-related deaths.Conclusion: Peri-bile duct cartilage is a unique finding and could represent an unusual form of heterotopia or connective tissue metaplasia.</p>
<p>doi: <a href="https://doi.org/10.1080/15513815.2019.1639091" class="uri">https://doi.org/10.1080/15513815.2019.1639091</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Mild maternal hyperglycemia in INSC93S transgenic pigs causes impaired glucose tolerance and metabolic alterations in neonatal offspring</strong> </summary></p>
<p><em>Disease models &amp; mechanisms 2019 08;12(8):</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31308048" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31308048</a></p>
<p>Alongside the obesity epidemic, the prevalence of maternal diabetes is rising worldwide, and adverse effects on fetal development and metabolic disturbances in the offspring’s later life have been described. To clarify whether metabolic programming effects are due to mild maternal hyperglycemia without confounding obesity, we investigated wild-type offspring of INSC93S transgenic pigs, which are a novel genetically modified large-animal model expressing mutant insulin (INS) C93S in pancreatic β-cells. This mutation results in impaired glucose tolerance, mild fasting hyperglycemia and insulin resistance during late pregnancy. Compared with offspring from wild-type sows, piglets from hyperglycemic mothers showed impaired glucose tolerance and insulin resistance (homeostatic model assessment of insulin resistance: +3-fold in males; +4.4-fold in females) prior to colostrum uptake. Targeted metabolomics in the fasting and insulin-stimulated state revealed distinct alterations in the plasma metabolic profile of piglets from hyperglycemic mothers. They showed increased levels of acylcarnitines, gluconeogenic precursors such as alanine, phospholipids (in particular lyso-phosphatidylcholines) and α-aminoadipic acid, a potential biomarker for type 2 diabetes. These observations indicate that mild gestational hyperglycemia can cause impaired glucose tolerance, insulin resistance and associated metabolic alterations in neonatal offspring of a large-animal model born at a developmental maturation status comparable to human babies.</p>
<p>doi: <a href="https://doi.org/10.1242/dmm.039156" class="uri">https://doi.org/10.1242/dmm.039156</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Feasibility of Using Hydrogel Spacers for Borderline-Resectable and Locally Advanced Pancreatic Tumors</strong> </summary></p>
<p><em>Gastroenterology 2019 10;157(4):933-935</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31306631" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31306631</a></p>
<p>doi: <a href="https://doi.org/10.1053/j.gastro.2019.07.012" class="uri">https://doi.org/10.1053/j.gastro.2019.07.012</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Reply to Comment on Zeng et al, Spatial Distribution of Pancreatic Stones in Chronic Pancreatitis</strong> </summary></p>
<p><em>Pancreas 2019 08;48(7):e59</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31306309" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31306309</a></p>
<p>doi: <a href="https://doi.org/10.1097/MPA.0000000000001351" class="uri">https://doi.org/10.1097/MPA.0000000000001351</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Mathematical Model and Study Design Could Be Optimized in Spatial Distribution Analysis of Pancreatic Stones</strong> </summary></p>
<p><em>Pancreas 2019 08;48(7):e58</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31306308" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31306308</a></p>
<p>doi: <a href="https://doi.org/10.1097/MPA.0000000000001362" class="uri">https://doi.org/10.1097/MPA.0000000000001362</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Reply to: The Relationship of Acute Pancreatitis and Pancreatic Cancer</strong> </summary></p>
<p><em>Pancreas 2019 08;48(7):e57-e58</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31306307" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31306307</a></p>
<p>doi: <a href="https://doi.org/10.1097/MPA.0000000000001358" class="uri">https://doi.org/10.1097/MPA.0000000000001358</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>The Relationship of Acute Pancreatitis and Pancreatic Cancer</strong> </summary></p>
<p><em>Pancreas 2019 08;48(7):e57</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31306306" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31306306</a></p>
<p>doi: <a href="https://doi.org/10.1097/MPA.0000000000001357" class="uri">https://doi.org/10.1097/MPA.0000000000001357</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Surgical and Oncological Outcomes of Laparoscopic Versus Open Pancreaticoduodenectomy in Patients With Pancreatic Duct Adenocarcinoma</strong> </summary></p>
<p><em>Pancreas 2019 08;48(7):861-867</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31306305" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31306305</a></p>
<p>It is not clear which of the 2 principal treatments for patients with pancreatic duct adenocarcinoma (PDAC), laparoscopic pancreaticoduodenectomy (LPD) and open pancreaticoduodenectomy (OPD), has greater safety and efficacy. We performed the present meta-analysis to assess the efficacy of both treatments for PDAC patients undergoing LPD. Multiple electronic databases were systematically searched to identify studies (up to October 2018) comparing LPD with OPD for PDAC. Short- and long-term oncological outcomes were evaluated. Six studies were qualified for inclusion criteria in this meta-analysis with a total of 9144 PDAC participants. Regarding safety, there were fewer overall postoperative complications associated with LPD (P = 0.005), but the results were similar in terms of pancreatic fistula and mortality. Laparoscopic pancreaticoduodenectomy was associated with a better trend of performance both in R0 resection (relative risk, 1.03; 95% confidence interval [CI], 1.00-1.07; P = 0.07) and preserved lymph nodes (median, 2.14; 95% CI, -0.21 to 4.49; P = 0.07). Long-term overall survival was comparable between LPD and OPD (hazard ratio, 1.03; 95% CI, 0.95-1.13; P = 0.49). In conclusion, LPD was found to be a suitable alternative to OPD in selected PDAC patients with respect to both surgical and oncological outcomes.</p>
<p>doi: <a href="https://doi.org/10.1097/MPA.0000000000001363" class="uri">https://doi.org/10.1097/MPA.0000000000001363</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Novel Methylated DNA Markers Discriminate Advanced Neoplasia in Pancreatic Cysts: Marker Discovery, Tissue Validation, and Cyst Fluid Testing</strong> </summary></p>
<p><em>The American journal of gastroenterology 2019 09;114(9):1539-1549</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31306149" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31306149</a></p>
<p>OBJECTIVES: Pancreatic cystic lesions (PCLs) may be precancerous. Those likely to harbor high-grade dysplasia (HGD) or pancreatic cancer (PC) are targets for surgical resection. Current algorithms to predict advanced neoplasia (HGD/PC) in PCLs lack diagnostic accuracy. In pancreatic tissue and cyst fluid (CF) from PCLs, we sought to identify and validate novel methylated DNA markers (MDMs) that discriminate HGD/PC from low-grade dysplasia (LGD) or no dysplasia (ND). METHODS: From an unbiased whole-methylome discovery approach using predefined selection criteria followed by multistep validation on case (HGD or PC) and control (ND or LGD) tissues, we identified discriminant MDMs. Top candidate MDMs were then assayed by quantitative methylation-specific polymerase chain reaction on archival CF from surgically resected PCLs. RESULTS: Of 25 discriminant MDMs identified in tissue, 13 were selected for validation in 134 CF samples (21 cases [8 HGD, 13 PC], 113 controls [45 ND, 68 LGD]). A tree-based algorithm using 2 CF-MDMs (TBX15, BMP3) achieved sensitivity and specificity above 90%. Discrimination was significantly better by this CF-MDM panel than by mutant KRAS or carcinoembryonic antigen, with areas under the receiver operating characteristic curve of 0.93 (95% confidence interval: 0.86-0.99), 0.71 (0.57-0.85), and 0.72 (0.60-0.84), respectively. Cutoffs for the MDM panel applied to an independent CF validation set (31 cases, 56 controls) yielded similarly high discrimination, areas under the receiver operating characteristic curve = 0.86 (95% confidence interval: 0.77-0.94, P = 0.2). DISCUSSION: Novel MDMs discovered and validated in tissue accurately identify PCLs harboring HGD/PC. A panel of 2 MDMs assayed in CF yielded results with potential to enhance current risk prediction algorithms. Prospective studies are indicated to optimize and further evaluate CF-MDMs for clinical use.</p>
<p>doi: <a href="https://doi.org/10.14309/ajg.0000000000000284" class="uri">https://doi.org/10.14309/ajg.0000000000000284</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Development of the Intrahepatic and Extrahepatic Biliary Tract: A Framework for Understanding Congenital Diseases</strong> </summary></p>
<p><em>Annual review of pathology 2020 01;15():1-22</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31299162" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31299162</a></p>
<p>The involvement of the biliary tract in the pathophysiology of liver diseases and the increased attention paid to bile ducts in the bioconstruction of liver tissue for regenerative therapy have fueled intense research into the fundamental mechanisms of biliary development. Here, I review the molecular, cellular and tissular mechanisms driving differentiation and morphogenesis of the intrahepatic and extrahepatic bile ducts. This review focuses on the dynamics of the transcriptional and signaling modules that promote biliary development in human and mouse liver and discusses studies in which the use of zebrafish uncovered unexplored processes in mammalian biliary development. The review concludes by providing a framework for interpreting the mechanisms that may help us understand the origin of congenital biliary diseases.</p>
<p>doi: <a href="https://doi.org/10.1146/annurev-pathmechdis-012418-013013" class="uri">https://doi.org/10.1146/annurev-pathmechdis-012418-013013</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Excess body weight at age &lt;50 years is linked to pancreatic cancer mortality</strong> </summary></p>
<p><em>Cancer 2019 08;125(15):2527</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31298753" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31298753</a></p>
<p>doi: <a href="https://doi.org/10.1002/cncr.32394" class="uri">https://doi.org/10.1002/cncr.32394</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Trends in biomarker discoveries for the early detection and risk stratification of pancreatic cancer using omics studies</strong> </summary></p>
<p><em>Expert review of molecular diagnostics 2019 08;19(8):651-654</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31298060" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31298060</a></p>
<p>doi: <a href="https://doi.org/10.1080/14737159.2019.1643718" class="uri">https://doi.org/10.1080/14737159.2019.1643718</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Reply to Deprescription during last year of life in patients with pancreatic cancer: Optimization or nihilism?</strong> </summary></p>
<p><em>Cancer 2019 Oct;125(19):3471-3472</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31291006" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31291006</a></p>
<p>doi: <a href="https://doi.org/10.1002/cncr.32390" class="uri">https://doi.org/10.1002/cncr.32390</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Deprescription during last year of life in patients with pancreatic cancer: Optimization or nihilism?</strong> </summary></p>
<p><em>Cancer 2019 Oct;125(19):3470-3471</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31290998" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31290998</a></p>
<p>doi: <a href="https://doi.org/10.1002/cncr.32389" class="uri">https://doi.org/10.1002/cncr.32389</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Better Defining the Role of Total Neoadjuvant Radiation: Changing Paradigms in Locally Advanced Pancreatic Cancer</strong> </summary></p>
<p><em>Annals of surgical oncology 2019 Oct;26(11):3701-3708</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31286306" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31286306</a></p>
<p>BACKGROUND: This study was designed to better define the role of radiation (Neo-Rad) in addition to neoadjuvant multiagent chemotherapy (NAT) for the treatment of locally advanced pancreatic cancer. METHODS: Retrospective cohort study using the NCDB. Individuals with AJCC clinical T3/T4 pancreatic carcinoma who underwent resection and multiagent chemotherapy were included. Kaplan-Meier, logistic-regression, and Cox proportional-hazard models were used for analysis. RESULTS: A total of 2703 patients were included; 2039 had T3 and 664 had T4 tumors, and 1092 (40.4%) received Neo-Rad. Median follow-up was 22.5 months. During the study period, there was increased use of NAT and a decline in the use of Neo-Rad. Addition of Neo-Rad did not affect 30-day (2.51% vs. 3.24%, p = 0.272) or 90-day mortality (5.23% vs. 6.38%, p = 0.216). Neo-Rad was not associated with improved overall survival on univariable (25.95 vs. 24.7 months, p = 0.202), or multivariable analyses (hazard ratio [HR] 0.94; 95% confidence interval [CI] 0.85-1.05). Time from diagnosis to definitive surgery was increased by Neo-Rad (204 vs. 115 days, p &lt; 0.001). Neo-Rad was associated with increased pathologic downstaging in T3 (32.8% vs. 14.4%) (odds ratio [OR] 2.90; 95% CI 2.30-3.66) and T4 tumors (88.9% vs. 77.8%) (OR 2.29; 95% CI 1.44-3.67); complete pathologic response (5.3% vs. 1.6%) (OR 2.89; 95% CI 1.73-4.83), and increased R0 resection rates (85.7% vs. 76.8%) (OR 1.79; 95% CI 1.44-2.23). CONCLUSIONS: The use of neoadjuvant therapy is increasing for the treatment of locally advanced pancreatic cancer. The addition of radiation to neoadjuvant chemotherapy is associated with improved antineoplastic effectiveness (downstaging, complete pathologic response), surgical resection (R0 rates), but has no effect on overall survival.</p>
<p>doi: <a href="https://doi.org/10.1245/s10434-019-07584-5" class="uri">https://doi.org/10.1245/s10434-019-07584-5</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Bispecific Antibodies Enable Synthetic Agonistic Receptor-Transduced T Cells for Tumor Immunotherapy</strong> </summary></p>
<p><em>Clinical cancer research : an official journal of the American Association for Cancer Research 2019 Oct;25(19):5890-5900</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31285373" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31285373</a></p>
<p>PURPOSE: Genetically engineered T cells are powerful anticancer treatments but are limited by safety and specificity issues. We herein describe an MHC-unrestricted modular platform combining autologous T cells, transduced with a targetable synthetic agonistic receptor (SAR), with bispecific antibodies (BiAb) that specifically recruit and activate T cells for tumor killing. EXPERIMENTAL DESIGN: BiAbs of different formats were generated by recombinant expression. T cells were retrovirally transduced with SARs. T-cell activation, proliferation, differentiation, and T-cell-induced lysis were characterized in three murine and human tumor models in vitro and in vivo. RESULTS: Murine T cells transduced with SAR composed of an extracellular domain EGFRvIII fused to CD28 and CD3ζ signaling domains could be specifically recruited toward murine tumor cells expressing EpCAM by anti-EGFRvIII × anti-EpCAM BiAb. BiAb induced selective antigen-dependent activation, proliferation of SAR T cells, and redirected tumor cell lysis. Selectivity was dependent on the monovalency of the antibody for EGFRvIII. We identified FAS ligand as a major mediator of killing utilized by the T cells. Similarly, human SAR T cells could be specifically redirected toward mesothelin-expressing human pancreatic cancer cells. In vivo, treatment with SAR T cells and BiAb mediated antitumoral activity in three human pancreatic cancer cell xenograft models. Importantly, SAR activity, unlike CAR activity, was reversible in vitro and in vivo. CONCLUSIONS: We describe a novel ACT platform with antitumor activity in murine and human tumor models with a distinct mode of action that combines adoptive T-cell therapy with bispecific antibodies.</p>
<p>doi: <a href="https://doi.org/10.1158/1078-0432.CCR-18-3927" class="uri">https://doi.org/10.1158/1078-0432.CCR-18-3927</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Survival Outcomes Associated With Clinical and Pathological Response Following Neoadjuvant FOLFIRINOX or Gemcitabine/Nab-Paclitaxel Chemotherapy in Resected Pancreatic Cancer</strong> </summary></p>
<p><em>Annals of surgery 2019 09;270(3):400-413</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31283563" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31283563</a></p>
<p>OBJECTIVE: To compare the survival outcomes associated with clinical and pathological response in pancreatic ductal adenocarcinoma (PDAC) patients receiving neoadjuvant chemotherapy (NAC) with FOLFIRINOX (FLX) or gemcitabine/nab-paclitaxel (GNP) followed by curative-intent pancreatectomy. BACKGROUND: Newer multiagent NAC regimens have resulted in improved clinical and pathological responses in PDAC; however, the effects of these responses on survival outcomes remain unknown. METHODS: Clinicopathological and survival data of PDAC patients treated at 7 academic medical centers were analyzed. Primary outcomes were overall survival (OS), local recurrence-free survival (L-RFS), and metastasis-free survival (MFS) associated with biochemical (CA 19-9 decrease ≥50% vs &lt;50%) and pathological response (complete, pCR; partial, pPR or limited, pLR) following NAC. RESULTS: Of 274 included patients, 46.4% were borderline resectable, 25.5% locally advanced, and 83.2% had pancreatic head/neck tumors. Vein resection was performed in 34.7% and 30-day mortality was 2.2%. R0 and pCR rates were 82.5% and 6%, respectively. Median, 3-year, and 5-year OS were 32 months, 46.3%, and 30.3%, respectively. OS, L-RFS, and MFS were superior in patients with marked biochemical response (CA 19-9 decrease ≥50% vs &lt;50%; OS: 42.3 vs 24.3 months, P &lt; 0.001; L-RFS-27.3 vs 14.1 months, P = 0.042; MFS-29.3 vs 13 months, P = 0.047) and pathological response [pCR vs pPR vs pLR: OS- not reached (NR) vs 40.3 vs 26.1 months, P &lt; 0.001; L-RFS-NR vs 24.5 vs 21.4 months, P = 0.044; MFS-NR vs 23.7 vs 20.2 months, P = 0.017]. There was no difference in L-RFS, MFS, or OS between patients who received FLX or GNP. CONCLUSION: This large, multicenter study shows that improved biochemical, pathological, and clinical responses associated with NAC FLX or GNP result in improved OS, L-RFS, and MFS in PDAC. NAC with FLX or GNP has similar survival outcomes.</p>
<p>doi: <a href="https://doi.org/10.1097/SLA.0000000000003468" class="uri">https://doi.org/10.1097/SLA.0000000000003468</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>A Novel Validated Recurrence Risk Score to Guide a Pragmatic Surveillance Strategy After Resection of Pancreatic Neuroendocrine Tumors: An International Study of 1006 Patients</strong> </summary></p>
<p><em>Annals of surgery 2019 09;270(3):422-433</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31283562" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31283562</a></p>
<p>OBJECTIVE: Despite heterogeneous biology, similar surveillance schemas are utilized after resection of all pancreatic neuroendocrine tumors (PanNETs). Given concerns regarding excess radiation exposure and financial burden, our aim was to develop a prognostic score for disease recurrence to guide individually tailored surveillance strategies. METHODS: All patients with primary nonfunctioning, nonmetastatic well/moderately differentiated PanNETs who underwent curative-intent resection at 9-institutions from 2000 to 2016 were included (n = 1006). A Recurrence Risk Score (RRS) was developed from a randomly selected derivation cohort comprised of 67% of patients and verified on the validation-cohort comprised of the remaining 33%. RESULTS: On multivariable analysis, patients within the derivation cohort (n = 681) with symptomatic tumors (jaundice, pain, bleeding), tumors &gt;2 cm, Ki67 &gt;3%, and lymph node (LN) (+) disease had increased recurrence. Each factor was assigned a score based on their weighted odds ratio that formed a RRS of 0 to 10: symptomatic = 1, tumor &gt;2 cm = 2, Ki67 3% to 20% = 1, Ki67 &gt;20% = 6, LN (+) = 1. Patients were grouped into low- (RRS = 0-2; n = 247), intermediate-(RRS = 3-5; n = 204), or high (RRS = 6-10; n = 9)-risk groups. At 24 months, 33% of high RRS recurred, whereas only 2% of low and 14% of intermediate RRS recurred. This persisted in the validation cohort (n = 325). CONCLUSIONS: This international, novel, internally validated RRS accurately stratifies recurrence-free survival for patients with resected PanNETs. Given their unique recurrence patterns, surveillance intervals of 12, 6, and 3 months are proposed for low, intermediate, and high RRS patients, respectively, to minimize radiation exposure and optimize cost/resource utilization.</p>
<p>doi: <a href="https://doi.org/10.1097/SLA.0000000000003461" class="uri">https://doi.org/10.1097/SLA.0000000000003461</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Cytologic features of pancreatobiliary neoplasm of duodenum</strong> </summary></p>
<p><em>Diagnostic cytopathology 2019 Oct;47(10):1059-1062</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31276311" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31276311</a></p>
<p>Small intestinal adenomas are uncommon. Majority of these occur in the region of the ampulla of Vater. Adenomas of the ampulla can be further subdivided into two types-intestinal and pancreatobiliary. While intestinal adenomas are more frequent, pancreatobiliary adenomas are rare. There is limited literature regarding the role of endoscopic ultrasound-guided fine needle aspiration (EUS-FNA) in the diagnosis of ampullary/peri-ampullary neoplasms. Here, we describe the cytologic features of a pancreatobiliary neoplasm of the duodenum that was sampled by EUS-FNA. The aspirate was cellular and revealed cells with moderately abundant oncocytic cytoplasm. The nuclei were round with fine chromatin and focally prominent nucleoli. Although the concurrent biopsy showed no high-grade dysplasia or invasive carcinoma, the EUS and imaging findings were highly suspicious for invasion. A broad differential diagnosis is under consideration for a duodenal mass that encompasses neoplasms of the biliary tract, pancreas, duodenum, and ampulla of Vater. To our knowledge, cytologic features of a pancreatobiliary neoplasm of the duodenum have not been previously reported. Our case highlights the features seen on cytology with histologic correlation in the hopes of elucidating features to better characterize these lesions.</p>
<p>doi: <a href="https://doi.org/10.1002/dc.24271" class="uri">https://doi.org/10.1002/dc.24271</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Impact of Changes in the American Joint Committee on Cancer Staging Manual, Eighth Edition, for Pancreatic Ductal Adenocarcinoma</strong> </summary></p>
<p><em>Pancreas 2019 08;48(7):876-882</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31268985" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31268985</a></p>
<p>OBJECTIVE: Consistent and reliable tumor staging is a critical factor in determining treatment strategy, selection of patients for adjuvant therapy, and for therapeutic clinical trials. The aim of this study was to evaluate the number and extent of pancreatic ductal adenocarcinoma (PDAC) cases that would have a different pT, pN, and overall stages based on the new eighth edition American Joint Committee on Cancer staging system when compared with the seventh edition. METHODS: Patients diagnosed with PDAC who underwent pancreaticoduodenectomy, total pancreatectomy, or distal pancreatectomy from 2007 to 2017 were retrospectively reviewed. A total of 340 cases were included. RESULTS: According to the seventh edition, the vast majority of tumors in our cohort were staged as pT3 tumors (88.2%). Restaging these cases with the new size-based pT system resulted in a more equal distribution among the 3 pT categories, with higher percentage of pT2 cases (55%). CONCLUSIONS: The newly adopted pT stage protocol for PDAC is clinically relevant, ensures a more equal distribution among different stages, and allows for a significant prognostic stratification. In contrast, the new pN classification (pN1 and pN2) based on the number of positive lymph nodes failed to show survival differences and remains controversial.</p>
<p>doi: <a href="https://doi.org/10.1097/MPA.0000000000001349" class="uri">https://doi.org/10.1097/MPA.0000000000001349</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>The Surveillance Patterns of Incidentally Detected Pancreatic Cysts Vary Widely and Infrequently Adhere to Guidelines</strong> </summary></p>
<p><em>Pancreas 2019 08;48(7):883-887</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31268984" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31268984</a></p>
<p>OBJECTIVES: We aimed to determine incidental pancreatic cyst (“cyst”) surveillance patterns, predictors of receiving surveillance, and guideline adherence. METHODS: We performed a retrospective cohort study of all patients receiving longitudinal care at a single tertiary care center with a newly diagnosed incidental pancreatic cyst over a 2-year period (2010-2011). All follow-up care was abstracted over a 5-year period. RESULTS: Of 3241 eligible imaging studies reviewed, 100 patients with newly diagnosed incidental cysts eligible for surveillance were identified. A majority (53%) received no follow-up. We identified 4 predictors of cyst surveillance: radiology report conclusion mentioning the cyst (odds ratio [OR], 14.9; 95% confidence interval [CI], 1.9-119) and recommending follow-up (OR, 5.5; 95% CI, 2.1-13.9), pancreas main duct dilation (OR, 10.7; 95% CI, 1.3-89), and absence of multiple cysts (OR, 2.5; 95% CI, 1.1-10.0). Of the 47 patients who received surveillance, 66% met minimum surveillance imaging intervals of at least one guideline. Conversely, 21% of patients met the criteria for overutilization in at least one guideline. CONCLUSIONS: Although guidelines recommend that surgically fit patients with incidental cysts undergo surveillance, most patients receive no follow-up. When follow-up occurs, surveillance patterns vary widely and infrequently conform to guidelines. Interventions to reduce care variation require study.</p>
<p>doi: <a href="https://doi.org/10.1097/MPA.0000000000001352" class="uri">https://doi.org/10.1097/MPA.0000000000001352</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Alternate Week Gemcitabine and Capecitabine: An Effective Treatment for Patients With Pancreatic Adenocarcinoma</strong> </summary></p>
<p><em>Pancreas 2019 08;48(7):927-930</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31268983" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31268983</a></p>
<p>OBJECTIVE: Determine whether a regimen of fixed dose rate gemcitabine plus capecitabine is effective and tolerable for advanced pancreatic adenocarcinoma. METHODS: We performed a retrospective analysis of 62 patients with locally advanced or metastatic pancreatic adenocarcinoma treated at the University of California San Francisco between 2008 and 2016. Treatment was an alternate week schedule of fixed dose rate 1000 mg/m gemcitabine and capecitabine 1000 mg/m (58 patients), 1200 mg/m (12 patients), or 650 mg/m (1 patient) for intended 12 cycles. We evaluated overall survival (OS), progression-free survival (PFS), radiologic response, and adverse events necessitating treatment modification. RESULTS: For metastatic patients, median OS was 10.3 months (95% confidence interval [CI], 6.7-12.1 months), and PFS was 5.6 months (95% CI, 2.6-7.7 months). In locally advanced patients, OS was 12.0 months (95% CI, 4.9-17.1 months), and PFS was 5.4 months (95% CI, 2.5-9.4 months). Radiologic response for metastatic disease (42 patients) was 19% objective response, 45% stable disease, and 36% progressive disease. Treatment required modification for 22 patients due to adverse events, most frequently hand-foot syndrome (18 patients). CONCLUSIONS: Alternate week schedule of fixed dose rate gemcitabine and capecitabine was active and tolerable for advanced pancreatic adenocarcinoma. Overall survival and PFS were comparable to first-line treatments. Importantly, adverse effects appear less severe than first-line treatments.</p>
<p>doi: <a href="https://doi.org/10.1097/MPA.0000000000001354" class="uri">https://doi.org/10.1097/MPA.0000000000001354</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Induction Therapy in Localized Pancreatic Cancer</strong> </summary></p>
<p><em>Pancreas 2019 08;48(7):913-919</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31268982" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31268982</a></p>
<p>OBJECTIVES: Pancreatic cancer (PDAC) with localized stage includes resectable (RPC), borderline resectable (BRPC), or locally advanced unresectable (LAPC). Standard of care for RPC is adjuvant chemotherapy. There are no prospective randomized trials for best treatment of BRPC and LAPC. We evaluate the impact of induction chemotherapy on localized PDAC. METHODS: Charts of PDAC patients treated at Emory University between 2009 and 2016 were reviewed. The primary end point was overall survival (OS). RESULTS: A total of 409 localized PDACs were identified. Resectability was prospectively determined at a multidisciplinary tumor conference. Median age was 67 years (range, 30-92 years), 49% were male, 66% were white, 171 had RPC, 131 had BRPC, and 107 had LAPC. Median OSs for RPC, BRPC, and LAPC were 19.5, 16.1, and 12.7 months, respectively. Type of chemotherapy and age were predictors of OS. Induction chemotherapy was used in 106 with BRPC (81%) and 74 with RPC (56.5%); patients with BRPC who received combination chemotherapy and resection had a median OS of 31.5 compared with 19.5 months in patients with RPC (P = 0.0049). Patients with LAPC had a median OS of 12.7 months. CONCLUSIONS: In patients with BRPC who undergo resection after induction treatment, the OS was significantly better than in patients with RPC. Neoadjuvant treatment should be considered for all localized PDACs.</p>
<p>doi: <a href="https://doi.org/10.1097/MPA.0000000000001353" class="uri">https://doi.org/10.1097/MPA.0000000000001353</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Acute Recurrent and Chronic Pancreatitis as Initial Manifestations of Cystic Fibrosis and Cystic Fibrosis Transmembrane Conductance Regulator-Related Disorders</strong> </summary></p>
<p><em>Pancreas 2019 08;48(7):888-893</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31268981" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31268981</a></p>
<p>OBJECTIVES: Recurrent pancreatitis is considered a rare manifestation of cystic fibrosis transmembrane conductance regulator (CFTR) dysfunction; this case series highlights that pancreatitis can be a presenting symptoms of cystic fibrosis (CF) or a CFTR-related disorder (CFTR-RD). METHODS: Retrospective review of patients younger than 30 years diagnosed as having acute recurrent pancreatitis (ARP) or chronic pancreatitis (CP) and subsequently diagnosed as having CF or CFTR-RD. RESULTS: Among 18 patients, median time from diagnosis of ARP/CP to diagnosis of CF was 0.4 years (range, 0-33 years). Eight were classified as having CF by elevated sweat chloride testing (SCT). Five had intermediate SCT (30-59 mmol/L) with 2 pathogenic mutations. Five had CFTR-RD with intermediate SCT and 0 to 1 pathogenic mutations. Eight patients (44%) had exocrine pancreatic insufficiency, and pancreatic fluid collections were more common in this group. Based on the CFTR mutation, 6 patients were eligible for CFTR potentiator therapy, although none received it during the study period. Nine of the 18 had ≥1 other likely CF manifestations, including sinusitis (33%), nasal polyps (11%), pneumonia (22%), and gallbladder disease (22%). CONCLUSIONS: Cystic fibrosis or CFTR-RD can present as ARP/CP. Complete diagnostic testing for CFTR-RD in patients with ARP/CP will broaden treatment options and help to identify comorbid illness.</p>
<p>doi: <a href="https://doi.org/10.1097/MPA.0000000000001350" class="uri">https://doi.org/10.1097/MPA.0000000000001350</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Significance of Lymph Node Metastasis in Resectable Well-differentiated Pancreatic Neuroendocrine Tumor</strong> </summary></p>
<p><em>Pancreas 2019 08;48(7):943-947</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31268980" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31268980</a></p>
<p>OBJECTIVES: Understanding the effect of lymph node metastasis (LNM) on prognosis in pancreatic neuroendocrine neoplasm is helpful for surgery and follow-up. In this study, we investigated the significance of LNM in well-differentiated pancreatic neuroendocrine tumors (PanNETs) according to the World Health Organization 2017 classification. METHODS: We retrospectively collected data for 95 consecutive patients with PanNET who underwent pancreatic resection with curative intent between January 2008 and December 2017 at 6 institutions. The clinicopathological factors were compared in patients with and without LNM, and prognostic factors were analyzed. RESULTS: Lymph node metastasis was significantly associated with malignant potential of PanNET, such as larger tumor size, higher Ki-67 index, higher tumor grade, and higher incidence of lymphatic, vessel, and neural invasion. Lymph node metastasis was also associated with disease-free but not overall survival. Multivariate analysis identified NET grade 2 (G2) and G3 as independent risk factors for recurrence after curative resection. CONCLUSIONS: World Health Organization 2017 classification was the most independent prognostic factor in patients with resectable well-differentiated PanNETs. Patients with G2 and higher-grade tumors require lymph node dissection to improve prognosis.</p>
<p>doi: <a href="https://doi.org/10.1097/MPA.0000000000001355" class="uri">https://doi.org/10.1097/MPA.0000000000001355</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Gastric Emptying and Distal Gastrectomy Independently Enhance Postprandial Glucagon-Like Peptide-1 Release After a Mixed Meal and Improve Glycemic Control in Subjects Having Undergone Pancreaticoduodenectomy</strong> </summary></p>
<p><em>Pancreas 2019 08;48(7):953-957</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31268979" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31268979</a></p>
<p>OBJECTIVES: New-onset diabetes frequently resolves after pancreaticoduodenectomy (PD). Glucagon-like peptide-1 (GLP-1) conceivably is involved as its release is enhanced by rapid gastric emptying and distal bowel exposure to nutrients. We aimed at studying factors associated with GLP-1 release after PD. METHODS: Fifteen PD subjects with distal gastrectomy (Whipple) and 15 with pylorus preservation were evaluated. A test meal containing 1 g paracetamol to measure gastric emptying was ingested. Blood for the measurement of paracetamol, glucose, insulin, and GLP-1 was drawn at baseline and 10, 20, 30, 60, 90, 120, 150, and 180 minutes thereafter. The Matsuda index of insulin sensitivity was calculated. RESULTS: In univariate analysis, gastric emptying correlated with GLP-1. Glucagon-like peptide-1 responses to the modes of operation did not differ. Multiple regression analysis confirmed gastric emptying and Whipple versus pylorus-preserving pancreaticoduodenectomy as independent predictors of GLP-1 release. The Matsuda index of insulin sensitivity correlated with GLP-1 concentrations and inversely with body mass index. Patients after Whipple procedure revealed lower glycated hemoglobin as compared with pylorus-preserving pancreaticoduodenectomy. CONCLUSIONS: Following PD, the postprandial GLP-1 release seems to be enhanced by rapid gastric emptying and to improve insulin sensitivity. Partial gastrectomy versus pylorus preservation enhanced the release of GLP-1, conceivably because of greater distal bowel exposure to undigested nutrients.</p>
<p>doi: <a href="https://doi.org/10.1097/MPA.0000000000001361" class="uri">https://doi.org/10.1097/MPA.0000000000001361</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Endogenous Gastrin Collaborates With Mutant KRAS in Pancreatic Carcinogenesis</strong> </summary></p>
<p><em>Pancreas 2019 08;48(7):894-903</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31268978" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31268978</a></p>
<p>OBJECTIVE: The KRAS gene is the most frequently mutated gene in pancreatic cancer, and no successful anti-Ras therapy has been developed. Gastrin has been shown to stimulate pancreatic cancer in an autocrine fashion. We hypothesized that reactivation of the peptide gastrin collaborates with KRAS during pancreatic carcinogenesis. METHODS: LSL-Kras; P48-Cre (KC) mutant KRAS transgenic mice were crossed with gastrin-KO (GKO) mice to develop GKO/KC mice. Pancreata were examined for 8 months for stage of pancreatic intraepithelial neoplasia lesions, inflammation, fibrosis, gastrin peptide, and microRNA expression. Pancreatic intraepithelial neoplasias from mice were collected by laser capture microdissection and subjected to reverse-phase protein microarray, for gastrin and protein kinases associated with signal transduction. Gastrin mRNA was measured by RNAseq in human pancreatic cancer tissues and compared to that in normal pancreas. RESULTS: In the absence of gastrin, PanIN progression, inflammation, and fibrosis were significantly decreased and signal transduction was reversed to the canonical pathway with decreased KRAS. Gastrin re-expression in the PanINs was mediated by miR-27a. Gastrin mRNA expression was significantly increased in human pancreatic cancer samples compared to normal human pancreas controls. CONCLUSIONS: This study supports the mitogenic role of gastrin in activation of KRAS during pancreatic carcinogenesis.</p>
<p>doi: <a href="https://doi.org/10.1097/MPA.0000000000001360" class="uri">https://doi.org/10.1097/MPA.0000000000001360</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>New-Onset Diabetes Mellitus After Chronic Pancreatitis Diagnosis: A Systematic Review and Meta-analysis</strong> </summary></p>
<p><em>Pancreas 2019 08;48(7):868-875</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31268977" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31268977</a></p>
<p>OBJECTIVES: The aim of this study was to assess the occurrence of new-onset diabetes mellitus (DM) after chronic pancreatitis (CP) diagnosis via systematic review and meta-analysis. METHODS: A systematic review of literature and meta-analysis of relevant reports were performed. The primary outcome measures studied were newly diagnosed DM and DM treated with insulin. For the binary outcomes, pooled prevalence and 95% confidence interval (CI) were calculated. METHODS: Fifteen studies involving 8970 patients were eligible. The incidence of new-onset DM after CP diagnosis was 30% (95% CI, 27%-33%). Among all patients, 17% (95% CI, 13%-22%) developed insulin-dependent new-onset DM. The prevalence of newly diagnosed DM after CP diagnosis increased from 15% within 36 months to 33% after 60 months. The proportion of alcoholic CP, sex, age, and body mass index had minimal effect on the studied outcomes. CONCLUSIONS: This systematic review identified a clinically relevant risk of new-onset DM after CP diagnosis. Therefore, patients should be informed of the risk of DM and monitored.</p>
<p>doi: <a href="https://doi.org/10.1097/MPA.0000000000001359" class="uri">https://doi.org/10.1097/MPA.0000000000001359</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>The Importance of a Conjoint Analysis of Tumor-Associated Macrophages and Immune Checkpoints in Pancreatic Cancer</strong> </summary></p>
<p><em>Pancreas 2019 08;48(7):904-912</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31268976" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31268976</a></p>
<p>OBJECTIVES: Tumor-associated macrophages are dominant players in establishing the inmmunosuppressive microenvironment in pancreatic ductal adenocarcinoma (PDAC). Immune checkpoint inhibitor monotherapy has achieved limited clinical effectiveness. To date, the interaction of macrophages and checkpoint regulators and their correlation with clinicopathologic characteristics in PDAC have been largely unavailable. METHODS: Macrophages and immune checkpoint expression were assessed by immunohistochemistry from 80 PDAC samples. Clinicopathologic features and the prognostic value of each marker were evaluated. In vitro changes in the expression of immune markers in cocultured macrophages and PDAC cells were detected by Western blot and immunosorbance assays. RESULTS: The macrophages marker CD163 and the checkpoint marker programmed death-ligand 1 (PD-L1) remained as the independent prognostic factors for overall survival (hazard ratio, 2.543; P = 0.017 and hazard ratio, 2.389; P = 0.021). Furthermore, integrated analysis of CD163 and PD-L1 served as more optimal indicators of survival (P = 0.000). In vitro coculture of macrophages and PDAC cells significantly increased the expression of CD163 and PD-L1, compared with monocultured counterpart (P &lt; 0.05). CONCLUSIONS: Combined analysis of CD163 and PD-L1 was enhanced indicators of survival in PDAC patients. The interaction of macrophages and immune checkpoints implied the value of the combination therapy.</p>
<p>doi: <a href="https://doi.org/10.1097/MPA.0000000000001364" class="uri">https://doi.org/10.1097/MPA.0000000000001364</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Correlation of DOTATOC Uptake and Pathologic Grade in Neuroendocrine Tumors</strong> </summary></p>
<p><em>Pancreas 2019 08;48(7):948-952</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31268975" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31268975</a></p>
<p>OBJECTIVES: Gallium (Ga)-DOTATOC is a somatostatin analog used to detect neuroendocrine tumors (NETs). Ki-67 proliferation index (Ki-67 PI) has been established as a prognostic factor in NETs. We aimed to evaluate whether a correlation exists between Ki-67 PI and somatostatin receptor positron emission tomography (SSTR-PET) uptake. METHODS: We retrospectively reviewed 238 DOTATOC PET scans between 2014 and 2016. Patients were excluded if DOTATOC PET was performed more than 365 days from the date of biopsy. Maximum standardized uptake values (SUVmax) of SSTR-PET from biopsied lesions were measured and correlated with Ki-67 PI using the Pearson correlation coefficient. RESULTS: Among 110 lesions from 90 patients, DOTATOC PET had 92.7% sensitivity and 100% specificity (102 true positives, 8 false negatives) for detection of NETs. Among 63 lesions from 54 patients with Ki-67 PI available, there were 27 grade 1 lesions [median Ki-67 PI, 1.0%; interquartile range (IQR), 1.0-2.0], 30 grade 2 lesions (median, Ki-67 PI 7.5%; IQR, 5-10), and 6 grade 3 lesions (median Ki-67 PI, 30%; IQR, 26-34). There was a correlation between Ki-67 PI and SUVmax (r = -0.3, P = 0.018). CONCLUSIONS: Our analysis demonstrates an inverse correlation between Ki-67 PI and SUVmax in NETs. Somatostatin receptor-PET provides additional information that can help guide management of NETs.</p>
<p>doi: <a href="https://doi.org/10.1097/MPA.0000000000001356" class="uri">https://doi.org/10.1097/MPA.0000000000001356</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Diagnostic and Management Challenges in Vasoactive Intestinal Peptide Secreting Tumors: A Series of 15 Patients</strong> </summary></p>
<p><em>Pancreas 2019 08;48(7):934-942</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31268974" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31268974</a></p>
<p>OBJECTIVES: Vasoactive intestinal peptide-secreting tumors (VIPomas) are rare functioning neuroendocrine tumors often characterized by a difficult-to-control secretory syndrome and high potential to develop metastases. We hereby present the characteristics of 15 cases of VIPomas and provide a recent literature review. METHODS: This was a retrospective data analysis of 15 patients with VIPoma from 3 different centers and literature research through PubMed database during the last 10 years. RESULTS: Fifteen patients with VIPomas (9 with hepatic metastases at diagnosis) with watery diarrhea and raised VIP levels were studied. Ten patients (67%) had grade 2 tumors, 6 of 15 had localized disease and underwent potentially curative surgery, whereas the remaining 9 received multiple systemic therapies; 3 patients died during follow-up. The median overall survival was 71 months (range, 41-154 months). Patients who were treated with curative surgery (n = 7) had longer median overall survival compared with patients who were treated with other therapeutic modalities (44 vs 33 months). CONCLUSIONS: The management of VIPomas is challenging requiring the application of multiple treatment modalities. Patients who underwent surgical treatment with curative intent appear to have higher survival rate. Central registration and larger prospective studies are required to evaluate the effect of currently employed therapies in these patients.</p>
<p>doi: <a href="https://doi.org/10.1097/MPA.0000000000001347" class="uri">https://doi.org/10.1097/MPA.0000000000001347</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Well-differentiated Pancreatic Neuroendocrine Tumor in a Patient With Familial Atypical Multiple Mole Melanoma Syndrome (FAMMM)</strong> </summary></p>
<p><em>The American journal of surgical pathology 2019 09;43(9):1297-1302</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31261289" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31261289</a></p>
<p>Germline mutations in CDKN2A result in Familial Atypical Multiple Mole Melanoma Syndrome (FAMMM), which is associated with an increased risk for pancreatic ductal adenocarcinoma and melanoma. CDKN2A is somatically inactivated in multiple neoplasms, raising the possibility that, although the data are not conclusive, germline CDKN2A mutation may also impose an increased risk for other neoplasms. We present a patient with a CDKN2A germline mutation (p16-Leiden mutation) and mosaicism for neurofibromatosis type 2, who presented with a small asymptomatic pancreatic lesion, detected during endoscopic ultrasound screening of the pancreas. After resection, the lesion was found to be a well-differentiated pancreatic neuroendocrine tumor (PanNET). Molecular analysis of the tumor showed somatic loss of the second allele, supporting a causal relation of the PanNET to the underlying FAMMM syndrome. Recent data, showing the association between certain single-nucleotide polymorphisms in the CDKN2A gene and an increased incidence for PanNET, further support a role for germline CDKN2A alterations in PanNET risk. We conclude that PanNETs can be a phenotypic expression of FAMMM syndrome. This can have implications for screening and for the diagnosis of pancreatic neoplasms in carriers of germline CDKN2A mutations.</p>
<p>doi: <a href="https://doi.org/10.1097/PAS.0000000000001314" class="uri">https://doi.org/10.1097/PAS.0000000000001314</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>miR-149-5p protects against high glucose-induced pancreatic beta cell apoptosis via targeting the BH3-only protein BIM</strong> </summary></p>
<p><em>Experimental and molecular pathology 2019 10;110():104279</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31260649" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31260649</a></p>
<p>Diabetes mellitus (DM) is characterized by the elevated blood glucose levels and is regarded as one of the most threatening diseases worldwide. The dysfunction of pancreatic beta cells is a key contributor for the pathophysiology of DM. There is growing evidence showing the role of microRNAs (miRNAs) in the regulation of pancreatic beta cell functions. In the present study, we determined the expression of miR-149-5p in pancreatic beta cells under high-glucose (HG) stimulation and explored the underlying mechanism of miR-149-5p-mediated functions of pancreatic beta cells. The results showed the down-regulation of miR-149-5p in the pancreatic beta cell line (MIN6 cells) under HG stimulation. Overexpression of miR-149-5p protected against HG-induced cell apoptosis and impairment of insulin secretion, and attenuated HG-induced an increase in reactive oxygen species (ROS) production in MIN6 cells; while inhibition of miR-149-5p suppressed cell viability, induced cell apoptosis, inhibited insulin secretion and enhanced ROS production in MIN6 cells. Further mechanistic studies revealed that miR-149-5p targeted the BH3-only protein BIM 3’ untranslated region and suppressed BIM expression in MIN6 cells. The rescue experimental assays showed that enforced expression of BIM attenuated the miR-149-5p-mediated effects in HG-stimulated pancreatic beta cells. In conclusion, the present study for the first time elucidated the biological functions of miR-149-5p in regulating pancreatic beta cell functions. The data from the present study provided evidence showing that miR-149-5p protected against HG-induced pancreatic beta cell apoptosis partly via suppressing BIM expression. The therapeutic potential of miR-149-5p in the treatment of DM still requires further detailed investigations.</p>
<p>doi: <a href="https://doi.org/10.1016/j.yexmp.2019.104279" class="uri">https://doi.org/10.1016/j.yexmp.2019.104279</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Mutational profiling and immunohistochemical analysis of a surgical series of ampullary carcinomas</strong> </summary></p>
<p><em>Journal of clinical pathology 2019 Nov;72(11):762-770</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31256008" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31256008</a></p>
<p>AIMS: Knowledge regarding the genetic features of ampullary carcinoma (AC) in European patients is limited. The utility of tumour markers for the establishment of a malignant diagnosis in biopsies from the ampullary region has not been fully elucidated. We aimed to describe the clinical, pathological, immunohistochemical (IHC) and genetic features of a Danish series of surgically resected ACs. METHODS: Surgically resected ACs (n=59) were examined regarding (1) clinicopathological features, (2) histological subtypes, (3) expression of IMP3, maspin, MUC5AC and S100P and (4) next-generation sequencing using a hybrid capture-based platform (Illumina HiSeq2500), including 315 cancer-related genes plus introns from 28 genes often rearranged or altered in cancer. Tumour mutational burden (TMB) and microsatellite instability (MSI) were also evaluated. RESULTS: Pancreatobiliary adenocarcinomas (PB-AC), intestinal adenocarcinomas (INT-AC), other ampullary tumours and mixed adenocarcinomas represented 45.8%, 23.7%, 16.9% and 13.6%. The proportion of IHC-positive ACs (score ≥2) was: Maspin (94.9%), IMP3 (67.8%), S100P (39.0%) and MUC5AC (18.6%). Most frequently altered genes were TP53 (59.3%), KRAS (40.7%), APC (27.8%), SMAD4 (20.4%), CDKN2A (16.7%) and ARID2/PIK3CA (each 11.1%). MUC5AC and S100P were frequently expressed in PB-AC, APC alterations frequent in INT-AC, SOX9 alterations were exclusive in INT-AC and MDM2 and FRS2 alterations in PB-AC. Four of 49 ACs (8.2%) were TMB-high/MSI-high and showed loss of MLH1 and PMS2. CONCLUSIONS: PB-AC was the most frequent histological subtype of AC. Maspin and IMP3 were the IHC tumour markers with the highest sensitivity. Adenocarcinoma subtypes differed regarding several genetic alterations, whose predictive value remains to be evaluated.</p>
<p>doi: <a href="https://doi.org/10.1136/jclinpath-2019-205912" class="uri">https://doi.org/10.1136/jclinpath-2019-205912</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>miR-199a-3p targets ETNK1 to promote invasion and migration in gastric cancer cells and is associated with poor prognosis</strong> </summary></p>
<p><em>Pathology, research and practice 2019 Sep;215(9):152511</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31255331" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31255331</a></p>
<p>PURPOSE: To investigate the prognostic significance of miR-199a-3p and its role in invasion and metastasis in gastric cancer. METHODS: miR-199a-3p expression in 436 formalin-fixed and 39 frozen gastric cancer tissues was investigated by in situ hybridization and RT-PCR, respectively. The role of miR-199a-3p in the migration and invasion of gastric cancer cells was determined in overexpression and inhibitor studies using transwell assays and the SGC-7901, BGC-823 and MGC-803 gastric cancer cells lines. The effect of miR-199a-3p expression on ethanolamine kinase 1 (ETNK1) levels was determined by western botting. RESULTS: miR-199a-3p was significantly up-regulated in AGS, SGC-7901, BGC-823 and MGC-803 gastric cancer cells, when compared with GES-1 non-malignant gastric epithelial cells. In situ hybridization studies revealed that human non-tumor gastric mucosa samples were negative for miR-199a-3p expression, while 162 of 436 (37.16%) cases of gastric cancer demonstrated positive expression. miR-199a-3p overexpression was associated with tumor size, Lauren classification, depth of invasion, lymph node and distant metastasis, TNM stage and prognosis. In patients with I, II and III stage tumors, high miR-199a-3p expression was associated with a significantly lower 5-year survival rate. miR-199a-3p overexpression was associated with increased cell migration and invasion. ETNK1 expression was inhibited following miR-199a-3p overexpression in BGC-823 and SGC-7901 cells, and elevated following miR-199a-3p suppression in MGC-803 cells. CONCLUSION: miR-199a-3p is highly expressed in gastric cancer, and correlates with invasion, metastasis and prognosis. miR-199a-3p regulates the invasion and migration of gastric cancer cells by targeting ETNK1. Consequently, miR-199a-3p may serve as a prognostic indicator in gastric cancer.</p>
<p>doi: <a href="https://doi.org/10.1016/j.prp.2019.152511" class="uri">https://doi.org/10.1016/j.prp.2019.152511</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Cytopathology of anaplastic carcinoma of the pancreas: Review of a rare entity and description of a variant with signet ring cell features</strong> </summary></p>
<p><em>Diagnostic cytopathology 2019 Sep;47(9):956-960</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31254330" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31254330</a></p>
<p>Anaplastic carcinoma of the pancreas (ACP) is a rare and aggressive variant of pancreatic ductal adenocarcinoma (PDAC). Several studies have attempted to characterize this subtype through case series or single case reports; however, ACP remains underrecognized by cytopathologists in particular, and often lumped under the umbrella of classic PDAC. Here, we review the most up to date data that literature provides about ACP, to bring familiarity with this entity to the cytopathology practice, and to elucidate the role cytopathologists can play in recognizing and diagnosing this subtype on pancreatic aspiration biopsy, before surgical resection. We also describe a rare case of ACP, demonstrating signet ring cell features, that was diagnosed on fine needle aspiration of a pancreatic mass.</p>
<p>doi: <a href="https://doi.org/10.1002/dc.24263" class="uri">https://doi.org/10.1002/dc.24263</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Of scientists and tweets</strong> </summary></p>
<p><em>Nature reviews. Cancer 2019 09;19(9):479-480</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31253855" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31253855</a></p>
<p>doi: <a href="https://doi.org/10.1038/s41568-019-0170-4" class="uri">https://doi.org/10.1038/s41568-019-0170-4</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Inpatient Opioid Use After Pancreatectomy: Opportunities for Reducing Initial Opioid Exposure in Cancer Surgery Patients</strong> </summary></p>
<p><em>Annals of surgical oncology 2019 Oct;26(11):3428-3435</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31243665" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31243665</a></p>
<p>BACKGROUND: Despite advances in enhanced surgical recovery programs, strategies limiting postoperative inpatient opioid exposure have not been optimized for pancreatic surgery. The primary aims of this study were to analyze the magnitude and variations in post-pancreatectomy opioid administration and to characterize predictors of low and high inpatient use. METHODS: Clinical characteristics and inpatient oral morphine equivalents (OMEs) were downloaded from electronic records for consecutive pancreatectomy patients at a high-volume institution between March 2016 and August 2017. Regression analyses identified predictors of total OMEs as well as highest and lowest quartiles. RESULTS: Pancreatectomy was performed for 158 patients (73% pancreaticoduodenectomy). Transversus abdominus plane (TAP) block was performed for 80% (n = 127) of these patients, almost always paired with intravenous patient-controlled analgesia (IV-PCA), whereas 15% received epidural alone. All the patients received scheduled non-opioid analgesics (median, 2). The median total OME administered was 423 mg (range 0-4362 mg). Higher total OME was associated with preoperative opioid prescriptions (p &lt; 0.001), longer hospital length of stay (LOS; p &lt; 0.001), and no epidural (p = 0.006). The lowest and best quartile cutoff was 180 mg of OME or less, whereas the highest and worst quartile cutoff began at 892.5 mg. After adjustment for inpatient team, only epidural use [odds ratio (OR) 0.3; p = 0.04] predicted lowest-quartile OME. Preoperative opioid prescriptions (OR 8.1; p &lt; 0.001), longer operative time (OR 3.4; p = 0.05), and longer LOS (OR 1.1; p = 0.007) predicted highest-quartile OME. CONCLUSIONS: Preoperative opioid prescriptions and longer LOS were associated with increased inpatient OME, whereas epidural use reduced inpatient OME. Understanding the predictors of inpatient opioid use and the variables predicting the lowest and highest quartiles can inform decision-making regarding preoperative counseling, regional anesthetic block choice, and novel inpatient opioid weaning strategies to reduce initial postoperative opioid exposure.</p>
<p>doi: <a href="https://doi.org/10.1245/s10434-019-07528-z" class="uri">https://doi.org/10.1245/s10434-019-07528-z</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Cytohistological diagnosis of pancreatic serous cystadenoma: a multimodal approach</strong> </summary></p>
<p><em>Journal of clinical pathology 2019 Sep;72(9):615-621</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31235542" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31235542</a></p>
<p>AIMS: Serous cystadenomata (SCAs) are benign pancreatic cystic neoplasms that present a diagnostic challenge despite many investigational approaches. Notwithstanding the promise of molecular diagnostics, these tests have limited accessibility in day-to-day surgical pathology practices. We aim to corroborate and build on recent evidence which suggests that positive α-inhibin immunohistochemistry (IHC) is a helpful adjunct in the biopsy confirmation of pancreatic SCA. METHODS: We retrospectively reviewed 22 fine-needle aspirates/biopsies from 14 patients (mean age 65 years, 47-83 years) with pancreatic multicystic lesions radiologically suspicious for SCA (location: 6 body, 2 head, 4 tail, 1 neck, 1 uncinate; cyst size: mean 3.7 cm, 2.0-7.6 cm), as well as an additional 10 pancreatic resection specimens with confirmed SCA; α-inhibin IHC was performed on all cell blocks, biopsy slides and representative resection specimen sections. Where available, associated cyst fluid was analysed for correlative vascular endothelial growth factor A (VEGF-A) and carcinoembryonic antigen levels. RESULTS: An α-inhibin IHC sensitivity of 80% was observed in the cases with resection confirmed SCA. Of the fine-needle aspirate/biopsy specimens, 59% (13/22) contained epithelial cells strongly positive for α-inhibin. When selecting for specimens that exhibited distinct strips of epithelium, the α-inhibin strong positivity rate increased to 73% (8/11). VEGF-A values were supportive of false-negative α-inhibin IHC in three cases and true-negative α-inhibin IHC in one case. CONCLUSION: This study postulates a diagnostic algorithm to confirm pancreatic SCA which may help to decrease unnecessary follow-up endoscopy/surgical resection and would decrease the associated morbidity, mortality and financial costs in patients with this otherwise benign condition.</p>
<p>doi: <a href="https://doi.org/10.1136/jclinpath-2019-205872" class="uri">https://doi.org/10.1136/jclinpath-2019-205872</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Targeted next-generation sequencing identifies distinct clinicopathologic and molecular entities of intraductal papillary neoplasms of the bile duct</strong> </summary></p>
<p><em>Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc 2019 11;32(11):1637-1645</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31231124" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31231124</a></p>
<p>Intraductal papillary neoplasm of the bile duct (IPNB) is a mass-forming neoplasm in the bile duct considered to be the biliary counterpart of pancreatic intraductal papillary mucinous neoplasm (IPMN). By its cell lineage, IPNB can be classified into gastric, intestinal, pancreatobiliary, and oncocytic types. Recently, a group of Japanese and Korean pathologists proposed that IPNB be classified into two types, with type 1, being the histological counterpart of IPMN and type 2, having a more complex histological architecture. We used targeted next-generation sequencing to study the molecular change of 37 IPNBs and identified frequent mutations of KRAS (49%), GNAS (32%), RNF43 (24%), APC (24%), TP53 (24%), and CTNNB1 (11%) in IPNBs. Intestinal-type IPNB was associated with KRAS, GNAS, and RNF43 mutations. Japan-Korea consensus type 1 was associated with KRAS and GNAS mutations. All four IPNBs with CTNNB1 mutations were of pancreatobiliary type and located in the extrahepatic bile duct. A hierarchical analysis identified three distinct groups within IPNB: group 1 was Japan-Korea consensus type 1 tumors with macroscopic mucin, old age, and frequent KRAS, GNAS, and RNF43 mutations. Group 2 was Japan-Korea consensus type 2 with intestinal differentiation and frequent KRAS mutation but rare GNAS mutation, MUC2 expression, and macroscopic mucin. Group 3 was characterized by CTNNB1 mutation, extrahepatic location, lack of expression of intestinal markers, Japan-Korea consensus type 2, and lack of mutations in KRAS, APC, RNF43, and GNAS. Our results indicated that IPNB is a heterogeneous disease and that the activation of Ras-mitogen-activated protein kinase (MAPK), Wnt/β-catenin, and G-protein-coupled receptor (GPCR)-cAMP signaling is the main oncogenic mechanism of IPNB.</p>
<p>doi: <a href="https://doi.org/10.1038/s41379-019-0306-9" class="uri">https://doi.org/10.1038/s41379-019-0306-9</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Accurate and Dynamic Monitoring of Pancreatic Endocrine Function Is Required in Discharged Patients With Necrotizing Pancreatitis</strong> </summary></p>
<p><em>Gastroenterology 2019 09;157(3):892</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31228436" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31228436</a></p>
<p>doi: <a href="https://doi.org/10.1053/j.gastro.2018.12.052" class="uri">https://doi.org/10.1053/j.gastro.2018.12.052</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Quality of Life Following Major Laparoscopic or Open Pancreatic Resection</strong> </summary></p>
<p><em>Annals of surgical oncology 2019 Sep;26(9):2985-2993</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31228131" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31228131</a></p>
<p>PURPOSE: This study was designed to compare quality of life (QoL) among patients who underwent open versus laparoscopic pancreatic resection, including distal pancreatectomy and pancreaticoduodenectomy, and to identify clinical characteristics that are associated with changes in QoL. METHODS: Quality of life (QoL) was assessed in patients undergoing pancreatic resection with the Functional Assessment of Cancer Therapy-Hepatobiliary questionnaire preoperatively and 2 weeks, 1, 3, and 6 months postoperatively. Multilevel regression modeling was used to determine the variability in each QoL domain within the first 2 weeks (postoperative period) and thereafter (recovery period). RESULTS: Among 159 patients, 60.4% underwent open and 39.6% underwent laparoscopic surgery. Physical, functional, hepatobiliary, and total QoL scores decreased in the postoperative period but returned to baseline levels by 6 months postoperatively. Emotional QoL improved from baseline by 2 weeks after surgery (p &lt; 0.001) and social QoL improved from baseline by 3 months after surgery (p &lt; 0.001). Emotional QoL was the only domain where significant differences were observed in QoL in the postoperative and recovery periods between patients who underwent open and laparoscopic pancreatic resection. Controlling for surgical approach, patients who experienced a grade III or IV complication experienced greater declines in physical, functional, hepatobiliary, and total QoL in the postoperative period. The negative impact of complications on QoL resolved by 6 months postoperatively. CONCLUSIONS: The impact of pancreatic resection on QoL was comparable between patients who underwent laparoscopic versus open pancreatic resection. Complications were strongly associated with changes in postoperative QoL, suggesting that performing a safe operation is the best approach for optimizing patient reported QoL.</p>
<p>doi: <a href="https://doi.org/10.1245/s10434-019-07449-x" class="uri">https://doi.org/10.1245/s10434-019-07449-x</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Dual Farnesyl and Geranylgeranyl Transferase Inhibitor Thwarts Mutant KRAS-Driven Patient-Derived Pancreatic Tumors</strong> </summary></p>
<p><em>Clinical cancer research : an official journal of the American Association for Cancer Research 2019 Oct;25(19):5984-5996</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31227505" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31227505</a></p>
<p>PURPOSE: Mutant KRAS is a major driver of pancreatic oncogenesis and therapy resistance, yet KRAS inhibitors are lacking in the clinic. KRAS requires farnesylation for membrane localization and cancer-causing activity prompting the development of farnesyltransferase inhibitors (FTIs) as anticancer agents. However, KRAS becomes geranylgeranylated and active when cancer cells are treated with FTIs. To overcome this geranylgeranylation-dependent resistance to FTIs, we designed FGTI-2734, a RAS C-terminal mimetic dual FT and geranylgeranyltransferase-1 inhibitor (GGTI). EXPERIMENTAL DESIGN: Immunofluorescence, cellular fractionation, and gel shift assays were used to assess RAS membrane association, Western blotting to evaluate FGTI-2734 effects on signaling, and mouse models to demonstrate its antitumor activity. RESULTS: FGTI-2734, but not the selective FTI-2148 and GGTI-2418, inhibited membrane localization of KRAS in pancreatic, lung, and colon human cancer cells. FGTI-2734 induced apoptosis and inhibited the growth in mice of mutant KRAS-dependent but not mutant KRAS-independent human tumors. Importantly, FGTI-2734 inhibited the growth of xenografts derived from four patients with pancreatic cancer with mutant KRAS (2 G12D and 2 G12V) tumors. FGTI-2734 was also highly effective at inhibiting, in three-dimensional cocultures with resistance promoting pancreatic stellate cells, the viability of primary and metastatic mutant KRAS tumor cells derived from eight patients with pancreatic cancer. Finally, FGTI-2734 suppressed oncogenic pathways mediated by AKT, mTOR, and cMYC while upregulating p53 and inducing apoptosis in patient-derived xenografts in vivo. CONCLUSIONS: The development of this novel dual FGTI overcomes a major hurdle in KRAS resistance, thwarting growth of patient-derived mutant KRAS-driven xenografts from patients with pancreatic cancer, and as such it warrants further preclinical and clinical studies.</p>
<p>doi: <a href="https://doi.org/10.1158/1078-0432.CCR-18-3399" class="uri">https://doi.org/10.1158/1078-0432.CCR-18-3399</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Complications to Chronic Pancreatitis and Etiological Risk Factors: A Continental Divide?</strong> </summary></p>
<p><em>The American journal of gastroenterology 2019 08;114(8):1353</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31211705" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31211705</a></p>
<p>doi: <a href="https://doi.org/10.14309/ajg.0000000000000302" class="uri">https://doi.org/10.14309/ajg.0000000000000302</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Outcomes of Lymph Node Dissection for Non-metastatic Pancreatic Neuroendocrine Tumors: A Propensity Score-Weighted Analysis of the National Cancer Database</strong> </summary></p>
<p><em>Annals of surgical oncology 2019 Sep;26(9):2722-2729</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31209670" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31209670</a></p>
<p>BACKGROUND: Although the National Comprehensive Cancer Network (NCCN) guidelines recommend use of lymph node dissection (LND) in patients with pancreatic neuroendocrine tumors (pNETs) &gt; 2 cm, there is limited evidence to support the association between use of LND and overall survival (OS). METHODS: Patients with resected pNETs were identified in the National Cancer Database (2004-2014). The inverse probability of treatment weighting (IPTW) method was used to reduce the selection bias. IPTW-adjusted Kaplan-Meier curves and Cox proportional hazards models were used to compare OS of patients in different treatment groups. RESULTS: A total of 2664 patients diagnosed met the study entry criteria. Of these, 2132 patients (80.6%) received LND, with a median of nine nodes removed. Positive nodes were identified in 28.0% of patients who underwent LND. IPTW-adjusted Kaplan-Meier analysis showed that median OS was similar between the LND and LND-omitted groups (152.8 vs. 147.3 months; p = 0.61). In IPTW-adjusted Cox proportional hazards regression analysis, LND was not associated with an OS benefit (hazard ratio [HR] 1.15, 95% confidence interval [CI] 0.94-1.42; p = 0.18). The results were consistent across subgroups stratified by clinical T and N stages. Among patients with lymph node metastasis, the number of removed nodes (NRN) above the median was not associated with an improved OS (HR 0.82, 95% CI 0.60-1.13; p = 0.22). CONCLUSIONS: LND had no additional therapeutic benefit among patients undergoing resection for pNETs. The present findings should be considered when managing patients with resectable pNETs.</p>
<p>doi: <a href="https://doi.org/10.1245/s10434-019-07506-5" class="uri">https://doi.org/10.1245/s10434-019-07506-5</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Morphological classification of pancreatic ductal adenocarcinoma that predicts molecular subtypes and correlates with clinical outcome</strong> </summary></p>
<p><em>Gut 2020 02;69(2):317-328</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31201285" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31201285</a></p>
<p>INTRODUCTION: Transcriptional analyses have identified several distinct molecular subtypes in pancreatic ductal adenocarcinoma (PDAC) that have prognostic and potential therapeutic significance. However, to date, an indepth, clinicomorphological correlation of these molecular subtypes has not been performed. We sought to identify specific morphological patterns to compare with known molecular subtypes, interrogate their biological significance, and furthermore reappraise the current grading system in PDAC. DESIGN: We first assessed 86 primary, chemotherapy-naive PDAC resection specimens with matched RNA-Seq data for specific, reproducible morphological patterns. Differential expression was applied to the gene expression data using the morphological features. We next compared the differentially expressed gene signatures with previously published molecular subtypes. Overall survival (OS) was correlated with the morphological and molecular subtypes. RESULTS: We identified four morphological patterns that segregated into two components (‘gland forming’ and ‘non-gland forming’) based on the presence/absence of well-formed glands. A morphological cut-off (≥40% ‘non-gland forming’) was established using RNA-Seq data, which identified two groups (A and B) with gene signatures that correlated with known molecular subtypes. There was a significant difference in OS between the groups. The morphological groups remained significantly prognostic within cancers that were moderately differentiated and classified as ‘classical’ using RNA-Seq. CONCLUSION: Our study has demonstrated that PDACs can be morphologically classified into distinct and biologically relevant categories which predict known molecular subtypes. These results provide the basis for an improved taxonomy of PDAC, which may lend itself to future treatment strategies and the development of deep learning models.</p>
<p>doi: <a href="https://doi.org/10.1136/gutjnl-2019-318217" class="uri">https://doi.org/10.1136/gutjnl-2019-318217</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Benchmark, Textbook or Optimal Pancreatic Surgery?</strong> </summary></p>
<p><em>Annals of surgery 2019 08;270(2):219-220</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31188222" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31188222</a></p>
<p>doi: <a href="https://doi.org/10.1097/SLA.0000000000003377" class="uri">https://doi.org/10.1097/SLA.0000000000003377</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Dissecting the Stromal Signaling and Regulation of Myeloid Cells and Memory Effector T Cells in Pancreatic Cancer</strong> </summary></p>
<p><em>Clinical cancer research : an official journal of the American Association for Cancer Research 2019 Sep;25(17):5351-5363</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31186314" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31186314</a></p>
<p>PURPOSE: Myeloid cells are a prominent immunosuppressive component within the stroma of pancreatic ductal adenocarcinoma (PDAC). Previously, targeting myeloid cells has had limited success. Here, we sought to target the myeloid cells through modifying a specific stromal component. EXPERIMENTAL DESIGN: A murine model of metastatic PDAC treated with an irradiated whole-cell PDAC vaccine and PDAC specimens from patients treated with the same type of vaccine were used to assess the immune-modulating effect of stromal hyaluronan (HA) degradation by PEGPH20. RESULTS: Targeting stroma by degrading HA with PEGPH20 in combination with vaccine decreases CXCL12/CXCR4/CCR7 immunosuppressive signaling axis expression in cancer-associated fibroblasts, myeloid, and CD8+ T cells, respectively. This corresponds with increased CCR7- effector memory T-cell infiltration, an increase in tumor-specific IFNγ, and improved survival. In the stroma of human PDACs treated with the same vaccine, decreased stromal CXCR4 expression significantly correlated with decreased HA and increased cytotoxic activities, suggesting CXCR4 is an important therapeutic target. CONCLUSIONS: This study represents the first to dissect signaling cascades following PDAC stroma remodeling via HA depletion, suggesting this not only overcomes a physical barrier for immune cell trafficking, but alters myeloid function leading to downstream selective increases in effector memory T-cell infiltration and antitumor activity.</p>
<p>doi: <a href="https://doi.org/10.1158/1078-0432.CCR-18-4192" class="uri">https://doi.org/10.1158/1078-0432.CCR-18-4192</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Comparisons of Outcomes of Real-World Patients With Advanced Pancreatic Cancer Treated With FOLFIRINOX Versus Gemcitabine and Nab-Paclitaxel: A Population-Based Cohort Study</strong> </summary></p>
<p><em>Pancreas 2019 08;48(7):920-926</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31180981" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31180981</a></p>
<p>OBJECTIVES: The aim of this study was to compare the efficacy and safety of FOLFIRINOX (5-FU/leucovorin, irinotecan, and oxaliplatin) and gemcitabine/nab-paclitaxel (GnP) in patients with advanced pancreatic cancer. METHODS: Patients with newly diagnosed advanced pancreatic cancer in Saskatchewan, Canada, from 2011 to 2016, who received FOLFIRINOX or GnP were assessed. A Cox proportional multivariate analysis was performed to evaluate prognostic variables. RESULTS: One hundred nineteen eligible patients with median age of 61 years and male/female ratio of 70:49 were identified. Seventy-seven percent had metastatic disease. Of 119 patients, 86 (72%) received FOLFIRINOX and 33 (28%) were treated with GnP. Median progression-free survival of the FOLFIRINOX group was 6.0 months [95% confidence interval (CI), 4.5-7.5] versus 4.0 months (95% CI, 2.9-5.1) with GnP (P = 0.39). The median overall survival of the FOLFIRINOX group was 9.0 months (95% CI, 7-11) compared with 9.0 months (95% CI, 4.2-13.8) with GnP (P = 0.88). On multivariate analysis, albumin [hazard ratio (HR), 0.63; 95% CI, 0.41-0.97], male sex (HR, 0.65; 95% CI, 0.43-0.97), and second-line therapy (HR, 0.50; 95% CI, 0.28-0.86) were correlated with survival. CONCLUSIONS: Our results showed that real-world patients with advanced pancreatic cancer treated with FOLFIIRNOX or GnP had comparable survival with different safety profile.</p>
<p>doi: <a href="https://doi.org/10.1097/MPA.0000000000001340" class="uri">https://doi.org/10.1097/MPA.0000000000001340</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Differences in Pancreatic Cancer Incidence Rates and Temporal Trends Across Asian Subpopulations in California (1988-2015)</strong> </summary></p>
<p><em>Pancreas 2019 08;48(7):931-933</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31180980" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31180980</a></p>
<p>OBJECTIVE: Ethnic disparities in pancreatic cancer (PanCan) incidence exist, but little is known about incidence trends in heterogeneous Asian Americans. We examined PanCan incidence and temporal patterns among detailed ethnic populations, including Asian American subgroups. METHODS: A total of 71,099 invasive exocrine PanCan cases were identified using the California Cancer Registry between 1988 and 2015. Cases were grouped into mutually exclusive groups of non-Hispanic (NH) white, NH black, Hispanic, NH Asian/Pacific Islander (API), and NH American Indian/Alaska Native (AIAN). Asians were further identified by specific ethnicity. RESULTS: The age-adjusted incidence rates (AAIRs, per 100,000) of PanCan varied significantly across racial/ethnic groups, ranging from the highest of 10.4 in NH blacks to 7.6 in NH whites, 7.1 in Hispanics, 6.2 in NH APIs, and to the lowest of 5.2 in NH AIAN. Despite the relatively low rate in the NH APIs, the rates across Asian subgroups varied significantly, with rates similar to NH whites in Japanese (8.1) and Koreans (7.5) to the low rate in South Asians (4.4). CONCLUSIONS: Significant heterogeneity of PanCan incidence in disaggregated Asian Americans is a novel finding. These results fill a gap regarding PanCan burden in Asian Americans and underscore the importance of disaggregating ethnic populations in cancer research.</p>
<p>doi: <a href="https://doi.org/10.1097/MPA.0000000000001337" class="uri">https://doi.org/10.1097/MPA.0000000000001337</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Intraductal Papillary Mucinous Neoplasms Arise From Multiple Independent Clones, Each With Distinct Mutations</strong> </summary></p>
<p><em>Gastroenterology 2019 10;157(4):1123-1137.e22</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31175866" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31175866</a></p>
<p>BACKGROUND &amp; AIMS: Intraductal papillary mucinous neoplasms (IPMNs) are lesions that can progress to invasive pancreatic cancer and constitute an important system for studies of pancreatic tumorigenesis. We performed comprehensive genomic analyses of entire IPMNs to determine the diversity of somatic mutations in genes that promote tumorigenesis. METHODS: We microdissected neoplastic tissues from 6-24 regions each of 20 resected IPMNs, resulting in 227 neoplastic samples that were analyzed by capture-based targeted sequencing. Somatic mutations in genes associated with pancreatic tumorigenesis were assessed across entire IPMN lesions, and the resulting data were supported by evolutionary modeling, whole-exome sequencing, and in situ detection of mutations. RESULTS: We found a high prevalence of heterogeneity among mutations in IPMNs. Heterogeneity in mutations in KRAS and GNAS was significantly more prevalent in IPMNs with low-grade dysplasia than in IPMNs with high-grade dysplasia (P &lt; .02). Whole-exome sequencing confirmed that IPMNs contained multiple independent clones, each with distinct mutations, as originally indicated by targeted sequencing and evolutionary modeling. We also found evidence for convergent evolution of mutations in RNF43 and TP53, which are acquired during later stages of tumorigenesis. CONCLUSIONS: In an analysis of the heterogeneity of mutations throughout IPMNs, we found that early-stage IPMNs contain multiple independent clones, each with distinct mutations, indicating their polyclonal origin. These findings challenge the model in which pancreatic neoplasms arise from a single clone. Increasing our understanding of the mechanisms of IPMN polyclonality could lead to strategies to identify patients at increased risk for pancreatic cancer.</p>
<p>doi: <a href="https://doi.org/10.1053/j.gastro.2019.06.001" class="uri">https://doi.org/10.1053/j.gastro.2019.06.001</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Cross Validation of the Monoclonal Antibody Das-1 in Identification of High-Risk Mucinous Pancreatic Cystic Lesions</strong> </summary></p>
<p><em>Gastroenterology 2019 09;157(3):720-730.e2</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31175863" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31175863</a></p>
<p>BACKGROUND &amp; AIMS: Although pancreatic cystic lesions (PCLs) are frequently and incidentally detected, it is a challenge to determine their risk of malignancy. In immunohistochemical and enzyme-linked immunosorbent assay (ELISA) analyses of tissue and cyst fluid from pancreatic intraductal papillary mucinous neoplasms, the monoclonal antibody Das-1 identifies those at risk for malignancy with high levels of specificity and sensitivity. We aimed to validate the ability of Das-1 to identify high-risk PCLs in comparison to clinical guidelines and clinical features, using samples from a multicenter cohort. METHODS: We obtained cyst fluid samples of 169 PCLs (90 intraductal papillary mucinous neoplasms, 43 mucinous cystic neoplasms, and 36 non-mucinous cysts) from patients undergoing surgery at 4 tertiary referral centers (January 2010 through June 2017). Histology findings from surgical samples, analyzed independently and centrally re-reviewed in a blinded manner, were used as the reference standard. High-risk PCLs were those with invasive carcinomas, high-grade dysplasia, or intestinal-type intraductal papillary mucinous neoplasms with intermediate-grade dysplasia. An ELISA with Das-1 was performed in parallel using banked cyst fluid samples. We evaluated the biomarker’s performance, generated area under the curve values, and conducted multivariate logistic regression using clinical and pathology features. RESULTS: The ELISA for Das-1 identified high-risk PCLs with 88% sensitivity, 99% specificity, and 95% accuracy, at a cutoff optical density value of 0.104. In 10-fold cross-validation analysis with 100 replications, Das-1 identified high-risk PCLs with 88% sensitivity and 98% specificity. The Sendai, Fukuoka, and American Gastroenterological Association guideline criteria identified high-risk PCLs with 46%, 52%, and 74% accuracy (P for comparison to Das-1 ELISA &lt;.001). When we controlled for Das-1 in multivariate regression, main pancreatic duct dilation &gt;5 mm (odds ratio, 14.98; 95% confidence interval, 2.63-108; P &lt; .0012), main pancreatic duct dilation ≥1 cm (odds ratio, 47.9; 95% confidence interval, 6.39-490; P &lt; .0001), and jaundice (odds ratio, 6.16; 95% confidence interval, 1.08-36.7; P = .0397) were significantly associated with high-risk PCLs. CONCLUSIONS: We validated the ability of an ELISA with the monoclonal antibody Das-1 to detect PCLs at risk for malignancy with high levels of sensitivity and specificity. This biomarker might be used in conjunction with clinical guidelines to identify patients at risk for malignancy.</p>
<p>doi: <a href="https://doi.org/10.1053/j.gastro.2019.05.014" class="uri">https://doi.org/10.1053/j.gastro.2019.05.014</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Effective Delivery of a Microtubule Polymerization Inhibitor Synergizes with Standard Regimens in Models of Pancreatic Ductal Adenocarcinoma</strong> </summary></p>
<p><em>Clinical cancer research : an official journal of the American Association for Cancer Research 2019 Sep;25(18):5548-5560</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31175095" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31175095</a></p>
<p>PURPOSE: Pancreatic ductal adenocarcinoma (PDA) is a deadly cancer that is broadly chemoresistant, due in part to biophysical properties of tumor stroma, which serves as a barrier to drug delivery for most classical chemotherapeutic drugs. The goal of this work is to evaluate the preclinical efficacy and mechanisms of PTC596, a novel agent with potent anticancer properties in vitro and desirable pharmacologic properties in vivo.Experimental Design: We assessed the pharmacology, mechanism, and preclinical efficacy of PTC596 in combination with standards of care, using multiple preclinical models of PDA. RESULTS: We found that PTC596 has pharmacologic properties that overcome the barrier to drug delivery in PDA, including a long circulating half-life, lack of P-glycoprotein substrate activity, and high systemic tolerability. We also found that PTC596 combined synergistically with standard clinical regimens to improve efficacy in multiple model systems, including the chemoresistant genetically engineered “KPC” model of PDA. Through mechanistic studies, we learned that PTC596 functions as a direct microtubule polymerization inhibitor, yet a prior clinical trial found that it lacks peripheral neurotoxicity, in contrast to other such agents. Strikingly, we found that PTC596 synergized with the standard clinical backbone regimen gemcitabine/nab-paclitaxel, yielding potent, durable regressions in a PDX model. Moreover, similar efficacy was achieved in combination with nab-paclitaxel alone, highlighting a specific synergistic interaction between two different microtubule-targeted agents in the setting of pancreatic ductal adenocarcinoma. CONCLUSIONS: These data demonstrate clear rationale for the development of PTC596 in combination with standard-of-care chemotherapy for PDA.</p>
<p>doi: <a href="https://doi.org/10.1158/1078-0432.CCR-18-3281" class="uri">https://doi.org/10.1158/1078-0432.CCR-18-3281</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>A Novel Oxoglutarate Dehydrogenase-Like Mediated miR-214/TWIST1 Negative Feedback Loop Inhibits Pancreatic Cancer Growth and Metastasis</strong> </summary></p>
<p><em>Clinical cancer research : an official journal of the American Association for Cancer Research 2019 Sep;25(17):5407-5421</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31175094" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31175094</a></p>
<p>PURPOSE: As a main rate-limiting subunit of the 2-oxoglutarate dehydrogenase multienzyme complex, oxoglutarate dehydrogenase like (OGDHL) is involved in the tricarboxylic acid cycle, and frequently downregulated in human carcinoma and suppresses tumor growth. However, little is known about the role of OGDHL in human cancer, especially pancreatic cancer. Our goal is to study the underlying mechanism and define a novel signaling pathway controlled by OGDHL modulating pancreatic cancer progression. EXPERIMENTAL DESIGN: The expression and functional analysis of OGDHL, miR-214, and TWIST1 in human pancreatic cancer tissues, cell lines, and xenograft tumor model were investigated. The correlations between OGDHL and those markers were analyzed. RESULTS: OGDHL was downregulated in human pancreatic cancer and predicted poor prognosis. OGDHL overexpression inhibited migration and invasion of pancreatic cancer cells and suppressed pancreatic cancer tumor growth. OGDHL was shown to be negatively regulated by miR-214. TWIST1 upregulation induced miR-214 expression in pancreatic cancer. OGDHL suppressed TWIST1 expression through promoting ubiquitin-mediated proteasomal degradation of HIF1α and regulating AKT pathways. A combination of OGDHL downregulation and TWIST1 and miR-214 overexpression predicted worse prognosis in patients with pancreatic cancer. CONCLUSIONS: We demonstrated the prognostic value of OGDHL, miR-214, and TWIST1 in pancreatic cancer, and elucidated a novel pathway in OGDHL-regulated inhibition of pancreatic cancer tumorigenesis and metastasis. These findings may lead to new targeted therapy for pancreatic cancer through regulating OGDHL, miR-214, and TWIST1.</p>
<p>doi: <a href="https://doi.org/10.1158/1078-0432.CCR-18-4113" class="uri">https://doi.org/10.1158/1078-0432.CCR-18-4113</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Usefulness of immunohistochemical staining for MUC5AC in differentiating primary pancreatic cancer from pancreatic metastasis of breast cancer</strong> </summary></p>
<p><em>Diagnostic cytopathology 2019 Oct;47(10):1037-1041</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31169985" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31169985</a></p>
<p>Diagnosis of pancreatic ductal adenocarcinoma (PDAC) and its differentiation from metastases to the pancreas from other organs remains challenging. We report a case in which immunohistochemical staining for MUC5AC was useful in distinguishing primary pancreatic cancer from breast cancer metastasis. A 51-year-old Japanese woman who underwent curative resection of her breast cancer was referred to our hospital with a pancreatic head tumor. Although we surmised her pancreatic tumor to be metastatic breast cancer based on her past history and imaging studies, she was subsequently diagnosed with PDAC on the basis of immunohistochemical staining for MUC5AC using specimens obtained by endoscopic ultrasound-fine-needle aspiration. Thus, MUC5AC may be a useful diagnostic marker for discriminating PDAC from a secondary malignancy.</p>
<p>doi: <a href="https://doi.org/10.1002/dc.24249" class="uri">https://doi.org/10.1002/dc.24249</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Genomic landscape of lymphoepithelioma-like hepatocellular carcinoma</strong> </summary></p>
<p><em>The Journal of pathology 2019 10;249(2):166-172</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31168847" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31168847</a></p>
<p>Lymphoepithelioma-like hepatocellular carcinoma (LEL-HCC) is a distinct variant of HCC that is characterized by dense tumor-infiltrating lymphocytes (TILs). Patients with LEL-HCC also show better clinical outcomes compared to conventional HCC (c-HCC), which is commonly presented with low TIL. Emerging evidence has begun to highlight tumor-intrinsic genetic abnormalities in the tumor-host immune interfaces. However, genome-wide characterization of LEL-HCC remains largely unexplored. Here, we defined the genomic landscape of 12 LEL-HCC using whole-exome sequencing, and further underpinned those genetic alterations related to an immune active microenvironment by comparing findings to 15 c-HCC that were sequenced in parallel. Overall, the mutational load between LEL-HCC and c-HCC was similar. Interestingly, SNV incidences of specific genes (CTNNB1, AXIN1, NOTCH1, and NOTCH2) were significantly higher in c-HCC than LEL-HCC, suggesting a plausible link between activated Wnt/β-catenin and Notch signaling pathways and immune avoidance. Marked focal amplification of chromosome 11q13.3 was prevalent in LEL-HCC. Using The Cancer Genome Atlas dataset, we further established oncogenes expressed from chromosome 11q13.3 (CCND1, FGF19, and FGF4) to be strongly associated with the immune checkpoint signature (CD274, PDCD1, BTLA, CTLA4, HAVCR2, IDO1, and LAG3). Our results have illustrated for the first time the somatic landscape of LEL-HCC, and highlighted molecular alterations that could be exploited in combinatory therapy with checkpoint inhibitors in targeting HCC. © 2019 Pathological Society of Great Britain and Ireland. Published by John Wiley &amp; Sons, Ltd.</p>
<p>doi: <a href="https://doi.org/10.1002/path.5313" class="uri">https://doi.org/10.1002/path.5313</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>The Pathologic and Genetic Characteristics of the Intestinal Subtype of Intraductal Papillary Neoplasms of the Bile Duct</strong> </summary></p>
<p><em>The American journal of surgical pathology 2019 09;43(9):1212-1220</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31166202" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31166202</a></p>
<p>The present study aimed to identify the pathologic and genetic characteristics of intestinal subtype of intraductal papillary neoplasm of the bile duct (iIPNB) showing columnar cells with pseudostratified, cigar-shaped nuclei, and basophilic or amphophilic cytoplasm with the diffuse immunohistochemical expression of CK20 and/or CDX2. A total of 34 cases of iIPNB were pathologically examined according to their anatomic location (the bile duct) and were then compared with the intestinal subtype of intraductal papillary mucinous neoplasm (iIPMN) of the pancreas (n=22). Mutations of 26 somatic genes were examined in formalin-fixed paraffin-embedded tissue specimens from 21 cases of iIPNB using the TruSight Tumor 26 gene panel and next-generation sequencing. iIPNB cases were divided into intrahepatic (n=6) and extrahepatic (n=28) categories. Intrahepatic IPNBs showed a less-complicated villous-papillary pattern, while extrahepatic IPNBs showed a papillary pattern with tubular and/or villous components and predominant high-grade dysplasia with complicated architectures. MUC5AC was frequently and extensively expressed in intrahepatic iIPNBs and iIPMNs but not in extrahepatic iIPNBs. CD10 was frequently expressed in extrahepatic IPNBs but not in intrahepatic iIPNBs or iIPMN. Genetic mutations of TP53 and PIK3CA, which were infrequent or absent in iIPMNs, were frequently detected in extrahepatic iIPNBs, while KRAS and GNAS, which were commonly observed in iIPMNs, were frequently detected in intrahepatic iIPNBs. Intrahepatic iIPNBs showed villous-papillary growth with features reminiscent of iIPMNs, while extrahepatic iIPNBs showed papillary growth with tubular and/or villous components, complicated histology and variable differences from iIPMNs, suggesting differences in the tumorigenesis of iIPNBs along the biliary tree.</p>
<p>doi: <a href="https://doi.org/10.1097/PAS.0000000000001295" class="uri">https://doi.org/10.1097/PAS.0000000000001295</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Oncogenic NRG1 Fusions: A New Hope for Targeted Therapy in Pancreatic Cancer</strong> </summary></p>
<p><em>Clinical cancer research : an official journal of the American Association for Cancer Research 2019 08;25(15):4589-4591</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31164372" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31164372</a></p>
<p>Approximately 8%-10% of pancreatic ductal adenocarcinoma cases are KRAS wild type. In a subset of these tumors, NRG1 gene fusions have been identified as targetable oncogenic drivers, a discovery that highlights the importance of deep molecular characterization for KRAS wild-type pancreatic cancers and provides a novel treatment strategy in this disease.See related article by Jones et al., p. 4674.</p>
<p>doi: <a href="https://doi.org/10.1158/1078-0432.CCR-19-1280" class="uri">https://doi.org/10.1158/1078-0432.CCR-19-1280</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Axon Guidance Molecules Promote Perineural Invasion and Metastasis of Orthotopic Pancreatic Tumors in Mice</strong> </summary></p>
<p><em>Gastroenterology 2019 09;157(3):838-850.e6</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31163177" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31163177</a></p>
<p>BACKGROUND &amp; AIMS: Little is known about mechanisms of perineural invasion (PNI) by pancreatic ductal adenocarcinomas (PDAs) or other tumors. Annexin A2 (ANXA2) regulates secretion of SEMA3D, an axon guidance molecule, which binds and activates the receptor PLXND1 to promote PDA invasion and metastasis. We investigated whether axon guidance molecules promote PNI and metastasis by PDA cells in mice. METHODS: We performed studies in a dorsal root ganglion (DRG) invasion system, wild-type C57BL/6 mice (controls), mice with peripheral sensory neuron-specific disruption of PlxnD1 (PLAC mice), LSL-KRASG12D/+;LSL-TP53R172H/+;PDX-1-CRE+/+ (KPC) mice, and KPC mice crossed with ANXA2-knockout mice (KPCA mice). PDA cells were isolated from KPC mice and DRG cells were isolated from control mice. Levels of SEMA3D or ANXA2 were knocked down in PDA cells with small hairpin and interfering RNAs and cells were analyzed by immunoblots in migration assays, with DRGs and with or without antibodies against PLXND1. PDA cells were injected into the pancreas of control and PLAC mice, growth of tumors was assessed, and tumor samples were analyzed by histology. DRG cells were incubated with SEMA3D and analyzed by live imaging. We measured levels of SEMA3D and PLXND1 in PDA specimens from patients with PNI and calculated distances between tumor cells and nerves. RESULTS: DRG cells increase the migration of PDC cells in invasion assays; knockdown of SEMA3D in PDA cells or antibody blockade of PLXND1 on DRG cells reduced this invasive activity. In mice, orthotopic tumors grown from PDA cells with knockdown of SEMA3D, and in PLAC mice, orthotopic tumors grown from PDA cells, had reduced innervation and formed fewer metastases than orthotopic tumors grown from PDA cells in control mice. Increased levels of SEMA3D and PLXND1 in human PDA specimens associated with PNI. CONCLUSIONS: DRG cells increase the migratory and invasive activities of pancreatic cancer cells, via secretion of SEMA3D by pancreatic cells and activation of PLXND1 on DRGs. Knockdown of SEMA3D and loss of neural PLXND1 reduces innervation of orthotopic PDAs and metastasis in mice. Increased levels of SEMA3D and PLXND1 in human PDA specimens associated with PNI. Strategies to disrupt the axon guidance pathway mediated by SEMA3D and PLXND1 might be developed to slow progression of PDA.</p>
<p>doi: <a href="https://doi.org/10.1053/j.gastro.2019.05.065" class="uri">https://doi.org/10.1053/j.gastro.2019.05.065</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer</strong> </summary></p>
<p><em>The New England journal of medicine 2019 07;381(4):317-327</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31157963" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31157963</a></p>
<p>BACKGROUND: Patients with a germline BRCA1 or BRCA2 mutation make up a small subgroup of those with metastatic pancreatic cancer. The poly(adenosine diphosphate-ribose) polymerase (PARP) inhibitor olaparib has had antitumor activity in this population. METHODS: We conducted a randomized, double-blind, placebo-controlled, phase 3 trial to evaluate the efficacy of olaparib as maintenance therapy in patients who had a germline BRCA1 or BRCA2 mutation and metastatic pancreatic cancer and disease that had not progressed during first-line platinum-based chemotherapy. Patients were randomly assigned, in a 3:2 ratio, to receive maintenance olaparib tablets (300 mg twice daily) or placebo. The primary end point was progression-free survival, which was assessed by blinded independent central review. RESULTS: Of the 3315 patients who underwent screening, 154 underwent randomization and were assigned to a trial intervention (92 to receive olaparib and 62 to receive placebo). The median progression-free survival was significantly longer in the olaparib group than in the placebo group (7.4 months vs. 3.8 months; hazard ratio for disease progression or death, 0.53; 95% confidence interval [CI], 0.35 to 0.82; P = 0.004). An interim analysis of overall survival, at a data maturity of 46%, showed no difference between the olaparib and placebo groups (median, 18.9 months vs. 18.1 months; hazard ratio for death, 0.91; 95% CI, 0.56 to 1.46; P = 0.68). There was no significant between-group difference in health-related quality of life, as indicated by the overall change from baseline in the global quality-of-life score (on a 100-point scale, with higher scores indicating better quality of life) based on the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (between-group difference, -2.47 points; 95% CI, -7.27 to 2.33). The incidence of grade 3 or higher adverse events was 40% in the olaparib group and 23% in the placebo group (between-group difference, 16 percentage points; 95% CI, -0.02 to 31); 5% and 2% of the patients, respectively, discontinued the trial intervention because of an adverse event. CONCLUSIONS: Among patients with a germline BRCA mutation and metastatic pancreatic cancer, progression-free survival was longer with maintenance olaparib than with placebo. (Funded by AstraZeneca and others; POLO ClinicalTrials.gov number, NCT02184195.).</p>
<p>doi: <a href="https://doi.org/10.1056/NEJMoa1903387" class="uri">https://doi.org/10.1056/NEJMoa1903387</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Proton Radiotherapy for Isolated Local Recurrence of Primary Resected Pancreatic Ductal Adenocarcinoma</strong> </summary></p>
<p><em>Annals of surgical oncology 2019 Aug;26(8):2587-2594</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31147994" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31147994</a></p>
<p>BACKGROUND: The optimal treatment for isolated local recurrence (ILR) of pancreatic adenocarcinoma (PDAC) after surgical resection remains unclear. This study aimed to evaluate the safety and efficacy of proton radiotherapy (PRT) for ILR of PDAC after surgery. METHODS: The medical records of patients with ILR of PDAC after surgery who underwent proton beam therapy between 2011 and 2015 at Hyogo Ion Beam Medical Center were retrospectively studied. RESULTS: The study analyzed 30 patients (14 women and 16 men) with a median age of 65 years (range 38-81 years) who had initially undergone pancreatoduodenectomy (n = 23) or distal pancreatectomy (n = 7) for their primary tumors. Upon ILR, PRT was administered with a median total cumulative dose of 67.5 gray equivalent (GyE) (range 50-67.5 GyE) using 19 to 25 fractions. For 25 patients, concurrent chemotherapy was administered using gemcitabine (n = 18) or S-1 (n = 7). Four patients (13.3%) experienced acute grade ≥ 3 gastrointestinal toxicities. After a median follow-up period of 17.6 months (range 2.1-50.4 months), 23 patients had experienced tumor progression and 10 had died. Nine patients (30%) experienced local tumor progression. The median overall, progression-free, and local progression-free survival rates were 26.1, 12.3, and 41.2 months, respectively. Pre-PRT serum levels of cancer antigen 19-9 higher than 100 U/mL and duke pancreatic monoclonal antigen type 2 higher than 150 U/mL were significantly associated with shorter progression-free survival rates. CONCLUSIONS: Proton radiotherapy for ILR of PDAC after surgery is well tolerated and produces good locoregional control and should be considered for eligible patients.</p>
<p>doi: <a href="https://doi.org/10.1245/s10434-019-07471-z" class="uri">https://doi.org/10.1245/s10434-019-07471-z</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Circulating Tumor DNA as a Clinical Test in Resected Pancreatic Cancer</strong> </summary></p>
<p><em>Clinical cancer research : an official journal of the American Association for Cancer Research 2019 Aug;25(16):4973-4984</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31142500" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31142500</a></p>
<p>PURPOSE: In research settings, circulating tumor DNA (ctDNA) shows promise as a tumor-specific biomarker for pancreatic ductal adenocarcinoma (PDAC). This study aims to perform analytical and clinical validation of a KRAS ctDNA assay in a Clinical Laboratory Improvement Amendments (CLIA) and College of American Pathology-certified clinical laboratory. EXPERIMENTAL DESIGN: Digital-droplet PCR was used to detect the major PDAC-associated somatic KRAS mutations (G12D, G12V, G12R, and Q61H) in liquid biopsies. For clinical validation, 290 preoperative and longitudinal postoperative plasma samples were collected from 59 patients with PDAC. The utility of ctDNA status to predict PDAC recurrence during follow-up was assessed. RESULTS: ctDNA was detected preoperatively in 29 (49%) patients and was an independent predictor of decreased recurrence-free survival (RFS) and overall survival (OS). Patients who had neoadjuvant chemotherapy were less likely to have preoperative ctDNA than were chemo-naïve patients (21% vs. 69%; P &lt; 0.001). ctDNA levels dropped significantly after tumor resection. Persistence of ctDNA in the immediate postoperative period was associated with a high rate of recurrence and poor median RFS (5 months). ctDNA detected during follow-up predicted clinical recurrence [sensitivity 90% (95% confidence interval (CI), 74%-98%), specificity 88% (95% CI, 62%-98%)] with a median lead time of 84 days (interquartile range, 25-146). Detection of ctDNA during postpancreatectomy follow-up was associated with a median OS of 17 months, while median OS was not yet reached at 30 months for patients without ctDNA (P = 0.011). CONCLUSIONS: Measurement of KRAS ctDNA in a CLIA laboratory setting can be used to predict recurrence and survival in patients with PDAC.</p>
<p>doi: <a href="https://doi.org/10.1158/1078-0432.CCR-19-0197" class="uri">https://doi.org/10.1158/1078-0432.CCR-19-0197</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Controversies on the endoscopic and surgical management of pain in patients with chronic pancreatitis: pros and cons!</strong> </summary></p>
<p><em>Gut 2019 08;68(8):1343-1351</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31129569" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31129569</a></p>
<p>doi: <a href="https://doi.org/10.1136/gutjnl-2019-318742" class="uri">https://doi.org/10.1136/gutjnl-2019-318742</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Results from a Phase IIb, Randomized, Multicenter Study of GVAX Pancreas and CRS-207 Compared with Chemotherapy in Adults with Previously Treated Metastatic Pancreatic Adenocarcinoma (ECLIPSE Study)</strong> </summary></p>
<p><em>Clinical cancer research : an official journal of the American Association for Cancer Research 2019 Sep;25(18):5493-5502</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31126960" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31126960</a></p>
<p>PURPOSE: Limited options exist for patients with advanced pancreatic cancer progressing after 1 or more lines of therapy. A phase II study in patients with previously treated metastatic pancreatic cancer showed that combining GVAX pancreas (granulocyte-macrophage colony-stimulating factor-secreting allogeneic pancreatic tumor cells) with cyclophosphamide (Cy) and CRS-207 (live, attenuated Listeria monocytogenes expressing mesothelin) resulted in median overall survival (OS) of 6.1 months, which compares favorably with historical OS achieved with chemotherapy. In the current study, we compared Cy/GVAX + CRS-207, CRS-207 alone, and standard chemotherapy in a three-arm, randomized, controlled phase IIb trial. PATIENTS AND METHODS: Patients with previously treated metastatic pancreatic adenocarcinoma were randomized 1:1:1 to receive Cy/GVAX + CRS-207 (arm A), CRS-207 (arm B), or physician’s choice of single-agent chemotherapy (arm C). The primary cohort included patients who had failed ≥2 prior lines of therapy, including gemcitabine. The primary objective compared OS between arms A and C in the primary cohort. The second-line cohort included patients who had received 1 prior line of therapy. Additional objectives included OS between all treatment arms, safety, and tumor responses. RESULTS: The study did not meet its primary efficacy endpoint. At the final study analysis, median OS [95% confidence interval (CI)] in the primary cohort (N = 213) was 3.7 (2.9-5.3), 5.4 (4.2-6.4), and 4.6 (4.2-5.7) months in arms A, B, and C, respectively, showing no significant difference between arm A and arm C [P = not significant (NS), HR = 1.17; 95% CI, 0.84-1.64]. The most frequently reported adverse events in all treatment groups were chills, pyrexia, fatigue, and nausea. No treatment-related deaths occurred. CONCLUSIONS: The combination of Cy/GVAX + CRS-207 did not improve survival over chemotherapy. (ClinicalTrials.gov ID: NCT02004262)See related commentary by Salas-Benito et al., p. 5435.</p>
<p>doi: <a href="https://doi.org/10.1158/1078-0432.CCR-18-2992" class="uri">https://doi.org/10.1158/1078-0432.CCR-18-2992</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Arginine Starvation and Docetaxel Induce c-Myc-Driven hENT1 Surface Expression to Overcome Gemcitabine Resistance in ASS1-Negative Tumors</strong> </summary></p>
<p><em>Clinical cancer research : an official journal of the American Association for Cancer Research 2019 Aug;25(16):5122-5134</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31113844" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31113844</a></p>
<p>PURPOSE: The response to acute and long-term arginine starvation results in a conditional adaptive metabolic reprogramming that can be harnessed for therapeutic opportunities in ASS1-negative tumors. Here, we investigate the underlying biology of priming ASS1- tumors with arginine deiminase (ADI-PEG20) before treatment with gemcitabine (GEM) and docetaxel (DTX) in sarcoma, pancreatic cancer, and melanoma cell lines. EXPERIMENTAL DESIGN: ASS1- tumor cell lines were treated to create LTAT (long-term ADI treated) cell lines (ASS1+) and used for drug combination studies. Protein expression of ASS1, dCK, RRM2, E2F1, c-MYC, and hENT1 was measured. c-MYC activity was determined, live-cell immunofluorescent studies for hENT1, uptake assays of FITC-cytosine probe, and rescue studies with a c-MYC inhibitor were all determined in the presence or absence of the ADI-PEG20:GEM:DTX. RESULTS: In examining modulations within the pyrimidine pathway, we identified that the addition of DTX to cells treated with ADI-PEG20 resulted in translocation of stabilized c-Myc to the nucleus. This resulted in an increase of hENT1 cell-surface expression and rendered the cells susceptible to GEM. In vivo studies demonstrate that the combination of ADI-PEG20:GEM:DTX was optimal for tumor growth inhibition, providing the preclinical mechanism and justification for the ongoing clinical trial of ADI-PEG20, GEM, and DTX in sarcoma. CONCLUSIONS: The priming of tumors with ADI-PEG20 and DTX results in the stabilization of c-MYC potentiating the effect of GEM treatment via an increase in hENT1 expression. This finding is applicable to ASS1-deficient cancers that are currently treated with GEM.</p>
<p>doi: <a href="https://doi.org/10.1158/1078-0432.CCR-19-0206" class="uri">https://doi.org/10.1158/1078-0432.CCR-19-0206</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>RAS Mutation Decreases Overall Survival After Optimal Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy of Colorectal Peritoneal Metastasis: A Modification Proposal of the Peritoneal Surface Disease Severity Score</strong> </summary></p>
<p><em>Annals of surgical oncology 2019 Aug;26(8):2595-2604</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31111351" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31111351</a></p>
<p>BACKGROUND: Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) are currently the most accepted treatment for peritoneal metastases from colorectal cancer. Restrictive selection criteria are essential to obtain the best survival benefits for this complex procedure. The most widespread score for patient selection, the peritoneal surface disease severity score (PSDSS), does not include current biological factors that are known to influence on prognosis. We investigated the impact of including RAS mutational status in the selection criteria for these patients. METHODS: We studied the risk factors for survival by multivariate analysis using a prospective database of consecutive patients with carcinomatosis from colorectal origin treated by CRS and HIPEC in our unit from 2009 to 2017. The risk factors obtained were validated in a multicentre, international cohort, including a total of 520 patients from 15 different reference units. RESULTS: A total of 77 patients were selected for local análisis. Only RAS mutational status (HR: 2.024; p = 0.045) and PSDSS stage (HR: 2.90; p = 0.009) were shown to be independent factors for overall survival. Early PSDSS stages I and II associated to RAS mutations impaired their overall survival with no significant differences with PSDSS stage III overall survival (p &gt; 0.05). These results were supported by the international multicentre validation. CONCLUSIONS: By including RAS mutational status, we propose an updated RAS-PSDSS score that outperforms PSDSS alone providing a quick and feasible preoperative assessment of the expected overall survival for patients with carcinomatosis from colorectal origin undergone to CRS + HIPEC.</p>
<p>doi: <a href="https://doi.org/10.1245/s10434-019-07378-9" class="uri">https://doi.org/10.1245/s10434-019-07378-9</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Nivolumab alone or in combination with cisplatin plus gemcitabine in Japanese patients with unresectable or recurrent biliary tract cancer: a non-randomised, multicentre, open-label, phase 1 study</strong> </summary></p>
<p><em>The lancet. Gastroenterology &amp; hepatology 2019 Aug;4(8):611-621</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31109808" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31109808</a></p>
<p>BACKGROUND: This study aimed to assess the safety and tolerability of the immune checkpoint inhibitor nivolumab, as monotherapy or combined with chemotherapy, in Japanese patients with biliary tract cancer. METHODS: This multicentre, open-label, phase 1 trial was done at four cancer centres in Japan. Eligible patients were aged 20-79 years, had biliary tract adenocarcinoma (intrahepatic bile duct cancer, extrahepatic bile duct cancer, gallbladder cancer, or ampullary cancer), Eastern Cooperative Oncology Group performance status 0 or 1, adequate hepatic, renal, and haematological function, and tumour tissue samples for PD-L1 expression analysis. Patients with unresectable or recurrent biliary tract cancer that was refractory or intolerant to gemcitabine-based treatment regimens received nivolumab monotherapy (240 mg every 2 weeks [monotherapy cohort]). Chemotherapy-naive patients with unresectable or recurrent biliary tract cancer received nivolumab (240 mg every 2 weeks) and cisplatin (25 mg/m2) plus gemcitabine (1000 mg/m2) chemotherapy (combined therapy cohort). The primary objective was to assess tolerability and safety. The primary objective was assessed in the safety population of all patients who had received at least one dose of nivolumab. This study is registered with www.clinicaltrials.jp, number JapicCTI-153098, and follow-up is ongoing. FINDINGS: 30 patients were enrolled into each cohort between Jan 13, 2016, and April 19, 2017. Data cutoff was Aug 31, 2017. In the monotherapy cohort, the most frequently reported treatment-related adverse events were decreased appetite (five [17%]), malaise (four [13%]), and pruritus (four [13%]). Grade 3-4 treatment-related adverse events were reported by three (10%) patients (rash, maculopapular rash, and amylase increase) and treatment-related serious adverse events were reported by one (3%) patient (pleurisy). In the combined therapy cohort, the most frequently reported treatment-related adverse events were neutrophil count decrease (any grade 25 [83%]; grade 3-4 in 23 [77%] patients) and platelet count decrease (any grade 25 [83%] of 30; grade 3-4 in 15 [50%] patients). Six (20%) patients reported 11 treatment-related serious adverse events (platelet count decrease [three patients], febrile neutropenia [two patients], neutrophil count decrease, anaemia, anaphylactic reaction, decreased appetite, pyrexia, and myocarditis [one patient each]). In the monotherapy cohort, median overall survival was 5·2 months (90% CI 4·5-8·7), median progression-free survival was 1·4 months (90% CI 1·4-1·4), and one of 30 patients had an objective response. In the combined therapy cohort, median overall survival was 15·4 months (90% CI 11·8-not estimable), median progression-free survival was 4·2 months (90% CI 2·8-5·6), and 11 of 30 patients had an objective response. INTERPRETATION: Nivolumab had a manageable safety profile and signs of clinical activity in patients with unresectable or recurrent biliary tract cancer. This initial assessment of nivolumab for the treatment of advanced biliary tract cancer provides supportive evidence for future larger randomised studies of nivolumab in this difficult to treat cancer. FUNDING: Ono Pharmaceutical Co Ltd and Bristol-Myers Squibb Inc.</p>
<p>doi: <a href="https://doi.org/10.1016/S2468-1253(19)30086-X" class="uri">https://doi.org/10.1016/S2468-1253(19)30086-X</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Cholangiographic Tumor Classification for Simple Patient Selection Prior to Hepatopancreatoduodenectomy for Cholangiocarcinoma</strong> </summary></p>
<p><em>Annals of surgical oncology 2019 Sep;26(9):2971-2979</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31102092" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31102092</a></p>
<p>BACKGROUND: Hepatopancreatoduodenectomy (HPD) is employed for patients with laterally advanced cholangiocarcinoma. However, the survival benefit of this extended approach remains controversial. The aim of this study is to identify a tumor feature benefiting from HPD from the standpoint of long-term survival. PATIENTS AND METHODS: Patients with cholangiocarcinoma who underwent HPD with curative intent between 2001 and 2017 were retrospectively analyzed. Tumors were radiologically classified by preoperative cholangiogram. Diffuse type was defined as significant tumor/stricture located from the hilar to intrapancreatic duct; localized type was defined as tumor otherwise. Univariable and multivariable analyses were performed to identify prognostic indicators. RESULTS: Of 100 study patients, 28 (28%) patients had diffuse tumor type, while the remaining 72 (72%) patients had localized tumors. The former group showed significantly longer lateral length (43 versus 22 mm, P &lt; 0.001) and more frequent pancreatic invasion (50% versus 32%, P = 0.110), advanced T classification (64% versus 49%, P = 0.185), and nodal metastasis (57% versus 47%, P = 0.504), compared with the latter group. The survival for patients with diffuse tumor type was significantly worse than that for patients with localized tumor type, with 5-year survival rates of 59.0% versus 26.3%, respectively (P = 0.003). Multivariable analysis identified four independent factors deteriorating long-term survival: cholangiographic diffuse tumor (P = 0.021), higher age (P = 0.020), percutaneous biliary drainage (P = 0.007), and portal vein resection (P = 0.007). CONCLUSIONS: Presurgical cholangiographic classification, diffuse or localized type, is a tumor-related factor closely associated with survival probability; therefore, it may be a useful feature for patient selection prior to HPD for cholangiocarcinoma.</p>
<p>doi: <a href="https://doi.org/10.1245/s10434-019-07457-x" class="uri">https://doi.org/10.1245/s10434-019-07457-x</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Understanding the mechanisms of reversal of type 2 diabetes</strong> </summary></p>
<p><em>The lancet. Diabetes &amp; endocrinology 2019 Sep;7(9):726-736</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31097391" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31097391</a></p>
<p>Clinical and pathophysiological studies have shown type 2 diabetes to be a condition mainly caused by excess, yet reversible, fat accumulation in the liver and pancreas. Within the liver, excess fat worsens hepatic responsiveness to insulin, leading to increased glucose production. Within the pancreas, the β cell seems to enter a survival mode and fails to function because of the fat-induced metabolic stress. Removal of excess fat from these organs via substantial weight loss can normalise hepatic insulin responsiveness and, in the early years post-diagnosis, is associated with β-cell recovery of acute insulin secretion in many individuals, possibly by redifferentiation. Collectively, these changes can normalise blood glucose levels. Importantly, the primary care-based Diabetes Remission Clinical Trial (DiRECT) showed that 46% of people with type 2 diabetes could achieve remission at 12 months, and 36% at 24 months, mediated by weight loss. This major change in our understanding of the underlying mechanisms of disease permits a reassessment of advice for people with type 2 diabetes.</p>
<p>doi: <a href="https://doi.org/10.1016/S2213-8587(19)30076-2" class="uri">https://doi.org/10.1016/S2213-8587(19)30076-2</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Rapid research autopsy is a stealthy but growing contributor to cancer research</strong> </summary></p>
<p><em>Cancer 2019 Sep;125(17):2915-2919</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31090935" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31090935</a></p>
<p>doi: <a href="https://doi.org/10.1002/cncr.32184" class="uri">https://doi.org/10.1002/cncr.32184</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Biomarkers to diagnose metastatic breast carcinoma to the pancreas: A case report and update</strong> </summary></p>
<p><em>Diagnostic cytopathology 2019 Sep;47(9):912-917</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31087784" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31087784</a></p>
<p>The patient is a 72-year-old female who presents with new onset jaundice. The patient has a past medical history significant for right-sided estrogen receptor (ER)-positive and left-sided ER-negative breast cancers in 2005 and 2009, respectively, and recent 1-year history of ER-positive right-sided breast cancer with bone and brain metastases. CT scan and endoscopic ultrasound (EUS) revealed a new 2 cm mass in the head of the pancreas, leading to EUS-guided fine-needle aspiration of the lesion. Pathologic workup revealed adenocarcinoma with signet-ring cells, representing either metastatic breast or primary pancreatic cancer. Immunohistochemistry and molecular diagnostic workup identified positive GATA-binding protein 3 (GATA3) immunoreactivity and a mutation in Erb-B2 receptor tyrosine kinase 2 (ERBB2), also known as human epidermal growth factor receptor 2 (HER2). Here, we review the diagnostic markers commonly used to differentiate metastatic breast vs primary pancreatic adenocarcinoma, and discuss the challenges of utilizing GATA3 immunoreactivity and ERBB2 mutations for diagnosis.</p>
<p>doi: <a href="https://doi.org/10.1002/dc.24210" class="uri">https://doi.org/10.1002/dc.24210</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Pancreatic panniculitis in active systemic lupus erythematosus</strong> </summary></p>
<p><em>Journal of cutaneous pathology 2019 Sep;46(9):688-690</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31081550" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31081550</a></p>
<p>This report documents the case of a 64-year-old African-American female with new end-stage renal disease (ESRD), diagnosed with systemic lupus erythematosus (SLE) on renal biopsy and serologies including a positive ANA (&gt;1:2560), positive anti-Sm antibodies, low titer anti-RNP antibodies, high titer anti-Ro antibodies, anti-dsDNA antibodies, lupus anticoagulant, and hypocomplementemia. She was also noted to have tender nodules on the bilateral shins. Excisional biopsy of one of the nodules showed marked fat necrosis with “ghost cells” and patchy basophilic granular debris consistent with pancreatic panniculitis. Further examination for pancreatic pathology showed an elevated lipase of 585 U/L (reference range 8-78 U/L) and amylase of 214 U/L (reference range 25-125 U/L). However, computed tomography imaging showed no evidence of pancreatitis or pancreatic tumors. This is very similar to another case recently reported in the literature. Similarities of these two cases (African-American females with lupus nephritis on dialysis) may represent a particular subset of SLE patients at increased risk for pancreatic panniculitis.</p>
<p>doi: <a href="https://doi.org/10.1111/cup.13493" class="uri">https://doi.org/10.1111/cup.13493</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Regulation of pH by Carbonic Anhydrase 9 Mediates Survival of Pancreatic Cancer Cells With Activated KRAS in Response to Hypoxia</strong> </summary></p>
<p><em>Gastroenterology 2019 09;157(3):823-837</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31078621" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31078621</a></p>
<p>BACKGROUND &amp; AIMS: Most pancreatic ductal adenocarcinomas (PDACs) express an activated form of KRAS, become hypoxic and dysplastic, and are refractory to chemo and radiation therapies. To survive in the hypoxic environment, PDAC cells upregulate enzymes and transporters involved in pH regulation, including the extracellular facing carbonic anhydrase 9 (CA9). We evaluated the effect of blocking CA9, in combination with administration of gemcitabine, in mouse models of pancreatic cancer. METHODS: We knocked down expression of KRAS in human (PK-8 and PK-1) PDAC cells with small hairpin RNAs. Human and mouse (KrasG12D/Pdx1-Cre/Tp53/RosaYFP) PDAC cells were incubated with inhibitors of MEK (trametinib) or extracellular signal-regulated kinase (ERK), and some cells were cultured under hypoxic conditions. We measured levels and stability of the hypoxia-inducible factor 1 subunit alpha (HIF1A), endothelial PAS domain 1 protein (EPAS1, also called HIF2A), CA9, solute carrier family 16 member 4 (SLC16A4, also called MCT4), and SLC2A1 (also called GLUT1) by immunoblot analyses. We analyzed intracellular pH (pHi) and extracellular metabolic flux. We knocked down expression of CA9 in PDAC cells, or inhibited CA9 with SLC-0111, incubated them with gemcitabine, and assessed pHi, metabolic flux, and cytotoxicity under normoxic and hypoxic conditions. Cells were also injected into either immune-compromised or immune-competent mice and growth of xenograft tumors was assessed. Tumor fragments derived from patients with PDAC were surgically ligated to the pancreas of mice and the growth of tumors was assessed. We performed tissue microarray analyses of 205 human PDAC samples to measure levels of CA9 and associated expression of genes that regulate hypoxia with outcomes of patients using the Cancer Genome Atlas database. RESULTS: Under hypoxic conditions, PDAC cells had increased levels of HIF1A and HIF2A, upregulated expression of CA9, and activated glycolysis. Knockdown of KRAS in PDAC cells, or incubation with trametinib, reduced the posttranscriptional stabilization of HIF1A and HIF2A, upregulation of CA9, pHi, and glycolysis in response to hypoxia. CA9 was expressed by 66% of PDAC samples analyzed; high expression of genes associated with metabolic adaptation to hypoxia, including CA9, correlated with significantly reduced survival times of patients. Knockdown or pharmacologic inhibition of CA9 in PDAC cells significantly reduced pHi in cells under hypoxic conditions, decreased gemcitabine-induced glycolysis, and increased their sensitivity to gemcitabine. PDAC cells with knockdown of CA9 formed smaller xenograft tumors in mice, and injection of gemcitabine inhibited tumor growth and significantly increased survival times of mice. In mice with xenograft tumors grown from human PDAC cells, oral administration of SLC-0111 and injection of gemcitabine increased intratumor acidosis and increased cell death. These tumors, and tumors grown from PDAC patient-derived tumor fragments, grew more slowly than xenograft tumors in mice given control agents, resulting in longer survival times. In KrasG12D/Pdx1-Cre/Tp53/RosaYFP genetically modified mice, oral administration of SLC-0111 and injection of gemcitabine reduced numbers of B cells in tumors. CONCLUSIONS: In response to hypoxia, PDAC cells that express activated KRAS increase expression of CA9, via stabilization of HIF1A and HIF2A, to regulate pH and glycolysis. Disruption of this pathway slows growth of PDAC xenograft tumors in mice and might be developed for treatment of pancreatic cancer.</p>
<p>doi: <a href="https://doi.org/10.1053/j.gastro.2019.05.004" class="uri">https://doi.org/10.1053/j.gastro.2019.05.004</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Fist-Sized Radiographic Consolidation in a Man With Difficulty Swallowing</strong> </summary></p>
<p><em>Gastroenterology 2019 10;157(4):e6-e7</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31078620" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31078620</a></p>
<p>doi: <a href="https://doi.org/10.1053/j.gastro.2019.05.006" class="uri">https://doi.org/10.1053/j.gastro.2019.05.006</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Multiple KRAS mutations in the non-mucinous epithelial lining in the majority of mucinous cystic neoplasms of the pancreas</strong> </summary></p>
<p><em>Histopathology 2019 Oct;75(4):559-567</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31077597" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31077597</a></p>
<p>AIMS: Mucinous cystic neoplasms (MCNs) of the pancreas are cystic neoplasms lined by mucinous lining epithelium (MLE) with associated ovarian-type stroma. Although a non-MLE (NMLE) can be observed in some MCNs, whether cystic neoplasms with ovarian-type stroma and NMLE should be classified as MCNs or separately designated is debated. METHODS AND RESULTS: To test this, NMLEs were defined as flat or cuboidal epithelial cells without intracytoplasmic mucin. A total of 112 MCNs were reviewed, and the epithelium was classified as NMLE or MLE. A total of 110 females and two males with a mean age of 46.5 ± 12.3 years were included in this study. At least focal NMLE was noted in 76.8% (86/112) of MCNs. The mean percentage of the neoplastic epithelium that was NMLE in these 86 cases was 46%. NMLE was predominant (&gt;50%) in 38.4% (43/112) of cases. MCNs with NMLE were smaller (42 ± 21 mm) than those with MLE (60 ± 36 mm, P &lt; 0.001), and all NMLEs had low-grade dysplasia. Twelve MCNs with NMLE or MLE were selected for KRAS mutation analysis with droplet digital polymerase chain reaction after laser capture microdissection. All 12 MCNs showed multiple types of KRAS mutation, which were detected in 92% (11/12) of NMLE foci and 89% (8/9) of MLE foci. Predominant NMLE was common in small MCNs with low-grade dysplasia. CONCLUSIONS: Clonal KRAS mutations were observed in both NMLE and MLE, supporting the hypothesis that MCNs with NMLE should be classified as MCNs.</p>
<p>doi: <a href="https://doi.org/10.1111/his.13897" class="uri">https://doi.org/10.1111/his.13897</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>In Patients with Localized and Resectable Gastric Cancer, What is the Optimal Extent of Lymph Node Dissection-D1 Versus D2 Versus D3?</strong> </summary></p>
<p><em>Annals of surgical oncology 2019 Sep;26(9):2912-2932</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31076930" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31076930</a></p>
<p>BACKGROUND: Despite advances in the treatment of patients with gastric cancer, the debate over the optimal extent of lymphadenectomy continues. METHOD: A review of the classification, rationale for, and boundaries of lymphadenectomy is presented. A review of the available literature comparing D1 versus D2 versus D3 lymphadenectomy was performed and included randomized controlled trials, and prospective and retrospective comparative and non-comparative studies. RESULTS: Earlier studies demonstrated increased morbidity with D2 compared with D1 lymphadenectomy, with no significant survival benefit. More recent studies have demonstrated survival benefit of a pancreas and spleen-sparing D2 lymphadenectomy in patients with advanced, node-positive tumors. Para-aortic/D3 dissections contribute to increased morbidity, with no survival benefit. CONCLUSIONS: In patients with resectable gastric adenocarcinoma, a D2 lymph node dissection preserving the pancreas and spleen should be considered standard for optimal staging and treatment, provided it is performed by surgeons with sufficient expertise. Extended lymph node dissections beyond D2 should not be routinely performed as it has been shown to have increased morbidity, with no improvement in outcomes. While systemic chemotherapy should be considered standard in patients undergoing D2 lymphadenectomy, the role of adjuvant radiation continues to evolve.</p>
<p>doi: <a href="https://doi.org/10.1245/s10434-019-07417-5" class="uri">https://doi.org/10.1245/s10434-019-07417-5</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>NRG1 Gene Fusions Are Recurrent, Clinically Actionable Gene Rearrangements in KRAS Wild-Type Pancreatic Ductal Adenocarcinoma</strong> </summary></p>
<p><em>Clinical cancer research : an official journal of the American Association for Cancer Research 2019 Aug;25(15):4674-4681</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31068372" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31068372</a></p>
<p>PURPOSE: Gene fusions involving neuregulin 1 (NRG1) have been noted in multiple cancer types and have potential therapeutic implications. Although varying results have been reported in other cancer types, the efficacy of the HER-family kinase inhibitor afatinib in the treatment of NRG1 fusion-positive pancreatic ductal adenocarcinoma is not fully understood. EXPERIMENTAL DESIGN: Forty-seven patients with pancreatic ductal adenocarcinoma received comprehensive whole-genome and transcriptome sequencing and analysis. Two patients with gene fusions involving NRG1 received afatinib treatment, with response measured by pretreatment and posttreatment PET/CT imaging. RESULTS: Three of 47 (6%) patients with advanced pancreatic ductal adenocarcinoma were identified as KRAS wild type by whole-genome sequencing. All KRAS wild-type tumors were positive for gene fusions involving the ERBB3 ligand NRG1. Two of 3 patients with NRG1 fusion-positive tumors were treated with afatinib and demonstrated a significant and rapid response while on therapy. CONCLUSIONS: This work adds to a growing body of evidence that NRG1 gene fusions are recurrent, therapeutically actionable genomic events in pancreatic cancers. Based on the clinical outcomes described here, patients with KRAS wild-type tumors harboring NRG1 gene fusions may benefit from treatment with afatinib.See related commentary by Aguirre, p. 4589.</p>
<p>doi: <a href="https://doi.org/10.1158/1078-0432.CCR-19-0191" class="uri">https://doi.org/10.1158/1078-0432.CCR-19-0191</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Contemporary Improvements in Postoperative Mortality After Major Cancer Surgery are Associated with Weakening of the Volume-Outcome Association</strong> </summary></p>
<p><em>Annals of surgical oncology 2019 Aug;26(8):2348-2356</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31065959" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31065959</a></p>
<p>BACKGROUND: Regionalization of complex visceral surgery across the United States has followed identification of a volume-outcome association. However, improvements in postoperative mortality overall during the last decade may have weakened the strength of this association. METHODS: The National Cancer Database was used to identify patients undergoing colon, esophageal, liver, and pancreatic surgery from 2003 to 2011. Hospitals were divided into low-volume (&lt; 33rd %tile), medium-volume (34-66th %tile), and high-volume (&gt; 67th %tile) groups. Annual cancer-specific adjusted observed versus expected (O/E) ratios for 30- and 90-day mortality for each volume strata were calculated and plotted over time. RESULTS: In the year 2003, the O/E ratios decreased from low- to medium- to high-volume hospitals for all cancer surgeries for both 30- and 90-day mortality, indicating a strong volume-outcome relationship. For all volume strata, the O/E ratios trended downward from 2003 to 2011 for both 30- and 90-day mortality for all cancer surgeries. This trend was more pronounced for low- and medium-volume than for high-volume hospitals. Consequently, by 2011 the confidence intervals of the O/E ratios for the low-volume groups, and particularly for the medium-volume groups, overlapped those for the high-volume groups for most of the cancer surgeries studied. CONCLUSIONS: The volume-outcome association for major cancer surgery is dynamic and has attenuated over time primarily due to improvements in postoperative mortality at low- and medium-volume hospitals.</p>
<p>doi: <a href="https://doi.org/10.1245/s10434-019-07413-9" class="uri">https://doi.org/10.1245/s10434-019-07413-9</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Mesothelin-Targeted Thorium-227 Conjugate (MSLN-TTC): Preclinical Evaluation of a New Targeted Alpha Therapy for Mesothelin-Positive Cancers</strong> </summary></p>
<p><em>Clinical cancer research : an official journal of the American Association for Cancer Research 2019 08;25(15):4723-4734</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31064781" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31064781</a></p>
<p>PURPOSE: Targeted thorium-227 conjugates (TTC) represent a new class of molecules for targeted alpha therapy (TAT). Covalent attachment of a 3,2-HOPO chelator to an antibody enables specific complexation and delivery of the alpha particle emitter thorium-227 to tumor cells. Because of the high energy and short penetration range, TAT efficiently induces double-strand DNA breaks (DSB) preferentially in the tumor cell with limited damage to the surrounding tissue. We present herein the preclinical evaluation of a mesothelin (MSLN)-targeted thorium-227 conjugate, BAY 2287411. MSLN is a GPI-anchored membrane glycoprotein overexpressed in mesothelioma, ovarian, pancreatic, lung, and breast cancers with limited expression in healthy tissue. EXPERIMENTAL DESIGN: The binding activity and radiostability of BAY 2287411 were confirmed bioanalytically. The mode-of-action and antitumor potency of BAY 2287411 were investigated in vitro and in vivo in cell line and patient-derived xenograft models of breast, colorectal, lung, ovarian, and pancreatic cancer. RESULTS: BAY 2287411 induced DSBs, apoptotic markers, and oxidative stress, leading to reduced cellular viability. Furthermore, upregulation of immunogenic cell death markers was observed. BAY 2287411 was well-tolerated and demonstrated significant antitumor efficacy when administered via single or multiple dosing regimens in vivo. In addition, significant survival benefit was observed in a disseminated lung cancer model. Biodistribution studies showed specific uptake and retention of BAY 2287411 in tumors and enabled the development of a mechanistic pharmacokinetic/pharmacodynamic model to describe the preclinical data. CONCLUSIONS: These promising preclinical results supported the transition of BAY 2287411 into a clinical phase I program in mesothelioma and ovarian cancer patients (NCT03507452).</p>
<p>doi: <a href="https://doi.org/10.1158/1078-0432.CCR-18-3476" class="uri">https://doi.org/10.1158/1078-0432.CCR-18-3476</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Gastroparesis Mimicry: Thinking Beyond the Pylorus</strong> </summary></p>
<p><em>Gastroenterology 2019 09;157(3):610-611</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31063781" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31063781</a></p>
<p>doi: <a href="https://doi.org/10.1053/j.gastro.2019.04.045" class="uri">https://doi.org/10.1053/j.gastro.2019.04.045</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Loss of SMAD4 protein expression in gastrointestinal and extra-gastrointestinal carcinomas</strong> </summary></p>
<p><em>Histopathology 2019 Oct;75(4):546-551</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31054158" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31054158</a></p>
<p>AIMS: SMAD4 (DPC4) is a tumour suppressor gene that is dysregulated in various tumour types, particularly pancreaticobiliary and gastrointestinal carcinomas. Corresponding loss of protein expression has been reported in approximately 50% of pancreatic and 25% of colonic adenocarcinomas. In the evaluation of carcinoma of unknown primary site, immunohistochemical loss of SMAD4 expression is often used to suggest pancreaticobiliary origin, but there are limited data on the spectrum of SMAD4 expression in carcinomas of other sites. This study evaluates the frequency of SMAD4 loss in a large cohort of carcinomas from diverse anatomical sites. METHODS AND RESULTS: Immunohistochemistry for SMAD4 was performed on tissue microarrays or whole tissue sections of 1210 carcinomas from various organs: gastrointestinal tract, liver, pancreas/biliary tract, lung, breast, thyroid, kidney, ovary and uterus. Expression was considered lost when there was complete absence of staining in tumour cell nuclei, in the presence of intact staining in non-neoplastic cells. SMAD4 loss was seen in 58% of pancreatic adenocarcinomas, 27% of appendiceal adenocarcinomas, 19% of colorectal adenocarcinomas, 16% of cholangiocarcinomas, 10% of lung adenocarcinomas and &lt;5% of oesophageal, breast, gastric and mucinous ovarian adenocarcinomas. All papillary thyroid, hepatocellular, non-mucinous ovarian, endometrial and renal cell carcinomas showed intact SMAD4 nuclear expression. CONCLUSION: In addition to pancreaticobiliary, appendiceal and colonic tumours, SMAD4 loss is also seen in a small subset of other carcinomas, specifically breast, lung, oesophageal and gastric adenocarcinomas, all of which are typically CK7-positive, similar to pancreaticobiliary carcinoma. Awareness of SMAD4 loss in these other carcinoma types is helpful in the evaluation of carcinomas of unknown or uncertain primary site.</p>
<p>doi: <a href="https://doi.org/10.1111/his.13894" class="uri">https://doi.org/10.1111/his.13894</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Advanced stage at diagnosis and elevated mortality among US patients with cancer infected with HIV in the National Cancer Data Base</strong> </summary></p>
<p><em>Cancer 2019 Aug;125(16):2868-2876</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31050361" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31050361</a></p>
<p>BACKGROUND: People living with HIV (PLWH) are at an increased risk of developing several cancers, but to the authors’ knowledge less is known regarding how HIV impacts the rate of progression to advanced cancer or death. METHODS: The authors compared stage of disease at the time of presentation and mortality after diagnosis between 14,453 PLWH and 6,368,126 HIV-uninfected patients diagnosed with cancers of the oral cavity, stomach, colorectum, anus, liver, pancreas, lung, female breast, cervix, prostate, bladder, kidney, and thyroid and melanoma using data from the National Cancer Data Base (2004-2014). Polytomous logistic regression and Cox proportional hazards regression were used to evaluate the association between HIV, cancer stage, and stage-adjusted mortality after diagnosis, respectively. Regression models accounted for the type of health facility at which cancer treatment was administered and the type of individual health insurance. RESULTS: HIV-infected patients with cancer were found to be more likely to be uninsured (HIV-infected: 5.0% vs HIV-uninfected: 3.3%; P &lt; .0001) and were less likely to have private health insurance (25.4% vs 44.7%; P &lt; .0001). Compared with those not infected with HIV, the odds of being diagnosed at an advanced stage of disease were significantly elevated in PLWH for melanoma and cancers of the oral cavity, liver, female breast, prostate, and thyroid (odds ratio for stage IV vs stage I range, 1.24-2.06). PLWH who were diagnosed with stage I to stage III disease experienced elevated mortality after diagnosis across 13 of the 14 cancer sites evaluated, with hazard ratios ranging from 1.20 (95% CI, 1.14-1.26) for lung cancer to 1.85 (95% CI, 1.68-2.04), 1.85 (95% CI, 1.51-2.27), and 2.93 (95% CI, 2.08-4.13), respectively, for cancers of the female breast, cervix, and thyroid. CONCLUSIONS: PLWH were more likely to be diagnosed with advanced-stage cancers and to experience elevated mortality after a cancer diagnosis, even after accounting for health care-related factors.</p>
<p>doi: <a href="https://doi.org/10.1002/cncr.32158" class="uri">https://doi.org/10.1002/cncr.32158</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>The role of rapid on-site evaluation on diagnostic accuracy of endoscopic ultrasound fine needle aspiration for pancreatic, submucosal upper gastrointestinal tract and adjacent lesions</strong> </summary></p>
<p><em>Cytopathology : official journal of the British Society for Clinical Cytology 2019 09;30(5):499-503</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31034112" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31034112</a></p>
<p>BACKGROUND AND AIM: Our aim was to assess adequacy and diagnostic accuracy of endoscopic ultrasound-fine needle aspiration (EUS-FNA) specimens with or without rapid on-site evaluation (ROSE) from pancreatic, upper gastrointestinal tract (UGIT) and adjacent masses. METHOD: A retrospective cohort study based on patients’ files who underwent EUS-FNA in Galilee Medical Center in a 4 years period. Number of needle passes, repeated EUS and ROSE effect on tissue adequacy and diagnostic accuracy were reported. RESULTS: One-hundred sixty-one patients were included. Ninety-three patients (57.7%) underwent EUS-FNA without ROSE (group A) compared to 68 patients (42.3%) with ROSE (group B). The most common location was in the pancreas (55% in group A vs 81% in group B). Addition of ROSE yielded a significantly higher specimen adequacy (65% in group A vs 92.6% in group B (Chi-Square &lt; 0.0001, OR 6.72, 95% CI 2.45-18.38). The matching rate (accuracy) between ROSE diagnosis and final histopathological diagnosis was noticed in 61 out of 68 patients (89.7%, 95% CI 0.7993-0.9576). The Kappa coefficient correlations of matching rate between ROSE and final histopathological diagnosis of all lesion and in pancreatic lesions were 0.7558, (95% CI 0.625-0.887) and 0.7814, (95% CI 0.639-0.924), respectively. CONCLUSIONS: EUS-FNA with ROSE significantly improve specimen adequacy and was associated with high diagnostic accuracy.</p>
<p>doi: <a href="https://doi.org/10.1111/cyt.12712" class="uri">https://doi.org/10.1111/cyt.12712</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Acute Methamphetamine-Induced Hepatic and Pancreatic Ischemia</strong> </summary></p>
<p><em>The American journal of forensic medicine and pathology 2019 Sep;40(3):285-288</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31033491" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31033491</a></p>
<p>Methamphetamine is a central nervous system stimulant that induces arousal, a positive mood, cardiac stimulation, and an acute improvement in cognitive domains. Its illicit exploitation is rapidly growing in North America. Typically, extended use of the drug induces organ damage via vasoconstriction and subsequent ischemia. This case specifically discusses hepatic and pancreatic pathology resulting from methamphetamine overdose alongside an unusual discovery of globally necrotic von Meyenburg complexes.</p>
<p>doi: <a href="https://doi.org/10.1097/PAF.0000000000000486" class="uri">https://doi.org/10.1097/PAF.0000000000000486</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>GNAS but Not Extended RAS Mutations Spectrum are Associated with a Better Prognosis in Intraductal Pancreatic Mucinous Neoplasms</strong> </summary></p>
<p><em>Annals of surgical oncology 2019 Aug;26(8):2640-2650</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31025231" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31025231</a></p>
<p>BACKGROUND: The management of intraductal papillary mucinous neoplasms (IPMNs) is mainly based on imaging features and clinical symptoms, and remains challenging. OBJECTIVE: The aim of this study was to assess GNAS, RAS family (KRAS, NRAS and HRAS), BRAF, and PIK3CA mutation status in resected IPMNs and correlate it with clinicopathological characteristics and patient survival. METHODS: Overall, 149 consecutive unselected patients who underwent pancreatectomy for IPMNs were included. After dissection from formalin-fixed and paraffin-embedded tumors, GNAS mutational screening was assessed by allelic discrimination using Taqman® probes and confirmed by SNaPshot analysis. RAS family, BRAF, and PIK3CA mutational screening was assessed by high resolution melt and Sanger sequencing. RESULTS: Gastric- and intestinal-type IPMNs were the most frequent lesions (52% and 41%, respectively). Intestinal-type IPMNs were more frequently associated high-grade dysplasia (49%) and were the only IPMNs associated with colloid-type carcinoma. All pancreatobiliary IPMNs were invasive lesions, located in the main pancreatic duct. GNAS-activating mutations were strongly associated with the intestinal phenotype (p &lt; 10-4), while RAS pathway mutations were not associated with any particular phenotype. Mutations within other members of the epidermal growth factor receptor (EGFR) pathway were very rare (2%). GNAS-mutated IPMNs were rarely invasive (11%) and almost exclusively (83%) of the colloid type. For invasive lesions, multivariate analyses determined that only node negativity was associated with improved cancer-specific survival, but, in univariate analysis, GNAS mutation was associated with prolonged survival. CONCLUSION: In patients selected for surgery, GNAS mutation analysis and tumor phenotype can help to better predict patient prognosis. In the near future, a more precise mutational analysis of IPMNs might help to better tailor their management.</p>
<p>doi: <a href="https://doi.org/10.1245/s10434-019-07389-6" class="uri">https://doi.org/10.1245/s10434-019-07389-6</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>The Pancreas as a Site of Metastasis or Second Primary in Patients with Small Bowel Neuroendocrine Tumors</strong> </summary></p>
<p><em>Annals of surgical oncology 2019 Aug;26(8):2525-2532</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31011904" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31011904</a></p>
<p>BACKGROUND: The small bowel and pancreas are the most common primary sites of neuroendocrine tumors (NETs) giving rise to metastatic disease. Some patients with small bowel NETs (SBNETs) present with synchronous or metachronous pancreatic NETs (PNETs), and it is unclear whether these are separate primaries or metastases from one site to the other. METHODS: A surgical NET database including patients undergoing operations for SBNETs or PNETs was reviewed. Patients with synchronous or metachronous tumors in both the small bowel and pancreas were identified, and available tissues from primary tumors and metastases were examined using a 4-gene quantitative polymerase chain reaction (qPCR) and immunohistochemistry (IHC) panel developed for evaluating NETs of unknown primary. RESULTS: Of 338 patients undergoing exploration, 11 had NETs in both the small bowel and pancreas. Tissues from 11 small bowel tumors, 9 pancreatic tumors, and 10 metastases were analyzed. qPCR and IHC data revealed that three patients had separate SBNET and PNET primaries, and five patients had SBNETs that metastasized to the pancreas. Pancreatic tissue was unavailable in two patients, and qPCR and IHC gave discrepant results in one patient. CONCLUSIONS: NETs in both the small bowel and pancreas were found in 3% of our patients. In nearly two-thirds of evaluable patients, the pancreatic tumor was a metastasis from the SBNET primary, while in the remaining one-third of patients it represented a separate primary. Determining the origin of these tumors can help guide the choice of systemic therapy and surgical management.</p>
<p>doi: <a href="https://doi.org/10.1245/s10434-019-07370-3" class="uri">https://doi.org/10.1245/s10434-019-07370-3</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Metastatic low-grade endometrial stromal sarcoma of uterus presenting as a primary pancreatic tumor: case presentation and literature review</strong> </summary></p>
<p><em>Diagnostic pathology 2019 Apr;14(1):30</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31010432" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31010432</a></p>
<p>BACKGROUND: Metastatic tumors to the pancreas are uncommon, accounting for approximately 2% of pancreatic malignancies. The most common primary tumors to give rise to pancreatic metastases are carcinomas. CASE PRESENTATION: A 50-year old female patient was investigated for a cause of abdominal discomfort. She had a 2-year history of menorrhagia and dysmenorrhea which was ascribed to a fibroid uterus. On imaging, she was found to have a large solid and cystic mass in the tail of the pancreas. Imaging also confirmed a fibroid uterus. A distal pancreatectomy and splenectomy showed a 9 cm circumscribed mass within, and grossly confined to, the parenchyma of the pancreatic tail. Microscopically, the pancreatic lesion was lobulated, and well-circumscribed, but focally infiltrative. It comprised sheets of uniform spindled to epithelioid cells with round to oval nuclei, coarse to vesicular chromatin, visible nucleoli, nuclear grooves and clear to eosinophilic cytoplasm. Prominent arterioles were identified. The stroma was collagenized in areas. Occasional hemosiderin-laden macrophages were seen, and focal cystic change was present. There was no evidence of nuclear pleomorphism, mitotic activity or necrosis, and there was no evidence of endometriosis despite multiple sections being taken. Immunohistochemistry showed that the tumor cells were positive for CD10, estrogen receptor (ER), progesterone receptor (PR), Wilms tumor-1 (WT-1) and smooth muscle actin (SMA). RNA sequencing detected a PHF1 rearrangement. The morphological, immunohistochemical and molecular features were of a low-grade endometrial stromal sarcoma (LG-ESS). Subsequent total hysterectomy and bilateral salpingo-oophorectomy 3 months later, showed uterine fibroids and a 5 cm low-grade endometrial stromal sarcoma confined to the uterus, with lymphatic invasion. CONCLUSIONS: To the best of our knowledge, this is the first documented case of metastatic endometrial stromal sarcoma of uterus presenting as a primary pancreatic neoplasm. An unexpected extra-uterine location and unusual presentation of ESS may make the diagnosis challenging, despite classic histological features. Morphological, immunohistochemical and molecular findings must be combined to render the correct diagnosis.</p>
<p>doi: <a href="https://doi.org/10.1186/s13000-019-0807-3" class="uri">https://doi.org/10.1186/s13000-019-0807-3</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>ASO Author Reflections: Tending Towards a Personalized Medicine for Colorectal Carcinomatosis by Adding the RAS Mutation Status in the Workup for CRS and HIPEC</strong> </summary></p>
<p><em>Annals of surgical oncology 2019 Aug;26(8):2605-2606</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31004296" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31004296</a></p>
<p>doi: <a href="https://doi.org/10.1245/s10434-019-07362-3" class="uri">https://doi.org/10.1245/s10434-019-07362-3</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Defining the Role of Lymphadenectomy for Pancreatic Neuroendocrine Tumors: An Eight-Institution Study of 695 Patients from the US Neuroendocrine Tumor Study Group</strong> </summary></p>
<p><em>Annals of surgical oncology 2019 Aug;26(8):2517-2524</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31004295" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31004295</a></p>
<p>BACKGROUND: Preoperative factors that reliably predict lymph node (LN) metastases in pancreatic neuroendocrine tumors (PanNETs) are unclear. The number of LNs needed to accurately stage PanNETs has not been defined. METHODS: Patients who underwent curative-intent resection of non-functional PanNETs at eight institutions from 2000 to 2016 were analyzed. Preoperative factors associated with LN metastases were identified. A procedure-specific target for LN retrieval to accurately stage patients was determined. RESULTS: Of 695 patients who underwent resection, 33% of tumors were proximal (head/uncinate) and 67% were distal (neck/body/tail). Twenty-six percent of patients (n = 158) had LN-positive disease, which was associated with a worse 5-year recurrence-free survival (RFS; 60% vs. 86%; p &lt; 0.001). The increasing number of positive LNs was not associated with worse RFS. Preoperative factors associated with positive LNs included tumor size ≥ 2 cm (odds ratio [OR] 6.6; p &lt; 0.001), proximal location (OR 2.5; p &lt; 0.001), moderate versus well-differentiation (OR 2.1; p = 0.006), and Ki-67 ≥ 3% (OR 3.1; p &lt; 0.001). LN metastases were also present in tumors without these risk factors: &lt; 2 cm (9%), distal location (19%), well-differentiated (23%), and Ki-67 &lt; 3% (16%). Median LN retrieval was 13 for pancreatoduodenectomy (PD), but only 9 for distal pancreatectomy (DP). Given that PD routinely includes a complete regional lymphadenectomy, a minimum number of LNs to accurately stage patients was not identified. However, for DP, removal of less than seven LNs failed to discriminate 5-year RFS between LN-positive and LN-negative patients (less than seven LNs: 72% vs. 83%, p = 0.198; seven or more LNs: 67% vs. 86%; p = 0.002). CONCLUSIONS: Tumor size ≥ 2 cm, proximal location, moderate differentiation, and Ki-67 ≥ 3% are preoperative factors that predict LN positivity in resected non-functional PanNETs. Given the 9-23% incidence of LN metastases in patients without such risk factors, routine regional lymphadenectomy should be considered. PD inherently includes sufficient LN retrieval, while DP should aim to remove seven or more LNs for accurate staging.</p>
<p>doi: <a href="https://doi.org/10.1245/s10434-019-07367-y" class="uri">https://doi.org/10.1245/s10434-019-07367-y</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Detection of NRG1 Gene Fusions in Solid Tumors</strong> </summary></p>
<p><em>Clinical cancer research : an official journal of the American Association for Cancer Research 2019 Aug;25(16):4966-4972</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=30988082" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=30988082</a></p>
<p>PURPOSE: NRG1 gene fusions are rare but potentially actionable oncogenic drivers that are present in some solid tumors. Details regarding the incidence of these gene rearrangements are lacking. Here, we assessed the incidence of NRG1 fusions across multiple tumor types and described fusion partners. EXPERIMENTAL DESIGN: Tumor specimens submitted for molecular profiling at a Clinical Laboratory Improvement Amendments (CLIA)-certified genomics laboratory and that underwent fusion testing by anchored multiplex PCR for targeted RNA sequencing were retrospectively identified. The overall and tumor-specific incidence was noted, as was the specific fusion partner. RESULTS: Out of 21,858 tumor specimens profiled from September 2015 to December 2018, 41 cases (0.2%) harbored an NRG1 fusion. Multiple fusion partners were identified. Fusion events were seen across tumor types. The greatest incidence was in non-small cell lung cancer (NSCLC, 25), though this represented only 0.3% of NSCLC cases tested. Other tumor types harboring an NRG1 fusion included gallbladder cancer, renal cell carcinoma, bladder cancer, ovarian cancer, pancreatic cancer, breast cancer, neuroendocrine tumor, sarcoma, and colorectal cancer. CONCLUSIONS: NRG1 fusions can be detected at a low incidence across multiple tumor types with significant heterogeneity in fusion partner.See related commentary by Dimou and Camidge, p. 4865.</p>
<p>doi: <a href="https://doi.org/10.1158/1078-0432.CCR-19-0160" class="uri">https://doi.org/10.1158/1078-0432.CCR-19-0160</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Tspan8 is expressed in breast cancer and regulates E-cadherin/catenin signalling and metastasis accompanied by increased circulating extracellular vesicles</strong> </summary></p>
<p><em>The Journal of pathology 2019 08;248(4):421-437</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=30982971" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=30982971</a></p>
<p>Tspan8 exhibits a functional role in many cancer types including pancreatic, colorectal, oesophagus carcinoma, and melanoma. We present a first study on the expression and function of Tspan8 in breast cancer. Tspan8 protein was present in the majority of human primary breast cancer lesions and metastases in the brain, bone, lung, and liver. In a syngeneic rat breast cancer model, Tspan8+ tumours formed multiple liver and spleen metastases, while Tspan8- tumours exhibited a significantly diminished ability to metastasise, indicating a role of Tspan8 in metastases. Addressing the underlying molecular mechanisms, we discovered that Tspan8 can mediate up-regulation of E-cadherin and down-regulation of Twist, p120-catenin, and β-catenin target genes accompanied by the change of cell phenotype, resembling the mesenchymal-epithelial transition. Furthermore, Tspan8+ cells exhibited enhanced cell-cell adhesion, diminished motility, and decreased sensitivity to irradiation. As a regulator of the content and function of extracellular vesicles (EVs), Tspan8 mediated a several-fold increase in EV number in cell culture and the circulation of tumour-bearing animals. We observed increased protein levels of E-cadherin and p120-catenin in these EVs; furthermore, Tspan8 and p120-catenin were co-immunoprecipitated, indicating that they may interact with each other. Altogether, our findings show the presence of Tspan8 in breast cancer primary lesion and metastases and indicate its role as a regulator of cell behaviour and EV release in breast cancer. © 2019 The Authors. The Journal of Pathology published by John Wiley &amp; Sons Ltd on behalf of Pathological Society of Great Britain and Ireland.</p>
<p>doi: <a href="https://doi.org/10.1002/path.5281" class="uri">https://doi.org/10.1002/path.5281</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Laparoscopic Complete Mesocolic Excision for Double Flexural Colon Cancers</strong> </summary></p>
<p><em>Annals of surgical oncology 2019 Aug;26(8):2516</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=30927197" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=30927197</a></p>
<p>BACKGROUND: Laparoscopic complete mesocolic excision (CME) for hepatic or splenic flexural colon cancer is considered technically demanding. The double (hepatic and splenic) flexural colon cancers are rare, and the laparoscopic CME procedure for such disease is not standardized. METHODS: This video presents laparoscopic CME for double (hepatic and splenic) flexural colon cancers using a medial and cranial approach. RESULTS: The patient was a 60-year-old woman with the diagnosis of splenic flexure cancer (cT4N1M0) and hepatic flexure cancer (cT3N0M0). Laparoscopic subtotal colectomy was performed. First, the left colic artery was divided at its origin, and the inferior mesenteric vein also was divided at the same level. The descending mesocolon was widely separated from the retroperitoneal tissues using a medial approach. Then, lymph node dissection along the surgical trunk was performed using a cranial approach. Finally, the transverse mesocolon was divided at the inferior border of the pancreas, and CME was achieved. The specimen was extracted through a small incision at the umbilicus, and side-to-side ileo-sigmoid anastomosis was performed extracorporeally. CONCLUSIONS: The approach presented in the video might be useful for standardization of laparoscopic CME for double flexural colon cancers.</p>
<p>doi: <a href="https://doi.org/10.1245/s10434-019-07329-4" class="uri">https://doi.org/10.1245/s10434-019-07329-4</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Response to Comment on “Letter to Editor Re Manuscript by Bannone et al.” Ann Surg. 2018 Dec 20</strong> </summary></p>
<p><em>Annals of surgery 2019 08;270(2):e60-e61</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=30870179" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=30870179</a></p>
<p>doi: <a href="https://doi.org/10.1097/SLA.0000000000003259" class="uri">https://doi.org/10.1097/SLA.0000000000003259</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Clear Cell Variant of Solid Pseudopapillary Neoplasm of the Pancreas: A Report of a Rare Variant and Review of the Literature</strong> </summary></p>
<p><em>International journal of surgical pathology 2019 Aug;27(5):535-540</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=30845855" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=30845855</a></p>
<p>The clear cell variant of solid pseudopapillary neoplasm (ccSPN) of the pancreas was first described in 2006. In this article, we report a case of this rare variant and review the few published reports. Both the current and previous reports show that ccSPN has several morphologic differences from conventional SPN, including clear vacuoles, fewer pseudopapillary formations, more solid/diffuse architecture, less hemorrhage, and fewer cholesterol clefts. Some of these features peculiar to ccSPN, such as solid/diffuse architecture, have been proposed to suggest aggressive behavior, though reports of ccSPN are rare and often have limited clinical follow-up. ccSPN also appears to occur more frequently in males than conventional SPNs. These clinical and pathologic features lead to unique set of differential diagnostic considerations for ccSPN, including metastatic renal cell carcinoma, perivascular epithelial cell tumor, and clear cell variants of other carcinomas. These unique features, atypical differential, and uncertain prognostic ramifications all make ccSPN an important variant to be aware of and report.</p>
<p>doi: <a href="https://doi.org/10.1177/1066896919833790" class="uri">https://doi.org/10.1177/1066896919833790</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Benchmarks in Pancreatic Surgery: A Novel Tool for Unbiased Outcome Comparisons</strong> </summary></p>
<p><em>Annals of surgery 2019 08;270(2):211-218</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=30829701" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=30829701</a></p>
<p>OBJECTIVE: To use the concept of benchmarking to establish robust and standardized outcome references after pancreatico-duodenectomy (PD). BACKGROUND: Best achievable results after PD are unknown. Consequently, outcome comparisons among different cohorts, centers or with novel surgical techniques remain speculative. METHODS: This multicenter study analyzes consecutive patients (2012-2015) undergoing PD in 23 international expert centers in pancreas surgery. Outcomes in patients without significant comorbidities and major vascular resection (benchmark cases) were analyzed to establish 20 outcome benchmarks for PD. These benchmarks were tested in a cohort with a poorer preoperative physical status (ASA class ≥3) and a cohort treated by minimally invasive approaches. RESULTS: Two thousand three hundred seventy-five (38%) low-risk cases out of a total of 6186 PDs were analyzed, disclosing low in-hospital mortality (≤1.6%) but high morbidity, with a 73% benchmark morbidity rate cumulated within 6 months following surgery. Benchmark cutoffs for pancreatic fistulas (B-C), severe complications (≥ grade 3), and failure-to-rescue rate were 19%, 30%, and 9%, respectively. The ASA ≥3 cohort showed comparable morbidity but a higher in hospital-mortality (3% vs 1.6%) and failure-to-rescue rate (16% vs 9%) than the benchmarks. The proportion of benchmark cases performed varied greatly across centers and continents for both open (9%-93%) and minimally invasive (11%-62%) PD. Centers operating mostly on complex PD cases disclosed better results than those with a majority of low-risk cases. CONCLUSION: The proposed outcome benchmarks for PD, established in a large-scale international patient cohort and tested in 2 different cohorts, may allow for meaningful comparisons between different patient cohorts, centers, countries, and surgical techniques.</p>
<p>doi: <a href="https://doi.org/10.1097/SLA.0000000000003223" class="uri">https://doi.org/10.1097/SLA.0000000000003223</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Updated Alternative Fistula Risk Score (ua-FRS) to Include Minimally Invasive Pancreatoduodenectomy: Pan-European Validation</strong> </summary></p>
<p><em>Annals of surgery 2019 Sep;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=30829699" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=30829699</a></p>
<p>OBJECTIVE: The aim of the study was to validate and optimize the alternative Fistula Risk Score (a-FRS) for patients undergoing minimally invasive pancreatoduodenectomy (MIPD) in a large pan-European cohort. BACKGROUND: MIPD may be associated with an increased risk of postoperative pancreatic fistula (POPF). The a-FRS could allow for risk-adjusted comparisons in research and improve preventive strategies for high-risk patients. The a-FRS, however, has not yet been validated specifically for laparoscopic, robot-assisted, and hybrid MIPD. METHODS: A validation study was performed in a pan-European cohort of 952 consecutive patients undergoing MIPD (543 laparoscopic, 258 robot-assisted, 151 hybrid) in 26 centers from 7 countries between 2007 and 2017. The primary outcome was POPF (International Study Group on Pancreatic Surgery grade B/C). Model performance was assessed using the area under the receiver operating curve (AUC; discrimination) and calibration plots. Validation included univariable screening for clinical variables that could improve performance. RESULTS: Overall, 202 of 952 patients (21%) developed POPF after MIPD. Before adjustment, the original a-FRS performed moderately (AUC 0.68) and calibration was inadequate with systematic underestimation of the POPF risk. Single-row pancreatojejunostomy (odds ratio 4.6, 95 confidence interval [CI] 2.8-7.6) and male sex (odds ratio 1.9, 95 CI 1.4-2.7) were identified as important risk factors for POPF in MIPD. The updated a-FRS, consisting of body mass index, pancreatic texture, duct size, and male sex, showed good discrimination (AUC 0.75, 95 CI 0.71-0.79) and adequate calibration. Performance was adequate for laparoscopic, robot-assisted, and hybrid MIPD and open pancreatoduodenectomy. CONCLUSIONS: The updated a-FRS (www.pancreascalculator.com) now includes male sex as a risk factor and is validated for both MIPD and open pancreatoduodenectomy. The increased risk of POPF in laparoscopic MIPD was associated with single-row pancreatojejunostomy, which should therefore be discouraged.</p>
<p>doi: <a href="https://doi.org/10.1097/SLA.0000000000003234" class="uri">https://doi.org/10.1097/SLA.0000000000003234</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>The Impact of Preoperative Immune Modulating Nutrition on Outcomes in Patients Undergoing Surgery for Gastrointestinal Cancer: A Systematic Review and Meta-analysis</strong> </summary></p>
<p><em>Annals of surgery 2019 08;270(2):247-256</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=30817349" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=30817349</a></p>
<p>OBJECTIVE: To define the influence of preoperative immune modulating nutrition (IMN) on postoperative outcomes in patients undergoing surgery for gastrointestinal cancer. BACKGROUND: Although studies have shown that perioperative IMN may reduce postoperative infectious complications, many of these have included patients with benign and malignant disease, and the optimal timing of such an intervention is not clear. METHODS: The Embase, Medline, and Cochrane databases were searched from 2000 to 2018, for prospective randomized controlled trials evaluating preoperative oral or enteral IMN in patients undergoing surgery for gastrointestinal cancer. The primary endpoint was the development of postoperative infectious complications. Secondary endpoints included postoperative noninfectious complications, length of stay, and up to 30-day mortality. The analysis was performed using RevMan v5.3 software. RESULTS: Sixteen studies reporting on 1387 patients (715 IMN group, 672 control group) were included. Six of the included studies reported on a mixed population of patients undergoing all gastrointestinal cancer surgery. Of the remaining, 4 investigated IMN in colorectal cancer surgery, 2 in pancreatic surgery, and another 2 in patients undergoing surgery for gastric cancer. There was 1 study each on liver and esophageal cancer. The formulation of nutrition used in all studies in the treated patients was Impact (Novartis/Nestlé), which contains ω-3 fatty acids, arginine, and nucleotides. Preoperative IMN in patients undergoing surgery for gastrointestinal cancer reduced infectious complications [odds ratio (OR) 0.52, 95% confidence interval (CI) 0.38-0.71, P &lt; 0.0001, I = 16%, n = 1387] and length of hospital stay (weighted mean difference -1.57 days, 95% CI -2.48 to -0.66, P = 0.0007, I = 34%, n = 995) when compared with control (isocaloric isonitrogeneous feed or normal diet). It, however, did not affect noninfectious complications (OR 0.98, 95% CI 0.73-1.33, P = 0.91, I = 0%, n = 1303) or mortality (OR 0.55, 95% CI 0.18-1.68, P = 0.29, I = 0%, n = 955). CONCLUSION: Given the significant impact on infectious complications and a tendency to shorten length of stay, preoperative IMN should be encouraged in routine practice in patients undergoing surgery for gastrointestinal cancer.</p>
<p>doi: <a href="https://doi.org/10.1097/SLA.0000000000003256" class="uri">https://doi.org/10.1097/SLA.0000000000003256</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Neuroendocrine Neoplasms Associated with Germline Pathogenic Variants in the Homologous Recombination Pathway</strong> </summary></p>
<p><em>Endocrine pathology 2019 Sep;30(3):237-245</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=30772928" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=30772928</a></p>
<p>Neuroendocrine neoplasms (NENs) have been primarily associated with germline pathogenic variants in genes involved in chromatin remodeling (MEN1), cell cycle control (CDKN1B), PI3K/mTOR signaling (TSC1/2, PTEN) as well as pseudohypoxia (VHL, SDHx). Recent work has implicated various genes involved in DNA repair pathways in the pathophysiology of a subset of pancreatic neuroendocrine neoplasms, including BRCA2, via the homologous recombination pathway (HRD). To date, germline variants in other HRD pathway genes have not been described to contribute to NEN. PALB2, RAD51C, and BARD1 are additional tumor suppressor genes which also mediate repair of double stranded DNA breaks through the HRD pathway and are implicated in hereditary breast (PALB2; BARD1) and ovarian (RAD51C) cancer. Here we report three cases of NEN associated with germline pathogenic variants in PALB2 (pancreatic NEN), RAD51C (thymic NEN), and BARD1 (pancreaticoduodenal NEN) respectively, further linking the DNA repair pathway to NENs.</p>
<p>doi: <a href="https://doi.org/10.1007/s12022-019-9569-4" class="uri">https://doi.org/10.1007/s12022-019-9569-4</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Beta-cell sensitivity to insulinotropic gut hormones is reduced after gastric bypass surgery</strong> </summary></p>
<p><em>Gut 2019 10;68(10):1838-1845</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=30772836" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=30772836</a></p>
<p>OBJECTIVE: Postprandial hyperinsulinaemia after Roux-en Y gastric bypass (GB) has been attributed to rapid nutrient flux from the gut, and an enhanced incretin effect. However, it is unclear whether surgery changes islet cell responsiveness to regulatory factors. This study tested the hypothesis that β-cell sensitivity to glucagon like-peptide 1 (GLP-1) and glucose-dependent insulinotropic peptide (GIP) is attenuated after GB. DESIGN: Ten non-diabetic subjects with GB, and 9 body mass index (BMI)-matched and age-matched non-surgical controls (CN) with normal glucose tolerance had blood glucose clamped at ~7.8 mM on three separate days. Stepwise incremental infusions of GLP-1 (15, 30, 60, 120 and 300 ng/LBkg/h), GIP (75, 150, 300, 600 and 1200 ng/LBkg/h) or saline were administered from 90 to 240 min and insulin secretion measured. RESULTS: GB subjects had similar fasting glucose levels but lower fasting insulin compared with CN, likely due to increased insulin clearance. The average insulin secretion rates (ISRs) to 7.8 mM glucose were ~30% lower in GB relative to CN subjects. However, incretin-stimulated ISRs, adjusted for insulin sensitivity and glucose-stimulated insulin secretion, were even more attenuated in the GB subjects, by threefold to fourfold (AUCISR(90-240 min) during GLP-1 and GIP: 47±8 and 44±12 nmol in GB and 116±16 and 161±44 in CN; p&lt;0.01). CONCLUSION: After GB, the sensitivity of insulin secretion to both glucose and incretins is diminished.</p>
<p>doi: <a href="https://doi.org/10.1136/gutjnl-2018-317760" class="uri">https://doi.org/10.1136/gutjnl-2018-317760</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>[Microcystic serous cystadenoma: An uncommon neoplasm of pancreas. Report of two cases]</strong> </summary></p>
<p><em>Annales de pathologie 2019 Aug;39(4):292-296</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=30711334" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=30711334</a></p>
<p>Microcystic variant of serous cystadenoma of the pancreas is a rare neoplasm; essentially located in the body or tail of the pancreas and associated with the von Hippel-Lindau. Often, patients are asymptomatic and the neoplasm is incidentally discovered. Usually radiographic manifestations are characteristic. Histopathological examination revealed uniform clear cuboidal cells; they can be confused with other clear cell neoplasms like renal cell carcinomas, well-differentiated neuroendocrine tumors and solid pseudopapillary tumors of the pancreas. Immunohistochemistry can be help to establish the diagnosis and to remove differential diagnosis. Serous cystadenoma is a benign neoplasm whose prognosis is excellent. We herein report two cases of microcystic serous cystadenomas of the pancreas diagnosed in two asymptomatic women and review analysis in the literature to remind the main features of this lesion and the main differential diagnosis.</p>
<p>doi: <a href="https://doi.org/10.1016/j.annpat.2018.12.007" class="uri">https://doi.org/10.1016/j.annpat.2018.12.007</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>STING signalling protects against chronic pancreatitis by modulating Th17 response</strong> </summary></p>
<p><em>Gut 2019 10;68(10):1827-1837</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=30705050" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=30705050</a></p>
<p>OBJECTIVE: Chronic pancreatitis (CP) is an inflammatory disease with progressive fibrosis leading to exocrine and endocrine dysfunction. Currently, there are no approved effective therapies for CP. Stimulator of interferon genes (STING) signalling is a key innate immune sensor of DNA. In this study, we evaluated the role of STING signalling in CP. DESIGN: We used an experimental model of CP to test the effect of STING signalling in STING wild-type and knockout mice as well as bone marrow chimaeras (BMCs). STING was activated using a pharmacological agent. Since we found changes in Th17 cells, we used neutralising and control antibodies to determine the role of IL-17A. The effect of STING signalling was further explored in IL-17A generation and we examined the effect of IL-17A on pancreatic stellate cells (PSCs). Human pancreas from patients with CP and without CP were also stained for IL-17A. RESULTS: STING activation decreased CP-associated pancreatic inflammation and fibrosis, whereas absence of STING led to worsening of the disease. BMCs showed that leucocytes play an important role in STING signalling-mediated amelioration of experimental CP. STING deletion was associated with increased Th17 cell infiltration in the pancreas, whereas STING agonist limited this Th17 response. Importantly, anti-IL-17A antibody treatment mitigated the severity of CP in the absence of STING signalling. STING deficiency promoted Th17 polarisation and PSCs express functional IL-17 receptor by upregulating fibrosis genes. Compared with tumour margins, pancreas from patients with CP had significant increase in IL-17A+ cells. CONCLUSION: Unlike acute pancreatitis, STING activation is protective in CP. STING signalling is important in regulating adaptive immune responses by diminishing generation of IL-17A during CP and presents a novel therapeutic target for CP.</p>
<p>doi: <a href="https://doi.org/10.1136/gutjnl-2018-317098" class="uri">https://doi.org/10.1136/gutjnl-2018-317098</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>What Is the Peri-Pancreas Cystic Lesion?</strong> </summary></p>
<p><em>Gastroenterology 2019 09;157(3):622-623</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=30615877" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=30615877</a></p>
<p>doi: <a href="https://doi.org/10.1053/j.gastro.2018.12.029" class="uri">https://doi.org/10.1053/j.gastro.2018.12.029</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>High Expression of Long Noncoding RNA HOTAIRM1 is Associated with the Proliferation and Migration in Pancreatic Ductal Adenocarcinoma</strong> </summary></p>
<p><em>Pathology oncology research : POR 2019 Oct;25(4):1567-1577</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=30613920" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=30613920</a></p>
<p>Pancreatic ductal adenocarcinoma (PDAC) is an incurable malignancy. Long noncoding RNA (LncRNA) HOTAIRM1 (HOX antisense intergenic RNA myeloid 1) has been shown to play important roles in the progression of several type cancers. However, the exact role of HOTAIRM1 in PDAC development remains largely unknown. This study aims to evaluate the potential function of HOTAIRM1 in the development and progress of PDAC. HOTAIRM1 expression was measured by RT-qPCR in forty seven paired human PDAC tissues and five PDAC cell lines. SW1990 and PANC-1 cells were transfected with siHOTAIRM1 to achieve HOTAIRM1 silence. MTT assay and colony formation assay were used to detect the effect of HOTAIRM1 knockdown on cell proliferation. The impact of HOTAIRM1 silence on cell cycle and apoptosis was assessed by flow cytometry assay. Transwell migration assay was performed to explore the influence of HOTAIRM1 downregulation on the migratory potential of PDAC cells. Western blot assay was applied to determine the expression changes of cell cycle, apoptosis, and migration-related genes before and after downregulating HOTAIRM1. HOTAIRM1 expression was abnormally upregulated in PDAC tissues and cells when compared with the control samples, and was positively associated with the expression of KRAS gene mutation. In vitro functional experiments, HOTAIRM1 expression was significantly downregulated by transfection with siHOTAIRM1 in SW1990 and PANC cell lines. HOTAIRM1 knockdown attenuated cell proliferation by inducing cell cycle arrest at G0/G1 phase, promoted cell apoptosis, and inhibited cell migration in PDAC cells by regulating related-genes expression. In conclusion, HOTAIRM1 plays a critical role in PDAC progression, which may be a novel diagnostic and rational therapeutic target for the treatment of pancreatic ductal adenocarcinoma.</p>
<p>doi: <a href="https://doi.org/10.1007/s12253-018-00570-4" class="uri">https://doi.org/10.1007/s12253-018-00570-4</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Response to Comment on “Characterization and Optimal Management of High-risk Pancreatic Anastomoses During Pancreatoduodenectomy: Response to Goussous and Cunningham”</strong> </summary></p>
<p><em>Annals of surgery 2019 08;270(2):e58-e59</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=30499813" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=30499813</a></p>
<p>doi: <a href="https://doi.org/10.1097/SLA.0000000000003121" class="uri">https://doi.org/10.1097/SLA.0000000000003121</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Comment on “Interpreting Clinical Benefits of Neoadjuvant Chemoradiation With Gemcitabine Versus Upfront Surgery in Patients With Borderline Resectable Pancreatic Cancer (BRPC)”</strong> </summary></p>
<p><em>Annals of surgery 2019 08;270(2):e48-e50</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=30499804" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=30499804</a></p>
<p>doi: <a href="https://doi.org/10.1097/SLA.0000000000003115" class="uri">https://doi.org/10.1097/SLA.0000000000003115</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Textbook Outcomes Among Medicare Patients Undergoing Hepatopancreatic Surgery</strong> </summary></p>
<p><em>Annals of surgery 2020 Jun;271(6):1116-1123</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=30499800" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=30499800</a></p>
<p>OBJECTIVE: To define and test “Textbook Outcome” (TO)-a composite measure for healthcare quality-among Medicare patients undergoing hepatopancreatic resections. Hospital variation in TO and Medicare payments were analyzed. BACKGROUND: Composite measures of quality may be superior to individual measures for the analysis of hospital performance. METHODS: The Medicare Provider Analysis and Review (MEDPAR) Inpatient Files were reviewed to identify Medicare patients who underwent pancreatic and liver procedures between 2013 and 2015. TO was defined as: no postoperative surgical complications, no prolonged length of hospital stay, no readmission ≤ 90 days after discharge, and no postoperative mortality ≤ 90 days after surgery. Medicare payments were compared among patients who achieved TO versus patients who did not. Multivariable logistic regression was used to investigate patient factors associated with TO. A nomogram to predict probability of TO was developed and validated. RESULTS: TO was achieved in 44% (n = 5919) of 13,467 patients undergoing hepatopancreatic surgery. Adjusted TO rates at the hospital level varied from 11.1% to 69.6% for pancreatic procedures and from 16.6% to 78.7% for liver procedures. Prolonged length of hospital stay represented the major obstacle to achieve TO. Average Medicare payments were substantially higher among patients who did not have a TO. Factors associated with TO on multivariable analysis were age, sex, Charlson comorbidity score, previous hospital admissions, procedure type, and surgical approach (all P &gt; 0.05). CONCLUSIONS: Less than one-half of Medicare patients achieved a TO following hepatopancreatic procedures with a wide variation in the rates of TO among hospitals. There was a discrepancy in Medicare payments for patients who achieved a TO versus patients who did not. TO could be useful for the public reporting of patient level hospital performance and hospital variation.</p>
<p>doi: <a href="https://doi.org/10.1097/SLA.0000000000003105" class="uri">https://doi.org/10.1097/SLA.0000000000003105</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Plasma miR-181a-5p Downregulation Predicts Response and Improved Survival After FOLFIRINOX in Pancreatic Ductal Adenocarcinoma</strong> </summary></p>
<p><em>Annals of surgery 2020 Jun;271(6):1137-1147</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=30394883" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=30394883</a></p>
<p>OBJECTIVE: The aim of the study was to identify plasma microRNA (miRNA) biomarkers for stratifying and monitoring patients with locally advanced or metastatic pancreatic ductal adenocarcinoma (PDAC) treated with FOLFIRINOX, and to investigate their functional roles. SUMMARY BACKGROUND DATA: FOLFIRINOX has become a standard therapy for patients with advanced PDAC and can be used to potentially downstage disease. However, only a subset of patients respond, and biomarkers to guide decision-making are urgently needed. METHODS: We used microarray-based profiling to discover deregulated miRNAs in pre- and postchemotherapy plasma samples from patients based on their progression-free survival (PFS) after FOLFIRINOX. Nine candidate plasma miRNAs were validated in an independent cohort (n = 43). The most discriminative plasma miRNA was correlated with clinicopathological factors and survival, and also investigated in an additional cohort treated with gemcitabine plus nab-paclitaxel. Expression patterns were further evaluated in matched tumor tissues. In vitro studies explored its function, key downstream gene-targets, and interaction with 5-fluorouracil, irinotecan, and oxaliplatin. RESULTS: Plasma miR-181a-5p was significantly downregulated in non-progressive patients after FOLFIRINOX. In multivariate analysis, this decline correlated with improved PFS and overall survival, especially when combined with CA19-9 decline [hazard ratio (HR) = 0.153, 95% confidence interval (CI), 0.067-0.347 and HR = 0.201, 95% CI, 0.070-0.576, respectively]. This combination did not correlate with survival in patients treated with gemcitabine plus nab-paclitaxel. Tissue expression of miR-181a-5p reflected plasma levels. Inhibition of miR-181a-5p coupled with oxaliplatin exposure in pancreatic cell lines decreased cell viability. CONCLUSIONS: Plasma miR-181a-5p is a specific biomarker for monitoring FOLFIRINOX response. Decline in plasma miR-181a-5p and CA19-9 levels is associated with better prognosis after FOLFIRINOX and may be useful for guiding therapeutic choices and surgical exploration.</p>
<p>doi: <a href="https://doi.org/10.1097/SLA.0000000000003084" class="uri">https://doi.org/10.1097/SLA.0000000000003084</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>DYRK1A modulates c-MET in pancreatic ductal adenocarcinoma to drive tumour growth</strong> </summary></p>
<p><em>Gut 2019 08;68(8):1465-1476</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=30343272" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=30343272</a></p>
<p>BACKGROUND AND AIMS: Pancreatic ductal adenocarcinoma (PDAC) is a very aggressive tumour with a poor prognosis using current treatments. Targeted therapies may offer a new avenue for more effective strategies. Dual-specificity tyrosine regulated kinase 1A (DYRK1A) is a pleiotropic kinase with contradictory roles in different tumours that is uncharacterised in PDAC. Here, we aimed to investigate the role of DYRK1A in pancreatic tumorigenesis. DESIGN: We analysed DYRK1A expression in PDAC genetic mouse models and in patient samples. DYRK1A function was assessed with knockdown experiments in pancreatic tumour cell lines and in PDAC mouse models with genetic reduction of Dyrk1a dosage. Furthermore, we explored a mechanistic model for DYRK1A activity. RESULTS: We showed that DYRK1A was highly expressed in PDAC, and that its protein level positively correlated with that of c-MET. Inhibition of DYRK1A reduced tumour progression by limiting tumour cell proliferation. DYRK1A stabilised the c-MET receptor through SPRY2, leading to prolonged activation of extracellular signal-regulated kinase signalling. CONCLUSIONS: These findings reveal that DYRK1A contributes to tumour growth in PDAC, at least through regulation of c-MET accumulation, suggesting that inhibition of DYRK1A could represent a novel therapeutic target for PDAC.</p>
<p>doi: <a href="https://doi.org/10.1136/gutjnl-2018-316128" class="uri">https://doi.org/10.1136/gutjnl-2018-316128</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Genetic Analysis of Small Well-differentiated Pancreatic Neuroendocrine Tumors Identifies Subgroups With Differing Risks of Liver Metastases</strong> </summary></p>
<p><em>Annals of surgery 2020 Mar;271(3):566-573</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=30339629" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=30339629</a></p>
<p>OBJECTIVE: The aim of this study was to investigate the key molecular alterations in small primary pancreatic neuroendocrine tumors (PanNETs) associated with the development of liver metastases. BACKGROUND: Well-differentiated PanNETs with small size are typically indolent; however, a limited subset metastasize to the liver. METHODS: A total of 87 small primary PanNETs (&lt;3 cm), including 32 metastatic cases and 55 nonmetastatic cases after a 5-year follow-up, were immunolabeled for DAXX/ATRX and analyzed for alternative lengthening of telomeres (ALT) by Fluorescence In Situ Hybridization. A subset of these cases, 24 that metastasized and 24 that did not metastasize, were assessed by targeted next-generation sequencing and whole-genome copy number variation. RESULTS: In the entire cohort, high Ki-67 (OR 1.369; 95% CI 1.121-1.673; P = 0.002), N-stage (OR 4.568; 95% CI 1.458-14.312; P = 0.009), and ALT-positivity (OR 3.486; 95% CI 1.093-11.115; P = 0.035) were independently associated with liver metastases. In the subset assessed by next-generation sequencing and copy number variation analysis, 3 molecular subtypes with differing risks of liver metastases were identified. Group 1 (n = 15; 73% metastasized) was characterized by recurrent chromosomal gains, CN-LOH, DAXX mutations, and ALT-positivity. Group 2 (n = 19; 42% metastasized, including 5 G1 tumors) was characterized by limited copy number alterations and mutations. Group 3 (n = 14; 35% metastasized) were defined by chromosome 11 loss. CONCLUSIONS: We identified genomic patterns of small PanNETs associated with a different risk for liver metastases. Molecular alterations, such as DAXX mutations, chromosomal gains, and ALT, are associated with an increased risk of metastasis in small PanNETs. Therefore, targeted sequencing and/or ALT analysis may help in the clinical decisions for these small PanNETs.</p>
<p>doi: <a href="https://doi.org/10.1097/SLA.0000000000003022" class="uri">https://doi.org/10.1097/SLA.0000000000003022</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>A Prospective, Randomized Phase II Study of Adjuvant Gemcitabine Versus S-1 After Major Hepatectomy for Biliary Tract Cancer (KHBO 1208): Kansai Hepato-Biliary Oncology Group</strong> </summary></p>
<p><em>Annals of surgery 2019 08;270(2):230-237</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=30339627" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=30339627</a></p>
<p>OBJECTIVE: To evaluate each arm independently and compare adjuvant gemcitabine (GEM) and S-1 chemotherapy after major hepatectomy (hemihepatectomy or trisectionectomy) for biliary tract cancer (BTC). BACKGROUND: Standardized adjuvant therapy is not performed after major hepatectomy for BTC, and we determined the recommended dose in the former study (KHBO1003). METHODS: We performed a multicenter, randomized phase II study. The primary measure was 1-year recurrence-free survival (RFS); the secondary measures were other RFS, overall survival (OS), and others. The following 6-month adjuvant chemotherapy was administered within 12 weeks of R0/1: GEM (1000 mg/m) every 2 weeks; or S-1 (80 mg/m/d) for 28 days every 6 weeks. Thirty-five patients were assigned to each arm (alpha error, 10%; beta error, 20%). RESULTS: No patients were excluded for the per-protocol analysis. There were no statistically significant differences in the patient characteristics of the 2 arms. The 1-year RFS and 1-year OS rates of the GEM arm were 51.4% and 80.0%, respectively, whereas those of the S-1 group were 62.9% and 97.1%. The comparison of the 2 arms revealed that 2-year RFS rate, 1 and 2-year OS rates, and OS curve of the S-1 arm were superior to GEM. With regard to OS, the hazard ratio of the S-1 group was 0.477 (90% confidence interval 0.245-0.927). CONCLUSION: The comparison of the survival of the 2 groups revealed that adjuvant S-1 therapy may be superior to adjuvant GEM therapy after major hepatectomy for BTC.</p>
<p>doi: <a href="https://doi.org/10.1097/SLA.0000000000002865" class="uri">https://doi.org/10.1097/SLA.0000000000002865</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Reappraising the Concept of Conditional Survival After Pancreatectomy for Ductal Adenocarcinoma: A Bi-institutional Analysis</strong> </summary></p>
<p><em>Annals of surgery 2020 Jun;271(6):1148-1155</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=30339622" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=30339622</a></p>
<p>OBJECTIVE: To reappraise the concept of conditional survival (CS) following pancreatectomy for pancreatic ductal adenocarcinoma (PDAC), accounting for the patient’s present disease status relative to recurrence. BACKGROUND: CS, defined as the probability of surviving an additional time frame based on accrued lifespan, offers dynamic survival projections as compared with baseline overall survival. METHODS: Patients undergoing pancreatectomy for PDAC at 2 institutions from 2000 to 2013 were retrospectively analyzed. The 12-month CS was estimated separately for patients who were disease-free or with recurrence at the given time points. Next, the conditional probability of reaching 60-months of survival was examined in each conditioning set across strata of prognostic covariates, including American Joint Committee on Cancer stage, tumor grade, R-status, and adjuvant treatment. RESULTS: The study population consisted of 1005 patients. In disease-free patients, the 12-month CS increased as a function of time already survived, showing an opposite trend compared with overall survival. In patients who recurred, the 12-month CS was lower than the disease-free counterpart, especially within 24 months postoperatively. When stratifying by the levels of prognostic covariates, the 60-months CS estimates for disease-free patients tended to level off progressively, indicating that factors independently associated with survival at the time of pancreatectomy lost power over time. This concept did not apply to the conditioning set of patients with recurrence, where CS estimates across variables strata diverged with accrued lifespan. CONCLUSION: This paper provides new information on how prognosis following pancreatectomy for PDAC evolves over time, adjusting for the time the patient already survived, and for the patient’s present disease status relative to recurrence.</p>
<p>doi: <a href="https://doi.org/10.1097/SLA.0000000000003083" class="uri">https://doi.org/10.1097/SLA.0000000000003083</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Concomitant Intraductal Papillary Mucinous Neoplasm in Pancreatic Ductal Adenocarcinoma Is an Independent Predictive Factor for the Occurrence of New Cancer in the Remnant Pancreas</strong> </summary></p>
<p><em>Annals of surgery 2020 May;271(5):941-948</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=30308608" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=30308608</a></p>
<p>OBJECTIVE: To determine the factors predicting the subsequent development of pancreatic ductal adenocarcinoma in remnant pancreas (PDAC-RP) after partial pancreatectomy for PDAC. SUMMARY BACKGROUND DATA: PDAC-RP after partial pancreatectomy for PDAC is currently not so rare because of improved prognosis of PDAC patients due to recent advances in surgical techniques and adjuvant therapy. However, the predictive factors related to PDAC-RP remain unknown. METHODS: We retrospectively reviewed the clinicopathological data of a consecutive series of 379 patients with PDAC treated by partial pancreatectomy between 1992 and 2015; 14 patients (3.69%) had PDAC-RP. Clinicopathological variables were compared between PDAC-RP and non-PDAC-RP. RESULTS: In univariate analysis, concomitant intraductal papillary mucinous neoplasm (IPMN) (P = 0.0005), cancer location (body/tail) (P = 0.0060), and lower T factor in UICC (P = 0.0039) were correlated with PDAC-RP development. Multivariate analysis revealed concomitant IPMN (P = 0.0135) to be an independent predictive factor for PDAC-RP. PDAC concomitant with IPMN had higher cumulative incidence of PDAC-RP (47.5%/10 yrs) than PDAC without IPMN (9.96%/10 yrs) (P = 0.0071). Moreover, the density of pancreatic intraepithelial neoplasia lesions in the background pancreas of cases of PDAC concomitant with IPMN (1.86/cm) was higher than that of cases of PDAC without IPMN (0.91/cm) (P = 0.0007). CONCLUSIONS: Concomitant IPMN in PDAC is an independent predictive factor for the development of new PDAC in remnant pancreas. Cancer susceptibility of remnant pancreas after resection for PDAC concomitant with IPMN is probably due to an increased density of pancreatic intraepithelial neoplasia lesions.</p>
<p>doi: <a href="https://doi.org/10.1097/SLA.0000000000003060" class="uri">https://doi.org/10.1097/SLA.0000000000003060</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Towards optimal pancreatic cyst fluid management: the need for standardisation</strong> </summary></p>
<p><em>Gut 2019 10;68(10):1906</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=30301772" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=30301772</a></p>
<p>doi: <a href="https://doi.org/10.1136/gutjnl-2018-317156" class="uri">https://doi.org/10.1136/gutjnl-2018-317156</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Single LAMS versus multigate plastic stent drainage of WON; fair comparison or apples versus oranges?</strong> </summary></p>
<p><em>Gut 2019 10;68(10):1904-1905</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=30301769" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=30301769</a></p>
<p>doi: <a href="https://doi.org/10.1136/gutjnl-2018-317387" class="uri">https://doi.org/10.1136/gutjnl-2018-317387</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Systems Oncology: Bridging Pancreatic and Castrate Resistant Prostate Cancer</strong> </summary></p>
<p><em>Pathology oncology research : POR 2019 Oct;25(4):1269-1277</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=30220022" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=30220022</a></p>
<p>Large investments by pharmaceutical companies in the development of new antineoplastic drugs have not been resulting in adequate advances of new therapies. Despite the introduction of new methods, technologies, translational medicine and bioinformatics, the usage of collected knowledge is unsatisfactory. In this paper, using examples of pancreatic ductal adenocarcinoma (PaC) and castrate-resistant prostate cancer (CRPC), we proposed a concept showing that, in order to improve applicability of current knowledge in oncology, the re-clustering of clinical and scientific data is crucial. Such an approach, based on systems oncology, would include bridging of data on biomarkers and pathways between different cancer types. Proposed concept would introduce a new matrix, which enables combining of already approved therapies between cancer types. Paper provides a (a) detailed analysis of similarities in mechanisms of etiology and progression between PaC and CRPC, (b) diabetes as common hallmark of both cancer types and (c) knowledge gaps and directions of future investigations. Proposed horizontal and vertical matrix in cancer profiling has potency to improve current antineoplastic therapy efficacy. Systems biology map using Systems Biology Graphical Notation Language is used for summarizing complex interactions and similarities of mechanisms in biology of PaC and CRPC.</p>
<p>doi: <a href="https://doi.org/10.1007/s12253-018-0467-8" class="uri">https://doi.org/10.1007/s12253-018-0467-8</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Circulating Tumor Cells are an Independent Predictor of Shorter Survival in Patients Undergoing Resection for Pancreatic and Periampullary Adenocarcinoma</strong> </summary></p>
<p><em>Annals of surgery 2020 Mar;271(3):549-558</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=30216219" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=30216219</a></p>
<p>OBJECTIVE: We evaluated the prognostic impact of circulating tumor cells (CTCs) for patients with presumed resectable pancreatic and periampullary cancers. SUMMARY OF BACKGROUND DATA: Initial treatment decisions for this group are currently taken without a reliable prognostic marker. The CellSearch system allows standardized CTC-testing and has shown excellent specificity and prognostic value in other applications. METHODS: Preoperative blood samples from 242 patients between September 2009 and December 2014 were analyzed. One hundred seventy-nine patients underwent tumor resection, of whom 30 with stage-I tumors and duodenal cancer were assigned to the low-risk group, and the others to the high-risk group. Further 33 had advanced disease, 30 benign histology. Observation ended in December 2016. Cancer-specific survival (CSS) and disease-free survival (DFS) were calculated by log-rank and Cox regression. RESULTS: CTCs (CTC-positive; ≥1 CTC/7.5 mL) were detected in 6.8% (10/147) of the high-risk patients and 6.2% (2/33) with advanced disease. No CTCs (CTC-negative) were detected in the low-risk patients or benign disease. In high-risk patients, median CSS for CTC-positive versus CTC-negative was 8.1 versus 20.0 months (P &lt; 0.0001), and DFS 4.0 versus 10.5 months (P &lt; 0.001). Median CSS in advanced disease was 7.7 months. Univariate hazard ratio (HR) of CTC-positivity was 3.4 (P &lt; 0.001). In multivariable analysis, CTC-status remained independent (HR: 2.4, P = 0.009) when corrected for histological type (HR: 2.7, P = 0.030), nodal status (HR: 1.7, P = 0.016), and vascular infiltration (HR: 1.7, P = 0.001). CONCLUSION: Patients testing CTC-positive preoperatively showed a detrimental outcome despite successful tumor resections. Although the low CTC-rate seems a limiting factor, results indicate high specificity. Thus, preoperative analysis of CTCs by this test may guide treatment decisions and warrants further testing in clinical trials.</p>
<p>doi: <a href="https://doi.org/10.1097/SLA.0000000000003035" class="uri">https://doi.org/10.1097/SLA.0000000000003035</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Pancreatectomy With Arterial Resection for Pancreatic Adenocarcinoma: How Can It Be Done Safely and With Which Outcomes?: A Single Institution’s Experience With 118 Patients</strong> </summary></p>
<p><em>Annals of surgery 2020 May;271(5):932-940</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=30188399" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=30188399</a></p>
<p>OBJECTIVE: This study assesses the safety and outcomes of the largest cohort of pancreatectomy with arterial resection (P-AR). BACKGROUND: A high postoperative mortality rate and uncertain oncologic benefits have limited the use of P-AR for locally advanced pancreatic adenocarcinoma. METHODS: We retrospectively reviewed a prospectively maintained database of patients who underwent P-AR between January 1990 and November 2017. Univariate and multivariate Cox analyses were used to assess prognostic factors for survival. RESULTS: There were 118 consecutive resections (51 pancreaticoduodenectomies, 18 total pancreatectomies, and 49 distal splenopancreatectomies). Resected arterial segments included the coeliac trunk (50), hepatic artery (29), superior mesenteric artery (35), and other segments (4). The overall mortality and morbidity were 5.1% and 41.5%, respectively. There were 84 (75.4%) patients who received neoadjuvant chemotherapy, 105 (89%) simultaneous venous resections, and 101 (85.5%) arterial reconstructions. The rates of R0 resection and pathologic invasion of venous and arterial walls were 52.4%, 74.2%, and 58%, respectively. The overall survival was 59%, 13%, and 11.8% at 1, 3, and 5 years, respectively. The median overall survival after resection was 13.70 months (CI 95%:11-18.5 mo). In multivariate analysis, R0 resection (HR: 0.60; 95% CI: 0.38-0.96; P = 0.01) and venous invasion (HR: 1.67; 95% CI: 1.01-2.63; P = 0.04) were independent prognostic factors. CONCLUSION: In a specialized setting, P-AR for locally advanced pancreatic adenocarcinoma can be performed safely with limited mortality and morbidity. Negative resection margin and the absence of associated venous invasion might predict favorable long-term outcomes.</p>
<p>doi: <a href="https://doi.org/10.1097/SLA.0000000000003010" class="uri">https://doi.org/10.1097/SLA.0000000000003010</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Response to Comment on “The Virtual Hepatectomy Changed the Practice of Liver Surgery: More Details, More Significance”</strong> </summary></p>
<p><em>Annals of surgery 2019 08;270(2):e33</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=30138165" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=30138165</a></p>
<p>doi: <a href="https://doi.org/10.1097/SLA.0000000000003009" class="uri">https://doi.org/10.1097/SLA.0000000000003009</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>[Heterotopic tissue in the gastrointestinal tract]</strong> </summary></p>
<p><em>Der Pathologe 2018 Sep;39(5):402-408</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=30105611" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=30105611</a></p>
<p>Heterotopia of the gastrointestinal tract is a common finding. This is due to the complex embryogenesis and the relative ease to detect heterotopic tissue during endoscopy. The reason for biopsy is mostly to rule out neoplasms or to define specific causes of inflammation. Heterotopic tissue can occur in any location of the gastrointestinal tract. The most frequent are gastric heterotopia, pancreatic heterotopia, and heterotopia of Brunner’s gland. On rare occasions, heterotopic tissue of salivary gland type as well as heterotopias of apocrine glands, thyroid, and prostatic tissue have been described. The most frequently involved organs are the small intestine, in particular the duodenum, the esophagus, and the stomach. Heterotopia of the large bowel occurs exclusively in the rectum. Most heterotopias do not cause symptoms and are easily diagnosed by biopsy and histology. However, depending on location, size, and the kind of underlying heterotopic tissue, they may cause significant complications, such as inflammation, ulceration and perforation, obstruction, intussusception, and severe life-threatening bleeding. Another rare but significant complication is neoplasia. Gastric heterotopias may give rise to pyloric gland adenomas within the bowel or rarely adenocarcinomas of the esophagus. Pancreatic heterotopia can be complicated by ductal type pancreatic adenocarcinomas, by acinus cell carcinomas, by intraductal papillary mucinous neoplasias, and also by endocrine tumors. The present paper summarizes our current knowledge about heterotopias in a topographic clinico-pathological manner.</p>
<p>doi: <a href="https://doi.org/10.1007/s00292-018-0466-2" class="uri">https://doi.org/10.1007/s00292-018-0466-2</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Acute Pancreatitis Caused by Isolated Pancreatic Metastasis From Uterine Choriocarcinoma</strong> </summary></p>
<p><em>International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists 2019 Sep;38(5):430-434</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=30028356" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=30028356</a></p>
<p>Choriocarcinoma is an aggressive gestational trophoblastic neoplasia known for its widely metastatic potential. However, isolated pancreatic metastasis is an extremely rare occurrence and has not been documented in the English literature to the best of our knowledge. The metastatic deposits in the index case led to widespread hemorrhage and necrosis of the pancreatic parenchyma, causing severe acute pancreatitis. The patient succumbed to her illness before chemotherapy was administered. Thus, we present an autopsy case of a uterine choriocarcinoma with isolated pancreatic metastasis presenting as severe acute pancreatitis in a 27-yr-old woman following a molar pregnancy.</p>
<p>doi: <a href="https://doi.org/10.1097/PGP.0000000000000532" class="uri">https://doi.org/10.1097/PGP.0000000000000532</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Determinants of Severity in Acute Pancreatitis: A Nation-wide Multicenter Prospective Cohort Study</strong> </summary></p>
<p><em>Annals of surgery 2019 08;270(2):348-355</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=29672416" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=29672416</a></p>
<p>OBJECTIVE: The aim of this study was to compare and validate the different classifications of severity in acute pancreatitis (AP) and to investigate which characteristics of the disease are associated with worse outcomes. SUMMARY OF BACKGROUND DATA: AP is a heterogeneous disease, ranging from uneventful cases to patients with considerable morbidity and high mortality rates. Severity classifications based on legitimate determinants of severity are important to correctly describe the course of disease. METHODS: A prospective multicenter cohort study involving patients with AP from 23 hospitals in Spain. The Atlanta Classification (AC), Revised Atlanta Classification (RAC), and Determinant-based Classification (DBC) were compared. Binary logistic multivariate analysis was performed to investigate independent determinants of severity. RESULTS: A total of 1655 patients were included; 70 patients (4.2%) died. RAC and DBC were equally superior to AC for describing the clinical course of AP. Although any kind of organ failure was associated with increased morbidity and mortality, persistent organ failure (POF) was the most significant determinant of severity. All local complications were associated with worse outcomes. Infected pancreatic necrosis correlated with high morbidity, but in the presence of POF, it was not associated to higher mortality when compared with sterile necrotizing pancreatitis. Exacerbation of previous comorbidity was associated with increased morbidity and mortality. CONCLUSION: The RAC and DBC both signify an advance in the description and differentiation of AP patients. Herein, we describe the complications of the disease independently associated to morbidity and mortality. Our findings are valuable not only when designing future studies on AP but also for the improvement of current classifications.</p>
<p>doi: <a href="https://doi.org/10.1097/SLA.0000000000002766" class="uri">https://doi.org/10.1097/SLA.0000000000002766</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Survival in Locally Advanced Pancreatic Cancer After Neoadjuvant Therapy and Surgical Resection</strong> </summary></p>
<p><em>Annals of surgery 2019 08;270(2):340-347</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=29596120" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=29596120</a></p>
<p>OBJECTIVE: The aim of the study was to identify the survival of patients with locally advanced pancreatic cancer (LAPC) and assess the effect of surgical resection after neoadjuvant therapy on patient outcomes. BACKGROUND: An increasing number of LAPC patients who respond favorably to neoadjuvant therapy undergo surgical resection. The impact of surgery on patient survival is largely unknown. MATERIALS AND METHODS: All LAPC patients who presented to the institutional pancreatic multidisciplinary clinic (PMDC) from January 2013 to September 2017 were included in the study. Demographics and clinical data on neoadjuvant treatment and surgical resection were documented. Primary tumor resection rates after neoadjuvant therapy and overall survival (OS) were the primary study endpoints. RESULTS: A total of 415 LAPC patients were included in the study. Stratification of neoadjuvant therapy in FOLFIRINOX-based, gemcitabine-based, and combination of the two, and subsequent outcome comparison did not demonstrate significant differences in OS of 331 non-resected LAPC patients (P = 0.134). Eighty-four patients underwent resection of the primary tumor (20%), after a median duration of 5 months of neoadjuvant therapy. FOLFIRINOX-based therapy and stereotactic body radiation therapy correlated with increased probability of resection (P = 0.006). Resected patients had better performance status, smaller median tumor size (P = 0.029), and lower median CA19-9 values (P &lt; 0.001) at PMDC. Patients who underwent surgical resection had significant higher median OS compared with those who did not (35.3 vs 16.3 mo, P &lt; 0.001). The difference remained significant when non-resected patients were matched for time of neoadjuvant therapy (19.9 mo, P &lt; 0.001). CONCLUSIONS: Surgical resection of LAPC after neoadjuvant therapy is feasible in a highly selected cohort of patients (20%) and is associated with significantly longer median overall survival.</p>
<p>doi: <a href="https://doi.org/10.1097/SLA.0000000000002753" class="uri">https://doi.org/10.1097/SLA.0000000000002753</a></p>
</details>
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<hr />
<p><a href="#top" target="_self">Back to top</a></p>
<hr />
<div style="page-break-after: always;"></div>
</div>
<div id="gallbladder" class="section level2">
<h2>Gallbladder</h2>
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Prediction Efficacy for Clinical Outcome of Prognostic Nutritional Index in Patients with Resectable Biliary Tract Cancer Depends on Sex and Obstructive Jaundice Status</strong> </summary></p>
<p><em>Annals of surgical oncology 2020 Jun;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=32548755" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=32548755</a></p>
<p>BACKGROUND: The Prognostic Nutritional Index (PNI), a marker of nutritional status and systemic inflammation, is a proven prognostic biomarker in some cancers. The predictive value of PNI in biliary tract cancer (BTC) has not been established. OBJECTIVE: The aim of this study was to determine the relationship between the PNI and outcomes of resectable BTC. METHODS: In total, 430 patients with stage I-III resectable BTC [gallbladder cancer (GBC), n = 212; cholangiocarcinoma (CHO), n = 218] who had attended Fudan University Zhongshan Hospital were enrolled. The relationship between the PNI and clinical outcomes was evaluated both in the whole cohort and in selected subgroups. RESULTS: Eligible patients were classified into PNI-low (PNI &lt; 45) and PNI-high (PNI ≥ 45) groups. The PNI-low group had significantly worse overall survival (OS) in both the whole cohort (p = 0.002) and in the GBC subgroup (p = 0.001), but had similar OS as the PNI-high group in the CHO subgroup (p = 0.328). Multivariate analysis revealed that low PNI is an independent risk factor for worse survival in GBC (hazard ratio 1.623, 95% confidence interval 1.063-2.480, p = 0.026). PNI was found to predict clinical outcome in women (p &lt; 0.001) and patients without obstructive jaundice (p = 0.017) with GBC, but was not a prognostic factor in any subgroup with CHO. The estimated area under the time-dependent receiver operating characteristic curve was significantly greater when TNM stage was combined with PNI in women with GBC. CONCLUSIONS: PNI is an independent predictor of OS in GBC, but not in CHO. It has no prognostic value in men with GBC or patients with obstructive jaundice.</p>
<p>doi: <a href="https://doi.org/10.1245/s10434-020-08728-8" class="uri">https://doi.org/10.1245/s10434-020-08728-8</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Diagnostic role of fine needle aspiration cytology (FNAC) in the evaluation of gall bladder lesions: an institutional experience</strong> </summary></p>
<p><em>Diagnostic cytopathology 2020 Jun;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=32506819" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=32506819</a></p>
<p>BACKGROUND: Carcinoma of the gall bladder is the most common malignancy of the biliary tract. Ultrasonography guided Fine Needle Aspiration Cytology (FNAC) plays a crucial role in early detection of gall bladder (GB) lesions. Early diagnosis of GB lesions is a necessity in view of rising trend in GB carcinoma related mortality in India. The aim of this study is to determine the diagnostic accuracy of pre-operative ultrasonography guided FNAC in the diagnosis of GB masses. METHODS: This was a retrospective observational study performed at a tertiary care university hospital over a period of one and a half years. A total of 47 patients with clinico-radiological suspicion of GB malignancy were subjected to USG guided FNA. 20 of these patients underwent diagnostic Trucut biopsy in addition to FNA. RESULTS: Forty-one out of 47 patients analyzed were positive for malignancy with female preponderance; MF ratio of 0.6:1. There were 29 females (61.8%) and 18 males (38.2%) in the range of 34 to 85 years. Cytomorphology was inconclusive for malignancy in two patients and unsatisfactory in one case. Two were labeled as chronic cholecystitis and one as acute cholecystitis. Adenocarcinoma was the most common malignancy found in 36 patients (76.6%). CONCLUSION: USG guided FNAC is a rapid, safe and successful diagnostic procedure with high sensitivity for diagnosis of GB lesions. In the present scenario of increasing incidence of GB malignancy, FNAC has proved to be a useful first choice of investigation in the detection of GB lesions.</p>
<p>doi: <a href="https://doi.org/10.1002/dc.24517" class="uri">https://doi.org/10.1002/dc.24517</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Expression of FAM83H and ZNF16 are associated with shorter survival of patients with gallbladder carcinoma</strong> </summary></p>
<p><em>Diagnostic pathology 2020 May;15(1):63</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=32460791" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=32460791</a></p>
<p>BACKGROUND: Recently, FAM83H was reported to have roles in cancer progression in conjunction with oncogenic molecules such as MYC and b-catenin. Moreover, the data from the public database indicates a molecular relationship between FAM83H and zinc finger proteins, especially between FAM83H and ZNF16. However, studies on FAM83H and ZNF16 in gallbladder cancer have been limited. METHODS: This study investigated the expression of FAM83H and ZNF16 in 105 gallbladder carcinomas. RESULTS: In human gallbladder carcinomas, immunohistochemical expression of FAM83H was significantly associated with ZNF16 expression. In univariate analysis, nuclear and cytoplasmic expression of FAM83H or ZNF16 were significantly associated with shorter survival of gallbladder carcinoma patients. Multivariate analysis revealed the nuclear expression of FAM83H as an independent indicator of poor prognosis of overall survival (p = 0.005) and relapse-free survival (p = 0.005) of gallbladder carcinoma patients. Moreover, co-expression patterns of nuclear FAM83H and ZNF16 were also independent indicators of shorter survival of gallbladder carcinoma patients (overall survival; p &lt;  0.001, relapse-free survival; p &lt;  0.001). CONCLUSIONS: This study suggests FAM83H and ZNF16 are associated with the progression of gallbladder carcinoma, and the expressions of FAM83H and ZNF16 might be novel prognostic indicators of gallbladder carcinoma patients.</p>
<p>doi: <a href="https://doi.org/10.1186/s13000-020-00985-1" class="uri">https://doi.org/10.1186/s13000-020-00985-1</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Testing for ROS1, ALK, MET, and HER2 rearrangements and amplifications in a large series of biliary tract adenocarcinomas</strong> </summary></p>
<p><em>Virchows Archiv : an international journal of pathology 2020 May;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=32447492" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=32447492</a></p>
<p>Biliary tract carcinomas are divided into intrahepatic, perihilar, distal extrahepatic cholangiocarcinomas, and gallbladder adenocarcinomas. Therapies targeting ROS1, ALK, MET, and HER2 alterations are currently evaluated in clinical trials. We assessed ROS1 and ALK translocations/amplifications as well as MET and HER2 amplifications for each tumor subtype by fluorescent in situ hybridization (FISH) and immunohistochemistry (IHC) in 73 intrahepatic, 40 perihilar bile duct, 36 distal extrahepatic cholangiocarcinomas, and 45 gallbladder adenocarcinomas (n = 194). By FISH, we detected targetable alterations in 5.2% of cases (n = 10): HER2 and MET amplifications were found in 4.1% (n = 8) and 1.0% (n = 2), respectively. The HER2-amplified cases were mostly gallbladder adenocarcinomas (n = 5). The MET- and HER2-amplified cases were all positive by IHC. Fourteen cases without MET amplification were positive by IHC, whereas HER2 over-expression was detected by IHC only in HER2-amplified cases. We detected no ALK or ROS1 translocation or amplification. Several alterations were consistent with aneuploidy: 24 cases showed only one copy of ROS1 gene, 4 cases displayed a profile of chromosomal instability, and an over-representation of centromeric alpha-satellite sequences was found in five cases. We confirm a relatively high rate of HER2 amplifications in gallbladder adenocarcinomas and the efficacy of IHC to screen these cases. Our results also suggest the value of IHC to screen MET amplification. Contrary to initial publications, ROS1 rearrangements seem to be very rare in biliary tract adenocarcinomas. We confirm a relatively high frequency of aneuploidy and chromosomal instability and reveal the over-representation of centromeric alpha-satellite sequences in intrahepatic cholangiocarcinomas.</p>
<p>doi: <a href="https://doi.org/10.1007/s00428-020-02822-8" class="uri">https://doi.org/10.1007/s00428-020-02822-8</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>The Contribution of Additional Sampling in Cholecystectomy Materials: A Multicenter Prospective Study</strong> </summary></p>
<p><em>Turk patoloji dergisi 2020 May;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=32364613" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=32364613</a></p>
<p>OBJECTIVE: Cholecystectomy materials are frequently encountered in routine practice. The aim of this study was to determine the true frequency of gallbladder lesions, the diagnostic consistency, and standardization of reports after macroscopic sampling and microscopic evaluation based on previously defined criteria. MATERIAL AND METHOD: 14 institutions participated in the study within the Hepato-Pancreato-Biliary Pathology Study Group. Routinely examined cholecystectomies within the last year were included in the study in these institutions. Additional sampling was performed according to the indications and criteria. The number of blocks and samples taken in the first macroscopic examination and the number of blocks and samples taken in the additional sampling were determined and the rate of diagnostic contribution of the additional examination was determined. RESULTS: A total of 5,244 cholecystectomy materials from 14 institutions were included in the study. Additional sampling was found to be necessary in 576 cases (10.98%) from all institutions. In the first macroscopic sampling, the mean of the numbers of samples was approximately 4 and the number of blocks was 2. The mean of the numbers of additional samples and blocks was approximately 8 and 4, respectively. The diagnosis was changed in 144 of the 576 new sampled cases while the remaining 432 stayed unaltered. CONCLUSION: In this study, it was observed that new sampling after the first microscopic examination of cholecystectomy materials contributed to the diagnosis. It was also shown that the necessity of having standard criteria for macroscopic and microscopic examination plays an important role in making the correct diagnosis.</p>
<p>doi: <a href="https://doi.org/10.5146/tjpath.2020.01483" class="uri">https://doi.org/10.5146/tjpath.2020.01483</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>TRAIL receptors are differentially regulated and clinically significant in gallbladder cancer</strong> </summary></p>
<p><em>Pathology 2020 Apr;52(3):348-358</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=32111400" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=32111400</a></p>
<p>Deregulation of the receptors of TNF-related apoptosis inducing ligand (TRAIL) has been reported in various cancers. In an effort to define the role of these receptors we profiled their expression in gallbladder cancer (GBC) and explored their clinical significance. Expression of TRAIL receptors’ mRNA in GBC was analysed through reverse transcriptase polymerase chain reaction (RT-PCR), and protein through western blotting, immunohistochemistry and enzyme-linked immunosorbent assay (ELISA). mRNA data show frequent higher expression of TRAIL receptors in GBC samples. Death receptors DR4 and DR5 showed significant negative correlation with tumour stage, T stage and tumour grade; DcR1 transcript showed positive correlation with tumour stage, N stage, M stage and tumour grade. Similarly, IHC showed frequent positive staining for DR4, DR5 and DcR1in GBC samples. Cytoplasmic and nuclear DR4 protein showed negative correlation with T stage and tumour grade, whereas cytoplasmic DcR1 protein showed positive correlation with tumour stage and N stage. Nuclear DcR1 showed positive correlation with N stage. ELISA results showed significantly higher expression of secretory DcR1 in GBC patients. Kaplan-Meier analysis demonstrated significantly decreased mean survival of patients with positive staining of cytoplasmic DcR1. High level of death receptors identified the patients with early gallbladder cancer, whereas high DcR1 expression served as a prognostic factor for poor outcome.</p>
<p>doi: <a href="https://doi.org/10.1016/j.pathol.2019.12.001" class="uri">https://doi.org/10.1016/j.pathol.2019.12.001</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Long-term outcomes of surgical resection for T1b gallbladder cancer: an institutional evaluation</strong> </summary></p>
<p><em>BMC cancer 2020 Jan;20(1):20</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31907021" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31907021</a></p>
<p>BACKGROUND: There is no comprehensive agreement concerning the overall performance of radical resection for T1b gallbladder cancer (GBC). This research focused on addressing whether T1b GBC may spread loco-regionally and whether radical resection is necessary. METHODS: A retrospective analysis was conducted of 1032 patients with GBC who underwent surgical resection at our centre and its affiliated institutions between January 1982 and December 2018. A total of 47 patients with T1b GBC, 29 (62%) of whom underwent simple cholecystectomy and 18 (38%) of whom underwent radical resection with regional lymph node dissection, were enrolled in the study. RESULTS: GBC was diagnosed pre-operatively in 16 patients (34%), whereas 31 patients (66%) had incidental GBC. There was no blood venous or perineural invasion in any patient on histology evaluation, except for lymphatic vessel invasion in a single patient. There were no metastases in any analysed lymph nodes. The open surgical approach was more prevalent among the 18 patients who underwent radical resection (open in all 18 patients) than among the 29 patients who underwent simple cholecystectomy (open in 21; laparoscopic in 8) (P = 0.017). The cumulative 10- and 20-year overall survival rates were 65 and 25%, respectively. The outcome following simple cholecystectomy (10-year overall survival rate of 66%) was akin to that following radical resection (64%, P = 0.618). The cumulative 10- and 20-year disease-specific survival rates were 93 and 93%, respectively. The outcome following simple cholecystectomy (10-year disease-specific survival rate of 100%) was equivalent to that following radical resection (that of 86%, P = 0.151). While age (&gt; 70 years, hazard ratio 5.285, P = 0.003) and gender (female, hazard ratio 0.272, P = 0.007) had a strong effect on patient overall survival, surgical procedure (simple cholecystectomy vs. radical resection) and surgical approach (open vs. laparoscopic) did not. CONCLUSIONS: Most T1b GBCs represent local disease. As pre-operative diagnosis, including tumour penetration of T1b GBC, is difficult, the decision of radical resection is justified. Additional radical resection is not required following simple cholecystectomy provided that the penetration depth is restricted towards the muscular layer and that surgical margins are uninvolved.</p>
<p>doi: <a href="https://doi.org/10.1186/s12885-019-6507-2" class="uri">https://doi.org/10.1186/s12885-019-6507-2</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Clinicopathologic and Prognostic Significance of Gallbladder and Cystic Duct Invasion in Distal Bile Duct Carcinoma</strong> </summary></p>
<p><em>Archives of pathology &amp; laboratory medicine 2019 Nov;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31755778" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31755778</a></p>
<p>CONTEXT.—: The roles of the gallbladder and cystic duct (CD) invasions in distal bile duct carcinoma (DBDC) have not been well elucidated. OBJECTIVE.—: To define the characteristics and prognostic significance of gallbladder or CD invasions in patients with DBDC. DESIGN.—: Organ invasion patterns with clinicopathologic features were assessed in 258 resected DBDCs. RESULTS.—: CD invasions (N = 31) were associated with frequent concomitant pancreatic and/or duodenal invasions (23 of 31, 74%) and showed stromal infiltration (16 of 31, 52%) and intraductal cancerization (15 of 31, 48%) patterns. In only 2 cases, invasions with intraductal cancerization were observed in the gallbladder neck. Conversely, all pancreatic (N = 175) and duodenal (83) invasions developed through stromal infiltration. CD invasions were associated with larger tumor size (P = .001), bile duct margin positivity (P = .001), perineural invasions (P = .04), and higher N categories (P = .007). Patients with pancreatic or duodenal invasions had significantly lower survival rates than those without pancreatic (median, 31.0 versus 93.9 months) or duodenal (27.5 versus 56.8 months, P &lt; .001, both) invasions. However, those with gallbladder or CD invasions did not have different survival times (P = .13). Patients with concomitant gallbladder/CD and pancreatic/duodenal invasions demonstrated significantly lower survival rates than those without organ invasions (P &lt; .001). CONCLUSIONS.—: Gallbladder invasions were rare in DBDCs as neck invasions with intraductal cancerization. CD invasions occurred by stromal infiltrations and intraductal cancerization, whereas all pancreatic and duodenal invasions had stromal infiltration patterns. Gallbladder and/or CD invasions did not affect survival rates of patients with DBDC, while pancreatic and duodenal invasions affected survival rates. Therefore, these differences in survival rates may originate from the different invasive patterns of DBDCs.</p>
<p>doi: <a href="https://doi.org/10.5858/arpa.2019-0218-OA" class="uri">https://doi.org/10.5858/arpa.2019-0218-OA</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Non-neoplastic Polyps of the Gallbladder: A Clinicopathologic Analysis of 447 Cases</strong> </summary></p>
<p><em>The American journal of surgical pathology 2020 Apr;44(4):467-476</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31725469" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31725469</a></p>
<p>There is no systematic histopathologic analysis of non-neoplastic polyps in the gallbladder. In this study, in addition to a computer search for cases designated as “polyp,” a systematic review of 2533 consecutive routinely sampled archival and 203 totally submitted prospective cholecystectomies were analyzed for &gt;2 mm polyps (cut-off was based on radiologic sensitivity). A total of 447 non-neoplastic polyps were identified. The frequency was 3% in archival cases and 5% in totally submitted cases. Only 21 (5%) were ≥1 cm. The average age was 52 years, and the female to male ratio was 3.1. Two distinct categories were delineated: (1) injury-related polyps (n=273): (a) Fibro(myo)glandular polyps (n=214) were small (mean=0.4 cm), broad-based, often multiple (45%), almost always (98%) gallstone-associated, and were composed of a mixture of (myo)fibroblastic tissue/lobular glandular units with chronic cholecystitis. Dysplasia seen in 9% seemed to be secondary involvement. (b) Metaplastic pyloric glands forming polypoid collections (n=42). (c) Inflammatory-type polyps associated with acute/subacute injury (11 granulation tissue, 3 xanthogranulomatous, 3 lymphoid). (2) Cholesterol polyps (n=174) occurred in uninjured gallbladders, revealing a very thin stalk, edematous cores devoid of glands but with cholesterol-laden macrophages in 85%, and cholesterolosis in the uninvolved mucosa in 60%. Focal low-grade dysplasia was seen in 3%, always confined to the polyp, unaccompanied by carcinoma. In conclusion, non-neoplastic polyps are seen in 3% of cholecystectomies and are often small. Injury-related fibromyoglandular polyps are the most common. Cholesterol polyps have distinctive cauliflower architecture, often in a background of uninjured gallbladders with cholesterolosis and may lack the cholesterol-laden macrophages in the polyp itself. Although dysplastic changes can involve non-neoplastic polyps, they do not seem to be the cause of invasive carcinoma by themselves.</p>
<p>doi: <a href="https://doi.org/10.1097/PAS.0000000000001405" class="uri">https://doi.org/10.1097/PAS.0000000000001405</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Ultrastructural Characteristics of Gallbladder Epithelial Inclusions Mimicking Cystoisospora</strong> </summary></p>
<p><em>American journal of clinical pathology 2020 Jan;153(1):88-93</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31600399" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31600399</a></p>
<p>OBJECTIVES: There is recently reported increased prevalence of Isospora organisms in cholecystectomy specimens from immunocompetent patients, especially in acalculous cholecystectomies. We performed an ultrastructural and molecular evaluation of these specimens. METHODS: From 28 gallbladders with intraepithelial inclusions, two specimens with diffuse involvement of the gallbladder epithelium were analyzed by electron microscopy. Polymerase chain reaction was performed on five samples for the ITS2 region of C belli and eukaryotic 18S region. The 18S products were sequenced by next-generation sequencing. RESULTS: Electron microscopic analysis showed cytoplasmic condensations leading to vacuole formation. In contrast with true C belli, there were no identifiable organelles or organization. None of these cases showed amplified products other than human on molecular analysis. CONCLUSIONS: Electron microscopic analysis demonstrates that the inclusions are condensed cytoplasmic material and not true organisms.</p>
<p>doi: <a href="https://doi.org/10.1093/ajcp/aqz137" class="uri">https://doi.org/10.1093/ajcp/aqz137</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>A 12-year trend analysis of the incidence of gastrointestinal cancers in East Azerbaijan: last updated results of an ongoing population-based cancer registry</strong> </summary></p>
<p><em>BMC cancer 2019 Aug;19(1):782</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31391032" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31391032</a></p>
<p>BACKGROUND: The most recent results of Global Cancer Statistics indicated that gastrointestinal cancers, including gastric, colorectal, esophageal, and liver cancers, are among the most commonly diagnosed cancers worldwide. Previous reports from cancer registries in East Azerbaijan have shown that there is a high incidence of gastrointestinal cancer in this region, so we performed a trend analysis to determine the pattern of change over the last decade. METHODS: In total, 12 years of cancer registry data were collected from different sources in East Azerbaijan, and a data quality check was performed to ensure clean data. Using the 2000 World Health Organization standard population, we then generated age-standardized incidence rates (ASRs) for different cancers, and for each year from 1383 to 1394 of the Persian calendar (i.e., 19 March 2004 to 20 March 2015). Annual percent changes (APCs) and Average annual percent changes (AAPCs) in the ASRs for esophageal, gastric, small intestine, colorectal, anal, liver, gallbladder, and pancreatic cancers were calculated using Joinpoint Software (Version 4.5.0.1, June 2017). RESULTS: An increase in most types of cancer was observed during the study period. The ASR for colorectal cancer increased from 2.9 to 13.6 per 100,000 women (APC, 9.7%) and from 2.2 to 17.8 per 100,000 men (APC, 10.2%). The ASR for gastric cancer showed a slight increasing trend from 10.5 to 13.5 per 100,000 women (APC, 1.3%) and from 3.1 to 29.9 per 100,000 men (APC, 3.2%). However, trend analysis showed a decreasing pattern for the ASR of esophageal cancer in both genders (APC,- 3%), with APCs of - 1.1% in females and - 0.4% in males. CONCLUSIONS: The latest results of the East Azerbaijan Population-Based Cancer Registry indicate that gastrointestinal cancers remain common, with significant increasing trends in their ASRs. Improved screening and early detection are needed in this region.</p>
<p>doi: <a href="https://doi.org/10.1186/s12885-019-6008-3" class="uri">https://doi.org/10.1186/s12885-019-6008-3</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Nivolumab alone or in combination with cisplatin plus gemcitabine in Japanese patients with unresectable or recurrent biliary tract cancer: a non-randomised, multicentre, open-label, phase 1 study</strong> </summary></p>
<p><em>The lancet. Gastroenterology &amp; hepatology 2019 Aug;4(8):611-621</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31109808" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31109808</a></p>
<p>BACKGROUND: This study aimed to assess the safety and tolerability of the immune checkpoint inhibitor nivolumab, as monotherapy or combined with chemotherapy, in Japanese patients with biliary tract cancer. METHODS: This multicentre, open-label, phase 1 trial was done at four cancer centres in Japan. Eligible patients were aged 20-79 years, had biliary tract adenocarcinoma (intrahepatic bile duct cancer, extrahepatic bile duct cancer, gallbladder cancer, or ampullary cancer), Eastern Cooperative Oncology Group performance status 0 or 1, adequate hepatic, renal, and haematological function, and tumour tissue samples for PD-L1 expression analysis. Patients with unresectable or recurrent biliary tract cancer that was refractory or intolerant to gemcitabine-based treatment regimens received nivolumab monotherapy (240 mg every 2 weeks [monotherapy cohort]). Chemotherapy-naive patients with unresectable or recurrent biliary tract cancer received nivolumab (240 mg every 2 weeks) and cisplatin (25 mg/m2) plus gemcitabine (1000 mg/m2) chemotherapy (combined therapy cohort). The primary objective was to assess tolerability and safety. The primary objective was assessed in the safety population of all patients who had received at least one dose of nivolumab. This study is registered with www.clinicaltrials.jp, number JapicCTI-153098, and follow-up is ongoing. FINDINGS: 30 patients were enrolled into each cohort between Jan 13, 2016, and April 19, 2017. Data cutoff was Aug 31, 2017. In the monotherapy cohort, the most frequently reported treatment-related adverse events were decreased appetite (five [17%]), malaise (four [13%]), and pruritus (four [13%]). Grade 3-4 treatment-related adverse events were reported by three (10%) patients (rash, maculopapular rash, and amylase increase) and treatment-related serious adverse events were reported by one (3%) patient (pleurisy). In the combined therapy cohort, the most frequently reported treatment-related adverse events were neutrophil count decrease (any grade 25 [83%]; grade 3-4 in 23 [77%] patients) and platelet count decrease (any grade 25 [83%] of 30; grade 3-4 in 15 [50%] patients). Six (20%) patients reported 11 treatment-related serious adverse events (platelet count decrease [three patients], febrile neutropenia [two patients], neutrophil count decrease, anaemia, anaphylactic reaction, decreased appetite, pyrexia, and myocarditis [one patient each]). In the monotherapy cohort, median overall survival was 5·2 months (90% CI 4·5-8·7), median progression-free survival was 1·4 months (90% CI 1·4-1·4), and one of 30 patients had an objective response. In the combined therapy cohort, median overall survival was 15·4 months (90% CI 11·8-not estimable), median progression-free survival was 4·2 months (90% CI 2·8-5·6), and 11 of 30 patients had an objective response. INTERPRETATION: Nivolumab had a manageable safety profile and signs of clinical activity in patients with unresectable or recurrent biliary tract cancer. This initial assessment of nivolumab for the treatment of advanced biliary tract cancer provides supportive evidence for future larger randomised studies of nivolumab in this difficult to treat cancer. FUNDING: Ono Pharmaceutical Co Ltd and Bristol-Myers Squibb Inc.</p>
<p>doi: <a href="https://doi.org/10.1016/S2468-1253(19)30086-X" class="uri">https://doi.org/10.1016/S2468-1253(19)30086-X</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>IL-33 overexpression in gallbladder cancers associated with pancreatobiliary maljunction</strong> </summary></p>
<p><em>Histopathology 2019 Sep;75(3):365-375</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=30882917" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=30882917</a></p>
<p>AIMS: To investigate whether genetic or inflammatory pro-oncogenic factors are relevant to the increased risk of gallbladder cancers in patients with pancreaticobiliary maljunction (PBM). METHODS AND RESULTS: Mutations in KRAS exon 2 were examined by a highly sensitive, droplet digital PCR platform using surgically resected specimens of PBM-associated (n = 31) and non-associated gallbladder cancers (n = 49). The tissue expression of IL-6 and IL-33, which are suspected to promote biliary carcinogenesis, was analysed by quantitative real-time PCR and in-situ hybridisation. The incidence of KRAS mutations was similarly low in PBM-associated (five of 32 cases; 16%) and non-associated cancers (four of 49 cases; 8%) (P = 0.272). The tissue expression of IL-33 mRNA, but not IL-6 mRNA, was significantly higher in PBM-associated gallbladder cancers than in gallbladder cancers without PBM (P = 0.004). A similar degree of IL-33 overexpression was also observed in the background non-cancerous mucosa in cases of PBM-associated gallbladder cancers, and was significantly greater than that in PBM cases with cholecystitis alone (P &lt; 0.001). The results of in-situ hybridisation indicated that the source of IL-33 production in PBM-associated carcinomas was the endothelium, cancer cells and non-neoplastic biliary epithelium. In a combined PBM-associated and non-associated cohort, IL-33 overexpression in gallbladder cancers correlated with less aggressive features (e.g. a lower pT stage and longer overall survival), similar to recently reported findings on large-duct cholangiocarcinomas. CONCLUSIONS: KRAS mutations do not appear to be associated with a high risk of malignancy in PBM, while IL-33 overexpression may provide a pro-oncogenic microenvironment in the gallbladder mucosa of patients with PBM.</p>
<p>doi: <a href="https://doi.org/10.1111/his.13863" class="uri">https://doi.org/10.1111/his.13863</a></p>
</details>
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<hr />
<p><a href="#top" target="_self">Back to top</a></p>
<hr />
<div style="page-break-after: always;"></div>
</div>
<div id="bileducts" class="section level2">
<h2>Bile Ducts</h2>
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Peribiliary glands pathology in a large series of end-stage alcohol-related liver disease</strong> </summary></p>
<p><em>Virchows Archiv : an international journal of pathology 2020 Jun;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=32506156" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=32506156</a></p>
<p>The peribiliary glands are intramural or extramural structures with multiple functions related to bile secretion. The peribiliary glands can develop cystic alterations in several conditions, such as alcohol addiction. Peribiliary cysts can enlarge till being radiologically visible and mimic cancer. We studied 217 consecutive explanted livers for end-stage alcohol-related liver disease from the Pathology Unit of the Liver Unit at the King’s College Hospital in Denmark Hill, with particular focus on peribiliary glands. Our cohort consisted of 31 females and 186 males, with a median age of 51 and of 56 years respectively. 92,2% had established cirrhosis, 73,3% had only alcohol-induced liver disease, whilst 26,7% had other co-morbidities. We found a mild ectasia of the peribiliary glands (&lt;2 mm) in 37,8% and peribiliary cysts (&gt; = 2 mm) in 22,6% of cases. The diameter of the peribiliary glands varied from 1 mm to 8 mm. Inflammation of the peribiliary glands was found in the majority of cases with dilatation (p value = 0,000). 4,6% of the peribiliary cysts had low-grade intraductal papillary neoplasm of the bile ducts confined to the peribiliary glands. Pancreatic heterotopia was found in 10,6% and associated with the presence of ectasia. Our findings fit with what is reported in literature, such as the alcohol-induced damage at the peribiliary glands. Moreover these results underline the possible role of peribiliary glands in the development of the intraductal papillary neoplasm of the bile ducts, the biliary counterpart of the branch type intraductal mucinous neoplasm of the pancreas.</p>
<p>doi: <a href="https://doi.org/10.1007/s00428-020-02851-3" class="uri">https://doi.org/10.1007/s00428-020-02851-3</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Three-dimensional analysis of extrahepatic cholangiocarcinoma and tumor budding</strong> </summary></p>
<p><em>The Journal of pathology 2020 Jun;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=32476131" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=32476131</a></p>
<p>Advances in tissue clearing and microscopy make it possible to study human diseases in 3-dimensions (3-D). High-grade tumor budding (TB) is known to be associated with poor prognosis in various cancers; however, little is known about the 3-D architecture of TB. Using tissue clearing, we analyzed the 3-D structure of TB and E-cadherin expression in 31 extrahepatic cholangiocarcinomas. A total of 31 thick slabs (up to 5 mm) were harvested from surgically resected tumor tissue, including 27 hilar and 4 distal cholangiocarcinomas. Twenty-eight cases were adenocarcinoma, and three were undifferentiated carcinoma. After clearing, the tissues were immunolabeled with antibodies to cytokeratin 19 and to E-cadherin, and then visualized using light-sheet and confocal laser scanning microscopy. TB was evaluated in hematoxylin and eosin stained sections (2-D) using standard pathological criteria. Of the 31 cancers, 13 showed low-grade TB and 18 showed high-grade TB. First, 3-D analysis revealed that the neoplastic cells in tumor buds of adenocarcinoma were typically not individual islands of cells, but rather tips of attenuated protrusions connected to the main tumor. Second, adenocarcinomas with low-grade TB were predominantly composed of tubules that only focally form cords at the periphery. By contrast, adenocarcinomas with high-grade TB predominantly formed cords in both centers and peripheries of the tumors. Third, adenocarcinoma with low-grade TB was characterized by few short protrusions with few branches, while adenocarcinoma with high-grade TB was characterized by longer protrusions with more branching. Finally, immunolabeling of E-cadherin was stronger in the center of the adenocarcinoma but decreased at the tips of protrusions. E-cadherin loss was more extensive in the protrusions of high-grade TB than in the protrusions of low-grade TB. Our findings suggest that tumor buds as seen in 2-D are, in fact, cross-sections of attenuated but contiguous protrusions extending from the main tumor. This article is protected by copyright. All rights reserved.</p>
<p>doi: <a href="https://doi.org/10.1002/path.5474" class="uri">https://doi.org/10.1002/path.5474</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Prognostic Effects of Histology-Based Tumour Microenvironment Scores in Resected Distal Bile Duct Cancer</strong> </summary></p>
<p><em>Histopathology 2020 May;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=32473032" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=32473032</a></p>
<p>AIMS: Histology-based tumour microenvironment (TME) scores are useful in predicting the prognosis of gastrointestinal cancer. However, their prognostic roles in distal bile duct cancer (DBDC) have not been previously studied. This study aimed to evaluate the prognostic significance of the TME scores using the Klintrup-Mäkinen (KM) grade, tumour stroma percentage (TSP), and the Glasgow microenvironment score (GMS), in resected DBDC. METHODS AND RESULTS: Eighty-one patients with DBDC who underwent curative resection were enrolled. DBDC was graded according to KM grade, TSP, and GMS. A high KM grade was found in 19 patients (24%), and a high TSP was found in 47 patients (58%). A high TSP was significantly correlated with a low KM grade (P&lt;0.001). The distribution of the GMS, which was developed by combining the KM grade and TSP, was as follows: 0 (n=19, 24%), 1 (n=19, 24%), and 2 (n=43, 52%). A low KM grade, high TSP, and high GMS were significantly associated with short overall survival (OS) (P&lt;0.001) and relapse-free survival (RFS) (P&lt;0.001). Furthermore, multivariate analysis showed that a low KM grade (hazard ratio [HR], 3.826; confidence interval [CI], 1.650-8.869; P=0.014), high TSP (HR, 2.193; CI, 1.173-4.100, P=0.002), and high GMS (HR, 7.148; CI, 2.811-18.173) were independent prognostic factors for short RFS; a low KM grade (HR, 4.324; CI, 1.594-11.733) and high GMS (HR, 6.332; CI, 2.743-14.594) were independent prognostic factors for short OS. CONCLUSION: Histology-based TME scores, including the KM grade, TSP, and GMS, are useful for predicting the survival of patients with resected DBDC.</p>
<p>doi: <a href="https://doi.org/10.1111/his.14163" class="uri">https://doi.org/10.1111/his.14163</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Tiny but mighty: use of next generation sequencing on discarded cytocentrifuged bile duct brushing specimens to increase sensitivity of cytological diagnosis</strong> </summary></p>
<p><em>Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc 2020 May;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=32457409" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=32457409</a></p>
<p>Bile duct brushing (BDB) is used to evaluate pancreatobiliary lesions as it widely samples lesions with a low complication rate. Cytological evaluation of BDB is a specific but insensitive test. There is limited literature on the use of post-cytocentrifuged (PCC) samples, which are usually discarded, for next-generation sequencing (NGS) as an adjunct to cytological diagnosis of BDB. In this study we investigate whether molecular analysis by NGS of PCC specimens improves the sensitivity of diagnosis. PCC samples from 100 consecutive BDB specimens spanning 93 unique patients were retained. DNA was extracted and mutational analysis was performed agnostic of morphologic or clinical findings. Each BDB specimen was characterized as negative, atypical or positive based on morphological analysis by trained cytopathologists. Performance characteristics for mutational profiling and morphological analysis were calculated on the basis of clinicopathologic follow-up. There was sufficient clinicopathologic follow-up to classify 94 of 100 cases as either malignant (n = 43) or benign (n = 51). Based on morphologic analysis of cytology, these 94 cases were classified as either benign (n = 55), atypical (n = 18), or as at least suspicious or positive for malignancy (n = 21). Morphologic analysis of cytology showed a sensitivity of 49% and a specificity of 100% if atypical cases were considered negative. NGS revealed oncogenic alterations in 40/43 (93%) of malignant cases based on clinicopathologic follow-up. The most common alterations were in KRAS and TP53, observed in 77% and 49% of malignant cases respectively. No alterations were observed in the 51 benign cases classified based on clinicopathologic follow-up. Supplementing cytomorphologic analysis with molecular profiling of PCC by targeted NGS analysis increased the sensitivity to 93% and maintained specificity at 100%. This study provides evidence for the utility of NGS molecular profiling of PCC specimens to increase the sensitivity of BDB cytology samples, although studies with larger cohorts are needed to verify these findings.</p>
<p>doi: <a href="https://doi.org/10.1038/s41379-020-0577-1" class="uri">https://doi.org/10.1038/s41379-020-0577-1</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Detailed Analysis of Margin Positivity and the Site of Local Recurrence After Pancreaticoduodenectomy</strong> </summary></p>
<p><em>Annals of surgical oncology 2020 May;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=32451945" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=32451945</a></p>
<p>BACKGROUND: The association between a positive surgical margin and local recurrence after resection of pancreatic adenocarcinoma (PDAC) has been reported. Assessment of the location of the a positive margin and the specific site of local recurrence has not been well described. METHODS: A prospectively maintained database was queried for patients who underwent R0/R1 pancreaticoduodenectomy for PDAC between 2000 and 2015. The pancreatic, posterior, gastric/duodenal, anterior peritoneal, and bile duct margins were routinely assessed. Postoperative imaging was reviewed for the site of first recurrence, and local recurrence was defined as recurrence located in the remnant pancreas, surgical bed, or retroperitoneal site outside the surgical bed. RESULTS: During the study period, 891 patients underwent pancreaticoduodenectomy, and 390 patients had an initial local recurrence with or without distant metastases. The 5-year cumulative incidence of local recurrence by site included the remnant pancreas (4%; 95% confidence interval [CI], 3-5%), the surgical bed (35%; 95% CI, 32-39%), and other regional retroperitoneal site (4%; 95% CI, 3-6%). In the univariate analysis, positive posterior margin (hazard ratio [HR], 1.50; 95% CI, 1.17-1.91; p = 0.001) and positive lymph nodes (HR, 1.36; 95% CI, 1.06-1.75; p = 0.017) were associated with surgical bed recurrence, and in the multivariate analysis, positive posterior margin remained significant (HR, 1.40; 95% CI, 1.09-1.81; p = 0.009). An isolated local recurrence was found in 197 patients, and a positive posterior margin was associated with surgical bed recurrence in this subgroup (HR, 1.51; 95% CI, 1.08-2.10; p = 0.016). CONCLUSION: In this study, the primary association between site of margin positivity and site of local recurrence was between the posterior margin and surgical bed recurrence. Given this association and the limited ability to modify this margin intraoperatively, preoperative assessment should be emphasized.</p>
<p>doi: <a href="https://doi.org/10.1245/s10434-020-08600-9" class="uri">https://doi.org/10.1245/s10434-020-08600-9</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Testing for ROS1, ALK, MET, and HER2 rearrangements and amplifications in a large series of biliary tract adenocarcinomas</strong> </summary></p>
<p><em>Virchows Archiv : an international journal of pathology 2020 May;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=32447492" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=32447492</a></p>
<p>Biliary tract carcinomas are divided into intrahepatic, perihilar, distal extrahepatic cholangiocarcinomas, and gallbladder adenocarcinomas. Therapies targeting ROS1, ALK, MET, and HER2 alterations are currently evaluated in clinical trials. We assessed ROS1 and ALK translocations/amplifications as well as MET and HER2 amplifications for each tumor subtype by fluorescent in situ hybridization (FISH) and immunohistochemistry (IHC) in 73 intrahepatic, 40 perihilar bile duct, 36 distal extrahepatic cholangiocarcinomas, and 45 gallbladder adenocarcinomas (n = 194). By FISH, we detected targetable alterations in 5.2% of cases (n = 10): HER2 and MET amplifications were found in 4.1% (n = 8) and 1.0% (n = 2), respectively. The HER2-amplified cases were mostly gallbladder adenocarcinomas (n = 5). The MET- and HER2-amplified cases were all positive by IHC. Fourteen cases without MET amplification were positive by IHC, whereas HER2 over-expression was detected by IHC only in HER2-amplified cases. We detected no ALK or ROS1 translocation or amplification. Several alterations were consistent with aneuploidy: 24 cases showed only one copy of ROS1 gene, 4 cases displayed a profile of chromosomal instability, and an over-representation of centromeric alpha-satellite sequences was found in five cases. We confirm a relatively high rate of HER2 amplifications in gallbladder adenocarcinomas and the efficacy of IHC to screen these cases. Our results also suggest the value of IHC to screen MET amplification. Contrary to initial publications, ROS1 rearrangements seem to be very rare in biliary tract adenocarcinomas. We confirm a relatively high frequency of aneuploidy and chromosomal instability and reveal the over-representation of centromeric alpha-satellite sequences in intrahepatic cholangiocarcinomas.</p>
<p>doi: <a href="https://doi.org/10.1007/s00428-020-02822-8" class="uri">https://doi.org/10.1007/s00428-020-02822-8</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>BRAF-Associated Bile Duct Adenomatosis: A New Entity?</strong> </summary></p>
<p><em>Histopathology 2020 May;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=32367668" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=32367668</a></p>
<p>Bile duct adenomas (BDAs) are benign intrahepatic biliary proliferations consisting of bile ducts arranged in small and tortuous tubules and embedded in a dense fibrous stroma [1]. Microscopically, tubules are lined by a single layer of cuboidal to columnar cells with nuclei showing neither atypia nor mitoses. BDAs were formerly considered reactive by some authors [2,3]. Recurrent BRAF V600E mutations were however further identified in these lesions, supporting the hypothesis that they are true neoplasms [4,5]. They are most often incidentally identified during intra-abdominal surgery and the main differential diagnosis of BDAs is metastatic adenocarcinoma, as mentioned by Levin et al. in the first report of bile duct adenomatosis of the liver [6].</p>
<p>doi: <a href="https://doi.org/10.1111/his.14125" class="uri">https://doi.org/10.1111/his.14125</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Robotic Resection of Hilar Cholangiocarcinoma</strong> </summary></p>
<p><em>Annals of surgical oncology 2020 May;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=32363511" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=32363511</a></p>
<p>BACKGROUND: Hilar cholangiocarcinoma is the most common malignant neoplasm of the biliary tract. Surgical resection is the only curative modality of treatment. The aim of this video is to present a robotic left hepatectomy extended to caudate lobe, combined with bile duct resection, lymphadenectomy, and Roux-en-Y biliary reconstruction. METHODS: A 76-year-old female presented with progressive jaundice due to hilar cholangiocarcinoma. She underwent chemoradiation and after 5 months of treatment was referred for second opinion; imaging reevaluation showed objective response and no arterial invasion. Multidisciplinary team decided for radical treatment, which consisted in robotic left hepatectomy, caudate lobe resection, resection of bile duct, lymphadenectomy, and hepaticojejunostomy. RESULTS: Operative time was 8 h. Estimated blood loss was 740 mL (received 2 U). The patient’s recovery was complicated by drainage clogging resulting in fever and perihepatic fluid collection, successfully treated by change of drainage. Pathology confirmed cholangiocarcinoma with free surgical margins (T1aN0). The patient is well, with no signs of disease 5 months after the procedure. CONCLUSIONS: Robotic resection of hilar cholangiocarcinoma is feasible and safe. The robotic approach has some technical advantages over laparoscopic approach. This video may help oncological surgeons to perform this complex procedure.</p>
<p>doi: <a href="https://doi.org/10.1245/s10434-020-08514-6" class="uri">https://doi.org/10.1245/s10434-020-08514-6</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>De novo perihilar cholangiocarcinoma arising in the allograft liver 15 years post-transplantation for biliary atresia</strong> </summary></p>
<p><em>Pathology international 2020 Apr;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=32350971" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=32350971</a></p>
<p>Most primary liver cancers diagnosed in allograft livers are recurrent tumors of the native liver origin, while donor-derived primary liver cancers are markedly less common. A 21-year-old woman who had liver transplantation for post-Kasai biliary atresia was recently referred for post-transplant biliary stricture. Her transplantation was performed at the age of 6 years using the whole liver graft from a 10-year-old donor and choledocho-jejunostomy. The post-transplant course was uneventful in the first 15 years until she presented with obstructive jaundice. The stricture was located at the level of the hepaticojejunostomy, and required percutaneous transhepatic drainage and bile duct dilatation. She underwent an exploratory laparotomy, which suggested a neoplastic process widely involving the extrahepatic and intrahepatic large bile ducts. The histological examination of the resected extrahepatic bile duct confirmed infiltrating moderately differentiated adenocarcinoma. Molecular tests of multiple short tandem repeat loci confirmed the donor origin of the tumor. After four cycles of chemotherapy with gemicitabine and cisplatin, she is currently on radiotherapy in view of potential re-transplantation. De novo, post-transplant cholangiocarcinoma of graft origin is extremely uncommon with only three other cases reported. Two were associated with recurrent primary sclerosing cholangitis, and all had choledocho-jejunostomy at the time of transplantation.</p>
<p>doi: <a href="https://doi.org/10.1111/pin.12944" class="uri">https://doi.org/10.1111/pin.12944</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Pathologic Manifestations of Gastrointestinal and Hepatobiliary Injury in Immune Checkpoint Inhibitor Therapy</strong> </summary></p>
<p><em>Archives of pathology &amp; laboratory medicine 2020 Apr;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=32338534" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=32338534</a></p>
<p>CONTEXT.—: Immune checkpoint inhibitors (CPIs), including cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) inhibitors and the programmed death receptor-1 (PD-1)/programmed death ligand-1 (PD-L1) inhibitors, are being increasingly used for treating many advanced malignancies. However, CPI therapy is also associated with gastrointestinal and hepatobiliary adverse effects. OBJECTIVES.—: To review the adverse effects of CPI therapy on the gastrointestinal tract and hepatobiliary system. To describe histopathologic patterns and discuss differential diagnostic considerations in the diagnosis of CPI injuries. DATA SOURCES.—: Published peer-reviewed literature in the English language and personal experience in the diagnosis of CPI injuries. CONCLUSIONS.—: The pathologic manifestations of CPI therapy-induced gastrointestinal and hepatobiliary injury are broad. The patterns of esophageal CPI injury include lymphocytic inflammation and ulcerative esophagitis, while those of gastric injury include chronic active gastritis, lymphocytic gastritis, focal enhancing gastritis, and periglandular inflammation. The duodenal injury may present as duodenitis with villous blunting and granulomas. We also noticed active colitis, microscopic colitis, chronic active colitis, increased apoptosis, ischemic colitis, and nonspecific inflammatory reactive changes in colonic injuries. The reported histologic features of hepatobiliary injuries are panlobular hepatitis, centrilobular necrosis, portal inflammation with bile duct injury, steatosis, nodular regenerative hyperplasia, and secondary sclerosing cholangitis. In summary, we here discuss the pathologic features and differential diagnosis of CPI therapy-induced gastrointestinal and hepatobiliary injury. Recognition of CPI injury is important to determine the proper management that often includes cessation of CPI therapy; and administration of steroids or other immunosuppressive agents, based on severity of injury.</p>
<p>doi: <a href="https://doi.org/10.5858/arpa.2020-0070-RA" class="uri">https://doi.org/10.5858/arpa.2020-0070-RA</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Epigenetic mechanisms and metabolic reprogramming in fibrogenesis: dual targeting of G9a and DNMT1 for the inhibition of liver fibrosis</strong> </summary></p>
<p><em>Gut 2020 Apr;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=32327527" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=32327527</a></p>
<p>OBJECTIVE: Hepatic stellate cells (HSC) transdifferentiation into myofibroblasts is central to fibrogenesis. Epigenetic mechanisms, including histone and DNA methylation, play a key role in this process. Concerted action between histone and DNA-mehyltransferases like G9a and DNMT1 is a common theme in gene expression regulation. We aimed to study the efficacy of CM272, a first-in-class dual and reversible G9a/DNMT1 inhibitor, in halting fibrogenesis. DESIGN: G9a and DNMT1 were analysed in cirrhotic human livers, mouse models of liver fibrosis and cultured mouse HSC. G9a and DNMT1 expression was knocked down or inhibited with CM272 in human HSC (hHSC), and transcriptomic responses to transforming growth factor-β1 (TGFβ1) were examined. Glycolytic metabolism and mitochondrial function were analysed with Seahorse-XF technology. Gene expression regulation was analysed by chromatin immunoprecipitation and methylation-specific PCR. Antifibrogenic activity and safety of CM272 were studied in mouse chronic CCl4 administration and bile duct ligation (BDL), and in human precision-cut liver slices (PCLSs) in a new bioreactor technology. RESULTS: G9a and DNMT1 were detected in stromal cells in areas of active fibrosis in human and mouse livers. G9a and DNMT1 expression was induced during mouse HSC activation, and TGFβ1 triggered their chromatin recruitment in hHSC. G9a/DNMT1 knockdown and CM272 inhibited TGFβ1 fibrogenic responses in hHSC. TGFβ1-mediated profibrogenic metabolic reprogramming was abrogated by CM272, which restored gluconeogenic gene expression and mitochondrial function through on-target epigenetic effects. CM272 inhibited fibrogenesis in mice and PCLSs without toxicity. CONCLUSIONS: Dual G9a/DNMT1 inhibition by compounds like CM272 may be a novel therapeutic strategy for treating liver fibrosis.</p>
<p>doi: <a href="https://doi.org/10.1136/gutjnl-2019-320205" class="uri">https://doi.org/10.1136/gutjnl-2019-320205</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Novel ABCB4 mutation in a Chinese female patient with progressive familial intrahepatic cholestasis type 3: a case report</strong> </summary></p>
<p><em>Diagnostic pathology 2020 Apr;15(1):39</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=32321542" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=32321542</a></p>
<p>BACKGROUND: Progressive familial intrahepatic cholestasis (PFIC) is a rare group of autosomal recessive hereditary hepatic diseases. There are three types of PFIC, classified according to the mutated gene. For example, PFIC type 3 (PFIC3) is due to mutations in the ABCB4 gene (encoding multidrug-resistant protein 3 [MDR3]). CASE PRESENTATION: We present a 19-year-old Chinese female patient who had a 2-year history of recurrent liver dysfunction, with mainly elevated alkaline phosphatase and γ-glutamyl transpeptidase(γ-GT) levels. After excluding other causes of abnormal liver function and cholestasis, the final diagnosis of PFIC3 was confirmed by histopathological examination and gene detection. The immunohistochemical results showed no MDR3 protein expression in the bile duct membrane. Genetic sequencing analysis revealed a novel heterozygous 2137G &gt; A; p. V713M mutation (Exon 17) and a synonymous 504C &gt; T; p. N168N mutation (Exon 6) in ABCB4. CONCLUSIONS: Our patient with long-term liver dysfunction demonstrated that elevated alkaline phosphatase and γ-GT levels should be associated with the diagnosis of PFIC3, and gene detection is the key to diagnosis. From our in silico analysis, the novel mutation p. V713M in Exon 17 was predicted to affect protein function, with a SIFT (Sorting Intolerant from Tolerant) score of 0.02, indicating a deleterious effect. Further studies are necessary to investigate the impact of the novel heterozygous 2137G &gt; A; p. V713M mutation (Exon 17) on functional defects of MDR3 and PFIC3.</p>
<p>doi: <a href="https://doi.org/10.1186/s13000-020-00955-7" class="uri">https://doi.org/10.1186/s13000-020-00955-7</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Utility of DNA flow cytometry in distinguishing between malignant and benign intrahepatic biliary lesions</strong> </summary></p>
<p><em>Virchows Archiv : an international journal of pathology 2020 Apr;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=32296928" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=32296928</a></p>
<p>The distinction between well-differentiated intrahepatic cholangiocarcinoma (iCCA) from its morphological mimics such as bile duct adenoma (BDA) and hamartoma (BDH) can be challenging, particularly in small biopsies. Although a few cases of BDA and BDH have been reported to undergo malignant transformation into iCCA, their neoplastic versus benign nature remains debated. DNA flow cytometry was performed on 47 formalin-fixed paraffin-embedded samples of iCCA, 14 BDA, and 18 BDH. Aneuploidy was detected in 22 iCCA (47%) but in none of the 32 BDA and BDH samples. Among the 34 iCCA patients who underwent complete resection and were followed up to tumor recurrence, tumor-related death, or at least for 1 year, the overall recurrence or death rates (regardless of flow cytometric results) were 18, 56, and 71% within 1, 3, and 5 years, respectively. The 1-, 3-, and 5-year recurrence or death rates in 18 iCCA patients with aneuploidy were 28, 66, and 66%, respectively, whereas 16 iCCA patients in the setting of normal DNA content had 1-, 3-, and 5-year rates of 6, 44, and 72%, respectively. Although aneuploid tumors were associated with worse outcomes during the first 3 years, this difference was not statistically significant (hazard ratio = 1.4, p = 0.473) in the present sample size. In conclusion, the frequency of aneuploidy was significantly higher in iCCA (47%) than in its benign morphological mimics (0%), suggesting that it may potentially serve as a diagnostic marker of malignancy in challenging situations. Our findings also suggest that most BDAs and BDHs, if not all, are benign entities and may not represent precursor lesions to iCCAs that often harbor aneuploidy. Although a larger cohort will be necessary to further determine the prognostic significance of aneuploidy in iCCA patients after resection, the patients with aneuploid tumors may have a higher risk for tumor progression, especially during the first 3 years.</p>
<p>doi: <a href="https://doi.org/10.1007/s00428-020-02812-w" class="uri">https://doi.org/10.1007/s00428-020-02812-w</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Hedgehog Signaling Demarcates a Niche of Fibrogenic Peribiliary Mesenchymal Cells</strong> </summary></p>
<p><em>Gastroenterology 2020 Apr;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=32289375" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=32289375</a></p>
<p>BACKGROUND &amp; AIMS: In response to tissue injury, stromal cells secrete extracellular matrix (ECM) components that remodel the tissue and lead to fibrosis. Parenchymal stellate cells are the primary contributors to fibrosis in models of hepatocellular and cholestatic injury. The liver comprises different, heterogenous compartments; stromal cells within those compartments might have unique identities and regional functions. The portal tract contains the bile duct, which is surrounded by stromal cells often called portal fibroblasts. We investigated the contributions of these cells to hepatic injury. METHODS: We performed studies with Gli1:CreERT2; Rosa26:lox-STOP-lox-tdTomato mice. Mice underwent bile duct ligation or were fed 3,5-diethoxycarbonyl-1,4-dihydrocollidine to induce cholestatic injury or were given CCL4 to induce liver fibrosis. Liver tissues were collected and analyzed by histology and immunofluorescence, and mesenchymal cells were isolated. We performed lineage tracing experiments to determine the fates of peribiliary mesenchymal cells (PMCs) that surround the bile duct after cholestatic and hepatocellular injury. We used cell sorting, combined with RNA-sequencing, to isolate stellate cells and PMCs, and identified determinants of cell identity within each population. Liver tissues were obtained from patients with primary sclerosing cholangitis, alcoholic liver disease, nonalcoholic steatohepatitis, or without disease and analyzed by quantitative reverse transcription PCR. RESULTS: Gli1 was a marker of mesenchymal cells that surround the biliary tree, but not epithelial cells of the canals of Hering. Lineage-traced Gli1+ PMCs proliferated and acquired a myofibroblast phenotype after cholestatic injury; Gli1+ PMCs were found only surrounding the main duct of a portal tract, but not the epithelial cells of the ductular reaction, which were instead encased by stellate cells. Compared with stellate cells, Gli1+ PMCs expressed a different subset of genes, including genes that are markers of active hedgehog signaling, Osr1 (encodes a transcription factor), and ECM-related genes. Loss of hedgehog signaling reduced expression of Osr1 and PMC-specific ECM genes. Liver tissues from patients with liver disease had increased expression of genes that define PMC identity, compared with control liver tissues. CONCLUSIONS: In lineage-tracing studies of mice, we found that Gli1+ PMCs are a subset of stromal cells characterized by active hedgehog signaling that proliferate, acquire a myofibroblast phenotype, and surround the biliary tree in response to cholestatic injury.</p>
<p>doi: <a href="https://doi.org/10.1053/j.gastro.2020.03.075" class="uri">https://doi.org/10.1053/j.gastro.2020.03.075</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Intraductal Tubulopapillary Neoplasm of the Pancreas and Bile Duct: A Review</strong> </summary></p>
<p><em>Pancreas 2020 Apr;49(4):498-502</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=32282762" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=32282762</a></p>
<p>Intraductal tubulopapillary neoplasms (ITPNs) of the pancreas and bile duct are contemporary entities. It is unclear on how to best manage patients with this diagnosis because little is known about its progression to cancer. This review provides an update on the current knowledge of ITPN of the pancreas and bile duct with an overview of clinical, radiological, histopathological, and molecular features, as well as the prognosis and management. Embase and Medline databases search were performed to identify studies that evaluated ITPN of the pancreas and bile duct. The infrequent exposure to this variant poses a diagnostic challenge. The diagnosis of ITPN is almost always made postoperatively because there are no characteristics on radiological studies to distinguish it from other cystic neoplasms of the pancreas. As ITPN has a favorable prognosis, it is crucial to establish an accurate diagnosis and differentiate it from other pancreatic and biliary variants. These neoplasms are considered to be precursor lesions to carcinomas, hence, surgery and close clinical surveillance are recommended. Further studies are essential to elucidate the natural history of ITPN, guide best treatment strategy and determine disease recurrence and survival.</p>
<p>doi: <a href="https://doi.org/10.1097/MPA.0000000000001518" class="uri">https://doi.org/10.1097/MPA.0000000000001518</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Clinicopathological significance of olfactomedin-4 in extrahepatic bile duct carcinoma</strong> </summary></p>
<p><em>Pathology, research and practice 2020 Mar;():152940</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=32276789" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=32276789</a></p>
<p>The clinicopathological and prognostic significance of olfactomedin-4 (OLFM4) expression has not yet been elucidated in extrahepatic bile duct carcinomas (EBDCs). Immunohistochemical analysis of OLFM4 expression in 31 normal biliary epithelia, 33 biliary intraepithelial neoplasias (BilINs), and 180 surgically resected EBDCs (54 perihilar and 126 distal) was performed and was used to analyze clinicopathological variables including patient survival. The expression of OLFM4 showed a progressive increase from normal biliary epithelia (0.2 ± 0.4) to BilINs (2.8 ± 3.2) to EBDCs (4.6 ± 4.2; P &lt; 0.001). OLFM4 was highly expressed in 26.1% (47/180) of the EBDC cases, and high OLFM4 levels were more frequently observed in tumors with nodular growth (P = 0.029), well differentiation (P = 0.011), and lower T-category (P = 0.025) and stage grouping (P = 0.013). Patients with EBDC having high expression of OLFM4 had better survival than those with low expression of OLFM4 (median, 43.3 vs. 29.2 months; P = 0.037). OLFM4 might play an important role in carcinogenesis and in the progression from BilINs to EBDCs. High OLFM4 expression predicted less aggressive clinical behavior in patients with EBDC.</p>
<p>doi: <a href="https://doi.org/10.1016/j.prp.2020.152940" class="uri">https://doi.org/10.1016/j.prp.2020.152940</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>DNA Flow Cytometric Analysis of Paraffin-Embedded Tissue for the Diagnosis of Malignancy in Bile Duct Biopsies</strong> </summary></p>
<p><em>Human pathology 2020 Apr;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=32272125" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=32272125</a></p>
<p>Differentiation of reactive versus neoplastic epithelial changes can be challenging in bile duct biopsies. The samples are often scant, distorted, and mixed with significant inflammation, ulceration, and/or debris. Histological confirmation of malignancy is often required before the initiation of surgical therapy, while an erroneous diagnosis of malignancy can lead to unnecessary clinical management. Aneuploidy assessment by DNA flow cytometry was performed on formalin-fixed paraffin-embedded (FFPE) tissue from 63 bile duct biopsies: 10 with a malignant diagnosis (7 adenocarcinoma and 3 at least high-grade dysplasia [HGD]); 3 with an “atypical” diagnosis showing rare atypical glands/cells, concerning but not definite for malignancy; 28 likely “reactive” biopsies with acute/chronic inflammation, ulceration, and/or mild nuclear atypia; and 22 additional benign biopsies without significant inflammation, ulceration, or nuclear atypia. Aneuploidy was detected in 7 (70%) of the 10 biopsies with definite neoplasia (5 of 7 adenocarcinoma and 2 of 3 at least HGD), all 3 (100%) “atypical” biopsies, and none of the 50 benign biopsies. All 3 “atypical” cases with aneuploidy were subsequently found to have adenocarcinoma (n = 2) or HGD (n = 1). Among the 2 cases of at least HGD with aneuploidy, 1 case developed adenocarcinoma, but no follow-up information was available in the other case. The remaining 1 case of at least HGD, despite having normal DNA content, was found to have adenocarcinoma on follow-up. None of the 50 benign cases (further supported by normal DNA content) developed adenocarcinoma within a mean follow-up time of 37 months (range: 0-282 months). The estimated sensitivity of aneuploidy as a diagnostic marker of malignancy (adenocarcinoma and HGD) was 70% with the specificity of 100%, positive predictive value of 100%, and negative predictive value of 94%. In conclusion, DNA flow cytometry using FFPE tissue from bile duct biopsies demonstrates a high rate of aneuploidy (70%) in malignant cases, and normal DNA content in all benign biopsies. Although the sample size is small, the results indicate that this assay can be potentially useful in challenging “atypical” cases, where morphological evaluation is limited by scarcity of atypical glands/cells, inflammation, and/or ulceration.</p>
<p>doi: <a href="https://doi.org/10.1016/j.humpath.2020.04.002" class="uri">https://doi.org/10.1016/j.humpath.2020.04.002</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Biliary intraductal tubule-forming neoplasm: A whole exome sequencing study of MUC5AC-positive and -negative cases</strong> </summary></p>
<p><em>Histopathology 2020 Mar;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=32181510" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=32181510</a></p>
<p>AIMS: Biliary intraductal tubular neoplasms that are non-mucinous and negative for MUC5AC are called intraductal tubulopapillary neoplasm (ITPNs). Intraductal tubular neoplasms with mucinous cytoplasm and MUC5AC positivity also occur, and their nature remains unclear although some pathologists may classify these as “IPNBs of gastric type”. This study aimed to elucidate genetic features of biliary intraductal tubular neoplasms. METHODS: Six resected cases of biliary intraductal neoplasm with &gt;70% tubular configuration were characterized by the clinicopathological examination and whole exome sequencing, and obtained findings were compared between MUC5AC-positive (n=2) and -negative cases (n=4). RESULTS: The intraductal tumours consisted of the pancreatobiliary-type epithelium with high-grade dysplasia arranged in back-to-back tubules. Both two MUC5AC-negative cases were non-invasive neoplasms developed in the liver, whereas all MUC5AC-positive cases had invasive carcinoma and were present in the intrahepatic (n=2), perihilar (n=1), and distal bile ducts (n=1). In an exome-sequencing study, MUC5AC-negative cases harboured mutations in CTNNB1, SF3B1, BAP1, and BRCA1 (one case each). KRAS mutations were observed in 3/4 MUC5AC-positive cases (75%) but none of MUC5AC-negative neoplasms. Compared to published data, known driver genes of other intraductal neoplasms of the pancreatobiliary systems (e.g., APC, CTNNB1, STK11, GNAS, and PIK3CA) were wild-type in all but one MUC5AC-negative case with CTNNB1 mutation. Chromatin modifiers (ARID1A, BAP1, and KMT2C) were also altered in MUC5AC-positive cases, similar to usual cholangiocarcinomas. CONCLUSIONS: This exome-sequencing study suggested that MUC5AC-negative biliary ITPNs are genetically distinct from pancreatic ITPNs and IPNBs. They may also biologically differ from MUC5AC-positive tubular neoplasms despite morphological resemblance.</p>
<p>doi: <a href="https://doi.org/10.1111/his.14103" class="uri">https://doi.org/10.1111/his.14103</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Validation of the T category for distal cholangiocarcinoma: Measuring the depth of invasion is complex but correlates with survival</strong> </summary></p>
<p><em>Annals of diagnostic pathology 2020 Mar;46():151489</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=32169826" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=32169826</a></p>
<p>According to the current 8th edition of the American Joint Committee of Cancer (AJCC), the T category of distal cholangiocarcinomas is classified based on the depth of invasion (DOI) (T1, &lt; 5 mm; T2, between 5 and 12 mm; T3, &gt; 12 mm). In consideration of the discrepancies between previous studies about the prognostic significance, we aimed to validate the current AJCC T staging system of distal cholangiocarcinomas. DOI was measured using three different methods: DOI1, DOI2, and DOI3. DOI1 was defined and stratified according to the AJCC 8th edition. DOI2 was measured as the distance from an imaginary curved line approximated along the distorted mucosal surface to the deepest invasive tumor cells. DOI3 was defined as the total tumor thickness. DOI2 and DOI3 were also divided into three categories using the same cut-off points as in the AJCC 8th edition. We compared these three DOI methods to the AJCC 7th edition as well. In contrast with the AJCC 7th edition, all three groups showed a correlation with patients’ overall survival. Above all, the DOI2 group demonstrated the best significance in multivariate analysis. However, when the C indices were compared between these groups, differential significance proved to be negligible (DOI1 vs DOI2, p = 0.915; DOI2 vs DOI3, p = 0.057). Therefore, the measurement of DOI does not need to be rigorously and stringently performed. In conclusion, we showed that the current T classification system better correlates with the overall survival of patients with distal cholangiocarcinomas than the previous system.</p>
<p>doi: <a href="https://doi.org/10.1016/j.anndiagpath.2020.151489" class="uri">https://doi.org/10.1016/j.anndiagpath.2020.151489</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Global trends in intrahepatic and extrahepatic cholangiocarcinoma incidence from 1993 to 2012</strong> </summary></p>
<p><em>Cancer 2020 Mar;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=32129902" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=32129902</a></p>
<p>BACKGROUND: Intrahepatic cholangiocarcinomas (ICCs) and extrahepatic cholangiocarcinomas (ECCs) are highly lethal bile duct tumors. Their incidence can be difficult to estimate because of changes in cancer coding over time. No studies to date have examined their global incidence and trends with high-quality topography- and histology-specific cancer registry data. Therefore, this study examined ICC and ECC incidence with the Cancer Incidence in Five Continents Plus database. METHODS: Regional and national cancer registry data were used to estimate age-standardized incidence rates (ASRs) per 100,000 person-years, 95% confidence intervals, and average annual percent changes (AAPCs) for ICC in 38 countries and for ECC in 33 countries from 1993 to 2012. ICC and ECC trends were tabulated and plotted by country. Rates versus birth cohort by age were plotted, and an age-period-cohort analysis was performed to assess age and cohort incidence rate ratios. RESULTS: The highest rates of ICC and ECC were in Asia, specifically South Korea (ASR for ICC, 2.80; ASR for ECC, 2.24), Thailand (ASR for ICC, 2.19; ASR for ECC, 0.71), and Japan (ASR for ICC, 0.95; ASR for ECC, 0.83). Between 1993 and 2012, incidence rates of both ICC and ECC increased in most countries. The largest ASR increases over the study period occurred in Latvia (AAPC, 20.1%) and China (AAPC, 11.1%) for ICC and in Thailand (AAPC, 8.8%) and Colombia (AAPC, 8.5%) for ECC. CONCLUSIONS: In the 20 years examined, ICC and ECC incidence increased in the majority of countries worldwide. ICC and ECC incidence may continue to increase because of metabolic and infectious etiologic factors. Efforts to further elucidate risk factors contributing to these increases in incidence are warranted.</p>
<p>doi: <a href="https://doi.org/10.1002/cncr.32803" class="uri">https://doi.org/10.1002/cncr.32803</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Intraductal papillary neoplasms of the bile duct consist of two distinct types specifically associated with clinicopathological features and molecular phenotypes</strong> </summary></p>
<p><em>The Journal of pathology 2020 Feb;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=32100878" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=32100878</a></p>
<p>Intraductal papillary neoplasm of the bile duct (IPNB) is a grossly visible papillary biliary neoplasm with morphological variations and occasional invasion. Recently a new classification of IPNB into type 1 and type 2 was proposed in which the type 1 IPNBs consist of fine papillary neoplastic glands and the type 2 IPNBs consist of complex branching glands, seldom with foci of solid-tubular components. However, clinicopathological and molecular characteristics of these types of IPNBs are yet to be identified. We aimed to uncover clinicopathological and molecular characteristics of the types of IPNBs. Thirty-six IPNBs were studied retrospectively. Clinicopathological features as well as molecular alterations of 31 genes were evaluated by means of targeted next-generation sequencing and immunohistochemical examination of expression of mucin and cancer-associated molecules. The 36 IPNBs were classified into 22 of type 1 and 14 of type 2. The type 1 IPNBs were associated with a non-invasive phenotype, intestinal and oncocytic subtypes, development in the intrahepatic bile duct, overt mucin production, and a relatively good prognosis. The type 2 IPNBs were associated with an invasive phenotype, the pancreatobiliary subtype, development within the extrahepatic bile duct, and worse prognosis compared with the type 1 IPNBs. In the molecular analysis, recurrent mutations were found in TP53 (34.3%), KRAS (31.4%), STK11 (25.7%), CTNNB1 (17.1%), APC (14.3%), SMAD4 (14.3%), GNAS (11.4%), PBRM1 (11.4%), ELF3 (8.6%), KMT2C (8.6%), NF1 (8.6%), PIK3CA (8.6%), ARID1A (5.7%), ARID2 (5.7%), BAP1 (5.7%), BRAF (5.7%), EPHA6 (5.7%), ERBB2 (5.7%), ERBB3 (5.7%), KMT2D (5.7%), and RNF43 (5.7%). Mutations in KRAS and GNAS were enriched in the type 1 IPNBs, whereas mutations in TP53, SMAD4, and KMT2C were enriched in the type 2 IPNBs. These results indicate that IPNBs consist of two distinct types of neoplasms specifically associated with clinicopathological features and molecular phenotypes. © 2020 Pathological Society of Great Britain and Ireland. Published by John Wiley &amp; Sons, Ltd.</p>
<p>doi: <a href="https://doi.org/10.1002/path.5398" class="uri">https://doi.org/10.1002/path.5398</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Recurrent Rearrangements in PRKACA and PRKACB in Intraductal Oncocytic Papillary Neoplasms of the Pancreas and��Bile Duct</strong> </summary></p>
<p><em>Gastroenterology 2020 02;158(3):573-582.e2</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31678302" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31678302</a></p>
<p>BACKGROUND &amp; AIMS: Intraductal oncocytic papillary neoplasms (IOPNs) of the pancreas and bile duct contain epithelial cells with numerous, large mitochondria and are cystic precursors to pancreatic ductal adenocarcinoma (PDAC) and cholangiocarcinoma (CCA), respectively. However, IOPNs do not have the genomic alterations found in other pancreatobiliary neoplasms. In fact, no recurrent genomic alterations have been described in IOPNs. PDACs without activating mutations in KRAS contain gene rearrangements, so we investigated whether IOPNs have recurrent fusions in genes. METHODS: We analyzed 20 resected pancreatic IOPNs and 3 resected biliary IOPNs using a broad RNA-based targeted sequencing panel to detect cancer-related fusion genes. Four invasive PDACs and 2 intrahepatic CCAs from the same patients as the IOPNs, were also available for analysis. Samples of pancreatic cyst fluid (n = 5, collected before surgery) and bile duct brushings (n = 2) were analyzed for translocations. For comparison, we analyzed pancreatobiliary lesions from 126 patients without IOPN (controls). RESULTS: All IOPNs evaluated were found to have recurring fusions of ATP1B1-PRKACB (n = 13), DNAJB1-PRKACA (n = 6), or ATP1B1-PRKACA (n = 4). These fusions also were found in corresponding invasive PDACs and intrahepatic CCAs, as well as in matched pancreatic cyst fluid and bile duct brushings. These gene rearrangements were absent from all 126 control pancreatobiliary lesions. CONCLUSIONS: We identified fusions in PRKACA and PRKACB genes in pancreatic and biliary IOPNs, as well as in PDACs and pancreatic cyst fluid and bile duct cells from the same patients. We did not identify these gene fusions in 126 control pancreatobiliary lesions. These fusions might be used to identify patients at risk for IOPNs and their associated invasive carcinomas.</p>
<p>doi: <a href="https://doi.org/10.1053/j.gastro.2019.10.028" class="uri">https://doi.org/10.1053/j.gastro.2019.10.028</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>DNAJB1-PRKACA fusions occur in oncocytic pancreatic and biliary neoplasms and are not specific for fibrolamellar hepatocellular carcinoma</strong> </summary></p>
<p><em>Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc 2020 04;33(4):648-656</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31676785" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31676785</a></p>
<p>Recently discovered DNAJB1-PRKACA oncogenic fusions have been considered diagnostic for fibrolamellar hepatocellular carcinoma. In this study, we describe six pancreatobiliary neoplasms with PRKACA fusions, five of which harbor the DNAJB1-PRKACA fusion. All neoplasms were subjected to a hybridization capture-based next-generation sequencing assay (MSK-IMPACT), which enables the identification of sequence mutations, copy number alterations, and selected structural rearrangements involving ≥410 genes (n = 6) and/or to a custom targeted, RNA-based panel (MSK-Fusion) that utilizes Archer Anchored Multiplex PCR technology and next-generation sequencing to detect gene fusions in 62 genes (n = 2). Selected neoplasms also underwent FISH analysis, albumin mRNA in-situ hybridization, and arginase-1 immunohistochemical labeling (n = 3). Five neoplasms were pancreatic, and one arose in the intrahepatic bile ducts. All revealed at least focal oncocytic morphology: three cases were diagnosed as intraductal oncocytic papillary neoplasms, and three as intraductal papillary mucinous neoplasms with mixed oncocytic and pancreatobiliary or gastric features. Four cases had an invasive carcinoma component composed of oncocytic cells. Five cases revealed DNAJB1-PRKACA fusions and one revealed an ATP1B1-PRKACA fusion. None of the cases tested were positive for albumin or arginase-1. Our data prove that DNAJB1-PRKACA fusion is neither exclusive nor diagnostic for fibrolamellar hepatocellular carcinoma, and caution should be exercised in diagnosing liver tumors with DNAJB1-PRKACA fusions as fibrolamellar hepatocellular carcinoma, particularly if a pancreatic lesion is present. Moreover, considering DNAJB1-PRKACA fusions lead to upregulated protein kinase activity and that this upregulated protein kinase activity has a significant role in tumorigenesis of fibrolamellar hepatocellular carcinoma, protein kinase inhibition could have therapeutic potential in the treatment of these pancreatobiliary neoplasms as well, once a suitable drug is developed.</p>
<p>doi: <a href="https://doi.org/10.1038/s41379-019-0398-2" class="uri">https://doi.org/10.1038/s41379-019-0398-2</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Minimally Invasive Treatment for Severe Acute Pancreatitis With Superior Mesenteric Vein and Common Bile Duct Stenosis: A Case Report and Review of the Literature</strong> </summary></p>
<p><em>Pancreas 2019 09;48(8):e61-e63</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31425486" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31425486</a></p>
<p>doi: <a href="https://doi.org/10.1097/MPA.0000000000001379" class="uri">https://doi.org/10.1097/MPA.0000000000001379</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Mutational profiling and immunohistochemical analysis of a surgical series of ampullary carcinomas</strong> </summary></p>
<p><em>Journal of clinical pathology 2019 Nov;72(11):762-770</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31256008" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31256008</a></p>
<p>AIMS: Knowledge regarding the genetic features of ampullary carcinoma (AC) in European patients is limited. The utility of tumour markers for the establishment of a malignant diagnosis in biopsies from the ampullary region has not been fully elucidated. We aimed to describe the clinical, pathological, immunohistochemical (IHC) and genetic features of a Danish series of surgically resected ACs. METHODS: Surgically resected ACs (n=59) were examined regarding (1) clinicopathological features, (2) histological subtypes, (3) expression of IMP3, maspin, MUC5AC and S100P and (4) next-generation sequencing using a hybrid capture-based platform (Illumina HiSeq2500), including 315 cancer-related genes plus introns from 28 genes often rearranged or altered in cancer. Tumour mutational burden (TMB) and microsatellite instability (MSI) were also evaluated. RESULTS: Pancreatobiliary adenocarcinomas (PB-AC), intestinal adenocarcinomas (INT-AC), other ampullary tumours and mixed adenocarcinomas represented 45.8%, 23.7%, 16.9% and 13.6%. The proportion of IHC-positive ACs (score ≥2) was: Maspin (94.9%), IMP3 (67.8%), S100P (39.0%) and MUC5AC (18.6%). Most frequently altered genes were TP53 (59.3%), KRAS (40.7%), APC (27.8%), SMAD4 (20.4%), CDKN2A (16.7%) and ARID2/PIK3CA (each 11.1%). MUC5AC and S100P were frequently expressed in PB-AC, APC alterations frequent in INT-AC, SOX9 alterations were exclusive in INT-AC and MDM2 and FRS2 alterations in PB-AC. Four of 49 ACs (8.2%) were TMB-high/MSI-high and showed loss of MLH1 and PMS2. CONCLUSIONS: PB-AC was the most frequent histological subtype of AC. Maspin and IMP3 were the IHC tumour markers with the highest sensitivity. Adenocarcinoma subtypes differed regarding several genetic alterations, whose predictive value remains to be evaluated.</p>
<p>doi: <a href="https://doi.org/10.1136/jclinpath-2019-205912" class="uri">https://doi.org/10.1136/jclinpath-2019-205912</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Nivolumab alone or in combination with cisplatin plus gemcitabine in Japanese patients with unresectable or recurrent biliary tract cancer: a non-randomised, multicentre, open-label, phase 1 study</strong> </summary></p>
<p><em>The lancet. Gastroenterology &amp; hepatology 2019 Aug;4(8):611-621</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31109808" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31109808</a></p>
<p>BACKGROUND: This study aimed to assess the safety and tolerability of the immune checkpoint inhibitor nivolumab, as monotherapy or combined with chemotherapy, in Japanese patients with biliary tract cancer. METHODS: This multicentre, open-label, phase 1 trial was done at four cancer centres in Japan. Eligible patients were aged 20-79 years, had biliary tract adenocarcinoma (intrahepatic bile duct cancer, extrahepatic bile duct cancer, gallbladder cancer, or ampullary cancer), Eastern Cooperative Oncology Group performance status 0 or 1, adequate hepatic, renal, and haematological function, and tumour tissue samples for PD-L1 expression analysis. Patients with unresectable or recurrent biliary tract cancer that was refractory or intolerant to gemcitabine-based treatment regimens received nivolumab monotherapy (240 mg every 2 weeks [monotherapy cohort]). Chemotherapy-naive patients with unresectable or recurrent biliary tract cancer received nivolumab (240 mg every 2 weeks) and cisplatin (25 mg/m2) plus gemcitabine (1000 mg/m2) chemotherapy (combined therapy cohort). The primary objective was to assess tolerability and safety. The primary objective was assessed in the safety population of all patients who had received at least one dose of nivolumab. This study is registered with www.clinicaltrials.jp, number JapicCTI-153098, and follow-up is ongoing. FINDINGS: 30 patients were enrolled into each cohort between Jan 13, 2016, and April 19, 2017. Data cutoff was Aug 31, 2017. In the monotherapy cohort, the most frequently reported treatment-related adverse events were decreased appetite (five [17%]), malaise (four [13%]), and pruritus (four [13%]). Grade 3-4 treatment-related adverse events were reported by three (10%) patients (rash, maculopapular rash, and amylase increase) and treatment-related serious adverse events were reported by one (3%) patient (pleurisy). In the combined therapy cohort, the most frequently reported treatment-related adverse events were neutrophil count decrease (any grade 25 [83%]; grade 3-4 in 23 [77%] patients) and platelet count decrease (any grade 25 [83%] of 30; grade 3-4 in 15 [50%] patients). Six (20%) patients reported 11 treatment-related serious adverse events (platelet count decrease [three patients], febrile neutropenia [two patients], neutrophil count decrease, anaemia, anaphylactic reaction, decreased appetite, pyrexia, and myocarditis [one patient each]). In the monotherapy cohort, median overall survival was 5·2 months (90% CI 4·5-8·7), median progression-free survival was 1·4 months (90% CI 1·4-1·4), and one of 30 patients had an objective response. In the combined therapy cohort, median overall survival was 15·4 months (90% CI 11·8-not estimable), median progression-free survival was 4·2 months (90% CI 2·8-5·6), and 11 of 30 patients had an objective response. INTERPRETATION: Nivolumab had a manageable safety profile and signs of clinical activity in patients with unresectable or recurrent biliary tract cancer. This initial assessment of nivolumab for the treatment of advanced biliary tract cancer provides supportive evidence for future larger randomised studies of nivolumab in this difficult to treat cancer. FUNDING: Ono Pharmaceutical Co Ltd and Bristol-Myers Squibb Inc.</p>
<p>doi: <a href="https://doi.org/10.1016/S2468-1253(19)30086-X" class="uri">https://doi.org/10.1016/S2468-1253(19)30086-X</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Surgical Outcomes of Hepatocellular Carcinoma With Bile Duct Tumor Thrombus: A Korea-Japan Multicenter Study</strong> </summary></p>
<p><em>Annals of surgery 2020 May;271(5):913-921</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=30216223" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=30216223</a></p>
<p>OBJECTIVE: To identify optimal surgical methods and the risk factors for long-term survival in patients with hepatocellular carcinoma accompanied by macroscopic bile duct tumor thrombus (BDTT). SUMMARY BACKGROUND DATA: Prognoses of patients with hepatocellular carcinoma accompanied by BDTT have been known to be poor. There have been significant controversies regarding optimal surgical approaches and risk factors because of the low incidence and small number of cases in previous reports. METHODS: Records of 257 patients from 32 centers in Korea and Japan (1992-2014) were analyzed for overall survival and recurrence rate using the Cox proportional hazard model. RESULTS: Curative surgery was performed in 244 (94.9%) patients with an operative mortality of 5.1%. Overall survival and recurrence rate at 5 years was 43.6% and 74.2%, respectively. TNM Stage (P &lt; 0.001) and the presence of fibrosis/cirrhosis (P = 0.002) were independent predictors of long-term survival in the Cox proportional hazards regression model. Both performing liver resection equal to or greater than hemihepatectomy and combined bile duct resection significantly increased overall survival [hazard ratio, HR = 0.61 (0.38-0.99); P = 0.044 and HR = 0.51 (0.31-0.84); P = 0.008, respectively] and decreased recurrence rate [HR = 0.59 (0.38-0.91); P = 0.018 and HR = 0.61 (0.42-0.89); P = 0.009, respectively]. CONCLUSIONS: Clinical outcomes were mostly influenced by tumor stage and underlying liver function, and the impact of BDTT to survival seemed less prominent than vascular invasion. Therefore, an aggressive surgical approach, including major liver resection combined with bile duct resection, to increase the chance of R0 resection is strongly recommended.</p>
<p>doi: <a href="https://doi.org/10.1097/SLA.0000000000003014" class="uri">https://doi.org/10.1097/SLA.0000000000003014</a></p>
</details>
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<hr />
<p><a href="#top" target="_self">Back to top</a></p>
<hr />
<div style="page-break-after: always;"></div>
</div>
<div id="ampulla" class="section level2">
<h2>Ampulla</h2>
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Alterations in Enteroendocrine Hormones After Total Pancreatectomy With Islet Autotransplantation</strong> </summary></p>
<p><em>Pancreas 2020 Jun;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=32541637" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=32541637</a></p>
<p>OBJECTIVE: When total pancreatectomy with islet autotransplantation (TPIAT) is performed for chronic pancreatitis, the pancreas and most of the duodenum are removed, with Roux-en-Y reconstruction of the gastrointestinal tract. Enteroendocrine cells in the intestines and pancreas secrete hormones coordinating digestion and motility, but anatomic reconstruction alters transit of nutrients to these cells. We hypothesized that TPIAT leads to changes in enteroendocrine hormones. METHODS: Glucagon-like peptide 1 (GLP-1), peptide YY (PYY), and pancreatic polypeptide (PP) were measured from mixed-meal tolerance tests of 34 clinical trial participants before and 18 months after TPIAT. Area under the curve of GLP-1 and PYY-stimulated responses were calculated by trapezoidal method, and the PP response was measured as the stimulated max minus baseline (ΔPP). RESULTS: Area under the curve of GLP-1 and PYY increased significantly after TPIAT (GLP-1 average +553.1 pg/mL per minute, P = 0.004; PYY average +4647.9 pg/mL per minute, P = 0.02). ΔPP trended toward lower after TPIAT (average, -52.2 pg/mL, P = 0.06). CONCLUSIONS: In this novel study of enteroendocrine hormones in TPIAT patients, stimulated levels of GLP-1 and PYY were significantly higher after versus before TPIAT. ΔPP was lower after TPIAT, but not significantly. These hormone changes have potential clinical implications that warrant further research.</p>
<p>doi: <a href="https://doi.org/10.1097/MPA.0000000000001582" class="uri">https://doi.org/10.1097/MPA.0000000000001582</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Exosomal miRNA signatures of pancreatic lesions</strong> </summary></p>
<p><em>BMC gastroenterology 2020 May;20(1):137</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=32375666" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=32375666</a></p>
<p>BACKGROUND: Pancreatic and peri-pancreatic neoplasms encompass a variety of histotypes characterized by a heterogeneous prognostic impact. miRNAs are considered efficient candidate biomarkers due to their high stability in tissues and body fluids. We applied Nanostring profiling of circulating exosomal miRNAs to distinct pancreatic lesions in order to establish a source for biomarker development. METHODS: A series of 140 plasma samples obtained from patients affected by pancreatic ductal adenocarcinoma (PDAC, n = 58), pancreatic neuroendocrine tumors (PanNET, n = 42), intraductal papillary mucinous neoplasms (IPMN, n = 20), and ampulla of Vater carcinomas (AVC, n = 20) were analyzed. Comprehensive miRNA profiling was performed on plasma-derived exosomes. Relevant miRNAs were validated by qRT-PCR and in situ hybridization (ISH). RESULTS: Lesion specific miRNAs were identified through multiple disease comparisons. Selected miRNAs were validated in the plasma by qRT-PCR and at tissue level by ISH. We leveraged the presence of clinical subtypes with each disease cohort to identify miRNAs that are differentially enriched in aggressive phenotypes. CONCLUSIONS: This study shows that pancreatic lesions are characterized by specific exosomal-miRNA signatures. We also provide the basis for further explorations in order to better understand the relevance of these signatures in pancreatic neoplasms.</p>
<p>doi: <a href="https://doi.org/10.1186/s12876-020-01287-y" class="uri">https://doi.org/10.1186/s12876-020-01287-y</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Misdiagnosis of multiple synchronous small bowel adenocarcinomas as intestinal tuberculosis: a case report</strong> </summary></p>
<p><em>BMC gastroenterology 2020 Apr;20(1):112</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=32299377" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=32299377</a></p>
<p>BACKGROUND: Small bowel adenocarcinoma (SBA) is a rare malignancy that primarily occurs in the duodenum. Multiple synchronous SBA is unique rare and difficult to diagnose due to non-specific disease presentation. Protocols to identify multiple synchronous SBA during early disease stages are urgently required. CASE PRESENTATION: An elderly man experienced left lower abdominal pain and melena for 3 months. Abdominal CT showed thickening of the multiple segmental small intestinal walls. As the patient had pulmonary tuberculosis simultaneously, he was misdiagnosis as intestinal tuberculosis and received anti-spasm therapy. The treatment delayed radical resection surgery and the patient underwent palliative segmental resection of the jejunum after 4 months due to intestinal obstruction. Resected specimens showed multiple synchronous SBA (five tumors). The patient accepted chemotherapy postoperatively. Six months postoperatively, the patient died of brain metastasis. CONCLUSIONS: We highlight how multiple synchronous SBA is rare and easily misdiagnosed. We should rule out multiple synchronous SBA when diagnosing intestinal diseases (e.g. inflammatory bowel disease, IBS). Intestinal tuberculosis may also be one of the risk factors for multiple synchronous SBA. High-risk patients should be assessed for known tumor makers, and receive gastroscopy, enteroscopy or capsule endoscopy. Doctors should obtain the pathology under endoscopy to the greatest possible degree. For suspected patients, laparotomy should be performed.</p>
<p>doi: <a href="https://doi.org/10.1186/s12876-020-01271-6" class="uri">https://doi.org/10.1186/s12876-020-01271-6</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Chemotherapy, host response and molecular dynamics in periampullary cancer: the CHAMP study</strong> </summary></p>
<p><em>BMC cancer 2020 Apr;20(1):308</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=32293352" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=32293352</a></p>
<p>BACKGROUND: Pancreatic cancer is a devastating disease with a dismal prognosis. Despite profound medical advances in systemic therapies for other types of aggressive tumours during recent years, a diagnosis of pancreatic cancer is still often synonymous with a fatal outcome. The term periampullary cancer includes pancreatic cancer and applies to the group of tumours found in proximity to the ampulla of Vater. Molecular events and immune response in the host during chemotherapy remain largely unexplored in this group of tumours. Therefore, the “Chemotherapy, Host Response and Molecular Dynamics in Periampullary Cancer (CHAMP)” study aims to monitor these processes to gain new insight into this perplexing disease. METHODS: The CHAMP study is a prospective, single-arm observational study. All patients diagnosed with pancreatic or other periampullary adenocarcinoma undergoing adjuvant or palliative chemotherapy treatment in the Department of Oncology, Skåne University Hospital, are invited to participate. Clinical and pathological data will be compiled at study entry. A single tissue microarray (TMA) block is constructed for each patient with a resected tumour and blood samples are drawn before, during and after chemotherapy in order to sample peripheral blood mononuclear cells (PBMC), cytokines and circulating tumour DNA (ctDNA). Next generation sequencing will be performed on tumour tissue and ctDNA to detect changes in the clonal landscape over space and time. DISCUSSION: Despite the recent emergence of some promising biomarkers for periampullary cancer, there has been a lack of success in clinical implementation. Cancer cells continuously adapt and become resistant to treatment during chemotherapy. To be able to keep pace with and hopefully overtake this rapid evolution we must, with the help of new diagnostic tools, be ready to adapt and alter treatment accordingly. It seems to us that the only way forward is to gain a better understanding of the dynamics of the disease during treatment. With insights gained from the CHAMP study we hope to find answers to key questions in this largely unexplored territory. TRIAL REGISTRATION: This study has been registered 30th October 2018 at clinicaltrials.gov as NCT03724994.</p>
<p>doi: <a href="https://doi.org/10.1186/s12885-020-06807-3" class="uri">https://doi.org/10.1186/s12885-020-06807-3</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Pancreaticoduodenectomy for a primary duodenal capicua transcriptional repressor (CIC) -rearranged sarcoma with severe bleeding: a case report</strong> </summary></p>
<p><em>BMC gastroenterology 2020 Apr;20(1):105</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=32293288" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=32293288</a></p>
<p>BACKGROUND: Capicua transcriptional repressor (CIC) -rearranged sarcoma is characterized by small round cells, histologically similar to Ewing sarcoma. However, CIC-rearranged sarcoma has different clinical, histological, and immunohistochemical features from Ewing sarcoma. It is important to differentiate between these tumors. CASE PRESENTATION: The patient is a 44-year-old man with a duodenal tumor diagnosed in another hospital who presented with a history of melena. Laboratory studies showed anemia with a serum hemoglobin of 6.0 g/dL. He was hospitalized and gastrointestinal bleeding was controlled successfully with endoscopy. However, he suffered from appetite loss and vomiting and progression of anemia a few weeks after presentation. Upper gastrointestinal endoscopy showed a circumferential soft tumor in the second portion of the duodenum and the endoscope could not pass distally. Computed tomography scan showed a greater than 10 cm tumor in the duodenum, with compression of the inferior vena cava and infiltrating the ascending colon. A definitive pathologic diagnosis could not be established despite four biopsies from the tumor edge. Due to gastrointestinal obstruction and progression of anemia, a pylorus-preserving pancreaticoduodenectomy with partial resection of the inferior vena cava and right hemicolectomy was performed as a complete tumor resection. The tumor was diagnosed as a CIC-rearranged sarcoma, but 2 months postoperatively local recurrence and distant metastases to the liver and lung were found. The patient died 3 months after surgery. CONCLUSIONS: Although the only definitive treatment for CIC-rearranged sarcoma is surgical resection, the CIC-rearranged sarcoma is highly malignant with a poor prognosis even after radical resection. More research is needed to establish optimal treatment strategies.</p>
<p>doi: <a href="https://doi.org/10.1186/s12876-020-01266-3" class="uri">https://doi.org/10.1186/s12876-020-01266-3</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Prognostic significance of stem cell/ epithelial-mesenchymal transition markers in periampullary/pancreatic cancers: FGFR1 is a promising prognostic marker</strong> </summary></p>
<p><em>BMC cancer 2020 Mar;20(1):216</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=32171280" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=32171280</a></p>
<p>BACKGROUND: Periampullary cancers (PAC) including pancreatic, ampulla of Vater (AOV), and common bile duct (CBD) cancers are highly aggressive with a lack of useful prognostic markers beyond T stage. However, T staging can be biased due to the anatomic complexity of this region. Recently, several markers related to cancer stem cells and epithelial-mesenchymal transition (EMT) such as octamer transcription factor-4 (Oct4) and fibroblast growth factor receptor 1 (FGFR1) respectively, have been proposed as new promising markers in other solid cancers. The aim of this study was to assess the expression and prognostic significance of stem cell/EMT markers in PACs. METHODS: Formalin-fixed, paraffin-embedded tissues of surgically excised PACs from the laboratory archives from 1998 to 2014 were evaluated by immunohistochemical staining for stem cell/EMT markers using tissue microarray. The clinicopathologic parameters were documented and statistically analyzed with the immunohistochemical findings. Survival and recurrence data were collected and analyzed. RESULTS: A total of 126 PAC cases were evaluated. The average age was 63 years, with 76 male and 50 female patient samples. Age less than 74 years, AOV cancers, lower T &amp; N stage, lower tumor size, no lymphatic, vascular, perineural invasion and histologic well differentiation, intestinal type, no fibrosis, severe inflammation were significantly associated with the better overall survival High expression levels of FGFR1 as well as CK20, CDX2, and VEGF were significantly related to better overall survival, while other stem cell markers were not related. Similar findings were observed for tumor recurrence using disease-free survival. CONCLUSIONS: In addition to other clinicopathologic parameters, severe fibrosis was related to frequent tumor recurrence, and high FGFR1 expression was associated with better overall survival. Histologic changes such as extensive fibrosis need to be investigated further in relation to EMT of PACs.</p>
<p>doi: <a href="https://doi.org/10.1186/s12885-020-6673-2" class="uri">https://doi.org/10.1186/s12885-020-6673-2</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Poorly Cohesive (Signet Ring Cell) Carcinoma of the Ampulla of Vater</strong> </summary></p>
<p><em>International journal of surgical pathology 2020 May;28(3):236-244</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31612756" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31612756</a></p>
<p>In the ampulla of Vater, carcinomas with “diffuse-infiltrative”/“signet ring cell” morphology, designated as “poorly cohesive carcinoma” (PCC) in the WHO classification, are very rare and poorly characterized. Nine cases with a classical PCC morphology constituting &gt;50% of the tumor were identified. Mean age was 64.8 years (vs 64.6 in ampullary carcinomas [ACs]) and 6 were males, 3 females. The mean invasive tumor size was 2.5 cm (vs 1.9 in ACs). Other morphologic patterns displayed included cord-like infiltration (n=2), plasmacytoid cells (n=2), and microglandular component (n=4), including goblet cell adenocarcinoma-like foci. None of the cases were associated with dysplasia. By immunohistochemistry, the carcinomas did not show intestinal differentiation (CDX2 0/9, CK20 1/9, MUC2 3/9), MUC1 was positive in 4/9, MUC5AC was positive in 7/8. E-cadherin loss was noted in 4/9. All cases were advanced stage (6/9-pT3, 3/9-pT4) (vs 43% in ACs). Lymph node metastases were identified in 44% (vs 45% in AC). Six patients (67%) died of disease at a median of 25 months, 3 were alive at 13, 15, and 60 months. Overall median survival was significantly worse than that of intestinal-type ACs (26 vs 122 months, P = .006) and trended toward worse than pancreatobiliary type (26 vs 42 months, P = .1). In conclusion, PCCs constitute 2.45% of all ACs. These present as advanced tumors and express upper-gastrointestinal immunoprofile with frequent MUC5AC labeling, which may be helpful in identifying subtle infiltration in the surface mucosa since MUC5AC is not expressed in the ampullary mucosa. Patients have poor prognosis.</p>
<p>doi: <a href="https://doi.org/10.1177/1066896919880968" class="uri">https://doi.org/10.1177/1066896919880968</a></p>
</details>
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<hr />
<p><a href="#top" target="_self">Back to top</a></p>
<hr />
<div style="page-break-after: always;"></div>
<hr />
<p><a href="#top" target="_self">Back to top</a></p>
<hr />
<div style="page-break-after: always;"></div>
</div>
</div>
<div id="feedback" class="section level1">
<h1>Feedback</h1>
<p><a href="https://docs.google.com/forms/d/e/1FAIpQLSeD3Z9J6Y7eMmiyM12f_SfAmHUlykb1zxZcwO6lg7cebGYQIQ/viewform">Google Feedback Form</a></p>
<script>var DISQUSWIDGETS,disqus_domain,disqus_shortname;
typeof DISQUSWIDGETS==="undefined"&&(DISQUSWIDGETS=function(){var f=document,a=f.getElementById("dsq-count-scr"),a=a&&a.src.match(/(https?:)?\/\/(?:www\.)?([\w_\-]+)\.((?:dev\.)?disqus\.(?:com|org)(?::\d+)?)/i),e={},s=f.head||f.body,j={},q={identifier:1,url:2};e.domain=a&&a[3]||disqus_domain||"disqus.com";e.forum=a&&a[2]||disqus_shortname;e.proto=a&&a[1]||"";e.getCount=function(b){var c;c=encodeURIComponent;var a=e.proto+"//"+e.forum+"."+e.domain+"/count-data.js?",d=[],k=0,l=10,r="",b=b||{};b.reset&&
(j={},r="&_="+ +new Date);for(var b=[f.getElementsByTagName("A"),f.getElementsByClassName&&f.getElementsByClassName("disqus-comment-count")||[]],m,i,g,h,n=0;n<b.length;n++){m=b[n];for(var o=0;o<m.length;o++){i=m[o];g=i.getAttribute("data-disqus-identifier");h=i.hash==="#disqus_thread"&&i.href.replace("#disqus_thread","")||i.getAttribute("data-disqus-url");if(g)h=q.identifier;else if(h)g=h,h=q.url;else continue;var p;j.hasOwnProperty(g)?p=j[g]:(p=j[g]={elements:[],type:h},d.push(c(h)+"="+c(g)));p.elements.push(i)}}d.sort();
for(c=d.slice(k,l);c.length;)b=f.createElement("script"),b.src=a+c.join("&")+r,s.appendChild(b),k+=10,l+=10,c=d.slice(k,l)};e.displayCount=function(b){for(var c,a,d,e=b.counts,b=b.text.comments;c=e.shift();)if(a=j[c.id]){switch(c.comments){case 0:d=b.zero;break;case 1:d=b.one;break;default:d=b.multiple}c=d.replace("{num}",c.comments);a=a.elements;for(d=a.length-1;d>=0;d--)a[d].innerHTML=c}};return e}());DISQUSWIDGETS.getCount();</script>
<div id="disqus_thread">

</div>
<script>

/**
*  RECOMMENDED CONFIGURATION VARIABLES: EDIT AND UNCOMMENT THE SECTION BELOW TO INSERT DYNAMIC VALUES FROM YOUR PLATFORM OR CMS.
*  LEARN WHY DEFINING THESE VARIABLES IS IMPORTANT: https://disqus.com/admin/universalcode/#configuration-variables*/
/*
var disqus_config = function () {
this.page.url = PAGE_URL;  // Replace PAGE_URL with your page's canonical URL variable
this.page.identifier = PAGE_IDENTIFIER; // Replace PAGE_IDENTIFIER with your page's unique identifier variable
};
*/
(function() { // DON'T EDIT BELOW THIS LINE
var d = document, s = d.createElement('script');
s.src = 'https://pbpath-org.disqus.com/embed.js';
s.setAttribute('data-timestamp', +new Date());
(d.head || d.body).appendChild(s);
})();
</script>
<noscript>
Please enable JavaScript to view the <a href="https://disqus.com/?ref_noscript">comments powered by Disqus.</a>
</noscript>
<hr />
<p><a href="#top" target="_self">Back to top</a></p>
<hr />
<div style="page-break-after: always;"></div>
<!-- rnb-text-end -->
</div>

<div id="rmd-source-code">---
title: "Pancreatobiliary Pathology Society Journal Watch"
output:
  html_notebook:
    code_folding: none
    fig_caption: yes
    highlight: null
    theme: paper
  pdf_document: 
    toc: yes
    number_sections: yes
    latex_engine: xelatex
    keep_tex: yes
  html_document:
    df_print: paged
date: "Last Update on `r format(Sys.Date())`"
subtitle: Recent Articles that will be Selected
header-includes:
- \renewcommand{\linethickness}{0.05em}
- \usepackage{booktabs}
- \usepackage{sectsty} \allsectionsfont{\nohang\centering \emph}
---

```{r global_options, include=FALSE}
knitr::opts_chunk$set(cache = TRUE)
```


```{r library, include=FALSE}
suppressPackageStartupMessages(library("tidyverse"))
suppressPackageStartupMessages(library("readxl"))
suppressPackageStartupMessages(library("RefManageR"))

```


```{r data load, include=FALSE}
articles <- readRDS("~/JournalWatchPBPath/articles.rds")
```


<style type="text/css">

h1{
  text-align: center;
}
h2{
  text-align: center;
}
h3{
  text-align: center;
}
h4{
  text-align: center;
}
h4.date{
  text-align: center;
}

</style>



<!-- Open all links in new tab-->  
<base target="_blank"/>  



---

# PBPath Journal Watch Articles {.tabset .tabset-fade .tabset-pills #pbpath_jw}


```{r strings , include=FALSE}
PubMedString <- "PubMed: https://www.ncbi.nlm.nih.gov/pubmed/?term="

doiString <- "doi: https://doi.org/"

```



```{r read PMID csv, include=FALSE, cache=FALSE}
pancreas_recent_PMID <-
    readr::read_csv(file      = "~/AutoJournalWatch/data/PMIDList_pancreas.csv",
                    col_names = c("PMID"),
                    readr::cols(PMID = readr::col_character()))

gallbladder_recent_PMID <-
    readr::read_csv(file      = "~/AutoJournalWatch/data/PMIDList_gallbladder.csv",
                    col_names = c("PMID"),
                    readr::cols(PMID = readr::col_character()))

bileducts_recent_PMID <-
    readr::read_csv(file      = "~/AutoJournalWatch/data/PMIDList_bileducts.csv",
                    col_names = c("PMID"),
                    readr::cols(PMID = readr::col_character()))

ampulla_recent_PMID <-
    readr::read_csv(file      = "~/AutoJournalWatch/data/PMIDList_ampulla.csv",
                    col_names = c("PMID"),
                    readr::cols(PMID = readr::col_character()))
```





```{r read PMID from previous JW, include=FALSE, cache=FALSE}
previousJW <- list.files(path = here::here("archive-of-published"),
                          pattern = ".Rmd",
                          full.names = TRUE)


text_previousJW <- unname(sapply(previousJW, readLines))
text_previousJW <- unlist(text_previousJW, use.names=FALSE)

# text_previousJW <- purrr::map(
#     .x = previousJW,
#     .f = readLines
# )



PMID_List_previousJW <-
    stringr::str_extract(
        string = text_previousJW,
        pattern =
            "PubMed_(\\d{8})"
    )


PMID_List_previousJW <- PMID_List_previousJW[!is.na(PMID_List_previousJW)]


PMID_List_previousJW <- PMID_List_previousJW %>%
  unique() %>%
  gsub(pattern = "PubMed_", replacement = "", x = .)

previousJW_PMID <- NULL
previousJW_PMID$PMID <- PMID_List_previousJW
previousJW_PMID <- as.data.frame(previousJW_PMID)

```




---

**Welcome to the PBPath Journal Watch!** 



This bi-monthly journal watch features exciting recently published pancreas and biliary pathology articles that will provide up to date medical knowledge in our field. These articles will be showcased in several convenient categories, including surgical pathology, cytopathology, molecular pathology, pancreas, gallbladder, bile ducts, and ampulla among others. The articles in each category are in no particular order. See the list of journals we search regularly [here](http://pbpath.org/pbpath-journal-watch/). Previous months’ issues may be found in our *[archive](http://pbpath.org/journal-watch-archive/)* and you may see [drafts of the upcoming issue here](http://pbpath.org/journal-watch-upcoming-issue/).  

We encourage members to actively participate by recommending new articles and providing feedback using the [forms provided below.](#feedback){target="_self"}  

**We hope that you will enjoy the new PBPath Journal Watch!**


```{r headerRecent,  child='~/JournalWatchPBPath/_headerRecent.Rmd'}
```



\pagebreak




## Pancreas {#pancreas}




```{r pancreasRecent,  child='~/JournalWatchPBPath/_pancreasRecent.Rmd'}
```

---

<a href="#top" target="_self">Back to top</a>

---

\pagebreak



## Gallbladder {#gallbladder}




```{r gallbladderRecent,  child='~/JournalWatchPBPath/_gallbladderRecent.Rmd'}
```


---

<a href="#top" target="_self">Back to top</a>

---

\pagebreak


## Bile Ducts {#bileducts}




```{r bileductsRecent,  child='~/JournalWatchPBPath/_bileductsRecent.Rmd'}
```



---

<a href="#top" target="_self">Back to top</a>

---

\pagebreak

## Ampulla {#ampulla}




```{r ampullaRecent,  child='~/JournalWatchPBPath/_ampullaRecent.Rmd'}
```



---

<a href="#top" target="_self">Back to top</a>

---

\pagebreak



---

<a href="#top" target="_self">Back to top</a>

---

\pagebreak


# Feedback {#feedback}


[Google Feedback Form](https://docs.google.com/forms/d/e/1FAIpQLSeD3Z9J6Y7eMmiyM12f_SfAmHUlykb1zxZcwO6lg7cebGYQIQ/viewform)  


<script id="dsq-count-scr" src="//pbpath-org.disqus.com/count.js" async></script>
<div id="disqus_thread"></div>
<script>

/**
*  RECOMMENDED CONFIGURATION VARIABLES: EDIT AND UNCOMMENT THE SECTION BELOW TO INSERT DYNAMIC VALUES FROM YOUR PLATFORM OR CMS.
*  LEARN WHY DEFINING THESE VARIABLES IS IMPORTANT: https://disqus.com/admin/universalcode/#configuration-variables*/
/*
var disqus_config = function () {
this.page.url = PAGE_URL;  // Replace PAGE_URL with your page's canonical URL variable
this.page.identifier = PAGE_IDENTIFIER; // Replace PAGE_IDENTIFIER with your page's unique identifier variable
};
*/
(function() { // DON'T EDIT BELOW THIS LINE
var d = document, s = d.createElement('script');
s.src = 'https://pbpath-org.disqus.com/embed.js';
s.setAttribute('data-timestamp', +new Date());
(d.head || d.body).appendChild(s);
})();
</script>
<noscript>Please enable JavaScript to view the <a href="https://disqus.com/?ref_noscript">comments powered by Disqus.</a></noscript>
                            


---

<a href="#top" target="_self">Back to top</a>

---

\pagebreak


</div>



</div>

<script>

// add bootstrap table styles to pandoc tables
function bootstrapStylePandocTables() {
  $('tr.header').parent('thead').parent('table').addClass('table table-condensed');
}
$(document).ready(function () {
  bootstrapStylePandocTables();
});

$(document).ready(function () {
  $('.knitsql-table').addClass('kable-table');
  var container = $('.kable-table');
  container.each(function() {

    // move the caption out of the table
    var table = $(this).children('table');
    var caption = table.children('caption').detach();
    caption.insertBefore($(this)).css('display', 'inherit');
  });
});

</script>

<!-- tabsets -->

<script>
$(document).ready(function () {
  window.buildTabsets("TOC");
});

$(document).ready(function () {
  $('.tabset-dropdown > .nav-tabs > li').click(function () {
    $(this).parent().toggleClass('nav-tabs-open')
  });
});
</script>

<!-- code folding -->
<script>
$(document).ready(function () {
  window.initializeSourceEmbed("RecentPBPathJW.Rmd");
});
</script>


<!-- dynamically load mathjax for compatibility with self-contained -->
<script>
  (function () {
    var script = document.createElement("script");
    script.type = "text/javascript";
    script.src  = "https://mathjax.rstudio.com/latest/MathJax.js?config=TeX-AMS-MML_HTMLorMML";
    document.getElementsByTagName("head")[0].appendChild(script);
  })();
</script>

</body>
</html>
